

Friday, April 26, 2024

Volume 40 No. 4



NOTICE – Items in this issue will be listed online weekly and printed monthly.

180 LIFE SCIENCES CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|--|--------------|-------------------|-------------------|
| Research & development expenses | 2,303,751 | 2,191,834 | 1,000,769 |
| Research & development expenses - related parties | 480,777 | 240,731 | 2,947,536 |
| General & administrative expenses | 10,646,417 | 15,459,788 | 11,230,118 |
| General & administrative expenses - related parties | 46,555 | 5,612 | 462,580 |
| Total operating expenses | 13,477,500 | 17,897,965 | 15,641,003 |
| Income (loss) from operations | (13,477,500) | (17,897,965) | (15,641,003) |
| Gain (loss) on settlement of liabilities | ... | ... | 926,829 |
| Other income | 21,074 | ... | (146,822) |
| Interest expense - related parties | 44,828 | 28,175 | 186,208 |
| Gain (loss) on extinguishment of convertible notes payable, net | ... | ... | (9,737) |
| Gain (loss) on goodwill impairment | ... | 33,547,278 | ... |
| Gain (loss) on in process research & development (IP R&D) impairment | ... | 3,342,084 | ... |
| Change in fair value of derivative liabilities | 75,323 | 15,144,986 | (4,677,388) |
| Change in fair value of accrued issuable equity | ... | ... | (9,405) |
| Offering costs allocated to warrant liabilities | ... | ... | 604,118 |
| Loss on IP R&D asset impairment | 9,063,000 | ... | ... |
| Gain on settlement of accrued liability | (204,405) | ... | ... |
| Total other income (expense), net | (8,807,026) | (21,771,043) | (4,706,849) |
| Income before income taxes - domestic | (20,025,289) | (37,727,021) | (15,078,170) |
| Income before income taxes - international | (2,259,237) | (1,941,987) | (5,269,682) |
| Income (loss) before income taxes | (22,284,526) | (39,669,008) | (20,347,852) |
| Deferred federal income taxes | (4,004,891) | (4,057,936) | (1,503,577) |
| Deferred state income taxes | (1,399,496) | (1,343,123) | (499,136) |
| Deferred | ... | ... | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| international income taxes | (591,583) | (353,038) | (547,944) |
| Deferred tax expense (benefits) | (5,995,970) | (5,754,097) | (2,550,657) |
| Change in valuation allowance | 3,646,556 | 4,811,348 | 2,527,453 |
| Income tax expense (benefit) | (2,349,414) | (942,749) | (23,204) |
| Net income (loss) | (19,935,112) | (38,726,259) | (20,324,648) |
| Net income (loss) attributable to common stockholders | ... | ... | (20,324,648) |
| Weighted average shares outstanding - basic | 379,089 | 100,021 | 82,514 |
| Weighted average shares outstanding - diluted | 379,089 | 100,021 | 82,514 |
| Year end shares outstanding | 534,719 | 197,209 | 89,568 |
| Net earnings (loss) per share - basic | \$(52.59) | \$(387.18) | \$(246.24) |
| Net earnings (loss) per share - diluted | \$(52.59) | \$(387.18) | \$(246.24) |
| Total number of employees | ... | ... | 57 |
| Number of common stockholders | 71 | ... | 69 |
| Foreign currency translation adjustments | ... | ... | 180,554 |

Reclassified to conform 2023 presentation; Reclassified to conform with 2022 presentation; Adjusted for 1-for-20 stock split, December 19, 2022; Shares increased due to the effect of issuance of shares and stock based compensation; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|-----------|-------------------|
| Cash | 1,975,799 | 6,970,110 |
| Prepaid expenses & other current assets | 279,039 | 1,958,280 |
| Prepaid expenses | 934,990 | ... |
| Value-added tax receivable | 9,917 | ... |
| Prepaid Expenses and other current assets | 1,664,107 | ... |
| Research and development expense tax credit receivable | 440,161 | ... |
| Total current assets | 3,639,906 | 8,928,390 |
| Intangible assets, net | 1,619,570 | 1,658,858 |
| In-process research & development | ... | 9,063,000 |
| Total assets | 5,259,476 | 19,650,248 |
| Accounts payable | 1,892,611 | 1,801,210 |
| Accounts payable - related parties | 266,009 | ... |
| Accrued expenses | ... | 2,284,516 |
| Accrued expenses - related parties | ... | 188,159 |
| Loans payable - current portion | 1,034,124 | 1,308,516 |
| Derivative liabilities | 58 | 75,381 |
| Employee and director compensation | 530,383 | ... |

| | | |
|---|---------------|---------------|
| Interest | 70,923 | ... |
| Other | 9,899 | ... |
| Consulting fees | 645,081 | ... |
| Accrued Expenses - Balancing value | 1,869,814 | ... |
| Research and development fees | 378,683 | ... |
| Professional fees | 184,846 | ... |
| Litigation accrual | 49,999 | ... |
| Total current liabilities | 5,062,616 | 5,657,782 |
| Loans payable - noncurrent portion | 19,936 | 31,189 |
| Deferred tax liability | 304,657 | 2,617,359 |
| Total liabilities | ... | 8,306,330 |
| Common stock | 54 | 375 |
| Additional paid-in capital | 130,117,209 | 121,637,611 |
| Accumulated other comprehensive income (loss) | (2,901,339) | (2,885,523) |
| Retained earnings (accumulated deficit) | (127,343,657) | (107,408,545) |
| Total stockholder's equity (deficit) | (127,733) | 11,343,918 |
| Total Equity | (127,733) | ... |

Recent Dividends:

1. 180 Life Sciences Corp common. No dividends paid.
2. 180 Life Sciences Corp class K preferred. No dividends paid.
3. 180 Life Sciences Corp common subject to possible redemption. No dividends paid.
4. 180 Life Sciences Corp class C preferred. No dividends paid.

Annual Dividends:

1. 180 Life Sciences Corp common. No dividends paid.
2. 180 Life Sciences Corp class K preferred. No dividends paid.
3. 180 Life Sciences Corp common subject to possible redemption. No dividends paid.
4. 180 Life Sciences Corp class C preferred. No dividends paid.

22ND CENTURY GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|--|-------------|-------------------|-------------------|
| Revenue | 32,204,000 | 40,501,000 | 30,948,000 |
| Total revenue | 32,204,000 | 40,501,000 | ... |
| Cost of goods sold (exclusive of depreciation shown separately below) - products | 40,900,000 | 38,654,000 | ... |
| Cost of goods sold | ... | ... | 29,462,000 |
| Gross profit (loss) | (8,696,000) | 1,847,000 | 1,486,000 |
| Research & development expenses | 2,644,000 | 3,578,000 | 3,912,000 |
| Sales, general & administrative expenses | 31,064,000 | 32,231,000 | 25,908,000 |
| Impairment of intangible assets | 1,375,000 | 35,000 | ... |

| | 2023 | 2022 | liability | 600,000 | 1,300,000 | per class A common stock subject to possible redemption | | | |
|--|--------------|-------------|---|--------------|------------|---|---|-------------|-----|
| Cash | 4,046,937 | 4,046,937 | Gain on deferred underwriting fees | | | - diluted | \$(0.02) | \$0.37 | |
| Cash & cash equivalents | 10,445,404 | ... | waiver | (146,443) | 513,188 | Net income (loss) | | | |
| Accounts receivable, net of allowance of \$2,909 and \$0, respectively | 64,792 | ... | Interest earned - bank | 10,031 | 62 | per non-redeemable common stock - diluted | \$(0.02) | \$0.37 | |
| Provision - Accounts & Notes Receivable - Trade | 2,909 | ... | Interest earned on marketable securities held in trust account | 672,439 | 22,784 | Net earnings (loss) per class B share - diluted | \$0.16 | ... | ... |
| Accounts receivable, net of allowance of \$191 and \$0 - Balancing value | 67,701 | ... | Interest (expense) | (9,866,821) | ... | Full-Time Employees (Period End) | 102 | ... | ... |
| Unbilled accounts receivable | 1,494,553 | 918,164 | Interest Income | 594,764 | ... | Total number of employees | 102 | 6 | 6 |
| Note receivable | 39,749 | ... | Other income (expense), net | (13,622,860) | 11,131,208 | 17,222,046 | Number of class A common stockholders | ... | ... |
| Raw materials | 457,393 | 755,218 | Income (loss) before provision for income tax | 10,503,022 | (591,079) | ... | Number of class B common stockholders | ... | ... |
| Work-in-process | 1,819,284 | 905,492 | Current federal income taxes | 706,686 | 41,592 | ... | Number of unitholders | ... | ... |
| Inventory | 2,276,677 | 1,660,710 | Deferred federal income taxes | 469,109 | (243,908) | ... | Investment Income from life insurance policies held using investment method | 17,980,987 | ... |
| Investments | ... | 1,944,464 | Current state income taxes | 195,679 | 10,893 | ... | Change in fair value of life insurance policies (policies held using fair value method) | 43,214,390 | ... |
| Prepaid expenses | 581,085 | 153,455 | Deferred state income taxes | 97,061 | (129,130) | ... | Total active management revenue | 61,195,377 | ... |
| Total current assets | 14,902,260 | 8,723,730 | Change in valuation allowance | ... | 373,038 | ... | Sales and marketing | 4,905,747 | ... |
| Office furniture & equipment | 251,747 | ... | Total current tax | 902,365 | ... | ... | Loss on change in fair value of debt | (2,356,058) | ... |
| Computer equipment (hardware) | 16,489 | ... | Total deferred tax | 566,170 | ... | ... | Unrealized loss (gain) on investments | 1,369,112 | ... |
| Total property and equipment | 44,510 | ... | Income tax expense | 1,468,535 | 52,485 | ... | Total portfolio servicing revenue | 1,002,174 | ... |
| Equipment - Gross | 190,748 | ... | NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST | 482,139 | ... | ... | Sales of Goods & Services - Net | 4,203,900 | ... |
| Less: accumulated depreciation | 20,776 | ... | Net Income After Extraordinary Items applicable to Common | 9,516,626 | ... | ... | Total revenues | 66,401,451 | ... |
| Property & equipment, net | 230,971 | 143,079 | Net income (loss) attributable to shareholders | 9,034,487 | (643,564) | 15,839,365 | Gross Profit | 59,911,074 | ... |
| Intangible asset, net | 988,029 | 1,050,022 | Weighted average class A common stock subject to possible redemption | ... | ... | 34,500,000 | COST OF REVENUES (Excluding depreciation stated below) | 6,390,921 | ... |
| Other assets | 1,219,000 | ... | Weighted average class B shares outstanding - basic | ... | 8,625,000 | 8,625,000 | Cost of Revenues | 99,456 | ... |
| Total long-term assets | ... | 1,193,101 | Weighted average class B shares outstanding - basic | 56,951,414 | ... | ... | Total cost of revenue | 6,490,377 | ... |
| Total assets | 16,121,260 | 9,916,831 | Weighted average class A common stock subject to possible redemption | 63,242,173 | 18,343,972 | 43,125,000 | Total operating expenses | 35,785,192 | ... |
| Accounts payable & accrued expenses | 572,297 | 1,449,582 | Net income (loss) attributable to shareholders | ... | ... | 15,839,365 | COMPREHENSIVE INCOME ATTRIBUTABLE TO COMMON STOCKHOLDERS | 8,586,468 | ... |
| Accrued liabilities & accrued vacation | 500,000 | ... | Weighted average class A common stock subject to possible redemption | ... | 23,637,084 | 34,500,000 | Depreciation and amortization expense | 3,409,928 | ... |
| Unearned revenue | 130,000 | 200,109 | Weighted average class B shares outstanding - basic | ... | 8,625,000 | 8,625,000 | General and administrative (including stock-based compensation) | 26,482,571 | ... |
| Other liabilities | 36,787 | 13,528 | Weighted average class A common stock subject to possible redemption | ... | 57,767,898 | ... | Common Shareholders - Number | 12 | ... |
| Accrued legal settlement | 135,000 | ... | Weighted average class B shares outstanding - basic | ... | ... | ... | | | |
| Total current liabilities | 1,374,084 | 1,663,219 | Weighted average class A common stock subject to possible redemption | ... | 63,242,173 | 18,343,972 | | | |
| Total liabilities | 1,374,084 | 1,663,219 | Net income (loss) per class A common stock subject to possible redemption | ... | \$(0.02) | \$0.37 | | | |
| Common stock | 13,266 | 12,669 | Net income (loss) per non-redeemable common stock - basic | ... | \$(0.02) | \$0.37 | | | |
| Additional paid-in capital | 30,684,943 | 16,110,221 | Net earnings (loss) per class B share - basic | \$0.17 | ... | ... | | | |
| Accumulated deficit | (15,953,504) | ... | Net income (loss) | ... | ... | ... | | | |
| Retained earnings (accumulated deficit) | ... | (7,849,982) | | | | | | | |
| Accumulated other comprehensive income (loss) | 2,471 | (19,296) | | | | | | | |
| Total stockholders' equity (deficiency) | 14,747,176 | 8,253,612 | | | | | | | |
| Total Equity | 14,747,176 | ... | | | | | | | |

Recent Dividends:

1. 374Water Inc series D convertible preferred.

No dividends paid.

2. 374Water Inc common.

No dividends paid.

Annual Dividends:

1. 374Water Inc series D convertible preferred.

No dividends paid.

2. 374Water Inc common.

No dividends paid.

ABACUS LIFE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|--------------|-------------|
| Formation & operating costs | 11,722,287 | 1,382,681 | |
| Loss from operations | 24,125,882 | (11,722,287) | (1,382,681) |
| Change in fair value of warrant liability | (4,204,360) | 9,335,550 | 15,899,200 |
| Change in fair value of forward purchase agreement | | | |

Non-consolidated; Shares decreased due to the effect of decreased in common stock subject to redemption; As of April 17, 2023; As of June 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|--------|
| Cash | ... | 86,572 |
| Prepaid expenses | ... | 64,914 |
| Cash and cash equivalents | 25,588,668 | ... |
| Prepaid expenses and other current assets | 699,127 | ... |
| Equity securities, at fair value | 2,252,891 | ... |
| Accounts receivable | 2,149,111 | ... |

| | | |
|--|--------------|--------------|
| Accounts receivable, related party | 79,509 | ... |
| Due from affiliates | 1,007,528 | ... |
| Total current assets | 31,776,834 | 151,486 |
| Cash & securities held in trust account | 998,945 | 99,222,704 |
| Property and equipment - Gross - Total | 470,482 | ... |
| accumulated depreciation | 69,762 | ... |
| Computer equipment | 356,939 | ... |
| Furniture and fixtures | 91,125 | ... |
| Leasehold Improvements | 22,418 | ... |
| Property and equipment net | 400,720 | ... |
| Operating right-of-use assets | 1,893,659 | ... |
| Life settlement policies, at cost | 1,697,178 | ... |
| Life settlement policies, at fair value | 122,296,559 | ... |
| Available for sale securities, at fair value | 1,105,935 | ... |
| Other investments | 1,650,000 | ... |
| Intangible Assets | 29,623,130 | ... |
| Goodwill | 140,287,000 | ... |
| Equity securities, at fair value | 96,107 | ... |
| Total assets | 331,826,067 | 99,374,190 |
| Accrued Expenses | 4,354,225 | ... |
| Current liabilities - accrued expenses | ... | 9,227,518 |
| Current liabilities - note payable to related party | ... | 4,924,356 |
| Income taxes payable | 751,734 | 52,485 |
| Warrant liability | 3,400,734 | 4,576,250 |
| Operating lease liabilities- current portion | 118,058 | ... |
| Current portion of long-term debt | 13,029,632 | ... |
| Due to affiliates | 5,236 | ... |
| Due to owners | 1,159,712 | ... |
| Contract liabilities - deposits on pending settlements | 507,000 | ... |
| Total current liabilities | 23,326,331 | ... |
| Operating lease liabilities- noncurrent portion | 1,796,727 | ... |
| Deferred tax liability | 9,199,091 | ... |
| Warrant liability | 6,642,960 | ... |
| Long-term debt, at fair value | 89,137,013 | ... |
| SPV purchase and sale note | 37,653,869 | ... |
| Total liabilities | 167,755,991 | 18,780,609 |
| Class A common stock subject to possible redemption | ... | 98,983,437 |
| Class B common stock | 6,339 | 863 |
| Additional paid-in capital | 199,826,278 | 24,137 |
| Retained earnings (accumulated deficit) | (34,726,135) | (18,414,856) |
| Accumulated other comprehensive income | 108,373 | ... |
| Treasury stock - at cost; 146,650 and ? shares, respectively | 1,283,062 | ... |
| Non-controlling interests | 138,283 | ... |
| Total stockholders' (deficit) | 164,070,076 | (18,389,856) |

Recent Dividends:
1. Abacus Life Inc class A common stock subject to possible redemption,
 No dividends paid.
2. Abacus Life Inc class A common.
 No dividends paid.
3. Abacus Life Inc class B common.
 No dividends paid.
Annual Dividends:

1. Abacus Life Inc class A common stock subject to possible redemption,
 No dividends paid.
2. Abacus Life Inc class A common.
 No dividends paid.
3. Abacus Life Inc class B common.
 No dividends paid.

**ABRDN ASIAN INCOME FUND LTD
 Annual Report
 Consolidated Income Statement, Years Ended Dec. 31**

| (£000): | 2023 | 2020 | 2019 |
|---|---------|---------|---------|
| Dividend income | ... | 16,560 | 20,516 |
| Interest income | ... | 320 | 406 |
| Traded option premiums | 4 | 62 | 74 |
| Dividend income | 23,590 | ... | ... |
| Interest income | 459 | ... | ... |
| Total revenue | 24,053 | 16,942 | 20,996 |
| Gains (losses) on investments held at fair value through profit or loss | (8,457) | 37,573 | 24,759 |
| Net currency gains (losses) | 701 | 217 | 934 |
| Investment management fee | (3,041) | (3,120) | (3,431) |
| Other operating expenses | (867) | (792) | (951) |
| Profit (loss) before finance costs & tax | 12,389 | 50,820 | 42,307 |
| Interest on bank loans | (2,009) | (830) | (1,072) |
| Amortisation of loan arrangement expenses | (16) | ... | ... |
| Finance costs | (2,025) | (830) | (1,072) |
| Profit (loss) before tax | 10,364 | 49,990 | 41,235 |
| Tax expense | (1,620) | (2,109) | (1,538) |
| Profit (loss) for the year | 8,744 | 47,881 | 39,697 |
| Weighted average ordinary shares outstanding-basic | 168,694 | 176,666 | 178,088 |
| Year end shares outstanding | 167,179 | 175,824 | 177,592 |
| Basic EPS Excluding ExtraOrdinary Items | £0.05 | ... | ... |
| Net earnings (loss) per share - basic | £0.05 | £0.27 | £0.22 |
| Diluted EPS Excluding ExtraOrd Items | £0.05 | ... | ... |
| Dividends per ordinary share | 0.12 | 0.09 | 0.09 |
| Directors fees | (175) | ... | ... |
| Other | (185) | ... | ... |
| Audit Fees - Statutory audit | (57) | ... | ... |
| Custody fees | (98) | ... | ... |
| Promotional activitiesA | (200) | ... | ... |
| As Reported Diluted Weighted Avg. Shares | 168,694 | ... | ... |
| Reported Diluted EPS | £0.05 | ... | ... |
| disbursements | (2) | ... | ... |
| Professional fees | (56) | ... | ... |
| Registrars fees | (58) | ... | ... |
| Printing & postage | (36) | ... | ... |
| Full-Time Employees (Period End) | 0 | ... | ... |
| Total number of employees | 0 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (£000):

| | 2023 | 2020 |
|--|------|------|
| Investments held at fair value through profit or | | |

| | | |
|--|---------|----------|
| loss | 429,636 | 462,823 |
| Non-current assets | ... | 462,823 |
| Cash & cash equivalents | 1,560 | 6,177 |
| Amounts due from brokers | 2,913 | ... |
| Prepayments & accrued income | ... | 1,422 |
| Other receivables | ... | 1,422 |
| Current assets | 4,473 | 7,599 |
| Total assets | 434,109 | 470,422 |
| Bank loans | 32,123 | 35,734 |
| Other payables | 1,503 | 2,518 |
| Creditors - amounts falling due within one year | 33,626 | 38,252 |
| Net current assets (liabilities) | ... | (30,653) |
| Total assets less current liabilities | ... | 432,170 |
| Deferred tax liability on indian capital gains | 1,615 | 694 |
| Creditors - amounts falling due after more than one year | 1,615 | 694 |
| Net assets (liabilities) | ... | 431,476 |
| Stated capital | 194,933 | 194,933 |
| Capital redemption reserve | 1,560 | 1,560 |
| Capital reserve | 187,549 | 222,751 |
| Revenue reserve | 14,826 | 12,232 |
| Equity shareholders funds | 398,868 | ... |
| Equity shareholders' funds | 398,868 | 431,476 |
| Net asset value per ordinary share | ... | £2.45 |
| Total Liabilities & Shareholders' Equity | 434,109 | ... |

Recent Dividends:
1. Abrdn Asian Income Fund Ltd ordinary.
 No dividends paid.
2. Abrdn Asian Income Fund Ltd C shares.
 No dividends paid.
Annual Dividends:
1. Abrdn Asian Income Fund Ltd ordinary.
 No dividends paid.
2. Abrdn Asian Income Fund Ltd C shares.
 No dividends paid.

**ACCELERATE DIAGNOSTICS INC
 Annual Report
 Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | (revised) 2021 |
|---------------------------------------|--------------|--------------|----------------|
| Net sales | 12,059,000 | 12,752,000 | 11,782,000 |
| Total revenues | 12,059,000 | ... | ... |
| Cost of sales of products & services | 8,325,000 | 9,449,000 | 7,663,000 |
| Inventory write-down | 1,184,000 | ... | 4,500,000 |
| Gross profit (loss) | 2,550,000 | 3,303,000 | (381,000) |
| Total cost of sales | 9,509,000 | 9,449,000 | 12,163,000 |
| Research & development | 25,353,000 | 26,915,000 | 21,943,000 |
| Sales, general & administrative | 31,225,000 | 39,193,000 | 49,236,000 |
| Total costs & expenses | 56,578,000 | 66,108,000 | 71,179,000 |
| Income (loss) from operations | (54,028,000) | (62,805,000) | (71,560,000) |
| Interest expense | 5,926,000 | 2,274,000 | 15,545,000 |
| Interest expense related-party | 1,817,000 | 1,497,000 | ... |
| Gain on extinguishment of debt | (6,499,000) | 3,565,000 | 9,793,000 |
| Interest income | 1,123,000 | 551,000 | 88,000 |
| Foreign currency exchange gain (loss) | 71,000 | 117,000 | (413,000) |
| Other expense, net | (108,000) | 227,000 | 20,000 |
| Gain on fair value adjustment | 12,955,000 | ... | ... |
| (Loss) on | ... | ... | ... |

| | | | |
|---|--------------|--------------|--------------|
| extinguishment of debt related party | (6,755,000) | ... | ... |
| Total other income (expense), net | (6,740,000) | 235,000 | (6,097,000) |
| Net income (loss) before income taxes - U.S. domestic | ... | (54,099,000) | (68,131,000) |
| Net income (loss) before income taxes - foreign | ... | (8,471,000) | (9,526,000) |
| Net income (loss) before income taxes | (60,768,000) | (62,570,000) | (77,657,000) |
| Current state provision (benefit) for income taxes | 54,000 | 19,000 | 18,000 |
| Current foreign provision (benefit) for income taxes | 796,000 | (96,000) | 27,000 |
| Total current provision (benefit) for income taxes | 850,000 | (77,000) | 45,000 |
| Provision (benefit) for income taxes | 850,000 | (77,000) | 45,000 |
| Net income (loss) | (61,618,000) | (62,493,000) | (77,702,000) |
| Weighted average shares outstanding - basic | 12,477,000 | 8,216,100 | 6,172,700 |
| Weighted average shares outstanding - diluted | 12,477,000 | 8,216,100 | 6,172,700 |
| Year end shares outstanding | 14,569,500 | 9,747,755 | 6,764,902 |
| Income (loss) per share - continuing operations - basic | \$(4.94) | ... | ... |
| Net income (loss) per share - basic | \$(4.94) | \$(7.60) | \$(12.60) |
| Income (loss) per share - continuing operations - diluted | \$(4.94) | ... | ... |
| Net income (loss) per share - diluted | \$(4.94) | \$(7.60) | \$(12.60) |
| Number of full time employees | 134 | ... | ... |
| Total number of employees | 134 | 179 | 220 |
| Number of common stockholders | 33 | 124 | 133 |
| Foreign currency translation adjustments | ... | (326,000) | (117,000) |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-10 stock split, July 12, 2023; Approximately; As of March 28, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------------|------------|------------|
| Cash & cash equivalents | 12,138,000 | 34,905,000 |
| Investments | 1,081,000 | 10,656,000 |
| Trade accounts receivable, gross | ... | 2,740,000 |
| Less: allowance for credit losses | ... | 324,000 |
| Trade accounts receivable, net | 2,622,000 | 2,416,000 |
| Raw materials | 1,268,000 | 1,827,000 |
| Work in process | 648,000 | 2,115,000 |
| Finished goods | 1,394,000 | 1,252,000 |
| Inventory | 3,310,000 | 5,194,000 |
| Prepaid expenses | 380,000 | 818,000 |
| Other current assets | 1,516,000 | 2,025,000 |
| Purchase obligation put option asset | 3,419,000 | ... |
| Total current assets | 24,466,000 | 56,014,000 |
| Computer equipment | 3,464,000 | 3,551,000 |
| Technical equipment | 3,135,000 | 3,236,000 |
| Facilities | 3,004,000 | 3,663,000 |
| Instruments | 13,400,000 | 3,735,000 |
| Leasehold improvements | 3,688,000 | ... |
| Capital projects in progress | 109,000 | 114,000 |

| | | | |
|---|---------------|---------------|-----|
| Total property & equipment | ... | 14,299,000 | ... |
| Accumulated depreciation - property & equipment | 11,011,000 | 10,821,000 | ... |
| Property & equipment, net | 2,389,000 | 3,478,000 | ... |
| Finance lease assets, net | 1,518,000 | 2,422,000 | ... |
| Operating lease right of use assets, net | 1,177,000 | 1,859,000 | ... |
| Other non-current assets | 1,816,000 | 1,242,000 | ... |
| Total assets | 31,366,000 | 65,015,000 | ... |
| Accounts payable | 4,796,000 | 4,501,000 | ... |
| Accrued liabilities | 3,243,000 | 2,682,000 | ... |
| Accrued interest | 164,000 | 472,000 | ... |
| Deferred revenue | 1,545,000 | 547,000 | ... |
| Current portion of convertible notes | 726,000 | 56,413,000 | ... |
| Operating lease, current | 977,000 | 829,000 | ... |
| Finance lease, current | 583,000 | 1,113,000 | ... |
| Total current liabilities | 12,034,000 | 66,557,000 | ... |
| Finance lease, non-current | 262,000 | 782,000 | ... |
| Operating lease, non-current | 570,000 | 1,545,000 | ... |
| Long-term deferred income | 1,122,000 | ... | ... |
| Other non-current liabilities | 1,164,000 | 874,000 | ... |
| Accrued interest, related-party | ... | 663,000 | ... |
| Secured note | ... | 34,934,000 | ... |
| Unamortized debt issuance discount | ... | (18,076,000) | ... |
| Long-term, debt related-party | ... | 16,858,000 | ... |
| Convertible notes | 36,102,000 | ... | ... |
| Total liabilities | 51,254,000 | 87,279,000 | ... |
| Common stock | 14,000 | 97,000 | ... |
| Preferred shares | ... | 4,000 | ... |
| Contributed capital | 694,634,000 | 630,341,000 | ... |
| Treasury stock | 45,067,000 | 45,067,000 | ... |
| Retained earnings (accumulated deficit) | (668,857,000) | (607,239,000) | ... |
| Accumulated other comprehensive income (loss) | (612,000) | (400,000) | ... |
| Total stockholders' equity (deficit) | (19,888,000) | (22,264,000) | ... |
| Total Equity | (19,888,000) | ... | ... |

Recent Dividends:
1. Accelerate Diagnostics Inc common. No dividends paid.
2. Accelerate Diagnostics Inc series A preferred. No dividends paid.

Annual Dividends:
1. Accelerate Diagnostics Inc common. No dividends paid.
2. Accelerate Diagnostics Inc series A preferred. No dividends paid.

ACELYRIN INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|--|-----------|----------|----------|
| Research & development | 355,886 | 55,632 | 38,230 |
| General & administrative | 66,178 | 13,547 | 3,564 |
| Total operating expenses | 422,064 | 69,179 | 41,794 |
| Income (loss) from operations | (422,064) | (69,179) | (41,794) |
| Interest income | 30,555 | 4,052 | ... |
| Change in fair value of derivative tranche liability | (423) | 487 | ... |
| Other expense, net | ... | 132 | 45 |
| Net income (loss) | (381,641) | (64,772) | (41,839) |
| Weighted average shares outstanding - basic | 98,365 | 1,558 | 687 |
| Weighted average | ... | ... | ... |

| | | | |
|--|-----------|-----------|-----------|
| shares outstanding - diluted | 98,365 | 1,558 | 687 |
| Year end shares outstanding | 97,866 | 2,767 | 2,860 |
| Net income (loss) per share - basic | \$(5.43) | \$(41.59) | \$(60.87) |
| Net income (loss) per share - diluted | \$(5.43) | \$(41.59) | \$(60.87) |
| Number of full time employees | ... | 51 | ... |
| Income from cont operations before income tax | (381,641) | ... | ... |
| Change in fair value of derivative tranche liability | 10,291 | ... | ... |

As is; As of March 15, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|-----------|---------|
| Cash & cash equivalents | 218,097 | 267,110 |
| Short-term marketable securities | 503,229 | 47,510 |
| Prepaid research & development expenses | 8,184 | 682 |
| Prepaid other services | 667 | 288 |
| Research & development credit receivable | ... | 250 |
| Interest receivable | 764 | 138 |
| Prepaid insurance & other current assets | 1,712 | 86 |
| Prepaid expenses & other current assets | 15,312 | 1,444 |
| Value-Added Tax (VAT) receivable | 3,985 | ... |
| Total current assets | 736,638 | 316,064 |
| Prepaid research & development expenses, non-current | 2,678 | 1,964 |
| ValenzaBio, Inc. acquisition transaction costs | ... | 1,121 |
| Deferred initial public offering offering costs | ... | 774 |
| Prepaid expenses & other assets, non-current | ... | 3,859 |
| Operating lease right-of-use asset | 1,195 | ... |
| Construction in Progress - Gross | 1,460 | ... |
| Furniture and fixtures | 306 | ... |
| Computer and other equipment | 407 | ... |
| Leasehold Improvements - Gross | 121 | ... |
| accumulated depreciation and amortization | 115 | ... |
| Property, Plant & Equipment - Gross - Total | 2,294 | ... |
| Property, plant and equipment | 2,179 | ... |
| Total assets | 742,690 | 319,923 |
| Accounts payable | 41,920 | 5,947 |
| Accrued research & development expenses | 35,436 | 5,717 |
| Accrued compensation & other current liabilities | 970 | 4,237 |
| Accrued compensation and other current liabilities | 6,833 | ... |
| Accrued compensation | 5,417 | ... |
| Accrued compensation and other current liabilities - Balancing value | 1,416 | ... |
| Total current liabilities | 85,159 | 15,901 |
| Derivative tranche liability | ... | 10,291 |
| Operating lease liability, non-current | 1,194 | ... |
| Total liabilities | 86,353 | 26,192 |
| Redeemable convertible preferred stock | ... | 396,593 |
| Additional paid-in capital | 1,144,893 | 4,302 |

| | | |
|---|-----------|-----------|
| Accumulated other comprehensive income (loss) | 162 | (86) |
| Retained earnings (accumulated deficit) | (488,719) | (107,078) |
| Common Stock | 1 | ... |
| Total stockholders' equity (deficit) | 656,337 | (102,862) |
| Total Equity | 656,337 | ... |

Recent Dividends:**1. ACELYRIN Inc common.**

No dividends paid.

Annual Dividends:**1. ACELYRIN Inc common.**

No dividends paid.

ACHIEVE LIFE SCIENCE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|-------------------|
| Research & development | 15,814,000 | 30,078,000 | 23,966,000 |
| General & administrative | 11,436,000 | 10,722,000 | 9,128,000 |
| Total operating expenses | 27,250,000 | 40,800,000 | 33,094,000 |
| Interest income | 825,000 | 199,000 | 17,000 |
| Interest expense | 2,853,000 | 1,789,000 | ... |
| Other income (expense) | (9,000) | 40,000 | (75,000) |
| Change in fair value of contingent consideration | (528,000) | ... | ... |
| Total other income (expense) | (2,565,000) | (1,550,000) | (58,000) |
| Net income (loss) before income taxes - U.S. | ... | (41,660,000) | (31,411,000) |
| Net income (loss) before income taxes - Foreign | ... | (690,000) | (1,741,000) |
| Net income (loss) before income taxes .. | (29,815,000) | (42,350,000) | (33,152,000) |
| Net income (loss) | (29,815,000) | (42,350,000) | (33,152,000) |
| Weighted average shares outstanding - basic | 19,827,354 | 10,593,034 | 8,119,836 |
| Weighted average shares outstanding - diluted | 19,827,354 | 10,593,034 | 8,119,836 |
| Year end shares outstanding | 21,165,760 | 17,897,029 | 9,453,542 |
| Net income (loss) per share - basic | \$(1.50) | \$(4.00) | \$(4.08) |
| Net income (loss) per share - diluted | \$(1.50) | \$(4.00) | \$(4.08) |
| Number of full time employees | 22 | ... | ... |
| Total number of employees | 22 | 20 | 16 |
| Number of common stockholders | 18 | 28 | 16 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(1.50) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(1.50) | ... | ... |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to issuance of shares on exercise of warrants, employee share purchase plan, private placement, purchase agreement and settlement with trade vendor and restricted shares; ³ Shares increased due to the effect of exercise of warrants, settlement with trade vendor, public offering, and restricted stock unit settlements; ⁴ Approximately; ⁵ As of February 22, 2023; ⁶ As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------------|------------|------------|
| Cash & cash equivalents | 15,546,000 | 24,771,000 |
| Grant receivable | 111,000 | 105,000 |

| | | |
|---|---------------|---------------|
| Prepaid expenses & other assets | 1,325,000 | 2,454,000 |
| Total current assets | 16,982,000 | 27,330,000 |
| Right-of-use assets | 66,000 | 123,000 |
| Restricted cash & other assets | 92,000 | 66,000 |
| License agreement | 1,197,000 | 1,418,000 |
| Goodwill | 1,034,000 | 1,034,000 |
| Total assets | 19,371,000 | 29,971,000 |
| Accounts payable | 618,000 | 1,660,000 |
| Accrued liabilities other | 351,000 | 403,000 |
| Accrued clinical liabilities | 280,000 | 1,729,000 |
| Accrued compensation | 2,311,000 | 1,678,000 |
| Current portion of long-term obligations | 63,000 | 58,000 |
| Convertible debt | 16,662,000 | 16,071,000 |
| Contingent consideration | 528,000 | ... |
| Total current liabilities | 20,813,000 | 21,599,000 |
| Long-term obligations | 6,000 | 69,000 |
| Total liabilities | 20,819,000 | 21,668,000 |
| Common stock | 90,000 | 87,000 |
| Additional paid-in capital | 164,209,000 | 144,148,000 |
| Retained earnings (accumulated deficit) | (165,751,000) | (135,936,000) |
| Unrealized gains & losses on available-for-sale marketable securities | ... | 4,000 |
| Accumulated other comprehensive income (loss) | 4,000 | 4,000 |
| Total stockholders' equity (deficiency) | (1,448,000) | 8,303,000 |
| Total Equity | (1,448,000) | ... |

Recent Dividends:**1. Achieve Life Science Inc common.**

No dividends paid.

2. Achieve Life Science Inc series B convertible preferred.

No dividends paid.

3. Achieve Life Science Inc series A convertible preferred.

No dividends paid.

Annual Dividends:**1. Achieve Life Science Inc common.**

No dividends paid.

2. Achieve Life Science Inc series B convertible preferred.

No dividends paid.

3. Achieve Life Science Inc series A convertible preferred.

No dividends paid.

ACLARION INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|--|-------------|-------------|-------------------|
| Revenue | 75,404 | ... | ... |
| Revenue | 75,404 | 60,444 | 60,292 |
| Cost of revenue | 75,728 | 65,298 | 69,175 |
| Net profit (loss) | (324) | (4,854) | (8,883) |
| Sales & marketing expenses | 757,004 | 537,069 | 330,814 |
| Research & development expenses | 873,336 | 1,088,778 | 787,850 |
| General & administrative expenses | 3,245,317 | 4,467,815 | 1,825,491 |
| Total operating expenses | 4,875,657 | 6,093,662 | 2,944,155 |
| Income (loss) from operations | (4,875,981) | (6,098,516) | (2,953,038) |
| Paycheck Protection Program ("PPP") loan forgiveness | ... | ... | 373,511 |
| Interest expense | 608,288 | 1,507,546 | 474,911 |
| Changes in fair value of redeemable preferred stock | ... | ... | (1,900,310) |
| Other income (expense), net | (562) | 520 | 4,458 |
| Changes in fair value of warrant | | | |

| | | | |
|--|-------------|-------------|-------------|
| and derivative liabilities | 646,319 | ... | ... |
| Loss on issuance of warrants | (72,862) | ... | ... |
| Total other income (expense) | (35,393) | (1,507,026) | (1,997,252) |
| Income (loss) before income taxes .. | (4,911,374) | (7,605,542) | (4,950,290) |
| Net income (loss) | (4,911,374) | (7,605,542) | (4,950,290) |
| Dividends accrued for preferred stockholders | ... | 415,523 | 1,005,598 |
| Net income (loss) allocable to common stockholders | (4,911,374) | (8,021,064) | (5,955,888) |
| Weighted average shares outstanding - basic | 556,808 | 381,598 | 56,605 |
| Weighted average shares outstanding - diluted | 556,808 | 381,598 | 56,605 |
| Year end shares outstanding | 825,459 | 491,345 | 56,605 |
| Net income (loss) per share - basic | \$(8.82) | \$(20.96) | \$(105.28) |
| Net income (loss) per share - diluted | \$(8.82) | \$(20.96) | \$(105.28) |
| Total number of employees | ... | 7 | 6 |
| Number of common stockholders | 137 | 153 | 180 |

¹ Reclassified to conform with 2022 presentation; ² As reported by the Company; ³ Adjusted for 1-for-16 stock split, January 4, 2024; ⁴ Shares increased due to the effect of preferred stock dividend payable, conversion of preferred stock to common stock, issuance of common stock and warrants related to IPO; ⁵ As of January 1, 2023; ⁶ As of January 1, 2022; ⁷ Approximately; ⁸ As of February 24, 2023; ⁹ As of April 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 1,021,069 | 1,472,806 |
| Restricted cash | 10,000 | 10,000 |
| Accounts receivable, gross | 13,270 | 18,569 |
| Accounts receivable, net | 13,270 | 18,569 |
| Deferred compensation | ... | 291,331 |
| Prepays & other current assets | 245,030 | 195,534 |
| Short term deposits | 50,000 | ... |
| Deferred offering costs | 100,588 | ... |
| Prepaid insurance other | 17,884 | ... |
| Prepaid, other | 41,635 | ... |
| Prepaid insurance D & O | 34,769 | ... |
| Receivables - Other - Net | 154 | ... |
| Total current assets | 1,289,369 | 1,988,240 |
| Computer & office equipment | 42,150 | 13,032 |
| Software | ... | 42,150 |
| Other equipment | ... | 18,190 |
| Computer & Office Equipmnt - Gross | 13,032 | ... |
| Property & equipment, at cost | 55,182 | 73,372 |
| Less: accumulated depreciation | 53,400 | 70,026 |
| Property & equipment, net | 1,782 | 3,346 |
| Intangible assets, net | 1,168,623 | 1,214,374 |
| Total non-current assets | 1,170,405 | 1,217,720 |
| Total assets | 2,459,774 | 3,205,961 |
| Accounts payable | 760,535 | 462,202 |
| Credit cards payable | 1,714 | ... |
| Accrued salaries & expenses | 857,722 | ... |
| Accrued interest | 98,685 | ... |
| Accounts payable & accrued liabilities | 758,821 | ... |
| Accrued & other liabilities | ... | 610,765 |
| Promissory note payable | 1,125,724 | ... |

| | | |
|---|--------------|--------------|
| Liability to issue equity | 33,297 | 345,243 |
| Warrant liability | 289,165 | ... |
| Derivative liability | 121,326 | ... |
| Accrued salaries and expenses | 162,887 | ... |
| Accrued board compensation | 62,500 | ... |
| Accrued committee compensation | 30,000 | ... |
| Accrued and other liabilities - Balancing value | 503,650 | ... |
| Total current liabilities | 3,187,769 | 1,418,209 |
| Common stock | 8 | 79 |
| Additional paid-in capital | 43,553,523 | 41,694,774 |
| Accumulated deficit | (44,281,526) | ... |
| Retained earnings (accumulated deficit) | ... | (39,907,101) |
| Total stockholders' equity (deficit) | (727,995) | 1,787,751 |
| Total Equity | (727,995) | ... |

| | | | |
|---|---------|---------|---------|
| Weighted average shares outstanding | | | |
| - basic | 336,076 | 345,600 | 356,199 |
| Weighted average class A shares outstanding - basic | 435,421 | 436,431 | 438,138 |
| Weighted average shares outstanding - diluted | 336,076 | 345,600 | 356,199 |
| Weighted average class A shares outstanding - diluted | 435,421 | 436,431 | 438,138 |
| Year end shares outstanding | 771,697 | 772,034 | 772,034 |
| Earnings (loss) per share - continuing operations - basic | \$0.66 | ... | ... |
| Net earnings (loss) per share - basic | \$0.66 | \$0.89 | \$1.92 |
| Net earnings (loss) per share - class A - basic | \$0.66 | \$0.89 | \$1.92 |
| Net earnings (loss) per share - diluted | \$0.66 | \$0.89 | \$1.92 |
| Net earnings (loss) per share - class A - diluted | \$0.66 | \$0.89 | \$1.92 |

| | | |
|--|------------|------------|
| Unearned premiums | 506,933 | 355,627 |
| Collateral held | ... | 11,707,362 |
| Reinsurance premiums payable | ... | 18,973 |
| Accounts payables & accrued liabilities | 1,015,199 | 1,127,299 |
| Deferred income taxes | ... | 400,994 |
| Mortgage note | ... | 925,000 |
| SBA Payroll Protection Program loan | ... | 154,270 |
| Long-term debt | ... | 1,079,270 |
| Reserves for losses and loss adjustment expenses | 9,158,519 | ... |
| Reinsurance premiums payable | 50,932 | ... |
| Collateral Held | 12,544,001 | ... |
| Total liabilities | 23,275,584 | 26,437,119 |
| Common stock | 336,076 | 336,146 |
| Class A stock | 435,421 | 435,688 |
| Retained earnings (accumulated deficit) | 29,047,166 | 29,247,010 |
| Accumulated other comprehensive income (loss) | (970,276) | 1,285,724 |
| Total stockholders' equity (deficit) | 28,848,387 | 31,304,568 |
| Rep Total Equity & Minority Interest | 28,848,387 | ... |

As reported by the Company

Recent Dividends:

1. Aclarion Inc common.
No dividends paid.

Annual Dividends:

1. Aclarion Inc common.
No dividends paid.

As reported from the 12/31/20 Annual Report

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2020

ACMAT CORP.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2023 2020 2019

| | | | |
|--|-------------|-----------|-----------|
| Premiums | 908,520 | 825,390 | 894,066 |
| Taxable interest | ... | 1,035,238 | 1,133,029 |
| Tax-exempt interest | ... | 374,390 | 409,262 |
| Dividends on equity securities | ... | 443,486 | 394,327 |
| Investment expenses & allowance for uncollectible amounts | ... | (19,133) | (19,800) |
| Net realized capital gains (losses) | (1,670,591) | 354,045 | 195,325 |
| Net unrealized capital (losses) gains on equity securities | 1,064,547 | (127,258) | 946,596 |
| Fee & other income | 73,360 | 136,021 | 53,833 |
| Total revenues | 2,148,011 | 3,022,179 | 4,006,638 |
| Net benefit recognized on loss & LAE reserves | (1,141,382) | (965,667) | (968,064) |
| Policy acquisition costs | 137,127 | 190,055 | 219,537 |
| General & administrative expenses | 2,747,472 | 2,865,365 | 2,773,898 |
| Interest expense | 27,798 | 75,137 | 133,553 |
| Total expenses | 1,771,015 | 2,164,890 | 2,158,924 |
| Earnings (loss) before income taxes | 376,996 | 857,289 | 1,847,714 |
| Current federal income taxes provision (benefit) | (169,886) | 196,238 | 892 |
| Current state income taxes provision (benefit) | 66,629 | 32,187 | 49,948 |
| Current income taxes provision (benefit) | (103,257) | 228,425 | 50,840 |
| Deferred federal income taxes provision (benefit) | ... | (67,153) | 274,403 |
| Deferred income taxes provision (benefit) | (29,971) | ... | ... |
| Provision (benefit) for income taxes | (133,228) | 161,272 | 325,243 |
| Net earnings (loss) | 510,224 | 696,017 | 1,522,471 |

| | | |
|--|------------|------------|
| Fixed maturities | 30,752,721 | 33,156,912 |
| Equity securities | 5,431,268 | 8,727,631 |
| Short-term investments | ... | 4,953,738 |
| Cash & cash equivalents | 1,094,204 | 1,841,655 |
| Accrued interest & dividend receivable | 381,108 | 320,364 |
| Premiums receivable, gross | 78,419 | 51,130 |
| Less: allowance for doubtful accounts | 8,039 | 10,000 |
| Premiums receivable, net | 70,380 | 41,130 |
| Reinsurance recoveries on unpaid losses & loss adjustment expenses | 210,816 | 260,946 |
| Prepaid expenses and other assets | 137,762 | ... |
| Prepaid expenses | ... | 122,438 |
| Income taxes receivable | ... | 100,320 |
| Building | 4,275,535 | 4,275,535 |
| Land | 562,397 | 562,397 |
| Equipment & automobiles | 6,663,687 | 1,099,752 |
| Furniture & office fixtures | ... | 661,533 |
| Equip/Vehicles | 1,214,784 | ... |
| Furniture and office fixtures | 558,243 | ... |
| In-process | 52,728 | ... |
| Property & equipment, at cost | ... | 6,599,217 |
| Less: accumulated depreciation | 2,628,199 | 2,275,725 |
| Property & equipment, net | 4,035,488 | 4,323,492 |
| Deferred policy acquisition costs | 108,031 | 71,553 |
| Ceded unearned premiums | 74,094 | 60,584 |
| Net cash surrender value on officers' life insurance | ... | 1,799,796 |
| Other assets | ... | 40,768 |
| Intangibles | ... | 1,920,360 |
| Organization costs, net | 2,382,554 | ... |
| Short-term investments | 4,761,109 | ... |
| Deferred income taxes, net | 508,535 | ... |
| Intangibles | 1,920,360 | ... |
| Income taxes receivable | 255,541 | ... |
| Total assets | 52,123,971 | 57,741,687 |
| Reserves for losses & loss adjustment expenses | ... | 11,747,594 |

Amortized cost - Fixed maturities: \$31,523,992; Historical cost - Equity securities: \$8,332,126; Net of allowance - Net cash surrender value on officers' life insurance: \$48,451

Recent Dividends:

1. ACMAT Corp. class A common.
No dividends paid.

2. ACMAT Corp. common.
No dividends paid.

Annual Dividends:

1. ACMAT Corp. class A common.
No dividends paid.

2. ACMAT Corp. common.
No dividends paid.

ACRIVON THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

2023 2022 2021 (revised)

| | | | |
|--|----------|----------|----------|
| Research & development expenses | 46,024 | 23,949 | 13,718 |
| General & administrative expenses | 21,079 | 8,708 | 2,466 |
| Total operating expenses | 67,103 | 32,657 | 16,184 |
| Income (loss) from operations | (67,103) | (32,657) | (16,184) |
| Other income, net | 6,715 | 1,490 | 21 |
| Change in fair value of preferred stock tranche rights | ... | ... | (50) |
| Change in fair value of anti-dilution right | ... | ... | (30) |
| Net Income before Tax | (60,388) | ... | ... |
| Total other income (expense), net | ... | 1,490 | (59) |
| Net income (loss) | (60,388) | (31,167) | (16,243) |
| Weighted average shares outstanding - basic | 22,078 | 4,122 | 1,743 |
| Weighted average shares outstanding - diluted | 22,078 | 4,122 | 1,743 |
| Year end shares outstanding | 22,523 | 21,920 | 1,770 |
| Net income (loss) per share - basic | \$(2.74) | \$(7.56) | \$(9.32) |
| Net income (loss) per share - diluted | \$(2.74) | \$(7.56) | \$(9.32) |

| | 2023 | 2022 | ¹ 2021 (revised) | 2021, and 2020 | 664 | ... |
|------------------------------------|------|-----------------|--------------------------------|---|----------|----------|
| Number of full time employees..... | 58 | ² 41 | ³ 39 | Trade receivables, net | ... | 3,034 |
| Number of part time employees..... | 3 | ² 3 | ³ 3 | Raw materials | 757 | 593 |
| Number of common stockholders..... | 7 | ² 21 | ... | Finished goods | 1,769 | 586 |
| Total number of employees..... | 61 | ... | ... | Inventories | 2,526 | 1,179 |
| | | | | Prepaid expenses | 198 | 473 |
| | | | | Governmental authorities | 84 | 130 |
| | | | | Accrued income | 58 | 75 |
| | | | | Prepaid expenses & other current assets | 340 | 678 |
| | | | | Total current assets | 5,912 | 10,907 |
| | | | | Computer, software, & electronic equipment | 9,747 | 8,575 |
| | | | | Office furniture & equipment | 872 | 872 |
| | | | | Leasehold improvements | 292 | 292 |
| | | | | Computer Software & Equipment - Tangible Assets - Gross | 8,583 | ... |
| | | | | Property & equipment, gross | ... | 9,739 |
| | | | | Less: accumulated depreciation | 9,686 | 9,659 |
| | | | | Property & equipment, net | 61 | 80 |
| | | | | Prepaid expenses | 592 | 492 |
| | | | | Restricted cash | 3,330 | 336 |
| | | | | Restricted bank deposits | 94 | 2,027 |
| | | | | Severance pay fund | 238 | 239 |
| | | | | Operating lease right of use assets | 918 | 726 |
| | | | | Long term deposits | 78 | 12 |
| | | | | Total non-current assets | 5,311 | 3,912 |
| | | | | Total assets | 11,223 | 14,819 |
| | | | | Current maturities of long-term loans | 1,335 | 553 |
| | | | | Warrants | ... | 8 |
| | | | | Trade payables | 1,769 | 1,781 |
| | | | | Deferred revenues | 389 | 484 |
| | | | | Employee & employee-related obligations | 737 | 793 |
| | | | | Accrued royalties | ... | 900 |
| | | | | Operating lease liabilities | 498 | 445 |
| | | | | Accrued expenses | ... | 1,190 |
| | | | | Accrued standard warranty | 1,062 | 48 |
| | | | | Other current liabilities | 1,122 | 1,238 |
| | | | | Total current liabilities | 6,912 | 6,202 |
| | | | | Long-term loan, net of current maturities | 3,154 | 4,625 |
| | | | | Deferred revenues | 71 | 164 |
| | | | | Operating lease liabilities | 405 | 237 |
| | | | | Accrued severance | 270 | 278 |
| | | | | Other long-term liabilities | 23 | 48 |
| | | | | Total non-current liabilities | 3,923 | 5,352 |
| | | | | Total liabilities | 10,835 | 11,554 |
| | | | | Common stock | 1 | 1 |
| | | | | Additional paid-in capital | 39,916 | 36,666 |
| | | | | Retained earnings (accumulated deficit) | (39,688) | (33,402) |
| | | | | WARRANTS TO PLACEMENT AGENT | 159 | ... |
| | | | | Total shareholders' equity (capital deficiency) | 388 | 3,265 |
| | | | | Total Equity | 388 | ... |

Recent Dividends:**1. Acrivon Therapeutics Inc common.**

No dividends paid.

Annual Dividends:**1. Acrivon Therapeutics Inc common.**

No dividends paid.

ACTELIS NETWORKS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):****Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 |
|--|-------|-------|
| Cash & cash equivalents | 620 | 3,943 |
| Short-term deposits | 197 | 1,622 |
| Restricted bank deposits | 1,565 | 451 |
| Trade receivables, gross | 832 | 3,159 |
| Less: allowance for doubtful | 168 | 125 |
| Trade receivables, net of allowance for doubtful debts of \$61 as of 31, | | |

Recent Dividends:**1. Actelis Networks Inc common.**

No dividends paid.

Annual Dividends:**1. Actelis Networks Inc common.**

No dividends paid.

ADIAL PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | ¹ 2022 (revised) | 2021 |
|--|------|--------------------------------|------|
| | | | |

| | | | |
|---|--------------------|---------------------|---------------------|
| Research & development expense | 1,267,077 | 1,950,308 | 8,395,648 |
| General & administrative expense | 5,620,870 | 8,909,167 | 9,344,678 |
| Impairment expenses | ... | ... | 1,548,397 |
| Total operating expenses | 6,887,947 | 10,859,475 | 19,288,723 |
| Income (loss) from operations | (6,887,947) | (10,859,475) | (19,288,723) |
| Interest income | 69,779 | 63,338 | 6,539 |
| Change in value of contingent liability | ... | ... | (281,713) |
| Other income | 10,162 | ... | 46,494 |
| Loss on equity method investment | (193,884) | ... | ... |
| Total other income (expense) | (113,943) | 63,338 | (228,680) |
| Income (loss) before provision for income taxes | (7,001,890) | (10,796,137) | (19,517,403) |
| Deferred income tax expense (benefit) - federal | ... | ... | (39,545) |
| Deferred income tax expense (benefit) - state & local | ... | ... | (54,532) |
| Income tax expense (benefit) | ... | ... | (94,077) |
| Net income (loss) | (5,123,341) | (12,731,416) | (19,423,326) |
| Weighted average shares outstanding - basic | 1,424,661 | 1,001,505 | 743,550 |
| Weighted average shares outstanding - diluted | 1,424,661 | 1,001,505 | 743,550 |
| Year end shares outstanding | 1,663,421 | 1,067,492 | 1,837,868 |
| Net earnings (loss) per share - basic | \$(3.60) | \$(12.71) | \$(26.00) |
| Net earnings (loss) per share - diluted | \$(3.60) | \$(12.71) | \$(26.00) |
| Number of full time employees | 4 | ... | 16 |
| Number of part time employees | 3 | ... | 5 |
| Total number of employees | 7 | ... | 21 |
| Number of common stockholders | 99 | ... | 186 |
| Income from continuing operations | (7,001,890) | (10,796,137) | ... |
| Discontinued operations | 1,878,549 | (1,935,279) | ... |
| Earnings per share - total discontinued opers | \$1.32 | \$(1.93) | ... |
| Earnings per share from continuing operations | \$(4.91) | \$(10.78) | ... |
| Earning per share - total discount opers - diluted | \$1.32 | \$(1.93) | ... |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(4.91) | \$(10.78) | ... |

⊠ Restated to reflect discontinued operations; ⊡ Shares increased due to the effect of issuance for stock-based compensation, options and warrant exercised, issuance in consideration of purchase of subsidiary and sale of common stock; ⊢ Approximately; ⊣ As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--------------------------------|-----------|-----------|
| | 2023 | 2022 |
| Cash & cash equivalents | 2,827,082 | 4,001,794 |
| Prepaid research & development | 371,597 | 428,700 |
| Prepaid expenses & other | ... | ... |

| | |
|--|--------------|
| current assets | 349,441 |
| Total current assets | 3,198,679 |
| Fixed assets, net | 50,424 |
| Intangible assets, net | 3,913 |
| Acquired in-process research & development | 455,000 |
| Right-to-use asset | 193,997 |
| Goodwill | 248,971 |
| Equity method investment | 1,534,013 |
| Total assets | 4,736,605 |
| Accounts payable | 103,325 |
| Accounts payable & accrued expenses | 24,062 |
| Accrued clinical research organization services & expenses | 477,747 |
| Accrued employee compensation | 421,365 |
| Pre-clinical & manufacturing expenses | 50,566 |
| Accrued legal & consulting services | 5,816 |
| Accrued expenses | 1,154,817 |
| Accrued expenses, related party | 47,942 |
| Lease liability, current | 56,828 |
| Other current liabilities | 10,387 |
| Total current liabilities | 653,076 |
| Contingent liabilities | 492,000 |
| Lease liability, non-current | 150,547 |
| Deferred tax liability | 22,897 |
| Total liabilities | 2,456,310 |
| Common stock | 1,663 |
| Additional paid in capital | 72,879,738 |
| Accumulated deficit | (68,797,872) |
| Retained earnings (accumulated deficit) | (63,674,531) |
| Total stockholders' equity (deficit) | 4,083,529 |
| Total Equity | 4,083,529 |

Recent Dividends:
1. ADial Pharmaceuticals Inc common.
 No dividends paid.
Annual Dividends:
1. ADial Pharmaceuticals Inc common.
 No dividends paid.

ADVANCED VOICE RECOGNITION SYSTEMS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|------------------|-----------------|-----------------|
| | 2023 | 2022 | 2021 |
| Contributed services | 72,241 | ... | ... |
| Compensation | 270,003 | 3,957 | 3,011 |
| Professional fees | ... | 32,288 | 52,765 |
| Office | 4,305 | 8,687 | 23,288 |
| Other operating expenses | 7,631 | 1,703 | 2,053 |
| Depreciation | 123 | ... | ... |
| Total operating expenses | 354,303 | 46,635 | 81,117 |
| Income (loss) from operations | (354,303) | (46,635) | (81,117) |
| Interest expense | 7,019 | 1,954 | 2,264 |
| Gain on early ext of debt | 50,445 | ... | ... |
| Net other income (expense) | 43,426 | (1,954) | (2,264) |
| Income (loss) before income taxes | (310,877) | (48,589) | (83,381) |
| Net income (loss) | (310,877) | (48,589) | (83,381) |
| Weighted average shares outstanding - basic | 5,475,587 | 2,870,547 | 2,815,371 |
| Weighted average shares outstanding - diluted | 5,475,587 | 2,870,547 | 2,815,371 |
| Year end shares outstanding | 5,476,685 | 2,849,203 | 2,845,869 |
| Net income (loss) | ... | ... | ... |

| | | | |
|---------------------------------------|-----|-----|--------|
| per share - basic | ... | ... | \$0.00 |
| Net income (loss) per share - diluted | ... | ... | \$0.00 |
| Full-Time Employees (Period End) | 3 | ... | ... |
| Total number of employees | 3 | 2 | 2 |
| Number of common stockholders | 77 | 76 | 76 |

⊠ Adjusted for 1-for-100 stock split, August 22, 2023; ⊡ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2022 |
| Cash | 480 | ... |
| Cash & cash equivalents | ... | 138 |
| Total current assets | 480 | 138 |
| Computer Software & Equipment - Tangible Assets - Accumulated Depreciation & Impairment | 123 | ... |
| Computer equipment | 929 | ... |
| Computer Software & Equipment - Tangible Assets - Gross | 1,052 | ... |
| Total assets | 1,409 | 138 |
| Accounts payable | ... | 101,778 |
| Payroll | 219,677 | 162,380 |
| Note payable AIP | 111,000 | 19,935 |
| Note payable related party | 123,500 | ... |
| Advance related party | 12,500 | 44,188 |
| Accrued interest | 7,019 | 15,450 |
| Total current liabilities | 350,196 | 343,731 |
| Total liabilities | 350,196 | 343,731 |
| Common stock | 5,477 | 284,920 |
| Escrow shares | ... | 262,580 |
| Additional paid-in capital | 8,588,626 | 7,740,920 |
| Accumulated Deficit | (8,942,890) | ... |
| Retained earnings (accumulated deficit) | ... | (8,632,013) |
| Total stockholders' equity (deficit) | (348,787) | (343,593) |
| Total Equity | (348,787) | ... |

Recent Dividends:
1. Advanced Voice Recognition Systems Inc common.
 No dividends paid.
Annual Dividends:
1. Advanced Voice Recognition Systems Inc common.
 No dividends paid.

AEHR TEST SYSTEMS
Earnings, 9 mos. to (Consol. - \$000):

| | | |
|-----------------------------|--------------|--------------|
| | 02/29/24 | 02/28/23 |
| Total revenues | 49,618 | ... |
| Net Sales | ... | 42,692 |
| Cost & expenses | 42,081 | 34,956 |
| Operating income | 7,537 | 7,736 |
| Interest expense | (1,796) | ... |
| Other income (expense), net | 2 | 1 |
| Net before taxes | 9,335 | 8,495 |
| Income taxes | 43 | 49 |
| Net income | 9,292 | 8,446 |
| Earnings common share | ... | ... |
| Primary | \$0.32 | \$0.31 |
| Fully Diluted | \$0.31 | \$0.29 |
| Common Shares: | ... | ... |
| Full Diluted | 29,670 | 29,080 |
| Year-end | 28,906 | 28,320 |

AEMETIS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---------------------|-------------|-------------|-------------|
| | 2023 | 2022 | 2021 |
| Revenues | 186,717,000 | 256,513,000 | 211,949,000 |
| Sales | 186,717,000 | ... | ... |
| Cost of goods sold | 184,700,000 | 262,048,000 | 204,010,000 |
| Gross profit (loss) | 2,017,000 | (5,535,000) | 7,939,000 |
| Research & | ... | ... | ... |

| | | | | | | | |
|--|---------------------|----------------------|-------------------------|--|---------------|---------------------------|---|
| development expenses | 152,000 | 180,000 | 88,000 | Cash & cash equivalents | 2,667,000 | ¹ 4,313,000 | ties - Prepaid expenses: \$858,000; ² Including Variable Interest Entities - Other current assets: \$725,000; ³ Including Variable Interest Entities - Property, plant & equipment: \$71,633,000; ⁴ Including Variable Interest Entities - Operating lease right-of-use assets: \$224,000; ⁵ Including Variable Interest Entities - Other assets: \$3,458,000; ⁶ Including Variable Interest Entities - Accounts payable: \$9,192,000; ⁷ Including Variable Interest Entities - Short term borrowings: \$19,831,000; ⁸ Including Variable Interest Entities - Current portion of operating lease liability: \$41,000; ⁹ Including Variable Interest Entities - Other current liabilities: \$645,000; ¹⁰ Including Variable Interest Entities - other long term debt: \$31,000; ¹¹ Including Variable Interest Entities - Series A preferred units: \$116,000,000; ¹² Including Variable Interest Entities - Operating lease liability: \$115,000 |
| Selling, general & administrative expenses | 39,266,000 | 28,686,000 | 23,676,000 | Accounts receivable, gross | ... | 1,264,000 | |
| Operating income (loss) | (37,401,000) | (34,401,000) | (15,825,000) | Less allowance | ... | 0 | |
| Interest rate expense | 32,995,000 | 21,407,000 | 20,136,000 | Accounts receivable | 8,633,000 | ² 1,264,000 | |
| Debt related fees & amortization expense | 6,524,000 | 7,363,000 | 3,921,000 | Raw materials | 9,907,000 | 2,971,000 | |
| Accretion & other expenses of series A preferred units | ... | 9,888,000 | 7,718,000 | Work-in-progress | 1,682,000 | 127,000 | |
| Gain (loss) on debt extinguishment | ... | (49,386,000) | 1,134,000 | Finished goods | 6,702,000 | 1,560,000 | |
| Gain (loss) on litigation | (25,313,000) | 1,400,000 | ... | Inventories | 18,291,000 | ³ 4,658,000 | |
| Other income (expense) | 2,077,000 | 14,340,000 | (809,000) | Prepaid expenses | 3,347,000 | ⁴ 4,248,000 | |
| Income (loss) before income taxes - United States | ... | (112,959,000) | (45,723,000) | Other current assets | 3,462,000 | ⁵ 3,653,000 | |
| Income (loss) before income taxes - foreign | ... | 6,254,000 | (1,552,000) | Total current assets | 36,400,000 | 18,136,000 | |
| Income (loss) before income taxes | (100,156,000) | (106,705,000) | (47,275,000) | Land | ... | 7,344,000 | |
| Current federal income tax expense (benefit) | (55,164,000) | ... | ... | Buildings | 136,318,000 | ... | |
| Current state & local income tax expense (benefit) | ... | 13,000 | 11,000 | Plant & buildings | ... | 99,116,000 | |
| Current foreign income tax expense (benefit) | 1,489,000 | 230,000 | ... | Furniture & fixtures | ... | 1,831,000 | |
| State and local | 13,000 | ... | ... | Machinery & equipment | 14,982,000 | 15,209,000 | |
| Total current income tax expense (benefit) | (53,662,000) | 243,000 | 11,000 | Leasehold & tenant improvements | 7,345,000 | ... | |
| Deferred foreign income tax expense (benefit) | (74,000) | 810,000 | (139,000) | Tenant improvements | ... | 56,000 | |
| Deferred Tax - Total | (74,000) | ... | ... | Construction in progress | 73,057,000 | 88,934,000 | |
| Income tax expense (benefit) | (53,736,000) | 1,053,000 | (128,000) | GAFI property, plant & equipment | 2,266,000 | ... | |
| Net income (loss) | (46,420,000) | (107,758,000) | (47,147,000) | Property held for development | 15,431,000 | 15,437,000 | |
| Weighted average shares outstanding - basic | 38,061,000 | 34,585,000 | 30,682,000 | Finance lease right of use assets | 2,889,000 | 3,045,000 | |
| Weighted average shares outstanding - diluted | 38,061,000 | 34,585,000 | 30,682,000 | Total gross property, plant & equipment | 252,288,000 | 230,972,000 | |
| Year end shares outstanding | 40,966,000 | 35,869,000 | ¹ 33,461,000 | Less accumulated depreciation | 57,180,000 | 50,531,000 | |
| Net income (loss) per share - basic | \$(1.22) | \$(3.12) | \$(1.54) | Property, plant & equipment, net | 195,108,000 | ² 180,441,000 | |
| Net income (loss) per share - diluted | \$(1.22) | \$(3.12) | \$(1.54) | Operating lease right-of-use assets | 2,056,000 | ³ 2,449,000 | |
| Number of full time employees | 205 | 168 | 158 | Other assets | 9,842,000 | ⁴ 6,088,000 | |
| Total number of employees | 205 | 168 | 158 | Total assets | 243,406,000 | 207,114,000 | |
| Number of common stockholders | 175 | ¹ 175 | ² 173 | Accounts payable | 32,132,000 | ⁵ 26,168,000 | |
| Foreign currency translation adjustments | ... | (1,102,000) | (236,000) | Current portion of long term debt | 13,585,000 | 12,465,000 | |
| Basic EPS Excluding ExtraOrdinary Items | \$(1.22) | ... | ... | Short term borrowings | 23,443,000 | ⁶ 36,754,000 | |
| Diluted EPS Excluding ExtraOrd Items | \$(1.22) | ... | ... | Mandatorily redeemable series B convertible preferred stock | 4,521,000 | 4,082,000 | |
| | | | | Accrued property taxes | ... | 1,206,000 | |
| | | | | Current portion of operating lease liability | 406,000 | ⁷ 338,000 | |
| | | | | Other current liabilities | 10,302,000 | ⁸ 7,268,000 | |
| | | | | Total current liabilities | 84,389,000 | 88,281,000 | |
| | | | | Senior secured notes & revolving notes | ... | 155,843,000 | |
| | | | | EB-5 notes | 51,717,000 | 29,500,000 | |
| | | | | Other long-term debt | 176,476,000 | ⁹ 11,678,000 | |
| | | | | Series A preferred units | 113,189,000 | ¹⁰ 116,000,000 | |
| | | | | Operating lease liability | 1,783,000 | ¹¹ 2,189,000 | |
| | | | | Other long term liabilities | 3,329,000 | 5,477,000 | |
| | | | | EB-5 notes payable | 29,500,000 | ... | |
| | | | | Total long term liabilities | 375,994,000 | 320,687,000 | |
| | | | | Series B convertible preferred stock | ... | 1,000 | |
| | | | | Common stock | 41,000 | 36,000 | |
| | | | | Additional paid-in capital | 264,058,000 | 232,546,000 | |
| | | | | Retained earnings (accumulated deficit) | (475,405,000) | (428,985,000) | |
| | | | | Accumulated other comprehensive income (loss) | (5,671,000) | (5,452,000) | |
| | | | | Total stockholders' equity (deficit) attributable to Aemetis, Inc. | (216,977,000) | (201,854,000) | |
| | | | | Total stockholders' equity (deficit) | (216,977,000) | (201,854,000) | |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of common stock issued, stock options and warrant exercised, and series B conversion to common stock; ³ As of March 1, 2023; ⁴ As of February 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
2023 2022

¹ Including Variable Interest Entities - Cash & cash equivalents: \$165,000; ² Including Variable Interest Entities - Accounts receivable: \$165,000; ³ Net of allowance for excess & obsolete inventory - inventories: \$1,040,000; ⁴ Including Variable Interest Entities

Recent Dividends:

1. Aemetis Inc common.

No dividends paid.

2. Aemetis Inc series B convertible preferred.

No dividends paid.

Annual Dividends:

1. Aemetis Inc common.

No dividends paid.

2. Aemetis Inc series B convertible preferred.

No dividends paid.

AEYE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| | | | (revised) |
| Cost of revenue | 15,319,000 | ... | ... |
| Prototype sales | 477,000 | 1,743,000 | 1,004,000 |
| Development contracts | 987,000 | 1,904,000 | 2,003,000 |
| Total revenue | 1,464,000 | 3,647,000 | 3,007,000 |
| Cost of revenue | 15,319,000 | 8,732,000 | 3,637,000 |
| Gross profit (loss) | (13,855,000) | (5,085,000) | (630,000) |
| Research & development | 26,171,000 | 37,644,000 | 26,543,000 |
| Sales & marketing | 12,528,000 | 19,317,000 | 10,548,000 |
| General & administrative | 25,234,000 | 36,762,000 | 25,514,000 |
| Impairment of long lived assets | 9,988,000 | ... | ... |
| Total operating expenses | 73,921,000 | 93,723,000 | 62,605,000 |
| Income (loss) from operations | (87,776,000) | (98,808,000) | (63,235,000) |
| Change in fair value of convertible note, embedded derivative liability & warrant liabilities | (858,000) | (14,000) | 223,000 |
| Gain on Paycheck Protection Program loan forgiveness | ... | ... | 2,297,000 |
| Interest income & other income | 1,317,000 | 1,545,000 | 561,000 |
| Interest on term loan debt | ... | ... | 630,000 |
| Interest on PPP loan | ... | ... | 11,000 |
| Interest on convertible note | ... | ... | 700,000 |
| Amortization of debt issuance costs | ... | ... | 725,000 |
| 2022 convertible note issuance costs | ... | 474,000 | ... |
| Amortization of debt discount | ... | ... | 752,000 |
| Amortization of debt premiums on marketable securities, net | ... | 778,000 | 456,000 |
| Realized losses on redemptions of marketable securities | ... | (77,000) | ... |
| Common stock purchase agreement costs | ... | 29,000 | 1,583,000 |
| Other interest | ... | ... | ... |

| | | | |
|--|---------------------|---------------------|---------------------|
| expense & other | 21,000 | | |
| Interest expense & other | (248,000) | 1,379,000 | 4,857,000 |
| Total other income (expense), net | 707,000 | 152,000 | (1,776,000) |
| Provision for income tax expense | 57,000 | 58,000 | |
| Net income (loss) attributable to common shares | (87,126,000) | (98,714,000) | (65,011,000) |
| Weighted average shares outstanding | | | |
| - basic | 5,827,721 | 5,245,624 | 3,635,196 |
| Weighted average shares outstanding - diluted | 5,827,721 | 5,245,624 | 3,635,196 |
| Year end shares outstanding | 6,310,090 | 5,436,637 | 5,171,241 |
| Net earnings (loss) per common share - basic | \$(14.95) | \$(18.90) | \$(18.00) |
| Net earnings (loss) per common share - diluted | \$(14.95) | \$(18.90) | \$(18.00) |
| Full-Time Employees (Period End) | 60 | | |
| Total number of employees | 60 | 160 | 100 |
| Number of common stockholders | | 75 | 160 |

Adjusted for 1-for-30 stock split, December 27, 2023; As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-------------|
| Cash & cash equivalents | 16,932,000 | 19,064,000 |
| Marketable securities | 19,591,000 | 75,135,000 |
| Accounts receivable, net | 131,000 | 617,000 |
| Raw materials | 405,000 | 2,022,000 |
| Work in-process | 159,000 | 2,484,000 |
| Finished goods | 19,000 | 47,000 |
| Inventories, net | 583,000 | 4,553,000 |
| Prepaid expenses | 2,386,000 | 4,203,000 |
| Demonstration units | | 281,000 |
| Advances to suppliers | 79,000 | 984,000 |
| Other prepaid & other current assets | | 713,000 |
| Prepaid & other current assets | 2,517,000 | 6,181,000 |
| Other Current Assets | 52,000 | |
| Total current assets | 39,754,000 | 105,550,000 |
| Right-of-use assets | 11,226,000 | 15,502,000 |
| Machinery & equipment | 171,000 | 2,528,000 |
| Computers, software & related equipment | 281,000 | 432,000 |
| Office furniture & equipment | 24,000 | 651,000 |
| Vehicles | 60,000 | 846,000 |
| Leasehold improvements | | 4,830,000 |
| Construction in progress | | 1,401,000 |
| Computers and related equipment | 26,000 | |
| Total property & equipment | | 10,688,000 |
| Less accumulated depreciation & amortization | | 3,023,000 |
| Property & equipment, net | 281,000 | 7,665,000 |
| Restricted cash | 2,150,000 | 2,150,000 |
| Non-current inventory | 208,000 | 1,491,000 |
| Security deposits | 72,000 | 901,000 |
| Long-term prepaid expenses | 626,000 | 81,000 |
| Other noncurrent assets | 906,000 | 2,473,000 |
| Total assets | 54,317,000 | 133,340,000 |
| Accounts payable | 3,442,000 | 3,218,000 |
| Accrued purchases & other current liabilities | | 4,092,000 |
| Operating lease liabilities - current | 2,415,000 | 2,455,000 |

| | | |
|---|---------------|---------------|
| Accrued bonuses | 2,053,000 | 1,022,000 |
| Accrued payroll | 540,000 | 1,148,000 |
| Warranty reserve | | 526,000 |
| Accrued payroll taxes | | 480,000 |
| Income tax payable | | 41,000 |
| Accrued expenses & other current liabilities | 783,000 | 9,764,000 |
| Contract liabilities | | 987,000 |
| Convertible notes | | 8,594,000 |
| Franchise tax payable | 317,000 | |
| Income tax payable | 75,000 | |
| Accrued expenses and other current liabilities | | |
| - Balancing value | 6,585,000 | |
| Accrued severance | 402,000 | |
| Total current liabilities | 10,027,000 | 22,563,000 |
| Operating lease liabilities, noncurrent | 14,858,000 | 16,681,000 |
| Other noncurrent liabilities | 409,000 | 126,000 |
| Total liabilities | 25,294,000 | 39,370,000 |
| Common stock | 1,000 | 16,000 |
| Additional paid in capital | 366,647,000 | 345,742,000 |
| Unrealized gains (losses) on available-for-sale securities | | (1,254,000) |
| Change in fair value due to instrument-specific credit risk | | (25,000) |
| Accumulated other comprehensive income (loss) | 10,000 | (1,279,000) |
| Retained earnings (accumulated deficit) | (337,635,000) | (250,509,000) |
| Total stockholders' equity | 29,023,000 | 93,970,000 |
| Total Equity | 29,023,000 | |

Recent Dividends:

- 1. AEye Inc common.**
No dividends paid.
 - 2. AEye Inc class A common.**
No dividends paid.
 - 3. AEye Inc class B common.**
No dividends paid.
- Annual Dividends:**
- 1. AEye Inc common.**
No dividends paid.
 - 2. AEye Inc class A common.**
No dividends paid.
 - 3. AEye Inc class B common.**
No dividends paid.

AGAPE ATP CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|----------------|
| Revenue | 1,431,088 | | |
| Revenue | 1,431,088 | 1,856,564 | 1,016,962 |
| Cost of revenue | 494,516 | 666,042 | 297,333 |
| Gross profit | 936,572 | 1,190,522 | 719,629 |
| Selling expenses | | 361,414 | 394,682 |
| Commission expenses | | 405,351 | 316,267 |
| General & administrative expenses | 2,366,016 | 1,957,023 | 1,745,734 |
| Provision for doubtful accounts | | | 121,514 |
| Commission | 88,132 | | |
| Selling | 629,003 | | |
| Total operating expenses | | 2,723,788 | 2,578,197 |
| Income (loss) from operations | (2,146,579) | (1,533,266) | (1,858,568) |
| Other income (expenses), net | 5,724 | (79,539) | (68,323) |
| Interest income | 29,249 | 16,190 | 25,570 |
| Unrealized holding gain (loss) on marketable securities | | (73,519) | (505,231) |
| Dividend income | | | |

| | | | |
|---|--------------------|--------------------|--------------------|
| from marketable securities | | | 18,939 |
| Gain on deemed disposal of shares in investee company | 3,493 | | |
| Gain on disposal of PPE | 1,753 | | |
| Total other income (expenses), net | 40,219 | (136,868) | (529,045) |
| Income (loss) before income taxes | | | |
| - United States | | (736,946) | (706,659) |
| Income (loss) before income taxes - Malaysia | | (864,794) | (1,064,314) |
| Income (loss) before income taxes - Hong Kong | | (68,394) | (616,640) |
| Income (loss) before income taxes | (2,106,360) | (1,670,134) | (2,387,613) |
| Current local income taxes | | | 22,205 |
| Current foreign income taxes (benefit) | 3,795 | 10,962 | 104,735 |
| Deferred foreign income taxes | (220) | (15,017) | 10,127 |
| Provision for (benefit of) income taxes | 3,575 | (4,055) | 137,067 |
| Net income (loss) | (2,109,935) | (1,666,079) | (2,524,680) |
| Net income (loss) attributable to non-controlling interests | 7,950 | (20,820) | 436 |
| Net income (loss) attributable to Agape ATP Corporation | (2,101,985) | (1,686,899) | (2,524,244) |
| Weighted average shares outstanding - basic | 75,814,507 | 87,822,337 | 376,216,452 |
| Weighted average shares outstanding - diluted | 75,814,507 | 87,822,337 | 376,216,452 |
| Year end shares outstanding | 76,966,712 | 75,452,012 | 290,460,047 |
| Net earnings (loss) per share - basic | \$(0.03) | \$(0.02) | \$(0.01) |
| Net earnings (loss) per share - diluted | \$(0.03) | \$(0.02) | \$(0.01) |
| Full-Time Employees (Period End) | 21 | | |
| Total number of employees | 21 | 30 | 36 |
| Number of common stockholders | 1,359 | 1,296 | 1,220 |
| EPS - Basic - excluding Extraordinary Items | | | |
| Applicable to Common - Total | \$(0.03) | | |
| EPS - Diluted - excluding Extraordinary Items | | | |
| Applicable to Common - Total | \$(0.03) | | |

Reclassified to conform with 2022 presentation; Shares decreased due to the effect of forfeiture of common stock

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Time deposits | 4,322,441 | |
| Cash in bank | 494,771 | |
| Cash and cash equivalents - Balancing value | 15,248 | |
| Cash & cash equivalents | 4,832,460 | 1,438,430 |
| Accounts receivable | 55,458 | 2,826 |
| Allowance for credit losses | 542 | |
| Accounts receivable - related party - Balancing value | 56,000 | |

| Amount due from related parties | ... | 10,534 | | | | Other prepaid expenses & other current assets | ... | 775,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---------------------|---------------------|---------------------|--|--|---|---------------|---------------|--|--|------|------|-------|---------------------|------------|-----|-----------|---------------------|------------|------------|-----------|--------------------------------|-----------|-----------|------------|--------------------|------------|-----------|-------------|------------------------------|-----------|-----------|-----------|---------------------------|------------|------------|------------|--------------------------------|------------|------------|------------|--|-----|--------------|-----|--------------------------------|------------|------------|------------|-------------------------------------|--------------|--------------|--------------|-----------------------|--------|--------|--------|------------------------|-----------|-----------|-----------|--|-----------|------------|-----------|---|-----------|------------|----------|---|--------------|--------------|--------------|---|-----|-------------|-----|--------------------------------|---------------------|---------------------|---------------------|---|-----------|----------|---------|---|-----------|----------|---------|-----------------------------------|-----------|----------|---------|---|----------|------------|---------------|---|----------|------------|---------------|-------------------------------------|----|----|-----|-------------------------------------|----|-----|-----|---------------------------------|----|-----|-----|--|------|------|-------------------------------|-----------|-----------|--------------------------------|-----------|-----------|-----------------|-----------|-----|----------------------|-----|-----------|-------------------------|---------|---------|--|------|------|------|---------------|--------|--------|-----|--------------------|--------|--------|--------|--------------------------|--------|--------|--------|---------------------------|-------|----------|-------|------------------------------|-------|-------|-------|-----------------------------|-------|-------|-----|----------------------------------|--------|--------|-----|---|-----|-----|--------|--|---------|---------|-------|--|-----|--------|-----|--|-----|-------|-----|--|-------|-----|-----|--------------------------------|--------|---------|--------|
| Finished goods | 47,907 | 46,277 | | | | Other | 402,000 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Inventories | 47,907 | 46,277 | | | | Total current assets | 9,530,000 | 11,358,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepaid taxes | 21,993 | 339,367 | | | | Office equipment | 132,000 | 132,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepaid expenses | 215,806 | ... | | | | Computer equipment | 121,000 | 121,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Receivables from sales distributors | 11,093 | 43,596 | | | | Property & equipment, gross | 253,000 | 253,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Deposits to suppliers | 91,997 | 147,504 | | | | Less: accumulated depreciation | 178,000 | 76,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepayments & deposits subtotal | ... | 191,100 | | | | Property & equipment, net | 75,000 | 177,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepayments - Short-Term | 123,809 | ... | | | | Right of use asset | 412,000 | 695,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepayments & deposits | ... | 191,100 | | | | Other non-current assets | 238,000 | 2,012,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Receivables - Other - Net | 435 | ... | | | | Total assets | 10,255,000 | 14,242,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total current assets | 5,185,152 | 2,028,534 | | | | Long-term debt, current portion | 1,515,000 | 1,426,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Computer & office equipment | 91,947 | 87,428 | | | | Accounts payable | 9,574,000 | 7,734,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Furniture & fixtures | 111,164 | 115,789 | | | | Gross to net accruals | 6,492,000 | 2,332,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Leasehold improvements | 184,155 | 191,965 | | | | Accrued compensation | 832,000 | 833,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Vehicle | 89,729 | 93,535 | | | | Accrued professional fees & other accrued liabilities | ... | 743,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Property & equipment subtotal | 476,995 | 488,717 | | | | Accrued professional fees and other | 1,807,000 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Less: accumulated depreciation | 399,137 | 346,568 | | | | Accrued expenses | 9,131,000 | 3,908,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Property & equipment, net | 77,858 | 142,149 | | | | Lease liability, current portion | 366,000 | 319,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Intangible assets, net | 17,458 | 24,044 | | | | Loan payable, current portion | 191,000 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Operating right-of-use assets | 357,301 | 81,133 | | | | Total current liabilities | 20,777,000 | 13,387,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Investment in marketable securities | 20,171 | 16,687 | | | | Lease liabilities, long-term | 100,000 | 466,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Deferred offering costs | ... | 499,202 | | | | Warrant liability | 5,696,000 | 5,934,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Deferred tax assets | 219 | ... | | | | Total liabilities | 26,573,000 | 19,787,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Finance lease assets | 86,335 | ... | | | | Common stock | 4,000 | 4,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total other assets | 559,342 | 763,215 | | | | Additional paid-in capital | 406,846,000 | 403,153,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total assets | 5,744,494 | 2,791,749 | | | | Retained earnings (accumulated deficit) | (423,168,000) | (408,702,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accounts payable | 55,585 | 28,833 | | | | Total stockholders' equity (deficit) | (16,318,000) | (5,545,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accounts payable - related parties | 34,848 | 25,611 | | | | Total Equity | (16,318,000) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Customer deposits | 101,575 | 363,018 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Operating lease liabilities | 138,548 | 82,708 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Professional fees | 348,664 | 324,629 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Promotion expenses | 726,061 | 38,583 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Payroll | 26,104 | 21,164 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Amounts held in ewallets | 185,137 | 216,049 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Tax penalty | ... | 75,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other payables & accrued liabilities | ... | 37,852 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other payables & accrued liabilities | 75,000 | 713,277 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other payable - related parties | 7,846 | 4,880 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Income tax payable | ... | 10,968 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Amounts due to a related party | 43,161 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Finance lease liabilities, current | 7,075 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Promotion expenses | 47,995 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total current liabilities | 1,071,538 | 1,229,295 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Operating lease liabilities | 219,530 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Capitalized Lease Obligations - Long-Term | 72,563 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total non-current liabilities | 292,093 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total liabilities | 1,363,631 | 1,229,295 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Common stock | 7,711 | 7,545 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Additional paid in capital | 11,378,743 | 6,470,716 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accumulated deficit | (7,047,571) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Retained earnings (accumulated deficit) | ... | (4,945,586) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accumulated other comprehensive income (losses) | 30,215 | 9,266 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Treasury Stock, par value \$0.0001; 135,300 and 0 shares as of 31, 2023 and 2022, respectively | 14 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total Agape Corporation stockholders' equity | 4,369,084 | 1,541,941 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Non-controlling interests | 11,779 | 20,513 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total equity | 4,380,863 | 1,562,454 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>□ Including consolidated variable interest entities - cash & cash equivalents: \$1,609; □ Including consolidated variable interest entities - prepaid taxes: \$1,741; □ Including consolidated variable interest entities - other payables & accrued liabilities: \$1,090</p> <p>Recent Dividends: 1. Agape ATP Corp common. No dividends paid. Annual Dividends: 1. Agape ATP Corp common. No dividends paid.</p> <p>AGILE THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> <th>□2021</th> </tr> </thead> <tbody> <tr> <td>Revenues, net</td> <td>19,593,000</td> <td>...</td> <td>(revised)</td> </tr> <tr> <td>Revenues, net</td> <td>19,593,000</td> <td>10,884,000</td> <td>4,101,000</td> </tr> <tr> <td>Cost of product revenues</td> <td>8,978,000</td> <td>6,836,000</td> <td>10,718,000</td> </tr> <tr> <td>Gross profit</td> <td>10,615,000</td> <td>4,048,000</td> <td>(6,617,000)</td> </tr> <tr> <td>Research & development</td> <td>2,225,000</td> <td>3,253,000</td> <td>6,246,000</td> </tr> <tr> <td>Selling & marketing</td> <td>17,769,000</td> <td>30,369,000</td> <td>43,444,000</td> </tr> <tr> <td>General & administrative</td> <td>10,505,000</td> <td>11,860,000</td> <td>14,698,000</td> </tr> <tr> <td>Gain (loss) on disposition of assets</td> <td>...</td> <td>(11,122,000)</td> <td>...</td> </tr> <tr> <td>Total operating expenses</td> <td>30,499,000</td> <td>56,604,000</td> <td>64,388,000</td> </tr> <tr> <td>Income (loss) from operations</td> <td>(19,884,000)</td> <td>(52,556,000)</td> <td>(71,005,000)</td> </tr> <tr> <td>Interest income</td> <td>78,000</td> <td>80,000</td> <td>25,000</td> </tr> <tr> <td>Interest expense</td> <td>1,419,000</td> <td>3,131,000</td> <td>3,914,000</td> </tr> <tr> <td>Unrealized gain on warrant liability</td> <td>6,760,000</td> <td>25,520,000</td> <td>3,827,000</td> </tr> <tr> <td>Total other income (expense), net</td> <td>5,419,000</td> <td>22,469,000</td> <td>(62,000)</td> </tr> <tr> <td>Income (loss) from provision (benefit) income taxes</td> <td>(14,465,000)</td> <td>(30,087,000)</td> <td>(71,067,000)</td> </tr> <tr> <td>Provision (benefit) from income taxes</td> <td>...</td> <td>(4,675,000)</td> <td>...</td> </tr> <tr> <td>Net income (loss)</td> <td>(14,465,000)</td> <td>(25,412,000)</td> <td>(71,067,000)</td> </tr> <tr> <td>Weighted average shares outstanding - basic</td> <td>2,156,726</td> <td>□432,219</td> <td>□48,536</td> </tr> <tr> <td>Weighted average shares outstanding - diluted</td> <td>2,156,726</td> <td>□432,219</td> <td>□48,536</td> </tr> <tr> <td>Year end shares outstanding</td> <td>2,963,657</td> <td>□859,403</td> <td>□60,698</td> </tr> <tr> <td>Net earnings (loss) per share - basic</td> <td>\$(6.71)</td> <td>□\$(59.00)</td> <td>□\$(1,464.00)</td> </tr> <tr> <td>Net earnings (loss) per share - diluted</td> <td>\$(6.71)</td> <td>□\$(59.00)</td> <td>□\$(1,464.00)</td> </tr> <tr> <td>Number of full time employees</td> <td>19</td> <td>22</td> <td>...</td> </tr> <tr> <td>Number of common stockholders</td> <td>13</td> <td>□11</td> <td>...</td> </tr> <tr> <td>Total number of employees</td> <td>19</td> <td>...</td> <td>...</td> </tr> </tbody> </table> <p>□ Restated to reflect the Company concluded that it incorrectly classified certain warrants; □ Adjusted for 1-for-50 stock split, April 11, 2023; □ Adjusted for 1-for-40 stock split, April 26, 2022; □ Shares increased due to issuance of shares pursuant to at-the-market stock sales, in public offering and upon exercise of stock options and vesting of restricted stock units; □ As of March 14, 2023</p> <p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> </tr> </thead> <tbody> <tr> <td>Cash & cash equivalents</td> <td>2,557,000</td> <td>5,246,000</td> </tr> <tr> <td>Accounts receivable, net</td> <td>3,392,000</td> <td>3,377,000</td> </tr> <tr> <td>Inventory</td> <td>2,738,000</td> <td>...</td> </tr> <tr> <td>Inventory, net</td> <td>...</td> <td>1,332,000</td> </tr> <tr> <td>Prepaid insurance</td> <td>441,000</td> <td>628,000</td> </tr> </tbody> </table> <p>AGRIFY CORP Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):</p> <table border="1"> <thead> <tr> <th></th> <th>2023</th> <th>2022</th> <th>2021</th> </tr> </thead> <tbody> <tr> <td>Revenue</td> <td>16,868</td> <td>58,259</td> <td>...</td> </tr> <tr> <td>Revenue, net</td> <td>16,868</td> <td>58,259</td> <td>59,859</td> </tr> <tr> <td>Cost of goods sold</td> <td>11,590</td> <td>90,054</td> <td>54,625</td> </tr> <tr> <td>Gross profit (loss)</td> <td>5,278</td> <td>(31,795)</td> <td>5,234</td> </tr> <tr> <td>Research & development</td> <td>2,295</td> <td>8,179</td> <td>3,925</td> </tr> <tr> <td>Selling and marketing</td> <td>4,134</td> <td>9,338</td> <td>...</td> </tr> <tr> <td>General and administrative</td> <td>19,005</td> <td>73,354</td> <td>...</td> </tr> <tr> <td>Selling, general & administrative expense</td> <td>...</td> <td>...</td> <td>34,970</td> </tr> <tr> <td>Change in contingent consideration</td> <td>(1,322)</td> <td>(2,156)</td> <td>1,412</td> </tr> <tr> <td>Impairment of goodwill and intangible assets</td> <td>...</td> <td>69,904</td> <td>...</td> </tr> <tr> <td>Impairment of property and equipment</td> <td>...</td> <td>2,912</td> <td>...</td> </tr> <tr> <td>Gain on disposal on property and equipment</td> <td>(144)</td> <td>...</td> <td>...</td> </tr> <tr> <td>Total operating expenses</td> <td>24,256</td> <td>161,531</td> <td>40,307</td> </tr> </tbody> </table> | | | | | | | | | | | 2023 | 2022 | □2021 | Revenues, net | 19,593,000 | ... | (revised) | Revenues, net | 19,593,000 | 10,884,000 | 4,101,000 | Cost of product revenues | 8,978,000 | 6,836,000 | 10,718,000 | Gross profit | 10,615,000 | 4,048,000 | (6,617,000) | Research & development | 2,225,000 | 3,253,000 | 6,246,000 | Selling & marketing | 17,769,000 | 30,369,000 | 43,444,000 | General & administrative | 10,505,000 | 11,860,000 | 14,698,000 | Gain (loss) on disposition of assets | ... | (11,122,000) | ... | Total operating expenses | 30,499,000 | 56,604,000 | 64,388,000 | Income (loss) from operations | (19,884,000) | (52,556,000) | (71,005,000) | Interest income | 78,000 | 80,000 | 25,000 | Interest expense | 1,419,000 | 3,131,000 | 3,914,000 | Unrealized gain on warrant liability | 6,760,000 | 25,520,000 | 3,827,000 | Total other income (expense), net | 5,419,000 | 22,469,000 | (62,000) | Income (loss) from provision (benefit) income taxes | (14,465,000) | (30,087,000) | (71,067,000) | Provision (benefit) from income taxes | ... | (4,675,000) | ... | Net income (loss) | (14,465,000) | (25,412,000) | (71,067,000) | Weighted average shares outstanding - basic | 2,156,726 | □432,219 | □48,536 | Weighted average shares outstanding - diluted | 2,156,726 | □432,219 | □48,536 | Year end shares outstanding | 2,963,657 | □859,403 | □60,698 | Net earnings (loss) per share - basic | \$(6.71) | □\$(59.00) | □\$(1,464.00) | Net earnings (loss) per share - diluted | \$(6.71) | □\$(59.00) | □\$(1,464.00) | Number of full time employees | 19 | 22 | ... | Number of common stockholders | 13 | □11 | ... | Total number of employees | 19 | ... | ... | | 2023 | 2022 | Cash & cash equivalents | 2,557,000 | 5,246,000 | Accounts receivable, net | 3,392,000 | 3,377,000 | Inventory | 2,738,000 | ... | Inventory, net | ... | 1,332,000 | Prepaid insurance | 441,000 | 628,000 | | 2023 | 2022 | 2021 | Revenue | 16,868 | 58,259 | ... | Revenue, net | 16,868 | 58,259 | 59,859 | Cost of goods sold | 11,590 | 90,054 | 54,625 | Gross profit (loss) | 5,278 | (31,795) | 5,234 | Research & development | 2,295 | 8,179 | 3,925 | Selling and marketing | 4,134 | 9,338 | ... | General and administrative | 19,005 | 73,354 | ... | Selling, general & administrative expense | ... | ... | 34,970 | Change in contingent consideration | (1,322) | (2,156) | 1,412 | Impairment of goodwill and intangible assets | ... | 69,904 | ... | Impairment of property and equipment | ... | 2,912 | ... | Gain on disposal on property and equipment | (144) | ... | ... | Total operating expenses | 24,256 | 161,531 | 40,307 |
| | 2023 | 2022 | □2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenues, net | 19,593,000 | ... | (revised) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenues, net | 19,593,000 | 10,884,000 | 4,101,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cost of product revenues | 8,978,000 | 6,836,000 | 10,718,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross profit | 10,615,000 | 4,048,000 | (6,617,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Research & development | 2,225,000 | 3,253,000 | 6,246,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Selling & marketing | 17,769,000 | 30,369,000 | 43,444,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General & administrative | 10,505,000 | 11,860,000 | 14,698,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gain (loss) on disposition of assets | ... | (11,122,000) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total operating expenses | 30,499,000 | 56,604,000 | 64,388,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Income (loss) from operations | (19,884,000) | (52,556,000) | (71,005,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interest income | 78,000 | 80,000 | 25,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interest expense | 1,419,000 | 3,131,000 | 3,914,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Unrealized gain on warrant liability | 6,760,000 | 25,520,000 | 3,827,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total other income (expense), net | 5,419,000 | 22,469,000 | (62,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Income (loss) from provision (benefit) income taxes | (14,465,000) | (30,087,000) | (71,067,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Provision (benefit) from income taxes | ... | (4,675,000) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) | (14,465,000) | (25,412,000) | (71,067,000) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Weighted average shares outstanding - basic | 2,156,726 | □432,219 | □48,536 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Weighted average shares outstanding - diluted | 2,156,726 | □432,219 | □48,536 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year end shares outstanding | 2,963,657 | □859,403 | □60,698 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net earnings (loss) per share - basic | \$(6.71) | □\$(59.00) | □\$(1,464.00) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net earnings (loss) per share - diluted | \$(6.71) | □\$(59.00) | □\$(1,464.00) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of full time employees | 19 | 22 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of common stockholders | 13 | □11 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total number of employees | 19 | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2023 | 2022 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cash & cash equivalents | 2,557,000 | 5,246,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Accounts receivable, net | 3,392,000 | 3,377,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Inventory | 2,738,000 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Inventory, net | ... | 1,332,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Prepaid insurance | 441,000 | 628,000 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2023 | 2022 | 2021 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue | 16,868 | 58,259 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue, net | 16,868 | 58,259 | 59,859 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cost of goods sold | 11,590 | 90,054 | 54,625 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross profit (loss) | 5,278 | (31,795) | 5,234 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Research & development | 2,295 | 8,179 | 3,925 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Selling and marketing | 4,134 | 9,338 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General and administrative | 19,005 | 73,354 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Selling, general & administrative expense | ... | ... | 34,970 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Change in contingent consideration | (1,322) | (2,156) | 1,412 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Impairment of goodwill and intangible assets | ... | 69,904 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Impairment of property and equipment | ... | 2,912 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gain on disposal on property and equipment | (144) | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total operating expenses | 24,256 | 161,531 | 40,307 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
|---|-----------|------------|----------|--|-----------|------|
| | | | | 2023 | 2022 | 2021 |
| Income (loss) from operations | (18,978) | (193,326) | (35,073) | 3,036 | 5,675 | |
| Interest income (expense), net | (1,853) | (8,750) | 74 | 1,887 | 4,605 | |
| Gain (loss) on extinguishment of notes payable | (4,311) | (38,985) | 2,685 | 1,149 | 1,070 | |
| Gain on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... | 45 | 23,449 | 24,960 | |
| Changes in fair value of derivative liabilities | 4,695 | 51,461 | ... | 924 | 15,506 | |
| Other expenses | ... | (1,316) | 31 | 7,438 | 13,352 | |
| Debt issuance | 1,799 | ... | ... | 19,094 | 53,818 | |
| Other income (expense), net | 330 | 5,042 | 2,773 | 17,599 | 32,422 | |
| Net income (loss) before income taxes | (18,648) | (188,284) | (32,300) | 4,882 | 21,396 | |
| State - Current | 2 | ... | ... | ... | ... | |
| Income Taxes - Total - Current | 2 | ... | ... | 454 | ... | |
| Income tax provision | 2 | 23 | 25 | 70 | ... | |
| Net income (loss) attributable to non-controlling interest | (18,650) | (188,307) | (32,325) | 116 | 504 | |
| Net income (loss) attributable to Agrify Corporation | (18,649) | (188,173) | (32,465) | 702 | 1,111 | |
| Accrued dividend attributable to preferred A stockholders | ... | ... | 61 | 904 | 1,049 | |
| Net income (loss) available for common shareholders | ... | ... | (32,526) | 606 | 606 | |
| Weighted average shares outstanding - basic | 1,491 | 209 | 1095 | 183 | 260 | |
| Weighted average shares outstanding - diluted | 1,491 | 209 | 1095 | ... | 602 | |
| Year end shares outstanding | 1,701 | 1,038 | 1111 | 78 | 78 | |
| Net earnings (loss) per share - basic | \$(12.51) | \$(902.19) | 1095 | 43 | 136 | |
| Net earnings (loss) per share - diluted | \$(12.51) | \$(902.19) | 1095 | 4,465 | ... | |
| Number of full time employees | 39 | 72 | 136 | 7,685 | 4,973 | |
| Number of part time employees | ... | ... | 5 | 2,894 | 2,372 | |
| Total number of employees | 39 | 72 | 141 | 2,943 | 7,443 | |
| Number of common stockholders | 62 | 58 | 62 | 7,734 | 10,044 | |
| Earnings per share from continuing operations | \$(12.51) | \$(902.19) | ... | 1,803 | 2,210 | |
| Earnings per share from continuing operations | \$(12.51) | \$(902.19) | ... | 141 | 326 | |
| | | | | 45,270 | 69,687 | |
| | | | | 20,766 | 20,543 | |
| | | | | 474 | ... | |
| | | | | 10,655 | ... | |
| | | | | 9,860 | ... | |
| | | | | ... | 16,380 | |
| | | | | 4,444 | ... | |
| | | | | 766 | 28,833 | |
| | | | | 4,019 | 4,112 | |
| | | | | 599 | 734 | |
| | | | | 321 | ... | |
| | | | | 41,249 | 70,602 | |
| | | | | ... | 147 | |
| | | | | 1,394 | 1,587 | |
| | | | | 16,047 | 407 | |
| | | | | 1,290 | 5,985 | |
| | | | | 59,980 | 78,728 | |
| | | | | 2 | 1 | |
| | | | | 250,855 | 237,875 | |
| | | | | (265,797) | ... | |
| | | | | ... | (247,148) | |
| | | | | (14,940) | (9,272) | |
| | | | | 230 | 231 | |
| | | | | (14,710) | ... | |

Adjusted for 1-for-10 stock split, October 18, 2022; Adjusted for 1-for-20 stock split, July 5, 2023; Shares increased due to the effect of conversion of convertible notes and preferred A stock, acquisition of Precision and Cascade and PurePressure, LLC, and exercise of options and warrants; Shares increased due to the effect of issuance of common stock in connection with acquisition, initial public offering, and secondary public offering; As is; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|-------------------------|------|--------|
| Restricted cash | ... | 10,000 |
| Cash & cash equivalents | 430 | 10,457 |
| Marketable securities | 4 | 460 |
| Accounts receivable, | | |

Recent Dividends:
1. Agrify Corp common.
 No dividends paid.
Annual Dividends:
1. Agrify Corp common.
 No dividends paid.
AIXIN LIFE INTERNATIONAL INC
Annual Report

Adjusted for 1-for-2 stock split, February 17, 2023; Approximately; As of March 15, 2022; As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Food and beverage revenues | 498,029 | ... |
| Others | 98,548 | ... |
| Products | 2,894,970 | ... |
| Sales revenue - products | ... | 1,851,676 |
| Sales revenue - advertising | ... | ... |
| Sales revenue - room revenues | ... | 262,605 |
| Sales revenue - food & beverage revenues | ... | 475,746 |
| Other sales revenue | ... | 118,533 |
| Room revenues | 598,252 | ... |
| Total revenue, net | 4,089,799 | 2,708,560 |
| Cost of goods sold | 1,613,950 | 1,103,160 |
| Hotel operating costs | 1,811,065 | 1,739,948 |
| Selling | 888,745 | 787,637 |
| General & administrative | 1,947,294 | 1,395,008 |
| Provision for (reversal of) bad debts | (43,988) | (119,274) |
| Stock-based compensation | 371,540 | 371,540 |
| Total operating costs & expenses | 6,588,606 | 5,278,019 |
| Income (loss) from operations | (2,498,807) | (2,569,459) |
| Interest income | 838 | 4,876 |
| Tax payable adjustment | (11,554) | ... |
| Other income | 438,348 | 51,856 |
| Other expenses | ... | 31,651 |
| Impairment loss | ... | 3,823,770 |
| Total non-operating income (expenses), net | 427,632 | (3,798,689) |
| Income (loss) before income tax | (2,071,175) | (6,368,148) |
| Current China income tax expense | ... | ... |
| Total current income tax expense | 4,367 | ... |
| Deferred China income tax benefit (expense) | ... | ... |
| Total deferred income tax benefit (expense) | 15,152 | ... |
| Income tax expense | 19,519 | 1,097 |
| Net income (loss) | (2,090,694) | (6,369,245) |
| Weighted average shares outstanding - basic | 24,999,834 | 24,999,842 |
| Weighted average shares outstanding - diluted | 24,999,834 | 24,999,842 |
| Year end shares outstanding | 24,999,834 | 24,999,842 |
| Net earnings (loss) per share - basic | \$(0.08) | \$(0.26) |
| Net earnings (loss) per share - diluted | \$(0.08) | \$(0.26) |
| Number of full time employees | ... | ... |
| Number of common stockholders | 635 | 635 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.08) | \$(0.26) |
| Diluted EPS Excluding ExtraOrdinary Items | \$(0.08) | \$(0.26) |

| | | | | | | | | | |
|--|--------------|------------|---|-------------|----------------|--|-------------|--------------|------------|
| Cash & cash equivalents | 443,758 | 510,128 | (accumulated deficit) | ... | (15,249,858) | Income from discontinued operations | ... | ... | 66,741 |
| Restricted cash | 23,208 | ... | Accumulated other comprehensive income (loss) | 181,150 | 172,849 | Gain on sale of WPT | ... | ... | 77,858,835 |
| Accounts receivable, gross | 334,226 | 835,081 | Total stockholders' equity (deficit) | (1,911,581) | (466,188) | Income from discontinued operations, net of tax | ... | ... | 77,925,576 |
| Bad debt allowance | 80,640 | ... | Total Equity | (1,911,581) | (466,188) | Net income (loss) | (3,595,361) | (10,823,885) | 62,865,731 |
| Accounts receivable, net | 253,586 | 562,581 | | | | Weighted average shares outstanding | | | |
| Other receivables & prepaid expenses | 170,831 | 42,631 | Recent Dividends: | | | - basic | 37,218,708 | 39,071,501 | 39,004,317 |
| Cash in escrow | ... | 109,772 | 1. AiXin Life International Inc common. | | | Weighted average shares outstanding | | | |
| Advances to suppliers | 12,400 | 83,102 | No dividends paid. | | | - diluted | 37,218,708 | 39,071,501 | 39,004,317 |
| Finished goods - health supplements | ... | 521 | Annual Dividends: | | | Year end shares outstanding | 36,805,686 | 38,503,724 | 39,116,907 |
| Drugs, pharmaceutical & nutritional products | 324,588 | 412,129 | 1. AiXin Life International Inc common. | | | Income (loss) per share from continuing operations - basic | \$(0.10) | \$(0.28) | \$(0.39) |
| Food & beverage, hotel supplies & consumables | 81,969 | 82,646 | No dividends paid. | | | Income (loss) per share from discontinued operations - basic | ... | ... | \$2.00 |
| Less: Inventory impairment allowance | 152,563 | 168,523 | ALLIED GAMING & ENTERTAINMENT INC | | | Net earnings (loss) per share - basic | \$(0.10) | \$(0.28) | \$1.61 |
| reserve for inventory | (79,464) | (73,821) | Annual Report | | | Income (loss) per share from continuing operations - diluted | \$(0.10) | \$(0.28) | \$(0.39) |
| Raw material | 114,005 | 62,462 | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | Income (loss) per share from discontinued operations - diluted | ... | ... | \$2.00 |
| Work in process | ... | 15,315 | | | | Net earnings (loss) per share - diluted | \$(0.10) | \$(0.28) | \$1.61 |
| Inventory | 441,098 | 499,252 | 2023 | 2022 | 2021 (revised) | Total number of employees | ... | 78 | 88 |
| Provision - Accounts & Notes Receivable - Trade | ... | 272,500 | In-person revenues | 6,100,912 | 4,201,259 | Number of common stockholders | 23 | 23 | 30 |
| Total current assets | 1,497,444 | 1,975,989 | Multiplatform content revenues | 2,000,586 | 251,558 | Foreign currency translation adjustments | ... | (49,931) | ... |
| Vehicle | 451,381 | 426,836 | In-person | 4,955,931 | ... | Research and development expenses | 162,888 | ... | ... |
| Electronic equipment | 25,899 | 20,607 | Casual mobile gaming | 698,522 | ... | | | | |
| Machinery | 1,314,902 | 1,241,778 | Total revenues | 7,655,039 | 6,352,470 | | | | |
| Leasehold improvements | 1,125,581 | 1,139,087 | In-person expenses (exclusive of depreciation & amortization) | 2,684,287 | 4,994,610 | | | | |
| Other property & equipment | 80,612 | 82,549 | Multiplatform content expenses (exclusive of depreciation & amortization) | 1,517,707 | 109,563 | | | | |
| Other | 11,997 | 17,485 | Interactive (exclusive of depreciation & amortization) | 593,894 | ... | | | | |
| Total property & equipment, gross | 3,010,372 | 2,928,342 | Selling & marketing expenses | ... | 234,813 | | | | |
| Less: accumulated depreciation | 1,330,697 | 956,549 | General & administrative expenses | 7,569,154 | 10,482,421 | | | | |
| Property & equipment, net | 1,679,675 | 1,971,793 | Depreciation & amortization | 1,499,980 | 2,065,348 | | | | |
| Intangible asset, net | 3,917 | 1,269 | Impairment of property & equipment | ... | 67,500 | | | | |
| Deferred tax asset | ... | 15,556 | Impairment of digital assets | ... | 164,411 | | | | |
| Security deposit | 84,508 | 86,992 | Total costs & expenses | 14,254,655 | 18,118,666 | | | | |
| Operating lease right-of-use assets | 1,576,814 | 999,285 | General & administrative expenses | 226,745 | ... | | | | |
| Total assets | 4,842,358 | 5,050,884 | Income (loss) from operations | (6,599,616) | (11,766,196) | | | | |
| Accounts payables & accrued liabilities | 478,456 | 398,469 | Gain on forgiveness of Paycheck Protection Program loans & interest | ... | 912,475 | | | | |
| Unearned revenue | 172,753 | 139,502 | Other income (expense), net | 46,684 | 153,009 | | | | |
| Taxes payable | 49,249 | 104,100 | Interest income (expense), net | 2,957,571 | 789,302 | | | | |
| Accrued employees' social insurance | ... | 270,349 | Total other income (expense) | 3,004,255 | 942,311 | | | | |
| Accrued professional fees | 250,505 | 233,894 | Income before taxes | (3,595,361) | ... | | | | |
| Accrued payroll & commission | 308,768 | 307,331 | Deferred federal income tax provision (benefit) | ... | (1,911,425) | | | | |
| Accrued rent expense | 2,163,066 | ... | Deferred state & local income tax provision (benefit) | ... | (182,041) | | | | |
| Accrued liability - travel cost | 231,983 | ... | Deferred foreign income tax provision (benefit) | ... | (79,577) | | | | |
| Other payables | ... | 83,910 | Change in valuation allowance | ... | 2,173,043 | | | | |
| Accrued liabilities & other payables | ... | 2,356,490 | Income (loss) from continuing operations | ... | (10,823,885) | | | | |
| Loan from third parties | 100,742 | 86,992 | | | | | | | |
| Operating lease liabilities - current | 864,519 | 883,583 | | | | | | | |
| Advance from related parties | 1,226,885 | 236,882 | | | | | | | |
| Accounts payable-related party | 1,776 | 165,958 | | | | | | | |
| Accrued liabilities and other payables - Balancing value | 1,271,068 | 1,461,006 | | | | | | | |
| Government grant | 923,238 | 950,371 | | | | | | | |
| Loan from third parties | 84,508 | ... | | | | | | | |
| Total current liabilities | 5,964,450 | 5,322,347 | | | | | | | |
| Operating lease liability - non-current | 789,489 | 194,725 | | | | | | | |
| Operating lease liabilities - non-current | 789,489 | 194,725 | | | | | | | |
| Total liabilities | 6,753,939 | 5,517,072 | | | | | | | |
| Common stock | 250 | 250 | | | | | | | |
| Additional paid in capital | 14,975,423 | 14,458,583 | | | | | | | |
| Statutory reserve | 151,988 | 151,988 | | | | | | | |
| Accumulated deficit | (17,220,392) | ... | | | | | | | |
| Retained earnings | ... | ... | | | | | | | |

□ Reclassified to conform with 2022 presentation; □ As of March 24, 2023; □ Approximately; □ As of May 20, 2022; □ As of March 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 16,320,583 | 11,167,442 |
| Short-term investments | 56,500,000 | 70,000,000 |
| Interest receivable | 792,223 | 677,397 |
| Accounts receivable | 529,369 | 72,739 |
| Prepaid expenses & other current assets | 3,700,000 | 459,274 |
| Prepaid expenses and other current assets | 498,886 | ... |
| Total current assets | 78,341,061 | 82,376,852 |
| Restricted cash | 5,000,000 | 5,000,000 |
| Equipment | 680,795 | ... |
| Office equipment | 46,351 | 793,395 |
| Computer equipment | 1,267,340 | 563,042 |
| Esports gaming truck | 1,225,945 | 1,222,406 |
| Furniture & fixtures | ... | 680,795 |
| Production equipment | 8,136,009 | 7,948,555 |
| Leasehold improvements | 4,711,996 | 4,578,081 |
| Property & equipment, gross | 16,068,436 | 15,786,274 |
| Less: accumulated depreciation & amortization | 12,234,243 | 11,780,652 |
| Property & equipment, net | 3,834,193 | 4,005,622 |
| Digital assets | 49,300 | 49,761 |
| Goodwill | 12,729,056 | ... |
| Intangible assets, net | 6,254,731 | 22,836 |

| | | |
|--|---------------|---------------|
| Deposits | 392,668 | 379,105 |
| Operating lease right-of-use asset | 5,415,678 | 5,845,549 |
| Other assets | ... | 49,950 |
| Total assets | 112,016,687 | 97,729,675 |
| Accounts payable | ... | 317,561 |
| Accrued compensation expense | 655,458 | 1,546,805 |
| Accrued event costs | 763,512 | 8,411 |
| Accrued legal & professional fees | 32,150 | 43,676 |
| Warrant liabilities | 100 | 100 |
| Other accrued expenses | 70,270 | 46,387 |
| Accrued expenses & other current liabilities | 5,534 | 1,645,379 |
| Deferred revenue | 103,748 | 108,428 |
| Operating lease liability, current portion | 1,482,977 | 1,227,164 |
| Convertible debt, net of discount | 9,230,168 | ... |
| Accounts payable & accrued expenses | 371,830 | ... |
| Total current liabilities | 11,952,235 | 3,298,532 |
| Operating lease liability, non-current portion | 5,560,251 | 6,527,075 |
| Deferred tax liability | 1,096,160 | ... |
| Total liabilities | 18,608,646 | 9,825,607 |
| Common stock | 3,909 | 3,909 |
| Additional paid in capital | 198,677,132 | 198,526,614 |
| Accumulated deficit | (113,671,029) | ... |
| Retained earnings (accumulated deficit) | ... | (110,235,568) |
| Accumulated other comprehensive income | 433,565 | 219,675 |
| Treasury stock, at cost, 581,746 and 0 shares at 31, 2022 and 2021, respectively | 2,693,653 | ... |
| Treasury stock, at cost | ... | 610,562 |
| Total stockholders' equity | 82,749,924 | 87,904,068 |
| Equity Minority Interests/Equity | ... | ... |
| Non-Controlling Interests | 10,658,117 | ... |
| Total Equity | 93,408,041 | ... |

Recent Dividends:

- Allied Gaming & Entertainment Inc common.**
No dividends paid.
 - Allied Gaming & Entertainment Inc common subject to possible redemption.**
No dividends paid.
- Annual Dividends:**
- Allied Gaming & Entertainment Inc common.**
No dividends paid.
 - Allied Gaming & Entertainment Inc common subject to possible redemption.**
No dividends paid.

ALSET INC

Annual Report

| | | | |
|---|------------|-----------|------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Rental revenue | 2,776,911 | 1,810,011 | 327,296 |
| Property revenue | ... | 1,278,617 | 13,886,083 |
| Biohealth revenue | ... | 753,651 | 5,543,066 |
| Digital transformation technology revenues | 28,117 | 69,915 | ... |
| Other revenue | ... | 568,248 | 42,377 |
| Property | 18,186,750 | ... | ... |
| Biohealth | 12,758 | ... | ... |
| Others | 1,083,971 | ... | ... |
| Total revenue | 22,088,507 | 4,480,442 | 19,798,822 |
| Cost of sales | 14,576,209 | 3,731,990 | 11,301,814 |
| General & administrative expenses | 9,529,100 | 7,837,826 | 23,491,130 |
| Inventory written off | 855,852 | ... | ... |

| | | | |
|--|---------------------|---------------------|----------------------|
| Total operating expenses | 24,961,161 | 11,569,816 | 34,792,944 |
| Operating income (loss) | (2,872,654) | (7,089,374) | (14,994,122) |
| Interest income | 394,553 | 67,470 | 183,636 |
| Interest expense | 3,979 | 1,853 | 317,281 |
| Gain (loss) on disposal of subsidiary | (21,657,036) | ... | ... |
| Foreign exchange transaction gain (loss) | (697,286) | (547,845) | 1,363,061 |
| Unrealized gain (loss) on securities investment | 6,607,215 | (7,794,139) | (1,959,664) |
| Unrealized Loss on Securities Investment - related party | (9,506,501) | (23,556,219) | (47,231,084) |
| Realized gain (loss) on securities investment | (11,375,747) | (7,308,580) | (4,698,078) |
| Gain (loss) on investment on security by equity method | (24,483,374) | (685,533) | (51,999) |
| Finance costs | ... | 450,000 | 50,871,869 |
| Other income | 2,277,107 | 1,153,568 | 93,823 |
| Interest Income | ... | ... | ... |
| Related Party | 131,319 | ... | ... |
| Total other income (expense), net | (58,313,729) | (39,123,131) | (103,489,455) |
| Net income (loss) before income taxes | (61,186,383) | (46,212,505) | (118,483,577) |
| Current federal income tax expense (benefit) | 92,350 | ... | 45,736 |
| Current state income tax expense (benefit) | ... | ... | 46,179 |
| Total current income tax expense (benefit) | 92,350 | ... | 91,916 |
| Deferred federal income tax expense (benefit) | 6,176,130 | (3,905,452) | (2,725,007) |
| Deferred state income tax expense (benefit) | (454,675) | 1,163,407 | (1,266,545) |
| Total deferred income tax expense (benefit) | 5,721,455 | (2,742,045) | (3,991,553) |
| Valuation allowance | (5,721,455) | 2,742,045 | 3,991,553 |
| Income tax expense (benefit) | 92,350 | ... | 534,014 |
| Net income (loss) | (61,278,733) | (46,212,505) | (119,017,591) |
| Net income (loss) attributable to non-controlling interest | 2,332,352 | 5,721,567 | 15,694,415 |
| Net income (loss) attributable to common stockholders | (58,946,381) | (40,490,938) | (103,323,176) |
| Weighted average shares outstanding - basic | 9,041,786 | 6,513,453 | 1,399,144 |
| Weighted average shares outstanding - diluted | 9,041,786 | 6,513,453 | 1,399,144 |
| Year end shares outstanding | 11,211,155 | 7,422,846 | 4,368,422 |
| Earnings (loss) per share from continuing operations - basic | \$(6.52) | ... | ... |
| Net earnings (loss) per share - basic | \$(6.52) | \$(6.22) | \$(73.85) |
| Earnings (loss) per share from continuing operations - | ... | ... | ... |

| | | | |
|--|----------|----------|-------------|
| diluted | \$(6.52) | ... | ... |
| Net earnings (loss) per share - diluted | \$(6.52) | \$(6.22) | \$(73.85) |
| Number of full time employees | ... | 48 | 32 |
| Number of common stockholders | 7 | 6 | 6 |
| Foreign currency translation adjustments | ... | 508,277 | (3,974,966) |

Reclassified to conform with 2022 presentation; As reported by the Company; Adjusted for 1-for-20 stock split, December 28, 2022; Shares increased due to issuance of shares, converting of preferred stock series A and B to common and converting related party note payable to common share; As of March 31, 2023; As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|---------------|---------------|
| | 2023 | 2022 |
| Cash and cash equivalents | 26,921,727 | ... |
| Cash | ... | 17,827,383 |
| Restricted cash | 967,566 | 694,520 |
| Account receivables, net | 77,517 | 46,522 |
| Other receivables | 2,576,454 | 446,798 |
| Note receivables - related parties | 1,693,946 | 3,617,176 |
| Prepaid expense | 253,689 | 188,070 |
| Inventory | 5,561 | 35,020 |
| Investment in securities at fair value | 2,148,500 | 6,288,236 |
| Investment in Securities at fair value - related party | 11,869,920 | 13,193,089 |
| Investment in securities at cost | 54,512 | 98,129 |
| Investment in securities at equity method | 7,551,153 | 52,987,224 |
| Deposits | 133,063 | ... |
| Convertible Note Receivables at Fair Value | ... | ... |
| Related Party | 1,207,627 | ... |
| Total current assets | 55,461,235 | 95,422,167 |
| Real estate - rental properties | 31,770,386 | 31,169,031 |
| Real estate - properties under development | 10,366,766 | 23,449,698 |
| Operating lease right-of-use asset | 1,467,372 | 1,614,159 |
| Deposit | 337,606 | 536,947 |
| Property & equipment, net | 742,072 | 1,298,334 |
| Cash and Marketable Securities Held in Trust | ... | ... |
| Account | 21,252,639 | ... |
| Goodwill | 60,343 | ... |
| Other Receivables - Long Term | 4,855,609 | ... |
| Total assets | 126,314,028 | 153,490,336 |
| Accounts payable & accrued expenses | 4,372,792 | 2,983,470 |
| Deferred revenue | 2,100 | 21,198 |
| Operating lease liability | 903,429 | 45,556 |
| Notes payable | 16,869 | 181,846 |
| Notes payable - related parties | ... | 12,668 |
| Bonds payable | 30,744 | ... |
| Deferred Underwriting Compensation | 3,018,750 | ... |
| Total current liabilities | 8,344,684 | 3,244,738 |
| Note payable, net of discount | 126,182 | ... |
| Operating lease liability | 595,834 | 1,582,483 |
| Total liabilities | 9,066,700 | 4,827,221 |
| Common Stock - Issued & Paid | 20,457,011 | ... |
| Common stock | 9,235 | 7,423 |
| Additional paid in capital | 332,455,457 | 322,534,891 |
| Accumulated Deficit | (247,885,656) | ... |
| Retained earnings (accumulated deficit) | ... | (188,724,411) |
| Unrealized gains & | ... | ... |

| | | |
|---|---------------|--------------|
| capital | 523,255,000 | 1,200,788 |
| Retained earnings (accumulated deficit) | (190,552,000) | (28,024,819) |
| Accumulated other comprehensive income (loss) | 9,222,000 | ... |
| Non-controlling interest in subsidiaries | 446,094,000 | ... |
| Total shareholder's equity (deficit) | 788,026,000 | (26,823,168) |

| | | |
|------------------------------------|---------------|-----------------------|
| applicable to Common | (162,606,000) | ... |
| Net income (loss) | (305,803,000) | 8,779,014 (1,035,380) |
| Compensation and employee benefits | 204,052,000 | ... |
| Systems, technology and telephone | 16,341,000 | ... |
| Sales, distribution and marketing | 2,217,000 | ... |
| Professional fees | 66,115,000 | ... |
| Travel and entertainment | 5,914,000 | ... |
| General, administrative and other | 19,495,000 | ... |

| | | |
|---|---------------|-----|
| Extraordinary Items | ... | ... |
| Applicable to Common - Total | \$(2.65) | ... |
| EPS - Diluted - including Extraordinary Items | ... | ... |
| Applicable to Common - Total | \$(2.65) | ... |
| Comprehensive Income - Attributable to Owners of Parent Company - Total | (153,385,000) | ... |

Recent Dividends:

- 1. **AITI Global Inc class A common.**
No dividends paid.
- 2. **AITI Global Inc class A ordinary shares subject to possible redemption.**
No dividends paid.

3. AITI Global Inc class B common.

No dividends paid.

Annual Dividends:

1. AITI Global Inc class A common.

No dividends paid.

2. AITI Global Inc class A ordinary shares subject to possible redemption.

No dividends paid.

3. AITI Global Inc class B common.

No dividends paid.

ALTI GLOBAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|-------------|----------------|
| Operating costs | 13,814,000 | 8,858,651 | 1,012,448 |
| Income (loss) from operations | ... | (8,858,651) | (1,012,448) |
| Interest earned on cash & marketable securities held in trust account | ... | 4,974,899 | 31,308 |
| Interest expense - debt discount | 14,501,000 | 32,145 | ... |
| Offering costs allocated to warrants | ... | ... | 868,131 |
| Excess of private warrants fair value over purchase price | ... | ... | 3,097,200 |
| Management/advisory fees | 184,824,000 | ... | ... |
| Incentive fees | 43,377,000 | ... | ... |
| Distributions from investments | 17,185,000 | ... | ... |
| Other income/fees | 5,494,000 | ... | ... |
| Change in fair value of warrant liability | ... | 12,562,468 | 3,911,091 |
| Total revenues | 250,880,000 | ... | ... |
| Unrealize gain (loss) treasury bills | ... | (22,368) | ... |
| Change in fair value of conversion option liability | ... | (40,776) | ... |
| Other income | (3,744,000) | 195,587 | ... |
| Gain (loss) on warrant liability | (12,866,000) | ... | ... |
| Gain (loss) on TRA | (233,000) | ... | ... |
| Impairment loss on goodwill and intangible assets | 206,507,000 | ... | ... |
| Gain (loss) on earn-out liability | 31,104,000 | ... | ... |
| Gain (loss) on investments | (15,483,000) | ... | ... |
| Total other income (expense) | 17,637,665 | (22,932) | ... |
| Net income (loss) attributed to non-controlling interests in subsidiaries | 143,197,000 | ... | ... |
| Net Income After Extraordinary Items | ... | ... | ... |

| | | | |
|--|---------------|------------|------------|
| Weighted average class A ordinary shares outstanding - basic | 34,500,000 | 29,112,329 | ... |
| Weighted average class B ordinary shares outstanding - basic | 8,625,000 | 8,449,315 | ... |
| Weighted average shares outstanding - basic | 61,396,692 | ... | ... |
| Weighted average class A ordinary shares outstanding - diluted | 34,500,000 | 29,112,329 | ... |
| Weighted average class B ordinary shares outstanding - diluted | 8,625,000 | 8,449,315 | ... |
| Weighted average shares outstanding - diluted | 61,396,692 | ... | ... |
| Year end shares outstanding | 118,330,588 | 43,125,000 | 43,125,000 |
| Net income (loss) per class A ordinary share - basic | ... | \$0.20 | \$(0.03) |
| Net income (loss) per class B ordinary share - basic | ... | \$0.20 | \$(0.03) |
| Net income (loss) per class A ordinary share - diluted | ... | \$0.20 | \$(0.03) |
| Net income (loss) per class B ordinary share - diluted | ... | \$0.20 | \$(0.03) |
| Full-Time Employees (Period End) | 480 | ... | ... |
| Total number of employees | 480 | 151 | 2 |
| Number of class A stockholders | 367 | 397 | 397 |
| Number of class B stockholders | ... | ... | 4 |
| Income from cont operations before income tax | (316,337,000) | ... | ... |
| Depreciation and amortization | 17,039,000 | ... | ... |
| Federal | 803,000 | ... | ... |
| Foreign | 880,000 | ... | ... |
| State and local | 170,000 | ... | ... |
| Income Taxes - Total - Current | 1,853,000 | ... | ... |
| Federal | (173,000) | ... | ... |
| Foreign | (11,351,000) | ... | ... |
| State and local | (863,000) | ... | ... |
| Income Taxes - Total - Deferred | (12,387,000) | ... | ... |
| Income tax (expense) benefit | (10,534,000) | ... | ... |
| Total operating expenses | 344,987,000 | ... | ... |
| EPS - Basic - including | ... | ... | ... |

□ Shares increased due to initial public offering of class A ordinary shares; □ As of April 14, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|-------------|
| Cash | ... | 85,540 |
| Prepaid expenses | 8,045,000 | ... |
| Cash and cash equivalents | 15,348,000 | ... |
| Fees receivable, net | 70,421,000 | ... |
| Accrued Income | 17,124,000 | ... |
| Sundry receivables | 5,664,000 | ... |
| Other receivables | 12,204,000 | ... |
| Total current assets | ... | 85,540 |
| Cash & marketable securities held in trust account | 48,182,000 | 349,983,839 |
| Investments at fair value | 165,894,000 | ... |
| Equity method investments | 14,194,000 | ... |
| Intangible assets, net of accumulated amortization | 435,677,000 | ... |
| Goodwill | 411,904,000 | ... |
| Operating lease right-of-use assets | 48,313,000 | ... |
| Fixed assets, net | 2,532,000 | ... |
| Property, Plant & Equipment - Gross - Total | 8,467,000 | ... |
| Property, Plant & Equipment - Accumulated Depreciation & Impairment | 5,935,000 | ... |
| Other assets | 2,613,000 | ... |
| Assets held for sale | 56,634,000 | ... |
| Land/Improvements - Gross | 4,978,000 | ... |
| Office equipment and furniture | 3,489,000 | ... |
| Total assets | 1,266,567,000 | 350,069,379 |
| Accounts payable & accrued expenses | 36,804,000 | 8,004,647 |
| Accrued compensation and profit sharing | 57,466,000 | ... |
| Accrued member distributions payable | 7,271,000 | ... |
| Earn-in consideration payable | 1,830,000 | ... |
| Total current liabilities | ... | 8,004,647 |
| Deferred underwriting fee | ... | 7,800,000 |
| Convertible promissory note - related party | ... | 490,814 |
| Conversion option liability | 63,444,000 | 82,107 |
| Warrant liabilities | ... | 10,531,140 |
| TRA liability | 17,607,000 | ... |
| Delayed share purchase agreement | 1,818,000 | ... |
| Operating lease liabilities | 56,123,000 | ... |
| Debt, net of unamortized deferred financing cost | 186,353,000 | ... |
| Deferred tax liability, net | 14,109,000 | ... |
| Deferred income | 66,000 | ... |
| Other liabilities | 21,858,000 | ... |
| Term Note B | 92,603,000 | ... |
| Line of Credit | 93,750,000 | ... |
| Liabilities held for sale | 13,792,000 | ... |
| Total liabilities | 478,541,000 | 26,908,708 |
| Class A ordinary shares subject to possible redemption | ... | 349,983,839 |
| Class B ordinary shares | 7,000 | 863 |

| | | |
|---|---------------|--------------|
| Additional paid in capital | 523,255,000 | 1,200,788 |
| Retained earnings (accumulated deficit) | (190,552,000) | (28,024,819) |
| Accumulated other comprehensive income (loss) | 9,222,000 | ... |
| Non-controlling interest in subsidiaries | 446,094,000 | ... |
| Total shareholder's equity (deficit) | 788,026,000 | (26,823,168) |

Recent Dividends:**1. AITI Global Inc class A common.**

No dividends paid.

2. AITI Global Inc class A ordinary shares subject to possible redemption.

No dividends paid.

3. AITI Global Inc class B common.

No dividends paid.

Annual Dividends:**1. AITI Global Inc class A common.**

No dividends paid.

2. AITI Global Inc class A ordinary shares subject to possible redemption.

No dividends paid.

3. AITI Global Inc class B common.

No dividends paid.

ALTI GLOBAL INC**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

| | 2023 | 2022 |
|-----------------------------------|----------------------|-------------------|
| Total revenues | 159,172,000 | ... |
| Cost & expenses | 226,152,000 | 948,203 |
| Operating income | (243,165,000) | (948,203) |
| Other income (expense), net | (150,374,000) | 16,747,493 |
| Gains or losses | (4,994,000) | ... |
| Net before taxes | (244,496,000) | ... |
| Income taxes | (12,578,000) | ... |
| Net income | (231,918,000) | 17,877,195 |
| Balance for common | 14,301,756 | ... |
| Earnings common share | | |
| Primary | \$(1.89) | \$0.41 |
| Fully Diluted | \$(1.89) | \$0.41 |
| Common Shares: | | |
| Full Diluted | 60,174,678 | 34,500,000 |
| Year-end | 64,770,908 | 43,125,000 |

ALTIGEN COMMUNICATIONS INC**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Net revenue - hosted services | 7,656,000 | 7,639,000 | 7,630,000 |
| Net revenue - software assurance ... | 1,551,000 | 1,867,000 | 2,283,000 |
| Net revenue - professional service & other revenue | 4,301,000 | 1,979,000 | 501,000 |
| Net revenue - software license | 173,000 | 406,000 | 576,000 |
| Total net revenue | 13,681,000 | 11,891,000 | 10,990,000 |
| Cost of revenue - hosted services | 3,119,000 | 2,971,000 | 2,941,000 |
| Cost of revenue - professional services & other revenue | 1,842,000 | 699,000 | ... |
| Cost of revenue - software license | 72,000 | 128,000 | 133,000 |
| Total cost of revenue | 5,033,000 | 3,798,000 | 3,074,000 |
| Gross profit (loss) | 8,648,000 | 8,093,000 | 7,916,000 |
| Research & development expenses | 5,066,000 | 4,651,000 | 3,848,000 |
| Sales & marketing expenses | 1,664,000 | 1,507,000 | 2,074,000 |
| General & administrative expenses | 2,354,000 | 2,515,000 | 1,701,000 |
| Litigation expenses ... | ... | ... | 313,000 |

| | | | |
|---|--------------------|------------------|------------------|
| Total operating expenses | 9,084,000 | 8,673,000 | 7,936,000 |
| Income (loss) from operations | (436,000) | (580,000) | (20,000) |
| Gain on extinguishment of debt - Paycheck Protection Program ("PPP") loan forgiveness | ... | ... | 804,000 |
| Interest & other income | 2,000 | 1,000 | ... |
| Interest expense | 74,000 | ... | ... |
| Income (loss) before income taxes .. | (508,000) | (579,000) | 784,000 |
| Provision for (benefit from) current state income taxes | 60,000 | 15,000 | (33,000) |
| Provision for (benefit from) current income taxes | ... | 15,000 | (33,000) |
| Provision for (benefit from) deferred federal income taxes | 1,713,000 | 49,000 | 1,332,000 |
| Provision for (benefit from) deferred state income taxes | 1,043,000 | 55,000 | (24,000) |
| Provision for (benefit from) deferred income taxes | ... | 104,000 | 1,308,000 |
| Provision for (benefit from) income taxes | 2,816,000 | 119,000 | 1,275,000 |
| Net income (loss) | (3,324,000) | (698,000) | (491,000) |
| Weighted average shares outstanding - basic | 24,550,000 | 24,016,000 | 23,279,000 |
| Weighted average shares outstanding - diluted | 24,550,000 | 24,016,000 | 23,279,000 |
| Year end shares outstanding | 24,918,656 | 24,222,809 | 23,748,432 |
| Net income (loss) per share - basic | \$(0.14) | \$(0.03) | \$(0.02) |
| Net income (loss) per share - diluted | \$(0.14) | \$(0.03) | \$(0.02) |
| Number of full time employees | ... | 75 | 61 |
| Number of common stockholders | ... | 57 | 71 |
| Number of beneficiary stockholders | ... | 1,972 | 1,766 |

□ Full-time equivalent

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 2,641,000 | 3,232,000 |
| Accounts receivable, gross | 1,426,000 | 1,190,000 |
| Less allowance for doubtful accounts | 40,000 | 75,000 |
| Accounts receivables, net | 1,386,000 | 1,115,000 |
| Unbilled accounts receivables | 109,000 | 105,000 |
| Prepaid expenses & other current assets | 236,000 | 206,000 |
| Total current assets | 4,372,000 | 4,658,000 |
| Furniture & equipment | 172,000 | 409,000 |
| Computer software | 98,000 | 105,000 |
| Leasehold improvements | 53,000 | 53,000 |
| Total property & equipment | 323,000 | 567,000 |
| Less: accumulated depreciation & amortization | 320,000 | 560,000 |
| Property & equipment, net | 3,000 | 7,000 |

| | | |
|---|--------------|--------------|
| Operating lease, right-of-use assets | 301,000 | 572,000 |
| Goodwill | 2,725,000 | 2,725,000 |
| Intangible assets, net | 1,568,000 | 1,882,000 |
| Capitalized software development costs, net | 1,215,000 | 1,331,000 |
| Deferred tax assets | 3,737,000 | 6,493,000 |
| Long-term deposit | ... | 37,000 |
| Total assets | 13,921,000 | 17,705,000 |
| Accounts payable | 58,000 | 53,000 |
| Accrued compensation & benefits | 417,000 | 364,000 |
| Accrued expenses | 455,000 | 530,000 |
| Deferred consideration, current | 510,000 | 500,000 |
| Operating lease liabilities, current | 324,000 | 383,000 |
| Deferred revenue, current | 477,000 | 566,000 |
| Total current liabilities | 2,241,000 | 2,396,000 |
| Deferred consideration, long term | 208,000 | 670,000 |
| Operating lease liabilities, long-term | ... | 233,000 |
| Deferred revenue, long-term | 134,000 | 206,000 |
| Total liabilities | 2,583,000 | 3,505,000 |
| Common stock | 24,000 | 24,000 |
| Treasury stock at cost | 1,565,000 | 1,565,000 |
| Additional paid-in capital | 73,133,000 | 72,671,000 |
| Retained earnings (accumulated deficit) | (60,254,000) | (56,930,000) |
| Total stockholders' equity | 11,338,000 | 14,200,000 |

Recent Dividends:**1. Altigen Communications Inc common.**

No dividends paid.

Annual Dividends:**1. Altigen Communications Inc common.**

No dividends paid.

ALZAMEND NEURO INC**Earnings, 9 mos. to Jan 31 (Consol. - \$):**

| | 2024 | 2023 |
|-------------------------|--------------------|---------------------|
| Cost & expenses | 9,087,581 | 11,565,457 |
| Operating income | (9,087,581) | (11,565,457) |
| Net before taxes | (9,096,217) | ... |
| Net income | (9,096,217) | (11,572,639) |
| Earnings common share | | |
| Primary | \$(1.35) | \$(1.80) |
| Fully Diluted | \$(1.35) | \$(1.80) |
| Common Shares: | | |
| Full Diluted | 6,726,926 | 6,517,698 |
| Year-end | 6,618,766 | 6,428,508 |

AMERICAN BATTERY MATERIALS, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-----------|
| General & administrative | ... | 1,135,088 | 393,376 |
| Total operating expenses | 2,453,700 | 1,135,088 | 393,376 |
| Operating income (loss) | (2,453,700) | (1,135,088) | (393,376) |
| Gain (loss) on change in fair value of derivative liabilities | ... | 211,345 | 2,871,910 |
| Gain on settlement of liabilities | (168,856) | 32,019 | 62,095 |
| Write-off of assets ... | ... | ... | 17,500 |
| Interest expense | 203,287 | 595,124 | 760,663 |
| Gain on settlement of liabilities | (441,041) | ... | ... |
| Total other income (expenses) | 68,898 | (351,760) | 2,155,842 |
| Income (loss) before income taxes - domestic | (2,384,802) | (1,486,848) | ... |
| Income (loss) from operations before | | | |

| | | | |
|---|--------------------|--------------------|------------------|
| income taxes | (2,384,802) | (1,486,848) | 1,762,466 |
| Current state income taxes | 659 | 3,285 | |
| Current income taxes | 659 | 3,285 | |
| Deferred federal income taxes (benefit) | (270,482) | (54,817) | |
| Deferred state income taxes (benefit) | (51,521) | (13,976) | |
| Less: increase in allowance | 322,003 | 68,793 | |
| Net income (loss) | (2,384,802) | (1,486,848) | 1,762,466 |
| Weighted average shares outstanding - basic | 11,158,353 | 10,119,263 | 701,592 |
| Weighted average shares outstanding - diluted | 11,158,353 | 10,119,263 | 1,247,967 |
| Year end shares outstanding | 11,373,793 | 10,818,522 | 10,119,263 |
| Net income (loss) per share - basic | \$(0.21) | \$0.00 | \$3.00 |
| Net income (loss) per share - diluted | \$(0.21) | \$0.00 | \$0.00 |
| Number of full time employees | 1 | 1 | 1 |
| Number of part time employees | 1 | 1 | 1 |
| Number of common stockholders | 739 | 725 | 700 |

¹ Reclassified to conform with 2022 presentation; ² As reported by the Company; ³ Adjusted for 1-for-300 stock split, December 8, 2023; ⁴ Shares increased due to the effect of shares issued for note conversion, warrant exercise and services; ⁵ Shares increased due to the effect of shares issued for note conversion; ⁶ As of April 13, 2023; ⁷ As of March 31, 2022; ⁸ As of April 19, 2023; ⁹ Approximately; ¹⁰ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 7,376 | 42,582 |
| Prepaid expenses & other assets | 143,202 | 62,717 |
| Total current assets | 150,578 | 105,299 |
| Mineral claims | 206,000 | 100,000 |
| Total assets | 356,578 | 205,299 |
| Accounts payable | 164,948 | 438,667 |
| Accrued expenses | 449,196 | 482,881 |
| Accrued interest | 251,570 | 190,901 |
| Senior convertible notes | 25,000 | ... |
| Promissory notes payable | 300,000 | 357,008 |
| Convertible notes payable | 1,971,503 | ... |
| Current capital lease obligation | 36,254 | 36,254 |
| Revolving note from related party | 175,000 | ... |
| Total current liabilities | 3,373,471 | 1,505,711 |
| Total liabilities | 3,373,471 | 1,505,711 |
| Preferred stock | ... | 5 |
| Common stock | 11,373 | 3,245,555 |
| Additional paid in capital | 17,211,373 | 13,308,865 |
| Accumulated deficit | (20,239,639) | ... |
| Retained earnings (accumulated deficit) | ... | (17,854,837) |
| Total stockholders' equity (deficit) | (3,016,893) | (1,300,412) |
| Total Equity | (3,016,893) | ... |

Recent Dividends:
1. American Battery Materials, Inc. common.
 No dividends paid.

Annual Dividends:
1. American Battery Materials, Inc. common.
 No dividends paid.

AMERICAN COASTAL INSURANCE CORP
Earnings, 9 mos. to Sep 30 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|--------------------|----------------------|
| Total revenues | 228,329,000 | 195,094,000 |
| Cost & expenses | 88,995,000 | 143,073,000 |
| Operating income | 71,217,000 | (17,887,000) |
| Other income (expense), net | 1,168,000 | 1,562,000 |
| Net before taxes | 72,385,000 | (16,325,000) |
| Income taxes | 7,293,000 | 24,705,000 |
| Income contin. oper. | 65,092,000 | (41,030,000) |
| Income discont. oper. | 230,535,000 | 132,166,000 |
| Net income | 295,627,000 | (173,196,000) |
| Earnings common share | | |
| Primary | \$6.84 | \$(4.02) |
| Fully Diluted | \$6.73 | \$(4.02) |
| Common Shares: | | |
| Full Diluted | 43,888,665 | 43,035,374 |
| Year-end | 43,411,686 | 43,285,807 |

AMERICAN ONCOLOGY NETWORK INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------|-------------|----------------|
| Formation & operating costs | 2,389,899 | 1,632,489 | ... |
| Income (loss) from operations | (49,154,000) | (2,389,899) | (1,632,489) |
| Interest income | 1,326,000 | 5,128,585 | 20,259 |
| Offering costs allocated to warrants | ... | ... | 659,746 |
| Change in fair value of warrant liability | 8,680,492 | 10,666,695 | ... |
| Unrealized gain (loss) on marketable securities held in trust account | ... | 139,897 | ... |
| Interest expense | 6,417,000 | ... | ... |
| Amortization of debt issuance costs | (8,262,000) | ... | ... |
| Total other income (loss) | 13,948,974 | 10,027,208 | ... |
| Patient service revenue, net | 1,265,719,000 | ... | ... |
| Other revenue | 13,466,000 | ... | ... |
| Income (loss) before provision for income taxes | (62,507,000) | 11,559,075 | 8,394,719 |
| Total revenues | 1,279,185,000 | ... | ... |
| Current federal income taxes | 451,637 | (287,882) | ... |
| Deferred federal income taxes | 400,000 | 441,357 | ... |
| Cost of revenue | 1,196,389,000 | ... | ... |
| Change in valuation allowance | 133,642 | 287,882 | ... |
| Income (loss) before equity loss in affiliate and noncontrolling interest | (62,891,000) | ... | ... |
| State | (16,000) | ... | ... |
| Income Taxes - Total - Deferred | 384,000 | ... | ... |
| Provision for income taxes | 384,000 | 1,026,636 | ... |
| Net income attributable to noncontrolling interest | 30,849,000 | ... | ... |
| Net income (loss) and noncontrolling interest attributable to Legacy AON Shareholders prior to the reverse recapitalization | 27,080,000 | ... | ... |
| Distribution for Preferred Shares | 2,089,000 | ... | ... |
| Distribution for Preferred Shares | 1,492,917 | ... | ... |
| Net income attributable to | ... | ... | ... |

| | | | |
|---|---------------------|-------------------|------------------|
| noncontrolling interest | (321,000) | ... | ... |
| Net income (loss) | (63,150,000) | 10,532,439 | 8,394,719 |
| Transaction expenses | 100,714,000 | ... | ... |
| Weighted average class A common stock outstanding - basic | ... | 33,350,000 | 26,954,110 |
| Weighted average class B common stock outstanding - basic | ... | 8,337,500 | 8,033,048 |
| Weighted average shares outstanding - basic | 6,685,515 | ... | ... |
| Weighted average class A common stock outstanding - diluted | ... | 33,350,000 | 26,954,110 |
| Weighted average class B common stock outstanding - diluted | ... | 8,337,500 | 8,033,048 |
| Weighted average shares outstanding - diluted | 6,685,515 | ... | ... |
| Year end shares outstanding | 34,627,367 | 41,687,500 | 41,687,500 |
| Net earnings (loss) per class A common share - basic | ... | \$0.25 | \$0.24 |
| Net earnings (loss) per class B common share - basic | ... | \$0.25 | \$0.24 |
| Net earnings (loss) per share - basic | \$(1.36) | ... | ... |
| Net earnings (loss) per class A common share - diluted | ... | \$0.25 | \$0.24 |
| Net earnings (loss) per class B common share - diluted | ... | \$0.25 | \$0.24 |
| Net earnings (loss) per share - diluted | \$(1.36) | ... | ... |
| Full-Time Employees (Period End) | 1,525 | ... | ... |
| Total number of employees | 1,525 | 2 | 2 |
| Number of unitsholders | 342 | 1 | ... |
| Number of class A common stockholders | ... | 3 | 1 |
| Number of class B common stockholders | ... | 3 | 5 |
| Total costs and expenses | 1,328,339,000 | ... | ... |
| Transaction expenses | 31,236,000 | ... | ... |
| Equity in loss of affiliate | (259,000) | ... | ... |

¹ Reclassified to conform with 2022 presentation; ² As of March 30, 2023; ³ As of April 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|---------|
| Cash | ... | 374,304 |
| Prepaid expenses | ... | 86,619 |
| Cash and cash equivalents | 28,539,000 | ... |
| Short-term marketable securities | 35,389,000 | ... |
| Patient accounts receivable, net | 129,151,000 | ... |
| Intravenous drugs | 32,388,000 | ... |
| Oral pharmaceuticals | 12,181,000 | ... |
| Inventories | 44,569,000 | ... |
| Other receivables | 34,274,000 | ... |
| Prepaid expenses and other current assets | 4,277,000 | ... |
| Current portion of notes receivable - related parties | 1,604,000 | ... |

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|--|--|---|-------------------|-------------------|------|-------------------|------------|------------|-----|----------------------|---------|---------|-----|---|--------|--------|-----|---------------|------------|------------|-----|------------------|------------|------------|-----|--------------------------|------------|------------|-----|-------------------|-----------|-----------|-----|-------------------------|-----------|-----------|-----|----------------|--------|---------|-----|-------------------------------|-----------|-----------|-----|--------------|-----------|-----------|-----|------------------------------------|-----------|-----------|-----|-----------------|---------|---------|-----|-----------------------------------|---------|---------|-------|---------------|---------|---------|-----|--------------|---------|--------|-----|-------------------|---------|---------|--------|-----------------------------|---------|---------|-----|-------------------------|---------|---------|-----|----------------------|---------|--------|-----|------------------------|---------|---------|-----|----------------|---------|--------|-----|------------------------|---------|--------|-----|--------------------------|-----------|-----------|--------|-----------------------------------|-------------|-----------|-----|--------------|-----------|---------|-----|---------------|---------|---------|-----|---------------------------------------|---------|-----------|-----|--------------------|--------|--------|-----|-------------------|---------|-----------|----------|---|------------|------------|-----------|---|------------|------------|-----------|-----------------------------|------------|------------|-----------|--|--------|----------|----------|--|--------|----------|----------|-------------------------------|-----|-----|-----|---------------------------|-----|-----|---|-------------------------------|----|-----|-----|---|--------|----------|-----|--------------------------------------|--------|----------|-----|--|--|------|------|-------------------|----------------------------|---------|-----|-----|---------|---------|---------|-----|--------------------------------|---------|---------|-----|-----------------------------------|---------|---------|---------|---------------------------|-----|---------|-----|--------------------------------------|--------|---------|-----|--------------------------|---------|-----------|---------|-----------------------------|---------|-----------|-----------|--------------------------------|-----|---------|-----|---------------------------|---------|-----|-----|------------------|-----|---------|-------|-------------------------|----------|-----|-----|-------------------------------|-----------|---------|---------|
| <p>Total current assets 277,803,000 460,923</p> <p>Cash & securities held in trust account 7,588,000 338,422,091</p> <p>Property, Plant & Equipment - Gross - Total 65,074,000 </p> <p>Accumulated depreciation and amortization 24,635,000 </p> <p>Leasehold Improvements - Gross 32,490,000 </p> <p>Furniture, fixtures and equipment - Gross 2,607,000 </p> <p>Medical equipment - Gross 15,666,000 </p> <p>Computer Equipment - Gross 3,285,000 </p> <p>Software - Gross 7,829,000 </p> <p>Construction in Progress - Gross 2,985,000 </p> <p>Signs- Gross 153,000 </p> <p>Automobiles - Gross 59,000 </p> <p>Property and equipment, net 40,439,000 </p> <p>Operating lease right-of-use assets 43,349,000 </p> <p>Notes receivable - related parties 1,150,000 </p> <p>Goodwill and intangibles, net 1,230,000 </p> <p>Deferred tax asset, net 2,894,000 </p> <p>Total assets 374,453,000 338,883,014</p> <p>Accrued offering costs & expenses 22,327,000 </p> <p>Accounts payable & accrued expenses 127,645,000 2,605,527</p> <p>Accrued compensation related costs 11,410,000 </p> <p>Excise taxes payable 971,000 </p> <p>Current portion of operating lease liabilities 6,692,000 </p> <p>Current portion of finance lease liability 1,189,000 </p> <p>Other 3,360,000 </p> <p>Excise taxes payable 2,700,000 </p> <p>Accrued other - Balancing value 15,078,000 </p> <p>Total current liabilities 169,045,000 2,605,527</p> <p>Deferred underwriting fee 11,672,500 </p> <p>Warrant liability 875,083 </p> <p>Deferred tax liability 574,998 </p> <p>Long-term debt, net 80,641,000 </p> <p>Long-term operating lease liabilities 39,803,000 </p> <p>Other long-term liabilities 14,251,000 </p> <p>Total liabilities 303,740,000 15,728,108</p> <p>Class A common stock subject to possible redemption 337,358,456 </p> <p>Class B common stock 1,000 834</p> <p>Retained earnings (accumulated deficit) (161,812,000) (14,204,384)</p> <p>Accumulated other comprehensive income (loss) 81,000 </p> <p>Series A convertible preferred stock 64,986,000 </p> <p>Class B Common Stock 3,000 </p> <p>Total stockholder's equity (deficit) (96,741,000) (14,203,550)</p> <p>Redeemable noncontrolling interest 167,025,000 </p> <p>Noncontrolling interest 429,000 </p> <p>Total Equity 70,713,000 </p> | <p>AMERIGUARD SECURITY SERVICES INC</p> <p>Annual Report</p> <p>Consolidated Income Statement, Years Ended Dec. 31 (\$):</p> <table border="0"> <tr> <td></td> <td style="text-align: center;">2023</td> <td style="text-align: center;">2022 (revised)</td> <td></td> </tr> <tr> <td>Security services</td> <td style="text-align: right;">24,327,153</td> <td style="text-align: right;">28,957,220</td> <td>...</td> </tr> <tr> <td>Other related income</td> <td style="text-align: right;">122,469</td> <td style="text-align: right;">192,717</td> <td>...</td> </tr> <tr> <td>Sales Returns, Allowances & Other Revenue Adjustments</td> <td style="text-align: right;">99,004</td> <td style="text-align: right;">10,534</td> <td>...</td> </tr> <tr> <td>Total revenue</td> <td style="text-align: right;">24,350,618</td> <td style="text-align: right;">29,139,403</td> <td>...</td> </tr> <tr> <td>Cost of revenues</td> <td style="text-align: right;">22,308,494</td> <td style="text-align: right;">25,959,005</td> <td>...</td> </tr> <tr> <td>Salaries & related taxes</td> <td style="text-align: right;">16,170,868</td> <td style="text-align: right;">17,026,802</td> <td>...</td> </tr> <tr> <td>Employee benefits</td> <td style="text-align: right;">3,266,243</td> <td style="text-align: right;">3,410,659</td> <td>...</td> </tr> <tr> <td>Sub contractor payments</td> <td style="text-align: right;">1,477,908</td> <td style="text-align: right;">3,683,379</td> <td>...</td> </tr> <tr> <td>Guard training</td> <td style="text-align: right;">94,516</td> <td style="text-align: right;">229,220</td> <td>...</td> </tr> <tr> <td>Vehicles & equipment expenses</td> <td style="text-align: right;">1,298,959</td> <td style="text-align: right;">1,608,944</td> <td>...</td> </tr> <tr> <td>Gross margin</td> <td style="text-align: right;">2,042,124</td> <td style="text-align: right;">3,180,399</td> <td>...</td> </tr> <tr> <td>Salaries, payroll taxes & benefits</td> <td style="text-align: right;">1,604,520</td> <td style="text-align: right;">1,161,982</td> <td>...</td> </tr> <tr> <td>Vehicle expense</td> <td style="text-align: right;">418,537</td> <td style="text-align: right;">461,498</td> <td>...</td> </tr> <tr> <td>General & administrative expenses</td> <td style="text-align: right;">646,509</td> <td style="text-align: right;">526,580</td> <td>4,728</td> </tr> <tr> <td>Loan interest</td> <td style="text-align: right;">277,205</td> <td style="text-align: right;">105,826</td> <td>...</td> </tr> <tr> <td>Depreciation</td> <td style="text-align: right;">110,581</td> <td style="text-align: right;">89,016</td> <td>...</td> </tr> <tr> <td>Professional fees</td> <td style="text-align: right;">531,317</td> <td style="text-align: right;">372,756</td> <td>16,589</td> </tr> <tr> <td>General liability insurance</td> <td style="text-align: right;">160,431</td> <td style="text-align: right;">120,485</td> <td>...</td> </tr> <tr> <td>Advertising & marketing</td> <td style="text-align: right;">144,747</td> <td style="text-align: right;">137,175</td> <td>...</td> </tr> <tr> <td>Licenses and permits</td> <td style="text-align: right;">108,749</td> <td style="text-align: right;">43,128</td> <td>...</td> </tr> <tr> <td>Communication services</td> <td style="text-align: right;">160,621</td> <td style="text-align: right;">130,239</td> <td>...</td> </tr> <tr> <td>Staff training</td> <td style="text-align: right;">185,004</td> <td style="text-align: right;">75,802</td> <td>...</td> </tr> <tr> <td>Livescan services fees</td> <td style="text-align: right;">125,815</td> <td style="text-align: right;">56,261</td> <td>...</td> </tr> <tr> <td>Total operating expenses</td> <td style="text-align: right;">4,474,036</td> <td style="text-align: right;">3,280,748</td> <td>21,316</td> </tr> <tr> <td>Net income (loss) from operations</td> <td style="text-align: right;">(2,431,912)</td> <td style="text-align: right;">(100,349)</td> <td>...</td> </tr> <tr> <td>Other income</td> <td style="text-align: right;">3,352,426</td> <td style="text-align: right;">461,423</td> <td>...</td> </tr> <tr> <td>Other expense</td> <td style="text-align: right;">775,115</td> <td style="text-align: right;">743,643</td> <td>...</td> </tr> <tr> <td>Net income (loss) before income taxes</td> <td style="text-align: right;">145,399</td> <td style="text-align: right;">(382,569)</td> <td>...</td> </tr> <tr> <td>Income tax expense</td> <td style="text-align: right;">22,763</td> <td style="text-align: right;">10,350</td> <td>...</td> </tr> <tr> <td>Net income (loss)</td> <td style="text-align: right;">122,636</td> <td style="text-align: right;">(392,919)</td> <td>(21,316)</td> </tr> <tr> <td>Weighted average shares outstanding - basic</td> <td style="text-align: right;">94,917,302</td> <td style="text-align: right;">94,917,302</td> <td>3,417,302</td> </tr> <tr> <td>Weighted average shares outstanding - diluted</td> <td style="text-align: right;">94,917,302</td> <td style="text-align: right;">94,917,302</td> <td>3,417,302</td> </tr> <tr> <td>Year end shares outstanding</td> <td style="text-align: right;">94,917,302</td> <td style="text-align: right;">94,917,302</td> <td>3,417,302</td> </tr> <tr> <td>Net income (loss) per common share - basic</td> <td style="text-align: right;">\$0.00</td> <td style="text-align: right;">\$(0.00)</td> <td>\$(0.20)</td> </tr> <tr> <td>Net income (loss) per common share - diluted</td> <td style="text-align: right;">\$0.00</td> <td style="text-align: right;">\$(0.00)</td> <td>\$(0.20)</td> </tr> <tr> <td>Number of full time employees</td> <td style="text-align: right;">203</td> <td style="text-align: right;">...</td> <td>...</td> </tr> <tr> <td>Total number of employees</td> <td style="text-align: right;">203</td> <td style="text-align: right;">...</td> <td>0</td> </tr> <tr> <td>Number of common stockholders</td> <td style="text-align: right;">95</td> <td style="text-align: right;">...</td> <td>...</td> </tr> <tr> <td>Basic EPS Excluding ExtraOrdinary Items</td> <td style="text-align: right;">\$0.00</td> <td style="text-align: right;">\$(0.00)</td> <td>...</td> </tr> <tr> <td>Diluted EPS Excluding ExtraOrd Items</td> <td style="text-align: right;">\$0.00</td> <td style="text-align: right;">\$(0.00)</td> <td>...</td> </tr> </table> | | 2023 | 2022 (revised) | | Security services | 24,327,153 | 28,957,220 | ... | Other related income | 122,469 | 192,717 | ... | Sales Returns, Allowances & Other Revenue Adjustments | 99,004 | 10,534 | ... | Total revenue | 24,350,618 | 29,139,403 | ... | Cost of revenues | 22,308,494 | 25,959,005 | ... | Salaries & related taxes | 16,170,868 | 17,026,802 | ... | Employee benefits | 3,266,243 | 3,410,659 | ... | Sub contractor payments | 1,477,908 | 3,683,379 | ... | Guard training | 94,516 | 229,220 | ... | Vehicles & equipment expenses | 1,298,959 | 1,608,944 | ... | Gross margin | 2,042,124 | 3,180,399 | ... | Salaries, payroll taxes & benefits | 1,604,520 | 1,161,982 | ... | Vehicle expense | 418,537 | 461,498 | ... | General & administrative expenses | 646,509 | 526,580 | 4,728 | Loan interest | 277,205 | 105,826 | ... | Depreciation | 110,581 | 89,016 | ... | Professional fees | 531,317 | 372,756 | 16,589 | General liability insurance | 160,431 | 120,485 | ... | Advertising & marketing | 144,747 | 137,175 | ... | Licenses and permits | 108,749 | 43,128 | ... | Communication services | 160,621 | 130,239 | ... | Staff training | 185,004 | 75,802 | ... | Livescan services fees | 125,815 | 56,261 | ... | Total operating expenses | 4,474,036 | 3,280,748 | 21,316 | Net income (loss) from operations | (2,431,912) | (100,349) | ... | Other income | 3,352,426 | 461,423 | ... | Other expense | 775,115 | 743,643 | ... | Net income (loss) before income taxes | 145,399 | (382,569) | ... | Income tax expense | 22,763 | 10,350 | ... | Net income (loss) | 122,636 | (392,919) | (21,316) | Weighted average shares outstanding - basic | 94,917,302 | 94,917,302 | 3,417,302 | Weighted average shares outstanding - diluted | 94,917,302 | 94,917,302 | 3,417,302 | Year end shares outstanding | 94,917,302 | 94,917,302 | 3,417,302 | Net income (loss) per common share - basic | \$0.00 | \$(0.00) | \$(0.20) | Net income (loss) per common share - diluted | \$0.00 | \$(0.00) | \$(0.20) | Number of full time employees | 203 | ... | ... | Total number of employees | 203 | ... | 0 | Number of common stockholders | 95 | ... | ... | Basic EPS Excluding ExtraOrdinary Items | \$0.00 | \$(0.00) | ... | Diluted EPS Excluding ExtraOrd Items | \$0.00 | \$(0.00) | ... | <p>Cash 2,166,118 1,751,489</p> <p>Accounts receivable, net 1,583,379 2,030,434</p> <p>Prepaid expenses 327,147 185,501</p> <p>Other current assets 61,575 38,000</p> <p>Current Portion Note Receivable 9,300 9,300</p> <p>Total current assets 4,147,519 4,014,724</p> <p>Leasehold improvements 274,133 224,132</p> <p>Machinery & equipment 290,892 278,551</p> <p>Vehicles 635,172 546,371</p> <p>Total fixed assets 1,200,197 1,049,054</p> <p>Less - accumulated depreciation 626,083 557,341</p> <p>Fixed assets, net 574,114 491,713</p> <p>Operating lease 1,005,633 302,695</p> <p>Note Receivable 340,700 340,700</p> <p>Total assets 6,067,966 5,149,832</p> <p>Accounts payable 449,921 824,098</p> <p>Accrued payroll 626,694 737,143</p> <p>Payroll liability - pension 507,793 466,075</p> <p>Accrued interest 49,035</p> <p>Long term debt, current portion 2,160,347 719,563</p> <p>Deferred revenue 722,327 887,327</p> <p>Total current liabilities 4,467,082 3,683,241</p> <p>Long term portion of notes payable 2,034,493 2,782,784</p> <p>Operating lease 1,060,015 294,387</p> <p>Total liabilities 7,561,590 6,760,412</p> <p>Common stock 159,846 159,346</p> <p>Retained earnings/(defecit) (1,653,470) (1,769,926)</p> <p>Total stockholders' equity (deficit) (1,493,624) (1,610,580)</p> <p>Total Equity (1,493,624) (1,610,580)</p> <p>□ Restated to reflect correction of errors</p> <p>Recent Dividends:</p> <p>1. Ameriguard Security Services Inc series A 8% redeemable convertible preferred. No dividends paid.</p> <p>2. Ameriguard Security Services Inc common. No dividends paid.</p> <p>Annual Dividends:</p> <p>1. Ameriguard Security Services Inc series A 8% redeemable convertible preferred. No dividends paid.</p> <p>2. Ameriguard Security Services Inc common. No dividends paid.</p> <p>AMERITEK VENTURES</p> <p>Annual Report</p> <p>Consolidated Income Statement, Years Ended Dec. 31 (\$):</p> <table border="0"> <tr> <td></td> <td style="text-align: center;">2023</td> <td style="text-align: center;">2021</td> <td style="text-align: center;">2020 (revised)</td> </tr> <tr> <td>Revenue: Operating Revenue</td> <td style="text-align: right;">949,438</td> <td style="text-align: right;">...</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Revenue</td> <td style="text-align: right;">949,438</td> <td style="text-align: right;">852,166</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Development & support expenses</td> <td style="text-align: right;">516,474</td> <td style="text-align: right;">956,641</td> <td style="text-align: right;">...</td> </tr> <tr> <td>General & administrative expenses</td> <td style="text-align: right;">223,505</td> <td style="text-align: right;">261,483</td> <td style="text-align: right;">174,500</td> </tr> <tr> <td>Salaries & wages expenses</td> <td style="text-align: right;">277</td> <td style="text-align: right;">187,094</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Depreciation & amortization expenses</td> <td style="text-align: right;">82,640</td> <td style="text-align: right;">160,645</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Total operating expenses</td> <td style="text-align: right;">822,896</td> <td style="text-align: right;">1,565,863</td> <td style="text-align: right;">174,500</td> </tr> <tr> <td>Net operating income (loss)</td> <td style="text-align: right;">126,542</td> <td style="text-align: right;">(713,697)</td> <td style="text-align: right;">(174,500)</td> </tr> <tr> <td>Gain on extinguishment of debt</td> <td style="text-align: right;">...</td> <td style="text-align: right;">874,535</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Interest (expense) income</td> <td style="text-align: right;">185,452</td> <td style="text-align: right;">...</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Interest expense</td> <td style="text-align: right;">...</td> <td style="text-align: right;">165,188</td> <td style="text-align: right;">2,749</td> </tr> <tr> <td>Net Income Before Taxes</td> <td style="text-align: right;">(58,910)</td> <td style="text-align: right;">...</td> <td style="text-align: right;">...</td> </tr> <tr> <td>Total other income (expenses)</td> <td style="text-align: right;">(185,452)</td> <td style="text-align: right;">709,347</td> <td style="text-align: right;">(2,749)</td> </tr> </table> | | 2023 | 2021 | 2020 (revised) | Revenue: Operating Revenue | 949,438 | ... | ... | Revenue | 949,438 | 852,166 | ... | Development & support expenses | 516,474 | 956,641 | ... | General & administrative expenses | 223,505 | 261,483 | 174,500 | Salaries & wages expenses | 277 | 187,094 | ... | Depreciation & amortization expenses | 82,640 | 160,645 | ... | Total operating expenses | 822,896 | 1,565,863 | 174,500 | Net operating income (loss) | 126,542 | (713,697) | (174,500) | Gain on extinguishment of debt | ... | 874,535 | ... | Interest (expense) income | 185,452 | ... | ... | Interest expense | ... | 165,188 | 2,749 | Net Income Before Taxes | (58,910) | ... | ... | Total other income (expenses) | (185,452) | 709,347 | (2,749) |
| | 2023 | 2022 (revised) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Security services | 24,327,153 | 28,957,220 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other related income | 122,469 | 192,717 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sales Returns, Allowances & Other Revenue Adjustments | 99,004 | 10,534 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total revenue | 24,350,618 | 29,139,403 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Cost of revenues | 22,308,494 | 25,959,005 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Salaries & related taxes | 16,170,868 | 17,026,802 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Employee benefits | 3,266,243 | 3,410,659 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Sub contractor payments | 1,477,908 | 3,683,379 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Guard training | 94,516 | 229,220 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Vehicles & equipment expenses | 1,298,959 | 1,608,944 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gross margin | 2,042,124 | 3,180,399 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Salaries, payroll taxes & benefits | 1,604,520 | 1,161,982 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Vehicle expense | 418,537 | 461,498 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General & administrative expenses | 646,509 | 526,580 | 4,728 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Loan interest | 277,205 | 105,826 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Depreciation | 110,581 | 89,016 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Professional fees | 531,317 | 372,756 | 16,589 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General liability insurance | 160,431 | 120,485 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Advertising & marketing | 144,747 | 137,175 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Licenses and permits | 108,749 | 43,128 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Communication services | 160,621 | 130,239 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Staff training | 185,004 | 75,802 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Livescan services fees | 125,815 | 56,261 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total operating expenses | 4,474,036 | 3,280,748 | 21,316 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) from operations | (2,431,912) | (100,349) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other income | 3,352,426 | 461,423 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Other expense | 775,115 | 743,643 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) before income taxes | 145,399 | (382,569) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Income tax expense | 22,763 | 10,350 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) | 122,636 | (392,919) | (21,316) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Weighted average shares outstanding - basic | 94,917,302 | 94,917,302 | 3,417,302 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Weighted average shares outstanding - diluted | 94,917,302 | 94,917,302 | 3,417,302 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Year end shares outstanding | 94,917,302 | 94,917,302 | 3,417,302 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) per common share - basic | \$0.00 | \$(0.00) | \$(0.20) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net income (loss) per common share - diluted | \$0.00 | \$(0.00) | \$(0.20) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of full time employees | 203 | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total number of employees | 203 | ... | 0 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Number of common stockholders | 95 | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Basic EPS Excluding ExtraOrdinary Items | \$0.00 | \$(0.00) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Diluted EPS Excluding ExtraOrd Items | \$0.00 | \$(0.00) | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2023 | 2021 | 2020 (revised) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue: Operating Revenue | 949,438 | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Revenue | 949,438 | 852,166 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Development & support expenses | 516,474 | 956,641 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| General & administrative expenses | 223,505 | 261,483 | 174,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Salaries & wages expenses | 277 | 187,094 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Depreciation & amortization expenses | 82,640 | 160,645 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total operating expenses | 822,896 | 1,565,863 | 174,500 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net operating income (loss) | 126,542 | (713,697) | (174,500) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Gain on extinguishment of debt | ... | 874,535 | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interest (expense) income | 185,452 | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Interest expense | ... | 165,188 | 2,749 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Net Income Before Taxes | (58,910) | ... | ... | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Total other income (expenses) | (185,452) | 709,347 | (2,749) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| <p>Recent Dividends:</p> <p>1. American Oncology Network Inc class A common. No dividends paid.</p> <p>2. American Oncology Network Inc class B common. No dividends paid.</p> <p>Annual Dividends:</p> <p>1. American Oncology Network Inc class A common. No dividends paid.</p> <p>2. American Oncology Network Inc class B common. No dividends paid.</p> | | <p>□ Restated to reflect correction of errors; □ Non-consolidated; □ As reported by the Company; □ Adjusted for 1-for-20 reverse stock split, March 17, 2022</p> <p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> <table border="0"> <tr> <td></td> <td style="text-align: center;">2023</td> <td style="text-align: center;">2022 (revised)</td> </tr> </table> | | | 2023 | 2022 (revised) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | 2023 | 2022 (revised) | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

| | | | |
|---|-------------|-------------|-------------|
| Net income (loss) | (58,910) | (4,350) | (177,249) |
| Weighted average shares outstanding | | | |
| - basic | 554,226,791 | 514,226,791 | 429,160,112 |
| Weighted average shares outstanding | | | |
| - diluted | 554,226,791 | 514,226,791 | 434,218,426 |
| Year end shares outstanding | 554,226,791 | 514,226,791 | 284,942,593 |
| Net income (loss) per share - basic | \$(0.00) | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | \$(0.00) | \$0.00 | \$0.00 |
| Number of common stockholders | 111 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.00) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.00) | ... | ... |

□ Shares increased due to the effect issuance of shares for conversion of debt

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|--|-------------|-------------|
| Cash | 5,618 | 32,830 |
| Accounts receivable, net | 132,380 | 254,105 |
| Prepaid expenses | 1,519 | 24,296 |
| Total current assets | 139,517 | 311,231 |
| Furniture & fixtures | ... | 7,694 |
| Computer & equipment | 28,568 | 30,651 |
| Software | 4,200 | 4,200 |
| Assets held under capital leases | 2,783 | 2,783 |
| Total property & equipment | 43,245 | 45,328 |
| Less: accumulated depreciation | 43,245 | 39,202 |
| Property & equipment, net | ... | 6,127 |
| Furniture & equipment, net | 7,694 | ... |
| Patent | 250,000 | 250,000 |
| Product development, net | ... | 559,207 |
| Goodwill, net | 2,184,715 | 2,397,002 |
| Product development | 524,117 | ... |
| Investment in securities | 661,886 | ... |
| Commitment fees (lines of credit) | 35,112 | ... |
| Total long-term assets | 3,655,830 | 3,206,209 |
| Total assets | 3,795,347 | 3,523,567 |
| Accounts payable | 987,071 | 784,067 |
| Deferred revenue | 151,005 | 245,372 |
| Accrued interest | ... | 309,624 |
| Short-term debt | 21,000 | 21,000 |
| Accrued interest and expenses | 547,204 | ... |
| Total current liabilities | 1,706,280 | 1,360,063 |
| Long term debts | 1,933,448 | ... |
| Long-term debts, net of current maturities | ... | 2,025,878 |
| Total long-term liabilities | ... | 2,025,878 |
| Total liabilities | 3,639,728 | 3,385,941 |
| Convertible preferred stock series A | 599,890 | ... |
| Preferred stock series A | ... | 74,887 |
| Preferred stock series B | ... | 100,000 |
| Preferred stock series C | ... | 368,890 |
| Preferred stock series D | ... | 90,836 |
| Preferred stock series E | ... | 230,000 |
| Common stock, \$0.001 par value, 185,000,000 shares | 554,227 | ... |
| Common stock | ... | 514,202 |
| Additional paid-in capital | 885,038 | 1,239,902 |
| Accumulated deficit | (2,379,259) | ... |
| Retained earnings (accumulated deficit) | ... | (2,481,091) |
| Preferred stock Series B, \$0001 par value, 5,000,000 shares | 100,000 | ... |
| Preferred Stock Series A- | | |

| | | |
|---|---------|---------|
| Convertible - Non-Redeemable | 74,887 | ... |
| Preferred Stock Series D-Convertible - Non-Redeemable | 90,836 | ... |
| Preferred Stock Series E - Convertible - Non-Redeemable | 230,000 | ... |
| Total stockholders' equity (deficit) | 155,619 | 137,626 |
| Total Equity | 155,619 | ... |

□ As reported by the Company

Recent Dividends:

- Ameritek Ventures series A convertible preferred.**
No dividends paid.
- Ameritek Ventures series A preferred.**
No dividends paid.
- Ameritek Ventures series C preferred.**
No dividends paid.
- Ameritek Ventures series B preferred (new).**
No dividends paid.
- Ameritek Ventures common.**
No dividends paid.
- Ameritek Ventures series E preferred.**
No dividends paid.
- Ameritek Ventures series B preferred.**
No dividends paid.
- Ameritek Ventures series D preferred.**
No dividends paid.

Annual Dividends:

- Ameritek Ventures series A convertible preferred.**
No dividends paid.
- Ameritek Ventures series A preferred.**
No dividends paid.
- Ameritek Ventures series C preferred.**
No dividends paid.
- Ameritek Ventures series B preferred (new).**
No dividends paid.
- Ameritek Ventures common.**
No dividends paid.
- Ameritek Ventures series E preferred.**
No dividends paid.
- Ameritek Ventures series B preferred.**
No dividends paid.
- Ameritek Ventures series D preferred.**
No dividends paid.

AMPLITECH GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|------------|-------------|
| Revenues | 15,584,577 | ... | ... |
| Revenue | 15,584,577 | 19,394,492 | 5,275,434 |
| Cost of goods sold | 8,308,949 | 10,469,628 | 3,982,797 |
| Gross profit | 7,275,628 | 8,924,864 | 1,292,637 |
| Selling, general & administrative expense | 7,511,319 | 7,631,250 | 4,564,658 |
| Impairment of goodwill | ... | 120,136 | ... |
| Research & development expense | 2,341,845 | 1,024,127 | 1,833,399 |
| Total operating expenses | 9,853,164 | 8,775,513 | 6,398,057 |
| Income (loss) from operations | (2,577,536) | 149,351 | (5,105,420) |
| Gain on extinguishment of debt | ... | ... | 232,200 |
| Other income | ... | ... | 255,083 |
| Realized loss on investments | 1,697 | ... | (97,862) |
| Loss on contingent revenue earnout | ... | (815,788) | ... |
| Interest expense, net | (19,281) | 13,013 | 42,806 |
| Unrealized gain (loss) on investments | 131,522 | 2,343 | ... |
| Loss on disposal of property and equipment | (16,403) | ... | ... |

| | | | |
|---|-------------|-----------|-------------|
| Total other income (expense) | 136,097 | (826,458) | 346,615 |
| Income (loss) before income taxes | (2,441,439) | (677,107) | (4,758,805) |
| Provision for income taxes | 24,000 | ... | ... |
| Net income (loss) | (2,465,439) | (677,107) | (4,758,805) |
| Weighted average shares outstanding | | | |
| - basic | 9,659,421 | 9,609,208 | 8,900,824 |
| Weighted average shares outstanding | | | |
| - diluted | 9,659,421 | 9,609,208 | 8,900,824 |
| Year end shares outstanding | 9,714,613 | 9,634,613 | 9,582,113 |
| Net income (loss) per share - basic | \$(0.26) | \$(0.07) | \$(0.53) |
| Net income (loss) per share - diluted | \$(0.26) | \$(0.07) | \$(0.53) |
| Number of full time employees | ... | 36 | 34 |
| Number of part time employees | ... | 4 | 6 |
| Number of common stockholders | 44 | 43 | 42 |
| Earnings per share from continuing operations | \$(0.26) | ... | ... |
| Earnings per share from continuing operations | \$(0.26) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of common stock issued in private placement, public offering, exercise of warrants, consulting, acquisition & additional shares issued in connection to reverse split; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 6,726,013 | 13,290,222 |
| Accounts receivables, gross | 2,542,710 | 1,801,769 |
| Accounts receivable, net | 2,542,710 | 1,801,769 |
| Raw materials | 959,645 | 872,184 |
| Work-in progress | 51,140 | 229,771 |
| Finished goods | 6,672,793 | 6,658,166 |
| Less: reserve for obsolescence | 1,146,000 | 1,128,000 |
| Total Inventory | 6,537,578 | 6,632,121 |
| Marketable securities | ... | 247,450 |
| Prepaid expenses | 1,342,335 | 194,635 |
| Total current assets | 17,148,636 | 22,166,197 |
| Lab equipment | 3,400,207 | 2,455,045 |
| Manufacturing equipment | 129,745 | 129,745 |
| Automobiles | 7,335 | 7,335 |
| Computer equipment & software | 170,643 | 148,987 |
| Leasehold improvements | 84,172 | 78,042 |
| Computer Equipment and Software | 194,238 | 210,240 |
| Property & equipment, gross | 3,986,340 | 3,029,394 |
| Less: accumulated depreciation | 1,386,892 | 1,005,707 |
| Property & equipment, net | 2,599,448 | 2,023,687 |
| Right of use operating lease assets | 3,538,798 | 4,197,324 |
| Intangible assets, net | 2,984,133 | 3,134,108 |
| Goodwill | 4,696,883 | 4,696,883 |
| Cost method investment | 348,250 | 348,250 |
| Security deposits | 91,481 | 113,185 |
| Total assets | 31,407,629 | 36,679,634 |
| Accounts payable & accrued expenses | 846,179 | 860,366 |
| Customer deposits | 14,239 | 210,848 |
| Current portion of financing lease | 16,799 | 33,480 |
| Current portion of operating lease | 541,324 | 586,379 |
| Current portion of notes payable | 80,841 | 144,358 |

| | | | | | |
|---|-------------|-------------------------------------|-------------|-------------|-------------|
| Revenue earned | 2,180,826 | attributable to common stockholders | (7,384,440) | (5,805,647) | (5,459,458) |
| Total current liabilities | 1,499,382 | 4,016,257 | | | |
| Finance lease, net of current portion | 32,537 | 49,336 | | | |
| Operating lease, net of current portion | 3,171,979 | 3,768,932 | | | |
| Notes payable, net of current portion | 89,597 | | | | |
| Deferred tax liability | 24,000 | | | | |
| Total liabilities | 4,727,898 | 7,924,122 | | | |
| Common stock | 9,715 | 9,635 | | | |
| Additional paid in capital | 36,439,739 | 36,050,161 | | | |
| Accumulated Deficit | (9,769,723) | (7,304,284) | | | |
| Total stockholders' equity (deficit) | 26,679,731 | 28,755,512 | | | |
| Total Equity | 26,679,731 | 28,755,512 | | | |

□ Reclassified to conform 2023 presentation

Recent Dividends:

1. AmpliTech Group Inc series A preferred.

No dividends paid.

2. AmpliTech Group Inc common.

No dividends paid.

Annual Dividends:

1. AmpliTech Group Inc series A preferred.

No dividends paid.

2. AmpliTech Group Inc common.

No dividends paid.

APPLIED DIGITAL CORP

Earnings, 9 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|--------------|--------------|
| Total revenues | 121,876,000 | 71,165,000 |
| Cost & expenses | 193,296,000 | (37,811,000) |
| Operating income | (71,420,000) | 1,125,000 |
| Interest expense | (2,353,000) | (94,000) |
| Other income (expense), net | (2,612,000) | (280,000) |
| Gains or losses | (85,221,000) | (39,030,000) |
| Net before taxes | (85,221,000) | (38,750,000) |
| Income taxes | (38,750,000) | (38,750,000) |
| Income contin. oper. | (85,221,000) | (38,750,000) |
| Net income | (85,221,000) | (38,750,000) |
| Earnings common share | | |
| Primary | \$(0.77) | \$(0.41) |
| Fully Diluted | \$(0.77) | \$(0.41) |
| Common Shares: | | |
| Full Diluted | 110,500,556 | 93,545,687 |
| Year-end | 122,417,839 | 94,469,399 |

APPLIED ENERGETICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Net sales | 2,631,443 | ... | ... |
| Revenue | 2,631,443 | 1,307,757 | ... |
| Cost of revenue | 637,697 | 305,675 | ... |
| Gross profit (loss) | 1,993,746 | 1,002,082 | ... |
| Selling & shipping expenses | 384,231 | ... | ... |
| General & administrative expenses | 8,771,901 | 6,129,781 | 4,903,081 |
| Selling & marketing expenses | ... | 321,384 | 317,350 |
| Research & development expenses | 233,722 | 320,506 | 281,896 |
| Total operating expenses | 9,389,854 | 6,771,671 | 5,502,327 |
| Operating income (loss) | (7,396,108) | (5,769,589) | (5,502,327) |
| Other income | 45,673 | 1,674 | 81,218 |
| Interest expense | ... | 3,727 | 4,344 |
| Total other income (expense) | 45,673 | (2,053) | 76,874 |
| Income (loss) before provision for income taxes | (7,350,435) | (5,771,642) | (5,425,453) |
| Net income (loss) | (7,350,435) | (5,771,642) | (5,425,453) |
| Preferred stock dividends | 34,005 | 34,005 | 34,005 |
| Net income (loss) | | | |

| | | | |
|--|-------------|-------------|-------------|
| Weighted average shares outstanding - basic | 211,084,080 | 208,128,246 | 200,854,103 |
| Weighted average shares outstanding - diluted | 211,084,080 | 208,128,246 | 200,854,103 |
| Year end shares outstanding | 211,236,688 | 210,848,671 | 207,562,461 |
| Earnings (loss) per share from continuing operations - basic | \$(0.03) | ... | ... |
| Net income (loss) per share - basic | \$(0.03) | \$(0.03) | \$(0.03) |
| Earnings (loss) per share from continuing operations - diluted | \$(0.03) | ... | ... |
| Net income (loss) per share - diluted | \$(0.03) | \$(0.03) | \$(0.03) |
| Total number of employees | ... | 14 | 7 |
| Number of common stockholders | 374 | 396 | 389 |

□ As of March 29, 2023; □ As of March 28, 2022; □ Approximately; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 1,319,526 | 5,640,308 |
| Contracts receivable | 567,792 | ... |
| Other assets | 148,338 | 92,774 |
| Total current assets | 2,035,656 | 6,086,231 |
| Security deposit | 17,004 | 17,004 |
| Property & equipment - net | 434,563 | 192,935 |
| Right of use asset - operating | 1,054,736 | 432,057 |
| Total long-term assets | 1,506,303 | 641,996 |
| Total assets | 3,541,959 | 6,728,227 |
| Accounts payable | 312,958 | 116,970 |
| Notes payable | ... | 400,000 |
| Due to related parties | 50,000 | 50,000 |
| Operating lease liability - current | 166,927 | 113,478 |
| Warranty reserve | 40,510 | ... |
| Accrued expenses | ... | 28,005 |
| Accrued dividends | 48,079 | 48,079 |
| Current portion of capital lease obligations | 308,908 | ... |
| Total current liabilities | 927,382 | 756,532 |
| Operating Lease Liability - non-current | 994,491 | 393,709 |
| Total long-term liabilities | 994,491 | 393,709 |
| Total liabilities | 1,921,873 | 1,150,241 |
| Series A convertible preferred stock | 14 | 14 |
| Common stock | 211,237 | 210,849 |
| Additional paid-in capital | 112,223,129 | 108,830,982 |
| Retained earnings (accumulated deficit) | (110,814,294) | (103,463,859) |
| Total stockholders' equity (deficit) | 1,620,086 | 5,577,986 |
| Rep Total Equity & Minority Interest | 1,620,086 | ... |

Recent Dividends:

1. Applied Energetics Inc series A redeemable convertible preferred.

No dividends paid.

2. Applied Energetics Inc common.

No dividends paid.

Annual Dividends:

1. Applied Energetics Inc series A redeemable convertible preferred.

No dividends paid.

2. Applied Energetics Inc common.

No dividends paid.

APPSOFT TECHNOLOGIES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-----------|-----------|----------------|
| Selling, general & administrative expense | 7,638 | 10,681 | 20,421 |
| Amortization or depreciation expense | ... | ... | 207 |
| Interest expense | 7,443 | 6,345 | 5,352 |
| Outside services expense | 2,881 | 1,888 | 22,659 |
| Professional fees | 40,380 | 12,525 | 2,215 |
| Total expense | 58,342 | 31,439 | 50,854 |
| Income (loss) from operations | (58,342) | (31,439) | (50,854) |
| Net income (loss) | (50,442) | (31,439) | (50,854) |
| Weighted average shares outstanding - basic | 4,504,103 | 4,504,103 | 4,504,103 |
| Weighted average shares outstanding - fully diluted | 4,504,103 | 4,504,103 | 4,504,103 |
| Year end shares outstanding | 4,504,103 | 4,504,103 | 4,504,103 |
| Net income (loss) per common share - basic | \$(0.01) | \$(0.01) | \$(0.01) |
| Net income (loss) per common share - fully diluted | \$(0.01) | \$(0.01) | \$(0.01) |
| Total number of employees | ... | 1 | 1 |
| Number of common stockholders | 56 | 55 | 55 |
| Income on Extinguishment of Debt | 7,900 | ... | ... |
| Net Income before Tax | (50,442) | ... | ... |

□ As of April 14, 2023; □ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash | 8 | 6 |
| Total current assets | 8 | 6 |
| Total assets | 8 | 6 |
| Accounts payable & accruals | 298 | 21,124 |
| Accrued interest | 27,541 | 20,097 |
| Total current liabilities | 27,839 | 41,221 |
| Note payable | 392,543 | 328,716 |
| Total liabilities | 420,382 | 369,937 |
| Series A cumulative, convertible preferred stock | ... | 193 |
| Common stock | 449 | 449 |
| Additional paid in capital | 533,858 | 491,458 |
| Additional paid in capital - stock warrants | ... | 42,400 |
| Accumulated Deficit | (954,875) | ... |
| Retained earnings (accumulated deficit) | ... | (904,432) |
| Convertible Preferred stock | 193 | ... |
| Total stockholder's equity (deficit) | (420,374) | (369,932) |
| Total Equity | (420,374) | ... |

Recent Dividends:

1. AppSoft Technologies Inc series A cumulative convertible preferred.

No dividends paid.

2. AppSoft Technologies Inc common.

No dividends paid.

Annual Dividends:

1. AppSoft Technologies Inc series A cumulative convertible preferred.

No dividends paid.

2. AppSoft Technologies Inc common.

No dividends paid.

APPTECH PAYMENTS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|-------------------|
| Revenues | 504,000 | ... | ... |
| Cost of revenues | 187,000 | 220,000 | 150,000 |
| Gross profit | 317,000 | 230,000 | 204,000 |
| Selling, general & administrative | 9,873,000 | 8,003,000 | 8,399,000 |
| Excess fair value of equity issuance over assets received | ... | 904,000 | 68,956,000 |
| Research and development, including stock based compensation of \$ 6,158 thousand and \$0, for the years ended 31, 2022 and 2021, respectively | 3,498,000 | ... | ... |
| Research & development | ... | 7,557,000 | 169,000 |
| Intangible assets | 6,131,000 | ... | ... |
| Total operating expenses | 19,502,000 | 16,464,000 | 77,524,000 |
| Income (loss) from operations | (19,185,000) | (16,234,000) | (77,320,000) |
| Interest expense | 52,000 | 417,000 | 3,111,000 |
| Change in fair value of derivative liability | 27,000 | 166,000 | (26,000) |
| Other income (expenses) | 715,000 | 204,000 | 1,211,000 |
| Loss on debt extinguishment | (17,000) | ... | ... |
| Total other income (expenses) | ... | (47,000) | (1,926,000) |
| Income (loss) before provision for income taxes | (18,512,000) | (16,281,000) | (79,246,000) |
| Net income (loss) | (18,512,000) | (16,281,000) | (79,246,000) |
| Deemed dividend related to warrant resets | 763,000 | ... | ... |
| Net income (loss) applicable to common shares | (19,275,000) | ... | ... |
| Weighted average outstanding shares - basic | 19,103,000 | 16,246,000 | 1,197,000 |
| Weighted average outstanding shares - diluted | 19,103,000 | 16,246,000 | 1,197,000 |
| Year end shares outstanding | 22,251,742 | 16,697,280 | 11,944,600 |
| Income (loss) per share from continuing operations - basic | \$(1.01) | ... | ... |
| Net income (loss) per common share - basic | \$(1.01) | \$(1.00) | \$(66.20) |
| Income (loss) per share from continuing operations - diluted | \$(1.01) | ... | ... |
| Net income (loss) per common share - diluted | \$(1.01) | \$(1.00) | \$(66.20) |
| Number of full time employees | 18 | 23 | 18 |
| Total number of employees | 18 | ... | ... |
| Number of common stockholders | ... | 4,512 | 280 |

Reclassified to conform with 2022 presentation; Shares increased due to issuance of shares for capitalized prepaid software development and license, convertible notes payable, accrued interest, derivative liabilities, accounts payable and services; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 1,281,000 | 3,462,000 |
| Accounts receivable | 30,000 | 51,000 |
| Prepaid expenses | 205,000 | 183,000 |
| Prepaid license fees - current | ... | 729,000 |
| Total current assets | 1,516,000 | 4,425,000 |
| Prepaid license fees - long term | ... | 2,700,000 |
| Intangible assets | ... | 311,000 |
| Note receivable | 26,000 | 26,000 |
| Right of use asset | 66,000 | 127,000 |
| Security deposit | 9,000 | 9,000 |
| Capitalized prepaid software development & license | ... | 4,921,000 |
| Goodwill | 1,161,000 | ... |
| Capitalized software development and license (net of accumulated amortization) | 1,147,000 | ... |
| Intangible assets, gross Intellectual Property | 4,428,000 | ... |
| Total assets | 8,353,000 | 12,519,000 |
| Accounts payable | ... | 347,000 |
| Accrued interest - third parties | 185,000 | 1,436,000 |
| Accrued payroll | 189,000 | 311,000 |
| Accrued residuals | 12,000 | 31,000 |
| Anti-dilution provision | 72,000 | 72,000 |
| Other accrued liabilities | 1,958,000 | 20,000 |
| Accrued liabilities | ... | 1,870,000 |
| Right of use liability | 78,000 | 64,000 |
| Stock repurchase liability | ... | 430,000 |
| Convertible notes payable | ... | 676,000 |
| Notes payable | 1,000 | 1,021,000 |
| Notes payable related parties | ... | 88,000 |
| Derivative liabilities | ... | 433,000 |
| Accounts payable & accrued liabilities | 1,799,000 | ... |
| Unearned income | 244,000 | ... |
| Payables due to seller for acquisitions | 1,500,000 | ... |
| Total current liabilities | 4,080,000 | 4,929,000 |
| Right of use liability | 14,000 | 99,000 |
| Notes payable, net of current portion | 65,000 | 67,000 |
| Total long-term liabilities | 79,000 | 166,000 |
| Total liabilities | 4,159,000 | 5,095,000 |
| Common stock | 22,000 | 17,000 |
| Additional paid-in capital | 163,921,000 | 147,881,000 |
| Accumulated deficit | (159,749,000) | ... |
| Retained earnings (accumulated deficit) | ... | (140,474,000) |
| Total stockholders' equity (deficit) | 4,194,000 | 7,424,000 |
| Total Equity | 4,194,000 | ... |

Recent Dividends:

- 1. AppTech Payments Corp series A convertible preferred.**
No dividends paid.
 - 2. AppTech Payments Corp series C convertible preferred.**
No dividends paid.
 - 3. AppTech Payments Corp common.**
No dividends paid.
- Annual Dividends:**
- 1. AppTech Payments Corp series A convertible preferred.**
No dividends paid.
 - 2. AppTech Payments Corp series C convertible preferred.**
No dividends paid.
 - 3. AppTech Payments Corp common.**

No dividends paid.

APPYEA INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|-------------------|
| Research & development expenses | 124,000 | 129,000 | 81,000 |
| Sales & marketing expenses | ... | 16,000 | 5,000 |
| Professional fees | 128,000 | ... | ... |
| General & administrative expenses | 1,386,000 | 2,017,000 | 632,000 |
| Operating income (loss) | (1,638,000) | (2,162,000) | (718,000) |
| Reverse merger cost | ... | ... | 2,457,000 |
| Change in fair value of convertible loans & warrant liability | 262,000 | 910,000 | ... |
| Financial expenses, net | 441,000 | 52,000 | 6,000 |
| Loss before income tax benefit | (1,817,000) | ... | ... |
| Consolidated net income (loss) | (1,817,000) | (1,304,000) | (3,181,000) |
| Non-controlling interests | ... | ... | 2,000 |
| Net income (loss) attributable to AppYea Inc | ... | (1,304,000) | (3,179,000) |
| Weighted average shares outstanding - basic | 257,223,239 | 219,588,562 | 118,852,344 |
| Weighted average shares outstanding - diluted | 257,223,239 | 219,588,562 | 118,852,344 |
| Year end shares outstanding | 328,836,657 | 220,930,798 | 218,246,326 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.03) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.03) |
| Full-Time Employees (Period End) | 9 | ... | ... |
| Total number of employees | 9 | 2 | ... |
| Number of common stockholders | ... | 103 | 48 |

Including net income to related party - Financial expenses, net: \$2,000; As of March 20, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------|---------|
| Cash & cash equivalents | 222,000 | 60,000 |
| Governmental authorities | ... | 12,000 |
| Other receivables | ... | 7,000 |
| Other accounts receivables | 42,000 | 19,000 |
| Inventory | 14,000 | ... |
| Total current assets | 278,000 | 79,000 |
| Computers | ... | 3,000 |
| Less: accumulated depreciation | ... | 1,000 |
| Property & equipment, net | 3,000 | 2,000 |
| Intangible assets, net | 193,000 | 124,000 |
| Total non-current asset | ... | 126,000 |
| Total assets | 474,000 | 205,000 |
| Trade payables | 51,000 | 67,000 |
| Accrued expenses | 109,000 | 62,000 |
| Deferred income | 7,000 | 6,000 |
| Government institutions | 204,000 | 4,000 |
| Employees & payroll accruals | 498,000 | 268,000 |
| Other accounts payable & related party payables | ... | 340,000 |
| Accruals | 694,000 | ... |
| Short-term loans from | ... | ... |

| | | | | | | | | | |
|---|-------------|-------------|---|-------------|------------|------------|---|---------------|---------------|
| related party | 79,000 | 80,000 | shares outstanding | | | | portion | 275,000 | 307,000 |
| Convertible loans related party | 796,000 | 36,000 | - basic | 93,931,948 | 75,811,034 | 70,002,180 | Note payable | 35,000 | 5,899,000 |
| Short-term loans | ... | 693,000 | Weighted average shares outstanding | | | | Accrued expenses | 2,467,000 | ... |
| Convertible loans - current portion | ... | 1,528,000 | - diluted | 93,931,948 | 75,811,034 | 70,002,180 | Other | 78,000 | ... |
| Warrants liability | ... | 24,000 | Year end shares outstanding | 107,880,095 | 79,481,751 | 70,416,552 | Accrued Expenses - Balancing value | 1,883,000 | ... |
| Convertible loans at fair value | 1,203,000 | ... | Net earnings (loss) per share - basic | \$(0.25) | \$(0.20) | \$(0.26) | Operating Lease Liabilities - Current Portion/Short-Term | 231,000 | ... |
| Government institutions | 80,000 | ... | Net earnings (loss) per share - diluted | \$(0.25) | \$(0.20) | \$(0.26) | Finance Leases - Current Portion | 44,000 | ... |
| Total current liabilities | ... | 2,768,000 | Number of full time employees | 53 | 30 | 23 | Total current liabilities | 4,613,000 | 12,311,000 |
| Total liabilities | ... | 2,768,000 | Gain on sale of property, plant & equipment | 23,000 | ... | ... | Lease liability, non-current portion | ... | 275,000 |
| Common Stock - Issued & Paid | 31,000 | ... | Total number of employees | 53 | ... | ... | Notes payables, non-current portion | 2,923,000 | ... |
| Common stock | ... | 21,000 | Number of common stockholders | 11 | 11 | 8 | Total liabilities | 7,536,000 | 12,586,000 |
| Additional paid-in capital | 3,197,000 | 1,912,000 | Earnings per share from continuing operations | \$(0.25) | ... | ... | Common stock | 108,000 | 79,000 |
| Stock payable | 559,000 | 27,000 | Earnings per share from continuing operations | \$(0.25) | ... | ... | Additional paid-in capital | 249,687,000 | 220,114,000 |
| Accumulated deficit | (6,326,000) | ... | | | | | Retained earnings (accumulated deficit) | (223,215,000) | (199,277,000) |
| Retained earnings (accumulated deficit) | ... | (4,509,000) | | | | | Treasury stock, at cost; common shares: 510,632 and nil as of 31, 2023 and 31, 2022, respectively | 516,000 | ... |
| Total AppYea Inc. stockholders' equity (deficiency) | (2,539,000) | (2,549,000) | | | | | Total stockholders' equity (deficit) | 26,064,000 | 20,916,000 |
| Non-controlling interests | (14,000) | (14,000) | | | | | Total Equity | 26,064,000 | ... |
| Total equity (deficiency) | (2,553,000) | (2,563,000) | | | | | | | |

Recent Dividends:**1. AppYea Inc. common.**

No dividends paid.

2. AppYea Inc. convertible preferred.

No dividends paid.

Annual Dividends:**1. AppYea Inc. common.**

No dividends paid.

2. AppYea Inc. convertible preferred.

No dividends paid.

AQUA METALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Impairment of tangible assets | 4,851,000 | ... | ... |
| Product sales | 25,000 | 4,000 | 173,000 |
| Plant operations & clean up | ... | 3,959,000 | 7,017,000 |
| Total revenues | 25,000 | ... | ... |
| Plant operations | 6,282,000 | ... | ... |
| Research & development cost | 1,741,000 | 1,813,000 | 933,000 |
| General & administrative expenses | 11,638,000 | 9,815,000 | 9,688,000 |
| Total operating expense | 24,489,000 | 15,587,000 | 17,638,000 |
| Income (loss) from operations | (24,464,000) | (15,583,000) | (17,465,000) |
| Insurance proceeds net of related expenses | ... | ... | (4,794,000) |
| Impairment expense | ... | 579,000 | 545,000 |
| Paycheck Protection Program loan forgiveness | ... | ... | 332,000 |
| Gain (loss) on disposal of property & equipment | ... | 596,000 | (5,665,000) |
| Interest expense | 621,000 | 125,000 | 21,000 |
| Interest & other income | 1,147,000 | 262,000 | 379,000 |
| Total other income (expense), net | 526,000 | 154,000 | (726,000) |
| Income (loss) before income tax expense (benefit) | (23,938,000) | (15,429,000) | (18,191,000) |
| Current state income taxes | ... | 2,000 | 2,000 |
| Income tax expense (benefit) | ... | 2,000 | 2,000 |
| Net income (loss) | (23,938,000) | (15,431,000) | (18,193,000) |
| Weighted average | | | |

Reclassified to conform with 2022 presentation; As of February 17, 2023; As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 16,522,000 | 7,082,000 |
| Accounts receivable | 67,000 | 12,000 |
| Lease receivable, current portion | ... | 15,527,000 |
| Finished goods | ... | 28,000 |
| Work in process | 135,000 | ... |
| Raw materials | 794,000 | 250,000 |
| Inventory | 929,000 | 278,000 |
| Assets held for sale | ... | 47,000 |
| Prepaid expenses & other current assets | 181,000 | 263,000 |
| Note receivable | 600,000 | ... |
| Total current assets | 18,299,000 | 23,209,000 |
| Operational equipment | 3,581,000 | 1,445,000 |
| Lab equipment | 817,000 | 730,000 |
| Computer equipment | 89,000 | 6,000 |
| Office furniture & equipment | 90,000 | 90,000 |
| Leasehold improvements | 80,000 | 80,000 |
| Land | 1,141,000 | ... |
| Building | 3,131,000 | ... |
| Equipment under construction | 3,047,000 | 6,486,000 |
| Property & equipment, gross | 11,976,000 | 8,837,000 |
| Less: accumulated depreciation | 1,629,000 | 1,494,000 |
| Property & equipment, net | 10,347,000 | 7,343,000 |
| Intellectual property, net | 281,000 | 461,000 |
| Investment in LINICO Corporation | ... | 2,000,000 |
| Alameda & Nevada facilities right of use assets | ... | 463,000 |
| Equipment deposits | ... | 6,000 |
| Other assets | ... | 20,000 |
| Other assets | 4,673,000 | 489,000 |
| Total non-current assets | 15,301,000 | 10,293,000 |
| Total assets | 33,600,000 | 33,502,000 |
| Accounts payable | 1,836,000 | 1,075,000 |
| Property & equipment related | ... | 770,000 |
| Class action settlement | ... | 500,000 |
| Payroll related | 506,000 | 418,000 |
| Professional services | ... | 51,000 |
| Other accrued liabilities | ... | 41,000 |
| Accrued liabilities | ... | 1,780,000 |
| Building purchase deposit, current portion | ... | 3,250,000 |
| Lease liability, current | ... | ... |

Recent Dividends:**1. Aqua Metals Inc common.**

No dividends paid.

Annual Dividends:**1. Aqua Metals Inc common.**

No dividends paid.

AQUABOUTY TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Total revenues | 2,472,659 | ... | ... |
| Product revenues | 2,472,659 | 3,136,954 | 1,174,832 |
| Product costs | 15,281,635 | 13,630,911 | 10,786,072 |
| Sales & marketing expenses | 795,931 | 1,138,781 | 1,261,764 |
| Research & development expenses | 703,823 | 903,981 | 2,145,548 |
| General & administrative expenses | 13,007,869 | 9,786,819 | 9,103,213 |
| Total costs & expenses | 29,789,258 | 25,460,492 | 23,296,597 |
| Operating income (loss) | (27,316,599) | (22,323,538) | (22,121,765) |
| Interest expense | 303,967 | 291,177 | 316,442 |
| Other income (expense), net | 62,665 | 457,520 | 115,619 |
| Total other income (expense) | (241,302) | 166,343 | (200,823) |
| Net income (loss) | (27,557,901) | (22,157,195) | (22,322,588) |
| Weighted average shares outstanding | | | |
| - basic | 3,844,239 | 3,553,426 | 3,471,403 |
| Weighted average shares outstanding - diluted | 3,844,239 | 3,553,426 | 3,471,403 |
| Year end shares outstanding | 3,847,022 | 3,555,536 | 3,551,287 |
| Earnings (loss) per share - basic | \$(7.17) | \$(6.20) | \$(6.40) |
| Earnings (loss) per share - diluted | \$(7.17) | \$(6.20) | \$(6.40) |
| Full-Time Employees (Period End) | 104 | ... | ... |
| Total number of employees | 104 | 100 | 95 |
| Number of common stockholders | ... | 214 | 281 |
| Foreign currency | | | |

| | | | |
|---|--------------|-----------|--------|
| translation adjustments | ... | (301,288) | 51,771 |
| Income from cont operations before income tax | (27,557,901) | ... | ... |
| Earnings per share from continuing operations | \$(7.17) | ... | ... |
| Earnings per share from continuing operations | \$(7.17) | ... | ... |

⊠ Adjusted for 1-for-20 stock split, October 16, 2023; ⊡ Shares increased due to the effect of cashless exercise of options for common stock, issuance of common stock, exercise of warrants and share based compensation; ⊢ Approximately; ⊣ As of March 3, 2023; ⊤ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|-------------|
| Cash & cash equivalents | 8,203,869 | 101,638,557 |
| Marketable securities | 9,651 | ... |
| Feed | 167,136 | 366,957 |
| Eggs & fry | 147,998 | 22,140 |
| Fish in process | 1,418,469 | 1,869,387 |
| Fish for sale | ... | 18,108 |
| Inventory | 1,733,603 | ... |
| Inventory, net | ... | 2,276,592 |
| Prepaid insurance | 388,049 | ... |
| Prepaid supplies | 85,988 | ... |
| Prepaid professional services | 1,700,273 | ... |
| Receivables | 1,216,585 | ... |
| Total current assets | 11,637,745 | 106,048,732 |
| Land | 2,974,685 | 2,968,561 |
| Building & improvements | 15,804,739 | 15,535,904 |
| Construction in process | 147,755,336 | 78,806,762 |
| Equipment | 18,285,038 | 17,259,301 |
| Office furniture & equipment | 231,758 | 258,972 |
| Vehicles | 108,120 | 106,074 |
| Total property & equipment | 185,159,676 | 114,935,574 |
| Less: accumulated depreciation & amortization - property, plant & equipment | 10,778,294 | 8,649,388 |
| Property, plant & equipment, net | 174,381,382 | 106,286,186 |
| Right of use assets, net | 281,104 | 222,856 |
| Intangible assets, net | 204,436 | 218,139 |
| Restricted cash | 1,000,000 | 1,000,000 |
| Other assets | 46,761 | 64,859 |
| Total assets | 187,551,428 | 213,840,772 |
| Accrued employee compensation | 754,621 | 1,021,740 |
| Current debt | 795,300 | 2,387,231 |
| Other current liabilities | 30,863 | 20,830 |
| Total current liabilities | 14,572,603 | 15,430,393 |
| Long-term lease obligation | 250,241 | 203,227 |
| Atlantic Canada Opportunities Agency ("ACOA") Atlantic Innovation Fund ("AIF") grant | ... | 2,119,476 |
| ACOA term loan | ... | 576,401 |
| Kubota Canada Ltd | ... | 21,077 |
| PEI finance term loan | ... | 1,752,547 |
| DFO term loan | ... | 854,885 |
| First Farmers Bank & Trust term loan | ... | 3,401,019 |
| Total debt | ... | 8,725,405 |
| Less: debt issuance costs | ... | (52,065) |
| Less: current portion | ... | 2,387,231 |
| Long-term debt | 7,711,866 | 6,286,109 |
| Total liabilities | 22,534,710 | 21,919,729 |
| Common stock | 3,847 | 71,111 |
| Additional paid-in capital | 385,998,213 | 385,388,684 |
| Accumulated other comprehensive income (loss) | (405,464) | (516,775) |
| Accumulated deficit | (220,579,878) | ... |

| | | |
|---|-------------|---------------|
| Retained earnings (accumulated deficit) | ... | (193,021,977) |
| Total stockholders' equity (deficit) | 165,016,718 | 191,921,043 |
| Total Equity | 165,016,718 | ... |

Recent Dividends:
1. AquaBounty Technologies Inc common.
 No dividends paid.
Annual Dividends:
1. AquaBounty Technologies Inc common.
 No dividends paid.

ARCADIA BIOSCIENCES INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | ⊡2022 (revised) | ⊡2021 (revised) |
|--|----------|-----------------|-----------------|
| Revenues - product | ... | ... | 6,587 |
| Revenues - license | ... | ... | 17 |
| Revenues - royalty | ... | ... | 176 |
| Product | ... | 6,422 | ... |
| License | 17 | 879 | ... |
| Royalty | 5,313 | 117 | ... |
| Total revenues | 5,330 | 7,418 | 6,780 |
| Cost of revenues | 3,300 | 6,101 | 8,708 |
| Research & development expense | 1,387 | 1,509 | 3,889 |
| Gain on sale of Verdeca LLC | ... | 1,138 | ... |
| Loss on sale of Arcadia Spain | ... | ... | (497) |
| Impairment of intangible asset | ... | 141 | 3,302 |
| Impairment of goodwill | ... | ... | 1,648 |
| Change in fair value of contingent consideration | ... | 70 | 210 |
| Loss (gain) on sale of property & equipment | 40 | 314 | ... |
| Impairment of property & equipment, net | 113 | 160 | 1,534 |
| Selling, general & administrative expense | 14,508 | 15,036 | 22,938 |
| Total operating expenses | 19,268 | 21,425 | 42,306 |
| Income (loss) from operations | (13,938) | (14,007) | (35,526) |
| Interest income (expense) | 695 | 289 | (20) |
| Other income, net | 48 | 9 | 10,114 |
| Change in fair value of common stock warrant & common stock adjustment feature liabilities | (6,076) | ... | ... |
| Change in fair value of common stock warrant & option liabilities | 6,544 | 3,209 | 8,946 |
| Gain on extinguishment of PPP loan | ... | ... | 1,123 |
| Issuance & offering costs | ... | ... | 769 |
| Income (loss) before income taxes | ... | ... | (16,006) |
| - domestic | ... | ... | (126) |
| Income (loss) before income taxes - foreign | ... | ... | (126) |
| Net income (loss) before income taxes | (13,157) | (10,814) | (16,132) |
| Current income tax provision (benefit) - state | 7 | 13 | 2 |
| Current income tax provision (benefit) | ... | ... | ... |

| | | | |
|---|-----------|-----------|------------|
| - foreign | 1 | 1 | ... |
| Total current income tax provision (benefit) | 8 | 14 | 2 |
| Net loss from continuing operations | (13,165) | (10,828) | ... |
| Income tax provision (benefit) | 8 | 14 | 2 |
| Net income (loss) | (13,986) | (15,612) | (16,134) |
| Net loss (income) attributable to non-controlling interest | 5 | 236 | ⊠1,474 |
| Net income (loss) attributable to common stockholders | (13,981) | (15,376) | (14,660) |
| Weighted average shares outstanding | | | |
| - basic | 1,237 | 599 | ⊠532 |
| Weighted average shares outstanding - diluted | 1,237 | 599 | ⊠532 |
| Year end shares outstanding | 1,285 | 616 | ⊠⊠555 |
| Net earnings (loss) per share - basic | \$(10.64) | \$(17.67) | ⊠\$(27.56) |
| Net earnings (loss) per share - diluted | \$(10.64) | \$(17.67) | ⊠\$(27.56) |
| Number of full time employees | 21 | ... | ⊠58 |
| Total number of employees | 21 | ... | ... |
| Number of common stockholders | 38 | ... | ⊠⊠43 |
| Income from continuing operations | (13,165) | (10,828) | ... |
| Discontinued operations | (821) | (4,784) | ... |
| Earnings per share from continuing operations | \$(10.64) | \$(17.67) | ... |
| Earnings per share-inc from discontinued oper | \$(0.66) | \$(7.98) | ... |
| Earnings per share-total discontinued opers | \$(0.66) | \$(7.98) | ... |
| Earnings per share from continuing operations | \$(10.64) | \$(17.67) | ... |
| Earn per share-inc from discount opers - diluted | \$(0.66) | \$(7.98) | ... |
| Earning per share-total discount opers - diluted | \$(0.66) | \$(7.98) | ... |
| Issuance and offering costs allocated to liability classified options | (430) | (314) | ... |

⊠ Restated to reflect correction of errors; ⊡ Reclassified to conform with 2022 presentation; ⊢ Shares increased due to the effect of issuance of shares for related to the PIPE, closing of Arcadia Wellness acquisition, exercise of service, performance warrants and employee stock purchase plan; ⊣ Adjusted for 1-for-40 stock split, March 1, 2023; ⊤ As is; ⊥ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 (revised) |
|--|-------|----------------|
| Cash & cash equivalents | 6,518 | 20,644 |
| Short-term investments | 5,124 | ... |
| Accounts receivable & other receivables, gross | ... | 1,290 |
| Allowance for doubtful accounts | ... | 3 |
| Accounts receivable and other receivables, net of allowance for doubtful | ... | ... |

| accounts of \$1 and \$3 as of 30, 2023 and 31, 2022, respectively | | No dividends paid. | | ARENA GROUP HOLDINGS INC DEL Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | Current income tax provision (benefit) | | | | | |
|---|-----------|--------------------|------|---|---|--------------------------|---|--------------|--|-------------------------|--------------|--------------|
| | | 2023 | 2022 | 2021 | | | | | | | | |
| Accounts receivable & other receivables, net | 514 | 1,287 | | | Revenue | 244,203,000 | 220,935,000 | 189,140,000 | Current income tax provision (benefit) - state | 88,000 | | |
| Inventories, net - current | 1,958 | 2,571 | | | Revenue | 244,203,000 | 220,935,000 | 189,140,000 | - state & local | | 77,000 | |
| Assets held for sale | 51 | 87 | | | Cost of revenue | 142,240,000 [Ⓐ] | 132,923,000 [Ⓐ] | 110,530,000 | Total current income tax provision (benefit) | 88,000 | 77,000 | |
| Prepaid expenses & other current assets | 807 | 809 | | | Gross profit (loss) | 101,963,000 | 88,012,000 | 78,610,000 | Deferred income tax provision (benefit) | | | |
| Total current assets | 14,972 | 25,398 | | | Selling & marketing | | 72,489,000 | 81,929,000 | - federal | 57,000 | (12,593,000) | (18,028,000) |
| Laboratory equipment | | 679 | | | Selling, general & administrative expenses | 74,245,000 | | | Deferred income tax provision (benefit) - state | 77,000 | | |
| Software & computer equipment | 273 | 407 | | | General & administrative | 44,152,000 | 53,499,000 | 55,612,000 | Deferred income tax provision (benefit) - state & local | | (3,506,000) | (4,440,000) |
| Machinery & equipment | 440 | 450 | | | Depreciation & amortization | 18,924,000 | 17,650,000 | 16,345,000 | Change in valuation allowance | | 14,959,000 | 20,794,000 |
| Furniture & fixtures | | 83 | | | Loss on impairment of assets | 325,000 | 257,000 | 1,192,000 | Total deferred income tax provision (benefit) | 134,000 | (1,140,000) | (1,674,000) |
| Vehicles | 202 | 306 | | | Loss on termination of lease | 119,000 | | 466,000 | Income tax provision (benefit) | 222,000 | (1,063,000) | (1,674,000) |
| Leasehold improvements | 1,590 | 1,590 | | | Total operating expenses | 137,765,000 | 143,895,000 | 162,889,000 | Income (loss) from operations | (55,582,000) | (67,388,000) | (89,940,000) |
| Assets under construction | 39 | | | | Income (loss) from operations | (35,802,000) | (55,883,000) | (84,279,000) | Income (loss) from discontinued operations, net of tax | | (3,470,000) | |
| Software and computer equipment | 349 | | | | Change in valuation of warrant derivative liabilities | | | 34,000 | Net income (loss) | (55,582,000) | (70,858,000) | (89,940,000) |
| Property & equipment, gross | 2,893 | 3,515 | | | Amortization of debt costs - senior secured notes | | 1,031,000 | | Weighted average shares outstanding - basic | 22,323,763 | 17,625,619 | 11,429,740 |
| Less accumulated depreciation & amortization | 2,509 | 2,811 | | | Amortization of debt costs - delayed draw term notes | | 464,000 | | Weighted average shares outstanding - diluted | 22,323,763 | 17,625,619 | 11,429,740 |
| Property & equipment, net | 384 | 704 | | | Amortization of debt costs - bridge notes | | 77,000 | | Year end shares outstanding | 23,836,706 [Ⓐ] | 18,303,193 | 12,635,591 |
| Right of use assets | 792 | 1,848 | | | Amortization of debt costs - line of credit | | 9,000 | | Income (loss) per share - continuing operations - basic | \$(2.49) | \$(3.82) | \$(7.87) |
| Inventories, net - noncurrent | 3,354 | 767 | | | Amortization of debt discount | | 1,581,000 | | Earnings per share-inc from discontinued oper | \$0.00 | | |
| Intangible assets, net | 39 | 40 | | | Accrued & noncash converted interest - bridge notes | | 204,000 | | Net income (loss) per share - basic | \$(2.49) | \$(4.02) | \$(7.87) |
| Other noncurrent assets | 164 | 165 | | | Accrued & noncash converted interest - parade | | 116,000 | | Income (loss) per share - continuing operations - diluted | \$(2.49) | \$(3.82) | \$(7.87) |
| Total assets | 19,705 | 28,922 | | | Accrued & noncash converted interest - other | | 980,000 | | Income (loss) per share - discontinued operations - diluted | \$0.00 | \$(0.20) | |
| Accounts payable - trade | 801 | 931 | | | Cash paid interest - senior secured notes | | 6,356,000 | | Net income (loss) per share - diluted | \$(2.49) | \$(4.02) | \$(7.87) |
| Payroll & benefits | 1,303 | 1,373 | | | Cash paid interest - delayed draw term notes | | 980,000 | | Number of full time employees | 441 | 391 | 333 |
| Inventory | | 69 | | | Cash paid interest - line of credit | | 1,328,000 | | Number of part time employees | 7 | 9 | 21 |
| Royalty fees due to unrelated parties | | 6 | | | Cash paid interest - other | | 864,000 | | Total number of employees | 448 | 400 | 364 |
| Consulting | | 8 | | | Cash paid interest - line of credit | | 1,328,000 | | Number of common stockholders | 162 | 186 | 190 |
| Rent & utilities | | 28 | | | Interest expense, net | | 17,965,000 | | | | | |
| Audit & tax fees | 218 | 99 | | | Liquidated damages | 583,000 | 1,140,000 | 2,637,000 | | | | |
| Legal | 40 | 69 | | | Gain upon debt extinguishment | | | 5,717,000 | | | | |
| Other accounts payable & accrued expenses | 58 | 298 | | | Gain on distribution of investment in ClearSign Combustion Corporation | (1,010,000) | | | | | | |
| Accrued interest on notes payable | 4 | | | | Total other income (expenses) | (19,558,000) | (12,568,000) | (7,335,000) | | | | |
| Amounts due to related parties | | 48 | | | Income (loss) before income taxes | (55,360,000) | (68,451,000) | (91,614,000) | | | | |
| Operating lease liability - current | 852 | 1,010 | | | | | | | | | | |
| Other current liabilities | 270 | 270 | | | | | | | | | | |
| Other | 44 | | | | | | | | | | | |
| Total current liabilities | 3,590 | 4,209 | | | | | | | | | | |
| Operating lease liability - noncurrent | 155 | 1,007 | | | | | | | | | | |
| Common stock warrant liabilities | 1,257 | | | | | | | | | | | |
| Common stock warrant & option liabilities | | 806 | | | | | | | | | | |
| Other noncurrent liabilities | 2,000 | 2,000 | | | | | | | | | | |
| Total liabilities | 7,002 | 8,022 | | | | | | | | | | |
| Common stock | 65 | 65 | | | | | | | | | | |
| Additional paid-in capital | 284,515 | 278,827 | | | | | | | | | | |
| Accumulated other comprehensive income (loss) | 101 | | | | | | | | | | | |
| Accumulated deficit | (271,840) | | | | | | | | | | | |
| Retained earnings (accumulated deficit) | | (257,859) | | | | | | | | | | |
| Total Arcadia Biosciences Inc. stockholders' equity (deficit) | 12,841 | 21,033 | | | | | | | | | | |
| Non-controlling interest | (138) | (133) | | | | | | | | | | |
| Total stockholders' equity (deficit) | 12,703 | 20,900 | | | | | | | | | | |

Recent Dividends:**1. Arcadia Biosciences Inc common.**

No dividends paid.

Annual Dividends:**1. Arcadia Biosciences Inc common.**

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Includes amortization of developed technology & platform development - Cost of revenue: \$9,459,000; [Ⓒ] Includes amortization of developed technology & platform development - Cost of revenue: \$8,829,000; [Ⓓ] As reported by the Company; [Ⓔ] Shares increased due to the effect of issuance of common stock for restricted stock units, withheld for taxes, connection with acquisition, merger, pro-

professional services and liquidated damages; [Ⓔ] Shares increased due to the effect of issuance of common stock upon conversion of Series H convertible preferred stock, in connection with public offering and upon exercise of stock options; [Ⓙ] Approximately; [Ⓚ] As of March 21, 2023; [Ⓛ] A of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash & cash equivalents | 9,284,000 | 13,871,000 |
| Restricted cash | ... | 502,000 |
| Accounts receivable, gross | 45,792,000 | 36,186,000 |
| Less: allowance for doubtful accounts | 981,000 | 2,236,000 |
| Accounts receivable, net | 44,811,000 | 33,950,000 |
| Subscription acquisition costs, current portion | 29,706,000 | 25,931,000 |
| Prepaid expenses | ... | 2,321,000 |
| Prepaid supplies | ... | 927,000 |
| Prepaid software license | 6,598,000 | ... |
| Refundable income & franchise taxes | ... | 957,000 |
| Unamortized debt costs | ... | 216,000 |
| Other receivables | ... | 20,000 |
| Prepayments & other current assets | ... | 4,441,000 |
| Total current assets | 90,399,000 | 78,695,000 |
| Office equipment and computers | 1,744,000 | ... |
| Less: accumulated depreciation | 1,582,000 | ... |
| Office equipment & computers | 166,000 | 1,744,000 |
| Furniture & fixtures | ... | 240,000 |
| Gross property & equipment | ... | 1,984,000 |
| Less accumulated depreciation & amortization | ... | 1,249,000 |
| Property & equipment, net | 328,000 | 735,000 |
| Operating lease right-of-use assets | 176,000 | 372,000 |
| Platform development, net | 8,723,000 | 10,330,000 |
| Subscription acquisition costs, net of current portion | 7,215,000 | 14,133,000 |
| Acquired & other intangible assets, net | ... | 58,970,000 |
| Intangible assets, net | 38,459,000 | ... |
| Other long-term assets | 1,003,000 | 1,140,000 |
| Goodwill | 42,575,000 | 39,344,000 |
| Total assets | 188,878,000 | 203,719,000 |
| Accounts payable | ... | 12,863,000 |
| General accrued expenses | ... | 6,339,000 |
| Accrued payroll & related taxes | ... | 5,221,000 |
| Accrued publisher expenses | ... | 4,911,000 |
| Deferred cash payments in connection with acquisitions | 1,571,000 | ... |
| Deferred cash payments | ... | 1,123,000 |
| Sales tax liability | ... | 645,000 |
| Restricted stock liabilities | 30,771,000 | ... |
| Lease termination liability | ... | 4,753,000 |
| Other accrued expenses | ... | 110,000 |
| Accrued expenses & other current liabilities | ... | 23,102,000 |
| Line of credit | ... | 14,092,000 |
| Unearned revenue | 59,786,000 | 58,703,000 |
| Subscription refund liability | 449,000 | 845,000 |
| Operating lease liabilities | 358,000 | 427,000 |
| Liquidated damages payable | 10,357,000 | 5,843,000 |
| Bridge notes | 7,887,000 | 34,805,000 |
| Current portion of long-term debt | 102,309,000 | 65,684,000 |
| Convertible debt | 19,609,000 | ... |
| Liquidated damages | ... | ... |

| | | |
|---|---------------|---------------|
| payable | 2,924,000 | ... |
| Total current liabilities | 236,021,000 | 216,364,000 |
| Unearned revenue, net of current portion | 10,679,000 | 19,701,000 |
| Operating lease liabilities, net of current portion | ... | 358,000 |
| Liquidating damages payable, net of current portion | ... | 494,000 |
| Other long-term liabilities | 406,000 | 5,307,000 |
| Deferred tax liabilities | 599,000 | 465,000 |
| Total liabilities | 247,705,000 | 242,689,000 |
| Series G redeemable & convertible preferred stock | 168,000 | 168,000 |
| Series H convertible preferred stock | ... | 13,008,000 |
| Total mezzanine equity | ... | 13,176,000 |
| Common stock | 237,000 | 182,000 |
| Additional paid-in capital | 319,421,000 | 270,743,000 |
| Accumulated Deficit | (378,653,000) | ... |
| Retained earnings (accumulated deficit) | ... | (323,071,000) |
| Total stockholders' equity (deficiency) | (58,995,000) | (52,146,000) |
| Total Equity | (58,995,000) | ... |

Recent Dividends:

1. Arena Group Holdings Inc DEL series J convertible preferred.

No dividends paid.

2. Arena Group Holdings Inc DEL common.

No dividends paid.

3. Arena Group Holdings Inc DEL series G redeemable and convertible preferred (stated value: \$1,000).

No dividends paid.

4. Arena Group Holdings Inc DEL series I convertible preferred.

No dividends paid.

5. Arena Group Holdings Inc DEL series H convertible preferred (stated value: \$1,000).

No dividends paid.

Annual Dividends:

1. Arena Group Holdings Inc DEL series J convertible preferred.

No dividends paid.

2. Arena Group Holdings Inc DEL common.

No dividends paid.

3. Arena Group Holdings Inc DEL series G redeemable and convertible preferred (stated value: \$1,000).

No dividends paid.

4. Arena Group Holdings Inc DEL series I convertible preferred.

No dividends paid.

5. Arena Group Holdings Inc DEL series H convertible preferred (stated value: \$1,000).

No dividends paid.

ARTS WAY MANUFACTURING CO INC

Earnings, 3 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|------------------|----------------|
| Total revenues | 5,723,394 | 7,086,864 |
| Cost & expenses | 6,103,476 | 6,543,418 |
| Operating income | (380,082) | 543,446 |
| Interest expense | 165,639 | 111,813 |
| Other income (expense), net | 8,685 | 11,993 |
| Net before taxes | (537,036) | 443,626 |
| Income taxes | (112,777) | 93,331 |
| Income contin. oper. | (424,259) | 350,295 |
| Net income | (465,040) | 342,210 |
| Earnings common share | | |
| Primary | \$(0.09) | \$0.07 |
| Fully Diluted | \$(0.09) | \$0.07 |
| Common Shares: | | |
| Full Diluted | 5,022,680 | 4,976,955 |
| Year-ended | 5,068,208 | 5,028,222 |

Consolidated Balance Sheet Items, as of (\$):

| | 2024 |
|--------------------|------------|
| Assets: | |
| Cash & equivalents | 2,485 |
| Inventories | 10,983,337 |
| Current assets | 14,710,695 |

| | |
|-----------------------|------------|
| Net property & equip. | 5,158,408 |
| Total assets | 24,253,995 |
| Liabilities: | |
| Current liabilities | 9,735,143 |
| Long-term debt | 3,302,788 |
| Stockholders' equity | 11,204,518 |
| Net current assets | 4,975,552 |

**ASP ISOTOPES INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓜ] 2021 (revised) |
|---|---------------------|-------------------------|-----------------------------|
| Research & development expenses | 764,581 | 1,273,536 | 41,610 |
| General & administrative expenses | 15,416,388 | 3,825,512 | 2,566,432 |
| Total operating expenses | 16,180,969 | 5,099,048 | 2,608,042 |
| Income (loss) from operations | (16,041,999) | (5,099,048) | (2,608,042) |
| Change in fair value of share liability | (194,540) | 150,527 | ... |
| Interest income | 9,074 | 3,382 | 115 |
| Revenue | 433,026 | ... | ... |
| Foreign exchange transaction gain | 45,753 | ... | ... |
| Interest expense | 118,547 | ... | ... |
| Total other income | (258,260) | 153,909 | 115 |
| Total revenues | 433,026 | ... | ... |
| Income (loss) from operations before taxes - domestic | ... | (3,205,342) | (2,388,630) |
| Income (loss) from operations before taxes - foreign | ... | (1,739,797) | (219,297) |
| Cost of goods sold | 294,056 | ... | ... |
| Income (loss) from operations before taxes | (16,300,259) | (4,945,139) | (2,607,927) |
| Net Income After Extraordinary Items applicable to Common | (16,286,234) | ... | ... |
| Minority Interest - Total | 7,892 | ... | ... |
| Net income (loss) | (16,294,126) | (4,945,139) | (2,607,927) |
| Weighted average shares outstanding - basic | 33,066,708 | 26,793,748 | 16,246,432 |
| Weighted average shares outstanding - diluted | 33,066,708 | 26,793,748 | 16,246,432 |
| Year end shares outstanding | 48,923,276 | [Ⓝ] 35,907,127 | 20,652,500 |
| Net income (loss) per share - basic | \$(0.49) | \$(0.18) | \$(0.16) |
| Net income (loss) per share - diluted | \$(0.49) | \$(0.18) | \$(0.16) |
| Number of full time employees | 76 | 4 | ... |
| Total number of employees | 76 | ... | [Ⓟ] 4 |
| Number of common stockholders | 30 | [Ⓠ] 55 | ... |
| Foreign currency translation adjustments | ... | 236,307 | ... |
| Income tax provision | (6,133) | ... | ... |
| As Reported Gross Profit | 138,970 | ... | ... |
| Cost of Revenues - Total | 294,056 | ... | ... |

[Ⓛ] From September 13, 2021 (inception); [Ⓜ] Reclassified to conform with 2022 presentation; [Ⓝ] Shares increased due to the effect of issuance of common shares in connection with initial public offering and upon exercise of warrants as well as issuance of restricted shares; [Ⓟ] As of September 30, 2022; [Ⓠ] As of March 29,

| 2023 | | | ASPIRA WOMENS HEALTH INC | | | ASSET ENTITIES INC | | |
|---|--------------|-------------|---|--|----------|---|-----------|-----------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | Annual Report | | | Annual Report | | |
| | | | Consolidated Income Statement, Years Ended Dec. 31 | | | Consolidated Income Statement, Years Ended Dec. 31 | | |
| | | | (\$000): | | | (\$000): | | |
| | | | 2023 | 2022 | 2021 | 2023 | 2022 | 2021 |
| | | | | | | (revised) | | |
| Cash | 7,908,181 | 2,389,140 | Revenue - product | 7,970 | 6,568 | Cash & cash equivalents | 2,597 | 13,306 |
| Prepaid expenses & other current assets | 1,664,023 | 913,005 | Revenue - genetics | 214 | 244 | Accounts receivable, gross | 1,474 | 1,254 |
| Accounts receivable | 216,504 | ... | Genetics | 1 | ... | Less: allowance for doubtful accounts | 15 | 9 |
| Receivable from noncontrolling interests | 721,548 | ... | Total revenue | 9,154 | 8,184 | Accounts receivable, net | 1,459 | 1,245 |
| Total current assets | 10,510,256 | 3,302,145 | Products | 3,892 | ... | Prepaid expenses & other current assets | 997 | 1,442 |
| Construction in progress | 9,108,923 | 8,200,595 | Cost of revenue - product | 3,698 | 3,016 | Inventories | 227 | 316 |
| Property and equipment, at cost | 60,447 | ... | Cost of revenue - genetics | 167 | 734 | Total current assets | 5,280 | 16,309 |
| Equipment | 60,447 | ... | Total cost of revenue | 3,892 | 3,865 | Machinery & equipment | 363 | 891 |
| Property and equipment, at cost | 39,849 | ... | Gross profit (loss) | 5,262 | 4,319 | Computer equipment & software | 189 | 1,386 |
| Property and equipment, at cost | 1,639 | ... | Research & development | 4,035 | 5,953 | Furniture & fixtures | ... | 181 |
| Property and equipment, at cost | 59,588 | ... | Sales & marketing | 7,812 | 14,948 | Leasehold improvements | 52 | 721 |
| Property and equipment, at cost | 21,446 | ... | General & administrative | 12,267 | 16,183 | Computer equipment and software | 1,377 | ... |
| Improvements | 21,446 | ... | Total operating expenses | 24,114 | 37,084 | Gross property & equipment | 1,981 | 3,179 |
| Property and equipment, at cost | 10,750,546 | ... | Income (loss) from operations | (18,852) | (32,765) | Accumulated depreciation & amortization | 1,816 | 2,811 |
| Accumulated depreciation | 37,707 | ... | Change in fair value of warrants | 629 | 5,472 | Property & equipment, net | 165 | 368 |
| Tools, machinery and equipment | 1,458,654 | ... | Interest income (expense), net | 48 | 17 | Right-of-use assets | 528 | 282 |
| Property & equipment, net | 10,712,839 | 8,200,595 | Gain (loss) on extinguishment of debt | 1,000 | ... | Restricted cash | 258 | 251 |
| Operating lease right of use asset | 1,258,701 | 853,889 | Other income (expense), net | 485 | 106 | Other assets | 31 | 163 |
| Other noncurrent assets | 1,793,014 | 139,636 | Income (loss) before income taxes | (16,690) | ... | Total assets | 6,262 | 17,373 |
| Goodwill | 3,267,103 | ... | Net income (loss) | (16,690) | (27,170) | Accounts payable | 1,261 | 881 |
| Total assets | 27,541,913 | 12,496,265 | Weighted average shares outstanding | 9,233 | 7,769 | Payroll & benefits related expenses | 1,189 | 2,051 |
| Accounts payable | 1,111,819 | 1,354,903 | - basic | 7,769 | 7,414 | Compensated absences | 951 | ... |
| Accrued professional | 447,295 | ... | - diluted | 9,233 | 7,769 | Collaboration & research agreements expenses | ... | 404 |
| Accrued salaries and other employee costs | 845,344 | ... | Year end shares outstanding | 10,645 | 8,306 | Professional services | ... | 556 |
| Accrued other | 18,606 | ... | Net income (loss) per share - basic | \$(1.81) | \$(3.45) | Other accrued liabilities | 506 | 639 |
| Accrued expenses | 1,311,245 | 361,246 | Net income (loss) per share - diluted | \$(1.81) | \$(3.45) | Accrued liabilities - Balancing value | 217 | ... |
| Notes payable | 470,396 | 33,854 | Number of full time employees | 64 | 85 | Current portion long-term debt | 166 | 403 |
| Operating lease liability - current | 336,564 | 45,903 | Total number of employees | 64 | 108 | Short-term debt | 670 | 764 |
| Share liability | 1,500,000 | 140,455 | Number of common stockholders | 40 | 77 | Lease liability | 159 | 77 |
| Deferred revenue | 882,000 | ... | Basic EPS Excluding ExtraOrdinary Items | \$(1.81) | ... | Total current liabilities | 5,119 | 5,775 |
| Finance lease liabilities - current | 61,941 | ... | Loss per share - basic and diluted | \$(1.81) | ... | Connecticut Department of Economic & Community Development ("DECD") loan, net of issuance costs | ... | 2,718 |
| Total current liabilities | 5,673,965 | 1,936,361 | Including non-cash stock-based compensation expense - Cost of revenue: \$80,000; Including non-cash stock-based compensation expense - Cost of revenue: \$161,000; Including non-cash stock-based compensation expense - Research & development: \$203,000; Including non-cash stock-based compensation expense - Research & development: \$311,000; Including non-cash stock-based compensation expense - Sales & marketing: \$356,000; Including non-cash stock-based compensation expense - Sales & marketing: \$1,132,000; Including non-cash stock-based compensation expense - General & administrative: \$2,037,000; Including non-cash stock-based compensation expense - General & administrative: \$1,935,000; Adjusted for 1-for-15 stock split, May 12, 2023; As is; As of March 20, 2023; As of March 18, 2022 | ... | ... | Less: current portion, net of issuance costs | ... | 403 |
| Operating lease liability - non-current | 1,066,647 | 742,443 | Recent Dividends: | 1. Aspira Womens Health Inc common. No dividends paid. | ... | Long-term debt | 1,430 | 2,315 |
| Deferred tax liabilities | 110,578 | ... | Annual Dividends: | 1. Aspira Womens Health Inc common. No dividends paid. | ... | Lease liability | 427 | 272 |
| Finance lease liabilities - non-current | 207,092 | ... | ASSET ENTITIES INC | ... | ... | Warrant liabilities | ... | 2,280 |
| Other liabilities | 1,653,000 | ... | Annual Report | ... | ... | Other non-current liabilities | 1,651 | ... |
| Total liabilities | 8,711,282 | 2,678,804 | Consolidated Income Statement, Years Ended Dec. 31 (\$): | ... | ... | Total liabilities | 8,627 | 10,642 |
| Common stock, \$001 par value; 50,000,000 shares authorized, 29,407,127 and 20,652,500 shares issued and outstanding at 30, 2022 and 31, 2021, respectively | 489,233 | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | 2023 | 2022 | Common stock | 11 | 125 |
| Common stock | 359,071 | ... | 2023 | 2022 | 2021 | Additional paid-in capital | 515,927 | 505,504 |
| Additional paid-in capital | 40,567,003 | 16,756,426 | 2023 | 2022 | 2021 | Accumulated deficit | (518,303) | ... |
| Accumulated deficit | (23,839,300) | ... | 2023 | 2022 | 2021 | Retained earnings (accumulated deficit) | ... | (498,898) |
| Retained earnings (accumulated deficit) | ... | (7,553,066) | 2023 | 2022 | 2021 | Total stockholders' equity (deficit) | (2,365) | 6,731 |
| Accumulated other comprehensive income (loss) | (920,982) | 255,030 | 2023 | 2022 | 2021 | Rep Total Equity & Minority Interest | (2,365) | ... |
| Total stockholders' equity | 16,295,954 | 9,817,461 | 2023 | 2022 | 2021 | Revenue | 277,038 | ... |
| Noncontrolling interests | 2,534,677 | ... | 2023 | 2022 | 2021 | Revenues | 277,038 | 829,618 |
| Total Equity | 18,830,631 | ... | 2023 | 2022 | 2021 | Contract labor | 176,773 | 160,251 |
| | | | 2023 | 2022 | 2021 | General & | ... | 801 |

| | | | |
|---|--------------------|---------------|--------------|
| administrative | 2,183,155 | 119,369 | 52,860 |
| Management compensation | 2,848,307 | 535,127 | 29,976 |
| Total operating expenses | 5,208,235 | 814,747 | 83,637 |
| Income (loss) from operations | 14,871 | 14,871 | 3,266 |
| Net income (loss) | (4,931,197) | 14,871 | 3,266 |
| Weighted average shares outstanding - basic | 13,577,993 | 9,767,364 | 9,756,000 |
| Weighted average shares outstanding - diluted | 13,577,993 | 9,767,364 | 9,756,000 |
| Year end shares outstanding | 14,174,410 | 10,000,000 | 9,756,000 |
| Earnings (loss) per share - basic | \$(0.36) | \$0.00 | \$0.00 |
| Earnings (loss) per share - diluted | \$(0.36) | \$0.00 | \$0.00 |
| Number of full time employees | ... | 26 | ... |
| Number of part time employees | ... | 28 | ... |
| Income from cont operations before income tax | (4,931,197) | ... | ... |
| Earnings per share from continuing operations | \$(0.36) | ... | ... |
| Earnings per share from continuing operations | \$(0.36) | ... | ... |
| Common Shareholders - Number | 26 | ... | ... |

□ From August 1, 2020 (inception); □ As of January 3, 2023

| | | | |
|--|-------------|-----------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2021 | |
| Cash | 2,924,323 | 33,731 | |
| Deferred offering costs | ... | 25,000 | |
| Prepaid expenses | 38,681 | ... | |
| Total current assets | 2,963,004 | 58,731 | |
| Office equipment | 13,559 | ... | |
| Accumulated depreciation | 734 | ... | |
| Property, Plant & Equipment - Net - Total | 12,825 | ... | |
| Intangible asset | 100,000 | ... | |
| Total Non-Current Assets | 112,825 | ... | |
| Total assets | 3,075,829 | 58,731 | |
| Credit card liability | 9,144 | 6,450 | |
| Contract liabilities | 3,445 | 6,450 | |
| Accounts payable and credit card liability | 150,096 | ... | |
| Total current liabilities | 153,541 | 15,594 | |
| Total liabilities | 153,541 | 15,594 | |
| Class A common stock | 839 | 976 | |
| Class B common stock | 604 | 24 | |
| Additional paid in capital | 8,656,036 | 249,976 | |
| Subscription receivable | ... | (225,976) | |
| Accumulated deficit | (5,558,315) | ... | |
| Retained earnings (accumulated deficit) | ... | 18,137 | |
| Treasury Stock, at cost: Class B Common Stock - 250,000 and 0 shares, respectively | 176,876 | ... | |
| Total stockholders' equity | 2,922,288 | 43,137 | |
| Total Equity | 2,922,288 | ... | |

Recent Dividends:
1. Asset Entities Inc class A common.
 No dividends paid.
2. Asset Entities Inc class B common.
 No dividends paid.
Annual Dividends:
1. Asset Entities Inc class A common.
 No dividends paid.
2. Asset Entities Inc class B common.
 No dividends paid.

| | | | |
|--|------------------|--------------------|--|
| ASTRA ENERGY INC | | | |
| Earnings, 6 mos. to (Consol. - \$): | | | |
| | 02/29/24 | 02/28/23 | |
| Cost & expenses | 675,344 | 2,577,489 | |
| Operating income | (675,344) | (2,577,489) | |
| Interest expense | 5,406 | 7,873 | |
| Other income (expense), net | (22,801) | (66,503) | |
| Foreign currency | (7,875) | (365) | |
| Net before taxes | (711,426) | (2,652,230) | |
| Net income | (711,426) | (2,652,230) | |
| Earnings common share | | | |
| Primary | \$(0.01) | \$(0.04) | |
| Fully Diluted | \$(0.01) | \$(0.04) | |
| Common Shares: | | | |
| Full Diluted | 72,763,982 | 66,048,782 | |
| Year-end | 72,763,982 | 73,528,982 | |

ATHENA GOLD CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|----------------|------------------|--------------------|
| | 2023 | 2022 | 2021 |
| Exploration, evaluation & project expenses | 351,132 | 617,262 | 137,983 |
| General & administrative expenses | 432,460 | 682,512 | 614,478 |
| Total operating expenses | 783,592 | 1,299,774 | 752,461 |
| Net operating income (loss) | (783,592) | (1,299,774) | (752,461) |
| Gain on extinguishment of debt | ... | ... | 3,880 |
| Interest expense | ... | 463 | 12,192 |
| Interest income | 2,598 | ... | ... |
| Net Income Before Taxes | 612,748 | ... | ... |
| Revaluation of warrant liability | 1,393,742 | 616,579 | (269,482) |
| Net income (loss) | 612,748 | (683,658) | (1,030,255) |
| Weighted average shares outstanding - basic | 146,153,300 | 127,608,629 | 65,902,198 |
| Weighted average shares outstanding - diluted | 146,153,300 | 127,608,629 | 65,902,198 |
| Year end shares outstanding | 167,138,069 | 136,091,400 | 119,858,700 |
| Earnings (loss) per share - continuing operations - basic | \$0.00 | ... | ... |
| Net earnings (loss) per share - basic | \$0.00 | \$(0.01) | \$(0.02) |
| Earnings (loss) per share - continuing operations - diluted | \$0.00 | ... | ... |
| Net earnings (loss) per share - diluted | \$0.00 | \$(0.01) | \$(0.02) |
| Number of part time employees | 1 | 1 | 1 |
| Total number of employees | 1 | 1 | 1 |
| Number of common stockholders | 92 | 92 | 60 |

□ Shares increased due to the effect of conversion of management fees, private placement, and common stock issued for mineral property, debt and accrued interest; □ Approximately; □ As of March 31, 2022

| | | | |
|--|-----------|-----------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash | 2,808 | 15,075 | |
| Prepaid expenses | 45,647 | 32,200 | |
| Total current assets | 48,455 | 47,275 | |
| Mineral rights | ... | 6,196,114 | |
| Manufacturing equipment | 6,196,114 | ... | |
| Investment in securities | 496,400 | ... | |
| Total assets | 6,740,969 | 6,243,389 | |
| Accounts payable | 144,695 | 143,939 | |

| | | |
|---|--------------|--------------|
| Accounts payable - related party | 100,500 | 30,006 |
| Notes payable | ... | 106,210 |
| Deed amendment liability - short-term portion | 46,000 | ... |
| Derivative liabilities | 29,151 | ... |
| Total current liabilities | 320,346 | 280,155 |
| Warrant liability | 102,811 | 999,820 |
| Total long-term liabilities | 102,811 | 999,820 |
| Total liabilities | 423,157 | 1,279,975 |
| Common stock | 16,714 | 13,609 |
| Additional paid-in capital | 17,391,148 | 16,652,603 |
| Accumulated deficit | (11,090,050) | ... |
| Retained earnings (accumulated deficit) | ... | (11,702,798) |
| Total stockholders' equity (deficit) | 6,317,812 | 4,963,414 |
| Total Equity | 6,317,812 | ... |

Recent Dividends:
1. Athena Gold Corp preferred.
 No dividends paid.
2. Athena Gold Corp common.
 No dividends paid.
Annual Dividends:
1. Athena Gold Corp preferred.
 No dividends paid.
2. Athena Gold Corp common.
 No dividends paid.

ATLANTICA, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|------------------|--------------------|------------------|
| | 2023 | 2022 | 2021 |
| General & administrative | 225,730 | 1,359,393 | 170,907 |
| Total expenses | 225,730 | 1,359,393 | 170,907 |
| Interest expense | 153,216 | 135,455 | 117,961 |
| Net Income Before Taxes | (378,946) | ... | ... |
| Total other income (expense) | (153,216) | (135,455) | (117,961) |
| Net income (loss) | (378,946) | (1,494,848) | (288,868) |
| Weighted average shares outstanding - basic | 2,458,590 | 2,458,590 | 2,458,590 |
| Weighted average shares outstanding - diluted | 2,458,590 | 2,458,590 | 2,458,590 |
| Year end shares outstanding | 2,458,590 | 2,458,590 | 2,458,590 |
| Net income (loss) per share - basic | \$(0.15) | \$(0.61) | \$(0.12) |
| Net income (loss) per share - diluted | \$(0.15) | \$(0.61) | \$(0.12) |
| Number of common stockholders | 670 | 661 | 661 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.15) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.15) | ... | ... |

| | | | |
|--|-------------|-------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Accounts payable | 1,654,146 | 1,591,151 | |
| Accounts payable - related parties | 1,933,948 | 1,803,339 | |
| Note payable - related parties | 713,653 | 681,527 | |
| Interest payable - related parties | 951,413 | 798,197 | |
| Total current liabilities | 5,253,160 | 4,874,214 | |
| Total liabilities | 5,253,160 | 4,874,214 | |
| Common stock | 246 | 246 | |
| Additional paid-in capital | 125,456 | 125,456 | |
| Retained earnings (accumulated deficit) | (5,378,862) | (4,999,916) | |
| Total stockholders' | ... | ... | |

equity (deficit) (5,253,160) (4,874,214)
 Total Equity (5,253,160) ...

Recent Dividends:**1. Atlantica, Inc. common.**

No dividends paid.

Annual Dividends:**1. Atlantica, Inc. common.**

No dividends paid.

ATLANTIS GLORY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|-------------------|
| General & administrative expenses | 68,026 | 62,301 | 282,811 |
| Total operating expenses | 68,026 | 62,301 | 282,811 |
| Income (loss) from operations | (68,026) | (62,301) | (282,811) |
| Effect of deconsolidation of foreign subsidiary | ... | (8,333,679) | ... |
| Total other income (expenses) | ... | 8,333,679 | ... |
| Income (loss) from operations before income taxes | (68,026) | 8,271,378 | (282,811) |
| Net income (loss) | (68,026) | 8,271,378 | (282,811) |
| Weighted average shares outstanding - basic | 603,970,000 | 603,970,000 | 603,970,000 |
| Weighted average shares outstanding - diluted | 603,970,000 | 603,970,000 | 603,970,000 |
| Year end shares outstanding | 603,970,000 | 603,970,000 | 603,970,000 |
| Net income (loss) per share - basic | ... | \$0.01 | \$0.00 |
| Net income (loss) per share - diluted | ... | \$0.01 | \$0.00 |
| Number of full time employees | 1 | 1 | 1 |
| Number of common stockholders | 74 | 74 | 74 |
| Total number of employees | 1 | ... | ... |

□ Non-consolidated

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-----------|
| Prepayments | ... | 9,000 |
| Total current assets | ... | 9,000 |
| Total assets | ... | 9,000 |
| Loan from related parties | 120,549 | ... |
| Accrued expenses & other liabilities | 10,400 | 6,950 |
| Amount due to a director | ... | 64,973 |
| Total current liabilities | 130,949 | 71,923 |
| Total liabilities | 130,949 | 71,923 |
| Preferred stock \$0.001 par value, 10,000,000 shares authorized, 10,000,000 and 0 shares outstanding as of 31, 2021 and 2020, respectively | 10,000 | ... |
| Preferred stock | ... | 10,000 |
| Common stock | 603,970 | 603,970 |
| Additional paid-in capital | ... | 321,809 |
| Capital surplus | 321,809 | ... |
| Retained earnings (accumulated deficit) | (1,066,728) | (998,702) |
| Total stockholders' equity (deficit) | (130,949) | (62,923) |
| Total Equity | (130,949) | ... |

Recent Dividends:**1. Atlantis Glory Inc preferred.**

No dividends paid.

2. Atlantis Glory Inc common.

No dividends paid.

Annual Dividends:**1. Atlantis Glory Inc preferred.**

No dividends paid.

2. Atlantis Glory Inc common.

No dividends paid.

ATOSSA THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|-------------------|
| Research & development expenses | 17,334,000 | 15,083,000 | 9,210,000 |
| General & administrative expenses | 14,043,000 | 12,608,000 | 11,311,000 |
| Total operating expenses | 31,377,000 | 27,691,000 | 20,521,000 |
| Operating income (loss) | (31,377,000) | (27,691,000) | (20,521,000) |
| Other income (expense), net | (70,000) | ... | ... |
| Interest income | 4,343,000 | 877,000 | 6,000 |
| Other expense, net | ... | 146,000 | 91,000 |
| Income (loss) before income taxes | (30,094,000) | (26,960,000) | (20,606,000) |
| Net income (loss) | (30,094,000) | (26,960,000) | (20,606,000) |
| Net income (loss) applicable to common shareholders | ... | (26,960,000) | (20,606,000) |
| Weighted average shares outstanding - basic | 126,081,602 | 126,624,000 | 116,950,000 |
| Weighted average shares outstanding - diluted | 126,081,602 | 126,624,000 | 116,950,000 |
| Year end shares outstanding | 125,304,064 | 126,624,000 | 126,624,000 |
| Earnings (loss) per share - continuing operations - basic | \$(0.24) | ... | ... |
| Net income (loss) per share - basic | \$(0.24) | \$(0.21) | \$(0.18) |
| Earnings (loss) per share - continuing operations - diluted | \$(0.24) | ... | ... |
| Net income (loss) per share - diluted | \$(0.24) | \$(0.21) | \$(0.18) |
| Number of full time employees | 10 | 9 | 4 |
| Number of part time employees | ... | ... | 2 |
| Total number of employees | 10 | ... | 6 |
| Number of common stockholders | 41 | 40 | 36 |
| Number of beneficiary stockholders | ... | ... | 122,180 |
| Impairment charge on investment in equity securities | 2,990,000 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of common stock, warrants, warrant exercise and option exercise; and conversion of series B convertible preferred stock to common stock; □ Approximately; □ As of March 16, 2023; □ As of February 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------|------------|-------------|
| Cash & cash equivalents | 88,460,000 | 110,890,000 |
| Restricted cash | 110,000 | 110,000 |
| Prepaid research & development | ... | 3,480,000 |
| Prepaid insurance | 794,000 | 387,000 |
| Professional services | 501,000 | 130,000 |
| Retainer & security deposits | 1,487,000 | ... |

| | | |
|---|---------------|---------------|
| Other prepaid expenses | ... | 34,000 |
| Prepaid clinical trial deposits | 805,000 | ... |
| Prepaid expenses | ... | 4,031,000 |
| Research & development tax rebate receivable | ... | 743,000 |
| Other current assets | 62,000 | 2,423,000 |
| Prepaid expenses and other current assets | 2,162,000 | ... |
| Total current assets | 92,219,000 | 118,197,000 |
| Investment in equity securities | 1,710,000 | 4,700,000 |
| Other assets | 2,323,000 | 635,000 |
| Total assets | 96,252,000 | 123,532,000 |
| Accounts payable | 806,000 | 2,965,000 |
| Accrued expenses | 973,000 | 1,059,000 |
| Accrued payroll | 284,000 | ... |
| Accrued bonuses | 236,000 | 1,060,000 |
| Accrued vacation | ... | 224,000 |
| Accrued payroll | 1,134,000 | 241,000 |
| Other current liabilities | 1,803,000 | 19,000 |
| Total current liabilities | 5,236,000 | 5,568,000 |
| Total liabilities | 5,236,000 | 5,568,000 |
| Additional paid-in capital - series B convertible preferred stock | ... | 582,000 |
| Common stock | 22,792,000 | 22,792,000 |
| Additional paid-in capital - common stock | 255,987,000 | 250,784,000 |
| Accumulated Deficit | (186,288,000) | ... |
| Retained earnings (accumulated deficit) | ... | (156,194,000) |
| Common Stock - Treasury/Repurchased | 1,475,000 | ... |
| Total stockholders' equity (deficit) | 91,016,000 | 117,964,000 |
| Total Equity | 91,016,000 | ... |

Recent Dividends:**1. Atossa Therapeutics Inc series B convertible preferred.**

No dividends paid.

2. Atossa Therapeutics Inc common.

No dividends paid.

Annual Dividends:**1. Atossa Therapeutics Inc series B convertible preferred.**

No dividends paid.

2. Atossa Therapeutics Inc common.

No dividends paid.

AUGMEDIX INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|-------------------|
| Revenues | 44,855,000 | ... | ... |
| Revenues | 44,855,000 | 30,933,000 | 22,165,000 |
| Cost of revenues | 23,329,000 | 16,979,000 | 12,158,000 |
| Gross profit | 21,526,000 | 13,954,000 | 10,007,000 |
| General & administrative expenses | 18,442,000 | 16,893,000 | 13,759,000 |
| Sales & marketing expenses | 10,687,000 | 9,283,000 | 7,121,000 |
| Research & development expenses | 11,176,000 | 10,149,000 | 6,678,000 |
| Total operating expenses | 40,305,000 | 36,325,000 | 27,558,000 |
| Income (loss) from operations | (18,779,000) | (22,371,000) | (17,551,000) |
| Interest expense | 2,253,000 | 1,675,000 | 2,252,000 |
| Interest income | 1,110,000 | 245,000 | 15,000 |
| Loss on debt extinguishment | ... | (1,097,000) | (246,000) |
| Forgiveness of paycheck protection program ("PPP") loan | ... | ... | 2,180,000 |
| Other income (expenses) | 1,001,000 | 560,000 | 437,000 |
| Change in fair value of warrant liability | (105,000) | ... | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| Total other income (expenses), net | (247,000) | (1,967,000) | 134,000 |
| Income (loss) before income taxes | (19,026,000) | (24,338,000) | (17,417,000) |
| Income tax expense (benefit) | 145,000 | 111,000 | 47,000 |
| Net income (loss) | (19,171,000) | (24,449,000) | (17,464,000) |
| Weighted average shares outstanding - basic | 43,946,263 | 37,418,463 | 28,914,909 |
| Weighted average shares outstanding - diluted | 43,946,263 | 37,418,463 | 28,914,909 |
| Year end shares outstanding | 48,613,714 | 37,442,663 | 37,387,472 |
| Net income (loss) per share - basic | \$(0.44) | \$(0.65) | \$(0.60) |
| Net income (loss) per share - diluted | \$(0.44) | \$(0.65) | \$(0.60) |
| Number of full time employees | 1,430 | ... | ... |
| Total number of employees | 1,430 | 1,040 | ... |
| Number of common stockholders | 3,820 | 1,246 | ... |
| Foreign currency translation adjustments | ... | (370,000) | ... |

⊠ Restated to reflect correction of error related to the Company's accounting for sales commissions; ⊡ Shares increased due to issuance of common stock, net exercise of common stock warrants, issuance of common stock to service provider, with exercise of warrants and exercise of common stock options; ⊢ Approximately; ⊣ As of March 15, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 46,217,000 | 21,251,000 |
| Restricted cash | 125,000 | 125,000 |
| Accounts receivable, gross | 8,682,000 | 6,456,000 |
| Less: allowance for doubtful accounts | 110,000 | 102,000 |
| Accounts receivable, net of allowance for doubtful accounts | 8,572,000 | ... |
| Accounts receivable, net | ... | 6,354,000 |
| Prepaid expenses & other current assets | 1,909,000 | 1,820,000 |
| Total current assets | 56,823,000 | 29,550,000 |
| Computer hardware, software & equipment | 4,730,000 | 7,229,000 |
| Leasehold improvements | 716,000 | 460,000 |
| Furniture & fixtures | 693,000 | 73,000 |
| Construction in progress | 393,000 | 163,000 |
| Capitalized internal-use software costs | 698,000 | ... |
| Total property & equipment | 7,230,000 | 7,925,000 |
| Less: accumulated depreciation | 3,491,000 | 6,352,000 |
| Property & equipment, net | 3,739,000 | 1,573,000 |
| Operating lease right of use asset | 5,220,000 | 1,567,000 |
| Restricted cash, non-current | ... | 612,000 |
| Deposits & other assets | 930,000 | 339,000 |
| Total assets | 66,712,000 | 33,641,000 |
| Loan payable, current portion | 5,000,000 | 3,750,000 |
| Accounts payable | 721,000 | 1,563,000 |
| Accrued compensation | 3,860,000 | 3,587,000 |
| Accrued vendor partner liabilities | ... | 871,000 |
| Accrued other | ... | 466,000 |
| Accrued value added tax ("VAT") & other taxes | ... | 279,000 |
| Accrued professional fees | ... | 118,000 |
| Deferred revenues | 8,963,000 | 7,254,000 |
| Operating lease liability, current | ... | ... |

| | | |
|--|---------------|---------------|
| portion | 1,494,000 | 872,000 |
| Customer deposits | ... | 554,000 |
| Accrued expenses and other current liabilities | 6,589,000 | ... |
| Accrued expenses and other current Balancing taxes | 2,336,000 | ... |
| Accrued VAT and other taxes | 393,000 | ... |
| Total current liabilities | 23,618,000 | 19,314,000 |
| Loan payable, net of current portion | 15,303,000 | 11,384,000 |
| Other liabilities | 421,000 | 509,000 |
| Operating lease liability, net of current portion | 4,049,000 | 968,000 |
| Total liabilities | 43,391,000 | 32,175,000 |
| Common stock | 5,000 | 4,000 |
| Additional paid-in capital | 169,197,000 | 127,693,000 |
| Retained earnings (accumulated deficit) | (144,962,000) | (125,791,000) |
| Accumulated other comprehensive income (loss) | (919,000) | (440,000) |
| Total stockholders' equity (deficit) | 23,321,000 | 1,466,000 |
| Total Equity | 23,321,000 | ... |

Recent Dividends:

1. Augmedix Inc common.

No dividends paid.

Annual Dividends:

1. Augmedix Inc common.

No dividends paid.

AUGUSTA GOLD CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------------|---------------------|------------------|
| General & administrative | 4,143,352 | 5,087,128 | 4,664,565 |
| Lease expense | 21,000 | 21,000 | 16,000 |
| Exploration, evaluation & project expense | 2,686,656 | 5,739,534 | 7,909,333 |
| Accretion expense | 111,548 | 77,941 | 24,749 |
| Depreciation expense | 44,057 | 44,057 | 44,057 |
| Total operating expenses | 7,006,613 | 10,969,660 | 12,658,704 |
| Net operating income (loss) | (7,006,613) | (10,969,660) | (12,658,704) |
| Gain (loss) on extinguishment of debt | ... | ... | 0 |
| Interest expense | 2,550,557 | 721,924 | 0 |
| Other income (loss) | 16,267,187 | ... | ... |
| Revaluation of warrant liability | ... | (7,852,349) | 15,857,500 |
| Foreign currency exchange gain (loss) | (52,007) | (176,279) | 253,236 |
| Income (loss) before income tax expense | 6,658,010 | ... | ... |
| Net income (loss) | 6,658,010 | (19,720,212) | 3,452,032 |
| Weighted average shares outstanding - basic | 85,561,252 | 75,373,892 | 68,251,261 |
| Weighted average shares outstanding - diluted | 85,682,086 | 75,373,892 | 69,070,013 |
| Year end shares outstanding | 85,929,753 | 79,204,606 | 70,519,188 |
| Net income (loss) per common share - basic | \$0.08 | \$(0.26) | \$0.05 |
| Net income (loss) per common share - diluted | \$0.08 | \$(0.26) | \$0.05 |
| Number of full time employees | 12 | 12 | 7 |
| Number of common | ... | ... | ... |

| | | | |
|--------------------------------------|--------|-----|-----|
| stockholders | 85 | 85 | 95 |
| Earnings (loss) per common share | \$0.08 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.08 | ... | ... |
| Total number of employees | 12 | ... | ... |

⊠ Shares increased due to the effect of private placement issued; ⊡ Approximately; ⊢ As of March 14, 2023; ⊣ As of March 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 300,734 | 332,813 |
| Prepaid | 55,999 | 156,959 |
| Deferred stock issuance costs | ... | 121,424 |
| Deposits | 7,028 | 7,028 |
| Total current assets | 363,761 | 618,224 |
| Property & equipment, net | ... | 1,088,449 |
| Mineral properties, net | 58,992,286 | 58,962,286 |
| Accumulated depreciation | 132,803 | ... |
| Property, Plant & Equipment - Gross - Total | 1,177,195 | ... |
| Equipment | 1,044,392 | ... |
| Total other assets | 61,152,491 | ... |
| Total assets | 61,516,252 | 60,668,959 |
| Accounts payable | 1,411,439 | 2,906,285 |
| Note payable & accrued interest - related party | 25,393,879 | 22,843,322 |
| Asset retirement obligation | 110,700 | 1,009,496 |
| Warrant liability | 692,949 | ... |
| Total current liabilities | 27,608,967 | 26,759,103 |
| Asset retirement obligation, net of current | 2,971,097 | 1,804,939 |
| Warrant liability | 417,758 | 15,615,406 |
| Total long term liabilities | 3,388,855 | 17,420,345 |
| Total liabilities | ... | 44,179,448 |
| Common stock | 8,593 | 7,920 |
| Additional paid in capital | 63,745,580 | 56,375,344 |
| Retained earnings (accumulated deficit) | ... | (39,893,753) |
| Accumulated deficit | (33,235,743) | ... |
| Total stockholders' equity (deficit) | 30,518,430 | 16,489,511 |
| Total stockholders equity | 30,518,430 | ... |

Recent Dividends:

1. Augusta Gold Corp series A preferred.

No dividends paid.

2. Augusta Gold Corp series B preferred.

No dividends paid.

3. Augusta Gold Corp common.

No dividends paid.

Annual Dividends:

1. Augusta Gold Corp series A preferred.

No dividends paid.

2. Augusta Gold Corp series B preferred.

No dividends paid.

3. Augusta Gold Corp common.

No dividends paid.

AUTHID INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--------------------------------|-----------|------------|------------|
| Products & services | 4,118 | ... | ... |
| Verified software license | ... | 156,646 | 64,799 |
| Legacy authentication services | 186,171 | 370,769 | 548,717 |
| Total revenues, net | 190,289 | 527,415 | 613,516 |
| General & administrative | 7,882,194 | 14,676,938 | 12,831,786 |

| | 2023 | [□] 2022 (revised) | 2021 (revised) |
|--|---------------|--------------------------------|---------------------------|
| Research & development | 2,800,373 | 6,269,175 | 2,878,952 |
| Impairment loss | ... | 1,101,867 | 831,075 |
| Depreciation & amortization | ... | 749,900 | 1,157,773 |
| Amortization of Intangibles excluding Goodwill .. | 255,858 | ... | ... |
| Acquired and Developed Software .. | 239,397 | ... | ... |
| Patents Pending | 16,461 | ... | ... |
| Total operating expenses | ... | 22,797,880 | 17,699,586 |
| Income (loss) from continuing operations | (10,748,136) | (22,270,465) | (17,086,070) |
| Gain on extinguishment of debt | (380,741) | ... | 971,522 |
| Other income (expense), net | 98,230 | (37,221) | 651 |
| Interest expense, net | 1,108,458 | 1,359,954 | 586,850 |
| Conversion expense .. | 7,476,000 | ... | ... |
| Other income (expense), net | (8,866,969) | (1,397,175) | 385,323 |
| Income (loss) before income taxes - United States | ... | (25,424,002) | (16,466,423) |
| Income (loss) before income taxes - outside United States | ... | 1,208,777 | (1,198,341) |
| Income (loss) from continuing operations before income taxes | (19,615,105) | [□] (23,667,640) | [□] (16,700,747) |
| Income tax expense .. | 2,864 | 7,670 | 10,746 |
| Income (loss) from continuing operations | (19,617,969) | (23,675,310) | (16,711,493) |
| Income (loss) from discontinued operations | 1,524 | (366,663) | (954,295) |
| Loss from sale of a discontinued operation | 216,069 | (188,247) | ... |
| Total Income (loss) from discontinued operations | ... | (554,910) | (954,295) |
| Net income (loss) | (19,400,376) | (24,230,220) | (17,665,788) |
| Weighted average shares outstanding - basic | 6,153,881 | [□] 3,065,364 | 2,666,160 |
| Weighted average shares outstanding - diluted | 6,153,881 | [□] 3,065,364 | 2,666,160 |
| Year end shares outstanding | 9,450,220 | [□] 3,164,887 | 2,911,753 |
| Net earnings (loss) per share from continuing operations - basic | \$(3.19) | [□] \$(7.76) | \$(6.24) |
| Net earnings (loss) per share from discontinued operations - basic | \$0.04 | [□] \$(0.16) | \$(0.32) |
| Net earnings (loss) per share - basic | \$(3.19) | [□] \$(7.92) | \$(6.56) |
| Net earnings (loss) per share from continuing operations - diluted | \$(3.19) | [□] \$(7.76) | \$(6.24) |
| Net earnings (loss) per share from discontinued operations - diluted | \$0.04 | [□] \$(0.16) | \$(0.32) |
| Net earnings (loss) per share - diluted | \$(3.19) | [□] \$(7.92) | \$(6.56) |
| Number of full time employees | 22 | ... | ... |
| Total number of employees | 22 | [□] 25 | ... |
| Number of common stockholders | 147 | [□] 180 | ... |
| Discontinued operations | 217,593 | ... | ... |
| [□] Restated to reflect the discontinued operations of the Multi-Pay correspondent bank, payments services in Colombia and the Cards Plus cards manufacturing and printing business in South Africa; [□] As reported by the Company; [□] Adjusted for 1-for-8 stock split, July 10, 2023; [□] Approximately; [□] As of March 24, 2023 | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash | 10,177,099 | 3,237,106 | |
| Accounts receivable, net | 91,277 | 261,809 | |
| Prepaid insurance | 184,492 | 244,215 | |
| Unamortized working capital facility fees - current | ... | 199,156 | |
| Prepaid Third Party Services | 291,512 | 135,405 | |
| Other current assets | 476,004 | 150,566 | |
| Other current assets | ... | 729,342 | |
| Current assets held for sale | ... | 118,459 | |
| Deferred contract costs | 157,300 | ... | |
| Total current assets | 10,901,680 | 4,346,716 | |
| Computer equipment | ... | 85,583 | |
| Furniture & equipment | ... | 54,016 | |
| Property & equipment, gross | ... | 139,599 | |
| Less: accumulated depreciation | ... | 139,599 | |
| Other assets | ... | 250,383 | |
| Intangible assets, net | 327,001 | 566,259 | |
| Goodwill | 4,183,232 | 4,183,232 | |
| Non-current assets held for sale | ... | 27,595 | |
| Total assets | 15,411,913 | 9,374,185 | |
| Trade payables | ... | 623,130 | |
| Accrued payroll & related expenses | 707,317 | 145,837 | |
| Other accrued expenses | 361,816 | 385,105 | |
| Deferred revenue | 131,628 | 81,318 | |
| Current liabilities held for sale | 124,150 | 13,759 | |
| Accounts payable and accrued expenses | 1,408,965 | ... | |
| Total current liabilities | 1,664,743 | 1,249,149 | |
| Convertible notes | ... | 9,125,205 | |
| Less unamortized debt discount expense | ... | (203,593) | |
| Less unamortized debt issuance expense | ... | (1,080,112) | |
| Convertible debt | 224,424 | 7,841,500 | |
| Accrued severance liability | 325,000 | ... | |
| Total liabilities | 2,214,167 | 9,090,649 | |
| Common stocks | 945 | 2,532 | |
| Additional paid in capital | 172,714,712 | 140,255,234 | |
| Retained earnings (accumulated deficit) | (159,530,535) | (140,130,159) | |
| Accumulated other comprehensive income (loss) | 12,624 | 155,929 | |
| Total stockholders' equity | 13,197,746 | 283,536 | |
| Total Equity | 13,197,746 | ... | |
| Recent Dividends: | | | |
| 1. authID Inc common. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. authID Inc common. | | | |
| No dividends paid. | | | |
| AUTOSCOPE TECHNOLOGIES CORP | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| Revenue - royalties ... | 12,960,000 | 8,183,000 | 8,532,000 |
| Revenue - product sales | 173,000 | 366,000 | 4,710,000 |
| Total revenue | 13,133,000 | 8,549,000 | 13,242,000 |
| Cost of revenue - royalties | 428,000 | 420,000 | 400,000 |
| Cost of revenue - products sales | 301,000 | 307,000 | 2,607,000 |
| Total cost of revenue | 729,000 | 727,000 | 3,007,000 |
| Gross profit (loss) | 12,404,000 | 7,822,000 | 10,235,000 |
| Selling, marketing & product support expenses | 1,867,000 | 1,890,000 | 2,127,000 |
| General & administrative expenses | 3,347,000 | 3,468,000 | 3,621,000 |
| Research & development expenses | 2,577,000 | 2,120,000 | 2,214,000 |
| Total operating expenses | 7,791,000 | 7,478,000 | 7,962,000 |
| Income from operations | 4,613,000 | 344,000 | 2,273,000 |
| Other income | 79,000 | 42,000 | 927,000 |
| Investment income ... | 377,000 | 24,000 | ... |
| Interest expense | 69,000 | 71,000 | ... |
| Income (loss) from operations before income taxes - domestic | 4,997,000 | 521,000 | 3,158,000 |
| Income (loss) from operations before income taxes - foreign | 3,000 | (182,000) | 42,000 |
| Income (loss) before income taxes .. | 5,000,000 | 339,000 | 3,200,000 |
| Current federal income tax expense (benefit) | 32,000 | ... | ... |
| Current state income tax expense (benefit) | 18,000 | 22,000 | 17,000 |
| Current foreign income tax expense (benefit) | 24,000 | 9,000 | 3,000 |
| Total current income tax expense (benefit) | 74,000 | 31,000 | 20,000 |
| Deferred federal income tax expense (benefit) | 415,000 | 247,000 | 894,000 |
| Deferred state income tax expense (benefit) | 12,000 | (33,000) | 49,000 |
| Deferred foreign income tax expense (benefit) | (2,000) | (55,000) | (58,000) |
| Total deferred income tax expense (benefit) | 425,000 | 159,000 | 885,000 |
| Income tax expense (benefit) | 499,000 | 190,000 | 905,000 |
| Net income (loss) from continuing operations | 4,501,000 | 149,000 | ... |
| Net income (loss) from discontinued operations, net of tax | 125,000 | 1,054,000 | ... |
| Gain on sale of discontinued operations, net of tax | 1,999,000 | ... | ... |
| Earnings from discontinued operations, net of tax | 2,124,000 | 1,054,000 | ... |
| Net income (loss) | 6,625,000 | 1,203,000 | 2,295,000 |
| Weighted average shares outstanding - basic | 5,423,000 | 5,383,000 | 5,342,000 |

| Weighted average shares outstanding | | | | Operating lease obligation | | | | Total operating expenses | | | |
|--|--|--|--|--|--|--|--|---|--|--|--|
| - diluted | | | | 19,000 | | | | 29,275,000 | | | |
| Year end shares outstanding | | | | 3,000 | | | | 55,491,000 | | | |
| Earnings (loss) per share from continuing operations- basic | | | | 60,000 | | | | 87,532,000 | | | |
| Earnings (loss) per share - discontinued operations- basic | | | | 58,000 | | | | (37,440,000) | | | |
| Net income (loss) per share - basic | | | | 108,000 | | | | (27,351,000) | | | |
| Earnings (loss) per share from continuing operations- diluted | | | | 1,545,000 | | | | (42,000) | | | |
| Earnings (loss) per share - discontinued operations- diluted | | | | 1,556,000 | | | | (20,000) | | | |
| Net income (loss) per share - diluted | | | | 3,101,000 | | | | (3,417,000) | | | |
| Total number of employees | | | | 25,765,000 | | | | (4,170,000) | | | |
| Number of common stockholders | | | | 25,566,000 | | | | (4,190,000) | | | |
| Foreign currency translation adjustments | | | | (552,000) | | | | (4,190,000) | | | |
| Restated to reflect discontinued operations; As of February 28, 2022 | | | | (478,000) | | | | (4,190,000) | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | (2,722,000) | | | | (4,190,000) | | | |
| 2023 | | | | (6,525,000) | | | | (31,530,000) | | | |
| 2022 (revised) | | | | 22,546,000 | | | | (41,630,000) | | | |
| Cash & cash equivalents | | | | Recent Dividends: | | | | Current income tax expense (benefit) - federal | | | |
| Accounts receivable, gross | | | | 1. Autoscope Technologies Corp common. | | | | Current income tax expense (benefit) - state | | | |
| Less: allowance for doubtful accounts | | | | ExDate Amt Declared Record Payable | | | | Total current income tax expense (benefit) - federal | | | |
| Accounts receivable, net | | | | 08/20/2021 0.12 08/10/2021 08/23/2021 08/30/2021 | | | | Deferred income tax expense (benefit) - federal | | | |
| Finished goods | | | | 11/19/2021 0.12 11/10/2021 11/22/2021 11/29/2021 | | | | Deferred income tax expense (benefit) - state | | | |
| Components | | | | 02/17/2022 0.12 02/02/2022 02/21/2022 02/28/2022 | | | | Total deferred income tax expense (benefit) - federal | | | |
| Inventories | | | | 05/20/2022 0.12 05/10/2022 05/23/2022 05/30/2022 | | | | Deferred income tax expense (benefit) - state | | | |
| Investments in available-for-sale debt securities | | | | 08/24/2022 0.12 08/11/2022 08/25/2022 08/31/2022 | | | | Total deferred income tax expense (benefit) - federal | | | |
| Investments in equity securities | | | | 11/25/2022 0.12 11/16/2022 11/28/2022 12/05/2022 | | | | Deferred income tax expense (benefit) - state | | | |
| Due from broker from sale of available-for-sale debt securities | | | | 05/26/2023 0.26 05/19/2023 05/30/2023 06/06/2023 | | | | Total deferred income tax expense (benefit) - federal | | | |
| Prepaid expenses & other current assets | | | | 09/29/2023 0.13 09/21/2023 10/02/2023 10/09/2023 | | | | Deferred income tax expense (benefit) - state | | | |
| Current assets held for sale | | | | 11/17/2023 0.13 11/09/2023 11/20/2023 11/30/2023 | | | | Total deferred income tax expense (benefit) - federal | | | |
| Total current assets | | | | 02/02/2024 1.32 01/24/2024 02/05/2024 02/12/2024 | | | | Deferred income tax expense (benefit) - state | | | |
| Furniture & fixtures | | | | 02/26/2024 0.13 02/15/2024 02/27/2024 03/05/2024 | | | | Total deferred income tax expense (benefit) - federal | | | |
| Leasehold improvements | | | | Annual Dividends: | | | | Income tax expense (benefit) | | | |
| Equipment | | | | 1. Autoscope Technologies Corp common. | | | | Income tax expense (benefit) | | | |
| Real property | | | | 2021 0.24 2022 0.48 2023 0.52 | | | | Income (loss) from continuing operations | | | |
| Property & equipment, gross | | | | 2024 1.45 | | | | Income (loss) from discontinued operations | | | |
| Accumulated depreciation - property & equipment | | | | AUTOSCOPE TECHNOLOGIES CORP | | | | Net income (loss) | | | |
| Property & equipment, net | | | | Earnings, 9 mos. to Sep 30(Consol. - \$000): | | | | Weighted average shares outstanding | | | |
| Intangible assets, net | | | | 2023 2022 | | | | - basic | | | |
| Deferred income taxes | | | | Total revenues | | | | Weighted average shares outstanding | | | |
| Long-term investments in available-for-sale debt securities | | | | Cost & expenses | | | | - diluted | | | |
| Operating lease asset, net | | | | Operating income | | | | Year end shares outstanding | | | |
| Long-term assets held for sale | | | | Interest expense | | | | Net income (loss) per common share from continuing operations - basic | | | |
| Total assets | | | | Other income (expense), net | | | | Net income (loss) per common share - basic | | | |
| Accounts payable | | | | Gains or losses | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| Deferred revenue | | | | Net before taxes | | | | Net income (loss) per common share - basic | | | |
| Warranty | | | | Income taxes | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| Accrued compensation | | | | Income contin. oper. | | | | Net income (loss) per common share - basic | | | |
| | | | | Income discount. oper. | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Net income | | | | Net income (loss) per common share - basic | | | |
| | | | | Earnings common share | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Primary | | | | Net income (loss) per common share - basic | | | |
| | | | | Fully Diluted | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Common Shares: | | | | Net income (loss) per common share - basic | | | |
| | | | | Full Diluted | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Year-end | | | | Net income (loss) per common share - basic | | | |
| | | | | AVALO THERAPEUTICS INC | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Annual Report | | | | Net income (loss) per common share - basic | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | 2023 2022 2021 (revised) | | | | Net income (loss) per common share - basic | | | |
| | | | | Product revenue, net | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | License & other revenue | | | | Net income (loss) per common share - basic | | | |
| | | | | Total revenues, net | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Cost of product sales | | | | Net income (loss) per common share - basic | | | |
| | | | | Research & development expenses | | | | Net income (loss) per common share from continuing operations - diluted | | | |
| | | | | Selling, general & administrative | | | | Net income (loss) per common share - basic | | | |
| | | | | Amortization expense | | | | Net income (loss) per common share from continuing operations - diluted | | | |

[□] Reclassified to conform with 2022 presentation; [▣] Adjusted for 1-for-240 stock split, December 29, 2023; [▢] Adjusted for 1-for-12 stock split, July 7, 2022; [▤] Shares increased due to issuance of common stock and pre-funded warrants, conversion of preferred stock, exercise of stock options and shares purchased through employee stock purchase plan; [▥] As of February 28, 2022; [▦] Approximately; [▧] As of March 24, 2023

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|---------------|---------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 7,415,000 | 13,172,000 |
| Other receivables | 136,000 | 1,919,000 |
| Inventory, net | ... | 20,000 |
| Prepaid expenses & other current assets | 843,000 | 1,290,000 |
| Restricted cash, current portion | 1,000 | 15,000 |
| Total current assets | 8,395,000 | 16,416,000 |
| Furniture & equipment | 248,000 | 280,000 |
| Computers & software | 2,507,000 | 56,000 |
| Right-of-use assets | 1,329,000 | 1,750,000 |
| Leasehold improvements | 896,000 | 739,000 |
| Computers and software | 34,000 | ... |
| Total property & equipment | ... | 2,825,000 |
| Less: accumulated depreciation | 542,000 | 414,000 |
| Property & equipment, net | 1,965,000 | 2,411,000 |
| Goodwill | 10,502,000 | 14,409,000 |
| Restricted cash, net of current portion | 131,000 | 131,000 |
| Total assets | 20,993,000 | 33,367,000 |
| Accounts payable | 446,000 | 2,882,000 |
| Deferred revenue | ... | 88,000 |
| Research & development | 352,000 | 6,293,000 |
| Compensation & benefits | 580,000 | 2,699,000 |
| Selling, general & administrative | ... | 1,008,000 |
| Sales & marketing | 830,000 | ... |
| Commercial operations | 1,873,000 | 1,694,000 |
| Royalty payment | ... | 508,000 |
| Lease liability, current | 537,000 | 532,000 |
| Other accrued expenses & other current liabilities | ... | 480,000 |
| Accrued expenses & other current liabilities | 4,172,000 | 13,214,000 |
| Notes payable, current | ... | 5,930,000 |
| Total current liabilities | 4,618,000 | 22,114,000 |
| Notes payable, non-current | ... | 13,486,000 |
| Royalty obligation | 2,000,000 | 2,000,000 |
| Deferred tax liability, net | 155,000 | 141,000 |
| Derivative liability | 5,550,000 | 4,830,000 |
| Other long-term liabilities | 1,366,000 | 1,711,000 |
| Other long-term liabilities | 1,366,000 | ... |
| Total liabilities | 13,689,000 | 44,282,000 |
| Common stock | 1,000 | 9,000 |
| Additional paid-in capital | 342,437,000 | 292,900,000 |
| Retained earnings (accumulated deficit) | (335,134,000) | (303,824,000) |
| Total stockholders' equity (deficit) | 7,304,000 | (10,915,000) |
| Total Equity | 7,304,000 | ... |

Recent Dividends:

- 1. Avalo Therapeutics Inc series B convertible preferred.**
No dividends paid.
 - 2. Avalo Therapeutics Inc series A-1 convertible preferred.**
No dividends paid.
 - 3. Avalo Therapeutics Inc common.**
No dividends paid.
 - 4. Avalo Therapeutics Inc series B convertible preferred.**
No dividends paid.
 - 5. Avalo Therapeutics Inc series A convertible preferred.**
No dividends paid.
- Annual Dividends:**

- 1. Avalo Therapeutics Inc series B convertible preferred.**
No dividends paid.
- 2. Avalo Therapeutics Inc series A-1 convertible preferred.**
No dividends paid.
- 3. Avalo Therapeutics Inc common.**
No dividends paid.
- 4. Avalo Therapeutics Inc series B convertible preferred.**
No dividends paid.
- 5. Avalo Therapeutics Inc series A convertible preferred.**
No dividends paid.

AVALON GLOBOCARE CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ▣ ₂₀₂₁ (revised) |
|---|--------------|-------------|--------------------------------|
| Real property rental | 1,255,681 | 1,202,169 | 1,203,560 |
| Medical related consulting services - related party | ... | ... | 187,412 |
| Total revenues | ... | 1,202,169 | 1,390,972 |
| Real property operating expenses | 1,017,493 | 929,441 | 829,287 |
| Medical related consulting services - related party | ... | ... | 147,167 |
| Total costs & expenses | ... | 929,441 | 976,454 |
| Real property operating income | ... | 272,728 | 374,273 |
| Gross profit (loss) from medical related consulting services | ... | ... | 40,245 |
| Gross profit from medical related consulting services - related party | 238,188 | ... | ... |
| Total gross profit | ... | 272,728 | 414,518 |
| Advertising & marketing | ... | 1,325,313 | 328,565 |
| Advertising expenses | 1,666,721 | ... | ... |
| Compensation & related benefits | 1,768,449 | 1,863,188 | 2,042,278 |
| Research & development expenses | 109,618 | 731,328 | 1,025,009 |
| Litigation settlement | ... | 1,350,000 | ... |
| Professional fees | 3,076,477 | 2,909,652 | 4,946,696 |
| Other general & administrative | ... | 886,142 | 905,800 |
| General & administrative expenses | 798,959 | ... | ... |
| INCOME FROM EQUITY METHOD INVESTMENT - LAB SERVICES MSO | (8,571,647) | ... | ... |
| Total other operating expenses | ... | 9,065,623 | 9,248,348 |
| Income (loss) from operations | (15,753,683) | (8,792,895) | (8,833,830) |
| Interest expense-amortization of debt discount & debt issuance cost | ... | 3,310,684 | ... |
| Interest expense | 544,010 | ... | ... |
| Interest expense-other | 773,780 | 185,751 | ... |
| Interest expense - related party | 33,712 | 79,898 | 200,477 |
| Change in fair value of warrants liabilities | 188,374 | ... | ... |
| Conversion inducement expense | ... | 344,264 | ... |
| Change in warrants derivative liabilities | ... | 600,749 | ... |
| Other income (expense) | ... | 223,759 | 4,271 |
| Loss from equity method investment | (18,175) | (41,863) | (60,463) |

| | | | |
|--|--------------|--------------|-------------|
| Other (expense) income | (324) | ... | ... |
| Impairment of equity method investment | 454,679 | ... | ... |
| Gain on debts extinguishment | 682,979 | ... | ... |
| Total other income (expense), net | (953,327) | (3,137,952) | (256,669) |
| United States income (loss) before income taxes | (15,928,780) | (11,567,154) | (8,504,426) |
| China income (loss) before income taxes | (778,230) | (363,693) | (586,073) |
| Income (loss) before income taxes | (16,707,010) | (11,930,847) | (9,090,499) |
| Deferred U.S. federal income taxes expense (benefit) | (3,256,007) | (1,729,700) | (1,810,264) |
| Deferred U.S. state & local income taxes expense (benefit) | ... | (585,627) | (612,904) |
| Deferred China income taxes expense (benefit) | (183,443) | 209,806 | (152,015) |
| US state and local - Deferred | (1,102,392) | ... | ... |
| Total deferred income taxes (benefit) | (4,541,842) | (2,105,521) | (2,575,183) |
| Change in valuation allowance | 4,541,842 | 2,105,521 | 2,575,183 |
| Net income (loss) | (16,707,010) | (11,930,847) | (9,090,499) |
| Net income (loss) attributable to Avalon GloboCare Corp. common shareholders | (16,707,010) | (11,930,847) | (9,090,499) |
| Weighted average shares outstanding | | | |
| - basic | 10,528,975 | 9,328,609 | ▣8,491,103 |
| Weighted average shares outstanding - diluted | 10,528,975 | 9,328,609 | ▣8,491,103 |
| Year end shares outstanding | 10,999,534 | 9,961,576 | ▣8,845,517 |
| Net income (loss) per share - basic | \$(1.59) | \$(1.28) | ▣\$(1.07) |
| Net income (loss) per share - diluted | \$(1.59) | \$(1.28) | ▣\$(1.07) |
| Number of full time employees | 5 | ▣5 | ▣5 |
| Number of part time employees | ... | ▣1 | ▣1 |
| Total number of employees | 5 | ▣6 | ▣6 |
| Number of common stockholders | 223 | ▣222 | ▣217 |

[□] Reclassified to conform with 2022 presentation; [▣] Adjusted for 1-for-10 stock split, January 5, 2023; [▢] As of March 30, 2023; [▤] As of March 30, 2022; [▥] Approximately; [▦] As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------|-----------|
| Cash | 285,400 | 1,990,910 |
| Rent receivable | 197,473 | 60,526 |
| Rent receivable - related party | ... | 74,100 |
| Prepaid directors & officers liability | ... | 29,301 |
| insurance premium | ... | 93,817 |
| Prepaid professional fees | ... | 174,107 |
| Deferred financing costs, net | ... | 3,531 |
| Recoverable VAT | 208,538 | 113,916 |
| Deferred leasing costs | ... | 19,084 |
| Security deposit | ... | 20,489 |
| Equipment held for sale | ... | ... |

| | | | | | | | | |
|--|------------|--|--------------|--------------|---|--------------|------------------------|------------------------|
| Long-term straight-line rent receivable | 144,094 | Note payable, net | 5,596,219 | 4,563,152 | for income taxes | (34,160,455) | (22,935,353) | (33,079,414) |
| Other current assets | 34,034 | Total non-current liabilities | 6,451,074 | 5,013,152 | Accretion of discounts to redemption value of H-7 convertible preferred stock | 3,980,274 | | |
| Total | 632,373 | Total liabilities | 13,213,760 | 8,592,957 | Preferred stock dividends | 697,991 | | |
| Less: non-current portion | (384,383) | Common stock | 1,105 | 1,005 | Deemed Dividend (Series H-5 warrants) | 199,000 | | |
| Other current assets | 247,990 | Series A convertible preferred stock | 11,000,000 | 9,000,000 | Net income (loss) | (34,160,455) | (22,935,353) | (33,079,414) |
| Prepaid expenses & other current assets | 367,994 | Additional paid in capital | 67,885,051 | 65,949,723 | Net income (loss) attributable to common shareholders | (39,037,720) | | (33,079,414) |
| Other | 62,015 | Less: common stock held in treasury, at cost | 522,500 | 522,500 | Weighted average shares outstanding | | | |
| Prepaid expenses - Balancing value | 60,254 | Accumulated deficit | (79,769,731) | | - basic | 4,764,494 | ² 4,631,122 | 4,396,492 |
| Due from broker | 37,187 | Retained earnings (accumulated deficit) | | (63,062,721) | Weighted average shares outstanding | | | |
| Total current assets | 850,867 | Statutory reserve | 6,578 | 6,578 | - diluted | 4,764,494 | ² 4,631,122 | 4,396,492 |
| Operating lease right-of-use assets, net | 128,250 | Accumulated other comprehensive loss - foreign currency translation adjustment | (231,727) | (213,137) | Year end shares outstanding | 4,913,907 | ² 4,655,205 | ³ 4,608,370 |
| Laboratory equipment | 100,548 | Series A Convertible Preferred Stock, \$ 0000 par value; 9,000 and 0 shares issued and outstanding at , 2022 and 202, respectively | | | Income (loss) per share from continuing operations - basic | \$(8.19) | | |
| Office equipment & furniture | 54,797 | Liquidation preference \$ 9 million at , 2022 | 9,000,000 | | Net income (loss) per share - basic | \$(8.19) | ² \$(4.96) | \$(7.52) |
| Property & equipment, gross | 155,345 | Total Avalon GloboCare Corp. stockholders' equity | 7,368,776 | 11,158,948 | Income (loss) per share from continuing operations - diluted | \$(8.19) | ² \$(4.96) | \$(7.52) |
| Less: accumulated depreciation | 117,262 | Total equity | 7,368,776 | 11,158,948 | Number of full time employees | 58 | 44 | 32 |
| Property & equipment, net | 38,083 | | | | Total number of employees | 58 | | |
| Property, Plant and Equipment, useful life | | | | | Number of common stockholders | 84 | ⁴ 79 | ⁴ 77 |
| Laboratory Equipment | 7,708,571 | | | | | | | |
| Investment Property - Accumulated Depreciation & Impairment | 1,046,539 | | | | | | | |
| Improvement | 529,372 | | | | | | | |
| Investment Property - Gross | 8,237,943 | | | | | | | |
| Investment in real estate, net | 7,191,404 | | | | | | | |
| Equity method investment | 12,095,020 | | | | | | | |
| Advances for equity interest purchase | 8,999,722 | | | | | | | |
| Other non-current assets | 278,912 | | | | | | | |
| Total non-current assets | 17,378,379 | | | | | | | |
| Total assets | 20,582,536 | | | | | | | |
| Accrued professional fees | 1,804,100 | | | | | | | |
| Accrued research & development fees | 838,001 | | | | | | | |
| Accrued payroll liability & directors' compensation | 588,722 | | | | | | | |
| Accrued litigation settlement | 450,000 | | | | | | | |
| Accrued tenants' improvement reimbursement | 43,500 | | | | | | | |
| Tenants' security deposit | 73,733 | | | | | | | |
| Accrued business expense reimbursement | 52,437 | | | | | | | |
| Accrued utilities | 15,631 | | | | | | | |
| Deferred rental income | 27,685 | | | | | | | |
| Accrued real property cleaning service fee | 23,564 | | | | | | | |
| Taxes payable | 7,337 | | | | | | | |
| Other accrued liabilities & other payables | 39,347 | | | | | | | |
| Other accrued liabilities & other payables | 208,772 | | | | | | | |
| Accrued liabilities & other payables - related parties | 206,458 | | | | | | | |
| Operating lease obligation | 129,396 | | | | | | | |
| Note payable - related party | 666,667 | | | | | | | |
| Convertible note payable, net | 1,925,146 | | | | | | | |
| Derivative liability | 24,796 | | | | | | | |
| Advance from sale of noncontrolling interest - related party | 485,714 | | | | | | | |
| Total current liabilities | 6,762,686 | | | | | | | |
| Operating lease obligation - noncurrent portion | 4,855 | | | | | | | |
| Loan payable | 850,000 | | | | | | | |
| Accrued litigation settlement - noncurrent portion | 450,000 | | | | | | | |

Recent Dividends:
1. Avalon GloboCare Corp series B convertible preferred.
 No dividends paid.
2. Avalon GloboCare Corp series A convertible preferred.
 No dividends paid.
3. Avalon GloboCare Corp common.
 No dividends paid.
Annual Dividends:
1. Avalon GloboCare Corp series B convertible preferred.
 No dividends paid.
2. Avalon GloboCare Corp series A convertible preferred.
 No dividends paid.
3. Avalon GloboCare Corp common.
 No dividends paid.

AYRO INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 |
|---|--------------|--------------|-------------------|
| | | | (revised) |
| Revenue | 498,917 | 2,990,497 | 2,683,597 |
| Cost of goods sold | 5,133,996 | 6,043,506 | 4,774,784 |
| Gross profit (loss) | (4,635,079) | (3,053,009) | (2,091,187) |
| Research & development | 7,418,026 | 6,845,451 | 11,449,617 |
| Sales & marketing | 1,721,191 | 1,874,658 | 2,419,168 |
| General & administrative | 14,382,132 | 11,503,788 | 17,168,898 |
| Total operating expenses | 23,521,349 | 20,223,897 | 31,037,683 |
| Income (loss) from operations | (28,156,428) | (23,276,906) | (33,128,870) |
| Interest expense | | | 2,312 |
| Realized gain on marketable securities | 941,950 | 160,990 | |
| Unrealized gain (loss) on marketable securities | 215,900 | (1,713) | |
| Other income, net | 441,443 | | |
| Interest income | | 182,276 | 51,768 |
| Change in fair value - warrant liability | (4,253,000) | | |
| Change in fair value - warrant liability | (3,350,320) | | |
| Total other income (expense), net | (6,004,027) | 341,553 | 49,456 |
| Net income (loss) prior to provision | | | |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-8 stock split, September 18, 2023; ³ Shares increased due to the effect of exercise of warrants, net of fees; ⁴ Approximately; ⁵ As of March 22, 2023; ⁶ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 33,440,867 | |
| Cash | | 39,096,562 |
| Marketable securities | | 9,848,804 |
| Restricted cash | 10,000,000 | |
| Trade receivable, gross | 272,696 | 512,420 |
| Less: allowance for doubtful accounts | 53,696 | 2,349 |
| Accounts receivable, net | 219,000 | 510,071 |
| Work-in-progress | 179,702 | |
| Raw materials | 3,252,280 | 330,931 |
| Finished goods | | 639,450 |
| Inventory | 3,431,982 | |
| Inventory, net | | 970,381 |
| Prepaid final assembly services | 1,887,782 | |
| Prepayments for inventory | | 1,174,466 |
| Prepayments for insurance | | 118,434 |
| Prepayments on advances on design | | 75,000 |
| Prepayments on software | | 103,851 |
| Prepaid other | | 7,094 |
| Prepaid expenses & other current assets | | 1,478,845 |
| Total current assets | 48,979,631 | 51,904,663 |
| Computer & equipment | 3,619,041 | 1,970,001 |
| Furniture & fixtures | | 323,789 |
| Lease improvements | 1,094,025 | 952,952 |
| Prototypes | 395,703 | |
| Computer software | 495,295 | 455,875 |
| Property & equipment, gross | 5,604,064 | 3,702,617 |
| Less: accumulated | | |

| | | |
|---|---------------|--------------|
| depreciation | 2,486,900 | 1,510,280 |
| Property & equipment, net | 3,117,164 | 2,192,337 |
| Operating lease - right-of-use asset | 671,451 | 819,401 |
| Deposits & other assets | 95,532 | 73,683 |
| Total assets | 52,863,778 | 54,990,084 |
| Accounts payable | 2,456,258 | 1,107,215 |
| Accrued expenses | 1,656,541 | 964,937 |
| Accrued severance | 575,111 | ... |
| Current portion lease obligation - operating lease | 196,682 | 165,767 |
| Accrued expenses and other current liabilities | ... | ... |
| - Balancing value | 1,081,430 | ... |
| Total current liabilities | 4,309,481 | 2,237,919 |
| Lease obligation - operating lease, net of current portion | 502,831 | 693,776 |
| Warrant liability | 13,319,800 | ... |
| Derivative liability - warrants | 9,400,000 | ... |
| Total liabilities | 27,532,112 | 2,931,695 |
| Preferred Stock - Redeemable - Series H 7 - Convertible | 11,193,939 | ... |
| Common Stock, (\$00001 par value; authorized 100,000,000 shares; issued and outstanding 36,304,362 and 27,088,584 shares, respectively) | 492 | ... |
| Common stock | ... | 3,724 |
| Additional paid-in capital | 129,467,274 | 133,224,249 |
| Accumulated deficit | (115,330,039) | ... |
| Retained earnings (accumulated deficit) | ... | (81,169,584) |
| Total stockholders' equity (deficit) | 14,137,727 | 52,058,389 |
| Total equity (deficit) | 14,137,727 | ... |

Recent Dividends:

| | |
|--|--------------------|
| 1. AYRO Inc series G-1 convertible preferred. | No dividends paid. |
| 2. AYRO Inc series H-3 convertible preferred. | No dividends paid. |
| 3. AYRO Inc series H-2 convertible preferred. | No dividends paid. |
| 4. AYRO Inc series F-1 convertible preferred. | No dividends paid. |
| 5. AYRO Inc series F convertible preferred. | No dividends paid. |
| 6. AYRO Inc series H-1 convertible preferred. | No dividends paid. |
| 7. AYRO Inc common. | No dividends paid. |
| 8. AYRO Inc series H-5 convertible preferred. | No dividends paid. |
| 9. AYRO Inc series H-4 convertible preferred. | No dividends paid. |
| 10. AYRO Inc series E convertible preferred. | No dividends paid. |
| 11. AYRO Inc series H convertible preferred. | No dividends paid. |
| 12. AYRO Inc series H-7 convertible redeemable preferred. | No dividends paid. |
| 13. AYRO Inc series G convertible preferred. | No dividends paid. |
| 14. AYRO Inc series H-6 convertible preferred. | No dividends paid. |
| Annual Dividends: | |
| 1. AYRO Inc series G-1 convertible preferred. | No dividends paid. |
| 2. AYRO Inc series H-3 convertible preferred. | No dividends paid. |
| 3. AYRO Inc series H-2 convertible preferred. | No dividends paid. |
| 4. AYRO Inc series F-1 convertible preferred. | No dividends paid. |
| 5. AYRO Inc series F convertible preferred. | No dividends paid. |
| 6. AYRO Inc series H-1 convertible preferred. | No dividends paid. |

| | | |
|--|---------------|---------------|
| No dividends paid. | | |
| 7. AYRO Inc common. | | |
| No dividends paid. | | |
| 8. AYRO Inc series H-5 convertible preferred. | | |
| No dividends paid. | | |
| 9. AYRO Inc series H-4 convertible preferred. | | |
| No dividends paid. | | |
| 10. AYRO Inc series E convertible preferred. | | |
| No dividends paid. | | |
| 11. AYRO Inc series H convertible preferred. | | |
| No dividends paid. | | |
| 12. AYRO Inc series H-7 convertible redeemable preferred. | | |
| No dividends paid. | | |
| 13. AYRO Inc series G convertible preferred. | | |
| No dividends paid. | | |
| 14. AYRO Inc series H-6 convertible preferred. | | |
| No dividends paid. | | |
| BAB INC | | |
| Earnings, 3 mos. to (Consol. - \$): | | |
| | 02/29/24 | 02/28/23 |
| Total revenues | 835,934 | 745,593 |
| Cost & expenses | 712,974 | 695,271 |
| Operating income | 121,980 | 49,399 |
| Interest income | 15,525 | 121 |
| Net before taxes | 137,505 | 49,520 |
| Income taxes | ... | 14,200 |
| Net income | 98,505 | 35,320 |
| Balance for common | ... | 35,320 |
| Earnings common share | | |
| Primary | \$0.01 | \$0.01 |
| Fully Diluted | \$0.01 | \$0.01 |
| Common Shares: | | |
| Full Diluted | 7,263,508 | 7,263,508 |
| Year-end | 7,263,508 | 7,263,508 |
| Consolidated Balance Sheet Items, as of (\$): | | |
| Assets: | | 2024 |
| Cash & equivalents | ... | 1,890,204 |
| Current assets | ... | 2,303,080 |
| Total assets | ... | 4,714,248 |
| Liabilities: | | |
| Current liabilities | ... | 774,159 |
| Stockholders' equity | ... | 3,132,428 |
| Net current assets | ... | 1,528,921 |

BAIYU HOLDINGS INC**Annual Report**

| | | | |
|---|-------------|-------------|-------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Sales of commodity products - third parties | 134,558,086 | 155,443,398 | 173,904,016 |
| Sales of commodity products - related parties | ... | ... | 24,049,999 |
| Supply chain management services - third parties | 67,981 | 1,391,903 | 3,180,227 |
| Total revenues | 134,626,067 | 156,835,301 | 201,134,242 |
| Cost of revenues - commodity product sales - third parties | 134,756,423 | 155,789,519 | 173,996,000 |
| Cost of revenues - commodity product sales - related parties | ... | ... | 24,045,511 |
| Cost of revenues - supply chain management services - third parties | 59,118 | 7,525 | 84,118 |
| Total operating costs | 134,815,541 | 155,797,044 | 198,125,629 |
| Gross profit (loss) | (189,474) | 1,038,257 | 3,008,613 |
| Selling, general, & administrative expenses | 16,591,688 | 8,844,739 | 8,137,481 |
| Share-based payment for service | ... | 44,000 | 1,836,442 |
| Total operating expenses | 16,591,688 | 8,888,739 | 9,973,923 |
| Interest income | 20,103,265 | 17,035,200 | 10,079,776 |
| Interest expenses | 605,430 | 523,980 | 313,965 |
| Amortization of | ... | ... | ... |

| | | | |
|--|--------------------|------------------|------------------|
| beneficial conversion feature relating to issuance of convertible promissory notes | 982,961 | 1,212,617 | 1,463,883 |
| Other income (expense), net | 15,019 | 59,088 | (285,774) |
| Total other income (expenses), net | 18,529,893 | 15,357,691 | 8,016,154 |
| Net income (loss) from continuing operations before income taxes (benefit) | 1,748,731 | 7,507,209 | 1,050,844 |
| Current income tax expenses (benefit) | 4,771,132 | 4,045,786 | 2,817,146 |
| Deferred income tax expenses (benefits) | (756,076) | (792,114) | (825,945) |
| Income tax expenses (benefit) | 4,015,056 | 3,253,672 | 1,991,201 |
| Net income (loss) | (2,266,325) | 4,253,537 | (940,357) |
| Less: net income (loss) attributable to noncontrolling interests | 1,546,536 | 271,590 | ... |
| Net income (loss) attributable to TD Holdings, Inc. stockholders | (719,789) | 4,525,127 | (940,357) |
| Weighted average shares outstanding | | | |
| - basic | 1,499,560 | 1,059,455 | 429,671 |
| Weighted average shares outstanding | | | |
| - diluted | 1,499,560 | 1,171,805 | 484,397 |
| Year end shares outstanding | 19,335,220 | 2,134,842 | 552,697 |
| Net income (loss) per share - basic | \$(0.48) | \$4.00 | \$(2.50) |
| Net income (loss) per share - diluted | \$(0.48) | \$3.50 | \$(2.50) |
| Number of full time employees | 51 | 58 | 69 |
| Number of common stockholders | 298 | 275 | 264 |
| Foreign currency translation adjustments | ... | (20,651,532) | 4,781,112 |
| Total number of employees | 51 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-50 stock split, October 30, 2023; □ Adjusted for 1-for-5 stock split, August 18, 2022; □ Shares increase due to the effect of issuance of common stocks in connection with private placements & pursuant to exercise of warrants; □ Shares increased due to issuance of common stock with private placements and offering, exercise of warrants and convertible promissory notes, and share-based payment for service

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 1,516,358 | 893,057 |
| Loans receivable from third parties | 240,430,865 | 143,174,634 |
| Aluminum ingots | ... | 475,096 |
| Less: impairment for inventories | ... | (16,939) |
| Inventories, net | 259,806 | 458,157 |
| Other current assets | 10,134,829 | 4,040,477 |
| Total current assets | 252,341,858 | 148,566,325 |
| Office equipment, cost | ... | 9,747 |
| Less: accumulated depreciation - office equipment | ... | 3,377 |
| Less: accumulated depreciation | 11,909 | ... |
| Cost office equipment | 43,999 | ... |
| Plant & equipment, net | 32,090 | 6,370 |
| Goodwill | 157,542,081 | 160,213,550 |
| Intangible assets, net | 45,285,617 | 54,114,727 |
| Right-of-use assets, net | 83,375 | 196,826 |

| | | |
|--|--------------|--------------|
| Total non-current assets | 202,943,163 | 214,531,473 |
| Total assets | 455,285,021 | 363,097,798 |
| Accounts payable | ... | 1,269 |
| Bank borrowings | 1,057,648 | 1,005,083 |
| Third party loans payable | 476,627 | 460,587 |
| Advances from customers | ... | 437,148 |
| Due to related parties | ... | 38,767,481 |
| Income tax payable | ... | 11,634,987 |
| Lease liabilities | 86,691 | 116,170 |
| Other payable | 3,352,643 | ... |
| Accrued payroll & benefit | 3,210,615 | 1,831,506 |
| Other tax payable (recoverable) | 16,187,826 | 3,451,928 |
| Other current liabilities | 6,578,349 | 65,212 |
| Convertible promissory notes | 4,284,622 | 4,208,141 |
| Others | 15,091 | ... |
| Total current liabilities | ... | 61,979,512 |
| Income tax payable | 2,256,696 | ... |
| Deferred tax liabilities | ... | 3,059,953 |
| Lease liabilities | ... | 84,164 |
| Other noncurrent liabilities | 38,121,056 | ... |
| Total noncurrent liabilities | ... | 3,144,117 |
| Total liabilities | 72,139,716 | 65,123,629 |
| Common stock | 19,335 | 106,742 |
| Additional paid-in capital | 438,980,687 | 344,295,992 |
| Statutory surplus reserve | 2,602,667 | 2,602,667 |
| Retained earnings (accumulated deficit) | (39,520,164) | (38,800,375) |
| Accumulated other comprehensive income (loss) | (16,144,752) | (8,984,925) |
| Total TD Holdings, Inc. shareholders' equity (deficit) | 385,937,773 | 299,220,101 |
| Non-controlling interest | (2,792,468) | (1,245,932) |
| Total equity | 383,145,305 | 297,974,169 |

Recent Dividends:

- 1. BAIYU Holdings Inc series A preferred stock.**
No dividends paid.
 - 2. BAIYU Holdings Inc series B preferred stock.**
No dividends paid.
 - 3. BAIYU Holdings Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. BAIYU Holdings Inc series A preferred stock.**
No dividends paid.
 - 2. BAIYU Holdings Inc series B preferred stock.**
No dividends paid.
 - 3. BAIYU Holdings Inc common.**
No dividends paid.

BAKHU HOLDINGS CORP

Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|-------------|-------------|
| Cost & expenses | 1,367,761 | 6,683,539 |
| Operating income | (1,434,597) | (6,750,375) |
| Interest expense | 140,639 | 95,493 |
| Other income (expense), net | 323,078 | ... |
| Gains or losses | ... | (65,748) |
| Net before taxes | (1,252,158) | (6,911,616) |
| Net income | (1,252,158) | (6,911,616) |
| Earnings common share | | |
| Primary | \$(0.02) | \$(0.02) |
| Fully Diluted | \$(0.02) | \$(0.02) |
| Common Shares: | | |
| Full Diluted | 301,302,983 | 301,290,592 |
| Year-end | 301,302,983 | 301,302,983 |

BARFRESH FOOD GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-------------------------------|-----------|-----------|-----------|
| | | (revised) | (revised) |
| Impairment of tangible assets | ... | 746,000 | ... |
| Revenue | 8,127,000 | 9,162,000 | ... |
| Revenue | 8,127,000 | 9,162,000 | 6,700,000 |
| Cost of revenue | 5,243,000 | 7,722,000 | 4,193,000 |

| | | | |
|---|-------------|-------------|-------------|
| Gross profit (loss) | 2,884,000 | 1,440,000 | 2,507,000 |
| Selling, marketing & distribution expenses | 2,614,000 | 2,861,000 | 1,810,000 |
| Personnel costs | 1,199,000 | 1,340,000 | 830,000 |
| Stock-based compensation & payment for outside services | 543,000 | 559,000 | 281,000 |
| Legal, professional & consulting fees | 310,000 | 499,000 | 396,000 |
| Director fees paid in cash | ... | 100,000 | 100,000 |
| Research & development expenses | 115,000 | 382,000 | 245,000 |
| Other general & administrative expenses | 527,000 | 669,000 | 318,000 |
| General & administrative expenses | 2,694,000 | 3,549,000 | 2,170,000 |
| Depreciation & amortization expenses | 400,000 | 418,000 | 622,000 |
| Total operating expenses | 5,708,000 | 7,574,000 | 4,602,000 |
| Operating income (loss) | ... | ... | (2,095,000) |
| Gain (loss) from derivative liability | ... | ... | 16,000 |
| Gain from debt extinguishment - Paycheck Protection Program | ... | ... | 1,136,000 |
| Interest expense | ... | ... | 128,000 |
| Gain (loss) on extinguishment of debt | ... | ... | (194,000) |
| Total other income (expense) | ... | ... | 830,000 |
| Net income (loss) | (2,824,000) | (6,134,000) | (1,265,000) |
| Weighted average shares outstanding - basic | 13,359,000 | 12,924,000 | 12,070,000 |
| Weighted average shares outstanding - fully diluted | 13,359,000 | 12,924,000 | 12,070,000 |
| Year end shares outstanding | 14,420,105 | 12,934,741 | 12,905,112 |
| Net earnings (loss) per share - basic | \$(0.21) | \$(0.47) | \$(0.10) |
| Net earnings (loss) per share - fully diluted | \$(0.21) | \$(0.47) | \$(0.10) |
| Number of full time employees | 10 | ... | 14 |
| Number of part time employees | ... | ... | 4 |
| Total number of employees | 10 | ... | ... |
| Number of common stockholders | 89 | ... | 102 |
| Income from cont operations before income tax | (2,824,000) | (6,134,000) | ... |
| Federal | (464,000) | (956,000) | ... |
| State | (155,000) | (323,000) | ... |
| Earnings per share from continuing operations | \$(0.21) | \$(0.47) | ... |
| Earnings per share from continuing operations | \$(0.21) | \$(0.47) | ... |
| Income Taxes - Other - Deferred | 619,000 | 1,279,000 | ... |

[¶] Reclassified to conform 2023 presentation; [¶] Reclassified to conform with 2022 presentation; [¶] As of March 1, 2022; [¶] As of March 2, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------|------|
|--|------|------|

| | | |
|--|--------------|--------------|
| Cash | 1,891,000 | 2,808,000 |
| Restricted cash | ... | 211,000 |
| Accounts receivable, gross | ... | 126,000 |
| Trade accounts receivable, net | 821,000 | 126,000 |
| Other receivables | 160,000 | 101,000 |
| Raw materials | 28,000 | 65,000 |
| Finished goods | 1,186,000 | 983,000 |
| Inventory | 1,214,000 | ... |
| Inventory, net | ... | 1,048,000 |
| Prepaid expenses & other current assets | 67,000 | 79,000 |
| Total current assets | 4,153,000 | 4,373,000 |
| Manufacturing equipment | 1,410,000 | ... |
| Manufacturing equipment & customer equipment | 1,546,000 | 3,637,000 |
| Other property | 2,956,000 | 69,000 |
| Property, plant & equipment, gross | ... | 3,706,000 |
| Less: accumulated depreciation | 2,547,000 | 3,317,000 |
| Property, plant & equipment, net of depreciation | 409,000 | 389,000 |
| Operating lease right-of-use assets, net | ... | 18,000 |
| Intangible assets, net of amortization | 241,000 | 306,000 |
| Deposits | 7,000 | 7,000 |
| Total assets | 4,810,000 | 5,093,000 |
| Accounts payable | 1,670,000 | 1,534,000 |
| Disputed co-manufacturer accounts payable | 499,000 | 499,000 |
| Accrued expenses | 85,000 | 286,000 |
| Accrued payroll & employee related | 53,000 | 233,000 |
| Lease liability | ... | 20,000 |
| Total current liabilities | 2,307,000 | 2,572,000 |
| Total liabilities | 2,307,000 | 2,572,000 |
| Common stock | 14 | ... |
| Additional paid in capital | 63,299,000 | 60,905,000 |
| Retained earnings (accumulated deficit) | (60,796,000) | (58,384,000) |
| Total stockholders' equity (deficit) | 2,503,000 | 2,521,000 |
| Total Equity | 2,503,000 | ... |

Recent Dividends:

- 1. Barfresh Food Group Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. Barfresh Food Group Inc common.**
No dividends paid.

BASANITE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| | | (revised) | (revised) |
| Products sales - rebar | ... | ... | 193,194 |
| Products sales | 376,096 | 1,356,165 | ... |
| Total revenue | 376,096 | 1,356,165 | ... |
| Total cost of goods sold | 248,313 | 2,025,926 | ... |
| Total cost of goods sold | ... | 2,025,926 | 1,970,604 |
| Gross profit (loss) | 127,783 | (669,761) | (1,777,410) |
| Selling, general, & administrative expenses | 1,730,733 | 3,585,955 | 8,018,152 |
| Total operating expenses | 1,730,733 | 3,585,955 | 8,018,152 |
| Net income (loss) from operations | (1,602,950) | (4,255,716) | (9,795,562) |
| Gain on settlement of legal contingency | ... | (426,759) | 409,127 |
| Gain on settlement of payables | ... | 52,712 | 39,902 |
| Miscellaneous | ... | ... | ... |

| | | | |
|---|--------------------|--------------------|---------------------|
| income | 30 | | |
| Gain (loss) on extinguishment of debt | (6,743,015) | | |
| Loan forgiveness | 170,096 | 124,143 | |
| Interest expense | 566,429 | 512,162 | 512,418 |
| LOSS FROM CONTINUING OPERATIONS | (2,169,379) | (4,971,799) | |
| Total other income (expense) | | | (6,682,261) |
| Income (loss) from continuing operations | | | (16,477,823) |
| Net income (loss) | (2,169,379) | (4,971,799) | (16,477,823) |
| Weighted average shares outstanding - basic | 256,834,618 | 251,488,656 | 235,473,411 |
| Weighted average shares outstanding - diluted | 256,834,618 | 251,488,656 | 235,473,411 |
| Year end shares outstanding | 259,156,796 | 251,884,069 | 248,840,144 |
| Net income (loss) per share - continuing operations - basic | \$(0.01) | \$(0.03) | |
| Net income (loss) per share - basic | \$(0.01) | \$(0.03) | \$(0.07) |
| Net income (loss) per share - continuing operations - diluted | \$(0.01) | \$(0.03) | |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.03) | \$(0.07) |
| Number of full time employees | 2 | | 23 |
| Total number of employees | 2 | | |
| Number of common stockholders | 277 | | 282 |

□ Restated to reflect correction of errors; ▢ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|-----------|----------------|
| Cash | 55,248 | 30,340 |
| Accounts receivable, net | 40,222 | 522,494 |
| Inventory | | (401,993) |
| Prepaid expenses | | 137,370 |
| Deposits & other current assets | | 177,875 |
| Total current assets | 95,470 | 466,085 |
| Lease right-of-use asset | 56,915 | 1,354,392 |
| Computer equipment | 203,193 | |
| Machinery | 728,245 | |
| Total fixed assets | 931,438 | |
| Less: accumulated depreciation | 529,167 | |
| Fixed assets, net | 402,271 | 2,946,877 |
| Total non current assets | 459,186 | 4,301,268 |
| Total assets | 554,656 | 4,767,354 |
| Accounts payable | 1,762,390 | 1,713,045 |
| Accrued expenses | 1,207,545 | 416,023 |
| Accrued legal liabilities | | 165,000 |
| Notes payable | 270,000 | 304,243 |
| Notes payable - related party | | 605,000 |
| Note payable - convertible, net | 1,750,000 | |
| Notes payable - convertible - related party, net | 2,144,357 | 2,144,357 |
| Subscription liability | | 1,805,000 |
| Lease liability - current portion | 56,915 | 426,898 |
| Due to shareholders | 475,000 | |
| Total current liabilities | 7,666,207 | 7,579,567 |
| Lease liability - net of current portion | | 994,809 |
| Total liabilities | 7,666,207 | 8,574,376 |
| Common stock | 259,157 | 253,218 |

| | | |
|---|--------------|--------------|
| Additional paid in capital | 48,891,681 | 47,455,915 |
| Accumulated Deficit | (56,262,389) | |
| Retained earnings (accumulated deficit) | | (51,516,155) |
| Total stockholders' equity (deficit) | (7,111,551) | (3,807,022) |
| Total stockholders' equity (deficit) | (7,111,551) | |

Recent Dividends:

1. Basanite Inc preferred.

No dividends paid.

2. Basanite Inc common.

No dividends paid.

Annual Dividends:

1. Basanite Inc preferred.

No dividends paid.

2. Basanite Inc common.

No dividends paid.

BASANITE INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Hudgens CPA, PLLC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheet of Basanite, Inc. (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of their operations and cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has a working capital deficit, has generated net losses since its inception and further losses are anticipated. The Company requires additional funds to meet its obligations and the costs of their operations. These factors raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

BBX CAPITAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|----------|---------|----------------|
| Trade sales | 250,436 | 280,125 | 238,078 |
| Sales of real estate inventory | 12,912 | 27,794 | 65,479 |
| Interest income | 9,180 | 5,993 | 6,413 |
| Net gains on sales of real estate assets | 2,210 | 24,289 | 643 |
| Other revenue | 1,146 | 3,844 | 2,984 |
| Real estate development and property management fees | 11,186 | | |
| Revenue from construction contracts | 114,187 | | |
| Total revenues | 401,257 | 342,045 | 313,597 |
| Cost of trade sales | 184,767 | 213,721 | 185,146 |
| Cost of real estate inventory sold | 3,071 | 11,463 | 29,690 |
| Interest expense | 3,142 | 2,399 | 1,439 |
| Recoveries from loan losses, net | (3,594) | (4,835) | (7,774) |
| Impairment losses | 615 | 549 | 38 |
| Selling, general & administrative expenses | 136,113 | 116,215 | 76,014 |
| Total costs & expenses | 446,474 | 339,512 | 284,553 |
| Operating income (losses) | (45,217) | 2,533 | 29,044 |

| | | | |
|---|-----------------|---------------|---------------|
| Equity in net earnings of unconsolidated real estate joint ventures | 4,219 | 38,414 | 18,154 |
| Gain on the consolidation of IT'SUGAR, LLC | | | 15,890 |
| Other income | 4,027 | 964 | 341 |
| Foreign exchange gain (loss) | (515) | 880 | 812 |
| Income (loss) before income taxes - U.S. | | 51,437 | 66,575 |
| Income (loss) before income taxes - foreign | | (8,646) | (2,334) |
| Income (loss) before income taxes | (21,723) | 42,791 | 64,241 |
| Current federal provision (benefit) for income taxes | 454 | 12,117 | 10,672 |
| Current state provision (benefit) for income taxes | | 3,630 | 2,855 |
| Total current provision (benefit) for income taxes | 454 | 15,747 | 13,527 |
| Deferred federal provision (benefit) for income taxes | (2,407) | (251) | 3,234 |
| Deferred state provision (benefit) for income taxes | (107) | (347) | 414 |
| Total deferred provision (benefit) for income taxes | (2,514) | (598) | 3,648 |
| Provision (benefit) for income taxes | (2,060) | 15,149 | 17,175 |
| Net income (loss) | (19,663) | 27,642 | 47,066 |
| Net loss (income) attributable to noncontrolling interests | (1,135) | 378 | (155) |
| Net income (loss) attributable to shareholders | (20,798) | 28,020 | 46,911 |
| Weighted average shares outstanding - basic | 14,411 | 15,471 | 17,840 |
| Weighted average shares outstanding - diluted | 14,411 | 15,508 | 17,840 |
| Year end shares outstanding | 13,896 | 14,354 | 15,475 |
| Net earnings (loss) per share - basic | \$(1.44) | \$1.81 | \$2.63 |
| Net earnings (loss) per share - diluted | \$(1.44) | \$1.81 | \$2.63 |
| Full-Time Employees (Period End) | 1,456 | | |
| Total number of employees | 1,456 | 1,553 | 1,387 |
| Number of class A common stockholders | | 191 | 176 |
| Number of class B common stockholders | | 79 | 76 |
| Comprehensive (loss) income attributable to shareholders | (20,308) | | |
| Gain on the consolidation of The Altman Companies | 3,746 | | |
| Gain on the consolidation of investment in real estate joint ventures | 12,017 | | |
| Cost of revenue from construction contracts | 122,360 | | |
| Common Shareholders | | | |

| | | | | | | | | | |
|--|--------------|--------------|---|-----------|------------------------|----------------------|--|------------|------------|
| liabilities, noncurrent | 455,000 | 1,070,000 | shares outstanding | | | Deferred revenue | 7,000 | 336,000 | |
| Long-term portion of auto loan | 160,000 | ... | - diluted | 705,185 | [□] 667,114 | 497,785 | Short-term financing | ... | 165,000 |
| Contingent consideration, noncurrent | 4,725,000 | ... | Year end shares outstanding | 729,026 | [□] 668,870 | [□] 662,417 | Other accrued liabilities | 2,085,000 | 261,000 |
| Deferred tax liabilities, noncurrent | 1,698,000 | ... | Net income (loss) per share - continuing operations - basic | \$(32.29) | ... | ... | Accrued & other liabilities | ... | 2,596,000 |
| Total liabilities | 28,101,000 | 14,523,000 | Net income (loss) per share - basic | \$(32.29) | [□] \$(58.96) | \$6.60 | Accounts payable & accrued liabilities | 6,928,000 | ... |
| Common stock, \$0.001 par value, 9,800,000 shares authorized, 5,208,170 and 2,906,630 shares issued or issuable and outstanding at 31, 2019 and 2018, respectively | 14,000 | ... | Net income (loss) per share - continuing operations - diluted | \$(32.29) | ... | ... | Operating lease liability | 57,000 | 52,000 |
| Common stock | ... | 10,000 | Net income (loss) per share - diluted | \$(32.29) | [□] \$(58.96) | \$6.16 | Accrued interest | 254,000 | ... |
| Additional paid-in-capital | 142,265,000 | 100,498,000 | Number of full time employees | 31 | 46 | 43 | Total current liabilities | 13,692,000 | 5,580,000 |
| Accumulated Deficit | (93,361,000) | ... | Number of part time employees | 1 | 1 | ... | Line of credit, net | ... | 11,444,000 |
| Retained earnings (accumulated deficit) | ... | (77,301,000) | Number of common stockholders | 154 | [□] 152 | [□] 156 | Operating lease liability | 67,000 | 124,000 |
| Accumulated Other Comprehensive Income (AOI) | 624,000 | ... | Total number of employees | 32 | ... | ... | Total non-current liabilities | 67,000 | 11,568,000 |
| Total stockholders' equity (deficit) | 49,542,000 | 23,207,000 | | | | | Total liabilities | 13,759,000 | 17,148,000 |
| Total Equity | 49,542,000 | ... | | | | | Common stock | 32,000 | 29,000 |

Recent Dividends:**1. Beam Global common.**

No dividends paid.

Annual Dividends:**1. Beam Global common.**

No dividends paid.

BETTER CHOICE CO INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|---------------------|----------------------|------------------|
| | | | (revised) |
| Revenue | 38,592,000 | ... | ... |
| Net sales | 38,592,000 | 54,660,000 | 46,006,000 |
| Cost of goods sold | 26,795,000 | 39,399,000 | 30,638,000 |
| Gross profit | 11,797,000 | 15,261,000 | 15,368,000 |
| Selling, general, & administrative expenses | 24,444,000 | 32,461,000 | 28,507,000 |
| Share-based compensation | ... | 2,969,000 | 4,140,000 |
| Impairment of goodwill | ... | 18,614,000 | ... |
| Impairment of intangible asset | 8,532,000 | ... | ... |
| Total operating expenses | 32,976,000 | 54,044,000 | 32,647,000 |
| Income (loss) from operations | (21,179,000) | (38,783,000) | (17,279,000) |
| Interest expense - fair value of derivative in excess of notes payable | 1,353,000 | ... | ... |
| Interest expense, net | ... | 551,000 | 3,217,000 |
| Gain (loss) on extinguishment of debt, net | ... | ... | 457,000 |
| Change in fair value of warrant liabilities | (236,000) | ... | 23,463,000 |
| Total other income (expense), net | ... | (551,000) | 20,703,000 |
| Net income (loss) before income taxes | (22,768,000) | (39,334,000) | 3,424,000 |
| Income tax expense (benefit) | 2,000 | (18,000) | 37,000 |
| Net income (loss) | (22,770,000) | (39,316,000) | 3,387,000 |
| Net income (loss) available to common stockholders | ... | (39,316,000) | 3,387,000 |
| Weighted average shares outstanding - basic | 705,185 | [□] 667,114 | 452,906 |
| Weighted average | | | |

[□] Adjusted for 1-for-44 stock split, March 21, 2024; [□] Shares increased due to the effect of shares and warrants issued pursuant to private placement, share-based compensation, warrant exercises, shares issued to third-party for services; [□] Shares increased due to the effect of conversion of series F shares to common stock, convertible notes to common stock, shares issued pursuant to IPO and shares issued in lieu of fractional shares; [□] As of March 24, 2023; [□] As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 4,455,000 | 3,173,000 |
| Restricted cash | ... | 6,300,000 |
| Prepaid marketing expenses | 451,000 | ... |
| Accounts receivable, net | 4,354,000 | 6,744,000 |
| Food, treats & supplements | 6,296,000 | 10,212,000 |
| Inventory packaging & supplies | 1,166,000 | 1,699,000 |
| Inventory reserve | 851,000 | 1,654,000 |
| Inventories, net | 6,611,000 | 10,257,000 |
| Prepaid advertising contract with iHeartMedia + Entertainment, Inc. | 812,000 | ... |
| Other orepaid expenses & other current assets | 361,000 | 1,051,000 |
| Prepaid expenses & other current assets | ... | 1,051,000 |
| Total current assets | 16,232,000 | 27,525,000 |
| Equipment | 18,000 | 7,000 |
| Furniture & fixtures | 221,000 | 221,000 |
| Computer software, including website development | 187,000 | 187,000 |
| Computer equipment | 108,000 | 129,000 |
| Property & equipment, gross | 534,000 | 544,000 |
| Less accumulated depreciation | 304,000 | 169,000 |
| Fixed assets, net | 230,000 | 375,000 |
| Right-of-use assets, operating leases | 120,000 | 173,000 |
| Intangible assets, net | ... | 10,059,000 |
| Other assets | 155,000 | 544,000 |
| Total assets | 16,737,000 | 38,676,000 |
| Short term loan, net | 2,881,000 | ... |
| PPP loans | 1,741,000 | ... |
| Accounts payable | ... | 2,932,000 |
| Accrued taxes | 294,000 | 110,000 |
| Accrued payroll & benefits | 487,000 | 688,000 |
| Accrued trade promotions | 848,000 | ... |
| Accrued trade promotions & advertising | 90,000 | 567,000 |
| Accrued interest | 105,000 | 84,000 |
| Accrued commissions | ... | 385,000 |

Recent Dividends:**1. Better Choice Co Inc series E convertible preferred.**

No dividends paid.

2. Better Choice Co Inc common.

No dividends paid.

3. Better Choice Co Inc redeemable series E convertible preferred.

No dividends paid.

4. Better Choice Co Inc series A preferred.

No dividends paid.

5. Better Choice Co Inc series B convertible preferred.

No dividends paid.

6. Better Choice Co Inc redeemable series F convertible preferred.

No dividends paid.

Annual Dividends:**1. Better Choice Co Inc series E convertible preferred.**

No dividends paid.

2. Better Choice Co Inc common.

No dividends paid.

3. Better Choice Co Inc redeemable series E convertible preferred.

No dividends paid.

4. Better Choice Co Inc series A preferred.

No dividends paid.

5. Better Choice Co Inc series B convertible preferred.

No dividends paid.

6. Better Choice Co Inc redeemable series F convertible preferred.

No dividends paid.

BIOADAPTIVES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|-----------|-----------|----------|
| Revenues | 28,565 | ... | ... |
| Revenue | 28,565 | 17,176 | 19,776 |
| Cost of revenue | 17,746 | 10,050 | 9,671 |
| Gross profit | 10,819 | 7,126 | 10,105 |
| General & administrative expenses | 101,478 | 254,119 | 268,268 |
| Professional fees | 110,088 | 112,759 | 80,227 |
| Stock based compensation | ... | ... | 163,900 |
| Amortization of license & patent | 28,174 | 62,148 | 133,791 |
| Total operating expenses | ... | 429,026 | 646,186 |
| Unrealized gain (loss) on marketable securities | (42) | (148) | (254) |
| Interest expense | 162,891 | 289,121 | 272,394 |
| Change in fair value of derivative liabilities | (307,412) | (184,401) | (90,219) |
| Gain (loss) on | | | |

| | | | |
|---|--------------------------|--------------------------|-------------------------|
| settlement of debt | (13,200) | ... | (51,000) |
| Total other income (expense) | (483,545) | (473,670) | (413,867) |
| Income (loss) before income taxes | (712,466) | (895,570) | (1,049,948) |
| Net income (loss) | (712,466) | (895,570) | (1,049,948) |
| Weighted average shares outstanding - basic | 559,069,032 | 106,011,449 | 33,742,920 |
| Weighted average shares outstanding - diluted | 559,069,032 | 106,011,449 | 33,742,920 |
| Year end shares outstanding | 895,760,225 [Ⓐ] | 252,554,765 [Ⓐ] | 50,819,780 [Ⓐ] |
| Net income (loss) per share - basic | \$0.00 | \$(0.01) | \$(0.03) |
| Net income (loss) per share - diluted | \$0.00 | \$(0.01) | \$(0.03) |
| Number of full time employees | 3 | 3 | ... |
| Number of part time employees | 3 | 4 | ... |
| Number of common stockholders | 10,873 | 13,633 [Ⓐ] | 187 [Ⓐ] |
| Total number of employees | 6 | ... | ... |

[Ⓐ] Shares increased due to the effect of common stock issued for conversion of debt; [Ⓑ] Shares increased due to the effect of issuance of common shares for conversion of debt and service; [Ⓒ] Approximately; [Ⓓ] As of March 24, 2023; [Ⓔ] As of March 20, 2022

| | | | |
|--|-------------|----------------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash | 60,776 | 25,405 | |
| Prepaid expense | 10,000 | ... | |
| Marketable securities | ... | 42 | |
| Inventory | 15,281 | 8,877 | |
| Deposit | 2,500 | ... | |
| Total current assets | 88,557 | 34,324 | |
| License & patent, net | 15,441 | 2,990 | |
| Total assets | 103,998 | 37,314 | |
| Accounts payable | ... | 6,939 | |
| Accrued salary | ... | 300,000 | |
| Accrued interest | ... | 101,966 | |
| Accrued liabilities | ... | 1,015 | |
| Accounts payable & accrued liabilities | 443,579 | 409,920 | |
| Derivative liabilities | 977,872 | 686,856 | |
| Current portion of convertible notes - net of discount | 321,658 | 381,793 [Ⓐ] | |
| Notes payable | 7,520 | ... | |
| Notes payable - related party | ... | 10,246 | |
| Total current liabilities | 1,750,629 | 1,488,815 | |
| Total liabilities | 1,750,629 | 1,488,815 | |
| Series A preferred stock | 225 | 160 | |
| Common stock | 89,576 | 25,255 | |
| Additional paid in capital | 6,527,428 | 6,074,763 | |
| Accumulated deficit | (8,264,145) | ... | |
| Retained earnings (accumulated deficit) | ... | (7,551,679) | |
| Series B Preferred Stock | 285 | ... | |
| Total stockholders' equity (deficit) | (1,646,631) | (1,451,501) | |
| Total Equity | (1,646,631) | ... | |

[Ⓐ] Net of discount - Current portion of convertible notes: \$7,647

Recent Dividends:

- 1. Bioadaptives Inc series A preferred.**
No dividends paid.
- 2. Bioadaptives Inc common.**
No dividends paid.
- 3. Bioadaptives Inc series B preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Bioadaptives Inc series A preferred.**
No dividends paid.
- 2. Bioadaptives Inc common.**
No dividends paid.

3. Bioadaptives Inc series B preferred.

No dividends paid.

BIOAFFINITY TECHNOLOGIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|--------------------|------------------------|------------------------|
| | 2023 | 2022 | 2021 [Ⓐ] |
| Net Revenue | 2,532,499 | ... | ... |
| Revenue | 2,532,499 | 4,803 | ... |
| Direct costs and expenses | 1,740,884 | ... | ... |
| Cost of sales | ... | 467 | ... |
| Gross profit | ... | 4,336 | ... |
| Research & development | 1,467,936 | 1,142,777 | 1,007,476 |
| Clinical development | 256,661 | 145,546 | 130,475 |
| Selling, general & administrative | ... | 2,727,071 | 1,068,871 |
| General & administrative expenses | 6,790,654 | ... | ... |
| Depreciation and amortization | 249,592 | ... | ... |
| Total operating expenses | 10,505,727 | 4,015,394 | 2,206,822 |
| Income (loss) from operations | (7,973,228) | (4,011,058) | (2,206,822) |
| Interest income | 122,131 | 46,708 | 424 |
| Interest expense | 37,125 | 2,532,640 | 1,001,854 |
| Gain on extinguishment of debt | ... | 212,258 | 239,200 |
| Fair value of warrants issued | ... | ... | (4,080,339) |
| Fair value adjustments on convertible notes payable | ... | (1,866,922) | 724,928 |
| Income (loss) before income taxes | (7,916,018) | (8,151,654) | (6,324,463) |
| Income tax expense | 20,993 | 2,459 | 1,950 |
| Net income (loss) | (7,937,011) | (8,154,113) | (6,326,413) |
| Weighted average shares outstanding - basic | 8,747,509 | 4,498,964 | 2,675,270 [Ⓐ] |
| Weighted average shares outstanding - diluted | 8,747,509 | 4,498,964 | 2,675,270 [Ⓐ] |
| Year end shares outstanding | 9,394,610 | 8,381,324 [Ⓐ] | 2,677,139 [Ⓐ] |
| Net income (loss) per common share - basic | \$(0.91) | \$(1.81) | \$(2.36) [Ⓐ] |
| Net income (loss) per common share - diluted | \$(0.91) | \$(1.81) | \$(2.36) [Ⓐ] |
| Number of full time employees | 75 | 14 | 14 |
| Number of common stockholders | 79 | 68 [Ⓐ] | 46 [Ⓐ] |
| Other Income | 3,325 | ... | ... |
| Other Expense | (31,121) | ... | ... |
| Total number of employees | 75 | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Adjusted for 1-for-7 stock split, June 23, 2022; [Ⓒ] Shares increased due to the effect of issuance of shares upon IPO, stock-based compensation, conversion of convertible preferred stock and notes payable, and exercise of warrants and stock options; [Ⓓ] Approximately; [Ⓔ] As of March 20, 2023; [Ⓕ] As of September 2, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|-----------------------------------|-----------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 2,821,570 | 11,413,759 |
| Accounts & other receivables, net | 811,674 | 10,489 |
| Inventory | 18,484 | 5,540 |
| Prepaid insurance | ... | 340,078 |
| Legal & professional | ... | 72,048 |
| Other prepaid expenses & | ... | ... |

| | | |
|--|--------------|--------------|
| other current assets | ... | 119,773 |
| Prepaid expenses & other current assets | 321,017 | 531,899 |
| Total current assets | 3,972,745 | 11,961,687 |
| Lab equipment | 647,214 | 462,155 |
| Computers & software | 68,682 | 21,463 |
| Leasehold Improvements - Gross | 9,941 | ... |
| vehicles | 105,919 | ... |
| Right of Use Tangible Assets - Capital/Finance Lease - Gross | 1,165,844 | ... |
| Total property & equipment, gross | ... | 483,618 |
| Less: accumulated depreciation & amortization | 373,123 | 269,180 |
| Property, Plant & Equipment - Net - Total | 831,756 | ... |
| Property & equipment, net | 458,633 | 214,438 |
| Other assets | 16,060 | 6,000 |
| Goodwill - Gross | 1,404,486 | ... |
| Right of Use Tangible Assets - Operating Lease - Gross | 370,312 | ... |
| Other Non-Current Assets - Total | 833,472 | ... |
| Total assets | 8,221,552 | 12,182,125 |
| Accounts payable | 604,789 | 345,042 |
| Accrued compensation | 857,037 | 340,680 |
| Accrued legal & professional | 257,926 | 144,440 |
| Accrued clinical | ... | 50,922 |
| Other accrued expenses | ... | 5,852 |
| Accrued expenses | 1,149,811 | 541,894 |
| Accrued interest | 15,350 | ... |
| Loan payable | ... | 251,746 |
| Other | 19,498 | ... |
| Unearned revenue | 33,058 | ... |
| Operating Lease Liabilities - Current | 94,708 | ... |
| Portion/Short-Term Capitalized Leases - Current Portion | 365,463 | ... |
| Total current liabilities | 2,247,829 | 1,138,682 |
| finance lease liability, net of current portion | 835,467 | ... |
| Operating Lease Liabilities - Long-Term | 283,001 | ... |
| Total liabilities | 3,366,297 | 1,138,682 |
| Common stock | 65,762 | 58,669 |
| Additional paid-in capital | 49,393,972 | 47,652,242 |
| Accumulated deficit | (44,604,479) | ... |
| Retained earnings (accumulated deficit) | ... | (36,667,468) |
| Total stockholders' equity (deficit) | 4,855,255 | 11,043,443 |
| Total Equity | 4,855,255 | ... |

Recent Dividends:

- 1. Bioaffinity Technologies Inc common.**
No dividends paid.

Annual Dividends:

- 1. Bioaffinity Technologies Inc common.**
No dividends paid.

BIOCARDIA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|-----------------------------------|--------------|--------------|-------------------|
| | 2023 | 2022 | 2021 [Ⓐ] |
| Net product revenue | 477,000 | 3,000 | 1,000 |
| Collaboration agreement revenue | ... | 1,349,000 | 1,014,000 |
| Total revenue | 477,000 | 1,352,000 | 1,015,000 |
| Research & development | 7,726,000 | 8,834,000 | 8,558,000 |
| Selling, general & administrative | 4,395,000 | 4,419,000 | 5,087,000 |
| Operating income (loss) | (11,644,000) | (11,901,000) | (12,630,000) |
| Other expense | 73,000 | ... | ... |

| | | | |
|--|--------------|--------------|--------------|
| Total other income (expense), net | 73,000 | (6,000) | 7,000 |
| Income (loss) before income tax provision | (11,571,000) | ... | ... |
| Net income (loss) | (11,571,000) | (11,907,000) | (12,623,000) |
| Weighted average shares outstanding - basic | 21,179,974 | 17,720,972 | 16,917,664 |
| Weighted average shares outstanding - diluted | 21,179,974 | 17,720,972 | 16,917,664 |
| Year end shares outstanding | 23,666,534 | 20,076,773 | 16,871,265 |
| Income (loss) per share from continuing operations - basic | \$(0.55) | ... | ... |
| Net income (loss) per share - basic | \$(0.55) | \$(0.67) | \$(0.75) |
| Income (loss) per share from continuing operations - diluted | \$(0.55) | ... | ... |
| Net income (loss) per share - diluted | \$(0.55) | \$(0.67) | \$(0.75) |
| Number of full time employees | 16 | 30 | 28 |
| Number of part time employees | 4 | 6 | 7 |
| Total number of employees | 20 | ... | ... |
| Number of common stockholders | 183 | 191 | 185 |

□ Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|-----------|-----------|
| | 2023 | 2022 |
| Cash & cash equivalents | 1,103,000 | 7,363,000 |
| Accounts receivable, gross | 97,000 | 212,000 |
| Less: allowance for doubtful accounts | 34,000 | 11,000 |
| Accounts receivable, net | 63,000 | 201,000 |
| Prepaid expenses & other current assets | 295,000 | 300,000 |
| Total current assets | 1,461,000 | 7,864,000 |
| Computer equipment & software | 788,000 | 161,000 |
| Laboratory & manufacturing equipment | 574,000 | 575,000 |
| Furniture & fixtures | 27,000 | 27,000 |
| Leasehold improvements | 26,000 | 26,000 |
| Computer equipment and software | 161,000 | ... |
| Property & equipment, gross | ... | 789,000 |
| Less accumulated depreciation | 694,000 | 619,000 |
| Property & equipment, net | 94,000 | 170,000 |
| Operating lease right-of-use asset, net | 1,261,000 | 1,588,000 |
| Other assets | 171,000 | 171,000 |
| Total assets | 2,987,000 | 9,793,000 |
| Accounts payable | 890,000 | 683,000 |
| Accrued expenses | 75,000 | 157,000 |
| Accrued salaries & employee benefits | 661,000 | 899,000 |
| Accrued clinical trial costs | 1,017,000 | 548,000 |
| Grant liability | 471,000 | 534,000 |
| Customer deposits | 90,000 | 90,000 |
| Payable to related party | 71,000 | 18,000 |
| Accrued expenses & other current liabilities | 2,385,000 | 2,246,000 |
| Deferred revenue | ... | 341,000 |
| Operating lease liability - current | 333,000 | 315,000 |
| Total current liabilities | 3,608,000 | 3,585,000 |
| Operating lease liability - noncurrent | 982,000 | 1,316,000 |

| | | |
|---|---------------|---------------|
| Total liabilities | 4,590,000 | 4,901,000 |
| Common stock | 24,000 | 20,000 |
| Additional paid-in capital | 150,548,000 | 145,476,000 |
| Retained earnings (accumulated deficit) | (152,175,000) | (140,604,000) |
| Total stockholders' equity (deficit) | (1,603,000) | 4,892,000 |
| Total Equity | (1,603,000) | ... |

Recent Dividends:

1. BioCardia Inc common.

No dividends paid.

Annual Dividends:

1. BioCardia Inc common.

No dividends paid.

BIOCORRX INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|-------------|-------------|-------------|
| | 2023 | 2022 | □2021 |
| | | | (revised) |
| Revenues, net | 89,160 | 213,841 | 48,272 |
| Cost of implants & other costs | 35,986 | 15,279 | 5,881 |
| Research & development | 891,063 | 1,459,458 | 1,605,907 |
| Selling, general & administrative | 2,875,119 | 3,409,649 | 3,740,783 |
| Impairment of intellectual property | 47,980 | ... | 141,480 |
| Depreciation & amortization | 26,808 | 27,450 | 64,328 |
| Total operating expenses | 3,876,956 | 4,911,836 | 5,558,379 |
| Income (loss) from operations | (3,787,796) | (4,697,995) | (5,510,107) |
| Interest expense - related parties | 692,586 | 935,806 | 546,260 |
| Interest expense, net | 194,041 | 150,969 | 19,424 |
| Gain (loss) on settlement of debt | (34,338) | (198,939) | ... |
| Loss on contingency | 932,996 | (322,000) | ... |
| Grant income | ... | 1,789,496 | 835,924 |
| Other miscellaneous income | 5,275 | 139,381 | 29,229 |
| Total other income (expenses), net | 17,306 | 321,163 | 299,469 |
| Net income (loss) before provision for income taxes | (3,770,490) | (4,376,832) | (5,210,638) |
| Net loss | (3,770,490) | ... | ... |
| Net income (loss) | (3,770,490) | (4,376,832) | (5,210,638) |
| Non-controlling interest | 3,577 | 7,419 | 2,384 |
| Net income (loss) attributable to BiocorRx, Inc. | (3,766,913) | ... | ... |
| Dividend attributable to down round feature of warrants | ... | ... | 70,127 |
| Net income (loss) attributable to BioCorRx Inc. | ... | (4,369,413) | (5,278,381) |
| Weighted average shares outstanding - basic | 8,344,079 | 7,198,312 | 6,491,067 |
| Weighted average shares outstanding - diluted | 8,344,079 | 7,198,312 | 6,491,067 |
| Year end shares outstanding | 8,674,029 | 7,718,636 | 6,698,968 |
| Net income (loss) per share - basic | \$(0.45) | \$(0.61) | \$(0.81) |
| Net income (loss) per share - diluted | \$(0.45) | \$(0.61) | \$(0.81) |
| Number of common stockholders | 156 | □□144 | □□145 |
| Total Revenue | 89,160 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.45) | ... | ... |

| | | | |
|--|----------|-----|-----|
| Diluted EPS Excluding ExtraOrd Items | \$(0.45) | ... | ... |
|--|----------|-----|-----|

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 30, 2023; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|------------|------------|
| | 2023 | 2022 |
| Cash | 65,222 | 68,615 |
| Accounts receivable, gross | ... | 35,378 |
| Allowance for doubtful accounts | ... | 0 |
| Grant receivable | 76,266 | 130,152 |
| Other accounts receivable | 740 | ... |
| Prepaid insurance | ... | 4,284 |
| Prepaid subscription services | ... | 49,901 |
| Prepaid research & development | ... | 7,480 |
| Other prepaid expenses | 44,891 | 21,100 |
| Prepaid expenses | ... | 82,765 |
| Total current assets | 187,119 | 316,910 |
| Office equipment | 45,519 | 45,519 |
| Computer equipment | 5,544 | 5,544 |
| Manufacturing equipment | 101,200 | 101,200 |
| Leasehold improvements | 42,288 | 42,288 |
| Property & equipment, gross | 194,551 | 194,551 |
| Less accumulated depreciation | 143,608 | 117,979 |
| Property & equipment, net | 50,943 | 76,572 |
| Right to use assets | 97,278 | 270,406 |
| Patents, net | ... | 10,206 |
| Software development costs | ... | 47,980 |
| Deposits, long term | 44,520 | 44,520 |
| Patents | 9,027 | ... |
| Total assets | 388,887 | 766,594 |
| Accounts payable | 2,473,457 | ... |
| Accounts payable & accrued expenses | ... | 2,013,250 |
| Interest payable on notes payable | 1,268,264 | 1,206,753 |
| Interest payable on notes payable, related parties | 478,920 | 332,567 |
| Accrual of loss on contingency | 322,000 | 322,000 |
| Interest payable on Economic Injury Disaster Loan ("EIDL") loan | 5,675 | 5,860 |
| Accrued expenses | 57,542 | 27,524 |
| Accounts payable & accrued expenses | ... | □3,907,954 |
| Deferred revenue, short term | ... | 33,256 |
| Lease liability, short term | 122,732 | 134,343 |
| Settlement payable | 4,649,179 | ... |
| Notes payable | 606,750 | 297,602 |
| Notes payable, related parties | 999,088 | 990,637 |
| Derivative liability | 53,460 | ... |
| Accrued stock-based compensation | 43,321 | ... |
| Total current liabilities | 6,431,209 | 5,363,792 |
| Economic Injury Disaster Loan ("EIDL") loan, long term | 72,466 | 73,850 |
| Royalty obligation - net of discount | 3,822,746 | □3,345,310 |
| Deferred revenue, long term | 4,045 | 4,045 |
| Lease liability, long term | 10,945 | 181,328 |
| Total liabilities | 10,341,411 | 8,968,325 |
| Series A convertible preferred stock | ... | 16,000 |
| Series B convertible preferred stock | ... | 5,616 |
| Preferred stock | 16,000 | ... |

| | | |
|---|--------------|--------------|
| Common stock | 8,674 | 7,719 |
| Common stock subscribed | 100,009 | 100,000 |
| Additional paid in capital | 68,149,029 | 66,130,296 |
| Accumulated deficit | (78,103,018) | ... |
| Retained earnings (accumulated deficit) | ... | (74,336,105) |
| Series B Preferred stock, no par value; 160,000 designated; 160,000 and -0- shares issued and outstanding as of 31, 2016 and 2015 | 5,616 | ... |
| Total stockholders' deficit attributable to BioCorRx, Inc. | (9,823,690) | (8,076,474) |
| Non-controlling interest | (128,834) | (125,257) |
| Total equity (deficit) | (9,952,524) | (8,201,731) |

□ Including related party payables - accounts payable & accrued expenses: \$1,077,088; □ Net of discount - royalty obligation: \$5,376,790

Recent Dividends:

- BioCorRx Inc common.**
No dividends paid.
 - BioCorRx Inc series A convertible preferred.**
No dividends paid.
 - BioCorRx Inc series B convertible preferred.**
No dividends paid.
- Annual Dividends:**
- BioCorRx Inc common.**
No dividends paid.
 - BioCorRx Inc series A convertible preferred.**
No dividends paid.
 - BioCorRx Inc series B convertible preferred.**
No dividends paid.

BIOETHICS LTD

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-----------|-----------|-----------|
| General & administrative | 50,442 | 47,303 | 59,367 |
| Total operating expenses | 50,442 | 47,303 | 59,367 |
| Income (loss) from operations | (50,442) | (47,303) | (59,367) |
| Interest expense | 46,707 | 45,900 | 47,816 |
| Total other income (expenses) | (46,707) | (45,900) | (47,816) |
| Net income (loss) before income taxes | (97,149) | (93,203) | (107,183) |
| Net income (loss) | (97,149) | (93,203) | (107,183) |
| Weighted average shares outstanding - basic | 1,135,194 | 1,135,194 | 1,135,194 |
| Weighted average shares outstanding - diluted | 1,135,194 | 1,135,194 | 1,135,194 |
| Year end shares outstanding | 1,135,194 | 1,135,194 | 1,135,194 |
| Net income (loss) per share - basic | \$(0.09) | \$(0.08) | \$(0.09) |
| Net income (loss) per share - diluted | \$(0.09) | \$(0.08) | \$(0.09) |
| Number of common stockholders | 384 | □384 | □384 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.09) | ... | ... |
| Diluted EPS Excluding ExtraOrdinary Items | \$(0.09) | ... | ... |
| Full-Time Employees (Period End) | 0 | ... | ... |
| Total number of employees | 0 | ... | ... |

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------|------|------|
| Cash & cash equivalents | 138 | 295 |

| | | |
|---|-------------|-------------|
| Total current assets | 138 | 295 |
| Total assets | 138 | 295 |
| Accounts payable | 122,400 | 100,265 |
| Accounts payable - related party | 14,500 | 8,500 |
| Accrued interest - related parties | 98,406 | 70,883 |
| Accrued interest | 98,363 | 79,179 |
| Notes payable | 160,000 | 160,000 |
| Notes payable - related | 247,734 | 225,584 |
| Convertible notes payable | 35,000 | 35,000 |
| Total current liabilities | 776,403 | 679,411 |
| Total liabilities | 776,403 | 679,411 |
| Common stock | 1,135 | 1,135 |
| Additional paid-in capital | 500,479 | 500,479 |
| Accumulated deficit | (1,277,879) | ... |
| Retained earnings (accumulated deficit) | ... | (1,180,730) |
| Total stockholders' equity (deficit) | (776,265) | (679,116) |
| Total Equity | (776,265) | ... |

Recent Dividends:

- Bioethics Ltd common.**
No dividends paid.
- Annual Dividends:**
- Bioethics Ltd common.**
No dividends paid.

BIOFORCE NANOSCIENCES HOLDINGS INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Board of directors compensation | 423,000 | 423,000 | 423,000 |
| General & administrative expense | 48,953 | 62,514 | 78,955 |
| Total expenses | 471,953 | 485,514 | 501,955 |
| Income (loss) before income tax expense | (471,953) | ... | ... |
| Net income (loss) | (471,953) | (485,514) | (501,955) |
| Weighted average shares outstanding - basic | 29,271,755 | 29,271,755 | 29,271,755 |
| Weighted average shares outstanding - diluted | 29,271,755 | 29,271,755 | 29,271,755 |
| Year end shares outstanding | 29,271,755 | 29,271,755 | 29,271,755 |
| Net income (loss) per common share - basic | \$(0.02) | \$(0.02) | \$(0.02) |
| Net income (loss) per common share - diluted | \$(0.02) | \$(0.02) | \$(0.02) |
| Number of full time employees | 3 | 3 | 2 |
| Number of common stockholders | 236 | □233 | □230 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.02) | ... | ... |
| Diluted EPS Excluding ExtraOrdinary Items | \$(0.02) | ... | ... |
| Total number of employees | 3 | ... | ... |

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | 638 | 734 |
| Total current assets | 638 | 734 |
| Total assets | 638 | 734 |
| Accounts payable & accrued expenses | ... | 398 |
| Accrued board of directors compensation | 1,596,517 | 1,173,517 |
| Due to related parties | 220,702 | 174,096 |

| | | |
|---|---------------|---------------|
| Stock payable | 2,649 | ... |
| Total current liabilities | 1,819,868 | 1,348,011 |
| Total liabilities | 1,819,868 | 1,348,011 |
| Common stock | 29,272 | 29,272 |
| Additional paid-in-capital | 158,781,227 | 158,781,227 |
| Accumulated deficit | (160,629,729) | ... |
| Retained earnings (accumulated deficit) | ... | (160,157,776) |
| Total stockholders' (deficit) | (1,819,230) | (1,347,277) |
| Total Equity | (1,819,230) | ... |

Recent Dividends:

- BioForce Nanosciences Holdings Inc common.**
No dividends paid.
- Annual Dividends:**
- BioForce Nanosciences Holdings Inc common.**
No dividends paid.

BIOLARGO INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 |
|---|-------------|-------------|-------------|
| Product revenue | 11,460,000 | 4,434,000 | 1,572,000 |
| Service revenue | 770,000 | 1,450,000 | 959,000 |
| Total revenue | 12,230,000 | 5,884,000 | 2,531,000 |
| Cost of goods sold | 5,681,000 | 2,177,000 | 781,000 |
| Cost of service | ... | 850,000 | 647,000 |
| Total cost of revenue | 6,076,000 | 3,027,000 | 1,428,000 |
| Gross profit (loss) | 6,154,000 | 2,857,000 | 1,103,000 |
| Salaries & payroll related | ... | 2,754,000 | 2,581,000 |
| Professional fees | ... | 629,000 | 662,000 |
| Consulting | ... | 867,000 | 920,000 |
| Office expense | 8,058,000 | 1,502,000 | 1,177,000 |
| Board of director expense | ... | 401,000 | 262,000 |
| Sales & marketing | ... | 287,000 | 315,000 |
| Investor relations | ... | 291,000 | 255,000 |
| Selling, general & administration expenses | ... | 6,731,000 | 6,172,000 |
| Research & development expenses | 2,282,000 | 1,319,000 | 1,367,000 |
| Cost of cigar sales | 395,000 | ... | ... |
| Impairment expense | ... | 197,000 | 342,000 |
| Impairment of property, plant & equipment | 394,000 | ... | ... |
| Total operating expenses | 10,734,000 | 8,247,000 | 7,881,000 |
| Operating income (loss) | (4,580,000) | (5,390,000) | (6,778,000) |
| PPP forgiveness | ... | 174,000 | 43,000 |
| Grant income | 36,000 | 74,000 | 55,000 |
| Tax credit income | ... | (63,000) | (20,000) |
| Interest expense | 91,000 | 53,000 | 234,000 |
| Reversal of accruals related to prior periods | (13,000) | ... | ... |
| Total other income (expense) | (68,000) | 258,000 | (116,000) |
| Income (loss) before income taxes | (4,648,000) | ... | ... |
| Income (loss) before extraordinary item | (4,648,000) | ... | ... |
| Net income (loss) | (4,648,000) | (5,132,000) | (6,894,000) |
| Net income (loss) attributable to noncontrolling interest | 1,144,000 | 659,000 | (186,000) |
| Net income (loss) from Co.'s controlling interests | (3,504,000) | ... | ... |
| Net income (loss) attributable to common shareholders | ... | (4,473,000) | (7,080,000) |
| Weighted average | ... | ... | ... |

| | | | |
|--|-------------|-------------|-------------|
| shares outstanding | | | |
| - basic | 285,956,852 | 268,302,234 | 247,203,625 |
| Weighted average shares outstanding | | | |
| - diluted | 285,956,852 | 268,302,234 | 247,203,625 |
| Year end shares outstanding | 292,945,747 | 278,462,706 | 255,893,726 |
| Income (loss) per share from continuing operations - basic | \$(0.02) | ... | ... |
| Net income (loss) per share - basic | \$(0.02) | \$(0.02) | \$(0.03) |
| Income (loss) per share from continuing operations - diluted | \$(0.02) | ... | ... |
| Net income (loss) per share - diluted | \$(0.02) | \$(0.02) | \$(0.03) |
| Number of full time employees | 31 | 33 | 27 |
| Total number of employees | 31 | ... | ... |
| Number of common stockholders | ... | 2533 | 2533 |
| Number of beneficiary stockholders | ... | ... | 5,000 |
| Foreign currency translation adjustments | ... | (34,000) | ... |

[□] Reclassified to conform with 2022 presentation; [□] Approximately; [□] As of March 29, 2023; [□] As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 3,539,000 | 1,851,000 |
| Accounts receivable | 2,696,000 | 1,076,000 |
| Less: allowance for doubtful accounts | 84,000 | 12,000 |
| Accounts receivable, net | 2,612,000 | ... |
| Accounts receivable, net of allowance | ... | 1,064,000 |
| Raw material | 79,000 | 46,000 |
| Finished goods | 74,000 | 74,000 |
| Inventories, net of allowance | 153,000 | 120,000 |
| Prepaid expenses & other current assets | 58,000 | 118,000 |
| Total current assets | 6,362,000 | 3,153,000 |
| Equipment, net of depreciation | 662,000 | 287,000 |
| Other non-current assets, net of amortization | 70,000 | 124,000 |
| Investment in South Korean joint venture | 19,000 | 33,000 |
| Right of use, operating lease, net of amortization | 1,092,000 | 867,000 |
| Clyra Medical Technologies, Inc. ("Clyra Medical") prepaid marketing | ... | 394,000 |
| Total assets | 8,205,000 | 4,858,000 |
| Debt obligations, net of discount | 66,000 | 100,000 |
| Accounts payable | ... | 717,000 |
| Accrued payroll | 251,000 | 198,000 |
| Accrued interest | 7,000 | 25,000 |
| Accounts payable & accrued expenses | 1,212,000 | ... |
| Accounts payable | ... | 186,000 |
| Accrued payroll | 13,000 | 45,000 |
| Accrued interest | 25,000 | 7,000 |
| Clyra Medical accounts payable & accrued expenses | 397,000 | 238,000 |
| Accounts payable & accrued expenses | 1,488,000 | ... |
| Discount on convertible notes payable, & line of | ... | ... |

| | | |
|---|---------------|---------------|
| credit, net of amortization | 234,000 | ... |
| Accrued Dividend | 242,000 | ... |
| Deferred revenue | ... | 17,000 |
| Lease liability | 105,000 | 97,000 |
| Deposits | 117,000 | 184,000 |
| Contract liabilities | 303,000 | ... |
| Total current liabilities | 2,710,000 | 1,576,000 |
| SBA Paycheck Protection Program loans | ... | 97,000 |
| SBA EIDL Loan | ... | 140,000 |
| Debt obligations, net of current | ... | 237,000 |
| Lease liability | 1,004,000 | 773,000 |
| Clyra Medical debt obligations | ... | 261,000 |
| Debt obligations | 289,000 | ... |
| Total long-term liabilities | 1,293,000 | 1,271,000 |
| Total liabilities | 4,003,000 | 2,847,000 |
| Common stock | 196,000 | 186,000 |
| Additional paid-in capital | 154,023,000 | 148,435,000 |
| Accumulated other comprehensive income (loss) | (277,000) | (149,000) |
| Accumulated Deficit | (147,098,000) | ... |
| Retained earnings (accumulated deficit) | ... | (143,594,000) |
| Total Biolargo Inc. & subsidiaries stockholders' equity (deficit) | 6,844,000 | 4,878,000 |
| Non-controlling interest | (2,642,000) | (2,867,000) |
| Total stockholders' equity (deficit) | 4,202,000 | 2,011,000 |

Recent Dividends:

- BioLargo Inc common.**
No dividends paid.
 - BioLargo Inc convertible preferred series A.**
No dividends paid.
- #### Annual Dividends:
- BioLargo Inc common.**
No dividends paid.
 - BioLargo Inc convertible preferred series A.**
No dividends paid.

BIOMERICA INC

Earnings, 9 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|-------------|-------------|
| Total revenues | 4,299,000 | 4,231,000 |
| Net Sales | 4,299,000 | 4,231,000 |
| Cost & expenses | 9,138,000 | 9,618,000 |
| Operating income | (4,839,000) | (5,387,000) |
| Other income (expense), net | 317,000 | 77,000 |
| Net before taxes | (4,522,000) | (5,310,000) |
| Income taxes | 35,000 | 38,000 |
| Net income | (4,557,000) | (5,348,000) |
| Earnings common share | | |
| Primary | \$(0.27) | \$(0.40) |
| Fully Diluted | \$(0.27) | \$(0.40) |
| Common Shares: | | |
| Full Diluted | 16,821,646 | 13,341,000 |
| Year-end | 16,821,646 | 13,488,313 |

BIONEXUS GENE LAB CORP

Annual Report

| | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
|-------------------------------|--|------------|------------|
| | 2023 | 2022 | 2021 |
| Revenue | 9,770,806 | ... | ... |
| Revenue | 9,770,806 | 10,928,707 | 13,362,567 |
| Cost of revenue | 8,441,308 | 9,669,678 | 11,168,747 |
| Gross profit (loss) | 1,329,498 | 1,259,029 | 2,193,820 |
| Other income | 486,036 | 179,283 | 66,491 |
| General & administrative | 4,409,122 | 1,729,489 | 1,204,484 |
| Profit (loss) from operations | ... | (291,177) | 1,055,827 |
| Finance costs | ... | 12,479 | 12,973 |
| Profit (loss) before tax | (2,607,517) | (303,656) | 1,042,854 |
| Deferred tax | (17,359) | 3,898 | 26,736 |

| | | | |
|---|-------------|------------|------------|
| Income tax | 38,885 | 48,412 | 264,547 |
| Total tax expense (benefit) | 21,526 | 52,310 | 291,283 |
| Net profit (loss) | (2,629,043) | (355,966) | 751,571 |
| Weighted average shares outstanding | | | |
| - basic | 15,875,455 | 14,409,732 | 14,268,179 |
| Weighted average shares outstanding | | | |
| - diluted | 15,875,455 | 14,409,732 | 14,268,179 |
| Year end shares outstanding | 17,667,663 | 14,476,513 | 14,268,179 |
| Net earnings (loss) per share - basic | \$(0.18) | \$(0.02) | \$0.04 |
| Net earnings (loss) per share - diluted | \$(0.18) | \$(0.02) | \$0.04 |
| Number of full time employees | ... | 27 | 27 |
| Number of part time employees | ... | 6 | 5 |
| Number of common stockholders | 324 | 316 | ... |
| Number of stockholders | ... | ... | 319 |
| FINANCE COSTS | 13,929 | ... | ... |

[□] Adjusted for 1-for-12 stock split, July 20, 2023; [□] As of April 6, 2022; [□] As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & bank balances | 2,623,965 | 611,849 |
| Fixed deposits placed with financial institutions | ... | 1,507,015 |
| Accounts & Notes Receivable - Trade | 2,107,182 | ... |
| Gross | 2,107,182 | ... |
| Provision - Accounts & Notes Receivable - Trade | 1,307,508 | ... |
| Trade receivables | 799,674 | 2,868,364 |
| Other receivables & deposits | 122,432 | ... |
| Other receivables, deposits & prepayments | 3,305,371 | 25,240 |
| Tax recoverable | 57,588 | 31,551 |
| Inventories | 1,137,770 | 977,807 |
| Total current assets | 8,046,800 | 6,021,826 |
| Right of Use Tangible Assets - Operating Lease | 169,009 | ... |
| Right of Use Tangible Assets - Operating Lease - Accumulated Depreciation | 27,466 | ... |
| Operating lease right of used assets | 141,544 | 55,730 |
| Air conditioner | 1,124 | 1,124 |
| Computer & software | ... | 2,516 |
| Equipment | 320,102 | 60,525 |
| Furniture & fittings | ... | 87,122 |
| Lab equipment | 100,118 | 320,102 |
| Land & buildings | 1,506,969 | 1,506,969 |
| Motor vehicle | 161,148 | 137,914 |
| Office equipment | 3,923 | 38,213 |
| Renovation | 98,597 | 107,414 |
| Signboard | 806 | 704 |
| Office equipment | 33,914 | ... |
| Total Plant and equipment | 109,509 | ... |
| Capital Work In Progress | 60,412 | ... |
| Equipment | ... | ... |
| Property, plant & equipment, gross | 2,396,622 | 2,262,603 |
| Less: accumulated depreciation | ... | 616,913 |
| Add: foreign translation differences | ... | (133,982) |
| Accumulated amortization | 885,004 | ... |
| Property, plant & equipment, net | 1,511,618 | 1,511,708 |
| Other investments | 1,699,831 | 1,150,898 |
| Total non-current assets | 3,352,993 | 2,718,336 |

| | | |
|--|------------------|-------------|
| Total assets | 11,399,793 | 8,740,162 |
| Trade payables | 1,402,180 | 1,861,015 |
| Other payables & accrued liabilities | 180,912 | 103,370 |
| Current portion of operating lease liabilities | 34,632 | 16,569 |
| Advance payment from customer | ... | 23,123 |
| Amount owing to director | 13,199 | ... |
| Total current liabilities | 1,630,923 | 2,004,077 |
| Non-current portion of operating lease liabilities | 98,763 | 40,206 |
| Deferred tax liabilities | 12,255 | 30,866 |
| Total non-current liabilities | 111,018 | 71,072 |
| Total liabilities | 1,741,941 | 2,075,149 |
| Common stock | 17,191,315 | 10,929,574 |
| Additional paid in capital | (5,011,891) | (5,011,891) |
| Accumulated surplus (loss) | (1,844,278) | 1,156,392 |
| Accumulated other comprehensive income (losses) | (677,294) | (409,062) |
| Total stockholders' equity (deficit) | 9,657,852 | 6,665,013 |
| TOTAL STOCKHOLDERS EQUITY | 9,657,852 | ... |

Recent Dividends:

1. BioNexus Gene Lab Corp common.

No dividends paid.

Annual Dividends:

1. BioNexus Gene Lab Corp common.

No dividends paid.

BIOQUAL INC

Annual Report

Consolidated Income Statement, Years Ended May 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|----------------|------------------|------------------|
| Contract revenue | 62,663,804 | ... | ... |
| Revenue | 62,663,804 | 66,150,373 | 57,683,502 |
| Contract expense | ... | 53,145,304 | 43,709,349 |
| Contract | 54,019,116 | ... | ... |
| General & administrative expense | 7,541,724 | 6,472,436 | 5,417,399 |
| Total operating expenses | 61,560,840 | 59,617,740 | 49,126,748 |
| Operating income | 1,102,964 | 6,532,633 | 8,556,754 |
| Interest income | 28,268 | 1,513 | 1,841 |
| Other income | 2,010 | 42,638 | 57,430 |
| Total other income (expense) | 30,278 | 44,151 | 59,271 |
| Income before provision for income taxes | 1,133,242 | 6,576,784 | 8,616,025 |
| Current tax expense | 308,494 | 1,123,215 | 2,644,200 |
| Deferred tax expense (benefit) | (10,800) | 193,000 | (355,000) |
| Provision for income taxes | 297,694 | 1,316,215 | 2,289,200 |
| Net income (loss) | 835,548 | 5,260,569 | 6,326,825 |
| Weighted average shares outstanding - basic | 894,416 | 894,416 | 894,054 |
| Weighted average shares outstanding - diluted | 894,416 | 894,423 | 894,054 |
| Year end shares outstanding | 894,416 | 894,416 | 894,416 |
| Income per share-continuing operations - basic | \$0.93 | ... | ... |
| Net earnings (loss) per share - basic | \$0.93 | \$5.88 | \$7.08 |
| Net earnings (loss) per share - diluted | \$0.93 | \$5.88 | \$7.08 |
| Dividends declared per share | \$1.00 | \$1.25 | \$1.10 |
| Number of common stockholders | ... | 154 | ... |

| | |
|--------------------------|--------|
| Diluted EPS | ... |
| Excluding ExtraOrd Items | \$0.93 |

Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended May 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 7,279,356 | 2,184,245 |
| Accounts receivable - other | 20,641,512 | ... |
| Accounts receivable Trade | ... | ... |
| - Balancing value | 17,451,519 | ... |
| Accounts receivable | ... | 26,763,589 |
| Prepaid expenses | 2,019,004 | ... |
| Prepaid expenses & other current assets | 3,189,993 | 2,780,212 |
| Total current assets | 29,939,872 | 31,728,046 |
| Leasehold improvements | 11,781,747 | 10,794,189 |
| Furniture, fixtures & equipment | 18,841,101 | 17,597,000 |
| Total property & equipment | 30,622,848 | 28,391,189 |
| Less: accumulated depreciation & amortization | 17,790,984 | 15,522,693 |
| Net property & equipment | 12,831,864 | 12,868,496 |
| Operating lease right-of-use assets | 17,516,721 | 17,717,506 |
| Goodwill | 1,028,408 | 1,028,408 |
| Total assets | 61,316,865 | 63,342,456 |
| Accounts payable | 1,594,010 | 3,289,119 |
| Accrued compensation & related liabilities | 2,304,290 | 2,240,152 |
| Deferred revenue | 956,875 | 1,165,061 |
| Operating lease liabilities, current portion | 3,441,982 | 3,071,111 |
| contract liabilities | 956,875 | ... |
| Total current liabilities | 8,297,157 | 9,765,443 |
| Operating lease liabilities, net of current portion | 15,166,190 | 15,653,827 |
| Deferred income taxes | 239,900 | 250,700 |
| Total liabilities | 23,703,247 | 25,669,970 |
| Common stock | 15,994 | 15,994 |
| Treasury stock, at cost | 1,041,240 | 1,041,240 |
| Additional paid-in capital | 7,364,934 | 7,364,934 |
| Retained Earnings | 31,273,930 | ... |
| Retained earnings (accumulated deficit) | ... | 31,332,798 |
| Total stockholders' equity | 37,613,618 | 37,672,486 |
| Total Equity | 37,613,618 | ... |

Recent Dividends:

1. Bioqual Inc common.

| ExDate | Amt | Declared | Record | Payable |
|--------|------------|------------|------------|------------|
| 1.25 | 09/16/2021 | 09/29/2021 | 10/20/2021 | |
| 1.00 | 10/05/2022 | 09/27/2022 | 10/06/2022 | 10/27/2022 |
| 0.50 | 10/05/2023 | 09/22/2023 | 10/06/2023 | 10/27/2023 |

Annual Dividends:

1. Bioqual Inc common.

| 2021 | 2022 | 2023 |
|------|------|------|
| 1.25 | 1.00 | 0.50 |

BIORESTORATIVE THERAPIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|--------------------------|------------|----------------|----------------|
| Revenues | 145,800 | ... | ... |
| Revenues | 145,800 | 119,800 | 46,000 |
| Research & development | 4,034,591 | 3,513,352 | 729,058 |
| General & administrative | 11,331,983 | 15,580,473 | 25,624,815 |
| Total operating expenses | 15,366,574 | 19,093,825 | 26,353,873 |
| Income (loss) from | ... | ... | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| operations | (15,220,774) | (18,974,025) | (26,307,873) |
| Interest income (expense) | 552,293 | 11,650 | (1,815,366) |
| Gain (loss) on extinguishment of notes payable, net | ... | ... | (16,180,056) |
| Gain (loss) on PPP loan forgiveness | ... | 250,000 | ... |
| Grant income | 83,333 | 110,518 | ... |
| Other expense | ... | (107,088) | ... |
| Other income | 169,664 | ... | ... |
| Total other income (expense) | 805,290 | 479,256 | (17,995,422) |
| Net income (loss) | (14,415,484) | (18,494,769) | (44,303,295) |
| Weighted average shares outstanding - basic | 4,218,347 | 3,617,858 | 1,187,741 |
| Weighted average shares outstanding - diluted | 4,218,347 | 3,617,858 | 1,187,741 |
| Year end shares outstanding | 4,706,917 | 3,677,775 | 3,520,391 |
| Net income (loss) per share - basic | \$(3.42) | \$(5.11) | \$(37.30) |
| Net income (loss) per share - diluted | \$(3.42) | \$(5.11) | \$(37.30) |
| Number of full time employees | 11 | 10 | 7 |
| Total number of employees | 11 | ... | ... |
| Number of common stockholders | 352 | ... | 359 |
| Income from cont operations before income tax | (14,415,484) | ... | ... |
| Earnings per share from continuing operations | \$(3.42) | ... | ... |
| Earnings per share from continuing operations | \$(3.42) | ... | ... |

Reclassified to conform with 2022 presentation; Shares increased due to issuance of shares for cash and in connection with the public offering, in exchange of notes payable and accrued interest and in cashless exercise of warrants; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|---|------------|----------------|
| Cash & cash equivalents | 884,377 | 1,676,577 |
| Investments held in marketable securities | 10,181,618 | 13,072,831 |
| Accounts receivable | 19,300 | 16,000 |
| Prepaid expenses & other current assets | 305,231 | 363,082 |
| Total current assets | 11,390,526 | 15,128,490 |
| Medical equipment | 123,486 | 352,133 |
| Furniture & fixtures | ... | 123,486 |
| Computer software & equipment | 352,133 | 117,544 |
| Office equipment | 136,205 | 18,779 |
| Manufacturing equipment | 395,232 | 242,852 |
| Leasehold improvements | 342,048 | 342,048 |
| office equipment | 18,779 | ... |
| Property & equipment, gross | 1,367,883 | 1,196,842 |
| Less: accumulated depreciation | 1,011,828 | 935,839 |
| Property & equipment, net | 356,055 | 261,003 |
| Right of use asset | 151,447 | 241,760 |
| Intangible assets, net | 713,692 | 803,438 |
| Total assets | 12,611,720 | 16,434,691 |
| Accounts payable | 189,389 | 170,902 |
| Accrued payroll | 638,000 | 26,250 |
| Accrued research & development expenses | 711,686 | ... |
| Accrued general & administrative expenses | 73,686 | 103,822 |
| Lease liability, current portion | 162,317 | 139,328 |
| Total current liabilities | 1,063,392 | 440,302 |

| | | |
|---|---------------|---------------|
| Lease liability, net of current portion | ... | 162,317 |
| Total liabilities | 1,063,392 | 602,619 |
| Series B convertible preferred stock | 13,982 | 15,182 |
| Common stock | 471 | 369 |
| Additional paid-in capital | 178,590,256 | 168,457,418 |
| Accumulated deficit | (167,056,381) | ... |
| Retained earnings (accumulated deficit) | ... | (152,640,897) |
| Total stockholders' equity (deficit) | 11,548,328 | 15,832,072 |
| Total Equity | 11,548,328 | ... |

| | | | | | |
|---|-----|-----|-----|-----|-----|
| Applicable to Common - Total | ... | ... | ... | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... | ... | ... |
| Applicable to Common - Total | ... | ... | ... | ... | ... |

□ Adjusted for 1-for-10 stock split, February 2, 2024; □ Shares increased due to the effect of common stock issued for services, sale of common stock and warrants, sale of common stock under At-the-market offering, common stock issued upon exercise of warra; □ As of March 30, 2023; □ As of March 30, 2022; □ Approximately

- BioSig Technologies Inc redeemable series A preferred.**
No dividends paid.
 - BioSig Technologies Inc redeemable series B preferred.**
No dividends paid.
 - BioSig Technologies Inc common.**
No dividends paid.
 - BioSig Technologies Inc series D convertible preferred.**
No dividends paid.
 - BioSig Technologies Inc 9% series C convertible preferred (stated value: \$1,000).**
No dividends paid.
- Annual Dividends:**
- BioSig Technologies Inc redeemable series A preferred.**
No dividends paid.
 - BioSig Technologies Inc redeemable series B preferred.**
No dividends paid.
 - BioSig Technologies Inc common.**
No dividends paid.
 - BioSig Technologies Inc series D convertible preferred.**
No dividends paid.
 - BioSig Technologies Inc 9% series C convertible preferred (stated value: \$1,000).**
No dividends paid.

Recent Dividends:**1. BioRestorative Therapies Inc common.**

No dividends paid.

Annual Dividends:**1. BioRestorative Therapies Inc common.**

No dividends paid.

BIO SIG TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Product sales | ... | 254,000 | 414,000 |
| Service | 18,000 | 32,000 | 27,000 |
| Revenue | 18,000 | 286,000 | 441,000 |
| Cost of goods sold | ... | 57,000 | 199,000 |
| Gross profit | 18,000 | 229,000 | 242,000 |
| Research & development | 5,092,000 | 5,821,000 | 5,602,000 |
| General & administrative expenses | 23,077,000 | 21,380,000 | 27,853,000 |
| Depreciation & amortization | 361,000 | 293,000 | 198,000 |
| Total operating expenses | 28,530,000 | 27,494,000 | 33,653,000 |
| Income (loss) from operations | (28,512,000) | (27,265,000) | (33,411,000) |
| Interest Income | 9,000 | ... | ... |
| Interest income (expense), net | (187,000) | 3,000 | 2,000 |
| Gain on settlement of debt | ... | ... | 553,000 |
| Income (loss) before income taxes | (28,690,000) | (27,262,000) | (32,856,000) |
| Net income (loss) | (28,690,000) | (27,262,000) | (32,856,000) |
| Non-controlling interest | (351,000) | 210,000 | 939,000 |
| Net income (loss) attributable to biosig technologies, inc. | (29,041,000) | (27,052,000) | (31,917,000) |
| Preferred stock dividend | 9,000 | 9,000 | 9,000 |
| Preferred stock deemed dividend | ... | 210,000 | ... |
| Net income (loss) attributable to common shareholders | (29,050,000) | (27,271,000) | (31,926,000) |
| Weighted average shares outstanding - basic | 7,351,794 | □4,263,260 | 3,351,194 |
| Weighted average shares outstanding - diluted | 7,351,794 | □4,263,260 | 3,351,194 |
| Year end shares outstanding | 9,040,043 | □□5,461,064 | 3,556,718 |
| Net income (loss) per share - basic | \$(3.95) | □\$(6.40) | \$(9.50) |
| Net income (loss) per share - diluted | \$(3.95) | □\$(6.40) | \$(9.50) |
| Number of full time employees | ... | □47 | □50 |
| Number of common stockholders | 392 | □□325 | □290 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash | 190,000 | 357,000 |
| Accounts receivable | 24,000 | 9,000 |
| Employee advance | 5,000 | ... |
| Inventory, short term | ... | 336,000 |
| Net investment in leases, short term | 103,000 | 101,000 |
| Prepaid expenses & vendor deposits | 206,000 | 325,000 |
| Total current assets | 528,000 | 1,128,000 |
| Computer equipment | 531,000 | 397,000 |
| Furniture & fixtures | 109,000 | 109,000 |
| Machinery & Equipment | 372,000 | 372,000 |
| Testing or demo equipment | 356,000 | 304,000 |
| Leasehold improvements | 84,000 | 84,000 |
| Property & equipment, gross | 1,452,000 | 1,266,000 |
| Less: accumulated depreciation | 943,000 | 601,000 |
| Property & equipment, net | 509,000 | 665,000 |
| Right-to-use assets, net | 412,000 | 705,000 |
| Inventory, long term | ... | 1,141,000 |
| Net investment in leases, long term | 17,000 | 120,000 |
| Patents, net | 288,000 | 307,000 |
| Other assets | 44,000 | 44,000 |
| Total assets | 1,798,000 | 4,110,000 |
| Accrued accounting & legal | ... | 646,000 |
| Accrued reimbursements & travel | 9,000 | 33,000 |
| Accrued consulting | 804,000 | 546,000 |
| Accrued research & development expenses | 802,000 | 625,000 |
| Accrued marketing | 333,000 | 256,000 |
| Accrued office & other | 290,000 | 220,000 |
| Accrued payroll | 601,000 | 513,000 |
| Accrued settlement related to arbitration | 1,277,000 | 13,000 |
| Stock based payable | 4,116,000 | ... |
| Deferred revenue, short term | ... | 5,000 |
| Dividends payable | 101,000 | 91,000 |
| Lease liability, short term | 349,000 | 313,000 |
| Customer deposits | 16,000 | ... |
| Total current liabilities | 4,582,000 | 3,261,000 |
| Lease liability, long term | 103,000 | 452,000 |
| Total long-term liabilities | 103,000 | 452,000 |
| Total liabilities | 4,685,000 | 3,713,000 |
| Series C convertible preferred stock | 105,000 | 105,000 |
| Common stock | 9,000 | 55,000 |
| Additional paid in capital | 241,988,000 | 216,232,000 |
| Accumulated deficit | (245,015,000) | ... |
| Retained earnings (accumulated deficit) | ... | (215,974,000) |
| Total stockholders' equity (deficit) | (3,018,000) | 313,000 |
| Non-controlling interest | 26,000 | (21,000) |
| Total equity | (2,992,000) | 292,000 |

BIOSTAX CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | □2021 (revised) |
|--|--------------------|--------------------|--------------------|
| Selling, general & administrative expenses | 957,114 | 1,149,257 | 585,502 |
| Research & development expense | 473,528 | 14,236 | 152,667 |
| Research and development expense | 54,308 | ... | ... |
| Total operating expenses | 1,484,950 | 1,163,493 | 738,169 |
| Income (loss) from operations | (1,484,950) | (1,163,493) | (738,169) |
| Gain on issuance of Forte Animal Health Inc. ("Forte") license | ... | 3,165,151 | ... |
| Interest expense | 125,607 | 120,403 | 210,919 |
| Receipt of common shares | ... | ... | 5,761,500 |
| Change in market value of common shares | ... | (2,645,000) | (3,116,500) |
| Gain (loss) on settlement of obligations & conversion of debt | (40,000) | (1,166,418) | 711,892 |
| Gain (loss) on derivative liability valuation | ... | ... | 1,178,230 |
| Charge from warrant modification & debt settlement | ... | 1,605,913 | ... |
| Net income/(loss) before income taxes | (1,650,557) | ... | ... |
| Total other income (expense) | (165,607) | (2,372,583) | 4,324,203 |
| Net income (loss) | (1,650,557) | (3,536,076) | 3,586,034 |
| Weighted average shares outstanding - basic | 83,510,001 | 36,290,359 | 482,826 |
| Weighted average shares outstanding - diluted | 83,510,001 | 36,290,359 | 9,394,164 |
| Year end shares outstanding | 83,657,853 | □83,045,857 | 483,714 |
| Net earnings (loss) per share - basic | \$(0.02) | \$(0.10) | \$7.43 |
| Net earnings (loss) per share - diluted | \$(0.02) | \$(0.10) | \$0.38 |
| Number of full time employees | ... | 0 | ... |
| Number of common stockholders | 675 | □□673 | □619 |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to issuance of common stock for services, intangible

Recent Dividends:

assets, and upon conversion of notes, exercise of warrants; [Ⓐ] As of March 31, 2022; [Ⓑ] As of March 31, 2023; [Ⓒ] As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash in Hand & with Banks | 29,785 | ... |
| Cash | ... | 150,491 |
| Total current assets | 29,785 | 150,491 |
| Patents & licenses, net | 708,192 | 762,500 |
| Deposits | 5,500 | 50,728 |
| Total assets | 743,477 | 963,719 |
| Accounts payable | 1,350,984 | 1,300,366 |
| Accrued payroll | 336,002 | 336,002 |
| Notes payable, net of debt discount | 1,104,594 | 696,478 |
| Due to related parties | 295,230 | 394,736 |
| Accrued interest | 152,315 | 64,455 |
| Accrued liabilities | 136,057 | 136,057 |
| License fees payable | ... | 549,079 |
| Notes payable | 1,183,978 | ... |
| Total current liabilities | 4,559,159 | 3,477,173 |
| Total liabilities | 4,559,159 | 3,477,173 |
| Common stock | 8,366 | 8,305 |
| Additional paid in capital | 380,795,003 | 380,436,432 |
| Stock issuances due | ... | 10,303 |
| Accumulated deficit | (384,619,050) | ... |
| Retained earnings (accumulated deficit) | ... | (382,968,494) |
| Total stockholders' equity (deficit) | (3,815,682) | (2,513,454) |
| Total stockholders' equity (deficit) | (3,815,682) | ... |

Recent Dividends:

1. Biostax Corp common.
No dividends paid.

Annual Dividends:

1. Biostax Corp common.
No dividends paid.

BIOTE CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 |
|--|--------------|--------------|-------------------|
| Product revenue | 182,573,000 | 163,133,000 | ... |
| Service revenue | 2,787,000 | 1,824,000 | ... |
| Total revenue | 185,360,000 | 164,957,000 | ... |
| Cost of products | 54,246,000 | 51,990,000 | ... |
| Cost of services | 3,631,000 | 2,585,000 | ... |
| Cost of revenue | 57,877,000 | 54,575,000 | ... |
| Commissions | ... | 974,000 | ... |
| Marketing expenses | ... | 4,628,000 | ... |
| Selling, general & administrative expenses | 98,826,000 | 165,502,000 | ... |
| Operating & formation costs | ... | ... | 3,121,694 |
| Franchise tax expense | ... | ... | 200,000 |
| Income (loss) from operations | 28,657,000 | (60,722,000) | (3,321,694) |
| Transaction costs allocated to warrant liabilities | ... | ... | 966,646 |
| Interest expense | 6,363,000 | 5,091,000 | ... |
| Net gain on investments held in trust account | ... | ... | 81,791 |
| Excess of private placement warrant fair value over purchase price | ... | ... | 3,507,000 |
| Gain from change in fair value of warrant liability | (13,411,000) | 5,127,000 | 18,826,459 |
| Gain from change in fair value of earnout liability | (8,990,000) | 61,770,000 | ... |
| Loss from extinguishment of debt | ... | (445,000) | ... |

| | | | |
|---|--------------------|------------------|-------------------------|
| Other income | (16,000) | 1,073,000 | ... |
| Total other income (expense), net | (28,780,000) | 62,434,000 | ... |
| Income (loss) before provision for income taxes - domestic | ... | 2,221,000 | ... |
| Income (loss) before provision for income taxes - foreign | ... | (509,000) | ... |
| Income (loss) before provision for income taxes | (123,000) | 1,712,000 | ... |
| Current income tax provision (benefit) - federal | 1,739,000 | 749,000 | ... |
| Current income tax provision (benefit) - state & local | 205,000 | 377,000 | ... |
| Current income tax provision (benefit) - foreign | 17,000 | 5,000 | ... |
| Current income tax provision (benefit) - federal | 711,000 | (714,000) | ... |
| Deferred income tax provision (benefit) - state & local | 10,000 | (29,000) | ... |
| Deferred income tax provision (benefit) | 721,000 | (743,000) | ... |
| Income tax provision (benefit) | 2,682,000 | 388,000 | ... |
| Net income (loss) | (2,805,000) | 1,324,000 | 11,112,910 |
| Less: net income attributable to noncontrolling interest | 6,121,000 | (2,293,000) | ... |
| Net income (loss) attributable to Biote Corp. stockholders | 3,316,000 | (969,000) | ... |
| Weighted average class A common stock outstanding - basic | ... | ... | 26,265,068 |
| Weighted average class B common stock outstanding - basic | ... | ... | 7,860,788 |
| Weighted average shares outstanding | 25,709,343 | 8,059,371 | ... |
| Weighted average class A common stock outstanding - diluted | ... | ... | 26,265,068 |
| Weighted average class B common stock outstanding - diluted | ... | ... | 8,058,048 |
| Weighted average shares outstanding - diluted | 25,709,343 | 8,059,371 | ... |
| Year end shares outstanding | 63,073,949 | 58,221,211 | [Ⓐ] 39,687,500 |
| Net income (loss) per class A common stock - basic | ... | ... | \$0.33 |
| Net income (loss) per class B common stock - basic | ... | ... | \$0.33 |
| Net income (loss) per common stock - basic | \$0.13 | \$(0.12) | ... |
| Net income (loss) per class A common stock - diluted | ... | ... | \$0.32 |
| Net income (loss) per class B common stock - diluted | ... | ... | \$0.32 |
| Net income (loss) | ... | ... | \$0.32 |

| | | | |
|---------------------------------------|-----------|-----------------|----------------|
| per common stock - diluted | \$0.13 | \$(0.12) | ... |
| Number of full time employees | 194 | ... | 4 |
| Total number of employees | 194 | 186 | ... |
| Number of class A common stockholders | ... | [Ⓐ] 43 | [Ⓐ] 1 |
| Number of class V common stockholders | ... | [Ⓐ] 9 | ... |
| Income tax expense (benefit) | 2,682,000 | ... | ... |
| Common Shareholders - Number | 45 | ... | ... |

[Ⓐ] Non-consolidated; [Ⓑ] Shares increased due to the effect of class A common stock subject to possible redemption; [Ⓒ] As of March 15, 2023; [Ⓓ] As of April 6, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash and cash equivalents | 89,002,000 | ... |
| Cash | ... | 79,231,000 |
| Accounts receivable, gross | ... | 7,922,000 |
| Allowance for doubtful accounts | ... | 974,000 |
| Accounts receivable, net | 6,809,000 | 6,948,000 |
| Product inventory - pellets | 7,200,000 | 6,213,000 |
| Less: obsolete & expired pellet allowance | 1,272,000 | 1,298,000 |
| Pellet inventory, net | ... | 4,915,000 |
| Product inventory - dietary supplements | 11,394,000 | 6,283,000 |
| Less: obsolete & expired dietary supplement allowance | 15,000 | 15,000 |
| Dietary supplement inventory, net | ... | 6,268,000 |
| Inventory, net | 17,307,000 | 11,183,000 |
| Prepaid expenses | ... | 2,939,000 |
| Advances | ... | 877,000 |
| Other current assets | 9,225,000 | 3,816,000 |
| Total current assets | 122,343,000 | 101,178,000 |
| Trocars | 4,644,000 | 4,645,000 |
| Leasehold improvements | 1,506,000 | 1,028,000 |
| Office equipment | 253,000 | 238,000 |
| Computer software | 140,000 | 140,000 |
| Furniture & fixtures | 181,000 | 161,000 |
| Computer equipment | 108,000 | 102,000 |
| Property & equipment, gross | 6,832,000 | 6,314,000 |
| Less: accumulated depreciation | 5,614,000 | 4,810,000 |
| Property & equipment, net | 1,218,000 | 1,504,000 |
| Capitalized software, net | 4,973,000 | 5,073,000 |
| Operating lease right-of-use assets | 1,877,000 | 2,052,000 |
| Deferred tax asset | 24,884,000 | 1,838,000 |
| Total assets | 155,295,000 | 111,645,000 |
| Accounts payable | 4,155,000 | 4,112,000 |
| Accrued professional fees | ... | 354,000 |
| Accrued employee-related costs | 6,068,000 | 4,221,000 |
| Other accrued expenses | ... | 1,699,000 |
| Accrued expenses | 8,497,000 | 6,274,000 |
| Term loan, current | 6,250,000 | 6,250,000 |
| Deferred revenue, current | 3,002,000 | 1,965,000 |
| Operating lease liabilities, current | 311,000 | 165,000 |
| Accrued expenses - Balancing value | 2,429,000 | ... |
| Total current liabilities | 22,215,000 | 18,766,000 |
| Term loan | ... | 121,875,000 |
| Less: current portion | ... | 6,250,000 |
| Total term loan | ... | 115,625,000 |
| Less: unamortized debt issuance costs | 106,630,000 | (3,539,000) |
| Term loan, net of current portion | ... | 112,086,000 |
| Deferred revenue, net of | ... | ... |

| | | |
|---|--------------|--------------|
| current portion | 1,322,000 | 926,000 |
| Operating lease liabilities, net of current portion | 1,680,000 | 1,927,000 |
| Warrant liability | 18,894,000 | 4,104,000 |
| Earnout liabilities | 41,100,000 | 32,110,000 |
| Total liabilities | 191,841,000 | 169,919,000 |
| Class A common stock | 3,000 | 1,000 |
| Class V voting stock | 3,000 | 5,000 |
| Retained earnings (accumulated deficit) | (29,391,000) | (44,460,000) |
| Accumulated other comprehensive income (loss) | (12,000) | (5,000) |
| Biote Corp.'s stockholder's equity (deficit) | (29,397,000) | (44,459,000) |
| Noncontrolling interests | (7,149,000) | (13,815,000) |
| Total stockholder's equity (deficit) | (36,546,000) | (58,274,000) |

Recent Dividends:**1. Biote Corp class V common.**

No dividends paid.

2. Biote Corp class B common.

No dividends paid.

3. Biote Corp class A common.

No dividends paid.

Annual Dividends:**1. Biote Corp class V common.**

No dividends paid.

2. Biote Corp class B common.

No dividends paid.

3. Biote Corp class A common.

No dividends paid.

BIOXYTRAN INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|--------------------|
| Research & development | 1,149,209 | 977,768 | 2,013,762 |
| General & administrative | 2,463,386 | 933,742 | 1,612,685 |
| General & administrative related party | 10,000 | 44,220 | 5,125 |
| Compensation expense | 197,552 | 178,382 | 582,862 |
| Total operating expenses | 3,820,147 | 2,134,112 | 4,214,434 |
| Income (loss) from operations | (3,820,147) | (2,134,112) | (4,214,434) |
| Interest expense | 193,191 | 207,117 | 236,577 |
| Amortization of intellectual property | 8,285 | 3,644 | ... |
| Debt discount amortization | 348,637 | 312,431 | 77,031 |
| Total other income (expenses) | (550,113) | (523,192) | (313,608) |
| Net income (loss) before provision for income taxes | (4,370,260) | (2,657,304) | (4,528,042) |
| Net income (loss) | (4,370,260) | (2,657,304) | (4,528,042) |
| Net income attributable to non-controlling interest | 90,258 | 193,372 | 496,297 |
| Net loss attributable to Bioxytran, Inc. | (4,280,002) | (2,463,932) | (4,031,745) |
| Weighted average shares outstanding - basic | 134,224,825 | 115,139,380 | 106,252,116 |
| Weighted average shares outstanding - diluted | 134,224,825 | 115,139,380 | 106,252,116 |
| Year end shares outstanding | 145,642,333 | 123,252,235 | 110,840,998 |
| Net earnings (loss) per share - basic | \$(0.03) | \$(0.02) | \$(0.04) |
| Net earnings (loss) | | | |

| | | | |
|---|----------|----------|----------|
| per share - diluted | \$(0.03) | \$(0.02) | \$(0.04) |
| Number of full time employees | ... | 3 | 2 |
| Number of common stockholders | 2,080 | 1,740 | 1,005 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.03) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.03) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 26,086 | 295,401 |
| Total current assets | 26,086 | 295,401 |
| Intangibles, net | 111,552 | 75,535 |
| Total assets | 137,638 | 370,936 |
| Accounts payable & accrued expenses | 296,312 | 749,395 |
| Accounts payable related party | 2,000 | 709,727 |
| Un-issued shares liability | 510,284 | 960 |
| Un-issued shares liability related party | 515,904 | 38,400 |
| Shareholder advance | 25,000 | ... |
| Convertible notes payable, net of premium & discount | ... | 2,165,000 |
| Convertible notes payable, net of discount, current portion | 1,900,000 | ... |
| Total current liabilities | 3,249,500 | 3,663,482 |
| Total liabilities | 3,249,500 | 3,663,482 |
| Common stock | 145,642 | 123,252 |
| Additional paid in capital | 12,920,984 | 8,392,430 |
| Non-controlling interests | (680,886) | (590,628) |
| Retained earnings (accumulated deficit) | (15,497,602) | (11,217,600) |
| Total stockholders' equity (deficit) | (3,111,862) | (3,292,546) |
| Total Equity | (3,111,862) | ... |

Recent Dividends:**1. Bioxytran Inc class A 6% cumulative convertible voting preferred.**

No dividends paid.

2. Bioxytran Inc common.

No dividends paid.

Annual Dividends:**1. Bioxytran Inc class A 6% cumulative convertible voting preferred.**

No dividends paid.

2. Bioxytran Inc common.

No dividends paid.

BIOXYTRAN INC**Earnings, 9 mos. to Sep 30(Consol. - \$):**

| | 2023 | 2022 |
|-----------------------------|--------------------|--------------------|
| Cost & expenses | 2,793,386 | 1,342,104 |
| Operating income | (3,301,927) | (1,342,104) |
| Other income (expense), net | (4,505) | (2,733) |
| Net before taxes | (3,301,927) | (1,800,574) |
| Net income | (3,301,927) | (1,800,574) |
| Earnings common share | | |
| Primary | \$(0.02) | \$(0.01) |
| Fully Diluted | \$(0.02) | \$(0.01) |
| Common Shares: | | |
| Full Diluted | 129,441,332 | 112,712,305 |
| Year-end | 144,355,355 | 123,013,985 |

BITECH TECHNOLOGIES CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2021 | 2020 |
|---------------------|------|---------|---------|
| REVENUE | 308 | ... | ... |
| Net service revenue | ... | 64,588 | 76,078 |
| Lease revenue | ... | 104,292 | 95,941 |
| Total revenue | 308 | 168,880 | 172,019 |
| Gross profit (loss) | 308 | ... | 172,019 |

| | | | |
|---|------------------|------------------|------------------|
| Operating, general & administrative expenses | 819,001 | 379,883 | 507,397 |
| Total operating expenses | 819,001 | ... | ... |
| Income (loss) from operations | (818,693) | (211,003) | (335,378) |
| Gain from forgiveness of debt | ... | ... | 64,097 |
| Other income | ... | 97,497 | 533 |
| Interest expense | ... | 26,859 | 26,646 |
| LOSS BEFORE INCOME TAXES | (811,693) | ... | ... |
| Interest and Other Income | 7,000 | ... | ... |
| Total other income (expense), net | 7,000 | 70,638 | 37,984 |
| Net income (loss) | (811,693) | (140,365) | (297,394) |
| Weighted average shares outstanding - basic | 479,080,612 | 20,240,882 | 20,240,882 |
| Weighted average shares outstanding - diluted | 479,080,612 | 20,240,882 | 20,240,882 |
| Year end shares outstanding | 484,464,194 | 20,240,882 | 20,240,882 |
| Net income (loss) per common share - basic | ... | \$(0.01) | \$(0.01) |
| Net income (loss) per common share - diluted | ... | \$(0.01) | \$(0.01) |
| Number of full time employees | 2 | ... | 1 |
| Number of part time employees | ... | 3 | 2 |
| Total number of employees | 2 | 3 | 3 |
| Number of common stockholders | 115 | 163 | 163 |
| Number of beneficiary stockholders | ... | 425 | 500 |

□ Approximately; □ As of March 16, 2022; □ As of March 26, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|--|-------------|--------------|
| Cash & cash equivalents | 152,417 | 16,437 |
| Accounts receivable, gross | ... | 474,389 |
| Allowance for doubtful accounts | ... | 447,126 |
| Accounts receivable, net | ... | 27,263 |
| Prepaid expenses | 11,000 | ... |
| Total current assets | 163,417 | 43,700 |
| Total assets | 163,417 | 43,700 |
| Notes payable | ... | 395,000 |
| Accounts payable & accrued liabilities | 35,229 | 37,495 |
| Total current liabilities | 35,229 | 432,495 |
| Common stock | ... | 20,241 |
| Common stock issuable | 484,464 | ... |
| Additional paid-in capital | 1,552,011 | 19,869,511 |
| Retained earnings (accumulated deficit) | ... | (20,278,547) |
| Retained earnings (deficit) accumulated during the development stage | (1,908,287) | ... |
| Total stockholders' equity (deficit) | 128,188 | (388,795) |
| Rep Total Equity & Minority Interest | 128,188 | ... |

Recent Dividends:**1. Bitech Technologies Corp common.**

No dividends paid.

Annual Dividends:**1. Bitech Technologies Corp common.**

No dividends paid.

BLACKBOXSTOCKS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|--------------------|--------------------|
| Subscriptions | 3,096,112 | 4,927,002 | 6,087,081 |
| Other revenues | 9,914 | 32,107 | 25,243 |
| Total revenues | 3,106,026 | 4,959,109 | 6,112,324 |
| Cost of revenues | 1,666,192 | 2,080,879 | 1,851,355 |
| Gross margin | 1,439,834 | 2,878,230 | 4,260,969 |
| Software development costs | 923,720 | 1,203,140 | 642,872 |
| Selling, general & administrative | 5,140,391 | 4,729,686 | 4,625,333 |
| Advertising & marketing | 629,984 | 1,468,702 | 1,250,882 |
| Depreciation & amortization | 43,410 | 22,728 | 19,721 |
| Total operating expenses | 6,737,505 | 7,424,256 | 6,538,808 |
| Operating income (loss) | (5,297,671) | (4,546,026) | (2,277,839) |
| Interest expense | 633 | 98,541 | 135,492 |
| Amortization of debt discount & issuance costs | ... | 46,597 | 247,522 |
| Gain on forgiveness of note payable | 575,000 | ... | 33,405 |
| Investment income (loss) | 58,849 | (328,718) | 11,712 |
| Total other income (expense) | 633,216 | (473,856) | (337,897) |
| Income (loss) before income taxes | (4,664,455) | (5,019,882) | (2,615,736) |
| Net income (loss) | (4,664,455) | (5,019,882) | (2,615,736) |
| Weighted average shares outstanding - basic | 3,219,224 | 13,186,236 | 11,241,243 |
| Weighted average shares outstanding - diluted | 3,219,224 | 13,186,236 | 11,241,243 |
| Year end shares outstanding | 3,223,015 | 13,191,707 | 3,274,818 |
| Net income (loss) per share - basic | \$(1.45) | \$(0.38) | \$(1.08) |
| Net income (loss) per share - diluted | \$(1.45) | \$(0.38) | \$(1.08) |
| Number of full time employees | ... | 14 | 15 |
| Number of common stockholders | 618 | 638 | 676 |

Adjusted for 1-for-4 stock split, April 11, 2023; Stocks increased due to the effect of issuance for cashless exercise of warrants and for common stock payable; Shares increased due to the effect of issuance of subscribed shares, settlement of liabilities, for services, conversion of series A preferred shares and for cashless exercise of warrants; As of April 6, 2023; As of March 30, 2022; As of April 11, 2023; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | ... | 425,578 |
| Accounts receivable, gross | 86,801 | 128,202 |
| Less: allowance for doubtful accounts | 68,589 | 68,589 |
| Accounts receivable, net | 18,212 | 59,613 |
| Inventory | 3,464 | 15,464 |
| Marketable securities | 2,955 | 3,216,280 |
| Prepaid expenses & other current assets | 35,161 | 190,120 |
| Cash on hand & in bank | 472,697 | ... |
| Other receivable | 475,000 | ... |
| Total current assets | 1,007,489 | 3,907,055 |
| Office, computer & related equipment, gross | 200,101 | 197,496 |
| Less: accumulated depreciation | ... | 104,410 |
| Office, computer & related equipment, net | 52,281 | 93,086 |
| Right of lease, gross | ... | 549,099 |

| | | |
|--|--------------|--------------|
| Less: accumulated depreciation - right of lease | ... | 213,459 |
| Right of use lease | 344,370 | 335,640 |
| Depreciation | 147,820 | ... |
| Total property & equipment | ... | 428,726 |
| Investments | 8,424,000 | ... |
| Total assets | 9,828,140 | 4,335,781 |
| Accounts payable | ... | 730,099 |
| Accrued interest | 1,613 | 1,613 |
| Accounts payable & accrued expenses | 842,404 | ... |
| Unearned subscriptions | 1,295,514 | 1,022,428 |
| Lease liability right of use, current | 64,818 | 70,002 |
| Note payable, current portion | ... | 28,733 |
| Notes payable | 28,064 | ... |
| Total current liabilities | 2,232,413 | 1,852,875 |
| Note payable | 11,550 | 39,614 |
| Lease liability right of use, long term | 287,417 | 265,639 |
| Total long term liabilities | 298,967 | 305,253 |
| Series A convertible preferred stock | 3,270 | 3,270 |
| Common stock | 3,223 | 13,192 |
| Common stock payable | ... | 23,340 |
| Treasury stock | 27,650 | 1,102,375 |
| Additional paid-in capital | 26,802,808 | 18,060,662 |
| Retained earnings (deficit) accumulated during the development stage | (19,484,891) | ... |
| Retained earnings (accumulated deficit) | ... | (14,820,436) |
| Total stockholders' equity (deficit) | 7,296,760 | 2,177,653 |
| Total Equity | 7,296,760 | ... |

Recent Dividends:
1. BlackBoxStocks Inc series A convertible preferred.
 No dividends paid.
2. BlackBoxStocks Inc common.
 No dividends paid.

Annual Dividends:
1. BlackBoxStocks Inc series A convertible preferred.
 No dividends paid.
2. BlackBoxStocks Inc common.
 No dividends paid.

BLUE BIOFUELS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-------------|-------------|-------------------|
| General & administrative | 1,339,789 | 1,541,959 | 1,034,948 |
| Research & development | 1,849,967 | 2,350,218 | 1,103,436 |
| Gain (loss) on disposal of assets | (1,159) | (40,099) | (33,484) |
| Total operating expenses | 3,190,915 | 3,932,276 | 2,171,868 |
| Income (loss) from operations | (3,190,915) | (3,932,276) | (2,171,868) |
| Loan forgiveness | ... | ... | 66,330 |
| Common stock rescission | 233,500 | 1,500 | ... |
| Interest expense - related party | 89,363 | 26,847 | 27,084 |
| Interest expense - other | 8,416 | 2,560 | 6,688 |
| Net Income before Tax | (3,055,194) | ... | ... |
| Total other income (expense) | 135,721 | (27,907) | 32,558 |
| Income (loss) before provisions for income taxes | ... | (3,960,183) | (2,139,310) |
| Deferred federal income taxes | ... | (831,638) | (449,255) |

| | | | |
|--|--------------------|--------------------|--------------------|
| Deferred state income taxes | ... | (217,810) | (95,413) |
| Change in valuation allowance | ... | 1,049,448 | 544,668 |
| Net income (loss) | (3,055,194) | (3,960,183) | (2,139,310) |
| Weighted average shares outstanding - basic | 299,950,813 | 278,830,924 | 269,643,759 |
| Weighted average shares outstanding - diluted | 299,950,813 | ... | ... |
| Year end shares outstanding | 302,750,963 | 289,941,623 | 274,003,883 |
| Income (loss) per share from continuing operations - basic | \$(0.01) | ... | ... |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.01) |
| Income (loss) per share from continuing operations - diluted | \$(0.01) | ... | ... |
| Net income (loss) per share - diluted | \$(0.01) | ... | ... |
| Number of full time employees | 5 | 7 | 7 |
| Number of part time employees | 1 | 20 | 5 |
| Total number of employees | 6 | ... | 12 |
| Number of common stockholders | 340 | 342 | 329 |

Reclassified to conform with 2022 presentation; Approximately; As of March 31, 2023; As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 41,008 | 211,901 |
| Prepaid expenses | 35,750 | 43,119 |
| Total current assets | 76,758 | 255,020 |
| Building & improvements | 13,596 | 9,370 |
| Machinery & equipment | 795,606 | 512,450 |
| Furniture & fixtures | ... | 13,649 |
| Computer equipment | 11,825 | 11,824 |
| Building and improvements | 9,370 | ... |
| Property & equipment, gross | 830,397 | 547,293 |
| Less accumulated depreciation | 243,089 | 127,178 |
| Property & equipment, net | 587,308 | 420,115 |
| Security deposits | 30,276 | 30,276 |
| Right of use assets, net | 81,091 | 178,399 |
| Patents | 254,786 | 222,109 |
| Total other assets | 953,461 | 850,899 |
| Total assets | 1,030,219 | 1,105,919 |
| Accounts payable | 22,798 | 37,135 |
| Accounts payable - related party | 72,670 | 72,670 |
| Deferred wages & director's fees - related party | 828,312 | 307,606 |
| Right of use lease liability - current | 85,983 | 95,172 |
| Chapter 11 settlement | ... | 50,000 |
| Convertible debentures - related party | 350,000 | ... |
| Interest payable - related party | 143,406 | 76,138 |
| Total current liabilities | 1,503,169 | 638,721 |
| Right of use lease liability, net of current portion | ... | 85,983 |
| Notes payable - related party | 2,821,562 | 2,521,562 |
| Notes payable - other | 266,570 | 216,570 |
| Total long term liabilities | 3,088,132 | 2,824,115 |
| Total liabilities | 4,591,301 | 3,462,836 |
| Common stock | 302,751 | 289,942 |
| Additional paid-in | ... | ... |

| | | | |
|--|-----------|-----------|------------|
| Cost of revenue | 1,542,450 | 1,278,239 | 1,284,876 |
| Gross profit | 2,865,861 | 2,597,988 | 3,374,517 |
| General & administrative expenses | 2,103,148 | 2,517,149 | 2,118,601 |
| Total expenses | 2,103,148 | 2,517,149 | 2,118,601 |
| Operating income (loss) | 762,713 | 80,839 | 1,255,916 |
| Gain on settlement of accounts payable | ... | ... | 533 |
| Interest expense | 242,959 | 194,643 | 583,149 |
| Disposition of fixed assets | 1,000 | ... | ... |
| Income (loss) on derivative | (169,573) | (180,724) | 1,077,289 |
| Total other income (expenses) | ... | (375,367) | 494,673 |
| Income (loss) before provision for income taxes | 351,181 | ... | ... |
| Net income (loss) | 351,181 | (294,528) | 1,750,589 |
| Weighted average shares outstanding - basic | 8,250,144 | 8,398,062 | 8,457,364 |
| Weighted average shares outstanding - diluted | 8,250,144 | 8,398,062 | 12,314,864 |
| Year end shares outstanding | 8,250,144 | 8,250,144 | 8,485,144 |
| Income (loss) per share from continuing operations - basic | \$0.04 | ... | ... |
| Net income (loss) per share - basic | \$0.04 | \$(0.04) | \$0.21 |
| Income (loss) per share from continuing operations - diluted | \$0.03 | ... | ... |
| Net income (loss) per share - diluted | \$0.03 | \$(0.04) | \$0.14 |
| Total number of employees | ... | 32 | 30 |
| Number of common stockholders | 216 | 216 | 215 |

Approximately; As of March 31, 2023; As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|-----------|-----------|
| | 2023 | 2022 |
| Cash & equivalents | 585,780 | 280,073 |
| Accounts receivable | 368,352 | 373,175 |
| Prepaid expenses & deposits | 34,174 | 31,553 |
| Total current assets | 988,306 | 684,801 |
| Right to use assets | 586,620 | 408,616 |
| Automotive vehicles | 637,386 | 565,695 |
| Furniture & equipment | 108,265 | 108,265 |
| Machinery & equipment | 135,706 | 135,706 |
| Leasehold improvements | 148,994 | 148,994 |
| Fixed assets, total | 1,030,351 | 958,660 |
| Total: accumulated depreciation | 776,180 | 704,433 |
| Security deposit | ... | 31,920 |
| Fixed assets of discontinued operations | 2,782 | 2,782 |
| Total long-term assets | 28,960 | 665,625 |
| Total fixed assets | 254,171 | ... |
| Total assets | 1,860,839 | 1,382,346 |
| Accounts payable & accrued liabilities | 511,622 | 555,445 |
| Financed lease liabilities | 22,022 | 31,719 |
| Notes payable - related parties | 152,771 | 152,771 |
| Convertible notes payable - related parties, net of unamortized discount | 638,500 | 604,256 |
| Current portion of operating lease obligation | 121,519 | 112,250 |
| Derivative liabilities | 503,584 | 451,119 |

| | | |
|---|--------------|--------------|
| Total current liabilities | 1,950,018 | 1,907,560 |
| Financed lease liabilities - long term | 15,545 | 37,568 |
| Notes payable - related parties | ... | 1,000,500 |
| Operating lease liability - long-term | 494,215 | 328,116 |
| Long-term debt | 773,989 | ... |
| Total long-term liabilities | 1,283,749 | 1,366,184 |
| Total liabilities | 3,233,767 | 3,273,744 |
| Preferred stock | 20,000 | 20,000 |
| Common stock | 8,251 | 8,251 |
| Common stock, owed but not issued | 13 | 13 |
| Additional paid-in capital | 10,213,385 | 10,046,096 |
| Accumulated deficit | (11,614,577) | ... |
| Retained earnings (accumulated deficit) | ... | (11,965,758) |
| Total stockholders' equity (deficit) | (1,372,928) | (1,891,398) |
| Total Equity | (1,372,928) | ... |

Recent Dividends:

1. Blue Line Protection Group Inc Preferred.

No dividends paid.

2. Blue Line Protection Group Inc common.

No dividends paid.

Annual Dividends:

1. Blue Line Protection Group Inc Preferred.

No dividends paid.

2. Blue Line Protection Group Inc common.

No dividends paid.

BLUE STAR FOODS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|-------------|--------------|-------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Revenue | 6,124,529 | ... | ... |
| Revenue, net | 6,124,529 | 12,767,145 | 9,973,264 |
| Cost of revenue | 5,966,452 | 13,419,133 | 7,979,830 |
| Gross profit (loss) | 158,077 | (651,988) | 1,993,434 |
| Commissions | ... | 24,482 | 42,332 |
| Salaries & wages | 1,858,004 | 2,032,457 | 1,827,607 |
| Depreciation & amortization | 4,521 | 584,386 | 384,963 |
| Impairment loss | ... | 5,797,906 | 374,300 |
| Settlement & warrant expense | 2,169 | ... | ... |
| Other operating expenses | 2,525,661 | 2,522,764 | 2,147,873 |
| Income (loss) from operations | (4,232,278) | (11,613,983) | (2,783,641) |
| Other income | 12,708 | 154,196 | 498,791 |
| Gain (loss) on conversion of debt | ... | 57,085 | ... |
| Interest expense | 1,771,942 | 1,678,097 | 320,524 |
| Income (loss) from operations before income taxes | (4,471,612) | ... | ... |
| Net income (loss) | (4,471,612) | (13,194,969) | (2,605,374) |
| Net income (loss) attributable to Blue Star Foods Corp. | ... | ... | (2,605,374) |
| Dividend on preferred stock | ... | ... | 28,260 |
| Net income (loss) attributable to Blue Star Foods Corp. common stockholders | ... | (13,194,969) | (2,633,634) |
| Weighted average shares outstanding - basic | 5,082,500 | 1,257,928 | 1,085,429 |
| Weighted average shares outstanding - diluted | 5,082,500 | 1,257,928 | 1,085,429 |
| Year end shares outstanding | 23,078,513 | 1,338,321 | 1,233,566 |
| Earnings (loss) per share - basic | \$(0.88) | \$(10.40) | \$(2.40) |

| | | | |
|--|-----------|-----------|----------|
| Earnings (loss) per share - diluted | \$(0.88) | \$(10.40) | \$(2.40) |
| Number of full time employees | ... | 35 | 21 |
| Number of common stockholders | 77 | 78 | 92 |
| LOSS ON SETTLEMENT OF DEBT | (977,188) | ... | ... |
| CHANGE IN FAIR VALUE OF DERIVATIVE AND WARRANT LIABILITIES | 2,497,088 | ... | ... |

Adjusted for 1-for-20 stock split, June 21, 2023; Shares increased due to the effect of issuance of shares to settle interest, cash, service, acquisitions, preferred stock conversions and warrants exercised; As of April 17, 2023; As of March 31, 2022; As of April 14, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|--------------|--------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 24,163 | 9,262 |
| Accounts receivable, net | 534,195 | 813,416 |
| Inventory, net | 2,608,521 | 4,808,152 |
| Advances to related parties | 95,525 | 218,525 |
| Other current assets | 833,472 | 671,933 |
| Total current assets | 4,095,876 | 6,521,288 |
| Related party long-term receivable | 435,545 | 435,545 |
| Computer equipment | 47,908 | 97,624 |
| RAS system | 140,214 | 2,089,909 |
| Automobiles | ... | 122,715 |
| Leasehold improvements | 17,904 | 89,055 |
| Total Building Improvements | 136,653 | ... |
| Total | 342,679 | 2,399,303 |
| Less: accumulated depreciation & amortization | 38,822 | ... |
| Less: accumulated depreciation & impairment | ... | 2,278,903 |
| Fixed assets, net | 303,857 | 120,400 |
| Right of use asset | 125,014 | 197,540 |
| Advances to related party | 1,299,984 | 1,299,984 |
| Other assets | 102,222 | 103,720 |
| Total assets | 6,362,498 | 8,678,477 |
| Accounts payable & accruals | 661,377 | 2,401,243 |
| Working capital line of credit | ... | 1,776,068 |
| Deferred income | 47,819 | 47,078 |
| Current maturities of long-term debt, net of discounts | 165,620 | 3,439,557 |
| Current maturities of lease liabilities | 35,428 | 57,329 |
| Current maturities of related party long-term notes | 100,000 | 100,000 |
| Loan payable | ... | 29,413 |
| Related party notes payable - subordinated | 156,938 | 893,000 |
| Other current liabilities | 790,881 | 790,881 |
| Derivative liability | 1,047,049 | ... |
| Warrants liability | 1,574 | ... |
| Customer refunds | 189,975 | ... |
| Total current liabilities | 3,196,661 | 9,534,569 |
| Long-term lease liability | 89,586 | 139,631 |
| Debt, net of current portion & discounts | 481,329 | ... |
| Related party notes, net of current portion | ... | 250,000 |
| Total liabilities | 3,767,576 | 9,924,200 |
| Common stock | 2,324 | 2,704 |
| Additional paid-in capital | 36,659,648 | 28,326,546 |
| Accumulated deficit | (33,810,732) | ... |
| Retained earnings (accumulated deficit) | ... | (29,339,120) |
| Accumulated other comprehensive income | ... | ... |

| | | | |
|---|-----------|-------------|--|
| (loss) | (179,995) | (235,853) | |
| Treasury stock | 76,323 | ... | |
| Total Blue Star Foods Corp. stockholder's deficit | 2,594,922 | (1,245,723) | |
| Total stockholders' equity (deficit) | 2,594,922 | (1,245,723) | |

Recent Dividends:**1. Blue Star Foods Corp series A 8% cumulative convertible preferred.**

No dividends paid.

2. Blue Star Foods Corp common.

No dividends paid.

Annual Dividends:**1. Blue Star Foods Corp series A 8% cumulative convertible preferred.**

No dividends paid.

2. Blue Star Foods Corp common.

No dividends paid.

BLUEJAY DIAGNOSTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|--------------------|
| Revenue | ... | 249,040 | ... |
| Cost of sales | ... | 200,129 | ... |
| Gross profit | ... | 48,911 | ... |
| Research & development | 5,714,574 | 4,152,152 | 1,147,955 |
| General & administrative | 4,313,200 | 4,763,114 | 1,792,482 |
| Marketing & business development | 283,443 | 451,421 | 289,726 |
| Total operating expenses | 10,311,217 | 9,366,687 | 3,230,163 |
| Operating income (loss) | (10,311,217) | (9,317,776) | (3,230,163) |
| Interest income (expense), net of amortization of premium | ... | ... | (367,459) |
| Impairment of property & equipment | ... | 237,309 | ... |
| State grant income | ... | ... | 75,000 |
| Other income (expense), net | 192,429 | 258,137 | 34,324 |
| Interest income | 164,900 | ... | ... |
| Total other income (expense), net | 357,329 | 20,828 | (258,135) |
| Net income (loss) | (9,953,888) | (9,296,948) | (3,488,298) |
| Weighted average shares outstanding | | | |
| - basic | 1,096,500 | 1,008,196 | 426,121 |
| Weighted average shares outstanding - diluted | 1,096,500 | 1,008,196 | 426,121 |
| Year end shares outstanding | 1,239,140 | 1,010,764 | 1,005,612 |
| Net income (loss) per share - basic | \$(9.08) | \$(9.20) | \$(8.20) |
| Net income (loss) per share - diluted | \$(9.08) | \$(9.20) | \$(8.20) |
| Number of full time employees | 10 | 16 | 9 |
| Number of common stockholders | 15 | 10 | 10 |
| Income from cont operations before income tax | (9,953,888) | ... | ... |
| Total number of employees | 10 | ... | ... |

⊠ Reclassified to conform with 2022 presentation; ⊡ Adjusted for 1-for-20 stock split, July 24, 2023; ⊢ Approximately; ⊣ As of February 28, 2023; ⊤ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|------|------|
| | 2023 | 2022 |
|--|------|------|

| | | | |
|--|--------------|--------------|--|
| Cash & cash equivalents | 2,208,516 | 10,114,990 | |
| Prepaid insurance | ... | 751,979 | |
| Vendor prepayments | ... | 681,218 | |
| Prepaid other | ... | 240,283 | |
| Other prepaid expenses & other current assets | 747,263 | ... | |
| Prepaid expenses & other current assets | ... | 1,673,480 | |
| Deferred offering costs | 265,081 | ... | |
| Total current assets | 3,220,860 | 11,788,470 | |
| Construction in process | 1,052,822 | 375,466 | |
| Furniture, fixtures, & equipment | 141,164 | 136,942 | |
| Software | 4,457 | 4,457 | |
| Lab equipment | 2,529,457 | 1,268,380 | |
| Leasehold improvements | 43,231 | 43,231 | |
| Lab equipment | 1,287,783 | ... | |
| Property & equipment, gross | ... | 1,828,476 | |
| Less: accumulated depreciation | 1,243,716 | 596,406 | |
| Property & equipment, net | 1,285,741 | 1,232,070 | |
| Operating lease right-of-use assets | 333,267 | 465,514 | |
| Other non-current assets | 28,663 | 35,211 | |
| Total assets | 4,868,531 | 13,521,265 | |
| Accounts payable | 491,474 | 635,818 | |
| Operating lease liability, current | 162,990 | 168,706 | |
| Accrued other | 154,575 | ... | |
| Accrued expenses - Balancing value | 149,768 | ... | |
| Accrued expenses - Balancing value | 396,249 | ... | |
| Accrued expenses | 1,116,911 | ... | |
| Accrued personnel costs | 566,087 | 533,577 | |
| Other accrued expenses & other current liabilities | ... | 302,153 | |
| Accrued expenses & other current liabilities | ... | 835,730 | |
| Finance Lease Liabilities - Current Portion/Short-Term | 4,807 | ... | |
| Total current liabilities | ... | 1,640,254 | |
| Operating lease liability, non-current | 189,987 | 323,915 | |
| Other non-current liabilities | 12,321 | 15,823 | |
| Non-current finance lease liabilities | 12,321 | ... | |
| Total liabilities | 1,973,683 | 1,979,992 | |
| Common stock | 124 | 2,022 | |
| Additional paid-in capital | 29,845,714 | 28,536,353 | |
| Retained earnings (accumulated deficit) | (26,950,990) | (16,997,102) | |
| Total stockholders' equity (deficit) | 2,894,848 | 11,541,273 | |
| Total Equity | 2,894,848 | ... | |

Recent Dividends:**1. Bluejay Diagnostics Inc series D convertible preferred.**

No dividends paid.

2. Bluejay Diagnostics Inc common.

No dividends paid.

Annual Dividends:**1. Bluejay Diagnostics Inc series D convertible preferred.**

No dividends paid.

2. Bluejay Diagnostics Inc common.

No dividends paid.

BLUM HOLDINGS INC

Acquisition Development On Feb. 9, 2024, Co. entered into a binding letter of intent (the "Operators Only LOI") with Operators Only Corp. ("Operators Only") and Golden Health & Wellness, Inc., Safe Accessible Solutions, Inc., and Sacramento Commercial Services, Inc. (together the "Targets" and each a "Target") pursuant to which Co. and the Targets intend to enter into a Stock Sale and Purchase Agreement in which Co. will acquire 100% of the common stock of Operators Only, and Operators Only will acquire 100% of the common stock of each Target from the shareholders of each Target (the "Target Shareholders"). At closing, Target Shareholders shall receive an aggregate of \$9,700,000

in consideration for the Targets as follows: (i) secured promissory notes in the aggregate principal amount of approximately \$1,900,000 to be paid in monthly installments of approximately \$55,600 per month over 34 to 42 months (the "Notes"); and (ii) the issuance of 1,835,330 shares of common stock of Co. The Notes may be converted into common stock of Co. at the transaction valuation, on terms to be agreed-upon.

BLUM HOLDINGS INC

Interest Sale Development On Feb. 5, 2024, Co.'s wholly owned subsidiary, Unrivaled Brands, Inc. divested its California cultivation facility, a decision which aligns to a broader realignment strategy concentrating Co.'s efforts on operating and expanding profitable cannabis assets and developing brands.

BLUM HOLDINGS INC

Legal Proceedings On Mar. 6, 2024, Co.'s subsidiary, Unrivaled Brands, Inc. filed a civil complaint against Bernard Steimann, Daniel Troup, and Troup Construction for civil theft, conversion, and declaratory relief arising from the alleged theft of Co.'s signage at approximately 5:30 a.m. the morning of Jan. 18, 2024 from the Blum Santa Ana store. A police report, a copy of which was attached to the complaint, was filed on Jan. 31, 2024 for "Grand Theft from Building \$950 or more".

BLUM HOLDINGS INC**Stock Trading Symbol** Stock symbol, BLMH.**BODY & MIND INC****Earnings, 6 mos. to Jan 31(Consol. - \$):**

| | 2024 | 2023 |
|-----------------------------------|----------------|--------------------|
| Net Sales | 8,986,886 | 9,066,119 |
| Cost & expenses | 10,711,587 | 11,069,183 |
| Operating income | (1,916,782) | (2,542,686) |
| Other income (expense), net | (108,646) | 59,688 |
| Gains or losses | 209,423 | ... |
| Foreign currency | (1,268) | 2,166 |
| Net before taxes | (3,852,378) | (3,250,492) |
| Income taxes | 1,363,515 | 746,946 |
| Income contin. oper. | (5,215,893) | (3,997,438) |
| Net income | (4,985) | (5,693,843) |
| Earnings common share | | |
| Primary | \$(0.00) | \$(0.03) |
| Fully Diluted | \$(0.00) | \$(0.03) |
| Common Shares: | | |
| Full Diluted | 146,080,668 | 122,255,170 |
| Year-end | 4,986,000 | 146,636,974 |

BOSTON OMAHA CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 (revised) | 2021 (revised) |
|---|------------|-------------------|-------------------|
| Revenues - billboard rentals, net | ... | ... | 31,499,235 |
| Revenues - broadband services | ... | ... | 15,234,266 |
| Revenues - premiums earned | ... | ... | 7,686,400 |
| Revenues - insurance commissions | ... | ... | 2,212,849 |
| Revenues - investment & other income | 2,156,199 | 662,270 | 339,061 |
| Insurance commissions | 1,884,007 | 2,050,838 | ... |
| Premiums earned | 13,932,659 | 10,649,089 | ... |
| Billboard Rentals | 42,940,369 | 39,244,726 | ... |
| Broadband services | 35,340,502 | 28,627,271 | ... |
| Total revenues | 96,253,736 | 81,234,194 | 56,971,811 |
| Cost of billboard revenues (exclusive of depreciation & amortization) | 15,136,817 | 14,395,627 | 12,094,834 |
| Cost of broadband revenues (exclusive of depreciation & amortization) | 9,955,518 | 7,538,501 | 3,313,760 |
| Cost of insurance revenues (exclusive of depreciation & amortization) | 6,808,167 | 4,755,583 | 3,182,497 |
| Employee costs | 32,561,929 | 26,343,272 | 34,245,526 |
| Professional fees | 4,665,515 | 5,300,275 | 7,703,901 |
| General & administrative | 16,112,243 | 12,861,992 | 9,756,257 |

| | | | |
|---|-------------|--------------|--------------|
| Amortization expense | 7,409,939 | 6,474,791 | 4,549,608 |
| Depreciation expense | 12,155,096 | 8,649,066 | 5,579,026 |
| Gain (loss) on disposition of assets | ... | ... | (178,911) |
| Accretion expense | 216,501 | 206,359 | 134,360 |
| Total cost & expenses | 105,106,139 | 86,464,089 | 80,738,680 |
| Net income (loss) from operations | (8,852,403) | (5,229,895) | (23,766,869) |
| Interest & dividend income | ... | ... | 999,682 |
| Dividend income | 2,609,148 | 434,941 | ... |
| Equity in income (loss) of unconsolidated affiliates | (7,888,765) | 2,697,420 | 878,921 |
| Other investment income (loss) | 6,132,791 | (15,635,690) | 93,163,697 |
| Gain recognized on deconsolidation of special purpose acquisition company | ... | 24,977,740 | ... |
| Remeasurement of warrant liability | ... | 1,837,211 | 2,854,407 |
| Interest expense | 1,147,234 | 1,207,544 | 956,050 |
| Net income (loss) before income taxes | (9,146,463) | 7,874,183 | 73,173,788 |
| Gain on sale of property, plant & equipment | (84,414) | 61,377 | ... |
| Current state income tax expense (benefit) | 166,223 | 256,971 | ... |
| Deferred federal income tax expense (benefit) | (2,138,204) | (1,004,743) | 13,322,593 |
| Deferred state income tax expense (benefit) | (1,006,757) | (1,757,161) | 4,371,387 |
| Income tax expense (benefit) | (2,978,738) | (2,504,933) | 17,693,980 |
| Net Income After Extraordinary Items applicable to Common | (7,004,009) | 10,233,400 | ... |
| Net income (loss) | (6,167,725) | 10,379,116 | 55,479,808 |
| Noncontrolling interest in subsidiary income | (836,284) | (145,716) | (2,731,631) |
| Net income (loss) attributable to common stockholders | ... | ... | 52,748,177 |
| Weighted average shares outstanding - basic | 31,092,850 | 29,698,732 | 28,978,223 |
| Weighted average shares outstanding - diluted | 31,092,850 | 29,766,247 | 29,046,514 |
| Year end shares outstanding | 31,311,299 | 29,706,248 | 29,698,361 |
| Net income (loss) per share - basic | \$(0.23) | \$0.34 | \$1.82 |
| Net income (loss) per share - diluted | \$(0.23) | \$0.34 | \$1.82 |
| Total number of employees | ... | ... | 256 |
| Number of class A common stockholders | 93 | ... | 78 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.23) | \$0.34 | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.23) | \$0.34 | ... |

mately; [□] As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|---|-------------|----------------|
| Cash & cash equivalents | 21,946,884 | 25,493,141 |
| Cash held by Boston Omaha Asset Management, LLC funds & other | 14,101,531 | 8,146,792 |
| Trade accounts | 12,311,549 | 4,798,827 |
| Premiums | 12,141,244 | 1,143,918 |
| Less: allowance for doubtful accounts | 170,305 | 111,379 |
| Accounts receivable, net | ... | 5,831,366 |
| Interest receivable | 185,482 | 196,066 |
| Short-term investments | ... | 6,288,828 |
| Marketable equity securities | 2,210,037 | 8,768,938 |
| U. S. treasury securities | 47,112,659 | 33,520,401 |
| U. S. Treasury securities available for sale | 24,753,469 | ... |
| Funds held as collateral assets | ... | 21,026,579 |
| Prepaid expenses | 5,571,454 | 4,689,132 |
| Cash held by BOAM funds and other | 3,364,789 | ... |
| Total current assets | 131,387,549 | 113,961,243 |
| Structures & displays | 65,736,121 | 63,585,845 |
| Fiber, towers, & broadband equipment | 97,974,753 | 50,216,957 |
| Land | 583,892 | 14,318,292 |
| Vehicles & equipment | 10,699,920 | 6,778,473 |
| Office furniture & equipment | 5,384,720 | 4,884,941 |
| Accumulated depreciation | 36,112,643 | 24,194,568 |
| Property & equipment, net | 144,266,763 | 115,589,940 |
| Goodwill | 182,380,136 | 179,463,522 |
| Intangible assets, net | 65,532,301 | 68,342,042 |
| Investments | 87,104,272 | 26,136,636 |
| Investments in unconsolidated affiliates | 94,244,788 | 114,133,349 |
| Deferred policy acquisition costs | 1,772,455 | 1,255,320 |
| Right of use assets | 61,399,460 | 64,719,405 |
| Deposit on business acquisition | 119,368 | ... |
| Other assets | ... | 116,402 |
| Total assets | 768,207,092 | 683,717,859 |
| Accounts payable & accrued expenses | ... | 10,963,784 |
| Short-term payables for business acquisitions | 18,438,647 | 4,219,358 |
| Lease liabilities | 5,085,221 | 5,203,981 |
| Funds held as collateral | ... | 21,026,579 |
| Unearned premiums | 9,699,544 | 7,158,726 |
| Current maturities of long-term debt | 814,667 | 1,545,090 |
| Deferred revenue | 2,628,139 | 2,531,222 |
| Other current liabilities | 14,101,531 | 330,000 |
| Short-term payables for business acquisitions | 618,003 | ... |
| Total current liabilities | 51,385,752 | 52,978,740 |
| Asset retirement obligations | 3,794,985 | 3,569,580 |
| Lease liabilities | 56,438,308 | 59,281,733 |
| Long-term debt, less current maturities | ... | 26,954,180 |
| Other long-term liabilities | 1,500,875 | 335,828 |
| Note payable, stockholder | 26,523,099 | ... |
| Deferred tax liability | 12,111,812 | 13,948,419 |
| Total liabilities | ... | 157,068,480 |
| Redeemable noncontrolling interest | 15,638,013 | 15,713,021 |
| Class A common stock | 1,056 | 28,651 |
| Class B common stock | 30,256 | 1,056 |
| Additional paid-in capital | 522,506,626 | 483,917,938 |
| Retained earnings (accumulated deficit) | 15,669,488 | 19,579,645 |
| Total Boston Omaha Corp. stockholders' equity | 538,207,426 | 503,527,290 |
| (deficit) | 62,606,822 | 7,409,068 |
| Noncontrolling interests | ... | ... |

Total equity (deficit) 600,814,248 510,936,358

Recent Dividends:

1. Boston Omaha Corp class B common.
No dividends paid.

2. Boston Omaha Corp class A common.
No dividends paid.

Annual Dividends:

1. Boston Omaha Corp class B common.
No dividends paid.

2. Boston Omaha Corp class A common.
No dividends paid.

BOSTON PROPERTIES L.P.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|-----------|-----------|----------------|
| Revenue - lease | 3,054,673 | 2,918,368 | 2,753,014 |
| Revenue - parking & other | 112,918 | 107,225 | 81,814 |
| Revenue - hotel | ... | 39,482 | 13,609 |
| Revenue - development & management services | 40,850 | 15,450 | 12,487 |
| Revenue - direct reimbursements of payroll & related costs from management services contracts | 17,771 | 28,056 | 27,697 |
| Hotel Revenue | 47,357 | ... | ... |
| Total revenue | 3,273,569 | 3,108,581 | 2,888,621 |
| Operating expenses - rental | ... | 1,108,070 | 1,021,151 |
| Operating expenses - hotel | ... | 27,478 | 12,998 |
| General & administrative expenses | 170,158 | 146,378 | 151,573 |
| Payroll & related costs from management services contracts | 17,771 | 15,450 | 12,487 |
| Transaction costs | 4,313 | 2,905 | 5,036 |
| Depreciation & amortization expenses | 823,805 | 742,293 | 709,035 |
| Total expenses | 2,232,219 | 2,042,574 | 1,912,280 |
| Income (loss) from unconsolidated joint ventures | (239,543) | (59,840) | (2,570) |
| Gains on sales of real estate | ... | 441,075 | 125,198 |
| Gain on sales-type lease | 5,556 | 10,058 | ... |
| Interest & other income (loss) | 69,964 | 11,940 | 5,704 |
| Other income - assignment fee | ... | 6,624 | ... |
| Gains (losses) from investments in securities | ... | (6,453) | 5,626 |
| Unrealized gain (loss) on non-real estate investment | 239 | (150) | ... |
| Gains (losses) from early extinguishment of debt | ... | ... | (45,182) |
| Interest expense | 579,572 | 437,139 | 423,346 |
| Net income | 298,432 | 1,032,122 | 641,771 |
| Net income (loss) attributable to noncontrolling interests - noncontrolling interests in property partnerships | (78,661) | (74,857) | (70,806) |
| Preferred distributions | ... | ... | (2,560) |
| Preferred unit | ... | ... | ... |

[□] Restated to reflect correction of errors; [□] Reclassified to conform with 2022 presentation; [□] As of March 1, 2022; [□] Approximate

| | | | | |
|---|-----------|---------|---------|--|
| redemption charge | ... | ... | (6,412) | |
| Net income attributable to Boston Properties Limited Partnership common unitholders | 957,265 | 561,993 | | |
| Weighted average units outstanding - basic | 174,796 | 174,360 | 173,150 | |
| Weighted average units outstanding - diluted | 175,134 | 174,771 | 173,410 | |
| Year end units outstanding | 155,186 | 156,758 | 156,545 | |
| Income per unit from continuing operations - basic | \$1.26 | ... | ... | |
| Net income per unit - basic | \$1.26 | \$5.48 | \$3.25 | |
| Income per unit from continuing operations - diluted | \$1.25 | ... | ... | |
| Net income per unit - diluted | \$1.25 | \$5.47 | \$3.24 | |
| Earnings Per Share After Allocation of Undistributed Earnings to Participating Securities Basic (dollars per share) | \$4.16 | ... | ... | |
| Distributions per common unit | ... | \$3.95 | \$3.92 | |
| Full-Time Employees (Period End) | 727 | ... | ... | |
| Total number of employees | 727 | □□780 | □□743 | |
| Number of common unitholders | 332 | □□329 | □□319 | |
| Rental | 1,183,947 | ... | ... | |
| Hotel operating | 32,225 | ... | ... | |
| Gains on sales of real estate | 517 | ... | ... | |
| Losses from interest rate contracts | (79) | ... | ... | |
| Comprehensive income attributable to the Company | 211,493 | ... | ... | |

□ As is; □ As of February 21, 2023; □ Approximately; □ As of February 14, 2022

| | | | |
|--|------------|------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000): | | | |
| | 2023 | 2022 | |
| Land | 5,156,515 | 5,095,102 | |
| Land held for future development | 697,061 | 721,501 | |
| Buildings & improvements | 16,336,200 | 15,547,919 | |
| Tenant improvements | 3,592,172 | 3,200,743 | |
| Furniture, fixtures & equipment | 53,716 | 50,310 | |
| Construction in progress | 547,280 | 406,574 | |
| Real estate, at cost | 401,680 | ... | |
| Right of use assets - finance leases | 20,350,561 | □237,510 | |
| Right of use assets - operating leases | 324,298 | 167,351 | |
| Less: accumulated depreciation | 6,758,361 | □6,180,474 | |
| Total real estate | ... | 19,246,536 | |
| Cash & cash equivalents | 1,531,477 | □690,333 | |
| Cash held in escrows | 81,090 | 46,479 | |
| Investment in securities | 36,337 | 32,277 | |
| Tenant & other receivables | 150,394 | ... | |
| Less: allowance for doubtful accounts | 27,987 | ... | |
| Accrued Rental Income - Balancing value | 1,756,371 | ... | |
| Tenant & other receivables, net | 122,407 | □81,389 | |

| | | | |
|--|------------|------------|--|
| Related party note receivable, net | ... | 78,576 | |
| Notes receivable, net | 88,779 | ... | |
| Sales-type lease receivable, net | 13,704 | 12,811 | |
| Accrued rental income, net | 1,355,212 | □1,276,580 | |
| Leasing costs, including lease related intangibles | ... | 1,095,231 | |
| Deferred financing costs | ... | 19,311 | |
| Less: accumulated amortization | ... | (381,260) | |
| Deferred charges, net | 760,421 | □733,282 | |
| Prepaid expenses & other assets | 64,230 | □43,589 | |
| Investments in unconsolidated joint ventures | 1,377,319 | 1,715,911 | |
| Accrued Rental allowance | 401,159 | ... | |
| Note receivable | 1,714 | ... | |
| Total assets | 25,783,251 | 23,957,763 | |
| Mortgage notes payable, net | 4,166,379 | □3,272,368 | |
| Unsecured senior notes, net | 10,491,617 | 10,237,968 | |
| Unsecured term loan, net | 1,198,301 | 730,000 | |
| Lease liabilities - finance leases | 8,383 | □249,335 | |
| Lease liabilities - operating leases | 350,391 | 204,686 | |
| Accounts payable & accrued expenses | 458,329 | □417,545 | |
| Dividends & distributions payable | 171,176 | 170,643 | |
| Accrued interest payable | 133,684 | 103,774 | |
| Other liabilities | 445,947 | □450,918 | |
| Lease liabilities - finance leases | 417,961 | ... | |
| Total liabilities | ... | 15,837,237 | |
| Redeemable deferred stock units | ... | 6,613 | |
| Noncontrolling interests - redeemable partnership units - common units & long term incentive units | 1,347,575 | 1,280,886 | |
| Boston Properties Limited Partnership partners' capital | 4,973,951 | 5,299,428 | |
| Accumulated other comprehensive income (loss) | (21,147) | (13,718) | |
| Total partners' capital | 4,952,804 | 5,285,710 | |
| Noncontrolling interests in property partnerships | 1,640,704 | 1,547,317 | |
| Total capital | 6,593,508 | 6,833,027 | |

□ Amounts related to variable interest entities ("VIEs") - right of use assets - finance leases: \$21,000,000; □ Amounts related to variable interest entities ("VIEs") - less: accumulated depreciation: (\$1,381,401,000); □ Amounts related to variable interest entities ("VIEs") - cash and cash equivalents: \$259,658,000; □ Amounts related to variable interest entities ("VIEs") - tenant and other receivables, net: \$16,521,000; □ Amounts related to variable interest entities ("VIEs") - accrued rental income, net: \$367,138,000; □ Amounts related to variable interest entities ("VIEs") - deferred charges, net: \$176,597,000; □ Amounts related to variable interest entities ("VIEs") - prepaid expenses and other assets: \$11,647,000; □ Amounts related to variable interest entities ("VIEs") - mortgage notes payable, net: \$3,272,368,000; □ Amounts related to variable interest entities ("VIEs") - lease liabilities - finance leases: \$20,604,000; □ Amounts related to variable interest entities ("VIEs") - accounts payable and accrued expenses: \$29,466,000; □ Amounts related to variable interest entities ("VIEs") - other liabilities: \$114,232,000

Recent Dividends:

1. **Boston Properties L.P. limited partner.**
No dividends paid.
2. **Boston Properties L.P. 5.25% series B cumulative redeemable preferred.**
No dividends paid.
3. **Boston Properties L.P. general partner.**
No dividends paid.

No dividends paid.

Annual Dividends:

1. **Boston Properties L.P. limited partner.**
No dividends paid.
2. **Boston Properties L.P. 5.25% series B cumulative redeemable preferred.**
No dividends paid.
3. **Boston Properties L.P. general partner.**
No dividends paid.

BRAINSTORM CELL THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$'000):

| | 2023 | 2022 | □2021 (revised) |
|--|----------|----------|-----------------|
| Research & development | 10,746 | 14,156 | 15,940 |
| Less: participation by the Israel Innovation Authorities | ... | ... | (141) |
| Less: participation by other grants | ... | (200) | (564) |
| Research & development, net | ... | 13,956 | 15,235 |
| General & administrative | 10,693 | 10,866 | 9,304 |
| Operating income (loss) | (21,439) | (24,822) | (24,539) |
| Financial income (expense), net | ... | 545 | 82 |
| Income (loss) from continuing operations before income taxes - United States | ... | (9,989) | (8,357) |
| Income (loss) from continuing operations before income taxes - Israel | ... | (14,288) | (16,100) |
| Income (loss) from continuing operations before income taxes | (17,192) | ... | ... |
| Net income (loss) | (17,192) | (24,277) | (24,457) |
| Weighted average shares outstanding - basic | 43,076 | 36,509 | 36,182 |
| Weighted average shares outstanding - diluted | 43,076 | 36,509 | 36,182 |
| Year end shares outstanding | 60,489 | 36,694 | 36,401 |
| Net income (loss) per share - basic | \$(0.40) | \$(0.66) | \$(0.68) |
| Net income (loss) per share - diluted | \$(0.40) | \$(0.66) | \$(0.68) |
| Number of full time employees | 29 | □43 | □43 |
| Total number of employees | 29 | □43 | □43 |
| Number of common stockholders | 30 | □□30 | □□30 |
| Earnings per share from continuing operations | \$(0.40) | ... | ... |
| Earnings per share from continuing operations | \$(0.40) | ... | ... |
| Financial expense (income), net | (447) | ... | ... |
| Gain on change in fair value of Warrants liability | 4,694 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ As is; □

Approximately; □ As of March 21, 2023; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$'000):

| | 2023 | 2022 |
|-----------------------------------|-------|-------|
| Cash & cash equivalents | 1,300 | 772 |
| Short-term deposit | ... | 2,211 |

| | | | | | | | |
|--|--------------------|------------------|--|---|---|---------------------|--------------------|
| 2023 | 2022 | 2021 | No dividends paid. | | Due to sponsor | 7,814,506 | 5,480,941 |
| General & administrative expense | 18,071 | 8,793 | 9,436 | Annual Dividends: | Warrant liabilities | 2,200,250 | 1,184,750 |
| Professional fees | 158,974 | 44,265 | 43,203 | 1. Bravo Multinational Inc series A preferred. | Total liabilities | 10,277,665 | 6,735,280 |
| Board of directors fees | 250,000 | 475,000 | 475,000 | No dividends paid. | Common stock subject to possible redemption | 12,647,701 | 17,730,156 |
| Total expenses | 427,045 | 528,058 | 527,639 | 2. Bravo Multinational Inc common. | Common stock | 315 | 315 |
| Income (loss) from operations | ... | (528,058) | (527,639) | No dividends paid. | Accumulated deficit | (9,682,008) | ... |
| Interest expense | ... | ... | 350 | BREEZE HOLDINGS ACQUISITION CORP | Retained earnings (accumulated deficit) | ... | (6,532,077) |
| Loss (gain) on loan payable forgiveness & write off | ... | ... | (11,940) | Annual Report | Total stockholders' equity (deficit) | (9,681,693) | (6,531,762) |
| Loss (gain) on write off of account payable | ... | ... | (95,923) | Consolidated Income Statement, Years Ended Dec. 31 (\$): | Total Equity | (9,681,693) | ... |
| Goodwill Impairment | 4,420,100 | ... | ... | 2023 | 2022 | 2021 | |
| Total other income (expenses), net | ... | ... | 107,513 | Operating & formation costs | 2,070,143 | 2,323,153 | 1,722,364 |
| Income (loss) before income taxes | (4,847,145) | (528,058) | (420,126) | Income (loss) from operations | (2,070,143) | (2,323,153) | (1,722,364) |
| Net income (loss) | (4,847,145) | (528,058) | (420,126) | Interest income | 554,701 | 813 | 764 |
| Weighted average shares outstanding | 49,084,847 | 47,641,010 | 47,641,010 | Unrealized gain on marketable securities held in trust account | ... | 188,903 | 47,076 |
| - basic | 49,084,847 | 47,641,010 | 47,641,010 | Change in fair value of warrant liabilities | (1,015,500) | 5,923,750 | 10,378,500 |
| Weighted average shares outstanding - diluted | 49,084,847 | 47,641,010 | 47,641,010 | Total other income (expenses), net | (460,799) | 6,113,466 | 10,426,340 |
| Year end shares outstanding | 47,641,010 | 47,641,010 | 47,641,010 | Income before income taxes | (2,530,942) | 3,790,313 | 8,703,976 |
| Net income (loss) per share - basic | \$(0.10) | \$(0.01) | \$(0.01) | Current federal income tax provision | 18,169 | 2,089 | ... |
| Net income (loss) per share - diluted | \$(0.10) | \$(0.01) | \$(0.01) | Deferred federal income tax provision | 226,958 | (284,667) | (267,403) |
| Number of common stockholders | 132 | 122 | 122 | Change in valuation allowance | ... | 284,667 | 267,403 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.10) | ... | ... | Income Taxes - Domestic - Deferred | (226,958) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.10) | ... | ... | Income tax expense | 18,169 | 2,089 | ... |
| Approximately | | | | Net income (loss) | (2,549,111) | 3,788,224 | 8,703,976 |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Weighted average shares outstanding | 4,427,788 | 9,294,000 | 14,631,082 |
| 2023 | 2022 | 2021 | outstanding | 4,427,788 | 9,294,000 | 14,631,082 | 4,427,788 |
| Cash & cash equivalents | 1,180 | 73 | Net earnings (loss) per share - basic | \$(0.58) | \$0.41 | \$0.59 | \$(0.58) |
| Accounts receivable, gross | 42,312 | 42,312 | Net earnings (loss) per share - diluted | \$(0.58) | \$0.41 | \$0.59 | \$(0.58) |
| Less: allowance for doubtful accounts | 42,312 | 42,312 | Total number of employees | ... | 4 | 4 | ... |
| Provision - Loan/Notes | 418,000 | ... | Number of common stockholders | 10 | 10 | 10 | ... |
| Receivables | 418,000 | ... | Reclassified to conform with 2022 presentation; Shares decreased due to the effect of redemption of common stock; As of February 15, 2023; As of February 15, 2022 | | | | |
| Notes Receivable - Related Party - Gross | 418,000 | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | |
| Total current assets | 1,180 | 73 | 2023 | 2022 | 2021 | | |
| Total assets | 1,180 | 73 | Cash in Hand & with Banks | 4,228 | ... | ... | ... |
| Accounts payable & accrued expenses | 12,453 | 750 | Cash | ... | 14,129 | ... | ... |
| Customer deposits | 35,800 | 35,800 | Due from sponsor | 18,672 | 18,073 | ... | ... |
| Due to related parties | ... | 193,570 | Prepaid income taxes | 36,742 | ... | ... | ... |
| Notes payable | 154,280 | ... | Prepaid expenses | 148,953 | 160,503 | ... | ... |
| Payroll liabilities | 100 | ... | Prepayment - franchise taxes | 57,550 | 10,000 | ... | ... |
| Accrued board of directors fees | 207,250 | 1,537,417 | Total current assets | 266,145 | 202,705 | ... | ... |
| Total liabilities | ... | 1,767,537 | Cash & marketable securities held in trust account | ... | 17,730,969 | ... | ... |
| Respectively | 4,763 | ... | Cash held in Trust | 12,977,528 | ... | ... | ... |
| Common stock | ... | 4,763 | Account | 13,243,673 | 17,933,674 | ... | ... |
| Additional paid-in-capital | 95,374,299 | 89,168,493 | Total assets | ... | ... | ... | ... |
| Accumulated Deficit | (95,787,765) | ... | Accounts payable & accrued expenses | ... | 67,500 | ... | ... |
| Retained earnings (accumulated deficit) | ... | (90,940,720) | Franchise tax payable | 56,270 | ... | ... | ... |
| Total stockholders' equity (deficit) | (408,703) | (1,767,464) | Income tax payable | ... | 2,089 | ... | ... |
| Total Equity | (408,703) | ... | Common stock payable | 206,639 | ... | ... | ... |
| | | | Total current liabilities | 8,077,415 | 5,550,530 | ... | ... |
| Recent Dividends: | | | | | | | |
| 1. Bravo Multinational Inc series A preferred. | | | | | | | |
| No dividends paid. | | | | | | | |
| 2. Bravo Multinational Inc common. | | | | | | | |
| No dividends paid. | | | | | | | |
| BREEZE HOLDINGS ACQUISITION CORP | | | | | | | |
| Annual Report | | | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| 2023 | 2022 | 2021 | | | | | |
| Operating & formation costs | 2,070,143 | 2,323,153 | 1,722,364 | Revenues | 66,708,000 | 46,388,000 | ... |
| Income (loss) from operations | (2,070,143) | (2,323,153) | (1,722,364) | Revenues | 66,708,000 | 46,388,000 | 39,384,182 |
| Interest income | 554,701 | 813 | 764 | Flight operations | 24,412,000 | 18,762,000 | 15,823,713 |
| Unrealized gain on marketable securities held in trust account | ... | 188,903 | 47,076 | Maintenance | 16,928,000 | 15,124,000 | 10,755,471 |
| Change in fair value of warrant liabilities | (1,015,500) | 5,923,750 | 10,378,500 | Total cost of revenues | 41,340,000 | 33,886,000 | 26,579,184 |
| Total other income (expenses), net | (460,799) | 6,113,466 | 10,426,340 | Gross profit | 25,368,000 | 12,502,000 | 12,804,998 |
| Income before income taxes | (2,530,942) | 3,790,313 | 8,703,976 | General & administrative | ... | ... | 10,849,400 |
| Current federal income tax provision | 18,169 | 2,089 | ... | Selling, general & administrative expense | 82,863,000 | 35,128,000 | ... |
| Deferred federal income tax provision | 226,958 | (284,667) | (267,403) | Business development | ... | ... | 365,627 |
| Change in valuation allowance | ... | 284,667 | 267,403 | Total operating expenses | ... | ... | 11,215,027 |
| Income Taxes - Domestic - Deferred | (226,958) | ... | ... | Operating income (loss) | (57,495,000) | (22,626,000) | 1,589,971 |
| Income tax expense | 18,169 | 2,089 | ... | Interest expense | 23,218,000 | 20,020,000 | 9,293,928 |
| Net income (loss) | (2,549,111) | 3,788,224 | 8,703,976 | Other income | 3,053,000 | 521,000 | 1,163,160 |
| Weighted average shares outstanding | 4,427,788 | 9,294,000 | 14,631,082 | Series A Preferred Stock adjustment for deemed dividend upon Closing | 48,300,000 | ... | ... |
| - basic | 4,427,788 | 9,294,000 | 14,631,082 | Net income (loss) | (77,358,000) | (42,125,000) | (6,540,797) |
| Weighted average shares outstanding - diluted | 4,427,788 | 9,294,000 | 14,631,082 | Liquidation preference on series A Preferred shares | ... | ... | 15,913,184 |
| Year end shares outstanding | 4,299,276 | 4,830,196 | 14,640,000 | Series C Preferred shares adjustment to maximum redemption value | 22,181,000 | 202,689,000 | ... |
| Net earnings (loss) per share - basic | \$(0.58) | \$0.41 | \$0.59 | Series A Preferred shares adjustment for redemption, extinguishment, & accrued interest | (156,363,000) | 85,663,000 | ... |
| Net earnings (loss) per share - diluted | \$(0.58) | \$0.41 | \$0.59 | Net income (loss) attributable to common shareholders | 8,524,000 | (330,477,000) | (22,453,981) |
| Total number of employees | ... | 4 | 4 | Weighted average shares outstanding | 45,269,201 | 40,287,478 | 40,122,651 |
| Number of common stockholders | 10 | 10 | 10 | - basic | 45,269,201 | 40,287,478 | 40,122,651 |
| Reclassified to conform with 2022 presentation; Shares decreased due to the effect of redemption of common stock; As of February 15, 2023; As of February 15, 2022 | | | | Weighted average shares outstanding - diluted | 78,908,017 | 40,287,478 | 40,122,651 |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Year end shares outstanding | 44,776,926 | 39,081,744 | 40,606,062 |
| 2023 | 2022 | 2021 | | Net income (loss) per share - basic | \$0.19 | \$(8.20) | \$(0.56) |
| Cash in Hand & with Banks | 4,228 | ... | ... | Net income (loss) per share - diluted | \$0.11 | \$(8.20) | \$(0.56) |
| Cash | ... | 14,129 | ... | | | | |
| Due from sponsor | 18,672 | 18,073 | ... | | | | |
| Prepaid income taxes | 36,742 | ... | ... | | | | |
| Prepaid expenses | 148,953 | 160,503 | ... | | | | |
| Prepayment - franchise taxes | 57,550 | 10,000 | ... | | | | |
| Total current assets | 266,145 | 202,705 | ... | | | | |
| Cash & marketable securities held in trust account | ... | 17,730,969 | ... | | | | |
| Cash held in Trust | 12,977,528 | ... | ... | | | | |
| Account | 13,243,673 | 17,933,674 | ... | | | | |
| Total assets | ... | ... | ... | | | | |
| Accounts payable & accrued expenses | ... | 67,500 | ... | | | | |
| Franchise tax payable | 56,270 | ... | ... | | | | |
| Income tax payable | ... | 2,089 | ... | | | | |
| Common stock payable | 206,639 | ... | ... | | | | |
| Total current liabilities | 8,077,415 | 5,550,530 | ... | | | | |

| | | | |
|---|--------------|--------------|-----|
| Number of full time employees | 148 | ... | 156 |
| Number of part time employees | ... | ... | 6 |
| Total number of employees | 148 | ... | ... |
| Number of common stockholders | 24 | ... | ... |
| Income from cont operations before income tax | (77,660,000) | (42,125,000) | ... |
| S. Federal | (273,000) | ... | ... |
| State and local | (69,000) | ... | ... |
| Total deferred tax benefit | (342,000) | ... | ... |
| Income Taxes - Local & State-Current | 40,000 | ... | ... |
| Income Taxes - Total - Current | 40,000 | ... | ... |
| Income tax benefit | (302,000) | ... | ... |

Restated to reflect correction of errors; December 31, 2021 and prior periods for Bridger Aerospace Group Holdings, LLC; As of October 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|-------------|----------------|
| Cash & cash equivalents | 22,956,000 | 30,163,000 |
| Restricted cash | 13,981,000 | 12,297,000 |
| Investments in marketable securities | 1,009,000 | 54,980,000 |
| Trade accounts receivable | 681,000 | 29,000 |
| Other receivables | 3,000,000 | 29,000 |
| Accounts receivable | 4,113,000 | ... |
| Aircraft support parts | 488,000 | 1,761,000 |
| Prepaid insurance | 1,324,000 | 969,000 |
| Prepaid subscriptions | 1,115,000 | 771,000 |
| Other current assets | 89,000 | 30,000 |
| Prepaid expenses & other current assets | 2,648,000 | 1,835,000 |
| Deferred offering costs | ... | 5,800,000 |
| Other receivables | 432,000 | ... |
| Deposits | 120,000 | 65,000 |
| Total current assets | 45,195,000 | 106,865,000 |
| Aircraft | 186,167,000 | ... |
| Less: accumulated depreciation | 25,656,000 | 1,705,000 |
| Aircraft | 160,511,000 | 160,113,000 |
| Buildings | 35,941,000 | 16,519,000 |
| Vehicles & equipment | 2,993,000 | 2,811,000 |
| Finance lease right-of-use-asset | 121,000 | 130,000 |
| Less: accumulated depreciation | 3,195,000 | 16,783,000 |
| Buildings & equipment, net | 36,100,000 | ... |
| Property, plant and equipment, gross | ... | 13,780,000 |
| Construction In Progress | ... | 235,000 |
| Licenses - Gross | 235,000 | 235,000 |
| Aircraft - Net | ... | 143,330,000 |
| Construction in Progress - Gross | 5,000 | 16,992,000 |
| Property, plant & equipment, net | 196,611,000 | 192,092,000 |
| Intangible assets, net | 1,730,000 | 208,000 |
| Goodwill | 13,163,000 | 2,458,000 |
| Other noncurrent assets | 16,771,000 | 4,356,000 |
| Investment in overwatch | 1,000,000 | 1,000,000 |
| Prepaid Subscriptions | 2,877,000 | 1,246,000 |
| Operating lease right-of-use asset | 7,777,000 | 671,000 |
| Interest rate swap | 1,117,000 | 1,407,000 |
| Investments in MAB Funding LLC | 4,000,000 | ... |
| Other assets | ... | 32,000 |
| Total assets | 273,470,000 | 305,979,000 |
| Accounts payable | 3,978,000 | 3,170,000 |
| Accrued expenses & other current liabilities | 17,146,000 | 18,647,000 |
| Operating right-of-use current liability | 2,153,000 | 21,000 |
| Current portion of | ... | ... |

| | | |
|--|---------------|---------------|
| long-term debt | 2,099,000 | 2,446,000 |
| Finance lease right of use liabilities | 22,000 | 23,000 |
| Accrued expenses and other current liabilities - Balancing value | 17,168,000 | 18,670,000 |
| Total current liabilities | 25,398,000 | 24,307,000 |
| Operating right-of-use noncurrent liability | 5,779,000 | 755,000 |
| Long-term debt, net | 204,585,000 | 205,471,000 |
| Long-term accrued expenses and other noncurrent liabilities - Balancing value | 10,777,000 | 46,000 |
| Total liabilities | 246,539,000 | 230,579,000 |
| Retained earnings (accumulated deficit) | (413,672,000) | (415,304,000) |
| Accumulated other comprehensive income (loss) | 987,000 | 1,678,000 |
| Common Stock | 5,000 | 4,000 |
| Series A Preferred Stock, \$00001 par value; 315,789473684 shares authorized, issued and outstanding at 30, 2023 | 354,840,000 | 489,022,000 |
| Additional paid-in capital | 84,771,000 | ... |
| Total members' equity (deficit) | 26,931,000 | 75,400,000 |
| Total Equity | 26,931,000 | 75,400,000 |

Restated to reflect correction of errors

Recent Dividends:

- Bridger Aerospace Group Holdings Inc series C preferred.**
No dividends paid.
 - Bridger Aerospace Group Holdings Inc series A preferred.**
No dividends paid.
 - Bridger Aerospace Group Holdings Inc common.**
No dividends paid.
- Annual Dividends:**
- Bridger Aerospace Group Holdings Inc series C preferred.**
No dividends paid.
 - Bridger Aerospace Group Holdings Inc series A preferred.**
No dividends paid.
 - Bridger Aerospace Group Holdings Inc common.**
No dividends paid.

BRIGHT MOUNTAIN MEDIA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|-------------|----------------|
| Revenue - advertising | ... | 19,580,000 | 12,925,000 |
| Revenue | 44,546,000 | ... | ... |
| Total revenue | 44,546,000 | ... | ... |
| Cost of revenue | 31,766,000 | ... | ... |
| Cost of revenue - advertising | ... | 10,493,000 | 6,350,000 |
| Gross margin | 12,780,000 | 9,087,000 | 6,575,000 |
| General & administrative expenses | 22,522,000 | 14,249,000 | 18,482,000 |
| Impairment expense - goodwill | 17,070,000 | ... | ... |
| Total operating expenses | ... | 14,249,000 | 18,482,000 |
| Income (loss) from operations | (26,812,000) | (5,162,000) | (11,907,000) |
| Other interest expense | 9,142,000 | 14,000 | 82,000 |
| Gain on forgiveness of PPP loan | ... | 1,137,000 | 2,172,000 |
| Other income | 437,000 | 163,000 | 2,000 |
| Interest expense | ... | 3,042,000 | 1,600,000 |
| Amortization | ... | 1,185,000 | 563,000 |
| Interest expense - centre lane senior secured credit | ... | ... | ... |

| | | | |
|---|--------------|-------------|--------------|
| facility- related party | ... | 4,227,000 | 2,163,000 |
| Interest expense - convertible promissory notes - related party | 20,000 | 22,000 | 22,000 |
| Amortization of debt discount | (27,000) | ... | ... |
| Total other income (expense) | (8,752,000) | ... | ... |
| Income (loss) before income tax - United States | (35,806,000) | (7,596,000) | (11,002,000) |
| Income (loss) before income tax - Foreign | 242,000 | (529,000) | (998,000) |
| Net income (loss) before income tax | ... | (8,125,000) | (12,000,000) |
| Total financing income (expense) | ... | (2,963,000) | (93,000) |
| Net income (loss) before tax | (35,564,000) | ... | ... |
| Net income (loss) | (35,564,000) | (8,125,000) | (12,000,000) |
| Common stock deemed dividend | ... | ... | 212,000 |
| Preferred stock dividends | ... | 5,000 | 242,000 |
| Net income (loss) attributable to common shareholders | (35,564,000) | (8,130,000) | (12,454,000) |

| | | | |
|---|-------------|-------------|-------------|
| Weighted average shares outstanding - basic | 164,845,671 | 149,191,057 | 128,163,616 |
| Weighted average shares outstanding - diluted | 164,845,671 | 149,191,057 | 128,163,616 |
| Year end shares outstanding | 171,277,959 | 149,619,461 | 148,985,208 |

Restated to reflect correction of errors

| | | | |
|---|----------|----------|----------|
| Net earnings (loss) for continuing operations per share - basic | \$(0.22) | ... | ... |
| Net earnings (loss) per share - basic | \$(0.22) | \$(0.05) | \$(0.10) |
| Net earnings (loss) for continuing operations per share - diluted | \$(0.22) | ... | ... |
| Net earnings (loss) per share - diluted | \$(0.22) | \$(0.05) | \$(0.10) |

| | | | |
|-------------------------------|-----|-----|-----|
| Number of full time employees | 190 | ... | ... |
| Total number of employees | 190 | 57 | 66 |
| Number of common stockholders | 407 | 404 | 682 |

Reclassified to conform with 2022 presentation; Shares increased due to the effects of service rendered, exercise of stock options and warrants, debt financing, conversion of preferred stock, deemed dividends, and, acquisition agreement.; As of April 30, 2022; As of March 22, 2023; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-----------|
| Cash & cash equivalents | 4,001,000 | 316,000 |
| Accounts receivables, gross | 15,051,000 | 3,447,000 |
| Unbilled receivables | 14,679,000 | 724,000 |
| Less: allowance for doubtful accounts | 372,000 | 586,000 |
| Accounts receivable, net | ... | 3,585,000 |
| Prepaid insurance | ... | 1,000 |
| Prepaid consulting service agreements - spartan | 1,057,000 | 285,000 |
| Deposits | ... | 137,000 |
| Other prepaid expenses & other current assets | ... | 314,000 |
| Less: non-current other assets - Spartan | ... | (137,000) |
| Prepaid expenses & other current assets | ... | 600,000 |

| | | |
|--|--------------|--------------|
| Building & improvements | 281,598,000 | 300,699,000 |
| Intangible lease assets | 33,374,000 | 41,228,000 |
| Construction in progress | 5,462,000 | 4,231,000 |
| Less accumulated depreciation & amortization | 51,890,000 | 42,047,000 |
| real estate properties, net - Balancing value | ... | 373,047,000 |
| Total real estate properties, net | 325,191,000 | ... |
| Cash & cash equivalents | 9,779,000 | 12,356,000 |
| Restricted cash | 4,018,000 | 4,675,000 |
| Tenant and accounts receivable, net of allowance of \$92 and \$171, respectively | 1,918,000 | 1,874,000 |
| Account receivable | 2,112,000 | 2,039,000 |
| Less: allowance | 194,000 | 165,000 |
| Furniture and equipment | 1,711,000 | 1,711,000 |
| Straight-line rent receivable | 3,090,000 | ... |
| Other assets, net | 6,327,000 | 10,334,000 |
| Derivative assets | 796,000 | ... |
| Total assets | 351,119,000 | 402,286,000 |
| Class action settlement costs & expenses | 15,457,000 | 15,411,000 |
| Accounts payable & accrued liabilities | 2,372,000 | ... |
| Payables due to related parties | 63,000 | 44,000 |
| Accrued expenses | 5,781,000 | ... |
| Deferred revenue | 827,000 | 1,252,000 |
| Accrued interest | 1,213,000 | ... |
| Derivative Liabilities - Hedging - Short-Term | 668,000 | ... |
| Income Taxes - Payable - Short-Term | 340,000 | ... |
| Security Deposits | 2,340,000 | ... |
| Real estate tax payable | 1,222,000 | ... |
| Unamortized intangible lease liabilities, net | 633,000 | 1,553,000 |
| Deferred tax liabilities | ... | 3,968,000 |
| Mortgage & other indebtedness, net | 231,049,000 | 267,616,000 |
| Operating Lease Liabilities - Long-Term & Short-Term | 1,521,000 | ... |
| Common stock | 334,000 | 323,000 |
| Additional paid in capital | 55,186,000 | 72,097,000 |
| Accumulated deficit | (36,387,000) | (33,294,000) |
| Accumulated other comprehensive income | 547,000 | 56,000 |
| Total Broad Street Realty, Inc. stockholders' equity (deficit) | 19,680,000 | 39,182,000 |
| Noncontrolling interest | (3,878,000) | (437,000) |
| Total equity (deficit) | 15,802,000 | 38,745,000 |
| Redeemable noncontrolling Fortress preferred interest | 87,288,000 | 73,697,000 |

Recent Dividends:

- 1. Broad Street Realty Inc series A preferred.**
No dividends paid.
- 2. Broad Street Realty Inc series A preferred.**
No dividends paid.
- 3. Broad Street Realty Inc series C preferred.**
No dividends paid.
- 4. Broad Street Realty Inc common.**
No dividends paid.
- 5. Broad Street Realty Inc series B preferred.**
No dividends paid.

Annual Dividends:

- 1. Broad Street Realty Inc series A preferred.**
No dividends paid.
- 2. Broad Street Realty Inc series A preferred.**
No dividends paid.
- 3. Broad Street Realty Inc series C preferred.**
No dividends paid.
- 4. Broad Street Realty Inc common.**
No dividends paid.
- 5. Broad Street Realty Inc series B preferred.**

No dividends paid.

**BT BRANDS INC
Annual Report**

Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 01/01/23 | 01/02/22 (revised) |
|--|------------------|------------------|--------------------|
| Total revenues | 14,076,653 | ... | ... |
| Sales | 14,076,653 | 12,601,169 | 8,451,870 |
| Food & paper costs | 5,597,167 | 4,854,321 | 3,285,752 |
| Labor costs | 5,458,351 | 4,126,837 | 2,383,206 |
| Occupancy costs | 1,312,717 | 1,147,744 | 681,560 |
| Other operating expenses | 841,894 | 780,564 | 469,822 |
| Depreciation & amortization expenses | 598,540 | 449,038 | 234,027 |
| (Loss) gain on sale of property, plant & equipment | 310,182 | ... | ... |
| General & administrative expenses | 1,650,755 | 1,633,829 | 416,791 |
| Total costs & expenses | ... | 12,992,333 | 7,471,158 |
| Income (loss) from operations | (1,072,589) | (391,164) | 980,712 |
| Unrealized loss on marketable securities | ... | 86,422 | ... |
| Interest & dividend income | 300,923 | 125,529 | ... |
| Other income (expense) | 103,848 | (80,649) | ... |
| Equity in net earnings (loss) of affiliate | (347,081) | (194,813) | ... |
| Interest expense | 97,608 | 114,766 | 172,861 |
| Income (loss) before taxes | (1,032,368) | (742,285) | 807,851 |
| Current income tax expense | ... | ... | 199,000 |
| Deferred income tax expense (benefit) | (145,000) | (180,000) | 1,000 |
| Income tax expense (benefit) | (145,000) | (180,000) | 200,000 |
| Net income (loss) | (887,368) | (562,285) | 607,851 |
| Weighted average shares outstanding - basic | 6,261,631 | 6,458,810 | 4,382,848 |
| Weighted average shares outstanding - diluted | 6,261,631 | 6,458,810 | 4,382,848 |
| Year end shares outstanding | 6,246,118 | 6,396,118 | 6,477,506 |
| Net income (loss) per common share - basic | \$(0.14) | \$(0.09) | \$0.14 |
| Net income (loss) per common share - diluted | \$(0.14) | \$(0.09) | \$0.14 |
| Number of full time employees | 24 | 20 | 17 |
| Number of part time employees | 62 | 61 | 90 |
| Total number of employees | 86 | 81 | 107 |
| Number of common shareholders | 38 | 41 | 54 |
| UNREALIZED GAIN (LOSS) ON MARKETABLE SECURITIES | 80,139 | ... | ... |

¹ Shares increased due to issuance of of common stock and common stock purchase warrants; ² As of April 1, 2023; ³ Approximately; ⁴ As of April 9, 2023; ⁵ As of March 15, 2022

Consolidated Balance Sheet, Years Ended (\$):

| | 12/31/23 | 01/01/23 |
|---------------------------|-----------|-----------|
| Cash and cash equivalents | 5,300,446 | ... |
| Cash | ... | 2,150,578 |
| Marketable securities | 1,392,060 | 5,994,295 |
| Receivables | 28,737 | 76,948 |

| | | |
|---|-------------|-------------|
| Inventory | 201,333 | 158,351 |
| Prepaid expenses & other current assets | 47,246 | 37,397 |
| Assets held for sale | 258,751 | 446,524 |
| Total current assets | 7,228,573 | 8,864,093 |
| Land | 435,239 | 485,239 |
| Equipment | 3,994,685 | 3,893,274 |
| Buildings & leasehold improvements | ... | 2,402,157 |
| Buildings | 2,463,626 | ... |
| Total property & equipment | 6,893,550 | 6,780,670 |
| Accumulated depreciation | 3,387,786 | 3,039,500 |
| Less - property held for sale | (258,751) | (446,526) |
| Property, equipment & leasehold improvements, net | 3,247,013 | 3,294,644 |
| Operating lease right-of-use assets | 1,789,285 | 2,004,673 |
| Investments | 1,022,806 | 1,369,186 |
| Deferred income taxes | 206,000 | 61,000 |
| Goodwill | 671,220 | 671,220 |
| Intangible assets, net | 395,113 | 453,978 |
| Other assets, net | 49,202 | 50,903 |
| Total assets | 14,609,212 | 16,769,697 |
| Accounts payable | 555,247 | 448,605 |
| Broker margin loan | 115,899 | 791,370 |
| Current maturities of long-term debt | 183,329 | 167,616 |
| Current operating lease obligations | 215,326 | 193,430 |
| Accrued real estate taxes | 49,357 | 202,436 |
| Accrued bonus compensation | 119,139 | 59,139 |
| Accrued payroll | 149,587 | 143,481 |
| Accrued payroll taxes | 11,343 | 12,764 |
| Accrued sales taxes payable | 81,683 | 70,270 |
| Accrued vacation pay | 17,663 | 17,663 |
| Accrued gift card liability | 26,844 | 25,965 |
| Other accrued expenses | 24,673 | 802 |
| Accrued expenses | 480,289 | 532,520 |
| Total current liabilities | 1,550,090 | 2,133,541 |
| Secured notes payable | ... | 2,864,484 |
| Minnesota Small Business Emergency loan | ... | 3,208 |
| Total long-term debt | ... | 2,867,692 |
| Less - unamortized debt issuance costs | 2,269,771 | (41,599) |
| Less: current maturities | ... | 167,616 |
| Long-term debt, less current portion | ... | 2,658,477 |
| Noncurrent lease obligations | 1,600,622 | 1,825,057 |
| Total liabilities | 5,420,483 | 6,617,075 |
| Common stock | 12,492 | 12,792 |
| cost of Treasury shares | 357,107 | ... |
| Less cost of common shares held in treasury | ... | 106,882 |
| Additional paid-in capital | 11,583,235 | 11,409,235 |
| Accumulated deficit | (2,049,891) | ... |
| Retained earnings (accumulated deficit) | ... | (1,162,523) |
| Total shareholders' equity (deficit) | 9,188,729 | 10,152,622 |
| Total Equity | 9,188,729 | ... |

Recent Dividends:

- 1. BT Brands Inc common.**
No dividends paid.

Annual Dividends:

- 1. BT Brands Inc common.**
No dividends paid.

BTCS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|-------------------|-----------|----------------|----------------|
| Validator revenue | 1,339,628 | 1,692,454 | 1,213,284 |
| Total revenues | 1,339,628 | 1,692,454 | 1,213,284 |

| | | | |
|---|------------|-------------------------|--------------|
| Validator expense | 359,778 | 426,440 | 268,346 |
| Gross profit | 979,850 | 1,266,014 | 944,938 |
| General & administrative expenses | 1,863,916 | 1,916,193 | 1,590,707 |
| Research & development | 687,288 | 611,758 | 712,736 |
| Compensation & related expenses | 2,129,144 | 3,313,638 | 15,583,258 |
| Marketing expenses | 12,153 | 78,171 | 180,290 |
| Impairment loss on crypto assets | ... | 13,348,874 | 3,845,899 |
| Realized gains (losses) on crypto asset transactions | (604,269) | 506,757 | 3,054,418 |
| Total operating expenses | ... | 18,761,877 | 18,858,472 |
| Interest expense | ... | ... | 186,740 |
| Amortization on debt discount | ... | ... | 1,868,059 |
| Change in fair value of warrant liabilities | ... | 1,638,750 | 3,918,750 |
| Distributions to warrant holders | ... | (35,625) | ... |
| Realized gains (loss) on digital asset or currency transactions | 12,135,648 | ... | ... |
| Total other income (expenses) | ... | 1,603,125 | 1,863,951 |
| Profit (loss) before taxation & currency translation gain (loss) | 7,818,728 | ... | ... |
| Net income (loss) | 7,818,728 | (15,892,738) | (16,049,583) |
| Deemed dividends related to amortization of beneficial conversion feature of Series C-2 convertible preferred stock | ... | ... | 45,541 |
| Deemed dividends related to recognition of downround adjustment to conversion amount for Series C-2 convertible preferred stock | ... | ... | 5,020,883 |
| Net income (loss) attributable to common stockholders | ... | (15,892,738) | (21,116,007) |
| Weighted average shares outstanding - basic | 14,092,233 | 12,732,914 | 6,840,665 |
| Weighted average shares outstanding - diluted | 14,092,233 | 12,732,914 | 6,840,665 |
| Year end shares outstanding | 15,320,281 | 13,107,149 [Ⓐ] | 10,528,212 |
| Net income (loss) per share - basic | \$0.55 | \$(1.25) | \$(3.09) |
| Net income (loss) per share - diluted | \$0.55 | \$(1.25) | \$(3.09) |
| Number of full time employees | 5 | 5 | ... |
| Total number of employees | 5 | ... | 4 |
| Number of common stockholders | 177 | 180 | Ⓐ118 |
| Basic EPS Excluding ExtraOrdinary Items | \$0.55 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.55 | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Adjusted for 1-for-10 stock split, August 17, 2021; [Ⓒ] Shares increased due to the effect of common stock issued including equity commit-

ment fee, warrants, and conversion of convertible preferred stock, warrant exercise and stock-based compensation; [Ⓐ] As of March 9, 2021

| | | | |
|--|---------------|-----------------|-----|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | Ⓐ2022 (revised) | |
| Banks | 1,458,327 | 2,146,783 | ... |
| Crypto assets | 302,783 | 982 | ... |
| Staked crypto assets | 24,900,146 | 1,826,307 | ... |
| Prepaid expense | 62,461 | 123,727 | ... |
| Stablecoins | 21,044 | ... | ... |
| Receivable for capital shares sold | 291,440 | ... | ... |
| Total current assets | 27,036,201 | 4,097,799 | ... |
| Property & equipment, net | 10,490 | 11,152 | ... |
| Staked crypto assets | ... | 5,708,624 | ... |
| Investment | 100,000 | 100,000 | ... |
| Total other assets | 110,490 | 5,819,776 | ... |
| Total assets | 27,146,691 | 9,917,575 | ... |
| Accrued compensation | 712,092 | 295,935 | ... |
| Accounts payable & accrued expense | 55,058 | 76,727 | ... |
| Warrant liabilities | 213,750 | 213,750 | ... |
| Total current liabilities | 980,900 | 586,412 | ... |
| Common stock | 15,322 | 13,108 | ... |
| Additional paid in capital | 162,263,634 | 160,800,263 | ... |
| Retained earnings (accumulated deficit) | (138,677,103) | (151,482,208) | ... |
| Preferred Stock - Redeemable - Convertible | 2,563,938 | ... | ... |
| Total stockholders' equity (deficit) | 26,165,791 | 9,331,163 | ... |
| Total Equity | 26,165,791 | 9,331,163 | ... |

[Ⓐ] Reclassified to conform 2023 presentation

Recent Dividends:

1. BTCS Inc series C-1 convertible preferred.

No dividends paid.

2. BTCS Inc series V non-convertible preferred.

No dividends paid.

3. BTCS Inc series C convertible preferred.

No dividends paid.

4. BTCS Inc common.

No dividends paid.

5. BTCS Inc series B convertible preferred.

No dividends paid.

Annual Dividends:

1. BTCS Inc series C-1 convertible preferred.

No dividends paid.

2. BTCS Inc series V non-convertible preferred.

No dividends paid.

3. BTCS Inc series C convertible preferred.

No dividends paid.

4. BTCS Inc common.

No dividends paid.

5. BTCS Inc series B convertible preferred.

No dividends paid.

BULLFROG AI HOLDINGS INC

Annual Report

| | | | |
|---|-------------|-------------|-----------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | Ⓐ2021 (revised) |
| Revenues, net | 65,000 | 10,000 | ... |
| Total net revenues | 65,000 | 10,000 | ... |
| Cost of goods sold | ... | 800 | ... |
| Total cost of goods sold | 5,200 | 800 | ... |
| Gross profit | 59,800 | 9,200 | ... |
| Research & development expenses | 1,432,614 | 609,270 | 25,000 |
| General & administrative expenses | 3,994,710 | 1,307,882 | 327,329 |
| Payroll & salary | ... | 98,250 | ... |
| Payroll & salary - related party | ... | 449,599 | 203,033 |
| Total operating expenses | 5,427,324 | 2,465,001 | 555,362 |
| Income (loss) from operations | (5,367,524) | (2,455,801) | (555,362) |

| | | | |
|---|-------------|-------------|------------|
| Interest expense, net | 79,089 | 347,145 | 40,395 |
| Other income | 183,703 | 459 | 9,917 |
| Loss on conversion of notes | (92,959) | ... | ... |
| Total other income (expense) | 11,655 | (346,686) | (30,478) |
| Net income (loss) | (5,355,869) | (2,802,487) | (585,840) |
| Weighted average shares outstanding - basic | 6,049,819 | 4,009,852 | 4,116,336 |
| Weighted average shares outstanding - diluted | 6,049,819 | 4,009,852 | 4,116,336 |
| Year end shares outstanding | 6,094,644 | Ⓐ4,021,935 | 27,259,547 |
| Cost of goods sold | 5,200 | ... | ... |
| Net income (loss) per share - basic | \$(0.89) | \$(0.70) | \$(14.00) |
| Net income (loss) per share - diluted | \$(0.89) | \$(0.70) | \$(14.00) |
| Total number of employees | ... | Ⓐ4 | Ⓐ4 |
| Number of common stockholders | 17 | Ⓐ19 | ... |
| Income from cont operations before income tax | (5,355,869) | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Shares decreased due to the effect of shares cancellation; [Ⓒ] As of February 10, 2023; [Ⓓ] As of April 14, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2022 |
| Cash and cash equivalents | 2,624,730 | ... |
| Cash | ... | 57,670 |
| Prepaid expense | 145,882 | 15,000 |
| Total current assets | 2,770,612 | 72,670 |
| Accumulated depreciation | 2,770 | ... |
| Equipment | 8,744 | ... |
| Property & equipment net | 5,974 | 7,699 |
| Total non-current assets | ... | 7,699 |
| Total assets | 2,776,586 | 80,369 |
| Accounts payable | 103,656 | 543,993 |
| Accrued expenses | 80,694 | 416,072 |
| Accrued expenses - related party | ... | 566,916 |
| Deferred revenue | ... | 32,000 |
| Convertible notes, net | ... | 1,323,890 |
| Convertible notes - related party, net | ... | 254,850 |
| Total current liabilities | 184,350 | 3,137,721 |
| Total liabilities | ... | 3,137,721 |
| Series A preferred stock | ... | 1 |
| Common stock | 61 | 40 |
| Additional paid-in capital | 12,347,098 | 1,341,662 |
| Retained earnings (accumulated deficit) | (9,754,924) | (4,399,055) |
| Preferred Stock - Redeemable - Convertible | 1 | ... |
| Total Bullfrog AI Holdings, Inc. stockholders' equity (deficit) | 2,592,236 | (3,057,352) |
| Total stockholders' equity (deficit) | 2,592,236 | (3,057,352) |

Recent Dividends:

1. BullFrog AI Holdings Inc common.

No dividends paid.

2. BullFrog AI Holdings Inc series A non-voting convertible preferred.

No dividends paid.

Annual Dividends:

1. BullFrog AI Holdings Inc common.

No dividends paid.

2. BullFrog AI Holdings Inc series A non-voting convertible preferred.

No dividends paid.

BUZZFEED INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|---------------|--------------|
| Cost of revenue | 142,366,000 | 194,348,000 | ... |
| Revenue | 252,677,000 | 342,554,000 | ... |
| Revenue | 252,677,000 | 342,554,000 | 397,564,000 |
| Cost of revenue, excluding depreciation & amortization | ... | ... | 207,397,000 |
| Sales & marketing | 38,989,000 | 47,293,000 | 54,981,000 |
| General & administrative expenses | 78,026,000 | 111,437,000 | 112,552,000 |
| Research & development | 11,179,000 | 27,100,000 | 24,928,000 |
| Depreciation & amortization | 21,941,000 | 24,263,000 | 22,860,000 |
| Impairment expense | ... | 66,464,000 | ... |
| Total costs & expenses | 292,501,000 | 470,905,000 | 422,718,000 |
| Income (loss) from operations | (39,824,000) | (128,351,000) | (25,154,000) |
| Other income (expense), net | (2,990,000) | (3,076,000) | (3,974,000) |
| Interest income (expense), net | (16,085,000) | (15,591,000) | (2,885,000) |
| Change in fair value of warrant liabilities | ... | ... | 4,740,000 |
| Change in fair value of derivative liability | 180,000 | 4,695,000 | 26,745,000 |
| Income (loss) before income taxes - domestic | (63,874,000) | (131,717,000) | (301,000) |
| Income (loss) before income taxes - foreign | 5,144,000 | (6,063,000) | (227,000) |
| Income (loss) before income taxes | (58,730,000) | (137,780,000) | (528,000) |
| Current tax provision (benefit) - federal | ... | 2,000 | (16,000) |
| Current tax provision - state | 92,000 | 77,000 | 112,000 |
| Current tax provision (benefit) - foreign | (1,689,000) | 2,756,000 | 1,666,000 |
| Total current tax provision | (1,597,000) | 2,835,000 | 1,762,000 |
| Deferred tax provision (benefit) - federal | 3,000 | 733,000 | (23,020,000) |
| Deferred tax provision (benefit) - state | (4,000) | 197,000 | (2,682,000) |
| Deferred tax provision (benefit) - foreign | 3,200,000 | (1,062,000) | (2,464,000) |
| Total deferred tax provision (benefit) | 3,199,000 | (132,000) | (28,166,000) |
| Income tax provision (benefit) | 1,602,000 | 2,703,000 | (26,404,000) |
| Net income (loss) | (89,322,000) | (201,326,000) | 25,876,000 |
| Net income attributable to the redeemable noncontrolling interest | ... | (164,000) | (936,000) |
| Net income attributable to noncontrolling interests | 743,000 | 533,000 | (228,000) |
| Net income (loss) attributable to BuzzFeed, Inc. | (88,579,000) | (200,957,000) | 24,712,000 |
| Weighted average shares outstanding - basic | 143,062,000 | 138,148,000 | 27,048,000 |
| Weighted average shares outstanding - diluted | 143,062,000 | 138,148,000 | 28,001,000 |

| Year end shares outstanding | 145,612,000 | 139,543,000 | 135,050,000 |
|--|--------------|---------------|-------------|
| Net income (loss) per share - basic | \$(0.62) | \$(1.45) | ... |
| Net income (loss) per share - diluted | \$(0.62) | \$(1.45) | \$(0.03) |
| Full-Time Employees (Period End) | 925 | ... | ... |
| Total number of employees | 925 | ... | 1,522 |
| Number of class A common stockholders | ... | ... | 306 |
| Number of class B common stockholders | ... | ... | 25 |
| Number of class C common stockholders | ... | ... | 1 |
| Number of class F common stockholders | 266 | ... | ... |
| Income from continuing operations | (60,332,000) | (140,483,000) | ... |
| (Loss) gain on investments | (11,000) | 4,543,000 | ... |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.42) | \$(1.01) | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.42) | \$(1.01) | ... |
| Discontinued Operations before Tax - Income/Expense | (28,990,000) | (61,520,000) | ... |
| Discontinued Operations - Tax Impacts - Current Income/Expense | ... | 677,000 | ... |
| Discontinued Operations - Net - Income/Expense | (28,990,000) | ... | ... |
| Earn per share-inc from discount ops - diluted | \$(0.20) | \$(0.44) | ... |
| Earning per share-total discount ops - diluted | \$(0.20) | \$(0.44) | ... |
| Earnings per share-inc from discontinued oper | \$(0.20) | \$(0.44) | ... |
| Earnings per share-total discontinued ops | \$(0.20) | \$(0.44) | ... |
| Depreciation | ... | 10,200,000 | ... |
| Amortization | ... | 4,400,000 | ... |
| Amortization of Capitalized Software | ... | 9,663,000 | ... |

Restated to reflect discontinued operations; Reclassified to conform with 2022 presentation; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash & cash equivalents | 35,637,000 | 55,774,000 |
| Accounts receivable, gross | 77,116,000 | 118,339,000 |
| Allowance for doubtful accounts | 1,424,000 | 1,879,000 |
| Accounts receivable, net | 75,692,000 | 116,460,000 |
| Prepaid expenses & other current assets | 21,460,000 | 26,373,000 |
| Total current assets | 132,789,000 | 198,607,000 |
| Leasehold improvements | 49,007,000 | 50,688,000 |
| Furniture & fixtures | 3,910,000 | 6,069,000 |
| Computer equipment | 3,057,000 | 5,629,000 |
| Video equipment | 439,000 | 792,000 |
| Property & equipment, gross | 56,413,000 | 63,178,000 |
| Less: accumulated | ... | ... |

| | | |
|---|---------------|---------------|
| depreciation | 44,557,000 | 45,404,000 |
| Property & equipment, net | 11,856,000 | 17,774,000 |
| Right-of-use assets | 46,715,000 | 66,581,000 |
| Capitalized software costs, net | ... | 19,259,000 |
| Intangible assets, net | 26,665,000 | 121,329,000 |
| Goodwill | 57,562,000 | 91,632,000 |
| Prepaid expenses & other assets | 9,508,000 | 14,790,000 |
| Capitalized software costs, net | 22,292,000 | ... |
| Noncurrent assets of discontinued operations | 104,089,000 | ... |
| Total assets | 411,476,000 | 529,972,000 |
| Accounts payable | 46,378,000 | 29,329,000 |
| Accrued expenses | 15,515,000 | 26,357,000 |
| Deferred revenue | 1,895,000 | 8,836,000 |
| Accrued compensation | 12,970,000 | 31,052,000 |
| Current lease liabilities | 21,659,000 | 23,398,000 |
| Other current liabilities | 4,401,000 | 3,900,000 |
| Current debt | 124,977,000 | ... |
| Total current liabilities | 227,795,000 | 122,872,000 |
| Noncurrent lease liabilities | 37,820,000 | 59,315,000 |
| Debt | 33,837,000 | 152,253,000 |
| Derivative liability | ... | 180,000 |
| Warrant liabilities | 406,000 | 395,000 |
| Other liabilities | 435,000 | 403,000 |
| Total liabilities | 300,293,000 | 335,418,000 |
| Class A common stock | 14,000 | 13,000 |
| Class B common stock | ... | 1,000 |
| Class C common stock | 1,000 | 1,000 |
| Additional paid-in capital | 723,081,000 | 716,233,000 |
| Accumulated other comprehensive income (loss) | (2,500,000) | (1,968,000) |
| Accumulated deficit | (611,768,000) | ... |
| Retained earnings (accumulated deficit) | ... | (523,063,000) |
| Total BuzzFeed, Inc. stockholders' equity | 108,828,000 | 191,217,000 |
| Noncontrolling interests | 2,355,000 | 3,337,000 |
| Total stockholders' equity (deficit) | 111,183,000 | 194,554,000 |

Recent Dividends:

- 1. BuzzFeed Inc class F common. No dividends paid.
- 2. BuzzFeed Inc class B common. No dividends paid.
- 3. BuzzFeed Inc class A common. No dividends paid.

Annual Dividends:

- 1. BuzzFeed Inc class F common. No dividends paid.
- 2. BuzzFeed Inc class B common. No dividends paid.
- 3. BuzzFeed Inc class A common. No dividends paid.

BYRNA TECHNOLOGIES INC

Earnings, 3 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|------------|-------------|
| Total revenues | 16,654,000 | 8,411,000 |
| Cost & expenses | 16,818,000 | 10,405,000 |
| Operating income | (164,000) | (1,994,000) |
| Interest income | ... | 143,000 |
| Other income (expense), net | (41,000) | (225,000) |
| Foreign currency | (58,000) | (136,000) |
| Net before taxes | 17,000 | (2,212,000) |
| Income taxes | ... | (59,000) |
| Net income | 17,000 | (2,153,000) |
| Balance for common | ... | (2,153,000) |
| Earnings common share | ... | ... |
| Primary | ... | \$(0.10) |
| Fully Diluted | ... | \$(0.10) |
| Common Shares: | ... | ... |
| Full Diluted | 22,838,827 | 21,860,200 |
| Year-end | 22,209,767 | 21,866,261 |

Consolidated Balance Sheet Items, as of (\$):

| Assets: | 2024 |
|--------------------|------------|
| Cash & equivalents | 24,176,000 |

| | |
|-----------------------|------------|
| Inventories | 12,128,000 |
| Current assets | 38,971,000 |
| Net property & equip. | 3,591,000 |
| Total assets | 52,742,000 |
| Liabilities: | |
| Current liabilities | 8,367,000 |
| Stockholders' equity | 43,169,000 |
| Net current assets | 30,604,000 |

| | | | |
|--|----|-----|-----|
| Total number of employees | 20 | ... | ... |
| [¶] Reclassified to conform with 2022 presentation; [¶] Including stock-based compensation - Compensation & related benefits expenses: \$1,039,943; [¶] Including stock-based compensation - Compensation & related benefits expenses: \$4,085,868; [¶] Shares increased due to the effects of shares issued for conversion of accounts payable, compensation, professional fees, conversion of preferred stock, debt, and inducement to extend note payable; [¶] Approximately; [¶] As of March 30, 2023; [¶] As of April 14, 2022 | | | |

| | | |
|---|-------------|--------------|
| Retained earnings (accumulated deficit) | ... | (62,693,184) |
| Total C-Bond Systems, Inc. shareholders' equity (deficit) | (4,466,419) | (7,201,411) |
| Noncontrolling interest | 141,884 | 150,742 |
| Total shareholders' equity (deficit) | (4,324,535) | (7,050,669) |

C-BOND SYSTEMS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | [¶] 2021 (revised) |
|---|--------------------------|--------------------------|--------------------------------|
| Sales - third parties | 2,488,493 | 2,232,646 | 1,475,628 |
| Sales - related party | ... | ... | 1,200 |
| Total revenue | 2,488,493 | ... | ... |
| Total sales | ... | 2,232,646 | 1,476,828 |
| Cost of sales (excluding depreciation expense) | 1,180,979 | 954,402 | 657,298 |
| Gross profit (loss) | 1,307,514 | 1,278,244 | 819,530 |
| Compensation & related benefits | 2,036,514 | [¶] 2,844,783 | [¶] 6,165,006 |
| Research & development | ... | ... | (3,250) |
| Professional fees | 601,214 | 815,542 | 1,031,540 |
| General & administrative expenses | 666,090 | 810,413 | 636,353 |
| Gain on sale of product line | 4,051,709 | ... | ... |
| Total operating expenses | ... | 4,470,738 | 7,829,649 |
| Income (loss) from operations | 2,055,405 | (3,192,494) | (7,010,119) |
| Gain (loss) on debt extinguishment, net | 481,832 | ... | ... |
| Gain (loss) on debt extinguishment & inducement expense, net | ... | (343,895) | 96,442 |
| Other income | ... | ... | 67,778 |
| Settlement expense | 175,000 | ... | ... |
| Interest expense | 469,767 | 1,610,062 | 282,959 |
| Interest expense - related party | 5,663 | 10,027 | ... |
| Total other income (expenses), net | (168,598) | (1,963,984) | (118,739) |
| Net income (loss) before income taxes | 1,886,807 | ... | ... |
| Net income (loss) | 1,886,807 | (5,156,478) | (7,128,858) |
| Net income (loss) of subsidiary attributable to noncontrolling interest | 8,858 | 38,513 | (15,525) |
| Preferred stock dividend & deemed dividend | 54,195 | 60,090 | 4,401,907 |
| Net income (loss) attributable to common shareholders | 1,841,470 | (5,178,055) | (11,546,290) |
| Weighted average shares outstanding - basic | 490,113,378 | 308,121,062 | 254,299,139 |
| Weighted average shares outstanding - diluted | 490,113,378 | 308,121,062 | 254,299,139 |
| Year end shares outstanding | 532,818,051 [¶] | [¶] 350,270,172 | 282,216,632 |
| Net income (loss) per common share - basic | \$0.00 | \$(0.02) | \$(0.05) |
| Net income (loss) per common share - diluted | \$0.00 | \$(0.02) | \$(0.05) |
| Number of full time employees | 20 | 1 | 2 |
| Number of common stockholders | 213 | [¶] 213 | [¶] 211 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|------------|
| Cash | 736,461 | 97,091 |
| Accounts receivable, gross | 459,414 | 304,964 |
| Less: allowance for doubtful accounts | 35,323 | 35,522 |
| Accounts receivable, net | 424,091 | 269,442 |
| Raw materials | ... | 1,501 |
| Finished goods | 181,663 | 75,945 |
| Inventory | ... | 77,446 |
| Inventory | 181,663 | 77,446 |
| Prepaid expenses & other current assets | 28,503 | 71,171 |
| Contract assets | 2,400 | 279 |
| Total current assets | 1,373,118 | 515,429 |
| Machinery & equipment | 73,411 | 124,133 |
| Furniture & office equipment | 2,061 | 32,306 |
| Vehicles | 68,050 | 62,195 |
| Leasehold improvements | 110,645 | 45,296 |
| Property & equipment, gross | 254,167 | 263,930 |
| Less: accumulated depreciation | 82,561 | 167,624 |
| Property & equipment, net | 171,606 | 96,306 |
| Right of use asset, net | 158,484 | 375,412 |
| Intangible asset, net | 229,414 | 279,918 |
| Goodwill | 350,491 | 350,491 |
| Security deposit | ... | 6,482 |
| Total other assets | 909,995 | 1,108,609 |
| Total assets | 2,283,113 | 1,624,038 |
| Convertible notes payable, net of discount | 180,000 | 1,031,250 |
| Notes payable, net of discount | 81,908 | 1,576,438 |
| Accounts payable | ... | 779,765 |
| Accounts payable & accrued liabilities | 710,222 | ... |
| Accrued expenses | 474,515 | 736,393 |
| Accrued interest payable - related party | ... | 10,027 |
| Accrued compensation | 717,204 | 590,632 |
| Contract liabilities | 500,720 | 22,637 |
| Lease liability, current portion | 60,503 | 117,671 |
| Total current liabilities | 2,725,072 | 4,864,813 |
| Convertible notes payable, net of current portion & discount | 918,091 | 251,263 |
| Note payable, net of current portion & discount | ... | 208,804 |
| Note payable - related party | ... | 250,000 |
| Lease liability, net of current portion | 97,249 | 258,895 |
| Convertible note payable, net of discount | 42,109 | ... |
| Total long-term liabilities | 1,057,449 | 968,962 |
| Total liabilities | 3,782,521 | 5,833,775 |
| Series B convertible preferred stock | 1,203,967 | 1,037,201 |
| Series C convertible preferred stock | 1,621,160 | 1,803,731 |
| Common stock | 532,818 | 350,270 |
| Additional paid-in capital | 55,852,477 | 55,141,503 |
| Accumulated deficit | (60,851,714) | ... |

Recent Dividends:**1. C-Bond Systems Inc series A mandatorily redeemable convertible preferred.**

No dividends paid.

2. C-Bond Systems Inc common.

No dividends paid.

3. C-Bond Systems Inc series C convertible preferred.

No dividends paid.

4. C-Bond Systems Inc series B convertible preferred.

No dividends paid.

Annual Dividends:**1. C-Bond Systems Inc series A mandatorily redeemable convertible preferred.**

No dividends paid.

2. C-Bond Systems Inc common.

No dividends paid.

3. C-Bond Systems Inc series C convertible preferred.

No dividends paid.

4. C-Bond Systems Inc series B convertible preferred.

No dividends paid.

CALCIMEDICA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

| | 2023 | 2022 | [¶] 2021 |
|--|----------|------------------------|-------------------|
| Research & development | 15,859 | 14,113 | 18,903 |
| General & administrative | 22,216 | 19,104 | 17,044 |
| Impairment of capital equipment & right-of-use asset | ... | 1,599 | ... |
| Severance & termination benefit expense | ... | 1,065 | ... |
| Other restructuring costs | ... | 299 | ... |
| Restructuring, impairment & other costs of terminated programs | ... | 2,963 | ... |
| Total operating expenses | ... | 36,180 | 35,947 |
| Income (loss) from operations | ... | (36,180) | (35,947) |
| Interest on convertible promissory notes payable | 110 | ... | ... |
| Interest income | ... | 575 | 126 |
| Net income (loss) | (34,357) | (35,605) | (35,821) |
| Net income (loss) attributable to common stockholders | ... | ... | (35,821) |
| Weighted average shares outstanding - basic | 4,486 | [¶] 1,535 | 1,514 |
| Weighted average shares outstanding - diluted | 4,486 | [¶] 1,535 | 1,514 |
| Year end shares outstanding | 5,755 | [¶] 1,550 | 1,526 |
| Net earnings (loss) per share - basic | \$(7.66) | [¶] \$(23.24) | \$(23.66) |
| Net earnings (loss) per share - diluted | \$(7.66) | [¶] \$(23.24) | \$(23.66) |
| Number of full time employees | 14 | [¶] 8 | [¶] 27 |
| Common Shareholders - Number | 92 | ... | ... |
| Number of | | | |

| | | | |
|--|----------|-----|-----|
| stockholders | ... | 35 | 34 |
| Total other income (expense), net | 660 | ... | ... |
| Income from cont operations before income tax | (34,357) | ... | ... |
| Change in fair value of warrant liability | 1,146 | ... | ... |
| Change in fair value of convertible promissory notes | 2,022 | ... | ... |
| Total number of employees | 14 | ... | ... |

□ Non-consolidated; □ Adjusted for 1-for-14 stock split, March 20, 2023; □ As is; □ As of March 3, 2023; □ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 5,530 | 17,304 |
| Short-term investments | 5,708 | 21,824 |
| Prepaid expenses | 367 | 503 |
| Interest & other receivables | ... | 39 |
| Prepaid expenses & other current assets | ... | 542 |
| Total current assets | 11,605 | 39,670 |
| Property & equipment, net | 167 | ... |
| Prepaid expenses & other non-current assets | 413 | ... |
| Total assets | 12,185 | 39,670 |
| Accounts payable | 1,419 | 1,716 |
| Accrued research & development | 1,141 | 200 |
| Operating lease liability, current | ... | 203 |
| Salaries & benefits | 935 | 698 |
| Professional services | ... | 431 |
| Holdback liability for acquisition of in-process research & development | ... | 250 |
| Severance & termination benefits | ... | 124 |
| Other current liabilities | ... | 77 |
| Other current liabilities | ... | 1,580 |
| Accrued other - Balancing value | 1,468 | ... |
| Accrued other - Balancing value | 533 | ... |
| Total current liabilities | 4,028 | 3,699 |
| Total liabilities | ... | 3,699 |
| Common stock | 1 | 2 |
| Additional paid-in capital | 154,218 | 240,799 |
| Accumulated deficit | (146,064) | ... |
| Retained earnings (accumulated deficit) | ... | (204,793) |
| Accumulated other comprehensive income (loss) | 2 | (37) |
| Total stockholders' equity (deficit) | 8,157 | 35,971 |
| Total stockholders equity (deficit) | 8,157 | ... |

Recent Dividends:
1. CalciMedica Inc common.
 No dividends paid.
Annual Dividends:
1. CalciMedica Inc common.
 No dividends paid.

CALETHOS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|----------------------------------|--------|------|------|
| Management compensation expenses | 51,000 | ... | ... |
| Office & general | ... | ... | ... |

| | | | |
|--|--------------------|------------------|--------------------|
| administration expenses | 344,000 | ... | ... |
| Professional fees | ... | 667,000 | 1,033,000 |
| Restricted stock grants | ... | 4,791,000 | (5,062,000) |
| General & administrative expenses | 38,000 | 52,000 | 57,000 |
| Impairment loss | ... | 154,000 | ... |
| Equity-based compensation | 3,032,000 | ... | ... |
| Total operating expenses (income) | 3,465,000 | (3,918,000) | 6,152,000 |
| Income (loss) from operations | (3,465,000) | 3,918,000 | (6,152,000) |
| Financing costs | 252,000 | 1,744,000 | 597,000 |
| Interest income | 50,000 | 7,000 | ... |
| Other income (expenses) | 23,000 | ... | ... |
| Loss on extinguishment of debt | (986,000) | ... | ... |
| Total other income (expenses) | (1,165,000) | (1,737,000) | (597,000) |
| Income (loss) before provision for income taxes | (4,630,000) | 2,181,000 | (6,749,000) |
| Net income (loss) | (4,630,000) | 2,181,000 | (6,749,000) |
| Weighted average common shares outstanding - basic | 19,157,230 | 14,495,621 | 19,482,261 |
| Weighted average common shares outstanding - diluted | 19,157,230 | 29,342,327 | 19,482,261 |
| Year end shares outstanding | 24,345,598 | 24,495,621 | 25,995,621 |
| Net income (loss) per share - basic | \$(0.24) | \$0.15 | \$(0.35) |
| Net income (loss) per share - diluted | \$(0.24) | \$0.08 | \$(0.35) |
| Total number of employees | ... | 1 | ... |
| Number of common stockholders | 67 | 56 | 55 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.24) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.24) | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------------|------------|------------|
| Cash & cash equivalents | 308,000 | 2,067,000 |
| Prepaid & other current expenses | 10,000 | 4,000 |
| Total current assets | 318,000 | 2,071,000 |
| Other assets | 2,262,000 | ... |
| Total assets | 2,580,000 | 2,071,000 |
| Accrued interest | 122,000 | ... |
| Accounts payable | ... | 186,000 |
| Accrued expenses | 330,000 | 28,000 |
| Accrued interest | ... | 326,000 |
| Accounts payable & accrued expenses | 218,000 | 540,000 |
| Notes payable | 11,000 | 61,000 |
| Convertible promissory notes, net | 341,000 | 4,613,000 |
| Accounts payable and accrued expenses | 670,000 | ... |
| Total current liabilities | 1,022,000 | 5,214,000 |
| Common stock | 24,000 | 24,000 |
| Additional paid-in capital | 20,807,000 | 11,480,000 |
| Other comprehensive income (loss) | 9,000 | 5,000 |
| Stock subscription | ... | ... |

| | | |
|--|--------------|--------------|
| receivable | (2,000) | (2,000) |
| Retained earnings (accumulated deficit) during the development stage | (19,280,000) | ... |
| Retained earnings (accumulated deficit) | ... | (14,650,000) |
| Total stockholders' equity (deficit) | 1,558,000 | (3,143,000) |
| Total Equity | 1,558,000 | ... |

Recent Dividends:
1. CalEthos Inc series A convertible preferred.
 No dividends paid.
2. CalEthos Inc common.
 No dividends paid.

Annual Dividends:
1. CalEthos Inc series A convertible preferred.
 No dividends paid.
2. CalEthos Inc common.
 No dividends paid.

CALIFORNIA FIRST LEASING CORP Earnings, 9 mos. to Mar 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------|-------------------|------------------|
| Cost & expenses | 2,054,000 | 2,139,000 |
| Operating income | 42,220,000 | ... |
| Net before taxes | 42,220,000 | ... |
| Income taxes | 12,020,000 | 2,190,000 |
| Net income | 30,200,000 | 8,103,000 |
| Earnings common share | | |
| Primary | \$3.17 | \$0.81 |
| Fully Diluted | \$3.17 | \$... |
| Common Shares: | | |
| Full Diluted | 9,533,000 | ... |
| Year-end | 9,309,000 | 9,703,000 |

CAPSTONE COMPANIES, INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Revenues net | 192,176 | ... | ... |
| Revenues, net | 192,176 | 346,474 | 685,854 |
| Increase in inventory reserve & write offs | 133,775 | 692,154 | ... |
| Cost of sales | 324,041 | 256,868 | 638,644 |
| Gross profit (loss) | (265,640) | (602,548) | 47,210 |
| Sales & marketing expense | 75,890 | 359,535 | 28,568 |
| Compensation expense | ... | 817,409 | 1,276,503 |
| Professional fees | 426,157 | 457,500 | 368,229 |
| Product development expense | 101,409 | 203,751 | 308,823 |
| Other general & administrative expense | 296,159 | 480,771 | 420,962 |
| Compensation | 469,599 | ... | ... |
| Total operating expenses | 1,369,214 | 2,318,966 | 2,403,085 |
| Operating income (loss) | (1,634,854) | (2,921,514) | (2,355,875) |
| Other income, net | 77,106 | 394,952 | 456,275 |
| Interest income (expense), net | ... | (69,686) | (48,974) |
| Interest expense | 103,741 | ... | ... |
| Total other income (expense), net | (26,635) | 325,266 | 407,301 |
| Income (loss) before income taxes | (1,661,489) | (2,596,248) | (1,948,574) |
| Current federal income tax expense (benefit) | ... | 55,278 | ... |
| Current state income tax expense (benefit) | ... | 800 | 823 |
| Deferred federal income tax expense (benefit) | 29,834 | (2,835) | 18,070 |
| Deferred state income tax expense (benefit) | 5,116 | 14,604 | (3,838) |

| | | | | | | | | | |
|---|-------------|-------------|-------------|---|--------------|-------------|---|-----------|----------|
| Income tax expense (benefit)..... | 34,950 | □67,503 | 15,055 | interest - less current portion | ... | 821,647 | possible redemption - basic | ... | \$(0.14) |
| Net income (loss) | (1,696,439) | (2,663,751) | (1,963,629) | Notes payable unrelated parties & accrued interest - less current portion | ... | 360,446 | Net income (loss) per common stock attributable to Mana Capital Acquisition Corp. - basic | ... | \$(0.09) |
| Weighted average shares outstanding - basic | 48,826,864 | 48,852,204 | 48,196,903 | Deferred tax liabilities - long-term | 320,329 | 285,379 | Net income (loss) per common stock subject to possible redemption - diluted | ... | \$(0.14) |
| Weighted average shares outstanding - diluted | 48,826,864 | 48,852,204 | 48,196,903 | Total long-term liabilities | 320,329 | 1,467,472 | Net income (loss) per common stock attributable to Mana Capital Acquisition Corp. - diluted | ... | \$(0.09) |
| Year end shares outstanding | 48,826,864 | 48,826,864 | 48,893,031 | Total liabilities | 3,665,428 | 2,434,583 | Total number of employees | ... | 1 |
| Net income (loss) per common share - basic | \$(0.03) | \$(0.05) | \$(0.04) | Preferred stock, series B-1 | 2 | 2 | Number of common stockholders | 37 | □4 |
| Net income (loss) per common share - diluted | \$(0.03) | \$(0.05) | \$(0.04) | Common stock | 4,884 | 4,884 | Total operating expenses | 7,259,524 | ... |
| Number of full time employees | 5 | ... | ... | Additional paid-in capital | 8,550,510 | 8,550,510 | Net loss per common share | \$(0.66) | ... |
| Total number of employees | 5 | 7 | 9 | Accumulated deficit | (10,797,216) | ... | Revenue | 17,065 | ... |
| Number of common stockholders | 240 | ... | ... | Retained earnings (accumulated deficit) | ... | (9,100,777) | Sales and marketing | 158,514 | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.03) | ... | ... | Total stockholders' equity (deficit) | (2,241,820) | (545,381) | Research and development | 145,182 | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.03) | ... | ... | Rep Total Equity & Minority Interest | (2,241,820) | ... | General and administrative expenses | 6,936,646 | ... |

Recent Dividends:**1. Capstone Companies, Inc series C convertible preferred.**

No dividends paid.

2. Capstone Companies, Inc common.

No dividends paid.

3. Capstone Companies, Inc series A preferred.

No dividends paid.

4. Capstone Companies, Inc series B-1 preferred.

No dividends paid.

5. Capstone Companies, Inc series B preferred.

No dividends paid.

Annual Dividends:**1. Capstone Companies, Inc series C convertible preferred.**

No dividends paid.

2. Capstone Companies, Inc common.

No dividends paid.

3. Capstone Companies, Inc series A preferred.

No dividends paid.

4. Capstone Companies, Inc series B-1 preferred.

No dividends paid.

5. Capstone Companies, Inc series B preferred.

No dividends paid.

CARDIO DIAGNOSTICS HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | | |
|--|-------------|------------|
| | 2023 | □2021 |
| Formation & operating costs | ... | 20,887 |
| Franchise tax expense | ... | 124,434 |
| Income (loss) from operations | (7,242,459) | (145,321) |
| Investment income on onvestment held in trust account | ... | 484 |
| Income (loss) before income taxes | (8,376,834) | (144,837) |
| Net income (loss) | (8,376,834) | (144,837) |
| Weighted average common stock subject to possible redemption outstanding - basic | ... | 1,001,327 |
| Weighted average common stock attributable to Mana Capital Acquisition Corp. outstanding - diluted | ... | 1,560,288 |
| Weighted average common stock subject to possible redemption outstanding - diluted | ... | 1,001,327 |
| Weighted average common stock attributable to Mana Capital Acquisition Corp. outstanding - diluted | ... | 1,560,288 |
| Year end shares outstanding | 20,540,409 | □8,125,000 |
| Net income (loss) per common stock subject to | | |

□ From May 19, 2021 (inception); □ Shares increased due to initial public offering of shares; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|--------------|------------|
| | 2023 | 2021 |
| Cash | 1,283,523 | 526,625 |
| Prepaid expenses | ... | 280,057 |
| Accounts receivable | 4,960 | ... |
| Prepaid expenses and other current assets | 1,477,197 | ... |
| Total current assets | 2,765,680 | 806,682 |
| Investments held in trust account | ... | 65,000,484 |
| Know-how license - Net | 21,333 | ... |
| Deposits | 12,850 | ... |
| Patent costs | 515,402 | ... |
| Office and computer equipment | 17,394 | ... |
| Furniture and fixtures | 76,099 | ... |
| Accumulated depreciation | 3,790 | ... |
| Leasehold Improvements - Gross | 482,170 | ... |
| Property and equipment | 571,873 | ... |
| Right of use asset, net | 575,227 | ... |
| Total assets | 4,462,365 | 65,807,166 |
| Note payable | 374,000 | ... |
| Franchise tax payable | ... | 124,434 |
| Accounts payable and accrued expenses | 243,213 | ... |
| Lease liability current | 223,929 | ... |
| Total current liabilities | 841,142 | 124,434 |
| Lease liability long term | 663,099 | ... |
| Total liabilities | 1,504,241 | 124,434 |
| Common stock subject to possible redemption | ... | 65,000,000 |
| Common stock | 205 | 16 |
| Additional paid-in capital | 17,326,299 | 827,553 |
| Accumulated deficit | (14,368,380) | ... |

□ As reported by the Company

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|-----------|-----------|
| | 2023 | 2022 |
| Cash | 36,466 | 61,463 |
| Trade accounts receivables at period end | ... | 7,716 |
| Accounts receivable | ... | 7,716 |
| Advances | 9,570 | ... |
| Inventories | ... | 945,515 |
| Less: allowances | ... | 533,254 |
| Inventories, net | ... | 412,261 |
| Prepaid expenses | 22,120 | 37,090 |
| Total current assets | 68,156 | 518,530 |
| Computer equipment & software | ... | 53,819 |
| Machinery & equipment | 42,970 | 76,928 |
| Furniture & fixtures | ... | 6,828 |
| Less: accumulated depreciation | ... | 86,290 |
| Less: impairment of long-lived asset | ... | 51,285 |
| Property & equipment, net | 42,970 | ... |
| Operating lease - right of use asset | ... | 34,151 |
| Deposit | ... | 24,039 |
| Goodwill | 1,312,482 | 1,312,482 |
| Total assets | 1,423,608 | 1,889,202 |
| Accrued compensation | 734,156 | ... |
| Accounts payable | 69,267 | 38,056 |
| Accrued warranty reserve | ... | 1,926 |
| Accrued compensation & deferred wages, marketing allowances, customer deposits & other liabilities | 1,200 | 269,457 |
| Accrued compensation, benefits, commissions & other expenses | 804,623 | ... |
| Accounts payable & accrued liabilities | ... | 309,439 |
| Notes payable related parties & accrued interest - current | ... | 413,425 |
| Notes payable unrelated party & accrued interest - current | 594,161 | 206,712 |
| Operating lease - current portion | ... | 37,535 |
| Notes & loans payable to related parties | 1,946,315 | ... |
| Total current liabilities | 3,345,099 | 967,111 |
| Notes payable related parties & accrued | | |

| | | |
|---|-----------|-----------|
| Retained earnings (accumulated deficit) | ... | (144,837) |
| Total stockholders' equity (deficit) | 2,958,124 | 682,732 |
| Total Equity | 2,958,124 | ... |

| | | | |
|--------------------|--------|-----|-----|
| Income Taxes | 74,518 | ... | ... |
|--------------------|--------|-----|-----|

□ As of March 31, 2022; □ Approximately; □ As of March 28, 2022

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|--|-----------------|-----------------|----------------|
| Research & development | 75,791 | 29,373 | 4,461 |
| General & administrative | 20,919 | 5,398 | 1,516 |
| Total operating expenses | 96,710 | 34,771 | 5,977 |
| Loss from operations | (96,710) | (34,771) | (5,977) |
| Interest expense | 1,604 | 4,942 | ... |
| Change in fair value of derivative liabilities | 6,453 | (1,216) | ... |
| Other income (expense), net | 4,813 | (22) | 127 |
| Net loss and comprehensive loss .. | (98,147) | (40,951) | (5,850) |
| Weighted average shares outstanding - basic | 41,206 | 392 | 152 |
| Weighted average shares outstanding - diluted | 41,206 | 392 | 152 |
| Year end shares outstanding | 41,206 | 1,092 | 811 |
| Net loss per share - basic | \$(2.38) | \$(0.10) | \$(0.04) |
| Net loss per share - diluted | \$(2.38) | \$(0.10) | \$(0.04) |
| Full-Time Employees (Period End) | 116 | ... | ... |
| Total number of employees | 116 | 74 | ... |
| Number of common stockholders | 44 | 44 | ... |
| Net Income before Tax | (98,147) | ... | ... |
| Net change in fair value of redeemable convertible preferred stock tranche obligations ... | (8,783) | ... | ... |
| Loss on extinguishment of convertible notes | (2,316) | ... | ... |

Recent Dividends:

- 1. Cardio Diagnostics Holdings Inc common.**
No dividends paid.
 - 2. Cardio Diagnostics Holdings Inc common subject to possible redemption.**
No dividends paid.
- Annual Dividends:**
- 1. Cardio Diagnostics Holdings Inc common.**
No dividends paid.
 - 2. Cardio Diagnostics Holdings Inc common subject to possible redemption.**
No dividends paid.

CAREVIEW COMMUNICATIONS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|---------------------|
| Subscription-based lease revenue | 4,382,578 | 5,114,487 | 5,404,623 |
| Sales-based equipment package revenue | 3,407,263 | 1,437,758 | 1,950,386 |
| Sales-based software bundle revenue | 1,894,777 | 1,349,096 | 447,217 |
| Total revenues | 9,684,618 | 7,901,341 | 7,802,226 |
| Cost of equipment ... | 407,309 | 245,532 | 179,531 |
| Network operations .. | 2,746,302 | 2,572,353 | 2,603,407 |
| General & administration | 3,239,940 | 3,344,447 | 3,226,310 |
| Sales & marketing ... | 1,033,608 | 781,329 | 549,419 |
| Research & development | 2,502,924 | 1,639,174 | 1,711,211 |
| Depreciation & amortization | 442,837 | 588,928 | 679,428 |
| Total operating expense | 10,372,920 | 9,171,763 | 8,949,306 |
| Operating income (loss) | (688,302) | (1,270,422) | (1,147,080) |
| Interest expense | 3,208,500 | 6,262,051 | 8,950,418 |
| Interest income | 19,031 | 497 | 138 |
| Gain on extinguishment of debt | ... | 1,489,357 | ... |
| Other income | ... | ... | 16,997 |
| Total other income (expense) | (3,189,469) | (4,777,197) | (8,933,283) |
| Income (loss) before taxes | (3,877,771) | (6,042,619) | (10,080,363) |
| Net income (loss) | (3,952,289) | (6,042,619) | (10,080,363) |
| Weighted average shares outstanding - basic | 448,488,967 | 141,880,748 | 139,380,748 |
| Weighted average shares outstanding - diluted | 448,488,967 | 141,880,748 | 139,380,748 |
| Year end shares outstanding | 583,880,748 | 141,880,748 | 139,380,748 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.04) | \$(0.07) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.04) | \$(0.07) |
| Number of full time employees | 63 | 56 | □55 |
| Number of common stockholders | 114 | 94 | □□91 |
| Number of beneficiary stockholders | ... | ... | □□913 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(0.01) | \$(0.04) | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | \$(0.04) | ... |
| Total number of employees | 63 | 56 | ... |
| Provision for | | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash & cash equivalents | 1,145,871 | 520,166 |
| Accounts receivable, net | 1,167,934 | 948,328 |
| Inventory | 294,435 | 301,446 |
| Other prepaid expenses | ... | 71,020 |
| Inventory assets (finished goods) | 294,435 | 301,446 |
| Total current assets | 2,943,331 | 1,840,960 |
| Network equipment | 9,204,511 | 12,620,258 |
| Vehicles | 133,616 | 232,411 |
| Test equipment | 230,365 | 230,365 |
| Furniture | 92,097 | 92,846 |
| Warehouse equipment | 18,788 | 9,524 |
| Leasehold improvements | 5,121 | 5,121 |
| Office equipment & software | 241,955 | 234,429 |
| Property & equipment, gross | 9,926,453 | 13,424,954 |
| Less: accumulated depreciation - property & equipment | 9,608,827 | 12,782,395 |
| Property & equipment, net | 317,626 | 642,559 |
| Intangible assets, net | 406,301 | 820,106 |
| Operating lease asset | 292,990 | 434,330 |
| Deferred installation costs | 48,310 | 33,461 |
| Deferred sales commissions | 159,762 | 65,857 |
| Prepaid license fee | 47,814 | 64,207 |
| Security deposit | 46,124 | 46,124 |
| Deferred installation costs, Gross | 1,397,720 | 1,352,041 |
| Acc Amort/Imp Deferred installation costs | 1,349,410 | 1,318,580 |
| Deferred Sales Commissions Gross | 439,221 | 163,973 |
| Deferred Sales Commissions -Amortization | 279,459 | 98,116 |
| Total assets | 4,262,258 | 3,947,604 |
| Accounts payable | 598,095 | 650,796 |
| Notes payable, related parties | 700,000 | ... |
| Senior secured notes - related parties, current portion net of debt discount & debt costs | 20,000,000 | 20,000,000 |
| Operating lease liability | 188,184 | 175,520 |
| Accrued interest | 16,479,139 | ... |
| Deferred revenue | 1,752,061 | ... |
| Loan payable | ... | 700,000 |
| Convertible notes | ... | 1,805,832 |
| Convertible notes | ... | 42,394,168 |
| Total current liabilities | 40,206,976 | 80,279,593 |
| Operating lease liability | 139,099 | 305,259 |
| Other liability | 178,907 | 23,481 |
| Total long-term liabilities | 318,006 | 328,740 |
| Total liabilities | 40,524,982 | 80,608,333 |
| Common stock | 583,881 | 141,881 |
| Additional paid in capital | 171,038,349 | 127,130,055 |
| Retained earnings (accumulated deficit) | (207,884,954) | (203,932,665) |
| Total stockholders' equity (deficit) | (36,262,724) | (76,660,729) |
| Total stockholders' equity (deficit) | (36,262,724) | (76,660,729) |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|---------|--------|
| Cash | ... | 1,872 |
| Prepaid research and development | 825 | 1,428 |
| Other receivables | 1,739 | 476 |
| Prepaid other | 1,181 | 151 |
| Prepaid expenses and other current assets | 3,745 | 2,055 |
| Cash and cash equivalents | 405,732 | ... |
| Total current assets | 409,477 | 3,927 |
| Operating lease right-of-use asset | 28,222 | 2,165 |
| Furniture and equipment | 87 | 2,793 |
| Leasehold improvements | 134 | 105 |
| Construction in progress | 1,833 | 891 |
| Laboratory Equipment | 9,644 | ... |
| Computer Equipment | 593 | ... |
| Property and equipment at cost | 12,291 | 3,789 |
| Less: accumulated depreciation | 1,912 | 421 |
| Property and equipment, net | 10,379 | 3,368 |
| Other non-current assets | 4,391 | 783 |
| Restricted Cash | 567 | ... |
| Total assets | 453,036 | 10,243 |
| Accounts payable | 5,013 | 3,483 |
| Accrued clinical and research and development expenses | 7,242 | 1,646 |
| Accrued compensation and related expenses | 5,391 | 2,385 |
| Accrued purchases of | | |

Recent Dividends:

- 1. CareView Communications Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. CareView Communications Inc common.**
No dividends paid.

CARGO THERAPEUTICS INC Annual Report

3. Carmell Corp class B common.
No dividends paid.

4. Carmell Corp common.
No dividends paid.

Annual Dividends:

1. Carmell Corp class A common.
No dividends paid.

2. Carmell Corp class A common subject to possible redemption.
No dividends paid.

3. Carmell Corp class B common.
No dividends paid.

4. Carmell Corp common.
No dividends paid.

CARMELL CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Adeptus Partners, LLC, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Carmell Corporation (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, changes in stockholders' equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years ended December 31, 2023 and 2022, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 4 to the financial statements, the Company has a net loss from operations, negative cash flows from operations, and an accumulated deficit that raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

CASI PHARMACEUTICALS INC (NEW)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Product sales | 33,879,000 | 38,047,000 | 30,020,000 |
| Lease income from a related party | ... | 60,000 | 148,000 |
| Sublicensing revenue from a related party | ... | 5,000,000 | ... |
| Total revenues | 33,879,000 | 43,107,000 | 30,168,000 |
| Cost of goods sold | ... | ... | 6,616,000 |
| Royalty fee | 13,827,000 | 15,827,000 | 5,941,000 |
| Total costs of revenues | 13,827,000 | 15,827,000 | 12,557,000 |
| Gross profit | 20,052,000 | 27,280,000 | 17,611,000 |
| Research & development expenses | 9,861,000 | 15,996,000 | 14,422,000 |
| General & administrative expenses | 25,387,000 | 23,449,000 | 23,766,000 |
| Selling & marketing expenses | 16,450,000 | 14,326,000 | 14,705,000 |
| Other operating income | 6,366,000 | ... | ... |
| Impairment of intangible assets | ... | 8,724,000 | ... |
| Acquired in-process research & development expenses | ... | ... | 6,555,000 |
| Foreign Exchange Gain/Loss - Non-Business | 200,000 | 3,241,000 | ... |
| Total operating expenses | 45,132,000 | 61,312,000 | 59,448,000 |
| Income (loss) from operations | (25,080,000) | (34,032,000) | (41,837,000) |
| Interest income (expense), net | 614,000 | 127,000 | 321,000 |
| Foreign exchange | ... | ... | ... |

| | | | |
|--|--------------|--------------|--------------|
| gain (losses) | ... | ... | 321,000 |
| Change in fair value of investments | ... | (8,895,000) | 5,660,000 |
| Impairment loss of long-term investments | 2,009,000 | ... | 865,000 |
| Change in fair value of investment in equity securities | ... | 5,325,000 | ... |
| Other income | 764,000 | 44,000 | 558,000 |
| Income (loss) before income taxes - United States | ... | (12,359,000) | (32,169,000) |
| Income (loss) before income taxes - People's Republic of China | ... | (25,072,000) | (3,673,000) |
| Income (loss) before income tax expense | (26,292,000) | (37,431,000) | (35,842,000) |
| Accretion to redeemable noncontrolling interest redemption value | 3,281,000 | ... | ... |
| Deemed dividends to Wuxi LP | 22,000 | ... | ... |
| Net income (loss) | (26,259,000) | (40,257,000) | (35,842,000) |
| Less: income (loss) attributable to redeemable noncontrolling interest | 2,602,000 | 8,740,000 | 700,000 |
| Accretion to redeemable noncontrolling interest redemption value | ... | (9,497,000) | (1,512,000) |
| Net income (loss) attributable to CASI Pharmaceuticals, Inc. | ... | (41,014,000) | (36,654,000) |
| Gain on sale of property, plant & equipment | ... | (2,058,000) | ... |
| Net income (loss) to common shareholders | (26,960,000) | ... | ... |
| Weighted average shares outstanding - basic | 13,360,185 | 13,647,455 | 13,610,554 |
| Weighted average shares outstanding - diluted | 13,360,185 | 13,647,455 | 13,610,554 |
| Year end shares outstanding | 13,378,175 | 13,457,625 | 13,979,749 |
| Net income (loss) per share - basic | \$(2.02) | \$(3.01) | Ⓜ\$(2.70) |
| Net income (loss) per share - diluted | \$(2.02) | \$(3.01) | Ⓜ\$(2.70) |
| Number of full time employees | 176 | 224 | 176 |
| Total number of employees | 176 | 224 | ... |
| Number of common stockholders | 72 | 63 | 254 |
| Foreign currency translation adjustments | ... | ... | 1,977,000 |
| Income tax expense | (81,000) | 1,980,000 | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(2.02) | \$(3.01) | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(2.02) | \$(3.01) | ... |
| Comprehensive loss attributable to ordinary shareholders | (24,154,000) | ... | ... |
| Share of net loss | ... | ... | ... |

in an equity investee (48,000) (846,000) ...

Change in fair value of investments (581,000) ...

Ⓜ Adjusted for 1-for-10 stock split, June 1, 2022, Ⓜ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 17,083,000 | 47,112,000 |
| Short-term investments | 1,675,000 | 2,763,000 |
| Accounts receivable, net | 9,551,000 | 12,973,000 |
| Inventories | 15,877,000 | 6,138,000 |
| Prepaid expenses & other current assets | 12,011,000 | 1,462,000 |
| Prepaid expenses and other | 2,560,000 | 2,975,000 |
| Receivable from a related party | 587,000 | ... |
| Total current assets | 59,344,000 | 73,423,000 |
| Furniture & equipment | 682,000 | 1,241,000 |
| Leasehold improvements | 7,190,000 | 7,161,000 |
| Construction in progress | 23,000 | 5,728,000 |
| Machinery and equipment | 5,997,000 | ... |
| Total property, plant & equipment, gross | 13,892,000 | 14,130,000 |
| Less: accumulated depreciation | 4,651,000 | 2,299,000 |
| Property, plant & equipment, net | 9,241,000 | 11,831,000 |
| Intangible assets, net | 1,839,000 | 1,063,000 |
| Long-term investments | 1,686,000 | 4,398,000 |
| Right of use assets | 2,392,000 | 1,398,000 |
| Deposits | ... | 3,065,000 |
| Other assets | 766,000 | 1,056,000 |
| Total assets | 75,268,000 | 96,234,000 |
| Accounts payable | 4,438,000 | 3,289,000 |
| Accrued Liabilities - Balancing value | 11,560,000 | 10,948,000 |
| Income tax payable | ... | 1,900,000 |
| Accrued & other current liabilities | 12,288,000 | 11,816,000 |
| Operating Lease Liabilities - Current Portion/Short-Term | 728,000 | 868,000 |
| Total current liabilities | 16,726,000 | 17,005,000 |
| Note payable, net of discount | 18,895,000 | ... |
| Other liabilities | 15,482,000 | 12,297,000 |
| Redeemable noncontrolling interest, at redemption value | ... | 22,358,000 |
| Common stock | 1,000 | 1,000 |
| Additional paid-in capital | 695,785,000 | 691,766,000 |
| Treasury stock, at cost | 9,604,000 | 9,330,000 |
| Accumulated other comprehensive income (loss) | (1,200,000) | (703,000) |
| Retained earnings (accumulated deficit) | (660,817,000) | (637,160,000) |
| Total stockholders' equity (deficit) | 24,165,000 | 44,574,000 |
| Rep Total Equity & Minority Interest | 24,165,000 | 44,574,000 |

Recent Dividends:

1. CASI Pharmaceuticals Inc (New) ordinary.
No dividends paid.

2. CASI Pharmaceuticals Inc (New) series A convertible preferred.
No dividends paid.

Annual Dividends:

1. CASI Pharmaceuticals Inc (New) ordinary.
No dividends paid.

2. CASI Pharmaceuticals Inc (New) series A convertible preferred.
No dividends paid.

CASTELLUM INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) | 2021 | 2022 | 2023 | 2022 | 2021 (revised) | | | |
|--|--------------|--------------|-------------------|---|-------|------|------------------|-------------------|------------|------------|-----|
| Sales | 45,243,812 | ... | ... | 214 | 2,111 | 234 | equity (deficit) | 12,948,689 | 17,531,916 | | |
| Revenues | 45,243,812 | 42,190,643 | 25,067,450 | Total equity | | | | | | 12,948,689 | ... |
| Cost of revenues | 26,568,485 | 24,593,326 | 13,992,898 | □ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-20 stock split, October 13, 2022; □ Approximately | | | | | | | |
| Gross profit | 18,675,327 | 17,597,317 | 11,074,552 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | | |
| Indirect costs | 8,935,113 | 11,859,401 | 3,409,649 | 2023 2022 | | | | | | | |
| Overhead | 1,884,059 | 1,560,252 | 850,999 | Cash 1,830,841 4,640,896 | | | | | | | |
| General & administrative expense | 17,697,886 | 13,586,600 | 14,539,053 | Accounts receivables 6,883,566 5,193,562 | | | | | | | |
| Gain (loss) from change in fair value of contingent earnout | 92,000 | (555,000) | ... | Contract asset 160,649 257,434 | | | | | | | |
| Goodwill impairment loss | 6,919,094 | ... | ... | Prepaid income taxes 216,909 351,116 | | | | | | | |
| Total operating expenses | 35,344,152 | 27,561,253 | 18,799,701 | Prepaid expenses & other current assets 404,228 222,995 | | | | | | | |
| Income (loss) from operations before other income (expense) | ... | (9,963,936) | (7,725,149) | Total current assets 9,496,193 10,666,003 | | | | | | | |
| Realized gain on investment | ... | ... | 38,851 | Equipment 258,091 ... | | | | | | | |
| Gain on disposal of fixed assets | ... | 303 | ... | Equipment & software 43,119 141,732 | | | | | | | |
| Change in fair value of derivative liability | 1,054,025 | (132,000) | ... | Furniture 32,574 ... | | | | | | | |
| Interest Expense, Supplemental | 3,248,914 | ... | ... | Leasehold improvements 192,959 83,266 | | | | | | | |
| Interest expense, net of interest income | ... | (3,992,809) | (2,516,775) | Total fixed assets 538,097 257,572 | | | | | | | |
| Loss on induced conversion | (300,000) | ... | ... | Accumulated depreciation 227,927 84,222 | | | | | | | |
| Other income, net | 106,419 | ... | ... | Fixed assets, net 310,170 173,350 | | | | | | | |
| Total other income (expense) | (2,388,470) | (4,124,506) | (2,477,924) | Right of use asset - operating lease 613,143 35,524 | | | | | | | |
| Income (loss) from operations before benefit for income taxes | (19,057,295) | (14,088,442) | (10,203,073) | Intangible assets, net 8,970,864 6,634,167 | | | | | | | |
| Current provision (benefit) from income taxes | 223,049 | 209,563 | 238,928 | Goodwill 10,716,907 15,533,964 | | | | | | | |
| Deferred provision (benefit) from income taxes | (1,480,166) | 610,033 | (2,895,571) | Total non-current assets 22,377,005 33,043,008 | | | | | | | |
| Provision (benefit) from income taxes | (1,257,117) | 819,596 | (2,656,643) | Total assets 30,107,277 33,043,008 | | | | | | | |
| Net income (loss) | (17,800,178) | (14,908,038) | (7,546,430) | Accounts payable & accrued expenses 1,617,596 ... | | | | | | | |
| Less: preferred stock dividends | 118,152 | 100,516 | 12,290 | Accrued payroll & payroll related expenses 2,925,312 1,869,517 | | | | | | | |
| Net income (loss) to common shareholders | (17,918,330) | (15,008,554) | (7,558,720) | Due to seller 280,000 ... | | | | | | | |
| Weighted average shares outstanding-basic | 47,177,950 | 27,468,226 | 18,259,283 | Credit card payable 784,965 ... | | | | | | | |
| Weighted average shares outstanding-diluted | 47,177,950 | 27,468,226 | 18,259,283 | Deferred rent obligation 380,000 ... | | | | | | | |
| Year end shares outstanding | 47,672,427 | 41,699,363 | 19,960,632 | Obligation to issue common & preferred stock 255,940 ... | | | | | | | |
| Earnings (loss) per common share - continuing operations - basic | \$(0.38) | ... | ... | Contingent consideration 350,000 ... | | | | | | | |
| Net income (loss) per share-basic | \$(0.38) | \$(0.55) | \$(0.41) | Contingent earnout 812,000 ... | | | | | | | |
| Earnings (loss) per common share - continuing operations - diluted | \$(0.38) | ... | ... | Derivative liability 157,600 824,000 | | | | | | | |
| Net income (loss) per share-diluted | \$(0.38) | \$(0.55) | \$(0.41) | Current maturities of long term debt 2,074,775 ... | | | | | | | |
| Number of full time employees | 260 | ... | ... | Revolving credit facility 625,025 300,025 | | | | | | | |
| Total number of employees | 260 | 207 | ... | Current portion of convertible notes - related parties, net of discounts 238,212 ... | | | | | | | |
| Number of common stockholders | ... | ... | ... | Current portion of notes payable, net of discounts 2,033,348 ... | | | | | | | |
| | | | | Current portion of lease liability - operating lease 185,263 22,054 | | | | | | | |
| | | | | Total current liabilities 7,977,092 7,758,540 | | | | | | | |
| | | | | Deferred tax liability 6,292 ... | | | | | | | |
| | | | | Unsecured promissory note 400,000 ... | | | | | | | |
| | | | | Lease liability - operating lease, net of current portion 435,204 12,632 | | | | | | | |
| | | | | Note payable - related party, net of current portion 400,000 ... | | | | | | | |
| | | | | Convertible promissory notes - related parties, net of discounts, net of current portion 2,000,000 999,430 | | | | | | | |
| | | | | Notes payable, net of discounts, net of current portion 6,000,000 6,340,490 | | | | | | | |
| | | | | Contingent earnout, net of current portion 340,000 ... | | | | | | | |
| | | | | Total non-current liabilities 9,181,496 7,752,552 | | | | | | | |
| | | | | Total liabilities 17,158,588 15,511,092 | | | | | | | |
| | | | | Series A Preferred stock 588 ... | | | | | | | |
| | | | | Series C Preferred stock 77 ... | | | | | | | |
| | | | | Preferred stock, series A 588 ... | | | | | | | |
| | | | | Preferred stock, series C 77 ... | | | | | | | |
| | | | | Common stock 4,767 4,170 | | | | | | | |
| | | | | Additional paid in capital 56,926,157 43,621,651 | | | | | | | |
| | | | | Retained earnings (accumulated deficit) (43,982,900) (26,094,570) | | | | | | | |
| | | | | Total stockholders' equity (deficit) 12,948,689 17,531,916 | | | | | | | |
| | | | | Total equity 12,948,689 ... | | | | | | | |
| | | | | Recent Dividends: | | | | | | | |
| | | | | 1. Castellum Inc series C preferred. No dividends paid. | | | | | | | |
| | | | | 2. Castellum Inc common. No dividends paid. | | | | | | | |
| | | | | 3. Castellum Inc series A preferred. No dividends paid. | | | | | | | |
| | | | | 4. Castellum Inc series B preferred. No dividends paid. | | | | | | | |
| | | | | Annual Dividends: | | | | | | | |
| | | | | 1. Castellum Inc series C preferred. No dividends paid. | | | | | | | |
| | | | | 2. Castellum Inc common. No dividends paid. | | | | | | | |
| | | | | 3. Castellum Inc series A preferred. No dividends paid. | | | | | | | |
| | | | | 4. Castellum Inc series B preferred. No dividends paid. | | | | | | | |
| | | | | CASTELLUM INC Earnings, 9 mos. to Sep 30(Consol. - \$): | | | | | | | |
| | | | | 2023 2022 | | | | | | | |
| | | | | Total revenues 34,153,979 32,166,104 | | | | | | | |
| | | | | Cost & expenses 49,290,562 37,821,549 | | | | | | | |
| | | | | Operating income (16,750,364) (5,655,445) | | | | | | | |
| | | | | Interest expense 2,484,263 2,579,915 | | | | | | | |
| | | | | Other income (expense), net 870,482 (97,000) | | | | | | | |
| | | | | Gains or losses 303 ... | | | | | | | |
| | | | | Net before taxes (16,750,364) (8,332,057) | | | | | | | |
| | | | | Income taxes (1,136,345) 902,820 | | | | | | | |
| | | | | Net income (15,614,019) (9,234,877) | | | | | | | |
| | | | | Balance for common (15,702,877) (9,305,324) | | | | | | | |
| | | | | Earnings common share | | | | | | | |
| | | | | Primary \$(0.34) \$(0.39) | | | | | | | |
| | | | | Fully Diluted \$(0.34) \$(0.39) | | | | | | | |
| | | | | Common Shares: | | | | | | | |
| | | | | Full Diluted 46,673,959 23,621,551 | | | | | | | |
| | | | | Year-end 47,579,402 24,788,132 | | | | | | | |
| | | | | CELCUITY INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| | | | | 2023 2022 2021 (revised) | | | | | | | |
| | | | | Research & development 60,594,005 35,289,548 25,758,006 | | | | | | | |
| | | | | General & administrative 5,636,326 4,101,543 2,597,909 | | | | | | | |
| | | | | Total operating expenses 66,230,331 39,391,091 28,355,915 | | | | | | | |
| | | | | Income (loss) from operations (66,230,331) (39,391,091) (28,355,915) | | | | | | | |
| | | | | Interest expense 5,326,387 2,106,111 1,262,350 | | | | | | | |
| | | | | Interest income 7,777,602 1,127,162 13,262 | | | | | | | |
| | | | | Gain (loss) on sale of fixed assets (263) | | | | | | | |
| | | | | Other income (expense), net 2,451,215 (978,949) (1,249,351) | | | | | | | |
| | | | | Net income (loss) before income taxes (63,779,116) (40,370,040) (29,605,266) | | | | | | | |
| | | | | Net income (loss) (63,779,116) (40,370,040) (29,605,266) | | | | | | | |
| | | | | Weighted average shares outstanding | | | | | | | |
| | | | | - basic 23,679,472 15,418,543 13,382,553 | | | | | | | |
| | | | | Weighted average shares outstanding - diluted 23,679,472 15,418,543 13,382,553 | | | | | | | |
| | | | | Year end shares outstanding 25,506,012 21,667,250 14,918,887 | | | | | | | |
| | | | | Net income (loss) per share - basic \$(2.69) \$(2.64) \$(2.21) | | | | | | | |
| | | | | Net income (loss) per share - diluted \$(2.69) \$(2.64) \$(2.21) | | | | | | | |
| | | | | Number of full time employees 55 45 39 | | | | | | | |
| | | | | Number of common stockholders 55 54 43 | | | | | | | |
| | | | | Total number of employees 55 | | | | | | | |

☐ Shares increased due to the effect of stock-based compensation, employee stock purchases, stock option, issuance of common & preferred stock upon closing of private placement offering and ATM offering; ☒ Shares increased due to the effect of issuance of common stock upon closing of follow-on offerings, net of underwriting discounts & offering costs; ☓ Approximately; ☑ As of March 14, 2023; ☒ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|--------------|
| Cash & cash equivalents | 30,662,774 | 24,571,557 |
| Investments | 149,919,974 | 144,015,954 |
| Deposits | ... | 22,009 |
| Deferred transaction costs | ... | 33,195 |
| Payroll tax receivable | ... | 203,665 |
| Directors & officers insurance | ... | 173,416 |
| Prepaid research & development | ... | 421,800 |
| Clinical trial | ... | 5,656,737 |
| Other prepaid assets | ... | 92,204 |
| Prepaid assets | ... | 6,344,157 |
| Other Current Assets | 10,007,849 | ... |
| Total current assets | 190,590,597 | 175,190,537 |
| Leasehold improvements | 302,577 | 302,577 |
| Furniture & equipment | 1,788,195 | 1,676,935 |
| Total property & equipment, gross | 2,090,772 | 1,979,512 |
| Less: accumulated depreciation | 1,861,990 | 1,719,218 |
| Property & equipment, net | 228,782 | 260,294 |
| Operating lease right-of-use assets | 400,019 | 246,266 |
| Total assets | 191,219,398 | 175,697,097 |
| Accounts payable | 5,076,699 | 2,627,076 |
| Finance lease liabilities | ... | 2,449 |
| Operating lease liabilities | 184,950 | 191,749 |
| Accrued compensation | 1,763,316 | 929,216 |
| Employee stock purchase plan | ... | 38,967 |
| Clinical trial costs | 6,464,772 | 2,246,573 |
| Accrued payroll | 57,494 | ... |
| Other accrued expenses | ... | 845,524 |
| Other | 641,512 | ... |
| Accrued expenses | 8,927,094 | 4,060,280 |
| Total current liabilities | 14,188,743 | 6,881,554 |
| Operating lease liabilities | 225,922 | 61,002 |
| Note payable, non-current | 37,035,411 | 34,983,074 |
| Total liabilities | 51,450,076 | 41,925,630 |
| Preferred stock | 854 | 1,121 |
| Common stock | 25,506 | 21,667 |
| Additional paid-in capital | 299,818,965 | 230,045,566 |
| Retained earnings (accumulated deficit) | (160,076,003) | (96,296,887) |
| Total stockholders' equity (deficit) | 139,769,322 | 133,771,467 |
| Total Equity | 139,769,322 | ... |

Recent Dividends:

- 1. Celucity Inc common.**
No dividends paid.
- 2. Celucity Inc preferred.**
No dividends paid.

Annual Dividends:

- 1. Celucity Inc common.**
No dividends paid.
- 2. Celucity Inc preferred.**
No dividends paid.

CELLECTAR BIOSCIENCES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ☒2021 (revised) |
|---------------------------------|------------|------------|-----------------|
| Research & development expenses | 28,211,460 | 19,219,603 | 17,586,469 |
| General & administrative | ... | ... | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| expenses | 10,749,183 | 9,594,170 | 6,544,811 |
| Total costs & expenses | 38,960,643 | 28,813,773 | 24,131,280 |
| Income (loss) from operations | (38,960,643) | (28,813,773) | (24,131,280) |
| Interest income | 387,147 | ... | ... |
| Other income | ... | ... | 6,634 |
| Interest income (expense), net | ... | 152,519 | 2,284 |
| Gain on valuation of warrants | (470,000) | ... | ... |
| Loss on revaluation of warrants | 1,000,000 | ... | ... |
| Total other income (expense), net | 917,147 | 152,519 | 8,918 |
| Income (loss) before income taxes | (38,043,496) | (28,661,254) | (24,122,362) |
| Current state income tax expense (benefit) | (60,000) | (60,000) | ... |
| Total current income tax expense (benefit) | (60,000) | (60,000) | ... |
| Deferred federal income tax expense (benefit) | (12,233,641) | (7,800,350) | (7,102,248) |
| Deferred state income tax expense (benefit) | ... | (2,633,146) | (1,071,157) |
| State | (2,764,638) | ... | ... |
| Total deferred income tax expense (benefit) | (14,998,279) | (10,433,496) | (8,173,405) |
| Change in valuation allowance | 14,998,279 | 10,433,496 | 8,173,405 |
| Income tax expense (benefit) | (60,000) | (60,000) | ... |
| Net income (loss) | (37,983,496) | (28,601,254) | (24,122,362) |
| Weighted average shares outstanding | | | |
| - basic | 12,221,571 | 7,055,665 | ☒5,551,572 |
| Weighted average shares outstanding - diluted | 12,221,571 | 7,055,665 | ☒5,551,572 |
| Year end shares outstanding | 20,744,110 | ☒9,385,272 | ☒6,110,126 |
| Net income (loss) per common share - basic | \$(3.11) | \$(4.05) | ☒\$(4.35) |
| Net income (loss) per common share - diluted | \$(3.11) | \$(4.05) | ☒\$(4.35) |
| Number of full time employees | 20 | 15 | 12 |
| Total number of employees | 20 | ... | ... |
| Number of common stockholders | 100 | ☒98 | ☒245 |
| Basic EPS Excluding ExtraOrdinary Items | \$(3.11) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(3.11) | ... | ... |

☐ Reclassified to conform with 2022 presentation; ☒ Adjusted for 1-for-10 stock split, July 22, 2022; ☓ Shares increased due to the effect of issuance of common share, pre-funded warrants and warrants; ☒ Shares increased due to the effect of issuance of common shares for conversion of warrants and retired shares; ☒ As of February 24, 2023; ☒ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 9,564,988 | 19,866,358 |
| Prepaid expenses & other current assets | 888,225 | 663,243 |
| Total current assets | 10,453,213 | 20,529,601 |
| Office & laboratory equipment | 1,661,316 | 797,278 |
| Computer software | 4,000 | 4,000 |
| Leasehold improvements | 309,897 | 309,897 |
| Total fixed assets | 1,975,213 | 1,111,175 |
| Less - accumulated | ... | ... |

| | | |
|--|---------------|---------------|
| depreciation & amortization | 884,909 | 692,534 |
| Fixed assets, net | 1,090,304 | 418,641 |
| Right-of-use asset, net | 502,283 | 560,334 |
| Long-term assets | 23,566 | 75,000 |
| Other assets | 6,214 | 6,214 |
| Total assets | 12,075,580 | 21,589,790 |
| Incentive compensation | ... | 916,000 |
| Accounts payable | 5,620,000 | 2,558,000 |
| Clinical project costs | 153,000 | 1,637,000 |
| Professional fees | ... | 359,000 |
| Other accounts payable & accrued liabilities | ... | 8,000 |
| Accounts payable & accrued liabilities | 1,251,645 | ☒5,478,443 |
| Accrued compensation | 2,069,000 | ... |
| Accrued dividends | 85,000 | ... |
| Derivative liability | 3,700,000 | ... |
| Lease liability | 58,979 | 50,847 |
| Accounts payable and accrued liabilities - Balancing value | 9,178,645 | ... |
| Total current liabilities | 12,937,624 | 5,529,290 |
| Lease liability, net of current portion | 494,003 | 552,981 |
| Total liabilities | 13,431,627 | 6,082,271 |
| Series D preferred stock | 1,382,023 | 1,382,023 |
| Common stock | 207 | 94 |
| Additional paid-in capital | 210,066,630 | 193,624,445 |
| Retained earnings (accumulated deficit) | (217,482,539) | (179,499,043) |
| Preferred stock | 4,677,632 | ... |
| Total stockholders' equity (deficit) | (1,356,047) | 15,507,519 |
| Total Equity | (1,356,047) | ... |

☐ Rounding difference, breakdown taken from the notes

Recent Dividends:

- 1. Collectar Biosciences Inc common.**
No dividends paid.
- 2. Collectar Biosciences Inc series E-2 convertible preferred.**
No dividends paid.
- 3. Collectar Biosciences Inc series E convertible preferred.**
No dividends paid.
- 4. Collectar Biosciences Inc series B preferred.**
No dividends paid.
- 5. Collectar Biosciences Inc series D preferred.**
No dividends paid.
- 6. Collectar Biosciences Inc series C convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Collectar Biosciences Inc common.**
No dividends paid.
- 2. Collectar Biosciences Inc series E-2 convertible preferred.**
No dividends paid.
- 3. Collectar Biosciences Inc series E convertible preferred.**
No dividends paid.
- 4. Collectar Biosciences Inc series B preferred.**
No dividends paid.
- 5. Collectar Biosciences Inc series D preferred.**
No dividends paid.
- 6. Collectar Biosciences Inc series C convertible preferred.**
No dividends paid.

CEPTON INC

Annual Report Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 12/31/22 | ☒03/31/21 |
|--|------------|-----------|-----------|
| Lidar sensor & prototype revenue | 10,270,000 | 5,616,000 | ... |
| Development revenue | 2,786,000 | 1,810,000 | ... |
| Total revenues | 13,056,000 | 7,426,000 | ... |
| Lidar sensor & prototype cost of revenue | 8,939,000 | 6,383,000 | ... |
| Development cost of revenue | 567,000 | 849,000 | ... |
| Total cost of revenue | 9,506,000 | 7,232,000 | ... |
| Gross profit | 3,550,000 | 194,000 | ... |
| General & administrative | ... | ... | ... |

| | | | | | | | | | | | |
|--|--------------|-------------------------|-----------|--|------------|---------------------|----------------|---|---|--------------|-----------------------------|
| expenses | ... | ... | 93,265 | basic | ... | ... | \$17.80 | Other long-term liabilities | 43,000 | 281,000 | |
| Research & development | 29,879,000 | 33,013,000 | ... | Net earnings (loss) per share - basic | \$(3.08) | ² \$0.60 | ... | Operating Lease Liabilities non-current | 8,720,000 | ... | |
| Selling, general & administrative exps | 24,374,000 | 28,629,000 | ... | Net income (loss) per class A share - diluted | ... | ... | \$0.00 | Total liabilities | 15,925,000 | 48,683,000 | |
| Total operating expenses | 54,253,000 | 61,642,000 | ... | Net income (loss) per class B share - diluted | ... | ... | \$17.80 | Class A common stock | 159 | ... | |
| Income (loss) from operations | (50,703,000) | (61,448,000) | (93,265) | Net earnings (loss) per share - diluted | \$(3.08) | ² \$0.60 | ... | Common stock | ... | 2,000 | |
| Gain on change in fair value of earnout liability | 827,000 | 74,078,000 | ... | Full-Time Employees (Period End) | 87 | ... | ... | Additional paid-in capital | 96,583,000 | 88,056,000 | |
| Gain on change in fair value of warrant liability | 397,000 | 2,875,000 | ... | Total number of employees | 87 | 143 | 2 | Accumulated other comprehensive income (loss) | (345,000) | (366,000) | |
| Foreign currency transaction loss, net | (757,000) | (2,168,000) | ... | Number of A common stockholders | ... | ... | ³ 1 | Accumulated deficit | (134,605,000) | ... | |
| Early extinguishment of debt | (1,123,000) | (958,000) | ... | Number of common stockholders | 31 | ⁴ \$37 | ... | Retained earnings (accumulated deficit) | ... | (86,059,000) | |
| Other income (expense), net | 37,000 | (472,000) | ... | Foreign currency translation adjustments | ... | (317,000) | ... | Convertible preferred stock | 98,891,000 | ... | |
| Interest income, net | 2,792,000 | ... | ... | ¹ 2021 and prior periods for Growth Capital Acquisition Corp. prior to reverse recapitalization with Cepton Technologies, Inc.; | ... | ... | ... | Total shareholders' equity (deficit) | 60,524,000 | 1,633,000 | |
| Interest income (expense), net | ... | (2,511,000) | ... | ² Adjusted for 1-for-10 stock split, September 22, 2023; ³ As of July 16, 2021; ⁴ Approximately; ⁵ As of March 1, 2023 | ... | ... | ... | Total Equity | 60,524,000 | ... | |
| Warrant transaction costs | ... | ... | 292,875 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Recent Dividends: | | | |
| Excess value of UW warrants | ... | ... | 1,293,750 | | | | 2023 | 2022 | | | |
| Unrealized gain on fair value changes of warrants | ... | ... | 9,936,000 | Cash & cash equivalents | 50,406,000 | 31,953,000 | 5,969,000 | 3,703,000 | 1. Cepton Inc series A convertible preferred. No dividends paid. | | |
| Interest income & realized gain from sale of treasury securities | ... | ... | 5,514 | Short-term investments | 5,969,000 | 3,703,000 | ... | ... | 2. Cepton Inc class B common. No dividends paid. | | |
| Income (loss) before income taxes - Domestic | ... | 9,620,000 | ... | Accounts receivable, net of allowance for doubtful accounts of \$0 and \$0, respectively | 3,625,000 | ... | 3,625,000 | 1,301,000 | 3. Cepton Inc class A common. No dividends paid. | | |
| Income (loss) before income taxes - Foreign | ... | (224,000) | ... | Accounts receivable | 3,625,000 | 1,301,000 | 1,182,000 | 1,179,000 | 4. Cepton Inc class A common subject to possible redemption. No dividends paid. | | |
| Income (loss) before income taxes | (48,530,000) | 9,396,000 | ... | Raw materials | 1,182,000 | 1,179,000 | 876,000 | 1,141,000 | 5. Cepton Inc common. No dividends paid. | | |
| Current foreign income taxes | 16,000 | 16,000 | ... | Work in process | 876,000 | 1,141,000 | 338,000 | 665,000 | Annual Dividends: | | |
| Current income taxes | 16,000 | 16,000 | ... | Finished goods | 338,000 | 665,000 | 2,396,000 | 2,985,000 | 1. Cepton Inc series A convertible preferred. No dividends paid. | | |
| Provision for income taxes | 16,000 | 16,000 | ... | Inventories | 2,396,000 | 2,985,000 | ... | ... | 2. Cepton Inc class B common. No dividends paid. | | |
| Net income (loss) | (48,546,000) | 9,380,000 | 8,261,624 | Right-of-use assets | ... | 121,000 | 365,000 | 2,533,000 | 3. Cepton Inc class A common. No dividends paid. | | |
| Weighted average class A shares subject to possible redemption | ... | ... | 240,499 | Prepaid insurance | 365,000 | 2,533,000 | 737,000 | 1,376,000 | 4. Cepton Inc class A common subject to possible redemption. No dividends paid. | | |
| Weighted average class B shares outstanding - basic | ... | ... | 464,861 | Other prepaid expenses | 737,000 | 1,376,000 | ... | 993,000 | 5. Cepton Inc common. No dividends paid. | | |
| Weighted average shares outstanding - basic | 15,776,387 | ² 14,691,793 | ... | Deferred transaction costs | ... | 993,000 | ... | 865,000 | CERO THERAPEUTICS HOLDINGS INC | | |
| Weighted average class A shares subject to possible redemption | ... | ... | 240,499 | Payroll tax receivable | ... | 865,000 | 151,000 | 384,000 | Annual Report | | |
| Weighted average class B shares outstanding - diluted | 15,776,387 | ² 15,572,845 | ... | Other current assets | 151,000 | 384,000 | ... | 6,151,000 | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
| Year end shares outstanding | 15,861,494 | ² 15,674,771 | 2,156,250 | Prepaid expenses & other current assets | ... | 6,151,000 | ... | ... | 2023 | 2022 | ¹ 2021 (revised) |
| Net income (loss) per class A share - basic | ... | ... | \$0.00 | Prepaid expenses | 1,253,000 | ... | 63,649,000 | 46,214,000 | 2,892,935 | 2,841,391 | 251,706 |
| Net income (loss) per class B share - | ... | ... | \$0.00 | Total current assets | 63,649,000 | 46,214,000 | 2,326,000 | 1,445,000 | 40,050 | 64,050 | 80,324 |
| | | | | Machinery & equipment | 2,326,000 | 1,445,000 | ... | 101,000 | ... | ... | ... |
| | | | | Vehicles | ... | 101,000 | 235,000 | 189,000 | (2,932,985) | ... | ... |
| | | | | Leasehold improvements | 235,000 | 189,000 | 116,000 | 116,000 | ... | 2,905,441 | 332,030 |
| | | | | Computer & equipment | 116,000 | 116,000 | ... | ... | ... | 2,905,441 | 332,030 |
| | | | | Less: accumulated depreciation & amortization | 1,272,000 | 869,000 | ... | ... | ... | ... | ... |
| | | | | Automobiles | 45,000 | ... | 1,450,000 | 982,000 | ... | ... | ... |
| | | | | Total property, and equipment | 2,722,000 | ... | 1,283,000 | 2,565,000 | 491,571 | 2,836,864 | ... |
| | | | | Property, plant & equipment, net | 1,450,000 | 982,000 | 10,067,000 | 555,000 | ... | ... | ... |
| | | | | Restricted cash | 1,283,000 | 2,565,000 | 76,449,000 | 50,316,000 | ... | ... | ... |
| | | | | Other assets | 10,067,000 | 555,000 | ... | 1,979,000 | (2,441,414) | (68,577) | (332,415) |
| | | | | Total assets | 76,449,000 | 50,316,000 | ... | ... | 94,819 | 599,159 | ... |
| | | | | Accounts payable | ... | 1,979,000 | 1,875,000 | 211,000 | ... | ... | ... |
| | | | | Operating lease liabilities | 1,875,000 | 211,000 | 878,000 | 1,300,000 | ... | ... | ... |
| | | | | Accrued payroll | 878,000 | 1,300,000 | 2,798,000 | 375,000 | ... | ... | ... |
| | | | | Accrued expenses & taxes | 2,798,000 | 375,000 | 367,000 | 525,000 | ... | ... | (69,807) |
| | | | | Deferred revenues | 367,000 | 525,000 | 23,000 | 65,000 | ... | ... | ... |
| | | | | Warranty reserve | 23,000 | 65,000 | ... | ... | ... | ... | 52,939 |
| | | | | Accrued expenses & other current liabilities | ... | 2,265,000 | ... | ... | 94,819 | 599,159 | (16,868) |
| | | | | Accounts payable & accrued expenses | 1,128,000 | ... | 4,066,000 | ... | (2,536,233) | (667,736) | (315,547) |
| | | | | Accrued offering costs | 4,066,000 | ... | ... | 42,587,000 | ... | ... | ... |
| | | | | Short term debt | ... | 42,587,000 | 7,069,000 | 47,042,000 | ... | 17,896,428 | 5,041,048 |
| | | | | Total current liabilities | 7,069,000 | 47,042,000 | ... | 440,000 | ... | ... | ... |
| | | | | Warrant liability | ... | 440,000 | ... | 920,000 | ... | ... | ... |
| | | | | Earnout liabilities | 93,000 | 920,000 | ... | ... | ... | ... | ... |

| | | | |
|--|------------|-----------|------------|
| class B common shares outstanding - basic | 4,596,250 | 4,607,658 | |
| Weighted average shares outstanding - basic | 6,528,668 | | |
| Weighted average class A common shares outstanding - diluted | 17,896,428 | 5,041,048 | |
| Weighted average class B common shares outstanding - diluted | 4,596,250 | 4,607,658 | |
| Weighted average shares outstanding - diluted | 6,528,668 | | |
| Year end shares outstanding | 6,246,207 | 6,769,548 | 22,981,250 |
| Net income (loss) per class A share - basic | \$(0.03) | \$4.15 | |
| Net income (loss) per class B share - basic | \$(0.03) | \$(0.03) | |
| Net income (loss) per class A share - diluted | \$(0.03) | \$4.15 | |
| Net income (loss) per class B share - diluted | \$(0.03) | \$(0.03) | |
| Total number of employees | 3 | 3 | |
| Number of units stockholders | 1 | 4 | 1 |
| Number of class A common stockholders | 1 | 4 | 1 |
| Total other income | 491,571 | | |
| EPS - Basic - including Extraordinary Items Applicable to Common - Total | \$(0.39) | | |
| EPS - Diluted - including Extraordinary Items Applicable to Common - Total | \$(0.39) | | |

¹ From June 8, 2021 (inception); ² Shares decreased due to the effect of redemption of class A common shares; ³ As of March 16, 2023; ⁴ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash | 96,873 | 475,870 |
| Prepaid expenses & other assets | | 225,188 |
| Prepaid expenses | 27,426 | |
| Restricted cash held in trust account | | 41,665,974 |
| Money market funds held in Trust Account | 8,436,311 | |
| Total current assets | 8,560,610 | 42,367,032 |
| Total assets | 8,560,610 | 42,367,032 |
| Accounts payable & accrued expenses | 3,535,084 | 1,653,120 |
| Income tax payable | 23,633 | 599,159 |
| Shareholder redemption liability | | 27,842,747 |
| Working capital loan - related party | 3,315 | 650,000 |
| Franchise tax payable | 56,389 | |
| Due to affiliate | | 3,315 |
| Working capital loan related party | 1,555,000 | |
| Total current liabilities | 5,173,421 | 30,748,341 |
| Deferred underwriting fee payable | 9,150,000 | 9,150,000 |
| Total liabilities | | 39,898,341 |
| Class A common stock subject to possible redemption | 8,436,311 | 13,224,068 |

| | | |
|---|--------------|--------------|
| Class A common stock | 547 | 88 |
| Class B common stock | | 459 |
| Accumulated deficit | (14,199,669) | |
| Retained earnings (accumulated deficit) | | (10,755,924) |
| Total stockholders' equity | (14,199,122) | (10,755,377) |
| Total Equity | (14,199,122) | |

Recent Dividends:

- CERo Therapeutics Holdings Inc class B common.**
No dividends paid.
- CERo Therapeutics Holdings Inc class A common.**
No dividends paid.
- CERo Therapeutics Holdings Inc class A common subject to possible redemption.**
No dividends paid.

Annual Dividends:

- CERo Therapeutics Holdings Inc class B common.**
No dividends paid.
- CERo Therapeutics Holdings Inc class A common.**
No dividends paid.
- CERo Therapeutics Holdings Inc class A common subject to possible redemption.**
No dividends paid.

CERO THERAPEUTICS HOLDINGS INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Citrin Cooperman & Company, LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheets of Phoenix Biotech Acquisition Corp. (the "Company") as of December 31, 2023 and 2022, and the related statements of operations, changes in stockholders' deficit and cash flows for each of the years in the two-year period ended December 31, 2023, and the related notes (collectively, the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt About the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company's expected working capital needs to fund its combined operations and meet obligations as a result of the acquisition of CERo Therapeutics, Inc. in February 2024, raise substantial doubt about its ability to continue as a going concern. The Company's continued operations are dependent upon its ability to raise additional funds through debt or equity financing. There can be no assurances that the Company will be able to secure any such additional financing on acceptable terms and conditions, or at all. Management's plan in regard to these matters is described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

CERVOMED INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|------------------------------------|-------------|--------------|-----------------------------|
| Grant revenue | 7,144,872 | | |
| Total revenues | 7,144,872 | | |
| Research & development | 8,438,499 | 7,237,165 | 8,499,414 |
| Intangible asset impairment charge | | | 8,639,000 |
| General & administrative | 6,519,268 | 8,735,015 | 7,445,277 |
| Depreciation | | | 93,416 |
| Total operating expenses | 14,957,767 | | |
| Income (loss) from operations | (7,812,895) | (15,972,180) | (24,677,107) |
| Other income (expense) | 5,421,592 | | |
| Interest income | 219,430 | 380,752 | 137,487 |
| Total other income (expenses) | 5,641,022 | | |
| Income (loss) before income taxes | (2,171,873) | (15,591,428) | (24,539,620) |
| Income tax expense (benefit) | | | (443,893) |

| | | | |
|---|-------------|--------------|--------------|
| Net income (loss) | (2,171,873) | (15,591,428) | (24,095,727) |
| Weighted average shares outstanding - basic | 2,661,416 | 1,359,261 | 1,301,690 |
| Weighted average shares outstanding - diluted | 2,661,416 | 1,359,261 | 1,301,690 |
| Year end shares outstanding | 5,674,520 | 1,359,705 | 1,358,857 |
| Net income (loss) per share - basic | \$(0.82) | \$(11.47) | \$(18.75) |
| Net income (loss) per share - diluted | \$(0.82) | \$(11.47) | \$(18.75) |
| Number of full time employees | 8 | 13 | 12 |
| Total number of employees | 8 | | |
| Number of common stockholders | 115 | 103 | 343 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.82) | | |
| Diluted EPS Excluding ExtraOrd Items | \$(0.82) | | |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-1.5 stock split, August 17, 2023; ³ Adjusted for 1-for-50 reverse stock split, April 19, 2022; ⁴ Shares increased due to the effect of issuance of common stock and warrants and upon exercise of warrants and vesting of restricted stock units; ⁵ As of March 14, 2023; ⁶ As March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|---------------|
| Cash & cash equivalents | 7,792,846 | 10,113,706 |
| Marketable securities | | 12,408,940 |
| Receivables | 915,404 | |
| Prepaid expenses & other current assets | 1,256,501 | 112,406 |
| Total current assets | 9,964,751 | 22,635,052 |
| Other assets | 7,770 | |
| Total assets | 9,972,521 | 22,635,052 |
| Accounts payable | 662,471 | 1,127,782 |
| Accrued expenses | 209,115 | |
| Accrued payroll & payroll related expenses | 1,026,054 | 131,777 |
| Accrued professional fees | 309,062 | 552,785 |
| Accrued clinical studies expenses | 389,045 | 475,141 |
| Other accrued expenses & other current liabilities | | 129,851 |
| Total liabilities | | 2,417,336 |
| Common stock | 5,674 | 2,040 |
| Additional paid-in capital | 61,811,889 | 165,847,590 |
| Accumulated other comprehensive income (loss) | | (35,375) |
| Accumulated deficit | (54,440,789) | |
| Retained earnings (accumulated deficit) | | (145,596,539) |
| Total stockholders' equity (deficit) | 7,376,774 | 20,217,716 |
| Total stockholders' equity (deficit) | 7,376,774 | |

Recent Dividends:

- CervoMed Inc series D 10% preferred.**
No dividends paid.
- CervoMed Inc series E 5% preferred.**
No dividends paid.
- CervoMed Inc series C 10% preferred.**
No dividends paid.
- CervoMed Inc common.**
No dividends paid.
- CervoMed Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- CervoMed Inc series D 10% preferred.**
No dividends paid.
- CervoMed Inc series E 5% preferred.**

| | | | |
|--|---------------------|--------------------|---------------------|
| No dividends paid. | | | |
| 3. CervoMed Inc series C 10% preferred. | | | |
| No dividends paid. | | | |
| 4. CervoMed Inc common. | | | |
| No dividends paid. | | | |
| 5. CervoMed Inc series A convertible preferred. | | | |
| No dividends paid. | | | |
| CFN ENTERPRISES INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Net revenues | 3,537,632 | ... | ... |
| Net revenues | 3,537,632 | 4,317,490 | 3,157,783 |
| Cost of revenue | 3,022,942 | 6,512,109 | 3,539,636 |
| Gross profit (loss) | 514,690 | (2,194,619) | (381,853) |
| Impairment expense | 8,676,430 | 3,615,961 | 9,355,657 |
| Selling, general & administrative expenses | 5,630,794 | 2,641,842 | 2,691,258 |
| Total operating expenses | 14,307,224 | 6,157,802 | 12,046,915 |
| Income (loss) from operations | (13,792,534) | (8,452,422) | (12,428,768) |
| Loss on conversion of debt | ... | 563,220 | ... |
| Unrealized gain (loss) on marketable securities | ... | (46,516) | (45,658) |
| Impairment of investments | ... | 200,000 | ... |
| Gain (loss) on extinguishment of debt | 48,112 | ... | (172,500) |
| Small Business Administration ("SBA") Paycheck Protection Program ("PPP") loan forgiveness | ... | ... | (526,000) |
| Interest expense | 1,631,564 | 694,380 | 93,170 |
| Interest income | 321 | 113 | 10,011 |
| Other income | 179,650 | 34,206 | ... |
| Gain on property and equipment | 9,253 | ... | ... |
| Total other income (expense), net | (1,394,228) | (1,469,797) | 224,683 |
| Net income (loss) before provision for income taxes | (15,186,762) | ... | ... |
| Net income (loss) | (15,186,762) | (9,922,219) | (12,204,085) |
| Preferred stock interest | ... | 240,000 | 240,000 |
| Net income (loss) available to common shareholders | (15,426,762) | (10,162,219) | (12,444,085) |
| Less dividends for series A & B preferred stock | 240,000 | ... | ... |
| Net income (loss) attributable to non-controlling interest | ... | 19,826 | 5,593 |
| Net income (loss) available to CFN Enterprises Inc. common shareholders | ... | (10,142,393) | (12,449,678) |
| Weighted average shares outstanding - basic | 61,232,637 | 34,258,898 | 16,227,143 |
| Weighted average shares outstanding - diluted | 61,232,637 | 34,258,898 | 16,227,143 |
| Year end shares outstanding | 82,210,664 | 37,690,664 | 31,679,481 |
| Net income (loss) from continuing operations per share - basic | \$(0.25) | ... | ... |
| Net income (loss) per share - basic | \$(0.25) | \$(0.30) | \$(0.77) |
| Net income (loss) from continuing | | | |

| | | | |
|---------------------------------------|--------------|----------|----------|
| operations per share - diluted | \$(0.25) | ... | ... |
| Net income (loss) per share - diluted | \$(0.25) | \$(0.30) | \$(0.77) |
| Number of full time employees | 14 | 14 | 14 |
| Total number of employees | 14 | ... | ... |
| Number of common stockholders | 171 | 495 | 1,036 |
| Federal | (11,921,729) | ... | ... |
| Income Taxes - Other - Deferred | 11,921,729 | ... | ... |

Reclassified to conform with 2022 presentation; As reported by the Company

| | | | |
|--|--------------|--------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash | 78,744 | 12,474 | |
| Restricted cash | 20,448 | 20,128 | |
| Accounts receivable, gross | 1,738,499 | 498,777 | |
| Less: allowance for bad debt | 796,251 | 470,532 | |
| Accounts receivable, net | 942,248 | 28,245 | |
| Inventory | 1,796,227 | ... | |
| Total current assets | 2,837,667 | 60,847 | |
| Deposits | 297,269 | ... | |
| Machinery & equipment | 50,000 | 50,000 | |
| Furniture & equipment & leasehold improvements | 14,773 | 14,772 | |
| Tradeshow booth | 162,200 | ... | |
| Property & equipment, gross | 226,973 | 64,772 | |
| Less: accumulated depreciation | 70,630 | 11,202 | |
| Property & equipment, net | 156,343 | 53,570 | |
| Right of use asset | 2,159,043 | 110,321 | |
| Other assets | 8,910 | 46,766 | |
| Assets held for sale | ... | 599,047 | |
| Total assets | 5,459,232 | 870,551 | |
| Accounts payable | 3,018,531 | 2,357,614 | |
| Accrued liabilities | 3,828,063 | 2,343,654 | |
| Payments made in advance of securities date | 208,000 | 217,500 | |
| Due to related party | 501,140 | 503,259 | |
| Deferred revenue | 484,212 | 10,978 | |
| Current portion of notes payable | 7,272,357 | 3,088,250 | |
| Current portion of right of use liability | 822,259 | 262,727 | |
| Current liabilities of discontinued operations | 79,823 | 79,823 | |
| Due to seller | 1,000,000 | ... | |
| Total current liabilities | 17,214,385 | 8,863,805 | |
| Right of use liability | 1,547,410 | 200,758 | |
| Long-term note payable, net of current portion & discounts | 128,443 | 978,337 | |
| Total liabilities | 18,890,238 | 10,042,900 | |
| Series A preferred stock | 1 | 1 | |
| Series B preferred stock | ... | 3 | |
| Preferred stock, B | 3 | ... | |
| Common shares | 82,210 | ... | |
| Common stock | ... | 37,690 | |
| Additional paid-in capital | 60,909,641 | 49,786,056 | |
| Accumulated deficit | (74,422,861) | ... | |
| Retained earnings (accumulated deficit) | ... | (58,996,099) | |
| Total stockholders' equity (deficit) | (13,431,006) | (9,172,349) | |
| Total stockholders' equity (deficit) | (13,431,006) | ... | |

Recent Dividends:

1. CFN Enterprises Inc series A preferred. No dividends paid.
2. CFN Enterprises Inc series B preferred. No dividends paid.
3. CFN Enterprises Inc series B preferred.

| | | | |
|---|--|--|--|
| No dividends paid. | | | |
| 4. CFN Enterprises Inc common. | | | |
| No dividends paid. | | | |
| 5. CFN Enterprises Inc series A preferred. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. CFN Enterprises Inc series A preferred. | | | |
| No dividends paid. | | | |
| 2. CFN Enterprises Inc series B preferred. | | | |
| No dividends paid. | | | |
| 3. CFN Enterprises Inc series B preferred. | | | |
| No dividends paid. | | | |
| 4. CFN Enterprises Inc common. | | | |
| No dividends paid. | | | |
| 5. CFN Enterprises Inc series A preferred. | | | |
| No dividends paid. | | | |

| | | | |
|---|--------------------|--------------------|------------------|
| CHARLIES HOLDINGS INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Net sales | 16,250,000 | ... | ... |
| Product revenue, net | ... | 26,424,000 | 21,496,000 |
| Total revenues | 16,250,000 | 26,424,000 | 21,496,000 |
| Cost of goods sold - product revenue | 10,206,000 | 16,439,000 | 10,423,000 |
| General & administrative expenses | 6,970,000 | 8,381,000 | 8,750,000 |
| Sales & marketing expenses | 1,107,000 | 2,605,000 | 1,734,000 |
| Research & development expenses | 169,000 | 804,000 | 24,000 |
| Total operating costs & expenses | ... | 28,229,000 | 20,931,000 |
| Total operating expenses | 18,452,000 | ... | ... |
| Income (loss) from operations | (2,202,000) | (1,805,000) | 565,000 |
| Interest expense | 477,000 | 155,000 | 34,000 |
| Change in fair value of derivative liabilities | ... | 270,000 | 3,545,000 |
| Gain on debt extinguishment | 36,000 | ... | 1,060,000 |
| Gain (loss) on disposal of asset | 550,000 | ... | ... |
| Other income | ... | 6,000 | 14,000 |
| Total other income (loss) | ... | 121,000 | 4,585,000 |
| Income (loss) before income taxes | (2,093,000) | (1,684,000) | 5,150,000 |
| Current US federal income taxes (benefit) | ... | (89,000) | 110,000 |
| Current US state income taxes (benefit) | ... | (3,000) | 232,000 |
| Total current provision (benefit) | ... | (92,000) | 342,000 |
| Income taxes provision (benefit) | ... | (92,000) | 342,000 |
| Net income (loss) | (2,093,000) | (1,592,000) | 4,808,000 |
| Weighted average shares outstanding - basic | 216,053,743 | 212,269,453 | 203,589,531 |
| Weighted average shares outstanding - diluted | 216,053,743 | 212,269,453 | 237,686,875 |
| Year end shares outstanding | 228,535,886 | 219,163,631 | 210,890,930 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$0.02 |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$0.01 |
| Number of full time employees | 30 | 35 | 40 |
| Total number of employees | 30 | ... | ... |
| Number of common stockholders | 199 | 199 | 4,200 |
| Number of series A | | | |

| | | |
|---|----------|-----|
| preferred stockholders | □94 | □95 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... |

□ As of April 17, 2023; □ As of March 17, 2022; □ Approximately; □ As of April 12, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash | 367,000 | 257,000 |
| Accounts receivable, gross | ... | 1,319,000 |
| Less: allowance for doubtful accounts | 24,000 | 158,000 |
| Accounts receivable, net - Balancing value | 313,000 | ... |
| Accounts receivable, net | 289,000 | 1,161,000 |
| Inventories, net | 3,826,000 | 3,652,000 |
| Prepaid expenses & other current assets | 604,000 | 780,000 |
| Total current assets | 5,086,000 | 5,850,000 |
| Machinery & equipment | 41,000 | 41,000 |
| Trade show booth | 202,000 | 202,000 |
| Office equipment | 539,000 | 539,000 |
| Leasehold improvements | 254,000 | 254,000 |
| Property & equipment, gross | 1,036,000 | 1,036,000 |
| Accumulated depreciation | 879,000 | 725,000 |
| Property, plant & equipment, net | 157,000 | 311,000 |
| Right-of-use asset, net | 424,000 | 799,000 |
| Other assets | 101,000 | 101,000 |
| Total non-current assets | 682,000 | 1,211,000 |
| Total assets | 5,768,000 | 7,061,000 |
| Accounts payable | 1,472,000 | ... |
| Accounts payable | ... | 1,222,000 |
| Accrued compensation | ... | 631,000 |
| Accrued income taxes | 128,000 | 137,000 |
| Other accrued expenses | 287,000 | 343,000 |
| Accounts payable & accrued expenses | 2,846,000 | 2,333,000 |
| Derivative liability | 79,000 | 629,000 |
| Lease liabilities | 355,000 | 373,000 |
| Note payable | 716,000 | 1,000,000 |
| Note payable, net - related party | 700,000 | 300,000 |
| Deferred revenue | 58,000 | 148,000 |
| Other accrued expenses | 573,000 | ... |
| Customer deposits | 386,000 | ... |
| Total current liabilities | 4,754,000 | 4,783,000 |
| Notes payable, net of current portion | 150,000 | 150,000 |
| Lease liabilities, net of current portion | 73,000 | 428,000 |
| Senior notes payable | 898,000 | ... |
| Total non-current liabilities | 1,121,000 | 578,000 |
| Total liabilities | 5,875,000 | 5,361,000 |
| Common stock | 229,000 | 219,000 |
| Additional paid-in capital | 8,204,000 | 7,928,000 |
| Accumulated deficit | (8,540,000) | ... |
| Retained earnings (accumulated deficit) | ... | (6,447,000) |
| Total stockholders' equity (deficit) | (107,000) | 1,700,000 |
| Total Equity | (107,000) | ... |

Recent Dividends:

- 1. Charlies Holdings Inc series A convertible preferred.**
No dividends paid.
- 2. Charlies Holdings Inc series B convertible preferred.**
No dividends paid.
- 3. Charlies Holdings Inc series D convertible preferred.**
No dividends paid.
- 4. Charlies Holdings Inc series A preferred.**
No dividends paid.
- 5. Charlies Holdings Inc series C convertible preferred.**
No dividends paid.

6. Charlies Holdings Inc common.
No dividends paid.

Annual Dividends:

- 1. Charlies Holdings Inc series A convertible preferred.**
No dividends paid.
- 2. Charlies Holdings Inc series B convertible preferred.**
No dividends paid.
- 3. Charlies Holdings Inc series D convertible preferred.**
No dividends paid.
- 4. Charlies Holdings Inc series A preferred.**
No dividends paid.
- 5. Charlies Holdings Inc series C convertible preferred.**
No dividends paid.
- 6. Charlies Holdings Inc common.**
No dividends paid.

CHARLIES HOLDINGS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|--------------------|------------------|
| Net sales | 16,250,000 | ... | ... |
| Product revenue, net | 26,424,000 | 21,496,000 | 21,496,000 |
| Total revenues | 16,250,000 | 26,424,000 | 21,496,000 |
| Cost of goods sold - product revenue | 10,206,000 | 16,439,000 | 10,423,000 |
| General & administrative expenses | 6,970,000 | 8,381,000 | 8,750,000 |
| Sales & marketing expenses | 1,107,000 | 2,605,000 | 1,734,000 |
| Research & development expenses | 169,000 | 804,000 | 24,000 |
| Total operating costs & expenses | ... | 28,229,000 | 20,931,000 |
| Total operating expenses | 18,452,000 | ... | ... |
| Income (loss) from operations | (2,202,000) | (1,805,000) | 565,000 |
| Interest expense | 477,000 | 155,000 | 34,000 |
| Change in fair value of derivative liabilities | ... | 270,000 | 3,545,000 |
| Gain on debt extinguishment | 36,000 | ... | 1,060,000 |
| Gain (loss) on disposal of asset | 550,000 | ... | ... |
| Other income | ... | 6,000 | 14,000 |
| Total other income (loss) | ... | 121,000 | 4,585,000 |
| Income (loss) before income taxes | (2,093,000) | (1,684,000) | 5,150,000 |
| Current US federal income taxes (benefit) | ... | (89,000) | 110,000 |
| Current US state income taxes (benefit) | ... | (3,000) | 232,000 |
| Total current provision (benefit) | ... | (92,000) | 342,000 |
| Income taxes provision (benefit) | ... | (92,000) | 342,000 |
| Net income (loss) | (2,093,000) | (1,592,000) | 4,808,000 |
| Weighted average shares outstanding - basic | 216,053,743 | 212,269,453 | 203,589,531 |
| Weighted average shares outstanding - diluted | 216,053,743 | 212,269,453 | 237,686,875 |
| Year end shares outstanding | 228,535,886 | 219,163,631 | 210,890,930 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$0.02 |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$0.01 |
| Number of full time employees | 30 | □35 | □40 |
| Total number of employees | 30 | ... | ... |
| Number of common stockholders | 199 | □199 | □4,200 |
| Number of series A preferred | ... | ... | ... |

| | | |
|---|----------|-----|
| stockholders | □94 | □95 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... |

□ As of April 17, 2023; □ As of March 17, 2022; □ Approximately; □ As of April 12, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash | 367,000 | 257,000 |
| Accounts receivable, gross | ... | 1,319,000 |
| Less: allowance for doubtful accounts | 24,000 | 158,000 |
| Accounts receivable, net - Balancing value | 313,000 | ... |
| Accounts receivable, net | 289,000 | 1,161,000 |
| Inventories, net | 3,826,000 | 3,652,000 |
| Prepaid expenses & other current assets | 604,000 | 780,000 |
| Total current assets | 5,086,000 | 5,850,000 |
| Machinery & equipment | 41,000 | 41,000 |
| Trade show booth | 202,000 | 202,000 |
| Office equipment | 539,000 | 539,000 |
| Leasehold improvements | 254,000 | 254,000 |
| Property & equipment, gross | 1,036,000 | 1,036,000 |
| Accumulated depreciation | 879,000 | 725,000 |
| Property, plant & equipment, net | 157,000 | 311,000 |
| Right-of-use asset, net | 424,000 | 799,000 |
| Other assets | 101,000 | 101,000 |
| Total non-current assets | 682,000 | 1,211,000 |
| Total assets | 5,768,000 | 7,061,000 |
| Accounts payable | 1,472,000 | ... |
| Accounts payable | ... | 1,222,000 |
| Accrued compensation | ... | 631,000 |
| Accrued income taxes | 128,000 | 137,000 |
| Other accrued expenses | 287,000 | 343,000 |
| Accounts payable & accrued expenses | 2,846,000 | 2,333,000 |
| Derivative liability | 79,000 | 629,000 |
| Lease liabilities | 355,000 | 373,000 |
| Note payable | 716,000 | 1,000,000 |
| Note payable, net - related party | 700,000 | 300,000 |
| Deferred revenue | 58,000 | 148,000 |
| Other accrued expenses | 573,000 | ... |
| Customer deposits | 386,000 | ... |
| Total current liabilities | 4,754,000 | 4,783,000 |
| Notes payable, net of current portion | 150,000 | 150,000 |
| Lease liabilities, net of current portion | 73,000 | 428,000 |
| Senior notes payable | 898,000 | ... |
| Total non-current liabilities | 1,121,000 | 578,000 |
| Total liabilities | 5,875,000 | 5,361,000 |
| Common stock | 229,000 | 219,000 |
| Additional paid-in capital | 8,204,000 | 7,928,000 |
| Accumulated deficit | (8,540,000) | ... |
| Retained earnings (accumulated deficit) | ... | (6,447,000) |
| Total stockholders' equity (deficit) | (107,000) | 1,700,000 |
| Total Equity | (107,000) | ... |

Recent Dividends:

- 1. Charlies Holdings Inc series A convertible preferred.**
No dividends paid.
- 2. Charlies Holdings Inc series B convertible preferred.**
No dividends paid.
- 3. Charlies Holdings Inc series D convertible preferred.**
No dividends paid.
- 4. Charlies Holdings Inc series A preferred.**
No dividends paid.
- 5. Charlies Holdings Inc series C convertible preferred.**
No dividends paid.
- 6. Charlies Holdings Inc common.**

No dividends paid.
Annual Dividends:
1. Charlies Holdings Inc series A convertible preferred.
 No dividends paid.
2. Charlies Holdings Inc series B convertible preferred.
 No dividends paid.
3. Charlies Holdings Inc series D convertible preferred.
 No dividends paid.
4. Charlies Holdings Inc series A preferred.
 No dividends paid.
5. Charlies Holdings Inc series C convertible preferred.
 No dividends paid.
6. Charlies Holdings Inc common.
 No dividends paid.

CHEETAH NET SUPPLY CHAIN SERVICE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|-------------|-------------|
| REVENUE | 38,315,974 | ... | ... |
| Revenue | 38,315,974 | 55,153,335 | 39,204,036 |
| Cost of vehicles | 32,183,676 | 48,534,282 | 34,508,079 |
| Fulfillment expenses | 1,885,382 | 2,149,672 | 1,694,615 |
| Total cost of revenue | 34,069,058 | 50,683,954 | 36,202,694 |
| Gross profit | 4,246,916 | 4,469,381 | 3,001,342 |
| Selling expenses | 668,172 | 898,852 | 294,169 |
| General & administrative expenses | 2,190,513 | 1,430,917 | 589,701 |
| Total operating expenses | 2,858,685 | 2,329,769 | 883,870 |
| Income (loss) from operations | 1,388,231 | 2,139,612 | 2,117,472 |
| Inventory financing | 112,769 | 747,298 | 436,808 |
| Letter of credit financing | 925,426 | 1,669,931 | 519,746 |
| Dealers finance charges | 3,975 | 2,332 | 14,093 |
| Other loan interest expenses | 31,197 | 18,641 | 65,685 |
| Credit card interest | 4,712 | 3,241 | 16,581 |
| Interest expenses | (1,239,297) | ... | ... |
| Line of Credit | 155,245 | ... | ... |
| Interest Expense - Net of Capitalized Interest | 5,974 | ... | ... |
| Interest income (expense), net | ... | (2,441,443) | (1,052,913) |
| Other income, net | 31,593 | 12,974 | 1,722 |
| Subsidy income from Business Recovery Grant Program | ... | 1,340,316 | ... |
| Gain on forgiveness of loans under Paycheck Protection Program | ... | ... | 327,796 |
| Total other income (expenses), net | (1,207,704) | (1,088,153) | (723,395) |
| Income (loss) before income tax provision | 180,527 | 1,051,459 | 1,394,077 |
| Current federal income tax provision | 7,385 | 42,881 | 43,344 |
| Current state income tax provision | 443 | 33,538 | ... |
| Total current income tax provision | 7,828 | 76,419 | 43,344 |
| Deferred federal income tax provision | 35,561 | 178,279 | 180,528 |
| Deferred state income tax provision | 3,268 | (20,219) | ... |
| Total deferred income tax provision | 38,829 | 158,060 | 180,528 |
| Provision for income taxes | 46,657 | 234,479 | 223,872 |

| | | | |
|---|------------|------------|------------|
| Net income (loss) | 133,870 | 816,980 | 1,170,205 |
| Weighted average shares outstanding | | | |
| - basic | 17,183,123 | 15,794,203 | 15,000,000 |
| Weighted average shares outstanding - diluted | 17,183,123 | 15,794,203 | 15,000,000 |
| Year end shares outstanding | 17,916,000 | 16,666,000 | 15,000,000 |
| Earnings (loss) per share - basic | \$0.01 | \$0.05 | \$0.08 |
| Earnings (loss) per share - diluted | \$0.01 | \$0.05 | \$0.08 |
| Number of full time employees | 18 | 20 | 23 |
| Total number of employees | 18 | ... | ... |
| Income tax provision | 46,657 | ... | ... |
| Common Shareholders - Number | 7 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 432,998 | 58,381 |
| Accounts receivable | 6,494,695 | ... |
| Accounts receivable | 6,494,695 | 7,086,651 |
| Vehicles | 1,515,270 | 5,965,935 |
| Subtotal | 1,515,270 | 5,965,935 |
| Inventories, net | ... | 5,965,935 |
| Other receivables | 410,920 | ... |
| Due from a related party | ... | 900,730 |
| Prepaid expenses & other current assets | 294,154 | 480,828 |
| Subtotal | 410,920 | ... |
| Vehicle Deposit | 162,159 | ... |
| Rent Deposit | 22,095 | ... |
| Sales tax refundable | 217,892 | ... |
| Others | 3,351 | ... |
| Loans receivable - Net | 672,500 | ... |
| Interest receivable | 5,423 | ... |
| Total current assets | 9,820,537 | 14,492,525 |
| Operating lease right-of-use assets | 190,823 | 140,145 |
| Deferred tax assets | 47,905 | 86,734 |
| Total assets | 10,059,265 | 14,719,404 |
| Short-term borrowings | 1,004,565 | 86,285 |
| Current portion of long-term borrowings | 32,887 | 31,281 |
| Loans payable from inventory financing | ... | 4,164,100 |
| Loans payable from letter of credit financing | ... | 7,105,873 |
| Loans payable from dealers finance | 148,621 | 41,747 |
| Due to a related party | 13,423 | ... |
| Operating lease liabilities, current | 39,703 | 149,458 |
| Other payables & other current liabilities | ... | 616,863 |
| Accounts payable | 40,430 | ... |
| Accrued liabilities and other current liabilities | 390,451 | ... |
| Loans payable from line of credit | 688,711 | ... |
| Total current liabilities | 2,358,791 | 12,195,607 |
| Small Business Administration | ... | 490,130 |
| Thread Capital Inc. | ... | 219,593 |
| Total long-term borrowings | ... | 709,723 |
| Less: current portion of long-term borrowings | ... | 31,281 |
| Non-current portion of long-term debt | 644,725 | ... |
| Long-term borrowings, non-current | ... | 678,442 |
| Operating lease liabilities, non-current | 151,121 | ... |
| Total liabilities | 3,154,637 | 12,874,049 |
| Class A common stock | 967 | 842 |
| Class B common stock | 825 | 825 |
| Additional paid-in | ... | ... |

| | | |
|---|-----------|-------------|
| capital | 6,994,595 | 3,269,317 |
| Subscription receivable | (600,000) | (1,800,000) |
| Retained earnings | 508,241 | ... |
| Retained earnings (accumulated deficit) | ... | 374,371 |
| Total stockholders' equity (deficit) | 6,904,628 | 1,845,355 |
| Total Equity | 6,904,628 | ... |

Recent Dividends:

1. Cheetah Net Supply Chain Service Inc class A.

No dividends paid.

2. Cheetah Net Supply Chain Service Inc class B.

No dividends paid.

Annual Dividends:

1. Cheetah Net Supply Chain Service Inc class A.

No dividends paid.

2. Cheetah Net Supply Chain Service Inc class B.

No dividends paid.

CHINA AUTOMOTIVE SYSTEMS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|----------------------------|----------------------------|-------------|
| | | | (revised) |
| Salaries and wages | 3,249,000 | ... | ... |
| Others expenses | 563,000 | ... | ... |
| Salaries and wages | 11,216,000 | ... | ... |
| Property and Other Taxes | 1,597,000 | ... | ... |
| Warehouse rent and inventory handling expenses | 2,508,000 | ... | ... |
| Transportation expense | 5,705,000 | ... | ... |
| Marketing and office expense | 3,526,000 | ... | ... |
| Selling Expenses - Other expenses | 622,000 | ... | ... |
| Labor insurance expenses | 2,199,000 | ... | ... |
| Listing expenses - legal, accounting and auditing fees | 1,303,000 | ... | ... |
| Maintenance and repair expenses | 1,012,000 | ... | ... |
| Office expense | 4,121,000 | ... | ... |
| Net product sales | 576,354,000 ⁽¹⁾ | 529,551,000 ⁽²⁾ | 497,993,000 |
| Cost of products sold | 472,603,000 ⁽³⁾ | 446,157,000 ⁽⁴⁾ | 425,914,000 |
| Net gain on other sales | 5,788,000 | 3,696,000 | 4,368,000 |
| Selling expenses | 15,610,000 | 16,910,000 | 18,278,000 |
| General & administrative expenses | 25,503,000 | 26,120,000 | 24,423,000 |
| Research & development expenses | 29,181,000 | 36,109,000 | 28,228,000 |
| Depreciation & amortization | 1,928,000 | ... | ... |
| Provision/(reversal) of allowance for doubtful accounts | 1,564,000 | ... | ... |
| Total operating expenses | 70,294,000 | 79,139,000 | 70,929,000 |
| Operating income (loss) | 39,245,000 | 7,951,000 | 5,518,000 |
| Other income (expense), net | 5,345,000 | 5,782,000 | 6,668,000 |
| Interest expense | 1,021,000 | 1,450,000 | 1,437,000 |
| Interest income | 1,524,000 | 1,247,000 | 1,242,000 |
| Interest income (expenses), net | 4,666,000 | ... | ... |
| Foreign exchange income (loss), net | 3,355,000 | 9,833,000 | (3,204,000) |
| Bank fees | 213,000 | 327,000 | 388,000 |
| Penalties income | (103,000) | ... | ... |
| Investment Income | 1,465,000 | ... | ... |
| Government subsidy | (3,777,000) | ... | ... |
| Income (loss) before income tax expenses & equity in earnings of | ... | ... | ... |

| | | | | | | | | | | |
|--|-------------------|-------------------|-------------------|---|-------------|-------------|---|-------------|-------------|------------|
| affiliated companies | 48,235,000 | 23,036,000 | 8,399,000 | parties | 1,991,000 | 10,907,000 | Advances payable | 282,000 | 2,144,000 | |
| Less: income taxes | 5,137,000 | 3,082,000 | 4,004,000 | Advance payments & other current assets - related parties | 14,008,000 | 1,439,000 | Operating lease liabilities - non-current portion | 52,000 | 255,000 | |
| Add: equity in earnings of affiliated companies | (360,000) | 2,389,000 | 6,331,000 | Raw materials | 28,505,000 | 24,502,000 | Long-term loans | 1,221,000 | 528,000 | |
| Accretion to redemption value of redeemable non-controlling interests | (30,000) | ... | ... | Work in process | 17,123,000 | 16,001,000 | Deferred tax liabilities | 3,943,000 | 4,010,000 | |
| Net income (loss) | 42,738,000 | 22,343,000 | 10,726,000 | Finished goods | 62,760,000 | 71,371,000 | Long-term taxes payable | 8,781,000 | 15,805,000 | |
| Net income (loss) attributable to non-controlling interest | (5,050,000) | (1,132,000) | 352,000 | Cost of research & development service | 4,004,000 | 362,000 | Total liabilities | 398,018,000 | 386,937,000 | |
| Net income (loss) attributable to parent company's | 37,658,000 | ... | ... | Total inventories | 112,392,000 | ... | Redeemable non-controlling interests | 613,000 | 582,000 | |
| Accretion to redemption value of redeemable non-controlling interests | ... | 30,000 | 28,000 | Inventories | ... | 112,236,000 | Common stock | 3,000 | 3,000 | |
| Net income (loss) attributable to parent company's common shareholders | 37,658,000 | 21,181,000 | 11,050,000 | Provision - Accounts & Notes Receivable - Trade | 1,404,000 | ... | Additional paid-in capital | 63,731,000 | 63,731,000 | |
| Weighted average shares outstanding - basic | 30,185,702 | 30,639,102 | 30,851,776 | Accounts receivable on sale of subsidiar | ... | 9,573,000 | Retained earnings - appropriated | ... | 11,851,000 | |
| Weighted average shares outstanding - diluted | 30,189,421 | 30,641,274 | 30,855,431 | Balancing value | 9,573,000 | ... | Retained earnings - unappropriated | ... | 247,174,000 | |
| Year end shares outstanding | 30,185,702 | 30,185,702 | 30,851,776 | Total current assets | 564,075,000 | 520,718,000 | Accumulated other comprehensive income (loss) | (8,258,000) | (3,413,000) | |
| Income per share - continued operation - basic | \$1.25 | ... | ... | Long-term time deposits | 3,554,000 | ... | Treasury stock | 7,695,000 | 7,695,000 | |
| Net income (loss) per share - basic | \$1.25 | \$0.69 | \$0.36 | Machinery & equipment | 241,761,000 | 239,385,000 | Appropriated | 11,851,000 | ... | |
| Income per share - continued operation - diluted | \$1.25 | ... | ... | Buildings | 64,390,000 | 64,928,000 | Unappropriated | 284,832,000 | ... | |
| Net income (loss) per share - diluted | \$1.25 | \$0.69 | \$0.36 | Electronic equipment | 5,804,000 | 6,242,000 | Total parent company stockholders' equity | 344,464,000 | 311,651,000 | |
| Full-Time Employees (Period End) | 4,095 | ... | ... | Motor vehicles | 4,587,000 | 4,308,000 | Non-controlling interests | 23,345,000 | 15,182,000 | |
| Total number of employees | 4,095 | 4,093 | 3,949 | Construction in progress | 11,821,000 | 8,238,000 | Total stockholders' equity | 367,809,000 | 326,833,000 | |
| Number of common stockholders | 60 | 54 | 56 | Land/Improvements - Net | 9,233,000 | ... | □ Allowance for doubtful accounts - Accounts and notes receivable: \$1,763,000; □ Allowance for doubtful accounts - Advance payments & others, net: \$115,000 | | | |
| Comprehensive income/(loss) attributable to parent company | 32,813,000 | ... | ... | Property, plant & equipment | 328,363,000 | 323,101,000 | Recent Dividends: | | | |
| | | | | Less: accumulated depreciation | 227,004,000 | 216,495,000 | 1. China Automotive Systems Inc common. | | | |
| | | | | Property, plant & equipment, net | 101,359,000 | 106,606,000 | No dividends paid. | | | |
| | | | | Land use rights, net | 5,759,000 | 9,555,000 | Annual Dividends: | | | |
| | | | | Intangible assets, net | 3,865,000 | 1,273,000 | 1. China Automotive Systems Inc common. | | | |
| | | | | Operating lease assets | 278,000 | 477,000 | No dividends paid. | | | |
| | | | | Long-term time deposits | 8,647,000 | ... | CHINA CHANGJIANG MINING & NEW ENERGY CO LTD | | | |
| | | | | Other receivables, net | ... | 46,000 | Annual Report | | | |
| | | | | Advance payment for property, plant & equipment - unrelated parties | ... | 6,331,000 | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | | | | Advance payment for property, plant & equipment - related parties | ... | 1,884,000 | | 2023 | 2022 | 2021 |
| | | | | Accounts & notes payable - related parties | 12,839,000 | 16,695,000 | Foreign exchange gains (losses), net | 62,173 | 371,024 | (119,757) |
| | | | | Customer deposits | 8,633,000 | 5,654,000 | Total other income (expense) | 62,173 | 371,024 | (119,757) |
| | | | | Accrued payroll & related costs | 11,282,000 | 11,628,000 | Income (loss) before tax | 62,173 | ... | ... |
| | | | | Accrued expenses | ... | 9,652,000 | Net profit (loss) | 62,173 | 371,024 | (119,757) |
| | | | | Warranty reserve | 44,771,000 | 32,435,000 | Weighted average shares outstanding - basic | 64,629,559 | 64,629,559 | 64,629,559 |
| | | | | Payable for the investment in Sentient AB | ... | 2,043,000 | Weighted average shares outstanding - diluted | 64,629,559 | 64,629,559 | 64,629,559 |
| | | | | Payables for overseas transportation & custom clearance | 400,000 | 294,000 | Year end shares outstanding | 64,629,559 | 64,629,559 | 64,629,559 |
| | | | | Dividends payable to non-controlling interests | 424,000 | 431,000 | Net income (loss) per share - basic | ... | \$0.00 | \$0.00 |
| | | | | Accrued interest | ... | 465,000 | Net income (loss) per share - diluted | ... | \$0.00 | \$0.00 |
| | | | | Liabilities in connection with warrants | 10,464,000 | ... | Total number of employees | ... | 2 | 0 |
| | | | | Other payables | ... | 2,991,000 | Number of common stockholders | 3,581 | 3,581 | 1,996 |
| | | | | Value-added tax payable | ... | 3,470,000 | □ As of March 31, 2021; □ Approximately; □ As of April 15, 2023; □ As of March 28, 2022 | | | |
| | | | | Tariffs payable | ... | 7,061,000 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | | | | Long-term taxes payable - current portion | ... | 5,270,000 | | 2023 | 2022 | |
| | | | | Income tax payable | ... | 680,000 | Taxes payable | 59,962 | 60,978 | |
| | | | | Other tax payable | ... | 1,117,000 | Salaries & welfares payable | ... | 661 | |
| | | | | Taxes payable | 17,267,000 | 17,598,000 | Accrued interest payable | 650 | ... | |
| | | | | Operating lease liabilities - current portion | 203,000 | 226,000 | Other payables | 1,134,416 | 1,153,653 | |
| | | | | Amounts due to shareholders/directors | 3,043,000 | ... | Other payables & accrued expenses | 1,195,028 | ... | |
| | | | | Warranty reserves | 30,440,000 | ... | Total current liabilities | 1,195,028 | 1,215,292 | |
| | | | | Total current liabilities | 383,739,000 | 364,195,000 | Due to related parties | 631,929 | 642,645 | |
| | | | | | | | Due to shareholders | 1,839,528 | 1,870,721 | |

| | | | | | | | | |
|---|--------------|--------------|--|----------|----------|---|---|-----------|
| Total non-current liabilities | 2,471,457 | 2,513,366 | expenses | 576,341 | 416,044 | 272,688 | improvements | 1,462,726 |
| Total liabilities | 3,666,485 | 3,728,658 | Gain on disposition of real estate & condominium developments, net | ... | ... | 83,045 | at cost | 154,217 |
| Series C convertible preferred stock | 1,000 | 1,000 | Merger-related expenses, net | ... | ... | 1,404 | Condominium developments | 87,581 |
| Common stock | 646,295 | 646,295 | Operating income (loss) | ... | ... | 174,678 | Total real estate assets, | 1,377,793 |
| Treasury stock | 489,258 | 489,258 | Gain on investment in unconsolidated entities | 11,723 | 11,952 | 606 | Less: accumulated depreciation & amortization | 169,163 |
| Additional paid-in capital | 16,032,106 | 16,032,106 | Unrealized gain (loss) on equity security | 4,751 | (15,117) | ... | Total real estate assets, net | 1,208,630 |
| Accumulated deficit | (19,856,628) | ... | Interest expense & other expense, net | ... | ... | 83,899 | Investment in unconsolidated entities | 126,777 |
| Retained earnings (accumulated deficit) | ... | (19,918,801) | Gain (loss) on extinguishment of debt | (7,788) | (19,644) | (4,895) | Real estate-related securities | 519,714 |
| Total stockholders' equity (deficit) | (3,666,485) | (3,728,658) | Gain (loss) on disposition of real estate, net | 53,341 | 121,902 | ... | Loans held-for-investment & related receivables, net | 4,397,063 |
| Total equity (deficit) | (3,666,485) | ... | Net Income before Tax | 28,086 | 143,866 | ... | Less: current expected credit losses | 132,598 |
| Recent Dividends: | | | Other income, net | (26,459) | 8,671 | ... | Total loans held-for-investment & related receivables, net | 4,264,465 |
| 1. China Changjiang Mining & New Energy Co Ltd common. | | | Total other income (expense) | 35,568 | 107,764 | (88,188) | Cash & cash equivalents | 247,500 |
| No dividends paid. | | | Net income (loss) | 28,086 | 143,866 | 86,490 | Restricted cash | 13,082 |
| 2. China Changjiang Mining & New Energy Co Ltd series C convertible preferred. | | | Net income (loss) allocated to noncontrolling interest | (8) | (66) | ... | Rents & tenant receivables, net | 17,082 |
| No dividends paid. | | | Net income (loss) attributable to the company | 28,078 | 143,800 | 86,490 | Prepaid expenses & other assets | 9,423 |
| Annual Dividends: | | | Weighted average shares outstanding - basic | 437,375 | 437,344 | 365,726 | Prepaid expenses, derivative assets & other assets | ... |
| 1. China Changjiang Mining & New Energy Co Ltd common. | | | Weighted average shares outstanding - diluted | 437,375 | 437,344 | 365,726 | Deferred costs, net | 12,121 |
| No dividends paid. | | | Year end shares outstanding | 437,255 | 437,397 | 437,374 | Accrued interest receivable | 27,682 |
| 2. China Changjiang Mining & New Energy Co Ltd series C convertible preferred. | | | Net income (loss) per common share - basic | \$0.06 | \$0.33 | \$0.24 | Total assets | 6,446,476 |
| No dividends paid. | | | Net income (loss) per common share - diluted | \$0.06 | \$0.33 | \$0.24 | Notes payable | ... |
| CHINA HEALTH INDUSTRIES HOLDINGS, INC. | | | Distributions declared per common share | ... | ... | \$0.36 | Notes payable - variable rate debt | ... |
| Earnings, 6 mos. to Dec 31(Consol. - \$): | | | Number of common stockholders | 74,566 | ... | 76,748 | First lien mortgage loan | ... |
| 2023 | | | Interest expense, net | 260,768 | 165,210 | ... | ABS mortgage notes | ... |
| 2022 | | | Real estate tax | 4,838 | 12,612 | ... | Credit facilities | ... |
| Total revenues | 38,346 | 32,650 | EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$0.06 | \$0.33 | ... | Repurchase facilities | 3,923,723 |
| Cost & expenses | 490,402 | 587,964 | EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$0.06 | \$0.33 | ... | Total debt | ... |
| Deprec., depl. & amort. | 177,456 | 348,242 | Full-Time Employees (Period End) | 0 | ... | ... | Deferred costs - credit facility | ... |
| Operating income | (629,512) | (903,556) | Total number of employees | 0 | ... | ... | Deferred costs - fixed rate debt & first lien mortgage loan | ... |
| Interest income | 1,819 | 60,529 | □ As of March 21, 2022 | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | |
| Interest expense | 43 | ... | 2023 | | | 2022 | | |
| Other income (expense), net | (175) | 1,315,885 | (revised) | | | (revised) | | |
| Net before taxes | (627,911) | 472,858 | Land | | | Investment Property - Land | | |
| Net income | (627,911) | 472,858 | Investment Property - Buildings, fixtures and improvements | | | Buildings, fixtures & improvements | | |
| Earnings common share | | | Land | | | Investment Property - Buildings, fixtures & improvements | | |
| Primary | \$(0.01) | \$0.01 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Fully Diluted | \$(0.01) | \$0.01 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Common Shares: | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Full Diluted | 65,539,737 | 65,539,737 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Year-end | 65,539,737 | 65,539,737 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| CIM REAL ESTATE FINANCE TRUST INC | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Annual Report | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$000): | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| 2023 | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| 2022 | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| 2021 | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| (revised) | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| (revised) | | | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Rental & other property income | 115,379 | 213,389 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Interest income | 453,480 | 238,757 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Total revenues | 568,859 | 452,146 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| General & administrative expense | 17,572 | 15,364 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Property operating expense | 13,350 | 20,790 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Real estate tax expense | ... | ... | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Expense reimbursements to related parties | 13,285 | 16,567 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Management fees | ... | ... | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Advisory fees & expenses | 50,975 | 52,564 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Transaction-related expense | 3,653 | 534 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Depreciation & amortization expense | 42,532 | 70,606 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Real estate impairment | 35,079 | 32,321 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Increase in provision for credit losses | 134,289 | 29,476 | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |
| Total operating | ... | ... | Investment Property - Buildings, fixtures & improvements | | | Buildings, fixtures & improvements | | |

| | | |
|--|-----------|-----------|
| Total stockholders' equity (deficit) | 2,266,077 | 2,456,083 |
| Non-controlling interests | ... | (8) |
| Total equity | 2,266,077 | 2,456,075 |

Recent Dividends:

- 1. **CIM Real Estate Finance Trust Inc common.**
No dividends paid.
- 2. **CIM Real Estate Finance Trust Inc redeemable common.**
No dividends paid.

Annual Dividends:

- 1. **CIM Real Estate Finance Trust Inc common.**
No dividends paid.
- 2. **CIM Real Estate Finance Trust Inc redeemable common.**
No dividends paid.

**CINGULATE INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Research & development | 15,493,304 | 8,995,280 | 8,410,489 |
| General & administrative | 7,265,885 | 8,506,438 | 12,268,909 |
| Operating income (loss) | (22,759,189) | (17,501,718) | (20,679,398) |
| Interest & other income (expense), net | (775,758) | (174,514) | (30,593) |
| Income (loss) before income taxes .. | (23,534,947) | (17,676,232) | (20,709,991) |
| Net income (loss) | (23,534,947) | (17,676,232) | (20,709,991) |
| Weighted average shares outstanding - basic | 905,225 | 565,471 | 370,679 |
| Weighted average shares outstanding - diluted | 905,225 | 565,471 | 370,679 |
| Year end shares outstanding | 1,167,520 | 565,471 | 565,471 |
| Net income (loss) per share - basic | \$(26.00) | \$(31.20) | \$(55.80) |
| Net income (loss) per share - diluted | \$(26.00) | \$(31.20) | \$(55.80) |
| Number of full time employees | 13 | 15 | 16 |
| Number of common stockholders | 223 | 244 | 282 |
| Non-Operating Income/Expense - Total | (775,758) | ... | ... |
| Total number of employees | 13 | ... | ... |

[□] Adjusted for 1-for-20 stock split, November 30, 2023; [□] As of March 3, 2023; [□] As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 52,416 | 5,356,276 |
| Miscellaneous receivables | 14,622 | 234,432 |
| Research & development | ... | 1,377,391 |
| Insurance | ... | 472,152 |
| Active pharmaceutical ingredients | ... | 209,156 |
| Deferred capital raise costs | ... | 100,339 |
| Professional fees | ... | 61,524 |
| Dues & subscriptions | ... | 37,684 |
| Other prepaid expenses & other current assets | ... | 20,698 |
| Prepaid expenses & other current assets | 511,556 | 2,278,944 |
| Total current assets | 578,594 | 7,869,652 |
| Equipment | 4,321,816 | 2,565,997 |
| Furniture & fixtures | ... | 145,754 |
| Computer equipment | 41,898 | 41,898 |
| Leasehold improvements | 471,505 | 471,505 |
| Construction-in-progress | 207,976 | 1,739,699 |
| Property, Plant & Equipment - Gross - Total | | |
| - Balancing value | 145,754 | ... |

| | | |
|---|--------------|--------------|
| Property & equipment, gross | 5,188,949 | 4,964,853 |
| Less: accumulated depreciation | 2,642,984 | 2,060,066 |
| Property & equipment, net | 2,545,965 | 2,904,787 |
| Operating lease right-of-use assets | 366,877 | 630,618 |
| Total assets | 3,491,436 | 11,405,057 |
| Accounts payable | 5,199,105 | 762,357 |
| Interest | 290,000 | 292,339 |
| Professional fees | 768,497 | 314,446 |
| Employee bonuses | 593,022 | 175,625 |
| Other accrued expenses | 1,651,519 | 112,225 |
| Accrued expenses | ... | 894,635 |
| Notes payable | 3,000,000 | 5,000,000 |
| Finance lease liability, current | 17,057 | 16,053 |
| Operating lease liabilities | 358,085 | 339,755 |
| Total current liabilities | 10,225,766 | 7,012,800 |
| Obligations under finance leases | 4,436 | ... |
| Finance lease liability, net of current | ... | 21,487 |
| Operating lease liability, net of current | 130,663 | 488,748 |
| Total long-term liabilities | 135,099 | 510,235 |
| Total liabilities | 10,360,865 | 7,523,035 |
| Common Stock - Issued & Paid | 118 | ... |
| Common stock | ... | 1,131 |
| Additional paid-in-capital | 86,073,896 | 73,289,387 |
| Accumulated deficit | (92,943,443) | ... |
| Retained earnings (accumulated deficit) | ... | (69,408,496) |
| Total stockholders' equity | (6,869,429) | 3,882,022 |
| Total Equity | (6,869,429) | ... |

Recent Dividends:

- 1. **Cingulate Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. **Cingulate Inc common.**
No dividends paid.

**CISO GLOBAL INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|------------|------------|-------------------|
| Professional services | 900,582 | ... | ... |
| Cost of payroll | 21,613,207 | ... | ... |
| Revenue - security managed services | 50,078,925 | 40,920,420 | 11,797,719 |
| Revenue - professional services | 6,979,832 | 5,629,197 | 3,344,840 |
| Total revenue | 57,058,757 | 46,549,617 | 15,142,559 |
| Cost of revenue - consulting services | 23,671,605 | ... | ... |
| Cost of revenue - security managed services | ... | 15,431,523 | 3,089,599 |
| Cost of revenue - professional services | ... | 844,287 | 515,171 |
| Cost of revenue - cost of payroll | ... | 20,036,182 | 7,596,972 |
| Cost of revenue - stock based compensation | ... | 7,512,304 | 2,132,554 |
| Stock based compensation | 4,823,829 | ... | ... |
| Total cost of revenue | 51,009,223 | 43,824,296 | 13,334,296 |
| Professional fees | 3,695,187 | 2,067,603 | 1,189,319 |
| Advertising & marketing expenses .. | 474,121 | 804,218 | 435,016 |
| Selling, general & | ... | ... | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| administrative | 26,744,543 | 23,106,451 | 9,809,200 |
| Stock based compensation | 7,712,671 | 9,885,191 | 8,076,688 |
| Impairment of goodwill | 45,194,717 | ... | 22,078,064 |
| Total operating expenses | 83,821,239 | 35,863,463 | 41,588,287 |
| Income (loss) from operations | (77,771,705) | (33,138,142) | (39,780,024) |
| Other income | (13,640) | 43,332 | (39,063) |
| Interest expense, net | 2,881,416 | 680,921 | 307,363 |
| Paycheck protection program loan forgiveness | ... | ... | 980,800 |
| Total other income (expense) | (2,895,056) | (637,589) | 634,374 |
| Income (loss) before income taxes .. | (80,666,761) | (33,775,731) | (39,145,650) |
| Income tax expense (benefit) - current - foreign | ... | 1,432 | ... |
| Income tax expense (benefit) - current - state | ... | 6,869 | ... |
| Income tax expense (benefit) - current - deferred - federal | ... | (95,018) | ... |
| Income tax expense (benefit) - deferred - foreign | (435,678) | 100,466 | ... |
| Income tax expense (benefit) - deferred - state | ... | (14,298) | ... |
| Income tax expense (benefit) - deferred | (435,678) | (8,850) | ... |
| Expense (benefit) from income taxes .. | (435,678) | (549) | ... |
| Net income (loss) | (80,231,083) | (33,775,182) | (39,145,650) |
| Weighted average shares outstanding - basic | 11,117,316 | 9,275,554 | 7,927,118 |
| Weighted average shares outstanding - diluted | 11,117,316 | 9,275,554 | 7,927,118 |
| Year end shares outstanding | 11,949,959 | 9,759,720 | 8,390,198 |
| Net income (loss) per common share - basic | \$(7.22) | \$(3.60) | \$(4.95) |
| Net income (loss) per common share - diluted | \$(7.22) | \$(3.60) | \$(4.95) |
| Number of full time employees | 397 | 443 | 184 |
| Number of part time employees | ... | 6 | 2 |
| Total number of employees | 397 | 449 | 186 |
| Number of common stockholders | 765 | 752 | 730 |
| Foreign currency translation adjustments | ... | 1,062,247 | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1- for -15 stock split, March 8, 2024; [□] Approximately; [□] As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 1,062,442 | 1,833,163 |
| Accounts receivable, gross | 5,904,868 | 8,132,308 |
| Less: allowances for doubtful accounts | 219,141 | 270,011 |
| Accounts receivable, net | 5,685,727 | 7,862,297 |
| Inventory | 218,890 | 11,803 |
| Prepaid cost of revenue | 2,592,828 | 2,634,667 |
| Prepaid expenses | 1,200,271 | 987,651 |

| | | |
|---|---------------|--------------|
| Prepaid taxes | 572,645 | |
| Prepaid insurance | 164,354 | |
| Prepaid expenses & other | | |
| current assets | 197,656 | 1,724,650 |
| Contract asset | 332,215 | |
| Total current assets | 10,957,814 | 14,398,795 |
| Building | 1,715,929 | 1,776,040 |
| Leasehold improvements | 527,705 | 541,647 |
| Computer equipment | 1,277,609 | 1,264,713 |
| Vehicles | 28,229 | |
| Furniture & fixtures | 128,904 | 151,142 |
| Software | 1,728,126 | 1,667,283 |
| Property & equipment gross | 5,378,273 | 5,429,054 |
| Less: accumulated depreciation | 1,700,799 | 748,559 |
| Property & equipment, net | 3,677,474 | 4,680,495 |
| Right of use asset, net | 762,228 | 255,687 |
| Intangible assets, net | 3,778,244 | 8,475,229 |
| Goodwill | 31,519,844 | 76,664,017 |
| Other assets | 71,523 | 22,592 |
| Prepaid cost of revenue, net of current portion | 888,255 | ... |
| Total assets | 51,655,382 | 104,496,815 |
| Accounts payable | ... | 5,267,492 |
| Accrued payroll | 1,873,848 | 1,274,919 |
| Accrued expenses | 2,443,971 | 1,296,382 |
| Accrued commissions | 100,000 | 305,768 |
| Accrued interest - related party | ... | 165,776 |
| Accounts payable & accrued expenses | 11,045,657 | 8,310,337 |
| Deferred revenue | 4,158,969 | 4,472,140 |
| Lease liability | 219,342 | 121,731 |
| Loans payable | 3,691,464 | 7,758,831 |
| Convertible notes payable | 2,050,000 | 2,550,000 |
| Accrued interest | 487,851 | ... |
| Accounts payable and accrued expenses - Balancing value | 15,951,327 | ... |
| Total current liabilities | ... | 23,213,039 |
| Secured term loans (US dollar denominated) | ... | 5,461,520 |
| Secured term loans (Chilean peso denominated) | ... | 6,541,113 |
| Less current portion | ... | 7,758,831 |
| Loans payable, net of current portion | 2,748,788 | 4,243,802 |
| Lease liability, net of current portion | 596,307 | 159,205 |
| Deferred tax liability | ... | 435,678 |
| Deferred revenue, net of current portion | 1,099,734 | ... |
| Convertible notes payable, related party | 5,000,000 | ... |
| Total liabilities | 35,515,931 | 28,051,724 |
| Common stock | 119 | 1,464 |
| Additional paid-in capital | 172,837,842 | 153,168,984 |
| Accumulated translation adjustment | (1,320,177) | (1,062,247) |
| Accumulated deficit | (158,018,687) | ... |
| Retained earnings (accumulated deficit) | ... | (77,787,604) |
| Total stockholders' equity | 16,139,451 | 76,445,091 |
| Total Equity | 16,139,451 | ... |

Recent Dividends:
1. CISO Global Inc common.

No dividends paid.

Annual Dividends:

1. CISO Global Inc common.

No dividends paid.

CLANCY CORP

Earnings, 6 mos. to Jan 31 (Consol. - \$):

| | | |
|---------------------------|----------|----------|
| | 2024 | 2023 |
| Cost & expenses | 26,235 | 30,020 |
| Operating income | (26,235) | (30,020) |
| Net before taxes | (26,235) | (30,020) |
| Income contin. oper. | (26,235) | (30,020) |

| | | |
|----------------------------|-------------|-------------|
| Income discont. oper. | (133,048) | (133,048) |
| Net income | (26,235) | (163,068) |
| Earnings common share | | |
| Primary | \$(0.00) | \$(0.00) |
| Fully Diluted | \$(0.00) | \$(0.00) |
| Common Shares: | | |
| Full Diluted | 153,105,464 | 153,105,464 |
| Year-end | 153,105,464 | 153,105,464 |

**CLEARONE INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|-------------|-------------|----------------|
| | 2023 | 2022 | 2021 (revised) |
| Total revenues | 18,704,000 | ... | ... |
| Revenue | 18,704,000 | 25,205,000 | 28,967,000 |
| Cost of goods sold | 12,347,000 | 15,748,000 | 17,051,000 |
| Gross profit | 6,357,000 | 9,457,000 | 11,916,000 |
| Sales & marketing expenses | 4,897,000 | 5,517,000 | 6,736,000 |
| Research & product development expenses | 3,671,000 | 4,390,000 | 5,794,000 |
| General & administrative expenses | 4,561,000 | 6,772,000 | 6,881,000 |
| Total operating expenses | 13,129,000 | 16,679,000 | 19,411,000 |
| Operating income (loss) | (6,772,000) | (7,222,000) | (7,495,000) |
| Interest expense | 537,000 | 420,000 | 514,000 |
| Other income (expense), net | 7,183,000 | 35,102,000 | 32,000 |
| Income (loss) before income taxes - domestic | ... | 28,754,000 | (6,201,000) |
| Income (loss) before income taxes - foreign | ... | (1,294,000) | (1,776,000) |
| Income (loss) before income taxes | (126,000) | 27,460,000 | (7,977,000) |
| Current federal provision for (benefit from) income taxes | 131,000 | 6,753,000 | (373,000) |
| Current state provision for (benefit from) income taxes | 219,000 | 98,000 | 9,000 |
| Current foreign provision for (benefit from) income taxes | 84,000 | 53,000 | 81,000 |
| Total current provision for (benefit from) income taxes | 434,000 | 6,904,000 | (283,000) |
| Deferred federal provision for (benefit from) income taxes | ... | (1,132,000) | (1,326,000) |
| Deferred state provision for (benefit from) income taxes | ... | 976,000 | (398,000) |
| Deferred foreign provision for (benefit from) income taxes | ... | (165,000) | (302,000) |
| Total deferred provision for (benefit from) income taxes | ... | (321,000) | (2,026,000) |
| Change in valuation allowance | ... | 321,000 | 2,026,000 |
| Provision for (benefit from) income taxes | 434,000 | 6,904,000 | (283,000) |
| Net income (loss) | (560,000) | 20,556,000 | (7,694,000) |
| Weighted average shares outstanding - basic | 23,958,184 | 23,937,962 | 19,859,817 |
| Weighted average shares outstanding - diluted | 23,958,184 | 25,189,147 | 19,859,817 |

| | | | |
|---|------------|------------|------------|
| Year end shares outstanding | 23,969,148 | 23,955,767 | 22,410,126 |
| Earnings (loss) per share - continuing operations-basic | \$(0.02) | ... | ... |
| Net income (loss) per common share - basic | \$(0.02) | \$0.86 | \$(0.39) |
| Net income (loss) per common share - diluted | \$(0.02) | \$0.83 | \$(0.39) |
| Cash dividends per share | \$1.00 | ... | ... |
| Number of full time employees | 82 | 82 | 107 |
| Total number of employees | 82 | ... | ... |
| Number of common stockholders | 295 | 294 | 300 |
| Foreign currency translation adjustments | ... | (45,000) | (27,000) |
| Diluted EPS Excluding ExtraOrd Items | \$(0.02) | ... | ... |

□ Approximately; □ As of March 30, 2023; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|------------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 17,835,000 | 984,000 |
| Marketable securities | 3,480,000 | ... |
| Legal settlement receivable | 4,000,000 | 55,000,000 |
| Accounts receivables, gross | 3,605,000 | ... |
| Allowance for doubtful accounts | 326,000 | ... |
| Receivables, net of allowance for doubtful accounts of \$60 and \$60, respectively | 3,279,000 | ... |
| Receivables, gross | ... | 3,929,000 |
| Less: allowance for doubtful accounts | ... | 326,000 |
| Receivables, net | ... | 3,603,000 |
| Raw materials | 2,086,000 | 4,499,000 |
| Finished goods | 8,539,000 | 4,462,000 |
| Inventories, net | ... | 8,961,000 |
| Inventories | 10,625,000 | ... |
| Income tax receivable | 36,000 | 1,071,000 |
| Prepaid expenses & other assets | 4,062,000 | 7,808,000 |
| Total current assets | 43,317,000 | 77,427,000 |
| Long-term marketable securities | 916,000 | ... |
| Long-term inventories, net | 3,143,000 | 2,707,000 |
| Office furniture & equipment | 70,000 | 66,000 |
| Leasehold improvements | 193,000 | 121,000 |
| Vehicles | 57,000 | 41,000 |
| Manufacturing & test equipment | 1,442,000 | 1,146,000 |
| Property & equipment, gross | 1,762,000 | 1,374,000 |
| Less: accumulated depreciation & amortization - property & equipment | 1,232,000 | 991,000 |
| Property & equipment, net | 530,000 | 383,000 |
| Operating lease - right of use assets, net | 990,000 | 1,047,000 |
| Intangibles, net | 1,689,000 | 2,071,000 |
| Other assets | 109,000 | 115,000 |
| Raw materials | 1,789,000 | ... |
| Finished goods | 1,354,000 | ... |
| Total assets | 50,694,000 | 83,750,000 |
| Accounts payable | 1,945,000 | 1,284,000 |
| Accrued salaries & other compensation | 632,000 | 1,148,000 |
| Accrued sales & | | |

| | | |
|--|-------------|------------|
| marketing programs & customer credit balances | 640,000 | 605,000 |
| Accrued product warranty | 194,000 | 194,000 |
| Current portion of operating lease liabilities | 383,000 | 641,000 |
| Other accrued liabilities | 2,290,000 | 453,000 |
| Accrued liabilities | ... | 3,041,000 |
| Accrued liabilities | 441,000 | ... |
| Deferred product revenue | 30,000 | 63,000 |
| Short-term debt | ... | 3,732,000 |
| Total current liabilities | 4,265,000 | 8,120,000 |
| Operating lease liability, net of current | 665,000 | 492,000 |
| Other long-term liabilities | 1,079,000 | 1,008,000 |
| Total liabilities | 6,009,000 | 9,620,000 |
| Common stock | 24,000 | 24,000 |
| Additional paid-in capital | 46,047,000 | 74,910,000 |
| Accumulated other comprehensive income (loss) | (310,000) | (288,000) |
| Accumulated deficit | (1,076,000) | ... |
| Retained earnings (accumulated deficit) | ... | (516,000) |
| Total shareholders' equity | 44,685,000 | 74,130,000 |
| Total shareholders' equity | 44,685,000 | ... |

Recent Dividends:

1. ClearOne Inc common.

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 06/01/2023 | 1.00 | 05/09/2023 | 05/22/2023 | 05/31/2023 |
| 04/11/2024 | 0.50 | 03/11/2024 | 04/02/2024 | 04/10/2024 |

Annual Dividends:

1. ClearOne Inc common.

| | | | |
|------|------|------|------|
| 2023 | 1.00 | 2024 | 0.50 |
|------|------|------|------|

CLOUDWEB INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------------|------------------|----------------------|
| Professional fees | ... | 46,849 | 35,660 |
| Web development cost | ... | 18,500 | ... |
| Stock based compensation | ... | 104,250,000 | ... |
| Selling, general & administrative expenses | 41,150 | ... | ... |
| Total operating expenses | 41,150 | 65,349 | 104,285,660 |
| Interest expense | 36,268 | 37,647 | 195,410 |
| Total other income (expense) | (36,268) | (37,647) | (195,410) |
| Income (loss) before income taxes | (77,418) | ... | ... |
| Net income (loss) | (77,418) | (102,996) | (104,481,070) |
| Weighted average shares outstanding - basic | 27,819,385 | 25,930,649 | 319,385 |
| Weighted average shares outstanding - diluted | 27,819,385 | 25,930,649 | 319,385 |
| Year end shares outstanding | 27,819,385 | 27,819,385 | 319,385 |
| Net earnings (loss) per common share - basic | ... | \$0.00 | \$(327.13) |
| Net earnings (loss) per common share - diluted | ... | \$0.00 | \$(327.13) |
| Total number of employees | ... | 0 | 0 |
| Number of common stockholders | 34 | 33 | 33 |

□ Shares increased due to the effect of issuance of shares for director compensation, and repayment of convertible note; □ As of March 20, 2023; □ As of February 27, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Accounts payable & accrued liabilities | 57,757 | 59,656 |
| Accrued interest | 217,326 | 181,058 |
| Promissory notes payable | ... | 2,160 |
| Convertible notes payable | 153,482 | 153,482 |
| Due to related party | 139,809 | 96,760 |
| Promissory notes payable & accrued interest | 2,160 | ... |
| Total current liabilities | 570,534 | 493,116 |
| Promissory notes payable | 67,326 | 67,326 |
| Total liabilities | 637,860 | 560,442 |
| Common stock, net | 237,937,821 | 237,937,821 |
| Additional paid-in capital | (5,091,518) | (5,091,518) |
| Retained earnings (accumulated deficit) | (233,387,947) | (233,310,529) |
| Retained earnings (accumulated deficit) from discontinued operations | (96,216) | (96,216) |
| Total stockholders' equity (deficit) | (637,860) | (560,442) |
| Total Equity | (637,860) | ... |

Recent Dividends:

1. CloudWeb Inc common.

No dividends paid.

Annual Dividends:

1. CloudWeb Inc common.

No dividends paid.

CLOVER LEAF CAPITAL CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|---------------|------------------|
| Formation & operating costs | 1,586,541 | 1,291,228 | 851,777 |
| Income (loss) from operations | (1,586,541) | (1,291,228) | (851,777) |
| Recovery of previously incurred costs | ... | 341,684 | ... |
| Interest & dividends earned on investments held in trust account | 737,057 | 1,195,135 | 17,690 |
| Interest earned on cash held in bank | 116 | 69 | ... |
| Total other income (expense) | 737,173 | 1,536,888 | 17,690 |
| Income (loss) before provision for income taxes | (849,368) | 245,660 | (834,087) |
| Federal income taxes - current | 177,066 | 138,094 | ... |
| Federal income taxes - deferred | (322,849) | (86,506) | (175,158) |
| State income taxes - current | 38,315 | 28,539 | ... |
| State income taxes - deferred | (109,934) | (30,765) | (23,313) |
| Other income tax expense | 413,993 | 136,060 | 198,471 |
| Provision for income taxes | 196,591 | 185,423 | ... |
| Net income (loss) | (1,045,959) | 60,237 | (834,087) |
| Weighted average class A shares outstanding - basic | ... | 12,204,321 | 7,700,506 |
| Weighted average class B shares outstanding - basic | ... | 3,457,807 | 3,189,105 |
| Weighted average shares outstanding - basic | 5,728,896 | ... | ... |
| Weighted average class A shares | ... | ... | ... |

| | | | |
|---|-----------|------------|------------|
| outstanding - diluted | ... | 12,204,321 | 7,700,506 |
| Weighted average class B shares outstanding - diluted | ... | 3,457,807 | 3,189,105 |
| Weighted average shares outstanding - diluted | 5,728,896 | ... | ... |
| Year end shares outstanding | 5,522,868 | 5,898,870 | 18,102,942 |
| Net income (loss) per class A share - basic | ... | \$0.00 | \$(0.08) |
| Net income (loss) per class B share - basic | ... | \$0.00 | \$(0.08) |
| Net income (loss) per share - basic | \$(0.18) | ... | ... |
| Net income (loss) per class A share - diluted | ... | \$0.00 | \$(0.08) |
| Net income (loss) per class B share - diluted | ... | \$0.00 | \$(0.08) |
| Net income (loss) per share - diluted | \$(0.18) | ... | ... |
| Total number of employees | ... | 3 | 3 |
| Number of class A common stockholders | ... | 2 | 2 |
| Number of class B common stockholders | ... | 1 | 1 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.18) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.18) | ... | ... |
| Number of Common Shareholders | 7 | ... | ... |

□ From February 25, 2021 (date of inception); □ Reclassified to conform with 2022 presentation; □ As reported by the Company; □ Shares decreased due to the effect of changes in the amount of common stock subject to possible redemption; □ As of April 14, 2023; □ As of April 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash | 162,933 | 303,449 |
| Prepaid expenses | 122,364 | ... |
| Prepaid expenses - current portion | ... | 104,876 |
| Total current assets | 285,297 | 408,325 |
| Investments held in trust account | 14,648,926 | 18,276,649 |
| Total assets | 14,934,223 | 18,684,974 |
| Accrued costs & expenses | 809,542 | 367,408 |
| Income taxes payable | 134,428 | 137,633 |
| Deferred income tax | ... | 18,790 |
| Due to related party | 10,000 | ... |
| Promissory note to related party | 3,842,015 | 2,767,015 |
| Excise Tax Payable | 42,099 | ... |
| Total current liabilities | 4,838,084 | 3,290,846 |
| Deferred underwriting commissions | 4,840,931 | 4,840,931 |
| Total liabilities | 9,679,015 | 8,131,777 |
| Class A common stock subject to possible redemption | ... | 18,283,387 |
| Class A common stock | 427 | 81 |
| Class B common stock | 14,830,241 | 346 |
| Retained earnings (accumulated deficit) | (9,575,460) | (7,730,617) |
| Total stockholders' equity (deficit) | 5,255,208 | (7,730,190) |
| Total Equity | 5,255,208 | ... |

| | | | | per share from discontinued operations - basic | | | Total stockholders' deficit | | | | |
|---|--------------------|--------------------|---------------------|---|--------------|--------------|-----------------------------|--|----------|---------|----------|
| | | | | 2023 | 2022 | 2021 | 2023 | 2022 | 2021 | | |
| Recent Dividends: | | | | operations - basic | \$(0.00) | \$(0.00) | ... | ... | ... | | |
| 1. Clover Leaf Capital Corp class A common. | | | | Net income (loss) per share - basic | ... | \$(0.01) | \$(0.23) | ... | ... | | |
| No dividends paid. | | | | Earn per share-inc from discount oper | ... | ... | ... | ... | ... | | |
| 2. Clover Leaf Capital Corp class B common. | | | | - diluted | \$(0.00) | \$(0.00) | ... | ... | ... | | |
| No dividends paid. | | | | Net income (loss) per share from discontinued operations - diluted | \$(0.00) | \$(0.00) | ... | ... | ... | | |
| Annual Dividends: | | | | Net income (loss) per share - diluted | ... | \$(0.01) | \$(0.23) | ... | ... | | |
| 1. Clover Leaf Capital Corp class A common. | | | | Number of full time employees | 3 | ... | 6 | ... | ... | | |
| No dividends paid. | | | | Total number of employees | 3 | ... | ... | ... | ... | | |
| 2. Clover Leaf Capital Corp class B common. | | | | Number of common stockholders | 452 | ... | 344 | ... | ... | | |
| No dividends paid. | | | | Net Income Before Extraordinary and Preferred Dividends | (1,997,345) | (6,359,056) | ... | ... | ... | | |
| CLUBHOUSE MEDIA GROUP INC | | | | [□] Restated to reflect discontinued operations; [□] Reclassified to conform with 2022 presentation; [□] As reported by the Company; [□] As of March 29, 2022 | | | | | | | |
| Annual Report | | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | | | | | |
| | | | | 2023 | | | 2022 | | | | |
| | | | | 2021 | | | 2021 | | | | |
| | | | | (revised) | | | (revised) | | | | |
| | | | | 2023 | | | 2022 | | | | |
| | | | | 2021 | | | 2021 | | | | |
| | | | | (revised) | | | (revised) | | | | |
| In-patient service revenue | 1,495,145 | 1,018,342 | ... | Cash & cash equivalents | 125,207 | 57,713 | ... | Rental income & related revenues | 26,920 | 26,862 | 30,101 |
| Total revenue, net | 1,495,145 | 1,018,342 | 4,253,765 | Accounts receivable, gross | 17,804 | 367,364 | ... | Resident fees & services | 314,560 | 295,799 | 265,321 |
| Cost of sales | 971,470 | 775,317 | 3,470,862 | Less: allowance of bad debt | 2,956 | 0 | ... | Total revenues | 341,480 | 322,661 | 295,422 |
| Gross profit | 523,675 | 243,025 | 782,903 | Accounts receivable, net | 14,848 | 367,364 | ... | Property operating expenses | 235,524 | 226,845 | 197,562 |
| Rent expense | ... | ... | 1,719,026 | Prepaid expense | ... | 4,000 | ... | General & administrative expenses | 9,101 | 10,209 | 9,116 |
| Advertising expenses | 42,359 | 54,301 | 118,697 | Discontinued operations - current | 199,619 | ... | ... | Asset management fees | 2,671 | 14,074 | 15,733 |
| General & administrative expenses | 106,561 | 678,424 | ... | Total current assets | 339,674 | 429,077 | ... | Property management fees | 15,438 | 14,703 | 12,981 |
| Selling, general & administrative | 415,985 | 275,721 | 2,584,686 | Equipment | ... | 118,638 | ... | Impairment provision | ... | ... | 9,790 |
| Salaries & wages | 720,277 | 1,033,759 | 2,315,444 | Property, plant & equipment, gross | ... | 118,638 | ... | Depreciation & amortization expenses | 51,234 | 54,242 | 50,417 |
| Professional & consultant fees | ... | ... | 8,551,532 | Less accumulated depreciation & amortization | ... | 81,153 | ... | Total operating expenses | 327,824 | 320,073 | 295,599 |
| Production expenses | ... | ... | 225,036 | Property, plant, & equipment, net | ... | 37,485 | ... | Gain on sale of real estate | ... | 6,282 | ... |
| Total operating expenses | 1,285,182 | 2,042,205 | 15,514,421 | Intangibles | 445,582 | 777,192 | ... | Operating income (loss) | 13,656 | 8,870 | (177) |
| Operating income (loss) | (761,507) | (1,799,180) | (14,731,518) | Assets Held for Sale/Discontinued Operations - Long-Term | 16,707 | ... | ... | Interest & other income | 3,113 | 4,663 | 720 |
| Interest expense, net | 750,212 | 1,459,053 | 2,151,553 | Total assets | 801,963 | 1,243,754 | ... | Interest expense & loan cost amortization | 41,873 | 21,781 | 19,696 |
| Amortization of debt discounts, net | ... | ... | 5,932,883 | Accounts payable & accrued liabilities | ... | 2,565,806 | ... | Gain on change of control of a joint venture | ... | 8,376 | ... |
| Loss in extinguishment of debt | 277,066 | (1,190,809) | ... | Accounts payable | 9,747 | ... | ... | Equity in earnings (loss) of unconsolidated entity | ... | ... | 471 |
| Gain (loss) in extinguishment of debt - related party | ... | ... | (297,138) | Accrued salary | 370,000 | ... | ... | Total other income (expense) | (38,760) | (8,742) | (18,505) |
| Interest expense - excess derivatives | ... | 758,265 | ... | Deferred revenue | ... | 27,500 | ... | Income (loss) before income tax | (25,104) | 128 | (18,682) |
| Gain in debt settlement | ... | 1,429,906 | ... | Convertible notes payable, net | ... | 4,504,103 | ... | Current federal income taxes expense (benefit) | 12 | 10 | 10 |
| Other income (expense), net | (140,144) | (2,415,346) | (162,093) | Shares to be issued | 318,042 | 573,333 | ... | Current state income taxes expense (benefit) | 548 | 530 | 532 |
| Change in fair value of derivative liability | (335,722) | (166,309) | 1,029,530 | Notes payable - related party | ... | 451,260 | ... | Total current income taxes expense (benefit) | 560 | 540 | 542 |
| Loss on impairment of intangible | 286,826 | ... | ... | Derivative liability | 873,913 | 799,988 | ... | Deferred federal income taxes expense (benefit) | ... | ... | 3,379 |
| Total other income (expenses) | (1,235,838) | (4,559,876) | (7,514,138) | Short-term loan | 4,162,778 | ... | ... | Deferred state income taxes expense (benefit) | ... | ... | 253 |
| Income (loss) before income taxes | (1,997,345) | (6,359,056) | (22,245,656) | Accrued interest | 1,626,590 | ... | ... | Total deferred income taxes expense (benefit) | ... | ... | 3,632 |
| Total income (loss) from discontinued operations | (372,575) | (1,551,841) | ... | Other | 121,520 | ... | ... | Income tax expense (benefit) | 560 | 540 | 4,174 |
| Net income (loss) | (2,369,920) | (7,910,897) | (22,245,656) | Accounts payable and accrued liabilities | 2,127,857 | ... | ... | Income (loss) from continuing operations | (25,664) | (412) | (22,856) |
| Net income (loss) attributable to non-controlling interest | (70,275) | 385,166 | ... | Discontinued operations - current | 510,173 | ... | ... | | | | |
| Weighted average shares outstanding - basic | 11,008,929,419 | 1,340,393,768 | 95,150,297 | Total current liabilities | 7,992,763 | 8,921,990 | ... | | | | |
| Weighted average shares outstanding - diluted | 11,008,929,419 | 1,340,393,768 | 95,150,297 | Total liabilities | 7,992,763 | 8,921,990 | ... | | | | |
| Year end shares outstanding | 16,372,179,486 | 6,830,378,163 | 97,785,107 | Common stock | 16,373 | 6,831 | ... | | | | |
| Earnings per share-inc from discontinued oper | \$(0.00) | \$(0.00) | ... | Additional paid-in capital | 27,662,827 | 24,744,738 | ... | | | | |
| Net income (loss) | ... | ... | ... | Retained earnings (accumulated deficit) | (35,184,891) | (32,814,971) | ... | | | | |
| | | | | Total Clubhouse Media stockholders' equity (deficit) | (7,505,691) | (8,063,402) | ... | | | | |
| | | | | Non-controlling interest | 314,891 | 385,166 | ... | | | | |

| | | | |
|--|----------|----------|----------|
| Income (loss) from discontinued operations | ... | ... | (10) |
| Net income (loss) | (25,664) | (412) | (22,866) |
| Net income (loss) from continuing operations attributable to noncontrolling interest | (34) | (1,041) | (16) |
| Net income (loss) attributable to common stockholders | (25,698) | (1,453) | (22,882) |
| Weighted average shares outstanding - basic | 173,958 | 173,960 | 173,960 |
| Weighted average shares outstanding - diluted | 173,958 | 173,960 | 173,960 |
| Year end shares outstanding | 175,274 | 173,960 | 173,960 |
| Net income (loss) from continuing operations per common share - basic | \$(0.15) | \$(0.01) | \$(0.13) |
| Net income (loss) from discontinued operations per common shares - basic | \$0.00 | ... | ... |
| Net income (loss) per common share - basic | \$(0.15) | \$(0.01) | \$(0.13) |
| Net income (loss) from continuing operations per common share - diluted | \$(0.15) | \$(0.01) | \$(0.13) |
| Net income (loss) from discontinued operations per common shares - diluted | \$0.00 | ... | ... |
| Net income (loss) per common share - diluted | \$(0.15) | \$(0.01) | \$(0.13) |
| Distributions declared per share of common stock | \$0.10 | \$0.10 | \$0.20 |
| Number of common stockholders | 46,183 | 46,343 | 46,233 |
| Comprehensive loss attributable to common stockholders | (28,254) | ... | ... |
| Earning per share - total discounters - diluted | \$0.00 | ... | ... |
| Earnings per share - total discontinued ops | \$0.00 | ... | ... |
| Asset management fees | 13,856 | ... | ... |
| Full-Time Employees (Period End) | 0 | ... | ... |
| Total number of employees | 0 | ... | ... |

As is

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|-----------|-----------|
| Land & land improvements | 137,393 | 136,416 |
| Building & building improvements | 1,502,579 | 1,495,552 |
| Furniture, fixtures & equipment | 113,034 | 105,784 |
| Less: accumulated depreciation - real estate investment properties | 473,869 | 424,314 |
| Real estate investment properties, net | ... | 1,313,438 |
| Real estate under | ... | ... |

| | | |
|--|-----------|-----------|
| development, including land | 1,279,137 | ... |
| Cash | 54,097 | 69,504 |
| Restricted cash | 1,791 | 4,070 |
| Other assets | 19,127 | 36,868 |
| Deferred rent & lease incentives | 11,386 | ... |
| Deferred rent, lease incentives & intangibles, net | ... | 13,423 |
| Total assets | 1,365,538 | 1,437,303 |
| Mortgages & other notes payable, net | 36,569 | 61,773 |
| Credit facilities | 541,840 | 546,100 |
| Accounts payable & accrued liabilities | 31,322 | 30,270 |
| Other liabilities | 10,475 | 7,469 |
| Due to related parties | 1,292 | 1,397 |
| Total liabilities | 621,498 | 647,009 |
| Common stock | 1,739 | 1,740 |
| Capital in excess of par value | 1,516,806 | 1,516,926 |
| Accumulated income (loss) | 74,710 | 100,408 |
| Accumulated distributions | (847,120) | (829,307) |
| Accumulated other comprehensive income (loss) | (2,572) | (16) |
| Total stockholders' equity | 743,563 | 789,751 |
| Noncontrolling interest | 477 | 543 |
| Total equity | 744,040 | 790,294 |

Including variable interest entities - real estate investment properties, net: \$30,906,000; Including variable interest entities - cash: \$646,000; Including variable interest entities - restricted cash: \$9,000; Including variable interest entities - other assets: \$554,000; Including variable interest entities - mortgages & other notes payable, net: \$21,142,000; Including variable interest entities - accounts payable & accrued liabilities: \$533,000; Including variable interest entities - other liabilities: \$91,000

Recent Dividends:
1. CNL Healthcare Properties Inc common.
 No dividends paid.
Annual Dividends:
1. CNL Healthcare Properties Inc common.
 No dividends paid.

CNS PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-------------------------------|--------------|--------------|--------------|
| General & administrative | 4,769,502 | 5,967,052 | 4,680,840 |
| Research & development | 14,095,606 | 9,300,055 | 9,805,075 |
| Total operating expenses | 18,865,108 | 15,267,107 | 14,485,915 |
| Income (loss) from operations | (18,865,108) | (15,267,107) | (14,485,915) |
| Interest expense | 13,805 | 7,027 | 9,285 |
| Interest income | 27,687 | ... | ... |
| Total other income (expenses) | 13,882 | (7,027) | (9,285) |
| Net income (loss) | (18,851,226) | (15,274,134) | (14,495,200) |

| | | | |
|---|-----------|-----------|-----------|
| Weighted average shares outstanding - basic | 3,767,372 | 1,361,737 | 878,443 |
| Weighted average shares outstanding - diluted | 3,767,372 | 1,361,737 | 878,443 |
| Year end shares outstanding | 6,214,598 | 1,617,325 | 949,052 |
| Net earnings (loss) per share - basic | \$(5.00) | \$(11.22) | \$(16.50) |
| Net earnings (loss) per share - diluted | \$(5.00) | \$(11.22) | \$(16.50) |
| Number of full time employees | ... | 3 | 3 |
| Number of part time employees | ... | 2 | 2 |

| | | |
|---|--------------|--------|
| Common Shareholders - Number | 11,500 | ... |
| Number of stockholders | ... | 10,000 |
| Income from cont operations before income tax | (18,851,226) | ... |
| Earnings per share from continuing operations | \$(5.00) | ... |
| Earnings per share from continuing operations | \$(5.00) | ... |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-30 stock split, November 29, 2022; Shares increased due to the effect of common stock issued for cash & exercise of warrants; As of March 29, 2023; As of March 3, 2022; Approximately; As of March 31, 2023; As of February 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 548,721 | 10,055,407 |
| Prepaid expenses and other current assets | 839,590 | ... |
| Prepaid expenses & other current assets | 202,859 | 2,509,238 |
| Total current assets | 1,591,170 | 12,564,645 |
| Prepaid expenses, net of current portion | 104,750 | 482,806 |
| Furniture & equipment, net | 4,933 | 5,664 |
| Total noncurrent assets | 109,683 | 488,470 |
| Total assets | 1,700,853 | 13,053,115 |
| Accounts payable | ... | 3,681,900 |
| Accounts payable & accrued expenses - related party | 5,832,162 | ... |
| Accrued expenses | ... | 828,391 |
| Notes payable | 300,806 | 409,968 |
| Total current liabilities | 6,132,968 | 4,920,259 |
| Total liabilities | 6,132,968 | 4,920,259 |
| Common stock | 6,214 | 1,617 |
| Additional paid-in capital | 65,128,574 | 58,846,916 |
| Accumulated deficit | (69,566,903) | ... |
| Retained earnings (accumulated deficit) | ... | (50,715,677) |
| Total stockholders' equity (deficit) | (4,432,115) | 8,132,856 |
| Total Equity | (4,432,115) | ... |

Recent Dividends:
1. CNS Pharmaceuticals Inc common.
 No dividends paid.
Annual Dividends:
1. CNS Pharmaceuticals Inc common.
 No dividends paid.

COCRYSTAL PHARMA INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-----------------------------------|--------------|--------------|--------------|
| Research & development expenses | 15,169,000 | 12,392,000 | 8,794,000 |
| General & administrative expenses | 5,990,000 | 5,745,000 | 5,427,000 |
| Legal settlement expenses | (2,600,000) | 1,600,000 | ... |
| Impairments expenses | ... | 19,092,000 | ... |
| Total operating expenses | 18,559,000 | 38,829,000 | 14,221,000 |
| Income (loss) from operations | (18,559,000) | (38,829,000) | (14,221,000) |
| Interest income (expense), net | 640,000 | ... | ... |
| Interest expense, net | ... | 2,000 | 4,000 |
| Change in fair | ... | ... | ... |

| | | | | | | | | | |
|---|---------------------|---------------------|---|---------------|---------------|---|----------------|--------------------|-----------|
| value of derivative liabilities | 12,000 | 49,000 | Operating lease liabilities | 1,613,000 | 57,000 | Year end shares outstanding | 35,331,036 | 19,566,839 | 9,375,000 |
| Foreign exchange loss | (65,000) | (18,000) | Total long-term liabilities | 1,613,000 | 57,000 | Selling, general & administrative expense | 3,945,531 | 34,166,746 | ... |
| Total other income (expense), net | 575,000 | (8,000) | Total liabilities | 4,875,000 | 1,273,000 | Net income (loss) per share subject to redemption - basic | ... | ... | \$1.62 |
| Income (loss) before income taxes | (17,984,000) | ... | Common stock | 10,000 | 8,000 | Net income (loss) per share, non-redeemable ordinary shares - basic | ... | ... | \$1.62 |
| Net income (loss) | (17,984,000) | (38,837,000) | Additional paid-in capital | 342,288,000 | 337,489,000 | Net income (loss) per share - basic | \$(0.83) | \$(2.63) | ... |
| Weighted average shares outstanding - basic | 9,651,000 | 8,143,000 | Retained earnings (accumulated deficit) | (315,914,000) | (297,930,000) | Net income (loss) per share subject to redemption - diluted | ... | ... | \$1.62 |
| Weighted average shares outstanding - diluted | 9,651,000 | 8,143,000 | Total stockholders' equity (deficit) | 26,384,000 | 39,567,000 | Net income (loss) per share - diluted | \$(0.83) | \$(2.63) | ... |
| Year end shares outstanding | 10,174,000 | 8,143,000 | Rep Total Equity & Minority Interest | 26,384,000 | ... | Part-Time Employees (Period End) | 2 | 1 | ... |
| Income (loss) per share - continuing operations - basic | \$(1.87) | ... | | | | Full-Time Employees (Period End) | 5 | 4 | ... |
| Net income (loss) per common share - basic | \$(1.87) | \$(4.77) | | | | Total number of employees | 7 | 5 | 2 |
| Income (loss) per share - continuing operations - diluted | \$(1.87) | ... | | | | Number of unitholders | ... | ... | 1 |
| Net income (loss) per common share - diluted | \$(1.87) | \$(4.77) | | | | Number of ordinary stockholders | 112 | 119 | 2 |
| Number of full time employees | ... | 12 | | | | Income from cont operations before income tax | (21,266,537) | (37,574,217) | ... |
| Number of common stockholders | 434 | 434 | | | | Total cost of operations | 21,491,125 | 34,195,964 | ... |
| | | | | | | Other income (expense) | (220,477) | ... | ... |
| | | | | | | Interest expense | 107,685 | ... | ... |
| | | | | | | Gain on change in fair value of derivative liability warrants | 567,750 | ... | ... |
| | | | | | | TOTAL OTHER INCOME (EXPENSE) | 224,588 | (3,378,253) | ... |

Adjusted for 1-for-12 stock split, October 11, 2022; Shares increased due to the effect issuance of common shares; As of March 21, 2023; Approximately; As of March 23, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|------------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 26,353,000 | ... |
| Cash | ... | 37,144,000 |
| Restricted cash | 75,000 | 75,000 |
| Tax credit receivable | 890,000 | 716,000 |
| Prepaid expenses & other current assets | 1,773,000 | 2,243,000 |
| Total current assets | 29,091,000 | 40,178,000 |
| Lab equipment (excluding equipment under finance leases) | 1,757,000 | 1,631,000 |
| Finance lease right-of-use lab equipment obtained in exchange for finance lease liabilities, net | 2,074,000 | 194,000 |
| Computer & office equipment | 155,000 | 131,000 |
| Finance lease right-of-use lab equipment | 162,000 | ... |
| Total property & equipment | ... | 1,956,000 |
| Less accumulated depreciation | 1,803,000 | 1,614,000 |
| Property & equipment, net | 271,000 | 342,000 |
| Deposits | 46,000 | 46,000 |
| Operating lease right-of-use assets, net | 1,851,000 | 274,000 |
| Total assets | 31,259,000 | 40,840,000 |
| Accounts payable | 1,222,000 | 614,000 |
| Accrued compensation | 109,000 | 130,000 |
| Accrued other expenses | 1,691,000 | 232,000 |
| Accounts payable & accrued expenses | 3,022,000 | 976,000 |
| Current maturities of finance lease liabilities | ... | 7,000 |
| Current maturities of operating lease liabilities | 240,000 | 233,000 |
| Total current liabilities | 3,262,000 | 1,216,000 |

| | | |
|---|---------------|---------------|
| Operating lease liabilities | 1,613,000 | 57,000 |
| Total long-term liabilities | 1,613,000 | 57,000 |
| Total liabilities | 4,875,000 | 1,273,000 |
| Common stock | 10,000 | 8,000 |
| Additional paid-in capital | 342,288,000 | 337,489,000 |
| Retained earnings (accumulated deficit) | (315,914,000) | (297,930,000) |
| Total stockholders' equity (deficit) | 26,384,000 | 39,567,000 |
| Rep Total Equity & Minority Interest | 26,384,000 | ... |

Including to related party - operating lease right-of-use assets net: \$99,000; Including to related party - current maturities of operating lease liabilities: \$59,000; Including to related party operating lease liabilities: \$42,000

Recent Dividends:

- Cocrystal Pharma Inc series B convertible preferred.**
No dividends paid.
- Cocrystal Pharma Inc common.**
No dividends paid.
- Cocrystal Pharma Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- Cocrystal Pharma Inc series B convertible preferred.**
No dividends paid.
- Cocrystal Pharma Inc common.**
No dividends paid.
- Cocrystal Pharma Inc series A convertible preferred.**
No dividends paid.

COEPTIS THERAPEUTICS HOLDINGS INC Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|---------------------|---------------------|-------------------|
| | 2023 | 2022 | 2021 |
| | | (revised) | |
| Operating costs | 6,668,244 | ... | 681,319 |
| Income (loss) from operations | (21,491,125) | ... | (681,319) |
| Change in fair value of warrant liabilities | ... | ... | 15,903,000 |
| Transaction costs allocable to the warrant liabilities | 15,000 | ... | ... |
| Other interest income | ... | ... | 71 |
| Interest income on marketable securities held in trust account | ... | ... | 7,577 |
| Net income (loss) | (21,266,537) | (37,574,217) | 15,229,329 |
| Weighted average shares outstanding subject to redemption - basic | ... | ... | 7,500,000 |
| Weighted average shares outstanding, non-redeemable ordinary shares - basic | ... | ... | 1,875,000 |
| Weighted average shares outstanding - basic | 25,689,989 | 14,295,678 | ... |
| Weighted average shares outstanding subject to redemption - diluted | ... | ... | 7,500,000 |
| Weighted average shares outstanding, non-redeemable ordinary shares - diluted | ... | ... | 1,875,000 |
| Weighted average shares outstanding - diluted | 25,689,989 | 14,295,678 | ... |
| Selling and marketing | 12,710 | 8,331 | ... |
| Professional services | 10,864,640 | 20,887 | ... |

| | | | |
|---|----------------|--------------------|-----------|
| Year end shares outstanding | 35,331,036 | 19,566,839 | 9,375,000 |
| Net income (loss) per share subject to redemption - basic | ... | ... | \$1.62 |
| Net income (loss) per share, non-redeemable ordinary shares - basic | ... | ... | \$1.62 |
| Net income (loss) per share - basic | \$(0.83) | \$(2.63) | ... |
| Net income (loss) per share subject to redemption - diluted | ... | ... | \$1.62 |
| Net income (loss) per share, non-redeemable ordinary shares - diluted | ... | ... | \$1.62 |
| Net income (loss) per share - diluted | \$(0.83) | \$(2.63) | ... |
| Part-Time Employees (Period End) | 2 | 1 | ... |
| Full-Time Employees (Period End) | 5 | 4 | ... |
| Total number of employees | 7 | 5 | 2 |
| Number of unitholders | ... | ... | 1 |
| Number of ordinary stockholders | 112 | 119 | 2 |
| Income from cont operations before income tax | (21,266,537) | (37,574,217) | ... |
| Total cost of operations | 21,491,125 | 34,195,964 | ... |
| Other income (expense) | (220,477) | ... | ... |
| Interest expense | 107,685 | ... | ... |
| Gain on change in fair value of derivative liability warrants | 567,750 | ... | ... |
| TOTAL OTHER INCOME (EXPENSE) | 224,588 | (3,378,253) | ... |

As of April 8, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|---|-----------|-----------|-----------|
| | 2023 | 2022 | (revised) |
| Current asset - cash | 1,469,134 | 3,791,302 | ... |
| Prepaid expenses | 241,601 | 142,356 | ... |
| Notes receivable | 3,500,000 | 8,075 | ... |
| Interest receivable | 38,978 | ... | ... |
| Total current assets | 5,249,713 | 3,941,733 | ... |
| Furniture and fixtures | 25,237 | 25,237 | ... |
| accumulated depreciation | 13,931 | 12,695 | ... |
| Furniture and fixtures, net | 11,306 | 12,542 | ... |
| Prepaid insurance | 158,333 | 348,333 | ... |
| Co-development options | 2,554,166 | 3,554,167 | ... |
| Right of use asset, net of accumulated amortization | 97,571 | 58,914 | ... |
| Total assets | 8,071,089 | 7,915,689 | ... |
| Accrued expenses | 555,950 | 181,998 | ... |
| Accounts payable & accrued expenses | 1,419,699 | 99,021 | ... |
| Notes payable, current portion | 975,000 | 1,850,000 | ... |
| Right of use liability, current portion | 38,047 | 41,618 | ... |
| Total current liabilities | 2,988,696 | 2,172,637 | ... |
| Notes payable | 150,000 | 150,000 | ... |
| Derivative liability warrants | 557,250 | 1,125,000 | ... |
| Right of use liability, non-current portion | 61,179 | 14,723 | ... |

| | | |
|---|--------------|--------------|
| TOTAL LONG TERM LIABILITIES | 768,429 | 1,289,723 |
| Total liabilities | 3,757,125 | 3,462,360 |
| Ordinary shares | 3,533 | 1,957 |
| Retained earnings (accumulated deficit) | (87,356,260) | (66,089,723) |
| Additional paid-in capital | 91,666,691 | 70,541,095 |
| Total shareholders' equity (deficit) | 4,313,964 | 4,453,329 |
| Total Equity | 4,313,964 | 4,453,329 |

□ Reclassified to conform 2023 presentation

Recent Dividends:

1. Coeptis Therapeutics Holdings Inc ordinary.
No dividends paid.

Annual Dividends:

1. Coeptis Therapeutics Holdings Inc ordinary.
No dividends paid.

COJAX OIL & GAS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|--------------------|
| Revenues | 927,983 | 106,554 | ... |
| Total revenues | 927,983 | 106,554 | 8,160 |
| General & administrative expenses | 1,038,473 | 2,111,761 | 1,461,534 |
| Operating expenses | 248,642 | 321,103 | 31,918 |
| Accretion expense | 393,430 | 42,321 | 2,416 |
| Impairment expense | 875,400 | 3,909,700 | ... |
| Total expenses | 2,555,945 | 6,384,885 | 1,495,868 |
| Income (loss) from operations | (1,627,962) | (6,278,331) | (1,487,708) |
| Interest income | ... | ... | 12 |
| Miscellaneous expense | (202) | (7) | 45 |
| Interest expense | 2,142 | 956 | 2,455 |
| Net loss | (1,629,902) | (6,237,615) | ... |
| Gain on forgiveness of debt | ... | 41,665 | ... |
| Total other income (expense) | (1,940) | 40,716 | (2,488) |
| Net income (loss) | (1,629,902) | (6,237,615) | (1,490,196) |
| Weighted average shares outstanding - basic | 9,279,410 | 6,683,773 | 4,269,524 |
| Weighted average shares outstanding - diluted | 9,279,410 | 6,683,773 | 4,269,524 |
| Year end shares outstanding | 9,315,902 | 9,114,446 | □5,780,576 |
| Net earnings (loss) per share - basic | \$(0.18) | \$(0.93) | \$(0.35) |
| Net earnings (loss) per share - diluted | \$(0.18) | \$(0.93) | \$(0.35) |
| Number of full time employees | 2 | ... | 2 |
| Number of common stockholders | ... | ... | □47 |
| Total number of employees | 2 | ... | ... |

□ Shares increase due to the effect of share issued for note payable debt exchange & share-based vendor payments & compensation; □ As of June 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash and cash equivalents | 75,908 | 37,750 |
| Accounts receivable | 205,306 | 52,050 |
| Total current assets | 281,214 | 89,800 |
| Oil and gas properties at cost | 4,509,679 | ... |
| Barrister proved property | 4,089,503 | 5,345,457 |
| Accumulated depletion | 420,176 | ... |
| Mining/Exploration Specific Assets - Net | 4,089,503 | ... |
| Oil and natural gas properties subject to amortization | ... | 5,345,457 |

| | | |
|---|--------------|-------------|
| Total assets | 4,370,717 | 5,435,257 |
| Accounts payable | 121,764 | 105,057 |
| Notes payable - related party | 103,001 | 113,001 |
| Accrued salaries & payroll taxes | 834,809 | 1,642,612 |
| Current portion of notes payable | 9,984 | 10,242 |
| Workover expense payable | 106,861 | 234,396 |
| Total current liabilities | 1,176,419 | ... |
| Barrister asset retirement obligation | 105,118 | 92,241 |
| Notes payable - SBA PPP | 21,094 | 30,724 |
| Total long-term liabilities | 126,212 | 122,965 |
| Total liabilities | 1,302,631 | ... |
| Preferred stock | 1,050 | 550 |
| Common stock | 93,159 | 91,144 |
| Additional paid-in capital | 13,727,918 | 12,249,429 |
| Retained earnings (accumulated deficit) | (10,764,041) | (9,134,139) |
| Subscriptions payable | 10,000 | ... |
| Total stockholders' equity | 3,068,086 | 3,206,984 |
| Total Equity | 3,068,086 | 3,206,984 |

Recent Dividends:

1. CoJax Oil & Gas Corp preferred.

No dividends paid.

2. CoJax Oil & Gas Corp common.

No dividends paid.

Annual Dividends:

1. CoJax Oil & Gas Corp preferred.

No dividends paid.

2. CoJax Oil & Gas Corp common.

No dividends paid.

COMPOSECURE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 |
|--|--------------------|--------------------|-------------------|
| Net sales | 390,629,000 | 378,476,000 | 267,948,000 |
| Cost of sales | 181,547,000 | 158,832,000 | 123,099,000 |
| Gross profit | 209,082,000 | 219,644,000 | 144,849,000 |
| Selling, general & administrative expenses | 89,995,000 | 104,749,000 | 63,424,000 |
| Income (loss) from operations | 119,087,000 | 114,895,000 | 81,425,000 |
| Unrealized gain on marketable securities held in trust account | 8,047,000 | ... | ... |
| Revaluation of warrant liability | ... | 18,930,000 | 3,485,000 |
| Revaluation of earnout consideration liability | 14,237,000 | 23,337,000 | 9,575,000 |
| Change in fair value of derivative liability - convertible notes redemption make-whole provision | (139,000) | 266,000 | ... |
| Interest expense, net of interest income | ... | 20,129,000 | 10,235,000 |
| Amortization of deferred financing costs | 1,608,000 | 2,415,000 | 1,693,000 |
| Other income | ... | 1,291,000 | ... |
| Interest Expense/Income - Net | (22,548,000) | ... | ... |
| Total other income (expenses), net | (2,011,000) | 21,280,000 | 1,132,000 |
| Income (loss) before income taxes | 117,076,000 | 136,175,000 | 82,557,000 |
| Current income tax expense (benefit) - federal | ... | 1,810,000 | 1,140,000 |
| Current income tax expense (benefit) - state | 79,000 | 27,000 | ... |
| Total current income tax expense (benefit) | 1,889,000 | 1,167,000 | ... |
| Deferred income tax expense (benefit) - federal | 3,091,000 | 3,477,000 | (856,000) |
| Deferred income tax expense (benefit) - state | (424,000) | (284,000) | (1,000) |
| Total deferred income tax expense (benefit) | 2,667,000 | 3,193,000 | (857,000) |
| Income tax expense (benefit) | 4,556,000 | 4,360,000 | (857,000) |
| Net income (loss) | 112,520,000 | 131,815,000 | 83,414,000 |
| Net income attributable to redeemable non-controlling interests | (93,281,000) | (113,158,000) | (80,260,000) |
| Net income attributable to CompoSecure, Inc. | 19,239,000 | 18,657,000 | 3,154,000 |
| Weighted average shares per class A common share outstanding - basic | 18,661,000 | 15,372,422 | 14,929,982 |
| Weighted average shares per class A common share outstanding - diluted | 35,312,000 | 32,555,317 | 94,569,858 |
| Year end shares outstanding | 79,373,545 | 76,771,805 | 76,066,782 |
| Net income (loss) per class A common share - basic | \$1.03 | \$1.21 | \$0.21 |
| Net income (loss) per class A common share - diluted | \$0.96 | \$1.13 | \$0.12 |
| Number of full time employees | ... | □850 | □715 |
| Number of class A common stockholders | ... | □6 | ... |
| Number of class A beneficial owners of class A common stockholders | ... | □1,500 | ... |
| Number of class B common stockholders | ... | □10 | ... |
| Common Shareholders - Number | 4 | ... | ... |
| Number of stockholders | ... | ... | □16 |
| Total Revenue | 390,629,000 | ... | ... |

□ Reclassified to conform 2022 presentation; □ Approximately; □ As of March 1, 2023; □ As of March 1, 2022; □ As of March 8, 2023; □ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|------------|
| Cash & cash equivalents | 41,216,000 | 13,642,000 |
| Accounts receivable, net | 40,488,000 | 37,272,000 |
| Raw materials | 50,867,000 | 43,313,000 |
| Work in process | 4,110,000 | 2,892,000 |
| Finished goods | 662,000 | 450,000 |
| Inventory reserve | 3,099,000 | 4,281,000 |
| Inventories | 52,540,000 | 42,374,000 |
| Prepaid expenses & other current assets | 5,133,000 | 3,824,000 |
| Total current assets | 139,377,000 | 97,112,000 |
| Total Furniture And Fixtures Member | 987,000 | ... |
| Total Software And Software Development Costs Member | 2,924,000 | ... |
| Total property & equipment, gross | 96,810,000 | 85,866,000 |

| | | |
|--|---------------|---------------|
| Machinery & equipment | 72,538,000 | 64,626,000 |
| Furniture & fixtures | 987,000 | 927,000 |
| Computer equipment | 14,981,000 | 11,993,000 |
| Leasehold improvements | 264,000 | 264,000 |
| Vehicles | 927,000 | 2,924,000 |
| Software | 4,189,000 | 4,145,000 |
| Construction in progress | 71,598,000 | 63,211,000 |
| Less: accumulated depreciation & amortization | 25,212,000 | 22,655,000 |
| Property & equipment, net | 7,473,000 | 8,932,000 |
| Right of use asset, net | 23,697,000 | 25,569,000 |
| Deferred tax asset | 5,258,000 | 8,651,000 |
| Derivative asset-interest rate swap | 24,000 | 24,000 |
| Deposits & other assets | 201,041,000 | 162,943,000 |
| Total assets | 10,313,000 | 14,372,000 |
| Current portion of long-term debt | 1,948,000 | 1,846,000 |
| Current portion of lease liabilities | 5,193,000 | 7,127,000 |
| Accounts payable | 1,425,000 | ... |
| Current portion of tax receivable agreement liability | 11,986,000 | 10,154,000 |
| Accrued expenses | 4,429,000 | 3,317,000 |
| Commission payable | 5,616,000 | 8,177,000 |
| Bonus payable | 40,910,000 | 44,993,000 |
| Total current liabilities | 198,331,000 | 216,276,000 |
| Long-term debt, net of deferred finance costs | 127,832,000 | 127,348,000 |
| Convertible notes | 425,000 | 285,000 |
| Derivative liability - convertible notes redemption make-whole provision | 8,294,000 | 16,341,000 |
| Warrant liability | 6,220,000 | 7,766,000 |
| Lease liabilities | 23,949,000 | 26,842,000 |
| Tax receivable agreement liability | 853,000 | 15,090,000 |
| Earnout consideration liability | 406,814,000 | 454,941,000 |
| Total liabilities | 596,587,000 | 600,234,000 |
| Redeemable non-controlling interest | 6,000 | 2,000 |
| Class A common stock | 2,000 | 6,000 |
| Class B common stock | 39,466,000 | 24,107,000 |
| Additional paid-in capital | 4,991,000 | 8,283,000 |
| Accumulated other comprehensive income | (846,825,000) | (924,630,000) |
| Retained earnings (accumulated deficit) | (802,360,000) | (892,232,000) |
| Total stockholders' equity (deficit) | | |

Recent Dividends:**1. Composecure Inc class A common.**

No dividends paid.

2. Composecure Inc class B common.

No dividends paid.

Annual Dividends:**1. Composecure Inc class A common.**

No dividends paid.

2. Composecure Inc class B common.

No dividends paid.

CONCRETE LEVELING SYSTEMS INC**Earnings, 6 mos. to Jan 31 (Consol. - \$):**

| | | |
|-----------------------|------------|------------|
| | 2024 | 2023 |
| Total revenues | 275 | 25,906 |
| Cost & expenses | (31,511) | (25,531) |
| Operating income | 5,220 | 5,102 |
| Interest expense | (36,456) | (30,633) |
| Net before taxes | (36,456) | (30,633) |
| Net income | (36,456) | (30,633) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 14,027,834 | 14,027,834 |
| Year-end | 14,027,834 | 14,027,834 |

CONCRETE PUMPING HOLDINGS INC**Earnings, 3 mos. to Jan 31 (Consol. - \$):**

| | | |
|-----------------------------|-------------|------------|
| | 2024 | 2023 |
| Total revenues | 97,711,000 | 93,575,000 |
| Cost & expenses | 96,255,000 | 84,162,000 |
| Operating income | 1,456,000 | 9,413,000 |
| Interest expense | 170,000 | 4,577,000 |
| Other income (expense), net | (4,837,000) | 7,119,000 |
| Net before taxes | (4,837,000) | 7,119,000 |
| Income taxes | (1,011,000) | 644,000 |
| Net income | (3,826,000) | 6,475,000 |
| Balance for common | (4,266,000) | 6,034,000 |
| Earnings common share | | |
| Primary | \$(0.08) | \$0.11 |
| Fully Diluted | \$(0.08) | \$0.11 |
| Common Shares: | | |
| Full Diluted | 53,314,654 | 54,457,125 |
| Year-end | 53,870,084 | 55,407,330 |

Consolidated Balance Sheet Items, as of (\$):

| | | |
|-----------------------|-------------|--|
| Assets: | 2024 | |
| Cash & equivalents | 14,688,000 | |
| Inventories | 6,230,000 | |
| Current assets | 79,628,000 | |
| Net property & equip. | 432,671,000 | |
| Total assets | 894,767,000 | |
| Liabilities: | | |
| Current liabilities | 72,359,000 | |
| Long-term debt | 372,231,000 | |
| Stockholders' equity | 307,940,000 | |
| Net current assets | 7,269,000 | |

CONNECTISYS CORP**Annual Report****Consolidated Income Statement, Years Ended (\$):**

| | | | |
|---|----------|----------|----------|
| | 12/31/23 | 12/31/22 | 09/30/22 |
| General & administrative expenses | 6,600 | 9,004 | 9,399 |
| Total operating expenses | 6,600 | 9,004 | 9,399 |
| Income (loss) from operations | ... | (9,004) | (9,399) |
| Income (loss) before income taxes | (6,600) | (9,004) | (9,399) |
| Net income (loss) | (6,600) | (9,004) | (9,399) |
| Weighted average shares outstanding - basic | 888,579 | 888,579 | 888,579 |
| Weighted average shares outstanding - diluted | 888,579 | 888,579 | 888,579 |
| Year end shares outstanding | 888,579 | 888,579 | 888,579 |
| Net earnings (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.01) |
| Net earnings (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.01) |
| Total number of employees | ... | 1 | ... |
| Number of common stockholders | 184 | 325 | 325 |
| Number of beneficiary stockholders | ... | ... | 350 |
| COMPREHENSIVE INCOME (LOSS) | (6,600) | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd | \$(0.01) | ... | ... |
| Items | \$(0.01) | ... | ... |

□ As of January 31, 2023; □ As of December 22, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|------------------------------|------------|------------|
| | 2023 | 2022 |
| Accounts payable | 35,700 | ... |
| Accrued expenses | 14,006 | 12,956 |
| Advances from former officer | ... | 30,150 |
| Total current liabilities | 49,706 | 43,106 |
| Total liabilities | 49,706 | 43,106 |
| Common stock | 32,246,441 | 32,246,441 |

| | | |
|---|--------------|--------------|
| Retained earnings (accumulated deficit) | (32,296,147) | (32,289,547) |
| Total stockholders' equity (deficit) | (49,706) | (43,106) |
| Total deficit | (49,706) | ... |

Recent Dividends:**1. ConectiSys Corp common.**

No dividends paid.

2. ConectiSys Corp class A preferred.

No dividends paid.

Annual Dividends:**1. ConectiSys Corp common.**

No dividends paid.

2. ConectiSys Corp class A preferred.

No dividends paid.

CONX CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | | | |
|--|-------------|------------|------------|
| | 2023 | 2022 | 2021 |
| General & administrative expenses | 1,178,513 | 888,749 | 555,487 |
| Income (loss) from operations | (1,178,513) | (888,749) | (555,487) |
| Fair value of private placement warrants in excess of proceeds | (325,000) | ... | ... |
| Change in fair value of derivative warrant liabilities | (4,693,000) | 21,359,166 | 19,855,000 |
| Interest income on securities held in Trust Account | 267,481 | 4,937,551 | 75,012 |
| Total other income | ... | 26,296,717 | 19,930,012 |
| Income (loss) before income tax expense | (5,929,032) | 25,407,968 | 19,374,525 |
| Federal income taxes - current expense | 65,469 | 995,966 | 15,035 |
| Federal income taxes - deferred benefit (expense) | 247,488 | 220,738 | 100,903 |
| State & local income taxes - current | ... | 217,252 | 3,413 |
| State & local income taxes - deferred | 40,965 | 55,054 | 23,108 |
| Change in valuation allowance | (288,453) | (275,792) | (124,010) |
| Income tax expense | 65,469 | 1,213,218 | 18,449 |
| Net income (loss) | (5,994,501) | 24,194,750 | 19,356,076 |
| Weighted average class A shares outstanding - basic | ... | 64,226,579 | 75,020,986 |
| Weighted average class B shares outstanding - basic | ... | 18,750,000 | 18,750,000 |
| Weighted average shares outstanding - basic | 23,797,364 | ... | ... |
| Weighted average class A shares outstanding - diluted | ... | 64,226,579 | 75,020,986 |
| Weighted average class B shares outstanding - diluted | ... | 18,750,000 | 18,750,000 |
| Weighted average shares outstanding - diluted | 23,797,364 | ... | ... |
| Year end shares outstanding | 20,870,269 | 27,128,384 | 93,780,000 |
| Net income (loss) per class A shares - basic | ... | \$0.29 | \$0.21 |
| Net income (loss) per class B shares | ... | ... | ... |

| | | | |
|--|----------|--------|--------|
| - basic | ... | \$0.29 | \$0.21 |
| Net earnings (loss) per share - basic | \$(0.25) | ... | ... |
| Net income (loss) per class A shares - diluted | ... | \$0.29 | \$0.21 |
| Net income (loss) per class B shares - diluted | ... | \$0.29 | \$0.21 |
| Net earnings (loss) per share - diluted | \$(0.25) | ... | ... |
| Total number of employees | ... | 0 | 0 |
| Number of common class A stockholders | ... | 24 | 24 |
| Number of common class B stockholders | ... | 21 | 21 |
| Number of common unit stockholders | 6 | 21 | 21 |

□ Shares decreased due to the effect of Class A common stock were redeemed in the extension redemptions; □ As of March 1, 2023; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 8,162 | 1,397,296 |
| Prepaid expenses | 9,166 | 23,105 |
| Total current assets | 17,328 | 1,420,401 |
| Cash & investments held in trust account | ... | 84,243,386 |
| Cash held in trust account | 21,966,104 | ... |
| Total assets | 21,983,432 | 85,663,787 |
| Accounts payable | 76,826 | 19,114 |
| Extension note | ... | 333,935 |
| Accrued excise tax payable | 639,193 | ... |
| Accrued expenses | 1,097,000 | 575,300 |
| Income taxes payable | 70,011 | 1,208,515 |
| Extension notes - related party | 1,708,426 | ... |
| Working capital loan - related party | 400,000 | ... |
| Total current liabilities | 3,991,456 | 2,136,864 |
| Deferred legal fees | 275,000 | 275,000 |
| Deferred underwriting fee payable | 26,250,000 | 26,250,000 |
| Derivative warrant liabilities | 9,205,500 | 4,512,500 |
| Equity forward liability | 325,000 | ... |
| Total liabilities | 40,046,956 | 33,174,364 |
| Class A common stock subject to possible redemption | ... | 84,243,386 |
| Class A common stock | 3 | 3 |
| Class B common stock | 1,875 | 1,875 |
| Accumulated deficit | (40,031,506) | ... |
| Retained earnings (accumulated deficit) | ... | (31,755,841) |
| Common Stock - Issued & Paid | 21,966,104 | ... |
| Total stockholders' equity (deficit) | (18,063,524) | (31,753,963) |
| Total Equity | (18,063,524) | ... |

Recent Dividends:

- 1. CONX Corp class A common stock subject to possible redemption.**
No dividends paid.
- 2. CONX Corp class A common.**
No dividends paid.
- 3. CONX Corp class B common.**
No dividends paid.

Annual Dividends:

- 1. CONX Corp class A common stock subject to possible redemption.**
No dividends paid.
- 2. CONX Corp class A common.**
No dividends paid.

3. CONX Corp class B common.
No dividends paid.

CORETEC GROUP INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|--------------------|
| Research & development expenses | 512,952 | 535,837 | 469,996 |
| General & administrative expenses | 1,791,910 | 2,132,996 | 5,615,038 |
| Interest expenses | ... | 202,751 | 229,525 |
| Total expenses | ... | 2,871,584 | 6,314,559 |
| Other income | 214,787 | 8,260 | 45,620 |
| Net income (loss) | (2,307,639) | (2,863,324) | (6,268,939) |
| Weighted average shares outstanding - basic | 277,732,088 | 258,337,996 | 243,964,924 |
| Weighted average shares outstanding - diluted | 277,732,088 | 258,337,996 | 243,964,924 |
| Year end shares outstanding | 284,104,032 | 268,871,202 | 254,055,581 |
| Net earnings (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.03) |
| Net earnings (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.03) |
| Total number of employees | ... | 6 | 8 |
| Number of common stockholders | 4,300 | 24,800 | 24,800 |
| Interest | 217,564 | ... | ... |
| Net Income Before Taxes | (2,307,639) | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

□ Approximately; □ As of March 17, 2023; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash | 523,988 | 2,356,348 |
| Prepaid expenses | 132,680 | 114,201 |
| Total current assets | 656,668 | 2,470,549 |
| Plant, Machinery & Equipment - Accumulated Depreciation & Impairment | 17,425 | ... |
| Property, plant and equipment, gross | 127,191 | ... |
| Equipment - Net | 109,766 | ... |
| Property & equipment, net | 109,766 | 73,462 |
| Intangibles, net | 824,345 | 906,975 |
| Goodwill | 166,000 | 166,000 |
| Deposits - other | 4,550 | 4,550 |
| Total other assets | 994,895 | 1,077,525 |
| Total assets | 1,761,329 | 3,621,536 |
| Notes payable | 571,451 | 61,398 |
| Accounts payable & accrued expenses | 75,918 | 316,992 |
| Current Portion of Long-Term | 476,075 | ... |
| Notes payable - Balancing value | 95,376 | ... |
| Total current liabilities | 647,369 | 378,390 |
| Promissory note | 1,003,816 | 1,485,617 |
| Less: warrant issued | ... | (51,755) |
| Less: debt issue costs | ... | (19,036) |
| Long term debt, net | ... | 1,414,826 |
| Total liabilities | 1,651,185 | 1,793,216 |
| Preferred stock, series A convertible | 69 | 69 |
| Common stock | 56,819 | 53,772 |
| Additional paid-in | | |

| | | |
|---|--------------|--------------|
| capital | 18,706,208 | 18,119,792 |
| Retained earnings (accumulated deficit) | (18,652,952) | (16,345,313) |
| Total stockholders' equity (deficiency) | 110,144 | 1,828,320 |
| Total Equity | 110,144 | ... |

Recent Dividends:

- 1. Coretec Group Inc common stock subject to put rights and call rights.**
No dividends paid.
- 2. Coretec Group Inc common.**
No dividends paid.
- 3. Coretec Group Inc series B convertible preferred.**
No dividends paid.
- 4. Coretec Group Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Coretec Group Inc common stock subject to put rights and call rights.**
No dividends paid.
- 2. Coretec Group Inc common.**
No dividends paid.
- 3. Coretec Group Inc series B convertible preferred.**
No dividends paid.
- 4. Coretec Group Inc series A convertible preferred.**
No dividends paid.

CORETEC GROUP INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------------|--------------------|--------------------|
| Cost & expenses | 1,292,990 | 1,721,260 |
| Operating income | (1,454,412) | (3,271) |
| Interest expense | 161,422 | ... |
| Other income (expense), net | 16,105 | 3,271 |
| Net before taxes | (1,438,307) | ... |
| Net income | (1,438,307) | (1,717,989) |
| Earnings common share | | |
| Primary | \$(0.01) | \$(0.01) |
| Fully Diluted | \$(0.01) | \$(0.01) |
| Common Shares: | | |
| Full Diluted | 275,948,520 | 255,923,378 |
| Year-end | 284,104,032 | 257,256,422 |

CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|---------------------|-------------------|
| | | | (revised) |
| REVENUES | 9,000 | ... | ... |
| Revenues | 9,000 | 88,600 | 87,754 |
| Cost of revenues | 3,600 | 28,491 | 47,949 |
| Gross profit (loss) | 5,400 | 60,109 | 39,805 |
| Research & development | 1,970,639 | 6,268,854 | 109,180 |
| Selling, general & administrative | 3,560,309 | 3,943,543 | 2,964,490 |
| Amortization of patent costs | 94,584 | 92,084 | 92,084 |
| Total expenses | 5,625,532 | 10,304,481 | 3,165,754 |
| Operating income (loss) | (5,620,132) | (10,244,372) | (3,125,949) |
| Interest expense | ... | ... | 4,278,433 |
| Interest income - related party | 333,558 | ... | ... |
| Gain (loss) on extinguishment of convertible notes | ... | ... | 585,601 |
| Change in fair value of derivatives liabilities | ... | ... | 26,030,549 |
| Other income | ... | 100,328 | ... |
| Total other income (expense) | 333,558 | 100,328 | 22,337,717 |
| Income (loss) before provision for income taxes | (5,286,574) | (10,144,044) | 19,211,768 |
| Net income (loss) | (5,286,574) | (10,144,044) | 19,211,768 |
| Weighted average number of shares outstanding - basic | 1,407,632 | 1,093,204 | 260,506 |
| Weighted average number of shares | | | |

| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | |
|--|-----------|-----------|---------|--|--------------|--------------|---|--|---------------|--------------|
| | | | | 2023 | 2022 | 2021 | | | | |
| outstanding - diluted | 1,407,632 | 1,093,204 | 324,862 | | | | employees | ... | ... | 4 |
| Year end shares outstanding | 1,373,626 | 1,407,624 | 633,886 | Revenue | 153,000 | ... | Number of full time employees | 17 | 16 | 30 |
| Income (loss) per share from continuing operations - basic | \$(3.76) | ... | ... | Revenue | 153,000 | ... | Number of common stockholders | 48 | 2,937 | 2,061 |
| Net income (loss) per share - basic | \$(3.76) | \$(9.30) | \$73.70 | Cost of revenue | 886,000 | ... | Income from cont operations before income tax | (28,984,000) | ... | ... |
| Income (loss) per share from continuing operations - diluted | \$(3.76) | ... | ... | Research & development expenses | 2,231,000 | 4,107,000 | 2,496,000 | Total number of employees | 17 | ... |
| Net income (loss) per share - diluted | \$(3.76) | \$(9.30) | \$56.10 | Selling, general & administrative expenses | 14,962,000 | 11,001,000 | 14,367,000 | □ For 9 months due to fiscal year end change; □ Adjusted for 1-for-60 stock split, August 15, 2023 | | |
| Number of full time employees | 4 | 4 | 4 | Depreciation and amortization | 733,000 | ... | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| Number of part time employees | ... | ... | 1 | Goodwill impairment charge | 649,000 | ... | ... | 2023 | 2022 | |
| Number of common stockholders | 75 | 75 | 75 | Total operating expenses | ... | 15,108,000 | 16,863,000 | Cash | 1,059,000 | 821,000 |
| Total number of employees | 4 | ... | ... | Income (loss) from operations | (19,308,000) | (15,108,000) | (16,863,000) | Accounts receivable | 83,000 | ... |
| | | | | Other expense | ... | 74,000 | 55,000 | Prepaid & other current assets | 128,000 | 590,000 |
| | | | | Interest expense | 9,417,000 | 7,000 | 7,000 | Prepaid and other current assets | 728,000 | ... |
| | | | | Change in fair value of warrant liability | 10,458,000 | 1,023,000 | ... | Insurance | 600,000 | ... |
| | | | | Change in fair value of notes | (7,040,000) | (149,000) | ... | Total current assets | 1,870,000 | 1,411,000 |
| | | | | Gain (loss) on extinguishment of debt | (2,345,000) | ... | 7,000 | Equipment | 3,155,000 | 1,457,000 |
| | | | | Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 431,000 | Computer software | 56,000 | 52,000 |
| | | | | Change in fair value of derivative liability | 401,000 | ... | ... | Leasehold improvements | 362,000 | 362,000 |
| | | | | Loss on extinguishment of warrant liability | (504,000) | ... | ... | Property and equipment, gross Vehicles | 395,000 | ... |
| | | | | Gain on issuance of convertible notes | 64,000 | ... | ... | Property and equipment, gross Construction In Progress | 77,000 | ... |
| | | | | Amortization expense | (1,293,000) | ... | ... | Furniture And Fixtures | 3,000 | ... |
| | | | | Total other income (expense) | (9,676,000) | 793,000 | 376,000 | Total property & equipment, gross | 4,048,000 | 1,871,000 |
| | | | | Deemed dividend on Series D preferred stock | 6,000 | ... | ... | Less: accumulated depreciation & amortization | 919,000 | 462,000 |
| | | | | Cumulative dividends on Series A preferred stock | 19,000 | ... | ... | Property & equipment, net | 3,129,000 | 1,409,000 |
| | | | | Cumulative dividends on Series B preferred stock | 107,000 | ... | ... | Intangible Assets - excluding Goodwill - Net | ... | ... |
| | | | | Cumulative dividends on Series C preferred stock | 30,000 | ... | ... | - Total | 1,382,000 | ... |
| | | | | Distribution for Preferred Shares | 272,000 | ... | ... | Intangible assets, net | ... | 1,598,000 |
| | | | | Distribution for Preferred Shares | 110,000 | ... | ... | Right of use asset | 1,701,000 | 1,842,000 |
| | | | | Distribution for Preferred Shares | 79,000 | ... | ... | Deferred debt issuance costs | 1,306,000 | 150,000 |
| | | | | Net income (loss) | (28,984,000) | (14,315,000) | (16,487,000) | Other assets | 139,000 | 180,000 |
| | | | | Cumulative dividends on Series D preferred stock | 53,000 | 55,000 | ... | Total assets | 9,527,000 | 6,590,000 |
| | | | | Net income (loss) attributable to common stockholders | (29,660,000) | (14,370,000) | ... | Accounts payable | 1,500,000 | 865,000 |
| | | | | Weighted average shares outstanding - basic | 5,429,259 | 290,603 | 243,267 | Payroll & other expenses | 112,000 | ... |
| | | | | Weighted average shares outstanding - diluted | 5,429,259 | 290,603 | 243,267 | General liability insurance | ... | 104,000 |
| | | | | Year end shares outstanding | 25,744,158 | 337,392 | 242,169 | Bonus | 1,000,000 | 510,000 |
| | | | | Net income (loss) per share - basic | \$(5.46) | \$(49.20) | \$(67.80) | Other accrued expenses | ... | 7,000 |
| | | | | Net income (loss) per share - diluted | \$(5.46) | \$(49.20) | \$(67.80) | Accrued expenses | 1,190,000 | 621,000 |
| | | | | Number of part time employees | ... | ... | ... | Lease liability - current portion | 655,000 | 574,000 |
| | | | | | | | | Warrant liability | ... | 972,000 |
| | | | | | | | | Notes payable at fair value | ... | 1,654,000 |
| | | | | | | | | Notes payable | 429,000 | 8,000 |
| | | | | | | | | Warrant liability | 27,000 | ... |
| | | | | | | | | Taxes | 51,000 | ... |
| | | | | | | | | Warranty customer liability | 2,000 | ... |
| | | | | | | | | Total current liabilities | 3,776,000 | 4,694,000 |
| | | | | | | | | Lease liability | 1,072,000 | 1,366,000 |
| | | | | | | | | Warranty customer liability long term | 2,000 | ... |
| | | | | | | | | Total liabilities | 4,850,000 | 6,060,000 |
| | | | | | | | | Common Stock - Issued & Paid | 7,000 | ... |
| | | | | | | | | Common stock | ... | 2,000 |
| | | | | | | | | Additional paid-in capital | 121,665,000 | 88,533,000 |
| | | | | | | | | Accumulated deficit | (116,995,000) | ... |
| | | | | | | | | Retained earnings (accumulated deficit) | ... | (88,005,000) |
| | | | | | | | | Total stockholders' equity (deficit) | 4,677,000 | 530,000 |
| | | | | | | | | Total Equity | 4,677,000 | ... |

Recent Dividends:

1. Creative Medical Technology Holdings Inc series A preferred.

No dividends paid.

2. Creative Medical Technology Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Creative Medical Technology Holdings Inc series A preferred.

No dividends paid.

2. Creative Medical Technology Holdings Inc common.

No dividends paid.

CROWN ELECTROKINETICS CORP
Annual Report

Recent Dividends:

1. **Crown Electrokinetics Corp series D preferred.**
No dividends paid.
2. **Crown Electrokinetics Corp series B preferred.**
No dividends paid.
3. **Crown Electrokinetics Corp series C preferred.**
No dividends paid.
4. **Crown Electrokinetics Corp common.**
No dividends paid.
5. **Crown Electrokinetics Corp series A preferred.**
No dividends paid.
6. **Crown Electrokinetics Corp series F-1 preferred.**
No dividends paid.
7. **Crown Electrokinetics Corp series F preferred.**
No dividends paid.

Annual Dividends:

1. **Crown Electrokinetics Corp series D preferred.**
No dividends paid.
2. **Crown Electrokinetics Corp series B preferred.**
No dividends paid.
3. **Crown Electrokinetics Corp series C preferred.**
No dividends paid.
4. **Crown Electrokinetics Corp common.**
No dividends paid.
5. **Crown Electrokinetics Corp series A preferred.**
No dividends paid.
6. **Crown Electrokinetics Corp series F-1 preferred.**
No dividends paid.
7. **Crown Electrokinetics Corp series F preferred.**
No dividends paid.

CRYO-CELL INTERNATIONAL INC

Earnings, 3 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|----------------|----------------|
| Total revenues | 7,852,235 | 7,824,415 |
| Cost & expenses | 6,997,826 | 5,860,400 |
| Operating income | 821,223 | 1,683,171 |
| Interest expense | 256,459 | 466,231 |
| Other income (expense), net | (45,225) | 1,268 |
| Gains or losses | 274,971 | (3,681) |
| Net before taxes | 794,510 | 1,214,527 |
| Income taxes | 238,269 | ... |
| Net income | 556,241 | 766,812 |

Earnings common share

| | 2024 | 2023 |
|---------------|--------|--------|
| Primary | \$0.07 | \$0.09 |
| Fully Diluted | \$0.07 | \$0.09 |

Consolidated Balance Sheet Items, as of (\$):

| | 2024 | 2023 |
|---------------------------|--------------------|------|
| Assets: | | |
| Cash & equivalents | 247,112 | ... |
| Inventories | 755,160 | ... |
| Current assets | 9,452,076 | ... |
| Net property & equip. | 21,605,273 | ... |
| Total assets | 61,710,774 | ... |
| Liabilities: | | |
| Current liabilities | 19,370,376 | ... |
| Long-term debt | 8,391,738 | ... |
| Stockholders' equity | (10,338,012) | ... |
| Net current assets | (9,918,300) | ... |

CUE BIOPHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-------------------|-------------------|-------------------|
| Total revenues | 5,490,000 | ... | ... |
| Collaboration revenue | 5,490,000 | 1,245,227 | 14,941,370 |
| General & administrative expenses | 16,680,000 | 16,168,586 | 17,306,678 |
| Research & development expenses | 40,802,000 | 38,578,083 | 41,346,765 |
| Gain on right-of-use asset termination | ... | 276,633 | ... |
| Total operating expenses | 57,639,000 | 54,470,036 | 58,653,443 |
| Income (loss) from operations | (52,149,000) | (53,224,809) | (43,712,073) |
| Interest income | 2,661,000 | 928,242 | 45,898 |
| Interest expense | 1,245,000 | 713,815 | ... |

| | | | |
|---|---------------------|---------------------|---------------------|
| Total other income (expense) | 1,416,000 | 214,427 | 45,898 |
| Income (loss) before provision for income taxes | (50,733,000) | (53,010,382) | (43,666,175) |
| Provision for income taxes | ... | ... | 495,000 |
| Net income (loss) | (50,733,000) | (53,010,382) | (44,161,175) |
| Weighted average shares outstanding - basic | 45,754,794 | 35,649,134 | 31,285,418 |
| Weighted average shares outstanding - diluted | 45,754,794 | 35,649,134 | 31,285,418 |
| Year end shares outstanding | 47,215,116 | 43,042,548 | 32,202,496 |
| Net earnings (loss) per common share - basic | \$(1.11) | \$(1.49) | \$(1.41) |
| Net earnings (loss) per common share - diluted | \$(1.11) | \$(1.49) | \$(1.41) |
| Number of full time employees | 53 | 51 | 57 |
| Number of part time employees | ... | 1 | 2 |
| Number of common stockholders | 86 | 108 | 51 |
| Gain on sale of property, plant & equipment | (157,000) | ... | ... |
| Total number of employees | 53 | ... | ... |

☐ Shares increased due to the effect of issuance of common stock for ATM offering, pre-funded warrants, exercise of warrants and restricted stock awards released; ☒ Approximately; ☓ As of March 13, 2023; ☔ As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------------|-------------------|
| Cash & cash equivalents | 48,514,000 | 51,614,102 |
| Marketable securities | ... | 24,674,903 |
| Accounts receivable | 1,698,000 | 57,252 |
| Prepaid expenses & other current assets | 1,242,000 | 841,217 |
| Total current assets | 51,454,000 | 77,187,474 |
| Laboratory equipment | 4,069,000 | 5,246,029 |
| Furniture & fixtures | 81,000 | 80,568 |
| Computer equipment | 143,000 | 296,342 |
| Leasehold-improvements | 118,000 | 117,821 |
| Total property & equipment, gross | 4,411,000 | 5,740,760 |
| Less accumulated depreciation | 3,616,000 | 4,241,497 |
| Property & equipment, net | 795,000 | 1,499,263 |
| Operating lease right-of-use asset | 6,323,000 | 9,202,670 |
| Deposits | 2,690,000 | 3,115,712 |
| Restricted cash | 151,000 | 150,000 |
| Other long term assets | 117,000 | 128,333 |
| Total assets | 61,530,000 | 91,283,452 |
| Accounts payable | 3,501,000 | 2,731,123 |
| Accrued employee & board compensation | 2,219,000 | 2,273,250 |
| Accrued contract manufacturing services | 163,000 | ... |
| Accrued professional services | 344,000 | 242,617 |
| Accrued contract research services | 1,411,000 | 1,038,344 |
| Accrued expenses | 4,137,000 | 3,554,211 |
| Research & development contract liabilities | 2,112,000 | ... |
| Operating lease liabilities, current portion | 3,368,000 | 3,300,173 |
| Current portion of long-term debt, net | 3,963,000 | 1,963,028 |
| Total current liabilities | 17,081,000 | 11,548,535 |
| Operating lease liabilities, net of | ... | ... |

| | | |
|---|-------------------|-------------------|
| current portion | 3,162,000 | 6,017,613 |
| Long-term debt, net | 4,202,000 | 8,034,729 |
| Total liabilities | 24,445,000 | 25,600,877 |
| Common stock | 47,000 | 43,042 |
| Additional paid-in capital | 338,228,000 | 316,192,002 |
| Accumulated other comprehensive income (loss) | ... | (95,873) |
| Retained earnings (accumulated deficit) | (301,190,000) | (250,456,596) |
| Total stockholders' equity (deficit) | 37,085,000 | 65,682,575 |
| Total Equity | 37,085,000 | ... |

Recent Dividends:

1. **Cue Biopharma Inc common.**
No dividends paid.

Annual Dividends:

1. **Cue Biopharma Inc common.**
No dividends paid.

CUENTAS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|---------------------|---------------------|
| Revenue | 2,346,000 | 2,994,000 | 593,000 |
| Total revenues | 2,346,000 | ... | ... |
| Total revenue | 2,346,000 | ... | ... |
| Cost of revenue | 2,733,000 | 2,508,000 | 469,000 |
| Gross profit (loss) | (387,000) | 486,000 | 124,000 |
| Impairment of intangible assets | ... | 3,600,000 | ... |
| Amortization of intangible assets | 11,000 | 1,810,000 | 1,809,000 |
| Selling, general & administrative | 6,011,000 | 9,431,000 | 8,980,000 |
| Total operating expenses | 6,022,000 | 14,841,000 | 10,789,000 |
| Operating income (loss) | (6,409,000) | (14,355,000) | (10,665,000) |
| Other income (expense), net | (441,000) | (132,000) | 1,000 |
| Interest income (expense) | ... | 6,000 | (172,000) |
| Gain (loss) on disposal of asset | 4,741,000 | ... | ... |
| Gain from change in fair value of stock-based liabilities | ... | 2,000 | 110,000 |
| NET LOSS BEFORE EQUITY LOSSES | (2,109,000) | ... | ... |
| Total other income (loss), net | 4,300,000 | (124,000) | (61,000) |
| NET INCOME (LOSS) BEFORE CONTROLLING INTEREST | (2,109,000) | ... | ... |
| Net income (loss) before controlling interest & equity income (losses) | (2,196,000) | (14,479,000) | (10,726,000) |
| Equity income (losses) in non-consolidated entity | ... | (52,000) | (2,000) |
| Net income (loss) attributable to Cuentas Inc. | ... | (14,531,000) | (10,728,000) |
| Weighted average shares outstanding - basic | 2,317,213 | 1,230,577 | 1,070,541 |
| Weighted average shares outstanding - diluted | 2,317,213 | 1,230,577 | 1,070,541 |
| Year end shares outstanding | 2,719,668 | 1,473,645 | 1,151,207 |
| Net income (loss) per share - basic | \$(0.95) | \$(11.81) | \$(9.32) |
| Net income (loss) per share - diluted | \$(0.95) | \$(11.81) | \$(9.32) |
| Number of full time | ... | ... | ... |

| | | | |
|--|----------|------------------|------------------|
| employees..... | 3 | ⁵ 6 | ⁶ 8 |
| Total number of employees..... | 3 | ... | ... |
| Number of common stockholders..... | 130 | ⁵ 128 | ⁶ 128 |
| Earnings per share from continuing operations..... | \$(0.95) | ... | ... |
| Earnings per share from continuing operations..... | \$(0.95) | ... | ... |
| Equity losses in unconsolidated entities..... | (87,000) | ... | ... |

⁵ Reclassified to conform with 2022 presentation; ⁶ Adjusted for 1-for-13 stock split, March 24, 2023; ⁷ Shares increased due to the effect of issuance of shares of common stock and shares issued for services; ⁸ Shares increased due to the effect of issuance of shares of common stock, shares issued for services and for employees; due to exercise of warrants; and due to conversion of convertible note; ⁹ As of March 31, 2023; ¹⁰ As of March 31, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|--------------|--------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents..... | 205,000 | 466,000 | |
| Accounts receivables, gross..... | ... | 386,000 | |
| Allowance for doubtful debt..... | ... | 177,000 | |
| Accounts receivables..... | 1,300,000 | 209,000 | |
| Accounts receivable, related party..... | 7,000 | ... | |
| Other receivable..... | 172,000 | ... | |
| Other current assets..... | 76,000 | 14,000 | |
| Total current assets..... | 1,760,000 | 689,000 | |
| Property & equipment, net..... | 13,000 | 6,000 | |
| Investment in unconsolidated entities..... | 2,928,000 | 776,000 | |
| Intangible assets..... | 19,000 | 28,000 | |
| Total assets..... | 4,720,000 | 1,499,000 | |
| Accrued expenses, interest & other liabilities..... | ... | 309,000 | |
| Accrued salaries & wages..... | ... | 105,000 | |
| Accrued bonuses..... | ... | 267,000 | |
| Other accounts liabilities..... | 1,497,000 | 681,000 | |
| Trade payable..... | ... | 1,231,000 | |
| Other accrued liabilities..... | 2,230,000 | ... | |
| Deferred revenue..... | 151,000 | 113,000 | |
| Notes & loan payable..... | 26,000 | 109,000 | |
| Derivative liability..... | 785,000 | ... | |
| Total current liabilities..... | 4,689,000 | 2,134,000 | |
| Long-term loans..... | 101,000 | ... | |
| Other long term liabilities..... | ... | 89,000 | |
| Total liabilities..... | 4,790,000 | 2,223,000 | |
| Common stock..... | 3,000 | 19,000 | |
| Additional paid-in capital..... | 54,906,000 | 52,036,000 | |
| Treasury stock..... | 33,000 | 29,000 | |
| Accumulated deficit..... | (54,946,000) | ... | |
| Retained earnings (accumulated deficit)..... | ... | (52,750,000) | |
| Total stockholders' equity (deficit)..... | (70,000) | (724,000) | |
| Total stockholders' equity (deficit)..... | (70,000) | ... | |

Recent Dividends:

- 1. Cuentas Inc series A preferred.**
No dividends paid.
 - 2. Cuentas Inc series B preferred.**
No dividends paid.
 - 3. Cuentas Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. Cuentas Inc series A preferred.**
No dividends paid.
 - 2. Cuentas Inc series B preferred.**

| | | | |
|---|---------------------|---------------------|-------------------------|
| No dividends paid. | | | |
| 3. Cuentas Inc common. | | | |
| No dividends paid. | | | |
| CURIOSITYSTREAM INC (NEW) | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Revenues..... | 56,889,000 | ... | ... |
| Revenues..... | 56,889,000 | 78,043,000 | 71,261,000 |
| Cost of revenues..... | 35,553,000 | 51,536,000 | 36,673,000 |
| Advertising & marketing..... | 17,390,000 | 40,709,000 | 52,208,000 |
| General & administrative..... | 29,447,000 | 37,479,000 | 34,859,000 |
| Impairment of goodwill & intangible assets..... | ... | 3,603,000 | ... |
| Total operating expenses..... | (101,360,000) | (133,327,000) | (123,740,000) |
| Operating income (loss)..... | (44,471,000) | (55,284,000) | (52,479,000) |
| Change in fair value of warrant liability..... | 213,000 | 5,404,000 | 15,182,000 |
| Interest & other income..... | 1,272,000 | 176,000 | 486,000 |
| Equity interests income (loss)..... | (5,404,000) | (846,000) | (464,000) |
| Income (loss) before income taxes..... | (48,390,000) | (50,550,000) | (37,275,000) |
| Current state & local income taxes..... | 77,000 | (25,000) | 11,000 |
| Current foreign income taxes..... | 429,000 | 396,000 | 345,000 |
| Total current provision..... | 506,000 | 371,000 | 356,000 |
| Deferred federal income taxes..... | ... | (3,000) | 3,000 |
| Deferred state & local income taxes..... | ... | (1,000) | 1,000 |
| Deferred income taxes..... | ... | (4,000) | 4,000 |
| Provision for income taxes..... | 506,000 | 367,000 | 360,000 |
| Net income (loss)..... | (48,896,000) | (50,917,000) | (37,635,000) |
| Net income (loss) attributable to common stockholders..... | ... | ... | (37,635,000) |
| Weighted average shares outstanding - basic..... | 53,044,000 | 52,787,000 | 51,482,000 |
| Weighted average shares outstanding - diluted..... | 53,044,000 | 52,787,000 | 51,789,000 |
| Year end shares outstanding..... | 53,286,000 | 52,853,000 | ⁵ 52,677,000 |
| Net earnings (loss) per share - basic..... | \$(0.92) | \$(0.96) | \$(0.73) |
| Net earnings (loss) per share - diluted..... | \$(0.92) | \$(0.96) | \$(1.02) |
| Number of full time employees..... | 48 | ² 65 | ⁹ 92 |
| Total number of employees..... | 48 | ... | ... |
| Number of common stockholders..... | 206 | ⁵ 134 | ⁶ 133 |
| Impairment of content assets..... | 18,970,000 | ... | ... |

⁵ Shares increased due to the effect of stock-based compensation, issuance of common stock, exercised warrants and options; ⁶ Approximately; ⁷ As of March 29, 2023; ⁸ As of March 29, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|------------|------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents..... | 37,715,000 | 40,007,000 | |
| Restricted cash..... | 500,000 | 500,000 | |
| Short-term investments in debt securities..... | ... | 14,986,000 | |
| Accounts receivable - Balancing value..... | 5,260,000 | ... | |
| Accounts receivable, net..... | 4,760,000 | 10,899,000 | |

| | | |
|--|---------------|---------------|
| Other current assets..... | 2,315,000 | 3,118,000 |
| Provision - Accounts & Notes Receivable - Trade..... | 500,000 | ... |
| Total current assets..... | 45,290,000 | 69,510,000 |
| Investments in equity method investees..... | 6,354,000 | 10,766,000 |
| Furniture & fixtures..... | ... | 108,000 |
| Equipment..... | 1,040,000 | 1,252,000 |
| Computer & software..... | ... | 857,000 |
| Website & application development..... | 570,000 | 37,000 |
| Leasehold improvements..... | 703,000 | 703,000 |
| Work-in-progress..... | 5,000 | 5,000 |
| Property, Plant & Equipment - Gross - Total - Balancing value..... | 101,000 | ... |
| Website and application development..... | 37,000 | ... |
| Property & equipment, gross..... | 2,456,000 | 2,962,000 |
| Less: accumulated depreciation & amortization..... | 1,729,000 | 1,868,000 |
| Property & equipment, net..... | 727,000 | 1,094,000 |
| Content assets, net..... | ... | 68,502,000 |
| Intangibles, net..... | 44,943,000 | 251,000 |
| Operating lease right-of-use assets..... | 3,350,000 | 3,702,000 |
| Other assets..... | 358,000 | 288,000 |
| Total assets..... | 101,022,000 | 154,113,000 |
| Content liabilities..... | 407,000 | 2,862,000 |
| Accounts payable..... | 4,765,000 | 6,065,000 |
| Accrued expenses & other liabilities..... | 3,305,000 | 7,752,000 |
| Deferred revenue..... | 14,521,000 | 14,281,000 |
| Operating Lease Liabilities - Current Portion/Short-Term..... | 400,000 | ... |
| Accrued expenses and other liabilities - Balancing value..... | 3,705,000 | ... |
| Total current liabilities..... | 23,398,000 | 30,960,000 |
| Warrant liability..... | 44,000 | 257,000 |
| Non-current operating lease liabilities..... | 4,283,000 | 4,648,000 |
| Other liabilities..... | 651,000 | 622,000 |
| Total liabilities..... | 28,376,000 | 36,487,000 |
| Common stock..... | 5,000 | 5,000 |
| Additional paid-in capital..... | 362,636,000 | 358,760,000 |
| Accumulated other comprehensive income (loss)..... | ... | (40,000) |
| Retained earnings (accumulated deficit)..... | (289,995,000) | (241,099,000) |
| Total stockholders' equity (deficit)..... | 72,646,000 | 117,626,000 |
| Total Equity..... | 72,646,000 | ... |

Recent Dividends:

- 1. CuriosityStream Inc (New) common.**
No dividends paid.
- 2. CuriosityStream Inc (New) class A common.**
No dividends paid.
- 3. CuriosityStream Inc (New) class B common.**
No dividends paid.
- 4. CuriosityStream Inc (New) common stock subject to possible redemption.**
No dividends paid.

Annual Dividends:

- 1. CuriosityStream Inc (New) common.**
No dividends paid.
- 2. CuriosityStream Inc (New) class A common.**
No dividends paid.
- 3. CuriosityStream Inc (New) class B common.**
No dividends paid.
- 4. CuriosityStream Inc (New) common stock subject to possible redemption.**
No dividends paid.

CV SCIENCES INC
Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | | |
|---|-------------|------------|
| Buildings & improvements | 12,798,000 | 12,530,000 |
| Machinery & equipment | 7,536,000 | 7,810,000 |
| Construction in progress | 167,000 | 12,000 |
| Totals at cost | 22,721,000 | 22,572,000 |
| Less: accumulated depreciation & amortization | 10,555,000 | 9,976,000 |
| Property, plant & equipment, net | 12,166,000 | 12,596,000 |
| Other assets | 9,000 | 10,000 |
| Intangible assets, net | 9,000 | 119,000 |
| Total assets | 35,025,000 | 37,912,000 |
| Accounts payable | 1,203,000 | 1,454,000 |
| Accrued expenses | 1,765,000 | 2,591,000 |
| Current maturities of long-term debt | 81,000 | 77,000 |
| Contract liabilities | 4,908,000 | 4,042,000 |
| Customer deposits | 597,000 | ... |
| Total current liabilities | 8,554,000 | 8,164,000 |
| Equipment loan payable | ... | 426,000 |
| Less: current maturities | ... | 77,000 |
| Long-term debt, net of current portion | 268,000 | 349,000 |
| Total liabilities | 8,822,000 | 8,513,000 |
| Common stock | 68,000 | 67,000 |
| Additional paid-in capital | 28,695,000 | 27,712,000 |
| Retained earnings (accumulated deficit) | (2,560,000) | 1,620,000 |
| Total stockholders' equity | 26,203,000 | 29,399,000 |
| Total Equity | 26,203,000 | ... |

Recent Dividends:**1. CVD Equipment Corp. common.**

No dividends paid.

Annual Dividends:**1. CVD Equipment Corp. common.**

No dividends paid.

CYBERLOQ TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|------------------|--------------------|
| Service revenue | 993 | 2,671 | 197 |
| License fee | 15,000 | ... | ... |
| Total revenue | 15,993 | 2,671 | 197 |
| Professional fees | 86,778 | 424,503 | 468,449 |
| Research | 11,036 | ... | 180,063 |
| Stock compensation | 210,000 | ... | ... |
| Officer's compensation | ... | 207,000 | 370,400 |
| Travel & entertainment | 7,818 | 1,011 | 1,766 |
| Rent | 9,573 | 9,117 | 9,031 |
| Computer & internet | 18,927 | 24,796 | 10,859 |
| Office supplies & expenses | 9,313 | 5,848 | 6,608 |
| Other operating expenses | 29,798 | 12,733 | 13,494 |
| Total operating expenses | 383,243 | 685,008 | 1,060,670 |
| Income (loss) from operations | (367,250) | (682,337) | (1,060,473) |
| Interest | 94,684 | 30,786 | 20,896 |
| Loss on settlement of payables | ... | ... | 6,343 |
| Loss on settlement with officer | ... | 18,086 | ... |
| Gain (loss) on settlement of debt | ... | (195,216) | ... |
| Amortization of debt discount | 564,596 | 52,623 | ... |
| Net Income before Tax | (1,026,530) | ... | ... |
| Total other income (expense) | (659,280) | (296,711) | (27,239) |
| Net income (loss) | (1,026,530) | (979,048) | (1,087,712) |
| Weighted average shares outstanding - basic | 121,035,587 | 98,649,370 | 78,428,682 |
| Weighted average | ... | ... | ... |

| | | | |
|-------------------------------------|--------------------------|-------------|------------|
| shares outstanding - diluted | 121,035,587 | 98,649,370 | 78,428,682 |
| Year end shares outstanding | 122,589,756 [□] | 119,089,754 | 82,754,515 |
| Earnings (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.01) |
| Earnings (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.01) |
| Number of full time employees | 2 | 2 | 2 |
| Number of common stockholders | 142 | 139 | 129 |
| Total number of employees | 2 | ... | ... |

[□] Shares increased due to the issuance of common shares for cash, services, settlement of debt and officers' fees

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash in Bank | 307,174 | ... |
| Cash | ... | 4,067 |
| Deposits & prepaids | 44,564 | 53,811 |
| Accounts receivable | ... | 10,000 |
| Total current assets | 361,738 | 57,878 |
| Cyberloq platform | 1,096,827 | 283,240 |
| Total assets | 1,458,565 | 341,118 |
| Accounts payable & accrued expenses | 96,506 | 56,322 |
| Accrued interest | 132,685 | 47,737 |
| Loans payable - related party | 150,000 | ... |
| Notes payable - stockholders | ... | 35,000 |
| Notes payable - related party | ... | 150,000 |
| Convertible debt - stockholders, net | ... | 2,623 |
| Loan payable - Small Business Administration ("SBA") | 35,000 | 2,088 |
| Convertible Notes | 574,718 | ... |
| Loan payable - SBA | 2,088 | ... |
| Total current liabilities | ... | 293,770 |
| Small Business Administration loan payable | 30,362 | 30,362 |
| Total long term liabilities | 30,362 | 30,362 |
| Total liabilities | 1,021,359 | 324,132 |
| Common stock | 122,590 | 119,090 |
| Series A preferred stock | 20 | 20 |
| Shares to be issued | 149,186 | 149,186 |
| Treasury stock | 50,000 | 50,000 |
| Additional paid in capital | 8,475,062 | 7,031,812 |
| Retained earnings (accumulated deficit) | (8,259,652) | (7,233,122) |
| Total stockholders' equity (deficit) | 437,206 | 16,986 |
| Total Equity | 437,206 | ... |

Recent Dividends:**1. Cyberloq Technologies Inc preferred.**

No dividends paid.

2. Cyberloq Technologies Inc common.

No dividends paid.

Annual Dividends:**1. Cyberloq Technologies Inc preferred.**

No dividends paid.

2. Cyberloq Technologies Inc common.

No dividends paid.

CYTODYN, INC.**Earnings, 9 mos. to (Consol. - \$):**

| | 02/29/24 | 02/28/23 |
|-------------------------------|---------------------|---------------------|
| Cost & expenses | 11,399,000 | 36,631,000 |
| Operating income | (11,424,000) | (36,796,000) |
| Other income (expense), net | (9,631,000) | (8,756,000) |
| Gains or losses | (971,000) | ... |
| Net before taxes | (33,054,000) | (61,188,000) |
| Net income | (33,054,000) | (61,188,000) |
| Earnings common share Primary | \$(0.04) | \$(0.08) |

| | | |
|----------------|-------------|-------------|
| Fully Diluted | \$(0.04) | \$(0.08) |
| Common Shares: | | |
| Full Diluted | 954,814,000 | 810,986,000 |
| Year-end | 989,925,000 | 832,215,000 |

DARE BIOSCIENCE INC Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|--|---------------------|---------------------|---------------------|
| License fee revenue | 1,000,000 | 10,000,000 | ... |
| Total revenue | 2,807,885 | 10,000,000 | ... |
| milestone revenue | 1,800,000 | ... | ... |
| royalty revenue | 7,885 | ... | ... |
| General & administrative expenses | 12,109,691 | 11,243,271 | 8,350,945 |
| Research & development expenses | 21,538,074 | 30,042,217 | 30,617,567 |
| License fee expense | 100,000 | 100,000 | 100,000 |
| Total operating expenses | 33,747,765 | 41,385,488 | 39,068,512 |
| Income (loss) from operations | (30,939,880) | (31,385,488) | (39,068,512) |
| Other income | 778,489 | 437,750 | 2,520 |
| Gain on extinguishment of note payable | ... | ... | 369,887 |
| Net income (loss) | (30,161,391) | (30,947,738) | (38,696,105) |
| Net income (loss) to common shareholders | ... | (30,947,738) | (38,696,105) |
| Weighted average shares outstanding - basic | 87,303,701 | 84,571,805 | 61,154,157 |
| Weighted average shares outstanding - diluted | 87,303,701 | 84,571,805 | 61,154,157 |
| Year end shares outstanding | 99,973,932 | 84,825,481 | 83,944,119 |
| Net earnings (loss) per common share - basic | \$(0.35) | \$(0.37) | \$(0.63) |
| Net earnings (loss) per common share - diluted | \$(0.35) | \$(0.37) | \$(0.63) |
| Number of full time employees | 23 | 25 | 20 |
| Number of part time employees | 3 | 5 | 8 |
| Total number of employees | 26 | 30 | 28 |
| Number of common stockholders | 34 | 35 | 35 |
| Foreign currency translation adjustments | ... | (196,338) | ... |
| Income from cont operations before income tax | (30,161,391) | ... | ... |

[□] Shares increased due to the issuance of common shares, exercise of share options, issuance of common share in connection with milestone payment; [□] As of March 29, 2023; [□] As of March 30, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------------|------------|------------|
| Cash & cash equivalents | 10,476,056 | 34,669,605 |
| Other receivables | 949,211 | 1,703,160 |
| Prepaid clinical expense | 5,023,140 | 5,928,090 |
| Prepaid insurance expense | 472,922 | 502,981 |
| Prepaid legal & professional expenses | 245,251 | 234,917 |
| Prepaid expenses | 6,118,272 | 6,665,988 |
| Prepaid development expense | 376,959 | ... |
| Total current assets | 17,543,539 | 43,038,753 |
| Property & equipment, net | 655,975 | 64,908 |
| Other non-current assets | 599,594 | 115,092 |

| | | |
|--|---------------|---------------|
| Deferred financing costs | 139,203 | |
| Deposits | 1,163,477 | 10,502 |
| Operating lease assets | 1,319,630 | 457,925 |
| Other non-current assets | 722,722 | |
| Total assets | 21,282,215 | 43,826,383 |
| Accounts payable | 3,385,551 | 2,027,953 |
| Accrued clinical expense | 1,195,744 | 6,665,443 |
| Accrued compensation & benefits expenses | 1,720,501 | |
| Accrued development expense | 2,102,310 | |
| Accrued legal & professional expenses | 239,348 | |
| Other accruals | 99,747 | |
| Accrued license fee expense | 66,667 | 66,667 |
| Accrued expenses | 2,889,005 | 10,894,016 |
| Deferred grant funding | 13,737,154 | 18,303,567 |
| Current portion of lease liabilities | 468,726 | 398,391 |
| Accrued Expenses - Balancing value | 1,359,406 | |
| Insurance financing payable | 267,188 | |
| Total current liabilities | 20,480,436 | 31,623,927 |
| Deferred license revenue | 1,000,000 | 1,000,000 |
| Lease liabilities long-term | 935,743 | 90,346 |
| Liability related to the sale of future royalties, net | 3,913,676 | |
| Total liabilities | 26,329,855 | 32,714,273 |
| Common stock | 9,997 | 8,482 |
| Accumulated other comprehensive income (loss) | (360,896) | (351,311) |
| Additional paid-in capital | 166,539,290 | 152,529,579 |
| Retained earnings (accumulated deficit) | (171,236,031) | (141,074,640) |
| Total stockholders' equity (deficit) | (5,047,640) | 11,112,110 |
| Total Equity | (5,047,640) | |

Recent Dividends:
1. Dare Bioscience Inc common.
 No dividends paid.
Annual Dividends:
1. Dare Bioscience Inc common.
 No dividends paid.

DARIOHEALTH CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|----------------|
| Revenues - services | 7,268,000 | 17,859,000 | 2,085,000 |
| Revenues - hardware & consumable products | 13,084,000 | 9,797,000 | 18,428,000 |
| Total revenues | 20,352,000 | 27,656,000 | 20,513,000 |
| Cost of revenues - services | 5,303,000 | 5,324,000 | 338,000 |
| Cost of revenues - hardware & consumable products | 4,679,000 | 8,320,000 | 12,106,000 |
| Amortization of acquired intangible assets | 4,386,000 | 4,357,000 | 4,106,000 |
| Total cost of revenues | 14,368,000 | 18,001,000 | 16,550,000 |
| Gross profit (loss) | 5,984,000 | 9,655,000 | 3,963,000 |
| Research & development expenses | 20,248,000 | 19,649,000 | 17,219,000 |
| Sales & marketing expenses | 23,785,000 | 30,323,000 | 39,706,000 |
| General & administrative expenses | 18,140,000 | 16,493,000 | 23,532,000 |
| Total operating expenses | 62,173,000 | 66,465,000 | 80,457,000 |
| Operating income (loss) | (56,189,000) | (56,810,000) | (76,494,000) |

| | | | |
|---|---------------------|---------------------|---------------------|
| Bank charges | 112,000 | 83,000 | 84,000 |
| Foreign currency adjustments income (expenses), net | (210,000) | 243,000 | (195,000) |
| Interest income | 1,868,000 | 506,000 | 44,000 |
| Loan interest expenses | 1,876,000 | | |
| Remeasurement of long-term loan | 4,894,000 | 3,858,000 | |
| Remeasurement of warrant liability | 670,000 | 1,020,000 | |
| Debt issuance cost | 533,000 | 724,000 | |
| Remeasurement of Financial Commitment Asset ("FCA") | 607,000 | | |
| Income (loss) before taxes - domestic | (23,477,000) | (22,902,000) | (21,065,000) |
| Income (loss) before taxes - foreign | (35,886,000) | (39,287,000) | (55,664,000) |
| Income (loss) before taxes | (59,363,000) | (62,189,000) | (76,729,000) |
| Net loss | (59,427,000) | | |
| Income tax | 64,000 | 4,000 | 32,000 |
| Net income (loss) | (59,427,000) | (62,193,000) | (76,761,000) |
| Deemed dividend | 4,084,000 | 1,643,000 | 2,005,000 |
| Net income (loss) attributable to shareholders | (63,511,000) | (63,836,000) | (78,766,000) |
| Weighted average shares outstanding - basic | 28,371,979 | 23,635,038 | 16,591,718 |
| Weighted average shares outstanding - diluted | 28,371,979 | 23,635,038 | 16,591,718 |
| Year end shares outstanding | 27,191,849 | 25,724,470 | 16,573,420 |
| Net earnings (loss) per share - basic | \$(1.93) | \$(2.54) | \$(4.07) |
| Net earnings (loss) per share - diluted | \$(1.93) | \$(2.54) | \$(4.07) |
| Number of full time employees | 241 | 200 | |
| Number of part time employees | 11 | 14 | |
| Number of common stockholders | 342 | 375 | 380 |
| Revaluation of marketable securities | 37,000 | | |
| Non-operating Income/(Expense), Net | (3,174,000) | | |
| Earnings per share from continuing operations | \$(1.93) | | |
| Earnings per share from continuing operations | \$(1.93) | | |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of shares to consultants and service provider, directors and employees, acquisitions, conversion of preferred stock and share-based compensation; Shares increased due to the effect of payment for executives, directors, exercise of options, agent warrants, issuance of common stock and conversion of preferred stock; As of February 28, 2023; As of March 10, 2022; As of March 1, 2023; As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash & cash equivalents | 36,797,000 | 49,357,000 |
| Short-term restricted bank deposits | 292,000 | 165,000 |
| Trade receivables | 3,155,000 | 6,416,000 |
| Raw materials | 1,015,000 | 1,346,000 |
| Finished products | 4,047,000 | 6,610,000 |
| Inventories | 5,062,000 | 7,956,000 |
| Prepaid expenses | | 908,000 |
| Costs to fulfill a contract | | |
| Government authorities | | 239,000 |
| Total current assets | 47,330,000 | 65,524,000 |
| Deposits | 6,000 | 6,000 |
| Operation lease right of use assets | 967,000 | 1,206,000 |
| Computers & peripheral equipment | 2,388,000 | 944,000 |
| Office furniture & equipment | 137,000 | 154,000 |
| Production lines | 988,000 | 988,000 |
| Leasehold improvement | 326,000 | 141,000 |
| Computers and peripheral equipment | 937,000 | |
| Property & equipment, cost | | 2,227,000 |
| Less: accumulated depreciation - computers & peripheral equipment | 542,000 | 534,000 |
| Less: accumulated depreciation - office furniture & equipment | 43,000 | 60,000 |
| Less: accumulated depreciation - production lines | 874,000 | 773,000 |
| Less: accumulated depreciation - leasehold improvement | 30,000 | 72,000 |
| Less: accumulated depreciation | 1,489,000 | 1,439,000 |
| Property & equipment, net | 899,000 | 788,000 |
| Long-term assets | 143,000 | 111,000 |
| Intangible assets, net | 5,404,000 | 9,916,000 |
| Goodwill | 41,640,000 | 41,640,000 |
| Total non-current assets | 49,059,000 | 53,667,000 |
| Total assets | 96,389,000 | 119,191,000 |
| Trade payables | | 2,322,000 |
| Deferred revenues | 997,000 | 1,320,000 |
| Operating lease liabilities | 111,000 | 293,000 |
| Employees & payroll accruals | 4,073,000 | 4,407,000 |
| Accrued expenses | 2,227,000 | 2,185,000 |
| Loan, current | 3,954,000 | 8,823,000 |
| Other accounts payable and accrued expenses | 6,300,000 | |
| Total current liabilities | 12,493,000 | 19,350,000 |
| Operating lease liabilities | 885,000 | 827,000 |
| Warrant liability | 240,000 | 910,000 |
| Earn-out liability | 36,000 | |
| Long-term loan | 24,591,000 | 18,105,000 |
| Total non-current liabilities | 25,752,000 | 19,842,000 |
| Common stock | 3,000 | 3,000 |
| Additional paid-in capital | 407,502,000 | 365,846,000 |
| Retained earnings (accumulated deficit) | (349,361,000) | (285,850,000) |
| Total stockholders' equity (deficit) | 58,144,000 | 79,999,000 |
| Total Equity | 58,144,000 | |

| | | |
|---|---------------|---------------|
| contract | | 483,000 |
| Government authorities | | 239,000 |
| Total current assets | 47,330,000 | 65,524,000 |
| Deposits | 6,000 | 6,000 |
| Operation lease right of use assets | 967,000 | 1,206,000 |
| Computers & peripheral equipment | 2,388,000 | 944,000 |
| Office furniture & equipment | 137,000 | 154,000 |
| Production lines | 988,000 | 988,000 |
| Leasehold improvement | 326,000 | 141,000 |
| Computers and peripheral equipment | 937,000 | |
| Property & equipment, cost | | 2,227,000 |
| Less: accumulated depreciation - computers & peripheral equipment | 542,000 | 534,000 |
| Less: accumulated depreciation - office furniture & equipment | 43,000 | 60,000 |
| Less: accumulated depreciation - production lines | 874,000 | 773,000 |
| Less: accumulated depreciation - leasehold improvement | 30,000 | 72,000 |
| Less: accumulated depreciation | 1,489,000 | 1,439,000 |
| Property & equipment, net | 899,000 | 788,000 |
| Long-term assets | 143,000 | 111,000 |
| Intangible assets, net | 5,404,000 | 9,916,000 |
| Goodwill | 41,640,000 | 41,640,000 |
| Total non-current assets | 49,059,000 | 53,667,000 |
| Total assets | 96,389,000 | 119,191,000 |
| Trade payables | | 2,322,000 |
| Deferred revenues | 997,000 | 1,320,000 |
| Operating lease liabilities | 111,000 | 293,000 |
| Employees & payroll accruals | 4,073,000 | 4,407,000 |
| Accrued expenses | 2,227,000 | 2,185,000 |
| Loan, current | 3,954,000 | 8,823,000 |
| Other accounts payable and accrued expenses | 6,300,000 | |
| Total current liabilities | 12,493,000 | 19,350,000 |
| Operating lease liabilities | 885,000 | 827,000 |
| Warrant liability | 240,000 | 910,000 |
| Earn-out liability | 36,000 | |
| Long-term loan | 24,591,000 | 18,105,000 |
| Total non-current liabilities | 25,752,000 | 19,842,000 |
| Common stock | 3,000 | 3,000 |
| Additional paid-in capital | 407,502,000 | 365,846,000 |
| Retained earnings (accumulated deficit) | (349,361,000) | (285,850,000) |
| Total stockholders' equity (deficit) | 58,144,000 | 79,999,000 |
| Total Equity | 58,144,000 | |

Recent Dividends:
1. DarioHealth Corp common.
 No dividends paid.
2. DarioHealth Corp series A convertible preferred stock.
 No dividends paid.
Annual Dividends:
1. DarioHealth Corp common.
 No dividends paid.
2. DarioHealth Corp series A convertible preferred stock.
 No dividends paid.

DATA I/O CORP.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|--------------------|--------|--------|--------|
| Total revenues | 28,064 | | |
| Net sales | 28,064 | 24,217 | 25,835 |
| Cost of goods sold | 11,878 | 11,007 | 11,115 |

| | | |
|--|--------------|--------------|
| Total current liabilities | 406,554 | 473,439 |
| Operating lease liability, less current portion | ... | 83,675 |
| Total long-term liabilities: | ... | 83,675 |
| Total liabilities | 406,554 | 557,114 |
| Common stock | 210 | 2,060 |
| Additional paid-in capital | 54,597,083 | 52,283,634 |
| Accumulated deficit | (48,134,088) | ... |
| Retained earnings (accumulated deficit) | ... | (39,729,118) |
| Treasury stock, at cost (479,845 shares on 31, 2023) | 397,969 | ... |
| Accumulated other comprehensive gain | 34,553 | ... |
| Preferred Stock - Convertible - Non-Redeemable | 200 | ... |
| Total stockholders' equity (deficit) | 6,099,989 | 12,556,576 |
| Total Equity | 6,099,989 | ... |

| | | | |
|---|------------------|------------------|------------------|
| expense (benefit) - state | (130,000) | 293,000 | (96,000) |
| Total deferred income tax expense (benefit) | (314,000) | 254,000 | (26,000) |
| Income tax expense | 1,132,000 | 1,265,000 | 116,000 |
| Net income (loss) | 2,487,000 | 3,111,000 | 1,414,000 |
| Weighted average shares outstanding - basic | 7,555,000 | 7,261,000 | 6,947,000 |
| Weighted average shares outstanding - diluted | 7,679,000 | 7,562,000 | 7,593,000 |
| Year end shares outstanding | 7,680,334 | 7,416,000 | 7,007,000 |
| Net earnings (loss) per share - basic | \$0.33 | \$0.43 | \$0.20 |
| Net earnings (loss) per share - diluted | \$0.32 | \$0.41 | \$0.19 |
| Number of full time employees | 210 | 116 | 100 |
| Total number of employees | 210 | ... | ... |
| Number of common stockholders | 121 | 121 | 279 |
| Earnings per share from continuing operations | \$0.33 | ... | ... |
| Earnings per share from continuing operations | \$0.32 | ... | ... |

| | | |
|--|--------------|--------------|
| Deferred revenues | 8,066,000 | 6,021,000 |
| Current portion of earnout consideration | 5,370,000 | ... |
| Current portion of long-term debt | 1,003,000 | 3,000 |
| Current portion of operating lease liabilities | 874,000 | 529,000 |
| Taxes payable | 1,661,000 | ... |
| Accrued expenses and other current liabilities - Balancing value | 1,938,000 | ... |
| Total current liabilities | 38,736,000 | 31,665,000 |
| EIDL promissory note | 3,639,000 | 143,000 |
| Long-term debt | ... | 143,000 |
| Revolving line of credit | 1,300,000 | ... |
| Long-term portion of earnout consideration | 4,316,000 | ... |
| Deferred revenue, net of current portion | 5,307,000 | 4,331,000 |
| Noncurrent portion of operating lease liabilities | 3,093,000 | 2,706,000 |
| Other liabilities | 6,000 | 130,000 |
| Total liabilities | 56,397,000 | 38,975,000 |
| Common stock | 8,000 | 7,000 |
| Additional paid-in capital | 38,902,000 | 38,429,000 |
| Accumulated deficit | (19,367,000) | ... |
| Retained earnings (accumulated deficit) | ... | (21,854,000) |
| Total stockholders' equity (deficit) | 19,543,000 | 16,582,000 |
| Rep Total Equity & Minority Interest | 19,543,000 | ... |

Recent Dividends:

- DatChat Inc common.**
No dividends paid.
- DatChat Inc series B preferred.**
No dividends paid.

Annual Dividends:

- DatChat Inc common.**
No dividends paid.
- DatChat Inc series B preferred.**
No dividends paid.

□ Approximately; □ As of March 31, 2022; □ As of March 24, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash | 4,300,000 | 7,642,000 |
| Accounts receivable, gross | 24,035,000 | ... |
| Allowance for doubtful accounts | 267,000 | ... |
| Accounts receivable, net | 23,768,000 | 17,085,000 |
| Inventory, net | 2,133,000 | 4,417,000 |
| Deferred costs | 3,826,000 | 2,729,000 |
| Prepaid expenses & other current assets | 630,000 | 399,000 |
| Total current assets | 34,657,000 | 32,272,000 |
| Operating lease assets | 3,392,000 | 2,681,000 |
| Software & computer equipment | 2,167,000 | 1,502,000 |
| Furniture & fixtures | ... | 176,000 |
| Leasehold improvements | 792,000 | 643,000 |
| Equipment | 582,000 | 311,000 |
| Property and equipment, gross - Balancing value | 208,000 | ... |
| Automobiles | 1,851,000 | ... |
| Property & equipment, gross | 5,600,000 | 2,632,000 |
| Less: accumulated depreciation | 2,627,000 | 815,000 |
| Property & equipment, net | 2,973,000 | 1,817,000 |
| Deferred costs, net of current portion | ... | 2,868,000 |
| Deferred tax assets | 3,689,000 | 848,000 |
| Intangible assets, net | 7,815,000 | 4,531,000 |
| Goodwill | 22,081,000 | 10,499,000 |
| Other assets | 172,000 | 41,000 |
| Deferred tax assets | 1,161,000 | ... |
| Total assets | 75,940,000 | 55,557,000 |
| Accounts payable | 16,857,000 | 19,755,000 |
| Salaries & benefits | 2,967,000 | 2,743,000 |
| Accrued purchase price for CMAC, Inc. acquisition | 6,566,000 | ... |
| Accrued earn out obligation related to acquisition | ... | 829,000 |
| Sales tax payable | ... | 1,016,000 |
| Professional fees | ... | 188,000 |
| Vendor purchases | ... | 44,000 |
| Customer deposits | ... | 265,000 |
| Other fees & expenses | ... | 272,000 |

Recent Dividends:

- DecisionPoint Systems Inc (New) series A cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series E cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) common.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series D cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series C cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series B cumulative convertible preferred.**
No dividends paid.
- Annual Dividends:**
- DecisionPoint Systems Inc (New) series A cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series E cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) common.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series D cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series C cumulative convertible preferred.**
No dividends paid.
 - DecisionPoint Systems Inc (New) series B cumulative convertible preferred.**
No dividends paid.

DEFENSE TECHNOLOGIES INTERNATIONAL CORP Earnings, 9 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|------------------|--------------------|
| Total revenues | 49,012 | ... |
| Cost & expenses | 474,614 | 1,476,788 |
| Operating income | (425,602) | (1,485,465) |
| Other income (expense), net | 8,472 | (609,783) |
| Net before taxes | (438,460) | (2,231,637) |
| Net income | (438,460) | (2,231,637) |
| Earnings common share | | |
| Primary | \$(0.11) | \$(3.89) |

DECISIONPOINT SYSTEMS INC (NEW)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|------------|----------------|
| Total revenues | 115,594,000 | ... | ... |
| Net sales - product | 79,079,000 | 50,480,000 | ... |
| Net sales - service | 18,336,000 | 15,463,000 | ... |
| Product | 73,494,000 | ... | ... |
| Service | 42,100,000 | ... | ... |
| Net sales | 97,415,000 | 65,943,000 | ... |
| Product | 59,607,000 | ... | ... |
| Service | 27,162,000 | ... | ... |
| Cost of sales - product | 62,214,000 | 39,943,000 | ... |
| Cost of sales - services | 12,106,000 | 10,696,000 | ... |
| Cost of sales | 86,769,000 | 74,320,000 | 50,639,000 |
| Gross profit | 28,825,000 | 23,095,000 | 15,304,000 |
| Sales & marketing expense | 9,957,000 | 9,218,000 | 7,354,000 |
| General & administrative expenses | 14,093,000 | 9,430,000 | 7,552,000 |
| Total operating expenses | 24,050,000 | 18,648,000 | 14,906,000 |
| Operating income (loss) | 4,775,000 | 4,447,000 | 398,000 |
| Interest expense | 1,156,000 | 56,000 | 79,000 |
| Gain (loss) on extinguishment of debt | ... | ... | 1,211,000 |
| Other expense | 15,000 | ... | ... |
| Income (loss) before income taxes | 3,619,000 | 4,376,000 | 1,530,000 |
| Current income tax expense (benefit) - federal | 1,069,000 | 910,000 | 7,000 |
| Current income tax expense (benefit) - state | 377,000 | 101,000 | 135,000 |
| Total current income tax expense (benefit) | 1,446,000 | 1,011,000 | 142,000 |
| Deferred income tax expense (benefit) - federal | (184,000) | (39,000) | 70,000 |
| Deferred income tax | ... | ... | ... |

| | | |
|----------------|-----------|----------|
| Fully Diluted | \$(0.11) | \$(3.89) |
| Common Shares: | | |
| Full Diluted | 3,424,670 | 567,088 |
| Year-end | 9,077,038 | 962,480 |

DEL CATH SYSTEMS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|---------------------|---------------------|---------------------|
| | | | (revised) |
| Product revenue | 2,065,000 | 2,548,000 | 1,300,000 |
| Other revenue | ... | 171,000 | 2,255,000 |
| Total revenues | 2,065,000 | 2,719,000 | 3,555,000 |
| Cost of goods sold | 635,000 | 686,000 | 671,000 |
| Gross profit (loss) | 1,430,000 | 2,033,000 | 2,884,000 |
| Research & development expenses | 17,502,000 | 18,583,000 | 13,778,000 |
| Selling, general & administrative expenses | 22,110,000 | 17,303,000 | 13,637,000 |
| Total operating expenses | 39,612,000 | 35,886,000 | 27,415,000 |
| Operating income (loss) | (38,182,000) | (33,853,000) | (24,531,000) |
| Interest expense, net | 1,439,000 | 2,685,000 | 1,186,000 |
| Gain (loss) on issuance of financial instrument | (7,998,000) | ... | ... |
| Other income (expense), net | (59,000) | 30,000 | 68,000 |
| Net income (loss) | (47,678,000) | (36,508,000) | (25,649,000) |
| Net income (loss) attributable to common stockholders | ... | (36,508,000) | (25,649,000) |
| Weighted average shares outstanding - basic | 16,229,931 | 8,864,615 | 7,145,754 |
| Weighted average shares outstanding - diluted | 16,229,931 | 8,864,615 | 7,145,754 |
| Year end shares outstanding | 22,761,554 | 10,046,571 | 7,906,728 |
| Earnings (loss) per common share - basic | \$(2.94) | \$(4.12) | \$(3.59) |
| Earnings (loss) per common share - diluted | \$(2.94) | \$(4.12) | \$(3.59) |
| Number of full time employees | ... | 52 | 55 |
| Number of common stockholders | 57 | 64 | 15,047 |
| Income from cont operations before income tax | (47,678,000) | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(2.94) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(2.94) | ... | ... |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of private placement -issuance of common shares and prefunded warrants, net of expenses; ³ Shares increased due to the effect of conversion of preferred stock into common stock, common stock issued in connection with At-the-Market Offering & exercise of warrants into common stock; ⁴ Approximately; ⁵ As of February 1, 2023; ⁶ As of March 9, 2022; ⁷ As of March 16, 2023; ⁸ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------|------------|-----------|
| Cash & cash equivalents | 12,646,000 | 7,671,000 |
| Restricted cash | 50,000 | 4,151,000 |
| Accounts receivable, net | 241,000 | 366,000 |
| Raw materials | 1,443,000 | 763,000 |
| Work-in-process | 1,753,000 | 1,102,000 |
| Finished goods | 126,000 | 133,000 |
| Inventories | 3,322,000 | 1,998,000 |
| Interest receivable | 151,000 | ... |

| | | |
|---|---------------|---------------|
| Clinical trial expenses | 222,000 | 1,630,000 |
| Insurance premiums | 157,000 | 123,000 |
| Professional fees | 133,000 | 121,000 |
| Other prepaid expenses & other current assets | ... | 95,000 |
| Short-term investments | 19,808,000 | ... |
| Other | 428,000 | ... |
| Total current assets | 37,158,000 | 16,155,000 |
| Buildings & land | ... | 1,301,000 |
| Enterprise hardware & software | 1,857,000 | 1,855,000 |
| Leaseholds | 1,787,000 | 1,774,000 |
| Equipment | 1,263,000 | 1,222,000 |
| Furniture | 202,000 | 201,000 |
| Land | 1,318,000 | ... |
| Property, plant & equipment, gross | 6,427,000 | 6,353,000 |
| Accumulated depreciation | 5,075,000 | 4,931,000 |
| Property, plant & equipment, net | 1,352,000 | 1,422,000 |
| Right-of-use assets | 103,000 | 285,000 |
| Total assets | 38,613,000 | 17,862,000 |
| Accounts payable | 1,012,000 | 2,018,000 |
| Clinical expenses | 1,129,000 | 1,470,000 |
| Compensation, excluding taxes | 1,859,000 | 1,040,000 |
| Professional fees | 272,000 | 1,087,000 |
| Interest on convertible note | 713,000 | 553,000 |
| Other accrued expenses | ... | 535,000 |
| Other | 691,000 | ... |
| Accrued expenses - Balancing value | 585,000 | ... |
| Lease liabilities, current | 37,000 | 186,000 |
| Loan payable, current | ... | 7,846,000 |
| Convertible notes payable, current | 4,911,000 | ... |
| Loan payable | 5,239,000 | ... |
| Total current liabilities | 16,448,000 | 14,735,000 |
| Loan payable, non-current | ... | 3,070,000 |
| Convertible notes payable, non-current | ... | 4,772,000 |
| Accrued expenses | 5,548,000 | ... |
| Other liabilities, non-current | 840,000 | 1,144,000 |
| Total liabilities | 22,836,000 | 23,721,000 |
| Common stock | 228,000 | 100,000 |
| Additional paid-in capital | 520,576,000 | 451,608,000 |
| Retained earnings (accumulated deficit) | (505,162,000) | (457,484,000) |
| Accumulated other comprehensive income (loss) | 135,000 | (83,000) |
| Total stockholders' equity (deficit) | 15,777,000 | (5,859,000) |
| Total Equity | 15,777,000 | ... |

Recent Dividends:

- Delcath Systems Inc common.**
No dividends paid.
- Delcath Systems Inc convertible preferred.**
No dividends paid.

Annual Dividends:

- Delcath Systems Inc common.**
No dividends paid.
- Delcath Systems Inc convertible preferred.**
No dividends paid.

DESTINY MEDIA TECHNOLOGIES INC**Earnings, 6 mos. to (Consol. - \$):**

| | 02/29/24 | 02/28/23 |
|-----------------------|----------------|----------------|
| Total revenues | 2,141,140 | ... |
| Cost & expenses | 1,880,499 | 1,603,303 |
| Operating income | 92,517 | 244,145 |
| Net before taxes | 119,504 | 260,590 |
| Net income | 119,504 | 256,990 |
| Earnings common share | | |
| Primary | \$0.01 | \$0.03 |
| Fully Diluted | \$0.01 | \$0.03 |
| Common Shares: | | |
| Full Diluted | 10,191,461 | 10,122,261 |
| Year-end | 9,787,310 | 10,122,261 |

DIAMONDHEAD CASINO CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|--------------------|
| | | | (revised) |
| Administrative & general expenses | 736,680 | 929,236 | 665,788 |
| Stock-based compensation expenses | 546,400 | ... | ... |
| Other costs & expenses | ... | 71,450 | 69,709 |
| Other costs & expenses | 67,975 | ... | ... |
| Total costs & expenses | 1,351,055 | 1,000,686 | 735,497 |
| Interest expense - related parties | 438,393 | 415,330 | 403,860 |
| Interest expense - other | 377,486 | 439,689 | 379,749 |
| Gain on the condemnation of land | (757,107) | ... | ... |
| Total other income (expense), net | (58,772) | (855,019) | (783,609) |
| Income (loss) before income taxes | (1,409,827) | ... | ... |
| Net income (loss) | (1,409,827) | (1,855,705) | (1,519,106) |
| Preferred stock dividends | 101,600 | 101,600 | 101,600 |
| Net income (loss) applicable to common stockholders | (1,511,427) | (1,957,305) | (1,620,706) |
| Weighted average shares outstanding - basic | 37,437,576 | 36,297,576 | 36,297,576 |
| Weighted average shares outstanding - diluted | 37,437,576 | 36,297,576 | 36,297,576 |
| Year end shares outstanding | 36,297,576 | 36,297,576 | 36,297,576 |
| Income (loss) per share from continued operations-basic | \$(0.04) | ... | ... |
| Net income (loss) per share - basic | \$(0.04) | \$(0.05) | \$(0.04) |
| Income (loss) per share from continued operations-dil. | \$(0.04) | ... | ... |
| Net income (loss) per share - diluted | \$(0.04) | \$(0.05) | \$(0.04) |
| Total number of employees | ... | 0 | 1 |
| Number of common stockholders | 768 | 772 | 772 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash | 426,124 | 55,885 |
| Total current assets | 426,124 | 55,885 |
| Land held for development | 5,233,204 | 4,934,323 |
| Licenses | ... | 77,000 |
| Engineering & costs associated with permitting | ... | 464,774 |
| Land | ... | 5,476,097 |
| Other assets | 80 | 80 |
| Other receivable | 154,622 | ... |
| Total assets | 5,814,030 | 5,532,062 |
| Accrued payroll due officers | ... | 3,569,711 |
| Accrued interest due officers & directors | 2,897,159 | 2,467,844 |
| Accrued director fees | ... | 838,750 |
| Base rents due to the president | ... | 403,274 |
| Associated rental costs | ... | 165,295 |
| Other accounts payables & accrued expenses | ... | 17,308 |
| Accounts payable & accrued expenses due | ... | ... |

| | | |
|---|--------------|--------------|
| related parties | 8,315,187 | 7,462,182 |
| Accrued interest | 3,115,463 | 2,841,520 |
| Accrued dividends | 1,270,000 | 1,168,400 |
| Accrued fines & penalties | 578,775 | 444,875 |
| Other accounts payables & accrued expenses | ... | 463,743 |
| Accounts payable & accrued expenses - others | ... | 4,918,538 |
| Convertible notes & line of credit payable | ... | 1,962,500 |
| Debenture payable | 50,000 | 50,000 |
| Convertible debenture payable | 1,800,000 | 1,800,000 |
| Short term notes & interest bearing advance | 65,504 | 80,504 |
| Current notes payable due related parties | 1,962,500 | ... |
| Notes payable due related parties | ... | 720,651 |
| Notes payable due others, current portion | 669,279 | ... |
| Current maturities of long-term debt | 541,739 | ... |
| Accounts payable & accrued expenses | 5,272,524 | ... |
| Due to stockholders | 308,286 | ... |
| Accrued Payroll | 3,869,711 | ... |
| Accounts payable and accrued expenses due related parties - Balancing value | 1,548,317 | ... |
| Notes payable due others | ... | 532,563 |
| Total liabilities | 18,676,733 | 17,526,938 |
| Preferred stock | 20,860 | 20,860 |
| Common stock | 39,052 | 39,052 |
| Additional paid-in capital | 36,663,780 | 36,122,078 |
| Unearned employee stock ownership plan ("ESOP") shares | 2,490,662 | 2,609,264 |
| Retained earnings (accumulated deficit) | (46,862,802) | (45,351,375) |
| Treasury stock | 232,931 | 216,227 |
| Total stockholders' equity (deficit) | (12,862,703) | (11,994,876) |
| Total Equity | (12,862,703) | ... |

Net of unamortized debt discount - notes payable due others: \$24,937

Recent Dividends:

- Diamondhead Casino Corp series S voting, non-convertible preferred.**
No dividends paid.
 - Diamondhead Casino Corp series S-PIK junior, cumulative, convertible, non-redeemable, non-voting preferred.**
No dividends paid.
 - Diamondhead Casino Corp series S-NR voting, non-convertible, non-redeemable preferred.**
No dividends paid.
 - Diamondhead Casino Corp common.**
No dividends paid.
- Annual Dividends:**
- Diamondhead Casino Corp series S voting, non-convertible preferred.**
No dividends paid.
 - Diamondhead Casino Corp series S-PIK junior, cumulative, convertible, non-redeemable, non-voting preferred.**
No dividends paid.
 - Diamondhead Casino Corp series S-NR voting, non-convertible, non-redeemable preferred.**
No dividends paid.
 - Diamondhead Casino Corp common.**
No dividends paid.

DIGERATI TECHNOLOGIES INC

Earnings, 6 mos. to Jan 31(Consol. - \$000):

| | | |
|-----------------------------|---------|---------|
| | 2024 | 2023 |
| Total revenues | 15,219 | 16,071 |
| Cost & expenses | 15,853 | 16,117 |
| Deprec., depl. & amort. | 1,812 | 1,919 |
| Operating income | (2,446) | (1,965) |
| Other income (expense), net | (150) | 379 |
| Gains or losses | (581) | 773 |

| | | |
|---|--------------|--------------|
| Net before taxes | (8,441) | ... |
| Income taxes | 63 | ... |
| Net income | (8,504) | (5,249) |
| Balance for common | (4,768) | ... |
| Earnings common share | ... | ... |
| Primary | \$(0.05) | \$(0.03) |
| Fully Diluted | \$(0.05) | \$(0.03) |
| Common Shares: | ... | ... |
| Full Diluted | 163,025 | 145,880 |
| Year-end | 174,897 | 152,488 |
| DIGITAL ALLY INC (NEW) | | |
| Annual Report | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
| | 2023 | 2022 |
| Product revenue | 9,347,945 | 10,999,892 |
| Service & other revenue | 18,900,399 | 26,010,003 |
| Total revenue | 28,248,344 | 37,009,895 |
| Product | 9,974,890 | ... |
| Service Other | 12,510,970 | ... |
| Product cost of revenue | ... | 14,372,115 |
| Service & other cost of revenue | ... | 20,315,839 |
| Total cost of revenue | 22,485,860 | 34,687,954 |
| Gross profit | 5,762,484 | 2,321,941 |
| Research & development expense | 2,618,746 | 2,290,293 |
| Selling, advertising & promotional expense | 7,137,529 | 9,312,204 |
| General & administrative expense | 18,246,762 | 20,452,702 |
| Total selling, general & administrative expenses | 28,003,037 | 32,055,199 |
| Operating income (loss) | (22,240,553) | (29,733,258) |
| Interest & other income | 95,717 | ... |
| Interest income | ... | 131,025 |
| Interest expense | 3,134,253 | 37,196 |
| Other expenses | ... | 230,744 |
| Change in fair value of short-term investments | ... | (84,818) |
| Change in fair value of warrant derivative liability | 1,846,642 | 6,726,638 |
| Change in fair value of contingent consideration | ... | ... |
| promissory notes & earn-out agreements | 177,909 | 516,970 |
| Warrant modification expense | ... | 295,780 |
| Gain (loss) on extinguishment of debt | 550,867 | 10,000 |
| Gain on extinguishment of warrant derivative liabilities | ... | 3,624,794 |
| Gain on sale of property, plant and equipment | ... | 212,831 |
| Other income (expense) | 144,735 | ... |
| Loss on accrual for legal settlement | 1,792,308 | ... |
| Loss on conversion of convertible debt | 1,112,705 | ... |
| Total other income (expense) | (3,223,396) | 10,859,500 |
| Income (loss) before income tax (benefit) | (25,463,949) | (18,873,758) |
| Net Income After | 25,530,961 | ... |

| | | |
|--|--------------|--------------|
| Extraordinary Items applicable to Common | (25,688,547) | ... |
| Net income (loss) | (25,463,949) | (18,873,758) |
| Net income attributable to noncontrolling interests of consolidated subsidiary | (224,598) | (407,933) |
| Loss on redemption - series A & B convertible redeemable preferred stock | ... | 2,385,000 |
| Net income (loss) attributable to common shareholders | (21,666,691) | 25,474,508 |
| Weighted average shares outstanding | ... | ... |
| - basic | 2,784,894 | 2,548,549 |
| Weighted average shares outstanding - diluted | 2,784,894 | 2,548,549 |
| Year end shares outstanding | 2,800,754 | 2,720,170 |
| Net earnings (loss) per share - basic | \$(9.22) | \$(8.50) |
| Net earnings (loss) per share - diluted | \$(9.22) | \$(8.50) |
| Number of full time employees | 170 | 201 |
| Total number of employees | 170 | ... |
| Number of common stockholders | 164 | 170 |
| Earnings per share from continuing operations | \$(9.22) | ... |
| Earnings per share from continuing operations | \$(9.22) | ... |

Adjusted for 1-for-20 stock split, February 8, 2023; Shares increased due to the restricted common stock grant, issuance of common stock through registered direct offering and exercise of pre-funded common stock purchase warrants; Approximately; As of April 15, 2022

| | | |
|---|------------|------------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| | 2023 | 2022 |
| Cash & cash equivalents | 680,549 | 3,532,199 |
| Accounts receivable - trade, gross | 1,785,330 | 2,196,792 |
| Less allowance for doubtful accounts | 200,668 | 152,736 |
| Other receivables | 3,107,634 | 4,076,522 |
| Accounts receivable - other | 1,584,662 | ... |
| Raw material & component parts - video solutions segment | 3,044,653 | 4,509,165 |
| Work-in-process - video solutions segment | 20,396 | 3,164 |
| Finished goods - video solutions segment | 4,623,489 | 6,846,091 |
| Finished goods - entertainment segment | 699,204 | 970,527 |
| Subtotal | ... | 12,328,947 |
| Reserve for excess & obsolete inventory - video solutions segment | 4,355,666 | 5,230,261 |
| Reserve for excess & obsolete inventory - entertainment segment | 186,795 | 259,280 |
| Inventories, net | 3,845,281 | 6,839,406 |
| Prepaid expenses | 6,366,368 | 8,466,413 |
| Total current assets | 15,584,494 | 24,958,596 |
| Building | 4,537,037 | 4,537,037 |
| Land | 739,734 | 739,734 |
| Office furniture, fixtures & equipment | 2,065,092 | ... |

| | | |
|--|---------------|--------------|
| Office furniture, fixtures, equipment, & aircraft | 8,787,559 | 2,048,169 |
| Warehouse & production equipment | 29,055 | 51,302 |
| Demonstration & tradeshow equipment | ... | 72,341 |
| Building improvements | 1,328,654 | 1,334,374 |
| Website development | 87,987 | ... |
| Total cost | ... | 8,782,957 |
| Less accumulated depreciation & amortization | ... | 884,271 |
| Less accumulated depreciation & amortization | 1,503,857 | ... |
| Property, plant, & equipment, net | 7,283,702 | 7,898,686 |
| Goodwill & other intangible assets, net | 16,510,422 | 17,872,970 |
| Operating lease right of use assets, net | 1,053,159 | 782,129 |
| Other assets | 6,597,032 | 5,155,681 |
| Total assets | 47,028,809 | 56,668,062 |
| Accounts payable | 10,732,089 | 9,477,355 |
| Accrued warranty expense | ... | 15,694 |
| Accrued litigation costs | 2,040,292 | 247,984 |
| Accrued sales commissions | 87,421 | 55,000 |
| Accrued payroll & related fringes | 367,826 | 504,020 |
| Accrued sales returns & allowances | 117,713 | 118,026 |
| Accrued taxes | 17,699 | 46,408 |
| Other accrued expenses | 3,269,330 | 103,835 |
| Other | 172,905 | ... |
| Accrued taxes | 150,981 | ... |
| Accrued interest - related party | 95,031 | ... |
| Accrued expenses | ... | 1,090,967 |
| Current portion of operating lease obligations | 279,538 | 294,617 |
| Contract liabilities - current | 2,937,168 | 2,154,874 |
| Debt obligations - current | 1,260,513 | 485,373 |
| Warrant derivative liabilities | 1,369,738 | ... |
| Income taxes payable | 61 | 8,097 |
| Customer deposits | 219,462 | ... |
| Notes payable - related party - current portion | 2,700,000 | ... |
| Total current liabilities | 22,548,437 | 13,511,283 |
| Economic injury disaster loan ("EIDL") | 4,853,237 | 150,000 |
| Contingent consideration promissory note | ... | 777,840 |
| Debt obligations | ... | 927,840 |
| Less: current maturities of debt obligations | ... | 485,373 |
| Debt obligations - long term | ... | 442,467 |
| Operating lease obligation, long term | 827,836 | 555,707 |
| Contract liabilities - long term | 7,340,459 | 5,818,082 |
| Lease Deposit | 10,445 | ... |
| Total liabilities | 35,580,414 | 20,327,539 |
| Common stock | 2,801 | 2,721 |
| Additional paid in capital | 128,441,083 | 127,869,342 |
| Noncontrolling interest in consolidated subsidiary | 673,292 | 448,694 |
| Accumulated Deficit | (117,668,781) | ... |
| Retained earnings (accumulated deficit) | ... | (91,980,234) |
| Total stockholders' equity (deficit) | 11,448,395 | 36,340,523 |
| Total Equity | 11,448,395 | ... |

[□] Includes due from related parties - other receivables: \$138,384

Recent Dividends:

1. Digital Ally Inc (New) common.

| | | |
|--|-------------|-------------|
| No dividends paid. | | |
| Annual Dividends: | | |
| 1. Digital Ally Inc (New) common. | | |
| No dividends paid. | | |
| DIGITAL BRAND MEDIA & MARKETING GROUP INC | | |
| Earnings, 6 mos. to (Consol. - \$): | | |
| | 02/29/24 | 02/28/23 |
| Total revenues | 166,334 | ... |
| Net Sales | ... | 122,860 |
| Cost & expenses | 357,690 | 368,151 |
| Operating income | (191,356) | (245,291) |
| Interest expense | 212,124 | 155,926 |
| Other income (expense), net | 158,287 | (338,091) |
| Gains or losses | (340,012) | ... |
| Net before taxes | (585,205) | ... |
| Net income | (585,205) | (739,308) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 825,218,631 | 788,490,690 |
| Year-end | 825,218,631 | 795,218,631 |

DIGITAL BRANDS GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [□] 2021 (revised) |
|---|--------------|--------------------------------------|---------------------------------------|
| Net revenues | 14,916,422 | ... | ... |
| Net revenues | 14,916,422 | 13,971,178 | 7,584,859 |
| Cost of net revenues | 8,372,642 | 8,030,908 | 5,716,587 |
| Gross profit | 6,543,780 | 5,940,270 | 1,868,272 |
| General & administrative | 14,299,389 | 16,371,536 | 16,752,516 |
| Sales & marketing | 4,035,835 | 4,950,635 | 3,810,583 |
| Distribution | 1,002,343 | 611,569 | 489,371 |
| Change in fair value of contingent consideration | (10,698,475) | 564,303 | 8,764,460 |
| Impairment | ... | 15,539,332 | 3,400,000 |
| Total operating expenses | 8,639,092 | 38,037,375 | 33,216,930 |
| Income (loss) from operations | (2,095,312) | (32,097,105) | (31,348,658) |
| Interest expense | 5,517,118 | 9,014,337 | 3,663,921 |
| Other non-operating income (expenses) | (704,166) | 3,068,080 | 1,554,502 |
| Total other income (expense), net | ... | (5,946,257) | (2,109,419) |
| Provision (benefit) for income taxes | 368,034 | ... | (1,100,120) |
| Net income (loss) | (10,247,133) | (38,043,362) | (32,357,957) |
| Weighted average shares outstanding | | | |
| - basic | 424,402 | [□] 30,852 | [□] 3,052 |
| Weighted average shares outstanding | | | |
| - diluted | 424,402 | [□] 30,852 | [□] 3,052 |
| Year end shares outstanding | 1,114,359 | [□] 178,758 | [□] 5,201 |
| Net earnings (loss) per share - basic | \$(20.46) | [□] _{\$(1,233.00)} | [□] _{\$(10,603.75)} |
| Net earnings (loss) per share - diluted | \$(20.46) | [□] _{\$(1,233.00)} | [□] _{\$(10,603.75)} |
| Full-Time Employees (Period End) | 56 | ... | ... |
| Total number of employees | 56 | 58 | 58 |
| Common Shareholders - Number | 3,747 | ... | ... |
| Number of stockholders | ... | [□] 3,747 | [□] 3,747 |
| Income from cont operations before income tax | (8,316,596) | ... | ... |
| Income from continuing operations | (8,684,630) | ... | ... |
| Sale of Discontinued Operations - Net - Gain/Loss | (1,562,503) | ... | ... |
| Earnings per share from continuing | | | |

| | | | |
|---|-----------|-----|-----|
| operations | \$(20.46) | ... | ... |
| Earnings per share-disp of discontinued opers | \$(3.68) | ... | ... |
| Earnings per share-total discontinued opers | \$(3.68) | ... | ... |
| Earnings per share from continuing operations | \$(20.46) | ... | ... |
| Earns per share-disp of discont opers - diluted | \$(3.68) | ... | ... |
| Earning per share-total discont opers - diluted | \$(3.68) | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-25 stock split, August 22, 2023; [□] Adjusted for 1-for-100 stock split, October 22, 2022; [□] Shares increased due to the effect of issuance of common stock and exercise of warrants in public offering, issuance with business combination, consulting agreement, notes and derivative liability; [□] Shares increased due to the effect of issuance of common stock in public offering, exercise of over-allotment options, conversion of debt into common stock and conversion of related party note; [□] As of April 17, 2023; [□] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------------------|
| Cash & cash equivalents | 20,773 | 1,283,282 |
| Accounts receivable, net | 74,833 | 628,386 |
| Due from factor, net | 337,811 | 839,400 |
| Raw materials | 695,580 | ... |
| Work in process | 585,387 | ... |
| Finished goods | 3,568,633 | ... |
| Inventory | 4,849,600 | 5,225,282 |
| Prepaid expenses & other current assets | 276,670 | 853,044 |
| Total current assets | 5,559,687 | 8,829,394 |
| Property, equipment & software, net | 55,509 | 76,657 |
| Goodwill | 8,973,501 | 10,103,812 |
| Intangible assets, net | 9,982,217 | 14,427,503 |
| Deposits | 75,431 | 198,341 |
| Right of use asset, net | 689,688 | 102,349 |
| Total assets | 25,336,033 | 33,738,056 |
| Accounts payable | 7,538,902 | 8,098,165 |
| Accrued expenses | 617,374 | 705,135 |
| Reserve for returns | 4,758,492 | 307,725 |
| Payroll related liabilities | 3,895,640 | 2,974,361 |
| Sales tax liability | ... | 339,843 |
| Other liabilities | 99,934 | 130,050 |
| Accrued expenses & other liabilities | ... | [□] 4,457,115 |
| Deferred revenue | ... | 202,129 |
| Due to related parties | ... | 556,225 |
| Contingent consideration liability | ... | 12,098,475 |
| Convertible notes, current | 100,000 | ... |
| Convertible note payable, net | ... | 2,721,800 |
| Accrued interest payable | 145,545 | 1,561,795 |
| Note payable - related party | 400,012 | 129,489 |
| Loan payable, current | 2,325,842 | 1,966,250 |
| Promissory note payable | 4,884,592 | 9,000,000 |
| Right of use liability, current portion | 1,210,814 | 102,349 |
| Accrued interest payable | 1,996,753 | ... |
| Total current liabilities | 23,215,407 | 40,893,792 |
| Loan payable | 150,000 | 297,438 |
| Deferred tax liability | 368,034 | ... |
| Total liabilities | 23,733,441 | 41,191,230 |
| Series A convertible preferred stock | 1 | 1 |
| Common stock, \$0.0001 par, 1,000,000,000 shares authorized, 1,114,359 and 178,758 shares issued and | | |

| | | |
|---|---------------|---------------|
| outstanding as of 31, 2023 and 2022, respectively | 110 | ... |
| Common stock | ... | 447 |
| Additional paid-in capital | 115,596,929 | 96,293,694 |
| Accumulated deficit | (113,994,449) | ... |
| Retained earnings (accumulated deficit) | ... | (103,747,316) |
| Series C convertible preferred stock, \$00001 par, 5,671 shares designated, 5,671 and 0 shares issued and outstanding as of 30, 2023 and 31, 2022, respectively | 1 | ... |
| Total stockholders' equity (deficit) | 1,602,592 | (7,453,174) |
| Total Equity | 1,602,592 | ... |

| | | | |
|--|----------|--------|----------|
| operations - basic | \$(0.01) | ... | ... |
| Net income (loss) per common share - basic | \$(0.01) | \$0.00 | \$(0.07) |
| Net income (loss) per share from continuing operations - diluted | \$(0.01) | ... | ... |
| Net income (loss) per common share - diluted | \$(0.01) | \$0.00 | \$(0.07) |
| Number of full time employees | ... | ... | 2 |
| Number of part time employees | 2 | 2 | ... |
| Total number of employees | 2 | ... | ... |
| Number of common stockholders | 80 | 100 | 78 |

No dividends paid.
3. Digital Locations Inc series C preferred.
 No dividends paid.
4. Digital Locations Inc series D preferred.
 No dividends paid.
5. Digital Locations Inc series B preferred.
 No dividends paid.
6. Digital Locations Inc series E preferred.
 No dividends paid.
Annual Dividends:
1. Digital Locations Inc series A preferred.
 No dividends paid.
2. Digital Locations Inc common.
 No dividends paid.
3. Digital Locations Inc series C preferred.
 No dividends paid.
4. Digital Locations Inc series D preferred.
 No dividends paid.
5. Digital Locations Inc series B preferred.
 No dividends paid.
6. Digital Locations Inc series E preferred.
 No dividends paid.

As reported by the Company

Shares increased due to the effect of issuance of common stock for conversion of notes payable & accrued interest payable, services, cancelled and conversion of series B preferred stock; Shares increased due to issuance of common stock for conversion of notes payable & accrued interest payable; Shares increased due to the effect of issuance of common stock for services and conversion of series B preferred stock; As of March 20, 2023; As of March 21, 2022

DISC MEDICINE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|---------------------|---------------------|---------------------|
| Research & development expenses | 69,264,000 | 33,437,000 | 48,717,000 |
| General & administrative expenses | 21,861,000 | 14,038,000 | 20,285,000 |
| Total operating expenses | 91,125,000 | 47,475,000 | 69,002,000 |
| Income (loss) from operations | ... | (47,475,000) | (69,002,000) |
| Interest expense | ... | ... | 2,158,000 |
| Interest income | 14,797,000 | 709,000 | 15,000 |
| Loss on conversion of convertible notes | ... | ... | 711,000 |
| Change in fair value of derivative liability | ... | (61,000) | ... |
| Other expense | 2,000 | ... | 13,000 |
| Total other income (expense), net | 14,795,000 | 648,000 | ... |
| Income (loss) before income tax expense | (76,330,000) | ... | ... |
| Net income (loss) | (76,429,000) | (46,827,000) | (71,869,000) |
| Net income (loss) attributable to common stockholders | ... | (46,827,000) | (71,869,000) |
| Weighted average shares outstanding - basic | 22,315,877 | 1,039,490 | 4,036,230 |
| Weighted average shares outstanding - diluted | 22,315,877 | 1,039,490 | 4,036,230 |
| Year end shares outstanding | 24,360,233 | 17,403,315 | 4,320,816 |
| Net earnings (loss) per share - basic | \$(3.42) | \$(45.05) | \$(17.80) |
| Net earnings (loss) per share - diluted | \$(3.42) | \$(45.05) | \$(17.80) |
| Number of full time employees | 74 | 46 | ... |
| Total number of employees | 74 | ... | 33 |
| Number of stockholders | ... | ... | 37 |
| Number of common stockholders | 19 | 66 | ... |
| Income tax expense | 99,000 | ... | ... |

Recent Dividends:

- Digital Brands Group Inc common.**
No dividends paid.
- Digital Brands Group Inc series A convertible preferred.**
No dividends paid.
- Digital Brands Group Inc series C convertible preferred.**
No dividends paid.

Annual Dividends:

- Digital Brands Group Inc common.**
No dividends paid.
- Digital Brands Group Inc series A convertible preferred.**
No dividends paid.
- Digital Brands Group Inc series C convertible preferred.**
No dividends paid.

DIGITAL LOCATIONS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|----------------|---------------------|
| Revenues | 25,846 | ... | ... |
| General & administrative expenses | 3,958,233 | 3,656,684 | 2,625,881 |
| Depreciation & amortization expenses | 2,000 | 2,000 | 2,000 |
| Impairment of assets | ... | ... | 2,096,089 |
| Total operating expenses | 3,960,233 | 3,658,684 | 4,723,970 |
| Income (loss) from operations | (3,934,387) | (3,635,616) | (4,699,941) |
| Interest expense | 985,562 | 509,633 | 919,095 |
| Gain (loss) on change in derivative liabilities | 196,755 | 5,108,229 | 8,979,516 |
| Gain (loss) on extinguishment of debt | ... | 6,034 | (16,490,508) |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 9,501 |
| Total other income (expense) | (788,807) | 4,604,630 | (8,420,586) |
| Income (loss) before income taxes | (4,723,194) | 969,014 | (13,120,527) |
| Net income (loss) | (4,723,194) | 969,014 | (13,120,527) |
| Weighted average shares outstanding - basic | 708,657,045 | 433,143,911 | 195,725,543 |
| Weighted average shares outstanding - diluted | 708,657,045 | 4,337,208,296 | 195,725,543 |
| Year end shares outstanding | 733,766,705 | 604,150,321 | 276,383,093 |
| Net income (loss) per share from continuing | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash | 44,104 | 31,113 |
| Total current assets | 44,104 | 31,113 |
| Deposits | 500 | 500 |
| Intangible assets, net | 4,000 | 6,000 |
| Total assets | 48,604 | 37,613 |
| Accounts payable | 124,342 | 113,187 |
| Accounts payable - related party | ... | 10,000 |
| Accrued expenses & other current liabilities | ... | 3,729 |
| Accrued interest, notes payable | 937 | 53,212 |
| Derivative liabilities | 2,166,112 | 1,233,679 |
| Convertible notes payable, in default | ... | 29,500 |
| Convertible notes - related parties | 58,600 | 58,600 |
| Convertible notes payable, net | 199,394 | 15,916 |
| Accrued interest, notes payable | 78,654 | ... |
| Convertible notes payable - related parties | 29,500 | ... |
| Total current liabilities | 2,657,539 | 1,517,823 |
| Long-term liabilities - convertible notes payable, net | 599,124 | 399,233 |
| Total liabilities | 3,256,663 | 1,917,056 |
| Preferred stock series B | ... | 1,424,100 |
| Preferred stock series E | ... | 4,060,000 |
| Preferred Stock - Convertible - Series E | 4,500,000 | ... |
| Series B, 14,462 and 15,055 shares issued and outstanding at 31, 2021 and 2020, respectively | 1,424,100 | ... |
| Common stock | 733,767 | 604,150 |
| Additional paid-in capital | 45,021,818 | 42,196,857 |
| Retained earnings (accumulated deficit) | (54,887,744) | (50,164,550) |
| Total stockholders' equity (deficit) | (3,208,059) | (7,363,543) |
| Total Equity | (3,208,059) | ... |

Net of discount - Convertible notes payable: \$600,767

Recent Dividends:

- Digital Locations Inc series A preferred.**
No dividends paid.
- Digital Locations Inc common.**

2021 and prior years for Gemini Therapeutics, Inc. prior to reverse merger with Disc Medicine, Inc. ("Private Disc"); Adjusted for 1-for-10 stock split, December 30, 2022; Shares increased due to issuance of common stock upon business combination, exercise of warrants and stock options, conversion of promis-

sory notes and vesting of restricted common stock; ⁽⁴⁾ As is; ⁽⁵⁾ As of February 28, 2023; ⁽⁶⁾ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 360,382,000 | 194,611,000 |
| Prepaid expenses & other current assets | 5,280,000 | 3,880,000 |
| Total current assets | 365,662,000 | 198,491,000 |
| Furniture & fixtures | 184,000 | 144,000 |
| Computer equipment | 231,000 | 169,000 |
| Less: accumulated depreciation | 245,000 | 145,000 |
| Property & equipment, net | 170,000 | 168,000 |
| Right-of-use assets, operating leases | 1,930,000 | 1,430,000 |
| Other assets | 234,000 | 116,000 |
| Total assets | 367,996,000 | 200,205,000 |
| Accounts payable | 12,629,000 | 16,162,000 |
| Accrued employee-related expenses | 5,790,000 | 3,623,000 |
| Accrued research & development | 1,986,000 | 1,817,000 |
| Accrued professional fees | 317,000 | 463,000 |
| Accrued other expenses | ... | 206,000 |
| Accrued expenses | 8,145,000 | 6,109,000 |
| Operating lease liabilities, current | 665,000 | 307,000 |
| Accrued other | 52,000 | ... |
| Total current liabilities | 21,439,000 | 22,578,000 |
| Operating lease liabilities, non-current | 1,436,000 | 1,027,000 |
| Total liabilities | 22,875,000 | 23,605,000 |
| Common stock | 2,000 | 2,000 |
| Additional paid-in capital | 533,764,000 | 288,814,000 |
| Retained earnings (accumulated deficit) | (188,645,000) | (112,216,000) |
| Total shareholders' equity | 345,121,000 | 176,600,000 |
| Total Equity | 345,121,000 | ... |

Recent Dividends:

1. Disc Medicine Inc class A common subject to possible redemption.

No dividends paid.

2. Disc Medicine Inc class A common.

No dividends paid.

3. Disc Medicine Inc class B common.

No dividends paid.

4. Disc Medicine Inc common.

No dividends paid.

Annual Dividends:

1. Disc Medicine Inc class A common subject to possible redemption.

No dividends paid.

2. Disc Medicine Inc class A common.

No dividends paid.

3. Disc Medicine Inc class B common.

No dividends paid.

4. Disc Medicine Inc common.

No dividends paid.

DLT RESOLUTION INC

Earnings, 3 mos. to Mar 31 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|------------|------------|
| Total revenues | 46,529 | 56,156 |
| Cost & expenses | 37,643 | 91,779 |
| Operating income | 718,292 | (56,012) |
| Interest expense | 1,829 | 3,657 |
| Other income (expense), net | 726,735 | ... |
| Foreign currency | ... | (2) |
| Net before taxes | 718,292 | (56,012) |
| Income contin. oper. | 718,292 | (56,012) |
| Income discount. oper. | ... | (936,520) |
| Net income | 718,292 | (992,532) |
| Earnings common share | | |
| Primary | \$0.03 | \$(0.04) |
| Fully Diluted | \$0.03 | \$(0.04) |
| Common Shares: | | |
| Full Diluted | 23,499,561 | 26,926,287 |
| Year-end | 23,499,561 | 23,111,287 |

Consolidated Balance Sheet Items, as of (\$):

| Assets: | 2023 |
|----------------------|-----------|
| Cash & equivalents | 3,612 |
| Current assets | 28,901 |
| Total assets | 153,319 |
| Liabilities: | |
| Current liabilities | 379,389 |
| Long-term debt | 5,000 |
| Stockholders' equity | (231,069) |
| Net current assets | (350,488) |

DOLPHIN ENTERTAINMENT INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ⁽¹⁾ 2021 (revised) |
|--|--------------|-------------|----------------------------------|
| Special charges/unusual items | 4,108,080 | ... | ... |
| Merger & acquisitions costs | 116,151 | ... | ... |
| Entertainment publicity & marketing | 43,123,075 | ... | ... |
| Revenues | 43,123,075 | 40,505,558 | 35,727,199 |
| Direct costs | 946,962 | 3,566,336 | 3,879,409 |
| Payroll & benefits | 35,030,257 | 28,947,730 | 23,819,327 |
| Selling, general & administrative | 8,434,549 | 6,572,020 | 5,836,235 |
| Acquisition costs | ... | 480,939 | 22,907 |
| Change in fair value of contingent consideration | 33,226 | (47,285) | 3,754,221 |
| Depreciation & amortization | 2,253,619 | 1,751,211 | 1,905,354 |
| Legal & professional fees | 2,485,096 | 2,903,412 | 2,013,436 |
| Impairment of intangible assets | 341,417 | ... | ... |
| Impairment of goodwill | 9,484,215 | 906,337 | ... |
| Total expenses | 63,233,572 | 45,080,700 | 41,230,889 |
| Income (loss) from operations | (20,110,497) | (4,575,142) | (5,503,690) |
| Gain (loss) on extinguishment of debt | ... | ... | 2,988,779 |
| Interest income | 2,877 | ... | ... |
| Change in fair value of warrant liability | 10,000 | ... | ... |
| Change in fair value of put rights | ... | ... | (71,106) |
| Change in fair value of convertible notes & derivative liabilities | ... | 654,579 | (570,844) |
| Change in fair value of warrant liability | ... | 120,000 | (2,482,877) |
| Interest expense | 2,085,107 | 555,802 | 785,209 |
| Change in fair value of convertible notes | (11,444) | ... | ... |
| Total other income (expense), net | (2,083,674) | 218,777 | (921,257) |
| Income (loss) before income taxes & equity in earnings (losses) of unconsolidated affiliates | (22,194,171) | (4,356,365) | (6,424,947) |
| Deferred federal income tax expense | (5,161,523) | (853,835) | (1,107,490) |
| Deferred state income tax expense (benefit) | (1,600,131) | (292,832) | (37,908) |
| Deferred income tax expense | (6,761,654) | (1,146,667) | (1,145,398) |
| Change in valuation allowance (benefit) | ... | 881,436 | 1,145,789 |
| - federal | ... | 881,436 | 1,145,789 |
| Change in valuation allowance (benefit) | ... | 442,212 | 36,965 |
| - state | ... | 442,212 | 36,965 |

| | 2023 | 2022 | 2021 |
|---|--------------|---------------------------|--------------------------|
| Change in valuation allowance (benefit) | ... | 1,323,648 | 1,182,754 |
| Valuation Allowance-Federal | 5,184,815 | ... | ... |
| Valuation Allowance-state | 1,630,343 | ... | ... |
| Income Taxes - Other - Deferred/Current | 6,815,158 | ... | ... |
| Income tax expense | 53,504 | 176,981 | 37,356 |
| Net income (loss) before equity in earnings (losses) of unconsolidated affiliates | ... | (4,533,346) | (6,462,303) |
| Equity in losses of unconsolidated affiliates | (2,149,050) | ... | ... |
| Earnings (loss) on equity method investment | ... | (246,789) | ... |
| Net income (loss) | (24,396,725) | (4,780,135) | (6,462,303) |
| Net income (loss) attributable to Dolphin Entertainment Inc common stock shareholders | ... | (4,780,135) | (6,462,303) |
| Weighted average shares outstanding | | | |
| - basic | 14,413,154 | 9,799,021 | 7,614,774 |
| Weighted average shares outstanding - diluted | 14,413,154 | 9,926,926 | 7,614,774 |
| Year end shares outstanding | 18,219,531 | ⁽²⁾ 12,340,664 | ⁽³⁾ 8,020,381 |
| Income (loss) per share from continuing operations - basic | \$(1.69) | ... | ... |
| Net income (loss) per share - basic | \$(1.69) | \$(0.49) | \$(0.85) |
| Income (loss) per share from continuing operations - diluted | \$(1.69) | ... | ... |
| Net income (loss) per share - diluted | \$(1.69) | \$(0.56) | \$(0.85) |
| Total number of employees | 245 | ... | ... |
| Number of full time employees | 245 | ⁽⁴⁾ 244 | ⁽⁵⁾ 202 |
| Number of common stockholders | 305 | ⁽⁶⁾ 302 | ⁽⁷⁾ 302 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------------|------------|------------|
| Cash & cash equivalents | 6,432,731 | 6,069,889 |
| Restricted cash | 1,127,960 | 1,127,960 |
| Accounts receivables, gross | 7,274,367 | 6,899,292 |
| Less: allowance for doubtful accounts | 1,456,752 | 736,820 |
| Trade accounts receivable, net | ... | 6,162,472 |
| Other receivables | 6,643,960 | 5,552,993 |
| Notes receivable | 5,817,615 | 4,426,700 |
| Other current assets | 701,335 | 523,812 |
| Total current assets | 20,723,601 | 23,863,826 |
| Capitalized production costs, net | 2,295,275 | 1,598,412 |
| Employee receivable | 796,085 | 604,085 |

⁽¹⁾ Reclassified to conform with 2022 presentation; ⁽²⁾ Shares increased due to the effect of employment agreement, conversion of note, Lincoln Park Capital LLC, restricted stock, The Door Marketing Group LLC, B/HI Communication Inc and Socialyte LLC; ⁽³⁾ Shares increased due to the effect of note payable, warrants, seller of Be Social, acquisition of The Door, B/HI Communications Inc, Shore Fire Media, put rights, bonus, debt and Lincoln Park Capital; ⁽⁴⁾ As of March 10, 2023; ⁽⁵⁾ As of March 1, 2022; ⁽⁶⁾ Approximately; ⁽⁷⁾ As of March 23, 2023; ⁽⁸⁾ As of April 28, 2022

| | | | | | | | |
|---------------------------|------------|------------|---------------------------|--------------------------|--------------|-------------|-------------|
| Right-of-use asset | 5,469,743 | 7,341,045 | value, 400,000,000 shares | value of warrant | | | |
| Intangible assets | 11,209,664 | 9,884,336 | authorized, 14,395,521 | liability | 120,000 | (2,482,877) | |
| Goodwill | 25,220,085 | 29,314,083 | and 4,094,618 , | Interest expense | 2,085,107 | 555,802 | 785,209 |
| Furniture & fixtures | 1,232,798 | 933,618 | respectively, issued and | Change in fair | | | |
| Computers, office | | | outstanding at 31, 2016 | value of | | | |
| equipment & software | 5,092,681 | 2,288,986 | and 2015 | convertible notes | (11,444) | | |
| Leasehold improvements | 784,403 | 505,424 | Common stock | Total other income | | | |
| Office furniture & | | | Preferred stock | (expense), net | (2,083,674) | 218,777 | (921,257) |
| equipment | 3,075,480 | | Preferred stock series C | Income (loss) | | | |
| Property, equipment & | | | Additional paid-in | before income taxes | | | |
| leasehold improvements, | | | capital | & equity in | | | |
| gross | | 3,728,028 | Accumulated Deficit | earnings (losses) | | | |
| Less: accumulated | | | Retained earnings | of unconsolidated | | | |
| depreciation | 4,898,458 | | (accumulated deficit) | affiliates | (22,194,171) | (4,356,365) | (6,424,947) |
| Less: accumulated | | | Total stockholders' | Deferred federal | | | |
| depreciation & | | 3,434,822 | equity | income tax expense | (5,161,523) | (853,835) | (1,107,490) |
| amortization | | | Total stockholders' | Deferred state | | | |
| Property, equipment & | | | equity (deficit) | income tax expense | | | |
| leasehold improvements, | | | | (benefit) | (1,600,131) | (292,832) | (37,908) |
| net | 194,223 | 293,206 | | Deferred income tax | | | |
| Other long-term assets | 216,305 | 2,477,839 | | expense | (6,761,654) | (1,146,667) | (1,145,398) |
| Deposits | 129,993 | | | Change in valuation | | | |
| Right of Use Tangible | | | | allowance (benefit) | | | |
| Assets - | | | | - federal | | 881,436 | 1,145,789 |
| Total/Unspecified - Net | 5,599,736 | | | Change in valuation | | | |
| Total assets | 66,254,974 | 75,376,832 | | allowance (benefit) | | | |
| Accounts payable | | 4,798,221 | | - state | | 442,212 | 36,965 |
| Accounts payable & | | | | Change in valuation | | | |
| accrued charges | 6,892,349 | | | allowance (benefit) | | 1,323,648 | 1,182,754 |
| Term loan, current | | | | Valuation | | | |
| portion | 400,000 | 408,905 | | Allowance-Federal | 5,184,815 | | |
| Notes payable, current | | | | Valuation | | | |
| portion | 3,500,000 | 3,868,960 | | Allowance-state | 1,630,343 | | |
| Deferred revenue | 1,451,709 | 1,641,459 | | Income Taxes - | | | |
| Lease liability | 2,141,240 | 2,073,547 | | Other - | | | |
| Contingent consideration | | 500,000 | | Deferred/Current | 6,815,158 | | |
| Accrued interest - | | | | Income tax expense | 53,504 | 176,981 | 37,356 |
| related party | 971,276 | 1,744,723 | | Net income (loss) | | | |
| Accrued compensation - | | | | before equity in | | | |
| related party | 2,625,000 | 2,625,000 | | earnings (losses) | | | |
| Accrued funding under Max | | | | of unconsolidated | | | |
| Steel marketing agreement | 620,000 | 620,000 | | affiliates | | (4,533,346) | (6,462,303) |
| Accrued audit, legal & | | | | Equity in losses of | | | |
| other professional fees | 310,797 | 573,049 | | unconsolidated | | | |
| Accrued commissions | 697,106 | 702,410 | | affiliates | (2,149,050) | | |
| Accrued bonuses | | 469,953 | | Earnings (loss) on | | | |
| Talent liability | 2,983,577 | 3,990,984 | | equity method | | | |
| Accumulated customer | | | | investment | | (246,789) | |
| deposits | 432,552 | 550,930 | | Net income (loss) | (24,396,725) | (4,780,135) | (6,462,303) |
| Other current liabilities | | 719,510 | | Net income (loss) | | | |
| Other current liabilities | 7,694,114 | 7,626,836 | | attributable to | | | |
| Term loan, current | | | | Dolphin | | | |
| portion | 980,651 | | | Entertainment Inc | | | |
| Accrued interest - | | | | common stock | | | |
| related party | 1,718,009 | | | shareholders | | (4,780,135) | (6,462,303) |
| Other | 1,678,806 | | | Weighted average | | | |
| Capitalized Leases - | | | | shares outstanding | | | |
| Current Portion | 50,973 | | | - basic | 14,413,154 | 9,799,021 | 7,614,774 |
| Lease Liabilities - | | | | Weighted average | | | |
| Unspecified - Current | | | | shares outstanding | | | |
| Portion/Short-Term | 2,192,213 | | | - diluted | 14,413,154 | 9,926,926 | 7,614,774 |
| Total current liabilities | 27,454,045 | 25,287,651 | | Year end shares | | | |
| Term loan, noncurrent | | | | outstanding | 18,219,531 | 12,340,664 | 8,020,381 |
| portion | 4,501,963 | 2,458,687 | | Income (loss) per | | | |
| Convertible note payable | 5,100,000 | | | share from | | | |
| Warrant liability | 5,000 | 15,000 | | continuing | | | |
| Convertible notes payable | | 5,050,000 | | operations - basic | \$(1.69) | | |
| Convertible notes payable | | | | Net income (loss) | | | |
| at fair value | 355,000 | 343,556 | | per share - basic | \$(1.69) | \$(0.49) | \$(0.85) |
| Notes payable, noncurrent | | | | Income (loss) per | | | |
| portion | | 500,000 | | share from | | | |
| Contingent consideration | | 238,821 | | continuing | | | |
| Lease liability | 3,986,787 | 6,012,049 | | operations - | | | |
| Deferred tax liability | 306,691 | 253,188 | | diluted | \$(1.69) | | |
| Loan form related party | 1,107,873 | 1,107,873 | | Net income (loss) | | | |
| Debt | 3,380,000 | | | per share - diluted | \$(1.69) | \$(0.56) | \$(0.85) |
| Other noncurrent | | | | Total number of | | | |
| liabilities | 18,915 | 18,915 | | employees | 245 | | |
| Lease Liabilities - | | | | Number of full time | | | |
| Unspecified - Long -Term | 4,068,642 | | | employees | 245 | 244 | 202 |
| Capitalized Lease | | | | Number of common | | | |
| Obligations - Long-Term | 81,855 | | | stockholders | 305 | 302 | 302 |
| Total liabilities | 46,298,129 | 41,285,740 | | | | | |
| Common stock, \$0.015 par | | | | | | | |

Reclassified to conform with 2022 presentation; Shares in-

created due to the effect of employment agreement, conversion of note, Lincoln Park Capital LLC, restricted stock, The Door Marketing Group LLC, B/Hi Communication Inc and Socialyte LLC; [Ⓜ] Shares increased due to the effect of note payable, warrants, seller of Be Social, acquisition of The Door, B/Hi Communications Inc, Shore Fire Media, put rights, bonus, debt and Lincoln Park Capital; [Ⓜ] As of March 10, 2023; [Ⓜ] As of March 1, 2022; [Ⓜ] Approximately; [Ⓜ] As of March 23, 2023; [Ⓜ] As of April 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 6,432,731 | 6,069,889 |
| Restricted cash | 1,127,960 | 1,127,960 |
| Accounts receivables, gross | 7,274,367 | 6,899,292 |
| Less: allowance for doubtful accounts | 1,456,752 | 736,820 |
| Trade accounts receivable, net | ... | 6,162,472 |
| Other receivables | 6,643,960 | 5,552,993 |
| Notes receivable | 5,817,615 | 4,426,700 |
| Other current assets | 701,335 | 523,812 |
| Total current assets | 20,723,601 | 23,863,826 |
| Capitalized production costs, net | 2,295,275 | 1,598,412 |
| Employee receivable | 796,085 | 604,085 |
| Right-of-use asset | 5,469,743 | 7,341,045 |
| Intangible assets | 11,209,664 | 9,884,336 |
| Goodwill | 25,220,085 | 29,314,083 |
| Furniture & fixtures | 1,232,798 | 933,618 |
| Computers, office equipment & software | 5,092,681 | 2,288,986 |
| Leasehold improvements | 784,403 | 505,424 |
| Office furniture & equipment | 3,075,480 | ... |
| Property, equipment & leasehold improvements, gross | ... | 3,728,028 |
| Less: accumulated depreciation | 4,898,458 | ... |
| Less: accumulated depreciation & amortization | ... | 3,434,822 |
| Property, equipment & leasehold improvements, net | 194,223 | 293,206 |
| Other long-term assets | 216,305 | 2,477,839 |
| Deposits | 129,993 | ... |
| Right of Use Tangible Assets - | | |
| Total/Unspecified - Net | 5,599,736 | ... |
| Total assets | 66,254,974 | 75,376,832 |
| Accounts payable | ... | 4,798,221 |
| Accounts payable & accrued charges | 6,892,349 | ... |
| Term loan, current portion | 400,000 | 408,905 |
| Notes payable, current portion | 3,500,000 | 3,868,960 |
| Deferred revenue | 1,451,709 | 1,641,459 |
| Lease liability | 2,141,240 | 2,073,547 |
| Contingent consideration | ... | 500,000 |
| Accrued interest - related party | 971,276 | 1,744,723 |
| Accrued compensation - related party | 2,625,000 | 2,625,000 |
| Accrued funding under Max Steel marketing agreement | 620,000 | 620,000 |
| Accrued audit, legal & other professional fees | 310,797 | 573,049 |
| Accrued commissions | 697,106 | 702,410 |
| Accrued bonuses | ... | 469,953 |
| Talent liability | 2,983,577 | 3,990,984 |
| Accumulated customer deposits | 432,552 | 550,930 |
| Other current liabilities | ... | 719,510 |
| Other current liabilities | 7,694,114 | 7,626,836 |
| Term loan, current portion | 980,651 | ... |
| Accrued interest - related party | 1,718,009 | ... |
| Other | 1,678,806 | ... |
| Capitalized Leases - | | |
| Current Portion | 50,973 | ... |

| | | |
|--|---------------|---------------|
| Lease Liabilities - Unspecified - Current Portion/Short-Term | 2,192,213 | ... |
| Total current liabilities | 27,454,045 | 25,287,651 |
| Term loan, noncurrent portion | 4,501,963 | 2,458,687 |
| Convertible note payable | 5,100,000 | ... |
| Warrant liability | 5,000 | 15,000 |
| Convertible notes payable | ... | 5,050,000 |
| Convertible notes payable at fair value | 355,000 | 343,556 |
| Notes payable, noncurrent portion | ... | 500,000 |
| Contingent consideration | ... | 238,821 |
| Lease liability | 3,986,787 | 6,012,049 |
| Deferred tax liability | 306,691 | 253,188 |
| Loan form related party | 1,107,873 | 1,107,873 |
| Debt | 3,380,000 | ... |
| Other noncurrent liabilities | 18,915 | 18,915 |
| Lease Liabilities - Unspecified - Long -Term | 4,068,642 | ... |
| Capitalized Lease Obligations - Long-Term | 81,855 | ... |
| Total liabilities | 46,298,129 | 41,285,740 |
| Common stock, \$0.015 par value, 400,000,000 shares authorized, 14,395,521 and 4,094,618 , respectively, issued and outstanding at 31, 2016 and 2015 | 273,293 | ... |
| Common stock | ... | 185,110 |
| Preferred stock | 1,000 | ... |
| Preferred stock series C | ... | 1,000 |
| Additional paid-in capital | 153,293,756 | 143,119,461 |
| Accumulated Deficit | (133,611,204) | ... |
| Retained earnings (accumulated deficit) | ... | (109,214,479) |
| Total stockholders' equity | 19,956,845 | 34,091,092 |
| Total stockholders' equity (deficit) | 19,956,845 | ... |

Recent Dividends:

- Dolphin Entertainment Inc series C convertible preferred.**
No dividends paid.
- Dolphin Entertainment Inc preferred.**
No dividends paid.
- Dolphin Entertainment Inc common.**
No dividends paid.

Annual Dividends:

- Dolphin Entertainment Inc series C convertible preferred.**
No dividends paid.
- Dolphin Entertainment Inc preferred.**
No dividends paid.
- Dolphin Entertainment Inc common.**
No dividends paid.

DOMINARI HOLDINGS INC

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|--------------|--------------|-------------------|
| | 2023 | 2022 | [Ⓜ] 2021 |
| Revenues | 2,039,000 | ... | ... |
| Selling, general & administrative expenses | 23,838,000 | ... | ... |
| General & administrative | ... | 11,683,000 | 7,734,000 |
| Research & development expense | 3,000 | 830,000 | 559,000 |
| Research & development - license acquired | (6,000) | 1,833,000 | 1,148,000 |
| Total operating expense | (23,835,000) | (14,346,000) | (9,441,000) |
| Income (loss) from operations | (21,796,000) | (14,346,000) | (9,441,000) |
| Interest income | 716,000 | 687,000 | 252,000 |
| Other income, net | 36,000 | 64,000 | 135,000 |

| | | | |
|--|--------------|------------------|------------------------|
| Gain (loss) on marketable securities | 630,000 | (5,952,000) | (1,743,000) |
| Gain on settlement of obligations | 780,000 | ... | ... |
| Change in fair value of investments | ... | (2,560,000) | 3,626,000 |
| Unrealized loss on note receivable | (3,248,000) | ... | ... |
| Total other income (expenses) | (1,086,000) | (7,761,000) | 2,270,000 |
| Income (loss) continuing operations before taxes | (22,882,000) | ... | ... |
| Net income (loss) | (22,882,000) | (22,107,000) | (7,171,000) |
| Deemed dividends related to series O & series P redeemable convertible preferred stock | ... | 4,109,000 | ... |
| Net income (loss) attributable to common stockholders | ... | (26,216,000) | (7,171,000) |
| Weighted average shares outstanding - basic | 5,229,477 | 5,334,075 | [Ⓜ] 4,846,925 |
| Weighted average shares outstanding - diluted | 5,229,477 | 5,334,075 | [Ⓜ] 4,846,925 |
| Year end shares outstanding | 5,934,917 | 5,017,079 | [Ⓜ] 5,275,368 |
| Income (loss) per share - continuing operations - basic | \$(4.38) | ... | ... |
| Net income (loss) per share - basic | \$(4.38) | \$(4.91) | [Ⓜ] \$(1.53) |
| Income (loss) per share - continuing operations - diluted | \$(4.38) | ... | ... |
| Net income (loss) per share - diluted | \$(4.38) | \$(4.91) | [Ⓜ] \$(1.53) |
| Number of full time employees | 26 | 7 | 4 |
| Number of part time employees | 2 | 1 | 1 |
| Total number of employees | 28 | ... | ... |
| Number of common stockholders | 136 | [Ⓜ] 135 | [Ⓜ] 127 |
| Revenues | 2,039,000 | ... | ... |

[Ⓜ] Reclassified to conform with 2022 presentation; [Ⓜ] Adjusted for 1-for-17 stock split, June 7, 2022; [Ⓜ] Share increased due to the issuance of common stock and warrants, exercise of warrants, research and development license acquired, conversion of preferred stock and stock-based compensation; [Ⓜ] Approximately; [Ⓜ] As of March 20, 2023; [Ⓜ] As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------------|------------|------------|
| Cash & cash equivalents | 2,833,000 | 33,174,000 |
| Marketable securities | 13,547,000 | 7,130,000 |
| Prepaid expenses & other assets | 7,687,000 | 564,000 |
| Prepaid acquisition cost | 898,000 | 301,000 |
| Short-term investments at fair value | ... | 13,000 |
| Notes receivable at fair value | 3,177,000 | 7,474,000 |
| Investment in FieldPoint Securities | ... | 2,000,000 |
| Total current assets | 28,142,000 | 50,656,000 |
| Notes receivable at fair value | 1,129,000 | 1,100,000 |
| Property & equipment, net | 344,000 | ... |
| Investments | 24,150,000 | 23,103,000 |
| Right-of-use assets | 3,335,000 | 919,000 |

| | | |
|---|---------------|---------------|
| Security deposit | 458,000 | 458,000 |
| Total assets | 57,558,000 | 76,236,000 |
| Accounts payable & accrued expenses | 1,036,000 | 447,000 |
| Accrued salaries & benefits | 51,000 | 1,260,000 |
| Lease liability - current | 421,000 | 82,000 |
| Accrued Commissions | 77,000 | ... |
| Other Current liability | 22,000 | ... |
| Total current liabilities | ... | 1,789,000 |
| Lease liability | 3,028,000 | 680,000 |
| Total liabilities | 4,635,000 | 2,469,000 |
| Common stock | 600 | ... |
| Additional paid-in-capital | 262,187,000 | 262,970,000 |
| Treasury stock | 501,000 | ... |
| Treasury stock, at cost | ... | 3,322,000 |
| Accumulated deficit | (208,763,000) | ... |
| Retained earnings (accumulated deficit) | ... | (185,881,000) |
| Total stockholders' equity | 52,923,000 | 73,767,000 |
| Total Equity | 52,923,000 | ... |

| | | | |
|--|--------------|--------------|-------------|
| administrative expenses | 26,389,000 | 41,566,000 | ... |
| Selling & marketing expenses | 12,623,000 | 13,671,000 | ... |
| Total operating expenses | 42,875,000 | 58,001,000 | ... |
| Income (loss) from operations | (27,429,000) | (33,997,000) | (357,674) |
| Other income | 19,000 | 40,000 | ... |
| Interest expense, net | 16,015,000 | 6,945,000 | ... |
| Warrant issuance costs | ... | ... | 18,797 |
| Gain (loss) on sale of private warrants | ... | ... | (1,253,928) |
| Net gain on investments held in trust account | ... | ... | 23,715 |
| Change in fair market value of warrant liability | 29,582,000 | 5,446,000 | 3,517,171 |
| Debt extinguishment | ... | (4,824,000) | ... |
| Total other income (expense) | 13,586,000 | (6,283,000) | ... |
| Income (loss) before taxes | (13,843,000) | (40,280,000) | ... |
| Current - Federal | (36,000) | ... | ... |
| Current ? State | 10,000 | ... | ... |
| Current income tax expense (benefit) | ... | (257,000) | ... |
| Deferred income tax expense (benefit) | ... | (452,000) | ... |
| Income tax expense (benefit) | (26,000) | (709,000) | ... |
| Net income (loss) | (13,817,000) | (39,571,000) | 1,910,487 |
| Net income (loss) available to common shareholders | ... | (39,571,000) | ... |
| Weighted average shares outstanding - basic | 52,786,481 | 38,565,307 | 7,732,021 |
| Weighted average shares outstanding - diluted | 52,786,481 | 38,565,307 | 7,991,952 |
| Year end shares outstanding | 60,260,282 | 43,272,728 | 15,812,500 |
| Net earnings (loss) per common share - basic | \$(0.26) | \$(1.03) | \$0.25 |
| Net earnings (loss) per common share - diluted | \$(0.26) | \$(1.03) | \$0.24 |
| Number of full time employees | 150 | 171 | ... |
| Number of part time employees | 1 | 2 | ... |
| Number of seasonal employees | ... | 4 | ... |
| Total number of employees | 151 | 177 | 2 |
| Number of unit stockholders | ... | ... | 1 |
| Number of separately traded public stockholders | ... | ... | 8 |
| Number of common stockholders | ... | 105 | ... |
| Net Sales | 64,392,000 | ... | ... |

| | | |
|---|--------------|--------------|
| doubtful accounts | ... | 90,000 |
| Accounts receivable, net of allowance for doubtful accounts | ... | 1,444,000 |
| Raw material | 31,604,000 | 42,586,000 |
| Finished goods | 7,174,000 | 7,260,000 |
| Inventory | 38,778,000 | 49,846,000 |
| Prepaid expenses | 772,000 | 1,624,000 |
| Prepaid inventory | 1,381,000 | 2,002,000 |
| Prepaid income tax | 519,000 | 525,000 |
| Other current assets | 118,000 | 267,000 |
| Total current assets | 55,920,000 | 73,489,000 |
| Machinery & equipment | 16,714,000 | 10,214,000 |
| Office furniture & equipment | 319,000 | 275,000 |
| Leasehold improvements | 1,727,000 | 1,709,000 |
| Vehicle | 33,000 | 195,000 |
| Total property & equipment | 18,793,000 | 12,393,000 |
| Less accumulated depreciation & amortization | 2,824,000 | 1,633,000 |
| Property & equipment, net | 15,969,000 | 10,760,000 |
| Operating lease right of use asset | 3,315,000 | 4,513,000 |
| Total assets | 75,204,000 | 88,762,000 |
| Accounts payable | 10,258,000 | 13,475,000 |
| Accrued payroll & other liabilities | 1,713,000 | 6,295,000 |
| Customer deposits | 201,000 | 238,000 |
| Uncertain tax position liability | 91,000 | 128,000 |
| Notes payable, current portion, net of debt issuance costs | ... | 19,242,000 |
| Operating lease liability, current portion | 1,288,000 | 1,188,000 |
| Notes payable, current portion | 19,683,000 | ... |
| Financing lease liability, current portion | 36,000 | ... |
| Accrued payroll and other liabilities | 7,107,000 | ... |
| Total current liabilities | 40,377,000 | 40,566,000 |
| Warrant liabilities | ... | 32,831,000 |
| Accrued expenses, long-term | ... | 492,000 |
| Operating lease liability, net of current portion | 2,234,000 | 3,541,000 |
| Financing lease liability, net of current portion | 4,463,000 | ... |
| Financing lease liability, net of current portion | 66,000 | ... |
| Accrued expenses-long term | 152,000 | ... |
| Total long-term liabilities | 6,915,000 | 36,864,000 |
| Total liabilities | 47,292,000 | 77,430,000 |
| Common stock | 6,000 | 4,000 |
| Additional paid-in capital | 69,445,000 | 38,461,000 |
| Accumulated deficit | (41,539,000) | ... |
| Retained earnings (accumulated deficit) | ... | (27,133,000) |
| Total stockholders' equity | 27,912,000 | 11,332,000 |
| Total Equity | 27,912,000 | ... |

Recent Dividends:

- 1. **Dominari Holdings Inc series F-1 convertible preferred.**
No dividends paid.
- 2. **Dominari Holdings Inc series D-1 convertible preferred.**
No dividends paid.
- 3. **Dominari Holdings Inc series H convertible preferred.**
No dividends paid.
- 4. **Dominari Holdings Inc series C convertible preferred.**
No dividends paid.
- 5. **Dominari Holdings Inc series D convertible preferred.**
No dividends paid.
- 6. **Dominari Holdings Inc series J convertible preferred.**
No dividends paid.
- 7. **Dominari Holdings Inc common.**
No dividends paid.
- 8. **Dominari Holdings Inc series I redeemable convertible preferred.**
No dividends paid.
- 9. **Dominari Holdings Inc series B convertible preferred.**
No dividends paid.
- 10. **Dominari Holdings Inc series K convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. **Dominari Holdings Inc series F-1 convertible preferred.**
No dividends paid.
- 2. **Dominari Holdings Inc series D-1 convertible preferred.**
No dividends paid.
- 3. **Dominari Holdings Inc series H convertible preferred.**
No dividends paid.
- 4. **Dominari Holdings Inc series C convertible preferred.**
No dividends paid.
- 5. **Dominari Holdings Inc series D convertible preferred.**
No dividends paid.
- 6. **Dominari Holdings Inc series J convertible preferred.**
No dividends paid.
- 7. **Dominari Holdings Inc common.**
No dividends paid.
- 8. **Dominari Holdings Inc series I redeemable convertible preferred.**
No dividends paid.
- 9. **Dominari Holdings Inc series B convertible preferred.**
No dividends paid.
- 10. **Dominari Holdings Inc series K convertible preferred.**
No dividends paid.

DRAGONFLY ENERGY HOLDINGS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):
2023 2022 ¹2021

| | | | |
|-----------------------------|------------|------------|---------|
| Net sales | 64,392,000 | 86,251,000 | ... |
| Cost of goods sold | 48,946,000 | 62,247,000 | ... |
| Gross profit | 15,446,000 | 24,004,000 | ... |
| Operating & formation costs | ... | ... | 292,074 |
| Franchise tax expense | ... | ... | 65,600 |
| Research & development | 3,863,000 | 2,764,000 | ... |
| General & | ... | ... | ... |

¹ 2021 and prior periods for Chardan Nextech Acquisition Corp. prior to reverse merger with Dragonfly Energy Corp; ² Shares increased due to the effect of recapitalization, issuance of shares due to share purchase agreement, exercise of share options and cashless exercise of liability classified warrants; ³ As of March 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|----------------------------|------------|------------|
| | 2023 | 2022 |
| Cash and cash equivalents | 12,713,000 | ... |
| Cash | ... | 17,781,000 |
| Accounts receivable, gross | 1,639,000 | 1,534,000 |
| Less: allowance for | ... | ... |

Recent Dividends:

- 1. **Dragonfly Energy Holdings Corp common.**
No dividends paid.

Annual Dividends:

- 1. **Dragonfly Energy Holdings Corp common.**
No dividends paid.

DRAGONFLY ENERGY HOLDINGS CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Marcum LLP, as it appeared in Co.'s 2023 10-K: "Opin-

on the Financial Statements We have audited the accompanying consolidated balance sheet of Dragonfly Energy Holdings Corp. (the "Company") as of December 31, 2023, the related consolidated statements of operations, stockholders' equity and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and the results of its operations and its cash flows for the year ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. As discussed in Note 15 to the financial statements, the 2022 financial statements have been revised to correct for the under reporting of tariffs. The financial statements of the Company for the year ended December 31, 2022, before the effects of the adjustments to correct the errors discussed in Note 15 to the financial statements, were audited by other auditors whose report, dated April 17, 2023, expressed an unqualified opinion on those statements and included an explanatory paragraph regarding the Company's ability to continue as a going concern. We have also audited the adjustments described in Note 15 that were applied to revise the 2022 financial statements to correct the errors. In our opinion, such adjustments are appropriate and have been properly applied. Except for the corrections described in Note 15 we were not engaged to audit, review, or apply any procedures to the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, other than stated above and, accordingly, we do not express an opinion or any other form of assurance on the 2022 financial statements taken as a whole. Explanatory Paragraph - Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company incurred loss from operations and had negative cash flow from operations and concluded it is probable the Company will not comply with future covenants of the Term Loan and does not have sufficient resources to repay the Term Loan, which raises substantial doubt about its ability to continue as a going concern. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

DROR ORTHO-DESIGN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|-------------|--------------------|
| Total revenue | ... | ... | (revised) 2,568 |
| Research & development | 1,004,443 | ... | ... |
| Professional fees | ... | 85,750 | 75,406 |
| Share-based compensation | 2,253,793 | ... | ... |
| Total operating expenses | 4,378,662 | 178,736 | 172,870 |
| Income (loss) from operations | (4,378,662) | (178,736) | (170,302) |
| Interest expense, net | ... | 14 | 207 |
| Other income (expense) | 720,632 | ... | ... |
| Financial income, net | 90,147 | ... | ... |
| Exchange Differences | 94,020 | ... | ... |
| Bank Fees | (3,873) | ... | ... |
| Total other income (expense) | 810,779 | (14) | (207) |
| Income (loss) before provision for income tax | (3,567,883) | (178,750) | (170,509) |
| Net income (loss) | (3,567,883) | (178,750) | (170,509) |
| Weighted-average common shares outstanding - basic | 296,664,409 | 202,308,728 | 202,308,728 |
| Weighted-average common shares outstanding - diluted | 296,664,409 | 202,308,728 | 202,308,728 |
| Year end shares outstanding | 495,454,546 | 202,308,728 | 202,308,728 |
| Net income (loss) per share - basic | \$(0.01) | \$0.00 | \$0.00 |
| Net income (loss) | | | |

| | per share - diluted | \$0.01 | \$0.00 | \$0.00 |
|---|---------------------|--------|--------|--------|
| Number of full time employees | ... | 0 | 0 | 0 |
| Number of common stockholders | 209 | 168 | 168 | 168 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... | ... |

As of March 31, 2023; As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 3,347,843 | 55,081 |
| Prepaid expenses | 114,100 | 5,348 |
| VAT Receivable | 73,784 | ... |
| Prepaid Expenses | 34,802 | ... |
| Other Current Assets | 5,514 | ... |
| Total current assets | 3,461,943 | 60,429 |
| Tooling | 9,567 | ... |
| Accumulated Dereciation | 7,239 | ... |
| Property & equipment, net | 2,328 | ... |
| Total assets | 3,464,271 | 60,429 |
| Accounts payable | 106,833 | ... |
| Trade payables | ... | 100,561 |
| Accrued expenses | 190,271 | 592 |
| Accounts payable & accrued expenses | ... | 101,153 |
| Accrued royalties | ... | 683,132 |
| Accrued payroll related liabilities | 95,566 | ... |
| Accrued expenses | 94,705 | ... |
| Total current liabilities | 297,104 | 784,285 |
| Accrued Severance | 5,243 | ... |
| Total liabilities | 302,347 | 784,285 |
| Common stock | 49,545 | 20,231 |
| Additional paid-in capital | 16,842,037 | 41,059,293 |
| Accumulated deficit | (13,730,705) | ... |
| Retained earnings (accumulated deficit) | ... | (41,803,380) |
| Preferred Stock | 1,047 | ... |
| Total stockholders' equity (deficit) | 3,161,924 | (723,856) |
| Total Equity | 3,161,924 | ... |

Recent Dividends:

1. Dror Ortho-Design Inc common.

No dividends paid.

Annual Dividends:

1. Dror Ortho-Design Inc common.

No dividends paid.

DSWISS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| Revenue | 1,470,071 | ... | ... |
| Cost of revenue | 1,110,846 | 1,404,054 | 1,459,531 |
| Gross profit (loss) | 359,225 | 444,993 | 499,124 |
| Other income | 6,904 | 4,823 | 8,390 |
| Selling, general & administrative expenses | 367,647 | 402,412 | 308,686 |
| Operating expenses | 1,342 | 1,303 | 1,464 |
| Finance cost | 2,919 | 6,212 | 2,600 |
| Lease expenses | 43,099 | 42,310 | 44,486 |
| Profit (loss) before income tax | (48,878) | (2,421) | 150,278 |
| Current provision for foreign income taxes | ... | 516 | 176 |
| Foreign Income taxes provision | 657 | 516 | 176 |
| Net profit (loss) | (49,535) | (2,937) | 150,102 |
| Non-controlling interests | ... | (11,354) | 23,357 |

| | Net income (loss) attributable to controlling interest | (49,535) | (14,291) | 173,459 |
|---|--|-------------|-------------|-------------|
| Weighted average shares outstanding - basic | 206,904,585 | 206,904,585 | 206,904,585 | 206,904,585 |
| Weighted average shares outstanding - diluted | 206,904,585 | 206,904,585 | 206,904,585 | 206,904,585 |
| Year end shares outstanding | 206,904,585 | 206,904,585 | 206,904,585 | 206,904,585 |
| Net income (loss) per share - basic | \$(0.00) | \$(0.00) | \$0.00 | |
| Net income (loss) per share - diluted | \$(0.00) | \$(0.00) | \$0.00 | |
| Number of full time employees | 11 | 12 | 9 | |
| Number of beneficiary stockholders | 426 | 428 | 419 | |
| TOTAL COMPREHENSIVE INCOME | 6,763 | ... | ... | |
| Total number of employees | 11 | ... | ... | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 249,110 | 214,269 |
| Accounts receivable | 36,148 | 17,492 |
| Prepaid expenses | 1,932 | 2,080 |
| Deposits | ... | 19,669 |
| Other receivables | 5,460 | ... |
| Other receivables, prepaid expenses & deposit | 17,140 | 21,749 |
| Prepaid expenses & deposits | 24,532 | ... |
| Tax recoverable | 299 | 745 |
| Finished goods, at cost | ... | 7,483 |
| Inventories - Finished Goods | 6,872 | ... |
| Inventories | 6,872 | 7,483 |
| Total current assets | 316,961 | 261,738 |
| Computers & software | 6,144 | 105,535 |
| Furniture & fittings | ... | 6,144 |
| Office equipment | ... | 21,152 |
| Motor vehicles | 135,868 | 135,868 |
| Renovation | 21,525 | ... |
| Computer and software | 102,064 | ... |
| Total property & equipment | 265,601 | 268,699 |
| Accumulated depreciation | 205,600 | 187,236 |
| Effect of translation exchange | (11,896) | (9,284) |
| Property & equipment, net | 48,105 | 72,179 |
| Intangible assets, net | 2,427 | 3,459 |
| Operating lease right-of-use assets, net | ... | 44,548 |
| Total non-current assets | 50,532 | 120,186 |
| Total assets | 367,493 | 381,924 |
| Accounts payable | 99,360 | 29,539 |
| Other payables | 114,964 | 100,385 |
| Accrued audit fees | 30,207 | 20,266 |
| Accrued other expenses | 15,222 | 16,683 |
| Accrued professional fees | 14,321 | 17,376 |
| Other payables & accrued liabilities | ... | 154,710 |
| Finance lease liability | 21,039 | 16,515 |
| Amount due to a director | 174,714 | ... |
| Operating lease liability | ... | 44,548 |
| Total current liabilities | 295,113 | 245,312 |
| Finance lease liability | 15,965 | 38,461 |
| Total non-current liabilities | 15,965 | 38,461 |
| Total liabilities | 311,078 | 283,773 |
| Common stock | 20,690 | 20,690 |
| Additional paid in capital | 1,395,426 | 1,395,426 |
| Accumulated other comprehensive income (losses) | 50,452 | (5,846) |

| | | |
|---|-------------|-------------|
| Retained earnings (accumulated deficit) | (1,410,153) | (1,324,002) |
| Total DSwiss, Inc. stockholders' equity (deficit) | 56,415 | 86,268 |
| Non-controlling interest | ... | 11,883 |
| Total stockholders' equity | 56,415 | 98,151 |

Recent Dividends:
1. DSwiss Inc common.
 No dividends paid.
Annual Dividends:
1. DSwiss Inc common.
 No dividends paid.

DUOS TECHNOLOGIES GROUP INC
Annual Report

| | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
|---|--|--------------------|--------------------|
| | 2023 | 2022 | 2021 (revised) |
| Technology systems revenue | ... | 11,190,292 | 5,871,666 |
| Services & consulting revenue | 3,853,176 | 3,822,074 | 2,388,251 |
| Sub Total | 3,618,022 | ... | ... |
| Total revenues | 7,471,198 | 15,012,366 | 8,259,917 |
| Cost of revenues - technology systems | 4,352,247 | 8,376,649 | 4,728,197 |
| Cost of revenues - services & consulting | 1,810,070 | 1,887,614 | 1,492,176 |
| Total cost of revenues | 6,162,317 | 10,264,263 | 6,220,373 |
| Gross margin | 1,308,881 | 4,748,103 | 2,039,544 |
| Sales & marketing | 1,493,309 | 1,337,186 | 1,233,851 |
| Research & development | 1,812,951 | 1,651,064 | 2,515,630 |
| General & administration | 9,449,187 | 8,625,002 | 5,747,014 |
| Total operating expenses | 12,755,447 | 11,613,252 | 9,496,495 |
| Income (loss) from operations | (11,446,566) | (6,865,149) | (7,456,951) |
| Interest expense | 7,159 | 9,191 | 20,268 |
| Other income, net | 212,007 | 9,557 | 1,468,318 |
| Total other income (expenses) | 204,848 | 366 | 1,448,050 |
| Income (loss) from operations before income taxes | (11,241,718) | ... | ... |
| Net income (loss) | (11,241,718) | (6,864,783) | (6,008,901) |
| Weighted average shares outstanding - basic | 7,204,177 | 6,175,193 | 3,694,293 |
| Weighted average shares outstanding - diluted | 7,204,177 | 6,175,193 | 3,694,293 |
| Year end shares outstanding | 7,305,339 | 7,155,552 | 4,109,723 |
| Net earnings (loss) per share - basic | \$(1.56) | \$(1.11) | \$(1.63) |
| Net earnings (loss) per share - diluted | \$(1.56) | \$(1.11) | \$(1.63) |
| Number of full time employees | 71 | 67 | 60 |
| Number of part time employees | ... | 8 | 8 |
| Total number of employees | 71 | 75 | 68 |
| Number of common stockholders | 3,070 | 1,709 | 286 |
| Earnings per share from continuing operations | \$(1.56) | ... | ... |
| Earnings per share from continuing operations | \$(1.56) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of series B & C preferred converted to common stock, cashless warrants exercised, services, cashless employee stock options exercised and rounding-split; □ Approximately; □ As of March 28, 2023; □ As of March 28, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|--------------|--------------|
| | 2023 | 2022 |
| Cash | 2,441,842 | 1,121,092 |
| Accounts receivable, gross | 1,462,463 | 3,418,263 |
| Accounts receivable, net | 1,462,463 | 3,418,263 |
| Cumulative revenues recognized | ... | 5,934,205 |
| Less: billings or cash received | ... | (5,508,483) |
| Contract assets | ... | 425,722 |
| Inventory | 1,526,165 | ... |
| Prepaid expenses & other current assets | 641,947 | 441,320 |
| Prepaid expenses and other current assets | 184,478 | ... |
| Total current assets | 6,256,895 | 6,834,757 |
| Furniture, fixtures & equipment | 132,018 | 1,606,451 |
| Leasehold improvements | 298,004 | ... |
| Property, Plant and Equipment, Gross | ... | ... |
| Equipment | 1,291,673 | ... |
| Property, Plant and Equipment, Gross | ... | ... |
| Software Development | 381,441 | ... |
| Less: accumulated depreciation | 1,376,629 | 976,961 |
| Property & equipment, net | 726,507 | 629,490 |
| Operating lease right of use asset | 4,373,155 | 4,689,931 |
| Security deposit | 550,000 | 600,000 |
| Software development costs, net | 652,838 | 265,208 |
| Patents & trademarks, net | ... | 69,733 |
| Patents and trademarks, net | 129,140 | ... |
| Convertible note receivable net | 153,750 | ... |
| Total assets | 12,842,285 | 13,089,119 |
| Accounts payable | 595,634 | 2,290,390 |
| Notes payable - financing agreements | 41,976 | 74,575 |
| Accrued expenses | 164,113 | 453,023 |
| Equipment financing agreements-current portion | ... | 22,851 |
| Operating lease obligation-current portion | 779,087 | 696,869 |
| Billings & or cash receipts on uncompleted contracts | ... | 4,355,470 |
| Less: cumulative revenues | ... | (4,144,018) |
| Contract liabilities, technology systems | ... | 211,452 |
| Contract Liabilities, services & consulting | ... | 746,545 |
| Contract liabilities | 1,666,243 | 957,997 |
| Total current liabilities | 3,247,053 | 4,495,705 |
| Operating lease obligation, less current portion | 4,228,718 | 4,542,943 |
| Total liabilities | 7,475,771 | 9,038,648 |
| Series B convertible preferred stock | 12 | ... |
| Series D convertible preferred stock | 1 | 1 |
| Common stock | 7,306 | 7,156 |
| Additional paid-in-capital | 69,120,199 | 56,562,600 |
| Accumulated deficit | (63,603,552) | ... |
| Retained earnings (accumulated deficit) | ... | (52,361,834) |
| Stockholders' equity (deficit) sub-total | ... | 4,207,923 |
| Less: treasury stock | 157,452 | 157,452 |
| Total stockholders' equity (deficit) | 5,366,514 | 4,050,471 |
| Total Stockholders' | ... | ... |

| | | | |
|---|-----------|----------|----------|
| Deficit | 5,366,514 | ... | |
| Recent Dividends: | | | |
| 1. Duos Technologies Group Inc common (new). | | | |
| No dividends paid. | | | |
| 2. Duos Technologies Group Inc series D convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 3. Duos Technologies Group Inc class A common. | | | |
| No dividends paid. | | | |
| 4. Duos Technologies Group Inc series E convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 5. Duos Technologies Group Inc class B common. | | | |
| No dividends paid. | | | |
| 6. Duos Technologies Group Inc series C convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 7. Duos Technologies Group Inc common. | | | |
| No dividends paid. | | | |
| 8. Duos Technologies Group Inc series B convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. Duos Technologies Group Inc common (new). | | | |
| No dividends paid. | | | |
| 2. Duos Technologies Group Inc series D convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 3. Duos Technologies Group Inc class A common. | | | |
| No dividends paid. | | | |
| 4. Duos Technologies Group Inc series E convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 5. Duos Technologies Group Inc class B common. | | | |
| No dividends paid. | | | |
| 6. Duos Technologies Group Inc series C convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| 7. Duos Technologies Group Inc common. | | | |
| No dividends paid. | | | |
| 8. Duos Technologies Group Inc series B convertible preferred (stated value: \$1,000). | | | |
| No dividends paid. | | | |
| DURECT CORP | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$000): | | | |
| | 2023 | 2022 | 2021 |
| Collaborative research & development & other revenue | 2,277 | 13,204 | 6,331 |
| Product revenue, net | 6,271 | 6,079 | 7,646 |
| Total revenues | 8,548 | 19,283 | 13,977 |
| Cost of product revenues | 1,717 | 1,588 | 1,955 |
| Research & development expenses | 29,351 | 36,862 | 31,846 |
| Selling, general & administrative expenses | 14,364 | 15,915 | 14,449 |
| Total operating expenses | 45,432 | 54,365 | 48,250 |
| Income (loss) from operations | (36,884) | (35,082) | (34,273) |
| Interest income | 2,129 | ... | ... |
| Interest & other income (expenses) | ... | 2,148 | 156 |
| Interest expense | 2,792 | 2,399 | 2,148 |
| Change in fair value of warrant liabilities | 13,583 | ... | ... |
| Issuance cost for warrants | (1,627) | ... | ... |
| Loss on issuance of warrants | (2,033) | ... | ... |
| Net other income (expense) | 9,260 | (251) | (1,992) |
| Income (loss) | ... | ... | ... |

| | | | | | | | | | | |
|--|-----------------|-----------------|-----------------|--|--------------------|--------------------|--|----------|----------|----------|
| before income taxes | (27,624) | ... | ... | Other long-term liabilities | 693 | 851 | diluted | \$(0.24) | \$(0.34) | \$(0.47) |
| Income (loss) from continuing operations | (35,333) | (36,265) | (36,265) | Common stock | 23 | 23 | Number of full time employees | 7 | ... | ... |
| Net income (loss) | (27,624) | (35,333) | (36,265) | Additional paid-in capital | 603,780 | 586,357 | Total number of employees | 7 | ... | 7 |
| Weighted average shares outstanding - basic | 26,256 | 22,777 | □22,505 | Accumulated other comprehensive income (loss) | (14) | (13) | Number of common stockholders | 50 | 51 | 53 |
| Weighted average shares outstanding - diluted | 26,256 | 22,777 | □22,505 | Retained earnings (accumulated deficit) | (589,006) | (561,382) | □ Reclassified to conform with 2022 presentation | | | |
| Year end shares outstanding | 30,334 | 22,785 | □22,768 | Stockholders' equity | 14,783 | 24,985 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| Income (loss) per share from continuing operations - basic | \$(1.05) | \$(1.55) | □\$(1.60) | Total Equity | 14,783 | ... | 2023 | 2022 | | |
| Net income (loss) per share - basic | \$(1.05) | \$(1.55) | □\$(1.60) | Recent Dividends: | | | | | | |
| Income (loss) per share from continuing operations - diluted | \$(1.05) | \$(1.55) | □(1.60) | 1. Durect Corp common. | | | | | | |
| Net income (loss) per share - diluted | \$(1.05) | \$(1.55) | □\$(1.60) | No dividends paid. | | | | | | |
| Total number of employees | ... | □79 | □79 | Annual Dividends: | | | | | | |
| Number of common stockholders | 71 | □79 | □96 | 1. Durect Corp common. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | DYADIC INTERNATIONAL INC | | | | | | |
| | | | | Annual Report | | | | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | |
| | | | | 2023 | 2022 | □2021 | | | | |
| | | | | | | (revised) | | | | |
| | | | | Research & development revenue | 2,545,865 | 2,683,244 | 2,403,831 | | | |
| | | | | License revenue | 352,941 | 247,059 | ... | | | |
| | | | | Total revenues | 2,898,806 | 2,930,303 | 2,403,831 | | | |
| | | | | Costs of research & development revenue | 1,975,849 | 2,123,193 | 1,944,438 | | | |
| | | | | Research & development expenses | 3,297,266 | 4,501,365 | 8,392,370 | | | |
| | | | | General & administrative expenses | 5,817,013 | 6,421,505 | 6,697,617 | | | |
| | | | | Foreign currency exchange gain (loss) | (38,417) | (49,918) | (96,893) | | | |
| | | | | Total costs & expenses | 11,128,545 | 13,095,981 | 17,131,318 | | | |
| | | | | Income (loss) from operations | (8,229,739) | (10,165,678) | (14,727,487) | | | |
| | | | | Interest income | 416,686 | 180,420 | 51,704 | | | |
| | | | | Other income | ... | 250,000 | 1,605,532 | | | |
| | | | | Gain from the sale of investments in BDI | 1,017,592 | ... | ... | | | |
| | | | | Total other income (expense) | 1,434,278 | 430,420 | 1,657,236 | | | |
| | | | | Income (loss) before income taxes - U.S. operations | ... | 9,828,427 | (13,115,869) | | | |
| | | | | Income (loss) before income taxes - foreign operations | ... | 93,169 | 45,618 | | | |
| | | | | Income (loss) before income taxes | (6,795,461) | ... | ... | | | |
| | | | | Net income (loss) | (6,795,461) | (9,735,258) | (13,070,251) | | | |
| | | | | Weighted average shares outstanding - basic | 28,798,833 | 28,364,482 | 27,838,047 | | | |
| | | | | Weighted average shares outstanding - diluted | 28,798,833 | 28,364,482 | 27,838,047 | | | |
| | | | | Year end shares outstanding | 28,811,061 | 28,563,100 | 28,229,157 | | | |
| | | | | Earnings (loss) per share from continuing operations - basic | \$(0.24) | ... | ... | | | |
| | | | | Net income (loss) per common share - basic | \$(0.24) | \$(0.34) | \$(0.47) | | | |
| | | | | Earnings (loss) per share from continuing operations - diluted | \$(0.24) | ... | ... | | | |
| | | | | Net income (loss) per common share - | | | | | | |
| Cash & cash equivalents | 28,400 | 43,483 | ... | | | | | | | |
| Short-term investments | 1,280 | ... | ... | | | | | | | |
| Accounts receivable, gross | 1,281 | 3,444 | ... | | | | | | | |
| Allowances | 20 | 21 | ... | | | | | | | |
| Accounts receivable, net | 1,261 | 3,423 | ... | | | | | | | |
| Raw materials | 165 | 168 | ... | | | | | | | |
| Work in-process | 1,164 | 1,151 | ... | | | | | | | |
| Finished goods | 890 | 794 | ... | | | | | | | |
| Inventories, net | 2,219 | 2,113 | ... | | | | | | | |
| Prepaid expenses & other current assets | 1,511 | 2,375 | ... | | | | | | | |
| Total current assets | 34,671 | 51,394 | ... | | | | | | | |
| Equipment | 6,737 | 10,791 | ... | | | | | | | |
| Leasehold improvements | 8,245 | 8,490 | ... | | | | | | | |
| Property & equipment, gross | 14,982 | 19,281 | ... | | | | | | | |
| Less accumulated depreciation & amortization | 14,891 | 19,093 | ... | | | | | | | |
| Property & equipment, net | 91 | 188 | ... | | | | | | | |
| Operating lease right-of-use assets | 3,980 | 1,943 | ... | | | | | | | |
| Goodwill | 6,169 | 6,169 | ... | | | | | | | |
| Long-term restricted investments | 150 | 150 | ... | | | | | | | |
| Other long-term assets | 128 | 256 | ... | | | | | | | |
| Total assets | 45,189 | 60,100 | ... | | | | | | | |
| Accounts payable | 1,777 | 3,106 | ... | | | | | | | |
| Accrued liabilities | 5,966 | 7,896 | ... | | | | | | | |
| Operating lease liabilities, current portion | 1,381 | 1,832 | ... | | | | | | | |
| Term loan, current portion, net | 16,663 | 21,170 | ... | | | | | | | |
| Accrued clinical costs | 1,578 | ... | ... | | | | | | | |
| Accrued compensation and benefits | 1,320 | ... | ... | | | | | | | |
| Accrued liabilities - Balancing value | 3,068 | ... | ... | | | | | | | |
| Warrant liabilities | 1,224 | ... | ... | | | | | | | |
| Total current liabilities | 27,011 | 34,004 | ... | | | | | | | |
| Operating lease liabilities, non-current portion | 2,702 | 260 | ... | | | | | | | |
| | | | | Recent Dividends: | | | | | | |
| | | | | 1. Dyadic International Inc common. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | Annual Dividends: | | | | | | |
| | | | | 1. Dyadic International Inc common. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | DYNARESOURCE INC | | | | | | |
| | | | | Annual Report | | | | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | |

| | 2023 | 2022 | ⁽¹⁾ 2021 (revised) | Total number of employees | 200 | 205 | 186 |
|---|--------------|---------------------------|----------------------------------|--|----------|--------------------|--------------------|
| REVENUE | 35,573,194 | ... | ... | Number of common stockholders | 424 | ⁽²⁾ 434 | ⁽³⁾ 439 |
| Revenue | 35,573,194 | 39,767,460 | 35,886,046 | Foreign currency translation adjustments | ... | 359,743 | (685,757) |
| Production cost applicable to sales | 8,256,062 | 4,413,649 | 2,909,401 | Basic EPS Excluding ExtraOrdinary Items | \$(0.65) | ... | ... |
| Mine production costs | 11,156,677 | 6,500,975 | 3,965,467 | Diluted EPS Excluding ExtraOrd Items | \$(0.65) | ... | ... |
| Mine exploration costs | 8,311,027 | 5,707,832 | 5,198,057 | | | | |
| Facilities expansion costs | 2,554,505 | 6,058,588 | 1,478,725 | | | | |
| Exploration drilling | 2,514,544 | 2,484,072 | ... | | | | |
| Camp, warehouse & facilities | 5,453,778 | 4,403,660 | 2,913,832 | | | | |
| Transportation | 2,898,272 | 2,261,681 | 1,330,414 | | | | |
| Property holding costs | 172,663 | 149,571 | 127,731 | | | | |
| Stock compensation expense | 881,250 | 881,250 | 1,005,223 | | | | |
| General & administrative | 8,592,745 | 4,134,902 | 3,768,250 | | | | |
| Depreciation & amortization | 12,239 | 2,729 | 3,249 | | | | |
| Net operating income (loss) | (15,230,568) | 2,768,551 | 13,185,697 | | | | |
| Foreign currency gain (loss) | (45,177) | 58,426 | 247,712 | | | | |
| Gain on sale of assets | 375,076 | ... | ... | | | | |
| Interest expense | 567,792 | 450,324 | 1,573,125 | | | | |
| Derivative mark-to-market gain (loss) | ... | 1,726,497 | (2,186,912) | | | | |
| Arbitration award expense | ... | ... | 1,111,111 | | | | |
| Other income (expense) | 2,218 | 2,242 | 1,072 | | | | |
| Total other income (expense) | (235,675) | 1,336,841 | (4,622,364) | | | | |
| Income (loss) before income taxes - domestic | ... | 3,221,618 | (10,064,644) | | | | |
| Income (loss) before income taxes - foreign | ... | 883,774 | 18,627,977 | | | | |
| Net income (loss) before taxes | (15,466,243) | 4,105,392 | 8,563,333 | | | | |
| Current federal income taxes | (148,666) | 220,000 | ... | | | | |
| Current foreign income taxes | (170,000) | 170,000 | 28,970 | | | | |
| Total current income taxes | (318,666) | 390,000 | 28,970 | | | | |
| Deferred federal income taxes | (983,296) | (510,629) | ... | | | | |
| Deferred foreign income taxes | 369,223 | (2,459,781) | ... | | | | |
| Total deferred income taxes | (614,073) | (2,970,410) | ... | | | | |
| Provision for income taxes | (932,739) | (2,580,410) | 28,970 | | | | |
| Net income (loss) | (14,533,504) | 6,685,802 | 8,534,363 | | | | |
| Deemed dividend for series C & D preferred | 234,299 | 234,299 | 188,699 | | | | |
| Net income (loss) attributable to common stockholders | (14,767,803) | 6,451,503 | 8,345,664 | | | | |
| Weighted average shares outstanding - basic | 22,705,923 | 19,456,765 | 17,797,528 | | | | |
| Weighted average shares outstanding - diluted | 22,705,923 | 22,890,246 | 17,797,528 | | | | |
| Year end shares outstanding | 23,334,528 | ⁽²⁾ 22,246,654 | 18,091,293 | | | | |
| Net income (loss) per share - basic | \$(0.65) | \$0.33 | \$0.47 | | | | |
| Net income (loss) per share - diluted | \$(0.65) | \$0.29 | \$0.47 | | | | |
| Full-Time Employees (Period End) | 200 | ... | ... | | | | |

⁽¹⁾ As reported by the Company

Recent Dividends:

1. **DynaResource Inc series B preferred.**
No dividends paid.
2. **DynaResource Inc series C senior convertible preferred.**
No dividends paid.
3. **DynaResource Inc series D senior convertible preferred.**
No dividends paid.
4. **DynaResource Inc series A preferred.**
No dividends paid.
5. **DynaResource Inc common.**
No dividends paid.

Annual Dividends:

1. **DynaResource Inc series B preferred.**
No dividends paid.
2. **DynaResource Inc series C senior convertible preferred.**
No dividends paid.
3. **DynaResource Inc series D senior convertible preferred.**
No dividends paid.
4. **DynaResource Inc series A preferred.**
No dividends paid.
5. **DynaResource Inc common.**
No dividends paid.

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|---------------------------|
| Cash & cash equivalents | 5,603,713 | 19,177,138 |
| Accounts receivable | 880,473 | 724,642 |
| Mined tonnage | ... | 2,610,116 |
| Gold-silver concentrates | ... | 110,695 |
| Inventories | 2,089,194 | 2,720,811 |
| Foreign tax receivable | 4,434,958 | 9,355,863 |
| Other current assets | 1,137,162 | 1,145,501 |
| Total current assets | 14,145,500 | 33,123,955 |
| Leasehold improvements | 21,274 | 9,340 |
| Office equipment | 42,483 | 31,012 |
| Office furniture & fixtures | ... | 78,802 |
| Other | 27,063 | ... |
| Sub-total | 115,273 | 119,154 |
| Less: accumulated depreciation & amortization | ... | 119,154 |
| Property & equipment, net | 103,034 | ... |
| Less: accumulated depreciation | 12,239 | ... |
| Right-of-use assets | 848,822 | 550,473 |
| Mining concessions | 24,453 | 4,132,678 |
| Mining Concessions | 4,132,678 | ... |
| Deferred tax asset | 4,264,115 | 2,970,410 |
| Other assets | 175,588 | 165,396 |
| Foreign tax receivable | 11,768,613 | ... |
| Total assets | 35,438,350 | 40,942,912 |
| Accounts payable | 2,768,634 | 2,057,880 |
| Accrued expenses | 7,727,621 | 5,756,961 |
| Customer advances | ... | 9,350,000 |
| Derivative liabilities | 1,797,341 | 2,334,377 |
| Current portion of operating lease payable | 104,117 | 28,868 |
| Current portion of long-term debt | 2,259,432 | ... |
| Installment notes payable | 9,750,000 | 1,968,251 |
| Total current liabilities | 24,407,145 | ⁽¹⁾ 21,334,377 |
| Operating lease payable, less current portion | 825,762 | 558,914 |
| Deferred tax liability | 334,236 | ... |
| Asset retirement obligation | 198,468 | ... |
| Total liabilities | 25,765,611 | 21,893,291 |
| Series C senior convertible preferred stock | 4,337,480 | 4,337,480 |
| Series D senior convertible preferred stock | 1,520,000 | 1,520,000 |
| Series A preferred stock | ... | 1 |
| Common stock | 233,717 | 222,467 |
| Preferred rights | 40,000 | 40,000 |
| Additional paid-in-capital | 61,509,032 | 56,889,031 |
| Treasury stock | 95,023 | 34,773 |
| Accumulated other comprehensive income (loss) | 697,700 | 112,078 |
| Retained earnings (accumulated deficit) | (58,570,167) | (44,036,663) |
| Total stockholders equity (deficit) | 3,815,259 | 13,192,141 |

EACO CORP

Earnings, 6 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------|-------------|-------------|
| Total revenues | 163,590,000 | 153,244,000 |
| Cost & expenses | 153,712,000 | 140,608,000 |
| Operating income | 9,878,000 | 12,636,000 |
| Gains or losses | (21,000) | 621,000 |
| Net before taxes | 9,773,000 | 13,255,000 |
| Income taxes | 2,496,000 | 3,444,000 |
| Net income | 7,277,000 | 9,811,000 |
| Balance for common | 7,239,000 | 9,773,000 |
| Earnings common share | | |
| Primary | \$1.49 | \$2.01 |
| Fully Diluted | \$1.48 | \$2.01 |
| Common Shares: | | |
| Full Diluted | 4,901,590 | 4,901,590 |
| Year-end | 4,861,590 | 4,861,590 |

EASTSIDE DISTILLING INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ⁽¹⁾ 2021 (revised) |
|---|-------------|--------------|----------------------------------|
| Sales | 10,798,000 | 14,327,000 | 12,890,000 |
| Less: customer programs & excise taxes | 299,000 | 444,000 | 496,000 |
| Net sales | 10,499,000 | 13,883,000 | 12,394,000 |
| Cost of sales | 9,438,000 | 11,442,000 | 9,484,000 |
| Gross profit | 1,061,000 | 2,441,000 | 2,910,000 |
| Sales & marketing expenses | 1,599,000 | 2,625,000 | 2,614,000 |
| General & administrative expenses | 4,646,000 | 6,407,000 | 6,777,000 |
| Gain (loss) on disposal of property & equipment | 364,000 | (58,000) | (419,000) |
| Total operating expenses | 5,881,000 | 9,090,000 | 9,810,000 |
| Income (loss) from operations | (4,820,000) | (6,649,000) | (6,900,000) |
| Interest expense | 1,108,000 | 2,216,000 | 1,254,000 |
| Impairment loss | 364,000 | 7,453,000 | ... |
| Other income | 78,000 | 52,000 | 2,100,000 |
| Other income (expense) | (1,321,000) | ... | ... |
| Total other income (expense), net | (2,715,000) | (9,617,000) | 846,000 |
| Income (loss) before income taxes | (7,535,000) | (16,266,000) | (6,054,000) |
| Net income (loss) from continuing operations | ... | (16,266,000) | (6,054,000) |
| Net income (loss) from discontinued operations | ... | ... | 3,858,000 |
| Net income (loss) | (7,535,000) | (16,266,000) | (2,196,000) |
| Preferred stock | | | |

| | | | |
|---|-------------|--------------|-------------|
| dividends | 150,000 | 150,000 | 27,000 |
| Deemed dividend-warrant price protection-revaluation adjustment | ... | ... | 2,288,000 |
| Net income (loss) attributable to common shareholders | (7,685,000) | (16,416,000) | (4,511,000) |
| Weighted average shares outstanding - basic | 1,091,000 | 766,850 | 635,400 |
| Weighted average shares outstanding - diluted | 1,091,000 | 766,850 | 635,400 |
| Year end shares outstanding | 1,705,987 | 809,963 | 739,572 |
| Net earnings (loss) per common share - basic | \$(7.04) | \$(21.40) | \$(7.00) |
| Net earnings (loss) per common share - diluted | \$(7.04) | \$(21.40) | \$(7.00) |
| Number of full time employees | ... | ... | 71 |
| Number of part time employees | ... | ... | 2 |
| Total number of employees | ... | 50 | ... |
| Number of common stockholders | 76 | 78 | 76 |
| Basic EPS Excluding ExtraOrdinary Items | \$(7.04) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(7.04) | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-20 stock split, May 15, 2023; [□] As of March 30, 2022; [□] As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash | 403,000 | 723,000 |
| Trade receivables, net | 559,000 | 876,000 |
| Raw materials | 2,253,000 | 3,127,000 |
| Finished goods | 959,000 | 1,315,000 |
| Inventories | 3,212,000 | 4,442,000 |
| Prepaid expenses & current assets | ... | 579,000 |
| Prepaid expenses and other current assets | 363,000 | ... |
| Total current assets | 4,537,000 | 6,620,000 |
| Furniture & fixtures | 3,410,000 | 4,093,000 |
| Digital can printer | 3,649,000 | 4,216,000 |
| Leasehold improvements | 1,529,000 | 1,529,000 |
| Vehicles | 156,000 | 222,000 |
| Support Digital can printer | 695,000 | ... |
| Total cost | 9,439,000 | 10,060,000 |
| Less accumulated depreciation | 4,671,000 | 4,319,000 |
| Property & equipment, net | 4,768,000 | 5,741,000 |
| Right-of-use assets | 2,602,000 | 2,988,000 |
| Intangible assets, net | 5,005,000 | 5,758,000 |
| Product branding | 396,000 | 400,000 |
| Future proceeds related to installment sales of equipment | 276,000 | ... |
| Deposits | 240,000 | 256,000 |
| Less: accumulated amortization | 344,000 | 287,000 |
| Other assets, net | 568,000 | 369,000 |
| Total assets | 17,480,000 | 21,476,000 |
| Accounts payable | 2,076,000 | 1,728,000 |
| Accrued liabilities | 575,000 | 1,509,000 |
| Deferred revenue | 88,000 | 18,000 |
| Current portion of secured credit facilities, net of debt issuance costs | ... | 3,442,000 |

| | | |
|---|--------------|--------------|
| Current portion of note payable, related party | 92,000 | 4,598,000 |
| Other current liabilities, related party | ... | 725,000 |
| Current portion of notes payable | 486,000 | ... |
| Current portion of lease liabilities | 888,000 | 991,000 |
| Total current liabilities | 4,205,000 | 13,011,000 |
| Lease liabilities, net of current portion | 1,824,000 | 2,140,000 |
| Note payable, related party | ... | 92,000 |
| Secured trade credit facility, net of debt issuance costs | 342,000 | ... |
| Notes payable, net of current portion | ... | 7,749,000 |
| Notes payable - less current portion and debt discount | 7,556,000 | ... |
| Secured credit facilities, related party | 2,700,000 | ... |
| Total liabilities | 16,627,000 | 22,992,000 |
| Common stock | 171 | 2,000 |
| Additional paid-in capital | 83,559,000 | 73,503,000 |
| Accumulated deficit | (82,706,000) | ... |
| Retained earnings (accumulated deficit) | ... | (75,021,000) |
| Total Eastside Distilling, Inc. stockholders' equity | 853,000 | (1,516,000) |
| Total stockholders' equity (deficit) | 853,000 | (1,516,000) |

Recent Dividends:

1. Eastside Distilling Inc series B convertible preferred.

No dividends paid.

2. Eastside Distilling Inc series A convertible preferred.

No dividends paid.

3. Eastside Distilling Inc series C convertible preferred.

No dividends paid.

4. Eastside Distilling Inc common.

No dividends paid.

Annual Dividends:

1. Eastside Distilling Inc series B convertible preferred.

No dividends paid.

2. Eastside Distilling Inc series A convertible preferred.

No dividends paid.

3. Eastside Distilling Inc series C convertible preferred.

No dividends paid.

4. Eastside Distilling Inc common.

No dividends paid.

ECA MARCELLUS TRUST I

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Royalty income | 2,884,833 | 11,622,745 | 6,295,004 |
| Net proceeds to trust | 2,884,833 | 11,622,745 | 6,295,004 |
| General & administrative expense | 1,169,560 | 1,123,128 | 1,107,241 |
| Interest income | 119,685 | 34,227 | 162 |
| Interest withheld on cash reserves | (88,573) | ... | ... |
| Cash reserves withheld (released) by trustee | 360,000 | 404,389 | 419,061 |
| Interest withheld on cash reserves | ... | 17,096 | 106 |
| Distributable income available to unitholders | 1,386,385 | 10,112,359 | 4,768,758 |
| Year end units outstanding | 17,605,000 | 17,605,000 | 17,605,000 |
| Distributable income per common unit | \$0.08 | \$0.57 | \$0.27 |
| Number of | ... | ... | ... |

| | | | |
|---|------------|-----|-----|
| unitholders | 24 | 25 | 26 |
| Income from cont operations before income tax | 1,386,385 | ... | ... |
| Weighted average shares outstanding | 17,605,000 | ... | ... |
| Weighted average shares outstanding - diluted | 17,605,000 | ... | ... |
| Earnings per share from continuing operations | \$0.08 | ... | ... |
| Earnings per share from continuing operations | \$0.08 | ... | ... |
| Earnings per share - net income - diluted | \$0.08 | ... | ... |
| Dividends per common share | \$0.17 | ... | ... |

[□] As of March 21, 2023; [□] As of March 26, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash | 2,660,054 | 2,169,420 |
| Royalty income receivable | 686,504 | 2,387,846 |
| Royalty interest in gas properties | 352,100,000 | 352,100,000 |
| Accumulated amortization | 340,685,825 | 339,477,839 |
| Net royalty interest in gas properties | 11,414,175 | 12,622,161 |
| Total assets | 14,760,733 | 17,179,427 |
| Distributions payable to unitholders | 524,350 | 2,187,332 |
| Total liabilities | ... | 2,187,332 |
| Trust corpus; 17,605,000 common units authorized, issued and outstanding | 14,236,383 | ... |
| Trust corpus | 14,236,383 | 14,992,095 |
| Total Equity | 14,236,383 | ... |

Recent Dividends:

1. ECA Marcellus Trust I common.

No dividends paid.

2. ECA Marcellus Trust I subordinated.

No dividends paid.

Annual Dividends:

1. ECA Marcellus Trust I common.

No dividends paid.

2. ECA Marcellus Trust I subordinated.

No dividends paid.

ECB BANCORP INC MARYLAND

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

| | 2023 | 2022 | 2021 |
|---|--------|--------|--------|
| Net gain on sales of loans | 21 | 84 | ... |
| Interest & fees on loans | 48,330 | 26,954 | 21,319 |
| Interest & dividends on securities | 2,701 | 1,488 | 1,012 |
| Other interest income | 3,745 | 715 | 44 |
| Total interest & dividend income | 54,776 | 29,157 | 22,375 |
| Interest on deposits | 21,413 | 4,566 | 3,546 |
| Interest on Federal Home Loan Bank advances | ... | ... | 135 |
| Interest on federal funds purchased | ... | 1 | ... |
| Interest on Federal Home Loan Bank advances | 8,573 | 948 | ... |
| Total interest expense | 29,986 | 5,515 | 3,681 |
| Net interest & dividend income | 24,790 | 23,642 | 18,694 |

| | | | | | | | | | |
|--|--------|---------|---------|---|-----------|-----------|---|-----------|------------|
| Provision for loan losses | 803 | 2,940 | 360 | securities (at fair value) | 5,003 | 5,001 | Certificates of deposit | 498,503 | ... |
| Net interest & dividend income after provision for loan losses | 23,987 | 20,702 | 18,334 | Debt securities issued by U.S. government-sponsored enterprises | 10,225 | 11,213 | Interest-bearing | 789,872 | 633,246 |
| Customer service fees | 508 | 446 | 393 | Mortgage-backed securities | 49,445 | 51,864 | Interest-bearing | 868,214 | 718,149 |
| Income from bank-owned life insurance | 479 | 828 | 355 | Corporate bonds | 14,408 | 11,612 | Federal Home Loan Bank advances | 234,000 | 174,000 |
| Net gain on sales of loans | ... | ... | 446 | U.S. Treasury securities | 2,901 | 2,902 | Other liabilities | 13,220 | 9,583 |
| Other income | 44 | 43 | ... | Investments in held-to-maturity securities, at cost | ... | 77,591 | Total liabilities | 1,115,434 | 901,732 |
| Salaries & employee benefits | 11,679 | 9,928 | 9,599 | Federal Home Loan Bank stock, at cost | 9,892 | 7,293 | Common Stock | 93 | ... |
| Director compensation | 581 | 429 | 430 | Real estate loan - one-to four-family residential | 1,039,214 | 355,381 | Common stock, par value | ... | 92 |
| Occupancy & equipment expense | 941 | 753 | 721 | Real estate loan - multi-family | ... | 241,951 | Additional paid-in capital | 87,431 | 89,286 |
| Data processing | 1,093 | 850 | 684 | Real estate loan - commercial | ... | 156,212 | Retained earnings | 83,854 | 80,076 |
| Computer software & licensing fees | 286 | 259 | 253 | Real estate loan - home equity lines of credit & loans | 173 | 27,783 | Net unrealized holding gains on securities available-for-sale, net of tax | ... | 9 |
| Advertising & promotions | 794 | 752 | 648 | Real estate loan - construction | ... | 107,317 | Unrecognized SERP credits (costs), net of tax | ... | 149 |
| Professional fees | 1,355 | 846 | 482 | Other loans - commercial loans | ... | 4,266 | Unrecognized director fee continuation plan credits (costs), net of tax | ... | 91 |
| Federal Deposit Insurance Corporation assessment | 793 | 225 | 156 | Other loans - consumer loans | ... | 222 | Accumulated other comprehensive income (loss) | 129 | 249 |
| Charitable contributions | 17 | 3,256 | 54 | Total other loans | ... | 893,132 | Unallocated common shares held by the employee stock ownership plan | ... | 6,973 |
| Other expense | 1,515 | 1,309 | 1,058 | Less: deferred loan fees | ... | 258 | Unallocated common shares held by the Employee Stock Ownership Plan | (6,606) | ... |
| Total noninterest expense | 19,054 | 18,607 | 14,085 | Less: allowance for loan losses | 8,591 | 7,200 | Stockholders' equity | 164,901 | 162,730 |
| Income (loss) before income tax expense | 5,985 | 3,496 | 5,471 | Loans, net of allowance for loan losses | ... | 885,674 | Total Equity | 164,901 | ... |
| Current federal income taxes | 1,179 | 1,582 | 1,757 | Land | ... | 594 | Recent Dividends: | | |
| Current state income taxes | 461 | 696 | 789 | Buildings & improvements | 5,699 | 5,699 | 1. ECB Bancorp Inc Maryland common. | | |
| Current income taxes | 1,640 | 2,278 | 2,546 | Leasehold improvements | ... | 301 | No dividends paid. | | |
| Deferred federal income taxes | (67) | (1,017) | (759) | Furniture & equipment | ... | 1,554 | Annual Dividends: | | |
| Deferred state income taxes | (44) | (485) | (358) | Leasehold improvements | ... | 345 | 1. ECB Bancorp Inc Maryland common. | | |
| Deferred income taxes | (111) | (1,502) | (1,117) | Furniture and equipment | 1,724 | ... | No dividends paid. | | |
| Income taxes | 1,529 | 776 | 1,429 | Property, plant & equipment, gross | 8,359 | 8,148 | EDIBLE GARDEN AG INC | | |
| Net income (loss) | 4,456 | 2,720 | 4,042 | Less: accumulated depreciation & amortization | ... | 4,450 | Annual Report | | |
| Weighted average shares outstanding - basic | 8,466 | 8,456 | ... | Accumulated depreciation and amortization | 4,605 | ... | Consolidated Income Statement, Years Ended Dec. 31 | | |
| Weighted average shares outstanding - diluted | 8,524 | 8,456 | ... | Property, plant & equipment, net | 3,754 | 3,698 | ((\$000): | | |
| Year end shares outstanding | 9,292 | 9,175 | ... | Accrued interest receivable | 3,766 | 2,632 | 2023 | 2022 | 2021 |
| Earnings (loss) per share - basic | \$0.53 | \$0.32 | ... | Deferred tax asset, net | 4,767 | 4,344 | Revenue | 14,049 | ... |
| Earnings (loss) per share - diluted | \$0.52 | \$0.32 | ... | Bank-owned life insurance | ... | 14,067 | Revenue | 14,049 | 11,552 |
| Number of full time employees | 68 | ... | ... | Other assets | 2,877 | 1,812 | Cost of goods sold | 13,227 | 11,188 |
| Number of common stockholders | 404 | ... | ... | Bank-owned life insurance | 14,472 | ... | Gross profit | 822 | 364 |
| Total number of employees | 68 | ... | ... | Investments in held-to-maturity securities (fair values of \$65,556 at 31, 2021 and \$54,726 at 31, 2020) | 76,979 | ... | Selling, general & administrative expenses | 10,009 | 9,368 |
| | | | | Loans, net of allowance for losses of \$4,236 as of 31, 2021 and \$3,876 as of 31, 2020 | 1,039,789 | ... | Income (loss) from operations | (9,873) | (9,004) |
| | | | | Loans - Commercial & Industrial - Gross | 9,219 | ... | Interest expense, net | 390 | 2,033 |
| | | | | Unearned Income - Customers | 226 | ... | Gain (loss) from extinguishment of debt | 70 | (826) |
| | | | | Loans, net of allowance for losses of \$4,236 as of 31, 2021 and \$3,876 as of 31, 2020 | 1,048,606 | ... | Other income (loss) | (5) | 590 |
| | | | | Total assets | 1,280,335 | 1,064,462 | Impairment of tangible assets | 686 | ... |
| | | | | Noninterest-bearing deposits | 78,342 | 84,903 | Total other income (expense) | (315) | (3,449) |
| | | | | Interest-bearing demand deposits | 22,158 | 28,942 | Net income (loss) | (10,188) | (12,453) |
| | | | | Regular savings deposits & other deposits | 137,848 | 148,351 | Weighted average shares outstanding - basic | 165 | 13 |
| | | | | Money market deposits | ... | 136,106 | - diluted | 165 | 13 |
| | | | | Certificates of deposit | ... | 319,847 | Year end shares outstanding | 285 | 18 |
| | | | | Money market deposits | 131,363 | ... | Net income (loss) per common share - basic | \$(61.60) | \$(973.60) |
| | | | | | | | Net income (loss) per common share - diluted | \$(61.60) | \$(973.60) |
| | | | | | | | Number of full time employees | 116 | 77 |
| | | | | | | | | | 44 |

Reclassified to conform 2023 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|-----------------------------------|---------|--------|-----------|
| Cash & due from banks | 3,786 | 3,123 | (revised) |
| Short-term investments | 115,250 | 58,927 | |
| Total cash & cash equivalents | 119,036 | 62,050 | |
| Interest-bearing time deposits | ... | 300 | |
| Investments in available-for-sale | | | |

| | | | | | | | | | |
|--|----------|-------|----|--|----------|----------|--|---------|---------|
| Number of part time employees..... | | | | liabilities..... | 4,040 | 4,316 | Lab equipment..... | 30,000 | 30,000 |
| Number of common stockholders..... | 1,618 | 1,618 | 10 | Total liabilities..... | 6,944 | 9,145 | Computer & office equipment..... | 154,000 | 149,000 |
| Income from cont operations before income tax..... | (10,188) | | | Common stock..... | 1 | 1 | Furniture & fixtures..... | 78,000 | 61,000 |
| Total number of employees..... | 116 | | | Additional paid-in capital..... | 29,971 | 17,891 | Leasehold improvements..... | 188,000 | 188,000 |
| | | | | Accumulated deficit..... | (30,260) | | Construction in progress..... | 14,000 | 29,000 |
| | | | | Retained earnings (accumulated deficit)..... | | (20,072) | Property & equipment, gross..... | 464,000 | 457,000 |
| | | | | Total stockholders' equity (deficit)..... | (288) | (2,180) | Less: accumulated depreciation & amortization..... | 324,000 | 216,000 |
| | | | | Total Equity..... | (288) | | Property & equipment, net..... | 140,000 | 241,000 |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-20 stock split, April 5, 2024; ³ Adjusted for 1-for-30 stock split, January 26, 2023; ⁴ Adjusted for 1-for-5 stock split, May 3, 2022; ⁵ Shares increased due to the effect of issuance of common stock in public offering, conversion of preferred series A stock to common stock, conversion of debt to common stock; ⁶ As is; ⁷ As of March 22, 2023; ⁸ As of May 5, 2022; ⁹ Approximately

Recent Dividends:**1. Edible Garden AG Inc common.**

No dividends paid.

Annual Dividends:**1. Edible Garden AG Inc common.**

No dividends paid.

EFFECTOR THERAPEUTICS INC Annual Report**Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | | 2023 | 2022 | 2021 | | 2023 | 2022 | 2021 |
|--|---------|---------|--|---|---------------------|---------------------|-------------------|---|-------|-------|
| Cash..... | 510 | 110 | | Grant revenue..... | 3,553,000 | 1,430,000 | | Revenues..... | | |
| Accounts receivable, gross..... | 138,107 | 1,204 | | Research & development..... | 22,919,000 | 23,313,000 | 19,956,000 | Net sales..... | 16 | |
| Reserve for doubtful accounts..... | 136,858 | 99 | | General & administrative..... | 10,925,000 | 12,643,000 | 13,371,000 | Revenues..... | 16 | 30 |
| Accounts receivable, net..... | 1,249 | 1,105 | | Total operating expenses..... | 33,844,000 | 35,956,000 | 33,327,000 | Selling, general & administrative expenses..... | 2,052 | 2,041 |
| Raw materials..... | 341 | 298 | | Operating income (loss)..... | (33,844,000) | (32,403,000) | (31,897,000) | Other operating expenses, net..... | 295 | 113 |
| Work-in-progress..... | 258 | 288 | | Interest income..... | 972,000 | 439,000 | 6,000 | Operating profit..... | | |
| Inventory..... | 678 | | | Interest expense..... | 2,919,000 | 2,251,000 | 1,764,000 | | | |
| Inventories - Finished Goods..... | 79 | | | Other income (expense), net..... | (26,000) | (574,000) | 1,035,000 | | | |
| Inventory, net..... | | 586 | | Change in fair value of earn-out liability..... | 6,000 | 12,124,000 | 48,910,000 | | | |
| Prepaid expenses & other current assets..... | 210 | 62 | | Loss (gain) on debt extinguishment..... | | | (492,000) | | | |
| Total current assets..... | 2,647 | 1,863 | | Total other income (expense)..... | (1,967,000) | 9,738,000 | 47,695,000 | | | |
| Furniture & equipment..... | 1,276 | 1,408 | | Income before income taxes..... | (35,811,000) | | | | | |
| Computer hardware..... | 5,243 | 4 | | Net income (loss)..... | (35,811,000) | (22,665,000) | 15,798,000 | | | |
| Leasehold improvements..... | 3,121 | 5,192 | | Net income attributable to common shareholders..... | | (22,665,000) | 15,798,000 | | | |
| Vehicles..... | 456 | 304 | | Weighted average shares outstanding - basic..... | 2,186,954 | 1,647,190 | 604,234 | | | |
| Land..... | 202 | 202 | | Weighted average shares outstanding - diluted..... | 2,186,954 | 1,647,190 | 1,440,163 | | | |
| Construction in progress..... | 182 | 4 | | Year end shares outstanding..... | 2,982,679 | 1,667,615 | 1,615,599 | | | |
| Computer hardware..... | 6 | | | Net earnings (loss) per share - basic..... | \$(16.37) | \$(13.75) | \$26.25 | | | |
| Subtotal..... | 7,114 | | | Net earnings (loss) per share - diluted..... | \$(16.37) | \$(13.75) | \$11.00 | | | |
| Less: accumulated depreciation..... | 1,350 | 2,223 | | Number of full time employees..... | | 15 | | | | |
| Property, equipment & leasehold improvements, net..... | 3,893 | 4,891 | | Number of part time employees..... | | 0 | | | | |
| Intangible assets, net..... | 47 | 50 | | Total number of employees..... | | | | | | |
| Other assets..... | 69 | 161 | | Number of common stockholders..... | 53 | 128 | 122 | | | |
| Total assets..... | 6,656 | 6,965 | | | | | | | | |
| Accounts payable..... | 1,233 | 1,728 | | | | | | | | |
| Accrued expenses..... | 3 | 542 | | | | | | | | |
| Accrued interest payable..... | 80 | 185 | | | | | | | | |
| Accrued payroll..... | 270 | 187 | | | | | | | | |
| Accrued vacation..... | | 53 | | | | | | | | |
| Current lease liability..... | 34 | 92 | | | | | | | | |
| Accounts payable & other accrued expenses..... | 2,517 | 2,787 | | | | | | | | |
| Short-term debt..... | 387 | 2,042 | | | | | | | | |
| Accrued interest payable..... | 32 | | | | | | | | | |
| Employee retention credit funds..... | 865 | | | | | | | | | |
| Total current liabilities..... | 2,904 | 4,829 | | | | | | | | |
| Secured promissory note..... | | 3,783 | | | | | | | | |
| Evergreen private placement..... | | 1,022 | | | | | | | | |
| Small Business Administration ("SBA") loan..... | | 150 | | | | | | | | |
| NJD Investments, LLC promissory note..... | | 1,155 | | | | | | | | |
| Vehicle loan..... | | 244 | | | | | | | | |
| Total gross debt..... | | 6,354 | | | | | | | | |
| Less: gross short term debt..... | | (2,042) | | | | | | | | |
| Less: debt discount..... | | (30) | | | | | | | | |
| Long-term debt, net of discounts..... | 4,040 | 4,282 | | | | | | | | |
| Long-term lease liabilities..... | | 34 | | | | | | | | |
| Total long-term | | | | | | | | | | |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-25 stock split, January 12, 2024; ³ As of February 28, 2023; ⁴ As of February 28, 2022; ⁵ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|------------|------------|
| Cash & cash equivalents..... | 14,875,000 | 8,708,000 |
| Short-term investments..... | 3,495,000 | 17,602,000 |
| Prepaid expenses & other current assets..... | 1,468,000 | 1,704,000 |
| Total current assets..... | 19,838,000 | 28,014,000 |

Recent Dividends:**1. eFFECTOR Therapeutics Inc class B common.**

No dividends paid.

2. eFFECTOR Therapeutics Inc class A common.

No dividends paid.

3. eFFECTOR Therapeutics Inc common.

No dividends paid.

Annual Dividends:**1. eFFECTOR Therapeutics Inc class B common.**

No dividends paid.

2. eFFECTOR Therapeutics Inc class A common.

No dividends paid.

3. eFFECTOR Therapeutics Inc common.

No dividends paid.

ELAH HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | | | |
|---|-------|-------|-------|
| Revenues..... | | | |
| Net sales..... | 16 | | |
| Revenues..... | 16 | 21 | 30 |
| Selling, general & administrative expenses..... | 2,052 | 2,076 | 2,041 |
| Other operating expenses, net..... | 295 | 678 | 113 |
| Operating profit..... | | | |

| | | | |
|---|----------------|----------------|----------------|
| (loss) | (2,331) | (2,733) | (2,124) |
| Income (loss) from continuing operations before income taxes - U.S. ... | ... | ... | (2,124) |
| Income (loss) from continuing operations before income taxes | (2,331) | (2,733) | (2,124) |
| Income (loss) from continuing operations | (2,331) | (2,733) | (2,124) |
| Earnings (loss) from discontinued operations, net of income taxes | ... | 380 | 258 |
| Total discontinued operations | (91) | ... | ... |
| Net earnings (loss) .. | (2,422) | (2,353) | (1,866) |
| Net earnings (loss) available to common stockholders | ... | ... | (1,866) |
| Weighted average shares outstanding - basic | 739 | 739 | 739 |
| Weighted average shares outstanding - diluted | 739 | 739 | 739 |
| Year end shares outstanding | 739 | 739 | 739 |
| Earnings (loss) per share from continuing operations - basic | \$(3.16) | \$(3.70) | \$(2.87) |
| Earnings per share-inc from discontinued oper | \$(0.12) | \$0.51 | ... |
| Earnings (loss) per share from discontinued operations - basic | \$(0.12) | \$0.51 | \$0.35 |
| Net earnings (loss) per share - basic | \$(3.28) | \$(3.18) | \$(2.52) |
| Earnings (loss) per share from continuing operations - diluted | \$(3.16) | \$(3.70) | \$(2.87) |
| Earn per share-inc from discount opers - diluted | \$(0.12) | \$0.51 | ... |
| Earnings (loss) per share from discontinued operations - diluted | \$(0.12) | \$0.51 | \$0.35 |
| Net earnings (loss) per share - diluted | \$(3.28) | \$(3.18) | \$(2.52) |
| Number of common stockholders | 189 | 199 | 202 |

As of March 11, 2022

| | | | |
|---|----------|----------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 9,252 | 11,575 | |
| Prepaid expenses & other current assets | 134 | 67 | |
| Current assets of discontinued operations | 405 | 402 | |
| Total current assets | 9,792 | 12,044 | |
| Total assets | 9,959 | 12,279 | |
| Trade payables | 147 | 41 | |
| Accrued liabilities | ... | 517 | |
| Total current liabilities | 660 | 558 | |
| Warrant liability | 513 | ... | |
| Total liabilities | 660 | 558 | |
| Common stock | 1 | 1 | |
| Additional paid-in capital | 36,978 | 36,978 | |
| Accumulated deficit | ... | (25,258) | |
| Retained earnings (accumulated deficit) | (27,680) | ... | |
| Total stockholders' | | | |

equity - Elah holdings, Inc. 9,299 11,721
 Total stockholders' equity (deficit)

Recent Dividends:
1. Elah Holdings Inc common.
 No dividends paid.
2. Elah Holdings Inc series B redeemable preferred.
 No dividends paid.

Annual Dividends:
1. Elah Holdings Inc common.
 No dividends paid.
2. Elah Holdings Inc series B redeemable preferred.
 No dividends paid.

ELEDON PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | | | |
|---|-----------------|-----------------|-----------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Research & development expenses | 30,312 | 27,080 | 23,735 |
| General & administrative expenses | 12,688 | 12,700 | 13,132 |
| Goodwill impairment expenses | ... | 48,648 | ... |
| Total operating expenses | 43,000 | 88,428 | 36,867 |
| Income (loss) from operations | (43,000) | (88,428) | (36,867) |
| Other income, net | 2,674 | 462 | 7 |
| Income (loss) before income tax expense (benefit) - U.S. | ... | (88,159) | (37,055) |
| Income (loss) before income tax expense (benefit) - non - U.S. | ... | 193 | 195 |
| Income (loss) before income tax expense (benefit) | (40,326) | (87,966) | (36,860) |
| Deferred federal income taxes provision (benefit) ... | ... | ... | (2,746) |
| Deferred state income taxes provision (benefit) ... | ... | ... | 392 |
| Deferred income taxes provision (benefit) | ... | ... | (2,354) |
| Income tax expense (benefit) | ... | ... | (2,354) |
| Net income (loss) | (40,326) | (87,966) | (34,506) |
| Weighted average shares outstanding - basic | 24,619 | 14,285 | 14,820 |
| Weighted average shares outstanding - diluted | 24,619 | 14,285 | 14,820 |
| Year end shares outstanding | 24,213 | 13,777 | 14,307 |
| Net earnings (loss) per share - basic | \$(1.64) | \$(6.16) | \$(2.33) |
| Net earnings (loss) per share - diluted | \$(1.64) | \$(6.16) | \$(2.33) |
| Number of full time employees | 20 | 17 | 12 |
| Total number of employees | 20 | 17 | 12 |
| Number of common stockholders | 44 | 21 | 35 |

ELICIO THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | | | |
|---|----------|----------|-----------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Contract revenue | ... | 2,301 | 27,506 |
| Grant revenue | ... | ... | 806 |
| Total revenue | ... | 2,301 | 28,312 |
| Cost of grant revenue | ... | ... | 433 |
| Research & development | 23,849 | 18,100 | 48,698 |
| General & administrative | 11,896 | 14,637 | 18,488 |
| Restructuring & impairment expenses . | ... | 9,185 | ... |
| Total operating expenses | 35,745 | 41,922 | 67,619 |
| Income (loss) from operations | (35,745) | (39,621) | (39,307) |
| Change in fair value of warrant liability | (2) | 95 | (2,919) |
| Change in fair | | | |

| | | |
|---|-----------|-----------|
| Prepaid insurance | 624 | 823 |
| Prepaid clinical | 4,128 | 2,115 |
| Prepaid other | 185 | 143 |
| Other current assets | 90 | 28 |
| Prepaid expenses & other current assets | 5,027 | 3,109 |
| Short-term investments | 46,490 | ... |
| Total current assets | 56,129 | 59,518 |
| Operating lease asset, net | 365 | 739 |
| In-process research & development | 32,386 | 32,386 |
| Other assets | 186 | 150 |
| Total assets | 89,066 | 92,793 |
| Accounts payable | 967 | 2,200 |
| Current operating lease liability | 383 | 363 |
| Accrued compensation & related expenses | 2,003 | 1,909 |
| Accrued clinical | 451 | 1,826 |
| Accrued professional services | 47 | 65 |
| Other accrued expenses | ... | 112 |
| Accrued other | 44 | ... |
| Accrued expenses & other liabilities | 2,545 | 3,912 |
| Total current liabilities | 3,895 | 6,475 |
| Deferred tax liability | 1,752 | 1,752 |
| Non-current operating lease liability | ... | 383 |
| Total liabilities | 5,647 | 8,610 |
| Common stock | 24 | 14 |
| Additional paid-in capital | 326,586 | 287,034 |
| Retained earnings (accumulated deficit) | (243,191) | (202,865) |
| Total stockholders' equity (deficit) | 83,419 | 84,183 |
| Total Equity | 83,419 | ... |

Recent Dividends:
1. Eledon Pharmaceuticals Inc common.
 No dividends paid.
2. Eledon Pharmaceuticals Inc series X non-voting convertible preferred.
 No dividends paid.
3. Eledon Pharmaceuticals Inc series X1 non-voting convertible preferred.
 No dividends paid.

Annual Dividends:
1. Eledon Pharmaceuticals Inc common.
 No dividends paid.
2. Eledon Pharmaceuticals Inc series X non-voting convertible preferred.
 No dividends paid.
3. Eledon Pharmaceuticals Inc series X1 non-voting convertible preferred.
 No dividends paid.

ELICIO THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | | | |
|---|----------|----------|-----------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Contract revenue | ... | 2,301 | 27,506 |
| Grant revenue | ... | ... | 806 |
| Total revenue | ... | 2,301 | 28,312 |
| Cost of grant revenue | ... | ... | 433 |
| Research & development | 23,849 | 18,100 | 48,698 |
| General & administrative | 11,896 | 14,637 | 18,488 |
| Restructuring & impairment expenses . | ... | 9,185 | ... |
| Total operating expenses | 35,745 | 41,922 | 67,619 |
| Income (loss) from operations | (35,745) | (39,621) | (39,307) |
| Change in fair value of warrant liability | (2) | 95 | (2,919) |
| Change in fair | | | |

As is; As of March 29, 2023; As of March 21, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | |
|-------------------------------|-------|--------|
| | 2023 | 2022 |
| Cash & cash equivalents | 4,612 | 56,409 |

| | | | | | | | | | | |
|--|----------|------------|-----------|---|-----------|-----------|---|-------------|-------------|--------------|
| value of convertible notes | ... | ... | (7,469) | Advanced Professional fees | 300 | ... | Rent - related party | 58,428 | 56,931 | 59,144 |
| Change in fair value of series C convertible preferred stock | ... | ... | (3,592) | Total current assets | 16,348 | 51,430 | Bad debt expense | 3,113 | 17,070 | ... |
| Foreign exchange transaction gain (loss) | 204 | (237) | (245) | Equipment | 1,574 | 866 | Depreciation & amortization | 53,404 | 48,319 | ... |
| Gain (loss) upon debt extinguishment | 605 | ... | 905 | Furniture & fixtures | 242 | 34 | Other general & administrative costs | 166,241 | 183,796 | 157,076 |
| Gain (loss) in equity method investment | ... | 151 | (99) | Leasehold improvements | 132 | 68 | Total operating expenses | 2,143,175 | 2,300,442 | 1,420,841 |
| Interest income (expense), net | 373 | 805 | (1,847) | Property & equipment, gross | 1,948 | 968 | Income (loss) from operations | (274,818) | (324,389) | (53,592) |
| Change in fair value of embedded derivatives | 429 | ... | ... | Less: accumulated depreciation | 1,231 | 695 | Foreign currency translation adjustment | (6,128) | 9,101 | ... |
| Interest expense | 1,059 | ... | ... | Property & equipment, net | 717 | 273 | Other income | 90,125 | 117,642 | ... |
| Total other income (expense) | 550 | 814 | (15,266) | Right of use assets | 6,563 | 152 | Government subsidy | ... | ... | 36,712 |
| Net income (loss) | (35,195) | ⊠(38,807) | (54,573) | Investments in related parties | ... | 874 | Loss from conversion of preferred stock to common stock | ... | ... | 43,147,786 |
| Net income (loss) attributable to common stockholders | ... | (38,807) | (54,573) | Other assets | 685 | 61 | Total other income (expense) | ... | 126,743 | (43,111,074) |
| Weighted average shares outstanding - basic | 5,056 | ⊠3,004 | 2,824 | Other long-term prepaid assets | 2,833 | ... | Net income (loss) before income tax | (190,821) | (197,646) | (43,164,666) |
| Weighted average shares outstanding - diluted | 5,056 | ⊠3,004 | 2,824 | Total assets | 27,146 | 52,790 | Current foreign provision (benefit) for income tax | 29,621 | 30,995 | ... |
| Year end shares outstanding | 9,604 | ⊠3,011 | ⊠2,996 | Accounts payable | 4,369 | 2,720 | Prior year foreign provision (benefit) for income tax | ... | 10,217 | 3,142 |
| Net earnings (loss) per share - basic | \$(6.96) | ⊠\$(12.90) | \$(19.30) | Accrued compensation | 1,849 | 112 | Income Taxes - Foreign - Current | 2,285 | ... | ... |
| Net earnings (loss) per share - diluted | \$(6.96) | ⊠\$(12.90) | \$(19.30) | Accrued restructuring costs | ... | 1,572 | Total current tax provision (benefit) | 31,906 | 41,212 | 3,142 |
| Number of full time employees | 32 | ⊠3 | ⊠71 | Accrued direct research expenses | ... | 774 | Provision for income taxes expense (benefit) | 31,906 | 41,212 | ⊠74 |
| Number of part time employees | ... | ⊠9 | ... | Accrued operating expenses | ... | 111 | Net income (loss) | (222,727) | (238,858) | (43,164,740) |
| Number of common stockholders | 245 | ⊠136 | ⊠150 | Accrued interest | 3,757 | ... | Weighted average shares outstanding - basic | 414,448,757 | 414,059,168 | 306,360,531 |
| Foreign currency translation adjustments | ... | 189 | 230 | Accrued Expenses - Balancing value | 1,908 | ... | Weighted average shares outstanding - diluted | 414,448,757 | 414,059,168 | 306,360,531 |
| Income from cont operations before income tax | (35,195) | ... | ... | Lease liability - current | 910 | 994 | Year end shares outstanding | 414,448,757 | 414,448,757 | ⊠406,548,757 |
| Federal | 7,743 | ... | ... | Financing obligation - current | 694 | 67 | Net income (loss) per common share - basic | ... | \$0.00 | \$(0.14) |
| State | 3,116 | ... | ... | Warrant liability | 11 | 19 | Net income (loss) per common share - diluted | ... | \$0.00 | \$(0.14) |
| Income Taxes - Other - Deferred | (10,859) | ... | ... | Unvested option exercise liability, current | 25 | ... | Number of full time employees | 20 | 23 | 10 |
| Total number of employees | 32 | ... | ... | Total current liabilities | 9,766 | 6,369 | Number of common stockholders | 87 | 87 | ⊠87 |
| | | | | Lease liability - noncurrent | 6,007 | 2,481 | Total number of employees | 20 | ... | ... |
| | | | | Financing obligation - noncurrent | ... | 168 | | | | |
| | | | | Total liabilities | 15,773 | 9,018 | | | | |
| | | | | Common stock | 96 | 301 | | | | |
| | | | | Treasury stock, at cost, 14,455 and no shares outstanding as of 31, 2023 and 2022, respectively | 150 | ... | | | | |
| | | | | Additional paid-in capital | 153,827 | 297,327 | | | | |
| | | | | Accumulated other comprehensive income (loss) | (197) | 86 | | | | |
| | | | | Accumulated deficit | (142,203) | ... | | | | |
| | | | | Retained earnings (accumulated deficit) | ... | (253,942) | | | | |
| | | | | Total stockholders' equity (deficit) | 11,373 | 43,772 | | | | |
| | | | | Total Equity | 11,373 | ... | | | | |

⊠ Reclassified to conform with 2022 presentation; ⊡ As reported by the Company; ⊢ Adjusted for 1-for-10 stock split, June 2, 2023; ⊣ Shares increased due to the effect of issuance upon initial public offering, concurrent private placement and conversion of convertible preferred stock and convertible notes into common stock upon IPO; ⊤ As is; ⊥ Approximately; ⊦ As of March 15, 2023; ⊧ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|--------|--------|
| Cash & cash equivalents | 12,894 | 50,487 |
| Grants receivable | 173 | ... |
| Prepaid insurance | 376 | 291 |
| Security deposit | ... | 101 |
| Angion Pty Ltd ("Angion Pty") tax receivable | ... | 305 |
| Other prepaid & other current assets | ... | 246 |
| Prepaid clinical fees | 2,732 | ... |
| Prepaid expenses & other current assets | ... | 943 |
| Restricted cash, current | 722 | ... |
| Prepaid research and development contract services | 1,883 | ... |

Recent Dividends:

1. Elicio Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Elicio Therapeutics Inc common.

No dividends paid.

ELVICTOR GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ⊠2021 (revised) |
|-----------------------------------|-----------|-----------|-----------------|
| Gross revenue | 1,841,180 | 2,045,558 | 1,986,862 |
| Net revenue | 520,613 | 430,102 | 400,158 |
| Total revenue | 2,361,793 | 2,475,660 | 2,387,020 |
| Less: cost of revenue | 423,616 | 399,717 | 370,193 |
| Cost of revenue - related party | 69,820 | 99,890 | 649,578 |
| Gross profit | 1,868,357 | 1,976,053 | 1,367,249 |
| Professional fees | 275,103 | 540,416 | 356,472 |
| Professional fees - related party | 62,444 | 137,004 | 127,957 |
| Salaries | 1,524,442 | 1,316,906 | 720,192 |

⊠ Reclassified to conform with 2022 presentation; ⊡ As reported by the Company; ⊢ Shares increased due to issuance of shares for cash and convertible bonds and preferred shares converted to common shares; ⊣ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | 699,346 | 503,981 |
| Accounts receivable | 369,904 | 330,864 |
| Other receivables | 37,857 | 7,194 |
| Other receivables - related party | ... | 369,800 |
| Value added tax (VAT) receivable | 418,904 | ... |
| Prepaid expenses & other current assets | 138,482 | 58,628 |
| Total current assets | 1,664,493 | 1,270,467 |
| Right of use asset - related party | 278,718 | 21,653 |
| Intangible Assets, Net | 130,266 | 168,000 |
| Office equipment, net | 14,358 | 19,211 |
| Total non-current assets | ... | 208,864 |
| Total assets | 2,087,835 | 1,479,331 |

| | | | | | | | | | |
|---|--------------|--------------|---|--------------|------------|--------------|---|--------------|--------------|
| Accounts payable | 32,312 | 34,336 | Income (loss) before taxes | (12,601,797) | 7,293,028 | (18,614,962) | Additional paid-in capital | 99,490,253 | 75,303,479 |
| Trade accounts payable | 152,461 | 310,892 | Income tax provision | (132,192) | 208,898 | ... | Retained earnings (accumulated deficit) | (64,618,818) | (52,149,213) |
| Trade accounts payable - related party | 194,481 | 56,434 | Net income (loss) | (12,469,605) | 7,084,130 | (18,614,962) | Total stockholders' equity (deficit) | 34,956,460 | 23,235,881 |
| Other payables | 861,878 | 485,675 | Weighted average shares outstanding - basic | 22,718,890 | 21,003,563 | 14,630,168 | Total Equity | 34,956,460 | ... |
| Lease liability - related party | 42,786 | 12,262 | Weighted average shares outstanding - diluted | 22,718,890 | 23,387,646 | 14,630,168 | | | |
| Accrued & other liabilities | 247,926 | 68,759 | Year end shares outstanding | 25,503,530 | 22,093,503 | 19,840,648 | | | |
| Due to related party | 90,195 | 48,991 | Net income (loss) per share - basic | \$(0.55) | \$0.34 | \$(1.27) | | | |
| Total current liabilities | 1,622,039 | 1,017,349 | Net income (loss) per share - diluted | \$(0.55) | \$0.30 | \$(1.27) | | | |
| Lease liability - related party | 235,932 | 9,391 | Number of full time employees | 50 | 40 | 31 | | | |
| Total non-current liabilities | 235,932 | 9,391 | Total number of employees | 50 | ... | ... | | | |
| Total liabilities | 1,857,971 | 1,026,740 | Number of common stockholders | 1,250 | 900 | 900 | | | |
| Common stock | 41,445 | 41,445 | Production and Ad Valorem Taxes | 3,044,411 | ... | ... | | | |
| Additional paid in capital | 45,050,884 | 45,050,884 | Diluted | \$(0.55) | ... | ... | | | |
| Accumulated deficit | (44,862,465) | ... | Diluted EPS | ... | ... | ... | | | |
| Retained earnings (accumulated deficit) | ... | (44,639,738) | Excluding ExtraOrd Items | \$(0.55) | ... | ... | | | |
| Total stockholders' equity (deficit) | 229,864 | 452,591 | | | | | | | |
| Total Equity | 229,864 | ... | | | | | | | |

Recent Dividends:

1. Elvictor Group Inc preferred.

No dividends paid.

2. Elvictor Group Inc common.

No dividends paid.

Annual Dividends:

1. Elvictor Group Inc preferred.

No dividends paid.

2. Elvictor Group Inc common.

No dividends paid.

EMPIRE PETROLEUM CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|--------------|------------|----------------|
| | 2023 | 2022 | 2021 (revised) |
| Oil sales | 36,684,494 | 44,978,554 | 22,326,289 |
| Gas sales | 1,726,754 | 4,534,370 | 2,288,481 |
| Natural gas liquids sales | ... | 3,659,451 | 2,888,747 |
| Total product revenues | ... | 53,172,375 | 27,503,517 |
| Other revenue | 70,480 | 102,429 | 174,609 |
| Gain (loss) on derivatives | (65,693) | (387,930) | (586,181) |
| NGL Sales | 1,660,256 | ... | ... |
| Total revenue | 40,076,291 | 52,886,874 | 27,091,945 |
| Lease operating expense | ... | 23,584,039 | 13,283,758 |
| Production & ad valorem taxes | 28,625,481 | 3,943,466 | 2,102,772 |
| Depletion, depreciation & accretion | 3,096,533 | ... | ... |
| Depreciation, depletion & amortization | ... | 1,949,191 | 2,502,275 |
| Accretion of asset retirement obligation | 1,756,022 | 1,357,906 | 1,214,479 |
| Impairment | ... | 936,620 | ... |
| General & administrative | 15,178,935 | 12,331,489 | 8,462,031 |
| Total cost & expenses | 51,701,382 | 44,102,711 | 27,565,315 |
| Operating income (loss) | (11,625,091) | 8,784,163 | (473,370) |
| Convertible debt modification inducement expense | ... | ... | 2,276,813 |
| Loss on convertible debt redemption option | ... | ... | 3,169,201 |
| Loss on embedded conversion option | ... | ... | 4,504,104 |
| Other income (expense) | 23,721 | (981,595) | 409,225 |
| Interest expense | 1,000,427 | 509,540 | 8,600,699 |

| | | | |
|---|--------------|------------|--------------|
| Income (loss) before taxes | (12,601,797) | 7,293,028 | (18,614,962) |
| Income tax provision | (132,192) | 208,898 | ... |
| Net income (loss) | (12,469,605) | 7,084,130 | (18,614,962) |
| Weighted average shares outstanding - basic | 22,718,890 | 21,003,563 | 14,630,168 |
| Weighted average shares outstanding - diluted | 22,718,890 | 23,387,646 | 14,630,168 |
| Year end shares outstanding | 25,503,530 | 22,093,503 | 19,840,648 |
| Net income (loss) per share - basic | \$(0.55) | \$0.34 | \$(1.27) |
| Net income (loss) per share - diluted | \$(0.55) | \$0.30 | \$(1.27) |
| Number of full time employees | 50 | 40 | 31 |
| Total number of employees | 50 | ... | ... |
| Number of common stockholders | 1,250 | 900 | 900 |
| Production and Ad Valorem Taxes | 3,044,411 | ... | ... |
| Diluted | \$(0.55) | ... | ... |
| Diluted EPS | ... | ... | ... |
| Excluding ExtraOrd Items | \$(0.55) | ... | ... |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-4 stock split, March 7, 2022; Approximately; As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | | |
|--|------------|------------|--|
| | 2023 | 2022 | |
| Cash | ... | 11,944,442 | |
| Derivative instruments | 406,806 | 121,584 | |
| Cash & cash equivalents | 7,792,508 | ... | |
| Prepays | 757,500 | ... | |
| Accounts receivable | 8,354,636 | 7,780,239 | |
| Inventory | 1,433,454 | ... | |
| Inventory - oil in tanks | ... | 1,840,274 | |
| Prepays | ... | 1,048,434 | |
| Total current assets | 18,744,904 | 22,734,973 | |
| Oil & natural gas properties, successful efforts | 93,509,803 | 63,986,339 | |
| Less: accumulated depreciation & depletion | 22,996,805 | ... | |
| Less: accumulated depreciation, depletion & impairment | ... | 20,116,696 | |
| Total oil & gas properties, net | ... | 43,869,643 | |
| Other property & equipment, gross | 2,998,018 | 1,878,325 | |
| Accumulated depreciation | 1,114,807 | 436,796 | |
| Other property & equipment, net | 1,883,211 | 1,441,529 | |
| Total property & equipment, net | ... | 45,311,172 | |
| Sinking fund | ... | 2,779,000 | |
| Utility & other deposits | 1,474,503 | 719,930 | |
| SubTotal | 70,512,998 | ... | |
| Total assets | 92,615,616 | 71,545,075 | |
| Accounts payable | 16,437,219 | 5,843,366 | |
| Accrued expenses | 7,075,302 | 9,461,010 | |
| Current portion of lease liability | 432,822 | 256,975 | |
| Current portion of long term notes payable | 1,060,004 | ... | |
| Current portion of long-term debt | 44,225 | 2,059,309 | |
| Total current liabilities | 25,049,572 | 17,620,660 | |
| Long-term debt | ... | 4,063,115 | |
| Long-term note payable - related party | 4,596,775 | 1,076,987 | |
| Long term lease liability | 544,382 | 547,692 | |
| Asset retirement obligations | 27,468,427 | 25,000,740 | |
| Total liabilities | 57,659,156 | 48,309,194 | |
| Common stock | 85,025 | 81,615 | |

| | | |
|---|--------------|--------------|
| Additional paid-in capital | 99,490,253 | 75,303,479 |
| Retained earnings (accumulated deficit) | (64,618,818) | (52,149,213) |
| Total stockholders' equity (deficit) | 34,956,460 | 23,235,881 |
| Total Equity | 34,956,460 | ... |

Recent Dividends:

1. Empire Petroleum Corp common.

No dividends paid.

Annual Dividends:

1. Empire Petroleum Corp common.

No dividends paid.

ENB FINANCIAL CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|-------------|------------|----------------|
| | 2023 | 2022 | 2021 (revised) |
| Interest income & fees on loans | 61,235,000 | 41,944,000 | 34,246,000 |
| Interest income on securities available for sale - taxable | 11,648,000 | 9,048,000 | 4,881,000 |
| Interest income on securities available for sale - tax-exempt | 3,001,000 | 4,214,000 | 3,975,000 |
| Interest income on deposits at other banks | 890,000 | 172,000 | 91,000 |
| Dividend income | 1,103,000 | 581,000 | 398,000 |
| Total interest & dividend income | 77,877,000 | 55,959,000 | 43,591,000 |
| Interest expense on deposits - demand | ... | 1,784,000 | 170,000 |
| Interest expense on deposits - savings | ... | 92,000 | 63,000 |
| Interest expense on time deposits | ... | 874,000 | 910,000 |
| Interest expense on deposits | 18,766,000 | 2,750,000 | 1,143,000 |
| Interest expense on borrowings | 5,072,000 | 2,626,000 | 1,877,000 |
| Total interest expense | 23,838,000 | 5,376,000 | 3,020,000 |
| Net interest income | 54,039,000 | 50,583,000 | 40,571,000 |
| Provision (credit) for loan losses | 520,000 | 1,300,000 | 475,000 |
| Net interest income after provision (credit) for loan losses | 53,519,000 | 49,283,000 | 40,096,000 |
| Trust & investment services income | 2,883,000 | 2,643,000 | 2,362,000 |
| Service fees | 4,746,000 | 2,938,000 | 2,512,000 |
| Commissions | 3,618,000 | 3,663,000 | 3,702,000 |
| Gains on sale of debt securities, net | (1,371,000) | 42,000 | 730,000 |
| Gains (losses) on equity securities, net | (125,000) | (32,000) | 324,000 |
| Gains (losses) on sale of mortgages | 767,000 | 1,302,000 | 5,526,000 |
| Earnings on bank-owned life insurance | 958,000 | 1,583,000 | 880,000 |
| Other income | 1,223,000 | 1,425,000 | 1,845,000 |
| Salaries & employee benefits expenses | 30,152,000 | 27,324,000 | 24,465,000 |
| Occupancy expenses | 3,259,000 | 2,846,000 | 2,621,000 |
| Equipment expenses | 1,302,000 | 1,240,000 | 1,053,000 |
| Advertising & marketing expenses | 1,404,000 | 1,083,000 | 992,000 |
| Computer software & data processing expenses | 6,891,000 | 5,591,000 | 4,420,000 |
| Shares tax expenses | 1,167,000 | 1,380,000 | 1,282,000 |

| | | |
|---|--------------|--------------|
| Right of use assets | 354,091 | 505,816 |
| Other assets | 5,986 | 5,986 |
| Vendor advance | 626,610 | 502,576 |
| Inventory | 2,622,865 | 2,644,717 |
| Total assets | 6,754,146 | 9,274,147 |
| Accounts payable | 360,401 | 613,961 |
| Accrued payroll | 150,293 | 60,638 |
| Accrued bonuses | 35,518 | 683,738 |
| Accrued employee benefits | 5,750 | 5,750 |
| Insurance premium financing | 148,792 | 158,925 |
| Accounts payable & accrued liabilities | 700,754 | 1,523,012 |
| Lease liabilities, current portion | 173,857 | 152,228 |
| Loans, long term | 28,484 | 28,484 |
| Total current liabilities | 903,095 | 1,703,724 |
| Lease liabilities, long term | 192,062 | 365,919 |
| Total long term liabilities | 192,062 | 365,919 |
| Total liabilities | 1,095,157 | 2,069,643 |
| Common stock | 1,039 | 317 |
| Stock payable | 5,233 | 6,073 |
| Additional paid in capital | 97,582,868 | 89,068,015 |
| Retained earnings (accumulated deficit) | (91,930,152) | (81,869,902) |
| Preferred stock | 1 | 1 |
| Total stockholders' equity (deficit) | 5,658,989 | 7,204,504 |
| Total Equity | 5,658,989 | 7,204,504 |

□ Reclassified to conform 2023 presentation

Recent Dividends:

- 1. ENDRA Life Sciences Inc common.**
No dividends paid.
- 2. ENDRA Life Sciences Inc series A convertible preferred.**
No dividends paid.
- 3. ENDRA Life Sciences Inc series B convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. ENDRA Life Sciences Inc common.**
No dividends paid.
- 2. ENDRA Life Sciences Inc series A convertible preferred.**
No dividends paid.
- 3. ENDRA Life Sciences Inc series B convertible preferred.**
No dividends paid.

ENDRA LIFE SCIENCES INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, RBSM LLP, as it appeared in Co.'s 2023 10K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of ENDRA Life Sciences Inc. and Subsidiaries (collectively, the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations, shareholders' equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes and schedules (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023 and 2022 in conformity with accounting principles generally accepted in the United States of America. The Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the accompanying consolidated financial statements, the Company has suffered recurring losses from operations, generated negative cash flows from operating activities, has an accumulated deficit and has stated that substantial doubt exists about Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans in regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

ENERGIOUS CORP

Annual Report

| | | | |
|---|---------|------|------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| Revenue | 474,184 | ... | ... |

| | | | |
|--|---------------------|---------------------|---------------------|
| Revenue | 474,184 | 851,321 | 756,793 |
| Cost of revenue | ... | 1,277,565 | ... |
| Research & development expenses | 10,810,570 | 12,497,781 | 20,572,580 |
| Sales & marketing expenses | 3,852,393 | 4,884,959 | 8,598,343 |
| General & administrative expenses | 7,272,464 | 8,078,950 | 9,001,483 |
| Severance expense | 359,419 | 798,391 | 4,017,172 |
| Cost of services revenue | 279,083 | ... | ... |
| Total operating expenses | 22,573,929 | 27,537,646 | 42,189,578 |
| Income (loss) from operations | (22,099,745) | (26,686,325) | (41,432,785) |
| Change in fair value of derivative liabilities | 2,515,425 | ... | ... |
| Interest income (expense) | ... | 411,065 | 5,492 |
| Interest income | 809,227 | ... | ... |
| Offering costs related to warrant liability | (591,670) | ... | ... |
| Total other income (expense) | 2,732,982 | 411,065 | 5,492 |
| Net income (loss) | (19,366,763) | (26,275,260) | (41,427,293) |

| | | | |
|--|--------------|------------|------------|
| Weighted average shares outstanding - basic | 4,663,594 | □3,874,286 | 3,246,326 |
| Weighted average shares outstanding - diluted | 4,663,594 | □3,874,286 | 3,246,326 |
| Year end shares outstanding | 5,471,121 | □3,947,248 | □3,833,360 |
| Net earnings (loss) per common share - basic | \$(4.15) | □\$(6.80) | \$(12.80) |
| Net earnings (loss) per common share - diluted | \$(4.15) | □\$(6.80) | \$(12.80) |
| Number of full time employees | ... | □43 | □38 |
| Number of common stockholders | 5 | □10 | □11 |
| Income from cont operations before income tax | (19,366,763) | ... | ... |
| Earnings per share from continuing operations | \$(4.15) | ... | ... |
| Earnings per share from continuing operations | \$(4.15) | ... | ... |

□ Adjusted for 1-for-20 stock split, August 16, 2023; □ Shares increased due to the effects of shares issued for restricted stock units, performance share units, at-the-market placement, and shares purchased from contributions to the ESPP; □ As of March 20, 2023; □ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|------------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 13,936,050 | 26,287,293 |
| Accounts receivable, net | 101,554 | 143,353 |
| Inventory | 429,638 | 105,821 |
| Prepaid expenses & other current assets | 539,145 | 827,551 |
| Total current assets | 15,006,387 | 27,364,018 |
| Computer software | 900,641 | 978,147 |
| Computer hardware | 2,283,837 | 2,144,364 |
| Furniture & fixtures | 488,465 | 488,465 |
| Leasehold improvements | 782,538 | 782,538 |
| Property & equipment, gross | 4,455,481 | 4,393,514 |
| Less - accumulated depreciation | 4,026,577 | 3,964,479 |
| Property & equipment, net | 428,904 | 429,035 |
| Operating right-of-use | ... | ... |

| | | |
|--|---------------|---------------|
| lease assets | 1,240,042 | 1,959,869 |
| Total assets | 16,675,333 | 29,752,922 |
| Accounts payable | 1,879,334 | 900,765 |
| Accrued compensation | 992,743 | 1,306,503 |
| Accrued legal expenses | 147,506 | 298,546 |
| Other accrued expenses | 113,688 | 185,365 |
| Accrued expenses | 1,253,937 | 1,790,414 |
| Accrued severance | 133,598 | 416,516 |
| Operating lease liabilities, current portion | 707,251 | 705,894 |
| Deferred revenue | 27,082 | 29,727 |
| Warrant liability | 619,575 | ... |
| Total current liabilities | 4,620,777 | 3,843,316 |
| Operating lease liabilities, long-term portion | 556,879 | 1,264,131 |
| Total liabilities | 5,177,656 | 5,107,447 |
| Common stock | 930 | 789 |
| Additional paid-in capital | 393,538,809 | 387,319,985 |
| Retained earnings (accumulated deficit) | (382,042,062) | (362,675,299) |
| Total stockholders' equity (deficit) | 11,497,677 | 24,645,475 |
| Total Equity | 11,497,677 | ... |

Recent Dividends:

- 1. Energoous Corp common.**
No dividends paid.

Annual Dividends:

- 1. Energoous Corp common.**
No dividends paid.

ENERGY FOCUS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

| | | | |
|--|----------------|-----------------|----------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Total revenues | 5,717 | ... | ... |
| Net sales | 5,717 | 5,968 | 9,865 |
| Cost of sales | 5,494 | 6,286 | 8,167 |
| Gross (loss) profit | 223 | (318) | 1,698 |
| Product development expenses | 587 | 1,491 | 1,891 |
| Selling, general, & administrative expenses | 3,607 | 7,148 | 8,535 |
| Loss on impairment | ... | 338 | ... |
| Restructuring expenses | ... | ... | (21) |
| Total operating expenses | 4,194 | 8,977 | 10,405 |
| Income (loss) from operations | (3,971) | (9,295) | (8,707) |
| Interest income | 57 | ... | ... |
| Interest expense | 380 | 954 | 792 |
| Gain (loss) on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... | 801 |
| Other income | (26) | 30 | 876 |
| Other expenses | ... | 56 | 65 |
| Income (loss) from operations before income taxes | (4,290) | (10,275) | (7,887) |
| Current provision for (benefit from) income taxes - state | 3 | 4 | (1) |
| Total current provision for (benefit from) income taxes | 3 | ... | ... |
| Provision for (benefit from) income taxes | 3 | 4 | (1) |
| Net income (loss) | (4,293) | (10,279) | (7,886) |
| Weighted average shares outstanding - basic | 3,241 | □1,159 | 652 |
| Weighted average | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash | 2,287,977 | 17,723,884 |
| Prepaid expenses & other current assets | 1,293,554 | 708,053 |
| Total current assets | 3,581,531 | 18,431,937 |
| Lap equipment | 836,709 | 831,123 |
| Computer equipment & leasehold improvements | 28,379 | 25,137 |
| Less: accumulated depreciation | 357,711 | 178,775 |
| Property & equipment, net | 507,377 | 677,485 |
| Right-of-use operating lease asset | ... | 63,817 |
| Intangible assets, net | 210,932 | 379,686 |
| Total other assets | 718,309 | 1,120,988 |
| Total assets | 4,299,840 | 19,552,925 |
| Accounts payable | 1,218,783 | 463,275 |
| Product development | ... | 195,104 |
| Accrued salaries & wages | 8,889 | 1,175,963 |
| Professional fees | ... | 83,255 |
| Patent costs | ... | 251,333 |
| Accrued liabilities | 1,075,643 | 1,705,655 |
| Current portion of right-of-use operating lease obligation | ... | 63,820 |
| Investment option liability | 23,608 | 851,008 |
| Warrant liability | 25,470 | 185,215 |
| Derivative liability | ... | 727,000 |
| Accrued liabilities - Balancing value | 1,066,754 | ... |
| Total current liabilities | 2,343,504 | 3,995,973 |
| Total liabilities | ... | 3,995,973 |
| Redeemable non-controlling interest | ... | 885,028 |
| Total temporary equity | ... | 885,028 |
| Common stock | 27,392 | 20,782 |
| Additional paid-in capital | 100,815,851 | 94,395,662 |
| Retained earnings (accumulated deficit) | (96,499,518) | (79,207,786) |
| Accumulated other comprehensive income (loss) | (569,749) | (536,734) |
| Stock subscription receivable | (1,817,640) | ... |
| Total shareholders' equity (deficit) | 1,956,336 | 14,671,924 |
| Total Equity | 1,956,336 | ... |

Recent Dividends:

- 1. Enveric Biosciences Inc common.**
No dividends paid.
 - 2. Enveric Biosciences Inc series B preferred.**
No dividends paid.
 - 3. Enveric Biosciences Inc series B-1 redeemable convertible preferred (stated value: \$10).**
No dividends paid.
 - 4. Enveric Biosciences Inc 9.0% series A cumulative preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Enveric Biosciences Inc common.**
No dividends paid.
 - 2. Enveric Biosciences Inc series B preferred.**
No dividends paid.
 - 3. Enveric Biosciences Inc series B-1 redeemable convertible preferred (stated value: \$10).**
No dividends paid.
 - 4. Enveric Biosciences Inc 9.0% series A cumulative preferred.**
No dividends paid.

ENVIROTECH VEHICLES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|----------------|-------|-----------|-----------|
| Total revenues | 2,863 | ... | ... |
| Sales | 2,863 | 4,504,621 | 2,042,844 |

| | | | |
|--|-----------------|---------------------|--------------------|
| Cost of sales | 1,857 | 2,772,673 | 1,281,468 |
| Gross profit | 1,006 | 1,731,948 | 761,376 |
| General & administrative | 8,171 | 7,996,906 | 8,238,530 |
| Consulting | 214 | 339,505 | 188,703 |
| Research & development | 236 | 149,912 | 58,139 |
| Goodwill impairment charge | 5,099 | 37,093,047 | ... |
| Total operating expenses, net | 13,720 | 45,579,370 | 8,485,372 |
| Income (loss) from operations | (12,715) | (43,847,422) | (7,723,996) |
| Interest income (expense), net | 35 | 45,026 | 4,412 |
| Gain on debt forgiveness, net of other expense | ... | ... | 288,185 |
| Other income (expense) | (4) | (1,764) | ... |
| Total other income (expense) | 31 | 43,262 | 292,597 |
| Income (loss) before income taxes | (12,684) | (43,804,160) | (7,431,399) |
| Income tax recovery (expense) | ... | ... | 220,700 |
| Net income (loss) | (12,684) | (43,804,160) | (7,652,100) |
| Weighted average shares outstanding - basic | 15,062 | 14,991,837 | 11,452 |
| Weighted average shares outstanding - diluted | 15,062 | 14,991,837 | 11,452 |
| Year end shares outstanding | 15,172 | 15,021,088 | 14,908 |
| Net earnings (loss) per share - basic | \$(0.84) | \$(2.92) | \$(0.60) |
| Net earnings (loss) per share - diluted | \$(0.84) | \$(2.92) | \$(0.60) |
| Number of full time employees | 14 | 13 | 12 |
| Number of common stockholders | 157 | 160 | 206 |
| Net loss | ... | (43,804,160) | ... |
| Total number of employees | 14 | ... | ... |

As reported by the Company; Adjusted for 1-for-20 stock split, June 27, 2022; Shares increased due to the effect of EVTDS common stock issued for cash, ADOMANI Inc., common stock issued in merger and post-merger common stock issued for cash; As of April 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|-----------------------------------|--------|------------|
| Cash & cash equivalents | 457 | 2,765,068 |
| Restricted cash | ... | 60,399 |
| Marketable securities | ... | 2,336,402 |
| Accounts receivable | 713 | 2,344,909 |
| Allowance for doubtful accounts | 21 | 271,218 |
| Accounts receivable | 692 | 2,073,691 |
| Inventory, net | ... | 5,671,326 |
| Inventory deposits | 3,300 | 4,829,933 |
| Prepaid expenses | 614 | 445,963 |
| Other current assets | 162 | 156,457 |
| Inventory | 6,831 | ... |
| Total current assets | 12,056 | 18,339,239 |
| Furniture & fixtures | 57 | 56,646 |
| Leasehold improvements | 137 | 122,711 |
| Machinery & equipment | 173 | 165,753 |
| Vehicles | 298 | 252,724 |
| Test or demo vehicles | 31 | 15,784 |
| Total property & equipment, gross | 695 | 613,618 |
| Less: accumulated depreciation | 374 | 245,157 |
| Property & equipment, net | 321 | 368,461 |
| Goodwill | 9,584 | 14,682,620 |
| Other non-current assets | 154 | 93,369 |
| Right-of-use asset | 539 | ... |

| | | |
|---|----------|--------------|
| Total assets | 22,653 | 33,483,689 |
| Accounts payable | 761 | 603,744 |
| Accrued liabilities | 452 | 652,528 |
| Notes payable - Current | 269 | 215,766 |
| Operating lease liability - short-term | 291 | ... |
| Total current liabilities | 1,774 | 1,472,038 |
| Notes payable - Long Term | 10 | 16,671 |
| Operating lease liability - long-term | 236 | ... |
| Total liabilities | 2,020 | 1,488,709 |
| Common stock | 0 | 150 |
| Additional paid-in capital | 85,246 | 83,923,350 |
| Retained earnings (accumulated deficit) | (64,612) | (51,928,520) |
| Total stockholders' equity (deficit) | 20,634 | 31,994,980 |
| Total Equity | 20,634 | ... |

Recent Dividends:

- 1. Envirotech Vehicles Inc common.**

No dividends paid.

Annual Dividends:

- 1. Envirotech Vehicles Inc common.**

No dividends paid.

ENVOY MED INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|-------------------|------------------|
| Formation & operating costs | ... | 4,888,124 | 5,204,970 |
| Income (loss) from operations | (18,371,000) | (4,888,124) | (5,204,970) |
| Interest earned on investments held in trust account | ... | 6,125,038 | 37,665 |
| Deferred offering cost forgiveness | 80,000 | 150,262 | ... |
| Offering costs allocated to warrant liabilities | ... | ... | 782,812 |
| Change in fair value of forward purchase agreements | 842,000 | (649,058) | 232,789 |
| Change in fair value of warrant liabilities | 942,000 | 19,997,306 | 5,465,695 |
| Income (loss) before income tax expense | (29,908,000) | 20,735,424 | (251,633) |
| Current income tax expense (benefit) - federal | ... | 1,175,834 | ... |
| Current income tax expense (benefit) - state | ... | 325,880 | ... |
| Deferred income tax expense (benefit) - federal | ... | (2,077,550) | (1,085,134) |
| Deferred income tax expense (benefit) - state | ... | (429,855) | ... |
| Change in valuation allowance | ... | 2,507,405 | 1,085,134 |
| Income tax expense | ... | 1,501,714 | ... |
| Net income (loss) | (29,908,000) | 19,233,710 | (251,633) |
| Weighted average class A common shares outstanding - basic | ... | 42,500,000 | 35,224,658 |
| Weighted average class B common shares outstanding - basic | ... | 10,625,000 | 10,589,629 |
| Weighted average shares outstanding - basic | 12,552,925 | ... | ... |
| Weighted average class A common shares outstanding - diluted | ... | 42,500,000 | 35,224,658 |

| | | | | | | | | | |
|--|--------------|------------|--|---------------|--------------|---|-------------|-------------|-------------|
| Weighted average class B common shares outstanding - diluted | 10,625,000 | 10,589,629 | Accrued expenses | 4,613,000 | 3,945,680 | before income tax provision | (631,936) | (1,922,252) | (1,084,973) |
| Weighted average shares outstanding - diluted | 12,552,925 | | Working capital loans | | 1,500,000 | Current income tax - Taiwan | | (10,093) | 16,592 |
| Year end shares outstanding | 19,599,982 | 53,125,000 | Income taxes payable | | 686,530 | Deferred tax assets for NOL carryforwards | (129,243) | | |
| Net income (loss) per class A share - basic | \$0.36 | 53,125,000 | Operating Lease Liabilities - Current Portion/Short-Term | 158,000 | | Deferred tax assets for NOL carryforwards | 129,243 | | |
| Net income (loss) per class B share - basic | \$0.36 | | Warranty liability, current portion | 311,000 | 7,309,756 | Income tax expenses | (10,093) | 16,592 | |
| Net income (loss) per share - basic | \$(2.38) | | Total current liabilities | 6,636,000 | | Net income (loss) | (631,936) | (1,912,159) | (1,101,565) |
| Net income (loss) per class A share - diluted | \$0.36 | 53,125,000 | Deferred underwriting fee payable | | 10,412,500 | Net income (loss) attributable to non-controlling interests | 4,782 | 41,294 | 21,231 |
| Net income (loss) per class B share - diluted | \$0.36 | | Derivative warrant liabilities | | 1,066,667 | Net income (loss) attributable to EOS & subsidiaries | (627,154) | (1,870,865) | (1,080,334) |
| Net income (loss) per share - diluted | \$(2.38) | | Warrant liability | 332,000 | | Weighted average number of shares outstanding - basic | 219,639,094 | 182,376,491 | 77,243,336 |
| Full-Time Employees (Period End) | 34 | | Product warranty liability, net of current portion | 1,923,000 | | Weighted average number of shares outstanding - diluted | 219,639,094 | 182,376,491 | 77,243,336 |
| Total number of employees | 34 | 2 | Operating Lease Liabilities - Long-Term | 404,000 | | Year end shares outstanding | 604,781,560 | 183,781,560 | 180,065,254 |
| Number of class A common stockholders | | 1 | Forward purchase agreement warrant liability | 4,000 | | Net earnings (loss) per share - basic | | \$(0.01) | \$(0.01) |
| Number of class B common stockholders | | 6 | Other Non-Current Liabilities | 103,000 | | Net earnings (loss) per share - diluted | | \$(0.01) | \$(0.01) |
| Total costs and operating expenses | 18,687,000 | | Total liabilities | 9,402,000 | 18,788,923 | Total number of employees | | 9 | 8 |
| Loss from changes in fair value of convertible notes payable (related party) | (13,332,000) | | Class A common stock subject to possible redemption | | 429,747,193 | Number of common stockholders | 551 | 373 | 359 |
| Change in fair value of Forward purchase agreement warrant liability | (69,000) | | Class B common stock | 2,000 | 1,063 | | | | |
| Total other income/(expense) | (11,537,000) | | Additional paid-in capital | 255,596,000 | | | | | |
| Net revenues | 316,000 | | Accumulated deficit | (257,242,000) | | | | | |
| Total Revenue | 316,000 | | Retained earnings (accumulated deficit) | | (17,915,833) | | | | |
| Cost of goods sold | 789,000 | | Accumulated other comprehensive loss | (118,000) | | | | | |
| Research and development | 8,956,000 | | Total stockholders' equity (deficit) | (1,762,000) | (17,914,770) | | | | |
| General and administrative | 7,276,000 | | Total Equity | (1,762,000) | | | | | |
| Sales and marketing | 1,666,000 | | | | | | | | |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of class A common stock subject to possible redemption; □ As of April 3, 2023; □ As of March 31, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|-----------|-------------|
| | 2023 | 2022 |
| Cash on hand | 4,218,000 | |
| Cash | | 107,773 |
| Prepaid expenses | 957,000 | 112,649 |
| Accounts & Notes | | |
| Receivable - Trade - Net | 70,000 | |
| Inventories | 1,404,000 | |
| Other receivable | 176,000 | |
| Raw Materials | 1,162,000 | |
| Work-in-progress | 158,000 | |
| Finished goods | 84,000 | |
| Total current assets | 6,825,000 | 220,422 |
| Investments held in trust account | | 430,047,193 |
| Forward purchase agreement assets | | 353,731 |
| Property and equipment, net | 351,000 | |
| Operating lease right-of-use assets (related party) | 464,000 | |
| Total assets | 7,640,000 | 430,621,346 |
| Accounts payable | 1,554,000 | 1,177,546 |

Recent Dividends:

- 1. Envoy Med Inc convertible series A preferred.**
No dividends paid.
 - 2. Envoy Med Inc class A common.**
No dividends paid.
 - 3. Envoy Med Inc class A common subject to possible redemption.**
No dividends paid.
 - 4. Envoy Med Inc class B common.**
No dividends paid.
- Annual Dividends:**
- 1. Envoy Med Inc convertible series A preferred.**
No dividends paid.
 - 2. Envoy Med Inc class A common.**
No dividends paid.
 - 3. Envoy Med Inc class A common subject to possible redemption.**
No dividends paid.
 - 4. Envoy Med Inc class B common.**
No dividends paid.

EOS INC

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|-----------|-------------|-------------|
| | 2023 | 2022 | 2021 |
| Net sales | 296,852 | 652,547 | 518,487 |
| Total revenues | 296,852 | | |
| Cost of sales | 102,975 | 365,282 | 312,951 |
| Gross profit | 193,877 | 287,265 | 205,536 |
| Selling, general & administrative exps | 966,486 | 2,208,876 | 1,274,616 |
| Income (loss) from operations | (772,609) | (1,921,611) | (1,069,080) |
| Interest income (expense) | (6,859) | (4,512) | (1,797) |
| Other income (expense) | 147,532 | 3,871 | (49,238) |
| Gain (loss) on investment in equity securities | | | 35,142 |
| Total other income (expense) | 140,673 | (641) | (15,893) |
| Income (loss) | | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 14,307 | 18,169 |
| Accounts receivable | 224,590 | 160,253 |
| Inventory | 79,482 | |
| Inventory, net | | 46,196 |
| Advances to suppliers | 161,179 | 166,594 |
| Security deposits | 3,802 | 6,608 |
| Prepaid expenses & other current assets | 3,959 | 28,096 |
| Total current assets | 487,319 | 425,916 |
| Property, plant & equipment, net | 5,660 | 4,692 |
| Operating lease right of use asset | 4,192 | 115,884 |
| Total non-current assets | 9,852 | 120,576 |
| Total assets | 497,171 | 546,492 |
| Accounts payable | 9,761 | |
| Other payable & accrued expenses | 309,103 | 73,352 |
| Due to shareholders | | 277,080 |
| Income taxes payable | 45,318 | 49,074 |
| Other current liabilities | 1,000,000 | 750,000 |
| Operating lease liabilities - current | 2,818 | 48,231 |
| Current portion of long-term loan payables | 53,165 | 68,497 |
| Due to related parties | 74,065 | |
| Total current liabilities | 1,494,230 | 1,266,234 |
| Long-term loan payables | 65,210 | 116,012 |
| Operating lease liabilities - non-current | 1,374 | 80,538 |
| Total non-current liabilities | 66,584 | 196,550 |
| Total liabilities | 1,560,814 | 1,462,784 |
| Preferred stock | 1,500 | 1,500 |
| Common stock | 604,781 | 183,781 |
| Deferred stock compensation | (40,674) | (40,674) |
| Additional paid-in capital | 175,268 | 67,249 |

□ Shares increased due to the effect of issuance of shares for liability converted and minority controlling interests of its subsidiary; □ As of March 27, 2023; □ Approximately; □ As of April 8, 2022

| | | |
|---|-------------|-----------|
| Accumulated loss | (1,802,695) | ... |
| Accumulated income | (1,165,665) | ... |
| Accumulated other comprehensive income (loss) | (1,823) | ... |
| Other comprehensive income | 42,964 | ... |
| Total shareholders' equity (deficit) | (1,063,643) | (910,845) |
| Non-controlling interest | (5,447) | ... |
| Total equity | (1,063,643) | (916,292) |

Recent Dividends:**1. EOS Inc common.**

No dividends paid.

2. EOS Inc preferred.

No dividends paid.

Annual Dividends:**1. EOS Inc common.**

No dividends paid.

2. EOS Inc preferred.

No dividends paid.

EQUATOR BEVERAGE COMPANY**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2021 | 2020 |
|---|------------|------------|------------|
| | | | (revised) |
| Revenue | 2,288,272 | ... | ... |
| Revenue | 2,288,272 | 1,918,882 | 1,741,919 |
| Cost of revenue | 1,276,411 | 1,069,844 | 917,639 |
| Gross profit (loss) | 1,011,861 | 849,038 | 824,279 |
| Selling, general & administrative expense | 1,175,478 | 844,654 | 910,218 |
| Total operating expenses | 1,175,478 | ... | ... |
| Income (loss) from operations | (163,617) | 4,384 | (85,938) |
| Other income | (13,099) | 35,508 | 2,219 |
| Income (loss) before provision for income taxes | (176,716) | 39,892 | (83,719) |
| Net income (loss) | (179,957) | 39,892 | (83,719) |
| Weighted average shares outstanding - basic | 16,660,452 | 15,540,259 | 15,018,924 |
| Weighted average shares outstanding - diluted | 16,660,452 | 15,540,259 | 15,018,924 |
| Year end shares outstanding | 16,933,346 | 15,548,790 | 15,305,120 |
| Net income (loss) per share - continuing operations - basic | \$(0.01) | ... | ... |
| Net income (loss) per share - basic | \$(0.01) | \$0.00 | \$0.00 |
| Net income (loss) per share - continuing operations - diluted | \$(0.01) | ... | ... |
| Net income (loss) per share - diluted | \$(0.01) | \$0.00 | \$0.00 |
| Number of full time employees | 2 | ... | ... |
| Total number of employees | 2 | 2 | 2 |
| Number of common stockholders | ... | 944 | 944 |
| Federal Tax Expense as of 31 (21% Tax Rate) | (50,777) | ... | ... |
| State of New Jersey Tax Expense as of 31 (9% Tax Rate) | 16,205 | ... | ... |
| (Taxable Income)/ Net Loss, 1 to 31 | 37,813 | ... | ... |
| Provision for Income Taxes | 54,018 | ... | ... |

☐ As reported by the Company; ☐ Adjusted for 1-for-2 stock split, July 20, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|---|--------------|--------------|
| Cash & cash equivalents | 87,339 | 46,481 |
| Accounts receivable, gross | ... | 108,635 |
| Allowance for doubtful accounts | ... | 0 |
| Accounts receivable, net | 135,061 | 108,635 |
| Inventory | 270,788 | 234,566 |
| Supplier deposits | 52,655 | 28,000 |
| Prepaid expenses | 35,650 | 11,702 |
| Security deposit | ... | 113 |
| Total current assets | 581,493 | 429,497 |
| Total assets | 581,493 | 429,497 |
| Accounts payable & accrued expenses | ... | 58,944 |
| Small Business Administration (SBA) loans | 230,000 | ... |
| Total current liabilities | 310,621 | 58,944 |
| Common stock | 16,934 | 31,098 |
| Additional paid in capital | 24,063,176 | 23,729,900 |
| Retained earnings (accumulated deficit) | (23,809,238) | (23,390,445) |
| Total stockholders' equity (deficit) | 270,872 | 370,553 |
| Total Equity | 270,872 | ... |

Recent Dividends:**1. Equator Beverage Company common.**

No dividends paid.

Annual Dividends:**1. Equator Beverage Company common.**

No dividends paid.

ESPORTS ENTERTAINMENT GROUP INC**Earnings, 6 mos. to Dec 31(Consol. - \$):**

| | 2023 | 2022 |
|-----------------------------|--------------|---------------|
| Total revenues | 5,271,844 | ... |
| Net Sales | ... | 16,014,669 |
| Cost & expenses | 26,815,531 | 43,576,399 |
| Operating income | (21,543,687) | (27,561,730) |
| Other income (expense), net | (582,014) | 11,290,239 |
| Gains or losses | 279,476 | ... |
| Net before taxes | (21,846,225) | (18,301,273) |
| Net income | (21,846,225) | (18,301,273) |
| Balance for common | (49,972,199) | (18,852,331) |
| Earnings common share | | |
| Primary | \$(180.08) | \$(12,800.00) |
| Fully Diluted | \$(180.08) | \$(12,800.00) |
| Common Shares: | | |
| Full Diluted | 277,506 | 1,469 |
| Year-end | 1,145,980 | 2,114 |

EUROSITE POWER INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---------------------------------------|-----------|-----------|-----------|
| | | | (revised) |
| Energy revenues | 7,399,047 | 5,660,878 | 4,411,770 |
| Turnkey revenues | 164,593 | ... | 30,195 |
| Other revenues | ... | 63,759 | ... |
| Total revenues | ... | 5,724,637 | 4,441,965 |
| Fuel, maintenance & installation cost | 4,464,357 | 3,354,517 | 2,334,184 |
| Turnkey costs | ... | ... | (11,207) |
| Site impairments | 131,806 | 29,342 | ... |
| Site depreciation expense | 723,556 | 701,627 | 795,262 |
| Total cost of sales | 4,085,485 | ... | 3,118,239 |
| Gross profit (loss) | 2,243,921 | 1,639,151 | 1,323,726 |
| General & administrative expenses | 766,046 | 729,053 | 706,557 |
| Selling expenses | ... | 376,331 | 298,238 |
| Engineering expenses | ... | 513,736 | 462,675 |
| Selling | 419,273 | ... | ... |
| Engineering | 545,114 | ... | ... |

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Total operating expenses | ... | 1,619,121 | 1,467,470 |
| Income (loss) from operations | 513,488 | 20,031 | (143,744) |
| Interest expense | ... | ... | ... |
| Debt conversion expense | 47,166 | ... | ... |
| Interest expense | ... | 99,559 | 123,059 |
| Total other income (expense) | ... | (99,559) | (123,059) |
| Income (loss) before income taxes | 466,322 | (79,528) | (266,803) |
| Provision (benefit) for income taxes | ... | 23,133 | (128,816) |
| Net income (loss) | 466,322 | (102,661) | (137,987) |
| Weighted average shares outstanding - basic | 82,263,525 | 82,263,525 | 82,263,525 |
| Weighted average shares outstanding - diluted | 82,263,525 | 82,263,525 | 82,263,525 |
| Year end shares outstanding | 82,263,525 | 82,263,525 | 82,263,525 |
| Net income (loss) per share - basic | \$0.01 | \$(0.00) | \$(0.00) |
| Net income (loss) per share - diluted | \$0.01 | \$(0.00) | \$(0.00) |
| Total number of employees | ... | 12 | 10 |
| Number of common stockholders | ... | 62 | 62 |

☐ As reported by the Company; ☐ Average; ☐ As of March 28, 2023; ☐ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 2,873,724 | 1,836,435 |
| Accounts receivable | 1,020,090 | 747,670 |
| Inventory | 356,982 | 177,462 |
| Other current assets | 311,551 | 257,409 |
| Total current assets | 4,562,347 | 3,018,976 |
| Property & equipment, net | 7,416,060 | 7,745,976 |
| Other assets, long term | ... | 613,381 |
| Total assets | 11,978,406 | 11,378,334 |
| Accounts payable | 261,201 | 100,473 |
| Accrued expenses & other current liabilities | 218,060 | 296,140 |
| Value added & other tax payable | 180,770 | 87,033 |
| Note payable - bank, short-term | 349,787 | 355,165 |
| Total current liabilities | 1,009,817 | 838,810 |
| Note payable - bank | 730,283 | 999,743 |
| Total liabilities | 1,740,100 | 1,838,553 |
| Common stock | 82,264 | 82,264 |
| Additional paid-in capital | 22,898,776 | 22,895,266 |
| Capital contributions | 72,938 | ... |
| Accumulated deficit | (12,815,671) | ... |
| Retained earnings (accumulated deficit) | ... | (13,281,993) |
| Cumulative translation adjustment (CTA) | ... | (155,755) |
| Total stockholders' equity | 10,238,307 | 9,539,781 |
| Total Equity | 10,238,307 | ... |

☐ As reported by the Company

Recent Dividends:**1. EuroSite Power Inc common.**

No dividends paid.

Annual Dividends:**1. EuroSite Power Inc common.**

No dividends paid.

EVOFEM BIOSCIENCES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|----------------|------------|------|-----------|
| | | | (revised) |
| Total revenues | 18,218,000 | ... | ... |

| | | | |
|--|-------------------|---------------------|----------------------|
| Product sales, net | 18,218,000 | 16,837,000 | 8,244,000 |
| Cost of goods sold | 6,512,000 | 4,415,000 | 4,055,000 |
| Research & development | 2,939,000 | 25,032,000 | 33,129,000 |
| Selling & marketing | 11,664,000 | 43,951,000 | 113,152,000 |
| General & administrative | 14,950,000 | 27,563,000 | 24,709,000 |
| Total operating expenses | 36,065,000 | 100,961,000 | 175,045,000 |
| Income (loss) from operations | (17,847,000) | (84,124,000) | (166,801,000) |
| Interest income | 31,000 | 85,000 | 15,000 |
| Gain (loss) on issuance of financial instruments, net | (6,776,000) | (72,993,000) | ... |
| Change in fair value of financial instruments | 4,879,000 | 82,465,000 | (33,657,000) |
| Other expenses, net | 2,628,000 | 2,087,000 | 4,732,000 |
| Gain (loss) on debt extinguishment | 75,337,000 | ... | ... |
| Total other income (expense), net | 70,843,000 | 7,470,000 | (38,374,000) |
| Income (loss) before income tax - United States | ... | (76,654,000) | (205,175,000) |
| Income (loss) before income tax | 52,996,000 | (76,654,000) | (205,175,000) |
| Current income tax provision - state | 17,000 | 44,000 | 17,000 |
| Total current income tax provision | 17,000 | 44,000 | 17,000 |
| Income tax expense | 17,000 | 44,000 | 17,000 |
| Deemed dividends | 2,984,000 | ... | ... |
| Net income (loss) | 52,979,000 | (76,698,000) | (205,192,000) |
| Series B-1 & B-2 convertible preferred stock deemed dividends | ... | 1,316,000 | 1,047,000 |
| Net income (loss) attributable to common stockholders | 49,995,000 | (78,014,000) | (206,239,000) |
| Weighted average shares outstanding - basic | 4,826,763 | □465,985 | □69,818 |
| Weighted average shares outstanding - diluted | 984,038,574 | □465,985 | □69,818 |
| Year end shares outstanding | 20,007,799 | □984,786 | □86,666 |
| Net income (loss) per share - basic | \$10.36 | □\$(167.50) | □\$(2,953.75) |
| Net income (loss) per share - diluted | \$0.05 | □\$(167.50) | □\$(2,953.75) |
| Number of full time employees | ... | □35 | □119 |
| Number of part time employees | ... | □2 | ... |
| Number of common stockholders | 14 | □61 | □114 |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$10.36 | ... | ... |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$0.05 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-125 stock split, May 18, 2023; □ Adjusted for 1-for-15 stock split, May 6, 2022; □ Shares increased due to the effect of issuance of common stock, noncash exercise of purchase rights, conversion of B-2 convertible preferred stock, restricted stock, cash repurchase of common stock; □ As of April 7, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|---------------|---------------|
| | 2023 | 2022 |
| Cash & cash equivalents | ... | 2,769,000 |
| Restricted cash | 580,000 | 1,207,000 |
| Trade accounts receivable, net | 5,738,000 | 1,126,000 |
| Inventories | 1,697,000 | 5,379,000 |
| Insurance | ... | 1,387,000 |
| Selling & marketing related costs | ... | 44,000 |
| Manufacturing related costs | ... | 82,000 |
| Other prepaid & other current assets | ... | 705,000 |
| Prepaid & other current assets | 1,195,000 | 2,218,000 |
| Raw materials | 520,000 | ... |
| Work in process | 386,000 | ... |
| Finished goods | 791,000 | ... |
| Total current assets | 9,210,000 | 12,699,000 |
| Research equipment | 586,000 | 653,000 |
| Computer equipment & software | 2,389,000 | 639,000 |
| Office furniture | ... | 881,000 |
| Leasehold improvements | ... | 3,388,000 |
| Construction in-process | 1,156,000 | 1,568,000 |
| Computer equipment and software | 647,000 | ... |
| Property & equipment, gross | ... | 7,129,000 |
| Less: accumulated depreciation | 1,186,000 | 3,189,000 |
| Property & equipment, net | 1,203,000 | 3,940,000 |
| Operating lease right-of-use assets | 106,000 | 4,406,000 |
| Restricted cash included in noncurrent assets | ... | 800,000 |
| Inventories, long-term | ... | 1,270,000 |
| Prepaid directors & officers' insurance | ... | 1,717,000 |
| Other noncurrent assets | 35,000 | 331,000 |
| Other noncurrent assets | 35,000 | 4,118,000 |
| Total assets | 10,554,000 | 25,163,000 |
| Accounts payable | 17,020,000 | 14,984,000 |
| Convertible notes payable - Baker Bros. notes | 14,731,000 | 39,416,000 |
| Convertible notes payable - Adjuvant Clinical trial related costs | 2,498,000 | 2,574,000 |
| Selling & marketing related costs | ... | 674,000 |
| Legal & other professional fees | 2,609,000 | ... |
| Other accrued expenses | ... | 876,000 |
| Accrued expenses | ... | 4,124,000 |
| Accrued compensation | ... | 2,175,000 |
| Operating lease liabilities - current | 97,000 | 2,311,000 |
| Derivative liabilities | 1,926,000 | 1,676,000 |
| Other current liabilities | 3,316,000 | 2,876,000 |
| Note payable to bank - current portion | 28,537,000 | ... |
| Other | 583,000 | ... |
| Accrued expenses - Balancing value | 4,227,000 | ... |
| Accrued royalty | 1,146,000 | ... |
| Total current liabilities | 72,463,000 | 93,830,000 |
| Operating lease liabilities - noncurrent | 8,000 | 3,133,000 |
| Total liabilities | 72,471,000 | 96,963,000 |
| Convertible preferred stock - series B-2 | 4,593,000 | ... |
| Common stock | 2,000 | 12,000 |
| Additional paid-in capital | 823,036,000 | 817,355,000 |
| Accumulated other comprehensive income | (849,000) | 49,527,000 |
| Retained earnings (accumulated deficit) | (888,699,000) | (938,694,000) |
| Total stockholders' equity (deficit) | (66,510,000) | (71,800,000) |
| Total Equity | (66,510,000) | ... |

Recent Dividends:

- 1. Evofem Biosciences Inc series E-1 convertible preferred.**
No dividends paid.
 - 2. Evofem Biosciences Inc series B-2 convertible preferred.**
No dividends paid.
 - 3. Evofem Biosciences Inc common.**
No dividends paid.
 - 4. Evofem Biosciences Inc series F-1 convertible preferred.**
No dividends paid.
- #### Annual Dividends:
- 1. Evofem Biosciences Inc series E-1 convertible preferred.**
No dividends paid.
 - 2. Evofem Biosciences Inc series B-2 convertible preferred.**
No dividends paid.
 - 3. Evofem Biosciences Inc common.**
No dividends paid.
 - 4. Evofem Biosciences Inc series F-1 convertible preferred.**
No dividends paid.

EXELA TECHNOLOGIES INC

Annual Report

| | | | |
|---|---------------|---------------|---------------|
| | 2023 | 2022 | □2021 |
| | | | (revised) |
| Revenue | 1,064,124,000 | ... | ... |
| Revenue | 1,064,124,000 | 1,077,157,000 | 1,166,606,000 |
| Cost of revenue (exclusive of depreciation & amortization) | 833,422,000 | 877,474,000 | 889,095,000 |
| Selling, general & administrative expenses (exclusive of depreciation & amortization) | 150,672,000 | 176,524,000 | 169,781,000 |
| Depreciation & amortization | 60,535,000 | 71,831,000 | 77,150,000 |
| Impairment of goodwill & other intangible assets | ... | 171,182,000 | ... |
| Related party expense | 11,444,000 | 8,923,000 | 9,191,000 |
| Operating profit (loss) | 8,051,000 | (228,777,000) | 21,389,000 |
| Interest expense, net | 139,656,000 | 164,870,000 | 168,048,000 |
| Debt modification & extinguishment costs (gain), net | ... | 4,522,000 | (16,689,000) |
| Gain (loss) on extinguishment of debt | 16,129,000 | ... | ... |
| Sundry expense (income), net | ... | (957,000) | 363,000 |
| Other income (expense), net | (973,000) | (14,170,000) | (401,000) |
| Income (loss) before income taxes - United States | ... | (422,135,000) | (135,299,000) |
| Income (loss) before income taxes - foreign | ... | 10,754,000 | 4,565,000 |
| Net income (loss) before income taxes | (115,565,000) | (411,382,000) | (130,734,000) |
| Deferred federal income tax expense (benefit) | ... | (1,597,000) | 5,000 |
| Current state income tax expense (benefit) | ... | 636,000 | 1,232,000 |
| Deferred state income tax expense (benefit) | ... | (123,000) | 351,000 |
| Current foreign income tax expense (benefit) | ... | 3,416,000 | 3,775,000 |
| Deferred foreign income tax expense (benefit) | ... | 1,867,000 | 6,293,000 |
| Foreign - Current | 8,755,000 | ... | ... |
| State - Current | 1,161,000 | ... | ... |
| Federal - Deferred | 666,000 | ... | ... |
| Foreign - Deferred | (1,560,000) | ... | ... |

| | | | | | | | | |
|---|---------------|---------------|---------------|---|---------------|---------------|--|-----------------|
| State - Deferred | (154,000) | ... | ... | Less: allowance for doubtful accounts | 6,628,000 | 6,402,000 | Long-term debt, net of current maturities | 942,035,000 |
| Income tax expense (benefit) | 8,868,000 | 4,199,000 | 11,656,000 | Accounts receivable, net | ... | 101,616,000 | Capital lease obligations, net of current maturities | 5,953,000 |
| Net income (loss) | (124,433,000) | (415,581,000) | (142,390,000) | Related party receivables & prepaid expenses | 296,000 | 759,000 | Finance lease liabilities, net of current portion | 9,448,000 |
| Net profit (loss) attributable to noncontrolling interest in XBP Europe, net of taxes | (723,000) | ... | ... | Work in process | 1,034,000 | 1,178,000 | Pension liabilities, net | 13,192,000 |
| Net loss attributable to Exela Technologies, Inc. | (125,156,000) | ... | ... | Finished goods | 7,682,000 | 10,804,000 | Deferred income tax liabilities | 11,692,000 |
| Cumulative dividends for series A preferred stock | 3,961,000 | 3,588,000 | 1,576,000 | Supplies & parts | 7,476,000 | 8,991,000 | Long-term income tax liabilities | 6,359,000 |
| Cumulative dividends for series B preferred stock | 4,718,000 | 3,665,000 | ... | Less: allowance for obsolescence | 4,690,000 | 4,125,000 | Operating lease liabilities, net of current portion | 26,703,000 |
| Net income (loss) attributable to common stockholders | (133,835,000) | (422,834,000) | (143,966,000) | Inventories, net | 11,502,000 | 16,848,000 | Deferred revenue | 1,180,000 |
| Weighted average shares outstanding - basic | 5,983,517 | Ⓔ307,967 | Ⓔ29,500 | Prepays | 23,425,000 | 23,347,000 | Accrued lease exit obligations | 373,000 |
| Weighted average shares outstanding - diluted | 5,983,517 | Ⓔ307,967 | Ⓔ29,500 | Deposits | 1,939,000 | 2,859,000 | Accrued compensation expense | 1,021,000 |
| Year end shares outstanding | 6,365,353 | ⒺⒺ1,393,276 | ⒺⒺ66,299 | Prepaid expenses & other current assets | 25,364,000 | 26,206,000 | Other long-term liabilities | 5,811,000 |
| Net income (loss) per share - basic | \$(22.37) | Ⓔ\$(1,372.00) | Ⓔ\$(4,880.00) | Other | 8,719,000 | ... | Total liabilities | 1,495,172,000 |
| Net income (loss) per share - diluted | \$(22.37) | Ⓔ\$(1,372.00) | Ⓔ\$(4,880.00) | Total current assets | 181,208,000 | 190,496,000 | Common stock | 261,000 |
| Number of full time employees | 13,650 | Ⓔ15,542 | Ⓔ16,629 | Land | 6,288,000 | 6,687,000 | Preferred stock | 1,000 |
| Number of part time employees | 450 | Ⓔ458 | Ⓔ371 | Buildings & improvements | 23,316,000 | 24,307,000 | Series A preferred stock | 1,000 |
| Total number of employees | 14,100 | Ⓔ16,000 | Ⓔ17,000 | Leasehold improvements | 37,930,000 | 37,383,000 | Additional paid in capital | 1,179,098,000 |
| Number of common stockholders | 38 | Ⓔ66 | Ⓔ77 | Vehicles | 443,000 | 289,000 | Less: common stock held in treasury, at cost | 10,949,000 |
| Number of beneficiary stockholders | ... | ⒺⒺ90,000 | ⒺⒺ90,000 | Machinery & equipment | 25,755,000 | 26,820,000 | Equity-based compensation | (57,073,000) |
| Foreign currency translation adjustments | ... | 2,675,000 | (44,000) | Computer equipment & software | 103,011,000 | 108,898,000 | Accumulated deficit | (2,084,114,000) |
| Other income, net | 884,000 | ... | ... | Furniture & fixtures | 8,597,000 | 8,574,000 | Retained earnings (accumulated deficit) | (1,948,009,000) |
| Basic EPS - Net Income excl Extra Items applicable to Common - (Company Level) | \$(22.37) | ... | ... | Finance lease right-of-use assets | 66,168,000 | 66,256,000 | Accumulated other comprehensive income (loss): foreign currency translation adjustment | (7,648,000) |
| Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level) | \$(22.37) | ... | ... | Property, plant & equipment, gross | 271,508,000 | 279,214,000 | Accumulated other comprehensive income (loss): unrealized pension actuarial gains (losses), net of tax | (174,000) |
| | | | | Less: accumulated depreciation and amortization | 213,142,000 | ... | Total accumulated other comprehensive income (loss) | (7,822,000) |
| | | | | Property, plant & equipment, net | 58,366,000 | 71,694,000 | Total stockholder's equity (deficit) | (855,503,000) |
| | | | | Operating lease right-of-use assets, net | 33,874,000 | 40,734,000 | Noncontrolling interest in XBP Europe | (3,332,000) |
| | | | | Goodwill | 170,452,000 | 186,802,000 | Total Equity | (858,835,000) |
| | | | | Intangible assets, net | 164,920,000 | 200,982,000 | | |
| | | | | Deferred income tax assets | 3,043,000 | 1,483,000 | | |
| | | | | Other noncurrent assets | 24,474,000 | 29,721,000 | | |
| | | | | Total assets | 636,337,000 | 721,912,000 | | |
| | | | | Accounts payable | 61,109,000 | 79,249,000 | | |
| | | | | Related party payables | 1,938,000 | 2,473,000 | | |
| | | | | Income tax payable | 2,080,000 | 2,045,000 | | |
| | | | | Accrued taxes (exclusive of income taxes) | 5,110,000 | 9,797,000 | | |
| | | | | Accrued professional & legal fees | 34,342,000 | 37,366,000 | | |
| | | | | Accrued legal reserve for pending litigation | 10,333,000 | 10,322,000 | | |
| | | | | Accrued transaction costs | 2,764,000 | 2,763,000 | | |
| | | | | Other accruals | 1,680,000 | 1,092,000 | | |
| | | | | Accrued interest | 52,389,000 | ... | | |
| | | | | Accrued taxes (exclusive of income taxes) | 9,470,000 | ... | | |
| | | | | Accrued liabilities | ... | 61,340,000 | | |
| | | | | Accrued compensation & benefits | 65,012,000 | 54,143,000 | | |
| | | | | Accrued interest | 63,699,000 | 60,901,000 | | |
| | | | | Customer deposits | 23,838,000 | 16,955,000 | | |
| | | | | Deferred revenue | 12,099,000 | 16,405,000 | | |
| | | | | Obligation for claim payment | 66,988,000 | 44,380,000 | | |
| | | | | Current portion of finance lease liabilities | 4,856,000 | 5,485,000 | | |
| | | | | Current portion of operating lease liabilities | 10,845,000 | 11,867,000 | | |
| | | | | Current portion of long-term debts | 30,029,000 | 154,802,000 | | |
| | | | | Total current liabilities | 394,882,000 | 510,045,000 | | |
| | | | | Other long-term debt | ... | 25,117,000 | | |
| | | | | First lien credit agreement | ... | 71,470,000 | | |
| | | | | Notes | ... | 931,721,000 | | |
| | | | | Secured borrowings under BRCC facility | ... | 68,529,000 | | |
| | | | | Total debt | 1,030,580,000 | 1,096,837,000 | | |
| | | | | Less: current portion of long-term debt | ... | 154,802,000 | | |

Recent Dividends:
1. Exela Technologies Inc common stock subject to possible redemption.
 No dividends paid.

2. Exela Technologies Inc unit.
 No dividends paid.

3. Exela Technologies Inc series A preferred.
 No dividends paid.

4. Exela Technologies Inc common.
 No dividends paid.

5. Exela Technologies Inc series B preferred.
 No dividends paid.

Annual Dividends:
1. Exela Technologies Inc common stock subject to possible redemption.
 No dividends paid.

2. Exela Technologies Inc unit.
 No dividends paid.

3. Exela Technologies Inc series A preferred.
 No dividends paid.

4. Exela Technologies Inc common.
 No dividends paid.

5. Exela Technologies Inc series B preferred.
 No dividends paid.

**EXPION360 INC
 Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

Ⓔ Reclassified to conform with 2022 presentation; Ⓕ Adjusted for 1-for-200 stock split, May 15, 2023; Ⓖ Adjusted for 1-for-20 stock split, July 26, 2022; Ⓗ Shares increased due to the effect of market offerings, vested RSUs and executive chairman under certain subscription agreement; Ⓘ Shares increased due to the effect of preferred shares converted to common stock; and issuance of common stock to existing directors under subscription agreements, market offering & private placement; Ⓚ Approximately; Ⓛ As of March 31, 2023; Ⓜ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-----------------------------|------------|------------|
| Cash & cash equivalents | 23,341,000 | 15,073,000 |
| Restricted cash | 43,812,000 | 29,994,000 |
| Billed receivables, gross | 50,926,000 | 72,852,000 |
| Unbilled receivables, gross | 23,876,000 | 25,741,000 |
| Other accounts receivable | 76,893,000 | 9,425,000 |

| | 2023 | 2022 | [□] 2021 (revised) | Total other assets | | | expenses | | | |
|---|-------------|-----------------|--------------------------------|--|--------------|--------------|--|-------------|-------------|------------------|
| Total revenues | 5,981,134 | ... | ... | Total assets | 11,905,331 | 16,698,931 | Total costs & expenses | 697,525 | 1,076,379 | 900,466 |
| Sales, net | 5,981,134 | 7,162,837 | 4,517,499 | Accounts payable | 286,985 | 230,250 | Operations income (loss) | (909,016) | (1,173,476) | 298,338 |
| Cost of sales | 4,405,611 | 4,874,392 | 2,871,770 | Customer deposits | 17,423 | 58 | Other income | 1,979 | 7,046 | 7,346 |
| Gross profit | 1,575,523 | 2,288,445 | 1,645,729 | Accrued salaries & payroll liabilities | 225,685 | 169,337 | Other expenses | 89 | 16 | 93 |
| Selling, general & administrative | 8,745,135 | 8,241,859 | 2,909,085 | Rebate liability | ... | 26,015 | Imputed interest expenses | ... | 82,583 | 29,603 |
| Income (loss) from operations | (7,169,612) | (5,953,414) | (1,263,356) | Deferred income & deposit (sublease) | 4,445 | 14,168 | Total other income (expenses) | 1,890 | (75,553) | (22,350) |
| Interest income | 125,854 | 239 | 169 | Commission | ... | 9,720 | Income (loss) before income tax | (907,126) | (1,249,029) | 275,988 |
| Debt conversion expense | ... | ... | 112,133 | Franchise tax | 5,262 | 400 | Current income taxes expense - local | ... | ... | 21,348 |
| Extinguishment gain (loss) on debt settlement | ... | ... | (2,791,087) | Accrued interest | 2,839 | 222 | Income Taxes - Local - Current | ... | 4,579 | ... |
| Interest expense | 124,511 | 1,605,916 | 554,044 | Other accrued expenses & other current liabilities | ... | 86,302 | Income taxes expense | ... | 4,579 | 21,348 |
| Gain (loss) on disposal of sale of property & equipment | (3,426) | 13,312 | 8,521 | Current portion of operating lease liability | 522,764 | 465,055 | Net income (loss) | (907,126) | (1,253,608) | 254,640 |
| Other income | 394 | 389 | 372 | Liability for sale of future revenues, net | 54,284 | ... | Weighted average shares outstanding - basic | 119,956,826 | 119,956,826 | 119,956,826 |
| Settlement expense | 281,680 | ... | ... | Current portion of long-term-debt | 50,839 | 571,426 | Weighted average shares outstanding - diluted | 119,956,826 | 119,956,826 | 119,956,826 |
| Total other income (expense) | (283,369) | (1,591,976) | (3,448,202) | Convertible note | 2,082,856 | ... | Year end shares outstanding | 119,956,826 | 119,956,826 | 119,956,826 |
| Income (loss) before taxes | (7,452,981) | (7,545,390) | (4,711,558) | Current portion of stockholder promissory notes | 762,500 | ... | Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$0.00 |
| State franchise tax | 3,293 | (8,850) | 9,300 | Total current liabilities | 4,015,882 | 1,572,953 | Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$0.00 |
| Tax expense (income) | 3,293 | (8,850) | 9,300 | Note payable - secured | ... | 510,475 | Number of full time employees | 28 | 46 | 57 |
| Net income (loss) | (7,456,274) | (7,536,540) | (4,720,858) | Long-term debt, net of current portion & discount | ... | 439,049 | Number of beneficiary stockholders | 163 | 153 | [□] 144 |
| Weighted average common shares outstanding - basic | 6,887,985 | 6,135,938 | 2,888,695 | Operating lease liability, net of current portion | 2,241,325 | 2,754,964 | Total number of employees | 28 | 46 | ... |
| Weighted average common shares outstanding - diluted | 6,887,985 | 6,135,938 | 2,888,695 | Shareholder promissory notes | 298,442 | 325,000 | Cash & cash equivalents | 266,542 | 454,980 | ... |
| Year end shares outstanding | 6,922,912 | 6,802,464 | [□] 4,300,000 | Total liabilities | 6,555,649 | 5,091,966 | Amount due from related party | 141 | 686 | ... |
| Net earnings (loss) per share - basic | \$(1.08) | \$(1.23) | \$(1.63) | Common stock | 6,923 | 6,802 | Prepayments | 28,763 | 43,066 | ... |
| Net earnings (loss) per share - diluted | \$(1.08) | \$(1.23) | \$(1.63) | Additional paid-in capital | 26,438,524 | 25,239,654 | Deposits paid, prepayments & other receivables | ... | 43,066 | ... |
| Number of full time employees | 23 | 25 | 21 | Retained earnings (accumulated deficit) | (21,095,765) | (13,639,491) | Income Tax receivables | 2,073 | 3,859 | ... |
| Number of common stockholders | 11 | [□] 15 | ... | Total stockholders' equity (deficit) | 5,349,682 | 11,606,965 | Prepaid expense and other assets | 28,763 | ... | ... |
| Total number of employees | 23 | ... | ... | Total Equity | 5,349,682 | ... | Total current assets | 297,519 | 502,591 | ... |

[□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect of issuance of shares upon conversion of convertible notes, exchange for building signage, cash, settlement of convertible notes and exchange for services; [□] As of March 27, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash & cash equivalents | 3,932,698 | 7,201,244 |
| Accounts receivable | 154,935 | 298,035 |
| Inventory | 3,825,390 | 4,530,136 |
| Prepaid or in-transit inventory | 163,948 | 141,611 |
| Prepaid expenses & other current assets | 189,418 | 171,791 |
| Total current assets | 8,266,389 | 12,342,817 |
| Vehicles & transport | 551,906 | 593,097 |
| Leasehold improvements | 314,819 | 314,819 |
| Office furniture & equipment | 188,131 | 188,131 |
| Manufacturing equipment | 179,274 | 179,274 |
| Warehouse equipment | ... | 81,164 |
| QA equipment | 33,032 | 22,142 |
| Molds | 81,164 | 15,992 |
| Property & equipment | 1,348,326 | 1,394,619 |
| Less: accumulated depreciation | 430,295 | 250,861 |
| Property & equipment, net | 918,031 | 1,143,758 |
| Operating leases - right-of-use assets | 2,662,015 | 3,148,455 |
| Deposits | 58,896 | 63,901 |

Recent Dividends:
1. **Expion360 Inc common.**
No dividends paid.

Annual Dividends:
1. **Expion360 Inc common.**
No dividends paid.

EZAGOO LTD Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------|---------|-----------|
| Revenue - non-related party | ... | ... | 2,130,269 |
| Related Party | ... | 9 | ... |
| Non-related parties | 166,396 | 286,045 | ... |
| Revenue | 166,396 | 286,054 | 2,130,269 |
| Cost of revenue for short video produce costs, related party | ... | ... | 620,435 |
| Cost of revenue for rental & related costs | ... | 44,661 | 61,933 |
| Cost of revenue for salaries & related expenses | ... | 196,970 | 94,334 |
| Related Party | 156,758 | 5,334 | ... |
| Cost of revenue for costs of goods sold and sales commission | 108,720 | ... | ... |
| Selling & marketing expenses | 112,409 | 136,186 | 154,763 |
| General & administrative | ... | ... | ... |

[□] As of April 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 266,542 | 454,980 |
| Amount due from related party | 141 | 686 |
| Prepayments | 28,763 | 43,066 |
| Deposits paid, prepayments & other receivables | ... | 43,066 |
| Income Tax receivables | 2,073 | 3,859 |
| Prepaid expense and other assets | 28,763 | ... |
| Total current assets | 297,519 | 502,591 |
| Office equipment | 42,332 | 42,332 |
| Less: accumulated depreciation | 42,332 | 41,208 |
| Property, plant & equipment, net | ... | 1,124 |
| Operating lease right-of-use assets | 21,603 | 181,520 |
| Total assets | 319,122 | 685,235 |
| Account payables | 13,527 | 20,594 |
| Other payables | 172,718 | 411,411 |
| Deposits received from customers | 55,236 | 101,704 |
| Accrued payroll & benefits | 39,374 | 32,424 |
| Amount due to directors | ... | 27,584 |
| Amount due (from) to related parties | 27,577 | 2,342,816 |
| Deferred revenue | ... | 2,837 |
| Operating lease liabilities, current | 21,603 | 156,015 |
| Other payable | 78,108 | 277,283 |
| Amounts due to the related parties | 3,215,486 | ... |
| Total current liabilities | 3,450,911 | 2,961,257 |
| Total liabilities | 3,450,911 | 2,961,257 |
| Common stock | 11,996 | 11,996 |
| Additional paid-in capital | 1,469,166 | 1,467,490 |

| | | |
|---|-------------|-------------|
| Accumulated other comprehensive income (loss) | 125,963 | 76,280 |
| Accumulated deficit | (4,738,914) | ... |
| Retained earnings (accumulated deficit) | ... | (3,831,788) |
| Total stockholders' equity (deficit) | (3,131,789) | (2,276,022) |
| Total Equity | (3,131,789) | (2,276,022) |

Recent Dividends:

1. Ezago Ltd common.

No dividends paid.

Annual Dividends:

1. Ezago Ltd common.

No dividends paid.

EZFILL HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|---------------------|---------------------|--------------------|
| Selling, general & administrative expense | 9,087,223 | ... | ... |
| Revenues | 15,044,721 | 7,233,957 | 7,233,957 |
| Sales - net | 23,216,423 | ... | ... |
| Total revenues | 23,216,423 | 15,044,721 | 7,233,957 |
| Cost of sales | 21,845,574 | 15,218,234 | 7,027,274 |
| Operating expenses | 12,648,629 | 8,102,934 | 8,102,934 |
| Impairment of goodwill & other intangible assets | 2,636,402 | ... | ... |
| Impairment of fixed assets | 258,114 | ... | ... |
| Depreciation & amortization | 1,108,186 | 1,769,621 | 872,834 |
| Total costs & expenses | 32,040,983 | 32,531,000 | 16,003,042 |
| Operating income (loss) | (8,824,560) | (17,486,279) | (8,769,085) |
| Interest income | 34,327 | 84,603 | ... |
| Other income | 64,800 | ... | 161,572 |
| Interest expense | 1,719,296 | 104,089 | 775,884 |
| Income (loss) before income taxes .. | (10,471,889) | (17,505,765) | (9,383,397) |
| Net income (loss) | (10,471,889) | (17,505,765) | (9,383,397) |
| Weighted average shares outstanding | | | |
| - basic | 3,753,038 | 3,301,484 | 2,524,931 |
| Weighted average shares outstanding | | | |
| - diluted | 3,753,038 | 3,301,484 | 2,524,931 |
| Year end shares outstanding | 4,776,531 | 3,335,674 | 3,280,434 |
| Net income (loss) per share - basic | \$(2.79) | \$(5.28) | \$(3.68) |
| Net income (loss) per share - diluted | \$(2.79) | \$(5.28) | \$(3.68) |
| Number of full time employees | ... | 53 | 42 |
| Number of common stockholders | 1,395 | 98 | 104 |
| Loss on sale of marketable debt securities | (27,160) | ... | ... |
| Total other income (expense) - net | (1,647,329) | ... | ... |
| Deferred | (2,588,000) | ... | ... |
| Valuation allowance .. | 2,588,000 | ... | ... |

Adjusted for 1-for-8 stock split, April 27, 2023; Shares increased due to the effect of initial public offering, stock based compensation, debt discount, acquisition shares, bonus, settlement shares, warrants, lender, technology and sale of share; Approximately; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------------------|---------|-----------|
| Cash & cash equivalents | 226,985 | 2,066,793 |
| Investment in debt securities | ... | 2,120,082 |

| | | |
|--|--------------|--------------|
| Accounts receivable, gross | 1,274,112 | 766,692 |
| Allowance for doubtful accounts | 81,772 | 0 |
| Accounts receivable, net | 1,192,340 | 766,692 |
| Prepaid expenses & other assets | ... | 329,351 |
| Inventory | 134,057 | 151,248 |
| Prepays and other | 220,909 | ... |
| Total current assets | 1,774,291 | 5,434,166 |
| Equipment | 9,471 | 265,637 |
| Leasehold improvements | 29,422 | 29,422 |
| Vehicles | 5,119,048 | 5,142,828 |
| Office furniture | 129,475 | 129,475 |
| Office equipment | ... | 9,471 |
| Vehicle construction in process | ... | 147,006 |
| Equipment | 265,637 | ... |
| Total fixed assets, gross | 5,553,053 | 5,723,839 |
| Less: accumulated depreciation | 2,242,866 | 1,134,680 |
| Fixed assets, net | 3,310,187 | 4,589,159 |
| Operating lease right of use asset | 297,394 | 521,782 |
| Other assets | ... | 52,737 |
| Deposits | 49,063 | ... |
| Operating lease - right-of-use asset - related party | 286,397 | ... |
| Total assets | 5,717,332 | 10,597,844 |
| Accounts payable | 845,275 | 987,012 |
| Accrued payroll | ... | 266,453 |
| Accrued interest | ... | 3,014 |
| Accounts payable & accrued liabilities | ... | 1,256,479 |
| Notes payable - related party | 4,802,115 | ... |
| Loans payable - current | 946,228 | 811,516 |
| Borrowings under revolving line of credit | ... | 1,000,000 |
| Operating lease liabilities | 246,880 | 230,014 |
| Accrued interest payable - related parties | 72,428 | ... |
| Operating lease liability - related party | 72,034 | ... |
| Total current liabilities | 6,984,960 | 3,298,009 |
| Loans payable - net of current portion | 353,490 | 1,198,380 |
| Operating lease liabilities, net of current portion | 69,128 | 316,008 |
| Operating Lease Liabilities - Long-Term | 215,960 | ... |
| Total liabilities | 7,623,538 | 4,812,397 |
| Common stock issuable | 26 | ... |
| Common stock | 451 | 2,669 |
| Additional paid in capital | 43,410,367 | 40,672,529 |
| Retained earnings (accumulated deficit) | (45,317,050) | (34,845,161) |
| Accumulated other comprehensive income (loss) | ... | (44,590) |
| Total stockholders' equity (deficit) | (1,906,206) | 5,785,447 |
| Total Equity | (1,906,206) | ... |

Recent Dividends:

1. EzFill Holdings Inc common.

No dividends paid.

Annual Dividends:

1. EzFill Holdings Inc common.

No dividends paid.

FALCONSTOR SOFTWARE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|----------------------------------|------------|------------|-------------------|
| Product revenue | 6,366,899 | 4,246,177 | 6,988,067 |
| Support & services revenue | 5,231,844 | 5,806,071 | 6,946,828 |
| Total revenue | 11,598,743 | 10,052,248 | 13,934,895 |

| | | | |
|--|----------------|--------------------|-----------------|
| Cost of product revenue | 81,814 | 97,270 | 325,089 |
| Cost of support & service revenue | 1,564,650 | 1,467,611 | 1,627,187 |
| Total cost of revenue | 1,646,464 | 1,564,881 | 1,952,276 |
| Gross profit | 9,952,279 | 8,487,367 | 11,982,619 |
| Research & development costs | 2,421,435 | 2,561,825 | 2,833,643 |
| Selling & marketing expenses .. | 3,511,722 | 4,003,764 | 5,672,023 |
| General & administrative expenses | 2,598,848 | 3,178,604 | 2,887,957 |
| Gain on litigation settlement | ... | ... | (632,600) |
| Restructuring costs (benefit) | ... | 744 | 833,313 |
| Total operating expenses | 8,532,005 | 9,744,937 | 11,594,336 |
| Operating income (loss) | 1,420,274 | (1,257,570) | 388,283 |
| Gain on debt extinguishment | ... | ... | 754,000 |
| Interest & other income (expense) | (362,176) | (330,927) | (657,773) |
| Income (loss) before income taxes - domestic | ... | (1,698,610) | 287,640 |
| Income (loss) before income taxes - foreign | ... | 110,113 | 196,870 |
| Income (loss) before income taxes .. | 1,058,098 | (1,588,497) | 484,510 |
| Current state & local income taxes provision (benefit) | 11,103 | 4,841 | (1,080) |
| Current foreign income taxes provision (benefit) | 141,048 | 138,275 | 266,205 |
| Total current income taxes provision (benefit) | ... | 143,116 | 265,125 |
| Deferred federal income taxes provision (benefit) | 893 | 1,785 | 1,785 |
| Deferred state & local income taxes provision (benefit) | (5,260) | 1,022 | 8,148 |
| Deferred foreign income taxes provision (benefit) | (68,069) | 64,535 | 251,705 |
| Total deferred income taxes provision (benefit) | ... | 67,342 | 261,638 |
| Income tax expense (benefit) | 79,715 | 210,458 | 526,763 |
| Net income (loss) | 978,383 | (1,798,955) | (42,253) |
| Less: accrual of Series A redeemable convertible preferred stock dividends | 1,579,232 | 1,494,057 | 1,143,697 |
| Less: accretion to redemption value of series A redeemable convertible preferred stock | 36,271 | 49,573 | 299,969 |
| Net income (loss) attributable to common stockholders | (637,120) | (3,342,585) | (1,485,919) |
| Weighted average shares outstanding - basic | 7,124,045 | 7,100,929 | 6,515,274 |
| Weighted average shares outstanding - diluted | 7,124,045 | 7,100,929 | 6,515,274 |
| Year end shares outstanding | 7,133,089 | 7,118,609 | 7,082,276 |
| Net income (loss) per share - basic | \$(0.09) | \$(0.47) | \$(0.23) |
| Net income (loss) per share - diluted | \$(0.09) | \$(0.47) | \$(0.23) |

Recent Dividends:

1. Femasys Inc common.

No dividends paid.

Annual Dividends:

1. Femasys Inc common.

No dividends paid.

FFBW INC (MD)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

| | 2023 | 2022 | 2021 |
|--|--------|--------|--------|
| Service charges and other fees | 532 | ... | ... |
| Occupancy and equipment | 1,158 | ... | ... |
| Interest & dividend income - loans, including fees | 14,006 | 10,942 | 10,268 |
| Interest & dividend income - securities - taxable | 1,095 | 1,032 | 814 |
| Interest & dividend income - securities - tax-exempt | 174 | 191 | 187 |
| Other interest & dividend income | 253 | 273 | 95 |
| Total interest & dividend income | 15,528 | 12,438 | 11,364 |
| Demand accounts | ... | ... | 34 |
| Money market accounts | ... | ... | 284 |
| Savings accounts | ... | ... | 36 |
| Health savings accounts | ... | ... | 16 |
| Certificates of deposit | ... | ... | 569 |
| Interest expense - interest-bearing deposits | 4,077 | 961 | 939 |
| Interest expense - borrowed funds | 438 | 18 | 50 |
| Total interest expense | 4,515 | 979 | 989 |
| Net interest income | 11,013 | 11,459 | 10,375 |
| Provision for loan losses | 166 | 194 | ... |
| Net interest income after provision for loan losses | 10,847 | 11,265 | 10,375 |
| Service charges & other fees | ... | 573 | 473 |
| Net gain on sale of loans | ... | 30 | 237 |
| Net gain (loss) on sale of securities | (102) | ... | ... |
| Increase in cash surrender value of insurance | 299 | 281 | 257 |
| Other noninterest income | 281 | 186 | 269 |
| Salaries & employee benefits | 5,539 | 5,330 | 5,207 |
| Occupancy & equipment | 531 | 1,156 | 1,045 |
| Data processing | 958 | 882 | 1,067 |
| Technology | 243 | 273 | 277 |
| Professional fees | ... | 549 | 444 |
| Other noninterest expense | 1,030 | 1,016 | 942 |
| Total noninterest expense | 9,459 | 9,206 | 8,982 |
| Income before income taxes | 2,398 | 3,129 | 2,629 |
| Current federal income taxes expense (benefit) | 484 | 635 | 309 |
| Current state income taxes expense (benefit) | ... | 270 | 163 |
| Total current | | | |

| | | | | | | |
|---|--------------|--------------|--------------|--|---------|---------|
| income taxes expense (benefit) | 484 | 905 | 472 | net | 6,388 | 6,668 |
| Deferred federal income taxes expense (benefit) | (98) | (91) | 136 | FHLB stock, at cost | 1,777 | ... |
| Deferred state income taxes expense (benefit) | ... | (27) | 38 | Other equity investments | ... | 1,517 |
| Total deferred income taxes expense (benefit) | (98) | (118) | 174 | Accrued interest receivable | 1,042 | 927 |
| Impact of deferred tax asset restatement | 503 | ... | ... | Cash value of life insurance | 10,609 | 10,310 |
| Provision (benefit) for income taxes | 889 | 787 | 646 | Other assets | 2,696 | 3,378 |
| Net earnings (loss) | 1,509 | 2,342 | 1,983 | Total assets | 318,041 | 323,035 |
| Weighted average shares outstanding - basic | 4,639 | 5,436 | 6,450 | Non interest-bearing checking deposits | 48,844 | 51,209 |
| Weighted average shares outstanding - diluted | 4,658 | 5,449 | 6,452 | Interest-bearing checking deposits | ... | 11,884 |
| Year end shares outstanding | 4,992 | 5,516 | 6,735 | Money market deposits | ... | 70,976 |
| Net earnings (loss) per share - basic | \$0.33 | \$0.43 | \$0.31 | Statement savings accounts deposits | 27,777 | 33,864 |
| Net earnings (loss) per share - diluted | \$0.32 | \$0.43 | \$0.31 | Health savings accounts deposits | 10,276 | 10,528 |
| Number of full time employees | ... | ... | 53 | Deposits held in escrow for stock subscriptions | 241,442 | ... |
| Number of common stockholders | ... | ... | 606 | Certificates of deposit | ... | 56,115 |
| | | | | Interest-bearing checking | 11,737 | ... |
| | | | | Money market | 60,319 | ... |
| | | | | Certificates of deposit | 82,489 | ... |
| | | | | Deposits | ... | 234,576 |
| | | | | Advance payments by borrowers for taxes & insurance | ... | 82 |
| | | | | Federal Home Loan Bank ("FHLB") advances | ... | 8,000 |
| | | | | Accrued interest payable | 204 | 21 |
| | | | | Other liabilities | 2,145 | 2,258 |
| | | | | Total liabilities | 243,791 | 244,937 |
| | | | | Common stock | 49 | 55 |
| | | | | Additional paid in capital | 37,823 | 43,630 |
| | | | | Unallocated common stock of employee stock ownership plan ("ESOP") | 4,894 | 5,200 |
| | | | | Retained earnings | 43,786 | 42,707 |
| | | | | Accumulated other comprehensive income (loss), net of income taxes | (2,514) | (3,094) |
| | | | | Total equity | 74,250 | 78,098 |
| | | | | Total Equity | 74,250 | ... |

As is; Full-time equivalent; As of March 18, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|---------|---------|
| Cash & due from banks | 5,754 | 10,887 |
| Cash and due from banks | 5,754 | ... |
| Cash & cash equivalents | ... | 10,887 |
| Available for sale securities, stated at fair value | 41,085 | 47,330 |
| Commercial loans - development | ... | 17,581 |
| Commercial loans - real estate | 16,391 | 114,328 |
| Commercial loans - commercial & industrial | ... | 22,302 |
| Residential real estate & consumer loans - one-to-four family owner-occupied | ... | 18,924 |
| Residential real estate & consumer loans - one-to-four family investor-owned | 28,263 | 28,497 |
| Residential real estate & consumer loans - multifamily loan | 110,882 | 40,445 |
| Residential real estate & consumer loans - consumer | 51,177 | 3,050 |
| Deferred loan fees | (445) | (476) |
| Allowance for loan losses | 3,175 | 2,633 |
| Commercial and industrial | 24,187 | ... |
| One-to-four family owner-occupied | 17,923 | ... |
| Consumer | 3,487 | ... |
| Loans - Gross | 252,310 | ... |
| Loans, net | 248,690 | 242,018 |
| Land | 844 | 844 |
| Buildings | 7,048 | 6,946 |
| Leasehold improvements | ... | 329 |
| Furniture & equipment | 1,615 | 1,567 |
| Automobiles | ... | 66 |
| Leasehold improvements | 329 | ... |
| Automobile | 66 | ... |
| Premises & equipment, gross | 9,902 | 9,752 |
| Less: accumulated depreciation | 3,514 | 3,084 |
| Premises & equipment, | | |

Recent Dividends:

1. FFBW Inc (MD) common.

No dividends paid.

Annual Dividends:

1. FFBW Inc (MD) common.

No dividends paid.

FINDIT INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2021 | 2020 (revised) |
|--|--------|---------|----------------|
| Findit services | 22,243 | 197,447 | 363,306 |
| Findit services - related party | ... | ... | 35,868 |
| Sales of essential oils | ... | 1,137 | 5,218 |
| Total revenue | 22,243 | 198,584 | 404,392 |
| Prurchases of materials & supplies | ... | 554 | 3,229 |
| Cost of goods sold - related party | ... | ... | 35,868 |
| Total cost of goods sold | ... | 554 | 39,097 |
| Gross margin | ... | 198,030 | 365,295 |
| Advertising, marketing & press release expense | ... | 7,383 | 260,870 |
| Amortization expense | 5,932 | 4,449 | 5,932 |
| Consulting services | ... | 6,350 | 21,408 |
| Content writing | ... | 43,100 | 88,649 |
| General & administrative expenses | 18,254 | 81,115 | 71,488 |
| Professional fees | 7,080 | 60,231 | 39,738 |

| | | | |
|---|-----------|---------------|------------------|
| per share - basic | \$(47.88) | □□ \$(420.00) | □□ \$(39,770.60) |
| Net earnings (loss) | | | |
| per share - diluted | \$(47.88) | □□ \$(420.00) | □□ \$(39,770.60) |
| Number of full time employees | 9 | 10 | □□ 17 |
| Number of common stockholders | 149 | □□ 100 | 161 |
| Foreign currency translation adjustments | ... | (487,236) | (111,589) |
| Earnings per share from continuing operations | \$(47.88) | ... | ... |
| Earnings per share from continuing operations | \$(47.88) | ... | ... |
| Total number of employees | 9 | ... | ... |

□ Adjusted for 1-for-7 stock split, January 18, 2023; □ Adjusted for 1-for-30 stock split, August 29, 2022; □ Adjusted for 1-for-20 stock split, December 18, 2023; □ Shares increased due to the effect of issuance of common stock for cash, intellectual property acquired, exercise of warrants, to consultants and upon exchange and conversion of preferred stock; □ Approximately; □ As of March 28, 2022; □ As of March 16, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 3,711,770 | 1,362,910 |
| Other receivables | ... | 93,014 |
| Prepaid expenses | 1,244,466 | 1,956,831 |
| Total current assets | 4,956,236 | 3,412,755 |
| Computer equipment & software | 87,818 | 11,540 |
| Office equipment | 11,540 | 48,278 |
| Leasehold improvements | 28,000 | 28,000 |
| Office equipment | 48,278 | ... |
| Total property, plant, & equipment | ... | 87,818 |
| Less accumulated depreciation | 73,253 | 43,979 |
| Property, equipment, & leasehold improvements, net | 14,565 | 43,839 |
| Restricted cash | 21,522 | 21,513 |
| Goodwill | 1,684,182 | 1,684,182 |
| Operating lease right-of-use assets | 195,440 | 259,261 |
| Deposits | 11,250 | 18,149 |
| Total other assets | ... | 1,983,105 |
| Total assets | 6,883,195 | 5,439,699 |
| Accrued expenses | 329,549 | ... |
| Accounts payable | 554,277 | 720,040 |
| Professional fees | ... | 309,867 |
| Clinical trials | ... | 5,340 |
| Consulting | ... | 4,969 |
| Payroll & benefits | 495,741 | ... |
| Accrued expenses | 825,290 | 320,176 |
| Accrued dividend payable | 1,069,616 | 761,488 |
| Note payable | 612,784 | 603,494 |
| Operating lease liabilities - current | 67,111 | 66,151 |
| Other current liabilities | 4,239 | 12,138 |
| Total current liabilities | 3,133,317 | 2,483,487 |
| Operating lease liabilities - non-current | 146,949 | 214,060 |
| Total liabilities | 3,280,266 | 2,697,547 |
| Common stock | 156 | 100 |
| Additional paid-in capital | 187,931,445 | 171,275,741 |
| Accumulated deficit | (184,328,672) | ... |
| Retained earnings (accumulated deficit) | ... | (168,533,689) |
| Total stockholders' equity (deficit) | 3,602,929 | 2,742,152 |
| Total Equity | 3,602,929 | ... |

Recent Dividends:
1. First Wave BioPharma Inc series B preferred.
 No dividends paid.
2. First Wave BioPharma Inc common.

No dividends paid.
Annual Dividends:
1. First Wave BioPharma Inc series B preferred.
 No dividends paid.
2. First Wave BioPharma Inc common.
 No dividends paid.

FITLIFE BRANDS, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 (revised) |
|---|------------------|------------------|------------------|
| Revenue | 52,700,000 | ... | ... |
| Revenue | 52,700,000 | 28,803,000 | 27,913,000 |
| Cost of goods sold | 31,268,000 | 16,769,000 | 15,409,000 |
| Gross profit (loss) | 21,432,000 | 12,034,000 | 12,504,000 |
| Selling, general & administrative | 12,161,000 | 6,267,000 | 6,215,000 |
| Depreciation & amortization | 94,000 | 66,000 | 59,000 |
| Depreciation and amortization | 52,000 | ... | ... |
| Depreciation and amortization - Balancing value | 42,000 | ... | ... |
| Merger and acquisition related expense | 1,627,000 | ... | ... |
| Total operating expense | 13,882,000 | 6,333,000 | 6,274,000 |
| Operating income (loss) | 7,550,000 | 5,701,000 | 6,230,000 |
| Interest income (expense) | 289,000 | ... | ... |
| Interest expense | 1,025,000 | ... | ... |
| Interest income | ... | 121,000 | 25,000 |
| Gain on debt forgiveness | ... | ... | 453,000 |
| Foreign exchange gain | 189,000 | ... | ... |
| Total other income (expense) | (547,000) | 121,000 | 478,000 |
| Pre-tax net income (loss) | 7,003,000 | 5,822,000 | 6,708,000 |
| Total current provision for income taxes | ... | 199,000 | 14,000 |
| Total deferred provision for income taxes | ... | 1,194,000 | 1,284,000 |
| Net Income After Taxes | 5,296,000 | ... | ... |
| Provision (benefit) for income taxes | 1,707,000 | 1,393,000 | 1,298,000 |
| Net income (loss) | 5,296,000 | 4,429,000 | 5,410,000 |
| Weighted average shares outstanding - basic | 4,490,000 | 4,552,533 | 4,406,614 |
| Weighted average shares outstanding - diluted | 4,905,000 | 4,974,596 | 4,801,370 |
| Year end shares outstanding | 4,598,241 | 4,507,361 | 4,552,485 |
| Net income (loss) per share - basic | \$1.18 | \$0.97 | \$1.23 |
| Net income (loss) per share - diluted | \$1.08 | \$0.89 | \$1.13 |
| Number of full time employees | 37 | 27 | 25 |
| Total number of employees | 37 | ... | ... |
| Number of common stockholders | 22 | 24 | 29 |
| Basic EPS Excluding ExtraOrdinary Items | \$1.18 | ... | ... |
| Diluted EPS Excluding ExtraOrdinary Items | \$1.08 | ... | ... |

□ Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------|-----------|------|
| Cash and cash equivalents | 1,139,000 | ... |

| | | |
|---|-------------|-------------|
| Cash | ... | 13,277,000 |
| Accounts receivable, gross | 2,063,000 | 755,000 |
| Less: allowance for doubtful accounts | 17,000 | 50,000 |
| Accounts receivable, net | 2,046,000 | 705,000 |
| Finished goods | 8,292,000 | 8,347,000 |
| Components | 961,000 | 865,000 |
| Allowance for obsolescence | 162,000 | 107,000 |
| Inventory | 9,091,000 | ... |
| Inventories, net | ... | 9,105,000 |
| Prepaid expenses & other current assets | 639,000 | ... |
| Restricted cash | 759,000 | ... |
| Sales tax receivable | 1,019,000 | ... |
| Total current assets | 14,693,000 | 23,203,000 |
| Equipment | 951,000 | 902,000 |
| Accumulated depreciation | 814,000 | 856,000 |
| Property & equipment, net | 137,000 | 46,000 |
| Right of use asset, net | 121,000 | 103,000 |
| Intangibles, gross | ... | 222,000 |
| Less: accumulated amortization | ... | 72,000 |
| Intangibles, net | 26,309,000 | 150,000 |
| Goodwill | 13,294,000 | 358,000 |
| Deferred tax asset | 792,000 | 1,847,000 |
| Total assets | 55,346,000 | 25,707,000 |
| Accounts payable | 3,261,000 | 2,995,000 |
| Accrued expense & other liabilities | 1,026,000 | 631,000 |
| Product returns | 571,000 | 590,000 |
| Lease liability - current portion | 87,000 | 54,000 |
| Income tax payable | 892,000 | ... |
| Term loan agreement, current portion | 4,500,000 | ... |
| Total current liabilities | 10,337,000 | 4,270,000 |
| Long-term lease liability, net of current portion | 51,000 | 49,000 |
| Paycheck protection program ("PPP") loan | 15,509,000 | ... |
| Deferred tax liability | 2,413,000 | ... |
| Total liabilities | 28,310,000 | 4,319,000 |
| Common stock | 46,000 | 45,000 |
| Additional paid-in capital | 30,699,000 | 30,056,000 |
| Accumulated deficit | (3,417,000) | ... |
| Retained earnings (accumulated deficit) | ... | (8,713,000) |
| Foreign currency translation adjustment | (292,000) | ... |
| Total stockholders' equity (deficit) | 27,036,000 | 21,388,000 |
| Total Equity | 27,036,000 | ... |

Recent Dividends:
1. FitLife Brands, Inc. common.
 No dividends paid.
2. FitLife Brands, Inc. series A convertible preferred.
 No dividends paid.
3. FitLife Brands, Inc. series C convertible preferred (stated value: \$10,000).
 No dividends paid.
4. FitLife Brands, Inc. 10% cumulative perpetual series B preferred (stated value: \$10,000).
 No dividends paid.
Annual Dividends:
1. FitLife Brands, Inc. common.
 No dividends paid.
2. FitLife Brands, Inc. series A convertible preferred.
 No dividends paid.
3. FitLife Brands, Inc. series C convertible preferred (stated value: \$10,000).
 No dividends paid.
4. FitLife Brands, Inc. 10% cumulative perpetual series B preferred (stated value: \$10,000).
 No dividends paid.

FLEXPOINT SENSOR SYSTEMS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | |
|---|--------------|-------------------------|
| Accrued expenses | 3,972,397 | 3,988,093 |
| Operating lease liability - current portion | 240,444 | 199,535 |
| Finance lease liability - current portion | 4,608 | 8,466 |
| Lease liability - current portion | 245,052 | 208,001 |
| Total current liabilities | ... | 12,228,312 |
| Loan payable under credit agreement to beneficial shareholder, net | 96,384,220 | [□] 80,847,748 |
| Promissory notes to related parties, net of current portion | ... | 10,750,000 |
| Promissory note related to acquisition, net | ... | 3,158,471 |
| Purchase consideration payable related to acquisition | ... | 8,703,684 |
| Operating lease liability- net of current portion | 1,321,578 | 1,562,022 |
| Finance lease liability - net of current portion | ... | 4,600 |
| Lease liabilities net of current portion | 1,321,578 | 1,566,622 |
| Loan payable under Basepoint credit agreement | 7,319,641 | ... |
| Promissory notes to related parties net of \$22,001 at 2019 and \$0 at 2018 of unamortized issuance costs and current portion | 10,100,047 | ... |
| Total liabilities | 127,259,604 | 117,254,837 |
| Series 1 convertible preferred stock | 851,660 | 851,660 |
| Series 2 convertible preferred stock | 21,952,000 | 21,952,000 |
| Common stock | 2,176 | 2,176 |
| Additional paid-in capital | 42,415,894 | 39,819,420 |
| Accumulated Deficit | (35,824,200) | ... |
| Retained earnings (accumulated deficit) | ... | (31,590,583) |
| Treasury shares | 166,757 | ... |
| Total stockholders' equity | 29,230,773 | 31,034,673 |
| Rep Total Equity & Minority Interest | 29,230,773 | ... |

[□] Net of unamortized issuance costs and current portion loan payable under credit agreement to beneficial shareholder: \$352,252

Recent Dividends:

1. FlexShopper Inc series 2 convertible preferred (stated value: \$1,000).

No dividends paid.

2. FlexShopper Inc series 1 convertible preferred (stated value: \$5.00).

No dividends paid.

3. FlexShopper Inc common.

No dividends paid.

Annual Dividends:

1. FlexShopper Inc series 2 convertible preferred (stated value: \$1,000).

No dividends paid.

2. FlexShopper Inc series 1 convertible preferred (stated value: \$5.00).

No dividends paid.

3. FlexShopper Inc common.

No dividends paid.

FOCUS UNIVERSAL INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [□] 2021 (revised) |
|-------------------------|-----------|---------|--------------------------------|
| Revenue | 986,655 | 303,837 | 1,405,362 |
| Revenue - related party | 65,543 | 49,782 | 29,084 |
| Total revenue | 1,052,198 | 353,619 | 1,434,446 |
| Cost of revenue | 958,413 | 330,899 | 1,137,287 |

| | | | |
|---|--------------------|--------------------|-------------------------|
| Gross profit (loss) | 93,785 | 22,720 | 297,159 |
| Selling expense | 140,994 | 142,372 | 39,821 |
| Compensation - officers & directors | 1,082,775 | 1,055,133 | 661,171 |
| Research & development expenses | ... | 1,060,385 | 220,469 |
| Professional fees | 705,234 | 896,385 | 1,030,159 |
| General & administrative expenses | 1,740,779 | 2,074,091 | 1,362,126 |
| Research & development | 1,386,810 | ... | ... |
| Total operating expenses | 5,056,592 | 5,228,366 | 3,313,746 |
| Income (loss) from operations | (4,962,807) | (5,205,646) | (3,016,587) |
| Interest income (expense), net | 38,339 | 3,887 | (37,608) |
| Forgiveness of debt | ... | 158,547 | 371,118 |
| Interest expense - related party | 38,333 | ... | ... |
| Change in fair value of warrant liability | ... | ... | (1,284,780) |
| Gain on settlement of derivative liability | ... | ... | 550,406 |
| Unrealized loss on marketable equity securities | 8,033 | (42,395) | ... |
| Realized loss on marketable equity securities | (2,002) | (21,205) | ... |
| Rental income | 160,910 | 166,288 | 186,212 |
| Other income | 77,718 | 13,587 | 10,262 |
| Total other income (expense) | 244,665 | 278,709 | (204,390) |
| Income (loss) before income taxes | (4,718,142) | (4,926,937) | (3,220,977) |
| Net income (loss) | (4,718,142) | (4,926,937) | (3,220,977) |
| Weighted average shares outstanding - basic | 60,314,871 | 43,413,080 | [□] 62,573,858 |
| Weighted average shares outstanding - diluted | 60,314,871 | 43,413,080 | [□] 62,573,858 |
| Year end shares outstanding | 63,608,777 | 43,530,915 | [□] 64,889,612 |
| Net income (loss) per share - basic | \$(0.08) | \$(0.11) | [□] \$(0.05) |
| Net income (loss) per share - diluted | \$(0.08) | \$(0.11) | [□] \$(0.05) |
| Number of full time employees | 43 | 25 | 13 |
| Number of part time employees | 3 | 7 | 4 |
| Total number of employees | 46 | 32 | ... |
| Number of common stockholders | 361 | [□] 366 | [□] 396 |
| Foreign currency translation adjustments | ... | (6,539) | (4) |
| Earnings per share from continuing operations | \$(0.08) | ... | ... |
| Earnings per share from continuing operations | \$(0.08) | ... | ... |
| doubtful accounts | ... | 249,603 | 222,972 |
| Accounts receivable, net | ... | 164,398 | 78,313 |
| Accounts receivable - related party | ... | ... | 34,507 |
| Parts | ... | 1,051 | 3,767 |
| Finished goods | ... | 281,020 | 100,005 |
| Inventories, net | ... | 282,071 | 103,772 |
| Other receivables | ... | 20,519 | ... |
| Prepaid expenses | ... | 96,301 | 142,342 |
| Marketable securities | ... | 36,735 | 105,470 |
| Total current assets | ... | 1,028,278 | 4,807,830 |
| Warehouse | ... | 3,789,773 | 3,789,773 |
| Land | ... | 731,515 | 731,515 |
| Building improvement | ... | 240,256 | 240,256 |
| Furniture & fixtures | ... | 39,223 | 37,785 |
| Equipment | ... | 119,556 | 101,076 |
| Software | ... | 1,995 | 1,995 |
| Total property & equipment, cost | ... | 4,922,318 | 4,902,400 |
| Less: accumulated depreciation | ... | 841,655 | 673,770 |
| Property & equipment, net | ... | 4,080,663 | 4,228,630 |
| Operating lease right-of-use asset | ... | 201,048 | 253,336 |
| Deposits | ... | 24,135 | 33,264 |
| Total assets | ... | 5,334,124 | 9,323,060 |
| Accounts payable & accrued liabilities | ... | ... | 267,685 |
| Treasury stock payable | ... | 482,523 | 1,000,000 |
| Other current liabilities | ... | ... | 6,496 |
| Lease liability, current portion | ... | 90,172 | 113,058 |
| Promissory note short term - related party | ... | 84,951 | ... |
| Related party loan | ... | 1,000,000 | ... |
| Total current liabilities | ... | 1,657,646 | 1,387,239 |
| Lease liability, less current portion | ... | 118,517 | 165,952 |
| Other liability | ... | 12,335 | 12,335 |
| Total non-current liabilities | ... | 130,852 | 178,287 |
| Total liabilities | ... | 1,788,498 | 1,565,526 |
| Common stock | ... | 64,771 | 43,531 |
| Treasury stock, 400,000 shares at par value \$000 | ... | 434,048 | ... |
| Treasury stock | ... | ... | 2,000,000 |
| Common stock subscription | ... | (22,582,170) | ... |
| Additional paid-in capital | ... | 26,436,161 | 27,536,499 |
| Shares to be issued, common shares | ... | 74,476 | 48,075 |
| Retained earnings (accumulated deficit) | ... | ... | (17,864,028) |
| Accumulated other comprehensive income (loss) | ... | (13,564) | (6,543) |
| Total stockholders' equity (deficit) | ... | 3,545,626 | 7,757,534 |
| Total Equity | ... | 3,545,626 | ... |

Recent Dividends:

1. Focus Universal Inc common.

No dividends paid.

Annual Dividends:

1. Focus Universal Inc common.

No dividends paid.

FORIAN INC**Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [□] 2021 (revised) |
|------------------------|------------|------------|--------------------------------|
| Information & software | ... | 26,185,945 | 14,952,247 |
| Services | ... | 1,545,656 | 1,122,528 |
| Other revenues | ... | 274,256 | 804,940 |
| Revenue | 20,481,330 | ... | ... |
| Total revenues | 20,481,330 | 28,005,857 | 16,879,715 |
| Cost of revenues | ... | 5,477,032 | 6,874,315 |
| Separation expenses | 349,832 | ... | ... |
| Research & development | 1,407,580 | 12,347,637 | 8,975,745 |
| Sales & marketing | ... | 5,870,794 | 4,142,190 |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 3-for-2 stock split, March 24, 2023; [□] As of March 22, 2022; [□] As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|----------------------------|---------|-----------|
| Cash | ... | 4,343,426 |
| Cash & cash equivalents | 428,254 | ... |
| Accounts receivable, gross | 414,001 | 301,285 |
| Less: allowance for | ... | ... |

| | | | |
|--|-------------------|---------------------|---------------------|
| General & administrative | 13,633,193 | 20,529,373 | 23,464,267 |
| Separation expenses | 599,832 | 5,611,857 | ... |
| Gain on sale of businesses, net | ... | 32,931 | ... |
| Depreciation & amortization | ... | 2,892,543 | 1,986,816 |
| Transaction related expenses | ... | ... | 1,210,279 |
| Total costs & expenses | ... | (54,093,588) | (44,496,472) |
| Selling, general & administrative expense | 4,884,267 | ... | ... |
| Depreciation | 74,438 | ... | ... |
| Severance costs | 250,000 | ... | ... |
| Total cost & expenses | 26,076,342 | ... | ... |
| Income (loss) from operations | (5,595,012) | (26,087,731) | (27,616,757) |
| Change in fair value of warrant liability | 3,984 | 364,687 | 878,481 |
| Interest & investment income | 2,327,974 | 267,133 | 6,809 |
| Interest expense | 834,785 | 873,336 | 322,379 |
| Foreign currency related gains, net | ... | 381,256 | 525,252 |
| Gain on debt redemption | 111,151 | ... | ... |
| Gain on sale of investment | 5,805,858 | ... | ... |
| Total other income (expense), net | 7,414,182 | 139,740 | 1,088,163 |
| Net income (loss) before income taxes - United States | ... | (25,777,526) | (26,398,610) |
| Net income (loss) before income taxes - foreign | ... | (170,465) | (129,984) |
| Net income (loss) before income taxes | 1,819,170 | (25,947,991) | (26,528,594) |
| Current state income taxes | 78,392 | 23,980 | 22,511 |
| Federal | 7,348 | ... | ... |
| Current income taxes | 85,740 | 23,980 | 22,511 |
| Income tax expense | 85,740 | 23,980 | 22,511 |
| Net income (loss) | 11,106,687 | (25,971,971) | (26,551,105) |
| Net loss attributable to common shareholders | ... | (25,971,971) | (26,551,105) |
| Weighted average shares outstanding - basic | 32,030,855 | 32,031,096 | 29,527,608 |
| Weighted average shares outstanding - diluted | 32,230,845 | 32,031,096 | 29,527,608 |
| Year end shares outstanding | 30,920,450 | 32,251,326 | 31,773,154 |
| Net income (loss) per common share - basic | \$0.34 | \$(0.81) | \$(0.90) |
| Net income (loss) per common share - diluted | \$0.34 | \$(0.81) | \$(0.90) |
| Number of full time employees | ... | 102 | 138 |
| Number of part time employees | ... | 2 | 2 |
| Total number of employees | ... | 104 | ... |
| Number of common stockholders | 307 | 314 | 314 |
| Foreign currency translation adjustments | ... | 381,256 | ... |
| Income from continuing operations | 1,733,430 | ... | ... |
| Income (loss) from discontinued operations, net of tax | 9,373,257 | ... | ... |

| | | | |
|--|--------|-----|-----|
| Earnings per share from continuing operations | \$0.05 | ... | ... |
| Earnings per share-disp of discontinued opers | \$0.29 | ... | ... |
| Earnings per share-total discontinued opers | \$0.29 | ... | ... |
| Earnings per share from continuing operations | \$0.05 | ... | ... |
| Earns per share-disp of discount opers - diluted | \$0.29 | ... | ... |
| Earning per share-total discount opers - diluted | \$0.29 | ... | ... |

Reclassified to conform with 2022 presentation; As of March 23, 2023; As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|--------------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 6,042,986 | 3,319,898 |
| Marketable securities | 42,296,589 | 17,396,487 |
| Accounts receivable, net | 2,572,931 | 2,547,538 |
| Contract assets | 1,126,713 | 2,252,958 |
| Prepaid expenses | 1,077,233 | 966,809 |
| Other assets | 2,515,509 | 432,338 |
| Proceeds receivable from sale of discontinued operations, net | 1,645,954 | ... |
| Total current assets | 57,277,915 | 26,916,028 |
| Personal computing equipment | 94,521 | 204,330 |
| Furniture & equipment | 167,781 | 77,153 |
| Software development costs | 73,260 | 2,985,827 |
| Property & equipment, gross | ... | 3,267,310 |
| Less: accumulated depreciation | 91,696 | 691,904 |
| Property & equipment, net | 76,085 | 2,575,406 |
| Intangible assets, net | ... | 6,775,841 |
| Goodwill | ... | 9,099,372 |
| Right of use assets, net | 10,664 | 636,196 |
| Deposits & other assets | 1,523,948 | 255,324 |
| Total assets | 58,888,612 | 46,258,167 |
| Accounts payable | 161,590 | 575,065 |
| Accrued salary, commission & bonus | 1,546,614 | 2,341,955 |
| Accrued expenses | 4,252,257 | 2,086,814 |
| Accrued engineering & technology expenses | 1,171,782 | ... |
| Accrued expenses - Balancing value | 1,533,861 | ... |
| Accrued expenses - Short-term operating lease liabilities | ... | 4,428,769 |
| Convertible notes payable, net of debt issuance costs | ... | 25,106,547 |
| Convertible notes payable, net of current portion | 24,870,181 | ... |
| Total long-term liabilities | 1,000,000 | ... |
| Total long-term liabilities | 25,870,181 | 25,483,116 |
| Total liabilities | 32,708,806 | 33,835,691 |
| Class A capital contributions | 30,920 | ... |
| Common stock | ... | 32,251 |
| Additional paid-in capital | 73,834,300 | 71,182,326 |
| Accumulated deficit | (47,685,414) | ... |

| | | |
|---|------------|--------------|
| Retained earnings (accumulated deficit) | ... | (58,792,101) |
| Total stockholders' equity | 26,179,806 | 12,422,476 |
| Rep Total Equity & Minority Interest | 26,179,806 | ... |

Recent Dividends:
1. Forian Inc common.
 No dividends paid.
Annual Dividends:
1. Forian Inc common.
 No dividends paid.

FORTRESS BIOTECH INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | | | |
|--|------------------|------------------|------------------|
| | 2023 | 2022 (revised) | 2021 (revised) |
| Product revenue, net | 59,662 | 70,995 | 63,134 |
| Collaboration revenue | 5,229 | 1,882 | 5,389 |
| Revenue - related party | ... | ... | 268 |
| Other revenue | 19,519 | 2,674 | ... |
| Net revenue | 103 | 192 | ... |
| Net revenue | 84,513 | 75,743 | 68,791 |
| Cost of goods sold - product revenue | 26,660 | 30,775 | 32,084 |
| Research & development expenses | ... | ... | 113,240 |
| Research & development expenses - licenses acquired | 4,324 | 677 | 15,625 |
| Selling, general & administrative expenses | 101,747 | 134,199 | 86,843 |
| Wire transfer fraud loss | ... | ... | 9,540 |
| General & administrative | 94,124 | 113,656 | ... |
| Total operating expenses | 226,855 | 279,307 | 257,332 |
| Income (loss) from operations | (142,342) | (203,564) | (188,541) |
| Interest income | 3,003 | 1,398 | 649 |
| Interest expense | 11,915 | ... | 11,394 |
| Amortization of fees | 3,400 | ... | 3,914 |
| Interest expense & financing fee | 15,315 | 13,642 | 15,308 |
| Change in fair value of derivative liability | ... | ... | (447) |
| Grant income | (3,403) | 1,215 | ... |
| Change in fair value of investments | ... | ... | 39,294 |
| Change in fair value of subsidiary's warrant liabilities | 4,424 | 1,129 | ... |
| Total other income (expense) | (11,291) | (9,900) | 24,188 |
| Income (loss) before income tax expense | (153,633) | (213,464) | (164,353) |
| Current state income tax expense | 254 | 449 | 473 |
| Income Taxes - Current-Federal | 33 | ... | ... |
| Income Taxes - Deferred-State | 39 | ... | ... |
| Income Taxes - Deferred-Federal | 194 | ... | ... |
| Income tax expense | 521 | 449 | 473 |
| Net income (loss) | (154,154) | (213,913) | (164,826) |
| Net income (loss) attributable to non-controlling | ... | ... | ... |

| | | | |
|---|----------|-------------|-------------|
| interests | 93,517 | 127,338 | 100,123 |
| Net loss attributable to Fortress | (60,637) | (86,575) | ... |
| Common stock dividend to series A convertible preferred stockholders | 8,032 | 8,032 | ... |
| Net income (loss) attributable to common stockholders | (68,669) | (94,607) | (64,703) |
| Weighted average shares outstanding - basic | 8,111 | 10,592 | 5,447 |
| Weighted average shares outstanding - diluted | 8,111 | 10,592 | 5,447 |
| Year end shares outstanding | 15,093 | 10,736 | 6,762 |
| Net income (loss) from continuing operations per common share - basic | \$(8.47) | 10\$(15.97) | ... |
| Net income (loss) per share - basic | \$(8.47) | 10\$(15.97) | 10\$(11.85) |
| Net income (loss) from continuing operations per common share - diluted | \$(8.47) | 10\$(15.97) | ... |
| Net income (loss) per share - diluted | \$(8.47) | 10\$(15.97) | 10\$(11.85) |
| Number of full time employees | 186 | ... | 10173 |
| Number of common stockholders | 432 | ... | 1010475 |
| Total number of employees | 186 | ... | ... |

¹ Restated to reflect correction of errors; ² Adjusted for 1-for-15 stock split, October 10, 2023; ³ As is; ⁴ Approximately; ⁵ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | | |
|---|---------|---------|-----------|
| | 2023 | 2022 | (revised) |
| Cash & cash equivalents | 80,927 | 178,266 | |
| Accounts receivable, gross | 15,722 | 28,608 | |
| Allowance for doubtful accounts | 500 | 400 | |
| Accounts receivable, net | 15,222 | 28,208 | |
| Raw materials | 4,640 | ... | |
| Work-in-process | 884 | ... | |
| Finished goods | 4,987 | ... | |
| Inventory reserve | 305 | ... | |
| Inventory | 10,206 | 14,159 | |
| Other receivables - related party | 167 | 138 | |
| Prepaid expenses & other current assets | 10,500 | 9,661 | |
| Total current assets | 117,022 | 230,432 | |
| Computer equipment | 595 | 739 | |
| Furniture & fixtures | 1,017 | 1,387 | |
| Machinery & equipment | ... | 8,632 | |
| Leasehold improvements | 13,175 | 13,175 | |
| Buildings | 581 | 581 | |
| Construction in progress | 29 | 952 | |
| Total property & equipment | 15,397 | 25,466 | |
| Less: accumulated depreciation | 8,892 | 12,446 | |
| Property & equipment, net | 6,505 | 13,020 | |
| Operating lease right-of-use asset, net | 16,990 | 19,991 | |
| Restricted cash | 2,438 | 2,688 | |
| Intangible asset - license | 20,287 | ... | |
| Intangible asset, net | ... | 27,197 | |
| Other assets | 4,284 | 973 | |

| | | | |
|---|-----------|-----------|--|
| Total assets | 167,526 | 294,301 | |
| Accounts payable | 34,810 | ... | |
| Accrued salaries, bonuses & employee benefits | 8,531 | ... | |
| Accounts payable | ... | 57,244 | |
| Professional fees | ... | 1,693 | |
| Salaries, bonus & related benefits | ... | 9,772 | |
| Research & development | ... | 7,390 | |
| Research & development - license maintenance fees | ... | 632 | |
| Research & development - milestones | ... | 4,600 | |
| Accrued royalties payable | 2,015 | 2,627 | |
| Accrued coupon & rebates | 9,987 | 7,604 | |
| Return reserve | 73,562 | 3,689 | |
| Accrued interest | ... | 342 | |
| Other accounts payable & accrued expenses | ... | 1,853 | |
| Accounts payable & accrued expenses | ... | 97,446 | |
| Deferred revenue | ... | 728 | |
| Accounts payable & accrued expenses - related party | 18,219 | ... | |
| Income taxes payable | 843 | 722 | |
| Common stock warrant liabilities | 886 | 13,869 | |
| Partner company convertible note, short-term, at fair value | 3,000 | ... | |
| Operating lease liabilities, short-term | 2,523 | 2,447 | |
| Partner company convertible preferred shares, short-term, net | 3,931 | 2,052 | |
| Partner company line of credit | ... | 2,948 | |
| Partner company installment payments - licenses, short-term | ... | 7,235 | |
| Other short-term liabilities | 163 | 268 | |
| Total current liabilities | 84,908 | 127,715 | |
| Notes payable, long-term, net | 60,856 | 91,730 | |
| Operating lease liabilities - long-term | 18,282 | 21,572 | |
| Partner company installment payments - licenses, long-term, net | ... | 1,412 | |
| Total liabilities | 165,939 | 244,276 | |
| Cumulative redeemable perpetual preferred stock | 3 | 3 | |
| Common stock | 15 | 110 | |
| Additional paid-in capital | 717,396 | 675,841 | |
| Retained earnings (accumulated deficit) | ... | (634,233) | |
| Accumulated deficit | (694,870) | ... | |
| Total stockholders' equity attributed to the Company | 22,544 | 41,721 | |
| Non-controlling interests | (20,957) | 8,304 | |
| Total stockholders' equity (deficit) | 1,587 | 50,025 | |

| | | | |
|---|-------------|-------------|-----------|
| FORZA X1 INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Net sales | 37,118 | ... | ... |
| Total revenues | 37,118 | ... | ... |
| Cost of sales | 123,893 | ... | ... |
| Cost of sales - related party | 33,744 | ... | ... |
| Cost of products sold | ... | 232,744 | ... |
| Gross profit | (120,519) | (232,744) | ... |
| Selling, general & administrative expenses | 1,112,920 | 473,900 | 28,806 |
| Salaries & wages expenses | 3,279,195 | 1,770,126 | 41,189 |
| Research & development expenses | 1,540,903 | 957,220 | 150,020 |
| Professional fees | 353,996 | 159,304 | 40,259 |
| Depreciation expenses | 185,900 | 59,965 | 3,075 |
| Total operating expenses | 6,472,914 | 3,420,515 | 263,349 |
| Income (loss) from operations | (6,593,433) | (3,653,259) | (263,349) |
| Interest expense | 3,694 | 3,286 | 7,281 |
| Interest income | 1,401 | 14,752 | ... |
| Dividend income | 507,794 | 43,294 | ... |
| Gain (loss) on disposal of assets | 50,878 | (31,582) | ... |
| Realized Gain | 103,941 | ... | ... |
| Total other income (expenses) | 660,320 | 23,178 | (7,281) |
| Income (loss) before income tax | (5,933,113) | (3,630,081) | (270,630) |
| Net income (loss) | (5,933,113) | (3,630,081) | (270,630) |
| Weighted average shares outstanding - basic | 13,365,613 | 8,332,735 | 7,000,000 |
| Weighted average shares outstanding - diluted | 13,365,613 | 8,332,735 | 7,000,000 |
| Year end shares outstanding | 15,754,774 | 10,450,000 | 7,000,000 |
| Net income (loss) per common share - basic | \$(0.44) | \$(0.44) | \$(0.04) |
| Net income (loss) per common share - diluted | \$(0.44) | \$(0.44) | \$(0.04) |
| Number of full time employees | ... | 1016 | 109 |
| Number of common stockholders | 3 | 103 | ... |

| | | |
|--|------------|------------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| | 2023 | 2022 |
| Cash & cash equivalents | 9,821,531 | 12,767,199 |
| Prepaid expenses & other current assets | 73,508 | 519,735 |
| Inventories | 493,460 | ... |
| Marketable Securities - Available for Sale | 2,981,720 | ... |
| Total current assets | 13,370,219 | 13,286,934 |
| Operating lease right-of-use asset | 75,147 | 162,069 |
| Security deposit | 7,517 | 7,517 |
| Building - construction in progress | 2,347,966 | 10,031 |
| Equipment | 325,377 | 59,806 |
| Computer hardware & software | 50,626 | 37,016 |
| Software & website development | 90,396 | 35,572 |
| Prototype | 142,526 | 142,526 |
| Molds & fixtures | 574,416 | 528,966 |

¹ Successor; ² From October 15, 2021; ³ Shares increased due to the effect of common stock issued ofr cash; ⁴ As of March 20, 2023; ⁵ As of July 28, 2022; ⁶ As of March 23, 2023

| | | |
|--|------------|------------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| | 2023 | 2022 |
| Cash & cash equivalents | 9,821,531 | 12,767,199 |
| Prepaid expenses & other current assets | 73,508 | 519,735 |
| Inventories | 493,460 | ... |
| Marketable Securities - Available for Sale | 2,981,720 | ... |
| Total current assets | 13,370,219 | 13,286,934 |
| Operating lease right-of-use asset | 75,147 | 162,069 |
| Security deposit | 7,517 | 7,517 |
| Building - construction in progress | 2,347,966 | 10,031 |
| Equipment | 325,377 | 59,806 |
| Computer hardware & software | 50,626 | 37,016 |
| Software & website development | 90,396 | 35,572 |
| Prototype | 142,526 | 142,526 |
| Molds & fixtures | 574,416 | 528,966 |

| | | |
|---|--------------|-------------|
| Vehicles..... | 48,825 | ... |
| Land..... | 119,758 | ... |
| Furniture and fixtures..... | 3,482 | ... |
| Property & equipment, gross..... | 3,703,372 | 813,917 |
| Less: accumulated depreciation..... | 234,411 | 48,511 |
| Property & equipment, net..... | 3,468,961 | 765,406 |
| Total assets..... | 16,921,844 | 14,221,926 |
| Accounts payable..... | 86,820 | 99,028 |
| Accrued wages and benefits..... | 59,177 | 56,581 |
| Accrued operating expenses..... | 403,204 | 36,186 |
| Accrued liabilities..... | 462,381 | 92,767 |
| Operating lease right of use liability..... | 68,532 | 86,245 |
| Contract liabilities - customer deposits..... | 5,700 | 5,300 |
| Due to Twin Vee..... | ... | 169,851 |
| Due to affiliated companies..... | 201,848 | ... |
| Finance leases - current portion..... | 17,313 | ... |
| Total current liabilities..... | 842,594 | 453,191 |
| Operating lease liability - noncurrent..... | ... | 68,532 |
| Finance leases - noncurrent..... | 58,717 | ... |
| Total liabilities..... | 901,311 | 521,723 |
| Common stock..... | 15,784 | 10,450 |
| Additional paid-in capital..... | 26,046,873 | 17,777,385 |
| Accumulated deficit..... | (10,020,745) | ... |
| Retained earnings (accumulated deficit)..... | ... | (4,087,632) |
| Treasury stock, at cost, 29,226 and 0 shares, respectively..... | 21,379 | ... |
| Total stockholder's equity..... | 16,020,533 | 13,700,203 |
| Total Equity..... | 16,020,533 | ... |

Recent Dividends:**1. Forza X1 Inc common.**

No dividends paid.

Annual Dividends:**1. Forza X1 Inc common.**

No dividends paid.

FREEFLOW INC**Annual Report**

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|------------------|--------------------|----------------|
| | 2023 | 2022 | 2021 |
| SubTotal..... | 4,032 | ... | ... |
| Sales..... | ... | 195,137 | 745,675 |
| Total revenues..... | 4,032 | 195,137 | 745,675 |
| Cost of goods sold..... | 16,564 | 195,529 | 349,892 |
| Gross profit..... | (12,532) | □(391) | 395,783 |
| General & administrative expenses..... | 253,919 | 341,971 | 516,980 |
| Total expenses..... | 253,919 | 341,971 | 516,980 |
| Net operating profit (loss)..... | (266,451) | (342,362) | (121,197) |
| Income (loss) before provision for income taxes..... | (232,156) | ... | ... |
| Other income (loss)..... | 34,295 | (2,418,950) | (26,562) |
| Increase in value of inventory..... | ... | ... | 691,657 |
| Net income (loss)..... | (232,156) | (2,761,312) | 543,898 |
| Weighted average shares outstanding - basic..... | 25,876,900 | 24,841,900 | 26,221,000 |
| Weighted average shares outstanding - diluted..... | 25,876,900 | ... | ... |
| Year end shares outstanding..... | 25,876,900 | 24,841,900 | 26,221,000 |
| Net income (loss) per share - basic..... | \$(0.01) | \$(0.11) | \$0.02 |

| | | | |
|--|----------|-----|-----|
| Net income (loss) per share - diluted..... | \$(0.01) | ... | ... |
| Number of full time employees..... | 2 | 3 | 7 |
| Number of part time employees..... | ... | ... | 2 |
| Total number of employees..... | 2 | ... | ... |
| Number of common stockholders..... | 256 | □78 | □84 |

□ As reported by the Company; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash & cash equivalents..... | 39,521 | 17,274 |
| Trade receivables - current..... | 95,440 | 94,641 |
| Refund due from IRS - ERTC..... | 32,730 | 77,643 |
| Rounding off the decimals - error..... | (2) | (2) |
| Auto parts..... | ... | 890 |
| Inventories..... | 4,800 | 890 |
| Total current assets..... | 172,489 | 190,446 |
| Land & building, without depreciation..... | 772,413 | 772,413 |
| Less: allowance for depreciation..... | 283,731 | 241,228 |
| Delivery trucks, before depreciation allowance..... | 2,500 | 2,500 |
| Allowance for depreciation..... | 2,500 | 2,500 |
| Improvements in progress..... | 11,697 | 10,697 |
| Equipment & delivery trucks, before depreciation allowance..... | 31,712 | 31,712 |
| Allowance for depreciation..... | 31,712 | 31,712 |
| Total other assets..... | ... | 10,697 |
| Total assets..... | 672,867 | 732,327 |
| Accounts payable..... | 138,669 | 1,647 |
| Notes payable..... | 2,500 | 10,402 |
| Notes payable - related parties..... | 9,634 | 9,634 |
| Total current liabilities..... | 150,803 | 21,683 |
| Incredible Bank - revolving line of credit..... | ... | 319,319 |
| PPP1..... | 29,517 | ... |
| EIDL..... | 319,319 | 499,900 |
| PayPal advance..... | ... | 33,528 |
| Incredible Bank..... | 847,817 | 851,817 |
| EIDL - Loan from SBA..... | 499,900 | ... |
| Incredible Bank - Property Tax..... | 40,587 | ... |
| Total long-term liabilities..... | 1,737,141 | □1,704,565 |
| Total liabilities..... | 1,887,944 | 1,726,247 |
| Series B redeemable preferred stock..... | ... | 330,000 |
| Series C preferred stock..... | ... | 470,935 |
| Redeemable Convertible Preferred Stock-series A..... | 1 | ... |
| Redeemable Convertible Preferred Stock-series B..... | 330,000 | ... |
| Redeemable Convertible Preferred Stock-series C..... | 470,935 | ... |
| Preferred stock..... | ... | 1 |
| Common stock..... | 2,620 | 2,620 |
| Additional paid in capital..... | 140,033 | 129,033 |
| Current year profit (loss)..... | (232,156) | (2,761,312) |
| Retained earnings (accumulated deficit) / net worth, brought forward..... | (1,926,509) | 834,803 |
| Total stockholders' equity (deficit)..... | (1,215,076) | (1,794,855) |
| Total Equity..... | (1,215,076) | ... |

□ As reported by the Company

Recent Dividends:**1. FreeFlow Inc series B redeemable preferred.**

No dividends paid.

2. FreeFlow Inc series C redeemable preferred.

No dividends paid.

3. FreeFlow Inc series A preferred.

No dividends paid.

4. FreeFlow Inc common.

No dividends paid.

Annual Dividends:**1. FreeFlow Inc series B redeemable preferred.**

No dividends paid.

2. FreeFlow Inc series C redeemable preferred.

No dividends paid.

3. FreeFlow Inc series A preferred.

No dividends paid.

4. FreeFlow Inc common.

No dividends paid.

FREEZE TAG INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|------------------|----------------|----------------|
| Revenues..... | 2,115,547 | ... | ... |
| Revenues..... | 2,115,547 | 2,099,055 | 2,136,358 |
| Cost of sales - product development..... | 428,656 | ... | ... |
| Cost of sales..... | ... | 366,624 | 276,098 |
| Selling, general & administrative expenses..... | 1,844,861 | 1,659,270 | 1,694,072 |
| Total operating costs & expenses..... | 2,273,517 | 2,025,894 | 1,970,170 |
| Income (loss) from operations..... | (157,970) | 73,161 | 166,188 |
| Gain on extinguishment of debt..... | ... | 176,441 | 174,420 |
| Interest expense..... | 45,396 | 47,346 | 48,815 |
| Total other income (loss), net..... | (45,396) | 129,095 | 125,605 |
| Income (loss) before income taxes..... | (203,366) | 202,256 | 291,793 |
| Provision for income taxes..... | 1,832 | 1,555 | 1,454 |
| Net income (loss)..... | (205,198) | 200,701 | 290,339 |
| Weighted average shares outstanding - basic..... | 75,056,123 | 75,056,123 | 75,056,123 |
| Weighted average shares outstanding - diluted..... | 75,056,123 | 94,115,107 | 95,933,671 |
| Year end shares outstanding..... | 75,056,123 | 75,056,123 | 75,056,123 |
| Net income (loss) per common share - basic..... | \$0.00 | \$0.00 | \$0.00 |
| Net income (loss) per common share - diluted..... | \$0.00 | \$0.00 | \$0.00 |
| Number of full time employees..... | 12 | ... | ... |
| Total number of employees..... | 12 | 12 | 12 |
| Number of common stockholders..... | 128 | □128 | □128 |

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------|---------|
| Cash..... | 383,362 | 741,163 |
| Accounts receivable..... | 20,298 | 16,875 |
| Prepaid royalties..... | 20,108 | ... |
| Prepaid expenses & other current assets..... | ... | 13,462 |
| Total current assets..... | 423,768 | 771,500 |
| Computer equipment..... | 7,170 | 7,170 |
| Office furniture & equipment..... | 62,392 | 8,613 |
| Vehicle..... | 46,609 | 46,609 |
| Office furniture and equipment..... | 8,613 | ... |
| Property & equipment, | | |

| | | | | | | | | | |
|--|-------------|-------------|--|-------------|-------------|-------------|--|--------------|--------------|
| gross | ... | 62,392 | expenses | ... | 2,495,308 | 4,133,856 | Insurance financing payable | 18,062 | ... |
| Accumulated depreciation | 51,517 | ... | Income (loss) from operations | ... | (2,495,308) | (4,133,238) | Accrued expenses - | ... | ... |
| Less: accumulated depreciation & amortization | ... | 42,195 | Interest income on bank deposit | ... | 5 | 14 | Balancing value | 1,378,536 | ... |
| Property & equipment, net | 10,875 | 20,197 | Interest expense, net | (907,013) | ... | ... | Total current liabilities | 7,284,148 | 122,352 |
| Capitalized software | 522,084 | ... | Gain on disposal of a non-operating department | (128,051) | ... | ... | Total liabilities | ... | 122,352 |
| Other assets | 853 | 371,492 | Other income (expenses) | ... | 349,023 | 38,870 | Common Stock, \$0.011 par value, unlimited shares authorized, 7,750,345 and 740,938 shares issued and outstanding at 30, 2022 and 31, 2021, respectively | 181,157 | ... |
| Total assets | 957,580 | 1,163,189 | Interest income from loans to third parties | ... | 750 | 365,000 | Common stock | ... | 37,679 |
| Accounts payable | 143,842 | 164,541 | Impairment loss on loans to third parties & property & equipment | ... | ... | 5,345,999 | Additional paid in capital | 32,897,836 | 36,524,982 |
| Unearned royalties | ... | 7,543 | Total other income (expenses), net | ... | 349,778 | (4,942,115) | Statutory reserve | ... | 3,032,854 |
| Notes payable - related party, current portion | 379,825 | 379,825 | Income (loss) before income tax expenses | (8,096,671) | (2,145,530) | (9,075,353) | Accumulated deficit | (29,987,945) | ... |
| Other current liabilities | 7,543 | ... | Income tax expenses (benefit) | 90,511 | ... | ... | Retained earnings (accumulated deficit) | ... | (36,683,506) |
| Notes payable, net of current portion | 10,569 | 10,268 | Net income (loss) | (8,187,182) | (2,145,530) | (9,075,353) | Accumulated other comprehensive income (loss) | 38,971 | (268,906) |
| Total current liabilities | 1,031,418 | 1,056,139 | Weighted average shares outstanding - basic | 390,563 | 29,874 | 29,119 | Series A preferred stock, \$5,000 par value, 30,500,000 shares authorized; 6,306,838 and 7,454,795 issued and outstanding at 30, 2022 and 31, 2021, respectively | 693 | ... |
| Other long-term liabilities | 5,812 | 8,917 | Weighted average shares outstanding - diluted | 390,563 | 29,874 | 29,119 | Series B preferred stock, \$5,000 par value, 21,000,000 shares authorized; 8,450,457 and 0 issued and outstanding at 30, 2022 and 31, 2021, respectively | 751 | ... |
| Notes payable - net of current portion | 152,686 | 163,255 | Year end shares outstanding | 164,688 | 34,325 | 29,119 | Total shareholders' equity (deficit) | 3,131,463 | 2,643,103 |
| Total liabilities | 1,189,916 | 1,228,311 | Net income (loss) per share - basic | (21.00) | (72.60) | (312.40) | Total Equity | 3,131,463 | ... |
| Preferred Stock - Convertible - Non-Redeemable | 25 | ... | Net income (loss) per share - diluted | (21.00) | (72.60) | (312.40) | | | |
| Preferred Stock - Convertible - Non-Redeemable | 44 | ... | Full-Time Employees (Period End) | 88 | ... | ... | | | |
| Series B preferred stock | ... | 25 | Total number of employees | 88 | 82 | 10 | | | |
| Series C preferred stock | ... | 44 | Foreign currency translation adjustments | 557,986 | 2,686,394 | ... | | | |
| Common stock | 751 | 751 | | | | | | | |
| Additional paid-in capital | 9,328,813 | 9,290,829 | | | | | | | |
| Common stock payable | 16,800 | 16,800 | | | | | | | |
| Accumulated deficit | (9,578,769) | ... | | | | | | | |
| Retained earnings (accumulated deficit) | ... | (9,373,571) | | | | | | | |
| Total stockholders' equity (deficit) | (232,336) | (65,122) | | | | | | | |
| Total Equity | (232,336) | ... | | | | | | | |

Recent Dividends:

1. Freeze Tag Inc series B preferred. No dividends paid.
2. Freeze Tag Inc common. No dividends paid.
3. Freeze Tag Inc series C preferred. No dividends paid.

Annual Dividends:

1. Freeze Tag Inc series B preferred. No dividends paid.
2. Freeze Tag Inc common. No dividends paid.
3. Freeze Tag Inc series C preferred. No dividends paid.

FREIGHT TECHNOLOGIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2022 | 2021 | 2020 (revised) |
|---|------------|-----------|----------------|
| Revenue - third parties | ... | ... | 618 |
| Revenue from Goods & Services | 25,888,436 | ... | ... |
| Total revenue | ... | ... | 618 |
| Cost of revenue (exclusive of depreciation and amortization shown separately below) | 23,625,317 | ... | ... |
| Gross profit | ... | ... | 618 |
| Selling & marketing expenses | ... | ... | 10,748 |
| General & administrative expenses | 3,560,615 | 2,495,308 | 4,123,108 |
| Sales and marketing | 557,471 | ... | ... |
| Compensation and employee benefits | 4,963,306 | ... | ... |
| Depreciation and amortization | 243,334 | ... | ... |
| Total operating | ... | ... | ... |

Adjusted for 1-for-10 stock split, March 24, 2023; Adjusted for 1-for-10 stock split, February 5, 2024; Adjusted for 1-for-2.2 stock split, February 15, 2022; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2022 | 2021 |
|---|------------|-----------|
| Cash | ... | 221,312 |
| Accounts receivable, net | 4,982,873 | ... |
| Other receivable | 1,891,023 | 55,740 |
| Loans to third parties, net | ... | 2,450,000 |
| Prepaid expenses and other current assets | 1,571,853 | ... |
| Prepayments | ... | 27,329 |
| Cash and cash equivalents | 1,013,000 | ... |
| Total current assets | 9,458,749 | 2,754,381 |
| Furniture | 9,517 | 1,949 |
| Electronic equipment | 84,806 | 11,520 |
| Total property & equipment | 94,323 | 13,469 |
| Less: accumulated depreciation | 66,716 | 2,395 |
| Plant & equipment, net | 27,607 | 11,074 |
| Intangible assets, net | 7,172 | ... |
| Other long-term asset | 154,062 | ... |
| Capitalized software, net | 749,855 | ... |
| Security deposits | 18,166 | ... |
| Total assets | 10,415,611 | 2,765,455 |
| Accrued payroll | 416,039 | ... |
| Accounts payable | 1,980,619 | ... |
| Other payables & accruals | ... | 122,252 |
| Due to a related party | ... | 100 |
| Short-term borrowings | 3,347,374 | ... |
| Accrued expenses | 1,794,575 | ... |
| Income tax payable | 143,518 | ... |

Recent Dividends:

1. Freight Technologies Inc series seed preferred. No dividends paid.
2. Freight Technologies Inc series B preferred. No dividends paid.
3. Freight Technologies Inc ordinary. No dividends paid.
4. Freight Technologies Inc series A preferred. No dividends paid.

Annual Dividends:

1. Freight Technologies Inc series seed preferred. No dividends paid.
2. Freight Technologies Inc series B preferred. No dividends paid.
3. Freight Technologies Inc ordinary. No dividends paid.
4. Freight Technologies Inc series A preferred. No dividends paid.

FS ENERGY & POWER FUND**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 (revised) |
|--|---------|---------|----------------|
| Interest income from non-controlled or unaffiliated investments | 118,530 | 119,003 | 102,342 |
| Paid-in-kind interest income from non-controlled or unaffiliated investments | 4,685 | 12,666 | 20,827 |
| Fee income from non-controlled or unaffiliated investments | 3,662 | 4,660 | 2,508 |
| Dividend income from non-controlled or unaffiliated investments | 14,801 | 21,804 | 870 |

| | | | | | | | | | | |
|--|---------------|---------------|---------------|--|-----------|---------|----------|--|--|-------------|
| Interest income from non-controlled or affiliated investments | 675 | 3,219 | 6,889 | (depreciation) on investments - non-controlled or unaffiliated | (74,827) | 54,379 | 304,707 | assets | 254 | 96 |
| Paid-in-kind interest income from non-controlled or affiliated investments | 97 | 105 | 215 | Net change in unrealized appreciation (depreciation) on investments - non-controlled or unaffiliated | 10,186 | (4,010) | 142,870 | Non-controlled/unaffiliated investments | 1,414,684 | ... |
| Fee income from non-controlled or affiliated investments | ... | 7,268 | ... | Net change in unrealized appreciation (depreciation) on investments - controlled or affiliated | (80,263) | 31,640 | (11,482) | Non-controlled/affiliated investments | 7,496 | ... |
| Dividend income from non-controlled or affiliated investments | ... | 5,417 | 1,574 | Net change in unrealized appreciation (depreciation) on swap contracts | 698 | (698) | ... | Controlled/affiliated investments | 101,016 | ... |
| Interest income from controlled or affiliated investments | 3,720 | 2,936 | 2,970 | Net change in unrealized appreciation (depreciation) on foreign currency | 36 | (45) | (12) | Total investments, at fair value (amortized cost???) | \$2,575,405 and \$4,125,706 respectively | ... |
| Paid-in-kind interest income from controlled or affiliated investments | 3,228 | 7,154 | 6,774 | Total net realized & unrealized gain (loss) | (202,546) | 114,733 | 162,616 | Cash and cash equivalents | 486,059 | ... |
| Fee income from controlled or affiliated investments | ... | ... | 9 | Net increase (decrease) in net assets resulting from operations | (121,183) | 184,502 | 205,875 | Total assets | 2,059,557 | 2,558,781 |
| Dividend income from controlled or affiliated investments | 8,324 | 735 | 5,729 | Weighted average shares outstanding - basic | 454,419 | 449,393 | 443,769 | Payable for investments purchased | 61,596 | ... |
| Total investment income | 157,722 | 184,967 | 150,707 | Weighted average shares outstanding - diluted | 454,419 | 449,393 | 443,769 | Credit facilities payable | 394,437 | 305,438 |
| Management fees | 35,377 | 44,559 | 41,561 | Year end shares outstanding | 455,506 | 451,466 | 446,089 | Secured note payable | ... | 454,671 |
| Administrative services expenses | 6,087 | 5,626 | 5,713 | Net investment income (loss) per share - basic | \$(0.27) | \$0.16 | \$0.09 | Unrealized depreciation on swap contracts | ... | 698 |
| Share transfer agent fees | 3,206 | 2,985 | 2,918 | Net investment income (loss) per share - diluted | \$(0.27) | \$0.16 | \$0.09 | Swap income payable | 259 | 26 |
| Accounting & administrative fees | 588 | 731 | 692 | Dividends per common share | \$0.19 | \$0.12 | \$0.12 | Shareholder distributions payable | 27,740 | 13,543 |
| Interest expense | 23,698 | 55,716 | 54,122 | Number of common stockholders | ... | 86,281 | 86,022 | Management fees payable | 8,416 | 11,185 |
| Trustees' fees | 667 | 742 | 787 | Full-Time Employees (Period End) | 0 | ... | ... | Administrative services expense payable | 108 | 1,086 |
| Other general & administrative expenses | 4,494 | 5,105 | 3,094 | Total number of employees | 0 | ... | ... | Interest payable | 1,603 | 13,371 |
| Less: management fee offset | (341) | (2,619) | (1,439) | | | | | Trustees' fees payable | 164 | 164 |
| Net expenses | 73,776 | 112,845 | 107,448 | | | | | Other accrued expenses & liabilities | 3,179 | 4,851 |
| Net investment income before taxes | 83,946 | 72,122 | 43,259 | | | | | Total liabilities | 497,502 | 805,033 |
| Federal income & excise taxes | 2,583 | 2,353 | ... | | | | | Common shares | 456 | 451 |
| Net investment income | 81,363 | 69,769 | 43,259 | | | | | Capital in excess of par value | 3,185,784 | 3,191,293 |
| Net realized gain (loss) on investments - non-controlled or unaffiliated | (29,350) | (21,652) | 9,454 | | | | | Accumulated earnings (deficit) | (1,624,185) | (1,437,996) |
| Net realized gain (loss) on investments - non-controlled or affiliated | (29,951) | 43,136 | (282,893) | | | | | Total shareholders' equity (deficit) | 1,562,055 | 1,753,748 |
| Net realized gain (loss) on investments - controlled or affiliated | ... | 15,899 | ... | | | | | Net assets value per common share | ... | \$3.88 |
| Net realized gain (loss) on foreign currency | (123) | (202) | (28) | | | | | Total Equity | 1,562,055 | ... |
| Net realized gain (loss) on swap contracts | 1,048 | (2,785) | ... | | | | | | | |
| Net realized gain (loss) on debt extinguishment | ... | (929) | ... | | | | | | | |
| Net change in unrealized appreciation | | | | | | | | | | |

□ Amortized cost - Investments, at fair value - non-controlled or unaffiliated investments: \$1,656,169,000; □ Amortized cost - Investments, at fair value - non-controlled or affiliated investments: \$94,068,000; □ Amortized cost - Investments, at fair value - controlled or affiliated investments: \$172,703,000; □ Amortized cost - Total investments, at fair value: \$1,922,940,000; □ Net of deferred financing costs - Credit facilities payable: \$238,000; □ Net of deferred financing costs - Secured note payable: \$1,253,000

Recent Dividends:
1. FS Energy & Power Fund common.
 No dividends paid.
Annual Dividends:
1. FS Energy & Power Fund common.
 No dividends paid.

FULLNET COMMUNICATIONS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--------------------------------------|----------------|----------------|----------------|
| REVENUE | 4,191,084 | ... | ... |
| Revenue | 4,191,084 | 4,268,263 | 4,135,516 |
| Cost of access service revenues | 1,052,930 | ... | ... |
| Cost of revenue | ... | 907,222 | 741,127 |
| Gross profit | 3,138,154 | 3,361,041 | 3,394,389 |
| Sales & marketing | 714,385 | 628,716 | 488,065 |
| General & administrative expenses | 1,894,997 | 1,886,431 | 1,723,131 |
| Depreciation & amortization expenses | 16,597 | 15,741 | 10,213 |
| Total operating costs & expenses | 2,625,979 | 2,530,888 | 2,221,409 |
| Income (loss) from operations | 512,175 | 830,153 | 1,172,980 |
| Other income | 147,658 | 72,605 | 20,835 |
| Net income before income tax | 659,833 | 902,758 | 1,193,815 |
| Income tax expense (benefit) | 127,694 | 230,522 | 300,838 |
| Net income (loss) | 532,139 | 672,236 | 892,977 |

□ Reclassified to conform with 2022 presentation; □ As is; □ As of February 28, 2023; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|--------|-----------|
| Investments, at fair value - non-controlled or unaffiliated investments | ... | 1,786,887 |
| Investments, at fair value - non-controlled or affiliated investments | ... | 65,777 |
| Investments, at fair value - controlled or affiliated investments | ... | 194,451 |
| Total investments, at fair value | ... | 2,047,115 |
| Cash | ... | 481,655 |
| Receivable for investments sold & repaid | 27,860 | 7,022 |
| Interest receivable | 15,093 | 21,932 |
| Restricted cash | 6,699 | ... |
| Dividends receivable | 360 | 878 |
| Swap income receivable | 36 | 83 |
| Prepaid expenses & other | ... | ... |

| | | | | | | | | | | |
|--|-------------|-------------|---|---|------------|------------|-----------------------|-----|--------------|--|
| Preferred stock dividends | 68,008 | 64,256 | 54,739 | Total Equity | 1,622,188 | ... | (accumulated deficit) | ... | (12,067,237) | |
| Net income (loss) available to common shareholders | 464,131 | 607,980 | 838,238 | Recent Dividends: | | | | | | |
| Weighted average shares outstanding - basic | 19,465,302 | 18,401,789 | 16,698,620 | 1. Fullnet Communications Inc series A convertible preferred. | | | | | | |
| Weighted average shares outstanding - diluted | 19,645,072 | 18,898,411 | 19,216,153 | No dividends paid. | | | | | | |
| Year end shares outstanding | 19,565,087 | 19,182,754 | 17,146,121 | 2. Fullnet Communications Inc common. | | | | | | |
| Net income (loss) per share from continuing operations - basic | \$0.03 | ... | ... | No dividends paid. | | | | | | |
| Net income (loss) per share - basic | \$0.03 | \$0.03 | \$0.05 | Annual Dividends: | | | | | | |
| Net income (loss) per share from continuing operations - diluted | \$0.03 | ... | ... | 1. Fullnet Communications Inc series A convertible preferred. | | | | | | |
| Full-Time Employees (Period End) | 15 | ... | ... | No dividends paid. | | | | | | |
| Total number of employees | 15 | 15 | 16 | 2. Fullnet Communications Inc common. | | | | | | |
| Number of beneficiary stockholders | 126 | 126 | 126 | No dividends paid. | | | | | | |
| Dividends Per Share - Common - Gross - by Period End Date | \$0.01 | ... | ... | FUSS BRANDS CORP Annual Report | | | | | | |
| □ Approximately; □ As of March 27, 2023; □ As of March 30, 2022 | | | Consolidated Income Statement, Years Ended Oct. 31 (\$): | | | | | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | Consolidated Income Statement, Years Ended Oct. 31 (\$): | | | | | | | |
| | | | 2023 2021 2020 | | | | | | | |
| Cash & cash equivalents | 3,130,331 | 2,753,551 | ... | Sales & distribution expenses | 503,078 | ... | ... | | | |
| Accounts receivable | 209,515 | 209,049 | ... | Administrative expenses | ... | 325,088 | ... | | | |
| Less allowance for doubtful accounts | 208,692 | 207,465 | ... | Total operating expenses | 503,078 | 325,088 | ... | | | |
| Accounts receivable, net | 823 | 1,584 | ... | Income (loss) from operations | (503,078) | (325,088) | ... | | | |
| Prepaid expenses & other current assets | 35,690 | 36,740 | ... | Income (loss) before income tax expenses | (505,197) | ... | ... | | | |
| Total current assets | 3,166,844 | 2,791,875 | ... | Net income (loss) | (505,197) | (325,088) | ... | | | |
| Computers & equipment | 33,929 | 315,542 | ... | Weighted average shares outstanding - basic | 16,356,328 | 14,322,290 | 1,432,290 | | | |
| Leasehold improvements | 961,506 | 961,506 | ... | Weighted average shares outstanding - diluted | 16,356,328 | 14,322,290 | 1,432,290 | | | |
| Software | 315,542 | ... | ... | Year end shares outstanding | 19,090,078 | 14,322,290 | 1,432,290 | | | |
| Furniture & fixtures | ... | 33,929 | ... | Net earnings (loss) per common share - basic | \$(0.03) | \$(0.26) | ... | | | |
| Property & equipment, gross | 1,310,977 | 1,310,977 | ... | Net earnings (loss) per common share - diluted | \$(0.03) | \$(0.26) | ... | | | |
| Less accumulated depreciation | 1,240,400 | 1,223,804 | ... | Number of full time employees | 1 | ... | ... | | | |
| Property & equipment, net | 70,577 | 87,173 | ... | Total number of employees | 1 | ... | ... | | | |
| Other assets & intangible assets | 19,910 | 18,250 | ... | Number of common stockholders | 189 | 78 | 78 | | | |
| Right of use leased asset | 145,449 | 279,086 | ... | Interest Expense | 2,119 | ... | ... | | | |
| Total assets | 3,402,780 | 3,176,384 | ... | Basic EPS Excluding ExtraOrdinary Items | \$(0.03) | ... | ... | | | |
| Accounts payable | 13,668 | 18,999 | ... | Diluted EPS Excluding ExtraOrd Items | \$(0.03) | ... | ... | | | |
| Accrued & other liabilities | 524,312 | 475,472 | ... | □ Adjusted for 1-for-26 stock split, July 22, 2022; □ As of November 16, 2021; □ As of July 5, 2021 | | | | | | |
| Operating lease liability - current portion | 145,449 | 133,637 | ... | Consolidated Balance Sheet, Years Ended Oct. 31 (\$): | | | | | | |
| Deferred revenue | 1,097,163 | 1,001,298 | ... | 2023 2021 | | | | | | |
| Total current liabilities | 1,780,592 | 1,629,406 | ... | Cash & cash equivalents | 9,448 | ... | ... | | | |
| Operating lease liability - less current portion | ... | 145,449 | ... | Prepayments | 129,917 | ... | ... | | | |
| Total liabilities | 1,780,592 | 1,774,855 | ... | Total current assets | 139,365 | ... | ... | | | |
| Preferred stock - series A convertible | 409,531 | 409,531 | ... | Total assets | 139,364 | ... | ... | | | |
| Common stock | 196 | 192 | ... | Accounts payable | 105,991 | ... | ... | | | |
| Additional paid-in capital | 9,122,004 | 9,108,410 | ... | Accrued liabilities | 156,978 | ... | ... | | | |
| Accumulated deficit | (7,909,543) | ... | ... | Notes payable - related party | 98,381 | 31,438 | ... | | | |
| Retained earnings (accumulated deficit) | ... | (8,116,604) | ... | Deferred revenue-net | 176,658 | ... | ... | | | |
| Total shareholders' equity (deficit) | 1,622,188 | 1,401,529 | ... | Convertible notes | 50,000 | ... | ... | | | |
| | | | FUSS BRANDS CORP Earnings, 3 mos. to Jan 31(Consol. - \$): | | | | | | | |
| | | | 2024 2023 | | | | | | | |
| | | | Cost & expenses | | | | | | | |
| | | | 45,009 68,325 | | | | | | | |
| | | | Operating income | | | | | | | |
| | | | (45,009) (68,325) | | | | | | | |
| | | | Net before taxes | | | | | | | |
| | | | (46,259) (68,325) | | | | | | | |
| | | | Net income | | | | | | | |
| | | | (46,259) (68,325) | | | | | | | |
| | | | Earnings common share | | | | | | | |
| | | | Common Shares: | | | | | | | |
| | | | Full Diluted | | | | | | | |
| | | | 19,090,078 15,275,078 | | | | | | | |
| | | | Year-end | | | | | | | |
| | | | 19,090,079 14,883,665 | | | | | | | |
| | | | Consolidated Balance Sheet Items, as of (\$): | | | | | | | |
| | | | Assets: | | | | | | | |
| | | | 2024 | | | | | | | |
| | | | Cash & equivalents | | | | | | | |
| | | | 5,444 | | | | | | | |
| | | | Current assets | | | | | | | |
| | | | 163,791 | | | | | | | |
| | | | Total assets | | | | | | | |
| | | | 163,791 | | | | | | | |
| | | | Liabilities: | | | | | | | |
| | | | Current liabilities | | | | | | | |
| | | | 658,694 | | | | | | | |
| | | | Stockholders' equity | | | | | | | |
| | | | (494,903) | | | | | | | |
| | | | Net current assets | | | | | | | |
| | | | (494,903) | | | | | | | |
| | | | FUTURE HEALTH ESG CORP Annual Report | | | | | | | |
| | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| | | | 2023 2022 □2021 | | | | | | | |
| | | | (revised) | | | | | | | |
| | | | General & administrative expenses | | | | | | | |
| | | | 627,731 2,206,911 125,004 | | | | | | | |
| | | | Franchise tax expense | | | | | | | |
| | | | 50,860 200,531 62,299 | | | | | | | |
| | | | Income (loss) from operations | | | | | | | |
| | | | (678,591) (2,407,442) (187,303) | | | | | | | |
| | | | Interest income on cash balance | | | | | | | |
| | | | 13,472 10,332 2,043 | | | | | | | |
| | | | Gain (loss) on marketable securities (net), dividends & interest, held in trust account | | | | | | | |
| | | | 770,686 2,601,727 4,349 | | | | | | | |
| | | | Income (loss) before income taxes | | | | | | | |
| | | | 105,567 204,617 (180,911) | | | | | | | |
| | | | Current federal income taxes | | | | | | | |
| | | | (130,569) 144,810 | | | | | | | |
| | | | Deferred federal income taxes | | | | | | | |
| | | | ... | | | | | | | |
| | | | Change in valuation allowance | | | | | | | |
| | | | (101,840) (37,991) | | | | | | | |
| | | | Income Taxes - Local - Current | | | | | | | |
| | | | 153,992 | | | | | | | |
| | | | Income Taxes - Other - | | | | | | | |
| | | | 130,569 | | | | | | | |
| | | | Provision for income taxes | | | | | | | |
| | | | 153,992 144,810 | | | | | | | |
| | | | Net income (loss) | | | | | | | |
| | | | (48,425) 59,807 (180,911) | | | | | | | |
| | | | Weighted average shares outstanding of common stock | | | | | | | |

| | | | | | | | | | |
|--|--------------|--------------|---|--------------|--------------|--------------|--|---------------|---------------|
| Goodwill | 1,091,000 | 1,091,000 | dividends | 120,000 | 97,000 | 171,000 | stock | ... | 1,723,000 |
| Other intangible assets, net | 12,755,735 | 13,906,111 | Warrant modification | 3,619,000 | ... | ... | Series A 12% convertible preferred stock | ... | 510,000 |
| Other assets | 321,140 | 273,323 | Net income (loss) applicable to common stockholders | (44,805,000) | (38,873,000) | (30,698,000) | Additional paid-in capital | 61,000 | 59,000 |
| Total assets | 40,475,800 | 42,010,516 | Weighted average shares outstanding - basic | 60,159,000 | 59,391,000 | 58,527,000 | Retained earnings (accumulated deficit) | 291,847,000 | 275,081,000 |
| Accounts payable | 1,002,061 | 1,129,869 | Weighted average shares outstanding - diluted | 60,159,000 | 59,391,000 | 58,527,000 | Commitments and contingencies | (354,372,000) | (309,567,000) |
| Accrued payroll & related | 1,350,956 | 1,703,703 | Year end shares outstanding | 61,852,914 | 59,426,005 | 59,341,305 | Series A 2% convertible preferred stock; 742,500 shares authorized, ,02,500 issued and outstanding at 0, 202 and , 2020, liquidation value \$,02,500 at 0, 202 | 500,000 | ... |
| Accrued interest | ... | 100,398 | Net income (loss) per share - basic | \$(0.74) | \$(0.65) | \$(0.52) | Total stockholders' equity (deficit) | (60,241,000) | (33,917,000) |
| Accrued commissions & royalties | 641,161 | 1,869,704 | Net income (loss) per share - diluted | \$(0.74) | \$(0.65) | \$(0.52) | Total Equity | (60,241,000) | ... |
| Other accrued expenses | 550,193 | 23,699 | Number of full time employees | ... | 12 | 9 | | | |
| Revenue contract liability | 167,014 | 16,667 | Number of common stockholders | 138 | 134 | 138 | | | |
| Current portion of long-term debt | 854,120 | 940,084 | Income from cont operations before income tax | (41,066,000) | ... | ... | | | |
| Current portion of operating lease liabilities | 268,541 | 248,317 | Earnings per share from continuing operations | \$(0.74) | ... | ... | | | |
| Interest | 41,921 | ... | Earnings per share from continuing operations | \$(0.74) | ... | ... | | | |
| Total current liabilities | 4,875,967 | 6,032,441 | | | | | | | |
| Long-term operating lease liabilities | 585,879 | 830,289 | As of February 28, 2023; As of February 28, 2022 | | | | | | |
| Fortress credit agreement | ... | 59,400,000 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | |
| Insurance notes payable | 53,196,585 | 340,084 | | | | | | | |
| Less: unamortized debt issuance costs | ... | (5,839,228) | Cash & cash equivalents | 25,660,000 | 18,592,000 | | | | |
| Less: current portion | ... | 940,084 | Prepaid expenses & other current assets | 2,050,000 | 1,960,000 | | | | |
| Long-term debt & liabilities, net | ... | 52,960,772 | Total current assets | 27,710,000 | 20,552,000 | | | | |
| Deferred tax liabilities, net | 60,790 | 72,401 | Leasehold improvements | 2,000 | 2,000 | | | | |
| Total liabilities | 58,719,221 | 59,895,903 | Computer & office equipment | ... | 13,000 | | | | |
| Common stock | 24,846 | 24,411 | Furniture & fixtures | 59,000 | 59,000 | | | | |
| Additional paid-in capital | 18,972,901 | 17,575,396 | Comp Software&Equip-grs | 13,000 | ... | | | | |
| Retained earnings (accumulated deficit) | (37,124,126) | (35,316,540) | Total property & equipment, gross | 74,000 | 74,000 | | | | |
| Accumulated other comprehensive income (loss) | (117,042) | (168,654) | Less accumulated depreciation & amortization | ... | 74,000 | | | | |
| Total stockholders' equity (deficit) | (18,243,421) | (17,885,387) | Less accumulated depreciation | 74,000 | ... | | | | |
| Total Equity | (18,243,421) | ... | Other assets | 490,000 | 733,000 | | | | |
| | | | Total assets | 28,200,000 | 21,285,000 | | | | |
| | | | Accounts payable | 6,431,000 | 3,890,000 | | | | |
| | | | Accrued legal & accounting fees | ... | 65,000 | | | | |
| | | | Accrued compensation | 1,129,000 | 973,000 | | | | |
| | | | Accrued lease liability | ... | 40,000 | | | | |
| | | | Accrued research & development costs & other accrued expenses | 7,967,000 | 7,980,000 | | | | |
| | | | Accrued dividends payable | 63,000 | 64,000 | | | | |
| | | | Lease liability | 46,000 | ... | | | | |
| | | | Accrued expenses - Balancing value | 40,000 | ... | | | | |
| | | | Total current liabilities | 15,676,000 | 13,012,000 | | | | |
| | | | Convertible notes payable & accrued interest, net of debt discounts - related party | 30,902,000 | 29,964,000 | | | | |
| | | | Derivative liabilities | 1,004,000 | 573,000 | | | | |
| | | | Borrowing & accrued interest under convertible line of credit, net of debt discount - related party | 40,839,000 | 9,864,000 | | | | |
| | | | Other liabilities | 20,000 | 66,000 | | | | |
| | | | Operating Lease Liabilities - Long-Term | 20,000 | ... | | | | |
| | | | Total liabilities | 88,441,000 | 53,479,000 | | | | |
| | | | Series C 6% super dividend redeemable convertible preferred | | | | | | |

Recent Dividends:

- Galaxy Gaming Inc common.**
No dividends paid.
 - Galaxy Gaming Inc series B preferred.**
No dividends paid.
 - Galaxy Gaming Inc series A preferred.**
No dividends paid.
- Annual Dividends:**
- Galaxy Gaming Inc common.**
No dividends paid.
 - Galaxy Gaming Inc series B preferred.**
No dividends paid.
 - Galaxy Gaming Inc series A preferred.**
No dividends paid.

GALECTIN THERAPEUTICS INC

| Annual Report | | | |
|---|---------------------|---------------------|---------------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Research & development expenses | 32,130,000 | 31,737,000 | 23,818,000 |
| General & administrative expenses | 5,942,000 | 6,615,000 | 6,361,000 |
| Total operating expenses | 38,072,000 | 38,352,000 | 30,179,000 |
| Total operating income (loss) | (38,072,000) | (38,352,000) | (30,179,000) |
| Interest income | 230,000 | 52,000 | 3,000 |
| Interest expense | 2,792,000 | 1,033,000 | 489,000 |
| Change in fair value of derivatives | (432,000) | 557,000 | 138,000 |
| Total other income (expense) | (2,994,000) | (424,000) | (348,000) |
| Net income (loss) | (41,066,000) | (38,776,000) | (30,527,000) |
| Preferred stock | | | |

Recent Dividends:

- Galectin Therapeutics Inc series B-2 12% redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series B-3 8% convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc common.**
No dividends paid.
 - Galectin Therapeutics Inc series C 6% super dividend redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series B-1 12% redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series A 12% convertible preferred.**
No dividends paid.
- Annual Dividends:**
- Galectin Therapeutics Inc series B-2 12% redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series B-3 8% convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc common.**
No dividends paid.
 - Galectin Therapeutics Inc series C 6% super dividend redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series B-1 12% redeemable convertible preferred.**
No dividends paid.
 - Galectin Therapeutics Inc series A 12% convertible preferred.**
No dividends paid.

GD CULTURE GROUP LTD

| Annual Report | | | |
|---|-----------|---------|-------------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Enterprise brand management services revenue | ... | 153,304 | ... |
| Total revenues | ... | 153,304 | ... |
| Total cost of revenues | ... | 97,770 | ... |
| Cost of enterprise brand management services | ... | 97,770 | ... |
| Gross profit | ... | 55,534 | ... |
| Selling, general & administrative | 4,682,804 | 475,857 | 19,546,151 |
| Provision for (recovery of) doubtful accounts | ... | 3,120 | ... |
| Formation, general & administrative expenses | 5,235,630 | ... | ... |
| Research & Development Expense | 2,072,500 | ... | ... |
| Total operating | | | |

| | | | |
|--|---------------------|---------------------|-------------------------------------|
| expenses | 11,990,934 | 478,977 | 19,546,151 |
| Income (loss) from operations | (11,990,934) | (423,443) | (19,546,151) |
| Interest income | 4,500 | 23 | 799 |
| Interest expense | 81 | 87 | ... |
| Other income (expense), net | ... | 1 | ... |
| Gain from disposal of subsidiaries | 100,000 | ... | ... |
| Total other income (expense), net | 104,419 | (63) | 799 |
| Income (loss) before income taxes from continuing operations | (11,886,515) | (423,506) | (19,545,352) |
| Provision for income taxes (tax benefit) | 327,822 | 1,146 | ... |
| Income (loss) from continuing operations | (12,214,337) | (424,652) | (19,545,352) |
| Income (loss) from discontinued operations, net of taxes | (2,132,049) | (26,336,694) | 3,745,098 |
| Gain (loss) on disposal, net of taxes | (362) | (4,060,609) | (11,170,638) |
| Net income | (14,346,748) | (30,821,955) | (26,970,892) |
| Minority Interest - Continuing Operations | 1,825,130 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (12,521,618) | ... | ... |
| Weighted average number of common shares outstanding - basic | 3,227,302 | 1,531,316 | ² 1,324,958 |
| Weighted average number of common shares outstanding - diluted | 3,227,302 | 1,531,316 | ² 1,324,958 |
| Year end common shares outstanding | 5,453,416 | 1,844,877 | ² ³ 1,543,793 |
| Earnings (loss) per share from continuing operations - basic | \$(3.22) | \$(0.28) | ² \$(14.75) |
| Earnings per share-disp of discontinued ops | \$(0.00) | ... | ... |
| Earnings per share-inc from discontinued ops | \$(0.66) | ... | ... |
| Earnings (loss) per share from discontinued operations - basic | \$(0.66) | \$(19.85) | ² \$(5.60) |
| Earnings (loss) per common share - basic | \$(3.88) | \$(20.13) | ² \$(20.36) |
| Earnings (loss) per share from continuing operations - diluted | \$(3.22) | \$(0.28) | ² \$(14.75) |
| Earns per share-disp of discount ops - diluted | \$(0.00) | ... | ... |
| Earn per share-inc from discount ops - diluted | \$(0.66) | ... | ... |
| Earnings (loss) per share from discontinued operations - diluted | \$(0.66) | \$(19.85) | ² \$(5.60) |
| Earnings (loss) per common share - diluted | \$(3.88) | \$(20.13) | ² \$(20.36) |

| | | | |
|--|-----|-------------------------------|-----|
| Number of full time employees | ... | ² 20 | ... |
| Number of common stockholders | 336 | ² ³ 325 | ... |
| Foreign currency translation adjustments | ... | (46,397) | ... |

² Restated to reflect the discontinued operations of Wuge Network Games Co., Ltd.; ³ Adjusted for 1-for-30 stock split, November 9, 2022; ⁴ Shares increased due to the effect of issuance of common stock for bonus, purchase bitcoin mining machines, purchase digital currency mining machines, cash and employee compensation; ⁵ As of March 31, 2023; ⁶ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | |
|---|--------------|--------------|--|
| Cash & cash equivalents | 5,175,518 | 389,108 | |
| Convertible notes receivable | 2,602,027 | ... | |
| Accounts receivable | ... | 197,640 | |
| Less: allowance for doubtful accounts | ... | 3,120 | |
| Accounts receivable, net | ... | 194,520 | |
| Other receivables, net | 9,459 | 1,026,293 | |
| Prepayments | 1,290,890 | ... | |
| Total current assets | 9,077,894 | 1,609,921 | |
| Office equipment & furniture | 14,190 | 10,039 | |
| Subtotal of plant & equipment | ... | 10,039 | |
| Less: accumulated depreciation | 1,679 | 9,537 | |
| Plant & equipment, net | 12,511 | 502 | |
| Right-of-use assets | 1,561,058 | ... | |
| Goodwill | ... | 2,190,485 | |
| Intangible assets, net | 3,307,949 | ... | |
| Total other assets | 250,740 | 2,190,485 | |
| Total assets | 14,210,152 | 3,800,908 | |
| Accounts payable | ... | 127,475 | |
| Other payables & accrued liabilities | 23,338 | 2,099 | |
| Other payables - related parties | 20,833 | 195,732 | |
| Lease liabilities - current | 358,998 | ... | |
| Taxes payable | ... | 8,478 | |
| Total current liabilities | 403,169 | 333,784 | |
| Lease liabilities - non-current | 1,317,678 | ... | |
| Deferred rent liabilities | 327,822 | ... | |
| Total other liabilities | 1,645,500 | ... | |
| Total liabilities | 2,048,669 | 333,784 | |
| Common stock | 545 | 184 | |
| Additional paid-in capital | 77,530,221 | 60,124,087 | |
| Statutory reserves | ... | 4,467 | |
| Accumulated deficit | (69,358,225) | ... | |
| Retained earnings (accumulated deficit) | ... | (56,841,074) | |
| Accumulated other comprehensive income (loss) | 175,306 | 179,460 | |
| Total stockholders' equity | 8,347,847 | 3,467,124 | |
| Noncontrolling interest | 3,813,636 | ... | |
| Total shareholders equity | 12,161,483 | ... | |

Recent Dividends:
1. GD Culture Group Ltd common.
 No dividends paid.
2. GD Culture Group Ltd common subject to possible redemption.
 No dividends paid.
Annual Dividends:
1. GD Culture Group Ltd common.
 No dividends paid.
2. GD Culture Group Ltd common subject to possible redemption.
 No dividends paid.

GENELUX CORP Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$000): | | | |
|--|-----------------|---------------------------------|---------------------------------|
| | 2023 | 2022 | ² 2021 (revised) |
| Revenues | 170 | ... | ... |
| Revenues | 170 | 11,068 | ... |
| Research & development | 12,767 | 9,078 | 6,319 |
| Employee compensation & related expenses | ... | 1,520 | 1,225 |
| Stock compensation, including the cost of stock option modifications | ... | 2,047 | 3,314 |
| Professional services | ... | 290 | 1,719 |
| Facility-related expenses | ... | 319 | 293 |
| Insurance expenses | ... | 334 | 316 |
| Consulting & contract labor expenses | ... | 305 | 1,082 |
| Other general & administrative expenses | ... | 188 | 345 |
| General & administrative | 11,568 | 5,003 | 8,294 |
| Total operating expenses | 24,335 | 14,081 | 14,613 |
| Income (loss) from operations | (24,165) | (3,013) | (14,613) |
| Interest expense | 173 | 1,150 | 1,221 |
| Debt discount amortization | 649 | 258 | 196 |
| Financing costs | 3,152 | ... | 398 |
| Gain on forgiveness of Paycheck Protection Program loan payable | (402) | 314 | ... |
| Gain on settlement of convertible notes payable | ... | ... | 50 |
| Interest income | 244 | ... | ... |
| Total other income (expenses), net | (4,132) | (1,094) | (1,765) |
| Income (loss) before provision for foreign income taxes | ... | (4,107) | (16,378) |
| Provision for foreign income taxes | ... | 1,100 | ... |
| Net income (loss) | (28,297) | (5,207) | (16,378) |
| Weighted average shares outstanding - basic | 24,429 | 9,116 | 9,033 |
| Weighted average shares outstanding - diluted | 24,429 | 9,116 | 9,033 |
| Year end shares outstanding | 26,356 | 9,127 | 9,110 |
| Net income (loss) per share - basic | \$(1.16) | \$(0.57) | \$(1.81) |
| Net income (loss) per share - diluted | \$(1.16) | \$(0.57) | \$(1.81) |
| Full-Time Employees (Period End) | 23 | ... | ... |
| Total number of employees | 23 | ² 15 | ² ³ 15 |
| Number of common stockholders | 1,101 | ² ³ 1,544 | ² ³ 1,405 |
| Income from cont operations before income tax | (28,297) | ... | ... |
| Federal | (6,014) | ... | ... |
| Income Taxes - State - Current | (2,547) | ... | ... |
| Income Taxes - Federal - Deferred | 4,876 | ... | ... |
| Income Taxes - State - Deferred | 2,227 | ... | ... |
| Income Taxes - Total - Deferred | 7,103 | ... | ... |

| | | | | |
|-------------------------------|---------|-----|-----|-----|
| Income Taxes - | | | | |
| Total - Current | (8,561) | ... | ... | ... |
| Change in Valuation Allowance | 1,458 | ... | ... | ... |

□ Reclassified to conform with 2022 presentation; □ As is; □ As of December 31, 2022; □ As of March 27, 2023; □ Approximately

| GENPREX INC | | | | |
|---|-----------|-----------|-------|-------|
| Annual Report | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | |
| | 2023 | 2022 | □2021 | □2021 |
| Cash and cash equivalents | 9,418 | ... | ... | ... |
| Cash | ... | 397 | ... | ... |
| Prepaid expenses & other current assets | 1,012 | 1,495 | ... | ... |
| Short-term investments | 13,773 | ... | ... | ... |
| Total current assets | 24,203 | 1,892 | ... | ... |
| Furniture & office equipment | 148 | 148 | ... | ... |
| Laboratory equipment | ... | 2,762 | ... | ... |
| Computer equipment | 127 | 127 | ... | ... |
| Leasehold improvements | 557 | 557 | ... | ... |
| Construction-in-progress | 995 | ... | ... | ... |
| Property, Plant & Equipment - Gross - Total | 2,792 | ... | ... | ... |
| - Balancing value | ... | ... | ... | ... |
| Property & equipment, gross | 4,619 | 3,594 | ... | ... |
| Less: accumulated depreciation & amortization | 3,449 | 2,950 | ... | ... |
| Property & equipment, net | 1,170 | 644 | ... | ... |
| Right of use assets | 2,428 | 1,335 | ... | ... |
| Deferred offering costs | ... | 1,568 | ... | ... |
| Other assets | 92 | 92 | ... | ... |
| Total other assets | 3,639 | 3,639 | ... | ... |
| Total assets | 27,893 | 5,531 | ... | ... |
| Accounts payable & accrued expenses | 3,784 | 6,775 | ... | ... |
| Accrued compensation | 2,117 | 2,852 | ... | ... |
| Accrued interest payable | ... | 1,178 | ... | ... |
| Accrued interest payable - director & shareholders | ... | 3,817 | ... | ... |
| Deferred revenue | ... | 170 | ... | ... |
| Warrant liabilities | ... | 169 | ... | ... |
| Lease liability, current portion | 653 | 266 | ... | ... |
| Notes payable - shareholders, net of debt discount | ... | □992 | ... | ... |
| Convertible notes payable - shareholders, current portion | ... | □15,407 | ... | ... |
| Total current liabilities | 6,554 | 31,626 | ... | ... |
| Lease liability, long-term portion | 1,866 | 1,164 | ... | ... |
| Convertible notes payable, net | ... | □8,524 | ... | ... |
| Total long-term liabilities | 1,866 | 9,688 | ... | ... |
| Total liabilities | 8,420 | 41,314 | ... | ... |
| Preferred stock, series A through K | ... | 22 | ... | ... |
| Common stock | 27 | 9 | ... | ... |
| Treasury stock | 433 | 433 | ... | ... |
| Additional paid-in capital | 241,389 | 154,401 | ... | ... |
| Accumulated other comprehensive income | 14 | 2 | ... | ... |
| Retained earnings (accumulated deficit) | (221,524) | (189,784) | ... | ... |
| Total shareholder's equity (deficit) | 19,473 | (35,783) | ... | ... |
| Total Equity | 19,473 | ... | ... | ... |

□ Net of debt discount - notes payable - shareholders: \$108,000;

□ Including past due - convertible notes payable - shareholders, current portion: \$105,000; □ Debt discount - Convertible notes payable, net: \$541,000

Recent Dividends:
1. Genelux Corp common.

| | | | | |
|--------------------------------|--|--|--|--|
| No dividends paid. | | | | |
| Annual Dividends: | | | | |
| 1. Genelux Corp common. | | | | |
| No dividends paid. | | | | |

| GENPREX INC | | | | |
|---|---------------------|---------------------|---------------------|-------|
| Annual Report | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | |
| | 2023 | 2022 | □2021 | □2021 |
| Depreciation | 15,004 | 25,575 | 22,534 | ... |
| Research & development | 17,616,605 | 11,510,074 | 8,970,865 | ... |
| General & administrative expenses | 13,443,961 | 12,295,070 | 11,676,703 | ... |
| Total costs & expenses | 31,075,570 | 23,830,719 | 20,670,102 | ... |
| Operating income (loss) | (31,075,570) | (23,830,719) | (20,670,102) | ... |
| Interest income | 215,109 | 90,098 | 5,133 | ... |
| Net income (loss) | (30,860,461) | (23,740,621) | (20,664,969) | ... |
| Weighted average shares outstanding - basic | 1,367,747 | 1,198,803 | 1,177,431 | ... |
| Weighted average shares outstanding - diluted | 1,367,747 | 1,198,803 | 1,177,431 | ... |
| Year end shares outstanding | 1,485,902 | 1,202,677 | 1,196,868 | ... |
| Net earnings (loss) per share - basic | \$(22.56) | \$(20.00) | \$(17.60) | ... |
| Net earnings (loss) per share - diluted | \$(22.56) | \$(20.00) | \$(17.60) | ... |
| Number of full time employees | ... | 28 | □17 | ... |
| Number of common stockholders | 158 | 145 | □148 | ... |
| Income from cont operations before income tax | (30,860,461) | ... | ... | ... |

□ Reclassified to conform with 2022 presentation; □ As of March 15, 2022; □ Approximately

| GENPREX INC | | | | |
|--|---------------|---------------|-------|-------|
| Annual Report | | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | |
| | 2023 | 2022 | □2021 | □2021 |
| Cash and cash equivalents | 6,737,629 | ... | ... | ... |
| Cash | ... | 20,954,069 | ... | ... |
| Accounts receivable | ... | 34,852 | ... | ... |
| Prepaid expenses & other current assets | ... | 484,224 | ... | ... |
| Prepaid expenses and other | 794,138 | ... | ... | ... |
| Total current assets | 7,531,767 | 21,473,145 | ... | ... |
| Property & equipment, net | 7,859 | 23,032 | ... | ... |
| Security deposits | ... | 21,818 | ... | ... |
| Supplies | 10,000 | 2,864,937 | ... | ... |
| Intellectual property, net | 2,347,488 | 702,095 | ... | ... |
| Total other assets | ... | 3,588,850 | ... | ... |
| Intellectual property, net | 773,478 | ... | ... | ... |
| Total assets | 10,670,592 | 25,085,027 | ... | ... |
| Accounts payable | 1,397,610 | 442,925 | ... | ... |
| Other current liabilities | 1,856,598 | 2,367,362 | ... | ... |
| Total current liabilities | 3,254,208 | 2,810,287 | ... | ... |
| Common stock | 1,486 | 48,106 | ... | ... |
| Additional paid-in capital | 141,103,178 | 125,054,453 | ... | ... |
| Accumulated deficit | (133,688,280) | ... | ... | ... |
| Retained earnings (accumulated deficit) | ... | (102,827,819) | ... | ... |
| Total stockholders' equity | 7,416,384 | 22,274,740 | ... | ... |
| Total Equity | 7,416,384 | ... | ... | ... |

Recent Dividends:
1. Genprex Inc common.
No dividends paid.
Annual Dividends:
1. Genprex Inc common.

| | | | |
|---|------|------|-------|
| No dividends paid. | | | |
| GIVEMEPower CORP | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | □2021 |

| | | | |
|---|-----------------|------------------|-----------------|
| Sales of investment under property | ... | 490,000 | 700,385 |
| Total revenue | ... | 490,000 | 700,385 |
| Cost of sales - property | ... | 545,309 | 722,341 |
| Total cost of goods sold | ... | 545,309 | 722,341 |
| Gross profit | ... | (55,309) | (21,956) |
| General & administrative | 11,620 | 23,163 | 25,756 |
| Professional fees | 28,973 | 31,880 | 22,434 |
| Advertising & promotions | ... | ... | 6,631 |
| Interest expense | ... | 1,074 | ... |
| Total operating expenses | 40,593 | 56,117 | 54,821 |
| Income (loss) from operations | (40,593) | (111,426) | (76,777) |
| Income (loss) before income tax provision | (40,593) | ... | ... |
| Net income (loss) | (40,593) | (111,426) | (76,777) |
| Weighted average shares outstanding - basic | 43,792,804 | 43,792,804 | 42,724,687 |
| Weighted average shares outstanding - diluted | 43,792,804 | 43,792,804 | 42,724,687 |
| Year end shares outstanding | 43,792,804 | 43,792,804 | 42,724,687 |
| Earnings (loss) per share - basic | \$(0.00) | \$(0.00) | \$(0.00) |
| Earnings (loss) per share - diluted | \$(0.00) | \$(0.00) | \$(0.00) |
| Number of full time employees | ... | 1 | 1 |
| Number of part time employees | ... | 3 | 3 |
| Number of common stockholders | 158 | 158 | 407 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.00) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.00) | ... | ... |

□ Reclassified to conform with 2022 presentation

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|-------------|-------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 516 | 44,592 |
| Total current assets | 516 | 44,592 |
| Total assets | 516 | 44,592 |
| Accounts payable | 7,727 | ... |
| Accrued expenses | 7,821 | 3,476 |
| Total current liabilities | 15,548 | 3,476 |
| Notes payable - related party | 222,349 | 237,903 |
| Total long-term liabilities | ... | 237,903 |
| Total liabilities | 237,897 | 241,379 |
| Preferred stock | 3 | 3 |
| Common stock | 43,793 | 43,793 |
| Additional paid in capital | 6,311,824 | 6,311,824 |
| Accumulated deficit | (6,593,000) | ... |
| Retained earnings (accumulated deficit) | ... | (6,552,407) |
| Total stockholders' equity | (237,380) | (196,787) |
| Total Stockholders Equity | (237,380) | ... |

Recent Dividends:

- 1. GiveMePower Corp common.
No dividends paid.
- 2. GiveMePower Corp preferred.
No dividends paid.

Annual Dividends:

- 1. GiveMePower Corp common.
No dividends paid.
- 2. GiveMePower Corp preferred.
No dividends paid.

**GLOBAL ACQUISITIONS CORP
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| General & administrative expenses | 69,875 | 57,428 | 98,362 |
| Total operating expenses | 69,875 | 57,428 | 98,362 |
| Income (loss) from operations | (69,875) | (57,428) | (98,362) |
| Net income (loss) before provision for income tax | (69,875) | (57,428) | (98,362) |
| Net income (loss) | (69,875) | (57,428) | (98,362) |
| Weighted average shares outstanding - basic | 5,658,123 | 5,658,123 | 5,658,123 |
| Weighted average shares outstanding - fully diluted | 5,658,123 | 5,658,123 | 5,658,123 |
| Year end shares outstanding | 5,658,123 | 5,658,123 | 5,658,123 |
| Income (loss) per share from continuing operations - basic | \$(0.01) | ... | ... |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.02) |
| Income (loss) per share from continuing operations - diluted | \$(0.01) | ... | ... |
| Net income (loss) per share - fully diluted | \$(0.01) | \$(0.01) | \$(0.02) |
| Number of common stockholders | 750 | 650 | 750 |

□ Approximately; □ As of March 10, 2023; □ As of February 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Prepaid expenses & other current assets | 38 | 38 |
| Total current assets | 38 | 38 |
| Total assets | 38 | 38 |
| Accounts payable & accrued expenses | ... | 9,034 |
| Due to related parties | 587,607 | 531,378 |
| Payable to Las Vegas Retail - related party | 22,680 | ... |
| Total current liabilities | 610,288 | 540,412 |
| Common stock | 5,658 | 5,658 |
| Additional paid-in capital | 28,728,912 | 28,728,912 |
| Retained earnings (accumulated deficit) | (29,344,820) | (29,274,944) |
| Total stockholder's equity (deficit) | (610,250) | (540,374) |
| Rep Total Equity & Minority Interest | (610,250) | ... |

Recent Dividends:

- 1. Global Acquisitions Corp common.
No dividends paid.
- Annual Dividends:**
- 1. Global Acquisitions Corp common.
No dividends paid.

**GLOBAL CLEAN ENERGY HOLDINGS, INC.
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Revenue | 4,839,000 | ... | ... |
| Revenues | 4,839,000 | 2,591,054 | 214,909 |
| Costs of goods sold | 5,974,000 | 2,021,683 | 141,242 |
| Gross profit | (1,135,000) | 569,371 | 73,667 |
| Amortization expense | ... | 1,287,867 | 924,012 |
| General & administrative expense | 49,124,000 | 43,047,093 | 25,165,361 |
| Facilities expense | 27,467,000 | 19,582,324 | 14,503,409 |
| Depreciation expense | 975,000 | 907,537 | 181,112 |
| Amortization of intangible assets | 1,087,000 | ... | ... |
| Loss on impairment of contract asset | 15,618,000 | ... | ... |
| Total operating expenses | 94,271,000 | 64,824,821 | 40,773,894 |
| Operating income (loss) | (95,406,000) | (64,255,450) | (40,700,227) |
| Interest expense, net | 4,216,000 | 3,821,280 | 2,907,657 |
| Other income | 1,592,000 | 412,753 | 365,322 |
| Change in fair value of class B units | 8,417,000 | 12,664,689 | (6,083,276) |
| Change in fair value of warrant commitment liability | ... | 4,515,307 | (3,210,885) |
| Loss (gain) on extinguishment of debt | ... | (3,972,568) | ... |
| Income (loss) before income taxes | (89,613,000) | (54,456,549) | (52,536,723) |
| Deferred federal income taxes (benefit) | ... | ... | (841,000) |
| Deferred state income taxes (benefit) | ... | ... | (280,000) |
| Deferred foreign income taxes | ... | (348,000) | ... |
| Income taxes (benefit) | 321,000 | (347,841) | (1,121,215) |
| Net income (loss) | (89,934,000) | (54,108,708) | (51,415,508) |
| Weighted average shares outstanding - basic | 45,681,818 | 42,285,350 | 38,802,588 |
| Weighted average shares outstanding - diluted | 45,681,818 | 42,285,350 | 38,802,588 |
| Year end shares outstanding | 49,999,345 | 42,344,827 | 42,013,433 |
| Income (loss) per share - continuing operations - basic | \$(1.97) | ... | ... |
| Net income (loss) per share - basic | \$(1.97) | \$(1.28) | \$(1.33) |
| Income (loss) per share - continuing operations - diluted | \$(1.97) | ... | ... |
| Net income (loss) per share - diluted | \$(1.97) | \$(1.28) | \$(1.33) |
| Number of full time employees | 150 | 134 | 125 |
| Number of part time employees | ... | 68 | 42 |
| Total number of employees | 150 | ... | 167 |
| Number of common stockholders | 1,553 | 1,548 | 1,560 |
| Number of series C preferred stockholders | ... | ... | 12 |
| Foreign currency translation adjustments | ... | 72,514 | ... |

□ Reclassified to conform with 2022 presentation ; □ Rounding difference, breakdown taken from the notes; □ As of March 31, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|-------------|
| Cash & cash equivalents | ... | 5,776,731 |
| Cash | 1,927,000 | ... |
| Accounts receivable, net | 1,841,000 | 732,095 |
| Restricted cash | 1,809,000 | 1,584,959 |
| Inventories, net | 4,554,000 | 7,383,343 |
| Prepaid expenses & other current assets | 1,728,000 | 1,413,207 |
| Total current assets | 11,859,000 | 16,890,335 |
| Restricted cash, net of current portion | ... | 102,255 |
| Operating lease right-of-use-assets | 3,158,000 | 5,332,110 |
| Intangible assets, net | 9,894,000 | 11,524,333 |
| Goodwill | 10,179,000 | 9,470,699 |
| Contract asset - related party | ... | 15,618,495 |
| Long term deposits | ... | 597,242 |
| Land | 7,856,000 | 7,855,872 |
| Office equipment | ... | 2,047,549 |
| Buildings | 2,857,000 | 2,684,402 |
| Refinery & industrial equipment | 90,314,000 | 88,057,913 |
| Transportation equipment | 469,000 | 468,587 |
| Construction in progress | 952,991,000 | 452,735,198 |
| Construction period interest | 776,000 | 95,795,804 |
| Construction Period Interest | 217,152,000 | ... |
| Property, plant & equipment, gross | 1,272,415,000 | 649,645,325 |
| Less: accumulated depreciation | 2,228,000 | 1,112,498 |
| Property, plant & equipment, net | 1,270,187,000 | 648,532,827 |
| Other assets | 5,029,000 | ... |
| Total assets | 1,310,306,000 | 708,068,296 |
| Accrued compensation & related liabilities | 6,503,000 | ... |
| Accrued interest payable | 2,209,000 | ... |
| Accounts payable | 12,236,000 | 7,404,276 |
| Accrued liabilities | 17,087,000 | 27,718,259 |
| Current portion of engineering, procurement and construction ("EPC") deferred payment | 3,073,000 | 35,748,779 |
| Current portion of operating lease obligations | 1,806,000 | 1,897,303 |
| Notes payable including current portion of long-term debt, net | 198,232,000 | 11,792,105 |
| Convertible notes payable | ... | 1,000,000 |
| Accrued liabilities - Balancing value | 5,302,000 | ... |
| Total current liabilities | 229,361,000 | 85,560,722 |
| Operating lease obligations, net of current portion | 1,154,000 | 3,090,002 |
| EPC deferred payment | 602,229,000 | 92,949,558 |
| Mandatorily redeemable equity instruments of subsidiary | 3,590,000 | ... |
| Mandatorily redeemable equity instruments of subsidiary, at fair value (Class B Units) | ... | 12,007,000 |
| Long-term debt, net | 1,550,000 | 12,248,752 |
| Senior credit agreement, net | ... | 401,239,399 |
| Asset retirement obligations, net of current portion | 18,819,000 | 18,255,155 |
| Environmental liabilities, net of current portion | ... | 16,018,650 |
| Deferred tax liabilities | 1,465,000 | 1,261,624 |
| Long-term debt, net | ... | ... |

| | | | | | | | | | | | | |
|---|---------------|---------------|---|------------|------------|------------|---|------|------------|------------|------------|------|
| (credit facility) | 420,351,000 | ... | to participating securities | ... | 23,567 | 22,063 | 09/15/2022 | 0.07 | 08/02/2022 | 09/16/2022 | 09/30/2022 | |
| Environmental liabilities | 16,079,000 | ... | Net income | ... | ... | ... | 12/14/2022 | 0.07 | 12/01/2022 | 12/15/2022 | 12/29/2022 | |
| Other long-term liabilities | 6,353,000 | ... | attributable to common stockholders | ... | 2,034,156 | 3,259,188 | 03/14/2023 | 0.07 | 03/01/2023 | 03/15/2023 | 03/31/2023 | |
| Total liabilities | 1,300,951,000 | 642,630,862 | Weighted average shares outstanding | ... | ... | ... | 06/14/2023 | 0.07 | 06/01/2023 | 06/15/2023 | 06/30/2023 | |
| Series C 15.00% preferred stock | 138,539,000 | 93,645,430 | - basic | 11,045,699 | 10,845,884 | 9,973,113 | 09/15/2023 | 0.07 | 09/01/2023 | 09/18/2023 | 09/29/2023 | |
| Common Shares | 500,000 | ... | Weighted average shares outstanding | ... | ... | ... | 12/14/2023 | 0.07 | 12/01/2023 | 12/15/2023 | 12/28/2023 | |
| Common stock | ... | 423,476 | - diluted | 11,087,217 | 10,900,041 | 10,004,061 | 03/14/2024 | 0.07 | 03/01/2024 | 03/15/2024 | 03/28/2024 | |
| Additional paid-in capital | 111,982,000 | 122,632,584 | Year end shares outstanding | 11,153,513 | 11,109,077 | 10,708,613 | Annual Dividends: | | | | | |
| Treasury stock | ... | 15,935 | Net earnings (loss) per share - basic | \$0.26 | \$0.19 | \$0.33 | 1. Global Self Storage Inc common. | | | | | |
| Accumulated deficit | (261,691,000) | ... | Net earnings (loss) per share - diluted | \$0.26 | \$0.19 | \$0.33 | 2021 | 0.26 | 2022 | 0.28 | 2023 | 0.29 |
| Retained earnings (accumulated deficit) | ... | (171,756,655) | Dividends per common share | \$0.29 | \$0.28 | \$0.26 | 2024 | | | | | |
| Accumulated other comprehensive income (loss) | (411,000) | 72,514 | Number of full time employees | 35 | ... | ... | 2024 | | | | | |
| Total stockholders' equity (deficit) attributable to Global Clean Energy Holdings, Inc. | (149,620,000) | (48,644,016) | Total number of employees | 35 | 31 | 28 | GLUCOTRACK INC | | | | | |
| Non-controlling interests | 20,436,000 | 20,436,020 | Number of common stockholders | 7,830 | 7,750 | 5,700 | Annual Report | | | | | |
| Total stockholders' equity (deficit) | (129,184,000) | (28,207,996) | Basic EPS Excluding ExtraOrdinary Items | \$0.26 | ... | ... | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | |
| | | | Diluted EPS Excluding ExtraOrd Items | \$0.26 | ... | ... | 2023 | | | | | |
| | | | | | | | 2022 | | | | | |
| | | | | | | | 2021 | | | | | |
| | | | | | | | (revised) | | | | | |
| | | | | | | | Salaries & related expenses | | | | | |
| | | | | | | | Professional fees | | | | | |
| | | | | | | | Expenses due to slow inventory write-off | | | | | |
| | | | | | | | Depreciation | | | | | |
| | | | | | | | Vehicle maintenance | | | | | |
| | | | | | | | Other research & development expenses | | | | | |
| | | | | | | | Research & development expenses | | | | | |
| | | | | | | | Salaries & related expenses | | | | | |
| | | | | | | | Professional fees | | | | | |
| | | | | | | | Other expenses | | | | | |
| | | | | | | | Marketing expenses | | | | | |
| | | | | | | | Salaries & related expenses | | | | | |
| | | | | | | | Professional fees | | | | | |
| | | | | | | | Bad debt expense | | | | | |
| | | | | | | | Vehicle maintenance | | | | | |
| | | | | | | | Depreciation | | | | | |
| | | | | | | | Insurance | | | | | |
| | | | | | | | Other general & administrative expense | | | | | |
| | | | | | | | General & administrative expenses | | | | | |
| | | | | | | | Total operating expenses | | | | | |
| | | | | | | | Operating income (loss) | | | | | |
| | | | | | | | Other income (expense) | | | | | |
| | | | | | | | Financing income (expense), net | | | | | |
| | | | | | | | Income (loss) for the period | | | | | |
| | | | | | | | Weighted average shares outstanding - basic | | | | | |
| | | | | | | | Weighted average shares outstanding - diluted | | | | | |
| | | | | | | | Year end shares outstanding | | | | | |
| | | | | | | | Net income (loss) per share - basic | | | | | |
| | | | | | | | Net income (loss) per share - diluted | | | | | |
| | | | | | | | Number of full time employees | | | | | |
| | | | | | | | Number of part time employees | | | | | |
| | | | | | | | Total number of employees | | | | | |
| | | | | | | | Number of common stockholders | | | | | |
| | | | | | | | Income from cont operations before income tax | | | | | |
| | | | | | | | Earnings per share | | | | | |

Recent Dividends:
1. Global Clean Energy Holdings, Inc. common.
No dividends paid.
2. Global Clean Energy Holdings, Inc. series A convertible preferred.
No dividends paid.
3. Global Clean Energy Holdings, Inc. series B convertible preferred.
No dividends paid.

Annual Dividends:
1. Global Clean Energy Holdings, Inc. common.
No dividends paid.
2. Global Clean Energy Holdings, Inc. series A convertible preferred.
No dividends paid.
3. Global Clean Energy Holdings, Inc. series B convertible preferred.
No dividends paid.

GLOBAL SELF STORAGE INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------------|------------------|------------------|
| Rental income | 11,719,165 | 11,485,511 | 10,051,371 |
| Other property related income | 392,577 | 375,571 | 381,534 |
| Management fees & other income | 78,973 | 83,768 | 75,925 |
| Total revenues | 12,190,715 | 11,944,850 | 10,508,830 |
| Property operations - General & administrative | 4,549,038 | 4,169,182 | 3,776,770 |
| Depreciation & amortization | 1,634,044 | 1,619,239 | 1,631,609 |
| Business development | 20,080 | 48,340 | 45,531 |
| Total expenses | 9,079,462 | 8,417,660 | 7,823,870 |
| Operating income | 3,111,253 | 3,527,190 | 2,684,960 |
| Dividend & interest income | 265,046 | 120,575 | 76,021 |
| Unrealized gain (loss) on marketable equity securities | 408,876 | (1,117,029) | 1,566,731 |
| Interest expense | 846,406 | 780,223 | 1,046,461 |
| Gain on paycheck protection program (PPP) loan forgiveness | ... | 307,210 | ... |
| Net realized and unrealized gain | 2,938,769 | ... | ... |
| Total other income (expense), net | (172,484) | (1,469,467) | 596,291 |
| Net income (loss) | 2,938,769 | 2,057,723 | 3,281,251 |
| Earnings & dividends allocated | | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|------------|
| Self storage properties | 67,037,562 | ... |
| Accumulated depreciation | 11,556,342 | ... |
| Land- Gross | 6,122,065 | ... |
| Buildings, improvements, and equipment - Gross | 60,915,497 | ... |
| Real estate assets, net | 55,481,220 | 56,884,160 |
| Cash & cash equivalents | 6,921,779 | 6,363,610 |
| Restricted cash | 106,767 | 151,397 |
| Investments in securities | 2,775,029 | 2,366,153 |
| Accounts receivable | 169,410 | 168,299 |
| Prepaid expenses & other assets | 629,196 | 479,458 |
| Line of credit issuance costs, net | 50,801 | 152,402 |
| Interest rate cap | 50,881 | 123,152 |
| Goodwill | 694,121 | 694,121 |
| Total assets | 66,879,204 | 67,382,752 |
| Note payable | 16,901,219 | ... |
| Note payable, net | ... | 17,420,854 |
| Accounts payable & accrued expenses | 1,677,759 | 1,622,784 |
| Operating Lease Liabilities | 54,199 | ... |
| Accounts Payable and Accrued Expenses - Balancing value | 1,731,958 | ... |
| Total liabilities | 18,633,177 | 19,043,638 |
| Common stock | 111,535 | 111,091 |
| Additional paid in capital | 49,229,020 | 49,029,712 |
| Accumulated deficit | (1,094,528) | ... |
| Retained earnings (accumulated deficit) | ... | (801,689) |
| Total stockholders' equity | 48,246,027 | 48,339,114 |
| Total Equity | 48,246,027 | ... |

Recent Dividends:
1. Global Self Storage Inc common.

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 03/12/2021 | 0.07 | 03/01/2021 | 03/15/2021 | 03/31/2021 |
| 06/14/2021 | 0.07 | 06/01/2021 | 06/15/2021 | 06/30/2021 |
| 09/14/2021 | 0.07 | 09/01/2021 | 09/15/2021 | 09/30/2021 |
| 12/14/2021 | 0.07 | 12/01/2021 | 12/15/2021 | 12/30/2021 |
| 03/14/2022 | 0.07 | 03/01/2022 | 03/15/2022 | 03/31/2022 |
| 06/14/2022 | 0.07 | 06/01/2022 | 06/15/2022 | 06/30/2022 |

| | | | | | | | | | |
|---|-------------|-------------|---|-------------|----------------|----------------|---|--------------|--------------|
| obligation | 67,000 | 2,206,000 | Current federal income tax provision | 653,044 | 759,647 | ... | Warrant liabilities | 2,041,667 | ... |
| Other payables | 888,000 | 1,204,000 | Deferred federal income tax provision (benefit) | (425,978) | (201,748) | (211,191) | Total liabilities | 18,626,384 | 10,795,319 |
| Total current liabilities | 11,325,000 | 24,682,000 | Change in valuation allowance | 425,978 | 201,748 | 211,191 | Class A common stock subject to possible redemption | 6,228,145 | 290,357,770 |
| Reclamation & remediation liabilities | 11,795,000 | 10,366,000 | Provision for income taxes | 653,044 | 759,647 | ... | Class B common stock | 705 | 719 |
| Gold & silver stream agreements liability | 44,932,000 | 43,466,000 | Net income (loss) | (1,467,612) | 9,846,711 | 5,268,961 | Retained earnings (accumulated deficit) | (18,178,122) | (10,086,295) |
| Deferred tax liabilities, net | 14,077,000 | 9,224,000 | Weighted average class A shares outstanding - basic | ... | 28,750,000 | 22,191,781 | Class B common stock | 14 | ... |
| Contingent consideration | 3,548,000 | 2,179,000 | Weighted average class B shares outstanding - basic | ... | 7,187,500 | 6,866,438 | Total stockholders' equity (deficit) | (18,177,403) | (10,085,576) |
| Accrued non-current labor obligation | ... | 1,050,000 | Weighted average class A shares outstanding - diluted | ... | 28,750,000 | 22,191,781 | Total Equity | (18,177,403) | ... |
| Share-based compensation liability | ... | 884,000 | Year end shares outstanding | 7,765,437 | 35,937,500 | 35,937,500 | | | |
| Other long-term liabilities | ... | 556,000 | Net income (loss) per class A share - basic | ... | \$0.27 | \$0.18 | | | |
| Other non-current liabilities | 1,516,000 | 2,490,000 | Net income (loss) per class B share - basic | ... | \$0.27 | \$0.18 | | | |
| Total liabilities | 87,193,000 | 92,407,000 | Net earnings (loss) per share - basic | \$(0.10) | ... | ... | | | |
| Common stock | 89,000 | 89,000 | Net income (loss) per class A share - diluted | ... | \$0.27 | \$0.18 | | | |
| Additional paid-in capital | 111,970,000 | 111,024,000 | Net income (loss) per class B share - diluted | ... | \$0.27 | \$0.18 | | | |
| Retained earnings (accumulated deficit) | (8,311,000) | 7,706,000 | Net earnings (loss) per share - diluted | \$(0.10) | ... | ... | | | |
| Treasury stock at cost | 5,884,000 | 5,884,000 | Total number of employees | ... | 1 | 1 | | | |
| Accumulated other comprehensive income (loss) | (1,171,000) | (1,171,000) | Number of units stockholders | 7 | 2 ¹ | 3 ¹ | | | |
| Total shareholders' equity | 96,693,000 | 111,764,000 | Number of common class A stockholders | ... | 2 ² | 3 ¹ | | | |
| Total Equity | 96,693,000 | ... | Number of common class B stockholders | ... | 2 ⁴ | 3 ⁵ | | | |

Recent Dividends:**1. Gold Resource Corp common.**

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 01/08/2021 | 0.00 | 12/28/2020 | 01/11/2021 | 01/25/2021 |
| 02/10/2021 | 0.00 | 01/27/2021 | 02/11/2021 | 02/23/2021 |
| 03/10/2021 | 0.00 | 02/23/2021 | 03/11/2021 | 03/23/2021 |
| 04/09/2021 | 0.00 | 03/22/2021 | 04/12/2021 | 04/23/2021 |
| 06/14/2021 | 0.01 | 04/29/2021 | 06/15/2021 | 06/30/2021 |
| 09/14/2021 | 0.01 | 07/28/2021 | 09/15/2021 | 09/30/2021 |
| 12/14/2021 | 0.01 | 10/28/2021 | 12/15/2021 | 12/29/2021 |
| 03/14/2022 | 0.01 | 02/24/2022 | 03/15/2022 | 03/31/2022 |
| 06/14/2022 | 0.01 | 04/28/2022 | 06/15/2022 | 06/30/2022 |
| 09/14/2022 | 0.01 | 07/28/2022 | 09/15/2022 | 09/30/2022 |
| 12/14/2022 | 0.01 | 11/01/2022 | 12/15/2022 | 12/30/2022 |

Annual Dividends:**1. Gold Resource Corp common.**

2021.....0.04 2022.....0.04

GOLDEN ARROW MERGER CORP Annual Report

| | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
|--|---|-------------|----------------|
| | 2023 | 2022 | 2021 (revised) |
| Formation & operational costs | 2,103,668 | 1,343,799 | 1,022,676 |
| Income (loss) from operations | (2,103,668) | (1,343,799) | (1,022,676) |
| Transaction costs allocated from initial public offering | ... | ... | 481,824 |
| Change in fair value of warrant liabilities | (1,895,834) | 7,138,542 | 6,756,458 |
| Change in fair value of convertible notes | ... | 811,150 | ... |
| Interest earned on marketable securities held in trust account | 8,240 | ... | ... |
| Interest earned on investment held in Trust Account | 3,176,694 | 4,000,465 | 17,003 |
| Total other income (expense), net | 1,289,100 | 11,950,157 | 6,291,637 |
| Income before provision for income taxes | (814,568) | 10,606,358 | 5,268,961 |

| | | | |
|---|-------------|----------------|----------------|
| Current federal income tax provision | 653,044 | 759,647 | ... |
| Deferred federal income tax provision (benefit) | (425,978) | (201,748) | (211,191) |
| Change in valuation allowance | 425,978 | 201,748 | 211,191 |
| Provision for income taxes | 653,044 | 759,647 | ... |
| Net income (loss) | (1,467,612) | 9,846,711 | 5,268,961 |
| Weighted average class A shares outstanding - basic | ... | 28,750,000 | 22,191,781 |
| Weighted average class B shares outstanding - basic | ... | 7,187,500 | 6,866,438 |
| Weighted average shares outstanding - basic | 14,699,029 | ... | ... |
| Weighted average class A shares outstanding - diluted | ... | 28,750,000 | 22,191,781 |
| Weighted average class B shares outstanding - diluted | ... | 7,187,500 | 7,187,500 |
| Weighted average shares outstanding - diluted | 14,699,029 | ... | ... |
| Year end shares outstanding | 7,765,437 | 35,937,500 | 35,937,500 |
| Net income (loss) per class A share - basic | ... | \$0.27 | \$0.18 |
| Net income (loss) per class B share - basic | ... | \$0.27 | \$0.18 |
| Net earnings (loss) per share - basic | \$(0.10) | ... | ... |
| Net income (loss) per class A share - diluted | ... | \$0.27 | \$0.18 |
| Net income (loss) per class B share - diluted | ... | \$0.27 | \$0.18 |
| Net earnings (loss) per share - diluted | \$(0.10) | ... | ... |
| Total number of employees | ... | 1 | 1 |
| Number of units stockholders | 7 | 2 ¹ | 3 ¹ |
| Number of common class A stockholders | ... | 2 ² | 3 ¹ |
| Number of common class B stockholders | ... | 2 ⁴ | 3 ⁵ |

¹ Reclassified to conform with 2022 presentation; ² As of March 22, 2023; ³ As of March 31, 2022**Consolidated Balance Sheet, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 |
|-------------------------------------|------------|-------------|
| Cash | 306,034 | 348,749 |
| Prepaid expenses | 152,663 | 72,297 |
| Total current assets | 458,697 | 421,046 |
| Investments held in trust account | 6,218,429 | 290,646,467 |
| Total assets | 6,677,126 | 291,067,513 |
| Accounts payable & accrued expenses | 1,135,140 | 249,489 |
| Promissory note - related party | 578,689 | ... |
| Convertible notes - related party | 1,484,326 | 88,850 |
| Income taxes payable | 453,342 | 248,647 |
| Excise tax payable | 2,870,720 | ... |
| Total current liabilities | 6,522,217 | 586,986 |
| Deferred underwriting fee payable | ... | 10,062,500 |
| Warrant liabilities | 10,062,500 | 145,833 |

| | | |
|---|--------------|--------------|
| Warrant liabilities | 2,041,667 | ... |
| Total liabilities | 18,626,384 | 10,795,319 |
| Class A common stock subject to possible redemption | 6,228,145 | 290,357,770 |
| Class B common stock | 705 | 719 |
| Retained earnings (accumulated deficit) | (18,178,122) | (10,086,295) |
| Class B common stock | 14 | ... |
| Total stockholders' equity (deficit) | (18,177,403) | (10,085,576) |
| Total Equity | (18,177,403) | ... |

Recent Dividends:**1. Golden Arrow Merger Corp class A common.**

No dividends paid.

2. Golden Arrow Merger Corp class A common subject to possible redemption.

No dividends paid.

3. Golden Arrow Merger Corp class B common.

No dividends paid.

Annual Dividends:**1. Golden Arrow Merger Corp class A common.**

No dividends paid.

2. Golden Arrow Merger Corp class A common subject to possible redemption.

No dividends paid.

3. Golden Arrow Merger Corp class B common.

No dividends paid.

GOLDEN ARROW MERGER CORP**Earnings, 9 mos. to Sep 30 (Consol. - \$):**

| | 2023 | 2022 |
|-----------------------------|------------|------------|
| Cost & expenses | 1,697,700 | 914,884 |
| Operating income | 853,419 | (914,884) |
| Other income (expense), net | (437,500) | 7,093,416 |
| Net before taxes | 853,419 | 7,756,594 |
| Income taxes | 596,110 | 261,453 |
| Net income | 257,309 | 7,495,141 |
| Earnings common share | | |
| Primary | \$0.02 | \$0.21 |
| Fully Diluted | \$0.02 | \$0.21 |
| Common Shares: | | |
| Full Diluted | 10,379,271 | 28,750,000 |
| Year-end | 9,287,981 | 35,937,500 |

GOLIATH FILM & MEDIA HOLDINGS**Earnings, 9 mos. to Jan 31 (Consol. - \$):**

| | 2024 | 2023 |
|-----------------------|-------------|-------------|
| Total revenues | 47,674 | ... |
| Cost & expenses | 31,143 | 32,757 |
| Operating income | 16,531 | (32,757) |
| Net before taxes | 16,531 | (32,757) |
| Net income | 16,531 | (32,757) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 138,964,917 | 177,118,116 |
| Year-end | 138,964,917 | 138,964,917 |

GOOD GAMING INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|-----------------------------|-----------|-------------|-----------|
| Revenues | 3,443 | ... | ... |
| Revenues | 3,443 | 9,609 | 374,881 |
| Cost of revenues | 293,234 | 305,574 | 37,687 |
| Gross profit (loss) | (289,791) | (295,965) | 337,194 |
| Prizes | 795,911 | ... | ... |
| General & administrative | (105,571) | 588,469 | 571,894 |
| Contract labor | ... | 51,800 | 63,050 |
| Payroll expense | 2,465 | ... | ... |
| Depreciation & amortization | 1,558 | 4,111 | 2,159 |
| Professional fees | ... | 1,013,027 | 673,338 |
| Total operating expenses | 694,363 | 1,657,407 | 1,310,441 |
| Operating income (loss) | (984,154) | (1,953,372) | (973,247) |
| Gain on digital assets | ... | 13,498 | 57,381 |
| Impairment cost | 220 | 168,027 | ... |
| Loss on disposal of | ... | ... | ... |

| | | | |
|---|------------------|--------------------------|----------------|
| fixed assets | 120,887 | | |
| Interest expense | | | 49,182 |
| Gain (loss) on change in fair value of derivative liability | | | 1,303,456 |
| Other Income | 668 | | |
| Other Expense | (2,160) | | |
| Net Income before Tax | (864,979) | | |
| Total other income (loss) | 119,175 | (154,529) | 1,311,655 |
| Net income (loss) | (864,979) | (2,107,901) | 338,408 |
| Weighted average shares outstanding - basic | 119,799,454 | 110,923,594 | 103,526,044 |
| Weighted average shares outstanding - diluted | 119,799,454 | 110,923,594 | 103,526,044 |
| Year end shares outstanding | 119,799,454 | 110,923,594 [¶] | 103,526,044 |
| Net income (loss) per share - basic | \$(0.01) | \$0.02 | \$0.00 |
| Net income (loss) per share - diluted | \$(0.01) | \$0.02 | \$0.00 |
| Number of full time employees | 3 | 3 | 3 |
| Number of part time employees | ... | 4 | 3 |
| Total number of employees | 3 | ... | 6 |
| Number of common stockholders | 93 | ¶93 | ¶69 |
| EPS - Basic - excluding Extraordinary Items | | | |
| Common - Total | \$(0.01) | | |
| EPS - Diluted - excluding Extraordinary Items | | | |
| Common - Total | \$(0.01) | | |

[¶] Shares increased due to issuance of shares, stock based compensation and conversion of preferred shares, debt and warrants to common shares; [¶] As of March 31, 2023; [¶] As of January 31, 2022

| | | |
|---|----------|---------|
| Preferred Stock - Convertible Class-B | 19 | |
| Preferred Stock - Convertible Class-c | 1 | |
| Preferred Stock - Convertible - Class E | 58 | |
| Total stockholders' equity (deficit) | (35,882) | 629,610 |
| Total Equity | (35,882) | |

[¶] As reported by the Company

Recent Dividends:

- 1. Good Gaming Inc class E preferred.**
No dividends paid.
- 2. Good Gaming Inc class B preferred.**
No dividends paid.
- 3. Good Gaming Inc class A preferred.**
No dividends paid.
- 4. Good Gaming Inc class D preferred.**
No dividends paid.
- 5. Good Gaming Inc class C preferred.**
No dividends paid.
- 6. Good Gaming Inc common.**
No dividends paid.

Annual Dividends:

- 1. Good Gaming Inc class E preferred.**
No dividends paid.
- 2. Good Gaming Inc class B preferred.**
No dividends paid.
- 3. Good Gaming Inc class A preferred.**
No dividends paid.
- 4. Good Gaming Inc class D preferred.**
No dividends paid.
- 5. Good Gaming Inc class C preferred.**
No dividends paid.
- 6. Good Gaming Inc common.**
No dividends paid.

GPO PLUS INC

Earnings, 9 mos. to Jan 31 (Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 3,277,888 | 186,941 |
| Net Sales | 3,277,888 | ... |
| Cost & expenses | 5,712,883 | 2,614,971 |
| Operating income | (2,434,995) | (2,428,030) |
| Interest expense | 650,321 | 226,237 |
| Other income (expense), net | 8,800 | ... |
| Net before taxes | (3,076,516) | ... |
| Net income | (3,076,516) | (2,654,267) |
| Earnings common share | | |
| Primary | \$(0.07) | \$(0.08) |
| Fully Diluted | \$(0.07) | \$(0.08) |
| Common Shares: | | |
| Full Diluted | 42,527,926 | 32,795,117 |
| Year-end | 44,223,860 | 35,833,790 |

GRAPHENE & SOLAR TECHNOLOGIES LTD

Earnings, 3 mos. to Dec 31 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|------------------|------------------|
| Cost & expenses | 367,147 | 177,645 |
| Operating income | (367,147) | (177,645) |
| Other income (expense), net | 8,040 | 6,300 |
| Net before taxes | (369,136) | (176,458) |
| Net income | (369,136) | (176,458) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 421,773,914 | 374,305,480 |
| Year-end | 421,292,610 | 374,305,480 |

Consolidated Balance Sheet Items, as of (\$):

| | 2023 | 2022 |
|-----------------------|-------------|------|
| Assets: | | |
| Cash & equivalents | 23,794 | |
| Current assets | 35,559 | |
| Net property & equip. | 904 | |
| Total assets | 37,439 | |
| Liabilities: | | |
| Current liabilities | 5,431,655 | |
| Stockholders' equity | (5,394,216) | |
| Net current assets | (5,396,096) | |

GRAYSCALE ZCASH TRUST (ZEC)
New Accountant On Mar. 1, 2024, Co. dismissed Marcum LLP and engaged KPMG LLP as Co.'s independent registered public accounting firm.

GREATER CANNABIS CO INC (THE)

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------------|------------------|------------------|
| Product sales | | | 12,630 |
| Total revenue | | | 12,630 |
| Cost of product sales | | | 12,655 |
| Gross profit (loss) | | | (25) |
| Officers' compensation | 120,000 | 120,000 | 151,000 |
| Amortization of right of first refusal agreement | 5,000 | 5,000 | 5,000 |
| Other operating expenses | 50,364 | 52,035 | 187,121 |
| Total operating expenses | 175,364 | 177,035 | 343,121 |
| Income (loss) from operations | (175,364) | (177,035) | (343,146) |
| Income (expense) from derivative liability | | | 407,371 |
| Loss on conversions of notes payable & accrued interest to common stock | | 60,500 | 379,434 |
| Interest expense | 13,038 | 24,391 | 18,163 |
| Amortization of debt discounts | | 98,342 | 268,854 |
| Total other income (expenses) | (13,038) | (183,233) | (259,080) |
| Income (loss) before provision for income taxes | (188,402) | (360,268) | (602,226) |
| Net income (loss) | (188,402) | (360,268) | (602,226) |
| Weighted average shares outstanding - basic | 755,154,636 | 587,774,769 | 489,502,790 |
| Weighted average shares outstanding - diluted | 755,154,636 | 587,774,769 | 489,502,790 |
| Year end shares outstanding | 804,638,436 [¶] | 732,638,436 | 508,638,436 |
| Income (loss) per share - basic | ... | \$0.00 | \$0.00 |
| Income (loss) per share - diluted | ... | \$0.00 | \$0.00 |
| Number of full time employees | 1 | 1 | 1 |
| Number of common stockholders | 337 | 337 | 335 |
| Total number of employees | 1 | ... | ... |

[¶] Shares increased due to the effect of conversion of note payable to common share

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------|---------|
| Cash | 166,859 | 270,030 |
| Total current assets | 166,859 | 270,030 |
| Right of first refusal agreement (net) | ... | 10,417 |
| Pharmedica, Ltd. exclusive license agreement | 5,417 | ... |
| Total assets | 172,276 | 280,447 |
| Accounts payable | 6,094 | 16,251 |
| Accrued interest | 55,627 | 42,589 |
| Accrued officer compensation | 340,350 | 263,000 |
| Loans payable to related parties | ... | 260,000 |
| Notes payable to third parties | 171,437 | 243,437 |
| Notes payable to related party | 260,000 | ... |
| Total current liabilities | 833,508 | 825,277 |
| Total liabilities | 833,508 | 825,277 |
| Series A convertible preferred stock | ... | 9,112 |
| Preferred stock | 9,112 | ... |
| Common stock | 804,639 | 732,639 |

| | | |
|---|-------------|-------------|
| Additional paid-in capital | 3,006,321 | 3,006,321 |
| Accumulated deficit | (4,481,304) | ... |
| Retained earnings (accumulated deficit) | ... | (4,292,902) |
| Total stockholders' equity (deficiency) | (661,232) | (544,830) |
| Total Equity | (661,232) | ... |

Recent Dividends:
1. Greater Cannabis Co Inc (The) series A convertible preferred.
 No dividends paid.
2. Greater Cannabis Co Inc (The) common.
 No dividends paid.
Annual Dividends:
1. Greater Cannabis Co Inc (The) series A convertible preferred.
 No dividends paid.
2. Greater Cannabis Co Inc (The) common.
 No dividends paid.

GREATER CANNABIS CO INC (THE) Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, OLAYINKA OYEBOLA & CO., as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Greater Cannabis Company, Inc. ("the Company") as of December 31, 2023, and 2022, the related consolidated statements of operations, changes in stockholder's deficit, and cash flows, for each of the two years in the period ended December 31, 2023, and 2022, and the related notes (collectively referred to as the "financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for each of the two years ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America. Material Uncertainty Relating to Going Concern The accompanying financial statements have been prepared assuming the company will continue as a going concern as disclosed in Note 3 to the financial statement, the Company has continuously incurred a net loss of \$(188,402) for the year ended December 31, 2023, working capital deficit of (666,649) and an accumulated deficit of \$(4,481,304) as at December 31, 2023. The continuation of the Company as a going concern through December 31, 2023, is dependent upon improving the profitability and the continuing financial support from its stockholders. Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due. These factors raise substantial doubt about the company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of the uncertainty."

GREEN PLANET BIOENGINEERING CO., LTD. Annual Report

| | | | |
|---|------------|------------|-------------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Administrative expenses | ... | 32,533 | 32,929 |
| Selling expenses | 47,370 | ... | ... |
| Finance costs | 300 | ... | ... |
| Income (loss) before income tax | (47,670) | (32,533) | (32,929) |
| Net income (loss) | (47,670) | (32,533) | (32,929) |
| Weighted average shares outstanding - basic | 20,006,402 | 20,006,402 | 20,006,402 |
| Weighted average shares outstanding - diluted | 20,006,402 | 20,006,402 | 20,006,402 |
| Year end shares outstanding | 20,006,402 | 20,006,402 | 20,006,402 |
| Net earnings (loss) per share - basic | \$(0.00) | ... | ... |
| Net earnings (loss) per share - diluted | \$(0.00) | ... | ... |
| Non-Operating Income/Expense - Total | (300) | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | | |
|--|-------------|-------------|-------------------|
| | 2023 | 2022 | |
| Other payables & accrued liabilities | 5,000 | ... | |
| Amount due to a related party | ... | 381,920 | |
| Amount due to a stockholder | 424,590 | ... | |
| Total current liabilities | 429,590 | 381,920 | |
| Common stock | 20,006 | 20,006 | |
| Additional paid-in-capital | 609,614 | 609,614 | |
| Retained earnings (accumulated deficit) | (1,059,210) | (1,011,540) | |
| Total stockholders' equity (deficit) | (429,590) | (381,920) | |
| Total Equity | (429,590) | ... | |
| Recent Dividends: | | | |
| 1. Green Planet Bioengineering Co., Ltd. common. No dividends paid. | | | |
| 2. Green Planet Bioengineering Co., Ltd. preferred. No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. Green Planet Bioengineering Co., Ltd. common. No dividends paid. | | | |
| 2. Green Planet Bioengineering Co., Ltd. preferred. No dividends paid. | | | |
| GREENLIT VENTURES INC Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| General & administrative expenses | 57,272 | 43,044 | 67,579 |
| Software development | ... | 11,000 | ... |
| Total operating expenses | 57,272 | 54,044 | 67,579 |
| Income (loss) from operations | (57,272) | (54,044) | (67,579) |
| Interest expense | 6,317 | 1,408 | 61 |
| Total other income (expense) | (6,317) | (1,408) | (61) |
| Income (loss) before income taxes | (63,589) | (55,452) | (67,640) |
| Net income (loss) | (63,589) | (55,452) | (67,640) |
| Weighted average shares outstanding - basic | 6,731,667 | 224,389 | 224,389 |
| Weighted average shares outstanding - diluted | 6,731,667 | 224,389 | 224,389 |
| Year end shares outstanding | 6,731,667 | 224,389 | 224,389 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.30) | \$(0.30) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.30) | \$(0.30) |
| Total number of employees | ... | 1 | ... |
| Number of common stockholders | 3 | 41 | 41 |
| ^[1] Reclassified to conform with 2022 presentation; ^[2] Adjusted for 1- for -30 stock split, January 24, 2024; ^[3] As of March 20, 2023 | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Accounts payable & accrued liabilities | 5,845 | 5,959 | |
| Accrued interest | 7,786 | 1,470 | |
| Promissory note payable | ... | 83,085 | |
| Total current liabilities | ... | 90,514 | |
| Convertible Debt - Long-Term | 140,472 | ... | |
| Total liabilities | 154,103 | 90,514 | |
| Common stock | 673 | 673 | |
| Additional paid-in-capital | 340,897 | 340,897 | |

| | | |
|---|-----------|-----------|
| Retained earnings (accumulated deficit) | (495,673) | (432,084) |
| Total stockholders' equity (deficit) | (154,103) | (90,514) |
| Total Equity | (154,103) | ... |

Recent Dividends:
1. Greenlit Ventures Inc common.
 No dividends paid.
Annual Dividends:
1. Greenlit Ventures Inc common.
 No dividends paid.

GREENPRO CAPITAL CORP Annual Report

| | | | |
|--|-------------|-------------|-------------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Service revenue | 2,725,466 | 2,820,950 | 128,830 |
| Rental revenue | 98,068 | 108,495 | ... |
| Sale of real estate properties | ... | 840,036 | ... |
| Total revenue | 3,379,596 | ... | ... |
| Total revenues | 3,477,664 | 3,673,997 | 2,949,780 |
| Cost of service revenue | 534,965 | 404,077 | 422,908 |
| Cost of real estate properties sold | ... | 573,343 | ... |
| Cost of rental revenue | 36,613 | 46,083 | 49,778 |
| Total cost of revenues | 571,578 | 1,023,503 | 472,686 |
| Gross profit | 2,906,086 | 2,650,494 | 2,477,094 |
| General & administrative expenses | 4,409,264 | 4,168,997 | 5,231,778 |
| Total operating expenses | 4,409,264 | 4,168,997 | 5,231,778 |
| Income (loss) from operations | (1,503,178) | (1,518,503) | (2,754,684) |
| Other income | ... | 104,846 | 46,740 |
| Interest income | 41,401 | 21,417 | 7,494 |
| Loss on other investments | (79,033) | ... | ... |
| Reversal of write-off notes receivable | 600,000 | 200,000 | 5,000,000 |
| Fair value (gains) losses of derivative liabilities associated with warrants | 1 | 9,934 | 70,051 |
| Fair value gains of derivative liabilities associated with convertible notes | ... | ... | 5,093,720 |
| Interest Expense on Financial Lease | 729 | ... | ... |
| Liabilities | 729 | ... | ... |
| Interest expense | 729 | ... | 12,950,750 |
| Loss on extinguishment of notes | ... | ... | (3,521,263) |
| Impairment of goodwill | ... | 263,247 | ... |
| Impairment of other receivable | 60,000 | 606,250 | ... |
| Impairment of other investment | 4,982,000 | 4,208,029 | 5,349,600 |
| Reversal of impairment of other investment (including \$6,882,000 of related party investment for the year ended 31, 2023) | (6,882,000) | ... | ... |
| Total other income (expense) | 2,559,706 | (4,741,329) | (11,603,608) |
| Income (loss) | ... | ... | ... |

| | | | |
|---|------------------|-------------------------------|--|
| before income tax | 1,056,528 | (6,259,832) | (14,358,292) |
| Current income taxes - foreign | 6,829 | 2,356 | 4,940 |
| Income tax expense | 6,829 | 2,356 | 4,940 |
| Net income (loss) | 1,049,699 | (6,262,188) | (14,363,232) |
| Net loss (income) attributable to noncontrolling interest | 23,886 | (88,684) | 13,876 |
| Net income (loss) attributed to common stockholders | ... | (6,350,872) | (14,349,356) |
| Weighted average shares outstanding - basic | 7,688,416 | 7,870,887 | ¹ 6,920,452 |
| Weighted average shares outstanding - diluted | 7,688,416 | 7,870,887 | ¹ 6,920,452 |
| Year end shares outstanding | 7,575,813 | 7,875,813 | ¹ 7,867,169 |
| Net earnings (loss) per share - basic | \$0.14 | \$(0.81) | ¹ \$(2.07) |
| Net earnings (loss) per share - diluted | \$0.14 | \$(0.81) | ¹ \$(2.07) |
| Total number of employees | ... | ² 48 | ³ 55 |
| Number of common stockholders | 191 | ² ¹ 196 | ³ ¹ ⁴ 212 |

¹ Reclassified to conform with 2022 presentation; ² Includes service revenue from related parties - service revenue: \$665,203; ³ Includes service revenue from related parties - service revenue: \$861,449; ⁴ Includes general and administrative expense to related party - General and administrative: \$193,802; ⁵ Includes general and administrative expense to related party - General and administrative: \$12,922; ⁶ Includes other income from a related party - Other income: \$5,850; ⁷ Including interest expense related to convertible notes - interest expense \$12,900,855; ⁸ Includes related party investment - impairment of other receivable: \$606,250; ⁹ Includes related party investment - impairment of other investment: \$4,208,029; ¹⁰ Includes related party investment - impairment of other investment: \$5,349,600; ¹¹ Adjusted for 1-for-10 stock split, July 29, 2022; ¹² As of March 31, 2023; ¹³ As of March 29, 2022; ¹⁴ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------------------|
| Cash and cash equivalents | | |
| - Balancing value | 2,056,716 | ... |
| Cash & cash equivalents | 2,223,197 | ¹ 3,911,535 |
| Accounts receivable, gross | 655,537 | 195,214 |
| Less allowance for doubtful accounts | 610,599 | 25,677 |
| Accounts receivable, net | 44,938 | ² 169,537 |
| Prepays & other current assets | 627,315 | ³ 773,040 |
| Due from related parties | 750,860 | 265,772 |
| Deferred costs of revenue | 16,291 | ⁴ 168,605 |
| Restricted Cash - Short-Term | 166,481 | ... |
| Total current assets | 3,662,601 | 5,288,489 |
| Furniture & fixtures | 51,721 | ... |
| Office equipment | 16,534 | ... |
| Leasehold improvement | 70,906 | ... |
| Less: accumulated depreciation | 320,931 | ... |
| Office properties- Gross | 780,518 | ... |
| Office leaseholds | 52,058 | 3,008,413 |
| Furniture & fixtures | ... | 52,058 |
| Office equipment | 62,148 | 62,148 |
| Leasehold improvement | 92,566 | 92,566 |
| Office leaseholds | 3,008,413 | ... |
| Property, Plant & Equipment - Other - Gross | 80,716 | ... |
| Property & equipment, gross | 3,295,901 | 3,215,185 |
| Less: accumulated depreciation | 882,363 | ... |
| Less: accumulated | | |

| | | | |
|--|--------------|------------------------|--|
| depreciation & amortization | ... | 701,618 | |
| Property & equipment, net | 2,413,538 | 2,513,567 | |
| Real estate held for sale | 1,659,207 | 1,659,207 | |
| Real estate held for investment, net | 598,748 | 650,223 | |
| Intangible assets, net | 1,181 | 1,900 | |
| Goodwill | 82,561 | 82,561 | |
| Other investments | 100,106 | ⁵ 5,406,106 | |
| Operating lease right-of-use assets | 114,551 | 17,510 | |
| Other non-current assets | 25,527 | 19,643 | |
| Investments in unconsolidated entities | 100,106 | ... | |
| Total assets | 8,658,020 | 15,639,206 | |
| Accounts payable & accrued liabilities | 724,796 | 758,909 | |
| Due to related parties | 389,274 | 448,251 | |
| Income tax payable | 292 | 858 | |
| Operating lease liabilities, current portion | 94,726 | 18,725 | |
| Deferred revenue | 1,075,404 | ⁶ 1,834,244 | |
| Derivative liabilities | ... | 1 | |
| Finance lease liabilities, current portion | 3,426 | ... | |
| Total current liabilities | 2,287,918 | 3,060,988 | |
| Operating lease liabilities, net of current portion | 19,825 | ... | |
| Finance lease liabilities, non-current portion | 13,638 | ... | |
| Total liabilities | 2,321,381 | 3,060,988 | |
| Common stock | 7,576 | 7,876 | |
| Additional paid-in capital | 42,897,029 | 50,102,729 | |
| Accumulated other comprehensive income (loss) | (310,169) | (224,891) | |
| Retained earnings (accumulated deficit) | (36,549,095) | (37,622,680) | |
| Total Greenpro Capital Corp. common stockholders' equity | 6,045,341 | 12,263,034 | |
| Noncontrolling interests in consolidated subsidiaries | 291,298 | 315,184 | |
| Total stockholders' equity | 6,336,639 | 12,578,218 | |

¹ Includes restricted cash - cash & cash equivalents: \$38,466; ² Including net accounts receivable from related parties - accounts receivable: \$129,292; ³ Includes deposit paid to a related party - prepaids and other current assets: \$80,000; ⁴ Includes related party - deferred cost of revenue: \$11,640; ⁵ Includes investments in related parties - other investments: \$5,406,106; ⁶ Includes due from related parties - Deferred revenue: \$849,400

Recent Dividends:

1. Greenpro Capital Corp common.
No dividends paid.

Annual Dividends:
1. Greenpro Capital Corp common.
No dividends paid.

GREENWICH LIFESCIENCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-------------------------------|--------------------|--------------------|--------------------|
| Research & development | 7,698,622 | 6,475,668 | 3,559,515 |
| General & administrative | 1,629,244 | 1,564,586 | 1,038,428 |
| Total operating expenses | ... | 8,040,254 | 4,597,943 |
| Income (loss) from operations | (9,327,866) | (8,040,254) | (4,597,943) |
| Interest income | 436,063 | 215,017 | 27,367 |
| Net income (loss) | (8,891,803) | (7,825,237) | (4,570,576) |
| Weighted average | | | |

| | | | |
|---|-------------|------------------------------|------------------------------|
| shares outstanding - basic | 12,848,165 | 12,913,848 | 12,944,134 |
| Weighted average shares outstanding - diluted | 12,848,165 | 12,913,848 | 12,944,134 |
| Year end shares outstanding | 12,848,165 | 12,848,165 | 13,147,829 |
| Net earnings (loss) per share - basic | \$(0.69) | \$(0.61) | \$(0.35) |
| Net earnings (loss) per share - diluted | \$(0.69) | \$(0.61) | \$(0.35) |
| Number of full time employees | ... | ¹ 3 | ² 3 |
| Number of part time employees | ... | ¹ 3 | ² 3 |
| Number of common stockholders | 16 | ¹ ¹ 16 | ² ¹ 15 |
| Income from cont operations before income tax | (8,891,803) | ... | ... |

¹ As of March 15, 2023; ² As of March 21, 2022; ³ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 6,989,424 | 13,468,026 |
| Total current assets | 6,989,424 | ... |
| Acquired patents, net | 5,391 | 9,003 |
| Total assets | 6,994,815 | 13,477,029 |
| Accounts payable & accrued interest | 256,317 | 220,845 |
| Unreimbursed expenses | 38,089 | 42,060 |
| Total current liabilities | 294,406 | 262,905 |
| Total liabilities | 294,406 | 262,905 |
| Common stock | 12,848 | 12,848 |
| Additional paid-in capital | 57,052,130 | 54,674,042 |
| Accumulated deficit | (50,364,569) | ... |
| Retained earnings (accumulated deficit) | ... | (41,472,766) |
| Total stockholders' equity (deficit) | 6,700,409 | 13,214,124 |
| Total Equity | 6,700,409 | ... |

Recent Dividends:

1. Greenwich LifeSciences Inc common.
No dividends paid.

Annual Dividends:
1. Greenwich LifeSciences Inc common.
No dividends paid.

GREYSTONE LOGISTICS INC

Earnings, 9 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|------------------|------------------|
| Total revenues | 46,990,716 | ... |
| Net Sales | 46,990,716 | 44,633,542 |
| Cost & expenses | 41,806,154 | 42,508,749 |
| Operating income | 5,184,562 | 2,124,793 |
| Interest expense | ... | 821,138 |
| Other income (expense), net | 180,004 | 3,460,338 |
| Gains or losses | ... | 569,997 |
| Net before taxes | 4,381,974 | 5,333,990 |
| Income taxes | 1,375,000 | 452,000 |
| Net income | 3,006,974 | 4,881,990 |
| Balance for common | 2,567,830 | 4,471,124 |
| Earnings common share | | |
| Primary | \$0.09 | \$0.16 |
| Fully Diluted | \$0.09 | \$0.15 |
| Common Shares: | | |
| Full Diluted | 28,774,701 | 32,105,424 |
| Year-end | 28,279,701 | 28,279,701 |

GRI BIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---------------------------------|-----------|-----------|-----------|
| Research & development expenses | 3,232,000 | 1,170,000 | 5,187,000 |
| General & administrative | | | |

| | | | |
|---|---------------------|--------------------|--------------------|
| expenses | 8,155,000 | 5,758,000 | 4,072,000 |
| Total operating expenses | 11,387,000 | 6,928,000 | 9,259,000 |
| Income (loss) from operations | (11,387,000) | (6,928,000) | (9,259,000) |
| Other income | ... | ... | 61,000 |
| Revaluation of derivative liability | ... | ... | (89,000) |
| Change in fair value of warrant liability | 182,000 | 384,000 | ... |
| Loss on warrant conversion | (250,000) | 506,000 | ... |
| Interest income (expense), net | (2,082,000) | 26,000 | (16,000) |
| Net income (loss) | (13,037,000) | (7,024,000) | (9,303,000) |
| Weighted average shares outstanding - basic | 461,566 | 48,301 | 31,148 |
| Weighted average shares outstanding - diluted | 461,566 | 48,301 | 31,148 |
| Year end shares outstanding | 645,738 | 64,202 | 32,442 |
| Net income (loss) per share - basic | \$(28.25) | \$(144.90) | \$(298.20) |
| Net income (loss) per share - diluted | \$(28.25) | \$(144.90) | \$(298.20) |
| Number of full time employees | ... | 2 | 3 |
| Number of part time employees | ... | 5 | 6 |
| Number of common stockholders | 17 | 7 | 7 |
| Income from cont operations before income tax | (13,037,000) | ... | ... |

Adjusted for 1-for-7 stock split, January 30, 2024; Adjusted for 1-for-30 stock split, April 21, 2023; Shares increased due to the effect of issuance of shares and warrants exercised; Shares increased due to the effect of common stock issued for convertible notes, IPO, net of issuance expenses and services; As of February 4, 2023; As of February 4, 2022

| | | | |
|--|--------------|--------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 1,808,000 | 3,781,000 | |
| Prepaid expenses & other current assets | 1,126,000 | 371,000 | |
| Total current assets | 2,934,000 | 4,152,000 | |
| Finance lease right-of-use asset, net | 14,000 | ... | |
| Property & equipment, net | 8,000 | ... | |
| Total assets | 2,956,000 | 4,152,000 | |
| Accounts payable | 1,410,000 | 977,000 | |
| Accrued research & development | ... | 42,000 | |
| Accrued general & administrative | ... | 268,000 | |
| Accrued payroll & related expenses | 736,000 | 401,000 | |
| Accrued expenses | 1,270,000 | 711,000 | |
| Warrant liability | 93,000 | 122,000 | |
| Other current liabilities | 441,000 | ... | |
| Finance lease liability, current | 14,000 | ... | |
| Warrant liability | 3,000 | ... | |
| Total current liabilities | 2,697,000 | 1,810,000 | |
| Total liabilities | 2,697,000 | 1,810,000 | |
| Common stock | 65 | 1,000 | |
| Additional paid-in-capital | 31,792,000 | 31,267,000 | |
| Retained earnings (accumulated deficit) | (31,533,000) | (28,926,000) | |
| Total stockholders' equity (deficit) | 259,000 | 2,342,000 | |
| Total Equity | 259,000 | ... | |

Recent Dividends:

| | | | |
|---|---------------------|---------------------|---------------------|
| 1. GRI Bio Inc common. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. GRI Bio Inc common. | | | |
| No dividends paid. | | | |
| GRYPHON DIGITAL MINING INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Software | 6,787,285 | 12,920,647 | 15,984,376 |
| Consulting | 39,750 | 682,309 | 1,510,413 |
| Other revenue | 9,409 | 42,074 | 132,308 |
| Total revenue | 6,836,444 | 13,645,030 | 17,627,097 |
| Cost of revenue | 3,401,441 | 5,412,388 | 7,433,884 |
| Gross profit | 3,435,003 | 8,232,642 | 10,193,213 |
| Depreciation | 27,191 | ... | ... |
| Product development | 2,335,609 | 4,690,967 | 5,892,022 |
| Sales & marketing | 2,293,767 | 6,053,172 | 7,708,265 |
| General & administrative | 5,677,485 | 8,344,613 | 10,173,630 |
| Depreciation & amortization | ... | 5,622,274 | 5,174,551 |
| Impairment of long-lived assets | ... | 38,967,295 | 14,354,114 |
| Total operating expenses | 10,334,052 | 63,678,321 | 43,302,582 |
| Income (loss) from operations | (6,899,049) | (55,445,679) | (33,109,369) |
| Interest (expense) income, net | (1,130,343) | ... | ... |
| Interest income (expense) net | ... | (853,716) | (1,530,703) |
| Change in fair value of convertible notes | (370,457) | (2,884,273) | (1,365,904) |
| Change in fair value of derivative liability | ... | 63,178 | 248,198 |
| Gain on forgiveness of Paycheck Protection Program loan | (202,820) | ... | 2,234,730 |
| Other income (expense) | ... | (221,101) | 186,420 |
| Total other income (expense) | ... | (3,895,912) | (227,259) |
| Net income (loss) from continuing operations before income taxes & equity in losses of investee | (8,602,669) | (59,341,591) | (33,336,628) |
| Current income taxes - U.S. federal | ... | (50,000) | ... |
| Current income taxes - U.S. state | ... | 2,827 | 4,300 |
| Current income taxes - foreign | ... | 6,308 | 6,270 |
| Total current income tax expense (benefit) | ... | (40,865) | 10,570 |
| Deferred income taxes - U.S. federal | ... | (675,290) | (2,274,295) |
| Total deferred income tax expense (benefit) | ... | (675,290) | (2,274,295) |
| Income tax expense (benefit) on continuing operations | ... | (716,155) | (2,263,725) |
| Equity in losses of investee | ... | ... | (7,564) |
| Net income (loss) from continuing operations | (8,602,669) | (58,625,436) | (31,080,467) |
| Income (loss) from discontinued operations, net of tax | (3,188,101) | (20,432,174) | (248,244) |
| Net income (loss) | (11,578,169) | (79,057,610) | (31,328,711) |
| Deemed dividends | | | |

| | | | |
|---|--------------|--------------|--------------|
| related to convertible redeemable preferred stock | ... | 955,500 | ... |
| Net income (loss) attributable to common stockholders | (11,578,169) | (80,013,110) | (31,328,711) |
| Weighted average shares outstanding - basic | 371,020 | 2,927,853 | 1,282,098 |
| Weighted average shares outstanding - diluted | 371,020 | 2,927,853 | 1,282,098 |
| Year end shares outstanding | 517,605 | 4,602,780 | 1,550,094 |
| Earnings (loss) per share from continuing operations - basic | \$(23.19) | \$(20.35) | \$(24.24) |
| Earnings (loss) per share from discontinued operations - basic | ... | \$(6.98) | \$(0.19) |
| Net earnings (loss) per share-basic | \$(31.21) | \$(27.33) | \$(24.44) |
| Earnings (loss) per share from continuing operations - diluted | \$(23.19) | \$(20.35) | \$(24.24) |
| Earnings (loss) per share from discontinued operations - diluted | ... | \$(6.98) | \$(0.19) |
| Net earnings (loss) per share-diluted | \$(31.21) | \$(27.33) | \$(24.44) |
| Number of full time employees | 3 | 112 | ... |
| Total number of employees | 3 | ... | ... |
| Number of common stockholders | 301 | 213 | ... |
| Foreign currency translation adjustments | ... | 40,577 | ... |
| Gain on sale of discontinued operations, net of tax | 212,601 | ... | ... |
| Discontinued operations | (2,975,500) | ... | ... |
| Earnings per share-total discontinued opers | \$(8.02) | ... | ... |
| Earning per share-total discount opers - diluted | \$(8.02) | ... | ... |
| Restated to reflect the discontinued operations of the 365 Cannabis and LCA; Adjusted for 1-for-20 stock split, November 8, 2022; Shares increased due to the effect of conversion of exchangeable shares to common stock, settlement of convertible notes, common shares and warrants issued in connection with unit offering, net of iss; Shares increased due to the effect of conversion exchangeable shares, settlement of convertible debt, issuance of shares for acquisitions, assets purchase, settlement of liabilities | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash | 768,461 | 877,755 | |
| Restricted cash | ... | 7,000,000 | |
| Account receivables, gross | 165,327 | 1,028,105 | |
| Allowance for doubtful accounts | 17,472 | 353,479 | |
| Accounts receivable, net | 147,855 | 674,626 | |
| Software & technology | 27,518 | 168,792 | |
| Professional services, dues & subscriptions | ... | 183,614 | |
| Insurance | ... | 224,785 | |
| Deferred contract costs | ... | 36,465 | |

| | | |
|--|---------------|---------------|
| Unbilled receivable | 370,326 | 544,212 |
| Rental deposit | 17,515 | ... |
| Other prepaid expenses & other current assets | ... | 51,755 |
| Prepaid expenses & other current assets | 420,082 | 1,209,623 |
| Assets held for sale | ... | 5,130,028 |
| Professional services | 4,723 | ... |
| Total current assets | 1,336,398 | 14,892,032 |
| Furniture & computer equipment | 80,759 | 185,308 |
| Fixed assets, gross | 80,759 | ... |
| Less: accumulated depreciation | 59,070 | 136,429 |
| Fixed assets, net | 21,689 | 48,879 |
| Capitalized software, net | ... | 654,556 |
| Intangible assets, net | ... | 2,164,722 |
| Goodwill | ... | 1,708,303 |
| Total assets | 1,358,087 | 19,468,492 |
| Accounts payable, accrued expenses & other current liabilities | ... | 4,426,419 |
| Accrued professional fees | 1,041,699 | ... |
| Contractors | 2,165,342 | ... |
| Accrued Leaf Data Systems contractors | 397,754 | ... |
| Settlements & legal | 107,923 | ... |
| Contractors | 160,739 | ... |
| Interest and other | 699,142 | ... |
| Contingent consideration payable | ... | 2,283,806 |
| Current portion of deferred revenue | 399,652 | 568,771 |
| Current portion of long-term debt | 5,149,000 | 13,200,000 |
| Liabilities held for sale | 248,031 | 2,246,222 |
| Accounts payable and accrued liabilities - Balancing value | 4,820,630 | ... |
| Total current liabilities | 10,369,282 | 22,725,218 |
| Deferred revenue, noncurrent | ... | 161,802 |
| Senior convertible notes (at fair value) | ... | 14,607,000 |
| Less: current maturities | ... | (13,200,000) |
| Long-term debt, less current portion | ... | 1,407,000 |
| Total liabilities | 10,369,282 | 24,294,020 |
| Special voting preferred stock | 1,900,138 | 2,185,391 |
| Common stock | ... | 460 |
| Class B common stock | 52 | ... |
| Additional paid-in capital | 164,583,630 | 160,207,367 |
| Accumulated other comprehensive income (loss) | 227,000 | 347,100 |
| Accumulated deficit | (179,144,015) | ... |
| Retained earnings (accumulated deficit) | ... | (167,565,846) |
| Series C Preferred stock | 3,422,000 | ... |
| Total stockholders' equity (deficit) | (9,011,195) | (4,825,528) |
| Total equity | (9,011,195) | ... |

Recent Dividends:

- 1. Gryphon Digital Mining Inc class B common.**
No dividends paid.
- 2. Gryphon Digital Mining Inc exchangeable.**
No dividends paid.
- 3. Gryphon Digital Mining Inc common.**
No dividends paid.
- 4. Gryphon Digital Mining Inc series C preferred.**
No dividends paid.
- 5. Gryphon Digital Mining Inc class A common.**
No dividends paid.
- 6. Gryphon Digital Mining Inc special voting preferred.**
No dividends paid.

Annual Dividends:

- 1. Gryphon Digital Mining Inc class B common.**
No dividends paid.
- 2. Gryphon Digital Mining Inc exchangeable.**
No dividends paid.
- 3. Gryphon Digital Mining Inc common.**

- No dividends paid.
- 4. Gryphon Digital Mining Inc series C preferred.**
No dividends paid.
- 5. Gryphon Digital Mining Inc class A common.**
No dividends paid.
- 6. Gryphon Digital Mining Inc special voting preferred.**
No dividends paid.

GSE SYSTEMS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|----------------|-----------------|----------------|
| Revenue | 45,041 | 47,734 | 55,183 |
| Cost of revenue | 33,111 | 35,824 | 43,325 |
| Gross profit (loss) | 11,930 | 11,910 | 11,858 |
| Selling, general & administrative | 16,092 | 17,028 | 14,908 |
| Research & development | 572 | 611 | 626 |
| Restructuring charges | ... | ... | 798 |
| Goodwill & intangible asset impairment charge | 1,391 | 7,505 | 3 |
| Depreciation | 185 | 304 | 284 |
| Amortization of definite-lived intangible assets | 508 | 868 | 1,213 |
| Total operating expenses | 18,748 | 26,316 | 17,832 |
| Operating income (loss) | (6,818) | (14,406) | (5,974) |
| Interest expense | 1,932 | 1,272 | 159 |
| Change in fair value of derivative instruments, net | 850 | 477 | 19 |
| Other income (loss), net | (802) | (91) | 16,884 |
| Income (loss) before income taxes - domestic | ... | (15,128) | 13,351 |
| Income (loss) before income taxes - foreign | ... | (164) | (2,581) |
| Income (loss) before taxes | (8,702) | (15,292) | 10,770 |
| Provision (benefit) for current federal income taxes | ... | ... | (75) |
| Provision (benefit) for current state income taxes | 33 | 42 | 74 |
| Provision (benefit) for current foreign income taxes | (23) | 95 | 71 |
| Subtotal provision (benefit) for current income taxes | 10 | 137 | 70 |
| Provision (benefit) for deferred federal income taxes | ... | (47) | 48 |
| Provision (benefit) for deferred state income taxes | 12 | (39) | 45 |
| Subtotal provision (benefit) for deferred income taxes | 12 | (86) | 93 |
| Provision (benefit) for income taxes | 22 | 51 | 163 |
| Net income (loss) | (8,724) | (15,343) | 10,607 |
| Net income (loss) attributed to common stockholders | ... | (15,343) | 10,607 |
| Weighted average shares outstanding - basic | 2,487 | 2,136 | 2,076 |
| Weighted average shares outstanding - diluted | 2,487 | 2,136 | 2,076 |
| Year end shares | | | |

| | | | |
|---|----------|----------|--------|
| outstanding | 3,034 | 2,245 | 2,093 |
| Income (loss) per share - continuing operations - basic | \$(3.51) | ... | ... |
| Net income (loss) per share - basic | \$(3.51) | \$(7.20) | \$5.10 |
| Income (loss) per share - continuing operations - diluted | \$(3.51) | ... | ... |
| Net income (loss) per share - diluted | \$(3.51) | \$(7.20) | \$5.10 |
| Part-Time Employees (Period End) | 53 | ... | ... |
| Full-Time Employees (Period End) | 218 | ... | ... |
| Total number of employees | 271 | 278 | 308 |
| Number of common stockholders | 710 | 708 | 725 |
| Foreign currency translation adjustments | ... | 110 | 1,110 |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-10 stock split, October 30, 2023; As is; Approximately; As of March 31, 2023; As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|--------|--------|
| Cash & cash equivalents | 2,250 | 2,789 |
| Restricted cash, current | 378 | 1,052 |
| Billed receivables | ... | 6,074 |
| Unbilled receivables | 10,449 | 5,146 |
| Allowance for doubtful accounts | 283 | 1,156 |
| Contract receivables, net | 10,166 | 10,064 |
| Income tax receivable | 38 | 78 |
| Prepaid expenses | 796 | 947 |
| Employee retention credit receivable | ... | 1,028 |
| Other current assets | 45 | 112 |
| Total current assets | 13,673 | 16,070 |
| Computer equipment | 2,381 | 2,363 |
| Software | 2,292 | 2,291 |
| Leasehold improvements | 805 | 659 |
| Furniture & fixtures | 840 | 838 |
| Equipment, software & leasehold improvements | 6,318 | 6,151 |
| Accumulated depreciation | 5,564 | 5,379 |
| Equipment, software & leasehold improvements, net | 754 | 772 |
| Software development costs, net | 750 | 574 |
| Goodwill | 4,908 | 6,299 |
| Intangible assets, net | 1,179 | 1,687 |
| Restricted cash - long term | 1,083 | 535 |
| Operating lease right-of-use assets, net | 413 | 506 |
| Other assets | 45 | 53 |
| Total assets | 22,805 | 26,496 |
| Current portion of long-term note | 810 | 3,038 |
| Accounts payable | 3,300 | 1,262 |
| Accrued expenses | 1,053 | 2,084 |
| Accrued compensation | 1,086 | 1,071 |
| Billings in excess of revenue earned | ... | 4,163 |
| Accrued warranty | 176 | 370 |
| Income taxes payable | 1,701 | 1,774 |
| Derivative liabilities | 1,132 | 603 |
| Other current liabilities | 956 | 1,286 |
| Other current liabilities held for sale | 5,119 | ... |
| Accrued legal settlements | 1,010 | ... |
| Total current liabilities | 16,343 | 15,651 |
| Long-term note, less current portion | 637 | 310 |
| Operating lease liabilities noncurrent | 357 | 160 |
| Other noncurrent | ... | ... |

| | | |
|---|----------|----------|
| liabilities | 126 | 144 |
| Total liabilities | 17,463 | 16,265 |
| Common stock | 32 | 240 |
| Additional paid-in capital | 86,983 | 82,911 |
| Retained earnings (accumulated deficit) | (78,708) | (69,927) |
| Accumulated other comprehensive income (loss) | 34 | 6 |
| Treasury stock at cost | 2,999 | 2,999 |
| Total stockholders' equity (deficiency) | 5,342 | 10,231 |
| Total Equity | 5,342 | ... |

Recent Dividends:**1. GSE Systems Inc common.**

No dividends paid.

2. GSE Systems Inc series A convertible preferred.

No dividends paid.

Annual Dividends:**1. GSE Systems Inc common.**

No dividends paid.

2. GSE Systems Inc series A convertible preferred.

No dividends paid.

GT BIOPHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|---------------------|---------------------|
| Research & development expense | 6,466,000 | 8,811,000 | 9,591,000 |
| Selling, general & administrative expense | 7,110,000 | 12,446,000 | 47,924,000 |
| Income (loss) from operations | (13,576,000) | (21,257,000) | (57,515,000) |
| Gain (loss) on disposal of assets | 4,797,000 | ... | ... |
| Interest income | 780,000 | 292,000 | 38,000 |
| Interest expense | 213,000 | 8,000 | 718,000 |
| Change in fair value of derivative liability | ... | 119,000 | 211,000 |
| Unrealized gain (loss) on marketable securities | 48,000 | (30,000) | (29,000) |
| Other income | 20,000 | ... | ... |
| Gain on extinguishment of debt | 547,000 | ... | ... |
| Net income (loss) | (7,597,000) | (20,884,000) | (58,013,000) |
| Weighted average shares outstanding - basic | 1,347,713 | 1,062,267 | 938,521 |
| Weighted average shares outstanding - diluted | 1,347,713 | 1,062,267 | 938,521 |
| Year end shares outstanding | 1,380,633 | 1,090,748 | 1,068,733 |
| Income (loss) per share from continuing operations - basic | \$(5.64) | ... | ... |
| Net income (loss) per share - basic | \$(5.64) | \$(19.80) | \$(61.80) |
| Income (loss) per share from continuing operations - diluted | \$(5.64) | ... | ... |
| Net income (loss) per share - diluted | \$(5.64) | \$(19.80) | \$(61.80) |
| Number of full time employees | 2 | 2 | 8 |
| Number of part time employees | ... | 8 | ... |
| Total number of employees | 2 | ... | ... |
| Number of common stockholders | 30 | 46 | 50 |

□ Including stock compensation to officers, directors and employees - research and development expense: \$718,000; □ Including stock compensation to officers, directors and employees - selling, general and administrative expense: \$3,903,000; □ Including stock compensation to officers, directors and employees - selling, general and administrative expense: \$17,234,000; □ Adjusted for 1- for -30 stock split, February 5, 2024; □ Shares increased due to issuance of shares upon mandatory conversion of notes payable and accrued interest, upon exercise of warrants, in public offering and for research and development agreement; □ As of March 30, 2023; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 1,079,000 | 5,672,000 |
| Prepaid expenses & other current assets | 84,000 | ... |
| Short-term investments | 12,893,000 | 10,836,000 |
| Prepaid expenses & other current assets | ... | 54,000 |
| Total current assets | 14,056,000 | 16,562,000 |
| Operating lease right-of-use asset | 53,000 | 165,000 |
| Deposits | ... | 9,000 |
| Total assets | 14,109,000 | 16,736,000 |
| Accounts payable | 4,328,000 | 3,140,000 |
| Accrued expenses | 1,195,000 | 1,669,000 |
| Current portion of operating lease liabilities | 58,000 | 110,000 |
| Derivative liability | ... | 19,000 |
| Warrant liability | 1,052,000 | ... |
| Total current liabilities | 6,633,000 | 4,938,000 |
| Non-current operating lease liability | ... | 64,000 |
| Total liabilities | 6,633,000 | 5,002,000 |
| Convertible series C preferred stock | 1,000 | 1,000 |
| Common stock | 1,000 | 33,000 |
| Additional paid in capital | 689,539,000 | 686,168,000 |
| Retained earnings (accumulated deficit) | (682,065,000) | (674,468,000) |
| Total stockholders' equity (deficit) | 7,476,000 | 11,734,000 |
| Total Equity | 7,476,000 | ... |

Recent Dividends:**1. GT Biopharma Inc series C convertible preferred.**

No dividends paid.

2. GT Biopharma Inc series H convertible preferred.

No dividends paid.

3. GT Biopharma Inc series J convertible preferred.

No dividends paid.

4. GT Biopharma Inc series E convertible preferred.

No dividends paid.

5. GT Biopharma Inc series I convertible preferred.

No dividends paid.

6. GT Biopharma Inc common.

No dividends paid.

Annual Dividends:**1. GT Biopharma Inc series C convertible preferred.**

No dividends paid.

2. GT Biopharma Inc series H convertible preferred.

No dividends paid.

3. GT Biopharma Inc series J convertible preferred.

No dividends paid.

4. GT Biopharma Inc series E convertible preferred.

No dividends paid.

5. GT Biopharma Inc series I convertible preferred.

No dividends paid.

6. GT Biopharma Inc common.

No dividends paid.

GUARDIAN HEALTH SCIENCES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|------------------------------|------------|------------|-------------------|
| Revenue - clinical nutrition | 12,248,550 | 11,031,053 | 6,952,359 |
| Revenue - | ... | ... | ... |

| | | | |
|--|----------------|---------------------|---------------------|
| diagnostics equipment | 340,683 | ... | ... |
| Other revenue | ... | 18,719 | 280,758 |
| Clinical nutrition | 11,907,867 | ... | ... |
| Total revenue | 12,248,550 | 11,049,772 | 7,233,118 |
| Cost of goods sold - clinical nutrition | 6,854,033 | 6,529,385 | 3,838,990 |
| Cost of goods sold - diagnostics equipment | 6,594,082 | ... | ... |
| Other cost of goods sold | ... | ... | 283,694 |
| Medical Devices | 259,951 | ... | ... |
| Total cost of goods sold | ... | 6,529,385 | 4,122,684 |
| Gross profit | 5,394,517 | 4,520,387 | 3,110,434 |
| Research & development | 150,684 | 193,800 | 64,358 |
| Selling & marketing | 1,704,680 | 2,069,660 | 2,324,569 |
| General & administrative | 7,480,925 | 9,577,987 | 11,204,885 |
| Transaction costs related to acquisition of Activ Nutritional, LLC | 394,546 | ... | ... |
| Goodwill impairment | ... | ... | 11,893,134 |
| Transaction costs related to acquisition | ... | ... | 2,103,680 |
| Impairment of right-of-use asset | ... | 24,257 | ... |
| Loss on lease termination | ... | ... | 106,477 |
| Loss on disposal of fixed assets | ... | (9,448) | (160,137) |
| Impairment of intangible assets | ... | 10,065,833 | ... |
| Total operating expenses | 9,730,834 | 21,940,985 | 27,857,240 |
| Income (loss) from operations | (4,336,317) | (17,420,598) | (24,746,806) |
| Gain on change in fair value of warrant derivative liability | 3,984,900 | 2,345,800 | ... |
| Interest income (expense), net | ... | 152,570 | 1,797 |
| Interest income | 379,520 | ... | ... |
| Gain on disposal of VectorVision subsidiary | 129,930 | ... | ... |
| Total other income (expenses) | 4,494,350 | 2,498,370 | 1,797 |
| Net income (loss) | 158,033 | (14,922,228) | (24,745,009) |
| Preferred stock deemed dividend | ... | 941,585 | ... |
| Net income (loss) attributable to common shareholders | 158,033 | (15,863,813) | (24,745,009) |
| Weighted average shares outstanding - basic | 1,270,846 | 1,121,000 | 473,772 |
| Weighted average shares outstanding - diluted | 1,270,846 | 1,121,000 | 473,772 |
| Year end shares outstanding | 1,275,239 | 1,267,340 | 488,540 |
| Net earnings (loss) per share - basic | \$0.12 | \$(14.15) | \$(52.23) |
| Net earnings (loss) per share - diluted | \$0.12 | \$(14.15) | \$(52.23) |
| Number of full time employees | 9 | 12 | 13 |
| Number of part time employees | ... | ... | 0 |
| Total number of employees | 9 | ... | ... |
| Number of common stockholders | 80 | 80 | 77 |
| Income from cont | ... | ... | ... |

operations before
income tax 158,033

□ Reclassified to conform with 2022 presentation; □ As reported by the Company; □ Adjusted for 1-for-50 stock split, January 9, 2023; □ Shares increased due to the effect of common stock issued for cash, exercise of warrants, vested restricted stock units and reverse split due to rounding; □ Shares increased due to the effect of common stock issued for cash, net of offering costs & common stock issued upon exercise of warrants; □ As of March 1, 2023; □ As of March 25, 2022; □ Approximately; □ As of March 15, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 6,359,646 | 10,655,490 |
| Restricted cash | ... | 5,250,000 |
| Accounts receivable, gross | ... | 1,926,349 |
| Less: allowance for doubtful accounts | ... | 1,996 |
| Accounts receivable, net | 2,274,394 | 1,924,353 |
| Raw materials | 35,404 | 49,637 |
| Finished goods | 2,641,708 | 3,069,784 |
| Inventories, net | 2,677,112 | 3,119,421 |
| Prepaid expenses & other assets | 573,780 | 687,933 |
| Total current assets | 11,884,932 | 21,637,197 |
| Furniture & fixtures | ... | 110,016 |
| Computer equipment and software | 111,670 | 66,115 |
| Office equipment | 68,253 | ... |
| Total property & equipment, gross | ... | 176,131 |
| Less: Accumulated depreciation & amortization | 146,678 | 127,260 |
| Property & equipment, net | 33,245 | 48,871 |
| Total assets | 11,918,177 | 21,686,068 |
| Accounts payable | 614,122 | 1,518,052 |
| Accrued expenses | 704,912 | 558,287 |
| Operating lease liability - current | ... | 3,807 |
| Warrant derivative liability - current | ... | 1,931,400 |
| Total current liabilities | 1,319,034 | 4,011,546 |
| Warrant derivative liability - long-term | 2,453,100 | 4,506,600 |
| Total liabilities | 3,772,134 | 8,518,146 |
| Series C convertible redeemable preferred stock | ... | 5,197,500 |
| Series D redeemable preferred stock | ... | 52,500 |
| Total redeemable preferred stock | ... | 5,250,000 |
| Common stock | 1,275 | 1,267 |
| Additional paid-in capital | 101,711,035 | 101,640,955 |
| Accumulated deficit | (93,566,267) | ... |
| Retained earnings (accumulated deficit) | ... | (93,724,300) |
| Total shareholders' equity (deficit) | 8,146,043 | 7,917,922 |
| Total Equity | 8,146,043 | ... |

Recent Dividends:

- Guardion Health Sciences Inc common.**
No dividends paid.
 - Guardion Health Sciences Inc preferred.**
No dividends paid.
 - Guardion Health Sciences Inc series D redeemable preferred.**
No dividends paid.
 - Guardion Health Sciences Inc series C convertible redeemable preferred.**
No dividends paid.
- Annual Dividends:**
- Guardion Health Sciences Inc common.**
No dividends paid.
 - Guardion Health Sciences Inc preferred.**

No dividends paid.
3. Guardion Health Sciences Inc series D redeemable preferred.

No dividends paid.
4. Guardion Health Sciences Inc series C convertible redeemable preferred.

No dividends paid.

GUIDED THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|---|----------------|----------------|----------------|
| Total revenue | 98 | ... | ... |
| Sales - devices & disposables | 98 | 13 | 81 |
| Cost of goods sold (recovered) | ... | 81 | 61 |
| Gross profit (loss) | 36 | (68) | 20 |
| Research & development | 228 | 77 | 69 |
| Sales & marketing | 268 | 181 | 141 |
| General & administrative | 2,997 | 3,007 | 2,172 |
| Total operating expenses | 3,493 | 3,265 | 2,382 |
| Income (loss) from operations | (3,457) | (3,333) | (2,362) |
| Other income (expense) | 39 | 16 | 507 |
| Interest expense | 278 | ... | ... |
| Interest income | 6 | ... | ... |
| Interest income (expense) | ... | (582) | (1,150) |
| Gain (loss) from extinguishment of debt | 196 | (469) | 578 |
| Change in fair value of derivative liability | 5 | 27 | (91) |
| Change in fair value of warrants | ... | ... | 448 |
| Total other income (expenses) | (32) | (1,008) | 292 |
| Income (loss) before income taxes | (3,489) | (4,341) | (2,070) |
| Deemed dividend for warrant exchanges | 99 | ... | ... |
| Net income (loss) | (3,489) | (4,341) | (2,070) |
| Preferred stock dividends | 171 | 631 | 361 |
| Net income (loss) attributable to common stockholders | (3,759) | (4,972) | (2,431) |
| Weighted average shares outstanding - basic | 51,131 | 32,505 | 13,377 |
| Weighted average shares outstanding - diluted | 51,131 | 32,505 | 13,377 |
| Year end shares outstanding | 54,105 | □48,596 | 13,673 |
| Income (loss) per share - continuing operations - basic | \$(0.07) | ... | ... |
| Net income (loss) per share - diluted | \$(0.07) | \$(0.15) | \$(0.18) |
| Full-Time Employees (Period End) | 4 | ... | ... |
| Total number of employees | 4 | □8 | □8 |
| Number of common stockholders | 159 | □□174 | □□171 |
| Cost of Goods Sold | 62 | ... | ... |

□ Shares increased due to the effects of shares issued to investors, warrants exercised, Auctus for exchange agreement, pay-

ment of preferred dividends, payment of interest and preferred stock converted; □ As is; □ As of March 27, 2023; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|-------|-------|
| Cash & cash equivalents | 591 | 2,313 |
| Accounts receivable, gross | 9 | 54 |
| Less: allowance for doubtful accounts | 2 | 48 |
| Accounts receivable, net | 7 | 6 |
| Raw materials | 1,360 | 1,260 |
| Work-in-progress | 46 | 68 |
| Finished goods | 44 | 38 |
| Inventory reserve | 818 | 818 |
| Inventory | 632 | ... |
| Inventory, net | ... | 548 |
| Other current assets | 163 | 137 |
| Total current assets | 1,393 | 3,004 |
| Equipment | 951 | 1,083 |
| Software | 634 | 656 |
| Furniture & fixtures | 17 | 41 |
| Leasehold improvements | 12 | 12 |
| Property & equipment, gross | 1,614 | 1,792 |
| Less accumulated depreciation | 1,582 | 1,750 |
| Property & equipment, net | 32 | 42 |
| Operating lease right-of-use assets, net of amortization | 227 | 303 |
| Other assets | 17 | 17 |
| Total non-current assets | 276 | 362 |
| Total assets | 1,669 | 3,366 |
| Current portion of long-term debt | 39 | 17 |
| Current portion of long-term debt, related parties | ... | 504 |
| Short term notes payable | 59 | 57 |
| Short-term notes payable, related parties | ... | 1 |
| Short-term convertible notes payable, including nonconvertible penalty | 1,203 | 230 |
| Accounts payable | 1,991 | 2,186 |
| Accounts payable, related parties | 32 | 39 |
| Accrued compensation | 401 | 444 |
| Accrued professional fees | 216 | 285 |
| Accrued interest | 970 | 189 |
| Accrued vacation | ... | 41 |
| Accrued preferred dividends | 228 | 231 |
| Stock subscription payable | ... | 36 |
| Other accrued expenses | 8 | 21 |
| Vacation | 27 | ... |
| Accrued liabilities | ... | 1,247 |
| Current portion of lease liability | 91 | 79 |
| Deferred revenue | 424 | 509 |
| Interest | 90 | ... |
| Total current liabilities | 4,809 | 4,869 |
| Long-term lease liability | 155 | 246 |
| Derivative liability | ... | 5 |
| Long-term convertible debt | ... | 1,046 |
| Long-term debt, related parties | 511 | 83 |
| Total long-term liabilities | 666 | 1,380 |
| Total liabilities | 5,475 | 6,249 |
| Series A convertible preferred stock | 838 | ... |
| Series C convertible preferred stock | 105 | 105 |
| Series C1 convertible preferred stock | 170 | 170 |
| Series C2 convertible preferred stock | 439 | 439 |
| Series D convertible | ... | ... |

| | | | | | | | | | | |
|---|---------------|---------------|---|---------------|--------------|---------------|---|---------------|---------------|----------|
| preferred stock | 159 | 159 | expenses | 68,648,000 | 64,790,000 | 32,172,000 | operations - diluted | \$66.46 | ... | ... |
| Series E convertible preferred stock | 834 | 839 | Taxes other than income | ... | 60,139,000 | 30,243,000 | Net income (loss) per common share - diluted | \$66.46 | \$40.32 | \$(5.71) |
| Series F convertible preferred shares | ... | 880 | Transportation, gathering, processing & compression | 348,631,000 | 357,246,000 | 212,013,000 | Full-Time Employees (Period End) | 226 | ... | ... |
| Series F-2 convertible preferred shares | ... | 489 | Depreciation, depletion & amortization | 319,715,000 | 267,761,000 | 160,913,000 | Total number of employees | 226 | 223 | 212 |
| Common stock | 3,441 | 3,437 | Impairment of oil & natural gas properties | ... | ... | 117,813,000 | Number of common stockholders | 8,635 | 823 | 450 |
| Additional paid-in capital | 140,983 | 138,090 | General & administrative expenses | 38,600,000 | 35,304,000 | 34,465,000 | □ Successor; □ From May 18, 2021; □ Reclassified to conform with 2022 presentation; □ Approximately; □ As of February 21, 2023; □ As of February 25, 2022 | | | |
| Treasury stock at cost | 132 | 132 | Restructuring & liability management expenses | ... | ... | 2,858,000 | | | | |
| Accumulated deficit | (151,118) | ... | Taxes other than income | 33,717,000 | ... | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): 2023 □ 2022 | | | |
| Retained earnings (accumulated deficit) | ... | (147,359) | Accretion expense | 2,782,000 | 2,746,000 | 1,214,000 | | | | |
| Series F-2 Preferred Stock - Redeemable - Convertible | 475 | ... | Restructuring costs | 4,762,000 | ... | ... | Cash & cash equivalents | 1,929,000 | 7,259,000 | |
| Total stockholders' equity (deficit) | (3,806) | (2,883) | Total operating expenses | 816,855,000 | 787,986,000 | 591,691,000 | Accounts receivable - oil & natural gas sales | 122,479,000 | 278,404,000 | |
| Total stockholders' equity (deficit) | (3,806) | ... | Income (loss) from operations | 974,847,000 | 543,126,000 | (55,926,000) | Accounts receivable - joint interest & other | 22,221,000 | 21,478,000 | |
| Recent Dividends: | | | Cash paid for interest | ... | 57,685,000 | 33,295,000 | Prepaid expenses & other current assets | 16,951,000 | 7,621,000 | |
| 1. Guided Therapeutics Inc series F convertible preferred. No dividends paid. | | | Change in accrued interest | ... | (826,000) | 6,061,000 | Short-term derivative instruments | 233,226,000 | 87,508,000 | |
| 2. Guided Therapeutics Inc series C convertible preferred. No dividends paid. | | | Capitalized interest | ... | ... | 198,000 | Total current assets | 396,806,000 | 402,270,000 | |
| 3. Guided Therapeutics Inc series E convertible preferred. No dividends paid. | | | Amortization of loan costs | ... | 2,914,000 | 1,663,000 | Oil & natural gas properties, full-cost accounting | ... | 2,418,666,000 | |
| 4. Guided Therapeutics Inc series B convertible preferred. No dividends paid. | | | Other interest expense | 57,069,000 | ... | 32,000 | Proved oil & natural gas properties | 2,904,519,000 | 178,472,000 | |
| 5. Guided Therapeutics Inc series C2 convertible preferred. No dividends paid. | | | Gain (loss) on debt extinguishment | ... | ... | (3,040,000) | Other depreciable property & equipment | ... | 5,977,000 | |
| 6. Guided Therapeutics Inc series D convertible preferred. No dividends paid. | | | Other income (expense), net | 27,982,000 | 11,348,000 | (13,049,000) | Land | ... | 386,000 | |
| 7. Guided Therapeutics Inc series A convertible preferred. No dividends paid. | | | Total other income (expense) | (29,087,000) | (48,425,000) | (56,942,000) | Unproved properties | 204,233,000 | ... | |
| 8. Guided Therapeutics Inc series F-2 convertible preferred. No dividends paid. | | | Current state income tax expense (benefit) | ... | ... | (39,000) | Total property & equipment | 3,117,917,000 | 2,603,501,000 | |
| 9. Guided Therapeutics Inc series C1 convertible preferred. No dividends paid. | | | Deferred state income tax expense (benefit) | (26,704,000) | ... | ... | Accumulated depletion, depreciation, amortization & impairment | 865,618,000 | 545,771,000 | |
| 10. Guided Therapeutics Inc common. No dividends paid. | | | Deferred federal income tax expense (benefit) | (498,452,000) | ... | ... | Property & equipment, net | 2,252,299,000 | 2,057,730,000 | |
| Annual Dividends: | | | Total deferred income taxes expense (benefits) | (525,156,000) | ... | ... | Long-term derivative instruments | 47,566,000 | 26,525,000 | |
| 1. Guided Therapeutics Inc series F convertible preferred. No dividends paid. | | | Income tax expense (benefit) | (525,156,000) | ... | (39,000) | Operating lease assets | 14,299,000 | 26,713,000 | |
| 2. Guided Therapeutics Inc series C convertible preferred. No dividends paid. | | | Net income (loss) | 1,470,916,000 | 494,701,000 | (112,829,000) | Other assets | 31,487,000 | 21,241,000 | |
| 3. Guided Therapeutics Inc series E convertible preferred. No dividends paid. | | | Preferred stock dividends | 4,840,000 | 5,444,000 | 4,573,000 | Deferred tax asset | 525,156,000 | ... | |
| 4. Guided Therapeutics Inc series B convertible preferred. No dividends paid. | | | Participating securities - preferred stock | 212,360,000 | 76,401,000 | ... | Total assets | 3,267,613,000 | 2,534,479,000 | |
| 5. Guided Therapeutics Inc series C2 convertible preferred. No dividends paid. | | | Net income (loss) applicable to common shareholders | 1,253,716,000 | 412,856,000 | (117,402,000) | Accounts payable & accrued liabilities | 309,532,000 | 437,384,000 | |
| 6. Guided Therapeutics Inc series D convertible preferred. No dividends paid. | | | Weighted average shares outstanding - basic | 18,645,000 | 20,185,000 | 20,545,000 | Short-term derivative instruments | 21,963,000 | 343,522,000 | |
| 7. Guided Therapeutics Inc series A convertible preferred. No dividends paid. | | | Weighted average shares outstanding - diluted | 18,902,000 | 20,347,000 | 20,545,000 | Current portion of operating lease liabilities | 12,959,000 | 12,414,000 | |
| 8. Guided Therapeutics Inc series F-2 convertible preferred. No dividends paid. | | | Year end shares outstanding | 18,300,000 | 19,035,000 | 20,599,000 | Total current liabilities | 344,454,000 | 793,320,000 | |
| 9. Guided Therapeutics Inc series C1 convertible preferred. No dividends paid. | | | Income (loss) per share - continuing operations - basic | \$67.24 | ... | ... | Long-term derivative instruments | 18,602,000 | 118,404,000 | |
| 10. Guided Therapeutics Inc common. No dividends paid. | | | Net income (loss) per common share - basic | \$67.24 | \$20.45 | \$(5.71) | Asset retirement obligation - long-term | 29,941,000 | 33,171,000 | |
| GULFPORT ENERGY CORP. | | | Income (loss) per share - continuing operations | ... | ... | ... | Non-current operating lease liabilities | 1,340,000 | 14,299,000 | |
| Annual Report | | | Net income (loss) applicable to common shareholders | 1,253,716,000 | 412,856,000 | (117,402,000) | Credit facility | ... | 145,000,000 | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | Weighted average shares outstanding - basic | 18,645,000 | 20,185,000 | 20,545,000 | Senior unsecured notes | ... | 550,000,000 | |
| 2023 □ 2022 □ 2021 (revised) | | | Weighted average shares outstanding - diluted | 18,902,000 | 20,347,000 | 20,545,000 | Net unamortized debt issuance costs | 667,382,000 | (845,000) | |
| Natural gas sales | 831,812,000 | 1,998,452,000 | 906,096,000 | ... | ... | ... | Total non-current liabilities | 717,265,000 | 860,029,000 | |
| Oil & condensate sales | 99,854,000 | 147,444,000 | 81,347,000 | ... | ... | ... | Total liabilities | 1,061,719,000 | 1,653,349,000 | |
| Natural gas liquid sales | 119,717,000 | 184,963,000 | 105,141,000 | ... | ... | ... | Mezzanine equity: new preferred stock | 44,214,000 | 52,295,000 | |
| Net gain (loss) on natural gas, oil & natural gas liquids derivatives | ... | (999,747,000) | (556,819,000) | ... | ... | ... | Common stock | 2,000 | 2,000 | |
| Net gain on gas, oil and NGL derivatives | 740,319,000 | ... | ... | ... | ... | ... | Additional paid-in capital | 315,726,000 | ... | |
| Total revenues | 1,791,702,000 | 1,331,112,000 | 535,765,000 | ... | ... | ... | Paid-in capital | ... | 449,243,000 | |
| Lease operating | ... | ... | ... | ... | ... | ... | Common stock held in reserve | ... | 1,996,000 | |
| | | | | | | | Retained Earnings | 1,847,948,000 | ... | |
| | | | | | | | Retained earnings (accumulated deficit) | ... | 381,872,000 | |

| | | | |
|--------------------------------------|---------------|-------------|--|
| Treasury stock | 1,996,000 | 286,000 | |
| Total stockholders' equity (deficit) | 2,161,680,000 | 828,835,000 | |
| Total Equity | 2,161,680,000 | | |

☐ Successor

Recent Dividends:

- Gulfport Energy Corp. common.**
No dividends paid.
- Gulfport Energy Corp. preferred.**
No dividends paid.

Annual Dividends:

- Gulfport Energy Corp. common.**
No dividends paid.
- Gulfport Energy Corp. preferred.**
No dividends paid.

GUOCHUN INTERNATIONAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ☐2021 (revised) |
|---|-----------|-----------|--------------------|
| Professional fees | ... | 15,126 | 30,097 |
| Amortization of software asset | ... | 1,257 | ... |
| Other general & administrative expenses | 22,926 | ... | ... |
| General & administrative expenses | 21 | 236 | 1,522 |
| Total operating expenses | 22,947 | 16,619 | 31,619 |
| Operating income (loss) | (22,947) | (16,619) | (31,619) |
| Income (loss) before income tax - United States | ... | (16,619) | (31,619) |
| Income (loss) before income tax | (22,947) | (16,619) | (31,619) |
| Net income (loss) | (22,947) | (16,619) | (31,619) |
| Weighted average shares outstanding - basic | 3,870,600 | 3,870,600 | 3,870,600 |
| Weighted average shares outstanding - diluted | 3,870,600 | 3,870,600 | 3,870,600 |
| Year end shares outstanding | 3,870,600 | 3,870,600 | 3,870,600 |
| Net income (loss) per share - basic | \$(0.01) | \$0.00 | \$(0.01) |
| Net income (loss) per share - diluted | \$(0.01) | \$0.00 | \$(0.01) |
| Total number of employees | ... | 1 | 1 |
| Number of common stockholders | 11 | 11 | 35 |

☐ Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ☐2021 (revised) |
|--|-----------|----------|--------------------|
| Accounts payable & accrued liabilities | 994 | 1,722 | ... |
| Amount due to the current & former sole director | ... | 3,358 | ... |
| Amount due to the sole officer and director | 27,033 | ... | ... |
| Total current liabilities | 28,027 | 5,080 | ... |
| Total liabilities | 28,027 | 5,080 | ... |
| Common stock, \$0.001 par value, 75,000,000 shares authorized; 3,000,000 shares issued and outstanding as of December 31, 2018 | 3,871 | ... | ... |
| Common stock | ... | 3,871 | ... |
| Additional paid in capital | 76,646 | 76,646 | ... |
| Accumulated deficit | (108,544) | ... | ... |
| Retained earnings (accumulated deficit) | ... | (85,597) | ... |
| Total stockholders' equity (deficit) | ... | (28,027) | (5,080) |
| Total Equity | ... | (28,027) | ... |

Recent Dividends:

- Guochun International Inc common.**
No dividends paid.

Annual Dividends:

- Guochun International Inc common.**
No dividends paid.

GUSKIN GOLD CORP

Earnings, 3 mos. to Dec 31(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|----------|----------|
| Cost & expenses | 80,295 | 97,874 |
| Operating income | (80,296) | (97,874) |
| Other income (expense), net | 315,766 | 306,145 |
| Net before taxes | 161,921 | 101,680 |
| Net income | 161,921 | 101,680 |

Earnings common share

| | | |
|----------------|------------|------------|
| Common Shares: | | |
| Full Diluted | 47,994,825 | 47,994,825 |
| Year-end | 47,994,825 | 47,994,825 |

Consolidated Balance Sheet Items, as of (\$):

| | 2023 | 2022 |
|-----------------------|-------------|-------------|
| Assets: | | |
| Cash & equivalents | 4,449 | 18,469 |
| Current assets | 150,497 | 168,966 |
| Net property & equip. | ... | ... |
| Total assets | 2,561,483 | (2,392,517) |
| Liabilities: | | |
| Current liabilities | 2,561,483 | (2,543,014) |
| Stockholders' equity | (2,392,517) | ... |
| Net current assets | (2,543,014) | ... |

GYRODYNE LLC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ☐2021 (revised) |
|----------------------------------|-----------|-----------|--------------------|
| Year end shares outstanding | 1,574,308 | 1,482,680 | 1,482,680 |
| Full-Time Employees (Period End) | 4 | ... | ... |
| Total number of employees | 4 | 4 | 4 |
| Number of common stockholders | 256 | ☐☐297 | ☐☐428 |

☐ Approximately; ☐ As of February 28, 2023; ☐ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Real estate held for sale | 53,780,000 | 53,670,000 |
| Cash & cash equivalents | 3,492,692 | 4,082,774 |
| Rent receivable | 119,471 | 99,683 |
| Other receivables | 12,601 | 36,009 |
| Total assets | 57,404,764 | 57,888,466 |
| Accounts payable | 2,640,662 | 1,445,487 |
| Payroll & related taxes | 1,641,347 | 37,494 |
| Professional fees | 1,696,508 | 183,744 |
| Deferred compensation to directors | 55,161 | 1,065,971 |
| Accrued liabilities | ... | 1,287,209 |
| Deferred rent liability | 37,515 | 38,746 |
| Tenant security deposits payable | 219,337 | 230,714 |
| Mortgage loans payable | 10,981,068 | 9,760,083 |
| Estimated liquidation & operating costs net of receipts | 11,108,640 | 14,758,728 |
| Total liabilities | 26,683,730 | 27,520,967 |
| Total stockholders' equity | 30,721,034 | ... |
| Net assets | ... | 30,367,499 |
| Total Equity | 30,721,034 | ... |

Recent Dividends:

- Gyrodyne LLC common.**
No dividends paid.

Annual Dividends:

- Gyrodyne LLC common.**
No dividends paid.

HAMMER FIBER OPTICS HOLDINGS CORP
Earnings, 3 mos. to Oct 31(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|-----------|-----------|
| Total revenues | 909,952 | 799,460 |
| Cost & expenses | 1,012,459 | 964,430 |
| Operating income | (117,479) | (180,894) |
| Interest expense | 34,292 | 67,807 |
| Other income (expense), net | (10,087) | 114,137 |
| Gains or losses | 72,000 | 49,892 |
| Net before taxes | (89,858) | (84,672) |
| Net income | (89,858) | (84,672) |

Earnings common share

| | | |
|----------------|------------|------------|
| Common Shares: | | |
| Full Diluted | 62,553,508 | 61,713,953 |
| Year-end | 62,078,537 | 60,853,341 |

Consolidated Balance Sheet Items, as of (\$):

| | 2023 |
|-----------------------|-------------|
| Assets: | |
| Cash & equivalents | 85,692 |
| Current assets | 361,125 |
| Net property & equip. | 83,611 |
| Total assets | 7,855,952 |
| Liabilities: | |
| Current liabilities | 3,135,711 |
| Stockholders' equity | 4,174,247 |
| Net current assets | (2,774,586) |

HAMMER FIBER OPTICS HOLDINGS CORP
Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|-----------|-----------|
| Total revenues | 1,736,554 | 1,543,511 |
| Cost & expenses | 1,961,225 | 1,948,758 |
| Operating income | (254,641) | (436,055) |
| Interest expense | 54,740 | 142,186 |
| Other income (expense), net | 155,684 | 114,124 |
| Gains or losses | 76,500 | 40,892 |
| Net before taxes | (77,197) | (423,225) |
| Net income | (77,197) | (423,225) |

Earnings common share

| | | |
|---------------|----|----------|
| Primary | \$ | \$(0.01) |
| Fully Diluted | \$ | \$(0.01) |

Common Shares:

| | | |
|--------------|------------|------------|
| Full Diluted | 62,680,947 | 62,078,537 |
| Year-end | 60,927,612 | 60,853,341 |

HAPI METAVERSE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ☐2021 (revised) |
|--------------------------------------|-----------|-----------|--------------------|
| Food & beverage | 201,873 | 41,772 | ... |
| Services rendered - related party | 28,117 | 28,143 | ... |
| Travel | 24,337 | ... | ... |
| Total of revenue | 254,327 | 69,915 | ... |
| Depreciation | ... | 4,821 | ... |
| Others cost of revenues | ... | 23,423 | ... |
| Depreciation in Cost of Revenues | 6,401 | ... | ... |
| Food & Beverage - Cost of revenues | 53,403 | ... | ... |
| Travel - Cost of revenues | 23,137 | ... | ... |
| Services Rendered - Cost of revenues | 9,153 | ... | ... |
| Total cost of revenues | 92,094 | 28,244 | ... |
| Gross profit (loss) | 162,233 | 41,671 | ... |
| Sales & marketing expenses | 960,473 | ... | ... |
| Depreciation expenses | 2,912 | 1,524 | 277 |
| General & administrative | ... | 410,038 | 172,093 |
| Total operating expenses | 963,385 | 411,562 | 172,370 |
| Income (loss) from operations | (801,152) | (369,891) | (172,370) |
| Other income | 1 | 3,065 | ... |
| Interest expenses | 97,622 | 5 | ... |
| Interest income | 66,315 | 11 | 7 |
| Gain on disposal of subsidiary | ... | 3,217 | ... |
| Gain on disposal of | ... | ... | ... |

| | | | |
|--|-------------|-------------|-------------|
| a subsidiary to related party | 2 | ... | ... |
| Dividend income | ... | ... | 32,500 |
| Withholding federal tax | ... | ... | 7,800 |
| Foreign exchange gain (loss) | 29,722 | 62,677 | (45,543) |
| Unrealized gain (loss) on securities investment | ... | (1,427,094) | 1,300,000 |
| Unrealized loss on Securities Investment - related party | (6,109,270) | ... | ... |
| Total other income (loss) | (6,110,852) | (1,358,129) | 1,279,164 |
| Income (loss) before taxes | (6,912,004) | (1,728,020) | 1,106,794 |
| Net income (loss) from continuing operations | ... | (1,728,020) | 1,106,794 |
| Net income (loss) from discontinued operations, net of tax | ... | (648) | (3,259) |
| Net Income After Extraordinary Items applicable to Common | (6,910,404) | ... | ... |
| Net income (loss) attributable to non-controlling interests | 1,600 | 233 | 2,266 |
| Net income (loss) applicable to common shareholders | ... | (1,728,435) | 1,105,801 |
| Weighted average shares outstanding - basic | 507,389,976 | 506,898,576 | 506,898,576 |
| Weighted average shares outstanding - diluted | 507,389,976 | 506,898,576 | 506,898,576 |
| Year end shares outstanding | 507,610,326 | 506,898,576 | 506,898,576 |
| Net income (loss) from continuing operations per share - basic | ... | \$0.00 | \$0.00 |
| Earnings per share-inc from discontinued oper | \$0.00 | ... | ... |
| Net income (loss) from discontinued operations per share - basic | \$0.00 | \$0.00 | \$0.00 |
| Net income (loss) per share - basic | \$(0.01) | \$0.00 | \$0.00 |
| Net income (loss) from continuing operations per share - diluted | ... | \$0.00 | \$0.00 |
| Earn per share-inc from discount oper | \$0.00 | ... | ... |
| Net income (loss) from discontinued operations per share - diluted | \$0.00 | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | \$(0.01) | \$0.00 | \$0.00 |
| Number of full time employees | ... | ... | 0 |
| Total number of employees | ... | 4 | ... |
| Number of common stockholders | 4,842 | 106 | ... |
| Net Income Before Extraordinary and Preferred Dividends | (6,912,004) | ... | ... |

¹ Restated to reflect the discontinued operations of HWH World Pte. Limited; ² As of March 29, 2023

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|--------------|-------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 745,719 | 514,260 |
| Prepaid expenses | 65,885 | ... |
| Prepaid expenses & other receivable | ... | 117,936 |
| Prepaid expenses & other receivable - related party | ... | 2,802 |
| Inventory | ... | 894 |
| Investment in securities - related party | 3,913,508 | 2,341,948 |
| Prepaid expenses and other current assets | 127,017 | ... |
| Total current assets | 4,852,129 | 2,977,840 |
| Leasehold improvement | 11,253 | 11,266 |
| Less: accumulated depreciation - leasehold improvement | 11,253 | 4,840 |
| Computer equipment | 11,794 | 5,685 |
| Less: accumulated depreciation - computer equipment | ... | 1,806 |
| Property & equipment, net | 6,574 | 10,305 |
| Other non-current assets | ... | 103 |
| Computer equipment | 6,574 | ... |
| Plant, Machinery & Equipment - Accumulated Depreciation & Impairment | 5,220 | ... |
| Goodwill | 60,273 | 60,343 |
| Operating lease right-of-use assets, net | 267,727 | 129,478 |
| Convertible promissory note receivable - related party | 1,207,627 | ... |
| Total assets | 6,394,330 | 3,178,069 |
| Accrued payroll | 13,146 | 3,309 |
| Accrued professional fees | 37,643 | 18,905 |
| Other including receipt in advance from customer | ... | 2,387 |
| Other including receipt in advance from customer - related party | 24,146 | 7,838 |
| Accounts payable & accrued expenses - related party | ... | 7,838 |
| Accrued interest | 371 | ... |
| Accrued taxes & franchise fees | ... | 3,816 |
| Amount due to related parties | 6,207,791 | 4,886,507 |
| Operating lease liabilities - current | 148,088 | 71,899 |
| Convertible promissory note payable - related party | 1,400,000 | ... |
| Total current liabilities | 7,831,185 | 4,994,661 |
| Operating lease liabilities - non-current | 126,810 | 59,196 |
| Promissory note payable - related party | 1,000,000 | ... |
| Total non-current liabilities | 1,126,810 | 59,196 |
| Total liabilities | 8,957,995 | 5,053,857 |
| Common stock | 50,761 | 50,690 |
| Accumulated other comprehensive income (loss) | (365,350) | (315,241) |
| Additional paid-in capital | 11,168,595 | 4,679,498 |
| Accumulated deficit | (13,414,222) | ... |
| Retained earnings (accumulated deficit) | ... | (6,288,884) |
| Total Hapi Metaverse Inc. stockholders' equity (deficit) | (2,560,216) | (1,873,937) |
| Non-controlling interests | (3,449) | (1,851) |
| Total stockholders' equity (deficit) | (2,563,665) | (1,875,788) |

Recent Dividends:

1. Hapi Metaverse Inc common.

No dividends paid.

2. Hapi Metaverse Inc convertible preferred.

No dividends paid.

Annual Dividends:

1. Hapi Metaverse Inc common.

No dividends paid.

2. Hapi Metaverse Inc convertible preferred.

No dividends paid.

HARBOR CUSTOM DEVELOPMENT INC Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|--------------|-----------------|-----------------------------------|
| | 2023 | 2022 | ¹ 2021 (revised) |
| Total revenues | 59,256,700 | ... | ... |
| Sales | 59,256,700 | 55,414,300 | 72,352,700 |
| Cost of sales | 110,691,900 | 55,866,800 | 50,419,400 |
| Gross profit (loss) | (51,435,200) | (452,500) | 21,933,300 |
| Operating expenses | 9,754,200 | 16,237,700 | 11,151,600 |
| Operating income (loss) | (61,189,400) | (16,690,200) | 10,781,700 |
| Other income | 51,500 | 38,000 | 127,200 |
| Gain (loss) on sale of equipment | (47,700) | (3,433,800) | (35,900) |
| Interest expense | 2,602,600 | 1,760,000 | 249,300 |
| Interest income | 151,000 | 465,600 | ... |
| Bankruptcy Expense | 392,500 | ... | ... |
| Total other income (expense) | ... | (4,690,200) | (158,000) |
| Income (loss) before income tax | (64,029,700) | (21,380,400) | 10,623,700 |
| Current federal income tax expense (benefit) | (107,500) | (456,300) | 2,394,500 |
| Current state income tax expense (benefit) | 28,700 | 8,400 | 21,400 |
| Total current income tax expense (benefit) | (78,800) | (447,900) | 2,415,900 |
| Deferred federal income tax expense (benefit) | (13,335,700) | (3,989,100) | (649,000) |
| Deferred state income tax expense (benefit) | (834,100) | (21,200) | ... |
| Total deferred income tax expense (benefit) | (14,169,800) | (4,010,300) | (649,000) |
| Valuation allowance | 18,838,000 | ... | ... |
| Income tax expense (benefit) | 4,589,400 | (4,458,200) | 1,766,900 |
| Net income (loss) | (68,619,100) | (16,922,200) | 8,856,800 |
| Net loss (income) attributable to non-controlling interests | ... | 500 | 1,700 |
| Preferred dividends | 7,614,800 | 7,759,900 | 2,724,900 |
| Net income (loss) attributable to common stockholders | (76,233,900) | (24,681,600) | 6,133,600 |
| Weighted average shares outstanding - basic | 1,945,233 | 699,490 | ² 716,837 |
| Weighted average shares outstanding - diluted | 1,945,233 | 699,490 | ² 1,089,678 |
| Year end shares outstanding | 2,686,431 | 718,835 | ² ³ 657,767 |
| Net earnings (loss) per share - basic | \$(39.19) | \$(35.29) | ² \$8.56 |
| Net earnings (loss) per shares - diluted | \$(39.19) | \$(35.29) | ² \$8.13 |
| Number of full time employees | ... | ⁴ 41 | ⁵ 80 |
| Number of common stockholders | 13 | ⁴ 12 | ⁵ ⁶ 6 |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-20 stock split, March 6, 2023; ³ Shares increased due to the effect of net proceeds from issuance of common stock, ex-

exercise of common stock, stock compensation expense and conversion of preferred stock; [Ⓐ] As of March 28, 2023; [Ⓑ] As of March 21, 2022; [Ⓒ] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|--------------|
| Cash | 3,574,500 | 9,665,300 |
| Restricted cash | 597,600 | 597,600 |
| Accounts receivable, gross | 379,800 | 1,707,000 |
| Allowance for doubtful accounts | 100,000 | 0 |
| Accounts receivable, net | 279,800 | 1,707,000 |
| Note receivable, net | 950,000 | 4,525,300 |
| Prepaid expense & other assets | 1,250,900 | 5,318,100 |
| Land held for development | 47,166,700 | ... |
| Construction in progress | 123,927,300 | ... |
| Held for sale | 34,384,200 | ... |
| Real estate | 156,738,400 | 205,478,200 |
| Machinery & equipment | 44,000 | 505,300 |
| Vehicles | ... | 26,200 |
| Furniture & fixtures | 692,100 | 695,600 |
| Leasehold improvements | 1,467,100 | 1,524,000 |
| Total fixed assets | 2,203,200 | 2,751,100 |
| Less: accumulated depreciation | 592,700 | 461,600 |
| Property & equipment, net | 1,610,500 | 2,289,500 |
| Right of use assets | 1,749,200 | 1,926,100 |
| Deferred tax asset | ... | 4,659,300 |
| Total assets | 166,750,900 | 236,166,400 |
| Construction loans, net | ... | 107,483,700 |
| Construction loans - related parties, net | ... | 8,122,800 |
| Trade accounts payable | 4,547,700 | 11,472,100 |
| Accrued compensation, bonuses & benefits | 143,200 | 384,700 |
| Accrued quarry reclamation costs | 10,000 | 76,200 |
| Retainage payable | 5,945,900 | 1,130,300 |
| Other accruals | 1,179,500 | 1,027,400 |
| Accounts payable & accrued expenses | ... | 14,090,700 |
| Dividends payable | ... | 634,700 |
| Contract liabilities | 25,300 | 497,400 |
| Equipment loans | ... | 2,057,100 |
| Right of use liabilities | ... | 2,779,400 |
| Note payable directors & officers's ("D&O") insurance | ... | 378,500 |
| Revolving line of credit loan, net | ... | 24,359,700 |
| Note payable paycheck protection program ("PPP") | 529,300 | ... |
| Finance leases | ... | 154,500 |
| Deferred revenue | 49,900 | 52,000 |
| Revolving Line of Credit Loan, net of Debt Discount of \$1.1 million and \$0 respectively | 14,178,700 | ... |
| Construction loans, net of debt discount | 125,322,300 | ... |
| Retainage Payable | 65,500 | ... |
| Liabilities Subject to Compromise | 12,221,500 | ... |
| Total liabilities | 158,272,900 | 160,610,500 |
| Preferred stock | 62,912,100 | 62,912,100 |
| Common stock | 43,030,200 | 35,704,700 |
| Additional paid in capital | 3,096,800 | 1,266,300 |
| Retained earnings (accumulated deficit) | (100,561,100) | (24,327,200) |
| Total stockholders' equity (deficit) | 8,478,000 | 75,555,900 |
| Total stockholders' equity (deficit) | 8,478,000 | 75,555,900 |

[Ⓐ] Net of debt discount - construction loans: \$1,900,000; [Ⓑ] Net of debt discount - construction loans - related party: \$100,000

Recent Dividends:
1. Harbor Custom Development Inc common.

No dividends paid.
2. Harbor Custom Development Inc 8.0% series A cumulative convertible preferred.

No dividends paid.
Annual Dividends:
1. Harbor Custom Development Inc common.

No dividends paid.
2. Harbor Custom Development Inc 8.0% series A cumulative convertible preferred.

No dividends paid.

HARVARD APPARATUS REGENERATIVE TECHNOLOGY INC

Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
|--|----------------|----------------|-----------------------------|
| Product revenue | 103 | ... | ... |
| Revenues | 103 | ... | ... |
| Cost of sales | 24 | ... | ... |
| Research & development | 3,062 | 1,742 | 1,592 |
| Selling, general & administrative | 294 | ... | ... |
| General & administrative expenses | 5,713 | 4,411 | 7,044 |
| Total operating expenses | ... | 6,153 | 8,636 |
| Total operating expenses | 9,093 | ... | ... |
| Operating income (loss) | (8,990) | (6,153) | (8,636) |
| Forgiveness of notes payable | ... | ... | 408 |
| Grant income | ... | ... | 165 |
| Sublease income | ... | 87 | ... |
| Change in fair value of warrant liability | ... | 2 | 15 |
| Other income (expense), net | (19) | (9) | 70 |
| Interest income | 64 | ... | ... |
| Total other income (expense), net | 45 | 80 | 658 |
| before income taxes | (8,945) | ... | ... |
| Net income (loss) | (8,945) | (6,073) | (7,978) |
| Less: preferred stock dividends | 77 | 180 | ... |
| Net income (loss) attributable to common stockholders | (9,022) | (6,253) | (7,978) |
| Weighted average shares outstanding - basic | 13,456 | 11,350 | 10,062 |
| Weighted average shares outstanding - diluted | 13,456 | 11,350 | 10,062 |
| Year end shares outstanding | 13,947 | 12,174 | 10,761 |
| Net income (loss) per share - basic | \$(0.67) | \$(0.54) | \$(0.79) |
| Net income (loss) per share - diluted | \$(0.67) | \$(0.54) | \$(0.79) |
| Number of full time employees | 10 | 7 | 6 |
| Number of part time employees | 2 | 1 | 1 |
| Total number of employees | 12 | 8 | 7 |
| Number of common stockholders | 140 | 141 | 155 |
| Basic EPS - Net Income excl Extra Items applicable to Common - (Company Level) | \$(0.67) | ... | ... |
| Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level) | \$(0.67) | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] As is; [Ⓒ] As of March 20, 2023; [Ⓓ] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|----------|----------|
| Cash and cash equivalents | 432 | ... |
| Cash | ... | 1,241 |
| Accounts receivable | 4 | ... |
| Inventory | 50 | ... |
| Prepaid research & development | 210 | 274 |
| Deposits | ... | 20 |
| Insurance | ... | 8 |
| Other current assets | ... | 51 |
| Prepaid expenses & other current assets | 87 | 79 |
| Total current assets | 783 | 1,594 |
| Leasehold improvements | 35 | 35 |
| Furniture, machinery & equipment | 1,414 | 1,405 |
| Computer equipment & software | 38 | 36 |
| Total property, plant & equipment | ... | 1,476 |
| Less: accumulated depreciation | 1,462 | 1,427 |
| Property, plant & equipment, net | 25 | 49 |
| Right-of-use assets, net | 48 | 147 |
| Deferred financing costs | 544 | 610 |
| Long-term prepaid contracts | 1,214 | ... |
| Total assets | 2,614 | 2,400 |
| Accounts payable | 445 | 682 |
| Advisory costs | ... | 300 |
| Audit services | 70 | 80 |
| Payroll | 79 | 55 |
| Legal costs | 475 | 135 |
| Research costs | 325 | ... |
| Other accrued & current liabilities | ... | 12 |
| Accrued & other current liabilities | ... | 582 |
| Warrant liability | 1 | ... |
| Current portion of operating lease liability | 48 | 99 |
| Total current liabilities | 968 | 1,363 |
| Operating lease liability, net of current portion | ... | 48 |
| Total liabilities | 968 | 1,411 |
| Series E convertible preferred stock | ... | 4,180 |
| Common stock | 139 | 122 |
| Additional paid-in capital | 93,463 | 79,698 |
| Accumulated deficit | (91,956) | ... |
| Retained earnings (accumulated deficit) | ... | (83,011) |
| Total stockholders' equity (deficit) | 1,646 | (3,191) |
| Total Equity | 1,646 | ... |

Recent Dividends:
1. Harvard Apparatus Regenerative Technology Inc common.

No dividends paid.
2. Harvard Apparatus Regenerative Technology Inc series D convertible preferred.

No dividends paid.

Annual Dividends:
1. Harvard Apparatus Regenerative Technology Inc common.

No dividends paid.
2. Harvard Apparatus Regenerative Technology Inc series D convertible preferred.

No dividends paid.

HEALTHCARE INTEGRATED TECHNOLOGIES INC
Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------|---------|---------|
| Total revenues | 21,769 | ... |
| Cost & expenses | 267,989 | 476,777 |

| | | | | | | |
|-----------------------------|------------|------------|---|--------------|--------------|---|
| Operating income | (357,614) | (488,642) | Inventories | 4,228,889 | 3,817,192 | No dividends paid. |
| Interest expense | 26,049 | 232,718 | Prepaid expenses & vendor deposits | 1,668,324 | 322,182 | 2. Healthier Choices Management Corp common. |
| Other income (expense), net | (139,631) | (139,631) | Investment | ... | 9,771 | No dividends paid. |
| Net before taxes | (383,663) | (383,663) | Other current assets | 65,556 | 1,224,171 | 3. Healthier Choices Management Corp series A convertible preferred. |
| Net income | (383,663) | (860,991) | Restricted cash | 553,232 | 1,778,232 | No dividends paid. |
| Earnings common share | | | Total current assets | 11,725,258 | 30,308,480 | 4. Healthier Choices Management Corp series B convertible preferred. |
| Primary | \$(0.01) | \$(0.02) | Displays | 312,146 | 312,146 | No dividends paid. |
| Fully Diluted | \$(0.01) | \$(0.02) | Building | 575,000 | 575,000 | HEALTHLYNKED CORP |
| Common Shares: | | | Furniture & fixtures | ... | 560,256 | Annual Report |
| Full Diluted | 68,637,514 | 42,473,648 | Leasehold improvements | 1,925,385 | 1,910,719 | Consolidated Income Statement, Years Ended Dec. 31 (\$): |
| Year-end | 70,725,011 | 42,830,061 | Computer hardware & equipment | 190,019 | 160,210 | |
| | | | Other property, plant, & equipment | 596,355 | 587,602 | 2023 |
| | | | Property, Plant & Equipment - Other - Gross | 688,774 | ... | 2022 |
| | | | Property, plant, & equipment, gross | 4,287,679 | 4,105,933 | 2021 |
| | | | Less: accumulated depreciation & amortization | ... | 993,025 | (revised) |
| | | | Less: accumulated depreciation | 1,552,427 | ... | |
| | | | Property, plant, & equipment, net of accumulated depreciation | 2,735,252 | 3,112,908 | |
| | | | Intangible assets, net of accumulated amortization | 4,376,682 | 5,005,511 | |
| | | | Goodwill | ... | 5,747,000 | |
| | | | Right of use asset - operating lease, net | 11,511,002 | 10,604,935 | |
| | | | Other assets | 621,385 | 476,196 | |
| | | | Total assets | 30,969,579 | 55,255,030 | |
| | | | Accounts payable & accrued expenses | 8,024,664 | 5,715,234 | |
| | | | Contingent consideration | ... | 774,900 | |
| | | | Contract liabilities | 207,513 | 198,606 | |
| | | | Operating lease liability, current | 2,842,829 | 2,228,852 | |
| | | | Line of credit | ... | 453,232 | |
| | | | Current portion of loan payment | 702,701 | 536,542 | |
| | | | Current portion of long-term debt | 453,232 | ... | |
| | | | Total current liabilities | 12,230,939 | 9,907,366 | |
| | | | Promissory note | ... | 2,913,788 | |
| | | | Other debt | ... | 815 | |
| | | | Total debt | ... | 2,914,603 | |
| | | | Current portion of long-term debt | ... | (536,542) | |
| | | | Loan payable, net of current portion | 2,403,807 | 2,378,061 | |
| | | | Operating lease liability, net of current | 8,465,617 | 8,041,504 | |
| | | | Total liabilities | 23,100,363 | 20,326,931 | |
| | | | Series E convertible preferred stock | ... | 14,722,075 | |
| | | | Series D convertible preferred stock | 1,111,100 | 800,000 | |
| | | | Common stock | 47,826,663 | 33,974,163 | |
| | | | Additional paid-in capital | 21,028,274 | 29,045,802 | |
| | | | Retained earnings (accumulated deficit) | (62,096,821) | (43,613,941) | |
| | | | Total stockholders' equity (deficiency) | 7,869,216 | 20,206,024 | |
| | | | Total Equity | 7,869,216 | ... | |

HEALTHIER CHOICES MANAGEMENT CORP Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------------|-----------------|-----------------|
| Vapor sales, net | 617 | 257,363 | 2,084,813 |
| Grocery sales, net | 55,689,793 | 29,009,640 | 11,235,041 |
| Total sales, net | ... | 29,267,003 | 13,319,854 |
| Total revenue | 55,690,410 | ... | ... |
| Cost of sales vapor | 787 | 112,880 | 839,599 |
| Cost of sales | | | |
| grocery | 35,341,569 | 18,929,905 | 7,187,701 |
| Gross profit (loss) | 20,348,054 | 10,224,218 | 5,292,554 |
| Impairment of goodwill | 6,104,000 | ... | ... |
| Selling, general & administrative expense | 32,219,733 | ... | ... |
| Total operating expenses | 38,323,733 | 18,877,302 | 10,033,048 |
| Income (loss) from operations | (17,975,679) | (8,653,084) | (4,740,494) |
| Gain on debt settlements | ... | ... | 767,930 |
| Other income (expense), net | (1,485,612) | 1,246,192 | (26) |
| Interest income (expense), net | 211,996 | 202,653 | (65,281) |
| Gain (loss) on investment | (8,485) | (13,372) | 412 |
| Change in contingent consideration | 774,900 | ... | ... |
| Total other income (expense), net | (507,201) | 1,435,473 | 703,035 |
| Income (loss) before income tax expense (benefit) | (18,482,880) | ... | ... |
| Induced conversions of preferred stock | 152,500 | ... | ... |
| Net income (loss) | (18,482,880) | (7,217,611) | (4,037,459) |
| Net income (loss) allocable to common shareholders | (18,635,380) | ... | ... |
| Weighted average shares outstanding | | | |
| - basic | 429,919,440,601 | 339,741,632,384 | 307,912,959,368 |
| Weighted average shares outstanding - diluted | 429,919,440,601 | 339,741,632,384 | 307,912,959,368 |
| Year end shares outstanding | 478,266,632,384 | 339,741,632,384 | 339,741,632,384 |
| Net income (loss) per share - basic | ... | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | ... | \$0.00 | \$0.00 |
| Number of common stockholders | 1,400 | 1,400 | 1,400 |

[□] Reclassified to conform with 2022 presentation; [□] Shares increased due to the effect of series C and D preferred stock exercised, stock options exercised, issuance of common stock in connection with rights offering, and issuance of awarded stock; [□] Approximately; [□] As of March 30, 2023; [□] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------|-----------|------------|
| Cash & cash equivalents | 5,081,086 | ... |
| Cash | ... | 22,911,892 |
| Accounts receivable | 128,171 | 55,815 |
| Notes receivable | ... | 189,225 |

Recent Dividends:

1. Healthier Choices Management Corp series C convertible preferred.

No dividends paid.

2. Healthier Choices Management Corp common.

No dividends paid.

3. Healthier Choices Management Corp series A convertible preferred.

No dividends paid.

4. Healthier Choices Management Corp series B convertible preferred.

No dividends paid.

Annual Dividends:

1. Healthier Choices Management Corp series C convertible preferred.

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|--------------|
| Patient service revenue, net | 5,484,278 | 5,407,416 | 5,764,186 |
| Subscription & event revenue | 58,901 | 20,835 | 14,883 |
| Product revenue | 179,200 | 429,951 | 718,062 |
| Total revenue | 5,722,379 | 5,858,202 | 6,497,131 |
| Practice salaries & benefits expenses | 3,231,117 | 3,335,695 | 3,114,991 |
| Other practice operating expenses | 2,205,085 | 2,566,191 | 2,349,279 |
| Cost of product revenue | 142,501 | 463,156 | 606,521 |
| Selling, general & administrative expenses | 3,623,402 | 4,577,490 | 4,929,668 |
| Depreciation & amortization | 352,027 | 829,481 | 827,696 |
| Impairment loss | 319,958 | 2,745,563 | ... |
| Depreciation | 123,868 | ... | ... |
| Amortization of Intangibles excluding Goodwill | 228,159 | ... | ... |
| Total operating expenses & costs | 9,874,090 | 14,517,576 | 11,828,155 |
| Income (loss) from operations | (4,151,711) | (8,659,374) | (5,331,024) |
| Gain (loss) on extinguishment of debt | (145,212) | ... | (4,957,168) |
| Change in fair value of debt | ... | ... | 19,246 |
| Financing cost | ... | 110,000 | ... |
| Amortization of original issue & debt discounts on note payable & convertible notes | 427,808 | 55,282 | ... |
| Change in fair value of contingent acquisition consideration | 92,641 | 779,999 | (373,656) |
| Interest income (expense) | ... | (22,825) | (19,144) |
| Gain from realization of contingent sale consideration receivable | 1,090,857 | ... | ... |
| Interest expense and other | 83,812 | ... | ... |
| Change in fair value of contingent acquisition consideration | 11,094 | ... | ... |
| Total other income (expenses) | 537,760 | 591,892 | (5,369,214) |
| Net income (loss) before provision for income taxes | (3,613,951) | (8,067,482) | (10,700,238) |
| Income (loss) from continuing operations | (3,613,951) | (8,067,482) | (10,700,238) |
| Income (loss) from discontinued operations | (72,321) | (748,262) | 287,656 |
| Net income (loss) | (1,012,203) | (8,815,744) | (10,412,582) |
| Deemed dividend - amortization of | | | |

| | | | |
|--|-------------|-------------|--------------|
| beneficial conversion feature | ... | 353,571 | 353,571 |
| Net income (loss) to common stockholders | (1,012,203) | (9,169,315) | (10,766,153) |
| Weighted average shares outstanding - basic | 262,891,873 | 243,419,736 | 224,658,709 |
| Weighted average shares outstanding - diluted | 262,891,873 | 243,419,736 | 224,658,709 |
| Year end shares outstanding | 275,964,958 | 255,940,389 | 237,893,473 |
| Income (loss) per share from continuing operations - basic | \$(0.01) | \$(0.03) | \$(0.05) |
| Net income (loss) per share - basic | ... | \$(0.04) | \$(0.05) |
| Income (loss) per share from continuing operations - diluted | \$(0.01) | \$(0.03) | \$(0.05) |
| Net income (loss) per share - diluted | ... | \$(0.04) | \$(0.05) |
| Total number of employees | ... | 53 | ... |
| Number of common stockholders | 305 | 298 | ... |
| Gain from disposal of discontinued operations | 2,674,069 | ... | ... |
| Earn per share-inc from discount opers - diluted | \$(0.00) | ... | ... |
| Earns per share-disp of discount opers - diluted | \$0.01 | ... | ... |
| Earning per share-total discount opers - diluted | \$0.01 | ... | ... |
| Earnings per share-inc from discontinued oper | \$(0.00) | ... | ... |
| Earnings per share-disp of discontinued opers | \$0.01 | ... | ... |
| Earnings per share-total discontinued opers | \$0.01 | ... | ... |

| | | |
|---|--------------|--------------|
| Contingent sale consideration receivable, current portion | 199,645 | ... |
| Total current assets | 656,160 | 2,144,540 |
| Medical equipment | 493,854 | 493,854 |
| Furniture, transport & office equipment | 317,963 | ... |
| Furniture, office equipment & leasehold improvements | ... | 316,463 |
| Total property, plant & equipment | 811,817 | 810,317 |
| Less: accumulated depreciation | 521,062 | 397,194 |
| Property, plant & equipment, net | 290,755 | 413,123 |
| Intangible assets, gross | ... | 1,142,538 |
| Less: accumulated amortization | ... | 30,531 |
| Intangible assets, net | 883,848 | 1,112,007 |
| Goodwill | ... | 319,958 |
| Right of use lease assets | 935,812 | 540,181 |
| Deferred equity compensation & deposits | 50,047 | 50,907 |
| Contingent sale consideration receivable, long term portion | 1,463,518 | ... |
| Total assets | 4,280,140 | 4,580,716 |
| Trade accounts payable | ... | 863,662 |
| Accrued payroll liabilities | ... | 190,633 |
| Accrued operating expenses | ... | 482,296 |
| Accrued interest | ... | 63,615 |
| Product return allowance | 611,989 | 2,352 |
| Accounts payable & accrued expenses | ... | 1,602,558 |
| Contract liabilities | 271,774 | 574,847 |
| Lease liability, current portion | 326,033 | 344,464 |
| Notes payable & other amounts due to related party, net | ... | 506,110 |
| Due to related party current portion | 471,742 | ... |
| Government & vendor notes payable, current portion | 584,323 | ... |
| Notes payable, current portion | ... | 291,650 |
| Liability-classified equity instruments, current portion | ... | 30,000 |
| Contingent acquisition consideration, current portion | ... | 100,068 |
| Current liabilities held for sale | ... | 25,000 |
| Indemnification liability | 143,974 | ... |
| Other current liabilities | 2,189 | ... |
| Total current liabilities | 2,412,024 | 3,474,697 |
| Government notes payable, long term portion | 450,000 | 450,000 |
| Liability-classified equity instruments, long term portion | ... | 45,000 |
| Contingent acquisition consideration, long term portion | ... | 98,239 |
| Lease liability, long term portion | 613,386 | 198,330 |
| Total liabilities | 3,475,410 | 4,266,266 |
| Common stock | 27,597 | 25,594 |
| Series B convertible preferred stock | 2,750 | 2,750 |
| Common stock issuable | 281,682 | 225,584 |
| Additional paid-in capital | 42,525,837 | 41,081,455 |
| Accumulated deficit | (42,033,136) | ... |
| Retained earnings (accumulated deficit) | ... | (41,020,933) |
| Total shareholders' equity (deficit) | 804,730 | 314,450 |
| Total Equity | 804,730 | ... |

Net of unamortized original issue discount - Notes payable, current portion: \$37,748

Recent Dividends:
1. HealthLynked Corp series B convertible preferred voting.
 No dividends paid.
2. HealthLynked Corp common.
 No dividends paid.

Annual Dividends:
1. HealthLynked Corp series B convertible preferred voting.
 No dividends paid.
2. HealthLynked Corp common.
 No dividends paid.

HEALTHY EXTRACTS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-----------|-------------|
| | | (revised) | (revised) |
| Gross revenue | ... | 2,251,469 | 1,676,598 |
| Net revenue | 2,485,866 | ... | ... |
| Net revenue | 2,485,866 | 2,251,469 | 1,676,598 |
| Total cost of revenue | 864,055 | ... | ... |
| Cost of goods sold | ... | 783,141 | 556,972 |
| Written off inventory | ... | 96,811 | 424,548 |
| Total cost of revenue | 864,055 | 879,951 | 981,520 |
| Gross profit | 1,621,810 | 1,371,517 | 695,078 |
| General & administrative | 3,865,654 | 2,283,107 | 2,584,256 |
| Total operating expenses | 3,865,654 | 2,283,107 | 2,584,256 |
| Interest expense, net of interest income | 176,948 | 64,690 | 52,453 |
| Change in fair value on derivative | ... | (9,484) | (85,325) |
| Small Business Administration (SBA) loan forgiveness | ... | ... | 39,833 |
| Gain on sale of asset | (52,140) | 2,643 | ... |
| Total other income (expense) | (229,088) | (71,531) | (97,945) |
| Net gain (loss) before income tax provision | (2,472,932) | (983,121) | (1,987,122) |
| Net gain (loss) | (2,472,931) | (983,121) | (1,987,122) |
| Weighted average shares outstanding - basic | 2,915,410 | 2,854,290 | 2,660,083 |
| Weighted average shares outstanding - diluted | 2,915,410 | 2,854,290 | 2,660,083 |
| Year end shares outstanding | 2,954,104 | 2,876,437 | 2,819,868 |
| Income (loss) per share- continuing operation - basic | \$(0.85) | ... | ... |
| Net income (loss) per share - basic | \$(0.85) | \$0.00 | \$(1.20) |
| Income (loss) per share- continuing operation - diluted | \$(0.85) | ... | ... |
| Net income (loss) per share - diluted | \$(0.85) | \$0.00 | \$(1.20) |
| Total number of employees | ... | ... | 2 |
| Number of common stockholders | 119 | ... | 111 |

Reclassified to conform with 2022 presentation; As reported by the Company; As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------|-----------|-----------|
| | | (revised) |
| Cash | 19,441 | 65,651 |
| Accounts receivable | 30,440 | 105,794 |
| Inventory | 1,626,283 | 1,819,128 |
| Prepaid acquisition cost | ... | 53,015 |
| Right of use asset, net | 71,583 | ... |
| Offering costs | 151,931 | ... |

Restated to reflect the discontinued operations of the Accountable Care Organization / Managed Service Organization division; Rounding difference, breakdown taken from the notes; Shares increased due to the sales of common shares, issuance of contingent acquisition consideration, conversion of convertible notes payable and exercise of warrants and options; As of March 30, 2023; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------|-----------|
| Cash | 247,222 | 61,891 |
| Accounts receivables, gross | ... | 72,284 |
| Less: allowance for doubtful accounts | ... | 0 |
| Accounts receivable, net | 20,861 | 72,284 |
| Inventory | 133,222 | 192,833 |
| Contract assets | 5,110 | 269,736 |
| Insurance prepayments | ... | 17,733 |
| Other expense prepayments | 50,100 | 6,989 |
| Rent deposits | ... | 44,125 |
| Deferred equity compensation | ... | 75,000 |
| Less: long term portion prepaid expenses & other current assets | ... | (50,907) |
| Prepaid expenses & other current assets | ... | 92,940 |
| Current assets held for sale | ... | 1,454,856 |

| | | | | | | | | | |
|--|--------------|--------------|--|-------------|-------------|------------|---|------------|------------|
| Total current assets | 1,899,678 | 2,043,587 | taxes | (291,596) | (8,694) | 330,502 | Long-term loan receivable from related party | 182,946 | 246,472 |
| Fixed assets, net | 3,306 | 5,501 | Income tax expense (benefit) | (133,664) | (5,918) | 341,945 | Other non-current assets | 71 | 661 |
| Patents or trademarks | 521,881 | 521,881 | Net income (loss) | (4,876,700) | (6,677,466) | (327,044) | Intangible asset, net | 4,515,625 | ... |
| Deposit | 16,890 | 16,890 | Less: net income (loss) attributable to non-controlling interest | 686,810 | ... | (11,112) | Goodwill | 3,276,441 | ... |
| Goodwill | 193,260 | 193,260 | HeartCore Enterprises, Inc. | (4,189,890) | (6,677,466) | (338,156) | Long-term investment in warrants | 2,004,308 | ... |
| Total other assets | 735,336 | 737,531 | Weighted average shares outstanding - basic | 20,404,642 | 17,922,585 | 15,242,454 | Long-term note receivable | 200,000 | ... |
| Total assets | 2,635,014 | 2,781,118 | Weighted average shares outstanding - diluted | 20,404,642 | 17,922,585 | 15,242,454 | Total non-current assets | 14,128,874 | 3,603,451 |
| Accounts payable | 116,842 | 91,316 | Year end shares outstanding | 20,842,690 | 17,649,886 | 15,546,454 | Total assets | 19,623,767 | 12,138,588 |
| Accrued liabilities | 215,069 | 94,554 | Net income (loss) per common share - basic | \$(0.21) | \$(0.37) | \$(0.02) | Accounts payable & accrued expenses | 1,757,038 | 497,742 |
| Notes payable - related party | 83,366 | 866 | Net income (loss) per common share - diluted | \$(0.21) | \$(0.37) | \$(0.02) | Accrued payroll & other employee costs | 723,305 | 360,222 |
| Convertible debt, net | 608,601 | 317,284 | Number of full time employees | 99 | 49 | 45 | Due to related parties, current | 1,476 | 402 |
| Convertible debt - related party, net | 361,093 | 275,370 | Number of common stockholders | 38 | 56 | 46 | Current portion of long-term debts | 371,783 | 697,877 |
| Accrued interest payable | 64,386 | 21,387 | Foreign currency translation adjustments | ... | 380,009 | 123,529 | Operating lease liabilities, current | 396,535 | 291,863 |
| Accrued interest payable - related party | 2,465 | ... | Earnings per share from continuing operations | \$(0.21) | ... | ... | Finance lease liabilities, current | 17,445 | 19,294 |
| Derivative liabilities | 154,150 | 102,011 | Earnings per share from continuing operations | \$(0.21) | ... | ... | Income tax payables | 162,689 | 2,747 |
| Lease liabilities - current | 65,229 | ... | Income tax benefit | (133,664) | ... | ... | Deferred revenue | 2,166,175 | 1,724,519 |
| Lease liabilities - long-term | 9,222 | ... | Total number of employees | 99 | ... | ... | Other current liabilities | 216,405 | 53,027 |
| Common stock | 354,492 | 345,172 | | | | | Short-term debt | 135,937 | ... |
| Additional paid-in capital | 18,999,770 | 17,459,899 | | | | | Factoring liability | 562,767 | ... |
| Accumulated Deficit | (18,399,673) | (15,926,742) | | | | | Total current liabilities | 6,511,555 | 3,647,693 |
| Total stockholders' equity (deficit) | 954,590 | 1,878,330 | | | | | Bond payable | ... | 228,956 |
| Total Equity | 954,590 | 1,878,330 | | | | | Loans with banks & other financial institutions | ... | 1,601,625 |

Recent Dividends:**1. Healthy Extracts Inc common.**

No dividends paid.

2. Healthy Extracts Inc preferred.

No dividends paid.

Annual Dividends:**1. Healthy Extracts Inc common.**

No dividends paid.

2. Healthy Extracts Inc preferred.

No dividends paid.

HEARTCORE ENTERPRISES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|------------|
| | | | (revised) |
| Cost of revenues | 13,778,416 | ... | ... |
| Revenues | 21,845,830 | ... | ... |
| Revenues | 21,845,830 | 8,818,312 | 10,822,514 |
| Cost of revenues | 13,778,416 | 5,467,017 | 5,634,737 |
| Gross profit | 8,067,414 | 3,351,295 | 5,187,777 |
| Selling expenses | 1,516,247 | 2,826,615 | 296,778 |
| General & administrative expenses | 9,651,381 | 6,579,734 | 4,321,241 |
| Research & development expenses | 1,019,141 | 641,025 | 510,740 |
| Total operating expenses | 12,186,769 | 10,047,374 | 5,128,759 |
| Income (loss) from operations | (4,119,355) | (6,696,079) | 59,018 |
| Interest income | 70,624 | 66,963 | 6,955 |
| Interest expense | 162,968 | 41,800 | 43,240 |
| Other income | 366,283 | 57,268 | 30,614 |
| Other expenses | ... | 69,736 | 38,446 |
| Changes in fair value of investment in warrants | (501,445) | ... | ... |
| Government grants | (124,595) | ... | ... |
| Government grants | 76,612 | ... | ... |
| Changes in fair value of investments in marketable securities | (615,520) | ... | ... |
| Total other income (expenses) | (891,009) | 12,695 | (44,117) |
| Income (loss) before income tax provision | (5,010,364) | (6,683,384) | 14,901 |
| Current income taxes | 157,932 | 2,776 | 11,443 |
| Deferred income | ... | ... | ... |

□ Approximately; □ As of March 31, 2023; □ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 1,012,479 | 7,177,326 |
| Accounts receivable | 2,623,682 | 551,064 |
| Accounts receivable | 2,623,682 | 551,064 |
| Prepayments to software vendors | 199,376 | 162,046 |
| Prepaid marketing & consulting fees | 92,546 | 99,770 |
| Prepaid selling expenses | 72,668 | ... |
| Prepaid subscription fees | 95,971 | 113,685 |
| Deferred offering expenses | 76,304 | ... |
| Prepaid insurance premium | ... | 66,023 |
| Other prepaid expenses | 536,865 | 96,706 |
| Prepaid expenses | ... | 538,230 |
| Due from related parties | 44,758 | 48,447 |
| Other current assets | 234,761 | 220,070 |
| Investments in marketable securities | 642,348 | ... |
| Current portion of long-term note receivable | 100,000 | ... |
| Investment in equity securities | 300,000 | ... |
| Total current assets | 5,494,893 | 8,535,137 |
| Leasehold improvements | 496,810 | 298,637 |
| Machinery & equipment | 706,145 | 316,827 |
| Vehicles | 89,859 | 106,490 |
| Software | 150,633 | 163,049 |
| Subtotal property & equipment | 1,443,447 | 885,003 |
| Accumulated depreciation | 679,717 | 681,376 |
| Property & equipment, net | 763,730 | 203,627 |
| Operating lease right-of-use assets | 2,467,889 | 2,644,957 |
| Deferred tax assets | 369,436 | 263,339 |
| Security deposits | 348,428 | 244,395 |

| | | |
|--|--------------|--------------|
| Long-term loan receivable from related party | 182,946 | 246,472 |
| Other non-current assets | 71 | 661 |
| Intangible asset, net | 4,515,625 | ... |
| Goodwill | 3,276,441 | ... |
| Long-term investment in warrants | 2,004,308 | ... |
| Long-term note receivable | 200,000 | ... |
| Total non-current assets | 14,128,874 | 3,603,451 |
| Total assets | 19,623,767 | 12,138,588 |
| Accounts payable & accrued expenses | 1,757,038 | 497,742 |
| Accrued payroll & other employee costs | 723,305 | 360,222 |
| Due to related parties, current | 1,476 | 402 |
| Current portion of long-term debts | 371,783 | 697,877 |
| Operating lease liabilities, current | 396,535 | 291,863 |
| Finance lease liabilities, current | 17,445 | 19,294 |
| Income tax payables | 162,689 | 2,747 |
| Deferred revenue | 2,166,175 | 1,724,519 |
| Other current liabilities | 216,405 | 53,027 |
| Short-term debt | 135,937 | ... |
| Factoring liability | 562,767 | ... |
| Total current liabilities | 6,511,555 | 3,647,693 |
| Bond payable | ... | 228,956 |
| Loans with banks & other financial institutions | ... | 1,601,625 |
| Less: unamortized debt issuance costs | ... | (8,969) |
| Less: current portion | ... | 697,877 |
| Long-term debts | 1,770,352 | 1,123,735 |
| Operating lease liabilities, non-current | 2,135,160 | 2,421,054 |
| Finance lease liabilities, non-current | 66,779 | 459 |
| Other non-current liabilities | 208,732 | 138,018 |
| Deferred tax liabilities | 1,264,375 | ... |
| Total non-current liabilities | 5,445,398 | 3,683,266 |
| Total liabilities | 11,956,953 | 7,330,959 |
| Common shares | 2,083 | 1,764 |
| Additional paid-in capital | 19,594,801 | 15,014,607 |
| Accumulated deficit | (14,763,469) | ... |
| Retained earnings (accumulated deficit) | ... | (10,573,579) |
| Accumulated other comprehensive income (loss) | 331,881 | 364,837 |
| Total HeartCore Enterprises, Inc.'s shareholders' equity (deficit) | 5,165,296 | 4,807,629 |
| Non-controlling interest | 2,501,518 | ... |
| Total shareholders' equity (deficit) | 7,666,814 | 4,807,629 |

Recent Dividends:**1. Heartcore Enterprises Inc common.**

No dividends paid.

Annual Dividends:**1. Heartcore Enterprises Inc common.**

No dividends paid.

HEPION PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|-----------------------------------|------------|------------|------------|
| Research & development expenses | 35,639,656 | 33,269,337 | 20,395,136 |
| General & administrative expenses | 9,618,298 | 10,348,465 | 10,008,173 |
| Impairment of goodwill | 3,190,000 | 1,870,924 | ... |
| Total operating expenses | 48,447,954 | 45,488,726 | 30,403,309 |

| | | | |
|---|---------------------|------------------------|------------------------|
| Income (loss) from operations | (48,447,954) | (45,488,726) | (30,403,309) |
| Interest expense | 9,465 | 10,164 | 8,859 |
| Change in fair value of derivative instruments (warrants) & contingent consideration | | 414,992 | (2,310,000) |
| Change in fair value of contingent consideration and derivative financial instruments | (877,645) | | |
| Income (loss) before income taxes | (49,335,064) | (45,083,898) | (32,722,168) |
| Income tax expense (benefit) | (409,022) | (2,883,849) | |
| Net income (loss) | (48,926,042) | (42,200,049) | (32,722,168) |
| Deemed dividend | | 3,137,500 | |
| Net income (loss) attributable to common shareholders | (48,926,042) | (45,337,549) | (32,722,168) |
| Weighted average shares outstanding | | | |
| - basic | 3,970,810 | [□] 3,811,472 | 3,514,577 |
| Weighted average shares outstanding - diluted | 3,970,810 | [□] 3,811,472 | 3,514,577 |
| Year end shares outstanding | 4,818,733 | [□] 3,811,481 | [□] 3,811,263 |
| Net earnings (loss) per share - basic | \$(12.32) | [□] \$(11.80) | \$(9.40) |
| Net earnings (loss) per share - diluted | \$(12.32) | [□] \$(11.80) | \$(9.40) |
| Full-Time Employees (Period End) | 22 | | |
| Total number of employees | 22 | 25 | 20 |
| Number of common stockholders | 344 | [□] 212 | [□] 211 |
| Foreign currency translation adjustments | | (90,168) | |

[□] Adjusted for 1-for-20 stock split, May 11, 2023; [□] Shares increased due to the issuance of shares & conversion of preferred stock; [□] As of March 23, 2023; [□] As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash | 14,785,880 | 51,189,088 |
| Prepaid expenses | 2,701,960 | 5,306,985 |
| Total current assets | 17,487,840 | 56,496,073 |
| Equipment | 346,770 | 326,382 |
| Furniture & fixtures | 62,183 | 62,183 |
| Less: accumulated depreciation | 379,466 | 306,945 |
| Property & equipment, net | 29,487 | 81,620 |
| Right-of-use assets | 212,878 | 50,585 |
| In-process research & development | | 3,190,000 |
| Other assets | 364,192 | 426,174 |
| Total assets | 18,094,397 | 60,244,452 |
| Accounts payable | 2,348,829 | 2,665,896 |
| Payroll & related costs | | 838,683 |
| Stock-based compensation | | 1,906,401 |
| Research & development | 1,268,560 | 1,716,035 |
| Legal fees | | 110,799 |
| Professional fees | 319,157 | 135,865 |
| Other accrued expenses | 2,439,351 | 92,200 |
| Accrued Expenses - Balancing value | 851,634 | |
| Accrued expenses | | 4,799,983 |
| Operating lease liabilities, current | 115,916 | 53,614 |
| Short-term portion of contingent consideration | 386,000 | 366,229 |
| Total current liabilities | 5,290,096 | 7,885,722 |
| Contingent consideration, non-current | 1,634,000 | 2,093,771 |

| | | | |
|--|---------------|---------------|--|
| Deferred tax liability | | 409,022 | |
| Operating lease liabilities, non-current | 93,104 | | |
| Derivative financial instruments, at estimated fair value - warrants | 3,796,390 | | |
| Total liabilities | 10,813,590 | 10,388,515 | |
| Series A convertible preferred stock | 855,808 | 855,808 | |
| Series C convertible preferred stock | 839,320 | 840,320 | |
| Common stock | 482 | 7,623 | |
| Additional paid in capital | 230,291,362 | 223,943,698 | |
| Accumulated other comprehensive income (loss) | (78,779) | (90,168) | |
| Accumulated deficit | (224,627,386) | | |
| Retained earnings (accumulated deficit) | | (175,701,344) | |
| Total stockholders' equity (deficit) | 7,280,807 | 49,855,937 | |
| Total Equity | 7,280,807 | | |

Recent Dividends:

1. Hephion Pharmaceuticals Inc series C convertible preferred (stated value: \$1,000).

No dividends paid.

2. Hephion Pharmaceuticals Inc common.

No dividends paid.

3. Hephion Pharmaceuticals Inc series A convertible preferred (stated value: \$10.00).

No dividends paid.

4. Hephion Pharmaceuticals Inc series B convertible preferred (stated value: \$10.00).

No dividends paid.

Annual Dividends:

1. Hephion Pharmaceuticals Inc series C convertible preferred (stated value: \$1,000).

No dividends paid.

2. Hephion Pharmaceuticals Inc common.

No dividends paid.

3. Hephion Pharmaceuticals Inc series A convertible preferred (stated value: \$10.00).

No dividends paid.

4. Hephion Pharmaceuticals Inc series B convertible preferred (stated value: \$10.00).

No dividends paid.

HESTIA INSIGHT INC

Annual Report

Consolidated Income Statement, Years Ended Nov. 30 (\$):

| | 2023 | 2021 | [□] 2020 (revised) |
|--|-----------|-------------|-----------------------------|
| Consulting revenue | 113,413 | 20,000 | 111,500 |
| Consulting revenue - related party | | 8,500 | |
| Origination fees | | | 31,350 |
| Total revenues | 113,413 | 28,500 | 142,850 |
| Cost of revenue - related party | | 1,478 | |
| Total cost of revenue | | 1,478 | |
| Gross profit | 113,413 | 27,022 | 142,850 |
| Selling, general & administrative expense | 415,061 | 247,217 | 149,254 |
| Total operating expenses | 415,061 | 247,217 | 149,254 |
| Operating income (loss) | (301,648) | (220,195) | (6,404) |
| Interest & dividend income | 3,676 | 521 | 5,844 |
| Realized gain (loss) on equity investments | 60,233 | 140,268 | (9,820) |
| Unrealized gain (loss) on equity investments | (182,592) | (9,687,011) | 11,538,061 |
| Interest expense | | | 3,219 |
| Interest income | 1 | | |
| Bad debt expense | 5,185 | | |
| Gain (loss) on sale of capital assets | (74,889) | | |

| | | | |
|---|------------------|--------------------|-------------------|
| Dividend income | 3,675 | | |
| Total other income (expense) | (198,757) | (9,546,222) | 11,530,866 |
| Income (loss) before taxes | (500,405) | (9,766,417) | 11,524,462 |
| Net income (loss) | (500,405) | (9,766,417) | 11,524,462 |
| Weighted average shares outstanding | | | |
| - basic | 27,939,260 | 28,039,826 | 28,405,532 |
| Weighted average shares outstanding - diluted | 27,939,260 | 28,039,826 | 28,405,532 |
| Year end shares outstanding | 27,939,260 | 22,816,200 | 23,810,200 |
| Net income (loss) per common share - basic | \$(0.02) | \$(0.35) | \$0.41 |
| Net income (loss) per common share - diluted | \$(0.02) | \$(0.35) | \$0.41 |
| Full-Time Employees (Period End) | 3 | | |
| Total number of employees | 3 | 3 | 1 |
| Number of common stockholders | 43 | [□] 32 | |
| Number of stockholders | | | [□] 33 |

[□] Reclassified to conform with 2021 presentation; [□] Approximately

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

| | 2023 | 2021 |
|---|-----------|-----------|
| Cash & cash equivalents | 93,890 | 524,741 |
| Investments in equities | 73,006 | 1,802,988 |
| Note receivable, net | | 4,910 |
| Total current assets | 166,896 | 2,332,639 |
| Right-of-use auto lease | | 14,426 |
| Vending machines-net | 27,442 | |
| Vending machines - Accumulated Depreciation | 6,510 | |
| Vending machines - Gross | 33,952 | |
| Total assets | 194,338 | 2,347,065 |
| Accounts payable & accrued liabilities | 16,214 | 15,134 |
| Right-of-use current liability | | 7,527 |
| Total current liabilities | 16,214 | 22,661 |
| Right-of-use long term liability | | 6,899 |
| Total liabilities | 16,214 | 29,560 |
| Common stock | 27,939 | 27,916 |
| Treasury stock | (5,100) | (5,100) |
| Additional paid in capital | 901,613 | 826,691 |
| Retained earnings (accumulated deficit) | (756,528) | 1,457,798 |
| Total stockholders' equity (deficit) | 178,124 | 2,317,505 |
| Total Equity | 178,124 | |

Recent Dividends:

1. Hestia Insight Inc common.

No dividends paid.

2. Hestia Insight Inc series B common.

No dividends paid.

Annual Dividends:

1. Hestia Insight Inc common.

No dividends paid.

2. Hestia Insight Inc series B common.

No dividends paid.

HF FOODS GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|-------------------------------|---------------|---------------|----------------|
| Net revenue - third parties | 1,142,648,000 | 1,163,525,000 | 787,829,000 |
| Net revenue - related parties | 5,845,000 | 6,942,000 | 9,055,000 |
| Total net revenue | 1,148,493,000 | 1,170,467,000 | 796,884,000 |

| | As of March 27, 2023; As of January 27, 2023 | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | |
|--|--|--------------|-------------|--|-------------|---|---------------|---------------|
| | | | | 2023 | 2022 | | | |
| Cost of revenue - third parties | 938,815,000 | 958,775,000 | 636,253,000 | | | liability, net of current portion | 6,891,000 | 5,472,000 |
| Cost of revenue - related parties | 5,647,000 | 6,180,000 | 9,119,000 | | | Total liabilities | 308,537,000 | 341,280,000 |
| Total cost of revenue | 944,462,000 | 964,955,000 | 645,372,000 | | | Common stock | 5,000 | 5,000 |
| Gross profit (loss) | 204,031,000 | 205,512,000 | 151,512,000 | Cash | 15,232,000 | Treasury stock, at cost | 7,750,000 | ... |
| Distribution, selling & administrative expenses | 195,062,000 | 194,953,000 | 122,030,000 | Accounts receivable | 49,643,000 | Additional paid-in capital | 603,094,000 | 598,322,000 |
| Income (loss) from operations | 8,969,000 | 10,559,000 | 29,482,000 | Less: allowance for doubtful accounts | 2,119,000 | Retained earnings (accumulated deficit) | (308,688,000) | (306,514,000) |
| Interest expense | 11,478,000 | 7,457,000 | 4,091,000 | Accounts receivable - related parties | 308,000 | Total shareholders' equity attributable to HF | | |
| Other income | 1,091,000 | 1,829,000 | 508,000 | Inventories | 105,618,000 | Foods Group, Inc. | 286,661,000 | 291,813,000 |
| Change in fair value of interest rate swap contracts | 1,580,000 | (817,000) | (1,425,000) | Prepaid expenses & other current assets | 2,214,000 | Noncontrolling interest | 1,322,000 | 4,436,000 |
| Lease guarantee expense | (377,000) | 5,744,000 | ... | Advances to suppliers, net | 3,340,000 | Total shareholders' equity | 287,983,000 | 296,249,000 |
| Total other income (expenses), net | ... | (10,555,000) | (2,158,000) | Prepaid expenses | 4,591,000 | | | |
| Income (loss) before income tax provision | (2,621,000) | 4,000 | 27,324,000 | Prepaid Expenses & Other Assets - Short-Term | 10,145,000 | | | |
| Current federal income taxes provision (benefit) | 4,237,000 | 3,620,000 | 9,044,000 | Total current assets | 178,827,000 | | | |
| Current state income taxes provision (benefit) | 1,219,000 | 1,161,000 | 2,329,000 | Automobiles | 37,883,000 | | | |
| Current income taxes provision (benefit) | 5,456,000 | 4,781,000 | 11,373,000 | Buildings | 63,145,000 | | | |
| Deferred federal income taxes provision (benefit) | (4,550,000) | (4,321,000) | (2,823,000) | Building improvements | 22,120,000 | | | |
| Deferred state income taxes provision (benefit) | (865,000) | (691,000) | (4,047,000) | Furniture & fixtures | ... | | | |
| Deferred income taxes provision (benefit) | (5,415,000) | (5,012,000) | (6,870,000) | Land | 49,929,000 | | | |
| Income tax provision (benefit) | 41,000 | (231,000) | 4,503,000 | Machinery & equipment | 12,090,000 | | | |
| Net income (loss) | (2,662,000) | 235,000 | 22,821,000 | Property, Plant & Equipment - Gross - Total | 474,000 | | | |
| Less: net income (loss) attributable to noncontrolling interests | 488,000 | 225,000 | (676,000) | - Balancing value | ... | | | |
| Net income (loss) attributable to HF Foods Group Inc. | (2,174,000) | 460,000 | 22,145,000 | Property & equipment, gross | 185,641,000 | | | |
| Weighted average shares outstanding - basic | 53,878,237 | 53,757,162 | 51,918,323 | Less: accumulated depreciation | 52,505,000 | | | |
| Weighted average shares outstanding - diluted | 53,878,237 | 53,863,448 | 52,091,822 | Property & equipment, net | 133,136,000 | | | |
| Year end shares outstanding | 52,155,968 | 53,813,777 | 53,706,392 | Operating lease right-of-use assets | 12,714,000 | | | |
| Net income (loss) per share - basic | \$(0.04) | \$0.01 | \$0.43 | Long-term investments | 2,388,000 | | | |
| Net income (loss) per share - diluted | \$(0.04) | \$0.01 | \$0.43 | Customer relationships, net | 147,181,000 | | | |
| Number of full time employees | 925 | 890 | ... | Trademarks & other intangibles, net | 30,625,000 | | | |
| Number of part time employees | ... | 180 | ... | Goodwill | 85,118,000 | | | |
| Total number of employees | 925 | 1,070 | 900 | Other long-term assets | 6,531,000 | | | |
| Number of common stockholders | 41 | 41 | 41 | Total assets | 596,520,000 | | | |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... | Checks issued not presented for payment | 4,494,000 | | | |
| Common - Total | \$(0.04) | ... | ... | Line of credit | 58,564,000 | | | |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... | Accounts payable | 51,617,000 | | | |
| Common - Total | \$(0.04) | ... | ... | Accounts payable - related parties | 397,000 | | | |
| | | | | Current portion of long-term debt, net | 5,450,000 | | | |
| | | | | Current portion of obligations under finance leases | 1,749,000 | | | |
| | | | | Current portion of obligations under operating leases | 3,706,000 | | | |
| | | | | Accrued expenses & other liabilities | 2,629,000 | | | |
| | | | | Liability under interest rate swap contracts | 1,723,000 | | | |
| | | | | Accrued compensation | 7,941,000 | | | |
| | | | | Accrued other | 4,994,000 | | | |
| | | | | Accrued expenses and other liabilities - Balancing value | 17,287,000 | | | |
| | | | | Total current liabilities | 143,264,000 | | | |
| | | | | Total debt before current portion | ... | | | |
| | | | | Less: current portion of long-term debt | ... | | | |
| | | | | Long-term debt, net of current portion | ... | | | |
| | | | | Promissory note payable - related party | 108,711,000 | | | |
| | | | | Obligations under finance leases, non-current | 11,229,000 | | | |
| | | | | Obligations under operating leases, non-current | 9,414,000 | | | |
| | | | | Deferred tax liabilities | 29,028,000 | | | |
| | | | | Lease guarantee | 34,443,000 | | | |

Recent Dividends:

1. HF Foods Group Inc common.

No dividends paid.

Annual Dividends:

1. HF Foods Group Inc common.

No dividends paid.

HG HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|--------|--------|----------------|
| Net premiums written | 3,903 | 10,927 | 1,608 |
| Escrow & other title fees | 2,605 | 2,199 | 790 |
| Management fees | ... | 1,356 | 37 |
| Total revenues | 11,108 | 14,482 | 2,435 |
| Management fees from related parties | 2,255 | ... | ... |
| Commission revenue | 2,345 | ... | ... |
| Underwriting expenses | 279 | 190 | 214 |
| Provision for title claim losses | 174 | 126 | 79 |
| Search & other fees | 122 | 92 | 33 |
| Total operating expenses | 575 | 408 | 326 |
| Gross underwriting profit (loss) | 10,533 | 14,074 | 2,109 |
| General & administrative expenses | 12,992 | 10,240 | 3,309 |
| Interest income | ... | 111 | 15 |
| Dividend income | 1,765 | 1,025 | 1,025 |
| Other income | (82) | 17 | 28 |
| Gain (loss) on sale of assets | ... | 123 | ... |
| Gain on extinguishment of debt | ... | ... | 545 |
| Gain on remeasurement of equity interest | (132) | ... | 3,327 |
| Gain (loss) from affiliate | ... | (435) | (381) |
| Loss on impairment | ... | 992 | 701 |
| Income (loss) from operations before income taxes | (908) | 3,683 | 2,658 |
| Current income tax expense (benefit) - federal | ... | ... | (102) |
| Current income tax expense (benefit) - state | 45 | 24 | ... |
| Total current income tax expense (benefit) | 45 | 24 | (102) |
| Income tax expense (benefit) | 45 | 24 | (102) |
| Net income (loss) | (953) | 3,659 | 2,760 |
| Net income (loss) attributable to noncontrolling | ... | ... | ... |

| | | | |
|--|----------|--------|--------|
| interest | 131 | 81 | ... |
| Net income (loss) after noncontrolling interests | (822) | 3,740 | 2,760 |
| Weighted average shares outstanding - basic | 2,867 | 2,857 | 2,838 |
| Weighted average shares outstanding - diluted | 2,867 | 2,857 | 2,873 |
| Year end shares outstanding | 2,862 | 2,873 | 2,873 |
| Income (loss) per share from continuing operations - basic | \$(0.29) | ... | ... |
| Net income (loss) per share - basic | \$(0.29) | \$1.31 | \$0.97 |
| Income (loss) per share from continuing operations - diluted | \$(0.29) | ... | ... |
| Net income (loss) per share - diluted | \$(0.29) | \$1.31 | \$0.96 |
| Number of full time employees | 73 | 76 | ... |
| Number of part time employees | ... | ... | 2 |
| Total number of employees | 73 | ... | ... |
| Number of beneficial stockholders | 453 | 491 | 625 |

□ As is; □ Approximately; □ As of March 27, 2023; □ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|--------|--------|
| Cash and cash equivalents | 10,247 | ... |
| Cash | ... | 9,458 |
| Restricted cash | 7,505 | 5,547 |
| Interest & dividend receivables | 293 | 335 |
| Fixed income securities, held-to-maturity | 3,122 | ... |
| Investments | 1,280 | 5,564 |
| Accounts receivables | 136 | 106 |
| Prepaid expenses & other current assets | ... | 301 |
| Prepaid expenses | 223 | ... |
| Total current assets | ... | 21,311 |
| Machinery & equipment | 13 | ... |
| Computers & equipment | 423 | 370 |
| Furniture & fixtures | ... | 3 |
| Property, plant & equipment, at cost | 436 | 373 |
| Less accumulated depreciation | 316 | 217 |
| Property, plant & equipment, net | 120 | 156 |
| Lease assets | 582 | 698 |
| Investment in affiliate | 10,834 | 10,850 |
| Goodwill | 6,492 | 6,492 |
| Intangibles assets, net | 267 | 342 |
| Other assets | 803 | 1,254 |
| Total assets | 41,904 | 41,103 |
| Accounts payable | 400 | 167 |
| Accrued salaries, wages & benefits | 350 | 169 |
| Lease liabilities, current portion | ... | 292 |
| Escrow liabilities | 7,454 | 5,497 |
| Other accrued expenses | 344 | 525 |
| Total current liabilities | ... | 6,650 |
| Reserve for title claims | ... | 287 |
| Unearned premiums | ... | 300 |
| Lease liabilities | 590 | 411 |
| Supplemental retirement plan | 313 | ... |
| Other long-term | ... | ... |

| | | |
|---|--------|--------|
| liabilities | 32 | 29 |
| Total long-term liabilities | ... | 1,027 |
| Total liabilities | 9,483 | 7,677 |
| Common stock | 53 | 54 |
| Capital in excess of par value | 30,491 | 30,491 |
| Retained earnings | 1,894 | ... |
| Retained earnings (accumulated deficit) | ... | 2,777 |
| Total stockholders' equity (deficit) | 32,438 | 33,322 |
| Noncontrolling interests | (17) | 104 |
| Total equity (deficit) | 32,421 | 33,426 |

Recent Dividends:
1. HG Holdings Inc common.
 No dividends paid.

Annual Dividends:
1. HG Holdings Inc common.
 No dividends paid.

HIGHEST PERFORMANCES HOLDINGS INC

Annual Report
Consolidated Income Statement, Years Ended Jun. 30 (Y000):

| | 2023 | 2022 | 2021 |
|---|-----------------|-----------------|-----------------|
| Wealth management | 95,013 | 171,541 | 176,589 |
| Asset management | 1,983 | 5,890 | 13,464 |
| Consulting & other revenues | 17,444 | 11,310 | 1,147 |
| Total net revenues | 114,440 | 188,741 | 191,200 |
| Cost of sales | 16,136 | 33,834 | 44,043 |
| Selling expenses | 64,709 | 126,743 | 130,145 |
| General & administrative expenses | 92,399 | 102,267 | 90,194 |
| Total operating costs & expenses | 173,244 | 262,844 | 264,382 |
| Income (loss) from operations | (58,804) | (74,103) | (73,182) |
| Investment income | 13,561 | ... | 1,899 |
| Interest income | 8,591 | 7,474 | 10,919 |
| Sundry income, net | 1,660 | ... | ... |
| Other income (expenses), net | ... | 5,037 | 4,690 |
| Income (loss) before income taxes | (34,992) | (61,592) | (55,674) |
| Current income tax expense (benefit) | 1,160 | ... | 1,072 |
| Deferred income tax expense (benefit) | 7,425 | ... | (10,680) |
| Income tax expense (benefit) | 8,585 | (925) | (9,608) |
| Net income (loss) | (43,577) | (60,667) | (46,066) |
| Less: net income (loss) attributable to non-controlling interests | ... | ... | (304) |
| Net income (loss) attributable to Puyi Inc.'s shareholders | ... | (60,667) | (46,370) |
| Weighted average shares outstanding - basic | 90,472 | 90,472 | 90,472 |
| Weighted average shares outstanding - diluted | 90,472 | 90,472 | 90,472 |
| Year end shares outstanding | 90,472 | 90,472 | 90,472 |
| Net earnings (loss) per share - basic | Y(0.48) | Y(0.67) | Y(0.51) |
| Net earnings (loss) per share - diluted | Y(0.48) | Y(0.67) | Y(0.51) |
| Full-Time Employees (Period End) | 288 | ... | ... |
| Total number of employees | 288 | 552 | 716 |
| Foreign currency translation adjustments | ... | 417 | ... |

□ Reclassified to conform with 2022 presentation; □ As is

Consolidated Balance Sheet, Years Ended Jun. 30 (Y000):

| | 2023 | 2022 |
|---|----------|---------|
| Cash & cash equivalents | 164,470 | 194,259 |
| Restricted cash | 8,258 | 118,796 |
| Accounts receivable, gross | 44,493 | ... |
| Allowance for doubtful accounts | 6,892 | ... |
| Accounts receivable, net | 37,601 | 59,507 |
| Short-term investments | ... | 5,000 |
| Other receivables & current assets | ... | 14,298 |
| Short-term loans receivable | 27,666 | ... |
| Amount due from related parties | ... | 2,895 |
| Total current assets | 237,995 | 394,755 |
| Furniture, office equipment, fixtures | 3,920 | 5,151 |
| Leasehold improvements | 737 | 11,405 |
| Motor vehicles | ... | 1,932 |
| Motor vehicles - Gross | 1,932 | ... |
| Property & equipment, gross | 6,589 | 18,488 |
| Less: accumulated depreciation | 5,023 | 9,332 |
| Property & equipment, net | 1,566 | 9,156 |
| Intangible assets, net | 1,791 | 1,114 |
| Long-term prepayments | 22 | 551 |
| Deferred tax assets | 16,552 | 23,978 |
| Right-of-use assets | 13,607 | 34,382 |
| Total assets | 271,533 | 463,936 |
| Accounts payable | 6,292 | 11,668 |
| Investors' deposit | 8,258 | 118,796 |
| Payroll payable | 7,665 | ... |
| Accrued expenses | 332 | ... |
| Other payables & accrued expenses | 9,163 | 19,445 |
| Lease liabilities, current | 4,793 | 11,889 |
| Income taxes payable | 1,757 | 3,536 |
| Amount due to related parties | ... | 292 |
| Advance receipts from related parties | 803 | 1,500 |
| Others | 680 | ... |
| Individual income tax | 486 | ... |
| Total current liabilities | 31,066 | 167,126 |
| Other tax liabilities, non-current | 13,760 | 13,500 |
| Lease liabilities, non-current | 9,673 | 23,259 |
| Total liabilities | 54,499 | 203,885 |
| Ordinary shares | 600 | 600 |
| Additional paid-in capital | 224,694 | 224,694 |
| Statutory reserves | 23,071 | 23,314 |
| Retained Earnings | (31,498) | ... |
| Retained earnings (accumulated deficit) | ... | 11,836 |
| Accumulated other comprehensive income (loss) | 167 | (393) |
| Total Puyi Inc.'s equity | 217,034 | 260,051 |
| Total equity | 217,034 | 260,051 |

□ Including the consolidated VIEs amount without recourse to the Company - Accounts payable: RMB11,125,000; □ Including the consolidated VIEs amount without recourse to the Company - Investors' deposit: RMB118,796,000; □ Including the consolidated VIEs amount without recourse to the Company - Other payables & accrued expenses: RMB62,479,000; □ Including the consolidated VIEs amount without recourse to the Company - Lease liabilities, current: RMB4,855,000; □ Including the consolidated VIEs amount without recourse to the Company - Income taxes payable: RMB3,536,000; □ Including the consolidated VIEs amount without recourse to the Company - Amount due to related parties: RMB292,000; □ Including the consolidated VIEs amount without recourse to the Company - Other tax liabilities,

non-current: RMB11,730,000; ^② Including the consolidated VIEs amount without recourse to the Company - Lease liabilities, non-current: RMB15,154,000

Recent Dividends:**1. Highest Performances Holdings Inc ordinary.**

No dividends paid.

2. Highest Performances Holdings Inc American Depository Receipt.

No dividends paid.

Annual Dividends:**1. Highest Performances Holdings Inc ordinary.**

No dividends paid.

2. Highest Performances Holdings Inc American Depository Receipt.

No dividends paid.

HIMALAYA TECHNOLOGIES INC**Earnings, 6 mos. to Jan 31(Consol. - \$):**

| | 2024 | 2023 |
|-----------------------------|------------------|------------------|
| Cost & expenses | 356,740 | 160,732 |
| Operating income | (359,371) | (163,053) |
| Interest expense | 19,571 | 15,878 |
| Other income (expense), net | (127,425) | (345,361) |
| Gains or losses | 42,000 | 112,000 |
| Net before taxes | (464,367) | (412,292) |
| Net income | (464,367) | (412,292) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 203,270,024 | 147,201,861 |
| Year-end | 281,077,890 | 147,201,861 |

HONG YUAN HOLDING GROUP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|-----------------|-----------------|-------------------|
| Selling, general & administrative expenses | 39,522 | ... | ... |
| General & administrative expenses | 198 | 21,289 | 5,255 |
| Professional fees | ... | 37,059 | 41,021 |
| Total operating expense | 39,720 | 58,348 | 46,276 |
| Operating income (loss) | (39,720) | (58,348) | (46,276) |
| Net income (loss) before provision for income taxes | (39,720) | ... | ... |
| Net profit (loss) | (39,720) | (58,348) | (46,276) |
| Weighted average shares outstanding - basic | 74,640,766 | 74,640,664 | 74,640,970 |
| Weighted average shares outstanding - diluted | 74,640,766 | 74,640,664 | 74,640,970 |
| Year end shares outstanding | 74,640,766 | 74,640,766 | 74,640,766 |
| Net earnings (loss) per share - basic | \$0.00 | \$0.00 | \$0.00 |
| Net earnings (loss) per share - diluted | \$0.00 | \$0.00 | \$0.00 |
| Total number of employees | ... | ... | 0 |
| Number of common shareholders | 206 | 206 | 206 |
| Number of beneficiary stockholders | ... | ②290 | ②290 |

^① Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------|---------|
| Other payables | 1,069 | ... |
| Accounts payable & accrued liabilities | ... | 1,833 |
| Due to related parties | 150,175 | 109,691 |
| Total current liabilities | 151,244 | 111,524 |
| Total liabilities | 151,244 | 111,524 |
| Preferred stock | 5,000 | 5,000 |
| Common stock | 74,641 | 74,641 |
| Additional Paid-in | | |

| | | |
|--|--------------|--------------|
| Capital | 97,186,036 | ... |
| Paid-in capital | ... | 97,186,036 |
| Retained earnings (accumulated deficit) during development stage | (97,416,921) | (97,377,201) |
| Total stockholders' equity (deficit) | (151,244) | (111,524) |
| Total equity (deficit) | (151,244) | ... |

Recent Dividends:**1. Hong Yuan Holding Group series A-1 preferred.**

No dividends paid.

2. Hong Yuan Holding Group common.

No dividends paid.

Annual Dividends:**1. Hong Yuan Holding Group series A-1 preferred.**

No dividends paid.

2. Hong Yuan Holding Group common.

No dividends paid.

HOTH THERAPEUTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | ②2021 (revised) |
|---|--------------------|---------------------|---------------------|
| Research & development | 3,480,053 | 4,844,578 | 7,354,708 |
| Research & development - licenses acquired (including stock-based compensation) | ... | 86,586 | 174,782 |
| Compensation & related expenses (including stock-based compensation) | ... | 2,588,595 | 3,036,034 |
| Professional fees (including stock-based compensation) | ... | 2,494,132 | 2,703,837 |
| Rent expenses | ... | 66,834 | 46,871 |
| Other general & administrative expenses | 4,212,189 | 984,829 | 785,208 |
| Total operating expenses | 7,692,242 | 11,065,554 | 14,101,440 |
| Income (loss) from operations | (7,692,242) | (11,065,554) | (14,101,440) |
| Gains (losses) on marketable securities | (209,320) | (386,909) | (152,682) |
| Change in fair value of investments in joint ventures | 4,400 | (377,000) | ... |
| Interest income | 781 | 6,370 | ... |
| Other income (expenses), net | ... | 451,140 | (59,583) |
| Dividend income | 50,991 | ... | ... |
| Total other income (expenses) | (153,148) | (306,399) | (212,265) |
| Net income (loss) | (7,845,390) | (11,371,953) | (14,313,705) |
| Deemed dividend to series B preferred stock being redeemed | ... | (990) | ... |
| Net loss attributable to common stockholders | ... | (11,370,963) | ... |
| Weighted average shares outstanding - basic | 3,409,190 | 1,197,521 | ②893,226 |
| Weighted average shares outstanding - diluted | 3,409,190 | 1,197,521 | ②893,226 |
| Year end shares outstanding | 4,348,129 | ③1,302,113 | ②④958,982 |
| Net earnings (loss) per share - basic | \$(2.30) | \$(9.50) | ②\$(16.02) |
| Net earnings (loss) per share - diluted | \$(2.30) | \$(9.50) | ②\$(16.02) |
| Number of full time | | | |

| | | | |
|---|-------------|-------|--------|
| employees | ... | ⑤2 | ⑥4 |
| Number of part time employees | ... | ⑤4 | ⑥2 |
| Number of common stockholders | 101 | ⑤98 | ⑥139 |
| Foreign currency translation adjustments | ... | 4,420 | 32,937 |
| Income from cont operations before income tax | (7,845,390) | ... | ... |

^① Reclassified to conform with 2022 presentation; ^② Adjusted for 1-for-25 stock split, October 26, 2022; ^③ Shares increased due to the effect of stock-based compensation, issuance of common stock and fractional shares adjusted for reverse split; ^④ Shares increased due to the effect of issuance of common stock, stock warrants and prefunded warrants, warrant exercised, and stock-based compensation; ^⑤ As of March 17, 2023; ^⑥ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 9,292,352 | 6,428,611 |
| Marketable equity securities, at fair value | ... | 209,320 |
| Prepaid expenses and other current assets | 135,361 | ... |
| Prepaid expenses | ... | 88,450 |
| Total current assets | 9,427,713 | 6,726,381 |
| Investment in joint ventures at fair value | 37,400 | 33,000 |
| Right of use asset ? operating lease | 55,165 | ... |
| Total assets | 9,520,278 | 6,759,381 |
| Accounts payable | 35,592 | 694,989 |
| Accrued expenses | 614,226 | 667,742 |
| Accrued license fee - current portion | ... | 25,000 |
| Lease liability, current | 28,839 | ... |
| Total current liabilities | 678,657 | 1,387,731 |
| Accrued license fee - less current portion | ... | 250,000 |
| Lease liability, noncurrent | 26,326 | ... |
| Total liabilities | 704,983 | 1,637,731 |
| Common stock | 435 | 130 |
| Additional paid-in capital | 61,732,106 | 50,198,630 |
| Retained earnings (accumulated deficit) | (52,944,506) | (45,099,116) |
| Accumulated other comprehensive income (loss) | 27,260 | 22,006 |
| Total stockholders' equity (deficit) | 8,815,295 | 5,121,650 |
| Total Equity | 8,815,295 | ... |

Recent Dividends:**1. Hoth Therapeutics Inc series A preferred.**

No dividends paid.

2. Hoth Therapeutics Inc common.

No dividends paid.

Annual Dividends:**1. Hoth Therapeutics Inc series A preferred.**

No dividends paid.

2. Hoth Therapeutics Inc common.

No dividends paid.

HOUR LOOP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | ②2022 (revised) | ②2021 (revised) |
|---------------------------|-------------|--------------------|--------------------|
| Revenues | 132,124,202 | 95,930,091 | ... |
| Revenues, net | 132,124,202 | 95,930,091 | 62,792,981 |
| Cost of revenues | 65,606,947 | 46,942,770 | 27,984,335 |
| Gross profit | 66,517,255 | 48,987,321 | 34,808,646 |
| Selling & marketing | 61,135,227 | 42,221,425 | 25,098,497 |
| Payroll | ... | ... | 3,164,718 |
| Legal & professional fees | ... | ... | 49,466 |
| Insurance expense | ... | ... | 158,185 |

| | | | |
|---|--------------------|--------------------|------------------|
| Storage & rental fees | ... | 126,718 | ... |
| Sales taxes | ... | 84,914 | ... |
| Outside services | ... | 170,876 | ... |
| Pension | ... | 62,319 | ... |
| Office expense | ... | 65,823 | ... |
| Software subscriptions expense | ... | 33,919 | ... |
| Manpower recruitment advertising expense | ... | 19,343 | ... |
| Meals & entertainment expense | ... | 88,125 | ... |
| Other general & administrative expenses | ... | 211,594 | ... |
| General & administrative | 8,385,451 | 8,681,682 | 4,236,000 |
| Total operating expenses | 69,520,678 | 50,903,107 | 29,334,497 |
| Income (loss) from operations | (3,003,423) | (1,915,786) | 5,474,149 |
| Other expense | 9,542 | 9,950 | 12,299 |
| Interest expense | 248,779 | 144,479 | 56,509 |
| Other income | 101,290 | 130,429 | 87,637 |
| Total other income (expenses), net | (157,031) | (24,000) | 18,829 |
| Income (loss) before income taxes | (3,160,454) | (1,939,786) | 5,492,978 |
| Current federal income taxes | (637,242) | 30,928 | ... |
| Current state income taxes | (117,654) | 10,741 | ... |
| Deferred federal income taxes | ... | (426,457) | 557,223 |
| Deferred state income taxes | 24,136 | (77,375) | 151,982 |
| Current Income Tax Expense, Total tax expense (benefit) | (754,896) | 41,669 | ... |
| Income Taxes - Total - Deferred | 24,136 | (503,832) | ... |
| Income tax expense (benefit) | (730,760) | (462,163) | 709,205 |
| Net income (loss) | (2,429,694) | (1,477,623) | 4,783,773 |
| Weighted average shares outstanding - basic | 35,066,592 | 34,991,666 | 33,300,000 |
| Weighted average shares outstanding - diluted | 35,066,592 | 34,991,666 | 33,300,000 |
| Year end shares outstanding | 35,082,464 | 35,047,828 | 33,300,000 |
| Net income (loss) per common share - basic | \$(0.07) | \$(0.04) | \$0.14 |
| Net income (loss) per common share - diluted | \$(0.07) | \$(0.04) | \$0.14 |
| Number of full time employees | 178 | ... | 3 |
| Number of common stockholders | 6 | ... | 6 |
| Foreign currency translation adjustments | ... | ... | 4,690 |
| Total number of employees | 178 | ... | ... |

Reclassified to conform 2023 presentation; Reclassified to conform with 2022 presentation; As of March 29, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--------------------------|------------|----------------|
| | 2023 | 2022 (revised) |
| Checking account | 338,733 | 939,323 |
| Savings account and cash | 2,145,420 | 3,623,266 |
| Cash & cash equivalents | 2,484,153 | 4,562,589 |
| Accounts receivable, net | 747,650 | 352,379 |
| Inventory | 13,377,530 | 14,911,735 |
| Inventory-in-transit | 1,574,911 | 4,732,057 |

| | | |
|--|-------------|------------|
| Allowance | 675,886 | 842,263 |
| Inventory, net | 14,276,555 | 18,801,529 |
| Prepaid expenses & other current assets | 504,973 | 741,243 |
| Total current assets | 18,013,331 | 24,457,740 |
| Property & equipment, gross | 368,729 | 353,574 |
| Less: accumulated depreciation & amortization | 219,941 | 79,379 |
| Property & equipment, net | 148,788 | 274,195 |
| Deferred tax assets | 1,304,215 | 549,320 |
| Right-of-use lease assets | 83,946 | 450,721 |
| Total assets | 19,550,280 | 25,731,976 |
| Short-term loan | 652,422 | 652,316 |
| Accounts payable | 3,812,954 | 6,651,721 |
| Sales tax payable | 288,466 | 288,466 |
| Accrued payroll | 297,059 | 295,673 |
| Accrued bonus | 399,067 | 468,209 |
| Accrued expenses | 215,485 | 182,294 |
| Other payables | 34,094 | 64,279 |
| Operating lease liabilities - current | 82,269 | 385,216 |
| Accrued expenses and other current liabilities | 1,972,512 | 1,742,972 |
| Accrued Interest | 29,712 | 159,042 |
| Accrued expenses and other current liabilities - Balancing value | 708,629 | 285,009 |
| Credit cards payable | 4,404,445 | 5,231,532 |
| Total current liabilities | 10,924,602 | 14,663,757 |
| Operating lease liabilities - non-current | 2,363 | 64,945 |
| Due to related parties | 4,170,418 | 4,170,418 |
| Total non-current liabilities | 4,172,781 | 4,235,363 |
| Total liabilities | 15,097,383 | 18,899,120 |
| Common stock | 3,508 | 3,506 |
| Additional paid-in capital | 5,727,650 | 5,675,320 |
| Retained earnings (accumulated deficit) | (1,252,622) | 1,177,072 |
| Accumulated other comprehensive income (loss) | (25,639) | (23,042) |
| Total stockholders' equity (deficit) | 4,452,897 | 6,832,856 |
| Total Equity | 4,452,897 | 6,832,856 |

Reclassified to conform 2023 presentation

Recent Dividends:
1. Hour Loop Inc common.
 No dividends paid.
Annual Dividends:
1. Hour Loop Inc common.
 No dividends paid.

HST GLOBAL INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|------------------|------------------|------------------|
| | 2023 | 2022 | 2021 (revised) |
| Consulting expenses, related party | ... | 120,000 | 120,000 |
| General & administrative expenses | 20,907 | 21,035 | 25,718 |
| Consulting | 120,000 | ... | ... |
| Total operating expenses | 140,907 | 141,035 | 145,718 |
| Net income (loss) from operations | (140,907) | (141,035) | (145,718) |
| Interest expense | 5,303 | 4,039 | 2,642 |
| Total other income (expense) | (5,303) | (4,039) | (2,642) |
| Income (loss) before income taxes | (146,210) | ... | ... |
| Net income (loss) | (146,210) | (145,074) | (148,360) |
| Weighted average shares outstanding - basic | 5,248,582 | 5,248,582 | 5,248,582 |
| Weighted average | ... | ... | ... |

| | | | |
|--|-----------|-----------|-----------|
| shares outstanding - diluted | 5,248,582 | 5,248,582 | 5,248,582 |
| Year end shares outstanding | 5,248,582 | 5,248,582 | 5,248,582 |
| Income (loss) per share from continuing operations - basic | \$(0.03) | ... | ... |
| Net earnings (loss) per share - basic | \$(0.03) | \$(0.03) | \$(0.03) |
| Income (loss) per share from continuing operations - diluted | \$(0.03) | ... | ... |
| Net earnings (loss) per share - diluted | \$(0.03) | \$(0.03) | \$(0.03) |
| Number of common stockholders | 602 | 602 | 602 |

Reclassified to conform with 2022 presentation; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 1,526 | 190 |
| Total current assets | 1,526 | 190 |
| Total assets | 1,526 | 190 |
| Short term borrowing | 98,319 | ... |
| Accounts payable & accrued expenses - related party | ... | 362,275 |
| Loans or advances from related party | ... | 76,077 |
| Accrued officer compensation | 480,000 | ... |
| Accrued related party interest | 12,999 | 7,695 |
| Other payables | 2,275 | ... |
| Total current liabilities | 593,593 | 446,047 |
| Total liabilities | 593,593 | 446,047 |
| Common stock | 5,248 | 5,248 |
| Additional paid-in capital | 5,417,236 | 5,417,236 |
| Retained earnings (accumulated deficit) | (6,014,551) | (5,868,341) |
| Total stockholders' equity (deficit) | (592,067) | (445,857) |
| Rep Total Equity & Minority Interest | (592,067) | ... |

Recent Dividends:
1. HST Global Inc common.
 No dividends paid.
Annual Dividends:
1. HST Global Inc common.
 No dividends paid.

ICAD INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|------------|----------------|----------------|
| | 2023 | 2022 (revised) | 2021 (revised) |
| Sales | 9,930,000 | 12,620,000 | ... |
| Revenue - products | ... | ... | 21,191,000 |
| Revenue - service & supplies | 7,388,000 | 7,182,000 | 12,447,000 |
| Total revenue | 17,318,000 | 19,802,000 | 33,638,000 |
| Product | 1,387,000 | 1,658,000 | ... |
| Service and supplies | 1,060,000 | 1,217,000 | ... |
| Cost of revenue - products | ... | ... | 5,653,000 |
| Cost of revenue - service & supplies | ... | ... | 3,425,000 |
| Cost of revenue - amortization & depreciation | 86,000 | 108,000 | 317,000 |
| Total cost of revenue | 2,533,000 | 2,983,000 | 9,395,000 |
| Gross profit | 14,785,000 | 16,819,000 | 24,243,000 |
| Engineering & product development | 5,161,000 | 5,493,000 | 9,194,000 |
| Marketing & sales | 7,740,000 | 10,790,000 | 15,135,000 |

| | | | | ☐ Restated to reflect correction of errors; ☒ As of March 21, 2022 | | 1. iCAD inc 7.0% series A convertible preferred. | | | | |
|--|-------------|--------------|--------------|--|---------------|---|---|--------------|-------------|------------|
| | | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | 2. iCAD inc common. | | | | |
| | | | | 2023 | | No dividends paid. | | | | |
| | | | | 2022 | | No dividends paid. | | | | |
| | | | | (revised) | | ICC HOLDINGS INC | | | | |
| | | | | | | Annual Report | | | | |
| | | | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | |
| | | | | 2023 | | 2022 | | | | |
| | | | | ☐2021 | | (revised) | | | | |
| General & administrative | 9,324,000 | 10,517,000 | 10,406,000 | Cash & cash equivalents | 21,670,000 | 21,313,000 | Net premiums earned | 75,717,108 | 69,057,343 | 53,893,020 |
| Amortization & depreciation | 249,000 | 217,000 | 240,000 | Trade accounts receivable, gross | 6,669,000 | 9,820,000 | Available for sale, fixed maturity securities | ... | 3,122,028 | 3,010,433 |
| Total operating expenses | 22,474,000 | 27,017,000 | 34,975,000 | Less: allowance for doubtful accounts | 277,000 | 922,000 | Investment property | ... | 904,533 | 802,071 |
| Income (loss) from operations | (7,689,000) | (10,198,000) | (10,732,000) | Trade accounts receivable, net | 6,392,000 | 8,898,000 | Equity securities | ... | 778,707 | 488,562 |
| Interest income | 729,000 | 213,000 | 15,000 | Raw materials | 583,000 | 2,658,000 | Other invested assets | ... | 154,332 | 80,761 |
| Interest expense capital lease | 16,000 | 10,000 | ... | Work in process | 55,000 | 101,000 | Cash & short-term investments | ... | 24,628 | 2,582 |
| Interest expense | ... | ... | 141,000 | Finished goods | 324,000 | 2,892,000 | Investment revenue | ... | 4,984,228 | ☐4,384,408 |
| Gain (loss) from extinguishment of debt | ... | ... | (386,000) | Inventories | 917,000 | 5,389,000 | Less investment expenses | 5,179,343 | (950,000) | (970,000) |
| Other income | (14,000) | (39,000) | ... | Prepaid expenses & other current assets | 699,000 | 2,641,000 | Net investment income | ... | 4,034,228 | 3,414,408 |
| Other income (expense), net | 699,000 | 164,000 | (512,000) | Total current assets | 29,678,000 | 38,241,000 | Net realized investment gains (losses) | ... | 874,470 | 982,547 |
| Income (loss) before income tax expense (benefit) | (6,990,000) | (10,034,000) | (11,244,000) | Equipment | 1,482,000 | 3,076,000 | Net unrealized gains (losses) on equity securities | 1,135,905 | (4,706,405) | 2,801,991 |
| Deferred provision (benefit) federal income taxes | 1,000 | ... | 1,000 | Leasehold improvements | 110,000 | 110,000 | Other income (loss) | 236,914 | 420,202 | 348,709 |
| Total deferred provision (benefit) income taxes | ... | ... | 1,000 | Furniture & fixtures | ... | 23,000 | Net realized investment gains (losses) | ... | 672,857 | ... |
| Foreign | 19,000 | (116,000) | ... | Marketing assets | 104,000 | ... | Premiums Written-Gross (Direct) | 92,990,535 | ... | ... |
| Income Taxes - Total - Deferred | 20,000 | (116,000) | ... | Internal-use software | 1,172,000 | ... | Premiums Ceded Out to Reinsurance-Written | (10,510,588) | ... | ... |
| Provision (benefit) for income taxes | 20,000 | (116,000) | 1,000 | Property & equipment, gross | 2,868,000 | 3,209,000 | Premiums Ceded Out to Reinsurance- Unearned | 192,751 | ... | ... |
| Net income (loss) | (4,847,000) | (13,656,000) | (11,245,000) | Less accumulated depreciation & amortization | 1,045,000 | 2,135,000 | Premiums Written-Gross (Assumed) - Change | 6,732,456 | ... | ... |
| Weighted average shares outstanding - basic | 25,613,000 | 25,202,000 | 24,778,000 | Property & equipment, net | 1,823,000 | 1,074,000 | Consolidated revenues | 82,942,127 | 69,679,838 | 61,440,675 |
| Weighted average shares outstanding - diluted | 25,613,000 | 25,202,000 | 24,778,000 | Operating lease assets | 461,000 | 3,361,000 | Losses & settlement expenses | 47,929,630 | 44,532,729 | 34,699,543 |
| Year end shares outstanding | 26,354,199 | 25,260,576 | 25,140,255 | Other assets | 849,000 | 69,000 | Policy acquisition costs & other operating expenses | 28,521,973 | 24,896,120 | 20,824,900 |
| Net income (loss) per share - basic | \$(0.19) | \$(0.54) | \$(0.45) | Intangible assets, gross | 8,636,000 | 9,414,000 | Interest expense on debt | 184,122 | 196,070 | 235,001 |
| Net income (loss) per share - diluted | \$(0.19) | \$(0.54) | \$(0.45) | Less: accumulated amortization | 8,488,000 | 8,932,000 | General corporate expenses | 784,308 | 776,747 | 723,350 |
| Number of full time employees | 67 | ... | 136 | Intangible assets, net | 148,000 | 482,000 | Total expenses | 77,420,033 | 70,401,666 | 56,482,794 |
| Number of part time employees | ... | ... | 1 | Goodwill | 8,362,000 | 8,362,000 | Earnings (loss) before income taxes | 5,522,094 | (721,828) | 4,957,881 |
| Total number of employees | 67 | ... | 137 | Deferred tax assets | 97,000 | 116,000 | Current income tax expense (benefit) | 1,176,081 | 984,897 | 400,355 |
| Number of common stockholders | 80 | ... | ☐89 | Total assets | 41,418,000 | 51,705,000 | Deferred income tax expense (benefit) | 89,118 | (1,125,063) | 414,747 |
| Income from continuing operations | (7,010,000) | (9,918,000) | ... | Accounts payable | 712,000 | 1,973,000 | Total income tax expense (benefit) | 1,265,199 | (140,166) | 815,102 |
| Discontinued Operations - Net - Income/Expense | (429,000) | (3,738,000) | ... | Accrued salary & related expenses | 952,000 | 1,248,000 | Net earnings (loss) | 4,256,895 | (581,662) | 4,142,779 |
| Sale of Discontinued Operations before Tax - Gain/Loss | 2,592,000 | ... | ... | Accrued accounts payable | 1,036,000 | 2,913,000 | Weighted average shares outstanding - basic | 2,946,892 | 3,032,155 | 3,047,433 |
| Discontinued operations | 2,163,000 | ... | ... | Accrued professional fees | 227,000 | 400,000 | Weighted average shares outstanding - diluted | 2,966,679 | 3,032,155 | 3,065,025 |
| Earnings per share from continuing operations | \$(0.27) | \$(0.39) | ... | Other accrued expenses | 20,000 | 120,000 | Year end shares outstanding | 3,138,976 | 3,153,741 | 3,291,852 |
| Earnings per share-inc from discontinued oper | ... | \$(0.15) | ... | Accrued & other expenses | 2,448,000 | 4,681,000 | Net earnings (loss) per share - basic | \$1.44 | \$(0.19) | \$1.36 |
| Earnings per share-total discontinued opers | \$0.08 | \$(0.15) | ... | Lease payable, current | 188,000 | 582,000 | Net earnings (loss) per share - diluted | \$1.43 | \$(0.19) | \$1.35 |
| Earnings per share from continuing operations | \$(0.27) | \$(0.39) | ... | Deferred revenue, current | 3,400,000 | 6,216,000 | Number of full time employees | 106 | ☐103 | ☐90 |
| Earn per share-inc from discount opers - diluted | ... | \$(0.15) | ... | Lease payable-current portion | 188,000 | ... | Number of common stockholders | 137 | ☐☐136 | ☐☐139 |
| Earning per share-total discount opers - diluted | \$0.08 | \$(0.15) | ... | Accrued and other expenses - Balancing value | 213,000 | ... | Total number of employees | 106 | ... | ... |
| | | | | Total current liabilities | 6,748,000 | 13,452,000 | | | | |
| | | | | Deferred revenue, long-term | 974,000 | 542,000 | | | | |
| | | | | Lease payable, long-term | 273,000 | 2,803,000 | | | | |
| | | | | Deferred tax | 6,000 | 6,000 | | | | |
| | | | | Contract Liabilities - Long-Term - Advance | ... | ... | | | | |
| | | | | Consideration & Progress | ... | ... | | | | |
| | | | | Billings in Excess of Unbilled Revenue | 974,000 | ... | | | | |
| | | | | Total liabilities | 8,001,000 | 16,803,000 | | | | |
| | | | | Common stock | 265,000 | 254,000 | | | | |
| | | | | Additional paid-in capital | 306,250,000 | 302,899,000 | | | | |
| | | | | Accumulated deficit | (271,683,000) | ... | | | | |
| | | | | Retained earnings (accumulated deficit) | ... | (266,836,000) | | | | |
| | | | | Treasury stock | 1,415,000 | ... | | | | |
| | | | | Treasury stock at cost | ... | 1,415,000 | | | | |
| | | | | Total stockholders' equity | 33,417,000 | 34,902,000 | | | | |
| | | | | Total Equity | 33,417,000 | ... | | | | |
| | | | | | | | | | | |
| | | | | Recent Dividends: | | | | | | |
| | | | | 1. iCAD inc 7.0% series A convertible preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 2. iCAD inc common. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | Annual Dividends: | | | | | | |

□ Reclassified to conform with 2022 presentation; □ As reported by the Company; □ Full-time equivalent employees; □ Approximately; □ As of March 9, 2023; □ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Fixed maturity securities | 110,955,697 | □93,388,971 |
| Common stocks at fair value | 20,438,907 | ... |
| Preferred stocks at fair value | 2,772,605 | ... |
| Other invested assets | 4,722,137 | ... |
| Property held for investment, gross | 6,611,515 | ... |
| Less: Accumulated depreciation - property held for investment | 609,282 | ... |
| Property held for investment, at cost, net of accumulated depreciation | 5,910,864 | ... |
| Property held for investment, at cost, net | ... | 6,002,233 |
| Cash and cash equivalents | 1,478,135 | ... |
| Cash & cash equivalents | ... | 3,139,986 |
| Total investments & cash | ... | 130,464,839 |
| Accrued investment income | 915,156 | 791,812 |
| Premiums & reinsurance balances receivable, net | □31,270,460 | ... |
| Ceded unearned premiums | ... | 947,851 |
| Reinsurance balances recoverable on unpaid losses & settlement expenses, net | ... | 13,610,295 |
| Income taxes - current | ... | 22,042 |
| Income taxes - deferred | 2,647,636 | 3,296,688 |
| Deferred policy acquisition costs, net | 8,552,459 | 7,167,036 |
| Automobiles | ... | 637,306 |
| Furniture & fixtures | ... | 520,835 |
| Computer equipment & software | 645,458 | 4,720,932 |
| Home office | 4,106,796 | 4,025,248 |
| Computer equipment and software | 5,037,301 | ... |
| Furniture and fixtures | 525,843 | ... |
| Total property & equipment cost | 10,315,398 | 9,904,321 |
| Accumulated depreciation | 6,990,076 | 6,590,602 |
| Property & equipment, at cost | 3,325,322 | 3,313,719 |
| Other assets | 2,405,577 | 1,277,469 |
| Premiums and reinsurance balances receivable, net | 37,220,433 | ... |
| Ceded unearned premiums | 755,099 | ... |
| Reinsurance balances recoverable on unpaid losses and settlement | 12,736,579 | ... |
| Income taxes - current | 127,730 | ... |
| Other invested assets | 8,898,409 | ... |
| Common stocks at fair value | 12,191,621 | ... |
| Total investments and cash | 142,331,022 | ... |
| Preferred stocks at fair value | 2,896,296 | ... |
| Total assets | 211,017,013 | 192,162,211 |
| Unpaid losses & settlement expenses | ... | 67,614,063 |
| Unearned premiums | 47,259,637 | 40,527,182 |
| Reinsurance balances payable | 1,132,301 | 1,405,337 |
| Debt agreements | 15,000,000 | 15,000,000 |
| Corporate debt | ... | 15,000,000 |
| Accrued expenses | 7,442,617 | ... |
| Accrued expenses | ... | 6,072,020 |
| Other liabilities | 1,259,324 | 1,102,678 |
| Unpaid losses and settlement expenses | 71,919,585 | ... |
| Total liabilities | 144,013,464 | 131,721,280 |
| Common stock | 35,000 | ... |
| Common stock | ... | 35,000 |

| | | |
|---|-------------|-------------|
| Treasury stock, at cost | 5,710,324 | ... |
| Treasury stock, at cost | ... | 5,463,535 |
| Additional paid-in capital | 33,330,846 | 33,119,125 |
| Unrealized gains & (losses) on available-for-sale fixed maturity securities | ... | (8,841,517) |
| Accumulated other comprehensive earnings, net of tax | (6,621,336) | ... |
| Accumulated other comprehensive earnings (loss), net of tax | ... | (8,841,517) |
| Retained earnings | 47,844,368 | ... |
| Retained earnings (accumulated deficit) | ... | 43,701,233 |
| Less: unearned employee stock ownership plan shares at cost | 1,875,005 | 2,109,375 |
| Total equity | 67,003,549 | 60,440,931 |
| Total Equity | 67,003,549 | ... |

□ Amortized cost - Fixed maturity securities: \$104,580,681; □ Net of allowances for uncollectible amounts - Premiums & reinsurance balances receivable: \$50,000

Recent Dividends:
1. ICC Holdings Inc common.
 No dividends paid.
Annual Dividends:
1. ICC Holdings Inc common.
 No dividends paid.

IDAHO STRATEGIC RESOURCES INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------------|--------------------|--------------------|
| Management | 255,579 | ... | ... |
| Revenue-gold sales | 13,656,733 | 9,580,189 | 7,630,416 |
| Total revenue | 13,656,733 | ... | ... |
| Cost of sales & other direct production costs | 8,224,994 | 7,042,185 | 6,328,117 |
| Depreciation & amortization | 1,466,703 | 984,083 | 814,422 |
| Total cost of sales | 9,691,697 | 8,026,268 | 7,142,539 |
| Gross profit (loss) | 3,965,036 | 1,553,921 | 487,877 |
| Exploration | 1,523,221 | ... | ... |
| Exploration expenses | ... | 2,110,137 | 1,417,605 |
| Loss on write-off of equipment | ... | 68,641 | ... |
| Management expenses | ... | 322,775 | 518,011 |
| Professional services expenses | 556,766 | 375,002 | 293,402 |
| General & administrative expenses | 630,126 | 1,229,603 | 1,319,145 |
| Net gain on sale of equipment | 13,026 | ... | ... |
| Income (loss) from operations | 1,012,370 | (2,552,237) | (3,060,286) |
| Gain on forgiveness of SBA loan | ... | 10,000 | ... |
| Equity income on investment in Buckskin | ... | 1,524 | 3,782 |
| Timber revenue | 20,724 | ... | 4,338 |
| Interest income | 85,491 | 12,453 | 146 |
| Interest expense | 44,202 | 102,832 | 208,341 |
| Equity in earnings (loss) of Golden Chest LLC | 4,517 | ... | ... |
| Loss on investment in equity securities | (5,451) | ... | ... |
| Total other income (expense) | 61,079 | (78,855) | (200,075) |
| Net income (loss) | 1,073,449 | (2,631,092) | (3,260,361) |
| Net income (loss) attributable to non-controlling interest | 84,297 | 95,663 | 100,192 |

| | | | |
|---|------------|-------------|-------------|
| Net income (loss) attributable to New Jersey Mining Company | 1,157,746 | (2,535,429) | (3,160,169) |
| Weighted average shares outstanding - basic | 12,254,539 | 11,783,258 | 10,192,465 |
| Weighted average shares outstanding - diluted | 12,260,539 | 11,783,258 | 10,192,465 |
| Year end shares outstanding | 12,397,615 | 12,098,070 | 10,940,969 |
| Net income (loss) per share - basic | \$0.09 | \$(0.22) | \$(0.31) |
| Net income (loss) per share - diluted | \$0.09 | \$(0.22) | \$(0.31) |
| Number of full time employees | 42 | 40 | 38 |
| Total number of employees | 42 | ... | ... |
| Number of common stockholders | 1,200 | □□1,200 | □□1,200 |
| Income from cont operations before income tax | 1,073,449 | ... | ... |
| Earnings per share from continuing operations | \$0.09 | ... | ... |
| Earnings per share from continuing operations | \$0.09 | ... | ... |

□ Approximately; □ As of March 1, 2023; □ As of March 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|-----------|
| Investment in marketable equity security at fair value | 5,649 | ... |
| Cash & cash equivalents | 2,286,999 | 1,638,031 |
| Gold sales receivable | 1,038,867 | 909,997 |
| Concentrate inventory - in process | ... | 111,741 |
| Concentrate inventory - finished goods | ... | 111,574 |
| Concentrate inventory | 268,139 | 223,315 |
| Supplies inventory - mine parts & supplies | ... | 233,465 |
| Supplies inventory - mill parts & supplies | ... | 83,963 |
| Supplies inventory - core drilling supplies & materials | ... | 77,570 |
| Supplies inventory | 608,542 | 394,998 |
| Inventories | 876,681 | 618,313 |
| Joint venture receivable | 2,080 | 1,926 |
| Other current assets | 236,837 | 192,025 |
| Total current assets | 4,447,113 | 3,360,292 |
| Mill - land | ... | 225,289 |
| Mill - building | ... | 536,193 |
| Milling - equipment | ... | 4,192,940 |
| Less accumulated depreciation - mill | ... | 1,249,445 |
| Building & equipment at cost | 7,814,561 | ... |
| Buildings | ... | 611,382 |
| Equipment | ... | 6,927,474 |
| Less accumulated depreciation - buildings & equipment | ... | 2,324,679 |
| Total land | 1,004,232 | 1,004,232 |
| Total building and equipment | 5,956,126 | ... |
| Mill - Accumulated Depreciation & Impairment | 1,430,323 | ... |
| Building and equipment-Gross | 9,411,149 | ... |
| Building and equipment - Balancing value | 3,455,023 | ... |
| Property, plant & equipment, net of accumulated depreciation | 10,484,457 | 9,923,386 |

| | | | | | | | | | | |
|--|--------------|--------------|---|-------------|------------|---|---|--------------|--------------|--|
| Mineral properties, net of accumulated amortization | 7,648,061 | 6,527,561 | Weighted average shares outstanding-basic | 6,190,746 | 6,157,866 | 5,937,520 | Common stock | 5,998 | 5,926 | |
| Investment in Buckskin Gold & Silver | ... | 334,252 | Weighted average shares outstanding-diluted | 6,190,746 | 6,157,866 | 5,937,520 | Additional paid-in capital | 107,116,362 | 105,011,318 | |
| Investment in joint venture | 435,000 | 435,000 | Year end shares outstanding | 5,996,697 | 5,924,680 | 5,892,446 | Treasury Stock | 13,210 | ... | |
| Reclamation bond | 251,310 | 327,020 | Net earnings (loss) per shares from continuing operations - basic | \$(1.61) | ... | ... | Treasury stock, at cost | ... | 13,210 | |
| Deposits | ... | 76,110 | Net earnings (loss) per share - basic | \$(1.61) | \$(1.17) | \$(0.80) | Accumulated Deficit | (97,049,450) | ... | |
| Investment in Golden Chest LLC | 338,769 | ... | Net earnings (loss) per shares from continuing operations - diluted | \$(1.61) | ... | ... | Retained earnings (accumulated deficit) | ... | (87,095,430) | |
| Other assets | 285,079 | ... | Net earnings (loss) per share - diluted | \$(1.61) | \$(1.17) | \$(0.80) | Total stockholders' equity (deficit) | 10,059,700 | 17,908,604 | |
| Mining/Exploration Specific Assets - Accumulated Depreciation & Impairment | 166,500 | ... | Number of full time employees | ... | 8 | 7 | Total Equity | 10,059,700 | ... | |
| Total assets | 23,889,789 | 20,983,621 | Number of Common Shareholders | 22 | ... | ... | Recent Dividends: | | | |
| Accounts payable & accrued expenses | 484,221 | 579,541 | Number of stockholders | ... | 23 | 31 | 1. Ideal Power Inc series A convertible preferred. | | | |
| Accrued payroll & related payroll expenses | 266,670 | 179,149 | □ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of shares issued in public offering and services, and exercise of options and warrants; □ As of February 28, 2023; □ As of February 28, 2022; □ As of March 24, 2023; □ As of March 23, 2022 | | | | No dividends paid. | | | |
| Notes payable related parties, current portion | ... | 12,226 | 2. Ideal Power Inc common. | | | | | | | |
| Notes payable, current portion | 978,246 | 859,393 | No dividends paid. | | | | | | | |
| Total current liabilities | 1,729,137 | 1,630,309 | Annual Dividends: | | | | | | | |
| Asset retirement obligation | 286,648 | 262,217 | 1. Ideal Power Inc series A convertible preferred. | | | | | | | |
| Notes payable related parties, long term | ... | 62,957 | No dividends paid. | | | | | | | |
| Notes payable, long term | 1,338,406 | 1,315,068 | 2. Ideal Power Inc common. | | | | | | | |
| Total long term liabilities | 1,625,054 | 1,640,242 | No dividends paid. | | | | | | | |
| Total liabilities | 3,354,191 | 3,270,551 | ILEARNINGENGINES INC | | | | | | | |
| Common stock | 34,963,739 | 33,245,622 | Annual Report | | | | | | | |
| Retained earnings (accumulated deficit) | (17,210,638) | (18,368,384) | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| Total New Jersey Mining Company stockholders' equity | 17,753,101 | 14,877,238 | 2023 | | | | 2022 | | | |
| Non-controlling interest | 2,782,497 | 2,835,832 | Cash & cash equivalents | 8,474,835 | 16,345,623 | General & administrative expenses | 5,487,905 | 1,555,038 | 3,858,771 | |
| Total stockholders' equity | 20,535,598 | 17,713,070 | Accounts receivable, net | ... | 65,936 | Income (loss) from operations | (5,487,905) | (1,555,038) | (3,858,771) | |
| Recent Dividends: | | | | | | | | | | |
| 1. Idaho Strategic Resources Inc common. | | | | | | | | | | |
| No dividends paid. | | | | | | | | | | |
| Annual Dividends: | | | | | | | | | | |
| 1. Idaho Strategic Resources Inc common. | | | | | | | | | | |
| No dividends paid. | | | | | | | | | | |
| IDEAL POWER INC | | | | | | | | | | |
| Annual Report | | | | | | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | | | | |
| | | | | 2023 | | 2022 | | | | |
| Grant revenue | 37,388 | 203,269 | 576,399 | 8,474,835 | 16,345,623 | 5,487,905 | 1,555,038 | 3,858,771 | ... | |
| Cost of grant revenue | 37,388 | 203,269 | 576,399 | 70,000 | ... | 3,492,690 | 3,945,497 | 23,634 | ... | |
| Commercial revenue | 161,483 | ... | ... | 70,000 | ... | ... | ... | ... | ... | |
| Total revenue | 198,871 | ... | ... | 81,450 | ... | (89,408) | ... | ... | ... | |
| Cost of commercial revenue | 123,225 | ... | ... | 213,357 | ... | Forward purchase agreement | (1,700,000) | ... | ... | |
| Total cost of revenue | 160,613 | ... | ... | 110,319 | ... | Change in fair value of forward purchase agreement | (1,500,000) | ... | ... | |
| Gross profit (loss) | 38,258 | ... | ... | 71,141 | ... | Total other income (expense) | 15,826,747 | 8,703,634 | ... | |
| Research & development | 5,743,211 | 3,366,776 | 1,927,743 | 9,109,175 | 16,902,924 | Income before provision for income taxes | (5,284,623) | 14,271,707 | 4,844,863 | |
| General & administrative | 3,533,383 | 3,123,852 | 2,408,425 | 392,395 | 233,431 | Current federal income tax | 564,005 | 750,410 | ... | |
| Sales & marketing | 1,113,752 | 852,331 | 512,807 | 10,245 | 10,245 | Deferred federal income tax | (1,001,136) | (244,686) | (645,774) | |
| Total operating expenses | 10,390,346 | 7,342,959 | 4,848,975 | 175,593 | 98,793 | Change in valuation allowance | 1,001,136 | 244,686 | 645,774 | |
| Income (loss) from operations | (10,352,088) | (7,342,959) | (4,848,975) | 578,233 | 342,469 | Provision for income taxes | 564,005 | 750,410 | ... | |
| Gain on forgiveness of long-term debt | ... | ... | 91,407 | 219,008 | 142,366 | Net income (loss) | (5,848,628) | 13,521,299 | 4,844,863 | |
| Interest income (expense), net | 398,068 | 153,609 | (12,701) | 359,225 | 200,103 | Weighted average class A common stock outstanding - basic | ... | 28,750,000 | 23,866,438 | |
| Net Income Before Tax | (9,954,020) | ... | ... | 2,580,066 | ... | Weighted average class B common stock outstanding - basic | ... | 7,187,500 | 7,025,685 | |
| Tax | (9,954,020) | ... | ... | 2,036,431 | 248,720 | Weighted average shares outstanding - basic | 15,761,695 | ... | ... | |
| Total other income (expense) | 398,068 | 153,609 | 78,706 | 13,034 | 11,189 | Weighted average class A common stock outstanding - diluted | ... | 28,750,000 | 23,866,438 | |
| Net income (loss) | (9,954,020) | (7,189,350) | (4,770,269) | 12,248,070 | 19,399,367 | Weighted average shares outstanding - diluted | ... | 7,187,500 | 7,187,500 | |
| | | | | 405,098 | 130,503 | | | | | |
| | | | | 185,494 | 70,261 | | | | | |
| | | | | ... | 50,000 | | | | | |
| | | | | ... | 62,500 | | | | | |
| | | | | 269,618 | ... | | | | | |
| | | | | 455,112 | 18,157 | | | | | |
| | | | | ... | 254,218 | | | | | |
| | | | | 70,683 | 64,597 | | | | | |
| | | | | 930,893 | 449,318 | | | | | |
| | | | | 132,304 | 202,987 | | | | | |
| | | | | ... | ... | | | | | |
| | | | | 1,125,173 | 838,458 | | | | | |
| | | | | 2,188,370 | 1,490,763 | | | | | |

| | | | |
|--|------------|------------|------------|
| outstanding | 11,633,313 | 35,937,500 | 35,937,500 |
| Earnings (loss) per class A common stock - basic | ... | \$0.38 | \$0.16 |
| Earnings (loss) per class B common stock - basic | ... | \$0.38 | \$0.16 |
| Earnings (loss) per share - basic | \$(0.37) | ... | ... |
| Earnings (loss) per class A common stock - diluted | ... | \$0.38 | \$0.16 |
| Earnings (loss) per class B common stock - diluted | ... | \$0.38 | \$0.16 |
| Earnings (loss) per share - diluted | \$(0.37) | ... | ... |
| Total number of employees | ... | 2 | 2 |
| Number of class A common stockholders | ... | 1 | 1 |
| Number of class B common stockholders | ... | 1 | 4 |
| Common Shareholders - Number | 2 | ... | ... |

□ As reported by the Company

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 145,669 | 145,980 |
| Prepaid income tax | 65,585 | ... |
| Prepaid expenses | ... | 76,350 |
| Prepaid expenses | 48,319 | ... |
| Total current assets | 259,573 | 222,330 |
| Cash & investments held in trust account | 46,744,889 | 290,737,917 |
| Total assets | 47,004,462 | 290,960,247 |
| Accounts payable & accrued expenses | 4,099,162 | 1,063,841 |
| Income tax payable | ... | 383,410 |
| Excise tax payable | 2,472,591 | ... |
| Convertible promissory note - related party | 2,180,000 | 1,500,000 |
| Convertible promissory notes - related party | 2,620,000 | ... |
| Forward purchase agreement liability | 1,500,000 | ... |
| Total current liabilities | ... | 2,947,251 |
| Deferred underwriting fee payable | 10,062,500 | 10,062,500 |
| Warrant liabilities | 1,810,000 | 110,000 |
| Total liabilities | 24,744,253 | 13,119,751 |
| Class A common stock subject to possible redemption | 46,744,889 | 290,317,507 |
| Class B common stock | 719 | 719 |
| Accumulated deficit | (24,485,399) | ... |
| Retained earnings (accumulated deficit) | ... | (12,477,730) |
| Total stockholder's equity | (24,484,680) | (12,477,011) |
| Total Equity | (24,484,680) | ... |

Recent Dividends:

- iLearningEngines Inc class A common.**
No dividends paid.
- iLearningEngines Inc class A common stock subject to possible redemption.**
No dividends paid.
- iLearningEngines Inc class B common.**
No dividends paid.

Annual Dividends:

- iLearningEngines Inc class A common.**
No dividends paid.
- iLearningEngines Inc class A common stock subject to possible redemption.**
No dividends paid.
- iLearningEngines Inc class B common.**
No dividends paid.

IMMIX BIOPHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|-------------|--------------|
| General & administrative expenses | 7,406,082 | 4,023,170 | 1,225,487 |
| Research & development expenses | 8,735,031 | 4,195,778 | 126,527 |
| Total operating expenses | 16,141,113 | 8,218,948 | 1,352,014 |
| Income (loss) from operations | (16,141,113) | (8,218,948) | (1,352,014) |
| Change in fair value of derivative liability | ... | ... | (22,759,829) |
| Gain (loss) on debt extinguishment | ... | ... | (86,170) |
| Interest expense | ... | 497 | 179,853 |
| Interest Income | 572,006 | ... | ... |
| Total other income (expense) | 572,006 | (497) | (23,025,852) |
| Income (loss) before provision for income taxes | (15,569,107) | (8,219,445) | (24,377,866) |
| Provision for income taxes | 26,415 | 10,268 | 6,013 |
| Net loss attributable to non-controlling interests | 169,474 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (15,426,048) | ... | ... |
| Net income (loss) | (15,595,522) | (8,229,713) | (24,383,879) |
| Weighted average shares outstanding - basic | 17,341,146 | 13,887,309 | 3,672,611 |
| Weighted average shares outstanding - diluted | 17,341,146 | 13,887,309 | 3,672,611 |
| Year end shares outstanding | 19,922,356 | 13,892,122 | 13,228,689 |
| Net income (loss) per common share - basic | \$(0.89) | \$(0.59) | \$(6.64) |
| Net income (loss) per common share - diluted | \$(0.89) | \$(0.59) | \$(6.64) |
| Number of full time employees | ... | 29 | 32 |
| Number of part time employees | ... | 2 | 7 |
| Number of common stockholders | 19 | 13 | 13 |
| Foreign currency translation adjustments | ... | (38,387) | 63,637 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.89) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.89) | ... | ... |

□ Shares increased due to issuance of shares for cash proceeds, for conversion of convertible notes payable, related accrued interest and settlement of derivative liability and stock-based compensation; □ As of March 17, 2023; □ As of March 23, 2022; □ As of December 15, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | ... | 13,436,714 |
| Tax receivable | 1,172,183 | 255,705 |
| Prepaid expenses & other current assets | ... | 44,582 |
| Cash and cash equivalents | 17,509,791 | 1,205,398 |
| Prepaid expenses and | ... | ... |

| | | |
|--|--------------|--------------|
| other current assets | 1,061,194 | ... |
| Total current assets | 19,787,750 | 14,897,817 |
| Other assets | ... | 6,724 |
| Equipment, net | 50,181 | 3,560 |
| Deferred offering costs | 87,229 | ... |
| Total assets | 19,925,160 | 14,908,101 |
| Accounts payable & accrued expenses | 3,721,783 | 1,273,296 |
| Accounts Payable | 1,433,022 | ... |
| Accrued Expenses | 2,288,761 | ... |
| Total current liabilities | 3,721,783 | 1,273,296 |
| Funds held for subsidiary private offering | ... | 475,000 |
| Total liabilities | 3,721,783 | 1,748,296 |
| Common stock | 2,000 | 1,397 |
| Additional paid-in capital | 69,779,706 | 51,156,597 |
| Accumulated other comprehensive income | 134,666 | 87,021 |
| Retained earnings (accumulated deficit) | (53,411,295) | (37,985,247) |
| Treasury stock | 99,963 | 99,963 |
| Total stockholders' equity (deficit) | 16,405,114 | 13,159,805 |
| Non-controlling interests | (201,737) | ... |
| Total stockholders equity | 16,203,377 | ... |

Recent Dividends:

- 1. Immix Biopharma Inc common.**
No dividends paid.

Annual Dividends:

- 1. Immix Biopharma Inc common.**
No dividends paid.

IMMUCELL CORP.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|-------------|------------|
| | | | (revised) |
| Product sales | 17,471,669 | 18,567,962 | 19,242,969 |
| Costs of goods sold | 13,602,385 | 10,919,183 | 10,587,040 |
| Gross margin | 3,869,284 | 7,648,779 | 8,655,929 |
| Product development expenses | 4,394,852 | 4,493,872 | 4,168,518 |
| Sales & marketing expenses | 3,088,215 | 3,190,033 | 2,503,926 |
| Administrative expenses | 2,134,295 | 2,263,817 | 1,726,100 |
| Operating expenses | 9,617,362 | 9,947,722 | 8,398,544 |
| Net operating income (loss) | (5,748,078) | (2,298,943) | 257,385 |
| Interest expense | 475,598 | 348,536 | 314,359 |
| Gain on disposal of fixed assets | (8,099) | ... | ... |
| Gain (loss) on disposal of property, plant & equipment | ... | 7,334 | (30,963) |
| Interest income | 96,570 | 153,100 | 18,810 |
| Income - other | 107 | 912 | ... |
| insurance recovery | (365,127) | ... | ... |
| Income (loss) before income taxes | (5,769,971) | (2,486,133) | (69,127) |
| Current state income tax expense (benefit) | 4,627 | 7,672 | 9,165 |
| Total current income tax expense (benefit) | 4,627 | 7,672 | 9,165 |
| Deferred federal income tax expense (benefit) | (1,179,474) | (576,780) | (63,097) |
| Deferred state income tax expense (benefit) | (145,802) | (88,533) | (14,990) |
| Deferred subtotal, gross | ... | 665,313 | 78,087 |
| Valuation allowance | 1,325,276 | 665,313 | 78,087 |
| Income tax expense (benefit) | 4,627 | 7,672 | 9,165 |
| Net income (loss) | (5,774,598) | (2,493,805) | (78,292) |
| Weighted average shares outstanding - basic | 7,747,686 | 7,745,122 | 7,592,290 |

| | | | |
|--|---------------------|---------------------|-------------------------|
| operations | (21,030,430) | (24,921,565) | (21,007,190) |
| Gain (loss) from change in earn-out milestone liability | ... | 5,396,000 | 1,622,000 |
| Impairment of goodwill & in-process research & development | 396,319 | 13,366,234 | 1,976,101 |
| Gain (loss) on debt extinguishment | (329,158) | ... | (234,419) |
| Gain (loss) from valuation of common stock warrant liability | 431,801 | ... | ... |
| Investment income (loss), net | ... | 453,356 | 10,996 |
| Interest income | 725,824 | ... | ... |
| Interest expense | 197,080 | 5,028,618 | 569,881 |
| Other income (expense) | ... | 1,801 | 1,899 |
| Investment income | 1,157,625 | ... | ... |
| Total other income (expense), net | 235,068 | (12,543,695) | (1,145,506) |
| Income (loss) before income tax expense (benefit) | (20,795,362) | (37,465,260) | (22,152,696) |
| Deferred state & local income tax expense (benefit) | ... | (1,567,026) | (1,383,446) |
| Income tax benefit | (1,280,385) | ... | ... |
| Income tax expense (benefit) | (1,280,385) | (1,567,026) | (1,383,446) |
| Net income (loss) | (19,514,977) | (35,898,234) | (20,769,250) |
| Weighted average shares outstanding - basic | 9,045,320 | 7,142,970 | [□] 5,426,953 |
| Weighted average shares outstanding - diluted | 9,045,320 | 7,142,970 | [□] 5,426,953 |
| Year end shares outstanding | 9,399,789 | 7,436,197 | ^{□□} 5,770,516 |
| Income (loss) per share - continuing operations - basic | \$(2.16) | ... | ... |
| Net income (loss) per common share - basic | \$(2.16) | \$(5.03) | [□] \$(3.83) |
| Income (loss) per share - continuing operations - diluted | \$(2.16) | ... | ... |
| Net income (loss) per common share - diluted | \$(2.16) | \$(5.03) | [□] \$(3.83) |
| Number of full time employees | ... | 31 | [□] 29 |
| Number of common stockholders | 28,000 | 28,000 | ^{□□} 54,000 |

[□] Adjusted for 1-for-15 reverse stock split, February 28, 2022;
^{□□} Shares increased due to sale of equity through equity financing facilities, issuance of common stock upon exercise of options, and pursuant to warrant exercises; [□] As of March 30, 2022; [□] Approximately

| | 2023 | 2022 | (revised) |
|---|------------|------------|-----------|
| Cash & cash equivalents | 5,838,566 | 11,492,841 | |
| Investment in debt securities - available for sale, at fair value | 9,857,087 | 21,254,485 | |
| Accrued interest receivable on investment securities | ... | 128,932 | |
| Money market investments, restricted cash | ... | 1,500,000 | |
| Advances & deposits on clinical programs & other current assets | 2,545,051 | 2,778,433 | |
| Total current assets | 18,240,704 | 37,154,691 | |
| Machinery & equipment | 2,055,192 | 2,468,388 | |
| Furniture & fixtures | 191,932 | 350,481 | |

| | | | |
|--|---------------|---------------|--|
| Leasehold improvements | 607,054 | 373,194 | |
| Property & equipment, at cost | 2,854,178 | 3,192,063 | |
| Less: accumulated depreciation & amortization | 2,102,272 | 2,643,762 | |
| Property and equipment (at cost, less accumulated depreciation & amortization) | 751,906 | 548,301 | |
| Money market investments, restricted cash | ... | 4,500,000 | |
| Deferred income tax asset | 1,280,385 | 1,567,026 | |
| Operating lease right-of-use assets, net | 1,595,074 | 155,876 | |
| Deposits & other assets | 50,000 | 50,000 | |
| Total assets | 21,918,069 | 43,975,894 | |
| Accounts payable - trade | 3,515,192 | 3,586,623 | |
| Amounts due to contract research organizations & other contractual agreements | 1,442,659 | 2,196,711 | |
| Accrued payroll & related benefits | 1,693,383 | 2,139,927 | |
| Accrued interest | ... | 37,583 | |
| Accrued professional fees | ... | 215,402 | |
| Other accrued liabilities | ... | 205,313 | |
| Notes payable - current portion, net of deferred financing costs | ... | 1,424,774 | |
| Operating lease liability - current portion | 485,421 | 230,749 | |
| Accrued professional fees | 234,479 | ... | |
| Other | 20,000 | ... | |
| Total current liabilities | 7,391,134 | 10,037,082 | |
| Notes payable - non-current portion, net of deferred financing costs | ... | 4,610,946 | |
| Operating lease liability - non-current portion | 1,139,293 | ... | |
| Total liabilities | 8,530,427 | 14,648,028 | |
| Common stock | 93,998 | 74,362 | |
| Additional paid-in capital | 401,500,838 | 397,980,023 | |
| Accumulated other comprehensive gain (loss) | 60,796 | 26,494 | |
| Retained earnings (accumulated deficit) | (388,182,802) | (368,667,825) | |
| Treasury stock | 85,188 | 85,188 | |
| Total stockholders' equity (deficit) | 13,387,642 | 29,327,866 | |
| Total Equity | 13,387,642 | ... | |

Recent Dividends:
1. Imunon Inc common.
 No dividends paid.
Annual Dividends:
1. Imunon Inc common.
 No dividends paid.

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|--------------------|
| Research & development expenses, net | 7,621,707 | 6,324,657 | 2,523,153 |
| General & administrative expenses | 8,756,767 | 8,586,249 | 5,205,955 |
| Total operating expenses | ... | 14,910,906 | 7,729,108 |
| Operating income (loss) | (16,378,474) | (14,910,906) | (7,729,108) |
| Other income, net | 955,003 | 588,108 | 17,722 |
| Income (loss) before income tax | (15,423,471) | ... | ... |
| Net income (loss) | (15,423,471) | (14,322,798) | (7,711,386) |
| Weighted average shares outstanding - basic | 8,401,047 | 8,262,119 | 4,090,599 |
| Weighted average | | | |

| | | | |
|---|-----------|----------------|-----------------|
| shares outstanding - diluted | 8,401,047 | 8,262,119 | 4,090,599 |
| Year end shares outstanding | 8,401,047 | 8,401,047 | 8,258,597 |
| Income (loss) per share - basic | \$(1.83) | \$(1.73) | \$(1.89) |
| Income (loss) per share - diluted | \$(1.83) | \$(1.73) | \$(1.89) |
| Number of full time employees | 7 | 6 | 5 |
| Total number of employees | 7 | ... | ... |
| Number of common stockholders | 8 | [□] 7 | [□] 10 |
| Non-operating Income/(Expense), Net | 955,003 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(1.83) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(1.83) | ... | ... |

[□] As of March 17, 2023; [□] As of March 16, 2022
Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 13,362,053 | 9,626,800 |
| Marketable securities | ... | 16,806,009 |
| Prepaid insurance | ... | 610,208 |
| Prepaid research & development | ... | 80,910 |
| Other prepaid expenses | ... | 120,315 |
| Total prepaid expenses & other current assets | 633,156 | 811,433 |
| Total current assets | 13,995,209 | 27,244,242 |
| Property & equipment, net | 735 | 2,019 |
| Operating lease right-of-use asset | 173,206 | 79,294 |
| Other assets | 754,728 | 738,251 |
| Total non-current assets | 928,669 | 819,564 |
| Total assets | 14,923,878 | 28,063,806 |
| Accounts payable | 806,004 | 1,378,316 |
| Accrued employee costs | 1,213,054 | 1,216,242 |
| Accrued professional fees | 39,165 | 172,356 |
| Accrued research & development | ... | 311,036 |
| Accrued board fees | ... | 116,000 |
| Delaware franchise taxes payable | 40,000 | 128,929 |
| Other accrued expenses | ... | 29,968 |
| Accounts payable & other current liabilities | 2,672,327 | 3,352,847 |
| Operating lease liability, current portion | 101,705 | 80,494 |
| Accounts payable and other current liabilities - Balancing value | 574,104 | ... |
| Total current liabilities | 2,774,032 | 3,433,341 |
| Operating lease liability, net of current portion | 73,348 | ... |
| Total non-current liabilities | 73,348 | ... |
| Total liabilities | 2,847,380 | 3,433,341 |
| Common stock | 84,011 | 84,011 |
| Additional paid-in capital | 57,409,643 | 54,443,705 |
| Retained earnings (accumulated deficit) | (45,417,156) | (29,993,685) |
| Accumulated other comprehensive income | ... | 96,434 |
| Total shareholders' equity | 12,076,498 | 24,630,465 |
| Total Equity | 12,076,498 | ... |

Recent Dividends:
1. Indaptus Therapeutics Inc ordinary.
 No dividends paid.
Annual Dividends:
1. Indaptus Therapeutics Inc ordinary.

No dividends paid.

**INHIBIKASE THERAPEUTICS INC
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Grant revenue | 260,501 | 123,440 | 3,100,605 |
| Total revenue | 260,501 | 123,440 | 3,100,605 |
| Research & development expenses | 13,618,348 | 12,034,985 | 11,359,104 |
| Selling, general & administrative expenses | 6,731,945 | 6,217,063 | 6,507,641 |
| Total costs & expenses | 20,350,293 | 18,252,048 | 17,866,745 |
| Income (loss) from operations | (20,089,792) | (18,128,608) | (14,766,140) |
| Interest income (expense) | 1,060,909 | 74,453 | (19,923) |
| Net income (loss) | (19,028,883) | (18,054,155) | (14,786,063) |
| Weighted average shares outstanding - basic | 5,333,096 | 4,201,954 | 3,034,866 |
| Weighted average shares outstanding - diluted | 5,333,096 | 4,201,954 | 3,034,866 |
| Year end shares outstanding | 6,186,280 | 4,204,509 | 4,192,533 |
| Net earnings (loss) per share - basic | \$(3.57) | \$(4.32) | \$(4.86) |
| Net earnings (loss) per share - diluted | \$(3.57) | \$(4.32) | \$(4.86) |
| Number of full time employees | ... | 6 | 6 |
| Number of part time employees | ... | 1 | 1 |
| Number of common stockholders | 14 | 14 | 15 |
| Income from cont operations before income tax | (19,028,883) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-6 stock split, June 30, 2023; □ Shares increased due to the effect of issuance of common stock, stock options exercised and underwritten public offering common stock; □ As of March 14, 2023; □ As of March 16, 2022; □ As of March 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 9,165,179 | 7,188,553 |
| Marketable securities | 4,086,873 | 15,861,620 |
| Accounts receivable | ... | 39,881 |
| Prepaid research & development | 219,817 | 1,117,616 |
| Prepaid expenses & other current assets | 739,179 | 163,452 |
| Total current assets | 14,211,048 | 24,371,122 |
| Furniture & office equipment | ... | 72,692 |
| Lab equipment | ... | 153,668 |
| IT equipment | ... | 16,895 |
| Equipment & improvements, gross | 103,825 | 243,255 |
| Less: accumulated depreciation | ... | 6,723 |
| Property, Plant & Equipment - Accumulated Depreciation & Impairment | 30,453 | ... |
| Equipment & improvements, net | 73,372 | 236,532 |
| Right-of-use asset | 222,227 | 328,643 |
| Total assets | 14,506,647 | 24,936,297 |
| Accounts payable | 646,767 | 1,151,173 |
| Lease obligation, current | 150,095 | 145,836 |
| Accrued consulting | 49,395 | 232,390 |
| Accrued compensation | 635,451 | 459,997 |
| Accrued research & development | 1,472,292 | 1,696,129 |
| Accrued other | 102,817 | 9,920 |

| | | |
|---|--------------|--------------|
| Accrued expenses & other current liabilities | 2,259,955 | 2,398,436 |
| Insurance premium financing payable | 381,784 | ... |
| Total current liabilities | 3,438,601 | 3,695,445 |
| Lease obligations, net of current portion | 90,124 | 205,451 |
| Total liabilities | 3,528,725 | 3,900,896 |
| Common stock | 6,186 | 25,227 |
| Additional paid-in capital | 77,871,584 | 68,777,298 |
| Accumulated other comprehensive income (loss) | 877 | 104,718 |
| Retained earnings (accumulated deficit) | (66,900,725) | (47,871,842) |
| Total stockholders' equity (deficit) | 10,977,922 | 21,035,401 |
| Total Equity | 10,977,922 | ... |

Recent Dividends:**1. Inhibikase Therapeutics Inc common.**

No dividends paid.

Annual Dividends:**1. Inhibikase Therapeutics Inc common.**

No dividends paid.

INHIBITOR THERAPEUTICS INC**Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|-------------------|-------------------|
| Research & development expense | 1,381,066 | 6,150 | 4,905 |
| General & administrative expense | 2,023,913 | 651,776 | 320,490 |
| Total expenses | 3,404,979 | 657,926 | 325,395 |
| Income (loss) from operations | (3,404,979) | (657,926) | (325,395) |
| Gain on loan forgiveness | ... | ... | 41,600 |
| Forgiveness of balances | ... | 12,619,492 | ... |
| Gain on forgiveness of legal fees | ... | 223,007 | ... |
| Interest income | 378,844 | ... | ... |
| Interest expense | ... | 23,234 | 14,837 |
| Income (loss) before income tax expense | (3,026,135) | 12,161,339 | (298,632) |
| Current federal income taxes | ... | 22,850 | ... |
| Current state income taxes | ... | 32,259 | ... |
| Current income taxes | ... | 55,109 | ... |
| Income tax expense | ... | 55,109 | ... |
| Net income (loss) | (3,026,135) | 12,106,230 | (298,632) |
| Preferred stock dividend | ... | 189,042 | 200,001 |
| Net income (loss) applicable to common shareholders | (3,026,135) | 11,917,188 | (498,633) |
| Weighted average shares outstanding - basic | 171,950,108 | 366,183,697 | 376,247,777 |
| Weighted average shares outstanding - diluted | 171,950,108 | 367,776,961 | 376,247,777 |
| Year end shares outstanding | 172,023,545 | 171,793,134 | 376,858,323 |
| Earnings (loss) per share from continuing operations before extraordinary gain (loss) - basic | \$(0.02) | ... | ... |
| Net earnings (loss) per share - basic | \$(0.02) | \$0.03 | \$0.00 |
| Earnings (loss) per share from continuing operations before | ... | ... | ... |

| | | | |
|---|----------|--------|--------|
| extraordinary gain (loss) - diluted | \$(0.02) | ... | ... |
| Net earnings (loss) per share - diluted | \$(0.02) | \$0.03 | \$0.00 |
| Number of full time employees | 3 | 3 | 1 |
| Number of part time employees | 6 | 3 | 1 |
| Total number of employees | 9 | ... | ... |
| Number of common stockholders | 86 | 64 | 65 |

□ Reclassified to conform with 2022 presentation; □ Shares decreased due to the effect of cancellation of preferred and common stock; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 8,839,912 | 11,951,224 |
| Prepaid expenses | 109,243 | 23,900 |
| Total current assets | 8,949,155 | 11,975,124 |
| Total assets | 8,949,155 | 11,975,124 |
| Accounts payable | 33,731 | 145,161 |
| Note payable, related party | ... | 411,000 |
| Accrued expenses & other liabilities | ... | 122,621 |
| Accrued interest | 631,433 | ... |
| Total current liabilities | 665,164 | 678,782 |
| Deferred revenue | 3,000,000 | ... |
| Deferred revenue, related party | ... | 3,000,000 |
| Total liabilities | 3,665,164 | 3,678,782 |
| Common stock | 17,202 | 17,179 |
| Additional paid-in capital | 54,046,845 | 54,033,084 |
| Accumulated deficit | (48,780,056) | ... |
| Retained earnings (accumulated deficit) | ... | (45,753,921) |
| Total stockholders' equity (deficit) | 5,283,991 | 8,296,342 |
| Total Equity | 5,283,991 | ... |

Recent Dividends:**1. Inhibitor Therapeutics Inc series A preferred.**

No dividends paid.

2. Inhibitor Therapeutics Inc common.

No dividends paid.

3. Inhibitor Therapeutics Inc series B convertible preferred.

No dividends paid.

Annual Dividends:**1. Inhibitor Therapeutics Inc series A preferred.**

No dividends paid.

2. Inhibitor Therapeutics Inc common.

No dividends paid.

3. Inhibitor Therapeutics Inc series B convertible preferred.

No dividends paid.

INLAND REAL ESTATE INCOME TRUST INC**Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 |
|-----------------------------------|---------|---------|---------|
| Rental income | 149,636 | 133,432 | 118,957 |
| Other property income | 336 | 214 | 183 |
| Total income | 149,972 | 133,646 | 119,140 |
| Property operating expenses | 30,088 | 25,073 | 21,649 |
| Real estate tax expense | 18,362 | 17,210 | 14,388 |
| General & administrative expenses | 5,237 | 5,400 | 4,784 |
| Business management fee | 9,632 | 10,212 | 8,950 |
| Depreciation & amortization | 59,542 | 55,319 | 48,906 |
| Total expenses | 122,861 | 113,214 | 98,677 |
| Interest expense | 42,451 | 33,069 | 23,240 |
| Interest & other | ... | ... | ... |

| | | | |
|---|-----------------|-----------------|----------------|
| income..... | 19 | 274 | |
| Interest income..... | 217 | | |
| Net income (loss)..... | (15,123) | (12,618) | (2,503) |
| Weighted average shares outstanding - basic..... | 36,197 | 36,135 | 36,031 |
| Weighted average shares outstanding - diluted..... | 36,197 | 36,135 | 36,031 |
| Year end shares outstanding..... | 36,164 | 36,184 | 36,041 |
| Net earnings (loss) per common share - basic..... | \$(0.42) | \$(0.35) | \$(0.07) |
| Net earnings (loss) per common share - diluted..... | \$(0.42) | \$(0.35) | \$(0.07) |
| Dividends per common share..... | | \$0.54 | \$0.41 |
| Number of common stockholders..... | 16,047 | 16,395 | 16,492 |
| Net Income before Tax..... | (15,123) | | |

¹ As of March 22, 2023; ² As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|-----------|-----------|
| Land..... | 330,456 | 330,456 |
| Building & other improvements..... | 1,209,740 | 1,198,309 |
| Total investment properties held & used, gross..... | 1,528,765 | 1,528,765 |
| Less: accumulated depreciation..... | 335,700 | 288,863 |
| Net investment properties held & used..... | 1,204,496 | 1,239,902 |
| Cash & cash equivalents..... | 5,975 | 4,857 |
| Restricted cash..... | 479 | 477 |
| Accounts & rent receivable..... | 23,645 | 20,114 |
| Acquired lease intangible assets, net..... | 61,827 | 76,961 |
| Operating lease right-of-use asset, net..... | 13,745 | 14,153 |
| Other assets..... | 33,873 | 42,774 |
| Total assets..... | 1,344,040 | 1,399,238 |
| Mortgages & credit facility payable, net..... | 843,890 | 852,345 |
| Accounts payable & accrued expenses..... | 11,182 | 10,265 |
| Operating lease liability..... | 24,992 | 24,716 |
| Distributions payable..... | 4,905 | 4,907 |
| Acquired intangible liabilities, net..... | 37,420 | 43,339 |
| Due to related parties..... | 2,796 | 4,034 |
| Other liabilities..... | 10,500 | 8,574 |
| Total liabilities..... | 935,685 | 948,180 |
| Common stock..... | 36 | 36 |
| Additional paid in capital..... | 816,047 | 814,949 |
| Accumulated distributions & net earnings (loss)..... | (432,854) | (398,097) |
| Accumulated other comprehensive income (loss)..... | 25,126 | 34,170 |
| Total stockholders' equity..... | 408,355 | 451,058 |
| Total Equity..... | 408,355 | |

Recent Dividends:
1. Inland Real Estate Income Trust Inc common.
No dividends paid.

Annual Dividends:
1. Inland Real Estate Income Trust Inc common.
No dividends paid.

**INMUNE BIO INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|--------------|---------|------|-----------------------------|
| Revenue..... | 155,000 | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| Revenue..... | 155,000 | 374,000 | 181,000 |
| General & administrative expenses..... | 9,623,000 | 9,258,000 | 8,791,000 |
| Research & development expenses..... | 20,273,000 | 17,067,000 | 20,543,000 |
| Total operating expenses..... | 29,896,000 | 26,325,000 | 29,334,000 |
| Income (loss) from operations..... | (29,741,000) | (25,951,000) | (29,153,000) |
| Other expense, net..... | 267,000 | 1,348,000 | 1,187,000 |
| Total other income (expense)..... | | (1,348,000) | (1,187,000) |
| Net income (loss)..... | (30,008,000) | (27,299,000) | (30,340,000) |
| Weighted average shares outstanding - basic..... | 17,980,791 | 17,927,327 | 16,130,539 |
| Weighted average shares outstanding - diluted..... | 17,980,791 | 17,927,327 | 16,130,539 |
| Year end shares outstanding..... | 18,026,473 | 17,945,995 | 17,843,303 |
| Net earnings (loss) per common share - basic..... | \$(1.67) | \$(1.52) | \$(1.88) |
| Net earnings (loss) per common share - diluted..... | \$(1.67) | \$(1.52) | \$(1.88) |
| Number of full time employees..... | 11 | 10 | 10 |
| Number of common stockholders..... | 26 | 28 | 26 |
| Income from cont operations before income tax..... | (30,008,000) | | |
| Earnings per share from continuing operations..... | \$(1.67) | | |
| Earnings per share from continuing operations..... | \$(1.67) | | |
| Part-Time Employees (Period End)..... | 6 | | |
| Total number of employees..... | 17 | | |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to issuance of shares for cash, settlement of warrant for cash and shares, exercise of warrants and exercise of stock options

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents..... | 35,848,000 | 52,153,000 |
| Research & development tax credit receivable..... | 1,905,000 | 8,099,000 |
| Other tax receivable..... | 537,000 | 362,000 |
| Prepaid expenses..... | 1,510,000 | |
| Prepaid expenses & other current assets..... | | 4,027,000 |
| Prepaid expenses - related party..... | 142,000 | 34,000 |
| Total current assets..... | 39,942,000 | 64,675,000 |
| Operating lease - right of use assets..... | 414,000 | 507,000 |
| Other assets..... | 131,000 | 99,000 |
| Acquired in-process research & development intangible assets..... | 16,514,000 | 16,514,000 |
| Total assets..... | 57,001,000 | 81,795,000 |
| Accounts payable & accrued liabilities..... | 7,901,000 | 5,206,000 |
| Accounts payable & accrued liabilities - related parties..... | 35,000 | 9,000 |
| Deferred liabilities..... | 489,000 | 616,000 |
| Current portion of long-term debt..... | 9,921,000 | 5,000,000 |
| Operating lease, current liabilities..... | 119,000 | 87,000 |
| Total current liabilities..... | 18,465,000 | 10,918,000 |
| Long-term debt, less debt discount..... | | 9,697,000 |

| | | |
|--|---------------|--------------|
| Long-term operating lease liabilities..... | 397,000 | 526,000 |
| Accrued liability - long-term..... | | 550,000 |
| Total liabilities..... | 18,862,000 | 21,691,000 |
| Redeemable common stock..... | 799,000 | |
| Common stock..... | 18,000 | 18,000 |
| Additional paid-in capital..... | 159,143,000 | 151,799,000 |
| Accumulated other comprehensive income (loss)..... | (799,000) | (699,000) |
| Retained earnings (accumulated deficit)..... | (121,022,000) | (91,014,000) |
| Total stockholders' equity (deficit)..... | 37,340,000 | 60,104,000 |
| Total Equity..... | 37,340,000 | |

Recent Dividends:

1. INmune Bio Inc redeemable common.

No dividends paid.

2. INmune Bio Inc common.

No dividends paid.

Annual Dividends:

1. INmune Bio Inc redeemable common.

No dividends paid.

2. INmune Bio Inc common.

No dividends paid.

INNOVATIVE EYEWEAR INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|--|--------------------|--------------------|-----------------------------|
| Total revenues..... | 1,152,479 | | |
| Revenues, net..... | 1,152,479 | 659,788 | 690,670 |
| Less: cost of goods sold..... | 1,271,808 | 716,077 | 542,416 |
| Gross profit (loss)..... | (119,329) | (56,289) | 148,254 |
| General & administrative..... | 3,886,960 | 2,796,669 | 1,386,079 |
| Sales and marketing..... | 2,047,069 | 2,059,012 | 1,771,012 |
| Research & development..... | 662,184 | 524,692 | 86,261 |
| Related party management fee..... | 140,000 | 140,000 | 109,975 |
| Total operating expenses..... | 6,736,213 | 5,520,373 | 3,353,327 |
| Other income..... | 195,150 | | |
| Interest expense..... | 3,036 | 105,171 | 39,433 |
| Net income (loss)..... | (6,663,428) | (5,681,833) | (3,244,506) |
| Weighted average shares outstanding - basic..... | 10,515,995 | 6,528,959 | 5,245,622 |
| Weighted average shares outstanding - diluted..... | 10,515,995 | 6,528,959 | 5,245,622 |
| Year end shares outstanding..... | 12,917,239 | 7,307,157 | 6,060,187 |
| Net earnings (loss) per share - basic..... | \$(0.63) | \$(0.87) | \$(0.62) |
| Net earnings (loss) per share - diluted..... | \$(0.63) | \$(0.87) | \$(0.62) |
| Number of full time employees..... | 11 | 9 | 9 |
| Number of part time employees..... | | | 10 |
| Number of common stockholders..... | 3,780 | 3,828 | |
| Income from cont operations before income tax..... | (6,663,428) | | |
| Earnings per share from continuing operations..... | \$(0.63) | | |
| Earnings per share from continuing operations..... | \$(0.63) | | |
| Total number of employees..... | 11 | | |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of shares issued for conversion of related

party convertible note, and initial public offering; [□] As of August 14, 2022; [▣] Approximately; [▨] As of December 30, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|--------------|--------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 4,287,447 | 3,591,109 |
| Accounts receivable, gross | 118,983 | 202,904 |
| Less: allowance | 25,772 | 92,646 |
| Accounts receivable | 93,211 | 110,258 |
| Prepaid expenses | 313,648 | 210,673 |
| Deferred offering costs | 6,256 | ... |
| Inventory prepayment | 323,520 | 197,750 |
| Other current assets | 59,447 | 36,240 |
| Inventory | 533,239 | 94,701 |
| Total current assets | 5,616,768 | 4,240,731 |
| Patent costs, net | 286,429 | 137,557 |
| Capitalized software costs | 110,073 | 110,073 |
| Mobile kiosk display | 127,333 | 63,395 |
| Computer equipment | 44,901 | 44,901 |
| Office equipment | 10,291 | 17,273 |
| Internal-use software | 31,300 | 16,775 |
| Property & equipment, gross | 213,825 | ▣142,343 |
| Less: accumulated depreciation | 80,977 | 22,599 |
| Property & equipment, net | 132,848 | 119,744 |
| Other non-current assets | 72,644 | 81,779 |
| Total assets | 6,218,762 | 4,689,884 |
| Accounts payable & accrued expenses | 581,986 | 275,660 |
| Deferred revenue | 42,500 | 30,000 |
| Due to parent & affiliates | ... | 232,989 |
| Related party convertible debt | ... | 61,356 |
| Total current liabilities | 624,486 | 600,005 |
| Deferred revenue | 35,450 | 65,450 |
| Total liabilities | 659,936 | 665,455 |
| Common stock | 129 | 73 |
| Additional paid-in capital | 22,528,112 | 14,330,343 |
| Retained earnings (accumulated deficit) | (16,969,415) | (10,305,987) |
| Total stockholders' equity (deficit) | 5,558,826 | 4,024,429 |
| Total Equity | 5,558,826 | ... |

[□] As reported by the Company

Recent Dividends:

1. Innovative Eyewear Inc common.

No dividends paid.

Annual Dividends:

1. Innovative Eyewear Inc common.

No dividends paid.

INNOVATIVE FOOD HOLDINGS INC

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|-------------|------------|-------------|
| | 2023 | ▣2022 | 2021 |
| | | (revised) | (revised) |
| Sales | 72,218,996 | 78,904,175 | ... |
| Revenue | 72,218,996 | 78,904,175 | 62,212,148 |
| Cost of goods sold | 54,693,359 | 61,377,384 | 45,261,401 |
| Gross margin | 17,525,637 | 17,526,791 | 16,950,747 |
| General & administrative expenses | 2,074,063 | ... | ... |
| Selling, general & administrative expenses | 17,389,351 | 18,332,503 | 20,540,229 |
| Impairment of intangible assets | 1,315,822 | ... | ... |
| Total operating expenses | 20,779,236 | 18,332,503 | 20,540,229 |
| Operating income (loss) | (3,253,599) | (805,712) | (3,589,482) |
| Gain on forgiveness of debt | ... | ... | 3,425,015 |
| Gain on contingent liability | ... | 295,600 | ... |

| | | | | | | |
|--|-------------|-------------|------------|---|--------------|--------------|
| Impairment of investment | (7,600) | (11,226) | 209,850 | discontinued operations | 95,861 | ... |
| Other leasing income | ... | ... | 10,840 | Assets held for sale | 649,884 | ... |
| Impairment of notes receivable | ... | 286,725 | ... | Total current assets | 13,641,149 | 13,212,077 |
| Gain on sale of fixed assets | 9,360 | ... | ... | Computer hardware & software | 940,960 | ... |
| Interest expense, net | ... | ... | 352,854 | Land | 1,079,512 | 1,256,895 |
| Other income | 14,925 | 294,000 | ... | Building | 6,571,496 | 7,191,451 |
| Interest income (expense), net | (876,452) | (587,285) | ... | Computer & office equipment | 597,834 | 609,018 |
| Gain (loss) on extinguishment of debt | ... | (40,556) | ... | Warehouse equipment | 477,090 | 378,957 |
| Loss on sale of subsidiaries | (45,022) | ... | ... | Furniture & fixtures | ... | 1,021,481 |
| Total other income (expense) | (889,589) | (313,740) | 2,873,151 | Vehicles | 58,353 | 109,441 |
| Net income (loss) before taxes | (4,143,188) | (1,119,452) | (716,331) | Right of Use Tangible Assets - Capital/Finance Lease - Gross | 960,274 | ... |
| Income tax expense | 15,834 | ... | ... | Total before accumulated depreciation | 9,725,245 | 10,567,243 |
| Net income (loss) from continuing operations | (4,159,022) | (1,119,452) | ... | Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation | 523,871 | ... |
| Discontinued operations | (196,130) | (230,550) | ... | Less: accumulated depreciation | 2,725,230 | 2,645,682 |
| Net income | (4,355,152) | (1,350,002) | (716,331) | Property & equipment, net | 7,000,015 | 7,921,561 |
| Weighted average shares outstanding - basic | 49,076,880 | 47,129,511 | 39,448,041 | Right of use assets, operating leases, net | 28,519 | 152,425 |
| Weighted average shares outstanding - diluted | 49,076,880 | 47,129,511 | 39,448,041 | Right of use assets, finance leases, net | 436,403 | 570,323 |
| Year end shares outstanding | 49,714,929 | 48,089,657 | 46,041,751 | Intangible assets, net | 217,000 | ... |
| Net income (loss) per share from continuing operations - basic | \$(0.08) | \$(0.02) | ... | Other amortizable intangible assets, net | ... | 30,994 |
| Net income (loss) per share from discontinued operations - basic | \$0.00 | \$0.00 | ... | Tradenames & other unamortizable intangible assets | ... | 1,532,822 |
| Net income (loss) per share - basic | \$(0.08) | \$(0.02) | \$(0.02) | Total assets | 21,323,086 | 23,420,202 |
| Net income (loss) per share from continuing operations - diluted | \$(0.08) | \$(0.02) | ... | Trade payables & accrued liabilities | 6,046,396 | 6,599,903 |
| Net income (loss) per share from discontinued operations - diluted | \$(0.08) | \$(0.02) | ... | Accrued payroll & commissions | 206,555 | 253,350 |
| Net income (loss) per share - diluted | \$(0.08) | \$(0.02) | \$(0.02) | Deferred revenue | 1,312,837 | 1,558,155 |
| Number of full time employees | 92 | ... | 127 | Line of credit | ... | 2,014,333 |
| Total number of employees | 92 | ... | ... | Accrued interest, current portion | ... | 18,104 |
| Number of common holders | 59 | ... | ▣55 | Notes payable - current portion, net of discount | 121,041 | 5,711,800 |
| | | | | Lease liability - operating leases, current | 17,131 | 64,987 |
| | | | | Lease liability - finance leases, current | 255,020 | 191,977 |
| | | | | Current liabilities - discontinued operations | 6,422 | ... |
| | | | | Accrued interest | 95,942 | ... |
| | | | | Lease liability financing leases, current | 115,738 | ... |
| | | | | Accrued separation costs, related parties, current portion | 463,911 | ... |
| | | | | Total current liabilities | 8,640,993 | 16,412,609 |
| | | | | Lease liability - operating leases, non-current | 11,388 | 87,438 |
| | | | | Lease liability - finance leases, non-current | 219,266 | 333,092 |
| | | | | Notes payable - director | 8,855,000 | ... |
| | | | | Accrued separation costs, related parties, non-current | 791,025 | ... |
| | | | | Total liabilities | 18,517,672 | 16,833,139 |
| | | | | Common stock | 5,251 | 5,088 |
| | | | | Additional paid-in capital | 42,762,811 | 42,189,471 |
| | | | | Treasury stock | 1,141,370 | 1,141,370 |
| | | | | Retained earnings (accumulated deficit) | (38,821,278) | (34,466,126) |
| | | | | Total Innovative Food Holdings, Inc. stockholders' equity (deficit) | 2,805,414 | 6,587,063 |
| | | | | Total stockholders' equity (deficit) | 2,805,414 | 6,587,063 |

[▣] Restated to reflect discontinued operations; [▨] Approximately; [▨] As of March 1, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|-----------|-----------|
| | 2023 | 2022 |
| | | (revised) |
| Cash & cash equivalents | 5,327,016 | 4,899,398 |
| Accounts receivable from customers | 4,354,203 | 5,309,620 |
| Accounts receivable, net | 4,307,726 | 4,969,395 |
| Allowance for doubtful accounts | 46,477 | 340,225 |
| Finished goods inventory | 3,162,716 | 3,053,852 |
| Inventory | 2,973,134 | ... |
| Allowance for slow moving & obsolete inventory | (189,582) | ... |
| Inventory, net | ... | 3,053,852 |
| Other current assets | 287,528 | 289,432 |
| Current assets - | | |

Recent Dividends:

1. Innovative Food Holdings Inc common.

No dividends paid.
Annual Dividends:
1. Innovative Food Holdings Inc common.
 No dividends paid.

INNOVATIVE PAYMENT SOLUTIONS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 |
|--|--------------------|---------------------|---------------------|
| Net Revenue | 410 | 847 | ... |
| Net revenue | 410 | 847 | ... |
| Cost of goods sold | 3,547 | 5,052 | ... |
| Gross profit (loss) | (3,137) | (4,205) | ... |
| General & administrative | 3,576,352 | 5,452,579 | 10,284,815 |
| Depreciation | 380,634 | 132,394 | 17,935 |
| Total expense | 3,956,986 | 5,584,973 | 10,302,750 |
| Income (loss) from operations | (3,960,123) | (5,589,178) | (10,302,750) |
| Investment impairment charge | 90,761 | 1 | ... |
| Loss on debt conversion | ... | ... | 5,498,820 |
| Loss on convertible notes | 73,562 | 4,602,709 | ... |
| Forgiveness of federal relief loans | ... | ... | 60,292 |
| Interest expense, net | 424,117 | 199,788 | 228,240 |
| Amortization of debt discount | ... | ... | 3,653,652 |
| Derivative liability movements | 1,501,446 | ... | 5,128,255 |
| Income (loss) before taxation | (4,897,830) | (10,243,124) | (14,494,915) |
| Net income (loss) from continuing operations | (5,301,112) | (10,243,124) | ... |
| Operating income (loss) from discontinued operations | (40,821) | (88,300) | ... |
| Profit on disposal of subsidiaries | (495,424) | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (5,835,760) | (10,288,157) | ... |
| Net income (loss) | (5,837,357) | (10,331,424) | (14,494,915) |
| Net income (loss) attributable to non-controlling interest | 1,597 | 43,267 | 12,789 |
| Net income (loss) attributable Innovative Payment Solutions, Inc. stockholders | ... | ... | (14,482,126) |
| Weighted average shares outstanding - basic | 12,844,609 | 12,406,677 | 11,144,794 |
| Weighted average shares outstanding - diluted | 12,844,609 | 12,406,677 | 11,144,794 |
| Year end shares outstanding | 13,819,889 | 12,563,389 | 12,263,389 |
| Net income (loss) per share from continuing operations - basic | \$(0.41) | \$(0.83) | ... |
| Earnings per share-disp of discontinued opers | \$(0.04) | \$0.00 | ... |
| Earnings per share-inc from discontinued oper | \$(0.00) | \$(0.01) | ... |
| Net income (loss) per share from discontinued operations - basic | \$(0.04) | \$(0.01) | ... |
| Net income (loss) per share - basic | \$(0.45) | \$(0.83) | \$(1.20) |
| Net income (loss) | | | |

per share from continuing operations - diluted
 \$(0.41) | \$(0.83) | ... || Earns per share-disp of discount opers - diluted | \$(0.04) | \$0.00 | ... |
| Earn per share-inc from discount opers - diluted | \$(0.00) | \$(0.01) | ... |
| Net income (loss) per share from discontinued operations - diluted | \$(0.04) | \$(0.01) | ... |
| Net income (loss) per share - diluted | \$(0.45) | \$(0.83) | \$(1.20) |
| Number of full time employees | 3 | ... | ... |
| Number of part time employees | 2 | ... | ... |
| Total number of employees | 5 | ... | 10 |
| Number of common stockholders | 68 | ... | 65 |
| Net loss from equity method investments | (403,282) | ... | ... |
| Loss on novation | 1,066,165 | ... | ... |
| Fair value of warrants issued | (14,176) | 411,752 | ... |
| Interest expense | 770,372 | 263,200 | ... |

□ Restated to reflect correction of errors; □ Approximately; □ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|--------------|-------------------|
| Cash | 50,433 | 374,765 |
| Other current assets | 38,818 | 97,042 |
| Total current assets | 89,251 | 471,807 |
| Plant & equipment | 7,027 | 40,362 |
| Intangible assets | ... | 1,692,811 |
| Security deposit | 5,000 | 47,592 |
| Investment | ... | 500,000 |
| Equity method investment | 703,938 | ... |
| Total non-current assets | 715,965 | 2,280,765 |
| Total assets | 805,216 | 2,752,572 |
| Accounts payable | 2,023,375 | 761,732 |
| Federal relief loans | 9,369 | ... |
| Notes payable | 1,062,007 | 964,268 |
| Convertible debt, net | 3,704,280 | 2,266,602 |
| Derivative liability | 1,434,196 | 2,550,642 |
| Total current liabilities | 8,233,227 | 6,543,244 |
| Federal relief loans | 150,000 | 163,978 |
| Total non-current liabilities | 150,000 | 163,978 |
| Total liabilities | 8,383,227 | 6,707,222 |
| Common stock, \$00001 par value; 100,000,000 shares authorized, 54,954,000 and 49,809,000 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively | 1,382 | ... |
| Common stock | ... | 37,690 |
| Additional paid-in-capital | 50,656,225 | 48,405,921 |
| Accumulated Deficit | (58,235,618) | ... |
| Retained earnings (accumulated deficit) | ... | (52,399,858) |
| Total equity (deficit) attributable to Innovative Payment Solutions, Inc. stockholders | (7,578,011) | (3,956,247) |
| Non-controlling interest | ... | 1,597 |
| Total equity (deficit) | (7,578,011) | (3,954,650) |

Recent Dividends:
1. Innovative Payment Solutions Inc common.

No dividends paid.
Annual Dividends:
1. Innovative Payment Solutions Inc common.
 No dividends paid.

INRAD OPTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|------------------|----------------|-------------------|
| Total revenue | 12,909,657 | 10,631,032 | 11,352,527 |
| Total revenues | 12,909,657 | ... | ... |
| Cost of goods sold | 7,984,129 | 7,529,893 | 7,874,076 |
| Selling, general & administrative expenses | 3,111,773 | 2,782,082 | 2,544,102 |
| Total costs & expenses | 11,095,902 | 10,311,975 | 10,418,178 |
| Income (loss) from operations | 1,813,756 | 319,057 | 934,349 |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 973,166 |
| Interest expense - net | 145,333 | 166,482 | 158,618 |
| Total other income (expense) | (145,333) | (166,482) | 814,548 |
| Income (loss) before income taxes | 1,668,422 | 152,575 | 1,748,897 |
| Income tax provision | (1,000,000) | ... | ... |
| Net income (loss) | 2,668,422 | 152,575 | 1,748,897 |
| Weighted average shares outstanding - basic | 14,196,490 | 14,018,227 | 13,871,420 |
| Weighted average shares outstanding - diluted | 17,231,568 | 14,724,895 | 16,630,239 |
| Year end shares outstanding | 14,230,975 | 14,088,320 | 13,962,657 |
| Net earnings (loss) per share - basic | \$0.19 | \$0.01 | \$0.13 |
| Net earnings (loss) per share - diluted | \$0.16 | \$0.01 | \$0.11 |
| Number of full time employees | ... | 59 | 53 |
| Number of common shareholders | 240 | 124 | 122 |
| Number of beneficiary stockholders | ... | 240 | 240 |
| Basic EPS Excluding ExtraOrdinary Items | \$0.19 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.16 | ... | ... |

□ As of March 30, 2023; □ As of March 30, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 2,973,384 | 2,003,485 |
| Accounts receivable, gross | 1,637,996 | 1,435,867 |
| Less: allowance for doubtful accounts | 46,000 | 46,000 |
| Accounts receivable, net | 1,591,996 | 1,389,867 |
| Raw materials | 718,000 | 1,065,000 |
| Work in process, including manufactured parts & components | 1,915,000 | 1,282,000 |
| Finished goods | 516,000 | 479,000 |
| Inventories, net - Balancing value | (292) | ... |
| Inventories, net | 3,148,708 | 2,825,987 |
| Other current assets | 665,262 | 309,287 |
| Total current assets | 8,379,350 | 6,528,626 |
| Office & computer equipment | 1,487,000 | 1,487,000 |
| Machinery & equipment | 12,458,000 | 12,126,000 |
| Leasehold improvements | 2,386,000 | 2,354,000 |
| Plant and equipment at | | |

| | | | | | | | | | |
|---|--------------|--------------|--|--------------|-------------|-------------|---|--------------|-------------|
| cost - Balancing value | (441) | ... | operations | (7,191,016) | (3,518,138) | (1,047,221) | Bridge note, net of discount | 1,713,831 | 3,899,156 |
| Plant & equipment, at cost | 16,330,559 | 15,967,537 | Interest income | 21 | 1,021 | 161 | Convertible debentures, net of issuance costs | 100,000 | ... |
| Less: accumulated depreciation & amortization | 15,034,667 | 14,723,869 | Interest expense | 2,538,710 | 1,425,260 | 194,811 | Loan payable, net of discount | 1,469,043 | ... |
| Total plant & equipment | 1,295,892 | 1,243,668 | Other expenses | ... | (357) | 14,861 | Notes payable, net of discount | ... | 1,549,861 |
| Precious metals | 561,909 | 561,909 | Other income | 1,134 | ... | ... | Cumulative Series A preferred stock dividends payable | 92,322 | ... |
| Lease right-of-use, net | 443,532 | 737,743 | Beneficial conversion feature | (4,137,261) | ... | ... | Total current liabilities | 7,581,815 | 7,249,840 |
| Deferred income taxes | 1,000,000 | ... | Loss on debt modification | 927,054 | ... | ... | Operating lease liabilities, non-current | 1,514,044 | 666,179 |
| Other assets | 26,993 | 26,993 | Total other expense | (7,601,870) | (1,423,882) | (209,511) | Convertible debentures | ... | 3,688,805 |
| Total assets | 11,707,676 | 9,098,939 | Loss before income taxes | (14,792,886) | (4,942,020) | (1,256,732) | FNBD Notes Payable | ... | 8,863,423 |
| Current portion of other long term notes | 71,362 | 67,513 | Current income tax benefit (expense) - federal | ... | ... | 33,982 | FSNB Notes Payable | ... | 6,531,377 |
| Accounts payable & accrued liabilities | 831,317 | ... | Current income tax benefit (expense) - state | ... | (30,094) | 40,348 | Car loan | ... | 6,653 |
| Trade accounts payable & accrued purchases | 412 | 446,000 | Provision (benefit) for income taxes | ... | (30,094) | 74,330 | Total notes payable | ... | 15,401,453 |
| Accrued payroll | 9 | 25,000 | Dividend on convertible series A preferred stock | 271,245 | ... | ... | Unamortized debt issuance costs | 13,483,375 | (135,240) |
| Accrued 401K company matching contribution | 141 | 137,000 | Net loss | (14,792,886) | (4,911,926) | (1,331,062) | Notes payable, net of issuance cost | ... | 15,266,213 |
| Accrued expenses - other | 270 | 133,000 | Weighted average outstanding class A & B common shares - basic | 6,692,515 | 5,160,182 | 5,001,699 | Less current portion | ... | 1,549,861 |
| Contract liabilities | 1,067,183 | 1,065,173 | Weighted average outstanding class A & B common shares - diluted | 6,692,515 | 5,160,182 | 5,001,699 | Notes payable - noncurrent | ... | 13,716,352 |
| Current portion of lease obligation | 309,618 | 295,978 | Year end shares outstanding | 10,933,606 | 5,270,457 | 5,145,456 | Total liabilities | ... | 25,321,176 |
| Total current liabilities | 2,280,312 | 2,169,945 | Net loss per class A and B common shares - basic | \$(2.25) | \$(0.95) | \$(0.27) | Common stock - Class A | 389 | 98 |
| Related party convertible notes payable | 245,379 | 2,500,000 | Net loss per class A and B common shares - diluted | \$(2.25) | \$(0.95) | \$(0.27) | Common stock - Class B | 705 | 430 |
| Other long term notes, net of current portion | ... | 316,740 | Full-Time Employees (Period End) | 156 | ... | ... | Additional paid in capital | 20,425,864 | 1,107,439 |
| Lease obligation, net of current portion | 133,915 | 444,462 | Total number of employees | 156 | ... | 30 | Accumulated deficit | ... | (6,243,448) |
| Unsecured demand convertible note | 2,500,000 | ... | Net Income After Extraordinary Items applicable to Common | (15,064,131) | ... | ... | Accumulated deficit | (21,215,257) | ... |
| Total liabilities | 5,159,606 | 5,431,147 | | | | | Preferred Stock - Redeemable - Convertible | 40 | ... |
| Common stock | 142,357 | 140,931 | | | | | Total stockholder's deficit | (788,259) | (5,135,481) |
| Capital in excess of par value | 20,135,722 | 19,925,292 | | | | | Total Equity | (788,259) | ... |
| Retained earnings (accumulated deficit) | (13,715,059) | (16,383,481) | | | | | | | |
| Less - common stock in treasury, at cost | 14,950 | 14,950 | | | | | | | |
| Total shareholders' equity (deficit) | 6,548,070 | 3,667,792 | | | | | | | |
| Total Equity | 6,548,070 | ... | | | | | | | |

□ Rounding difference, breakdown taken from the notes

Recent Dividends:

1. Inrad Optics Inc 10% convertible series B preferred.

No dividends paid.

2. Inrad Optics Inc common.

No dividends paid.

3. Inrad Optics Inc 10% convertible series A preferred.

No dividends paid.

Annual Dividends:

1. Inrad Optics Inc 10% convertible series B preferred.

No dividends paid.

2. Inrad Optics Inc common.

No dividends paid.

3. Inrad Optics Inc 10% convertible series A preferred.

No dividends paid.

INSPIRE VETERINARY PARTNERS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-------------------------------------|------------|------------|-----------|
| Service revenue | 11,879,934 | 7,032,800 | 1,813,621 |
| Product revenue | 4,795,459 | 2,801,978 | 735,513 |
| Total revenue | 16,675,393 | 9,834,778 | 2,549,134 |
| Cost of service revenue | 9,700,963 | 5,308,104 | 1,284,407 |
| Cost of product revenue | 3,420,515 | 1,981,046 | 435,437 |
| General and administrative expenses | 9,476,287 | 5,467,642 | 1,792,046 |
| Depreciation and amortization | 1,252,539 | 596,124 | 84,465 |
| Debt extinguishment loss | 16,105 | ... | ... |
| Total operating expenses | 23,866,409 | 13,352,916 | 3,596,355 |
| Loss from | | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash and cash equivalents | 178,961 | 444,253 |
| Due from former owners | 32,519 | 269,883 |
| Inventory | 571,512 | 582,019 |
| Refundable income tax | 151,796 | 192,139 |
| Prepaid expenses and other current assets | 388,759 | 253,795 |
| Accounts receivable | 28,573 | ... |
| Total current assets | 1,352,120 | 1,742,089 |
| Land | ... | 1,839,596 |
| Computers and equipment | 1,425,774 | 1,321,708 |
| Furniture and fixtures | 143,874 | 143,874 |
| Automobile | 101,269 | 69,083 |
| Leasehold improvements | 499,310 | 95,991 |
| Buildings | 4,607,874 | 4,162,088 |
| Land - Gross | 1,983,810 | ... |
| Property & equipment, subtotal | 8,761,911 | 7,632,340 |
| Less - accumulated depreciation | 812,767 | 309,290 |
| Property and equipment, net | 7,949,144 | 7,323,050 |
| Right-of-use assets | 1,616,198 | 746,973 |
| Other intangibles, net | 2,513,028 | 2,729,574 |
| Goodwill | 8,147,590 | 7,614,553 |
| Other assets | 12,895 | 29,456 |
| Restricted cash - non-current | 200,000 | ... |
| Total assets | 21,790,975 | 20,185,695 |
| Accounts payable | 3,206,594 | 1,018,931 |
| Accrued expenses | 858,334 | 690,740 |
| Operating lease liabilities | 141,691 | 91,152 |

Recent Dividends:

1. Inspire Veterinary Partners Inc convertible series A preferred.

No dividends paid.

2. Inspire Veterinary Partners Inc class A common.

No dividends paid.

3. Inspire Veterinary Partners Inc class B common.

No dividends paid.

Annual Dividends:

1. Inspire Veterinary Partners Inc convertible series A preferred.

No dividends paid.

2. Inspire Veterinary Partners Inc class A common.

No dividends paid.

3. Inspire Veterinary Partners Inc class B common.

No dividends paid.

INSPIRED ENTERTAINMENT INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|-------------|-------------|
| Service | 261,200,000 | 251,800,000 | 183,300,000 |
| Product sales | 61,800,000 | 33,600,000 | 25,600,000 |
| Total revenue | 323,000,000 | 285,400,000 | 208,900,000 |
| Cost of service | 75,100,000 | 49,300,000 | 34,300,000 |
| Cost of product sales | 52,600,000 | 22,700,000 | 16,400,000 |
| Selling, general & administrative expenses | 115,500,000 | 126,400,000 | 110,200,000 |
| Acquisition & integration related transaction expenses | ... | 500,000 | 1,600,000 |
| Depreciation & amortization | 39,900,000 | 37,600,000 | 47,000,000 |
| Net operating income (loss) | 39,900,000 | 48,900,000 | (600,000) |
| Interest expense, net | 27,700,000 | 25,400,000 | 44,300,000 |
| Change in fair value of warrant liability | ... | ... | 900,000 |
| Gain on disposal of | ... | ... | ... |

| | | | | | | | | | |
|---|------------------|-------------------|---------------------|---|-------------|-----------------------|---|---------------|---------------|
| business | 900,000 | | | Unbilled accounts receivable | 18,200,000 | current portion | 3,700,000 | | |
| Pension interest cost | 2,100,000 | 1,600,000 | | Prepaid expenses & other current assets | 39,600,000 | 32,100,000 | Operating lease liabilities | 9,800,000 | 5,900,000 |
| Expected return on pension plan assets | 3,200,000 | 2,700,000 | | Total current assets | 152,500,000 | 128,600,000 | Asset retirement obligations | | 1,100,000 |
| Foreign currency translation on senior bank debt | | | 4,600,000 | Short-term leasehold property | 3,500,000 | 3,100,000 | Other creditors | 7,100,000 | 800,000 |
| Other finance income (expense) | 400,000 | 1,100,000 | 5,700,000 | Server based gaming terminals | 200,000,000 | 167,900,000 | Pension liability | | 2,100,000 |
| Total other income (expense), net | (27,300,000) | (23,400,000) | (37,700,000) | Computer equipment | 12,700,000 | 10,900,000 | Other long-term liabilities | 4,100,000 | 4,000,000 |
| Income (loss) before income taxes - United States | | | (14,100,000) | Plant & machinery | 220,300,000 | 3,900,000 | Total liabilities | 418,900,000 | 367,100,000 |
| Income (loss) before income taxes - foreign jurisdictions | | | 39,600,000 | Plant and machinery | 4,100,000 | | Common stock | | 2,622 |
| Income (loss) before income taxes | 12,600,000 | 25,500,000 | (38,300,000) | Property & equipment, gross | | 185,800,000 | Additional paid in capital | 386,100,000 | 378,200,000 |
| Current income tax expense (benefit) - federal | 3,000,000 | 1,600,000 | | Less: accumulated depreciation | 157,500,000 | | Unrecognized pension benefit costs | (33,800,000) | |
| Current income tax expense (benefit) - state | 400,000 | 200,000 | | Less: accumulated depreciation & amortization | | 141,100,000 | Foreign currency translation adjustments | 78,300,000 | 79,700,000 |
| Current income tax expense (benefit) - foreign | 1,600,000 | 1,400,000 | (1,600,000) | Property & equipment, net | 62,800,000 | 44,700,000 | Change in fair value of hedging instrument | | (300,000) |
| Total current income tax expense (benefit) | | 3,200,000 | (1,600,000) | Software development costs, net | 21,800,000 | 35,800,000 | Unrecognized pension benefit costs | | (33,100,000) |
| Income tax expense (benefit) | 5,000,000 | 3,200,000 | (1,600,000) | Other acquired intangible assets subject to amortization, net | 13,400,000 | 14,700,000 | Accumulated other comprehensive income (loss) | 44,500,000 | 46,300,000 |
| Net income (loss) | 7,600,000 | 22,300,000 | (36,700,000) | Goodwill | 58,800,000 | 73,900,000 | Accumulated deficit | (508,600,000) | |
| Weighted average shares outstanding - basic | 28,073,408 | 26,446,374 | 22,897,997 | Operating lease right of use asset | 14,200,000 | 8,300,000 | Retained earnings (accumulated deficit) | | (482,200,000) |
| Weighted average shares outstanding - diluted | 29,214,583 | 29,035,785 | 22,897,997 | Long term finance lease receivable | 4,800,000 | 200,000 | Total stockholders' equity (deficit) | (78,000,000) | (57,700,000) |
| Year end shares outstanding | 26,219,021 | 25,909,516 | 26,433,562 | Long term prepaid expenses & other assets | 9,400,000 | 200,000 | Total Equity | (78,000,000) | |
| Net earnings (loss) per share - basic | \$0.27 | \$0.84 | \$(1.60) | Other assets | 8,000,000 | 3,400,000 | | | |
| Net earnings (loss) per share - diluted | \$0.26 | \$0.77 | \$(1.60) | Long term prepaid expenses and other assets | 200,000 | | | | |
| Number of full time employees | 1,620 | 1,500 | 1,500 | Total assets | 340,900,000 | 309,400,000 | | | |
| Number of part time employees | | 100 | 100 | Accounts payable | | 25,700,000 | | | |
| Total number of employees | 1,620 | 1,600 | 1,600 | Payroll & related costs | 5,500,000 | 10,200,000 | | | |
| Number of common stockholders | 33 | 35 | 44 | Cost of sales including inventory | | 9,100,000 | | | |
| Foreign currency translation adjustments | | 8,200,000 | | Non-current asset costs | | 2,200,000 | | | |
| | | | | Interest payable - cash | 6,400,000 | 1,800,000 | | | |
| | | | | Selling, general & administrative costs | | 1,700,000 | | | |
| | | | | Tax and professional fees | | 1,700,000 | | | |
| | | | | Asset retirement obligations & other property related costs | | 1,500,000 | | | |
| | | | | Other creditors | 7,000,000 | 300,000 | | | |
| | | | | Accrued expenses | | 28,500,000 | | | |
| | | | | Account payable & accrued expenses | 41,900,000 | | | | |
| | | | | Corporate tax & other current taxes payable | 6,300,000 | 9,300,000 | | | |
| | | | | Deferred revenue, current | 5,600,000 | 4,800,000 | | | |
| | | | | Operating lease liabilities | 4,700,000 | 2,800,000 | | | |
| | | | | Customer prepayments & deposits | 2,900,000 | 2,400,000 | | | |
| | | | | Foreign exchange contract liabilities | | 200,000 | | | |
| | | | | Fair value of hedging instrument | 600,000 | | | | |
| | | | | Other current liabilities | 4,200,000 | 2,600,000 | | | |
| | | | | Current portion of long-term debt | 19,100,000 | | | | |
| | | | | Current portion of finance lease liabilities | 700,000 | 1,000,000 | | | |
| | | | | Accounts Payable and Accrued Expenses | 60,800,000 | | | | |
| | | | | Total current liabilities | 100,700,000 | 74,700,000 | | | |
| | | | | Senior bank debt | | 282,900,000 | | | |
| | | | | Finance lease liabilities | 1,600,000 | | | | |
| | | | | Unamortized deferred financing charge | | (5,300,000) | | | |
| | | | | Total long-term debt outstanding | | 277,600,000 | | | |
| | | | | Long-term debt | 295,600,000 | 277,600,000 | | | |
| | | | | Finance lease liabilities, net of current portion | | 1,200,000 | | | |
| | | | | Deferred revenue, net of | | | | | |

Recent Dividends:

1. **Inspired Entertainment Inc deferred non-voting shares.**
No dividends paid.
 2. **Inspired Entertainment Inc class B non-voting shares.**
No dividends paid.
 3. **Inspired Entertainment Inc common.**
No dividends paid.
 4. **Inspired Entertainment Inc Class B2 non-voting shares.**
No dividends paid.
 5. **Inspired Entertainment Inc class A voting shares.**
No dividends paid.
 6. **Inspired Entertainment Inc Class B3 voting shares.**
No dividends paid.
 7. **Inspired Entertainment Inc class B1 non-voting shares.**
No dividends paid.
- Annual Dividends:**
1. **Inspired Entertainment Inc deferred non-voting shares.**
No dividends paid.
 2. **Inspired Entertainment Inc class B non-voting shares.**
No dividends paid.
 3. **Inspired Entertainment Inc common.**
No dividends paid.
 4. **Inspired Entertainment Inc Class B2 non-voting shares.**
No dividends paid.
 5. **Inspired Entertainment Inc class A voting shares.**
No dividends paid.
 6. **Inspired Entertainment Inc Class B3 voting shares.**
No dividends paid.
 7. **Inspired Entertainment Inc class B1 non-voting shares.**
No dividends paid.

INTELGEX TECHNOLOGIES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------|------------|-----------|
| Revenues | 1,039,000 | 950,000 | 1,535,000 |
| Total revenues | 1,039,000 | 950,000 | 1,535,000 |
| Cost of royalty, license & other revenue | 1,733,000 | | |
| Research & development expenses | 3,274,000 | 3,031,000 | 2,717,000 |
| Manufacturing expense | | 1,858,000 | 2,256,000 |
| Selling, general & administrative expenses | 4,757,000 | 4,697,000 | 3,753,000 |
| Depreciation of tangible assets | 766,000 | 777,000 | 791,000 |
| Total expenses | 10,530,000 | 10,363,000 | 9,517,000 |
| Operating income | | | |

¹ Approximately; ² As of March 13, 2023; ³ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-------------|
| Cash | 40,000,000 | 25,000,000 |
| Trade receivables | 39,800,000 | 44,600,000 |
| Less: long term receivable recorded in other assets | | (3,000,000) |
| Finance lease receivables | 1,900,000 | 200,000 |
| Allowance for doubtful accounts | 1,100,000 | 1,300,000 |
| Accounts receivable, net | 40,600,000 | 40,500,000 |
| Component parts | 32,300,000 | 21,400,000 |
| Work in progress | 400,000 | 3,600,000 |
| Finished goods | 8,600,000 | 6,000,000 |
| Component parts | 23,300,000 | |
| Inventory, net | | 31,000,000 |
| Fair value of hedging instrument | 24,000,000 | |
| Prepaid expenses & other assets | 15,600,000 | 13,900,000 |

| | | | | | | | | | | |
|--|--------------------|---------------------|--------------------|--|------------|------------|---|----------------|---------------|------------------|
| (loss) | (9,491,000) | (9,413,000) | (7,982,000) | equipment, net | 3,958,000 | 4,425,000 | services | ... | 3,908,205 | 3,709,348 |
| Interest income | 41,000 | ... | ... | Security deposits | 250,000 | 245,000 | Cost of revenues - storage & retrieval services | ... | 353,817 | 378,465 |
| Finance & interest income | ... | 4,000 | 152,000 | Operating lease right-of-use-asset | 633,000 | 732,000 | Total cost of revenues | 6,322,426 | 5,107,770 | 4,517,283 |
| Financing & interest expense | 1,625,000 | 1,281,000 | 1,488,000 | Total assets | 8,282,000 | 9,190,000 | Gross profit (loss) | 10,563,955 | 8,909,158 | 6,942,982 |
| Gain on debt extinguishment | 1,148,000 | ... | ... | Accounts payable & accrued liabilities | 2,661,000 | 2,102,000 | General & administrative expenses | 6,455,088 | 4,945,214 | 4,044,296 |
| Net financing & interest expense | (436,000) | (1,277,000) | (1,336,000) | Current portion of operating lease liability | 248,000 | 236,000 | Change in fair value of earnout liabilities | ... | 87,652 | 141,414 |
| Income (loss) before income taxes .. | (9,927,000) | (10,690,000) | (9,318,000) | Current portion of finance lease liability | 90,000 | 36,000 | Transaction costs | ... | 355,281 | ... |
| Deferred income tax .. | ... | ... | (6,000) | Deferred revenue | 1,118,000 | ... | Sales & marketing expenses | 2,026,871 | 1,971,493 | 1,378,352 |
| Net income (loss) | (9,927,000) | (10,690,000) | (9,312,000) | Convertible debentures | 2,557,000 | ... | Depreciation & amortization expenses | 974,527 | 722,197 | 413,932 |
| Weighted average shares outstanding - basic | 174,654,565 | 164,746,054 | 137,003,313 | Term loan | 500,000 | ... | Total operating expenses | 9,456,486 | 8,081,837 | 5,977,994 |
| Weighted average shares outstanding - diluted | 174,654,565 | 164,746,054 | 137,003,313 | Accrued interest expense | 1,249,000 | ... | Income (loss) from operations | 1,107,469 | 827,321 | 964,988 |
| Year end shares outstanding | 174,658,096 | 174,646,196 | 154,571,289 | Total current liabilities | 8,423,000 | 2,374,000 | Gain on extinguishment of debt | ... | ... | 845,083 |
| Net earnings (loss) per common share - basic | \$(0.06) | \$(0.07) | \$(0.07) | Loans payable | 7,401,000 | 5,500,000 | Interest expense, net | 588,203 | 803,294 | 452,120 |
| Net earnings (loss) per common share - diluted | \$(0.06) | \$(0.07) | \$(0.07) | Convertible notes | 4,438,000 | 4,272,000 | Total other income (expense), net | ... | (803,294) | 392,963 |
| Number of common stockholders | 49 | 48 | 48 | Operating lease liability | 230,000 | 425,000 | Income (loss) before income taxes .. | 519,266 | 24,027 | 1,357,951 |
| Foreign currency translation adjustments | ... | 6,000 | ... | Finance lease liability | 37,000 | 42,000 | Net income (loss) | 519,266 | 24,027 | 1,357,951 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(0.06) | ... | ... | Total liabilities | 20,529,000 | 12,613,000 | Weighted average shares outstanding - basic | 4,074,194 | 3,767,299 | 2,822,972 |
| Diluted EPS Excluding ExtraOrd Items | \$(0.06) | ... | ... | Capital stock | 1,000 | 1,000 | Weighted average shares outstanding - diluted | 4,652,058 | 4,295,817 | 3,104,820 |
| | | | | Additional paid-in capital | 68,662,000 | 67,340,000 | Year end shares outstanding | 4,113,621 | 4,073,757 | 2,823,072 |

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 29, 2023; □ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | 2,282,000 | 1,210,000 |
| Short-term investments | ... | 1,317,000 |
| Accounts receivable | 622,000 | 709,000 |
| Prepaid expenses | 223,000 | 137,000 |
| Investment tax credits receivable | 168,000 | 159,000 |
| Security deposits | 75,000 | 194,000 |
| Raw materials | ... | 62,000 |
| Inventory | 71,000 | 62,000 |
| Total current assets | 3,441,000 | 3,788,000 |
| Manufacturing equipment, cost | 2,755,000 | 4,589,000 |
| Less: accumulated depreciation - manufacturing equipment | 2,034,000 | 1,695,000 |
| Laboratory & office equipment, cost | 382,000 | 1,536,000 |
| Less: accumulated depreciation - laboratory & office equipment | ... | 1,117,000 |
| Computer equipment, cost | ... | 152,000 |
| Less: accumulated depreciation - computer equipment | 1,239,000 | 118,000 |
| Leasehold improvements, cost | 3,366,000 | 3,267,000 |
| Less: accumulated depreciation - leasehold improvements | 2,574,000 | 2,189,000 |
| Leasehold improvements, net | 792,000 | 1,078,000 |
| Computer Software | 29,000 | ... |
| Leased improvements & equipment, gross | ... | 9,544,000 |
| Less: accumulated depreciation - leasehold improvements & equipment | ... | 5,119,000 |
| Accumulated Depreciation, Computer Software | 132,000 | ... |
| Leasehold improvements & | | |

Recent Dividends:
1. IntelGenx Technologies Corp common.
No dividends paid.

Annual Dividends:
1. IntelGenx Technologies Corp common.
No dividends paid.

INTELLINETICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------|------------|------------|
| Sale of software | 25,736 | ... | ... |
| Software as a service | 889,135 | ... | ... |
| Software maintenance services | 59,373 | ... | ... |
| Professional services | 4,992,826 | ... | ... |
| Storage and Retrieval Services | 355,356 | ... | ... |
| Revenues - sale of software | 100,260 | 159,084 | 78,450 |
| Revenues - software as a service | ... | 4,017,409 | 1,441,683 |
| Revenues - software maintenance services | 1,407,064 | 1,387,885 | 1,350,470 |
| Revenues - professional services | ... | 7,357,937 | 7,468,716 |
| Revenues - storage & retrieval services | 1,078,414 | 1,094,613 | 1,120,946 |
| Professional services | 9,167,428 | ... | ... |
| Total revenues | 16,886,381 | 14,016,928 | 11,460,265 |
| Third party services | 5,133,215 | ... | ... |
| Cost of revenues - sale of software | ... | 64,577 | 14,828 |
| Cost of revenues - software as a service | ... | 701,433 | 333,001 |
| Cost of revenues - software maintenance services | ... | 79,738 | 81,641 |
| Cost of revenues - professional | | | |

| | | | |
|---|--------|--------|--------|
| per share - basic | \$0.13 | \$0.01 | \$0.48 |
| Net income (loss) per share - diluted | \$0.11 | \$0.01 | \$0.44 |
| Number of full time employees | 171 | 27 | ... |
| Number of part time employees | 31 | 139 | ... |
| Total number of employees | 202 | 166 | 104 |
| Number of common stockholders | 76 | 147 | 75 |
| Earnings per share from continuing operations | \$0.13 | ... | ... |
| Earnings per share from continuing operations | \$0.11 | ... | ... |

□ Stocks increased due to the effect of issuance of stock; □ As of March 23, 2023; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | 1,215,248 | 2,696,481 |
| Accounts receivable, net | 1,850,375 | 1,121,083 |
| Accounts receivable, unbilled | 1,320,837 | 596,410 |
| Parts & supplies, net | 110,272 | 73,221 |
| Other contract assets | ... | 80,378 |
| Prepaid expenses & other current assets | 140,165 | 325,466 |
| Prepaid expenses and other current assets | 367,478 | ... |
| Total current assets | 5,004,375 | 4,893,039 |
| Computer hardware & purchased software | 324,296 | 1,595,652 |
| Leasehold improvements | 395,919 | 395,918 |
| Furniture & fixtures | ... | 71,325 |
| Computer hardware and purchased software | 1,437,023 | ... |
| Right of Use Tangible | | |

| | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | |
|---|--------------|--------------|---|------------|-----------|--|----------|---------|----------|
| | | | 2023 | 2022 | 2021 | | | | |
| | | | | (revised) | | | | | |
| Assets - Capital/Finance | | | | | | Revenue, net | 13,940 | 7,493 | 7,478 |
| Lease - Gross | 268,600 | ... | | | | Cost of revenue | 7,381 | 3,632 | 3,420 |
| Property & equipment, gross | 2,157,238 | 2,062,895 | 13,709,377 | 13,099,377 | 3,410,103 | Gross profit | 6,559 | 3,861 | 4,058 |
| Right of Use Tangible Assets - Capital/Finance | | | | | | Engineering, research & development | | | |
| Lease - Accumulated | | | 13,709,377 | 13,099,377 | 3,410,103 | Selling, general & administrative | 4,672 | 3,309 | 3,244 |
| Depreciation | 48,823 | ... | 13,709,377 | 3,410,103 | 3,410,103 | Total operating expenses | 6,998 | 4,529 | 4,137 |
| Less: accumulated depreciation | 1,232,981 | 994,189 | | | | Income (loss) from operations | (439) | (668) | (79) |
| Property & equipment, net | 924,257 | 1,068,706 | | | | Other income (expense), net | 164 | 2,611 | (50) |
| Right of use assets, operating | 2,532,928 | 3,200,191 | | | | Total other income (expense), net | 164 | ... | ... |
| Right of use asset, finance | 219,777 | 154,282 | | | | Income (loss) before income tax provision (benefit) - domestic | ... | (1,363) | 921 |
| Intangible assets, net | 3,909,338 | 4,419,646 | | | | Income (loss) before income tax provision (benefit) - foreign | ... | 580 | 792 |
| Goodwill | 5,789,821 | 5,789,821 | | | | Income (loss) before income taxes | (275) | 1,943 | (129) |
| Other assets | 645,764 | 417,457 | | | | Current federal income taxes (benefit) | 27 | 254 | (113) |
| Total assets | 19,026,260 | 19,943,142 | | | | Current state income taxes (benefit) | 10 | 13 | 1 |
| Accounts payable | 194,454 | 370,300 | | | | Current foreign income taxes (benefit) | 154 | 130 | 198 |
| Accrued compensation | 337,884 | 411,683 | | | | Total current income taxes (benefit) | 191 | 397 | 86 |
| Accrued expenses | 164,103 | 114,902 | | | | Deferred federal income taxes (benefit) | ... | ... | 267 |
| Lease liabilities, operating - current | 712,607 | 692,074 | | | | Deferred state income taxes (benefit) | ... | ... | 253 |
| Lease liability, finance - current | 49,926 | 22,493 | | | | Deferred foreign income taxes (benefit) | (83) | (126) | (1) |
| Deferred revenues | 2,927,808 | 2,754,064 | | | | Total deferred income taxes (benefit) | (83) | (126) | 519 |
| Earnout liabilities - current | ... | 700,000 | | | | Income tax expense (benefit) | 108 | 271 | 605 |
| Notes payable - current | ... | 936,966 | | | | Net income (loss) Less: preference stock dividends | 400 | 400 | 48 |
| Total current liabilities | 4,386,782 | 6,002,482 | | | | Net income (loss) applicable to common stockholders | (783) | 1,272 | (782) |
| Unrelated notes | ... | 2,364,500 | | | | Weighted average shares outstanding - basic | 9,887 | 22,285 | 22,278 |
| Notes | ... | 980,450 | | | | Weighted average shares outstanding - diluted | 9,887 | 22,285 | 22,278 |
| Total notes payable | 560,602 | 3,344,950 | | | | Year end shares outstanding | 9,860 | 22,309 | 22,282 |
| Less unamortized debt issuance costs | ... | (300,904) | | | | Income (loss) per share from continuing operations - basic | \$(0.08) | ... | ... |
| Less unamortized debt discount | ... | (22,045) | | | | Net earnings (loss) per share - basic | \$(0.08) | \$0.06 | \$(0.04) |
| Less current portion | ... | 936,966 | | | | Income (loss) per share from continuing operations - diluted | \$(0.08) | ... | ... |
| Notes payable - related party | ... | 529,084 | | | | Net earnings (loss) per share - diluted | \$(0.08) | ... | ... |
| Lease liabilities, operating - net of current portion | 1,942,970 | 2,624,608 | | | | Net income (loss) per share - diluted | \$(0.08) | \$0.06 | \$(0.04) |
| Lease liability, finance - net of current portion | 175,943 | 133,131 | | | | Number of full time employees | 107 | 98 | 89 |
| Total long-term liabilities | 4,888,757 | 5,371,858 | | | | | | | |
| Total liabilities | 9,275,539 | 11,374,340 | | | | | | | |
| Common stock | 4,114 | 4,074 | | | | | | | |
| Additional paid-in capital | 30,841,630 | 30,179,017 | | | | | | | |
| Retained earnings (accumulated deficit) | (21,095,023) | (21,614,289) | | | | | | | |
| Total stockholders' equity (deficit) | 9,750,721 | 8,568,802 | | | | | | | |
| Total Equity | 9,750,721 | ... | | | | | | | |

| Recent Dividends: | | | Annual Dividends: | | |
|---|-------------|-------------|------------------------------|--|--|
| 1. Intellinetics Inc common. | | | 1. Intellinetics Inc common. | | |
| No dividends paid. | | | No dividends paid. | | |
| INTENSITY THERAPEUTICS INC | | | | | |
| Annual Report | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | |
| | 2023 | 2022 | 2021 | | |
| | | (revised) | | | |
| Research & development costs | 4,786,000 | 5,132,000 | 5,856,499 | | |
| General & administrative costs | 3,533,000 | 2,418,000 | 2,157,223 | | |
| Total operating expenses | 8,319,000 | 7,550,000 | 8,013,722 | | |
| Income (loss) from operations | (8,319,000) | (7,550,000) | (8,013,722) | | |
| Interest income | 324,000 | 2,000 | 2,609 | | |
| Other income | 24,000 | 48,000 | 115,513 | | |
| Preferred stock deemed dividend | 1,324,000 | ... | ... | | |

| Recent Dividends: | | | Annual Dividends: | | |
|--|-------------|-------------|---------------------------------------|--|--|
| 1. Intensity Therapeutics Inc common. | | | 1. Intensity Therapeutics Inc common. | | |
| No dividends paid. | | | No dividends paid. | | |
| INTERLINK ELECTRONICS INC | | | | | |
| Annual Report | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$000): | | | | | |
| | 2023 | 2022 | 2021 | | |
| | | (revised) | | | |
| Research & development costs | 4,786,000 | 5,132,000 | 5,856,499 | | |
| General & administrative costs | 3,533,000 | 2,418,000 | 2,157,223 | | |
| Total operating expenses | 8,319,000 | 7,550,000 | 8,013,722 | | |
| Income (loss) from operations | (8,319,000) | (7,550,000) | (8,013,722) | | |
| Interest income | 324,000 | 2,000 | 2,609 | | |
| Other income | 24,000 | 48,000 | 115,513 | | |
| Preferred stock deemed dividend | 1,324,000 | ... | ... | | |

| | | | | Annual Report | | | | | | | |
|--|----------|--------------------|-----------------|--|-------------|------------------|------------------|---|------------|------------|--|
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| | | | | 2023 | 2022 | 2021 | | | | | |
| | | | | (revised) | | | | | | | |
| Total number of employees..... | 107 | □ | □ | Sale of product | 12,267,385 | 11,181,988 | 9,661,942 | disposal costs, net | 6,611 | 228,125 | |
| Number of common stockholders..... | 24 | □ ²³ | □ ²⁶ | Total revenue | 12,267,385 | ... | ... | Financing lease right-of-use asset | ... | 12,621 | |
| Foreign currency translation adjustments | (194) | □ | □ | Cost of product | 4,888,409 | 4,891,927 | 3,924,142 | Operating lease right-of-use asset | 2,183,988 | 2,311,082 | |
| Revenue, net | 13,940 | □ | □ | Gross profit (loss) | 7,378,976 | 6,290,061 | 5,737,800 | Goodwill | 1,384,255 | 1,384,255 | |
| □ Reclassified to conform with 2022 presentation; □ Adjusted for 50% stock dividend, March 25, 2024; □ As is | | | | Salaries & contract labor expenses | 4,032,155 | 3,390,652 | 2,687,735 | Patents & other intangibles, net | 3,538,458 | 3,703,353 | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | | General, administrative & consulting expenses .. | 3,545,766 | 3,568,590 | 3,459,143 | Capitalized lease disposal costs, net | 688,462 | ... | |
| | 2023 | 2022 | | Research & development expense . | 577,354 | 533,716 | 271,714 | Total long-term assets | 11,147,603 | 10,503,971 | |
| Cash & cash equivalents | 4,304 | 10,091 | | Total operating expenses | 8,155,275 | 7,492,958 | 6,418,592 | Total assets | 16,905,087 | 16,244,596 | |
| Accounts receivable, net | 2,167 | 1,178 | | Operating income (loss) | (776,299) | (1,202,897) | (680,792) | Accounts payable | 559,597 | 382,392 | |
| Raw materials | 1,986 | 1,632 | | Other income | 160,173 | 2,110,576 | 683,253 | Accrued liabilities | 1,482,179 | 1,472,504 | |
| Work-in-process | 232 | 192 | | Interest income | 78,890 | 9,502 | 111 | Unearned revenue | 932,682 | 879,365 | |
| Finished goods | 258 | 285 | | Interest expense | 331,780 | 613,943 | 791,532 | Current portion of operating lease right-of-use liability | 140,733 | 131,572 | |
| Inventories | 2,476 | □ ^{2,112} | | Net Income Before Taxes | (869,016) | ... | ... | Current portion of financing lease liability | 2,832 | 5,513 | |
| Prepaid expenses & other current assets | 381 | 321 | | Total other income (expense) | (92,717) | 1,506,135 | (108,168) | Current portion of related party notes payable, net of debt discount | ... | 620,000 | |
| Total current assets | 9,328 | 13,702 | | Net income (loss) attributable to noncontrolling interest | ... | ... | (113,387) | Current installments of notes payable | 155,733 | 23,348 | |
| Furniture, machinery & equipment | 2,009 | 1,688 | | International Isotopes Inc. | ... | 303,238 | (902,347) | Total current liabilities | 3,273,756 | 3,514,694 | |
| Leasehold improvements | 412 | 417 | | Weighted average shares outstanding - basic | 517,777,847 | 510,794,145 | 477,723,996 | Accrued long-term liabilities | 75,000 | 112,500 | |
| Property & equipment, gross | 2,421 | 2,105 | | Weighted average shares outstanding - diluted | 517,777,847 | 510,794,145 | 477,723,996 | Related party notes payable, net of current portion & debt discount | 1,620,000 | 1,000,000 | |
| Less: accumulated depreciation | 2,108 | 1,921 | | Year end shares outstanding | 519,787,870 | 514,889,916 | 502,584,176 | Notes payable, net of current portion | 270,732 | 34,406 | |
| Property, plant & equipment, net | 313 | 184 | | Net income (loss) per share - basic | ... | \$0.00 | \$0.00 | Asset retirement obligation | 1,474,463 | 942,378 | |
| Intangible assets, net | 2,654 | 76 | | Net income (loss) per share - diluted | ... | \$0.00 | \$0.00 | Financing lease liability, net of current portion | ... | 2,832 | |
| Goodwill | 2,461 | 650 | | Number of full time employees | 40 | 32 | 30 | Operating lease right-of-use liability, net of current portion | 2,091,511 | 2,232,244 | |
| Right-of-use assets | 143 | 172 | | Total number of employees | 40 | 33 | 32 | Mandatorily redeemable convertible preferred stock, net of current portion & discount | 4,063,000 | 4,063,000 | |
| Deferred tax assets | 83 | 134 | | Number of common stockholders | 486 | □ ⁴⁹⁰ | □ ⁵⁰³ | Total long-term liabilities | 9,594,706 | 8,387,360 | |
| Other assets | 80 | 65 | | □ Reclassified to conform with 2022 presentation; □ As of March 11, 2023; □ As of March 22, 2021 | | | | Total liabilities | 12,868,462 | 11,902,054 | |
| Total assets | 15,062 | 14,983 | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | | |
| Accounts payable | 464 | 273 | | 2023 | 2022 | | | | | | |
| Accrued wages & benefits | 204 | 320 | | Cash & cash equivalents | 2,688,141 | 2,375,817 | | | | | |
| Accrued vacation | 185 | 223 | | Accounts receivable, gross | 1,469,298 | ... | | | | | |
| Accrued other liabilities | 103 | 25 | | Accounts receivable | 1,469,298 | 1,596,886 | | | | | |
| Accrued liabilities | 492 | 568 | | Work in progress | ... | 744,793 | | | | | |
| Lease liabilities, current | 126 | 131 | | Inventories | 927,111 | 744,793 | | | | | |
| Accrued income taxes | 293 | 117 | | Prepays & other current assets | 672,934 | 1,023,129 | | | | | |
| Total current liabilities | 1,375 | 1,089 | | Total current assets | 5,757,484 | 5,740,625 | | | | | |
| Lease liabilities, long term | 33 | 46 | | Restricted cash | 880,752 | 840,049 | | | | | |
| Deferred tax liabilities | 626 | ... | | Furniture & fixtures | 287,463 | 284,020 | | | | | |
| Total long-term liabilities | 659 | 46 | | Transportation equipment | 114,708 | 114,708 | | | | | |
| Total liabilities | 2,034 | 1,135 | | Plant & improvements | 526,205 | 501,334 | | | | | |
| Series A convertible preferred stock | ... | 2 | | Production equipment | 4,569,980 | 3,997,193 | | | | | |
| Common stock | 10 | 7 | | Property, plant & equipment, gross | 5,498,356 | 4,897,255 | | | | | |
| Additional paid-in-capital | 62,279 | 62,617 | | Less accumulated depreciation | 3,033,279 | 2,872,769 | | | | | |
| Accumulated other comprehensive income (loss) | 200 | (98) | | Property, plant & equipment, net | 2,465,077 | 2,024,486 | | | | | |
| Accumulated deficit | (49,463) | ... | | Capitalized lease | | | | | | | |
| Retained earnings (accumulated deficit) | ... | (48,680) | | | | | | | | | |
| Preferred Stock | 2 | ... | | | | | | | | | |
| Total stockholders' equity | 13,028 | 13,848 | | | | | | | | | |
| Rep Total Equity & Minority Interest | 13,028 | ... | | | | | | | | | |
| | | | | Recent Dividends: | | | | | | | |
| | | | | 1. International Isotopes Inc common. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 2. Interlink Electronics Inc series A convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | Annual Dividends: | | | | | | | |
| | | | | 1. International Isotopes Inc series C redeemable convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 2. International Isotopes Inc series B mandatorily redeemable convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 3. International Isotopes Inc common. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | INTERNATIONAL STEM CELL CORP | | | | | | | |
| | | | | Annual Report | | | | | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | | |
| | | | | 2023 | 2022 | 2021 | | | | | |
| | | | | (revised) | | | | | | | |

| | | | |
|--|------------------|------------------|------------------|
| Product sales | 7,789,000 | 8,180,000 | 7,176,000 |
| Total revenue | 7,789,000 | ... | ... |
| Cost of sales | 3,181,000 | 3,269,000 | 2,935,000 |
| Research & development | 511,000 | 492,000 | 695,000 |
| Selling & marketing | 1,246,000 | 1,245,000 | 1,383,000 |
| General & administrative | 3,514,000 | 3,357,000 | 4,084,000 |
| Total operating expenses | 8,452,000 | 8,363,000 | 9,097,000 |
| Income (loss) from operations | (663,000) | (183,000) | (1,921,000) |
| Gain on forgiveness of debt | ... | ... | 1,137,000 |
| Interest expense | 139,000 | 135,000 | 128,000 |
| Other income (expense), net | 8,000 | (13,000) | 13,000 |
| Miscellaneous income (expense) | 663,000 | ... | ... |
| Total other income (expense), net | 532,000 | (148,000) | 1,022,000 |
| Income (loss) before provision for income taxes | (131,000) | ... | ... |
| Net income (loss) | (131,000) | (331,000) | (899,000) |
| Weighted average common shares outstanding - basic | 8,004,389 | 8,004,000 | 7,833,000 |
| Weighted average common shares outstanding - diluted | 8,004,389 | 8,004,000 | 7,833,000 |
| Year end common shares outstanding | 8,004,389 | 8,004,389 | 8,004,389 |
| Net income (loss) per common share - basic | \$(0.02) | \$(0.04) | \$(0.11) |
| Net income (loss) per common share - diluted | \$(0.02) | \$(0.04) | \$(0.11) |
| Number of full time employees | 29 | 29 | 29 |
| Number of part time employees | ... | 2 | ... |
| Total number of employees | 29 | ... | ... |
| Number of common stockholders | 632 | 636 | 636 |
| Number of preferred stockholders | ... | 4 | 7 |
| Net loss per common share - basic and diluted | \$(0.02) | ... | ... |
| Net loss per common share - diluted | \$(0.02) | ... | ... |

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | ... | 742,000 |
| Accounts receivable, gross | ... | 750,000 |
| Less: allowance for doubtful accounts | ... | 3,000 |
| Accounts receivable, net | 574,000 | 747,000 |
| Raw materials | ... | 615,000 |
| Work in process | ... | 498,000 |
| Finished goods | ... | 1,194,000 |
| Inventory, gross | ... | 2,307,000 |
| Less: allowance for inventory excess & obsolescence | ... | 637,000 |
| Total current & non-current inventory, net | ... | 1,670,000 |
| Non-current inventory | ... | (286,000) |
| Inventories | 1,263,000 | ... |
| Inventory, net | ... | 1,384,000 |
| Prepaid expenses & other current assets | 96,000 | 90,000 |
| Cash | 1,588,000 | ... |
| Total current assets | 3,521,000 | 2,963,000 |

| | | |
|---|---------------|---------------|
| Non-current inventory, net | 266,000 | 286,000 |
| Machinery & equipment | 1,602,000 | 1,603,000 |
| Computer equipment & software | 89,000 | 217,000 |
| Office equipment | 221,000 | 89,000 |
| Leasehold improvements | 617,000 | 558,000 |
| Construction in progress | 12,000 | ... |
| Property & equipment, gross | 2,541,000 | 2,467,000 |
| Less: accumulated depreciation & amortization | 2,326,000 | 2,219,000 |
| Property & equipment, net | 215,000 | 248,000 |
| Intangible assets, net | 800,000 | 878,000 |
| Right-of-use assets | 557,000 | 727,000 |
| Deposits & other assets | 31,000 | 33,000 |
| Total assets | 5,390,000 | 5,135,000 |
| Accounts payable | 364,000 | 322,000 |
| Accrued liabilities | 485,000 | 508,000 |
| Operating lease liabilities, current | 276,000 | 230,000 |
| Advances | 250,000 | 250,000 |
| Related party note payable | 3,457,000 | 3,325,000 |
| Total current liabilities | 4,832,000 | 4,635,000 |
| Operating lease liabilities, net of current portion | 445,000 | 720,000 |
| Total liabilities | 5,277,000 | 5,355,000 |
| Series D redeemable convertible preferred stock | 4,300,000 | 4,300,000 |
| Non-redeemable convertible preferred stock | 5,000 | 5,000 |
| Common stock | 8,000 | 8,000 |
| Additional paid-in capital | 106,276,000 | 105,812,000 |
| Accumulated deficit | (110,476,000) | ... |
| Retained earnings (accumulated deficit) | ... | (110,345,000) |
| Total stockholders' equity (deficit) | (4,187,000) | (4,520,000) |
| Total Equity | (4,187,000) | ... |

Recent Dividends:

- 1. International Stem Cell Corp series H-2 convertible preferred.**
No dividends paid.
 - 2. International Stem Cell Corp series G convertible redeemable preferred.**
No dividends paid.
 - 3. International Stem Cell Corp series A preferred.**
No dividends paid.
 - 4. International Stem Cell Corp preferred.**
No dividends paid.
 - 5. International Stem Cell Corp series H-1 convertible preferred.**
No dividends paid.
 - 6. International Stem Cell Corp series I-2 non-redeemable convertible preferred.**
No dividends paid.
 - 7. International Stem Cell Corp series D redeemable convertible preferred.**
No dividends paid.
 - 8. International Stem Cell Corp series C preferred.**
No dividends paid.
 - 9. International Stem Cell Corp series B non-redeemable convertible preferred.**
No dividends paid.
 - 10. International Stem Cell Corp common.**
No dividends paid.
 - 11. International Stem Cell Corp series I-1 non-redeemable convertible preferred.**
No dividends paid.
 - 12. International Stem Cell Corp series G non-redeemable convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. International Stem Cell Corp series H-2 convertible preferred.**
No dividends paid.

- 2. International Stem Cell Corp series G convertible redeemable preferred.**
No dividends paid.
- 3. International Stem Cell Corp series A preferred.**
No dividends paid.
- 4. International Stem Cell Corp preferred.**
No dividends paid.
- 5. International Stem Cell Corp series H-1 convertible preferred.**
No dividends paid.
- 6. International Stem Cell Corp series I-2 non-redeemable convertible preferred.**
No dividends paid.
- 7. International Stem Cell Corp series D redeemable convertible preferred.**
No dividends paid.
- 8. International Stem Cell Corp series C preferred.**
No dividends paid.
- 9. International Stem Cell Corp series B non-redeemable convertible preferred.**
No dividends paid.
- 10. International Stem Cell Corp common.**
No dividends paid.
- 11. International Stem Cell Corp series I-1 non-redeemable convertible preferred.**
No dividends paid.
- 12. International Stem Cell Corp series G non-redeemable convertible preferred.**
No dividends paid.

**INTERPACE BIOSCIENCES INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|-------------|-------------|
| | | | □ (revised) |
| Revenue, net | 40,214,000 | ... | ... |
| Revenue, net | 40,214,000 | 31,838,000 | 33,117,000 |
| Cost of revenue | 16,310,000 | 13,607,000 | 14,314,000 |
| Gross profit | 23,904,000 | 18,231,000 | 18,803,000 |
| Sales & marketing expenses | 10,233,000 | 9,125,000 | 9,177,000 |
| Research & development expenses | 636,000 | 703,000 | 1,493,000 |
| General & administrative expenses | ... | 10,973,000 | 10,705,000 |
| Transition expense | ... | ... | 897,000 |
| Loss on MiamiR transaction | ... | ... | 13,000 |
| Other selling, general & administrative expenses | 9,363,000 | ... | ... |
| Acquisition related amortization expense | 861,000 | 1,270,000 | 3,192,000 |
| Change in fair value of contingent consideration | 7,000 | (223,000) | (338,000) |
| Total operating expenses | 21,100,000 | 21,848,000 | 25,139,000 |
| Operating income (loss) from continuing operations | 2,804,000 | (3,617,000) | (6,336,000) |
| Interest accretion expense | 112,000 | 158,000 | 496,000 |
| Related party interest | ... | ... | 424,000 |
| Note payable interest | 896,000 | 850,000 | 120,000 |
| Other income (expense), net | (667,000) | (1,211,000) | (366,000) |
| Income (loss) from continuing operations before tax | 1,129,000 | (5,836,000) | (7,742,000) |
| Current provision (benefit) for state income taxes | 17,000 | 29,000 | (705,000) |
| Total current provision (benefit) for income taxes | 17,000 | 29,000 | (705,000) |
| Provision (benefit) | | | |

| | | | |
|--|----------------|---------------------|---------------------|
| for income taxes | 17,000 | 29,000 | (705,000) |
| Income (loss) from continuing operations | 1,112,000 | (5,865,000) | (7,037,000) |
| Income (loss) from discontinued operations, net of tax | (310,000) | (16,093,000) | (7,906,000) |
| Net income (loss) | 802,000 | (21,958,000) | (14,943,000) |
| Net income (loss) attributable to common stockholders | ... | (21,958,000) | (14,943,000) |
| Weighted average shares outstanding - basic | 4,317,000 | 4,238,000 | 4,135,000 |
| Weighted average shares outstanding - diluted | 4,364,000 | 4,238,000 | 4,135,000 |
| Year end shares outstanding | 4,351,445 | 4,296,710 | 4,195,412 |
| Income (loss) per share from continuing operations - basic | \$0.26 | \$(1.38) | \$(1.70) |
| Earnings per share-inc from discontinued oper | \$(0.07) | ... | ... |
| Income (loss) per share from discontinued operations - basic | \$(0.07) | \$(3.80) | \$(1.91) |
| Net income (loss) per share - basic | \$0.19 | \$(5.18) | \$(3.61) |
| Income (loss) per share from continuing operations - diluted | \$0.25 | \$(1.38) | \$(1.70) |
| Earn per share-inc from discount opers - diluted | \$(0.07) | ... | ... |
| Income (loss) per share from discontinued operations - diluted | \$(0.07) | \$(3.80) | \$(1.91) |
| Net income (loss) per share - diluted | \$0.18 | \$(5.18) | \$(3.61) |
| Number of full time employees | ... | 294 | ... |
| Total number of employees | ... | 294 | ... |
| Number of common stockholders | 191 | 197 | ... |

¹ Restated to reflect the discontinued operations of Interpace Pharma Solutions, Inc.; ² Approximately; ³ As of February 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------------|------------|------------|
| Cash & cash equivalents | 3,498,000 | 4,828,000 |
| Accounts receivable, gross | 4,983,000 | 5,032,000 |
| Less: allowance for doubtful accounts | ... | 0 |
| Accounts receivable | 4,983,000 | 5,032,000 |
| Lab supplies | 1,227,000 | 1,224,000 |
| Prepaid expenses | 590,000 | 390,000 |
| Funds in escrow | ... | 500,000 |
| Other current assets | ... | 180,000 |
| Other current assets | 1,841,000 | 2,294,000 |
| Other | 24,000 | ... |
| Total current assets | 10,322,000 | 12,154,000 |
| Furniture & fixtures | 69,000 | 69,000 |
| Lab & office equipment | 253,000 | 2,243,000 |
| Computer equipment | 233,000 | 233,000 |
| Internal-use software | ... | 139,000 |
| Leasehold improvements | 269,000 | 175,000 |
| Lab and office equipment | 2,510,000 | ... |
| Property & equipment | 3,334,000 | 2,859,000 |
| Less: accumulated depreciation | 2,544,000 | ... |

| | | | |
|---|---------------|---------------|-----|
| Less: accumulated depreciation & amortization | ... | 2,379,000 | ... |
| Property & equipment, net | 790,000 | 480,000 | ... |
| Other intangible assets, net | ... | 861,000 | ... |
| Operating lease right of use assets | 1,864,000 | 2,439,000 | ... |
| Other long-term assets | 45,000 | 45,000 | ... |
| Total assets | 13,021,000 | 15,979,000 | ... |
| Accounts payable | 1,544,000 | 1,050,000 | ... |
| Accrued income taxes | 261,000 | ... | ... |
| Accrued salary & bonus | 1,969,000 | 1,456,000 | ... |
| Accrued royalties | ... | 4,909,000 | ... |
| Contingent consideration | ... | 569,000 | ... |
| Operating lease liability | 377,000 | 578,000 | ... |
| Accrued sales & marketing - diagnostics | 43,000 | 40,000 | ... |
| Accrued lab costs - diagnostics | 68,000 | 167,000 | ... |
| Accrued professional fees | 241,000 | 641,000 | ... |
| Taxes payable | 455,000 | 262,000 | ... |
| Unclaimed property | 35,000 | 565,000 | ... |
| Upfront Medicare payment | 453,000 | ... | ... |
| Accrued interest | 6,268,000 | ... | ... |
| All others accrued expenses | ... | 688,000 | ... |
| Line of credit - current | ... | 2,500,000 | ... |
| Note payable at fair value, current | 5,100,000 | ... | ... |
| Current liabilities of discontinued operations | 660,000 | 858,000 | ... |
| Total current liabilities | 17,474,000 | 14,283,000 | ... |
| Contingent consideration | ... | 518,000 | ... |
| Operating lease liabilities, net of current portion | 1,472,000 | 1,848,000 | ... |
| Note payable at fair value | 4,243,000 | 11,165,000 | ... |
| Total liabilities | 28,157,000 | 32,515,000 | ... |
| Redeemable preferred stock - series B | 46,536,000 | 46,536,000 | ... |
| Common stock | 405,000 | 405,000 | ... |
| Additional paid-in capital | 188,146,000 | 187,516,000 | ... |
| Retained earnings (accumulated deficit) | (248,215,000) | (249,017,000) | ... |
| Treasury stock | 2,008,000 | 1,976,000 | ... |
| Total stockholders' equity (deficit) | (61,672,000) | (63,072,000) | ... |

Recent Dividends:

1. Interpace Biosciences Inc series B convertible preferred.

No dividends paid.

2. Interpace Biosciences Inc common.

No dividends paid.

3. Interpace Biosciences Inc series A convertible preferred.

No dividends paid.

Annual Dividends:

1. Interpace Biosciences Inc series B convertible preferred.

No dividends paid.

2. Interpace Biosciences Inc common.

No dividends paid.

3. Interpace Biosciences Inc series A convertible preferred.

No dividends paid.

INTRUSION INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|--------------------------|-----------|-----------|-----------------------------|
| Revenue | 5,611,000 | ... | ... |
| Total revenue | 5,611,000 | 7,529,000 | 7,277,000 |
| Cost of revenue | 1,257,000 | 3,354,000 | 3,621,000 |
| Total cost of revenue | ... | 3,354,000 | 3,621,000 |
| Gross profit (loss) | 4,354,000 | 4,175,000 | 3,656,000 |
| Sales & marketing | 5,670,000 | 6,510,000 | 10,935,000 |
| Research & development | 5,556,000 | 6,465,000 | 6,328,000 |
| General & administrative | 5,174,000 | 7,483,000 | 5,896,000 |
| Operating income | ... | ... | ... |

| | | | |
|--|---------------------|---------------------|---------------------|
| (loss) | (12,046,000) | (16,283,000) | (19,503,000) |
| Interest & other income | 43,000 | 2,028,000 | 722,000 |
| Interest expense | 1,888,000 | 2,359,000 | 21,000 |
| Gain on lease termination | ... | (385,000) | ... |
| Income (loss) before income taxes | (13,891,000) | (16,229,000) | (18,802,000) |
| Net income (loss) | (13,891,000) | (16,229,000) | (18,802,000) |
| Weighted average shares outstanding | | | |
| - basic | 1,212,000 | 989,550 | 899,600 |
| Weighted average shares outstanding - diluted | 1,212,000 | 989,550 | 899,600 |
| Year end shares outstanding | 1,790,000 | 1,059,400 | 956,250 |
| Income (loss) per share from continuing operations - basic | \$(11.46) | ... | ... |
| Net income (loss) per share - basic | \$(11.46) | \$(16.40) | \$(21.00) |
| Income (loss) per share from continuing operations - diluted | \$(11.46) | ... | ... |
| Net income (loss) per share - diluted | \$(11.46) | \$(16.40) | \$(21.00) |
| Number of full time employees | 44 | 63 | 56 |
| Number of part time employees | 5 | 4 | 4 |
| Total number of employees | 49 | 67 | 60 |
| Number of common stockholders | 95 | 89 | 86 |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-20 stock split, March 25, 2024; ³ Approximately; ⁴ As of March 24, 2023; ⁵ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 139,000 | 3,015,000 |
| Accounts receivable | 364,000 | 530,000 |
| Prepaid insurance | ... | 107,000 |
| Prepaid licenses | ... | 98,000 |
| Employee retention credit receivable | ... | 1,363,000 |
| Prepaid maintenance | 635,000 | ... |
| Prepaid other | ... | 309,000 |
| Prepaid expenses & other assets | ... | 1,877,000 |
| Total current assets | 1,138,000 | 5,422,000 |
| Equipment | 2,069,000 | 2,865,000 |
| Capitalized software development | 2,791,000 | 1,380,000 |
| Furniture & fixtures | ... | 43,000 |
| Leasehold improvements | 15,000 | 78,000 |
| Property & equipment, gross | 4,875,000 | 4,366,000 |
| Accumulated depreciation & amortization | 1,955,000 | 2,208,000 |
| Property & equipment, net | 2,920,000 | 2,158,000 |
| Finance leases, right-of-use assets, net | 382,000 | 1,048,000 |
| Operating leases, right-of-use assets, net | 1,637,000 | 504,000 |
| Other assets | 171,000 | 143,000 |
| Total noncurrent assets | 5,110,000 | 3,853,000 |
| Total assets | 6,248,000 | 9,275,000 |
| Accounts payable, trade | ... | 1,273,000 |
| Accounts payable & accrued expenses | 2,215,000 | ... |
| Accrued legal & professional fees | 6,000 | 189,000 |
| Accrued payroll | 141,000 | 195,000 |
| Employee benefits payable | 23,000 | 36,000 |
| Other accrued expenses | 222,000 | 26,000 |
| Accrued expenses | ... | 446,000 |

| | | |
|---|--------------------|--------------------|
| Finance leases liabilities, current portion | 384,000 | 667,000 |
| Operating lease liabilities, current portion | 178,000 | 294,000 |
| Notes payable | 10,823,000 | 10,114,000 |
| Deferred revenue | 439,000 | 455,000 |
| Total current liabilities | 14,261,000 | 13,249,000 |
| Finance lease liabilities, noncurrent portion | 3,000 | 10,000 |
| Operating lease liabilities, noncurrent portion | 1,539,000 | 231,000 |
| Total non-current liabilities | 1,542,000 | 241,000 |
| Common stock | 18,000 | 212,000 |
| Common stock held in treasury, at cost | 362,000 | 362,000 |
| Additional paid-in-capital | 101,049,000 | 92,304,000 |
| Accumulated deficit | (110,217,000) | ... |
| Retained earnings (accumulated deficit) | ... | (96,326,000) |
| Accumulated other comprehensive income (loss) | (43,000) | (43,000) |
| Total stockholders' equity (deficit) | (9,555,000) | (4,215,000) |
| Total Equity | (9,555,000) | ... |

Recent Dividends:

- 1. Intrusion Inc series 3 5% convertible preferred.**
No dividends paid.
 - 2. Intrusion Inc common.**
No dividends paid.
 - 3. Intrusion Inc series 2 5% convertible preferred.**
No dividends paid.
 - 4. Intrusion Inc series 1 5% convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Intrusion Inc series 3 5% convertible preferred.**
No dividends paid.
 - 2. Intrusion Inc common.**
No dividends paid.
 - 3. Intrusion Inc series 2 5% convertible preferred.**
No dividends paid.
 - 4. Intrusion Inc series 1 5% convertible preferred.**
No dividends paid.

**INVESTVIEW INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-------------------|-------------------|-------------------|
| Subscription revenue, net of refunds, incentives, credits, & chargebacks | 56,036,052 | 48,260,197 | 40,918,453 |
| Mining revenue | 11,348,156 | 11,796,215 | 23,056,457 |
| Mining equipment repair revenue | 23,378 | 172,056 | 7,460 |
| Cryptocurrency revenue | 513,285 | 1,614,568 | 8,249,310 |
| Digital wallet revenue | ... | 5,868 | ... |
| Total revenue, net | 67,920,871 | 61,848,904 | 72,231,680 |
| Cost of sales & service | 10,736,709 | 8,249,790 | 6,107,358 |
| Commissions | 31,716,399 | 26,986,048 | 29,127,854 |
| Selling & marketing expenses | 560,065 | 58,617 | 76,662 |
| Salary & related expenses | 7,112,954 | 7,441,829 | 3,946,151 |
| Professional fees | 1,378,367 | 2,615,016 | 1,574,292 |
| Impairment expense | ... | 14,632,823 | 140,233 |
| Bad debt expense | ... | 3,975 | 719,342 |
| Gain (loss) on disposal of assets | (223,630) | 266,838 | 12,927 |
| General & administrative expenses | ... | ... | ... |

| | | | |
|--|----------------------|----------------------|----------------------|
| expenses | 10,740,430 | 58,927,950 | ... |
| Selling, general & administrative expenses | 9,531,431 | ... | ... |
| Impairment loss | 2,056,386 | ... | ... |
| Total operating costs & expenses | 63,315,941 | 70,461,690 | 100,606,915 |
| Net income (loss) from operations | 4,604,930 | (8,612,786) | (28,375,235) |
| Gain (loss) on debt extinguishment | ... | 455 | 571,466 |
| Gain (loss) on fair value of derivative liability | 18,691 | 44,945 | 352,931 |
| Realized gain (loss) on cryptocurrency | 255,268 | (1,575,164) | 1,291,082 |
| Interest expense | 18,750 | 18,750 | 16,660 |
| Interest expense, related parties | ... | 2,650,324 | 2,279,397 |
| Other income (expense) | 1,389,796 | 193,235 | 91,220 |
| Debt discount | (1,239,603) | ... | ... |
| Total other income (expense) | 405,402 | (4,005,603) | 10,642 |
| Income before income taxes - domestic | ... | (12,618,389) | (28,278,452) |
| Income before income taxes - foreign | ... | ... | (86,141) |
| Income (loss) before income taxes | 5,010,332 | (12,618,389) | (28,364,593) |
| Current federal income taxes | 2,138,412 | 52,167 | 797,827 |
| Current state income taxes | 40,000 | 274,388 | 10,000 |
| Total current income tax expense | 2,178,412 | 326,555 | 807,827 |
| Income tax expense (benefit) | 2,178,412 | 326,555 | 807,827 |
| Net income (loss) | 2,831,920 | (12,944,944) | (29,172,420) |
| Dividends on preferred stock | 819,340 | 819,340 | 614,504 |
| Net income (loss) applicable to common shareholders | 2,012,580 | (13,764,284) | (29,786,924) |
| Weighted average shares outstanding - basic | 2,559,093,504 | 2,677,718,626 | 2,986,026,570 |
| Weighted average shares outstanding - diluted | 3,595,522,075 | 2,677,718,626 | 2,986,026,570 |
| Year end shares outstanding | 2,333,356,496 | 2,636,275,489 | 2,904,210,762 |
| Net income (loss) per common share - basic | ... | \$(0.01) | \$(0.01) |
| Net income (loss) per common share - diluted | ... | \$(0.01) | \$(0.01) |
| Number of full time employees | ... | 29 | 33 |
| Number of part time employees | ... | 4 | 4 |
| Total number of employees | ... | 33 | 37 |
| Number of common stockholders | 630 | 730 | 730 |
| Income Taxes - Total | 2,178,412 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------|------------|------------|
| Cash & cash equivalents | 20,912,276 | 20,467,256 |
| Restricted cash, current | 230,354 | 781,537 |
| Prepaid assets | 492,607 | 366,561 |
| Receivables | 2,232,725 | 1,255,542 |
| Inventory | ... | 249,480 |

| | | |
|---|-------------------|-------------------|
| Income tax paid in advance | ... | 535,932 |
| Other current assets | 585,632 | 2,360,957 |
| Total current assets | 24,453,594 | 26,017,265 |
| Furniture, fixtures, & equipment | 717 | 76,716 |
| Computer equipment | 11,308 | 12,869 |
| Leasehold improvements | ... | 40,528 |
| Data processing equipment | ... | 13,200,939 |
| Software | 14,084,670 | ... |
| Fixed assets, gross | 14,096,695 | 13,331,052 |
| Less: accumulated depreciation | 7,559,872 | 4,822,778 |
| Fixed assets, net | 6,536,823 | 8,508,274 |
| Restricted cash, long term | ... | 240,105 |
| Other restricted assets, long term | ... | 113,139 |
| Operating lease right-of-use asset | 110,427 | 223,692 |
| Deposits | 2,588,127 | 473,598 |
| Total assets | 33,688,971 | 35,576,073 |
| Accrued salaries & wages | 187,419 | ... |
| Payroll liabilities | ... | 197,300 |
| Income tax payable | 1,004,535 | 240,603 |
| Customer advance | ... | 96,609 |
| Deferred revenue | 2,703,398 | 2,074,574 |
| Derivative liability | 5,732 | 24,426 |
| Dividend liability | 256,392 | 236,630 |
| Operating lease liability, current | 109,628 | 148,226 |
| Related party payables, net of discounts, current | ... | 1,201,927 |
| Debt, net of discounts, current | 715,127 | 2,938,757 |
| Related party payables | 1,203,247 | ... |
| Total current liabilities | 12,039,571 | 11,767,838 |
| Operating lease liability, long term | 6,048 | 79,432 |
| Less: current portion | 1,162,349 | ... |
| Related party debt, net of discounts, long term | 501,062 | 824,581 |
| Loan with the U.S. small business administration | ... | 543,237 |
| Long term notes for APEX lease buyback | ... | 7,925,166 |
| Total debt, long term portion | ... | 8,468,403 |
| Less: current portion | ... | (2,938,757) |
| Debt, net of discounts, long term | ... | 5,529,646 |
| Accrued liabilities, long term | 1,189,643 | ... |
| Total long term liabilities | 2,859,102 | 6,433,659 |
| Total liabilities | 14,898,673 | 18,201,497 |
| Preferred stock | ... | 252 |
| Common stock | 2,333,356 | 2,636,275 |
| Additional paid in capital | 104,056,807 | 104,350,746 |
| Accumulated other comprehensive income (loss) | (23,218) | (23,218) |
| Accumulated deficit | (87,576,899) | ... |
| Retained earnings (accumulated deficit) | ... | (89,589,479) |
| Preferred stock, par value: \$0.001; 50,000,000 shares authorized, 46,612 and none issued and outstanding as of 30, 2020 and 31, 2020, respectively | 252 | ... |
| Total Investview Inc. stockholders' equity (deficit) | 18,790,298 | 17,374,576 |
| Total stockholders' equity (deficit) | 18,790,298 | ... |

Recent Dividends:

- 1. InvestView Inc series B cumulative redeemable perpetual preferred (stated value: \$25 per share).**
No dividends paid.

[¶] For 9 months due to fiscal year end change; [¶] As of March 24, 2023; [¶] As of March 31, 2022; [¶] Approximately; [¶] As of April 13, 2022

| | | | |
|--|------------|------------|------------|
| Year end shares outstanding | 69,931,056 | 63,110,764 | 53,586,023 |
| Net earnings (loss) per share - basic | \$(0.07) | \$(0.06) | \$(0.02) |
| Net earnings (loss) per share - dilutive | \$(0.07) | \$(0.06) | \$(0.02) |
| Number of common stockholders | 719 | 710 | 705 |
| Financial Income - Total | 2,000 | | |
| Interest Expense/Income - Net | 20,000 | | |
| Net Financial Income/Expense - Other | (1,000) | | |

¹ Shares increased due to the effect private placement of common stock and warrants, net; ² Shares increased due to the effect of issuance of common stock, exercise of warrants, private placement of common stock & warrants; ³ As of March 29, 2022; ⁴ As of January 27, 2021

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|---------|-----------|--|
| | 2023 | 2021 | |
| Cash - NIS | | 59,000 | |
| Cash - US dollars | | 2,756,000 | |
| Cash & cash equivalents | 767,000 | 2,815,000 | |
| Funds in trust | 81,000 | | |
| Prepaid expenses | 30,000 | 1,000 | |
| Government institutions | | 63,000 | |
| Related parties | | 3,000 | |
| Accounts receivable - Balancing value | 51,000 | | |
| Accounts receivable | | 67,000 | |
| Total current assets | 848,000 | | |
| Long term deposits | | 30,000 | |
| Computers equipment | 45,000 | 32,000 | |
| Furniture & equipment | 10,000 | 6,000 | |
| Leasehold improvements | 19,000 | 3,000 | |
| Laboratory equipment | 19,000 | | |
| Property & equipment, gross | 93,000 | 41,000 | |
| Less: accumulated depreciation | | 10,000 | |
| Property, Plant & Equipment - Accumulated Depreciation & Impairment | 37,000 | | |
| Property & equipment, net | 56,000 | 31,000 | |
| Long term restricted deposits | 11,000 | | |
| Right of use assets | 84,000 | | |
| Total non-current assets | 151,000 | 61,000 | |
| Total assets | 999,000 | 2,943,000 | |
| Trade payables | | 58,000 | |
| Accrued expenses | 160,000 | 140,000 | |
| Payroll & related | 98,000 | 129,000 | |
| Related parties | | 65,000 | |
| Other trade & other payable | | 3,000 | |
| Trade & other payables | 473,000 | 395,000 | |
| Accounts Payable | 62,000 | | |
| Trade and other payables - Balancing value | 64,000 | | |
| Advance from customer | 50,000 | | |
| Operating Lease Liabilities - Current | | | |
| Portion/Short-Term | 39,000 | | |
| Total current liabilities | 473,000 | | |
| Stockholders loans | 161,000 | 177,000 | |
| Total non-current liabilities | 161,000 | | |
| Total liabilities | 634,000 | 572,000 | |
| Common Stock, par value \$0001 per share, 250,000,000 shares authorized: 53,586,023 and 30,185,183 issued and outstanding as of 31, 2020 and 2019, | | | |

| | | | |
|---|--------------|-------------|--|
| respectively | 69,000 | | |
| Common stock | | 64,000 | |
| Additional paid in capital | 15,135,000 | 7,503,000 | |
| Accumulated deficit | (14,839,000) | | |
| Retained earnings (accumulated deficit) | | (5,196,000) | |
| Total stockholders' equity (deficit) | 365,000 | 2,371,000 | |
| Total Equity | 365,000 | | |

Recent Dividends:
1. IR Med Inc common.
 No dividends paid.
Annual Dividends:
1. IR Med Inc common.
 No dividends paid.

ITAFOS INC Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|---------------|---------------|---------------|
| | 2023 | 2021 | 2020 |
| Revenues | 465,525,000 | 413,247,000 | 260,185,000 |
| Cost of goods sold | (346,963,000) | (276,372,000) | (267,957,000) |
| Impairments | (66,000,000) | | |
| Write-off of mineral properties | | | (8,449,000) |
| Gross margin (loss) | 52,562,000 | 136,875,000 | 16,221,000 |
| Payroll expenses | | (12,368,000) | (9,794,000) |
| Professional fees | | (4,799,000) | (3,435,000) |
| Share-based payment expense (recovery) | | (4,127,000) | (446,000) |
| Insurance expenses | | (1,136,000) | (1,438,000) |
| Office, travel & general administrative expense | | (2,831,000) | (3,383,000) |
| Directors fees | | (635,000) | (939,000) |
| Operating income (loss) | 24,566,000 | 110,979,000 | (35,656,000) |
| Foreign exchange gain (loss) | (596,000) | (634,000) | (5,394,000) |
| Other income (expense), net | | 541,000 | (1,759,000) |
| Gain (loss) on asset disposal | | (97,000) | (1,209,000) |
| Interest expense | (12,354,000) | (28,572,000) | (27,189,000) |
| Interest capitalized in property, plant & equipment | | | 3,345,000 |
| Amortization of deferred financing costs related to the Credit Facilities | (1,517,000) | (1,260,000) | (1,846,000) |
| Amortization of financing costs of the term loan | | (1,509,000) | |
| Loss on debt extinguishment of the credit facility | | (2,012,000) | |
| Loss on debt extinguishment of the promissory note | | (1,546,000) | |
| Environmental & asset retirement obligation accretion expense | (6,016,000) | (1,159,000) | (1,307,000) |
| Interest on lease liabilities | (1,109,000) | (1,191,000) | (1,046,000) |
| Interest income | 1,435,000 | 5,000 | 13,000 |
| Foreign exchange loss | (175,000) | | |
| Finance income (expense), net | (19,561,000) | (37,244,000) | (28,030,000) |
| Profit (loss) before income taxes | 4,234,000 | 73,545,000 | (72,048,000) |
| Current & deferred income tax expense (recovery) | (1,142,000) | (22,106,000) | 9,742,000 |
| Net income (loss) | 3,092,000 | 51,439,000 | (62,306,000) |
| Net profit (loss) | | | |

| | | | |
|---|-------------|-------------|--------------|
| attributable to non-controlling interest | (769,000) | 411,000 | 754,000 |
| Net profit (loss) attributable to shareholders of the Company | 3,861,000 | 51,028,000 | (63,060,000) |
| Weighted average shares outstanding - basic | 190,009,296 | 186,413,304 | 184,651,199 |
| Weighted average shares outstanding - diluted | 192,714,264 | 189,547,355 | 186,709,113 |
| Year end shares outstanding | 190,608,358 | 186,814,842 | 185,462,284 |
| Basic EPS Excluding ExtraOrdinary Items | \$0.02 | | |
| Net income (loss) per share - basic | \$0.02 | \$0.28 | \$(0.34) |
| Diluted EPS Excluding ExtraOrd Items | \$0.02 | | |
| Net income (loss) per share - diluted | \$0.02 | \$0.27 | \$(0.34) |
| Number of full time employees | | 377 | |
| Number of part time employees | | 383 | |
| Total number of employees | | 760 | |
| Total Revenue | 465,525,000 | | |

¹ Reclassified to conform with 2021 presentation

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|---------------|---------------|
| | 2023 | 2021 |
| Cash & cash equivalents | 30,753,000 | 31,565,000 |
| Accounts receivable | 37,449,000 | 39,688,000 |
| Inventories, net | 119,813,000 | 112,704,000 |
| Other current assets | 10,978,000 | 11,173,000 |
| Tax credits | 4,442,000 | |
| Prepaid expenses | 5,558,000 | |
| Advances to suppliers | 176,000 | |
| Deposits | 292,000 | |
| Other | 510,000 | |
| Total current assets | 198,993,000 | 195,130,000 |
| Long-term inventories, net | 1,307,000 | 1,505,000 |
| Property, plant & equipment, cost | 438,466,000 | 488,864,000 |
| Less: accumulated depreciation | (228,471,000) | (175,791,000) |
| Property, plant & equipment, net | 209,995,000 | 313,073,000 |
| Mineral properties, net | 161,626,000 | 120,746,000 |
| Deferred tax assets, net | 11,082,000 | |
| Other long-term assets | 4,226,000 | 3,399,000 |
| Total non-current assets | 388,236,000 | 438,723,000 |
| Total assets | 587,229,000 | 633,853,000 |
| Trade payables | 31,660,000 | 25,295,000 |
| Taxes payable | 1,224,000 | 13,221,000 |
| Accrued liabilities & other | 15,091,000 | 9,537,000 |
| Payroll & related taxes payable | 10,193,000 | 8,838,000 |
| Rebates | 2,247,000 | 1,028,000 |
| Other payables | 5,904,000 | 3,550,000 |
| Accounts payable & accrued liabilities | 66,319,000 | 61,469,000 |
| Provisions | 6,902,000 | 4,072,000 |
| Current debt | 29,127,000 | 52,838,000 |
| Contract liabilities | 386,000 | 913,000 |
| Other current liabilities | 3,882,000 | 2,544,000 |
| Total current liabilities | 106,616,000 | 114,148,000 |
| Long-term debt | | 187,010,000 |
| Deferred tax liabilities | | 1,670,000 |
| Long-term provisions | 142,713,000 | 170,232,000 |
| Other long-term liabilities | 17,725,000 | 18,500,000 |
| Long-term debentures | 61,441,000 | |
| Total long-term liabilities | 221,879,000 | 385,100,000 |
| Total liabilities | 328,495,000 | 499,248,000 |
| Common shares | 538,727,000 | 532,390,000 |

| | | |
|---|---------------|---------------|
| Share capital | 532,390,000 | |
| Contributed surplus | 246,626,000 | 246,626,000 |
| Cumulative translation adjustment reserve | 4,660,000 | 4,660,000 |
| Retained earnings (deficit) | (531,279,000) | (650,236,000) |
| Shareholders' equity | 258,734,000 | 133,440,000 |
| Non-controlling interest | ... | 1,165,000 |
| Total equity | 258,734,000 | 134,605,000 |
| Total liabilities & equity | 587,229,000 | 633,853,000 |

□ As reported by the Company

Recent Dividends:

1. Itafos Inc common.

No dividends paid.

Annual Dividends:

1. Itafos Inc common.

No dividends paid.

IVEDA SOLUTIONS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|-------------------|
| Equipment sales | 6,052,298 | 4,159,398 | 1,647,996 |
| Service revenue | 443,567 | 308,881 | 264,402 |
| Other revenue | ... | ... | 5,450 |
| Total revenue | 6,495,865 | 4,468,279 | 1,917,848 |
| Cost of revenue | 5,428,261 | 3,504,778 | 1,085,593 |
| Gross profit | 1,067,604 | 963,501 | 832,255 |
| General & administrative expense | 4,478,553 | 4,292,820 | 3,557,603 |
| Total operating expenses | 4,478,553 | 4,292,820 | 3,557,603 |
| Income (loss) from operations | (3,410,949) | (3,329,320) | (2,725,349) |
| Miscellaneous income (expense) | (28,099) | (17,078) | ... |
| Interest income | 131,881 | 57,397 | 354 |
| Interest expense | 7,254 | 53,323 | 273,649 |
| Total other income (expense) | ... | (13,004) | (273,295) |
| Income (loss) before income taxes .. | (3,314,421) | (3,342,324) | (2,998,644) |
| Provision (benefit) for income taxes | 18,308 | 2,947 | ... |
| Joint Venture Non-Controlled Interest | 97,605 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (3,235,124) | ... | ... |
| Net income (loss) | (3,332,729) | (3,345,270) | (2,998,644) |
| Weighted average shares outstanding - basic | 15,973,422 | 12,846,848 | 8,940,367 |
| Weighted average shares outstanding - diluted | 15,973,422 | 12,846,848 | 8,940,367 |
| Year end shares outstanding | 16,169,89 | 15,066,739 | 9,668,369 |
| Net income (loss) per share - basic | \$(0.20) | \$(0.26) | \$(0.34) |
| Net income (loss) per share - diluted | \$(0.20) | \$(0.26) | \$(0.34) |
| Number of full time employees | 32 | 32 | 35 |
| Total number of employees | 32 | ... | ... |
| Number of common stockholders | 103 | 109 | 289 |
| Number of beneficiary stockholders | ... | 700 | 700 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(0.20) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.20) | ... | ... |

□ As reported by the Company; □ Adjusted for 1-for-8 stock split, March 31, 2022; □ Shares increased due to the effect of common stock issued for conversion error and services, exercise of options and warrants and common stock offering for cash; □ Shares increased due to the effect of common stock and pre-funded warrant offering for cash and 8 for 1 conversion adjustment; □ Shares increased due the effect of common stock issued for cash, accounts payable, and cost of financing; and preferred stock - series B shares & dividend payable to common stock; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|-------------------|
| Cash & cash equivalents | 4,754,597 | 7,312,095 | ... |
| Restricted cash | 129,778 | 129,527 | ... |
| Trade receivables, gross | ... | 1,222,690 | ... |
| Allowance for doubtful accounts | ... | 0 | ... |
| Accounts receivable, net | 281,049 | 1,222,690 | ... |
| Inventory | 324,515 | ... | ... |
| Inventory, Net | ... | 526,470 | ... |
| Total current assets | 5,925,520 | 9,562,772 | ... |
| Property & equipment, net | 891,187 | 32,911 | ... |
| Total assets | 7,261,430 | 9,863,070 | ... |
| Accounts payable | ... | 360,395 | ... |
| Accrued expenses | 900,928 | 1,243,027 | ... |
| Deferred revenue & customer deposits | 29,211 | 35,305 | ... |
| Loan agreement with Shanghai Bank | ... | 398,409 | ... |
| Short term debt | 348,771 | 398,409 | ... |
| Current portion of long-term debt | ... | 65,408 | ... |
| Accounts and Other Payables | 1,110,087 | ... | ... |
| Total current liabilities | 1,458,858 | 2,102,544 | ... |
| Loans from Shanghai Bank | ... | 256,184 | ... |
| Less: current portion | ... | (65,408) | ... |
| Long term debt | ... | 190,776 | ... |
| Common Stock, \$0.00001 par value; 37,500,000 shares authorized; 11,677,265 and 9,668,369, shares issued and outstanding as of 30, 2022 and 31, 2021, respectively | 162 | ... | ... |
| Common stock | ... | 150 | ... |
| Additional paid-in capital | 54,065,633 | 52,496,914 | ... |
| Accumulated comprehensive income (loss) | (222,380) | (220,643) | ... |
| Retained earnings (accumulated deficit) during the development stage | (47,941,796) | ... | ... |
| Retained earnings (accumulated deficit) | ... | (44,706,671) | ... |
| Joint Venture Non-Controlled Equity Portion | (99,048) | ... | ... |
| Total stockholders' equity (deficit) | 5,802,572 | 7,569,750 | ... |

Recent Dividends:

1. Iveda Solutions Inc series B preferred.

No dividends paid.

2. Iveda Solutions Inc series A preferred.

No dividends paid.

3. Iveda Solutions Inc common.

No dividends paid.

Annual Dividends:

1. Iveda Solutions Inc series B preferred.

No dividends paid.

2. Iveda Solutions Inc series A preferred.

No dividends paid.

3. Iveda Solutions Inc common.

No dividends paid.

IZEA WORLDWIDE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|--------------|-------------------|
| Revenue | 36,214,598 | ... | ... |
| Revenue | 36,214,598 | 41,095,937 | 30,022,377 |
| Cost of revenue | 21,621,445 | 24,737,699 | 14,461,702 |
| Sales & marketing expenses | 10,547,322 | 9,523,894 | 8,795,038 |
| General & administrative expenses | 13,214,978 | 11,637,044 | 11,034,246 |
| Depreciation | 99,408 | ... | ... |
| Amortization of Intangibles excluding Goodwill .. | 16,067 | ... | ... |
| Amortization of Computer Software .. | 597,660 | ... | ... |
| Depreciation & amortization | 713,135 | 828,161 | 1,089,118 |
| Total costs & expenses | 46,096,880 | (46,726,798) | (35,380,104) |
| Income (loss) from operations | (9,882,282) | (5,630,861) | (5,357,727) |
| Interest expense | 8,226 | 799 | 25,320 |
| Change in fair value of warrant liability | 6,104 | ... | ... |
| Other income (expense), net | 2,535,044 | 1,162,162 | 2,242,426 |
| Net Income Before Taxes | (7,349,360) | ... | ... |
| Total other income (expense), net | ... | 1,161,363 | 2,217,106 |
| Net income (loss) | (7,349,360) | (4,469,498) | (3,140,621) |
| Weighted average shares outstanding - basic | 16,368,216 | 15,549,845 | 15,101,980 |
| Weighted average shares outstanding - diluted | 16,368,216 | 15,549,845 | 15,101,980 |
| Year end shares outstanding | 16,236,300 | 15,603,482 | 15,511,221 |
| Net income (loss) per common share - basic | \$(0.45) | \$(0.28) | \$(0.20) |
| Net income (loss) per common share - diluted | \$(0.45) | \$(0.28) | \$(0.20) |
| Number of full time employees | 152 | 123 | 125 |
| Number of part time employees | 1 | 3 | 6 |
| Total number of employees | 153 | 126 | 131 |
| Number of common stockholders | 99 | 146 | 62,176,505 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(0.45) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.45) | ... | ... |

□ Adjusted for 1-for-4 stock split, June 16, 2023; □ Shares increased due to the effect of sale of securities, stock purchase plan & option exercise issuances, stock issued for payment of services and stock-based compensation; □ Approximately; □ As of March 24, 2023; □ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-----------------------------------|------------|------------|
| Cash & cash equivalents | 37,446,728 | 24,600,960 |
| Accounts receivables, gross | 5,217,373 | 5,819,727 |
| Reserve for allowances | 205,000 | 155,000 |
| Accounts receivable, net | 5,012,373 | 5,664,727 |
| Prepaid expenses | 739,988 | 3,927,453 |
| Short term investments | 17,126,057 | 16,106,758 |
| Other current assets | 26,257 | 66,441 |
| Total current assets | 60,351,403 | 50,366,339 |
| Furniture & fixtures | 29,848 | ... |
| Office equipment | 8,506 | 3,843 |
| Computer equipment | 281,950 | 323,700 |
| Total property & equipment | 320,304 | 327,543 |

| | | | | | | | | | |
|---|--------------|--------------|---|--------------|--------------|--------------|--|-------------|-------------|
| Less accumulated depreciation | 114,927 | 170,769 | Income (loss) from operations | (34,291,000) | (34,415,000) | (40,708,000) | equipment at cost - Balancing value | 18,000 | ... |
| Property & equipment, net of accumulated depreciation | 205,377 | 156,774 | Interest expense | 6,382,000 | 12,723,000 | 8,421,000 | Total property & equipment at cost | 961,000 | 961,000 |
| Goodwill | 5,280,372 | 4,016,722 | Loss on extinguishment of debt | 3,697,000 | (2,187,000) | (753,000) | Less: accumulated depreciation | 465,000 | 404,000 |
| Intangible assets, net | 1,749,441 | 64,953 | Other income (expense), net | 200,000 | 950,000 | (765,000) | Property & equipment, net | 496,000 | 557,000 |
| Software development costs, net | 2,056,972 | 1,774,033 | Change in fair value of financial instruments & hybrid instrument designated at fair value option | (5,125,000) | (20,000) | (1,953,000) | Intangible assets, net | 20,116,000 | 22,439,000 |
| Long term investments | 9,618,996 | 29,296,069 | Income (loss) before income tax expense | (41,901,000) | (48,395,000) | (52,600,000) | Other assets | 1,012,000 | 995,000 |
| Digital assets | 162,905 | ... | Net Income After Extraordinary Items applicable to Common | (41,300,000) | ... | ... | Total assets | 50,763,000 | 47,452,000 |
| Total assets | 79,425,466 | 85,674,890 | Net income (loss) | (41,901,000) | (48,395,000) | (52,600,000) | Accounts payable | 4,974,000 | 5,808,000 |
| Accounts payable | 1,504,348 | 1,968,322 | Net loss attributable to noncontrolling interest | 601,000 | 941,000 | 5,000 | Accrued interest | 2,017,000 | 5,489,000 |
| Accrued payroll liabilities | 2,153,617 | 1,967,677 | Net income (loss) attributable to common stockholders | ... | (47,454,000) | (52,595,000) | Accrued audit & tax services | 162,000 | 575,000 |
| Accrued taxes | 253,677 | 39,405 | Weighted average shares outstanding - basic | 23,068,423 | 1,311,519 | 596,154 | Accrued vacation | 377,000 | 310,000 |
| Current portion of finance obligation | 59,386 | 42,858 | Weighted average shares outstanding - diluted | 23,068,423 | 1,311,519 | 596,154 | Accrued payroll & commission | 208,000 | 263,000 |
| Accrued other expenses | 616,780 | 80,762 | Year end shares outstanding | 73,413,257 | 4,302,870 | 672,978 | Accrued legal costs | 117,000 | 36,000 |
| Accrued expenses | 3,083,460 | 2,130,702 | Net earnings (loss) per share - basic | \$(1.79) | \$(36.18) | \$(88.22) | Accrued local tax | 122,000 | 9,000 |
| Contract liabilities | 114,400 | 11,247,746 | Net earnings (loss) per share - diluted | \$(1.79) | \$(36.18) | \$(88.22) | Accrued payroll | 8,000 | ... |
| Contract Liabilities | 8,891,205 | ... | Full-Time Employees (Period End) | 49 | ... | ... | Accrued payroll tax | 68,000 | 1,000 |
| Total current liabilities | 13,593,413 | 15,346,770 | Total number of employees | 49 | 60 | 52 | Accrued other expenses | 3,798,000 | 1,482,000 |
| Finance obligation, less current portion | ... | 62,173 | Number of common stockholders | 22 | 18 | 28 | Accrued liabilities | ... | 8,165,000 |
| Deferred rent, less current portion | 60,600 | ... | Foreign currency translation adjustments | ... | (680,000) | ... | Operating lease liability, current | 348,000 | 483,000 |
| Notes payable, less current portion | 63,419 | ... | | | | | Notes payable, current | ... | 15,883,000 |
| Deferred tax liability | 394,646 | ... | | | | | Notes payable, net of discount | 4,867,000 | ... |
| Total liabilities | 14,112,078 | 15,408,943 | | | | | Accrued interest | 719,000 | ... |
| Common stock | 1,660 | 6,241 | | | | | Total current liabilities | 13,987,000 | 30,339,000 |
| Additional paid-in capital | 152,027,110 | 149,143,567 | | | | | Operating lease liability, net of current portion | 886,000 | 725,000 |
| Accumulated deficit | (85,444,794) | ... | | | | | Notes payable, net of discount, net of current portion | 30,993,000 | 17,744,000 |
| Retained earnings (accumulated deficit) | ... | (78,103,066) | | | | | Total liabilities | 45,866,000 | 48,808,000 |
| Accumulated other comprehensive income (loss) | (250,591) | (780,795) | | | | | Common stock - voting | 1 | ... |
| Treasury stock | 1,019,997 | ... | | | | | Common stock | 7,000 | ... |
| Total stockholders' equity (deficit) | 65,313,388 | 70,265,947 | | | | | Additional paid-in capital | 313,854,000 | 266,971,000 |
| Total Equity | 65,313,388 | ... | | | | | Noncontrolling interest | (64,000) | (699,000) |

Recent Dividends:

- 1. **IZEA Worldwide Inc series A convertible preferred.**
No dividends paid.
- 2. **IZEA Worldwide Inc common.**
No dividends paid.

Annual Dividends:

- 1. **IZEA Worldwide Inc series A convertible preferred.**
No dividends paid.
- 2. **IZEA Worldwide Inc common.**
No dividends paid.

JAGUAR HEALTH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------|------------|------------|
| | | | (revised) |
| Sales and marketing | 6,460,000 | ... | ... |
| Product revenue | ... | 11,956,000 | 4,335,000 |
| Product | 9,761,000 | ... | ... |
| Total revenue | 9,761,000 | 11,956,000 | 4,335,000 |
| Cost of product | ... | ... | ... |
| Research & development expense | 18,596,000 | 17,647,000 | 15,079,000 |
| Selling & marketing expense | ... | 8,837,000 | 8,894,000 |
| General & administrative expenses | 16,588,000 | 17,868,000 | 17,103,000 |
| Impairment of indefinite-lived intangible assets | 371,000 | ... | ... |
| Series 3 warrants inducement expense | ... | ... | 1,462,000 |
| Equity line of credit, warrants inducement expense | ... | ... | 172,000 |
| Total operating expenses | 44,052,000 | 46,371,000 | 45,043,000 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 6,469,000 | 5,469,000 |
| Accounts receivable | 1,967,000 | 1,879,000 |
| Other receivable | 217,000 | 588,000 |
| Raw material | 2,057,000 | 2,101,000 |
| Work in process | 6,517,000 | 3,599,000 |
| Finished goods | 615,000 | 1,324,000 |
| Inventory | 9,189,000 | 7,024,000 |
| Prepaid expenses & other current assets | 10,121,000 | 7,361,000 |
| Total current assets | 27,963,000 | 22,321,000 |
| Operating lease - right-of-use asset | 1,176,000 | 1,140,000 |
| Land | 396,000 | 396,000 |
| Lab equipment | ... | 477,000 |
| Software | 63,000 | 63,000 |
| Furniture & fixtures | ... | 18,000 |
| Computers & peripherals | 477,000 | 7,000 |
| Computers and peripherals | 7,000 | ... |
| Total property and | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|---------------|---------------|
| equipment at cost - Balancing value | 18,000 | ... |
| Total property & equipment at cost | 961,000 | 961,000 |
| Less: accumulated depreciation | 465,000 | 404,000 |
| Property & equipment, net | 496,000 | 557,000 |
| Intangible assets, net | 20,116,000 | 22,439,000 |
| Other assets | 1,012,000 | 995,000 |
| Total assets | 50,763,000 | 47,452,000 |
| Accounts payable | 4,974,000 | 5,808,000 |
| Accrued interest | 2,017,000 | 5,489,000 |
| Accrued audit & tax services | 162,000 | 575,000 |
| Accrued vacation | 377,000 | 310,000 |
| Accrued payroll & commission | 208,000 | 263,000 |
| Accrued legal costs | 117,000 | 36,000 |
| Accrued local tax | 122,000 | 9,000 |
| Accrued payroll | 8,000 | ... |
| Accrued payroll tax | 68,000 | 1,000 |
| Accrued other expenses | 3,798,000 | 1,482,000 |
| Accrued liabilities | ... | 8,165,000 |
| Operating lease liability, current | 348,000 | 483,000 |
| Notes payable, current | ... | 15,883,000 |
| Notes payable, net of discount | 4,867,000 | ... |
| Accrued interest | 719,000 | ... |
| Total current liabilities | 13,987,000 | 30,339,000 |
| Operating lease liability, net of current portion | 886,000 | 725,000 |
| Notes payable, net of discount, net of current portion | 30,993,000 | 17,744,000 |
| Total liabilities | 45,866,000 | 48,808,000 |
| Common stock - voting | 1 | ... |
| Common stock | 7,000 | ... |
| Additional paid-in capital | 313,854,000 | 266,971,000 |
| Noncontrolling interest | (64,000) | (699,000) |
| Accumulated deficit | (308,248,000) | ... |
| Retained earnings (accumulated deficit) | ... | (266,948,000) |
| Accumulated other comprehensive income (loss) | (652,000) | (680,000) |
| Total stockholders' equity (deficit) | 4,897,000 | (1,356,000) |
| Total Equity | 4,897,000 | ... |

Recent Dividends:

- 1. **Jaguar Health Inc series A convertible preferred.**
No dividends paid.
- 2. **Jaguar Health Inc series B convertible preferred stock.**
No dividends paid.
- 3. **Jaguar Health Inc series I convertible preferred.**
No dividends paid.

- 4. **Jaguar Health Inc common.**
No dividends paid.
- 5. **Jaguar Health Inc convertible non-voting common.**
No dividends paid.
- 6. **Jaguar Health Inc series G convertible preferred.**
No dividends paid.
- 7. **Jaguar Health Inc series B-2 convertible preferred stock.**
No dividends paid.

Annual Dividends:

- 1. **Jaguar Health Inc series A convertible preferred.**
No dividends paid.
- 2. **Jaguar Health Inc series B convertible preferred stock.**
No dividends paid.
- 3. **Jaguar Health Inc series I convertible preferred.**
No dividends paid.
- 4. **Jaguar Health Inc common.**
No dividends paid.
- 5. **Jaguar Health Inc convertible non-voting common.**
No dividends paid.
- 6. **Jaguar Health Inc series G convertible preferred.**
No dividends paid.
- 7. **Jaguar Health Inc series B-2 convertible preferred stock.**
No dividends paid.

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-75 stock split, January 23, 2023; □ Shares increased due to the effect of shares issued in at the market offering, Streteerville and Iliad in exchange of notes, Synworld and other third party for services, vesting and release of stock; □ Shares increased due to the effect of issuance of shares for financing, public offering, extinguishment of exchange, warrants, conversion of Napo merger common, services and exercise of options; □ Approximately; □ As of March 24, 2023; □ As of March 10, 2022

JANONE INC
Annual Report
Consolidated Income Statement, Years Ended (\$000):

| | 12/30/23 | 12/31/22 (revised) | 01/01/22 (revised) |
|---|----------------|-----------------------|-----------------------|
| Revenues | ... | ... | 40,022 |
| Cost of revenues | ... | ... | 31,154 |
| Gross profit | ... | ... | 8,868 |
| Selling, general & administrative expenses | 4,746 | 3,149 | 12,089 |
| Impairment charges | 15,100 | ... | ... |
| Total operating expenses | 19,846 | 3,149 | 12,089 |
| Operating income (loss) | (19,846) | (3,149) | (3,221) |
| Gain on debt settlement | ... | ... | 1,799 |
| Interest expense, net | (2,250) | (468) | 773 |
| Loss (gain) on litigation settlement | ... | (1,950) | 1,950 |
| Gain on settlement of vendor advance payments | ... | ... | 952 |
| Gain on reversal of contingent liabilities | ... | 637 | ... |
| Unrealized gain (loss) on marketable securities | (926) | (631) | ... |
| Other income (expense), net | 998 | 2,124 | 152 |
| Total other income (expense), net | 2,322 | 4,548 | 180 |
| Income (loss) before provision for (benefit from) income taxes - U.S. | ... | ... | (16,074) |
| Income (loss) before provision for (benefit from) income taxes - Canada | ... | ... | (540) |
| Income (loss) before provision for (benefit from) income taxes | (17,524) | 1,399 | (3,041) |
| Current income tax expense (benefit) - state | ... | ... | 75 |
| Total current income tax expense (benefit) | ... | ... | 75 |
| Deferred income tax expense (benefit) - domestic | ... | ... | 198 |
| Income tax provision (benefit) | (429) | (6,621) | 273 |
| Net income (loss) from continuing operations | (17,095) | 8,020 | (3,314) |
| Income (loss) from discontinued operations | 10,254 | 5,081 | (13,573) |
| Income tax provision for discontinued operations | (971) | (2,109) | ... |
| Net income (loss) from discontinued operations | ... | ... | (13,573) |
| Net income (loss) | (7,812) | 10,992 | (16,887) |
| Weighted average shares outstanding - basic | 4,005 | 3,150 | 2,659 |
| Weighted average shares outstanding - diluted | 4,005 | 3,150 | 2,659 |
| Year end shares outstanding | 4,958 | 3,150 | 2,827 |

| | 12/30/23 | 12/31/22 (revised) | 01/01/22 (revised) |
|--|----------|-----------------------|-----------------------|
| Net income (loss) per share from continuing operations - basic | \$(4.27) | \$2.55 | \$(1.25) |
| Net income (loss) per share from discontinued operations - basic | \$2.32 | \$0.94 | \$(5.11) |
| Net income (loss) per share - basic | \$(1.95) | \$3.49 | \$(6.35) |
| Net income (loss) per share from continuing operations - diluted | \$(4.27) | \$2.55 | \$(1.25) |
| Net income (loss) per share from discontinued operations - diluted | \$2.32 | \$0.94 | \$(5.11) |
| Net income (loss) per share - diluted | \$(1.95) | \$3.49 | \$(6.35) |
| Number of full time employees | 5 | ... | ... |
| Total number of employees | 5 | ... | ... |
| Number of common stockholders | 50 | ... | ... |
| Discontinued operations | 9,283 | 2,972 | ... |

Consolidated Balance Sheet, Years Ended (\$000):

| | 12/30/23 | 12/31/22 (revised) |
|---|----------|-----------------------|
| Cash & cash equivalents | 5 | 115 |
| Trade receivables, net | 266 | 7,312 |
| Other receivables | 266 | 610 |
| Trade & other receivables, net | ... | 7,922 |
| Appliances held for resale | ... | 366 |
| Inventories | ... | 366 |
| Prepaid insurance | 3 | 465 |
| Prepaid other expenses & other current assets | ... | 305 |
| Prepaid expenses & other current assets | 75 | 770 |
| Prepaid other | 72 | ... |
| Total current assets | 346 | 9,173 |
| Buildings & improvements | ... | 85 |
| Equipment | ... | 3,915 |
| Projects under construction | ... | 1,447 |
| Property & equipment, gross | ... | 5,447 |
| Less: accumulated depreciation - property & equipment | ... | 2,742 |
| Property & equipment, net | ... | 2,705 |
| Right of use asset - operating leases | ... | 5,290 |
| Intangible assets - Soin Therapeutics LLC, net | 17,842 | 19,293 |
| Intangible assets, net | 4 | 740 |
| Note receivable, net | ... | 8,974 |
| Marketable securities | 286 | 315 |
| Deposits & other assets | 9 | 266 |
| Total assets | 18,487 | 46,756 |
| Accounts payable | 2,272 | 6,699 |
| Accrued sales tax estimate, including interest | 3,494 | ... |
| Accrued compensation & benefits | 37 | 767 |
| Accrued contract liability | ... | 290 |
| Accrued incentive & rebate checks | ... | 2,037 |
| Accrued guarantees | ... | 130 |

| | | |
|--|----------|----------|
| Accrued taxes | ... | 223 |
| Accrued litigation settlement | ... | 510 |
| Accrued interest | 3,633 | ... |
| Other accrued expenses | ... | 326 |
| Accrued liabilities - other | ... | 4,283 |
| Accrued liability - California sales taxes | ... | 6,264 |
| Lease obligation short term - operating leases | ... | 1,632 |
| Accrued income taxes | 102 | ... |
| Short term debt | ... | 4,553 |
| Current portion of note payable | ... | 274 |
| Related party note | ... | 233 |
| Total current liabilities | 5,905 | 23,938 |
| Related Party Note | 707 | ... |
| Lease obligation long term - operating leases | ... | 3,816 |
| Deferred income taxes, net | 639 | 195 |
| AFCO Credit Corporation finance | ... | 274 |
| KLC Financial, Inc. financial | ... | 1,781 |
| Gulf Coast Bank and Trust Company | ... | 4,206 |
| Total debt | ... | 6,261 |
| Less unamortized debt issuance costs | ... | (95) |
| Net amount | ... | 6,166 |
| Less current portion | ... | 4,827 |
| Notes payable - long term portion | ... | 1,339 |
| Long-term portion related party note payable | ... | 605 |
| Other noncurrent liabilities | 34 | 46 |
| Total liabilities | 7,285 | 29,939 |
| Convertible preferred stock, series S | 14,510 | 14,510 |
| Common stock | 3 | 2 |
| Additional paid in capital | 47,323 | 45,748 |
| Accumulated deficit | (50,634) | ... |
| Retained earnings (accumulated deficit) | ... | (42,822) |
| Accumulated other comprehensive income (loss) | ... | (621) |
| Total shareholders' equity (deficit) | (3,308) | 2,307 |
| Total equity (deficit) | (3,308) | ... |

Recent Dividends:
1. JanOne Inc series S convertible preferred.

No dividends paid.

2. JanOne Inc series A convertible preferred.

No dividends paid.

3. JanOne Inc common.

No dividends paid.

Annual Dividends:
1. JanOne Inc series S convertible preferred.

No dividends paid.

2. JanOne Inc series A convertible preferred.

No dividends paid.

3. JanOne Inc common.

No dividends paid.

JONES SODA CO.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--------------------------|------------|------------|-------------------|
| Revenue | 16,669,000 | ... | ... |
| Revenue | 16,669,000 | 19,085,000 | 14,792,000 |
| Cost of goods sold | 11,814,000 | 13,942,000 | 10,394,000 |
| Gross profit | 4,855,000 | 5,143,000 | 4,398,000 |
| Selling & marketing | 4,378,000 | 4,965,000 | 3,003,000 |
| General & administrative | 5,355,000 | 6,271,000 | 3,302,000 |
| Income (loss) from | ... | ... | ... |

| | | | |
|---|--------------------------|--------------------|--------------------|
| operations | (4,878,000) | (6,093,000) | (1,907,000) |
| Interest expense | 377,000 | 225,000 | |
| Interest income | 52,000 | 6,000 | 4,000 |
| Other income (expense), net | 5,000 | 88,000 | 344,000 |
| Income (loss) before income taxes - United States | (6,469,000) | (1,881,000) | |
| Income (loss) before income taxes - foreign | 93,000 | 97,000 | |
| Income (loss) before income taxes | (4,821,000) | (6,376,000) | (1,784,000) |
| Current state income tax expense (benefit) | 13,000 | 7,000 | 4,000 |
| Current foreign income tax expense (benefit) | 20,000 | 21,000 | 23,000 |
| Total current income tax expense (benefit) | 28,000 | 27,000 | |
| Income tax expense (benefit), net | 33,000 | 28,000 | 27,000 |
| Net income (loss) | (4,854,000) | (6,404,000) | (1,811,000) |
| Weighted average shares outstanding - basic | 100,922,834 | 94,177,863 | 65,542,609 |
| Weighted average shares outstanding - diluted | 100,922,834 | 94,177,863 | 65,542,609 |
| Year end shares outstanding | 101,258,135 [Ⓐ] | 100,263,135 | 67,840,941 |
| Net income (loss) per share - basic | \$(0.05) | \$(0.07) | \$(0.03) |
| Net income (loss) per share - diluted | \$(0.05) | \$(0.07) | \$(0.03) |
| Number of full time employees | 27 | 29 | 22 |
| Number of part time employees | ... | ... | 1 |
| Total number of employees | 27 | 29 | 23 |
| Number of common stockholders | 228 | 244 [Ⓐ] | 234 [Ⓐ] |
| Foreign currency translation adjustments | (109,000) | (15,000) | |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.05) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.05) | ... | ... |

[Ⓐ] Shares increased due to the effect of common stock issued upon conversion of notes payable; and common stock and warrants issued; [Ⓑ] Approximately; [Ⓒ] As of March 20, 2023; [Ⓓ] As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|-----------|------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 3,867,000 | 7,971,000 |
| Accounts receivable - other | 2,118,000 | ... |
| Accounts receivable, gross | 2,378,000 | 3,280,000 |
| Allowance for doubtful accounts | 260,000 | 110,000 |
| Accounts receivable, net | ... | 3,170,000 |
| Finished goods | 1,380,000 | 1,234,000 |
| Raw materials | 1,012,000 | 1,387,000 |
| Total Inventory - Balancing value | 2,392,000 | ... |
| Inventory | ... | 2,621,000 |
| Prefunded insurance premiums - financing | 357,000 | 612,000 |
| Prepaid expenses & other current assets | 861,000 | 601,000 |
| Total current assets | 9,595,000 | 14,975,000 |
| Vehicles | 65,000 | 37,000 |
| Office & computer equipment | 203,000 | 189,000 |
| Equipment | 235,000 | 210,000 |

| | | |
|---|--------------|--------------|
| Fixed assets, gross | 503,000 | 436,000 |
| Accumulated depreciation | 366,000 | 309,000 |
| Fixed assets, net | 137,000 | 127,000 |
| Other assets | 174,000 | ... |
| Total assets | 9,906,000 | 15,102,000 |
| Accounts payable | 716,000 | 1,069,000 |
| Accrued employee benefits | 317,000 | 604,000 |
| Accrued selling & marketing | 302,000 | 465,000 |
| Other accruals | 664,000 | 575,000 |
| Accrued expenses | ... | 1,644,000 |
| Insurance premium | ... | ... |
| financing | 357,000 | 612,000 |
| Taxes payable | ... | 10,000 |
| Current portion of accrued interest expense | 1,283,000 | ... |
| Total current liabilities | 2,356,000 | 3,335,000 |
| Total liabilities | 2,356,000 | 3,335,000 |
| Common stock | ... | 89,680,000 |
| Accumulated other comprehensive income (loss) | 331,000 | 287,000 |
| Accumulated deficit | (83,054,000) | ... |
| Retained earnings (accumulated deficit) | ... | (78,200,000) |
| Total shareholders' equity (deficit) | 7,550,000 | 11,767,000 |
| Total Equity | 7,550,000 | ... |

Recent Dividends:

1. Jones Soda Co. common.

No dividends paid.

Annual Dividends:

1. Jones Soda Co. common.

No dividends paid.

JOURNEY MEDICAL CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

| | | | |
|---|---------|----------|-----------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Product revenue, net | 59,662 | 70,995 | 63,134 |
| Other revenue | 19,519 | 2,674 | ... |
| Total revenue | 79,181 | 73,669 | 63,134 |
| Cost of goods sold - product revenue | 26,660 | 30,775 | 32,084 |
| Research & development | 7,541 | 10,943 | 2,739 |
| Research & development - licenses acquired | ... | ... | 13,819 |
| Selling, general & administrative | 43,910 | 59,468 | 39,833 |
| Wire transfer fraud loss | ... | ... | 9,540 |
| Total operating expenses | 81,254 | 101,186 | 98,015 |
| Income (loss) from operations | (2,073) | (27,517) | (34,881) |
| Interest income | 322 | 60 | 2 |
| Interest payments on EWB term loan & LOC | ... | 1,153 | ... |
| Imputed interest on acquired intangible assets | 1,698 | 519 | 781 |
| Amortization/accretion | ... | 347 | 2,572 |
| Impairment of intangible assets | 3,143 | ... | ... |
| Interest & fees on convertible preferred shares | ... | ... | 2,845 |
| Dividends payable on convertible preferred shares | ... | ... | 820 |
| EWB LOC fees | ... | ... | 16 |
| Interest expense | ... | 2,019 | 7,034 |
| Foreign exchange transaction gains (losses) | (183) | (89) | ... |
| Change in fair | ... | ... | ... |

| | | | |
|---|----------------|------------------|---------------------|
| value of derivative liability | ... | ... | (447) |
| Total other income (expense) | (1,559) | (2,048) | (7,479) |
| Income (loss) before income taxes | (3,632) | (29,565) | (42,360) |
| Current federal income tax expense (benefit) | 34 | ... | ... |
| Current state income tax expense (benefit) | 187 | 63 | 67 |
| Total current income tax expense (benefit) | 221 | 63 | 67 |
| Deferred federal income tax expense (benefit) | (753) | (6,701) | (7,829) |
| Deferred state income tax expense (benefit) | (94) | (1,737) | (1,474) |
| Total deferred income tax expense (benefit) | (847) | (8,438) | (9,303) |
| Valuation allowance | 847 | 8,438 | 10,870 |
| Income tax expense (benefit) | 221 | 63 | 1,634 |
| Net income (loss) | (3,853) | (29,628) | (43,994) |
| Weighted average shares outstanding - basic | 18,232 | 17,531 | 10,190 |
| Weighted average shares outstanding - diluted | 18,232 | 17,531 | 10,190 |
| Year end shares outstanding | 19,324 | 17,766 | 17,316 [Ⓐ] |
| Net income (loss) per share - basic | \$(0.21) | \$(1.69) | \$(4.32) |
| Net income (loss) per share - diluted | \$(0.21) | \$(1.69) | \$(4.32) |
| Number of full time employees | 58 | 20 [Ⓐ] | ... |
| Number of part time employees | ... | 60 [Ⓐ] | ... |
| Total number of employees | 58 | 80 [Ⓐ] | 90 [Ⓐ] |
| Number of common stockholders | ... | 164 [Ⓐ] | 206 [Ⓐ] |
| Number of class A common stockholders | ... | 61 [Ⓐ] | 1 [Ⓐ] |
| Foreign currency translation adjustments | ... | (89) | ... |
| Common Shareholders - Number | 45 | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Shares increased due to the effect of issuance of common stock related to equity plans and initial public offering; [Ⓒ] Shares increased due to the effect of conversion of class A preferred stock settled note, related party payables, placement agent warrants and contingent payment warrants; [Ⓓ] As is; [Ⓔ] Approximately; [Ⓕ] As of March 29, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | |
|---|--------|--------|
| | 2023 | 2022 |
| Cash & cash equivalents | 27,439 | 32,003 |
| Accounts receivable, gross | 15,722 | 28,608 |
| Less: allowance for doubtful accounts | 500 | 400 |
| Accounts receivable, net of reserves | 15,222 | 28,208 |
| Raw materials | 4,640 | 6,454 |
| Work in process | 884 | 395 |
| Finished goods | 4,987 | 7,739 |
| Inventory reserves | 305 | 429 |
| Inventory | 10,206 | 14,159 |
| Prepaid expenses & other current assets | 3,588 | 3,309 |
| Total current assets | 56,455 | 77,679 |
| Intangible assets, net | 20,287 | 27,197 |
| Operating lease | ... | ... |

| | | |
|---|---------------|----------------|
| right-of-use asset, net | 101 | 189 |
| Other assets | 6 | 95 |
| Total assets | 76,849 | 105,160 |
| Accounts payable | 18,149 | 36,570 |
| Due to related party | 195 | 413 |
| Accrued coupon & rebates | ... | 7,604 |
| Accrued compensation | 3,374 | 2,586 |
| Accrued royalties payable | ... | 2,627 |
| Accrued return reserve | ... | 3,689 |
| Accrued inventory | ... | 112 |
| Accrued research & development | ... | 1,404 |
| Accrued legal, accounting & tax | ... | 334 |
| Accrued iPledge program | ... | 447 |
| Other accrued expenses | 20,350 | 585 |
| Accrued expenses | ... | 19,388 |
| Accrued interest | 16,976 | 160 |
| Income taxes payable | 53 | 35 |
| Line of credit | ... | 2,948 |
| Deferred cash payment | ... | 4,991 |
| Installment payments - licenses, short-term | 3,000 | 2,244 |
| Operating lease liability, short-term | 99 | 83 |
| Accrued interest | 22 | ... |
| Total current liabilities | 41,868 | 66,832 |
| Term loan | 14,622 | 19,826 |
| Installment payments - licenses, long-term | ... | 1,412 |
| Operating lease liability, long-term | 9 | 108 |
| Total liabilities | 56,499 | 88,178 |
| Common stock | 1 | 1 |
| Common stock - class A | 1 | 1 |
| Additional paid-in capital | 92,703 | 85,482 |
| Accumulated deficit | (72,355) | ... |
| Retained earnings (accumulated deficit) | ... | (68,502) |
| Total stockholders' equity | 20,350 | 16,982 |
| Total Equity | 20,350 | ... |

Recent Dividends:

1. Journey Medical Corp class A common.

No dividends paid.

2. Journey Medical Corp common.

No dividends paid.

Annual Dividends:

1. Journey Medical Corp class A common.

No dividends paid.

2. Journey Medical Corp common.

No dividends paid.

**KAANAPALI LAND LLC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|----------------|
| Sales | ... | 9,063 | 4,576 |
| Sales & rental revenues | 2,990 | ... | ... |
| Interest & other income | 1,726 | 161 | 177 |
| Crop insurance proceeds | 538 | ... | ... |
| Total revenues | 5,254 | 9,224 | 4,753 |
| Cost of sales | 2,858 | 6,840 | 5,217 |
| Selling, general & administrative | (804) | 1,626 | (777) |
| Depreciation & amortization | 198 | 243 | 269 |
| Total cost & expenses | ... | 8,709 | 4,709 |
| Operating income (loss) before other income & income taxes | ... | 515 | 44 |
| Settlement gain on pension plan assets (before taxes) | ... | 2,479 | ... |
| Total other income | ... | 2,479 | ... |

| | | | |
|---|--------------|--------------|--------------|
| Income (loss) before income taxes | 364 | 2,994 | 44 |
| Deferred U.S. federal income taxes (benefit) | (2,674) | 163 | 282 |
| Deferred state income taxes (benefit) | (669) | 39 | 68 |
| Deferred income taxes (benefit) | (3,343) | 202 | 350 |
| Income tax expense (benefit) | (3,343) | 202 | 350 |
| Net income (loss) | 3,707 | 2,792 | (306) |
| Less: net income (loss) attributable to non controlling interests | ... | 58 | 551 |
| Net income (loss) attributable to shareholders | ... | 2,850 | 245 |
| Weighted average shares outstanding-basic | 1,845 | 1,845 | 1,845 |
| Weighted average shares outstanding-diluted | 1,845 | 1,845 | 1,845 |
| Year end shares outstanding | 1,845 | 1,845 | 1,845 |
| Income (loss) per share - continuing operations - basic | \$2.01 | ... | ... |
| Net income (loss) per share - basic | \$2.01 | \$1.55 | \$0.13 |
| Income (loss) per share - continuing operations - diluted | \$2.01 | ... | ... |
| Net income (loss) per share - diluted | \$2.01 | \$1.55 | \$0.13 |
| Number of full time employees | ... | 24 | 23 |
| Number of common stockholders | 628 | 630 | 633 |
| Excise tax expense | 2,952 | ... | ... |
| Casualty loss insurance proceeds | (314) | ... | ... |

Reclassified to conform with 2022 presentation; As is; As of March 1, 2023; As of March 1, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------|---------------|----------------|
| Cash & cash equivalents | 26,260 | 19,815 | ... |
| Land | ... | 58,381 | ... |
| Buildings | ... | 1,229 | ... |
| Machinery & equipment | ... | 5,244 | ... |
| Property, gross | ... | 64,854 | ... |
| Less: accumulated depreciation | 4,962 | 5,866 | ... |
| Property, net | 60,200 | 58,988 | ... |
| Pension plan assets | 5,067 | 19,115 | ... |
| Other assets | 1,492 | 596 | ... |
| Investment Property - Gross | 65,162 | ... | ... |
| Total assets | 93,019 | 98,514 | ... |
| Accounts payable & accrued expenses | 346 | 643 | ... |
| Deposits & deferred gains | 1,433 | 1,371 | ... |
| Deferred income taxes | 5,979 | 9,322 | ... |
| Other liabilities | 1,550 | 7,174 | ... |
| Total liabilities | 9,308 | 18,510 | ... |
| Additional paid-in capital | 5,471 | 5,471 | ... |
| Accumulated earnings | 78,240 | ... | ... |
| Retained earnings (accumulated deficit) | ... | 74,533 | ... |
| Stockholders' equity (deficit) | 83,711 | 80,004 | ... |
| Total equity | 83,711 | 80,004 | ... |

Recent Dividends:

1. Kaanapali Land LLC class C common.

No dividends paid.

2. Kaanapali Land LLC common.

No dividends paid.

Annual Dividends:

1. Kaanapali Land LLC class C common.

No dividends paid.

2. Kaanapali Land LLC common.

No dividends paid.

KAIVAL BRANDS INNOVATIONS GROUP INC

Earnings, 3 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 3,211,573 | 2,525,918 |
| Cost & expenses | 4,926,195 | 5,532,779 |
| Operating income | (2,112,971) | (2,994,909) |
| Other income (expense), net | (98,432) | ... |
| Net before taxes | (2,112,971) | (2,994,909) |
| Income taxes | 715 | ... |
| Net income | (2,113,686) | (2,994,909) |
| Balance for common | (2,181,186) | ... |
| Earnings common share | ... | ... |
| Primary | \$(0.76) | \$(1.05) |
| Fully Diluted | \$(0.76) | \$(1.05) |
| Common Shares: | ... | ... |
| Full Diluted | 2,854,850 | 2,674,719 |
| Year-end | 2,863,002 | 2,674,719 |

Consolidated Balance Sheet Items, as of (\$):

| | 2024 |
|-----------------------|-------------------|
| Assets: | ... |
| Cash & equivalents | 591,293 |
| Inventories | 2,058,070 |
| Current assets | 4,035,411 |
| Net property & equip. | 2,668 |
| Total assets | 16,269,383 |
| Liabilities: | ... |
| Current liabilities | 3,704,494 |
| Stockholders' equity | 11,747,783 |
| Net current assets | 330,917 |

KALA BIO INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|---------------|---------------|----------------|
| Product revenues, net | ... | 3,892 | 11,240 |
| Cost of product revenues | ... | 2,560 | 4,097 |
| Selling, general & administrative expenses | 20,567 | 65,035 | 105,061 |
| Research & development | 18,586 | 17,653 | 11,515 |
| Acquired in-process research & development | ... | ... | 26,617 |
| Loss (gain) on fair value remeasurement of deferred purchase consideration | 230 | (638) | 5,805 |
| Gain on fair value remeasurement of contingent consideration | (740) | 288 | ... |
| Total costs & expenses | 39,663 | 85,598 | 141,485 |
| Income (loss) from operations | (39,663) | (81,706) | (130,245) |
| Interest income | 2,711 | 664 | 104 |
| Interest expense | 5,814 | 7,266 | 8,380 |
| Gain (loss) on extinguishment of debt | ... | (2,583) | (5,395) |
| Gain on sale of commercial business | ... | 46,995 | ... |
| Grant income | 4,825 | ... | ... |
| Gain on lease modification | ... | ... | 1,311 |
| Other income (expense), net | (4,258) | (926) | ... |
| Total interest income (expense) & other income (expense) | (2,536) | 36,884 | (12,360) |

| | | |
|--|--------------|--------------|
| Land | 17,703 | 533,778 |
| Leasehold improvements | 32,304 | 147,636 |
| Machinery & equipment | 55,067 | 69,312 |
| Sign | ... | 12,758 |
| Structural | 56,978 | ... |
| Vehicle | 24,000 | 24,000 |
| Total property & equipment | 241,765 | 911,192 |
| Less: accumulated depreciation | 216,890 | 358,396 |
| Property & equipment, net | 24,875 | 557,796 |
| Investment in subsidiaries | ... | 22,188 |
| Other assets | 40,479 | 27,175 |
| Goodwill | 23,682 | ... |
| Total non-current assets | 118,901 | 784,763 |
| Total assets | 215,856 | 843,241 |
| Accounts payable & accrued expense | 589,085 | 961,396 |
| Accounts payable & accrued expense - related parties | 514,972 | 273,190 |
| Accrued interest | 2,369,015 | 1,759,669 |
| Right-of-use liability - operating lease | 30,885 | 93,067 |
| Taxable payable | 899,344 | 876,017 |
| Convertible notes payable - net of discount | ... | 240,293 |
| Notes payable | 124,312 | 9,312 |
| Derivative liabilities | 2,752,321 | 6,204,878 |
| Current portion of installment agreement | 125,000 | ... |
| Total current liabilities | 7,404,934 | 10,417,822 |
| Notes payable-related party | ... | 250,000 |
| Convertible notes payable - related party - net of discount | 250,000 | ... |
| Total convertible debt | ... | 7,807,152 |
| Less: discount | 500,000 | (387,814) |
| Convertible debt, net of discounts | ... | 7,419,338 |
| Convertible debt, net of discounts, current | ... | 240,293 |
| Convertible notes payable - net of discount | 7,311,410 | 7,179,045 |
| Accrued expense-related parties | ... | 500,000 |
| Right-of-use liability - operating lease | ... | 100,115 |
| Accrued expense-related parties | 500,000 | ... |
| Total non-current liabilities | 8,561,410 | 8,029,160 |
| Total liabilities | 15,966,344 | 18,446,983 |
| Common stock, \$.001 par value; 250,000,000 shares authorized; 68,494,325 and 70,949,325 shares issued and outstanding at March 31, 2014 and December 31, 2013, respectively | 22,173 | ... |
| Common stock | ... | 22,173 |
| Subscriptions payable | 163,630 | 163,630 |
| Additional paid in capital | 22,493,783 | 22,277,612 |
| Accumulated Deficit | (36,462,263) | ... |
| Retained earnings (accumulated deficit) | ... | (38,071,960) |
| Accumulated other comprehensive income | (12,617) | (11,027) |
| Total stockholders' deficit attributable to parent company | (13,795,294) | (15,619,572) |
| Non-controlling interest | (1,955,194) | (1,984,169) |
| Total stockholders' deficit | (15,750,488) | (17,603,741) |

□ As reported by the Company

Recent Dividends:

1. Kaya Holdings Inc common.
No dividends paid.

2. Kaya Holdings Inc series D convertible preferred.

No dividends paid.

3. Kaya Holdings Inc series C convertible preferred.

No dividends paid.

Annual Dividends:

1. Kaya Holdings Inc common.

No dividends paid.

2. Kaya Holdings Inc series D convertible preferred.

No dividends paid.

3. Kaya Holdings Inc series C convertible preferred.

No dividends paid.

KBS REAL ESTATE INVESTMENT TRUST III, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31

(\$000):

| | | | |
|---|-----------|----------|-----------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Rental income | 270,158 | 275,026 | 280,144 |
| Dividend income from real estate equity securities | 11,850 | 14,850 | ... |
| Other operating income | 18,669 | 18,141 | 16,617 |
| Total revenues | 300,677 | 308,017 | 296,761 |
| Operating, maintenance & management | 75,914 | 74,783 | 68,806 |
| Real estate taxes & insurance | 52,789 | 51,811 | 57,687 |
| Asset management fees to affiliate | 20,839 | 20,102 | 19,832 |
| General & administrative expenses | 7,297 | 8,115 | 6,116 |
| Depreciation & amortization | 115,235 | 111,860 | 110,984 |
| Interest expense | 120,475 | 60,259 | 34,564 |
| Net loss (gain) on derivative instruments | (14,907) | (51,932) | (5,263) |
| Impairment charges on real estate | 45,459 | ... | ... |
| Total expenses | 423,101 | 274,998 | 292,726 |
| Other interest income | 505 | 63 | 52 |
| Equity in income (loss) of an unconsolidated entity | ... | ... | 8,698 |
| Loss from extinguishment of debt | ... | ... | (214) |
| Unrealized gain (loss) on real estate equity securities | (35,614) | (92,812) | 16,765 |
| Write-off of prepaid offering costs | ... | 2,728 | ... |
| Gain on sale of real estate, net | ... | ... | 114,321 |
| Net Income Before Tax | (157,533) | ... | ... |
| Total other income (loss), net | (35,109) | (95,477) | 139,622 |
| Net income (loss) | (157,533) | (62,458) | 143,657 |
| Net income (loss) attributable to common stockholders | (157,533) | (62,458) | 143,657 |
| Weighted average shares outstanding - basic | 148,739 | 149,164 | 172,331 |
| Weighted average shares outstanding - diluted | 148,739 | 149,164 | 172,331 |
| Year end shares outstanding | 148,516 | 147,965 | 153,151 |
| Net income (loss) per common share - basic | \$(1.06) | \$(0.42) | \$0.83 |
| Net income (loss) per common share - diluted | \$(1.06) | \$(0.42) | \$0.83 |
| Distributions | | | |

declared per common share

... \$0.60 \$0.60

Number of common stockholders

... 30,101 31,000

Basic EPS - Net

Income excl Extra

Items applicable to

Common - (Company

Level) ...

Diluted EPS - Net

Income excl Extra

Items applicable to

Common - (Company

Level) ...

□ Reclassified to conform with 2022 presentation; □ As is; □

Approximately; □ As of March 8, 2023; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | |
|--|-------------|-----------|
| | 2023 | 2022 |
| Land | ... | 290,121 |
| Buildings & improvements | 2,244,090 | 2,235,676 |
| Tenant origination & absorption costs | 34,574 | 42,555 |
| Total real estate held for investment, cost | ... | 2,568,352 |
| Less accumulated depreciation & amortization | 713,501 | 656,401 |
| Land - Real Estate | 274,315 | ... |
| Real estate equity securities | 1,839,478 | 87,416 |
| Total real estate & real estate-related investments, net | ... | 1,999,367 |
| Cash & cash equivalents | 36,836 | 47,767 |
| Restricted cash | 14,086 | 6,070 |
| Rents & other receivables, net | 99,024 | 93,100 |
| Above-market leases, net | 189 | 262 |
| Due from affiliates | ... | 10 |
| Prepaid expenses & other assets | 97,970 | 112,411 |
| Real estate equity securities | 51,802 | ... |
| Total assets | 2,139,385 | 2,258,987 |
| Notes payable, net | 1,735,896 | 1,667,288 |
| Accounts payable & accrued liabilities | ... | 56,071 |
| Due to affiliate | 17,408 | 10,365 |
| Distributions payable | ... | 7,374 |
| Below-market leases, net | 1,069 | 1,911 |
| Redeemable common stock payable | 49,646 | 711 |
| Other liabilities | 67,954 | 60,918 |
| Total liabilities | 1,871,973 | 1,804,638 |
| Redeemable common stock | ... | 32,681 |
| Common stock | 1,485 | 1,480 |
| Additional paid-in-capital | 1,313,299 | 1,275,833 |
| Cumulative distributions in excess of net income | (1,047,372) | (855,645) |
| Total stockholders' equity | 267,412 | 421,668 |
| Total equity | 267,412 | ... |

Recent Dividends:

1. KBS Real Estate Investment Trust III, Inc. common.

No dividends paid.

Annual Dividends:

1. KBS Real Estate Investment Trust III, Inc. common.

No dividends paid.

KEWEENAW LAND ASSOCIATION LTD.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---------------------|---------|---------|---------|
| | 2023 | 2022 | 2021 |
| Lease income | 292,415 | 270,125 | 202,148 |
| Cost of sales | 242,323 | 97,408 | ... |
| Total cost of sales | 242,323 | ... | ... |
| Gross profit (loss) | 50,092 | 172,717 | ... |
| Selling, general & | | | |

| | | | |
|--|----------------|------------------|--------------------|
| administrative expenses | 497,039 | 702,095 | 57,676 |
| Other income (expense) | 419,204 | ... | ... |
| Other Expense | (180,630) | ... | ... |
| Interest Income | 410,681 | ... | ... |
| Income (loss) before income tax expense | 202,308 | (529,378) | 144,472 |
| Current provision (benefit) for federal income tax | ... | ... | 28,519 |
| Current provision (benefit) for state income taxes | ... | ... | 8,668 |
| Income Taxes - Domestic - Deferred | 37,765 | ... | ... |
| Income Taxes - Local - Deferred | (12,957) | ... | ... |
| Income Taxes - Total - Deferred | 24,808 | ... | ... |
| Income Taxes - Domestic - Current | 8,898 | ... | ... |
| Current income taxes | 8,898 | ... | ... |
| Income tax expense (benefit) - continuing operation | 33,706 | (127,950) | 37,187 |
| Income (loss) from continuing operation | 168,602 | (401,428) | 107,285 |
| Earnings (loss) from discontinued operations | ... | (614,729) | 5,972,122 |
| Gain (loss) on disposal of discontinued operations | ... | ... | 146,674,761 |
| Income tax expense (benefit) - discontinued operations | ... | 165,977 | (39,550,088) |
| Income from discontinued operations | ... | (448,752) | 113,096,795 |
| Net income (loss) | 168,602 | (850,180) | 113,204,080 |
| Weighted average shares outstanding - basic | 1,177,917 | 1,180,983 | 1,296,173 |
| Weighted average shares outstanding - diluted | 1,177,917 | 1,180,983 | 1,296,173 |
| Year end shares outstanding | 1,177,917 | 1,180,983 | 1,296,173 |
| Earnings per share - continuing operations - basic | \$0.14 | \$(0.34) | \$0.08 |
| Earnings per share-inc from discontinued oper | \$0.00 | ... | ... |
| Earnings per share - discontinued operations - basic | \$0.00 | \$(0.38) | \$87.25 |
| Net earnings per share - basic | \$0.14 | \$(0.72) | \$87.33 |
| Earnings per share - continuing operations - diluted | \$0.14 | \$(0.34) | \$0.08 |
| Earn per share-inc from discount opers - diluted | \$0.00 | ... | ... |
| Earnings per share - discontinued operations - diluted | \$0.00 | \$(0.38) | \$87.25 |
| Net earnings per share - diluted | \$0.14 | \$(0.72) | \$87.33 |
| Number of full time employees | 2 | 2 | 4 |
| Number of common stockholders | ... | 168 | ... |
| Total Revenues | 292,415 | ... | ... |

| | | | |
|---|------------|----------------|-----------------------|
| Total number of employees | 2 | ... | ... |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 8,438,539 | 9,941,840 | |
| Cash held in escrow | 4,336 | ... | |
| Accounts receivable | 2,500 | 7,500 | |
| Receivable - accrued interest | 54,699 | ... | |
| Prepaid assets | 10,632 | 15,533 | |
| Federal income tax receivable | 103 | 3,664 | |
| Notes Receivable | 99,307 | ... | |
| Total current assets | 8,610,116 | 9,968,537 | |
| Mineral rights | 6,688,389 | 5,147,317 | |
| Land & timberlands | 50,850 | 115,850 | |
| Property, plant & equipment, net of depreciation | 19,972 | 21,509 | |
| Exploration & evaluation | 306,420 | 306,420 | |
| Total non-current assets | 7,065,631 | 5,591,096 | |
| Total assets | 15,675,747 | 15,559,633 | |
| Accounts payable | 9,903 | 7,335 | |
| Other accrued liabilities | 36,533 | 55,918 | |
| Total current liabilities | 46,436 | 63,253 | |
| Non-current state & federal deferred income tax liability | 274,691 | 249,883 | |
| Total liabilities | 321,127 | 313,136 | |
| Common Stock Issued | 77,029 | ... | |
| Common stock | ... | 77,229 | |
| Retained Earnings | 15,277,591 | ... | |
| Retained earnings (accumulated deficit) | ... | 15,169,268 | |
| Total stockholders' equity (deficit) | 15,354,620 | 15,246,497 | |
| Total Equity | 15,354,620 | ... | |
| Recent Dividends: | | | |
| 1. Keweenaw Land Association Ltd. common. | | | |
| ExDate | Amt | Declared | Record Payable |
| 01/03/2022 | 92.00 | | 12/27/2021 12/31/2021 |
| Annual Dividends: | | | |
| 1. Keweenaw Land Association Ltd. common. | | | |
| 2021 | 92.00 | | |
| KEYSTAR CORP | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Jun. 30 (\$): | | | |
| | 2023 | 2022 (revised) | 2021 (revised) |
| Cash | 355,396 | 66,241 | ... |
| KN-95 masks | ... | 1,167 | ... |
| Total inventory | ... | 1,167 | ... |
| Less: inventory reserve | ... | 175 | ... |
| Inventory, net | ... | 992 | ... |
| Prepaid expenses | 1,194,288 | 9,063 | ... |
| Total current assets | 1,549,684 | 76,296 | ... |
| Security deposit | 9,683 | 1,523 | ... |
| Total other assets | 5,672,151 | 1,523 | ... |
| Equipment, net | 3,813 | ... | ... |
| Intangible Assets - Net - Total | 8,067,198 | ... | ... |
| accumulated depreciation | 1,167 | ... | ... |
| Equipment - Gross | 4,980 | ... | ... |
| Total assets | 15,302,529 | 77,819 | ... |
| Accounts payable & accrued expenses | 1,219,018 | 381,870 | ... |
| Notes payable - related party | 1,306,655 | 65,000 | ... |
| Line of credit - related party | 3,851,877 | 166,539 | ... |
| Players balances | 134,946 | ... | ... |
| Accrued expenses - related party | 323,904 | ... | ... |
| Derivative liability | 6,859,452 | ... | ... |
| Notes Payable | 1,189,694 | ... | ... |
| Total current liabilities | 14,885,546 | 613,409 | ... |
| Notes payable - long-term | 850,000 | ... | ... |
| Total long-term liabilities | 850,000 | ... | ... |

| | | | |
|---|---------------------|------------------|-----------------|
| Net Income before Tax | (11,328,496) | (729,810) | ... |
| Total other expense | (3,456,490) | (83,048) | (5,995) |
| deemed dividend from the purchase of Series C preferred stock | 1,006,000 | ... | ... |
| Net income (loss) | (11,337,876) | (715,974) | (51,638) |
| Weighted average shares outstanding - basic | 38,330,589 | 29,800,000 | 29,127,479 |
| Weighted average shares outstanding - diluted | 38,330,589 | 29,800,000 | 29,127,479 |
| Year end shares outstanding | 41,905,000 | 29,800,000 | 29,800,000 |
| Earnings (loss) per share - basic | \$(0.32) | \$(0.02) | \$0.00 |
| Earnings (loss) per share - diluted | \$(0.32) | \$(0.02) | \$0.00 |
| Number of full time employees | 13 | ... | ... |
| Total number of employees | 13 | ... | 2 |
| Number of common stockholders | 62 | ... | 36 |
| Discontinued Operations - Net - Income/Expense | (9,380) | 13,836 | ... |
| Net Income After Extraordinary Items applicable to Common | (12,343,876) | ... | ... |
| Net Income Before Extraordinary and Preferred Dividends | (11,328,496) | (729,810) | ... |
| Earn per share-inc from discount opers - diluted | \$(0.00) | \$0.00 | ... |
| Earning per share-total discount opers - diluted | \$(0.00) | \$0.00 | ... |
| Earnings per share-inc from discontinued oper | \$(0.00) | \$0.00 | ... |
| Earnings per share-total discontinued opers | \$(0.00) | \$0.00 | ... |

□ Restated to reflect correction of errors; □ Non-consolidated; □ Approximately; □ As of September 27, 2021

| | | | |
|--|------------|---------|-----------|
| Consolidated Balance Sheet, Years Ended Jun. 30 (\$): | | | |
| | 2023 | 2022 | (revised) |
| Cash | 355,396 | 66,241 | ... |
| KN-95 masks | ... | 1,167 | ... |
| Total inventory | ... | 1,167 | ... |
| Less: inventory reserve | ... | 175 | ... |
| Inventory, net | ... | 992 | ... |
| Prepaid expenses | 1,194,288 | 9,063 | ... |
| Total current assets | 1,549,684 | 76,296 | ... |
| Security deposit | 9,683 | 1,523 | ... |
| Total other assets | 5,672,151 | 1,523 | ... |
| Equipment, net | 3,813 | ... | ... |
| Intangible Assets - Net - Total | 8,067,198 | ... | ... |
| accumulated depreciation | 1,167 | ... | ... |
| Equipment - Gross | 4,980 | ... | ... |
| Total assets | 15,302,529 | 77,819 | ... |
| Accounts payable & accrued expenses | 1,219,018 | 381,870 | ... |
| Notes payable - related party | 1,306,655 | 65,000 | ... |
| Line of credit - related party | 3,851,877 | 166,539 | ... |
| Players balances | 134,946 | ... | ... |
| Accrued expenses - related party | 323,904 | ... | ... |
| Derivative liability | 6,859,452 | ... | ... |
| Notes Payable | 1,189,694 | ... | ... |
| Total current liabilities | 14,885,546 | 613,409 | ... |
| Notes payable - long-term | 850,000 | ... | ... |
| Total long-term liabilities | 850,000 | ... | ... |

| | | |
|--|--------------|-------------|
| Total liabilities | 15,735,546 | 613,409 |
| Preferred stock, series A | 11,693 | 200 |
| Preferred stock, series B | ... | 11,693 |
| Preferred stock, series C | ... | 67 |
| Common stock | 4,191 | 2,980 |
| Additional paid-in capital | 12,669,930 | 1,074,537 |
| Subscriptions receivable | ... | (102,760) |
| Retained earnings (accumulated deficit) | (13,119,081) | (1,522,307) |
| Preferred stock, series C, \$00001 par value, 25,000,000 shares | ... | ... |
| Authorized 666,666 and 0 shares issued and outstanding as of 30, 2022 and 30, 2021, respectively | 250 | ... |
| Total stockholders' equity (deficit) | (433,017) | (535,590) |
| Total Equity | (433,017) | ... |

| | | | |
|---------------------------------------|-----------|-----------|-----------|
| shares outstanding | | | |
| - basic | 1,640,191 | 1,532,497 | 1,129,669 |
| Weighted average shares outstanding | | | |
| - diluted | 1,640,191 | 1,532,497 | 1,129,669 |
| Year end shares outstanding | 1,872,433 | 1,537,639 | 1,523,567 |
| Net income (loss) per share - basic | \$(6.04) | \$(4.95) | \$(5.25) |
| Net income (loss) per share - diluted | \$(6.04) | \$(4.95) | \$(5.25) |
| Number of full time employees | 14 | 25 | 31 |
| Common Shareholders - Number | 24 | ... | ... |
| Number of stockholders | ... | 18 | 20 |
| Total number of employees | 14 | ... | ... |

| Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|---------------------|---------------------|---------------------|
| | 2023 | 2022 | 2021 (revised) |
| Research & development expenses | 4,027,037 | 3,448,925 | 5,350,264 |
| General & administrative expenses | 4,663,146 | 8,277,993 | 5,323,649 |
| Goodwill impairment | ... | ... | 4,037,811 |
| Change in fair value of contingent consideration | 1,992,399 | 582,605 | (475,956) |
| In-Process R&D Impairment | 1,904,314 | ... | ... |
| Total operating expenses | 12,586,896 | 12,309,523 | 14,235,768 |
| Operating income (loss) before other income | (12,586,896) | (12,309,523) | (14,235,768) |
| Gain on forgiveness of loan | ... | ... | 278,190 |
| Gain on disposal of fixed assets | (28,379) | 4,211 | ... |
| Change in fair value of warrant liability | 28,841 | (1,425,102) | ... |
| Interest income | 173,989 | 56,891 | 1,141 |
| Interest expense | 11,132 | 8,599 | 6,851 |
| Foreign currency gain (loss) | ... | (14,498) | ... |
| Total other income, net | 163,319 | (1,387,097) | 272,480 |
| Income (loss) before income taxes - domestic | (9,384,178) | (10,563,302) | (10,639,818) |
| Income (loss) before income taxes - foreign | (3,039,399) | (3,133,318) | (3,323,470) |
| Income (loss) before income tax expense (benefit) | (12,423,577) | (13,696,620) | (13,963,288) |
| Deferred federal income tax expense | (280,954) | 4,954 | (24,086) |
| Deferred state income tax expense | 371,273 | (117,964) | (168,517) |
| Total deferred income tax expense | 90,319 | (113,010) | (192,603) |
| Income tax expense (benefit) | ... | (113,010) | (192,603) |
| Net income (loss) | (12,513,896) | (13,583,610) | (13,770,685) |
| Deemed dividend on preferred stock | 530,985 | ... | ... |
| Net income (loss) attributable to EyeGate Pharmaceuticals, Inc. stockholders | (13,044,881) | ... | ... |
| Weighted average shares outstanding - basic | 4,842,067 | 732,303 | 241,099 |
| Weighted average shares outstanding - diluted | 4,842,067 | 732,303 | 241,099 |
| Year end shares outstanding | 7,705,640 | 1,796,472 | 316,599 |
| Net income (loss) per common share - basic | \$(2.69) | \$(18.55) | \$(57.12) |
| Net income (loss) per common share - diluted | \$(2.69) | \$(18.55) | \$(57.12) |
| Number of full time employees | 12 | 12 | 14 |
| Number of common stockholders | ... | 47 | 143 |
| Foreign currency translation adjustments | ... | (96,310) | ... |
| Total number of employees | 12 | ... | ... |

Recent Dividends:

- 1. KeyStar Corp series B preferred. No dividends paid.
- 2. KeyStar Corp common. No dividends paid.
- 3. KeyStar Corp series C preferred. No dividends paid.

Annual Dividends:

- 1. KeyStar Corp series B preferred. No dividends paid.
- 2. KeyStar Corp common. No dividends paid.
- 3. KeyStar Corp series C preferred. No dividends paid.

KIDPIK CORP

Annual Report

| Consolidated Income Statement, Years Ended (\$): | | | |
|--|--------------------|--------------------|--------------------|
| | 12/30/23 | 12/31/22 | 01/01/22 (revised) |
| Net sales | 14,240,724 | ... | ... |
| Revenues, net | 14,240,724 | 16,477,984 | 21,834,518 |
| Cost of goods sold | 8,228,458 | 6,600,007 | 8,836,884 |
| Gross profit | 6,012,266 | 9,877,977 | 12,997,634 |
| Shipping & handling | 4,308,265 | 4,334,928 | 6,087,283 |
| Payroll, related costs & non-cash stock-based compensation | 3,974,438 | 5,276,719 | 4,258,604 |
| General & administrative | 7,586,540 | 8,061,825 | 8,288,119 |
| Depreciation & amortization | 48,119 | 27,914 | 26,914 |
| Total operating expenses | 15,917,362 | 17,701,386 | 18,660,920 |
| Operating income (loss) | (9,905,096) | (7,823,409) | (5,663,286) |
| Interest expense | 686 | 78,646 | 711,974 |
| Other income (expense), net | ... | 286,794 | 429,045 |
| Total other income (expenses) | (686) | 208,148 | (282,929) |
| Income (loss) before provision for income taxes | (9,905,782) | (7,615,261) | (5,946,215) |
| Current state income taxes | ... | ... | 1,332 |
| Total current income taxes | ... | ... | 1,332 |
| Deferred federal income taxes | ... | 1,532,719 | ... |
| Deferred state income taxes | ... | ... | 130,211 |
| Total deferred income taxes | ... | 1,662,930 | ... |
| Change in valuation allowance | ... | (1,662,930) | ... |
| Provision for income taxes | ... | ... | 1,332 |
| Net income (loss) | (9,905,782) | (7,615,261) | (5,947,547) |
| Weighted average | | | |

Consolidated Balance Sheet, Years Ended (\$):

| | 12/30/23 | 12/31/22 |
|---|--------------|--------------|
| Cash | 194,515 | 600,595 |
| Accounts receivable | 211,739 | 336,468 |
| Finished goods | 4,854,641 | 12,625,948 |
| Goods in transit | 4,854,641 | ... |
| Inventory | ... | 12,625,948 |
| Restricted cash | 4,618 | 4,618 |
| Prepaid expenses & other current assets | 761,969 | 1,043,095 |
| Total current assets | 6,027,482 | 14,610,724 |
| Computer equipment | 120,459 | 117,841 |
| Furniture & fixtures | 185,290 | 174,504 |
| Leasehold improvements | 139,121 | 65,523 |
| Machinery & equipment | 32,666 | 42,369 |
| Leasehold improvements & equipment, cost | 477,536 | 400,237 |
| Less: accumulated depreciation | 380,400 | 332,280 |
| Leasehold improvements & equipment, net | 97,136 | 67,957 |
| Operating lease right-of-use assets, net | 992,396 | 1,469,665 |
| Total assets | 7,117,014 | 16,148,346 |
| Accounts payable | 1,862,266 | 2,153,389 |
| Accounts payable, related party | 1,868,411 | 1,107,665 |
| Accrued expenses & other current liabilities | 438,034 | 587,112 |
| Operating lease liabilities | 281,225 | 438,957 |
| Short-term debt, related party | 850,000 | 2,050,000 |
| Total current liabilities | 5,299,936 | 6,337,123 |
| Operating lease liabilities, net of current portion | 780,244 | 1,061,469 |
| Total liabilities | 6,080,180 | 7,398,592 |
| Common stock | 1,872 | 7,688 |
| Additional paid-in capital | 52,475,189 | 50,276,511 |
| Accumulated deficit | (51,440,227) | ... |
| Accumulated stockholders' equity (deficit) | ... | (41,534,445) |
| Total stockholders' equity (deficit) | 1,036,834 | 8,749,754 |
| Total Equity | 1,036,834 | ... |

Recent Dividends:

- 1. Kidpik Corp common. No dividends paid.

Annual Dividends:

- 1. Kidpik Corp common. No dividends paid.

KIORA PHARMACEUTICALS INC

¹ Reclassified to conform with 2022 presentation; ² As reported by the Company; ³ Adjusted for 1-for-40 stock split, September 28, 2022; ⁴ Shares increased due to the issuance of Panoptes Hold-back shares, common share from public offering and warrant indenture, conversion of series E preferred share and exercise of warrant; ⁵ Shares increased due to the issuance of shares from warrants, private placement and direct offering, conversion of preferred share and issuance of shares to Bayon Shareholders at acquisition; ⁶ As of March 20, 2023; ⁷ As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash & cash equivalents | 2,454,684 | 5,964,556 |
| Prepaid expenses & other current assets | 233,382 | 343,069 |
| Tax receivables | 2,049,965 | 1,373,041 |
| Total current assets | 4,738,031 | 7,680,666 |
| Laboratory equipment | 11,832 | 88,399 |
| Office equipment | ... | 3,409 |
| Office furniture | ... | 58,119 |
| Leasehold improvements | ... | 22,569 |
| Furniture, fixtures, & office equipment | 2,521 | ... |
| Total property & equipment, gross | 14,353 | 172,496 |
| Less: accumulated depreciation | 6,289 | 117,319 |
| Property & equipment, net | 8,065 | 55,177 |
| Restricted cash | 4,267 | 49,260 |
| Intangible assets & in-process research & development, net | 8,813,850 | 10,743,164 |
| Operating lease assets with right-of-use | 106,890 | 116,992 |
| Other assets | 40,767 | 33,000 |
| Total assets | 13,711,870 | 18,678,259 |
| Accounts payable | 206,260 | 1,008,262 |
| Payroll & benefits | 875,254 | 1,312,443 |
| Professional fees | 43,387 | 282,721 |
| Clinical trials | 397,465 | 57,020 |
| Other accrued expenses | ... | 183,750 |
| Accrued Expenses - Balancing value | 1,380,666 | ... |
| Accrued expenses | ... | 1,835,934 |
| Operating lease liabilities | 47,069 | 105,782 |
| Contingent consideration, short-term | 64,560 | 322,385 |
| Total current liabilities | 1,633,995 | 3,272,363 |
| Contigent consideration | 5,128,959 | 3,309,175 |
| Deferred tax liability | 779,440 | 689,121 |
| Non-current operating lease liabilities | 59,822 | ... |
| Total non-current liabilities | 5,968,221 | 3,998,296 |
| Total liabilities | 7,602,216 | 7,270,659 |
| Common stock | 77,078 | 17,986 |
| Additional paid-in capital | 153,192,228 | 146,035,314 |
| Retained earnings (accumulated deficit) | (146,976,855) | (134,462,959) |
| Accumulated other comprehensive income (loss) | (182,801) | (182,741) |
| Preferred Stock, \$001 Par Value: 10,000,000 shares authorized at 30, 2023 and 31, 2022; 3,750 designated Series A, 0 shares issued and outstanding at 30, 2023 and 31, 2022; 10,000 designated Series B, 0 shares issued and outstanding at 30, 2023 and | 4 | ... |
| Total stockholders' equity (deficit) | 6,109,654 | 11,407,600 |
| Total Equity | 6,109,654 | ... |

Recent Dividends:

1. Kiora Pharmaceuticals Inc series C convertible preferred.

| | | | |
|---|--|--|--|
| No dividends paid. | | | |
| 2. Kiora Pharmaceuticals Inc series B convertible preferred. | | | |
| No dividends paid. | | | |
| 3. Kiora Pharmaceuticals Inc series C convertible preferred. | | | |
| No dividends paid. | | | |
| 4. Kiora Pharmaceuticals Inc series D convertible preferred. | | | |
| No dividends paid. | | | |
| 5. Kiora Pharmaceuticals Inc series D convertible preferred. | | | |
| No dividends paid. | | | |
| 6. Kiora Pharmaceuticals Inc series A convertible preferred. | | | |
| No dividends paid. | | | |
| 7. Kiora Pharmaceuticals Inc common. | | | |
| No dividends paid. | | | |
| 8. Kiora Pharmaceuticals Inc series F convertible preferred. | | | |
| No dividends paid. | | | |
| 9. Kiora Pharmaceuticals Inc series B convertible preferred. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. Kiora Pharmaceuticals Inc series C convertible preferred. | | | |
| No dividends paid. | | | |
| 2. Kiora Pharmaceuticals Inc series B convertible preferred. | | | |
| No dividends paid. | | | |
| 3. Kiora Pharmaceuticals Inc series C convertible preferred. | | | |
| No dividends paid. | | | |
| 4. Kiora Pharmaceuticals Inc series D convertible preferred. | | | |
| No dividends paid. | | | |
| 5. Kiora Pharmaceuticals Inc series D convertible preferred. | | | |
| No dividends paid. | | | |
| 6. Kiora Pharmaceuticals Inc series A convertible preferred. | | | |
| No dividends paid. | | | |
| 7. Kiora Pharmaceuticals Inc common. | | | |
| No dividends paid. | | | |
| 8. Kiora Pharmaceuticals Inc series F convertible preferred. | | | |
| No dividends paid. | | | |
| 9. Kiora Pharmaceuticals Inc series B convertible preferred. | | | |
| No dividends paid. | | | |

KLDISCOVERY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|----------------|
| Revenues | 345,799,000 | ... | ... |
| Revenues | 345,799,000 | 317,432,000 | 320,477,000 |
| Cost of Revenues | 171,912,000 | ... | ... |
| Cost of revenues | 171,912,000 | 165,454,000 | 163,958,000 |
| Gross profit | 173,887,000 | 151,978,000 | 156,519,000 |
| General & administrative | 65,159,000 | 63,294,000 | 61,245,000 |
| Research & development | 13,133,000 | 13,486,000 | 10,265,000 |
| Sales & marketing | 41,165,000 | 43,570,000 | 39,892,000 |
| Impairment of intangible asset | ... | ... | 22,529,000 |
| Depreciation & amortization | 20,133,000 | 19,593,000 | 27,863,000 |
| Total operating expenses | 139,590,000 | 139,943,000 | 161,794,000 |
| Income (loss) from operations | 34,297,000 | 12,035,000 | (5,275,000) |
| Other expense | ... | 54,000 | 25,000 |
| Change in fair value of private warrants | 20,000 | 1,207,000 | 1,969,000 |
| Interest expense | 66,743,000 | 54,650,000 | 50,402,000 |
| Gain (loss) on extinguishment of debt | ... | ... | (7,257,000) |
| Income (loss) before income taxes - domestic | ... | (40,326,000) | (57,135,000) |
| Income (loss) before income taxes - foreign | ... | (1,136,000) | (3,855,000) |
| Income (loss) before income taxes | (31,854,000) | (41,462,000) | (60,990,000) |
| Current income tax provision (benefit) - state | 70,000 | 56,000 | 37,000 |
| Current income tax provision (benefit) - foreign | 832,000 | 885,000 | 605,000 |
| Deferred income tax provision (benefit) - federal | 307,000 | 370,000 | 345,000 |

| | | | |
|---|---------------------|---------------------|---------------------|
| Deferred income tax provision (benefit) - state | 999,000 | 697,000 | 794,000 |
| Deferred income tax provision (benefit) - foreign | 751,000 | (296,000) | (2,228,000) |
| Income tax provision (benefit) | 2,959,000 | 1,712,000 | (447,000) |
| Net income (loss) | (34,813,000) | (43,174,000) | (60,543,000) |
| Weighted average shares outstanding - basic | 43,013,825 | 42,709,706 | 42,601,745 |
| Weighted average shares outstanding - diluted | 43,013,825 | 42,709,706 | 42,601,745 |
| Year end shares outstanding | 43,086,267 | 42,920,136 | 42,684,549 |
| Net earnings (loss) per share - basic | \$(0.81) | \$(1.01) | \$(1.42) |
| Net earnings (loss) per share - diluted | \$(0.81) | \$(1.01) | \$(1.42) |
| Number of full time employees | 2,687 | 1,163 | 1,220 |
| Number of temporary employees | ... | 1,271 | 1,635 |
| Total number of employees | 2,687 | 2,434 | 2,855 |
| Number of common stockholders | 53 | 55 | 51 |
| Foreign currency translation adjustments | ... | (6,938,000) | (4,465,000) |
| Change in fair value of Private Warrants | 572,000 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash & cash equivalents | 15,351,000 | 32,629,000 |
| Accounts receivable, gross | 104,899,000 | 101,130,000 |
| Less: allowance for doubtful accounts | 3,642,000 | 5,403,000 |
| Accounts receivable, net | 101,257,000 | 95,727,000 |
| Prepaid expenses | 15,787,000 | 10,726,000 |
| Other current assets | 1,585,000 | 1,175,000 |
| Total current assets | 133,980,000 | 140,257,000 |
| Computer software & hardware | 2,262,000 | 71,720,000 |
| Leasehold improvements | 26,313,000 | 25,869,000 |
| Furniture, fixtures & other equipment | ... | 2,209,000 |
| Less: accumulated depreciation | 73,045,000 | 79,958,000 |
| Computer software and hardware | 61,731,000 | ... |
| Property & equipment, net | 17,261,000 | 19,840,000 |
| Operating lease right of use assets, net | 10,078,000 | 12,412,000 |
| Intangible assets, net | 39,729,000 | 46,862,000 |
| Goodwill | 396,283,000 | 391,114,000 |
| Other assets | 8,262,000 | 8,957,000 |
| Total assets | 605,593,000 | 619,442,000 |
| Current portion of long-term debt, net | 546,845,000 | 3,000,000 |
| Accounts payable & accrued expense | 9,153,000 | 25,009,000 |
| Operating lease liabilities | 5,906,000 | 7,850,000 |
| Current portion of contingent consideration | 650,000 | ... |
| Deferred revenue | 3,181,000 | 4,536,000 |
| Accrued expenses | 1,301,000 | ... |
| Capitalized Leases - Current Portion | 135,000 | ... |
| Accrued interest | 532,000 | ... |
| Accrued salaries | 14,229,000 | ... |
| Current taxes payable | 742,000 | ... |
| Accounts payable and accrued expense - Balancing value | 25,957,000 | ... |
| Other accrued expenses - | ... | ... |

| | | |
|---|---------------|---------------|
| Balancing value | 1,166,000 | ... |
| Total current liabilities | 582,539,000 | 40,395,000 |
| Convertible debenture notes | 244,808,000 | ... |
| Credit agreement | 294,750,000 | ... |
| Less: unamortized original issue discount | (10,751,000) | ... |
| Less: unamortized debt issuance costs | (1,278,000) | ... |
| Less: current portion of debt | 3,000,000 | ... |
| Long-term debt, net | 524,529,000 | ... |
| Deferred tax liabilities | 8,941,000 | 7,793,000 |
| Long term operating lease liabilities | 7,870,000 | 10,340,000 |
| Other liabilities | 2,176,000 | 2,694,000 |
| Total liabilities | 601,526,000 | 585,751,000 |
| Common stock | 4,000 | 4,000 |
| Additional paid-in capital | 395,461,000 | 391,977,000 |
| Retained earnings (accumulated deficit) | (393,954,000) | (359,141,000) |
| Accumulated other comprehensive income | 2,556,000 | 851,000 |
| Total stockholders' equity (deficit) | 4,067,000 | 33,691,000 |
| Total Equity | 4,067,000 | ... |

Recent Dividends:

- 1. KLDDiscovery Inc class A common.**
No dividends paid.
- 2. KLDDiscovery Inc class B common.**
No dividends paid.
- 3. KLDDiscovery Inc common.**
No dividends paid.

Annual Dividends:

- 1. KLDDiscovery Inc class A common.**
No dividends paid.
- 2. KLDDiscovery Inc class B common.**
No dividends paid.
- 3. KLDDiscovery Inc common.**
No dividends paid.

KONATEL INC**Annual Report**

| | | | |
|---|-------------|-------------|----------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Revenue | 18,223,745 | ... | ... |
| Revenue | 18,223,745 | 20,023,340 | 12,834,844 |
| Cost of revenue | 14,850,105 | 15,033,733 | 7,105,464 |
| Gross profit | 3,373,640 | 4,989,607 | 5,729,380 |
| Payroll & related expenses | 3,995,698 | 4,974,989 | 2,702,495 |
| Professional & other expenses | 191,556 | 1,509,269 | 697,594 |
| Operating & maintenance expense | 5,804 | 8,129 | 1,887 |
| Bad debt expense | 215 | 29,133 | 31,318 |
| Utilities & facilities | ... | 206,380 | 146,254 |
| Depreciation & amortization expense | 12,352 | 12,352 | 833,016 |
| General & administrative expenses | 155,734 | 300,042 | 156,386 |
| Marketing & advertising expenses | 154,533 | 106,402 | 90,635 |
| Application development costs | 138,600 | 146,400 | 266,191 |
| Taxes & insurance expense | 312,804 | 251,196 | 165,257 |
| Total operating expenses | 6,494,243 | 7,544,292 | 5,091,033 |
| Professional and Other Expenses | 1,526,947 | ... | ... |
| Operating income (loss) | (3,120,603) | (2,554,685) | 638,347 |
| Interest expense | ... | 399,031 | 15,361 |
| Other income (expense), net | 30 | 1,356 | ... |
| Interest expense | 820,254 | ... | ... |

| | | | |
|---|--------------------|--------------------|----------------|
| Total other income & expenses | (820,224) | (397,675) | (15,361) |
| Net income (loss) before provision for income tax | (3,940,827) | ... | ... |
| Tax at statutory federal rate | (850,623) | ... | ... |
| Income Taxes - Other - | ... | ... | ... |
| Deferred/Current | 850,623 | ... | ... |
| Net income (loss) | (3,940,827) | (2,952,360) | 622,986 |
| Weighted average shares outstanding - basic | 42,773,269 | 41,863,283 | 40,909,085 |
| Weighted average shares outstanding - diluted | 42,773,269 | 41,863,283 | 42,891,011 |
| Year end shares outstanding | 43,145,720 | 42,240,406 | 41,615,406 |
| Net income (loss) per share - basic | \$(0.09) | \$(0.07) | \$0.02 |
| Net income (loss) per share - diluted | \$(0.09) | \$(0.07) | \$0.01 |
| Number of full time employees | 34 | 35 | 21 |
| Number of part time employees | 1 | 2 | 2 |
| Total number of employees | 35 | 37 | 23 |
| Number of common stockholders | 555 | 556 | 561 |

Reclassified to conform with 2022 presentation; As of March 20, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|--------------|-------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 777,103 | 2,055,634 |
| Accounts receivable, net | 1,496,799 | 1,510,118 |
| Inventory, net | 1,229,770 | 526,337 |
| Prepaid expenses | 129,706 | 61,241 |
| Other current asset | ... | 164 |
| Total current assets | 3,633,378 | 4,153,494 |
| Lease improvements | 46,950 | 46,950 |
| Furniture & fixtures | 102,946 | 102,946 |
| Billing software | 461,611 | 217,163 |
| Office equipment | 217,163 | 94,552 |
| Office Equipment | 94,552 | ... |
| Property & equipment, gross | ... | 461,611 |
| Less: accumulated depreciation | 437,427 | 425,075 |
| Property & equipment, net | 24,184 | 36,536 |
| Right to use assets, net | 443,328 | ... |
| Intangible Assets, Net - Balancing value | 634,251 | ... |
| Intangible assets, net | ... | 1,187,937 |
| Other assets | 74,543 | 73,883 |
| Total other assets | ... | 1,261,820 |
| Total assets | 4,809,684 | 5,451,850 |
| Accounts payable & accrued expenses | 3,709,691 | 1,348,931 |
| Loans payable, net of loan fees | ... | 3,070,947 |
| Note payable - current portion | 3,655,171 | ... |
| Right of use operating lease obligation - current | 127,716 | 118,382 |
| Total current liabilities | 7,492,578 | 4,538,260 |
| Right of use operating lease obligation - long term | 330,511 | 458,227 |
| Total long term liabilities | 330,511 | 458,227 |
| Total liabilities | 7,823,089 | 4,996,487 |
| Common stock | 43,146 | 42,240 |
| Additional paid in capital | 9,182,140 | 8,710,987 |
| Retained earnings (accumulated deficit) | (12,238,691) | (8,297,864) |
| Total stockholders' equity (deficit) | (3,013,405) | 455,363 |

| | | |
|--------------|-------------|-----|
| Total Equity | (3,013,405) | ... |
|--------------|-------------|-----|

Recent Dividends:

- 1. KonaTel Inc series A preferred.**
No dividends paid.
- 2. KonaTel Inc 6% series A convertible preferred.**
No dividends paid.
- 3. KonaTel Inc common.**
No dividends paid.

Annual Dividends:

- 1. KonaTel Inc series A preferred.**
No dividends paid.
- 2. KonaTel Inc 6% series A convertible preferred.**
No dividends paid.
- 3. KonaTel Inc common.**
No dividends paid.

KORRO BIO INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

| | | | |
|---|-----------------|-----------------|-----------------|
| | 2023 | 2022 | 2021 (revised) |
| Revenue | ... | ... | 14,068 |
| Research & development expenses | 57,250 | 49,418 | 60,923 |
| General & administrative expenses | 27,284 | 33,584 | 37,176 |
| Total operating expenses | 84,534 | 83,002 | 98,099 |
| Income (loss) from operations | (84,534) | (83,002) | (84,031) |
| Interest income | ... | 1,327 | 397 |
| Interest expense | ... | 961 | 764 |
| Realized (loss) gain on investments | ... | 3 | (23) |
| Foreign exchange gain (loss) | ... | (5) | 16 |
| Other income (expense), net | 3,389 | 1,056 | (266) |
| Income (loss) before income taxes - domestic | ... | (81,586) | (84,624) |
| Income (loss) before income taxes - foreign | ... | 4 | (47) |
| Income (loss) before income taxes | (81,145) | (81,582) | (84,671) |
| Provision for current income taxes - state | 27 | (2) | 15 |
| Total provision for current income taxes | 27 | ... | ... |
| Provision for income taxes | 27 | (2) | 15 |
| Net income (loss) | (81,172) | (81,580) | (84,686) |
| Weighted average shares outstanding - basic | 1,529 | 702 | 687 |
| Weighted average shares outstanding - diluted | 1,529 | 702 | 687 |
| Year end shares outstanding | 8,017 | 705 | 692 |
| Net earnings (loss) per share - basic | \$(53.08) | \$(116.50) | \$(123.50) |
| Net earnings (loss) per share - diluted | \$(53.08) | \$(116.50) | \$(123.50) |
| Number of full time employees | 101 | 46 | 72 |
| Number of part time employees | 1 | 2 | 2 |
| Total number of employees | 102 | 48 | 74 |
| Number of common stockholders | 96 | 67 | 78 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to | ... | ... | ... |

| | | | |
|--|-----------|-----|-----|
| Common - Total | \$(53.08) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(53.08) | ... | ... |

No dividends paid.
Annual Dividends:
1. Korro Bio Inc common.
 No dividends paid.
KORU MEDICAL SYSTEMS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|-----------------------------|---------|-----|-----|
| Depreciation & amortization | 870,390 | ... | ... |
|-----------------------------|---------|-----|-----|

□ Approximately; □ As of March 8, 2023; □ As of February 28, 2022

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-50 stock split, November 6, 2023; □ As Is; □ As of March 8, 2022; □ Approximately; □ As of February 1, 2023

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | |
|---|-----------|-----------|--|
| | 2023 | 2022 | |
| Cash | ... | 51,954 | |
| Short-term marketable securities | ... | 31,143 | |
| Research & development expenses | ... | 2,084 | |
| Accounts receivable | ... | 449 | |
| Insurance | ... | 1,608 | |
| Other prepaid expenses | 3,015 | 255 | |
| Prepaid expenses & other current assets | ... | 4,396 | |
| Cash and cash equivalents | 166,150 | ... | |
| Restricted cash | ... | 3,563 | |
| Total current assets | 172,728 | 87,493 | |
| Lab equipment | 11,187 | 5,706 | |
| Furniture & office equipment | 481 | 3,238 | |
| Software | 241 | 291 | |
| Leasehold improvements | 3,356 | ... | |
| Construction in progress | 8,242 | ... | |
| Total property & equipment, gross | 23,507 | 9,235 | |
| Less: Accumulated depreciation | 7,842 | 6,496 | |
| Property & equipment, net | 15,665 | 2,739 | |
| Right of use assets | 27,150 | 28,980 | |
| Other long-term assets | ... | 327 | |
| Restricted cash | ... | 1,699 | |
| Other non-current assets | 2,714 | ... | |
| Restricted Cash, net of current portion | 3,406 | ... | |
| Total assets | 221,663 | 121,238 | |
| Accounts payable | ... | 7,280 | |
| Payroll & employee related expenses | 7,896 | 4,216 | |
| Professional fees | 219 | 377 | |
| Third-party research & development expenses | 1,255 | 773 | |
| Accrued taxes & other accrued expenses | 447 | 525 | |
| Other accrued expenses | 10,212 | 5,891 | |
| Accrued expenses | ... | ... | |
| Lease liabilities, current portion | 1,991 | 2,021 | |
| Term loan, current portion | ... | 10,000 | |
| CVR liability, current | 395 | ... | |
| Total current liabilities | 19,483 | 21,026 | |
| Lease liabilities, net of current portion | 31,216 | 26,761 | |
| Term loan, net of current portion | ... | 4,167 | |
| Other long-term liabilities | 1,053 | 89 | |
| Total liabilities | 51,752 | 52,043 | |
| Common stock | 8 | 35 | |
| Additional paid-in capital | 352,908 | 331,023 | |
| Accumulated other comprehensive income (loss) | ... | (198) | |
| Accumulated deficit | (183,005) | ... | |
| Retained earnings (accumulated deficit) | ... | (261,665) | |
| Total stockholders' equity (deficit) | 169,911 | 69,195 | |
| Total stockholders equity | 169,911 | ... | |

| | 2023 | 2022 | 2021 (revised) |
|--|---------------------|--------------------|--------------------|
| Total revenues | 28,517,666 | ... | ... |
| Sale of impotence treatment | 28,517,666 | ... | ... |
| Net revenues | ... | 27,896,037 | 23,490,175 |
| Cost of goods sold | 11,809,384 | 12,527,051 | 9,720,597 |
| Gross profit (loss) | 16,708,282 | 15,368,986 | 13,769,578 |
| Selling, general & administrative expenses | 20,365,617 | 20,606,507 | 17,862,314 |
| Research & development expenses | 5,742,254 | 4,956,215 | 2,473,669 |
| Depreciation & amortization expenses | 870,390 | 587,137 | 463,130 |
| Total operating expenses | 26,978,261 | 26,149,859 | 20,799,113 |
| Net operating profit (loss) | (10,269,979) | (10,780,873) | (7,029,535) |
| Gain (loss) on foreign currency exchange | (5,124) | (39,874) | (28,905) |
| Gain (loss) on disposal of fixed assets | (59,807) | ... | 1,009 |
| Other income, net | 561,328 | 145,587 | 13,083 |
| Total other income (expenses) | 496,397 | 105,713 | 665,094 |
| Income (loss) before taxes | (9,773,582) | (10,675,160) | (6,364,441) |
| Current state income tax expense (benefit), net of refund | ... | 0 | 12,800 |
| Deferred federal income tax expense (benefit) | ... | (2,014,018) | (1,814,418) |
| Income Taxes - Domestic - Deferred | (2,035,297) | ... | ... |
| Write-off of deferred tax asset | 6,002,777 | ... | ... |
| Income tax expense (benefit) | 3,967,480 | (2,014,018) | (1,801,618) |
| Net income (loss) | (13,741,062) | (8,661,142) | (4,562,823) |
| Weighted average shares outstanding - basic | 45,601,346 | 45,002,074 | 44,385,032 |
| Weighted average shares outstanding - diluted | 45,601,346 | 45,002,074 | 44,385,032 |
| Year end shares outstanding | 45,669,362 | 45,441,389 | 44,623,660 |
| Income (loss) per share from continuing operations - basic | \$(0.30) | ... | ... |
| Net income (loss) per share - basic | \$(0.30) | \$(0.19) | \$(0.10) |
| Income (loss) per share from continuing operations - diluted | \$(0.30) | ... | ... |
| Net income (loss) per share - diluted | \$(0.30) | \$(0.19) | \$(0.10) |
| Number of full time employees | 82 | 85 | 77 |
| Number of part time employees | ... | 1 | ... |
| Total number of employees | 82 | ... | ... |
| Number of common stockholders | 471 | □□516 | □□552 |

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|--------------|-------------|-----|
| | 2023 | 2022 | |
| Other cash & cash equivalents | 11,482,240 | ... | ... |
| Cash & cash equivalents | ... | 17,408,257 | |
| Accounts receivable, gross | 4,069,988 | 3,580,343 | |
| Less: allowance for doubtful accounts | 24,777 | 21,459 | |
| Accounts receivable | 4,045,211 | 3,558,884 | |
| Raw materials | 1,869,356 | ... | |
| Raw materials & work-in-process | ... | 3,853,034 | |
| Finished goods | 1,862,525 | 2,611,951 | |
| Total inventory | ... | 6,464,985 | |
| Less: reserve for obsolete inventory | 250,580 | 60,118 | |
| Inventory | 3,481,301 | 6,404,867 | |
| Other receivables | 28,889 | 972,396 | |
| Prepaid expenses & other current assets | ... | 1,457,232 | |
| Prepaid expenses & other receivables | 1,218,288 | ... | |
| Total current assets | 20,255,929 | 29,801,636 | |
| Furniture & office equipment | 1,412,164 | 1,456,745 | |
| Leasehold Improvements | 1,953,653 | 2,413,820 | |
| Manufacturing equipment & tooling | 3,193,113 | 2,810,813 | |
| Total property & equipment | 6,558,930 | 6,681,378 | |
| Less: accumulated depreciation & amortization | 2,721,273 | 2,794,403 | |
| Property & equipment, net | 3,837,657 | 3,886,975 | |
| Patents, net | 754,361 | ... | |
| Intangible assets, gross | ... | 1,113,054 | |
| Less: accumulated amortization - intangibles assets | ... | 325,872 | |
| Intangible assets, net | ... | 787,182 | |
| Operating lease right-of-use assets | 3,514,055 | 3,786,545 | |
| Deferred income tax assets, net | ... | 3,967,480 | |
| Other assets | 98,970 | 102,625 | |
| Total assets | 28,460,972 | 42,332,443 | |
| Accounts payable | 975,193 | 2,391,799 | |
| Accrued expenses | 1,711,427 | 2,889,941 | |
| Note payable | 314,344 | 433,295 | |
| Other current liabilities | 512,520 | 257,337 | |
| Accrued payroll & related taxes | 462,941 | 542,399 | |
| Finance lease liability - current | 109,540 | 98,335 | |
| Operating lease liability - current | 368,313 | 345,834 | |
| Total current liabilities | 4,454,278 | 6,958,940 | |
| Finance lease liability, net of current portion | 316,623 | 394,283 | |
| Operating lease liability, net of current portion | 3,336,300 | 3,653,257 | |
| Total liabilities | 8,107,201 | 11,006,480 | |
| Common stock | 490,899 | 488,619 | |
| Additional paid-in capital | 47,018,707 | 44,252,117 | |
| Treasury stock | 3,843,562 | 3,843,562 | |
| Retained Deficit | (23,312,273) | ... | |
| Retained earnings (accumulated deficit) | ... | (9,571,211) | |
| Total stockholders' equity (deficit) | 20,353,771 | 31,325,963 | |
| Total Liabilities and Stockholders | 20,353,771 | ... | |

Recent Dividends:
1. Korro Bio Inc common.

Recent Dividends:

1. KORU Medical Systems Inc 8% cumulative convertible preferred.

No dividends paid.

2. KORU Medical Systems Inc common.

No dividends paid.

Annual Dividends:

1. KORU Medical Systems Inc 8% cumulative convertible preferred.

No dividends paid.

2. KORU Medical Systems Inc common.

No dividends paid.

KRAIG BIOCRAFT LABORATORIES, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|--------------------|
| General & administrative | 1,454,295 | 825,460 | 1,496,725 |
| Professional fees | 125,222 | 339,710 | 326,982 |
| Officer's salary | 797,406 | 779,742 | 734,427 |
| Rent - related party | ... | ... | 3,683 |
| Research & development | 237,871 | 176,431 | 197,745 |
| Total operating expenses | 2,614,794 | 2,121,343 | 2,759,562 |
| Income (loss) from operations | (2,614,794) | (2,121,343) | (2,759,562) |
| Gain (loss) on debt extinguishment (paycheck protection program) | ... | ... | 90,100 |
| Interest income | 109,559 | ... | ... |
| Net change in unrealized depreciation on investment in gold bullion | (55,985) | (38) | 13,004 |
| Interest expense | 484,658 | 609,129 | 660,419 |
| Amortization of debt issue costs | ... | 1,111,580 | 4,702,918 |
| Asset impairment expense | 95,872 | ... | ... |
| Total other income (expenses) | (414,986) | (1,720,671) | (5,286,241) |
| Net income (loss) before provision for income taxes (benefit) | (3,029,780) | (3,842,014) | (8,045,803) |
| Net income (loss) | (3,029,780) | (3,842,014) | (8,045,803) |
| Weighted average shares outstanding - basic | 1,033,122,597 | 974,307,366 | 877,612,187 |
| Weighted average shares outstanding - diluted | 1,033,122,597 | 974,307,366 | 877,612,187 |
| Year end shares outstanding | 1,038,374,219 | 1,030,940,008 | 927,378,166 |
| Net income (loss) per share - basic | ... | \$0.00 | \$(0.01) |
| Net income (loss) per share - diluted | ... | \$0.00 | \$(0.01) |
| Number of full time employees | 7 | 36 | 38 |
| Number of part time employees | 7 | 5 | 3 |
| Total number of employees | 14 | ... | ... |
| Number of class A common stockholders | 33 | 33 | 34 |
| Number of series A preferred stockholders | ... | ... | 1 |

Reclassified to conform with 2022 presentation; Approximately; As of March 29, 2023; As of March 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------|-----------|-----------|
| Cash and cash equivalents | 2,551,834 | ... |
| Cash | ... | 3,862,716 |
| Inventory | 6,884 | 6,580 |

| | | |
|---|--------------|--------------|
| Prepaid expenses | 14,902 | 15,665 |
| Deposits | ... | 98,480 |
| Total current assets | 2,573,620 | 3,983,441 |
| Automobile | 41,805 | 41,805 |
| Laboratory equipment | 130,310 | 123,911 |
| Office equipment | 7,260 | 7,260 |
| Leasehold improvements | 82,739 | 82,739 |
| Less: accumulated depreciation | 195,474 | 167,854 |
| Property & equipment, net | 66,640 | 87,861 |
| Investment in gold bullions | 493,236 | 437,251 |
| Operating lease right-of-use asset, net | 95,808 | 58,849 |
| Security deposit | 3,518 | 3,518 |
| Total assets | 3,232,822 | 4,570,920 |
| Accounts payable & accrued expenses | 541,637 | 540,339 |
| Current portion of loan payable | 35,244 | ... |
| Note payable - related party | 1,617,000 | 1,617,000 |
| Royalty agreement payable - related party | 65,292 | 65,292 |
| Accounts payable & accrued expenses - related party | 6,584,648 | 5,715,008 |
| Operating lease liability, current | 41,789 | 39,200 |
| Loan payable | ... | 95,244 |
| Total current liabilities | 8,885,610 | 8,072,083 |
| Operating lease liability, net of current | 54,368 | 20,697 |
| Total liabilities | 8,939,978 | 8,092,780 |
| Preferred stock series A | 5,217,800 | 5,217,800 |
| Common stock class A | 22,000 | 27,060,611 |
| Common stock issuable | 27,385,611 | 22,000 |
| Additional paid-in capital | 11,354,213 | 10,834,729 |
| Retained earnings (accumulated deficit) | ... | (46,657,000) |
| Accumulated Deficit | (49,686,780) | ... |
| Total stockholders' equity (deficit) | (5,707,156) | (3,521,860) |
| Total Equity | (5,707,156) | ... |

Cost - investment in gold bullions: \$450,216

Recent Dividends:

1. Kraig Biocraft Laboratories, Inc. class A common.

No dividends paid.

2. Kraig Biocraft Laboratories, Inc. series A preferred stock.

No dividends paid.

Annual Dividends:

1. Kraig Biocraft Laboratories, Inc. class A common.

No dividends paid.

2. Kraig Biocraft Laboratories, Inc. series A preferred stock.

No dividends paid.

KRAIG BIOCRAFT LABORATORIES, INC.**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, M&K CPAS, PLLC., as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Kraig Biocraft Laboratories, Inc. (the Company) as of December 31, 2023 and 2022, and the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for each of the years in the two-years ended December 31, 2023, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the two years in the period ended December 31, 2023 in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered net losses from operations and has a net capital deficiency, which raises substantial doubt about its ability to continue as a going concern. Management's plans regarding

those matters are discussed in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

LADRX CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|----------------|--------------------|---------------------|
| General & administrative expenses | 3,532,302 | 4,545,884 | 5,966,415 |
| Settlement with former chief executive officer | 279,489 | ... | 6,096,597 |
| Depreciation & amortization expenses | 11,835 | 15,004 | 13,978 |
| Total expenses | 3,823,626 | 4,560,888 | 12,076,990 |
| Loss from operations | (3,823,626) | (4,560,888) | ... |
| Liquidated damage expense | ... | ... | 1,109,653 |
| Forgiveness of accounts payable | ... | 351,241 | ... |
| Interest income | 55,434 | 11,689 | 16,822 |
| Other income (expense), net | 1,416 | (2,615) | (6,842) |
| Income (loss) before provision (benefit) for income taxes | 400,443 | ... | (13,176,663) |
| Net income (loss) | 400,443 | (4,200,573) | (13,176,663) |
| Dividends paid on preferred shares | 68,809 | 561,381 | 171,668 |
| Net income (loss) attributable to common stockholders | 331,634 | (4,761,954) | (13,348,331) |
| Weighted average shares outstanding - basic | 488,392 | 433,592 | 375,847 |
| Weighted average shares outstanding - diluted | 488,392 | 433,592 | 375,847 |
| Year end shares outstanding | 495,092 | 450,374 | 387,800 |
| Income (loss) per share from continuing operations - basic | \$0.68 | ... | ... |
| Net income (loss) per share - basic | \$0.68 | \$(11.00) | \$(35.00) |
| Income (loss) per share from continuing operations - diluted | \$0.68 | ... | ... |
| Net income (loss) per share - diluted | \$0.68 | \$(11.00) | \$(35.00) |
| Number of full time employees | 2 | 3 | 3 |
| Total number of employees | 2 | ... | ... |
| Number of common stockholders | 180 | 180 | 193 |
| Depreciation & amortization | 11,835 | ... | ... |
| Sale of royalty and milestone rights, net of transaction costs | (4,167,219) | ... | ... |

Adjusted for 1-for-100 stock split, May 17, 2023; As of March 23, 2022; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 2,070,075 | 1,374,992 |
| Prepaid expenses & other current assets | 191,783 | 628,745 |
| Total current assets | 2,261,858 | 2,003,737 |
| Equipment & furnishings, gross | 48,742 | 48,742 |

LEADER HILL CORP**Annual Report****Consolidated Income Statement, Years Ended Nov. 30 (\$):**

2023 2022 2021

| | | | |
|---|----------------|-----------------|-----------------|
| General & administrative expenses | 3,080 | 48,934 | 33,900 |
| Income (loss) before income tax | (3,080) | (48,934) | (33,900) |
| Net income (loss) | (3,080) | (48,934) | (33,900) |
| Weighted average shares outstanding - basic | 4,825,000 | 4,825,000 | 4,825,000 |
| Weighted average shares outstanding - diluted | 4,825,000 | 4,825,000 | 4,825,000 |
| Year end shares outstanding | 4,825,000 | 4,825,000 | 4,825,000 |
| Net earning (loss) per share - basic | \$0.00 | \$(0.01) | \$(0.01) |
| Net earning (loss) per share - diluted | \$0.00 | \$(0.01) | \$(0.01) |
| Total number of employees | ... | ... | 1 |
| Number of common stockholders | 19 | 19 | 34 |

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

2023 2022

| | | |
|---|-----------|-----------|
| Less: loss on disposal of office equipment | 2,154 | 2,154 |
| Less: accumulated depreciation | 1,425 | 333 |
| Office equipment, net | 729 | 1,821 |
| Total non-current assets | 729 | 1,821 |
| Total assets | 729 | 1,821 |
| Amount due to director | 58,630 | 70,630 |
| Accrued expenses | 12,508 | 10,520 |
| Total current liabilities | 71,138 | 81,150 |
| Total liabilities | 71,138 | 81,150 |
| Common stock | 4,825 | 4,825 |
| Additional paid-in capital | 106,177 | 106,177 |
| Accumulated other comprehensive income (loss) | (1,483) | (1,483) |
| Retained earnings (accumulated deficit) | (194,928) | (191,848) |
| Total stockholders' equity (deficit) | (85,409) | (82,329) |

Recent Dividends:**1. Leader Hill Corp common.**

No dividends paid.

Annual Dividends:**1. Leader Hill Corp common.**

No dividends paid.

LEAFY HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**2023 2022 ⁽¹⁾2021

| | | | |
|----------------------------------|-------------|--------------|-------------|
| Revenue | 42,252,000 | ... | ... |
| Cost of revenue | 4,801,000 | 5,860,000 | ... |
| Gross profit | 37,451,000 | 41,503,000 | ... |
| Sales & marketing expense | 12,504,000 | 27,080,000 | ... |
| Product development expense | 9,848,000 | 14,988,000 | ... |
| General & administrative expense | 22,150,000 | 27,440,000 | ... |
| Operating costs | ... | ... | 2,699,363 |
| Total operating expenses | 44,502,000 | 69,508,000 | ... |
| Income (loss) from operations | (7,051,000) | (28,005,000) | (2,699,363) |
| Interest expense, net | 2,778,000 | 2,811,000 | ... |
| Interest earned on | ... | ... | ... |

| | | | |
|--|--------------------|--------------------------|--------------------|
| marketable securities held in trust account | ... | ... | 29,303 |
| Change in fair value of warrant liability | ... | ... | (3,032,292) |
| Other Non-Operating Income/Expense | 22,000 | ... | ... |
| Other income (expense), net | ... | ... | (3,002,989) |
| Change in fair value of derivatives | 309,000 | 36,823,000 | ... |
| Other expense, net | ... | 937,000 | ... |
| Income (loss) before provision for income taxes | (9,498,000) | ... | (5,702,352) |
| Net income (loss) | (9,498,000) | 5,070,000 | (5,702,352) |
| Weighted average shares outstanding, common stock subject to possible redemption - basic | 2,005,549 | ⁽²⁾ 1,754,000 | 168,519 |
| Weighted average shares outstanding, common stock subject to possible redemption - diluted | ... | ... | 634,764 |
| Weighted average shares outstanding - diluted | 2,005,549 | ⁽²⁾ 1,887,000 | 168,519 |
| Year end shares outstanding | 2,238,513 | ⁽²⁾ 2,009,700 | 622,225 |
| Net income (loss) per share, common stock subject to possible redemption - basic | ... | ... | \$(7.00) |
| Net income (loss) per share - basic | \$(4.74) | ⁽²⁾ \$2.80 | \$(7.00) |
| Net income (loss) per share, common stock subject to possible redemption - diluted | ... | ... | \$(7.00) |
| Net income (loss) per share - diluted | \$(4.74) | ⁽²⁾ \$2.60 | \$(7.00) |
| Part-Time Employees (Period End) | 1 | ... | ... |
| Full-Time Employees (Period End) | 130 | ... | ... |
| Total number of employees | 131 | 204 | 236 |
| Number of common stockholders | 221 | ⁽³⁾ 613 | 442 |

⁽¹⁾ December 31, 2021 and prior periods for Leafly Holdings, Inc. prior to reverse merger with Merida Merger Corp. I; ⁽²⁾ Adjusted for 1-for-20 stock split, September 12, 2023; ⁽³⁾ Approximately; ⁽⁴⁾ As of March 20, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

| | | |
|--|------------|------------|
| Cash & cash equivalents | 15,293,000 | 24,594,000 |
| Accounts receivable, gross | 4,033,000 | 4,206,000 |
| Allowance for doubtful accounts | 1,398,000 | 908,000 |
| Accounts receivable, net of allowance for doubtful accounts of \$1,682 and \$1,848, respectively | 2,635,000 | ... |
| Accounts receivable, net | ... | 3,298,000 |
| Prepaid expenses | 350,000 | ... |
| Prepaid subscriptions | 568,000 | 1,051,000 |
| Prepaid insurance | ... | 533,000 |
| Other prepaid assets | 82,000 | 272,000 |
| Other current assets | 74,000 | 71,000 |
| Prepaid expenses & other | ... | ... |

| | | |
|--|--------------|--------------|
| current assets | 1,074,000 | 1,927,000 |
| Total current assets | 19,002,000 | 30,427,000 |
| Restricted cash | ... | 608,000 |
| Marketable securities held in trust account | 28,000 | ... |
| Cash & marketable securities held in trust account | 251,000 | ... |
| Furniture & equipment | 447,000 | 740,000 |
| Capitalized internal-use software | 3,655,000 | 2,310,000 |
| Property, equipment, & software, gross | 4,102,000 | 3,050,000 |
| Less: accumulated depreciation & amortization | 1,548,000 | 765,000 |
| Property, equipment, & software, net | 2,554,000 | 2,285,000 |
| Total assets | 21,835,000 | 32,712,000 |
| Accounts payable | 813,000 | 1,625,000 |
| Accrued bonuses | ... | 1,309,000 |
| Other employee-related liabilities | 969,000 | 2,403,000 |
| Accrued interest | 2,503,000 | 1,000,000 |
| Other accrued expenses | 535,000 | 1,523,000 |
| Accrued expenses & other current liabilities | ... | 6,235,000 |
| Deferred revenue | 1,764,000 | 1,958,000 |
| Accrued interest | 999,000 | ... |
| Total current liabilities | 5,080,000 | 9,818,000 |
| Non-current portion of convertible promissory notes, net | 29,085,000 | 28,863,000 |
| Private warrants | ... | ... |
| derivative liability | 104,000 | 182,000 |
| Escrow shares derivative liability | 4,000 | 52,000 |
| Stockholder earn-out rights derivative liability | 20,000 | 204,000 |
| Total non-current liabilities | 29,213,000 | 29,301,000 |
| Total liabilities | 34,293,000 | 39,119,000 |
| Treasury stock | 31,663,000 | 31,663,000 |
| Common stock | ... | 4,000 |
| Additional paid-in capital | 93,403,000 | 89,952,000 |
| Accumulated Deficit | (74,198,000) | ... |
| Retained earnings (accumulated deficit) | ... | (64,700,000) |
| Total stockholders' equity (deficit) | (12,458,000) | (6,407,000) |
| Total Equity | (12,458,000) | ... |

Recent Dividends:**1. Leafly Holdings Inc common.**

No dividends paid.

2. Leafly Holdings Inc common stock subject to possible redemption.

No dividends paid.

Annual Dividends:**1. Leafly Holdings Inc common.**

No dividends paid.

2. Leafly Holdings Inc common stock subject to possible redemption.

No dividends paid.

LEATT CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

2023 2022 2021

| | | | |
|-----------------------------------|------------|------------|------------|
| Revenues | 47,241,187 | 76,335,539 | 72,475,813 |
| Cost of revenues | 27,435,115 | 45,202,712 | 41,029,710 |
| Product royalty income | 93,696 | 240,044 | 182,698 |
| Salaries & wages expenses | 5,443,685 | 6,148,179 | 5,003,640 |
| Commissions & consulting expenses | 434,657 | 563,689 | 812,097 |
| Professional fees | 748,608 | 586,474 | 1,072,912 |
| Advertising & marketing expenses | 4,127,798 | 3,342,791 | 2,170,788 |
| Office lease & | ... | ... | ... |

| | | | |
|--|----------------|------------------|-------------------|
| expenses | 596,862 | 689,068 | 428,608 |
| Research & development costs | 2,526,550 | 2,179,996 | 1,826,846 |
| Bad debt expense (recovery) | (10,288) | 474,019 | 222,250 |
| General & administrative expenses | 3,438,746 | 3,273,346 | 2,450,376 |
| Depreciation expenses | 1,174,664 | 1,098,433 | 1,025,536 |
| Total operating expenses | 18,355,995 | 15,013,053 | |
| Income (loss) from operations | 1,418,486 | 13,016,876 | 16,615,748 |
| Interest & other income (expenses), net | (39,138) | (13,550) | (163) |
| Total other income (expenses) | (39,138) | (13,550) | (163) |
| Income (loss) before income taxes | 1,379,348 | 13,003,326 | 16,615,585 |
| Current federal income tax expense (benefit) | 678,000 | 3,037,973 | 3,057,420 |
| Current state income tax expense (benefit) | 66,889 | 182,000 | 676,428 |
| Total current income tax expense (benefit) | 744,889 | 3,219,973 | 3,733,848 |
| Deferred federal income tax expense (benefit) | (168,700) | (177,100) | 307,300 |
| Total deferred income tax expense (benefit) | (168,700) | (177,100) | 307,300 |
| Income taxes expense (benefit) | 576,189 | 3,042,873 | 4,041,148 |
| Net income (loss) | 803,159 | 9,960,453 | 12,574,437 |
| Net income (loss) available to common shareholders | 9,960,453 | 12,574,437 | |
| Weighted average shares outstanding - basic | 5,992,072 | 5,821,119 | 5,480,375 |
| Weighted average shares outstanding - diluted | 6,287,849 | 6,136,781 | 6,068,276 |
| Year end shares outstanding | 6,215,440 | 5,971,340 | 5,673,683 |
| Net income (loss) per common share - basic | \$0.13 | \$1.71 | \$2.29 |
| Net income (loss) per common share - diluted | \$0.13 | \$1.62 | \$2.07 |
| Number of full time employees | 89 | 85 | 57 |
| Number of part time employees | ... | 30 | 41 |
| Total number of employees | 89 | ... | ... |
| Number of common stockholders | 164 | ... | 170 |
| Basic EPS Excluding ExtraOrdinary Items | \$0.13 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.13 | ... | ... |

□ Approximately; □ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------------|------------|------------|
| Cash & cash equivalents | 11,347,420 | 7,102,945 |
| Accounts receivable, gross | ... | 13,583,218 |
| Less: allowance for doubtful accounts | ... | 743,621 |
| Accounts receivable | 6,970,322 | 12,839,597 |
| Inventory | ... | 22,910,534 |
| Less: reserve for obsolescence | ... | 105,072 |
| Inventory | 20,391,873 | 22,805,462 |

| | | |
|---|-------------|-------------|
| Payments in advance | 664,754 | 1,047,137 |
| Income tax refunds receivable | 623,081 | ... |
| Deferred tax asset | 9,601 | ... |
| Deferred asset, net | ... | 1,016,815 |
| Prepaid expenses & other current assets | 2,297,934 | 2,878,112 |
| Total current assets | 42,304,985 | 47,690,068 |
| Land | 403,218 | 285,752 |
| Moulds & tools | 9,215,686 | 7,904,381 |
| Computer equipment & software | 883,055 | 965,837 |
| Office & other equipment | ... | 828,652 |
| Vehicles | 267,841 | 251,047 |
| Leasehold improvements | 120,670 | 126,975 |
| Computer equipment and software | 1,239,354 | ... |
| Buildings - Gross | 270,824 | ... |
| Property & equipment, gross | 12,400,648 | 10,362,644 |
| Less: accumulated depreciation - property & equipment | 8,373,827 | 7,258,308 |
| Property & equipment, net | 4,026,821 | 3,104,336 |
| Operating lease right-of-use assets, net | 845,209 | 1,092,170 |
| Deferred tax asset, net | 84,200 | ... |
| Other receivables | 309,947 | ... |
| Deposits | 36,210 | 40,796 |
| Total assets | 47,607,372 | 51,927,370 |
| Accounts payable & accrued expenses | 5,202,368 | 6,011,390 |
| Note payable, current | 112,858 | 108,398 |
| Operating lease liabilities, current | 299,432 | 280,743 |
| Deferred compensation, current | ... | 400,000 |
| Income tax payable | ... | 3,382,700 |
| Short term loan, net of finance charges | 1,135,761 | 1,030,196 |
| Total current liabilities | 6,750,419 | 11,213,427 |
| Deferred tax liability, net | ... | 66,200 |
| Note payable, net of current portion | 30,652 | 141,967 |
| Operating lease liabilities, net of current portion | 545,777 | 811,427 |
| Preferred stock | 3,000 | 3,000 |
| Common stock | 130,553 | 130,309 |
| Additional paid-in capital | 10,745,384 | 10,645,497 |
| Accumulated other comprehensive income (loss) | (1,398,258) | (1,081,143) |
| Retained earnings (accumulated deficit) | 30,799,845 | 29,996,686 |
| Total stockholders' equity (deficit) | 40,280,524 | 39,694,349 |
| Total Equity | 40,280,524 | ... |

Recent Dividends:
1. Leatt Corp class A voting convertible preferred.
 No dividends paid.
2. Leatt Corp common.
 No dividends paid.
Annual Dividends:
1. Leatt Corp class A voting convertible preferred.
 No dividends paid.
2. Leatt Corp common.
 No dividends paid.

LEATT CORP Earnings, 9 mos. to Sep 30 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------|------------------|-------------------|
| Cost & expenses | 33,270,680 | 49,968,310 |
| Operating income | 3,321,147 | 14,827,291 |
| Net before taxes | 3,282,199 | 14,832,883 |
| Income taxes | 1,022,365 | 3,795,085 |
| Net income | 2,259,834 | 11,037,798 |
| Balance for common | ... | 11,037,798 |
| Earnings common share | | |
| Primary | \$0.38 | \$1.90 |

| | | |
|----------------|-----------|-----------|
| Fully Diluted | \$0.36 | \$1.77 |
| Common Shares: | | |
| Full Diluted | 6,270,691 | 6,237,039 |
| Year-end | 5,971,340 | 5,826,892 |

LEXARIA BIOSCIENCE CORP Earnings, 6 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------|--------------------|--------------------|
| Total revenues | 296,278 | 117,760 |
| Cost & expenses | 2,103,425 | 3,136,804 |
| Operating income | (1,837,771) | (3,079,944) |
| Gains or losses | (37,942) | (79,631) |
| Net before taxes | (1,837,771) | (3,079,944) |
| Net income | (1,837,771) | (3,079,944) |
| Earnings common share | | |
| Primary | \$(0.18) | \$(0.52) |
| Fully Diluted | \$(0.18) | \$(0.52) |
| Common Shares: | | |
| Full Diluted | 9,970,489 | 5,950,998 |
| Year-end | 12,387,673 | 5,950,998 |

LEXEO THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|--|-----------------|-----------------|-----------------|
| Grant revenue | ... | 654 | 1,657 |
| Total revenues | ... | 654 | 1,657 |
| Research and development | 53,130 | 49,162 | 45,121 |
| General and administrative | 15,383 | 12,001 | 7,173 |
| Total operating expenses | 68,513 | 61,163 | 52,294 |
| Operating income (loss) | (68,513) | (60,509) | (50,637) |
| Other expense, net | 13 | 2 | ... |
| Interest expense | ... | ... | ... |
| Interest income | 205 | 91 | ... |
| Interest income | 2,867 | 1,325 | 15 |
| Foreign Exchange Gain/Loss - Non-Business | (13) | ... | ... |
| Gain (loss) on fair value adjustment to convertible SAFE | (530) | ... | ... |
| Total other income and expense | 2,119 | 1,232 | 15 |
| Income (loss) from operations before income taxes | (66,394) | (59,277) | (50,622) |
| Net income (loss) and comprehensive income (loss) | (66,394) | (59,277) | (50,622) |
| Weighted average shares outstanding - basic | 24,668 | 1,630 | 1,553 |
| Weighted average shares outstanding - diluted | 24,668 | 1,630 | 1,553 |
| Year end shares outstanding | 26,646 | 1,607 | 1,581 |
| Net income (loss) per common share - basic | \$(2.69) | \$(36.36) | \$(32.60) |
| Net income (loss) per common share - diluted | \$(2.69) | \$(36.36) | \$(32.60) |
| Number of full time employees | 58 | 53 | ... |
| Number of preferred stockholders | ... | 44 | ... |
| Total number of employees | 58 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|-------------------------|---------|--------|
| Cash & cash equivalents | 121,466 | 77,335 |
| Prepaid expenses | 2,825 | 2,342 |
| Other current assets | 3 | 371 |
| Total current assets | 124,294 | 80,048 |
| Security deposits | 63 | ... |

| | | | | | | | | | | |
|---|-----------|-----------|---|----------|-----------|----------|--|----------|----------|----------|
| Restricted cash | 3,252 | 3,253 | administrative expenses | 38,969 | 34,659 | 37,660 | Earnings (loss) per share from continuing operations - diluted | \$(2.14) | \$(0.53) | \$(0.33) |
| Internal use software | 296 | ... | Restructuring costs | 4,184 | 8,359 | 3,759 | Earnings (loss) per share from discontinued operations - diluted | \$(1.18) | \$(3.44) | \$(0.79) |
| Furniture and fixtures | 380 | ... | Legal settlement charge | ... | ... | 1,763 | Net earnings (loss) per share - diluted | \$(3.32) | \$(3.97) | \$(1.12) |
| Lab equipment | 514 | ... | Income (loss) from sale of Fielder's Choice Direct | 2,108 | ... | ... | Number of full time employees | 459 | ... | ... |
| Leasehold improve | 247 | ... | Operating income (loss) | (21,796) | (11,791) | (134) | Total number of employees | 459 | ... | ... |
| Property, Plant & Equipment - Gross - Total | 1,437 | ... | Interest income | 68 | 81 | 48 | Number of common stockholders | 47 | ... | ... |
| Right of Use Tangible Assets - Capital/Finance Lease - Accumulated Depreciation | 500 | ... | Interest expense, net | 17,649 | 15,551 | 10,387 | | | | |
| Property, Plant & Equipment - Accumulated Depreciation & Impairment | 381 | ... | Transition services income | 349 | 5,814 | ... | | | | |
| Right of Use Tangible Assets - Capital/Finance Lease - Gross | 2,200 | ... | Loss on debt refinancing | ... | ... | 1,110 | | | | |
| Property and equipment, net | 1,056 | 998 | Gain (loss) on debt refinancing | (23,741) | ... | ... | | | | |
| Lease right-of-use assets - finance, net | 1,763 | 2,069 | Other income (expense), net | (1,159) | 760 | 111 | | | | |
| Lease right-of-use assets - operating | 9,442 | 10,708 | Net income (loss) from continuing operations before taxes | (63,928) | (20,687) | (11,472) | | | | |
| Total assets | 139,807 | 97,076 | Current federal income tax expense (benefit) | (1) | ... | (38) | Cash & cash equivalents | 19,091 | 991 | |
| Accounts payable | 3,794 | 2,678 | Current state income tax expense (benefit) | 55 | 23 | 74 | Accounts receivables, gross | 29,509 | 38,836 | |
| Taxes payable | 157 | 506 | Current foreign income tax expense (benefit) | ... | 356 | 56 | Allowance for credit losses | 485 | 522 | |
| Accrued expenses and other current liabilities | ... | 6,420 | Total current income tax expense (benefit) | 54 | 379 | 92 | Accounts receivable, Net | 29,024 | 38,314 | |
| Accrued bonuses | 2,810 | 1,911 | Deferred federal income tax expense (benefit) | 234 | (4,936) | (1,536) | Finished goods | 13,141 | 13,397 | |
| Current portion of lease liabilities - finance | 518 | 547 | Deferred state income tax expense (benefit) | 20 | (654) | (459) | Raw materials | 17,351 | 15,488 | |
| Current portion of lease liabilities - operating | 2,087 | 2,287 | Total deferred income tax expense (benefit) | 254 | (5,590) | (1,995) | Work in progress | 10,349 | 7,115 | |
| Accrued payroll expenses | 242 | ... | Net income (loss) from continuing operations | (64,236) | (15,476) | (9,569) | Inventory, gross | 40,841 | 36,000 | |
| Accrued professional fees | 1,078 | ... | Income (loss) from discontinued operations | (35,327) | (101,929) | (28,994) | Prepaid expenses & other current assets | 4,919 | 2,053 | |
| Other current liabilities | 169 | ... | Discontinued operations - income tax expense (benefit) | ... | 690 | 5,898 | Current assets, discontinued operations | ... | 39,310 | |
| Accrued expenses and other current liabilities - Balancing value | 7,873 | ... | Income (loss) from discontinued operations - income tax expense (benefit) | (99,563) | (116,715) | (32,665) | Total current assets | 93,875 | 116,668 | |
| Accrued research and development expenses | 6,384 | ... | Weighted average shares outstanding - basic | 29,958 | 29,466 | 29,294 | Leasehold improvements | 4,019 | 4,019 | |
| Total current liabilities | 17,239 | 14,349 | Weighted average shares outstanding - diluted | 29,958 | 29,466 | 29,294 | Computer, capitalized software, machinery, equipment & autos | 2,182 | 2,091 | |
| Non-current portion of lease liabilities - finance | 1,247 | 1,648 | Year end shares outstanding | 30,322 | 29,513 | 29,333 | Construction in process | 45,587 | 26,892 | |
| Non-current portion of lease liabilities - operating | 7,786 | 9,000 | Earnings (loss) per share from continuing operations - basic | \$(2.14) | \$(0.53) | \$(0.33) | Land & buildings | 64,427 | 62,069 | |
| Accrued liabilities | 26,272 | 24,997 | Earnings (loss) per share from discontinued operations - basic | \$(1.18) | \$(3.44) | \$(0.79) | Computer Capitalized Software Machinery Equipment And Auto | 75,181 | 70,462 | |
| Series A convertible preferred stock | ... | 85,268 | Net earnings (loss) per share - basic | \$(3.32) | \$(3.97) | \$(1.12) | Equipment | 191,396 | 165,533 | |
| Series B convertible preferred stock | ... | 99,765 | | | | | Less accumulated depreciation & amortization | 57,006 | 46,863 | |
| Common stock | 3 | ... | | | | | Property & equipment, net | 134,390 | 118,670 | |
| Additional paid-in capital | 295,372 | 2,492 | | | | | Operating lease right-of-use assets | 4,282 | 5,553 | |
| Retained earnings | (181,840) | (115,446) | | | | | Goodwill, net | 13,881 | 13,881 | |
| Total stockholders' deficit | 113,535 | (112,954) | | | | | Intangible Assets - excluding Goodwill - Net | ... | 12,842 | |
| Total Equity | 113,535 | ... | | | | | - Total | 4,200 | 4,200 | |
| | | | | | | | Other assets | 2,917 | 2,889 | |
| | | | | | | | Other assets, discontinued operations | ... | 12,842 | |
| | | | | | | | Total assets | 253,545 | 274,703 | |
| | | | | | | | Accounts payable | 22,097 | 12,952 | |
| | | | | | | | Accrued compensation | 4,145 | 8,941 | |
| | | | | | | | Current portion of lease liabilities | 1,270 | 4,368 | |
| | | | | | | | Other accrued liabilities | 7,142 | 6,479 | |
| | | | | | | | Deferred revenue | 4,055 | 919 | |
| | | | | | | | Lines of credit | ... | 40,000 | |
| | | | | | | | Current portion of long-term debt, net | 580 | 98,178 | |
| | | | | | | | Current portion of capital lease obligations | 123 | ... | |
| | | | | | | | Current liabilities, discontinued operations | ... | 4,744 | |
| | | | | | | | Operating Lease Liabilities - Current | ... | ... | |
| | | | | | | | Portion/Short-Term | 1,147 | ... | |
| | | | | | | | Total current liabilities | 39,289 | 176,581 | |
| | | | | | | | Term loan | 84,256 | ... | |
| | | | | | | | Credit agreement with | ... | ... | |

Recent Dividends:

1. Lexeo Therapeutics Inc common.
No dividends paid.

Annual Dividends:

1. Lexeo Therapeutics Inc common.
No dividends paid.

LIFECORE BIOMEDICAL INC

Annual Report

Consolidated Income Statement, Years Ended (\$000):

| | 05/28/23 | 05/29/22 (revised) | 05/30/21 (revised) |
|---------------------------------|----------|-----------------------|-----------------------|
| Product sales revenue | 103,269 | 111,270 | 171,546 |
| Total revenues | 103,269 | 111,270 | ... |
| Cost of product sales | 75,284 | 72,204 | 121,075 |
| Gross profit | 27,985 | 39,066 | 50,471 |
| Research & development expenses | 8,736 | 7,839 | 7,423 |
| Selling, general & | | | |

□ Restated to reflect correction of errors; □ Restated to reflect the discontinued operations of the Eat Smart business

Consolidated Balance Sheet, Years Ended (\$000):

| | 05/28/23 | 05/29/22 (revised) |
|--|----------|-----------------------|
| Cash & cash equivalents | 19,091 | 991 |
| Accounts receivables, gross | 29,509 | 38,836 |
| Allowance for credit losses | 485 | 522 |
| Accounts receivable, Net | 29,024 | 38,314 |
| Finished goods | 13,141 | 13,397 |
| Raw materials | 17,351 | 15,488 |
| Work in progress | 10,349 | 7,115 |
| Inventory, gross | 40,841 | 36,000 |
| Prepaid expenses & other current assets | 4,919 | 2,053 |
| Current assets, discontinued operations | ... | 39,310 |
| Total current assets | 93,875 | 116,668 |
| Leasehold improvements | 4,019 | 4,019 |
| Computer, capitalized software, machinery, equipment & autos | 2,182 | 2,091 |
| Construction in process | 45,587 | 26,892 |
| Land & buildings | 64,427 | 62,069 |
| Computer Capitalized Software Machinery Equipment And Auto | 75,181 | 70,462 |
| Gross property & equipment | 191,396 | 165,533 |
| Less accumulated depreciation & amortization | 57,006 | 46,863 |
| Property & equipment, net | 134,390 | 118,670 |
| Operating lease right-of-use assets | 4,282 | 5,553 |
| Goodwill, net | 13,881 | 13,881 |
| Intangible Assets - excluding Goodwill - Net | ... | 12,842 |
| - Total | 4,200 | 4,200 |
| Other assets | 2,917 | 2,889 |
| Other assets, discontinued operations | ... | 12,842 |
| Total assets | 253,545 | 274,703 |
| Accounts payable | 22,097 | 12,952 |
| Accrued compensation | 4,145 | 8,941 |
| Current portion of lease liabilities | 1,270 | 4,368 |
| Other accrued liabilities | 7,142 | 6,479 |
| Deferred revenue | 4,055 | 919 |
| Lines of credit | ... | 40,000 |
| Current portion of long-term debt, net | 580 | 98,178 |
| Current portion of capital lease obligations | 123 | ... |
| Current liabilities, discontinued operations | ... | 4,744 |
| Operating Lease Liabilities - Current | ... | ... |
| Portion/Short-Term | 1,147 | ... |
| Total current liabilities | 39,289 | 176,581 |
| Term loan | 84,256 | ... |
| Credit agreement with | ... | ... |

| | | |
|--|-----------|----------|
| Wells Fargo | 16,809 | ... |
| Long-term lease liabilities | 9,709 | 7,658 |
| Deferred taxes, net | 380 | 126 |
| Other non-current liabilities | 3,114 | 190 |
| Non-current liabilities, discontinued operations | ... | 2,325 |
| Debt derivative liability | 64,900 | ... |
| Total liabilities | 218,457 | 186,880 |
| Redeemable convertible preferred stock | 39,318 | ... |
| Common stock | 30 | 30 |
| Additional paid-in capital | 174,276 | 167,352 |
| Retained earnings (accumulated deficit) | (178,536) | (78,973) |
| Accumulated other comprehensive income (loss) | ... | (586) |
| Total stockholders' equity (deficit) | (4,230) | 87,823 |
| Total equity | (4,230) | 87,823 |

⊠ Restated to reflect correction of errors

Recent Dividends:

1. Lifecore Biomedical Inc common.

No dividends paid.

Annual Dividends:

1. Lifecore Biomedical Inc common.

No dividends paid.

LIGHTSTONE VALUE PLUS REAL ESTATE INVESTMENT TRUST III, INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ⊠2021 (revised) |
|--|--------------------|------------------|--------------------|
| Revenues | 29,088,000 | ... | ... |
| Revenues | 29,088,000 | 28,311,000 | 21,778,000 |
| Property operating expenses | 20,015,000 | 18,141,000 | 13,798,000 |
| Real estate taxes | 1,172,000 | 1,272,000 | 1,390,000 |
| General & administrative costs | 2,606,000 | 2,621,000 | 2,462,000 |
| Depreciation & amortization | 4,105,000 | 4,865,000 | 5,114,000 |
| Total operating expenses | 27,898,000 | 26,899,000 | 22,764,000 |
| Interest expense | 5,361,000 | 3,415,000 | 2,946,000 |
| Gain on forgiveness of debt | ... | 1,893,000 | 1,470,000 |
| Earnings (loss) from investments in unconsolidated affiliated real estate entities | (3,308,000) | 3,000 | (333,000) |
| Other income (expense), net | 641,000 | (108,000) | 62,000 |
| Net income (loss) | (6,838,000) | (215,000) | (2,733,000) |
| Net income (loss) applicable to company's common shares | (6,838,000) | (215,000) | (2,733,000) |
| Weighted average of common shares outstanding - basic | 12,967,000 | 13,080,000 | 13,215,000 |
| Weighted average of common shares outstanding - diluted | 12,967,000 | 13,080,000 | 13,215,000 |
| Year end common shares outstanding | 12,932,000 | 13,043,000 | 13,153,000 |
| Net earnings (loss) per common share - basic | \$(0.53) | \$(0.02) | \$(0.21) |
| Net earnings (loss) per common share - diluted | \$(0.53) | \$(0.02) | \$(0.21) |
| Number of common stockholders | 3,725 | ⊠⊠3,750 | ⊠3,762 |
| EPS - Basic - excluding | | | |

| | | |
|------------------------------|-------------|-----|
| Extraordinary Items | | |
| Applicable to Common - Total | \$(0.53) | ... |
| EPS - Diluted - excluding | | |
| Extraordinary Items | | |
| Applicable to Common - Total | \$(0.53) | ... |
| Comprehensive (loss)/income | (6,754,000) | ... |

⊠ Reclassified to conform with 2022 presentation; ⊡ As is; ⊢ As of March 15, 2023; ⊣ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Land & improvements | 21,722,000 | 21,711,000 |
| Building & improvements | 92,493,000 | 91,987,000 |
| Furniture & fixtures | 16,960,000 | 16,463,000 |
| Construction in progress | 27,000 | 47,000 |
| Gross investment property | 131,202,000 | 130,208,000 |
| Less: accumulated depreciation | 36,479,000 | 32,438,000 |
| Net investment property | 94,723,000 | 97,770,000 |
| Investments in unconsolidated affiliated real estate entities | 20,240,000 | 21,755,000 |
| Cash & cash equivalents | 3,848,000 | 18,391,000 |
| Marketable securities, available for sale | 7,196,000 | 3,314,000 |
| Accounts receivable & other assets | 1,971,000 | 1,585,000 |
| Total assets | 127,978,000 | 142,815,000 |
| Accounts payable & other accrued expenses | 2,511,000 | 2,960,000 |
| Revolving credit facility | ... | 34,573,000 |
| Home 2 Suites loan | ... | 26,750,000 |
| Less: deferred financing costs | 57,161,000 | (509,000) |
| Due to related parties | 363,000 | 302,000 |
| Distributions payable | 970,000 | ... |
| Total liabilities | 61,005,000 | 64,076,000 |
| Common stock | 129,000 | 130,000 |
| Additional paid-in capital | 110,462,000 | 111,585,000 |
| Accumulated other comprehensive income (loss) | (166,000) | (250,000) |
| Retained earnings (accumulated deficit) | (55,544,000) | (44,818,000) |
| Total company stockholders' equity | 54,881,000 | 66,647,000 |
| Noncontrolling interests | 12,092,000 | 12,092,000 |
| Total stockholders' equity | 66,973,000 | 78,739,000 |

Recent Dividends:

1. Lightstone Value Plus Real Estate Investment Trust III, Inc common.

No dividends paid.

Annual Dividends:

1. Lightstone Value Plus Real Estate Investment Trust III, Inc common.

No dividends paid.

LINKBANCORP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ⊠2021 (revised) |
|--|------------|------------|-----------------|
| Loans receivable, including fees | 58,791,000 | 36,396,000 | 15,924,000 |
| Investment securities & certificates of deposit - taxable | 1,181,000 | 2,175,000 | 873,000 |
| Investment securities & certificates of deposit - exempt from federal income tax | 3,260,000 | 1,160,000 | 1,252,000 |
| Other | 1,966,000 | 533,000 | 447,000 |
| Total interest & | | | |

| | | | |
|--|---------------------|------------------|----------------|
| dividend income | 65,198,000 | 40,264,000 | 18,496,000 |
| Deposits | 22,638,000 | 5,337,000 | 2,091,000 |
| Other borrowings | 1,923,000 | 441,000 | 50,000 |
| Subordinated debt | ... | 1,501,000 | 249,000 |
| Subordinated Debt | 1,926,000 | ... | ... |
| Total interest expense | 26,487,000 | 7,279,000 | 2,390,000 |
| Net interest income before provision for loan losses | 38,711,000 | 32,985,000 | 16,106,000 |
| Provision for loan losses | 9,295,000 | 1,290,000 | 648,000 |
| Net interest income after provision for loan losses | 29,416,000 | 31,695,000 | 15,458,000 |
| Service charges on deposit accounts | 978,000 | 832,000 | 733,000 |
| Bank-owned life insurance | 738,000 | 497,000 | 253,000 |
| Net realized gains on the sales of debt securities, available for sale | (2,370,000) | 13,000 | 74,000 |
| Gain on sale of loans | 465,000 | 753,000 | 316,000 |
| Other noninterest income | 1,276,000 | 862,000 | 763,000 |
| Total noninterest income | 1,087,000 | 2,957,000 | 2,139,000 |
| Salaries & employee benefits | 20,612,000 | 16,224,000 | 6,999,000 |
| Occupancy | 3,015,000 | 2,119,000 | 913,000 |
| Equipment & data processing | 3,720,000 | 3,047,000 | 1,437,000 |
| Professional fees | 1,698,000 | 1,236,000 | 685,000 |
| FDIC insurance | 817,000 | 640,000 | 231,000 |
| Bank shares tax | 1,158,000 | 786,000 | 434,000 |
| Merger & system conversion related expenses | ... | 973,000 | 4,584,000 |
| Merger related expenses | 11,176,000 | ... | ... |
| Other noninterest expense | 3,636,000 | 2,807,000 | 2,214,000 |
| Total noninterest expense | 45,832,000 | 27,832,000 | 17,497,000 |
| Income before income tax expense (benefit) | (15,329,000) | 6,820,000 | 100,000 |
| Current income tax (benefit) | 85,000 | 38,000 | (265,000) |
| Deferred income tax (benefit) | (3,446,000) | 1,184,000 | 76,000 |
| Income tax expense (benefit) | (3,361,000) | 1,222,000 | (189,000) |
| Net income | (11,968,000) | 5,598,000 | 289,000 |
| Weighted average shares outstanding - basic | 17,753,914 | 11,310,386 | 6,879,658 |
| Weighted average shares outstanding - dilutec | 17,753,914 | 11,310,386 | 7,250,463 |
| Year end shares outstanding | 37,340,700 | 14,939,640 | 9,826,435 |
| Earnings per share - basic | \$(0.67) | \$0.49 | \$0.04 |
| Earnings per share - basic | \$(0.67) | \$0.49 | \$0.04 |
| Dividends Per Share - Common - Gross - by Period End Date | \$0.30 | ... | ... |
| Dividends per share | ... | \$0.30 | \$0.20 |
| Number of full time employees | 342 | 132 | 101 |
| Number of part time employees | 36 | 10 | 9 |
| Number of common stockholders | 786 | ⊠525 | ⊠468 |
| Total number of employees | 378 | ... | ... |

⊠ Reclassified to conform with 2022 presentation; ⊡ As of March 28, 2023; ⊢ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|--------------|------------|
| Accrued Expenses | 796,390 | ... |
| Deferred Revenue | 2,100 | ... |
| Total liabilities | 30,289,784 | ... |
| Common stock | 704,043 | 704,043 |
| Additional paid in capital | 32,816,924 | 32,542,720 |
| Accumulated Deficit | (4,701,911) | ... |
| Retained earnings (accumulated deficit) | (10,907,442) | ... |
| Total Liquid Value Development Inc. stockholders' equity (deficit) | 28,819,056 | 22,339,321 |
| Non-controlling interests | 79,959 | 74,260 |
| Total stockholders' equity (deficit) | 28,899,015 | 22,413,581 |

Recent Dividends:

1. LiquidValue Development Inc common.

No dividends paid.

Annual Dividends:

1. LiquidValue Development Inc common.

No dividends paid.

LITHIUM CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|----------------|
| Depreciation | 7,332 | 7,332 | ... |
| Professional fees | 61,818 | 57,740 | 74,521 |
| Exploration expenses - related party | ... | 15,151 | 12,234 |
| Exploration expenses | 50,334 | 144,816 | 33,756 |
| Consulting fees - related party | 127,337 | 459,772 | 120,000 |
| Consulting fees | 288,000 | 474,425 | 560,880 |
| Transfer agent & filing fees | 32,856 | 26,679 | 27,893 |
| Travel expenses | ... | 16,085 | 12,711 |
| General & administrative expenses | 35,549 | 32,619 | 13,789 |
| Travel | 7,748 | ... | ... |
| Total operating expenses | 610,974 | 1,234,619 | 855,784 |
| Income (loss) from operations | (610,974) | (1,234,619) | (855,784) |
| Gain (loss) on sale of marketable securities | 5,805 | ... | ... |
| Gain (loss) on sale of mineral property | (199,611) | ... | ... |
| Change in fair value of marketable securities | ... | (258,689) | (987,489) |
| Other income | 75,327 | 10,284 | ... |
| Other income - related party | 10,000 | 59,500 | 98,000 |
| Gain on return of mineral property | 101,260 | ... | ... |
| Total other income (expense) | (7,219) | (188,905) | (889,489) |
| Income (loss) before income taxes | (618,193) | (1,423,524) | (1,745,273) |
| Net income (loss) | (618,193) | (1,423,524) | (1,745,273) |
| Weighted average shares outstanding - basic | 116,108,879 | 107,814,085 | 99,843,819 |
| Weighted average shares outstanding - diluted | 116,108,879 | 107,814,085 | 99,843,819 |
| Year end shares outstanding | 117,092,441 | 113,692,441 | 103,492,441 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.02) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.02) |
| Number of common stockholders | 15 | 52 | 52 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |

| | | |
|--|----------|-----|
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... |
| Full-Time Employees (Period End) | 0 | ... |
| Total number of employees | 0 | ... |

Reclassified to conform with 2022 presentation; As of April 14, 2023; As of April 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash | 3,667,617 | 3,576,911 |
| Marketable securities | 332,082 | 372,972 |
| Deposits | 700 | 700 |
| Other prepaid expenses | 22,850 | 14,918 |
| Prepaid transfer agent fees | ... | 18,413 |
| Prepaid expenses | ... | 37,832 |
| Total current assets | 4,023,249 | 3,988,415 |
| Equipment, net of accumulated depreciation | 20,986 | 28,318 |
| Total assets | 4,044,235 | 4,016,733 |
| Accounts payable & accrued liabilities | 8,386 | 5,598 |
| Accounts payable & accrued liabilities - related party | 26,489 | 25,718 |
| Allowance for optioned properties | 2,191,102 | 1,999,364 |
| Total current liabilities | ... | 2,030,680 |
| Total liabilities | ... | 2,030,680 |
| Common stock | 117,893 | 113,683 |
| Additional paid in capital | 8,948,385 | 8,571,524 |
| Additional paid in capital - options | 957,247 | 887,910 |
| Additional paid in capital - warrants | 369,115 | 369,115 |
| Accumulated deficit | (8,574,382) | ... |
| Retained earnings (accumulated deficit) | ... | (7,956,189) |
| Total stockholders' equity (deficit) | 1,818,258 | 1,986,053 |
| Total Equity | 1,818,258 | ... |

As reported by the Company

Recent Dividends:

1. Lithium Corp common.

No dividends paid.

Annual Dividends:

1. Lithium Corp common.

No dividends paid.

LM FUNDING AMERICA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|------------|------------|----------------|
| Interest on delinquent association fees | ... | 359,012 | 471,923 |
| Administrative & late fees | ... | 70,686 | 69,369 |
| Recoveries in excess of cost - special product | ... | 100,470 | 95,904 |
| Underwriting fees & other revenues | 12,289,131 | 96,605 | 120,176 |
| Rental revenue | 144,514 | 161,618 | 141,569 |
| Digital mining revenues, net | ... | 945,560 | ... |
| Specialty finance revenue | 550,445 | ... | ... |
| Total revenues | 12,984,090 | 1,733,951 | 898,941 |
| Digital mining cost of revenues | 9,406,940 | 1,033,226 | ... |
| Staff costs & payroll | 5,858,736 | 19,422,723 | 6,257,375 |
| Professional fees | 1,863,038 | 3,158,446 | 2,271,808 |
| Settlement costs with associations | 10,000 | 160 | 2,000 |

| | | | |
|--|--------------|--------------|-------------|
| Selling, general & administrative expenses | 851,806 | 635,268 | 417,963 |
| Real estate management & disposal | 146,716 | 110,465 | 132,283 |
| Depreciation & amortization expenses | 4,983,480 | 478,020 | 11,087 |
| Other write-offs | 965,967 | ... | ... |
| Collection costs | 29,875 | (12,213) | 4,459 |
| Impairment loss on mined digital assets | ... | 79,794 | ... |
| Recovery of cost from related party receivable | ... | ... | (200,000) |
| Provision for credit losses | ... | (10,177) | (10,000) |
| Realized gain on sale of mined digital assets | 2,070,508 | ... | ... |
| Other operating expenses | 999,959 | 1,514,224 | 444,345 |
| Total operating costs & expenses | 23,046,009 | 26,409,936 | 9,331,320 |
| Operating income (loss) from continuing operations | (10,061,919) | (24,675,985) | (8,432,379) |
| Gain (loss) on disposal of assets | (9,389) | (38,054) | ... |
| Digital assets other income | 1,052,542 | 5,658 | 3,775 |
| Realized gain (loss) on securities | 4,420 | (349,920) | 13,817,863 |
| Realized gain on convertible debt securities | ... | 287,778 | ... |
| Unrealized loss on convertible debt security | ... | ... | (407,992) |
| Unrealized loss on marketable securities | 13,570 | (56,830) | (1,387,590) |
| Unrealized gain on investment & equity securities | (9,771,050) | 4,423,985 | 886,543 |
| Realized gain on digital assets | 1,917 | 20,254 | 502,657 |
| Impairment loss on digital assets | 750,678 | 467,406 | 23,720 |
| Impairment loss on prepaid mining machine deposits | 36,691 | 3,150,000 | ... |
| Impairment loss on prepaid hosting deposits | 184,236 | 1,790,712 | ... |
| Credit loss on debt securities | ... | 1,052,542 | ... |
| Interest expense | ... | 4,416 | 653 |
| Interest income | 249,586 | 399,094 | 211,427 |
| Dividend income | ... | 3,875 | 2,113 |
| Gain on forgiveness of note payable | ... | ... | 157,250 |
| Other income - coupon sales | 639,472 | ... | ... |
| Other income - finance revenue | 37,660 | ... | ... |
| Income (loss) from continuing operations before income taxes | (18,814,796) | (26,445,221) | 5,329,294 |
| Current federal tax expense (benefit) | 60,571 | 1,196,415 | 290,238 |
| Current state tax expense (benefit) | ... | 241,651 | 35,940 |
| Total current tax expense (benefit) | 60,571 | 1,438,066 | 326,178 |
| Deferred tax expense - federal | (4,540,213) | (4,181,816) | 1,126,450 |
| Deferred tax expense - state | (1,091,907) | (1,041,813) | ... |

| | | | | | | | | | | |
|--|---------------------|---------------------|------------------|--|--------------|--------------|--|-------------|-------------|------------|
| Valuation allowance (expense) | 5,632,121 | 5,223,628 | (1,126,450) | Other assets | 86,798 | 10,726 | outstanding | 120,937,442 | 120,937,442 | 50,634,536 |
| Income tax expense (benefit) | 60,571 | 1,438,066 | 326,178 | Notes receivable from Seastar Medical Holding Corporation | 1,440,498 | ... | Net earnings (loss) per common share - basic | \$0.00 | \$0.02 | \$(0.05) |
| Net income (loss) | (18,875,367) | (27,883,287) | 5,003,116 | Total long-term assets | 27,559,230 | 42,697,957 | Net earnings (loss) per common share - diluted | \$0.00 | \$0.02 | \$(0.05) |
| Losses (income) attributable to non-controlling interest | 2,931,113 | (1,356,914) | (243,898) | Total assets | 37,712,797 | 53,189,618 | Number of common stockholders | ... | 70 | 68 |
| Net income (loss) attributable to LM Funding America Inc. | (15,944,254) | (29,240,201) | 4,759,218 | Note payable | 567,586 | 475,775 | □ Shares increased due to issuance of shares to settle debt | | | |
| Weighted average shares outstanding - basic | 2,283,836 | 2,180,698 | 1,138,117 | Accounts payable & accrued expenses | 22,845 | 1,570,906 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| Weighted average shares outstanding - diluted | 2,283,836 | 2,180,698 | 1,321,209 | Due to related party payable | ... | 75,488 | 2023 | 2022 | | |
| Year end shares outstanding | 2,492,964 | 2,181,981 | 2,169,657 | Current portion of lease liability | 110,384 | 90,823 | Cash | 2,474 | 886 | |
| Net earnings (loss) per common share - basic | \$(6.98) | \$(13.38) | \$4.20 | Accounts payable and accrued expenses | 2,064,909 | ... | Total current assets | 2,474 | 886 | |
| Net earnings (loss) per common share - diluted | \$(6.98) | \$(13.38) | \$3.60 | Total current liabilities | 2,765,724 | 2,212,992 | Total assets | 2,474 | 886 | |
| Number of full time employees | ... | 8 | 8 | Lease liability - long-term | 85,775 | 179,397 | Accounts payable & accrued liabilities | 14,689 | 7,260 | |
| Number of common stockholders | 5 | 5 | 4 | Total long-term liabilities | ... | 179,397 | Due to related parties & accrued interest | ... | 20,136 | |
| | | | | Total liabilities | 2,851,499 | 2,392,389 | Loans payable | 77,235 | ... | |
| | | | | Common stock | 2,493 | 13,092 | Total current liabilities | 91,924 | 27,396 | |
| | | | | Additional paid-in capital | 95,145,376 | 92,195,341 | Total liabilities | ... | 27,396 | |
| | | | | Accumulated deficit | (58,961,461) | ... | Common shares | 73,757 | 73,757 | |
| | | | | Retained earnings (accumulated deficit) | ... | (43,017,207) | Additional paid-in capital | 4,163,056 | 4,163,056 | |
| | | | | Total LMF Acquisition Opportunities stockholders' equity (deficit) | 36,186,408 | 49,191,226 | Retained earnings (accumulated deficit) | (4,326,263) | (4,263,323) | |
| | | | | Non-controlling interest | (1,325,110) | 1,606,003 | Total stockholders' equity (deficiency) | (89,450) | (26,510) | |
| | | | | Total stockholders' equity (deficit) | 34,861,298 | 50,797,229 | Total Equity | (89,450) | ... | |

□ Reclassified to conform with 2022 presentation; □ As reported by the Company; □ Adjusted for 1-for-6 stock split, March 12, 2024; □ Shares increased due to the effect of stock issued for warrants exercised, stock issued for cash in public offering and stock issued for services; □ As of March 31, 2023; □ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-------------|
| Cash | 2,401,831 | 4,238,006 |
| Digital assets | 3,416,256 | 888,026 |
| Notes receivable from Seastar Medical Holding Corporation | ... | 3,807,749 |
| Marketable securities | 17,860 | 4,290 |
| Prepaid expenses & other assets | 4,067,212 | 1,233,322 |
| Income tax receivable | 31,187 | 293,466 |
| Receivable from sale of Symbiont assets | 200,000 | ... |
| Total current assets | 10,153,567 | 10,491,661 |
| Mining machines | 29,799,782 | 27,637,041 |
| Furniture, computer & office equipment | 230,063 | 216,312 |
| Property, Plant & Equipment - Other - Gross | 80,057 | ... |
| Gross fixed assets | 30,109,902 | 27,853,353 |
| Less: accumulated depreciation | 5,590,292 | 661,036 |
| Fixed assets, net | 24,519,610 | 27,192,317 |
| Real estate assets owned | ... | 80,057 |
| Less: Allowance for losses on debt security | ... | (1,052,542) |
| Long-term investments - debt security | ... | 2,402,542 |
| Long-term investments - debt security, net | ... | 1,350,000 |
| Long-term investments - equity securities | ... | 464,778 |
| Operating lease - right of use assets | 189,009 | 265,658 |
| Investment in Seastar Medical Holding Corporation | 1,145,486 | 10,608,750 |
| Investments in unconsolidated affiliates | 156,992 | ... |
| Deposit on mining equipment | 20,837 | 525,219 |
| Finance receivables | 19,221 | 26,802 |
| Hosting services deposit | ... | 2,200,452 |

Recent Dividends:

1. LM Funding America Inc common.

No dividends paid.

Annual Dividends:

1. LM Funding America Inc common.

No dividends paid.

LODE-STAR MINING INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-----------------|------------------|--------------------|
| Consulting services | 1,855 | 58,321 | 125,117 |
| Corporate support services | ... | 1,953 | 2,010 |
| Exploration & evaluation | ... | 274 | 28,443 |
| Mineral option fees | ... | ... | 75,000 |
| Office, foreign exchange & sundry | 2,631 | 7,032 | 7,475 |
| Professional fees | 47,667 | 57,976 | 46,232 |
| Transfer & filing fees | 10,787 | 29,962 | 25,047 |
| Total operating expenses | 62,940 | 155,518 | 309,324 |
| Operating income (loss) | (62,940) | (155,518) | (309,324) |
| Acquired in-process research & development | ... | ... | 2,186,917 |
| Rescinded Sapir Pharmaceuticals, Inc. transaction | ... | 2,186,917 | ... |
| Interest, bank & finance charges | ... | 468 | 72,933 |
| Net Income before Tax | (62,940) | ... | ... |
| Total other items | ... | 2,186,449 | (2,259,850) |
| Net income (loss) for the year | (62,940) | 2,030,931 | (2,569,174) |
| Weighted average common shares outstanding - basic | 120,937,442 | 87,808,401 | 50,629,605 |
| Weighted average common shares outstanding - diluted | 120,937,442 | 87,808,401 | 50,629,605 |
| Year end shares | ... | ... | ... |

Recent Dividends:

1. Lode-Star Mining Inc common.

No dividends paid.

Annual Dividends:

1. Lode-Star Mining Inc common.

No dividends paid.

LONGWEN GROUP CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 |
|--|-------------|-----------|---------|
| Consulting service income | 15,004 | 36,418 | ... |
| Online product sales | ... | 1,788 | ... |
| Aquaculture product sales, net | ... | 2,931 | ... |
| Online product sales | 6,082 | ... | ... |
| Revenues | 21,086 | 41,137 | ... |
| Offline product sales | 2,199 | ... | ... |
| Gross profit | 18,887 | ... | ... |
| General & administrative expenses | ... | ... | 6,500 |
| Professional expenses | 169,255 | 106,482 | ... |
| Share-based compensation | 576,000 | 425,000 | ... |
| Selling, general & administrative expenses | 287,830 | 255,691 | ... |
| Total operating expenses | ... | 787,173 | ... |
| Total operating costs & expenses | ... | ... | 6,500 |
| Income (loss) from operations | (1,014,198) | (746,036) | (6,500) |
| Interest expense | ... | 500 | 500 |
| Interest expense | 365 | ... | ... |
| Other income, net | (7,989) | 110 | ... |
| Total other income (expense), net | (8,354) | (390) | (500) |
| Income (loss) before income taxes | (1,022,552) | (746,426) | (7,000) |
| Income (loss) from continuing operations | (1,022,552) | ... | ... |

Discontinued

| | | | | | | |
|--|-------------|------------|------------|--------------------------------------|----------|---------|
| Operations | (3,906) | ... | ... | (loss) | (326) | 5,840 |
| Net income (loss) | (1,026,458) | (746,426) | (7,000) | Total shareholders' equity (deficit) | (76,435) | 270,955 |
| Weighted average shares outstanding - basic | 79,197,184 | 67,215,968 | 65,127,061 | Rep Total Equity & Minority Interest | (76,435) | ... |
| Weighted average shares outstanding - diluted | 79,197,184 | 67,215,968 | 65,127,061 | | | |
| Year end shares outstanding | 78,775,094 | 74,108,926 | 65,127,061 | | | |
| Income (loss) per share from continuing operations - basic | \$(0.01) | ... | ... | | | |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$0.00 | | | |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$0.00 | | | |
| Number of full time employees | 8 | ... | ... | | | |
| Total number of employees | 8 | 10 | ... | | | |
| Number of common stockholders | 304 | 236 | 175 | | | |
| Earnings per share-inc from discontinued oper | \$(0.00) | ... | ... | | | |
| Earnings per share-total discontinued opers | \$(0.00) | ... | ... | | | |
| Earn per share-inc from discount opers - diluted | \$(0.00) | ... | ... | | | |
| Earning per share-total discount opers - diluted | \$(0.00) | ... | ... | | | |

1 Non-consolidated; 2 As of March 27, 2023; 3 As of March 24, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 18,449 | 68,121 |
| Inventory | 40,373 | ... |
| Prepaid consulting fee | 16,713 | 38,000 |
| Prepaid rent & parking lot | ... | 14,903 |
| Deposit & other | ... | 5,510 |
| Prepaid expenses & other current assets | ... | 58,413 |
| Prepaid expenses | 26,127 | ... |
| Prepaid royalties | 2,788 | ... |
| Current assets of discontinued operations | 480,569 | ... |
| Other current assets | 45,628 | ... |
| Total current assets | 585,019 | 126,534 |
| Equipment | 7,209 | 7,419 |
| Property | 263,651 | 271,319 |
| Less: accumulated depreciation | 16,282 | 4,368 |
| Property & equipment, net | 254,578 | 274,370 |
| Intangible assets | 2,994 | 3,625 |
| Goodwill | 1,132 | 1,132 |
| Total assets | 843,723 | 405,661 |
| Accounts payable & accrued expenses | ... | 31,962 |
| Shareholder loan | 198,510 | 90,494 |
| Commercial loans | 84,533 | 12,250 |
| Current liabilities of discontinued operations | 484,475 | ... |
| Accounts payable & accrued liabilities | 119,469 | ... |
| Deferred revenue | 33,171 | ... |
| Total current liabilities | 920,158 | 134,706 |
| Total liabilities | 920,158 | 134,706 |
| Common stock | 7,878 | 7,411 |
| Additional paid-in capital | 19,970,306 | 19,285,539 |
| Accumulated deficit | (20,054,293) | ... |
| Retained earnings (accumulated deficit) | ... | (19,027,835) |
| Accumulated other comprehensive income | ... | ... |

Recent Dividends:

1. Longwen Group Corp common.

No dividends paid.

Annual Dividends:

1. Longwen Group Corp common.

No dividends paid.

LONGWEN GROUP CORP

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Simon & Edward, LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheets of Longwen Group Corp. and its subsidiaries (the "Company") as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive income, stockholders' (deficit) equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt About the Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 3 to the consolidated financial statements, the Company has suffered recurring losses from operations, has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter."

LQR HOUSE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|-------------|-------------|
| Revenue - services | 474,048 | 470,359 | 182,765 |
| Revenue - product | 646,574 | 130,772 | 132,527 |
| Total revenues | 1,120,622 | 601,131 | 315,292 |
| Cost of revenue - services | 351,823 | 668,654 | 520,193 |
| Cost of revenue - product | 563,775 | 134,490 | 157,254 |
| Total cost of revenue | 915,598 | 803,144 | 677,447 |
| Gross profit (loss) | 205,024 | (202,013) | (362,155) |
| Sales and marketing | 2,480,001 | 655,151 | 464,011 |
| General and administrative | 11,426,747 | 985,011 | 1,136,560 |
| Impairment expense | 1,875,000 | ... | ... |
| Total operating expenses | 15,781,748 | 1,640,162 | 1,600,571 |
| Income (loss) from operations | (15,576,724) | (1,842,175) | (1,962,726) |
| Net income (loss) | (15,747,724) | (1,842,175) | (1,962,726) |
| Weighted average shares outstanding - basic | 7,244,157 | 225,376 | 186,087 |
| Weighted average shares outstanding - diluted | 7,244,157 | 225,376 | 186,087 |
| Year end shares outstanding | 7,244,157 | 230,010 | 223,448 |
| Net income (loss) per share - basic | \$(2.17) | \$(8.00) | \$(10.40) |
| Net income (loss) per share - diluted | \$(2.17) | \$(8.00) | \$(10.40) |
| Number of full time employees | ... | 3 | ... |
| Interest expense | 171,000 | ... | ... |
| Net Income before Tax | (15,747,724) | ... | ... |

| | | | |
|------------------------------|-----------|-----|-----|
| Total other expense | (171,000) | ... | ... |
| Common Shareholders - Number | 25 | ... | ... |

1 From January 11, 2021 (inception); 2 Adjusted for 50% stock dividend, March 4, 2024; 3 Adjusted for 1- for -60 stock split, November 30, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|-------------|
| Cash & cash equivalents | 7,064,348 | 7,565 |
| Accounts receivable, related party | 172,493 | 224,692 |
| Advances to related party | 177,340 | 314,766 |
| Prepaid expenses | 2,189,955 | ... |
| Deposits in escrow | 5,470,000 | ... |
| Total current assets | 15,074,136 | 547,023 |
| Intangible assets, net | 10,000 | 2,083,333 |
| Right of use asset | 8,402 | ... |
| Total assets | 15,092,538 | 2,630,356 |
| Accounts payable | 265,229 | 287,457 |
| Accounts payable, related party | 58,589 | 104,002 |
| Accrued expenses | 138,585 | 199,256 |
| Right of use liability, current portion | 7,324 | ... |
| Right of use liability | 2,534 | ... |
| Total Current Liabilities | 469,727 | ... |
| Total liabilities | ... | 590,715 |
| Class B Common Stock | 482 | ... |
| Common stock | ... | 920 |
| Additional paid-in capital | 34,172,420 | 5,843,622 |
| Accumulated deficit | (19,552,625) | ... |
| Retained earnings (accumulated deficit) | ... | (3,804,901) |
| Total stockholders' equity (deficit) | 14,620,277 | 2,039,641 |
| Total Equity | 14,620,277 | ... |

Recent Dividends:

1. LQR House Inc common.

No dividends paid.

Annual Dividends:

1. LQR House Inc common.

No dividends paid.

LQR HOUSE INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, dbmckennon, as it appeared in Co.'s 2023 10-K: "We have audited the accompanying consolidated balance sheets of LQR House, Inc., and subsidiary (the "Company") as of December 31, 2023 and 2022, and the related consolidated statements of operations, stockholders' equity, and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has sustained net losses and negative cash flow from operations and requires additional capital to operate, which raises substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

LUDUSON G INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-----------------------------------|---------|---------|-----------|
| Revenue, net | ... | 52,361 | 1,001,438 |
| Cost of revenue | ... | 7,663 | 230,840 |
| Gross profit | ... | 44,698 | 770,598 |
| General & administrative expenses | 285,568 | 278,403 | 236,198 |
| Debt discount | ... | 116,667 | ... |

| | | |
|---|--------------|--------------|
| Operating lease liability - current | 1,982,281 | 4,293,085 |
| Other miscellaneous items | 21,125,090 | ... |
| Accrued payroll and related liabilities | 2,024,000 | ... |
| Initial Direct Costs | 486,390 | ... |
| Leases - Current | 23,182,305 | ... |
| Accounts payable and accrued expenses | 33,215 | ... |
| Accrued interest | 25,439,614 | ... |
| Total current liabilities | 1,459,172 | 4,189,193 |
| Loans payable | 242,488,610 | 81,626,338 |
| Operating lease liability - noncurrent | 5,667,857 | ... |
| Development Incentive Advances - Non Current | 4,050,000 | ... |
| Initial Direct Costs | 85,815,531 | ... |
| Leases - Noncurrent | 111,255,145 | ... |
| Total long-term liabilities | 5,775,596 | ... |
| Total liabilities | 394 | 276 |
| 13% Redeemable Preferred Stock; Liquidation Preference \$25 per Share; 10,000,000 Shares Authorized; 294,144 and 0 shares issued and outstanding at 31, 2023 and 2022 | 90,437,155 | 17,726,592 |
| Common stock | (99,710,503) | ... |
| Additional paid in capital | ... | (21,018,992) |
| Accumulated deficit | ... | (9,272,954) |
| Retained earnings (accumulated deficit) | ... | (3,292,124) |
| Total stockholders' equity (deficit) | ... | ... |

Recent Dividends:
1. LuxUrban Hotels Inc common.
 No dividends paid.
2. LuxUrban Hotels Inc 13.00% series A cumulative redeemable preferred.
 No dividends paid.
Annual Dividends:
1. LuxUrban Hotels Inc common.
 No dividends paid.
2. LuxUrban Hotels Inc 13.00% series A cumulative redeemable preferred.
 No dividends paid.

MACE SECURITY INTERNATIONAL, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-----------|
| Operating agreements | 6,595,000 | ... | ... |
| Net sales | 8,758,000 | 13,072,000 | ... |
| Total revenues | 6,595,000 | 8,758,000 | ... |
| Cost of goods sold | 4,846,000 | 5,417,000 | 8,014,000 |
| Gross profit | 1,749,000 | 3,341,000 | 5,058,000 |
| Selling, general & administrative expenses | 4,256,000 | 4,760,000 | 4,753,000 |
| Amortization of intangible assets | 260,000 | 260,000 | 294,000 |
| Asset impairment charges | 1,507,000 | ... | ... |
| Operating income (loss) | (4,274,000) | (1,679,000) | 11,000 |
| Interest expense | 212,000 | ... | ... |
| Interest expense | 71,000 | 25,000 | ... |
| Gain (loss) on forgiveness of PPP loan & accrued interest | ... | ... | 625,000 |
| Gain (loss) on extinguishment of debt | ... | ... | 8,000 |
| Other income (expenses), net | ... | 12,000 | 28,000 |
| Income (loss) from before income tax | ... | ... | ... |

| | | | |
|---|--------------------|--------------------|----------------|
| provision (benefit) | (4,429,000) | (1,738,000) | 647,000 |
| Current income tax expense (benefit) | ... | ... | 8,000 |
| Income tax provision (benefit) | 2,000 | ... | 8,000 |
| Net income (loss) | (4,431,000) | (1,738,000) | 639,000 |
| Weighted average shares outstanding - basic | 65,368,953 | 64,882,655 | 64,505,716 |
| Weighted average shares outstanding - diluted | 65,368,953 | 64,882,655 | 64,937,285 |
| Year end shares outstanding | 65,726,501 | 64,948,482 | 64,703,965 |
| Income (loss) per share - continuing operations - basic | \$(0.07) | \$(0.03) | ... |
| Net income (loss) per share - basic | \$(0.07) | \$(0.03) | \$0.01 |
| Income (loss) per share - continuing operations - diluted | \$(0.07) | \$(0.03) | ... |
| Net income (loss) per share - diluted | \$(0.07) | \$(0.03) | \$0.01 |
| Gain on derivative liability | 57,000 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash & cash equivalents | 239,000 | 62,000 |
| Accounts receivable, gross | 880,000 | 1,362,000 |
| Allowance for doubtful accounts | 125,000 | 257,000 |
| respectively | 755,000 | 1,105,000 |
| Raw materials & supplies | ... | 2,319,000 |
| Raw materials | 1,353,000 | ... |
| Finished goods | 2,045,000 | 1,819,000 |
| Fuel, merchandise inventory & car wash supplies | 3,398,000 | ... |
| Inventories | ... | 4,138,000 |
| Other current assets | 535,000 | 502,000 |
| Total current assets | 4,927,000 | 5,807,000 |
| Buildings & leasehold improvements | 109,000 | 111,000 |
| Machinery & equipment | 2,179,000 | 2,387,000 |
| Buildings and leasehold improvements | 257,000 | 260,000 |
| Total property & equipment | 2,545,000 | 2,758,000 |
| Accumulated depreciation | 2,491,000 | 2,297,000 |
| Total property & equipment, net | 54,000 | 461,000 |
| Operating lease - right-of-use asset, net of amortization | 1,122,000 | 1,335,000 |
| Finance lease - right-of-use asset, net of amortization | 31,000 | 50,000 |
| Goodwill | 739,000 | 1,031,000 |
| Intangible assets, net | 608,000 | 1,833,000 |
| Other non-current assets | 14,000 | 14,000 |
| Total assets | 7,495,000 | 10,531,000 |
| Current portion of long-term debt | 1,329,000 | 515,000 |
| Current operating lease obligation | 223,000 | 198,000 |
| Current portion of capital lease obligations | 19,000 | 16,000 |
| Accounts payable | 577,000 | 520,000 |
| Income taxes payable | 56,000 | ... |
| Accrued employee compensation | 22,000 | 75,000 |
| Vendor provided financing | 370,000 | ... |
| Accrued commissions | 15,000 | 14,000 |
| Accrued non-income based taxes | 20,000 | 20,000 |
| Property & other non-income taxes | ... | 55,000 |
| Accrued expenses & other current liabilities | ... | 270,000 |

| | | |
|---|-------------|--------------|
| Derivative liability | 99,000 | ... |
| Total current liabilities | 2,673,000 | 1,683,000 |
| Convertible debt | 461,000 | ... |
| Non-current operating lease obligations | 920,000 | 1,143,000 |
| Non-current finance lease obligations | 12,000 | 34,000 |
| Total liabilities | 4,066,000 | 2,860,000 |
| Common stock | 658,000 | 650,000 |
| Additional paid-in capital | 104,199,000 | 104,018,000 |
| Retained earnings (accumulated deficit) | ... | (96,975,000) |
| Treasury stock | 22,000 | ... |
| Less treasury stock at cost | ... | 22,000 |
| Total stockholders' equity | 3,429,000 | 7,671,000 |
| Total Equity | 3,429,000 | 7,671,000 |

Recent Dividends:
1. Mace Security International, Inc. common.
 No dividends paid.
Annual Dividends:
1. Mace Security International, Inc. common.
 No dividends paid.

MANGOCEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|-----------------|
| Revenues | 731,493 | ... | ... |
| Revenues | 731,493 | 8,939 | ... |
| Cost of revenues | 154,900 | 4,089 | ... |
| Gross profit (loss) | 431,501 | 4,850 | ... |
| General & administrative expenses | 3,319,417 | 1,996,432 | 17,520 |
| Salary and benefits | 977,890 | ... | ... |
| Advertising and marketing | 2,097,505 | ... | ... |
| Investor relations | 1,100,465 | ... | ... |
| Stock based compensation | 2,155,114 | ... | ... |
| Total operating expenses | 9,650,391 | 1,996,432 | 17,520 |
| Income (loss) from operations | (9,218,890) | (1,991,582) | (17,520) |
| Imputed interest - related party | ... | 6,473 | 181 |
| Other income | 6,473 | ... | ... |
| Total other income (expense) | ... | (6,473) | (181) |
| Income (loss) before income taxes | (9,212,417) | (1,998,055) | (17,701) |
| Net income (loss) | (9,212,417) | (1,998,055) | (17,701) |
| Weighted average shares outstanding - basic | 16,113,029 | 10,798,083 | 8,000,000 |
| Weighted average shares outstanding - diluted | 16,113,029 | 10,798,083 | 8,000,000 |
| Year end shares outstanding | 21,419,500 | 13,365,000 | 8,000,000 |
| Net income (loss) per share - basic | \$(0.57) | \$(0.19) | \$0.00 |
| Net income (loss) per share - diluted | \$(0.57) | \$(0.19) | \$0.00 |
| Cost of revenues - related party | 145,092 | ... | ... |
| Common Shareholders - Number | 34 | ... | ... |

¹ From October 7, 2021 (inception) ; ² Related party cost of revenues - Cost of revenues: \$3,255; ³ Shares increased due to the effect of issuance of common stock for services and issuance of units for cash

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------|---------|---------|
| Cash & cash equivalents | 739,006 | 682,860 |
| Prepaid expenses - | ... | ... |

| | | | | | | | | | | |
|---------------------------|--------------|-------------|---------------------|--------|--------|----------|--------------------------|--------------|--------------|--------------|
| related party | 60,953 | ... | Net income (loss) | | | | amortization | | | |
| Prepaid expenses | ... | 11,745 | per share - basic | \$0.00 | \$0.00 | \$(0.01) | expenses | 3,896,833 | 3,538,237 | 1,961,733 |
| Inventory | 18,501 | ... | Net income (loss) | | | | Facilities expenses | ... | 1,012,827 | 589,926 |
| Total current assets | 818,460 | 694,605 | per share - diluted | \$0.00 | \$0.00 | \$(0.01) | Gain (loss) on | | | |
| Computers | 5,062 | 5,062 | Number of full time | | | | disposal of assets | (335,106) | (273,430) | ... |
| Equipment | 119,819 | 116,300 | employees | ... | ... | 0 | Impairment of | | | |
| Less: accumulated | | | Number of common | | | | goodwill | 3,017,600 | ... | ... |
| depreciation | 28,752 | 3,863 | stockholders | 635 | 635 | 635 | Depreciation | 340,673 | ... | ... |
| Property, Plant & | | | | | | | Amortization of | | | |
| Equipment - Gross - Total | 124,881 | ... | | | | | Computer Software | 2,461,013 | ... | ... |
| Property & equipment, | | | | | | | Amortization of | | | |
| net | 96,129 | 117,499 | | | | | Intangibles | | | |
| Total fixed assets | ... | 117,499 | | | | | excluding Goodwill | 1,095,147 | ... | ... |
| Deposits | 16,942 | 16,942 | | | | | Gain on sale of | | | |
| Right of use - asset | 119,262 | 174,241 | | | | | business unit | 1,748,641 | ... | ... |
| Total other assets | ... | 191,183 | | | | | Total costs & | | | |
| Total assets | 1,050,793 | 1,003,287 | | | | | expenses | 65,132,033 | 51,298,729 | 30,088,042 |
| Accounts payable & | | | | | | | Operating income | | | |
| accrued liabilities | 140,765 | 33,675 | | | | | (loss) | (27,976,983) | (26,956,855) | (15,861,248) |
| Payroll tax liabilities | 6,595 | 2,717 | | | | | Other income, net | 488,869 | 234,472 | 172,513 |
| Notes payable to related | | | | | | | Interest expense | 1,527,449 | 266,778 | 427,178 |
| parties | ... | 89,200 | | | | | Foreign exchange | | | |
| Notes payable | ... | 78,260 | | | | | gain (loss) | (26,475) | (361) | (18,922) |
| Right-of-use liability - | | | | | | | Income (loss) | | | |
| operating lease | 63,718 | 56,725 | | | | | before provision | | | |
| Total current liabilities | ... | 260,577 | | | | | for income taxes | (29,042,038) | (26,989,522) | (16,134,835) |
| Right-of-use liability - | | | | | | | Income tax expense | | | |
| operating lease | 64,961 | 128,680 | | | | | (benefit) | (290,138) | (521,132) | (150,000) |
| Total long-term | | | | | | | Net income (loss) | (28,751,900) | (26,468,390) | (15,984,835) |
| liabilities | ... | 128,680 | | | | | Weighted average | | | |
| Total liabilities | ... | 389,257 | | | | | shares outstanding | | | |
| Common stock | 2,142 | 1,337 | | | | | - basic | 6,951,669 | 5,059,959 | 2,519,124 |
| Additional paid in | | | | | | | Weighted average | | | |
| capital | 12,000,785 | 2,628,449 | | | | | shares outstanding | | | |
| Accumulated deficit | (11,228,173) | ... | | | | | - fully diluted | 6,951,669 | 5,059,959 | 2,519,124 |
| Retained earnings | | | | | | | Year end shares | | | |
| (accumulated deficit) | ... | (2,015,756) | | | | | outstanding | 7,960,938 | 5,319,758 | 5,074,932 |
| Total stockholders' | | | | | | | Net income (loss) | | | |
| equity (deficit) | 774,754 | 614,030 | | | | | per share - basic | \$(4.14) | \$(5.24) | \$(6.36) |
| Total Equity | 774,754 | ... | | | | | Net income (loss) | | | |
| | | | | | | | per share - fully | | | |
| | | | | | | | diluted | \$(4.14) | \$(5.24) | \$(6.36) |
| | | | | | | | Number of full time | | | |
| | | | | | | | employees | 162 | 303 | 148 |
| | | | | | | | Number of common | | | |
| | | | | | | | stockholders | 38 | 40 | 40 |
| | | | | | | | Total number of | | | |
| | | | | | | | employees | 162 | ... | ... |

Recent Dividends:**1. Mangoceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. Mangoceuticals Inc common.**

No dividends paid.

MANHATTAN SCIENTIFICS, INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|--------------------|
| Revenue | ... | 50,000 | 50,000 |
| General & administrative | 693,000 | 718,000 | 727,000 |
| Research & development | 10,000 | 11,000 | 10,000 |
| Total operating expenses | 703,000 | 729,000 | 737,000 |
| Income (loss) from operations | (703,000) | (679,000) | (687,000) |
| Gain (loss) on fair value adjustment of investments | (477,000) | (2,030,000) | (2,974,000) |
| Gain (loss) on settlement of legal fees | ... | ... | 48,000 |
| Interest expense | ... | 21,000 | 26,000 |
| Gain on settlement of debt | 15,000 | ... | ... |
| Total other income (expense) | (462,000) | (2,051,000) | (2,952,000) |
| Net income (loss) before income taxes | (1,165,000) | ... | ... |
| Net income (loss) | (1,165,000) | (2,730,000) | (3,639,000) |
| Weighted average shares outstanding - basic | 559,281,064 | 559,281,064 | 559,281,064 |
| Weighted average shares outstanding - diluted | 559,281,064 | 559,281,064 | 559,281,064 |
| Year end shares outstanding | 559,281,064 | 559,281,064 | 559,281,064 |

Recent Dividends:**1. Manhattan Scientifics, Inc. series B convertible preferred.**

No dividends paid.

2. Manhattan Scientifics, Inc. common.

No dividends paid.

3. Manhattan Scientifics, Inc. series D convertible preferred.

No dividends paid.

Annual Dividends:**1. Manhattan Scientifics, Inc. series B convertible preferred.**

No dividends paid.

2. Manhattan Scientifics, Inc. common.

No dividends paid.

3. Manhattan Scientifics, Inc. series D convertible preferred.

No dividends paid.

MARPAI INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|------------|------------|------------|
| Facilities | 2,472,192 | ... | ... |
| Revenue | 37,155,050 | ... | ... |
| Revenue | 37,155,050 | 24,341,874 | 14,226,794 |
| Cost of revenue (exclusive of depreciation & amortization) | 24,239,117 | 17,136,330 | 10,289,578 |
| General & administrative expenses | 19,176,895 | 12,318,529 | 8,055,572 |
| Sales & marketing expenses | 6,596,981 | 6,938,513 | 4,965,209 |
| Information technology expenses | 5,834,255 | 6,372,795 | 2,492,060 |
| Research & development expenses | 1,311,695 | 3,708,068 | 1,733,964 |
| Depreciation & | | | |

Adjusted for 1-for-4 stock split, June 29, 2023; Shares increased due to issuance of common shares of Marpai, Inc. and in connection with initial public offering, conversion of convertible notes to common stock, exercise of warrant and stock options; As of March 21, 2023; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 1,146,801 | 13,764,508 |
| Restricted cash | 12,344,583 | 9,352,608 |
| Accounts receivable, gross | ... | 1,461,244 |
| Allowance for credit losses | 24,617 | 23,458 |
| Unbilled receivable | 768,374 | ... |
| Accounts receivable - Balancing value | 1,149,776 | ... |
| Accounts receivable | 1,125,159 | 1,437,786 |
| Unbilled receivable | 800,000 | 350,393 |
| Prepaid expenses & other current assets | 891,526 | 1,601,920 |
| Other receivables | 8,506 | 30,634 |
| Total current assets | 17,084,949 | 26,537,849 |
| Equipment | 620,870 | 402,675 |
| Furniture & fixtures | ... | 1,007,699 |
| Leasehold improvements | ... | 745,453 |
| Equipment | 140,890 | ... |
| Total cost | 761,760 | 2,155,827 |
| Less: accumulated depreciation | 150,900 | 649,745 |
| Property & equipment, net | 610,860 | 1,506,082 |
| Capitalized software, net | 2,127,694 | 4,588,706 |
| Operating lease | | |

| | | |
|---|---------------------|-------------------|
| right-of-use assets | 2,372,839 | 3,841,810 |
| Goodwill | 3,017,600 | 5,837,060 |
| Intangible assets, net | 5,176,772 | 6,323,279 |
| Security deposits | 1,266,632 | 1,293,166 |
| Other long-term asset | 21,668 | 21,668 |
| Total assets | 31,679,014 | 49,949,620 |
| Accounts payable | 4,648,837 | 1,457,670 |
| Accrued employee compensation | 1,202,145 | 1,433,327 |
| Accrued bonuses | 178,000 | 1,712,009 |
| Accrued performance guarantee liabilities | 165,464 | 244,029 |
| Other accrued expenses & liabilities | 1,270,545 | 1,885,351 |
| Accrued expenses | 2,816,154 | 5,274,716 |
| Accrued fiduciary obligations | 11,572,713 | 9,024,463 |
| Deferred revenue | 660,826 | 288,499 |
| Current portion of operating lease liabilities | 512,416 | 1,311,295 |
| Due to related party | ... | 3,201 |
| Other short-term liability | 631,584 | ... |
| Total current liabilities | 20,842,530 | 17,359,844 |
| Convertible notes payable, net | 19,401,398 | ... |
| Other long-term liabilities | ... | 20,203,700 |
| Operating lease liabilities, net of current portion | 3,683,822 | 4,771,871 |
| Deferred tax liabilities | 1,189,742 | 1,479,880 |
| Total liabilities | 45,117,492 | 43,815,295 |
| Common stock, \$00001 par value, 50,000,000 shares authorized; 2,446,826 issued and outstanding at 30, 2021 and 31,250 issued and outstanding at 31, 2020 | 796 | ... |
| Common stock | ... | 2,128 |
| Additional paid-in capital | 63,306,726 | 54,126,297 |
| Accumulated deficit | (76,746,000) | ... |
| Retained earnings (accumulated deficit) | ... | (47,994,100) |
| Total stockholders' equity (deficit) | (13,438,478) | 6,134,325 |
| Total stockholders (deficit) equity | (13,438,478) | ... |

Recent Dividends:
1. Marpai Inc common.
 No dividends paid.
Annual Dividends:
1. Marpai Inc common.
 No dividends paid.

MARVION INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--------------------------------------|---------------------|---------------------|--------------------|
| Revenues | 14,454,869 | ... | ... |
| Revenues | 14,454,869 | 11,482,606 | 297,092 |
| Cost of revenue | 8,669,109 | ... | ... |
| Cost of revenue | 8,669,109 | 8,694,945 | 87,823 |
| Gross profit | 5,785,760 | 2,787,661 | 209,269 |
| Technology & development | 21,032,584 | 9,004,045 | 124,148 |
| Sales & marketing | 4,281,170 | 784,133 | 185,363 |
| Corporate development | 4,092,000 | 285,361 | 680,000 |
| Impairment loss on digital assets | ... | 4,076 | 1,640 |
| General & administrative | 1,666,727 | 2,743,432 | 1,334,066 |
| Loss on impairment of digital assets | (358) | ... | ... |
| Total operating expenses | 31,072,839 | 12,821,047 | 2,325,217 |
| Income (loss) from operations | (25,287,079) | (10,033,386) | (2,115,948) |

| | | | |
|--|---------------------|---------------------|--------------------|
| Gain (loss) on sale, use or exchange of digital assets | (230,326) | (18,556) | ... |
| Sundry income | 310 | 459 | ... |
| Amortization of deferred financing costs | 118,145 | ... | ... |
| Interest income | 33 | ... | ... |
| Other expenses | (208) | ... | ... |
| Total other income (expense), net | (348,336) | (18,097) | ... |
| Net income (loss) before income taxes | (25,635,415) | (10,051,483) | (2,115,948) |
| Current foreign income taxes | ... | (3,821) | 5,126 |
| Income tax expense (credit) | ... | (3,821) | 5,126 |
| Net income (loss) | (25,635,415) | (10,047,662) | (2,121,074) |
| Net income (loss) attributable to common shareholders | ... | (10,047,662) | (2,121,074) |
| Weighted average shares outstanding - basic | 73,488,882,079 | 1,880,010,643 | 1,349,528,828 |
| Weighted average shares outstanding - diluted | 73,488,882,079 | 1,880,010,643 | 1,349,528,828 |
| Year end shares outstanding | 143,146,265,860 | 1,942,681,876 | 1,867,681,876 |
| Net earnings (loss) per share - basic | ... | \$(0.01) | \$0.00 |
| Net earnings (loss) per share - diluted | ... | \$(0.01) | \$0.00 |
| Number of full time employees | ... | 1 | 1 |
| Number of part time employees | ... | 10 | 10 |
| Number of common stockholders | ... | 49 | ... |

Reclassified to conform with 2022 presentation; Approximately: As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------------|------------------|
| Cash & cash equivalents | 123,991 | 99,274 |
| Digital assets, net | 10,648 | 10,203 |
| Inventories, net | 7,770,000 | 1,387,500 |
| Prepayment for technical knowhow license & service | ... | 2,940,440 |
| Other prepayments | ... | 113,689 |
| Other receivables | ... | 3,213 |
| Prepaid expenses & other current assets | 702,093 | 3,057,342 |
| Short-Term Investments | 667,287 | ... |
| Total current assets | 9,274,019 | 4,554,319 |
| Deferred financing cost | 138,505 | 176,250 |
| Intangible assets, net | 40,605 | 94,205 |
| Total non-current assets | 179,110 | 270,455 |
| Total assets | 9,453,129 | 4,824,774 |
| Accrued liabilities & other payables | ... | 105,381 |
| Accrued interest | 15,334,410 | ... |
| Accrued consulting & service fee | 2,154,106 | 5,172,537 |
| Amounts due to related parties | 1,987,162 | 1,544,729 |
| Income tax payable | ... | 1,272 |
| Convertible note payable | 170,000 | ... |
| Notes payable (Freedom boat) | 16 | ... |
| Total current liabilities | 19,645,694 | 6,823,919 |
| Total liabilities | 19,645,694 | 6,823,919 |
| Series A preferred stock | ... | 1,000 |
| Series B preferred stock | ... | 37 |
| Series C preferred stock | ... | 1 |
| Common stock | 15,178,847 | 194,268 |
| Common stock to be issued | 829,202 | 14,079,430 |
| Additional paid-in capital | 25,637,059 | 9,936,191 |
| Accumulated other comprehensive income | ... | ... |

| | | |
|---|---------------------|--------------|
| (loss) | 1,733 | (5,043) |
| Accumulated deficit | (51,840,444) | ... |
| Retained earnings (accumulated deficit) | ... | (26,205,029) |
| Preferred Stock, Series A | 1,000 | ... |
| Preferred Stock, Series B | 37 | ... |
| Accounts receivables | 1 | ... |
| Total shareholders' equity (deficit) | (10,192,565) | (1,999,145) |
| Total Equity | (10,192,565) | ... |

Recent Dividends:

1. Marvion Inc series A preferred.
 No dividends paid.
2. Marvion Inc series A preferred.
 No dividends paid.
3. Marvion Inc series B preferred.
 No dividends paid.
4. Marvion Inc common.
 No dividends paid.
5. Marvion Inc series C preferred.
 No dividends paid.

Annual Dividends:
1. Marvion Inc series A preferred.
 No dividends paid.
2. Marvion Inc series A preferred.
 No dividends paid.
3. Marvion Inc series B preferred.
 No dividends paid.
4. Marvion Inc common.
 No dividends paid.
5. Marvion Inc series C preferred.
 No dividends paid.

MAWSON INFRASTRUCTURE GROUP INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|---------------------|---------------------|
| Cost of revenues (excluding depreciation) | 28,557,004 | ... | ... |
| Cryptocurrency mining revenue | 21,590,523 | 43,106,162 | 38,446,438 |
| Hosting co-location revenue | 16,364,767 | 13,340,143 | 852,954 |
| Sale of equipment | 262,158 | 14,237,860 | 2,157,651 |
| Net energy benefits | 5,354,272 | 13,701,242 | ... |
| Other revenue | ... | ... | 2,405,613 |
| Total revenues | 43,571,720 | 84,385,407 | 43,862,656 |
| Less: cost of revenues (excluding depreciation) | 28,557,004 | 47,714,895 | 9,904,273 |
| Gross profit | 15,014,716 | 36,670,512 | 33,958,383 |
| Selling, general & administrative | 19,177,492 | 25,850,177 | 16,061,088 |
| LO2A write off | ... | ... | 23,963,050 |
| Share based payments | 10,834,838 | 3,012,480 | 22,491,100 |
| Depreciation & amortization | 38,080,506 | 63,200,178 | 14,113,730 |
| Total operating expenses | 75,334,719 | 92,062,835 | 76,628,968 |
| Change in fair value of derivative asset | 7,241,883 | (11,299,971) | ... |
| Income (loss) from operations | (60,320,003) | (44,092,352) | (42,670,585) |
| Income from sale & revaluation of marketable securities | 1,437,230 | ... | ... |
| Gains (losses) on foreign currency transactions | (1,738,845) | (6,673,124) | (932,866) |
| Share of net gain (loss) of associates accounted for using the equity method | (36,356) | (1,254,025) | (368,426) |
| Other income | 517,918 | 2,401,555 | 902,629 |
| Interest expense | 3,048,770 | 6,063,894 | 1,643,724 |
| Loss on write off property, plant & | ... | ... | ... |

| | | | |
|--|---------------------|---------------------|---------------------|
| equipment | 1,560,541 | 470,975 | |
| Profit on sale of site | 3,353,130 | 8,276,440 | |
| Unrealized gain (loss) on marketable securities | (1,694,388) | | |
| Impairment of financial assets | 1,837,063 | 3,375,230 | |
| Income (loss) before income taxes | (52,596,474) | (54,035,559) | (45,183,947) |
| Current income tax expense - foreign | 2,204,454 | | 277,717 |
| Federal | 2,381,973 | | |
| State | 995,545 | | |
| Total current | 5,581,972 | | |
| Federal | 366,647 | | |
| Income Taxes - Total - Deferred | 366,647 | | |
| Income tax expenses | 5,948,619 | | 277,717 |
| Net income (loss) | (58,545,093) | (54,035,559) | (45,461,664) |
| Less: net loss attributable to non-controlling interests | (1,876,729) | 1,273,251 | 497,944 |
| Net income (loss) attributed to Mawson Infrastructure Group shareholders | (60,421,822) | (52,762,308) | (44,963,720) |
| Weighted average shares outstanding | | | |
| - basic | 15,659,241 | 12,695,654 | 9,383,971 |
| Weighted average shares outstanding - diluted | 15,659,241 | 12,695,654 | 9,383,971 |
| Year end shares outstanding | 16,644,711 | 13,625,882 | 11,791,085 |
| Net income (loss) per share - basic | \$(3.86) | \$(4.16) | \$(4.79) |
| Net income (loss) per share - diluted | \$(3.86) | \$(4.16) | \$(4.79) |
| Number of full time employees | | 40 | |
| Number of part time employees | | 3 | |
| Total number of employees | | 43 | 40 |
| Number of common stockholders | 118 | 136 | 271 |
| Foreign currency translation adjustments | | 5,542,561 | |
| Earnings per share from continuing operations | \$(3.86) | | |
| Earnings per share from continuing operations | \$(3.86) | | |
| Other expenses | (396,691) | | |
| Gain on Deconsolidation | 9,472,976 | | |
| Non-operating Income/(Expense) | | | |
| Net | 7,723,529 | | |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-6 stock split, February 9, 2023; □ Shares increased due to the effect of exchange of stock and reverse recapitalization of Wize Pharma Inc., issuance of common stock, exercise of warrants & restricted stock-units (RSUs), and other; □ Shares increased due to the effect of issuance of common stock for stock based compensation, settlement of convertible note interest, and conversion of Series A preferred stock and convertible notes; □ As of March 11, 2023; □ As of February 28, 2022; □ Approximately; □ As of March 17, 2023; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------|-----------|------------|
| Cash & cash equivalents | 4,476,339 | 946,265 |
| Prepaid expenses | | 3,488,868 |
| Trade receivables | | 10,413,031 |

| | | |
|---|---------------|---------------|
| Goods & service tax refund | | 45,045 |
| Trade & other receivables | 12,105,387 | 10,458,076 |
| Assets held for sale | | 5,446,059 |
| Prepaid expenses | 3,556,933 | |
| Total current assets | 20,138,659 | 20,339,268 |
| Operating lease right-of-use asset | 2,307,399 | 2,819,933 |
| Equity accounted investments | 106,807 | 2,085,373 |
| Marketable securities | | 3,243,957 |
| Security deposits | 415,000 | 2,524,065 |
| Plant & equipment, gross | 4,973,191 | 4,263,662 |
| Computer equipment, gross | 125,695 | 163,060 |
| Furniture & fixtures, gross | | 29,492 |
| Processing machines (miners), gross | 102,984,186 | 103,337,719 |
| Modular data center, gross | 25,449,717 | 19,713,534 |
| Motor vehicles, gross | 199,246 | 326,704 |
| Transformers, gross | 149,825,787 | 8,886,576 |
| Transformers, net | 9,843,359 | |
| Low-cost assets, gross | 998,815 | 995,292 |
| Assets under construction, gross | 4,764,051 | 11,592,582 |
| Leasehold improvements, gross | 487,527 | 487,527 |
| Total property & equipment, gross | | 149,796,148 |
| Less: accumulated depreciation | 92,085,496 | 54,489,966 |
| Reclassification to assets held for sale | | (4,289,684) |
| Property & equipment, net | 57,740,291 | 91,016,498 |
| Derivative asset | 4,058,088 | 11,299,971 |
| Total assets | 84,766,244 | 133,329,065 |
| Liability to HCW | 32,513,113 | |
| Trade payables | | 18,152,399 |
| Accrued expenses | | 2,164,178 |
| Deferred income | | 2,000,000 |
| Employee payables | | 1,881,897 |
| Tax payables | | 1,702,032 |
| Less: long-term | | (15,328,445) |
| Trade & other payables | | 10,572,061 |
| Current portion of operating lease liability | 1,416,310 | 1,300,062 |
| Current portion of finance lease liability | 33,059 | 30,702 |
| Borrowings | | 23,610,583 |
| Current portion of long-term borrowings | 19,352,752 | |
| Total current liabilities | 53,315,234 | 35,513,408 |
| Trade & other payables | | 15,328,445 |
| Operating lease liability, net of current portion | 1,016,216 | 1,727,975 |
| Finance lease liability, net of current portion | 50,164 | 83,223 |
| Long-term borrowings | | 4,509,894 |
| Total liabilities | 54,381,614 | 57,162,945 |
| Common stock | 16,645 | |
| Additional paid-in capital | 211,279,176 | 194,308,185 |
| Translation adjustments | | 5,021,467 |
| Accumulated other comprehensive income (loss) | 608,688 | 5,021,467 |
| Accumulated deficit | (182,666,465) | |
| Retained earnings (accumulated deficit) | | (122,257,628) |
| Total stockholders' equity (deficit) | 29,238,044 | 77,072,024 |
| Non-controlling interest | 1,146,586 | (905,904) |
| Total Equity | 30,384,630 | |

Recent Dividends:

1. Mawson Infrastructure Group Inc series A preferred. No dividends paid.
2. Mawson Infrastructure Group Inc common. No dividends paid.

Annual Dividends:

1. Mawson Infrastructure Group Inc series A preferred.

No dividends paid.

2. Mawson Infrastructure Group Inc common.

No dividends paid.

MAXCYTE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Revenue | 41,288,000 | 44,261,500 | 33,894,100 |
| Cost of goods sold | 4,742,000 | 5,098,400 | 3,647,400 |
| Gross profit (loss) | 36,546,000 | 39,163,100 | 30,246,700 |
| Research & development | 23,817,000 | 19,514,400 | 15,407,300 |
| Sales & marketing expenses | 26,975,000 | 18,652,900 | 13,002,900 |
| General & administrative expenses | 30,068,000 | 25,828,700 | 18,676,000 |
| Depreciation & amortization | 3,985,000 | 2,527,600 | 1,349,100 |
| Total operating expenses | 84,845,000 | 66,523,600 | 48,435,300 |
| Operating income (loss) | (48,299,000) | (27,360,500) | (18,188,600) |
| Interest & other expense | | 126,900 | 1,044,400 |
| Interest income | 10,376,000 | 3,916,600 | 150,800 |
| Net Income before Tax | (37,923,000) | | |
| Total other income (expense) | | 3,789,700 | (893,600) |
| Net income (loss) | (37,923,000) | (23,570,800) | (19,082,200) |
| Weighted average shares outstanding | | | |
| - basic | 103,268,502 | 101,702,664 | 90,619,057 |
| Weighted average shares outstanding - diluted | 103,268,502 | 101,702,664 | 90,619,057 |
| Year end shares outstanding | 103,961,670 | 102,397,913 | 101,202,705 |
| Net income (loss) per share - basic | \$(0.37) | \$(0.23) | \$(0.21) |
| Net income (loss) per share - diluted | \$(0.37) | \$(0.23) | \$(0.21) |
| Number of full time employees | 143 | 125 | 84 |
| Total number of employees | 143 | | |
| Number of common stockholders | 35 | 160 | 118 |
| Federal | (8,752,000) | | |
| State | (3,542,000) | | |
| Change in valuation allowance | 12,294,000 | | |

□ Approximately; □ As of March 8, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash & cash equivalents | 46,506,000 | 11,064,700 |
| Short-term investments, at amortized cost | 121,782,000 | 216,274,900 |
| Accounts receivable | 5,778,000 | 11,654,600 |
| Accounts receivable - tenant improvement allowance | | 1,912,400 |
| Raw materials | 5,694,000 | 5,650,500 |
| Work in process | 558,000 | |
| Finished goods | 5,977,000 | 2,930,300 |
| Inventory | 12,229,000 | 8,580,800 |
| Prepaid expenses & other current assets | 3,899,000 | 2,778,800 |
| Total current assets | 190,194,000 | 252,266,200 |
| Furniture & equipment | 12,288,000 | 9,516,500 |
| Instruments | 2,441,000 | 2,440,300 |
| Leasehold improvements | 14,654,000 | 14,195,500 |
| Construction & internal-use software in process | | 627,400 |
| Internal-use software | 4,106,000 | 3,220,500 |
| Purchased software | 310,000 | |
| Accumulated depreciation | | |

| | | |
|---|---------------|---------------|
| & amortization | 10,286,000 | 6,275,500 |
| Property & equipment, net | 23,513,000 | 23,724,700 |
| Right-of-use asset - operating leases | 11,241,000 | 9,853,500 |
| Other assets | 388,000 | 809,000 |
| Investments, non-current, at amortized cost | 42,938,000 | ... |
| Total assets | 268,274,000 | 286,653,400 |
| Accounts payable | 743,000 | 531,800 |
| Accrued expenses & other current liabilities | ... | 8,025,300 |
| Operating lease liability, current | 774,000 | 156,800 |
| Deferred revenues, current portion | 5,069,000 | 6,712,600 |
| Accrued expenses and other | 11,269,000 | ... |
| Total current liabilities | 17,855,000 | 15,426,500 |
| Operating lease liability, net of current portion | 17,969,000 | 15,938,100 |
| Other liabilities | 283,000 | 1,321,600 |
| Total liabilities | 36,107,000 | 32,686,200 |
| Common stock | 1,040,000 | 1,024,000 |
| Additional paid-in capital | 406,925,000 | 390,818,500 |
| Accumulated deficit | (175,798,000) | ... |
| Retained earnings (accumulated deficit) | ... | (137,875,300) |
| Total stockholders' equity (deficit) | 232,167,000 | 253,967,200 |
| Total Equity | 232,167,000 | ... |

Recent Dividends:

- 1. MaxCyte Inc series B redeemable convertible preferred.**
No dividends paid.
 - 2. MaxCyte Inc series E redeemable convertible preferred.**
No dividends paid.
 - 3. MaxCyte Inc common.**
No dividends paid.
 - 4. MaxCyte Inc series C redeemable convertible preferred.**
No dividends paid.
 - 5. MaxCyte Inc series A redeemable convertible preferred.**
No dividends paid.
 - 6. MaxCyte Inc series D redeemable convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. MaxCyte Inc series B redeemable convertible preferred.**
No dividends paid.
 - 2. MaxCyte Inc series E redeemable convertible preferred.**
No dividends paid.
 - 3. MaxCyte Inc common.**
No dividends paid.
 - 4. MaxCyte Inc series C redeemable convertible preferred.**
No dividends paid.
 - 5. MaxCyte Inc series A redeemable convertible preferred.**
No dividends paid.
 - 6. MaxCyte Inc series D redeemable convertible preferred.**
No dividends paid.

MAYS (J.W.), INC.

Annual Report

| | | | |
|---|------------|------------|------------|
| Consolidated Income Statement, Years Ended Jul. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Rental income | 22,576,455 | 21,396,035 | 20,212,879 |
| Total revenues | 22,576,455 | 21,396,035 | 20,212,879 |
| Real estate operating expenses | 15,383,378 | 14,662,851 | 14,306,967 |
| Administrative & general expenses | 5,280,853 | 5,647,733 | 4,958,227 |
| Depreciation expenses | ... | 1,742,458 | 1,785,468 |
| Depreciation | 1,688,557 | ... | ... |
| Total expenses | 22,352,788 | 22,053,042 | 21,050,662 |
| Income (loss) from operations | 223,667 | (657,007) | (837,783) |
| Gain (loss) on disposition of asset | 130,009 | ... | ... |
| Interest income | ... | 222 | 850 |
| Dividend income | 98,335 | 168,369 | 98,915 |
| Gain (loss) on sale | ... | ... | ... |

| | | | |
|---|-----------------|------------------|----------------|
| of marketable securities | ... | 131,786 | 73,783 |
| Investment income (loss) | 228,344 | 300,377 | 173,548 |
| Change in fair value of marketable securities | (366,206) | (393,763) | 446,126 |
| Interest expense | 230,769 | 251,978 | 265,585 |
| Extinguishment of debt | ... | ... | 722,726 |
| Total income (loss) & interest income (expense) | ... | (345,364) | 1,076,815 |
| Income (loss) before income taxes | (144,964) | (1,002,371) | 239,032 |
| Deferred federal income tax provision (benefit) | (33,000) | (220,000) | (108,000) |
| Deferred state income tax provision (benefit) | (29,000) | (70,000) | (51,000) |
| Income tax provision (benefit) | (62,000) | (290,000) | (159,000) |
| Net income (loss) | (82,964) | (712,371) | 398,032 |
| Weighted average shares outstanding - basic | 2,015,780 | 2,015,780 | 2,015,780 |
| Weighted average shares outstanding - diluted | 2,015,780 | 2,015,780 | 2,015,780 |
| Year end shares outstanding | 2,015,780 | 2,015,780 | 2,015,780 |
| Income (loss) per share - continuing operations - basic | \$(0.04) | ... | ... |
| Net income (loss) per common share - basic | \$(0.04) | \$(0.35) | \$0.20 |
| Net income (loss) per common share - diluted | \$(0.04) | \$(0.35) | \$0.20 |
| Full-Time Employees (Period End) | 30 | ... | ... |
| Total number of employees | 30 | 31 | 29 |
| Number of common stockholders | 800 | 800 | 800 |
| Diluted EPS | ... | ... | ... |
| Excluding ExtraOrd Items | \$(0.04) | ... | ... |
| Total investment income and interest expense | (368,631) | ... | ... |

Approximately; As of September 6, 2022; As of September 6, 2021

Consolidated Balance Sheet, Years Ended Jul. 31 (\$):

| | | |
|---|------------|------------|
| | 2023 | 2022 |
| Land | 6,067,805 | 6,067,805 |
| Buildings, improvements & fixtures | 77,703,358 | 75,794,089 |
| Construction in progress | 1,767,444 | 2,653,212 |
| Property & equipment - at cost | ... | 78,447,301 |
| Accumulated depreciation | 38,123,199 | 36,457,448 |
| Buildings - net | 41,347,603 | 41,989,853 |
| Property & equipment - net | 47,415,408 | 48,057,658 |
| Cash & cash equivalents | 1,215,921 | 1,020,585 |
| Receivables, gross | ... | 3,164,121 |
| Allowance for uncollectible receivables | ... | 393,000 |
| Receivables, net | 3,044,190 | 2,771,121 |
| Restricted cash | 1,001,814 | 1,049,312 |
| Deferred charges, net | 3,250,700 | 3,614,640 |
| Deferred charges, net - Available-for-sale - mutual funds | 5,599,420 | ... |
| Available-for-sale - corporate equity securities | ... | 798,376 |
| Marketable securities | 2,300,441 | 1,962,693 |
| Prepays & other assets | 2,773,004 | 2,761,069 |

| | | |
|--|--------------|------------|
| Operating lease right-of-use assets | 30,913,904 | 32,108,363 |
| Accumulated amortization | 2,348,720 | ... |
| SubTotal | 79,470,802 | ... |
| Total assets | 91,915,382 | 94,011,318 |
| Mortgages payable | ... | 6,358,289 |
| Tax obligations | 5,144,205 | ... |
| Security deposits payable | 1,005,925 | 1,051,428 |
| Deferred income taxes | (10,343,000) | ... |
| Total long-term debt | 3,836,134 | ... |
| Deferred income taxes | 4,230,000 | 4,292,000 |
| Deferred Tax - Credit - Liability | 14,573,000 | ... |
| Accounts payable & accrued expenses | 1,718,435 | 2,321,764 |
| Operating lease liabilities | 26,512,112 | 26,600,168 |
| Note payable - related party | 1,308,071 | ... |
| Total liabilities | 38,610,677 | 40,623,649 |
| Common stock | 2,178,297 | 2,178,297 |
| Additional paid in capital | 3,346,245 | 3,346,245 |
| Retained earnings | 49,068,015 | 49,150,979 |
| Stockholders' equity before treasury stock | ... | 54,675,521 |
| Common stock held in treasury | 1,287,852 | 1,287,852 |
| Total shareholders' equity | 53,304,705 | 53,387,669 |
| Total Equity | 53,304,705 | ... |

Recent Dividends:

- 1. Mays (J.W.), Inc. common.**
No dividends paid.

Annual Dividends:

- 1. Mays (J.W.), Inc. common.**
No dividends paid.

MCX TECHNOLOGIES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|------------------|------------------|------------------|
| | 2023 | 2022 | 2021 |
| Revenue, net | ... | 101,409 | 752,167 |
| Cost of goods sold | ... | 99,350 | 380,247 |
| Gross profit (loss) | ... | 2,059 | 371,920 |
| Administrative costs | 238,745 | ... | ... |
| Salaries & wages expenses | ... | ... | 39,066 |
| Contract services expenses | ... | 75,212 | 291,411 |
| Other general & administrative expenses | ... | 386,850 | 400,979 |
| Total expenses | 238,745 | 462,062 | 731,456 |
| Net operating income (loss) | (238,745) | (460,003) | (359,536) |
| Other income (expense) | 41,615 | ... | ... |
| Other expense | ... | 5,549 | 1,142 |
| Income (loss) before income taxes | (197,130) | ... | ... |
| Income (loss) from continuing operations | ... | ... | (360,678) |
| Net income (loss) | (197,130) | (465,552) | (360,678) |
| Weighted average shares outstanding - basic | 20,426,158 | 20,426,158 | 20,426,158 |
| Weighted average shares outstanding - diluted | 20,426,158 | 20,426,158 | 20,426,158 |
| Year end shares outstanding | 20,426,158 | 20,426,158 | 20,426,158 |
| Earnings (loss) per share - continuing operations - basic | \$(0.01) | \$(0.02) | \$(0.02) |
| Net earnings (loss) per share - basic | \$(0.01) | \$(0.02) | \$(0.02) |
| Earnings (loss) per share - continuing operations - | ... | ... | ... |

| | | | | | | | | | | |
|--|-------------|-------------|----------------|--|----------|----------|----------|--|-------------|-------------|
| diluted | \$(0.01) | \$(0.02) | \$(0.02) | Provision (benefit) for income taxes | 308 | 336 | 348 | Leasehold improvements | 1,102 | 8,474 |
| Net earnings (loss) per share - diluted | \$(0.01) | \$(0.02) | \$(0.02) | Net income (loss) from continuing operations | (7,421) | (9,795) | (4,198) | Broadcasting equipment | 3,516 | 5,786 |
| Total number of employees | ... | ... | 3 | Income (loss) from discontinued operations before income taxes | (284) | (3,081) | (1,874) | Office equipment, computer equipment, software & automobiles | 1,027 | 1,973 |
| Number of common stockholders | 43 | 41 | 41 | Gain on sale of discontinued operations | ... | 46,875 | ... | Construction in progress | 740 | 31 |
| [□] As of March 31, 2023; [□] As of April 14, 2022 | | | | Income tax expense from discontinued operations | 74 | (3,085) | (10) | Property & equipment, gross | 6,385 | 16,264 |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Net income (loss) from discontinued operations | (210) | 40,709 | (1,884) | Less: accumulated depreciation & amortization | 5,005 | 15,683 |
| | 2023 | 2022 | | Preferred stock dividends | 2,415 | 3,330 | 2,752 | Total property & equipment, net | 1,380 | 581 |
| Cash & cash equivalents | 46,069 | 2,595 | | Net income (loss) attributable to common shareholders | (10,046) | 27,584 | (8,834) | Indefinite lived intangibles | 63,266 | 63,266 |
| Other current assets | ... | 15,521 | | Weighted average shares outstanding - diluted | 24,876 | 13,380 | 7,217 | Other intangibles | 3,737 | 3,649 |
| Total current assets | 46,069 | 18,116 | | Year end shares outstanding | 26,155 | 25,856 | 8,470 | Less: accumulated amortization | 2,410 | 2,212 |
| Notes receivable - related party | 16,126 | 252,738 | | Net income (loss) from continuing operations per share - basic | \$(0.39) | \$(0.98) | \$(0.96) | Total intangible assets, net | 64,593 | 64,703 |
| Total assets | 62,195 | 270,854 | | Net income (loss) from discontinued operations per share - basic | \$(0.01) | \$3.04 | \$(0.26) | Operating lease right-of-use assets | 13,614 | 5,088 |
| Accounts payable & accrued liabilities | ... | 116,497 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Deposits & other assets | 1,996 | 78 |
| Credit cards payable | 88,767 | ... | | Net income (loss) from continuing operations per share - diluted | \$(0.39) | \$(0.98) | \$(0.96) | Total assets | 95,491 | 96,705 |
| Notes payable - related party | 16,201 | ... | | Net income (loss) from discontinued operations per share - diluted | \$(0.01) | \$3.04 | \$(0.26) | Accounts payable & accrued expenses | 2,625 | 3,880 |
| Total current liabilities | 104,968 | 116,497 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Current maturities of long-term debt | 6,458 | ... |
| Total liabilities | 104,968 | 116,497 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Accrued salaries & commissions | 539 | 875 |
| Additional paid-in capital | 6,620,217 | 6,620,217 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Deferred revenue | 557 | 825 |
| Accumulated deficit | (6,662,990) | ... | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Income taxes payable | 29 | 3,008 |
| Retained earnings (accumulated deficit) | ... | (6,465,860) | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Operating lease liabilities | 1,444 | 1,816 |
| Total shareholders' equity (deficit) | (42,773) | 154,357 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Other current liabilities | 65 | 35 |
| Total Equity | (42,773) | ... | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Current liabilities of discontinued operations | ... | 659 |
| Recent Dividends: | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Total current liabilities | 11,717 | 11,098 |
| 1. MCX Technologies Corp common. | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Notes payable to Emmis | ... | 5,950 |
| No dividends paid. | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Long-term debt, net of current portion | ... | 5,950 |
| Annual Dividends: | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Operating lease liabilities, net of current | 14,333 | 3,808 |
| 1. MCX Technologies Corp common. | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Deferred income taxes | 2,775 | 2,483 |
| No dividends paid. | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Other noncurrent liabilities | 502 | 51 |
| MEDIACO HOLDING INC | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Total liabilities | 29,327 | 23,390 |
| Annual Report | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Series A cumulative convertible participating preferred stock | 28,754 | 26,339 |
| Consolidated Income Statement, Years Ended Dec. 31 (\$000): | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Class A common stock | 54 | 207 |
| | 2023 | 2022 | 2021 (revised) | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Class B common stock | 210 | 54 |
| Total revenues | 32,391 | ... | ... | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Additional paid-in capital | 60,294 | 59,817 |
| Net revenues | 32,391 | 38,595 | 41,727 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Accumulated deficit | (23,148) | ... |
| Operating expenses excluding depreciation & amortization expense | 32,633 | 32,847 | 28,667 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Retained earnings (accumulated deficit) | ... | (13,102) |
| Corporate expenses | 5,451 | 6,463 | 8,434 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Total equity (deficit) | 37,410 | 46,976 |
| Depreciation & amortization | 568 | 666 | 688 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Recent Dividends: | | |
| Gain (loss) on disposal of assets | (526) | (5) | ... | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 1. MediaCo Holding Inc class B common. | | |
| Total operating expenses | 39,178 | 39,981 | 37,789 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Operating income (loss) | (6,787) | (1,386) | 3,938 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 2. MediaCo Holding Inc series A cumulative convertible participating preferred. | | |
| Interest expense, net | 426 | 6,980 | 7,707 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Other income | 100 | 125 | ... | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 3. MediaCo Holding Inc class A common. | | |
| Gain (loss) on debt extinguishment | ... | (1,218) | (81) | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Total other income (expense) | (326) | (8,073) | (7,788) | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Annual Dividends: | | |
| Income (loss) from continuing operations before income taxes | (7,113) | (9,459) | (3,850) | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 1. MediaCo Holding Inc class B common. | | |
| Current federal income taxes | 36 | ... | ... | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Current income taxes | 36 | ... | ... | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 2. MediaCo Holding Inc series A cumulative convertible participating preferred. | | |
| Deferred federal income taxes | 68 | 90 | 91 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Deferred state income taxes | 204 | 246 | 257 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 3. MediaCo Holding Inc class A common. | | |
| Deferred income taxes | 272 | 336 | 348 | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | No dividends paid. | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | MEDICINE MAN TECHNOLOGIES INC | | |
| | 2023 | 2022 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Annual Report | | |
| Cash & cash equivalents | 3,817 | 10,925 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | |
| Restricted cash | 1,337 | 4,376 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | 2023 | 2022 | 2021 |
| Accounts receivable, gross | 7,028 | 8,690 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | (revised) | (revised) | (revised) |
| Allowance for doubtful accounts | 353 | 122 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Retail | 155,463,816 | 141,254,893 |
| Accounts receivable, net | 6,675 | 8,568 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | Wholesale | 16,765,425 | 17,819,938 |
| Prepaid expenses | 891 | 979 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | | | 34,434,091 |
| Other current assets | 1,188 | 341 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | | | |
| Current assets of discontinued operations | ... | 1,066 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | | | |
| Total current assets | 13,908 | 26,255 | | Net income (loss) per share - diluted | \$(0.40) | \$2.06 | \$(1.22) | | | |

| | | | |
|--|--------------|--------------|-------------|
| Other operating revenues | 218,545 | 304,388 | 225,138 |
| Other | 172,447,786 | 159,379,219 | 108,420,239 |
| Total revenue | 96,424,150 | 79,090,461 | 59,066,545 |
| Cost of goods & services | 96,424,150 | 79,090,461 | ... |
| Total cost of goods & services | 76,023,636 | 80,288,758 | 49,353,694 |
| Gross profit | 39,916,518 | 29,036,962 | 16,616,306 |
| Selling, general & administrative expenses | 1,801,740 | 8,011,405 | ... |
| Professional services | 23,883,354 | 20,990,290 | 11,943,409 |
| Loss on impairment | 3,574,831 | 2,672,713 | 5,037,879 |
| Salaries | 3,558,501 | 6,722,554 | ... |
| Stock based compensation expense | 72,734,944 | 67,433,924 | 38,944,528 |
| Conference & travel expenses | 3,288,692 | 12,854,834 | 10,409,166 |
| Total operating expenses | ... | (30,139,645) | ... |
| Income (loss) from operations | (32,069,082) | ... | (7,014,279) |
| Amortization of debt discount | ... | ... | ... |
| Interest income (expense), net | ... | ... | ... |
| Unrealized gain (loss) on derivative liabilities | 15,870,233 | ... | 15,061,142 |
| Other gain (loss) | 1,816 | 18,414,760 | ... |
| Loss on business disposition | (1,968,807) | (4,684,366) | ... |
| Gain on sale of assets | ... | ... | 242,494 |
| (Gain) loss on investment, net | ... | (39,270) | 216,771 |
| Other Loss | 68,400 | 24,136 | ... |
| Total other income (expense) | (18,097,441) | (16,424,385) | 8,506,128 |
| Pre-tax net income (loss) | (14,808,749) | (3,569,551) | 18,915,294 |
| Current federal income taxes (benefit) | 20,745,917 | 17,127,037 | 4,284,163 |
| Current state income taxes (benefit) | 1,900,829 | 483,037 | 112,001 |
| Total current income taxes (benefit) | 22,646,746 | 17,610,074 | 4,396,164 |
| Deferred federal income taxes | (725,879) | (611,750) | ... |
| Deferred state income taxes | (2,180,272) | (2,100,260) | ... |
| Total deferred income taxes | (2,906,151) | (2,712,010) | ... |
| Provision for income taxes (benefit) | 19,740,595 | 14,898,064 | 4,396,164 |
| Net income (loss) | (34,549,344) | (18,467,615) | 14,519,130 |
| Less: accumulated preferred stock dividends for the period | 8,154,993 | 7,802,809 | 7,346,153 |
| Net income (loss) attributable to common stockholders | (42,704,337) | (26,270,424) | 7,172,977 |
| Weighted average shares outstanding - basic | 64,535,245 | 53,637,003 | 43,339,092 |
| Weighted average shares outstanding - diluted | 64,535,245 | 53,637,003 | 101,368,958 |
| Year end shares outstanding | 73,968,242 | 55,212,547 | 44,717,046 |
| Net earnings (loss) per share - basic | \$(0.66) | \$(0.49) | \$0.17 |
| Net earnings (loss) per share - diluted | \$(0.66) | \$(0.49) | \$(0.06) |
| Number of full time | | | |

| | | | |
|-------------------------------|-----|-----|-----|
| employees | ... | ... | 389 |
| Number of part time employees | ... | ... | 29 |
| Number of common stockholders | 122 | ... | 117 |

As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|-------------|----------------|
| Cash & cash equivalents | 19,248,932 | 38,949,253 |
| Accounts receivable, gross | 4,558,585 | 4,564,918 |
| Less: allowance for doubtful accounts | 297,426 | 92,940 |
| Accounts receivable | 4,261,159 | 4,471,978 |
| Raw materials | 2,005,306 | 2,325,482 |
| Work in process | 5,814,290 | 14,504,490 |
| Finished goods | 17,968,197 | 5,724,210 |
| Inventory | 25,787,793 | 22,554,182 |
| Note receivable - current, net | ... | 11,944 |
| Marketable securities | 456,099 | 454,283 |
| Prepaid expenses & other current assets | 3,914,064 | 5,293,393 |
| Total current assets | 53,668,047 | 71,735,033 |
| Land | 3,716,438 | 3,716,438 |
| Building | 4,830,976 | 4,830,976 |
| Leasehold improvements | 15,917,124 | 4,100,165 |
| Furniture & fixtures | ... | 655,698 |
| Vehicles machinery & tools | ... | 3,796,695 |
| Software servers & equipment | 651,676 | 4,132,621 |
| Construction in progress | 5,293,698 | 10,756,410 |
| Vehicles | 4,040,908 | ... |
| Software | 5,404,592 | ... |
| Fixed assets, gross | ... | 31,989,003 |
| Less: accumulated depreciation | 8,741,782 | 4,899,977 |
| Fixed assets, net | 31,113,630 | 27,089,026 |
| Investment | 2,000,000 | 2,000,000 |
| Goodwill | 67,499,199 | 94,605,301 |
| Intangibles, gross | ... | 124,017,580 |
| Less: accumulated amortization - intangibles | ... | 16,290,862 |
| Intangible assets, net | 166,167,877 | 107,726,718 |
| Deferred tax assets, net | 1,996,489 | ... |
| Other noncurrent assets | 1,263,837 | 1,527,256 |
| Operating lease asset - non-current | 34,233,142 | 18,199,399 |
| Assets held for sale | 202,111 | ... |
| Total non-current assets | 304,476,285 | 251,147,700 |
| Total assets | 358,144,332 | 322,882,733 |
| Accounts payable | 13,341,561 | 7,848,613 |
| Accounts payable - related party | ... | 22,380 |
| Accrued expenses | 7,774,691 | 10,314,958 |
| Derivative liabilities | 638,020 | 16,508,253 |
| Lease liabilities - current | 4,922,724 | 3,139,289 |
| Current portion of long term debt | 3,547,011 | 2,250,000 |
| Income taxes payable | 25,232,782 | 7,297,815 |
| Accrued Payroll | 981,112 | ... |
| Total Current Liabilities | 2,900,000 | ... |
| Accrued interest | 3,370,000 | ... |
| Accrued expenses - Balancing value | 523,579 | ... |
| Total current liabilities | 55,456,789 | 47,381,308 |
| Term loan | ... | 15,000,000 |
| Seller notes | ... | 61,250,000 |
| Investor note | ... | 99,118,391 |
| Less: unamortized debt issuance costs | ... | (6,603,695) |
| Less: unamortized debt discount | ... | 40,993,176 |
| Total long term debt | ... | 127,771,520 |
| Less: Current portion-other (long-term debt) | ... | 2,250,000 |
| Long term debt | 153,262,203 | 125,521,520 |
| Lease liabilities | 30,133,452 | 17,314,464 |

| | | |
|---|--------------|--------------|
| Deferred income taxes, net | ... | 502,070 |
| Total long-term liabilities | 183,395,655 | 143,338,054 |
| Total liabilities | 238,852,444 | 190,719,362 |
| Preferred stock | 86 | 87 |
| Common stock | 74,888 | 56,353 |
| Additional paid-in capital | 202,040,968 | 180,381,641 |
| Retained earnings (accumulated deficit) | (80,790,927) | (46,241,583) |
| Common stock held in treasury | 2,033,127 | 2,033,127 |
| Total stockholders' equity (deficit) | 119,291,888 | 132,163,371 |
| Total Equity | 119,291,888 | ... |

Recent Dividends:

- 1. Medicine Man Technologies Inc preferred. No dividends paid.
- 2. Medicine Man Technologies Inc common. No dividends paid.

Annual Dividends:

- 1. Medicine Man Technologies Inc preferred. No dividends paid.
- 2. Medicine Man Technologies Inc common. No dividends paid.

MENTOR CAPITAL INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|---|-------------|----------------|----------------|
| Service fees | ... | (2,585) | 5,969,674 |
| Finance lease revenue | ... | 37,659 | 40,764 |
| Total revenue | ... | 35,074 | 6,010,438 |
| Cost of revenue | ... | ... | 4,138,785 |
| Gross profit | ... | ... | 1,871,653 |
| Selling, general & administrative expenses | 1,775,210 | 495,400 | 2,275,989 |
| Operating income (loss) | (1,775,210) | (460,326) | (404,336) |
| Gain (loss) on investments in securities | (2,484) | ... | 1,017 |
| Recovery (impairment) of investments | ... | ... | (22,718) |
| Interest income | 74,780 | 58,725 | 70,229 |
| Gain (loss) on investments | ... | (170,418) | ... |
| Interest expense | 15,847 | 33,878 | 62,392 |
| Gain (loss) on equipment disposal | ... | ... | 86 |
| Paycheck protection program loans forgiven | ... | ... | 87,122 |
| Other income (expense) | 1,291 | 555 | 38,870 |
| Gain on sale of discontinued operations | 4,805,389 | ... | ... |
| Total other income & expense | 4,863,129 | (145,016) | 157,650 |
| Income (loss) before provision for income taxes | 3,087,919 | (605,342) | (246,686) |
| Current provision for income taxes - state | 8,160 | 6,768 | 9,780 |
| Total current provision for income taxes | 8,160 | 6,768 | 9,780 |
| Deferred provision income taxes - federal | 273,400 | (107,700) | (500,400) |
| Deferred provision income taxes - state | (1,100) | (18,300) | (150,000) |
| Change in valuation | (272,300) | 126,000 | 650,400 |
| Provision for income taxes | 8,160 | 6,768 | 9,780 |

| | | | | | | | | | | |
|------------------------------------|------------|------------|------------|-------------------------------------|-------------|--------------|--------------------------------|--------------|-------------|-------------|
| Net income (loss) | 3,157,658 | (366,925) | (256,466) | Finance lease | | | expenses | 4,809,000 | 7,645,000 | ... |
| Gain (loss) | | | | right-of-use assets | ... | 895,323 | Depreciation & | | | |
| attributable to | | | | Investment in account | | | amortization | 18,552,000 | 17,418,000 | 16,306,000 |
| non-controlling | | | | receivable, net of | | | Income (loss) from | | | |
| interest | ... | (104,461) | (16,382) | discount & current | | | operations | 17,798,000 | 13,973,000 | 18,073,000 |
| Net income (loss) | | | | portion | 238,849 | 315,309 | Interest expense - | | | |
| attributable to | | | | Deposits | | 25,575 | swap | ... | ... | (1,036,000) |
| Mentor Capital, | | | | Long term investments | 104,431 | 94,431 | Interest expense | 11,939,000 | 8,156,000 | 7,745,000 |
| Inc. | 3,157,658 | (471,386) | (272,848) | Goodwill | | 1,426,182 | Interest expense | | | 6,709,000 |
| Weighted average | | | | Total assets | 4,446,841 | 4,993,892 | Other income | | | |
| shares outstanding | | | | Accounts payable | 3,152 | 32,092 | (expense) | 1,053,000 | 3,858,000 | 11,934,000 |
| - basic | 22,977,395 | 22,941,357 | 22,850,947 | Accrued expenses | 91,460 | 658,743 | Total other income | | | |
| Weighted average | | | | Economic injury disaster | | | (expense) | (10,886,000) | (4,298,000) | 5,225,000 |
| shares outstanding | | | | loan - current portion | ... | 3,191 | Income (loss) | | | |
| - diluted | 25,865,216 | 22,941,357 | 22,850,947 | Finance lease liability - | | | before income taxes . . | 6,912,000 | 9,675,000 | 23,298,000 |
| Year end shares | | | | current portion | ... | 232,058 | Current income tax | | | |
| outstanding | 24,686,105 | 22,941,357 | 22,850,947 | Operating lease liability | | | expense (benefit) | 583,000 | 494,000 | 1,036,000 |
| Net income (loss) | | | | - current portion | ... | 62,861 | Deferred income tax | | | |
| per share - basic | \$0.14 | \$(0.02) | \$(0.01) | Current portion of | | | expense (benefit) | ... | ... | 4,060,000 |
| Net income (loss) | | | | long-term debt | ... | 29,011 | Deferred expense | 305,000 | 92,000 | ... |
| per share - diluted | \$0.12 | \$(0.02) | \$(0.01) | Total current liabilities | 94,612 | 1,017,956 | Consolidated Net | | | |
| Number of full time | | | | Accrued salary, | | | Income Net (Loss) | | | |
| employees | 2 | ... | 2 | retirement & incentive | | | Income Attributable | | | |
| Number of common | | | | fee - related party | 436,512 | 1,153,948 | to Noncontrolling | 6,024,000 | ... | ... |
| stockholders | 6,185 | ... | 11,232 | Economic injury disaster | | | Income tax expense | | | |
| Total provision | | | | loan | ... | 157,869 | (benefit) | 888,000 | 586,000 | 5,096,000 |
| (benefit) | 8,160 | 6,768 | ... | Finance lease liability, | | | Consolidated net | | | |
| Net Income (loss) | | | | net of current portion | ... | 575,852 | income (loss) | 6,024,000 | 9,089,000 | 18,202,000 |
| from discontinued | | | | Operating lease | | | Less: consolidated | | | |
| operations before | | | | liability, net of current | | | net income (loss) | | | |
| tax | (5,783) | (7,615) | ... | portion | ... | 307,303 | attributable to | | | |
| Net Income Before | | | | Notes payable | ... | 83,876 | noncontrolling | | | |
| Extraordinary and | | | | Less: current maturities | ... | 29,011 | interest in | | | |
| Preferred Dividends . . | 3,079,759 | (612,110) | ... | Total long-term | | | variable interest | | | |
| Net Income (loss) | | | | liabilities | 436,512 | 2,249,837 | entity | 114,000 | (604,000) | (757,000) |
| from discontinued | | | | Total liabilities | 531,124 | 3,267,793 | Consolidated net | | | |
| operations before | | | | Common stock | 2,469 | 2,294 | income (loss) | | | |
| tax | 83,682 | 252,800 | ... | Additional paid in | | | attributable to | | | |
| Net income (loss) - | | | | capital | 12,101,055 | 13,085,993 | controlling | | | |
| from discontinued | | | | Accumulated deficit | (8,187,807) | ... | interest | 6,138,000 | ... | 17,445,000 |
| operations | 77,899 | 245,185 | ... | Retained earnings | | | Preferred stock | | | |
| Earn per share-inc | | | | (accumulated deficit) | ... | (11,345,465) | dividends | ... | ... | 2,027,000 |
| from discount opers | | | | Non-controlling interest | ... | (16,723) | Income (loss) | | | |
| - diluted | \$0.00 | \$0.01 | ... | Total stockholders' | | | available to common | | | |
| Earning per | | | | equity (deficit) | 3,915,717 | 1,726,099 | shareholders | ... | 8,485,000 | 15,418,000 |
| share-total discount | | | | Total shareholders equity | 3,915,717 | ... | Weighted average | | | |
| opers - diluted | \$0.00 | \$0.01 | ... | | | | shares outstanding | | | |
| Earnings per | | | | | | | - basic | 6,512,000 | 6,585,000 | 6,703,000 |
| share-inc from | | | | | | | Weighted average | | | |
| discontinued oper | \$0.00 | \$0.01 | ... | | | | shares outstanding | | | |
| Earnings per | | | | | | | - diluted | 8,264,000 | 8,694,000 | 9,631,000 |
| share-total | | | | | | | Year end shares | | | |
| discontinued opers . . . | \$0.00 | \$0.01 | ... | | | | outstanding | 6,517,965 | 6,503,924 | 6,545,089 |
| Total number of | | | | | | | Income (loss) per | | | |
| employees | 2 | ... | ... | | | | share - continuing | | | |

□ Restated to reflect correction of errors; □ Reclassified to conform with 2022 presentation; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|---|-----------|-------------------|
| Cash & cash equivalents | 2,431,299 | 789,930 |
| Investments in securities, at fair value | 647,363 | ... |
| Accounts receivables, gross | ... | 687,470 |
| Less: allowance | ... | 53,692 |
| Accounts receivable, net | 1,800 | 633,778 |
| Other receivable | 15,000 | 230,322 |
| Convertible notes receivable, current portion | 1,000,000 | ... |
| Total current assets | 4,101,970 | 1,720,030 |
| Computers | 33,626 | 31,335 |
| Furniture & fixtures | 14,613 | 27,374 |
| Machinery & vehicles | 48,239 | 297,016 |
| Property & equipment, gross | ... | 355,725 |
| Accumulated depreciation & amortization | 46,648 | 208,847 |
| Property & equipment, net | 1,591 | 146,878 |
| Operating lease right-of-use assets | ... | 370,164 |

MERITAGE HOSPITALITY GROUP INC

Annual Report

Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 01/01/23 | 01/02/22 |
|--|-------------|-------------|-------------|
| Occupancy fee expenses | ... | 77,942,000 | ... |
| Food & beverage revenue | 672,494,000 | 626,043,000 | 577,127,000 |
| Total revenue | 672,494,000 | 626,043,000 | ... |
| Food & beverages | 184,247,000 | 172,001,000 | 150,774,000 |
| Labor & related expenses | 213,808,000 | 201,852,000 | 183,396,000 |
| Occupancy | 86,806,000 | ... | 76,467,000 |
| Advertising | 26,273,000 | 24,442,000 | 22,295,000 |
| Franchise fee | 25,439,000 | ... | 21,841,000 |
| Other operating expenses | 62,750,000 | 56,143,000 | 51,761,000 |
| Operating expenses | ... | 23,818,000 | ... |
| General & administrative | 32,012,000 | 30,809,000 | 32,225,000 |
| Preopening, acquisition & closing expenses | ... | ... | 3,989,000 |
| Preopening & acquisition | | | |

| | | | |
|--|-----------|-----------|-----------|
| Weighted average shares outstanding - basic | 6,512,000 | 6,585,000 | 6,703,000 |
| Weighted average shares outstanding - diluted | 8,264,000 | 8,694,000 | 9,631,000 |
| Year end shares outstanding | 6,517,965 | 6,503,924 | 6,545,089 |
| Income (loss) per share - continuing operations - basic | \$0.61 | ... | ... |
| Net earnings (loss) per share - basic | \$0.61 | \$1.29 | \$2.30 |
| Incomes (loss) per share - continuing operations - diluted | \$0.56 | ... | ... |
| Net earnings (loss) per share - diluted | \$0.56 | \$0.98 | \$1.81 |
| Dividends per common share | \$0.18 | \$0.30 | \$0.32 |
| Number of full time employees | 2,800 | 2,600 | 2,000 |
| Number of part time employees | ... | 8,400 | 9,000 |
| Total number of employees | 2,800 | 11,000 | 11,000 |
| Number of common stockholders | 56 | 56 | 59 |
| Number of beneficiary stockholders | 655 | 684 | 723 |
| Number of preferred B stockholders | 18 | 18 | 22 |
| Number of preferred C stockholders | 7 | 7 | 7 |
| Number of preferred D stockholders | 24 | 24 | 24 |
| Number of preferred | | | |

| | | | |
|--|-------------|-------------|----|
| E stockholders | 13 | 13 | 14 |
| □ Approximately | | | |
| Consolidated Balance Sheet, Years Ended (\$): | | | |
| | 12/31/23 | 01/01/23 | |
| Cash | 19,434,000 | 35,372,000 | |
| Receivables | 2,412,000 | 368,000 | |
| Inventories | 5,189,000 | 4,754,000 | |
| Prepaid expenses & other current assets | 7,101,000 | 6,619,000 | |
| Total current assets | 34,136,000 | 47,113,000 | |
| Land & improvements | 29,201,000 | 34,505,000 | |
| Buildings & improvements | 112,817,000 | 98,403,000 | |
| Leasehold improvements | 24,099,000 | 23,230,000 | |
| Construction in progress | 11,875,000 | 23,660,000 | |
| Buildings and improvements | 80,911,000 | 72,499,000 | |
| Property & equipment, total cost | 258,903,000 | 252,297,000 | |
| Accumulated depreciation | 106,306,000 | 91,134,000 | |
| Property & equipment, net | 152,597,000 | 161,163,000 | |
| Goodwill | 205,703,000 | 177,552,000 | |
| Intangible assets | 7,580,000 | 6,132,000 | |
| Operating lease right-of-use assets, net | 399,156,000 | 379,343,000 | |
| Long-term investments | ... | 1,786,000 | |
| Deposits & other assets | 17,733,000 | 18,229,000 | |
| Total assets | 816,905,000 | 791,318,000 | |
| Trade accounts payable | 21,958,000 | 28,445,000 | |
| Current portion of long-term debt | 20,365,000 | 14,041,000 | |
| Current portion of operating lease obligations payable | 28,091,000 | 25,841,000 | |
| Short-term borrowings | 26,257,000 | 31,848,000 | |
| Accrued payroll & related payroll taxes | 1,199,000 | 14,207,000 | |
| Accrued interest expense | 4,454,000 | ... | |
| Accrued impairment charges | ... | 6,899,000 | |
| Other accrued liabilities | ... | 1,391,000 | |
| Sales Tax | 3,270,000 | 3,329,000 | |
| Payroll and related payroll taxes | 12,850,000 | ... | |
| Total current liabilities | 118,444,000 | 126,001,000 | |
| Unearned vendor allowances | 2,301,000 | 1,154,000 | |
| Operating lease obligations payable | 376,946,000 | 359,318,000 | |
| Other long-term liabilities | 17,093,000 | 16,720,000 | |
| Deferred income taxes | 15,803,000 | 15,821,000 | |
| Total liabilities | 694,865,000 | ... | |
| Convertible preferred stock | 15,000 | 14,000 | |
| Common stock | 65,000 | 66,000 | |
| Paid in Capital | 33,577,000 | 29,117,000 | |
| Comprehensive Income - Accumulated | 6,342,000 | ... | |
| Accumulated other comprehensive income | ... | 8,959,000 | |
| Retained Earnings | 81,144,000 | ... | |
| Retained earnings (accumulated deficit) | ... | 77,992,000 | |
| Total stockholders' equity (deficit) | 121,143,000 | 116,148,000 | |
| Non-controlling interests | 897,000 | 1,049,000 | |
| Total equity (deficit) | 122,040,000 | 117,197,000 | |

Recent Dividends:

1. Meritage Hospitality Group Inc series B nonvoting convertible cumulative preferred.

No dividends paid.

2. Meritage Hospitality Group Inc series A convertible cumulative preferred.

No dividends paid.

3. Meritage Hospitality Group Inc series C nonvoting convertible preferred.

| | | | | |
|------------|------|------------|------------|------------|
| ExDate | Amt | Declared | Record | Payable |
| 03/12/2021 | 0.08 | 03/02/2021 | 03/15/2021 | 03/26/2021 |

4. Meritage Hospitality Group Inc common.

No dividends paid.

5. Meritage Hospitality Group Inc series D convertible preferred shares.

No dividends paid.

6. Meritage Hospitality Group Inc series E convertible preferred shares.

No dividends paid.

Annual Dividends:

1. Meritage Hospitality Group Inc series B nonvoting convertible cumulative preferred.

No dividends paid.

2. Meritage Hospitality Group Inc series A convertible cumulative preferred.

No dividends paid.

3. Meritage Hospitality Group Inc series C nonvoting convertible preferred.

| | | | | | |
|------|------|------|------|------|------|
| 2021 | 0.24 | 2022 | 0.32 | 2023 | 0.18 |
| 2024 | 0.06 | | | | |

4. Meritage Hospitality Group Inc common.

No dividends paid.

5. Meritage Hospitality Group Inc series D convertible preferred shares.

No dividends paid.

6. Meritage Hospitality Group Inc series E convertible preferred shares.

No dividends paid.

MESO NUMISMATICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 (revised) |
|--|-----------|-----------|-----------------|
| Revenue | 2,409,953 | ... | ... |
| Revenue | 2,409,953 | 1,530,223 | 437,887 |
| Cost of revenue | 734,285 | 653,256 | 287,750 |
| Gross profit (loss) | 1,675,668 | 876,967 | 150,137 |
| Advertising & promotion expense | 9,000 | ... | ... |
| Advertising & marketing expense | ... | 317,796 | 133,451 |
| Compensation expense | 90,000 | ... | ... |
| Professional fees | ... | 886,651 | 966,974 |
| Officer compensation | ... | 90,000 | 563,072 |
| Depreciation & amortization expense | 310,102 | 152,739 | 40,058 |
| Investor relations | ... | 190,382 | 100,496 |
| General & administrative expense - related party | ... | ... | 8,116,269 |
| General & administrative expense | 752,527 | 424,258 | 149,374 |
| Marketing | 476,989 | ... | ... |
| Office expense | 752,277 | ... | ... |
| Total operating expenses | 2,390,894 | 2,061,826 | 10,069,694 |
| Interest expense | 6,491,538 | 4,403,774 | 2,724,351 |
| Gain (loss) on debt settlement | 1,511,297 | ... | ... |
| Gain (loss) on derivative financial instruments | 4,798 | 13,498 | 3,744 |
| Settlement of lawsuit | ... | ... | 231,109 |
| Other income (expense) | 2,463 | ... | ... |
| Income (loss) from continuing | | | |

| | | | |
|---|-------------|-------------|--------------|
| operations | ... | (5,575,135) | (12,871,273) |
| Gain (loss) on sale of discontinued operations | ... | 68,313 | (13,207) |
| Income (loss) from discontinued operations | ... | 68,313 | (13,207) |
| Net income (loss) | (9,813,666) | (5,506,822) | (12,884,480) |
| Weighted average common shares outstanding - basic | 12,447,089 | 12,219,502 | 11,482,399 |
| Weighted average common shares outstanding - diluted | 12,447,089 | 12,219,502 | 11,482,399 |
| Year end shares outstanding | 12,493,938 | 12,443,938 | 12,085,125 |
| Net income (loss) per common share from continuing operations - basic | \$(0.79) | \$(0.46) | \$(1.12) |
| Net income (loss) per common share from discontinued operations - diluted | ... | \$0.01 | ... |
| Net income (loss) per common share - basic | \$(0.79) | \$(0.45) | \$(1.12) |
| Net income (loss) per common share from continuing operations - diluted | \$(0.79) | \$(0.46) | \$(1.12) |
| Net income (loss) per common share from discontinued operations - basic | ... | \$0.01 | ... |
| Net income (loss) per common share - diluted | \$(0.79) | \$(0.45) | \$(1.12) |
| Number of full time employees | ... | 1 | 1 |
| Number of common stockholders | 142 | □142 | □144 |
| Impairment of goodwill | 4,125,460 | ... | ... |
| Net Income before Tax | (9,813,666) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ As of April 28, 2023; □ As of April 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 530,540 | 1,645,185 |
| Accounts receivable | 23,956 | 49,766 |
| Prepaid expenses | 20,500 | ... |
| Total current assets | 574,996 | 1,694,951 |
| Computer & office equipment, gross | 166,774 | 149,196 |
| Leasehold improvements | 501,226 | 133,208 |
| Less: accumulated depreciation | 308,697 | 96,135 |
| Property & equipment, net | 359,303 | 186,269 |
| Other assets | 5,568 | 5,568 |
| Intangible assets, net | 256,544 | 354,084 |
| Right of use asset, net | 2,714 | 33,963 |
| Goodwill | 1,679,978 | 5,805,438 |
| Total assets | 2,879,103 | 8,080,273 |
| Accounts payable & accrued liabilities | 421,334 | 245,463 |
| Accrued interest | 6,597,422 | 4,657,530 |
| Customer advances | 2,000 | 10,450 |
| Derivative liability | 2,146 | 6,944 |
| Lease liability | 2,714 | 32,568 |
| Notes payable, net | 15,223,519 | 7,046,666 |
| Total current liabilities | 22,249,135 | 11,999,621 |
| Lease liability, net of current portion | ... | 1,395 |
| Convertible notes payable, net of current portion | 35,023 | 37,419 |

| | | | | | | | | | | | | |
|---|--------------|--------------|--|---------------|--------------|--------------|---|------------|-----|--|------------|-------------|
| Notes payable - related parties | 7,800 | 7,800 | Total operating expenses | 413,525,203 | 90,428,660 | 41,464,382 | from continuing operations | □\$(69.67) | ... | ... | | |
| Notes payable, net of current portion | 2,382,648 | 8,016,330 | Loss from operations | (408,833,821) | (83,264,683) | (38,057,838) | Earnings per share from continuing operations | □\$(69.67) | ... | ... | | |
| Total liabilities | 24,674,605 | 20,062,565 | Non-cash interest accretion | 372,000 | 403,317 | 904,925 | | □\$(69.67) | ... | ... | | |
| Preferred stock - series AA | 1,050 | 1,050 | Interest & bank charges | 55,756 | (133,518) | 220,460 | | | | □ Adjusted for 1- for -100 stock split, January 29, 2024; □ | | |
| Preferred stock - series DD | 10 | 10 | Interest income | 49,099 | 95,565 | 18,940 | | | | Shares increased due to the effect of issuance of common stock and warrant, exercise of stock option and warrants, settlement of restricted stock units and stock-based compensation; □ As of February 28, 2023; □ As of February 28, 2022 | | |
| Common stock | 12,494 | 12,444 | Interest income (expense), net | (378,657) | (174,234) | (1,106,445) | | | | | | |
| Additional paid-in capital | 40,181,074 | 40,180,669 | Unrealized gain (loss) on foreign exchange, net | 1,992,445 | ... | ... | | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| Accumulated deficit | (61,990,131) | ... | Loss on foreign exchange, net | (368,522) | (2,054,447) | (205,882) | | | | 2023 | 2022 | |
| Retained earnings (accumulated deficit) | ... | (52,176,465) | Gain on deconsolidation of wholly-owned subsidiary | ... | 3,990,737 | ... | | | | Accounts receivable | 942,793 | ... |
| Total stockholders' equity (deficit) | (21,795,503) | (11,982,292) | Gain (loss) on financial instruments, net | ... | (40,540,091) | ... | | | | Accounts receivable, related parties | 881,100 | ... |
| Total stockholders' deficit | (21,795,503) | ... | Consulting income | 6,750,195 | ... | ... | | | | Notes receivable | ... | 2,211,900 |
| | | | Total other income (expense), net | 7,258,070 | (1,671,701) | (53,791,486) | | | | Cash & cash equivalents | 9,723,690 | 10,090,858 |
| Recent Dividends: | | | Oil & gas assets maintenance cost | ... | (3,859,851) | (14,155,851) | | | | Restricted Cash | 578,406 | 1,720,613 |
| 1. Meso Numismatics Inc series CC preferred. | | | Credit loss expense | 1,799,977 | ... | ... | | | | Accounts & other receivables | ... | 902,718 |
| No dividends paid. | | | Interest income from Next Bridge | 966,827 | ... | ... | | | | Raw materials | 558,837 | 490,077 |
| 2. Meso Numismatics Inc common. | | | Government assistance | 582,756 | 218,532 | 1,733,966 | | | | Supplies | 10,747 | 11,345 |
| No dividends paid. | | | Other income | 335,163 | 72,038 | 8,850 | | | | Work in process | 45,912 | 51,589 |
| 3. Meso Numismatics Inc series AA preferred. | | | Fair value gain (loss) on long-term debt | (53,711) | 56,185 | 2,278 | | | | Finished goods | 43,922 | 42,058 |
| No dividends paid. | | | Fair value gain (loss) on funding obligation | (768,449) | 79,339 | 471,689 | | | | Inventory provision | 490,671 | 127,042 |
| 4. Meso Numismatics Inc series BB preferred. | | | Other income (expenses), net | (737,391) | (3,433,757) | (11,939,068) | | | | Inventory | 168,747 | 468,027 |
| No dividends paid. | | | Income before income taxes - local | (305,558,883) | (58,490,568) | (30,552,839) | | | | Prepaid expenses | 5,071,363 | 2,835,660 |
| 5. Meso Numismatics Inc series DD preferred. | | | Income before income taxes - foreign | (96,016,868) | (26,445,816) | (61,296,485) | | | | Other current assets | ... | 365,583 |
| No dividends paid. | | | Income (loss) before taxes | (401,575,751) | (84,936,384) | (91,849,324) | | | | Taxes receivable | ... | 4,000,856 |
| Annual Dividends: | | | Current income taxes - local | 1,737 | 1,256 | 800 | | | | Prepaid expenses & other current assets | ... | 7,202,099 |
| 1. Meso Numismatics Inc series CC preferred. | | | Current income taxes - total | 1,737 | 1,256 | 800 | | | | Due from related parties | 29,906 | 8,461 |
| No dividends paid. | | | Deferred income taxes - local | ... | (4,893,000) | ... | | | | Total current assets | 17,396,005 | 22,604,676 |
| 2. Meso Numismatics Inc common. | | | Deferred income taxes - foreign | (3,345,950) | (942,416) | (852,863) | | | | Intangible assets, net | 18,030,301 | 56,313,317 |
| No dividends paid. | | | Deferred income taxes - total | (3,345,950) | (5,835,416) | (852,863) | | | | Land | 449,872 | 439,309 |
| 3. Meso Numismatics Inc series AA preferred. | | | Income tax expense (recovery) | (3,344,213) | (5,834,160) | (852,063) | | | | Building | 5,184,826 | 5,063,091 |
| No dividends paid. | | | Net income (loss) | (398,231,538) | (79,102,224) | (90,997,261) | | | | Computer equipment | 1,583,617 | 775,736 |
| 4. Meso Numismatics Inc series BB preferred. | | | Weighted average shares outstanding - basic | □5,763,446 | 3,283,505 | 2,328,984 | | | | Computer software | 815,777 | 606,729 |
| No dividends paid. | | | Weighted average shares outstanding - diluted | □5,763,446 | 3,283,505 | 2,328,984 | | | | Manufacturing equipment | 23,979,024 | 22,701,761 |
| 5. Meso Numismatics Inc series DD preferred. | | | Year end shares outstanding | □5,659,438 | □3,622,479 | 2,845,733 | | | | Office furniture | ... | 660,549 |
| No dividends paid. | | | Net income (loss) per share - basic | □\$(69.67) | \$(24.00) | \$(39.00) | | | | Leasehold improvements | 22,794,726 | 2,172,134 |
| META MATERIALS INC | | | Net income (loss) per share - diluted | □\$(69.67) | \$(24.00) | \$(39.00) | | | | Enterprise Resource Planning software | 202,400 | 197,648 |
| Annual Report | | | Total number of employees | 103 | □239 | □130 | | | | Assets under construction | 62,301,597 | 20,337,338 |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | Number of common stockholders | 181 | 154 | 87 | | | | Less: accumulated depreciation & impairment | 43,699,983 | 10,279,596 |
| | 2023 | 2022 | 2021 | | | | | | | Assets under construction | 6,377,090 | ... |
| | | | (revised) | | | | | | | Enterprise Resource Planning software | 914,265 | ... |
| Stock-based compensation expense | (298,528) | ... | ... | | | | | | | Property, plant & equipment, net | 18,601,614 | 42,674,699 |
| Licensing revenue | 625,151 | ... | ... | | | | | | | Operating lease right-of-use assets | 1,200,417 | 5,576,824 |
| Total revenue | 7,965,646 | 10,200,167 | 4,082,517 | | | | | | | Goodwill | ... | 281,748,466 |
| Product sales | 117,354 | 1,211,746 | 407,915 | | | | | | | Total assets | 55,228,337 | 408,917,982 |
| Development revenue | 7,223,141 | 8,988,421 | 3,674,602 | | | | | | | Trade & other payables | 7,249,291 | 16,694,211 |
| Cost of sales (exclusive of items shown separately below) | 2,900,290 | ... | ... | | | | | | | Current portion of long-term debt | 801,628 | 483,226 |
| Stock-based compensation expense included in cost of sales | 334,645 | ... | ... | | | | | | | Current portion of deferred government assistance | 590,954 | 799,490 |
| Depreciation and amortization expense included in cost of sales | 39,329 | ... | ... | | | | | | | Current portion of deferred revenues | 1,054,557 | 730,501 |
| Cost of goods sold | ... | 3,036,190 | 675,973 | | | | | | | Current portion of operating lease liabilities | 1,452,863 | 967,126 |
| Gross profit (loss) | 4,691,382 | 7,163,977 | 3,406,544 | | | | | | | Accounts payable | 10,270,386 | ... |
| Selling & marketing | 4,346,226 | 6,244,883 | 2,267,354 | | | | | | | Restructuring costs accrual | 1,182,112 | ... |
| General & administrative expense | 25,151,098 | 61,543,282 | 29,699,601 | | | | | | | Current portion of funding obligation | 982,912 | ... |
| Research & development | 19,206,128 | 22,640,495 | 9,497,427 | | | | | | | Total current liabilities | 23,584,703 | 19,674,554 |
| Depreciation & amortization expense | 13,483,380 | ... | ... | | | | | | | Deferred revenues | 419,035 | 479,808 |
| Restructuring expense | 3,883,706 | ... | ... | | | | | | | Deferred government assistance | 391,148 | 319,017 |
| Goodwill impairment | 282,173,053 | ... | ... | | | | | | | Deferred tax liabilities | ... | 3,253,985 |
| Impairment of long-lived assets | 65,580,140 | ... | ... | | | | | | | Long-term operating lease liabilities | 5,973,657 | 3,375,031 |
| | | | | | | | | | | Funding obligation | ... | 180,705 |
| | | | | | | | | | | Interest-free loans | ... | 3,553,955 |

| | | |
|---|---------------|---------------|
| Less: current portion | ... | 483,226 |
| Long-term debt | 2,922,989 | 3,070,729 |
| Total liabilities | 33,291,532 | 30,353,829 |
| Common stock | 543,046 | 340,425 |
| Additional paid-in capital | 635,860,437 | 590,962,866 |
| Accumulated other comprehensive income (loss) | (5,455,145) | (5,242,810) |
| Retained earnings (accumulated deficit) | (609,011,533) | (207,496,328) |
| Total stockholders' equity | 21,936,805 | 378,564,153 |
| Total Equity | 21,936,805 | ... |

| | | | |
|-------------------------------|-----|-----------------|-----------------|
| employees | ... | [Ⓐ] 7 | 4 |
| Number of part time employees | ... | [Ⓐ] 12 | 17 |
| Number of common stockholders | 18 | [Ⓐ] 28 | [Ⓐ] 45 |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] As reported by the Company; [Ⓒ] Shares increased due to the effects of share issued for cash, stock compensation, and stock issued to settle accounts payable; [Ⓓ] As of March 31, 2023; [Ⓔ] As of March 30, 2023; [Ⓕ] As of January 12, 2023

| | | | |
|--|---------------------|---------------------|---------------------|
| expenses | ... | 1,813,000 | 1,391,000 |
| Government fees | ... | 35,000 | 170,000 |
| Share-based compensation | ... | 1,365,000 | 1,203,000 |
| Professional services | ... | 998,000 | 1,298,000 |
| Insurance | ... | 733,000 | 732,000 |
| Public & investor relations | ... | 220,000 | 203,000 |
| Office & maintenance expenses | ... | 120,000 | 108,000 |
| Travel | ... | 180,000 | 42,000 |
| Other general & administrative expenses | 4,131,000 | 81,000 | 57,000 |
| General & administrative | ... | 5,545,000 | 5,204,000 |
| Operating income (loss) | (9,855,000) | (13,281,000) | (11,357,000) |
| License & settlement agreement, net | 1,111,000 | ... | ... |
| Income from cont operations before income tax | (10,740,000) | ... | ... |
| Gain (loss) on disposal of property, plant & equipment | (2,000) | ... | ... |
| Financing income (expenses), net | 228,000 | 118,000 | 44,000 |
| Capital gain (loss) | ... | (5,000) | ... |
| Net income (loss) | (10,740,000) | (13,168,000) | (11,313,000) |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | |
|--|--------------|-------------|--|
| Cash & cash equivalents | 934,911 | ... | |
| Cash | ... | 113,952 | |
| Accounts receivable | 64,474 | 101,837 | |
| Other current assets | 15,364 | 7,864 | |
| Prepaid royalty expense | 183,146 | 147,769 | |
| Finished goods | 724,553 | 69,546 | |
| Inventories - Balancing value | 724,553 | ... | |
| Inventory | ... | 69,546 | |
| Total current assets | 1,922,448 | 440,968 | |
| Property and equipment, net | 319,462 | ... | |
| Total assets | 2,241,910 | 440,968 | |
| Accounts payable | 397,192 | 648,129 | |
| Accounts payable - related party | 50,881 | 22,533 | |
| Accrued liabilities | 449,665 | 52,540 | |
| Accrued payroll | 367,230 | 746,050 | |
| Other current liabilities | ... | 13,634 | |
| Current portion of loan payable | ... | 10,793 | |
| Loans payable - related parties | ... | 123,850 | |
| Accrued royalty expense | 55,194 | ... | |
| Total current liabilities | ... | 1,617,529 | |
| Total liabilities | ... | 1,617,529 | |
| Common stock | 144 | 117 | |
| Additional paid in capital | 14,450,087 | 4,963,340 | |
| Accumulated deficit | (12,940,040) | ... | |
| Retained earnings (accumulated deficit) | ... | (5,796,636) | |
| Total MGO stockholders' equity (deficit) | 1,510,191 | (833,179) | |
| Non-controlling interest | (588,443) | (361,382) | |
| Total stockholders' equity (deficit) | 921,748 | (1,194,561) | |

Recent Dividends:
1. MGO Global Inc common.
 No dividends paid.

Annual Dividends:
1. MGO Global Inc common.
 No dividends paid.

MICROBOT MEDICAL INC Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|-----------|-----------|-----------------------------|
| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
| Payroll and related expenses | 3,558,000 | 3,030,000 | ... |
| Share-based compensation | 387,000 | 183,000 | ... |
| Professional services | 2,097,000 | 1,532,000 | ... |
| Materials | 559,000 | 703,000 | ... |
| Patents | 341,000 | 251,000 | ... |
| Rent expense | 224,000 | 206,000 | ... |
| Office & maintenance expenses | 100,000 | 123,000 | ... |
| Depreciation | 102,000 | 72,000 | ... |
| Other research & development expenses | 368,000 | 53,000 | ... |
| Research & development | 5,724,000 | 7,736,000 | 6,153,000 |
| Payroll and related | ... | ... | ... |

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|-----------|-----------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents | 2,468,000 | 2,442,000 | |
| Marketable securities | ... | 5,760,000 | |
| Short-term deposit | ... | 3,000 | |
| Restricted cash | 49,000 | 77,000 | |
| Marketable securities, current | 3,917,000 | ... | |
| Prepaid assets | 91,000 | ... | |
| Amounts due from government institutions | 61,000 | 103,000 | |
| Prepaid expenses others | ... | 429,000 | |
| Prepaid expenses & other current assets | 152,000 | 532,000 | |
| Insurance recovery receivable related to legal settlement and legal expenses | 1,335,000 | ... | |
| Total current assets | 7,921,000 | 8,814,000 | |
| Research equipment & software | 177,000 | 71,000 | |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] As of March 30, 2023; [Ⓒ] Approximately; [Ⓓ] As of March 28, 2023; [Ⓔ] As of March 29, 2022

Recent Dividends:

1. Meta Materials Inc preferred.
 No dividends paid.
2. Meta Materials Inc common.
 No dividends paid.

Annual Dividends:

1. Meta Materials Inc preferred.
 No dividends paid.
2. Meta Materials Inc common.
 No dividends paid.

MGO GLOBAL INC

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|---|--------------------|-------------------------|-----------------------------|
| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
| Sales, net | 5,359,875 | 1,048,012 | 880,340 |
| Cost of sales | 2,013,095 | ... | ... |
| Cost of goods sold | ... | 337,631 | 392,407 |
| Total revenues | 5,359,875 | ... | ... |
| Gross profit | 3,346,780 | 710,381 | 487,933 |
| Royalty expenses | 1,269,556 | 1,273,105 | 180,246 |
| Selling, general & administrative expense | 5,331,313 | 1,402,106 | 745,554 |
| Rent expense - related party | ... | 15,026 | 14,568 |
| Professional fees | 4,128,771 | 509,853 | 5,670 |
| Total operating expenses | 10,729,640 | [Ⓐ] 3,349,346 | [Ⓐ] 1,407,192 |
| Operating income (loss) | (7,382,860) | (2,638,965) | (919,259) |
| Interest expense | 456 | ... | ... |
| Finance expense | ... | 236,231 | 103,987 |
| Paycheck protection program (PPP) loan forgiveness | ... | ... | 41,600 |
| Other income (expense), net | ... | (2,161) | (4,249) |
| Exchange gain/loss, net | (31,105) | ... | ... |
| Gain on settlement of debt | (3,500) | ... | ... |
| Interest income | 40,456 | ... | ... |
| Total other income (expenses) | 12,395 | (238,392) | (66,636) |
| Income (loss) before income taxes | (7,370,465) | (2,877,357) | (985,895) |
| Net income (loss) | (7,370,465) | (2,877,357) | (985,895) |
| Net income (loss) attributable to noncontrolling interest | 227,061 | 294,411 | 79,569 |
| Net income (loss) attributable to MGO stockholders | (7,143,404) | (2,582,946) | (906,326) |
| Weighted average shares outstanding - basic | 14,126,816 | 10,542,419 | 10,019,110 |
| Weighted average shares outstanding - diluted | 14,126,816 | 10,542,419 | 10,019,110 |
| Year end shares outstanding | 14,266,125 | [Ⓐ] 11,689,230 | 9,593,000 |
| Net income (loss) per share - basic | \$(0.51) | \$(0.25) | \$(0.09) |
| Net income (loss) per share - diluted | \$(0.51) | \$(0.25) | \$(0.09) |
| Number of full time | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 2,468,000 | 2,442,000 |
| Marketable securities | ... | 5,760,000 |
| Short-term deposit | ... | 3,000 |
| Restricted cash | 49,000 | 77,000 |
| Marketable securities, current | 3,917,000 | ... |
| Prepaid assets | 91,000 | ... |
| Amounts due from government institutions | 61,000 | 103,000 |
| Prepaid expenses others | ... | 429,000 |
| Prepaid expenses & other current assets | 152,000 | 532,000 |
| Insurance recovery receivable related to legal settlement and legal expenses | 1,335,000 | ... |
| Total current assets | 7,921,000 | 8,814,000 |
| Research equipment & software | 177,000 | 71,000 |

| | | |
|---|--------------|--------------|
| Leasehold improvement | 229,000 | 229,000 |
| Furniture & office equipment | ... | 308,000 |
| Furniture & fixtures | 233,000 | ... |
| Property & equipment, gross | 639,000 | 608,000 |
| Less: accumulated depreciation - research equipment & software | ... | 63,000 |
| Less: accumulated depreciation - leasehold improvement | 181,000 | 135,000 |
| Less: accumulated depreciation - furniture & office equipment | ... | 189,000 |
| Research equipment and software- Accumulated Depreciation & Impairment | 109,000 | ... |
| Furniture and office equipment- Other - Accumulated Depreciation & Impairment | 203,000 | ... |
| Total accumulated depreciation | 493,000 | 387,000 |
| Property & equipment, net | 146,000 | 221,000 |
| Operating right-of-use assets | 260,000 | 502,000 |
| Total assets | 8,327,000 | 9,537,000 |
| Accounts payables | 357,000 | 116,000 |
| Lease liabilities | 191,000 | 283,000 |
| Employee-related liabilities | 725,000 | 1,372,000 |
| Other current liabilities | 302,000 | 298,000 |
| Legal settlement accrual | 2,211,000 | ... |
| Accrued liabilities | 1,027,000 | 1,670,000 |
| Total current liabilities | 3,786,000 | 2,069,000 |
| Long-term lease liabilities | 40,000 | 179,000 |
| Total liabilities | 3,826,000 | 2,248,000 |
| Common stock | 118,000 | 80,000 |
| Additional paid-in capital | 83,884,000 | 75,970,000 |
| Retained earnings (accumulated deficit) | (79,501,000) | (68,761,000) |
| Total stockholders' equity | 4,501,000 | 7,289,000 |
| Total Equity | 4,501,000 | ... |

Recent Dividends:**1. Microbot Medical Inc series A convertible preferred.**

No dividends paid.

2. Microbot Medical Inc common.

No dividends paid.

3. Microbot Medical Inc common (temporary equity).

No dividends paid.

Annual Dividends:**1. Microbot Medical Inc series A convertible preferred.**

No dividends paid.

2. Microbot Medical Inc common.

No dividends paid.

3. Microbot Medical Inc common (temporary equity).

No dividends paid.

MICROPAC INDUSTRIES, INC.**Earnings, 3 mos. to (Consol. - \$000):**

| | | |
|-----------------------------|----------|----------|
| | 02/24/24 | 02/25/23 |
| Total revenues | 6,118 | ... |
| Net Sales | 6,118 | 6,190 |
| Cost & expenses | 5,910 | 6,397 |
| Operating income | 208 | (207) |
| Other income (expense), net | 147 | 139 |
| Net before taxes | 213 | (68) |
| Income taxes | 36 | (12) |
| Net income | 177 | (56) |
| Earnings common share | | |
| Primary | \$0.07 | \$(0.02) |
| Fully Diluted | \$0.07 | \$(0.02) |
| Common Shares: | | |
| Full Diluted | 2,610 | 2,578 |
| Year-end | 2,578 | 3,078 |

Consolidated Balance Sheet Items, as of (\$000):

| | | |
|-----------------------|--------|--|
| Assets: | 2024 | |
| Cash & equivalents | 9,869 | |
| Inventories | 14,500 | |
| Current assets | 29,943 | |
| Net property & equip. | 23,873 | |
| Total assets | 54,291 | |
| Liabilities: | | |
| Current liabilities | 3,853 | |
| Long-term debt | 15,212 | |
| Stockholders' equity | 35,226 | |
| Net current assets | 26,090 | |

MICROWAVE FILTER CO., INC.**Annual Report****Consolidated Income Statement, Years Ended Sept. 30 (\$):**

| | | | |
|--|-----------|-----------|-----------|
| | 2023 | 2022 | 2021 |
| Total revenues | 3,834,940 | 5,215,008 | ... |
| Net sales | 3,834,940 | 5,215,008 | 5,180,753 |
| Cost of goods sold | 2,707,689 | 3,446,222 | 3,634,493 |
| Gross profit | 1,127,251 | 1,768,786 | 1,546,260 |
| Selling, general & administrative expenses | 1,309,796 | 1,434,724 | 1,279,779 |
| Operating lease expense | 5,705 | 3,402 | 6,804 |
| Income (loss) before other income (expense) | (188,250) | 330,660 | 259,677 |
| Interest income | 13,174 | ... | ... |
| Interest expense | ... | 677 | 5,866 |
| Other income | ... | ... | 8,687 |
| Paycheck protection program loan forgiveness | ... | 309,682 | 298,282 |
| Miscellaneous | 4,145 | 14,755 | ... |
| Total other income (expense) | 17,319 | 323,760 | 301,103 |
| Income (loss) before provision for income taxes | (170,931) | 654,420 | 560,780 |
| Currently payable state income taxes provision (benefit) | 50 | 100 | 100 |
| Provision for (benefit from) income taxes | 50 | 100 | 100 |
| Net income (loss) | (170,981) | 654,320 | 560,680 |
| Weighted average shares outstanding | | | |
| - basic | 2,576,166 | 2,577,512 | ... |
| Weighted average shares outstanding - diluted | 2,576,166 | 2,577,512 | ... |
| Year end shares outstanding | 2,576,166 | 2,577,512 | 2,577,531 |
| Net income (loss) per share - basic | \$(0.07) | \$0.25 | ... |
| Net income (loss) per share - diluted | \$(0.07) | \$0.25 | ... |
| Number of common stockholders | 434 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.07) | \$0.25 | ... |
| Diluted EPS Excluding ExtraOrd | \$(0.07) | \$0.25 | ... |
| Items | \$(0.07) | \$0.25 | ... |

Consolidated Balance Sheet, Years Ended Sept. 30 (\$):

| | | |
|----------------------------------|---------|---------|
| | 2023 | 2022 |
| Cash & cash equivalents | 920,921 | 838,878 |
| Trade accounts receivable, gross | 499,212 | 637,900 |
| ACCOUNTS RECEIVABLE | 495,212 | ... |
| Trade accounts receivable, net | ... | 633,900 |
| Work-in-process | 16,630 | 126,600 |
| Finished goods | 88,660 | 125,141 |
| Inventories, gross | 196,531 | 335,680 |
| Less: reserve for obsolescence | 284,000 | 411,774 |
| Raw Materials | 375,241 | 495,713 |
| Prepaid expenses & other | ... | ... |

| | | |
|--|-----------|-----------|
| current assets | 74,885 | 57,074 |
| Allowances | 4,000 | 4,000 |
| Total current assets | 1,687,549 | 1,865,532 |
| Land | 143,000 | 143,000 |
| Buildings | 2,254,258 | 2,254,258 |
| Machinery & equipment | 481,262 | 495,596 |
| Office equipment & fixtures | 131,082 | 131,082 |
| Property, plant & equipment, gross | 3,009,602 | 3,023,936 |
| Less: accumulated depreciation | 2,261,774 | 2,164,218 |
| Property, plant & equipment, net | 747,828 | 859,718 |
| Right-of-use lease asset, net of current portion | 16,326 | ... |
| Total assets | 2,451,703 | 2,725,250 |
| Accounts payable | 140,658 | 244,868 |
| Customer deposits | 36,746 | 14,371 |
| Current portion of lease liability | 2,958 | ... |
| Accrued expenses | 137,777 | 174,161 |
| Total current liabilities | 318,139 | 433,400 |
| Lease liability - net of current portion | 13,368 | ... |
| Total liabilities | 331,507 | 433,400 |
| Common stock | 432,414 | 432,414 |
| Additional paid-in capital | 3,248,706 | 3,248,706 |
| Retained earnings (accumulated deficit) | 135,802 | 306,783 |
| Treasury stock, at cost | 1,696,726 | 1,696,053 |
| Total stockholders' equity (deficit) | 2,120,196 | 2,291,850 |
| Total Equity | 2,120,196 | 2,291,850 |

Recent Dividends:**1. Microwave Filter Co., Inc. common.**

No dividends paid.

Annual Dividends:**1. Microwave Filter Co., Inc. common.**

No dividends paid.

MIDWEST ENERGY EMISSIONS CORP.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | | | |
|--|--------------|-------------|-------------|
| | 2023 | 2022 | 2021 |
| Revenues | 17,940,370 | ... | ... |
| Revenues | 17,940,370 | 21,620,153 | 13,012,049 |
| Cost of sales | 12,172,374 | 14,598,745 | 7,938,947 |
| Selling, general & administrative expenses | 14,206,761 | 6,117,421 | 5,934,132 |
| Gain (loss) on forgiveness of debt | ... | ... | 600,677 |
| Loss on change in fair value of profit share liability | ... | (801,517) | (531,435) |
| Interest expense | 1,570,446 | 2,817,895 | ... |
| Gain (loss) on investment | ... | (95,500) | ... |
| Impairment of fixed assets | 219,707 | ... | ... |
| Total costs & expenses | ... | 23,183,629 | 16,621,732 |
| Operating income (loss) | (8,658,472) | ... | ... |
| Interest expense | 1,362,401 | ... | ... |
| Loss on change in fair value of profit share | (11,209,677) | ... | ... |
| Income from legal claims | (27,607,776) | ... | ... |
| Total other income (expense) | 15,035,698 | ... | ... |
| Net income (loss) before provision for income taxes | 6,377,226 | (1,563,476) | (3,609,683) |
| Current state & local provision (benefit) for income taxes | ... | 18,000 | 23,000 |

| | | | |
|--|------------------|--------------------|--------------------|
| Income Taxes -State and local - Current Provision (benefit) for income taxes | 473,213 | 18,000 | 23,000 |
| Net income (loss) | 5,904,013 | (1,581,476) | (3,632,683) |
| Weighted average shares outstanding - basic | 94,171,695 | 90,025,209 | 84,666,319 |
| Weighted average shares outstanding - diluted | 97,452,397 | 90,025,209 | 84,666,319 |
| Year end shares outstanding | 94,360,107 | 93,087,796 | 89,115,951 |
| Earnings (loss) per share from continuing operations - basic | \$0.06 | ... | ... |
| Net earnings (loss) per common share - basic | \$0.06 | \$(0.02) | \$(0.04) |
| Earnings (loss) per share from continuing operations - diluted | \$0.06 | ... | ... |
| Net earnings (loss) per common share - diluted | \$0.06 | \$(0.02) | \$(0.04) |
| Number of full time employees | 9 | 11 | 11 |
| Number of part time employees | 2 | ... | ... |
| Total number of employees | 11 | ... | ... |
| Number of common stockholders | 396 | 408 | 409 |
| As Reported Gross Profit | 5,767,996 | ... | ... |
| Cost of Revenues - Total | 12,172,374 | ... | ... |

Reclassified to conform with 2022 presentation; Related party - selling, general and administrative expenses: \$325,676; Related party - interest expense: \$1,570,446; Related party - interest expense: \$2,018,289; As of May 12, 2023; As of April 5, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-----------|
| Cash | 20,939,762 | 1,504,225 |
| Accounts receivable | 2,233,211 | 2,777,607 |
| Raw materials | 200,496 | 577,126 |
| Spare parts | 17,912 | 90,374 |
| Finished goods | 576,756 | 294,701 |
| Inventory | 795,164 | 991,131 |
| Prepaid expenses & other current assets | 183,621 | 267,393 |
| Total current assets | 24,151,758 | 5,540,356 |
| Security deposits | 5,175 | 10,175 |
| Equipment & installation | 1,095,139 | 1,095,140 |
| Trucking equipment | 845,102 | 845,102 |
| Office equipment, computer equipment & software | 1,874 | 20,295 |
| Leasehold Improvements - Gross | 101,821 | ... |
| Total equipment | 2,043,936 | 1,960,537 |
| Less: accumulated depreciation | 2,035,978 | 1,939,652 |
| Construction in process | 1,588,000 | 1,807,707 |
| Property & equipment, net | 1,595,958 | 1,828,592 |
| Right of use asset | 10,639 | 51,563 |
| Intellectual property | 1,704,063 | 1,909,597 |
| Total assets | 27,467,593 | 9,340,283 |
| Accounts payable & accrued expenses | 1,558,450 | 2,946,835 |
| Income taxes payable | 437,821 | ... |
| Current portion of operating lease liability | 11,157 | 43,262 |
| Customer credits | 167,000 | 167,000 |
| Accrued salaries | 8,936 | 67,478 |
| Total current liabilities | 2,183,364 | 3,224,575 |

| | |
|--|--------------|
| Operating lease liability | 11,289 |
| Convertible notes payable, net of discount & issuance costs | 10,979,723 |
| Profit share liability - related party | 14,847,937 |
| Secured note payable, net of discount - related party | 219,962 |
| Unsecured note payable, net of discount & issuance costs - related party | 239,466 |
| Total liabilities | 28,250,490 |
| Common stock | 94,360 |
| Additional paid-in capital | 61,917,119 |
| Accumulated deficit | (62,794,376) |
| Retained earnings (accumulated deficit) | (68,698,389) |
| Total stockholders' equity (deficit) | (782,897) |
| Total Equity | (782,897) |

As reported by the Company; Related party - accounts payable and accrued expenses: \$25,000

Recent Dividends:
1. Midwest Energy Emissions Corp. series A preferred.
 No dividends paid.
2. Midwest Energy Emissions Corp. common.
 No dividends paid.
Annual Dividends:
1. Midwest Energy Emissions Corp. series A preferred.
 No dividends paid.
2. Midwest Energy Emissions Corp. common.
 No dividends paid.

MILESTONE SCIENTIFIC INC. Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------------|--------------------|--------------------|
| Products sales, net | 9,827,444 | 8,805,906 | 10,304,711 |
| Total revenues | 9,827,444 | ... | ... |
| Cost of products sold | 3,034,832 | 3,905,092 | 3,992,811 |
| Total cost of revenue | 3,034,832 | ... | ... |
| Gross profit (loss) | 6,792,612 | 4,900,814 | 6,311,900 |
| Selling, general & administrative expenses | 13,135,796 | 12,514,323 | 12,738,362 |
| Depreciation & amortization expense | 61,912 | 63,755 | 73,836 |
| Research & development expenses | 701,378 | 1,150,209 | 878,210 |
| Total operating expenses | 13,899,086 | 13,728,287 | 13,690,408 |
| Income (loss) from operations | (7,106,474) | (8,827,473) | (7,378,508) |
| Interest income (expense) | 125,527 | 54,607 | (16,360) |
| Gain on debt extinguishment-PPP | ... | ... | 276,180 |
| Income (loss) before provision for income taxes & equity investments | (6,980,947) | (8,772,866) | (7,118,688) |
| Provision (benefit) for income taxes | ... | ... | 333 |
| Income (loss) before equity investment | (6,980,947) | (8,772,866) | (7,119,021) |
| Deferred profit & divesture-equity investment | ... | ... | 242,589 |
| Net income (loss) | (6,980,947) | (8,772,866) | (6,876,432) |
| Net loss (income) attributable to noncontrolling interests | 51,843 | 66,735 | 58,115 |
| Net income (loss) attributable to | ... | ... | ... |

| | | | |
|---|-------------|-------------|-------------|
| Milestone Scientific Inc. | (6,929,104) | (8,706,131) | (6,818,317) |
| Weighted average shares outstanding - basic | 72,775,781 | 70,607,338 | 68,829,860 |
| Weighted average shares outstanding - diluted | 72,775,781 | 70,607,338 | 68,829,860 |
| Year end common shares outstanding | 75,848,507 | 69,273,164 | 68,120,003 |
| Net income (loss) per share - basic | \$(0.10) | \$(0.12) | \$(0.10) |
| Net income (loss) per share - diluted | \$(0.10) | \$(0.12) | \$(0.10) |
| Number of full time employees | 17 | 20 | 26 |
| Total number of employees | 17 | ... | ... |
| Number of common shareholders | 3,318 | 499 | 68 |
| Number of beneficiary stockholders | ... | 3,911 | 5,125 |
| Earnings per share from continuing operations | \$(0.10) | ... | ... |
| Earnings per share from continuing operations | \$(0.10) | ... | ... |

Reclassified to conform with 2022 presentation; As of March 31, 2023; Approximately; As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 2,977,713 | 8,715,279 |
| Accounts receivable, gross | 322,664 | 703,717 |
| Allowance for doubtful accounts | 10,000 | 10,000 |
| Accounts receivable, net | 312,664 | 693,717 |
| Prepaid expenses & other current assets | 517,785 | 443,872 |
| Dental finished goods, net | 2,404,970 | 1,315,263 |
| Medical finished goods, net | 14,730 | 334,124 |
| Component parts & other materials | 218,486 | 142,948 |
| Inventories, net | ... | 1,792,335 |
| Advances on contracts | 1,371,548 | 1,325,301 |
| Marketable securities | 2,976,573 | ... |
| Total current assets | 10,794,469 | 12,970,504 |
| Leasehold improvements | 24,734 | 24,734 |
| Office furniture & equipment | 181,745 | 178,058 |
| Molds | 7,200 | 7,200 |
| Trade show displays | 151,462 | 151,462 |
| Computers & software | 281,256 | 280,066 |
| Tooling Safety Wand | 63,752 | 125,022 |
| Tooling equipment - STA, Wand & Medical | 82,363 | ... |
| Tooling equipment - STA & Wand | 11,100 | 11,100 |
| EPI & IA instruments | ... | 82,363 |
| STA trials instruments | ... | 63,752 |
| Tooling Safety Wand | 125,022 | ... |
| Total furniture, fixtures & equipment | 928,634 | 923,757 |
| Less accumulated depreciation | 918,610 | 905,611 |
| Furniture, fixtures & equipment, net | 10,024 | 18,146 |
| Intangibles, net | ... | 227,956 |
| Right of use assets finance lease | 8,998 | 17,645 |
| Right of use assets operating lease | 355,235 | 443,685 |
| Other assets | 24,150 | 24,150 |
| Patents, net of accumulated amortization | 178,636 | ... |
| Total assets | 11,371,512 | 13,702,086 |
| Accounts payable | 689,604 | 1,102,729 |

| | | | | | | | | | |
|--|---------------|---------------|---|-------------|-------------|-------------|--|--------------|--------------|
| Accounts payable, related party | 410,512 | 803,492 | investments | (641,433) | ... | ... | Note receivable | 250,000 | ... |
| Accrued expenses & other payables | 1,511,717 | 1,124,839 | Total other income (expense) | (1,200,062) | ... | ... | Prepaid expenses | 165,301 | 49,219 |
| Accrued expenses, related party | ... | 167,549 | Net investment gain (loss) | (1,165,506) | 1,440,576 | 1,301,450 | Receivable for sale of investments | 264,413 | ... |
| Current portion of finance leases liabilities | 10,264 | 9,365 | Net realized gain on investments | ... | 133,019 | 4,118,001 | Interest & dividend receivables | ... | 250,879 |
| Current portion of operating lease liabilities | 103,427 | 91,701 | Net change in unrealized appreciation (depreciation) on investments | ... | (816,989) | (1,533,703) | Short term non banking loans | 16,961,766 | ... |
| Accrued expenses, related party | 137,189 | ... | Net realized & unrealized gain (loss) on investments | ... | (683,970) | 2,584,298 | Right-of-use operating lease asset | 9,283 | 16,398 |
| Accrued liabilities noncontrolling interests | 214,000 | ... | Net increase in net assets resulting from operations before taxes | ... | 756,606 | 3,885,748 | Deferred taxes | 757,000 | 201,000 |
| Total current liabilities | 3,076,713 | 3,299,675 | Provision for income taxes | ... | 178,869 | 1,054,698 | Total assets | 19,106,697 | 18,565,569 |
| Non-current portion of finance lease liabilities | 434 | 10,698 | Net increase in net assets resulting from operations | ... | 577,737 | 2,831,050 | Accounts payable | 71,702 | 136,514 |
| Non-current portion of operating lease liabilities | 281,853 | 385,279 | Weighted average shares outstanding - basic | 6,249,913 | 5,333,028 | □4,795,242 | Accrued payroll liabilities | 435,449 | ... |
| Total liabilities | 3,359,000 | 3,695,652 | Weighted average shares outstanding - diluted | 6,249,913 | 5,333,028 | □4,795,242 | Operating lease liability | 9,283 | ... |
| Common stock | 75,881 | 69,306 | Year end shares outstanding | 6,385,255 | □6,185,255 | □4,795,739 | Operating lease liability | 9,283 | 16,562 |
| Additional paid in capital | 132,187,656 | 127,478,325 | Net investment income (loss) per share - basic | \$(0.18) | \$0.11 | □\$0.59 | Deferred interest income | ... | 70,154 |
| Retained earnings (accumulated deficit) | (123,339,509) | (116,410,405) | Net investment income (loss) per share - diluted | \$(0.18) | \$0.11 | □\$0.59 | Total liabilities | 516,434 | 223,230 |
| Treasury stock | 911,516 | 911,516 | Full-Time Employees (Period End) | 3 | ... | ... | Common stock | 6,385 | 12,215 |
| Total Milestone Scientific Inc. stockholders' equity (deficit) | 8,012,512 | 10,225,710 | Total number of employees | 3 | 3 | 2 | Additional paid-in capital | 15,473,121 | 15,043,291 |
| Noncontrolling interest | ... | (219,276) | Number of common stockholders | 253 | □253 | □253 | Accumulated Deficit | (1,159,665) | ... |
| Total stockholders' equity (deficit) | 8,012,512 | 10,006,434 | Income from cont operations before income tax | (1,620,060) | ... | ... | Retained earnings (accumulated deficit) | ... | (1,159,665) |
| | | | Net increase (decrease) in net assets resulting from operations | (1,165,506) | ... | ... | Accumulated undistributed investment gain (loss) | (1,052,183) | (615,960) |
| | | | Current federal | 83,402 | ... | ... | Accumulated undistributed net realized gains (losses) on investment transactions | 5,155,200 | 5,713,829 |
| | | | Current state | 18,044 | ... | ... | Net unrealized appreciation (depreciation) in value of investments | (1,292,804) | (651,371) |
| | | | Income Taxes - Domestic - Deferred | (556,000) | ... | ... | Additional paid-in capital - stock options | 1,460,209 | ... |
| | | | Provision for (Benefit from) Income Taxes | (454,554) | ... | ... | Total shareholders' equity (net assets) | 18,590,263 | 18,342,339 |
| | | | Earnings per share from continuing operations | \$(0.18) | ... | ... | Net asset value per common share | ... | \$2.97 |
| | | | Earnings per share from continuing operations | \$(0.18) | ... | ... | Total Equity | 18,590,263 | ... |
| | | | □ Adjusted for 1- for -2.25 reverse stock split, August 9, 2022; | | | | | | |
| | | | □ Shares increased due to the effect of common shares issued in public offering net of underwriting costs & warrants; □ Approximately; □ As of April 17, 2023; □ As of March 14, 2022 | | | | | | |
| | | | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | |
| | | | | | 2023 | 2022 | | | |
| | | | Investment Securities - Total | 17,284,676 | ... | ... | Total revenues | 26,106,271 | ... |
| | | | Investment Securities - Total - Balancing value | 322,910 | ... | ... | Net sales | 26,106,271 | 50,622,143 |
| | | | Investments, at fair value: | ... | □16,708,432 | ... | Cost of goods sold | 25,635,383 | 38,695,605 |
| | | | Cash | 376,024 | 1,089,641 | ... | Gross profit | 470,888 | 11,926,538 |
| | | | Note receivable, related party | ... | 250,000 | ... | Selling & marketing | 9,472,527 | 15,022,638 |
| | | | | | | | General & administrative | 4,758,357 | 6,124,034 |
| | | | | | | | Research & development | 3,446,595 | 5,824,906 |
| | | | | | | | Sale of trademark, net | ... | 3,955,626 |
| | | | | | | | Total operating expenses | 17,677,479 | 26,971,578 |
| | | | | | | | Operating profit (loss) | (17,206,591) | (15,045,040) |
| | | | | | | | Interest income | 2,554 | 457 |
| | | | | | | | Interest expense | 385,952 | 394,615 |
| | | | | | | | Other income (expense), net | (1,316) | 2,302 |
| | | | | | | | Gain on forgiveness of debt | ... | 20,000 |
| | | | | | | | Total other income (expense) | (384,714) | (391,856) |
| | | | | | | | Income (loss) before income taxes | (17,591,305) | (15,436,896) |
| | | | | | | | Current income tax | ... | (2,134,894) |

□ Cost - Investments, at fair value: non-control and non-affiliate investments: \$17,359,804

Recent Dividends:

1. Mill City Ventures III Ltd. common.

No dividends paid.

Annual Dividends:

1. Mill City Ventures III Ltd. common.

No dividends paid.

MINIM INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2023 2022 □2021 (revised)

Total revenues

Net sales

Cost of goods sold

Gross profit

Selling & marketing

General & administrative

Research & development

Sale of trademark, net

Total operating expenses

Operating profit (loss)

Interest income

Interest expense

Other income (expense), net

Gain on forgiveness of debt

Total other income (expense)

Income (loss) before income taxes

Current income tax

| | | | |
|---|---------------------|---------------------|--------------------|
| expense - state & local | 16,623 | 59,846 | 32,069 |
| Current income tax expense - foreign | 25,996 | 52,502 | 31,704 |
| Total current income tax expense | 42,619 | ... | ... |
| Income tax provision | 42,619 | 112,348 | 63,773 |
| Net income (loss) | (17,633,924) | (15,549,244) | (2,198,667) |
| Weighted average shares outstanding | | | |
| - basic | 1,941,800 | 1,855,965 | 1,590,445 |
| Weighted average shares outstanding - diluted | 1,941,800 | 1,855,965 | 1,590,445 |
| Year end shares outstanding | 2,632,809 | 1,877,970 | 1,835,402 |
| Net income (loss) per share - basic | \$(9.08) | \$(8.50) | \$(1.50) |
| Net income (loss) per share - diluted | \$(9.08) | \$(8.50) | \$(1.50) |
| Number of full time employees | 43 | ... | ... |
| Total number of employees | 43 | 93 | ... |
| Number of common stockholders | 59 | 128 | ... |
| Earnings per share from continuing operations | \$(9.08) | ... | ... |
| Earnings per share from continuing operations | \$(9.08) | ... | ... |

¹ Restated to reflect the adoptions of critical accounting policies and estimates; ² Adjusted for 1-for-25 stock split, April 17, 2023; ³ Shares increased due to the effect of the exercise of share option and issuance pursuant to public offering; ⁴ As of March 29, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 709,322 | 530,110 |
| Restricted cash | ... | 500,000 |
| Accounts receivable, gross | 1,014,360 | 2,896,737 |
| Allowance for doubtful accounts | 312,983 | 138,331 |
| Accounts receivable, net | 701,377 | 2,758,406 |
| Materials | 210,318 | 397,133 |
| Work in process | 1,640,347 | 5,842,251 |
| Finished goods | 8,101,982 | 19,175,822 |
| Inventories, net | 9,952,647 | 25,415,206 |
| Prepaid expenses & other current assets | 35,768 | 360,735 |
| Total current assets | 11,399,114 | 29,564,457 |
| Computer hardware & software | 2,652,020 | 497,913 |
| Machinery & equipment | 726,326 | 725,568 |
| Molds, tools & dies | 1,242,711 | 1,187,541 |
| Office furniture & fixtures | 79,147 | 78,728 |
| Computer hardware and software | 603,836 | ... |
| Equipment, gross | ... | 2,489,750 |
| Accumulated depreciation | 2,219,515 | 1,852,777 |
| Equipment, net | 432,505 | 636,973 |
| Operating lease right-of-use assets | 22,512 | 173,480 |
| Intangible assets, net | 33,247 | 73,301 |
| Other assets | 472,587 | 511,795 |
| Total assets | 12,359,965 | 30,960,006 |
| Bank credit line | ... | 4,758,663 |
| Accounts payable | 11,143,693 | 2,837,191 |
| Current maturities of bridge loan agreement | ... | 1,000,000 |
| Current maturities of operating lease liabilities | 22,512 | 150,968 |
| Accrued inventory purchases | ... | 24,901 |
| Accrued payroll & related benefits | ... | 430,358 |

| | | |
|--|--------------|--------------|
| Accrued professional fees | 229,950 | 290,588 |
| Accrued professional fees | ... | 1,650,000 |
| Accrued sales allowances | 697,884 | 1,226,856 |
| Accrued sales & use tax | 150,009 | 113,200 |
| Other accrued expenses | ... | 704,821 |
| Accrued expenses | 1,077,843 | 4,440,724 |
| Deferred revenue - current | ... | 633,542 |
| Total current liabilities | 12,244,048 | 13,821,088 |
| Operating lease liabilities, less current maturities | ... | 22,512 |
| Deferred revenue - noncurrent | ... | 771,738 |
| Total liabilities | 12,244,048 | 14,615,338 |
| Common stock | 479,335 | 469,492 |
| Additional paid-in capital | 92,105,360 | 90,710,030 |
| Accumulated deficit | (92,468,778) | ... |
| Retained earnings (accumulated deficit) | ... | (74,834,854) |
| Total stockholders' equity (deficit) | 115,917 | 16,344,668 |
| Total Equity | 115,917 | ... |

Recent Dividends:
1. Minim Inc common.
 No dividends paid.

Annual Dividends:
1. Minim Inc common.
 No dividends paid.

MIRA PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|--------------------|--------------------|
| General and administrative expenses | 6,499,537 | 2,992,125 | 770,115 |
| Related party travel costs | 453,550 | 1,704,350 | 697,600 |
| Research and development expenses | 1,572,962 | 2,351,465 | 684,447 |
| Total operating costs | 8,526,049 | 7,047,940 | 2,152,162 |
| Interest expense | 3,456,294 | 10,250 | 24,374 |
| Net loss | (11,982,343) | (7,058,190) | (2,176,536) |
| Year end shares outstanding | 14,780,885 | 13,313,000 | 12,673,800 |
| Number of full time employees | ... | 1 | ... |
| Number of part time employees | ... | 5 | ... |
| Weighted average common stock shares outstanding | 14,780,885 | ... | ... |
| Basic loss per share | \$(0.64) | ... | ... |
| Weighted average common stock shares outstanding - diluted | 14,780,885 | ... | ... |
| Diluted loss per share | \$(0.64) | ... | ... |
| Net Income before Tax | (11,982,343) | ... | ... |
| Non-Operating Income/Expense - Total | (3,456,294) | ... | ... |

¹ Adjusted for 1-for-5 stock split, June 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------------|-----------|---------|
| Cash | 4,602,566 | 350,978 |
| Deferred offering costs | ... | 143,427 |
| Prepaid expenses | 243,802 | ... |
| Other receivables | 11,862 | ... |
| Total current assets | 4,858,230 | 494,405 |
| Operating lease, right of use assets | 5,061 | 164,910 |
| Related party operating | ... | ... |

| | | |
|--|--------------|-------------|
| lease, right of use assets | ... | 198,759 |
| Related party accounts receivable | 69,152 | ... |
| Total assets | 4,932,443 | 858,074 |
| Trade accounts payable and accrued liabilities | 538,564 | 811,738 |
| Related party accounts payable | ... | 116,350 |
| Related party line of credit | ... | 133,062 |
| Related party accrued interest | 14,472 | 34,987 |
| Current portion of operating lease liabilities | 5,061 | 75,143 |
| Related party current portion of operating lease liabilities | ... | 198,759 |
| Total current liabilities | 558,097 | 1,370,039 |
| Non-current operating lease liabilities | ... | 84,267 |
| Total liabilities | ... | 1,454,306 |
| Common Stock | 1,478 | 6,657 |
| Additional paid-in capital | 25,657,930 | 8,699,830 |
| Accumulated deficit | (21,285,062) | (9,302,719) |
| Total stockholders' (deficit) equity | 4,374,346 | (596,232) |
| Total Equity | 4,374,346 | ... |

Recent Dividends:
1. Mira Pharmaceuticals Inc common.
 No dividends paid.

Annual Dividends:
1. Mira Pharmaceuticals Inc common.
 No dividends paid.

MITEK SYSTEMS, INC.
Annual Report
Consolidated Income Statement, Years Ended Sept. 30 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|-------------|-------------|
| Software & hardware | 88,374,000 | 72,928,000 | 60,069,000 |
| Service & other revenue | 84,178,000 | 71,876,000 | 59,728,000 |
| Total revenue | 172,552,000 | 144,804,000 | 119,797,000 |
| Cost of revenue - software & hardware | 1,413,000 | 1,576,000 | 2,468,000 |
| Cost of revenue - service & other | ... | ... | 12,072,000 |
| Cost of sales - professional services, education & other | 21,538,000 | 18,432,000 | ... |
| Selling & marketing expenses | 40,551,000 | 38,841,000 | 32,497,000 |
| Research & development expenses | 28,988,000 | 30,192,000 | 28,042,000 |
| General & administrative expenses | 43,338,000 | 26,591,000 | 22,490,000 |
| Acquisition-related costs & expenses | 19,046,000 | 15,172,000 | 8,951,000 |
| Restructuring costs | 2,114,000 | 1,800,000 | ... |
| Total operating costs & expenses | 156,988,000 | 132,604,000 | 106,520,000 |
| Operating income (loss) | 15,564,000 | 12,200,000 | 13,277,000 |
| Interest expense | 9,063,000 | 8,232,000 | 5,129,000 |
| Other income, net | ... | ... | 654,000 |
| Other income (expense), net | 3,840,000 | (366,000) | ... |
| Income (loss) before income taxes - domestic | 23,836,000 | 11,483,000 | 10,966,000 |
| Income (loss) before income taxes - foreign | (13,495,000) | (7,881,000) | (2,164,000) |
| Income (loss) before income taxes | 10,341,000 | 3,602,000 | 8,802,000 |

| | | | | | | |
|---|-------------|-------------|-------------|---|-------------|-------------|
| Provision (benefit) for federal income taxes - deferred | | | 1,387,000 | Less: accumulated depreciation & amortization | 7,778,000 | 6,056,000 |
| Provision (benefit) for state income taxes - current | | | 78,000 | Property & equipment, net | 2,829,000 | 3,493,000 |
| Provision (benefit) for state income taxes - deferred | | | (457,000) | Intangible assets, net | 64,674,000 | 75,756,000 |
| Provision (benefit) for foreign income taxes - current | | | 1,119,000 | Goodwill | 123,548,000 | 115,632,000 |
| Provision (benefit) for foreign income taxes - deferred | (4,178,000) | (3,337,000) | (1,303,000) | Right-of-use assets | 4,140,000 | 5,155,000 |
| Federal-current | 1,215,000 | 325,000 | ... | Deferred income tax assets | 11,645,000 | 10,110,000 |
| State-current | 4,414,000 | 233,000 | ... | Convertible senior notes hedge | 5,579,000 | 4,218,000 |
| state-deferred | (819,000) | (513,000) | ... | Other non-current assets | 1,647,000 | 1,628,000 |
| Federal-deferred | 659,000 | 1,400,000 | ... | Total assets | 405,375,000 | 364,479,000 |
| Foreign-current | 1,023,000 | 1,800,000 | ... | Accounts payable | 7,589,000 | 4,974,000 |
| Total current provision for income taxes | 6,652,000 | 2,358,000 | ... | Accrued payroll & related taxes | 10,554,000 | 10,393,000 |
| Total deferred provision for income taxes | (4,338,000) | (2,450,000) | ... | Deferred revenue, current portion | 17,360,000 | 21,350,000 |
| Income tax provision (benefit) | 2,314,000 | (92,000) | 824,000 | Lease liabilities, current portion | 1,902,000 | 2,110,000 |
| Net income (loss) | 8,027,000 | 3,694,000 | 7,978,000 | Acquisition-related contingent consideration | 7,976,000 | 5,920,000 |
| Weighted average share outstanding - basic | 45,533,000 | 44,595,000 | 43,509,000 | Restructuring accrual | ... | 901,000 |
| Weighted average share outstanding - diluted | 46,461,000 | 45,780,000 | 45,083,000 | Other current liabilities | 1,482,000 | 2,402,000 |
| Year end shares outstanding | 45,591,199 | 44,680,429 | 44,168,745 | Deferred rent, current | 17,360,000 | 21,350,000 |
| Net income (loss) per share - basic | \$0.18 | \$0.08 | \$0.18 | Income tax payables | 4,329,000 | 206,000 |
| Net income (loss) per share - diluted | \$0.17 | \$0.08 | \$0.18 | Accrued interest payable | 305,000 | 202,000 |
| Number of full time employees | 573 | ... | 435 | Total current liabilities | 51,497,000 | 48,458,000 |
| Number of part time employees | ... | ... | 13 | Deferred revenue, non current portion | 957,000 | 1,775,000 |
| Total number of employees | 573 | ... | 448 | Lease liabilities, non-current portion | 2,867,000 | 4,106,000 |
| Number of common stockholders | 226 | ... | 246 | Deferred income tax liabilities | 6,476,000 | 9,578,000 |
| Foreign currency translation adjustments | ... | ... | (455,000) | Long-term liabilities | 957,000 | 1,775,000 |
| Earnings per share from continuing operations | \$0.18 | \$0.08 | ... | Other non-current liabilities | 2,874,000 | 1,613,000 |
| Earnings per share from continuing operations | \$0.17 | \$0.08 | ... | Total liabilities | 200,187,000 | 193,500,000 |

□ Restated to reflect correction of errors; □ As of November 30, 2021

| Consolidated Balance Sheet, Years Ended Sept. 30 (\$): | | |
|--|-------------|-----------------|
| | 2023 | □2022 (revised) |
| Cash & cash equivalents | 58,913,000 | 32,059,000 |
| Short-term investments | 74,700,000 | 58,268,000 |
| Accounts receivable, gross | 33,632,000 | 36,822,000 |
| Less: allowance for doubtful accounts | 1,500,000 | 900,000 |
| Accounts receivable, net | 32,132,000 | 35,922,000 |
| Contract assets | 18,355,000 | 7,037,000 |
| Prepaid expenses | 3,513,000 | 1,946,000 |
| Other current assets | 2,396,000 | 2,622,000 |
| Total current assets | 190,009,000 | 137,854,000 |
| Long-term investments | 1,304,000 | 10,633,000 |
| Leasehold improvements | 2,612,000 | 2,554,000 |
| Equipment | 3,657,000 | 3,384,000 |
| Capitalized internal-use software development costs | 3,610,000 | 2,902,000 |
| Furniture & fixtures | 728,000 | 709,000 |
| Property & equipment - at cost | 10,607,000 | 9,549,000 |

| | | | |
|---|---------------|--------------------|-------------|
| Stockholders' equity | 213,798,000 | Net current assets | 146,364,000 |
| MMEK RESOURCES CORP | | | |
| Earnings, 9 mos. to Jan 31 (Consol. - \$): | | | |
| | 2024 | 2023 | |
| Cost & expenses | 961,522 | 1,475,845 | |
| Deprec., depl. & amort. | 27,296 | 27,296 | |
| Operating income | (988,818) | (1,503,141) | |
| Interest expense | 297,833 | 193,190 | |
| Other income (expense), net | (752,150) | 16,540 | |
| Net before taxes | (2,038,801) | (1,679,791) | |
| Net income | (2,038,801) | (1,679,791) | |
| Balance for common | (2,038,801) | (4,214,193) | |
| Earnings common share | | | |
| Primary | \$ (0.15) | \$ (0.15) | |
| Fully Diluted | \$ (0.15) | \$ (0.15) | |
| Common Shares: | | | |
| Full Diluted | 6,507,122,563 | 27,819,443 | |
| Year-end | 8,874,007,854 | 48,890,638 | |

MOBIQUITY TECHNOLOGIES INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 (revised) |
|---|-------------|-------------|-----------------|
| Revenues | 860,090 | ... | ... |
| Revenues | 860,090 | 4,167,272 | 2,672,615 |
| Cost of service revenue | 480,160 | ... | ... |
| Cost of revenues | ... | 2,295,404 | 1,954,383 |
| Gross profit (loss) | 379,930 | 1,871,868 | 718,232 |
| General & administrative expenses | 5,243,414 | 9,213,632 | 13,607,759 |
| Depreciation and amortization | 685,264 | ... | ... |
| Total operating expenses | 5,928,678 | ... | ... |
| Income (loss) from operations | (5,548,748) | (7,341,764) | (12,889,527) |
| Interest expense | 771,899 | 152,393 | 1,417,268 |
| Impairment of intangible asset | ... | ... | 3,600,000 |
| Amortization of debt discount | ... | ... | 692,430 |
| Gain (loss) on extinguishment of debt - related party | (396,322) | (855,296) | ... |
| Inducement expense | ... | 101,000 | ... |
| Interest income | ... | 2,303 | ... |
| Gain (loss) on disposal of fixed assets | ... | (3,673) | ... |
| Gain on settlement of liability | ... | 389,495 | ... |
| Gain on forgiveness of debt | ... | ... | 265,842 |
| Interest income | 2,506 | ... | ... |
| Gain (loss) on abandonment of fixed assets | (695) | ... | ... |
| Total other income (expense) - net | ... | (720,564) | (5,443,856) |
| Net income (loss) | (6,533,117) | (8,062,328) | (18,333,383) |
| Weighted average shares outstanding - basic | 2,055,059 | 8,143,126 | 3,351,335 |
| Weighted average shares outstanding - diluted | 2,055,059 | 8,143,126 | 3,351,335 |
| Year end shares outstanding | 3,992,426 | □9,274,139 | □6,423,251 |
| Net income (loss) per share for continuing operations - basic | \$(3.18) | ... | ... |
| Net income (loss) per share - basic | \$(3.18) | \$(0.99) | \$(5.47) |
| Net income (loss) per share for continuing operations - | | | |

MIITEK SYSTEMS, INC.
Earnings, 3 mos. to Dec 31 (Consol. - \$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Total revenues | 36,917,000 | 45,703,000 |
| Cost & expenses | 43,833,000 | 32,509,000 |
| Operating income | (6,916,000) | 8,373,000 |
| Other income (expense), net | 1,642,000 | 340,000 |
| Net before taxes | (7,537,000) | 6,576,000 |
| Income taxes | (1,744,000) | 1,846,000 |
| Net income | (5,793,000) | 4,730,000 |
| Earnings common share | | |
| Primary | \$(0.13) | \$0.11 |
| Fully Diluted | \$(0.13) | \$0.10 |
| Common Shares: | | |
| Full Diluted | 46,294,000 | 45,634,000 |
| Year-end | 46,631,594 | 45,248,743 |
| Consolidated Balance Sheet Items, as of (\$): | | |
| Assets: | | 2023 |
| Cash & equivalents | ... | 64,538,000 |
| Current assets | ... | 185,964,000 |
| Net property & equip. | ... | 2,695,000 |
| Total assets | ... | 405,390,000 |
| Liabilities: | | |
| Current liabilities | ... | 39,600,000 |
| Long-term debt | ... | 137,486,000 |

| | | | |
|---|-------------|----------|----------|
| diluted | \$(3.18) | ... | ... |
| Net income (loss) per share - diluted | \$(3.18) | \$(0.99) | \$(5.47) |
| Total number of employees | ... | 14 | ... |
| Number of common stockholders | 114 | 136 | ... |
| Number of beneficiary stockholders | ... | 1,576 | ... |
| Income from cont operations before income tax | (6,715,158) | ... | ... |
| Income tax benefit | (182,041) | ... | ... |

Restated to reflect the correction made on certain misstatements; Shares increased due to the effect of stock issued for services, cash and conversion of long-term debt; Shares increased due to the effect of common stock issued for services & cash; note conversion; original issue discount; warrant conversion; and conversion of preferred series C and series AAA; As of February 8, 2023; As of February 1, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash & cash equivalents | 528,272 | ... |
| Cash | ... | 220,854 |
| Accounts receivable, gross | 1,192,538 | 1,431,935 |
| Less: allowance for doubtful accounts | 1,157,910 | 1,091,000 |
| Accounts receivable, net | 34,628 | ... |
| Accounts receivable, net | ... | 340,935 |
| Prepaid & other current assets | 149,635 | 59,200 |
| Total current assets | 712,535 | 620,989 |
| Property & equipment | 7,298 | 15,437 |
| Goodwill | 1,352,865 | 1,352,865 |
| Intangible assets | 76,488 | 646,284 |
| Capitalized software development costs, net | 2,049,908 | ... |
| Total assets | 4,199,094 | 2,635,575 |
| Current portion of debt | 168,717 | ... |
| Accounts payable & accrued expenses | 1,626,914 | 2,302,807 |
| Contract liabilities | 193,135 | 193,598 |
| Total current liabilities | 1,990,766 | 2,496,405 |
| Long-term debt, less current portion | ... | 150,000 |
| Total liabilities | 1,990,766 | 2,646,405 |
| Preferred stock series AAA | 3 | 3 |
| Preferred stock series C | 78 | ... |
| Preferred stock series E | 6 | 6 |
| Common stock | 400 | 931 |
| Treasury stock | 1,350,000 | 1,350,000 |
| Additional paid in capital | 220,598,180 | 211,845,452 |
| Accumulated Deficit | (217,040,339) | ... |
| Retained earnings (accumulated deficit) | ... | (210,507,222) |
| Total stockholders' equity (deficit) | 2,208,328 | (10,830) |
| Total Equity | 2,208,328 | ... |

Recent Dividends:

- 1. Mobyvity Technologies Inc series AAAA preferred.**
No dividends paid.
- 2. Mobyvity Technologies Inc series C preferred.**
No dividends paid.
- 3. Mobyvity Technologies Inc common.**
No dividends paid.
- 4. Mobyvity Technologies Inc series AAA preferred.**
No dividends paid.
- 5. Mobyvity Technologies Inc series H preferred.**
No dividends paid.
- 6. Mobyvity Technologies Inc series I convertible preferred.**
No dividends paid.
- 7. Mobyvity Technologies Inc series E preferred.**
No dividends paid.
- 8. Mobyvity Technologies Inc series AA preferred.**

- No dividends paid.
Annual Dividends:
- 1. Mobyvity Technologies Inc series AAAA preferred.**
No dividends paid.
 - 2. Mobyvity Technologies Inc series C preferred.**
No dividends paid.
 - 3. Mobyvity Technologies Inc common.**
No dividends paid.
 - 4. Mobyvity Technologies Inc series AAA preferred.**
No dividends paid.
 - 5. Mobyvity Technologies Inc series H preferred.**
No dividends paid.
 - 6. Mobyvity Technologies Inc series I convertible preferred.**
No dividends paid.
 - 7. Mobyvity Technologies Inc series E preferred.**
No dividends paid.
 - 8. Mobyvity Technologies Inc series AA preferred.**
No dividends paid.

MOBIVITY HOLDINGS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|-------------|
| Revenues | 6,977,696 | ... | ... |
| Revenues | 6,977,696 | 7,533,912 | 8,174,884 |
| Cost of revenues | 5,129,627 | 5,328,483 | 4,302,370 |
| Gross profit | 1,848,069 | 2,205,429 | 3,872,514 |
| Bad debt | 18,060 | 40,383 | 774,312 |
| General & administrative | 6,406,512 | 4,306,929 | 3,584,721 |
| Sales & marketing expenses | ... | 2,616,596 | 4,002,565 |
| Engineering, research & development expenses | 3,515,705 | 3,060,029 | 3,583,773 |
| Goodwill impairment | ... | 411,183 | 85,169 |
| Intangible asset impairment | ... | 552,476 | 8,286 |
| Depreciation & amortization | 178,746 | 440,326 | 707,073 |
| Office & administrative expenses | 2,735,062 | ... | ... |
| Total operating expenses | 12,854,085 | 11,427,922 | 12,745,899 |
| Income (loss) from operations | (11,006,016) | (9,222,493) | (8,873,385) |
| Interest income | ... | ... | 5 |
| Other interest expense | 1,027,682 | ... | ... |
| Interest expense | ... | 737,745 | 267,966 |
| Gain on extinguishment of debt | ... | ... | 891,103 |
| Loss on disposal of fixed assets | ... | ... | (880) |
| Settlement losses | 19,250 | 53,500 | ... |
| Loss on settlement of debt | (10,857) | (49,503) | ... |
| Foreign currency gain (loss) | (394) | 2,119 | (8,661) |
| Total other income (expense) | (1,058,183) | (838,629) | 613,601 |
| Income (loss) before income taxes | (12,064,199) | (10,061,122) | (8,259,784) |
| Net income (loss) | (12,064,199) | (10,061,122) | (8,259,784) |

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Weighted average shares outstanding - basic | 65,822,081 | 59,241,798 | 55,410,695 |
| Weighted average shares outstanding - diluted | 65,822,081 | 59,241,798 | 55,410,695 |
| Year end shares outstanding | 67,949,709 | 61,311,155 | 55,410,695 |
| Net earnings (loss) per share - basic | \$(0.18) | \$(0.17) | \$(0.15) |
| Net earnings (loss) per share - diluted | \$(0.18) | \$(0.17) | \$(0.15) |
| Number of full time employees | ... | 38 | 37 |
| Number of part time employees | ... | ... | 1 |

| | | | |
|--|-----|----------|----------|
| Total number of employees | ... | ... | 38 |
| Number of common stockholders | 148 | 149 | 145 |
| Foreign currency translation adjustments | ... | (48,875) | (28,642) |

As of March 22, 2023; As of March 20, 2022; As of March 20, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash | 416,395 | 426,740 |
| Accounts receivable, gross | 892,572 | 1,115,629 |
| Allowance for doubtful accounts | 16,107 | 34,446 |
| Accounts receivable, net | 876,465 | 1,081,183 |
| Other current assets | 135,916 | 195,017 |
| Total current assets | 1,428,776 | 1,702,940 |
| Right to use lease assets | 770,623 | 981,896 |
| Intangible assets & software development costs, net | 65,916 | 194,772 |
| Other assets | 69,036 | 137,917 |
| Total assets | 2,334,351 | 3,017,525 |
| Accounts payable | 3,372,141 | 3,412,612 |
| Accrued interest | 21,474 | 443,448 |
| Accrued & deferred personnel compensation | 272,247 | 569,347 |
| Deferred revenue - related party | 155,472 | ... |
| Deferred revenue & customer deposits | ... | 902,727 |
| Related party notes payable, net - current maturities | 7,154 | 2,711,171 |
| Notes payable, net - current maturities | ... | 32,617 |
| Operating lease liability | 276,072 | 251,665 |
| Other current liabilities | 248,434 | 49,541 |
| Related party notes payable | 3,072,500 | ... |
| Total current liabilities | 7,425,494 | 8,373,128 |
| Related party notes payable, net - long term | 4,413,987 | 2,481,290 |
| Notes payable, net - long term | 265,959 | 31,092 |
| Operating lease liability | 660,852 | 936,924 |
| Total non-current liabilities | 5,340,798 | 3,449,306 |
| Total liabilities | 12,766,292 | 11,822,434 |
| Common stock | 67,950 | 61,311 |
| Equity payable | 989,947 | 324,799 |
| Additional paid-in capital | 118,624,601 | 108,806,353 |
| Accumulated other comprehensive income (loss) | (153,831) | (100,963) |
| Accumulated deficit | (129,960,608) | ... |
| Retained earnings (accumulated deficit) | ... | (117,896,409) |
| Total stockholders' equity (deficit) | (10,431,941) | (8,804,909) |
| Total Equity | (10,431,941) | ... |

Recent Dividends:

- 1. Mobyvity Holdings Corp common.**
No dividends paid.
- Annual Dividends:**
- 1. Mobyvity Holdings Corp common.**
No dividends paid.

MOLECULIN BIOTECH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--------------------------------|------------|------------|------------|
| Research & development expense | 19,487,000 | 18,968,000 | 14,418,000 |
| General & administrative | ... | ... | ... |

| | | | | | | | | | |
|--|--------------|--------------|--------------|---|---------------|---------------|---|--------------|--------------|
| expense | 10,017,000 | 11,542,000 | 8,386,000 | Furniture & equipment, net | 272,000 | 275,000 | debt issuance costs | 6,563,000 | |
| Depreciation | 127,000 | | | Intangible assets | 11,148,000 | 11,148,000 | Interest expense | 26,654,000 | |
| Depreciation & amortization expenses | | 130,000 | 164,000 | Operating lease right-of-use asset | 524,000 | 403,000 | Gain on extinguishment of PPP loan | 2,009,000 | |
| Total operating expenses | 29,631,000 | 30,640,000 | 22,968,000 | Total assets | 38,217,000 | 57,422,000 | Changes in fair value of warrant liability | 108,000 | |
| Income (loss) from operations | (29,631,000) | (30,640,000) | (22,968,000) | Accounts payable | 2,498,000 | 2,095,000 | Other income | (9,677,000) | 308,000 |
| Gain (loss) from change in fair value of warrant liability | (1,044,000) | 1,335,000 | 6,728,000 | Accrued research & development | 2,845,000 | 1,337,000 | Interest earned on marketable securities held in Trust Account | | 97,231 |
| Other income, net | 48,000 | 40,000 | 40,000 | Accrued payroll & bonuses | 765,000 | 748,000 | Unrealized gain on marketable securities held in Trust Account | 1,156,000 | 3,392 |
| Interest income (expense), net | 1,368,000 | 240,000 | 306,000 | Accrued legal & professional fees | 547,000 | | Transaction costs allocated to warrant liabilities | 510,000 | |
| Transaction costs allocated to warrant liabilities | 510,000 | | | Accrued legal, regulatory, professional & other | | 437,000 | Net loss before taxes | (29,769,000) | |
| Net loss before taxes | (29,769,000) | | | Accrued liabilities due to related party | 60,000 | 86,000 | Change in fair value of warrant liabilities | | 4,720,125 |
| Net income (loss) | (29,769,000) | (29,025,000) | (15,894,000) | Operating lease liability - current | 100,000 | 116,000 | Other income, net | | 4,145,397 |
| Weighted average shares outstanding - basic | 1,975,610 | 1,906,960 | 1,791,728 | Accrued expenses & other current liabilities | 4,317,000 | 2,724,000 | Total other income (expense) | (23,808,000) | |
| Weighted average shares outstanding - diluted | 1,975,610 | 1,906,960 | 1,791,728 | Total current liabilities | 6,815,000 | 4,819,000 | Income (loss) before income taxes | | |
| Year end shares outstanding | 2,227,516 | 1,908,522 | 1,905,223 | Operating lease liability - long-term, net of current portion | 474,000 | 335,000 | - United States | (76,838,000) | (90,611,000) |
| Net earnings (loss) per common share - basic | \$(15.07) | \$(15.15) | \$(8.85) | Warrant liability - long-term | 4,855,000 | 77,000 | Income (loss) before income taxes - International | 13,490,000 | 500,000 |
| Net earnings (loss) per common share - diluted | \$(15.07) | \$(15.15) | \$(8.85) | Total liabilities | 12,144,000 | 5,231,000 | Income (loss) before income taxes - Current federal | (63,348,000) | (90,111,000) |
| Number of full time employees | 18 | 15 | 13 | Common stock | 33,000 | 29,000 | Current state income taxes | (235,000) | |
| Number of part time employees | | 4 | 4 | Additional paid-in capital | 157,653,000 | 153,985,000 | Current state income taxes - international | 889,000 | 109,000 |
| Total number of employees | 18 | | | Accumulated other comprehensive income | (9,000) | 12,000 | Current international income taxes | 183,000 | 455,000 |
| Number of common stockholders | 138 | 136 | 140 | Retained earnings (accumulated deficit) | (131,604,000) | (101,835,000) | Current income taxes | 837,000 | 564,000 |
| Foreign currency translation adjustments | | (29,000) | (24,000) | Total stockholders' equity (deficit) | 26,073,000 | 52,191,000 | Deferred federal income taxes | (2,978,000) | (11,000) |
| Comprehensive loss | (29,790,000) | | | Total Equity | 26,073,000 | | Deferred state income taxes | (469,000) | (195,000) |
| Earnings per share from continuing operations | \$(15.07) | | | | | | Deferred international income taxes | 79,000 | (231,000) |
| Earnings per share from continuing operations | \$(15.07) | | | | | | Deferred income taxes | | (437,000) |
| | | | | | | | Provision for income taxes | (2,531,000) | 127,000 |
| | | | | | | | Cumulative dividends allocated to preferred stockholders | 11,557,000 | |
| | | | | | | | Net income (loss) | (60,817,000) | (90,238,000) |
| | | | | | | | Weighted average class A ordinary shares subject to possible redemption outstanding - basic | | 22,098,904 |
| | | | | | | | Weighted average non-redeemable class A & class B ordinary shares outstanding - basic | | 6,588,288 |
| | | | | | | | Weighted average shares outstanding - basic | 77,213,602 | 67,368,620 |
| | | | | | | | Weighted average class A ordinary shares subject to possible redemption outstanding - diluted | | 22,098,904 |
| | | | | | | | Weighted average non-redeemable class A & class B ordinary shares outstanding - basic | | 6,655,171 |
| | | | | | | | Weighted average | | |

Adjusted for 1-for-15 stock split, March 22, 2024; Shares increased due to issuance of shares for cash, with consulting agreement, with equity purchase agreement and upon vesting of restricted units, warrants exercised and reverse stock split; Approximately; As of March 14, 2022

Recent Dividends:
1. Moleculin Biotech Inc common.
No dividends paid.

Annual Dividends:
1. Moleculin Biotech Inc common.
No dividends paid.

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 23,550,000 | 43,145,000 |
| Prepaid insurance | | 600,000 |
| Vendor prepayments & deposits | 545,000 | 801,000 |
| Prepaid sponsored research | 564,000 | 1,028,000 |
| Non-trade receivable | | 2,000 |
| Related party receivables | 4,000 | 20,000 |
| Prepaid expenses & other current assets | 95,000 | 2,451,000 |
| Prepaid expenses and other current assets | 2,723,000 | |
| Prepaid sponsored research | 1,515,000 | |
| Total current assets | 26,273,000 | 45,596,000 |
| Furniture & equipment, gross | 1,168,000 | 1,044,000 |
| Less: accumulated depreciation | 896,000 | 769,000 |

MONDEE HOLDINGS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|-----------|
| Revenues, net | 223,325,000 | | |
| Revenues | 223,325,000 | 159,484,000 | |
| Sales & marketing expenses | 153,708,000 | 114,111,000 | |
| Personnel expenses | | 82,057,000 | |
| General & administrative expenses | | 9,662,000 | |
| Information technology expenses | 4,820,000 | 5,333,000 | |
| Provision for doubtful accounts receivable & contract assets | 393,000 | 312,000 | |
| Depreciation & amortization | 16,068,000 | 11,770,000 | |
| Restructuring & related costs | 2,371,000 | 2,542,000 | |
| Formation & operational costs | | | 833,758 |
| Total operating expenses | 243,831,000 | 225,787,000 | |
| Income (loss) from operations | (20,506,000) | (66,303,000) | (833,758) |
| Interest income | 1,053,000 | 637,000 | |
| Cash interest expense | 35,374,000 | 10,903,000 | |
| Payment in kind interest, net | | 9,036,000 | |
| LOC commitment charges | | 152,000 | |
| Amortization of | | | |

| | | | |
|--|--------------|------------|------------|
| shares outstanding - diluted | 77,213,602 | 67,368,620 | ... |
| Sales and marketing expenses | 43,280,000 | ... | ... |
| General and administrative expenses, including non-employee stock-based compensation of \$352 and \$0 respectively | 23,191,000 | ... | ... |
| Year end shares outstanding | 78,628,508 | 82,266,160 | 30,187,500 |
| Net income (loss) per share - basic | \$(0.94) | \$(1.34) | ... |
| Net income (loss) per class A ordinary shares subject to possible redemption - diluted | ... | ... | \$0.12 |
| Net income (loss) per non-redeemable class A & class B ordinary share - basic | ... | ... | \$0.12 |
| Net income (loss) per share - diluted | \$(0.94) | \$(1.34) | ... |
| Net income (loss) per class A ordinary shares subject to possible redemption - diluted | ... | ... | \$0.12 |
| Net income (loss) per non-redeemable class A & class B ordinary share - diluted | ... | ... | \$0.12 |
| Number of full time employees | 1,226 | 927 | ... |
| Number of part time employees | ... | 5 | ... |
| Total number of employees | 1,226 | 932 | 2 |
| Number of common stockholders | 173 | 196 | ... |
| Number of class A ordinary stockholders | ... | ... | 1 |
| Number of class B ordinary stockholders | ... | ... | 4 |
| Number of unitholders | ... | ... | 3 |
| Foreign currency translation adjustments | ... | (348,000) | ... |
| Total other expense, net | (42,842,000) | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (72,374,000) | ... | ... |

| | | |
|---|-------------|--------------|
| and \$5,005 as of 30, 2022 and 31, 2021, respectively | 116,632,000 | ... |
| Amount receivables, net | 21,733,000 | ... |
| Contract assets | 13,228,000 | 5,794,000 |
| Prepaid expenses & other current assets | 7,250,000 | 4,673,000 |
| Total current assets | 173,097,000 | 119,680,000 |
| Capitalized software | 288,000 | 32,283,000 |
| Computer equipment | 1,079,000 | 912,000 |
| Furniture & office equipment | ... | 332,000 |
| Leasehold improvements | ... | 14,000 |
| Capitalized software development in process | 4,148,000 | 4,107,000 |
| Capitalized software-Gross | 44,078,000 | ... |
| Total property and equipment Furniture And Fixtures | 194,000 | ... |
| Total property & equipment | 49,787,000 | 37,648,000 |
| Less: accumulated depreciation & amortization | 32,476,000 | 26,316,000 |
| Property & equipment, net | 17,311,000 | 11,332,000 |
| Goodwill, net | 88,056,000 | 66,420,000 |
| Intangible assets, net | 102,029,000 | 57,370,000 |
| Operating lease right-of-use assets | 3,232,000 | 1,384,000 |
| Deferred income taxes | 752,000 | 237,000 |
| Other non-current assets | 7,871,000 | 1,674,000 |
| Amounts receivable from related parties | 43,000 | ... |
| Total assets | 392,391,000 | 258,097,000 |
| Accounts payable | 114,989,000 | 33,749,000 |
| Deferred underwriting fee | ... | 500,000 |
| Amounts payable to related parties | 42,000 | 13,000 |
| Paycheck Protection Program (PPP) & other government loans, current portion | 66,000 | 72,000 |
| Accrued expenses & other current liabilities | 25,115,000 | 9,319,000 |
| Deferred revenue | 5,686,000 | 5,828,000 |
| Long-term debt, current portion | 10,828,000 | 7,514,000 |
| Accrued payable & accrued expenses | 16,366,000 | ... |
| Current portion of operating lease liabilities | 1,133,000 | ... |
| Accrued compensation and benefits | 7,209,000 | ... |
| Other Current Liabilities | 4,843,000 | ... |
| Other Current Liabilities | 407,000 | ... |
| Total current liabilities | 161,569,000 | 56,995,000 |
| Deferred income taxes | 12,334,000 | 307,000 |
| Note payable to related party | 201,000 | 197,000 |
| PPP & other government loans excluding current portion | 142,000 | 159,000 |
| Warrant liabilities | 137,000 | 1,293,000 |
| TCW Credit Agreement | ... | 106,250,000 |
| Cumulative PIK interest for TCW Credit Agreement | ... | 46,518,000 |
| Other debt | ... | 14,000 |
| Less: Unamortized debt issuance costs & discounts | ... | (18,386,000) |
| Less : Current portion of long term debt | ... | 7,514,000 |
| Long-term debt excluding current portion | 150,679,000 | 126,882,000 |
| Deferred revenue excluding current portion | 11,797,000 | 14,656,000 |
| Operating lease liabilities excluding current portion | 2,561,000 | 1,620,000 |
| Other long-term liabilities | 8,073,000 | 2,713,000 |

| | | |
|--|---------------|---------------|
| Earn-out liability, excluding current portion | 4,322,000 | ... |
| Total liabilities | 351,815,000 | 204,822,000 |
| Class A ordinary shares | 8,000 | ... |
| Series A Preferred stock | ... | 82,597,000 |
| Common stock, net | ... | 7,000 |
| Shareholder receivable | ... | (20,336,000) |
| Additional paid-in capital | 306,326,000 | 271,883,000 |
| Accumulated other comprehensive income (loss) | 1,598,000 | (621,000) |
| Accumulated deficit | (341,072,000) | ... |
| Retained earnings (accumulated deficit) | ... | (280,255,000) |
| Treasury Stock - 2,033,578 and 0 shares of Common stock, respectively | 32,088,000 | ... |
| Series A Preferred stock - 85,000 authorized, \$00001 par value, 85,000 shares issued and outstanding as of 30, 2022 | 105,804,000 | ... |
| Total stockholders' equity (deficit) | 40,576,000 | (29,322,000) |
| Total Equity | 40,576,000 | ... |

Net of allowance - contract assets: \$750,000

Recent Dividends:

1. **Mondee Holdings Inc class B ordinary.**

No dividends paid.

2. **Mondee Holdings Inc class A ordinary.**

No dividends paid.

Annual Dividends:

1. **Mondee Holdings Inc class B ordinary.**

No dividends paid.

2. **Mondee Holdings Inc class A ordinary.**

No dividends paid.

MONOGRAM ORTHOPAEDICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Product revenue | 364,999 | ... | 628,246 |
| Cost of goods sold | ... | ... | 458,675 |
| Gross profit | ... | ... | 169,571 |
| Research & development expenses | 10,585,884 | 4,972,881 | 5,278,768 |
| Marketing & advertising expenses | 2,994,389 | 2,714,421 | 3,271,600 |
| General & administrative expenses | 4,052,755 | 2,925,845 | 1,896,839 |
| Total operating expenses | 17,633,028 | 10,613,147 | 10,447,207 |
| Income (loss) from operations | (17,268,029) | (10,613,147) | (10,277,636) |
| Grant income | ... | 256,000 | ... |
| Change in fair value of warrant liability | 3,088,533 | (3,431,865) | (1,563,439) |
| Interest income & other, net | 434,279 | 98,065 | 26,107 |
| Total other income (expense) | 3,522,812 | (3,333,800) | (1,537,332) |
| Net income (loss) before taxes | (13,745,217) | (13,690,947) | (11,814,968) |
| Net Income after Tax | (13,745,217) | ... | ... |
| Net income (loss) | (13,745,217) | (13,690,947) | (11,814,968) |
| Weighted average shares outstanding - basic | 22,409,222 | 9,673,870 | 9,673,870 |
| Weighted average shares outstanding - diluted | 22,409,222 | 9,673,870 | 9,673,870 |
| Year end shares outstanding | 31,338,391 | 9,673,870 | 9,673,870 |
| Earnings (loss) per | | | |

2021 and prior periods for ITHAX Acquisition Corporation prior to reverse recapitalization with Mondee Holdings Inc.; Including share-based compensation - personnel expenses: \$61,690,000; Including non-employee stock-based compensation - general and administrative expenses: \$352,000; As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|------------|
| Cash & cash equivalents | 27,994,000 | 78,841,000 |
| Restricted short-term investments | 7,993,000 | 8,639,000 |
| Amount receivables, gross | 121,817,000 | 26,594,000 |
| Less: allowance for doubtful debt | 5,185,000 | 4,861,000 |
| Accounts receivable, net of allowance of \$5,144, | | |

| | | | |
|---|----------|----------|----------|
| share - basic | \$(0.61) | \$(1.42) | \$(1.22) |
| Earnings (loss) per share - diluted | \$(0.61) | \$(1.42) | \$(1.22) |
| Number of full time employees..... | 28 | 24 | ... |
| Total Revenue | 364,999 | ... | ... |
| Total number of employees..... | 28 | ... | ... |

□ As reported by the Company; □ As of September 21, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 13,589,028 | 10,468,645 |
| Inventory | ... | 4,550 |
| Account receivable | 364,999 | ... |
| Receivable from investment platform vendor | ... | 157,598 |
| Advance paid to vendor for supply development contract | ... | 250,000 |
| Other prepaid expenses | ... | 375,856 |
| Prepaid expenses & other current assets | 664,262 | 788,004 |
| Total current assets | 14,618,289 | 11,256,650 |
| Computer equipment | 146,573 | 98,391 |
| Furniture | 33,413 | 27,405 |
| Engineering equipment | 214,547 | 214,547 |
| Medical equipment | 192,009 | 184,379 |
| Robot equipment | 527,599 | 524,506 |
| Software | 537,839 | 537,839 |
| Equipment, gross | 1,651,980 | 1,587,067 |
| Less: accumulated depreciation | 706,960 | 504,625 |
| Equipment, net of accumulated depreciation | 945,020 | 1,082,442 |
| Intangible assets, net | 548,750 | 758,750 |
| Operating lease right-of-use assets | 466,949 | 592,221 |
| Total assets | 16,579,008 | 13,690,063 |
| Accounts payable | 2,462,268 | 663,170 |
| Accrued liabilities | 227,684 | ... |
| Accrued expenses | ... | 748,460 |
| Warrant liability | ... | 7,519,101 |
| Operating lease liabilities, current | 128,266 | 118,166 |
| Total current liabilities | 2,818,218 | 9,048,897 |
| Operating lease liabilities, non-current | 363,724 | 491,989 |
| Total liabilities | 3,181,942 | 9,540,886 |
| Series A preferred Stock | ... | 4,898 |
| Series B preferred Stock | ... | 3,196 |
| Series C preferred Stock | ... | 438 |
| Common stock | 31,338 | 9,674 |
| Additional paid-in capital | 64,874,392 | 41,894,417 |
| Retained earnings (accumulated deficit) | (51,508,664) | (37,763,447) |
| Total stockholders' equity (deficit) | 13,397,066 | 4,149,176 |
| Total Equity | 13,397,066 | ... |

□ As reported by the Company

Recent Dividends:

1. Monogram Orthopaedics Inc common.
No dividends paid.

Annual Dividends:

1. Monogram Orthopaedics Inc common.
No dividends paid.

MONOPAR THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--------------------------------|-----------|------------|-----------|
| Research & development | 5,600,193 | 7,591,601 | 6,493,208 |
| General & administrative | 3,231,042 | 2,945,276 | 2,634,040 |
| Total operating expenses | 8,831,235 | 10,536,877 | 9,127,248 |
| Income (loss) from | | | |

| | | | |
|---|-------------|--------------|-------------|
| operations | (8,831,235) | (10,536,877) | (9,127,248) |
| Interest income | 429,039 | 21,239 | 24,024 |
| Income (loss) from before income tax benefit | (8,402,196) | ... | ... |
| Net income (loss) | (8,402,196) | (10,515,638) | (9,103,224) |
| Weighted average shares outstanding - basic | 13,823,951 | 12,718,166 | 12,472,217 |
| Weighted average shares outstanding - diluted | 13,823,951 | 12,718,166 | 12,472,217 |
| Year end shares outstanding | 14,904,497 | 12,946,573 | 12,598,125 |
| Net earnings (loss) per share - basic | \$(0.61) | \$(0.83) | \$(0.73) |
| Net earnings (loss) per share - diluted | \$(0.61) | \$(0.83) | \$(0.73) |
| Number of full time employees | ... | 11 | 9 |
| Number of part time employees | ... | 1 | 1 |
| Total number of employees | ... | 12 | 10 |
| Number of common stockholders | 3,200 | 30 | 32 |
| Number of beneficiary stockholders | ... | 2,700 | 800 |
| Foreign currency translation adjustments | ... | (2,937) | 4,713 |

□ As of March 5, 2021; □ As of March 11, 2022; □ As of March 10, 2023; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 7,266,080 | 8,186,194 |
| Investments | ... | 4,933,550 |
| Other current assets | 66,433 | 45,982 |
| Total current assets | 7,332,513 | 13,165,726 |
| Operating lease right-of-use asset | 12,646 | 61,228 |
| Total assets | 7,345,159 | 13,226,954 |
| Accounts payable, accrued expenses & other current liabilities | 1,748,985 | 3,128,894 |
| Operating Lease Liabilities - Current | 8,408 | ... |
| Accounts payable, accrued expenses and other current - Balancing value | 1,757,393 | ... |
| Total current liabilities | 1,757,393 | 3,128,894 |
| Non-current operating lease liability | ... | 8,408 |
| Total liabilities | 1,757,393 | 3,137,302 |
| Common stock | 14,905 | 12,947 |
| Additional paid-in capital | 65,793,210 | 61,871,784 |
| Retained earnings (accumulated deficit) | (60,206,217) | (51,804,021) |
| Accumulated other comprehensive income (loss) | (14,132) | 8,942 |
| Total stockholders' equity | 5,587,766 | 10,089,652 |
| Total Equity | 5,587,766 | ... |

Recent Dividends:

1. Monopar Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Monopar Therapeutics Inc common.

No dividends paid.

MOSAIC IMMUNOENGINEERING INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|------------------------|------|------|-----------|
| Research & development | | | (revised) |

| | | | |
|---|-------------|-------------|-------------|
| expenses | 435,449 | 1,048,457 | 1,456,119 |
| General & administrative expenses | 964,319 | 1,579,065 | 2,045,047 |
| Total operating expenses | 1,399,768 | 2,627,522 | 3,501,166 |
| Income (loss) from operations | (1,399,768) | (2,627,522) | (3,501,166) |
| Gain (loss) on redemption of preferred stock of Holocom, Inc. ("Holocom") | 46,700 | 343,000 | ... |
| Interest income | 3,408 | 33 | 36 |
| Change in fair value of derivative liability | ... | 57,600 | (20,800) |
| Non-cash interest expense related to notes payable | 15,842 | ... | ... |
| Non-cash interest expense on convertible notes | 73,333 | 69,738 | 30,121 |
| Accretion to redemption value on convertible notes | 433,000 | (81,843) | (130,027) |
| Total other income (expense), net | 393,933 | 249,052 | (180,912) |
| Income (loss) before provision (benefit) for income taxes | (1,005,835) | (2,378,470) | (3,682,078) |
| Current state income tax provision (benefit) | 2,400 | 2,400 | 2,400 |
| Total current income tax provision (benefit) | 2,400 | 2,400 | 2,400 |
| Provision (benefit) for income taxes | 2,400 | 2,400 | 2,400 |
| Net income (loss) | (1,008,235) | (2,380,870) | (3,684,478) |
| Weighted average shares outstanding - basic | 7,236,447 | 7,235,609 | 6,712,675 |
| Weighted average shares outstanding - diluted | 7,236,447 | 7,235,609 | 6,712,675 |
| Year end shares outstanding | 7,242,137 | 7,242,137 | 7,241,137 |
| Income (loss) per share - continuing operations - basic | \$(0.14) | ... | ... |
| Net income (loss) per common share - basic | \$(0.14) | \$(0.33) | \$(0.55) |
| Income (loss) per share - continuing operations - diluted | \$(0.14) | ... | ... |
| Net income (loss) per common share - diluted | \$(0.14) | \$(0.33) | \$(0.55) |
| Number of full time employees | 3 | 4 | 3 |
| Number of part time employees | 5 | 4 | 4 |
| Total number of employees | 8 | ... | ... |
| Number of common stockholders | 645 | 693 | 693 |

□ Shares increased due to the effect of conversion of series A convertible voting preferred stock & issuance of common stock upon vesting of restricted stock units; □ As of March 1, 2023; □ As of January 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------|---------|
| Cash & cash equivalents | 156,178 | 220,645 |
| Prepaid expenses & other current assets | ... | 40,632 |
| Prepaid expenses | 23,355 | ... |
| Total current assets | 179,533 | 261,277 |

| | | |
|---|-------------|-------------|
| Total assets | 179,533 | 261,277 |
| Accounts payable | 118,478 | 133,464 |
| Derivative liability | ... | 46,700 |
| Accrued compensation | 3,184,911 | 2,399,132 |
| Accrued consulting | 787,903 | 753,570 |
| Accrued consulting | 641,763 | ... |
| Crossflo acquisition liability | 177,244 | 177,244 |
| Accrued patent expenses | 33,646 | 382,207 |
| Other accrued expenses | 430,873 | 25,357 |
| Total current liabilities | 4,733,055 | 3,917,674 |
| Convertible notes, net | 1,317,536 | 1,228,361 |
| Total liabilities | 6,050,591 | 5,146,035 |
| Series B Convertible Voting Preferred Stock; 70,000 shares designated; 70,000 shares issued and outstanding as of 30, 2021 and 31, 2020 | 1 | ... |
| Series B convertible voting preferred stock | ... | 1 |
| Common stock, \$0.00001 par value; 100,000,000 shares authorized; 7,228,093 and 805,803 shares issued and outstanding as of 30, 2021 and 31, 2020, respectively | 72 | ... |
| Common stock | ... | 72 |
| Additional paid-in capital | 2,045,206 | 2,023,271 |
| Accumulated Deficit | (7,916,337) | ... |
| Retained earnings (accumulated deficit) | ... | (6,908,102) |
| Total stockholders' equity (deficit) | (5,871,058) | (4,884,758) |
| Rep Total Equity & Minority Interest | (5,871,058) | ... |

Recent Dividends:

1. Mosaic ImmunoEngineering Inc series B convertible voting preferred.

No dividends paid.

2. Mosaic ImmunoEngineering Inc common.

No dividends paid.

3. Mosaic ImmunoEngineering Inc series A convertible voting preferred.

No dividends paid.

Annual Dividends:

1. Mosaic ImmunoEngineering Inc series B convertible voting preferred.

No dividends paid.

2. Mosaic ImmunoEngineering Inc common.

No dividends paid.

3. Mosaic ImmunoEngineering Inc series A convertible voting preferred.

No dividends paid.

MOTORSPORT GAMES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---------------------------------|--------------|--------------|----------------|
| Revenues | 6,909,674 | ... | ... |
| Cost of revenue | 3,620,495 | 4,960,317 | 7,529,155 |
| Gross profit | 3,289,179 | 5,364,242 | 7,546,375 |
| Sales & marketing | 1,690,772 | 6,172,324 | 6,475,867 |
| Development | 7,237,154 | 10,417,260 | 9,621,712 |
| General & administrative | 9,367,030 | 13,764,177 | 25,378,149 |
| Impairment of goodwill | ... | 4,788,270 | ... |
| Impairment of intangible assets | 4,004,627 | 4,828,478 | 317,113 |
| Depreciation & amortization | 398,701 | 420,137 | 280,192 |
| Total operating expenses | 22,698,284 | 40,390,646 | 42,073,033 |
| Income (loss) from operations | (19,409,105) | (35,026,404) | (34,526,658) |
| Interest expense | 772,989 | 1,148,204 | 504,156 |
| Gain (loss) | ... | ... | ... |

| | | | |
|---|--------------|--------------|--------------|
| attributable to equity method investment | ... | ... | 1,370,837 |
| Other income (expense), net | 5,858,909 | (665,846) | (44,768) |
| Income (loss) before income taxes | (14,323,185) | ... | ... |
| Net income (loss) | (14,323,185) | (36,840,454) | (33,704,745) |
| Less: net income (loss) attributable to noncontrolling interest | 1,272,046 | 849,649 | 542,754 |
| Net income (loss) attributable to Motorsport Gaming US, LLC | (13,051,139) | (35,990,805) | (33,161,991) |
| Weighted average shares outstanding - basic | 2,577,451 | 1,171,323 | 1,137,675 |
| Weighted average shares outstanding - diluted | 2,577,451 | 1,171,323 | 1,137,675 |
| Year end shares outstanding | 3,422,728 | 1,883,812 | 1,863,590 |
| Net earnings (loss) per share - basic | \$(5.06) | \$(30.73) | \$(29.15) |
| Net earnings (loss) per share - diluted | \$(5.06) | \$(30.73) | \$(29.15) |
| Number of full time employees | 50 | 133 | 188 |
| Number of part time employees | 21 | 1 | 1 |
| Total number of employees | 71 | 134 | 189 |
| Number of class A common stockholders | ... | 15 | 7 |
| Number of class B common stockholders | ... | 1 | 1 |
| Number of common stockholders | 12 | ... | ... |
| Foreign currency translation adjustments | ... | 11,969 | (950,303) |

[¶] Includes related party expenses - Cost of revenues: \$6,228;
[¶] Includes related party expenses - Sales and marketing: \$565,759;
[¶] Includes related party expenses - Sales and marketing: \$75,378;
[¶] Includes related party expenses - Development: \$76,093;
[¶] Includes related party expenses - Development: \$44,423;
[¶] Includes related party expenses - General and administrative: \$394,358;
[¶] Includes related party expenses - General and administrative: \$1,803,709;
[¶] Includes related party expenses - Interest expense: \$75,616;
[¶] Includes related party expenses - Interest expense: \$105,845;
[¶] Adjusted for 1-for-10 stock split, November 10, 2022;
[¶] Approximately; [¶] As of March 24, 2023; [¶] As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 1,675,210 | 979,306 |
| Accounts receivable, gross | 1,185,839 | 4,061,493 |
| Less: sales allowances | 450,000 | 2,252,383 |
| Accounts receivable, net | 735,839 | 1,809,110 |
| Due from related parties | ... | 206,532 |
| Prepaid expenses & other current assets | 1,106,848 | 1,048,392 |
| Total current assets | 3,517,897 | 4,043,340 |
| Furniture & fixtures | ... | 17,450 |
| Computer software & equipment | 17,498 | 760,887 |
| Office equipment | 784,355 | ... |
| Leasehold improvements | 160,606 | 146,370 |
| Property & equipment, gross | 962,459 | 924,707 |
| Less: accumulated depreciation | 714,766 | 402,274 |
| Property & equipment, net | 247,693 | 522,433 |
| Operating lease right of | ... | ... |

| | | |
|--|--------------|--------------|
| use assets | 197,307 | 971,789 |
| Intangible assets, net | 5,795,807 | 13,360,230 |
| Total assets | 9,758,704 | 18,897,792 |
| Accounts payable | 813,659 | 2,372,219 |
| Accrued royalties | 217,868 | 274,085 |
| Accrued professional fees | 110,008 | 693,803 |
| Accrued consulting fees | ... | 26,667 |
| Accrued development costs | 32,214 | 172,164 |
| Esports prize money | ... | 125,202 |
| Accrued taxes | 40,000 | 149,842 |
| Accrued payroll | 500,522 | 372,358 |
| Deferred revenue | 270,845 | 311,945 |
| Loss contingency reserve | 545,920 | 1,100,000 |
| Accrued other | 173,938 | 190,358 |
| Accrued expenses & other liabilities | 1,891,315 | 3,416,424 |
| Due to a related parties | 77,716 | 4,589,211 |
| Purchase commitments | 4,656,538 | 2,563,216 |
| Operating lease liabilities | 153,015 | 380,538 |
| Total current liabilities | 7,592,243 | 13,321,608 |
| Operating lease liabilities | ... | 617,288 |
| Other non-current liabilities | 31,098 | 3,055,498 |
| Operating lease liabilities (non-current) | 45,659 | ... |
| Total liabilities | 7,669,000 | 16,994,394 |
| Class A common stock | 269 | 117 |
| Class B common stock | 91,923,311 | 70 |
| Additional paid-in capital | ... | 76,446,061 |
| Accumulated deficit | (87,030,270) | ... |
| Retained earnings (accumulated deficit) | ... | (73,979,131) |
| Accumulated other comprehensive income (loss) | (1,850,216) | (933,406) |
| Class B common stock \$ 0.0001 par value; authorized 7,000,000 shares; 7,000,000 and 0 shares issued and outstanding as of 31, 2021 and 31, 2020, respectively | 70 | ... |
| Total stockholders' equity/member's equity (deficit) strributable to Motorsport Games Inc. | 3,043,164 | 1,533,711 |
| Noncontrolling interest | (953,460) | 369,687 |
| Total stockholders' equity/member's equity | 2,089,704 | 1,903,398 |

Recent Dividends:

1. Motorsport Games Inc class B common.

No dividends paid.

2. Motorsport Games Inc class A common.

No dividends paid.

Annual Dividends:

1. Motorsport Games Inc class B common.

No dividends paid.

2. Motorsport Games Inc class A common.

No dividends paid.

MOTORSPORT GAMES INC

Earnings, 9 mos. to Sep 30 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|--------------|--------------|
| Total revenues | 5,162,356 | 6,553,918 |
| Net Sales | 5,162,356 | ... |
| Cost & expenses | 21,574,025 | 36,068,661 |
| Deprec., depl. & amort. | 277,822 | 326,499 |
| Operating income | (16,689,491) | (29,841,242) |
| Interest expense | 674,060 | 638,211 |
| Other income (expense), net | 369,345 | (1,511,978) |
| Net before taxes | (16,994,206) | ... |
| Net income | (16,994,206) | (31,991,431) |
| Earnings common share | ... | ... |
| Primary | \$(6.60) | \$(26.61) |
| Fully Diluted | \$(6.60) | \$(26.61) |
| Common Shares: | ... | ... |
| Full Diluted | 2,538,863 | 1,167,178 |
| Year-end | 2,720,328 | 1,867,359 |

MOVEIX INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**2023 2022 [□]2021

| | | | |
|---|------------|------------|-------------------------|
| General & administrative expenses | 51,910 | ... | ... |
| Administrative expenses - related party | ... | 39,741 | 31,377 |
| Stock-based compensation - related party | ... | ... | 250,000 |
| Total operating expenses | 51,910 | 39,741 | 281,377 |
| Income (loss) from operations | (51,910) | (39,741) | (281,377) |
| Income (loss) before provision for income taxes | (51,910) | (39,741) | (281,377) |
| Net income (loss) | (51,910) | (39,741) | (281,377) |
| Weighted average shares outstanding - basic | 87,230,654 | 87,230,654 | 87,230,654 |
| Weighted average shares outstanding - diluted | 87,230,654 | 87,230,654 | 87,230,654 |
| Year end shares outstanding | 87,230,654 | 87,230,654 | [□] 87,230,654 |
| Earnings (loss) per common share - basic | ... | \$0.00 | \$0.00 |
| Earnings (loss) per common share - diluted | ... | \$0.00 | \$0.00 |
| Total number of employees | ... | 0 | 0 |
| Number of common stockholders | 33 | 33 | 33 |

[□] For 7 months due to fiscal year end change; [□] Shares increased due to the issuance of preferred and common stock for services

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

| | | |
|---|-----------|-----------|
| Prepaid expenses | 5,500 | ... |
| Total current assets | 5,500 | ... |
| Total assets | 5,500 | ... |
| Notes payable - related party | 114,465 | 57,055 |
| Total current liabilities | 114,465 | 57,055 |
| Total liabilities | 114,465 | 57,055 |
| Preferred stock | 10,000 | 10,000 |
| Common stock | 87,231 | 87,231 |
| Additional paid in capital | 215,218 | 215,218 |
| Accumulated deficit | (421,414) | ... |
| Retained earnings (accumulated deficit) | ... | (369,504) |
| Total stockholders' equity (deficit) | (108,965) | (57,055) |
| Total Equity | (108,965) | ... |

Recent Dividends:**1. Moveix Inc preferred.**

No dividends paid.

2. Moveix Inc common.

No dividends paid.

Annual Dividends:**1. Moveix Inc preferred.**

No dividends paid.

2. Moveix Inc common.

No dividends paid.

MU GLOBAL HOLDING INC**Earnings, 6 mos. to Jan 31(Consol. - \$):**

| | | | |
|-----------------------------|----------|----------|------|
| Total revenues | 343 | 128,241 | 2023 |
| Cost & expenses | 50,787 | 181,750 | 2023 |
| Operating income | (50,444) | (53,509) | |
| Other income (expense), net | 6,205 | 2,358 | |
| Net before taxes | (44,239) | (51,151) | |
| Net income | (44,239) | (51,151) | |

| | | | |
|-----------------------|------------|------------|--|
| Earnings common share | | | |
| Primary | \$(0.00) | \$(0.00) | |
| Fully Diluted | \$(0.00) | \$(0.00) | |
| Common Shares: | | | |
| Full Diluted | 59,434,838 | 59,434,838 | |
| Year-end | 59,434,838 | 59,434,838 | |

MY CITY BUILDERS INC**Earnings, 6 mos. to Jan 31(Consol. - \$):**

| | | | |
|-----------------------------|-------------|----------|------|
| Total revenues | 19,768 | 2024 | 2023 |
| Cost & expenses | 137,179 | 59,027 | |
| Operating income | (129,681) | (31,203) | |
| Other income (expense), net | (947,500) | | |
| Net before taxes | (1,093,043) | (73,203) | |
| Net income | (1,093,043) | (73,203) | |
| Earnings common share | | | |
| Primary | \$(0.72) | \$(0.12) | |
| Fully Diluted | \$(0.72) | \$(0.12) | |
| Common Shares: | | | |
| Full Diluted | 1,516,034 | 595,986 | |
| Year-end | 1,986,686 | 595,986 | |

MY SIZE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31**

(\$000):

2023 2022 [□]2021

| | | | |
|------------------------|-------|-------|-------|
| Revenues | 6,996 | ... | ... |
| Costs | 6,996 | 4,459 | 131 |
| Gross profit | 4,265 | 3,825 | ... |
| Research & development | 974 | 1,701 | 4,248 |
| Salaries | ... | 836 | 574 |
| Subcontractors | ... | 583 | 1,086 |
| Marketing | ... | 481 | 283 |
| Selling fees | ... | 489 | ... |

Share based

payments post Orgad International Marketing Ltd. acquisition

2023 2022 [□]2021

| | | | |
|--|-------|-------|-------|
| Share based payments for consultants & employees | ... | 127 | 180 |
| Travel | ... | 211 | 42 |
| Other sales & marketing expenses | ... | 145 | 171 |
| Sales & marketing | ... | 3,143 | 2,336 |
| Salaries | ... | 1,007 | 461 |
| Professional services | 3,856 | 705 | 1,832 |
| Share based payments for consultants, directors & employees | ... | 180 | 98 |
| Rent, office expenses & communication | ... | 442 | 372 |
| Insurance | ... | 564 | 627 |
| Cash liability & equity liability | ... | ... | ... |
| expenses related to Orgad International Marketing Ltd. acquisition | ... | 310 | ... |
| Cash liability expenses related to Naiz Bespoke Technologies, S.L. acquisition | ... | 217 | ... |
| Settlement fees | ... | ... | 345 |
| Directors | ... | 82 | 59 |
| Other general & administrative expenses | ... | 393 | 330 |
| General & administrative | 3,971 | 3,900 | 4,124 |
| Impairment of | ... | ... | ... |

| | | | |
|---|----------|-----------------|------------------------|
| goodwill | 671 | ... | ... |
| Total operating expenses | 9,472 | 8,744 | 10,708 |
| Operating income (loss) | (6,741) | (8,110) | (10,577) |
| Financial income (expense), net | 99 | (236) | 57 |
| Income (loss) before taxes | (6,713) | (8,346) | (10,520) |
| Taxes on income | (333) | (36) | ... |
| Net income (loss) for the year | (6,380) | (8,310) | (10,520) |
| Weighted average shares outstanding | | | |
| - basic | 2,551 | 1,112 | [□] 420 |
| Weighted average shares outstanding | | | |
| - diluted | 2,551 | 1,112 | [□] 42,038 |
| Year end shares outstanding | 3,622 | 1,464 | [□] 959 |
| Net income (loss) per share - basic | \$(2.50) | \$(7.47) | [□] \$(17.75) |
| Net income (loss) per share - diluted | \$(2.50) | \$(7.47) | [□] \$(17.75) |
| Number of full time employees | ... | [□] 30 | [□] 30 |
| Number of part time employees | ... | [□] 5 | [□] 2 |
| Total number of employees | ... | [□] 35 | [□] 32 |
| Common Shareholders - Number | 68 | ... | ... |
| Number of stockholders | ... | [□] 70 | [□] 58 |
| Equity loss of equity method investees | (71) | ... | ... |
| Earnings per share from continuing operations | \$(2.50) | ... | ... |
| Earnings per share from continuing operations | \$(2.50) | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-25 stock split, December 9, 2022; [□] Shares increased due to exercise of options granted to employees, issuance of restricted shares and shares, and exercise of warrants; [□] As is; [□] As of March 31, 2022; [□] As of March 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

2023 2022

| | | |
|---|-------|-------|
| Cash & cash equivalents | 2,187 | 2,100 |
| Restricted cash | 77 | 263 |
| Inventory | 2,879 | 997 |
| Account receivables | 615 | 1,940 |
| Other receivables & prepaid expenses | 22 | 758 |
| Other receivables and prepaid expenses | 847 | ... |
| Total current assets | 6,627 | 6,058 |
| Long term deposits | 7 | 28 |
| Computers & peripheral equipment, at cost | 238 | 236 |
| Less: accumulated depreciation - computers & peripheral equipment | ... | 172 |
| Office furniture & equipment, at cost | 79 | 78 |
| Less: accumulated depreciation - office furniture & equipment | 27 | 26 |
| Leasehold improvements, at cost | 17 | 54 |
| Less: accumulated depreciation - leasehold improvements | 37 | 30 |
| Property and equipment, cost, beginning balance | ... | ... |
| Leasehold Improvements | 54 | ... |
| Computer Software & Equipment - Tangible | ... | ... |

2. Nano Magic Inc class Z common.

No dividends paid.

3. Nano Magic Inc class B common.

No dividends paid.

NANO MAGIC INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, UHY LLP, as it appeared in the Company's 2023 10K. "Opinion on the Financial Statements We have audited the accompanying balance sheets of Nano Magic Inc. (the "Company") as of December 31, 2023 and 2022, and the related statements of operations, stockholders' equity and cash flows for the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has recurring losses from operations, negative cash flow from operations, and an accumulated deficit. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 1. The financial statements do not include any adjustment that might result from the outcome of this uncertainty. Our opinion is not modified with respect to this matter."

NANOPHASE TECHNOLOGIES CORP.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|-------------------|
| Product revenue | 36,641,000 | 36,731,000 | 29,325,000 |
| Other revenue | 656,000 | 586,000 | 150,000 |
| Total revenue | 37,297,000 | 37,317,000 | 29,475,000 |
| Cost of revenue | 29,472,000 | 28,957,000 | 20,785,000 |
| Gross profit (loss) | 7,825,000 | 8,360,000 | 8,690,000 |
| Research & development expense | 3,837,000 | 3,037,000 | 2,235,000 |
| Selling, general & administrative expense | 7,534,000 | 7,581,000 | 3,896,000 |
| Income (loss) from operations | (3,546,000) | (2,258,000) | 2,559,000 |
| Interest expense | 838,000 | 382,000 | 1,154,000 |
| Other income, net | ... | ... | 952,000 |
| Income (loss) before provision for income taxes | (4,384,000) | (2,640,000) | 2,357,000 |
| Provision for income taxes | 6,000 | (17,000) | 37,000 |
| Net income (loss) | (4,390,000) | (2,623,000) | 2,320,000 |
| Weighted average shares outstanding - basic | 49,556,305 | 49,117,000 | 45,021,173 |
| Weighted average shares outstanding - diluted | 49,556,305 | 49,117,000 | 47,039,173 |
| Year end shares outstanding | 49,627,254 | 49,320,680 | 48,893,573 |
| Net income (loss) per share - basic | \$(0.09) | \$(0.05) | \$0.05 |
| Net income (loss) per share - diluted | \$(0.09) | \$(0.05) | \$0.05 |
| Number of full time employees | 79 | 82 | 58 |
| Number of common stockholders | 121 | 121 | 120 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.09) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.09) | ... | ... |
| Total number of employees | 79 | ... | ... |

¹ As of March 22, 2023; ² As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------|------|
|--|------|------|

| | | | |
|---|---------------|---------------|-----|
| Cash & cash equivalents | 1,722,000 | ... | ... |
| Cash | ... | 2,186,000 | ... |
| Trade accounts receivable, gross | 3,692,000 | 4,873,000 | ... |
| Less: allowance for doubtful accounts | 225,000 | 139,000 | ... |
| Trade accounts receivable, net | 3,467,000 | ... | ... |
| Trade accounts receivable | ... | 4,734,000 | ... |
| Raw materials | 7,847,000 | 6,797,000 | ... |
| Finished goods | 2,184,000 | 2,041,000 | ... |
| Inventories, gross | 10,031,000 | ... | ... |
| Inventories, net | ... | 8,839,000 | ... |
| Prepaid expenses & other current assets | 1,082,000 | 866,000 | ... |
| Total current assets | 16,302,000 | 16,625,000 | ... |
| Machinery & equipment | 23,339,000 | 19,899,000 | ... |
| Office equipment | 1,014,000 | 1,014,000 | ... |
| Office furniture | 126,000 | 110,000 | ... |
| Leasehold improvements | 5,157,000 | 5,140,000 | ... |
| Construction in progress | 931,000 | 2,952,000 | ... |
| Equipment & leasehold improvements, gross | 30,567,000 | 29,115,000 | ... |
| Less: accumulated depreciation & amortization | 21,899,000 | 21,166,000 | ... |
| Equipment & leasehold improvements, net | 8,668,000 | 7,949,000 | ... |
| Operating leases, right of use | 7,907,000 | 8,978,000 | ... |
| Other assets, net | 4,000 | 6,000 | ... |
| Total assets | 32,881,000 | 33,558,000 | ... |
| Line of credit, related party | ... | 7,282,000 | ... |
| Current portion of long-term debt, related party | 2,000,000 | ... | ... |
| Current portion of operating lease obligations | 1,297,000 | ... | ... |
| Accounts payable | 6,260,000 | 6,363,000 | ... |
| Current portion of deferred revenue | 2,353,000 | 2,167,000 | ... |
| Accrued payroll & related expenses | 255,000 | 288,000 | ... |
| Accrued account payable | ... | 403,000 | ... |
| Tenant security deposit / advance rent | ... | 61,000 | ... |
| Other accrued expenses | ... | 271,000 | ... |
| Accrued expenses - Balancing value | 614,000 | ... | ... |
| Line of credit ? accounts receivable, related party | 2,810,000 | ... | ... |
| Total current liabilities | 15,589,000 | 16,835,000 | ... |
| Long-term portion of operating lease obligations | 9,152,000 | 9,823,000 | ... |
| Long-term debt, related party | ... | 1,000,000 | ... |
| Paycheck Protection Program ("PPP") loan (SBA) | 1,000,000 | ... | ... |
| Long-term portion of deferred revenue | ... | 21,000 | ... |
| Asset retirement obligations | 238,000 | 230,000 | ... |
| Long-term line of credit ? inventory, related party | 5,000,000 | ... | ... |
| Total long-term liabilities | 15,390,000 | 11,074,000 | ... |
| Common stock | 496,000 | 493,000 | ... |
| Additional paid-in capital | 106,069,000 | 105,226,000 | ... |
| Retained earnings (accumulated deficit) | (104,663,000) | (100,070,000) | ... |
| Total stockholders' equity (deficit) | 1,902,000 | 5,649,000 | ... |
| Total Equity | 1,902,000 | ... | ... |

³ As reported by the Company

Recent Dividends:**1. Nanophase Technologies Corp. common.**

No dividends paid.

Annual Dividends:**1. Nanophase Technologies Corp. common.**

No dividends paid.

NANOVIBRONIX INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31****(\$000):**

| | 2023 | 2022 | ¹ 2021 (revised) |
|--|----------------|-----------------------|--------------------------------|
| Revenues | 2,283 | ... | ... |
| Revenues | 2,283 | 752 | 1,695 |
| Cost of revenues | 746 | 585 | 925 |
| Gross profit | 1,537 | 167 | 770 |
| Research & development expenses | 185 | 283 | 293 |
| Selling & marketing expenses | 864 | 965 | 1,101 |
| General & administrative expenses | 3,924 | 3,931 | 5,059 |
| Total operating expenses | 4,973 | 5,179 | 6,453 |
| Income (loss) from operations | (3,436) | (5,012) | (5,683) |
| Interest expense | 135 | 347 | ... |
| Interest on promissory notes | 111 | ... | ... |
| Financial income (expense), net | ... | (54) | (48) |
| Change in fair value of derivative liabilities | ... | ... | (6,956) |
| Gain on purchase of warrants | ... | ... | 64 |
| Warrant modification expense | ... | ... | 1,627 |
| Income (loss) before income taxes - domestic | ... | 5,557 | 14,333 |
| Income (loss) before income taxes - foreign | ... | (144) | (82) |
| Income (loss) before taxes | (3,682) | (5,413) | (14,250) |
| Current foreign tax expense (benefit) | (25) | 37 | 32 |
| Total current tax expense (benefit) | ... | 37 | 32 |
| Deferred federal tax expense (benefit) | (1,226) | (1,545) | (1,263) |
| Deferred state tax expense (benefit) | (43) | 653 | (131) |
| Deferred foreign tax expense (benefit) | 2 | (1) | (4) |
| Total deferred tax expense (benefit) | ... | (893) | (1,398) |
| Less: valuation allowance | 1,267 | 893 | 1,398 |
| Income tax expense (benefit) | 29 | ² 35 | 32 |
| Net income (loss) | (3,711) | (5,448) | (14,282) |
| Weighted average shares outstanding - basic | 1,750 | ³ 1,420 | 1,258 |
| Weighted average shares outstanding - diluted | 1,750 | ³ 1,420 | 1,258 |
| Year end shares outstanding | 2,046 | ³ 1,641 | ³ 1,400 |
| Net income (loss) per share - basic | \$(2.12) | ³ \$(3.84) | \$(11.35) |
| Net income (loss) per share - diluted | \$(2.12) | ³ \$(3.84) | \$(11.35) |
| Number of full time employees | 10 | ⁴ 9 | ⁴ 12 |
| Number of part time employees | 6 | ⁵ 5 | ⁵ 4 |
| Total number of | | | |

| | | | |
|---|----------|-----------------|------------------|
| employees | 16 | ... | ... |
| Number of common stockholders | 131 | [Ⓔ] 96 | [Ⓔ] 120 |
| Foreign currency translation adjustments | ... | (78) | ... |
| Earnings per share from continuing operations | \$(2.12) | ... | ... |
| Earnings per share from continuing operations | \$(2.12) | ... | ... |

[Ⓔ] Reclassified to conform with 2022 presentation; [Ⓕ] As reported by the Company; [Ⓖ] Adjusted for 1-for-20 stock split, February 9, 2023; [Ⓗ] Shares increased due to the effect of exercise of warrants and conversion of series C, D and E preferred shares to common shares; [Ⓙ] As is; [Ⓚ] As of April 17, 2023; [Ⓛ] As of April 14, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | |
|--|----------|----------|--|
| | 2023 | 2022 | |
| Cash | 3,283 | 2,713 | |
| Trade receivables | 318 | 9 | |
| Raw materials | 210 | 30 | |
| Finished goods | 2,522 | 2,145 | |
| Inventory - Balancing value | 2,732 | ... | |
| Inventories | ... | 2,175 | |
| Prepaid expenses | 47 | 612 | |
| Other accounts receivables | ... | 100 | |
| Prepaid expenses & other receivables | 154 | 712 | |
| Other receivables | 107 | ... | |
| Total current assets | 6,487 | 5,609 | |
| Property & equipment, net | 7 | 7 | |
| Other assets | 1 | 3 | |
| Severance pay fund | 174 | 179 | |
| Operating lease right-of-use assets, net | 5 | 81 | |
| Total non-current assets | 187 | 270 | |
| Total assets | 6,674 | 5,879 | |
| Trade payables | 138 | 66 | |
| Other accounts payable & accrued expenses | 2,265 | 2,148 | |
| Deferred revenue | 46 | 21 | |
| Operating lease liabilities, current | 5 | 81 | |
| Total current liabilities | 2,454 | 2,316 | |
| Accrued severance pay | 217 | 223 | |
| Deferred licensing income | 15 | 107 | |
| Total liabilities | 2,686 | 2,646 | |
| Common stock | 2 | 2 | |
| Additional paid-in capital | 70,149 | 65,634 | |
| Accumulated other comprehensive income | (67) | (18) | |
| Accumulated Deficit | (66,096) | ... | |
| Retained earnings (accumulated deficit) | ... | (62,385) | |
| Total stockholders' equity (deficiency) | 3,988 | 3,233 | |
| Total Equity | 3,988 | ... | |

Recent Dividends:

- 1. NanoVibronix Inc common.**
No dividends paid.
- 2. NanoVibronix Inc series E preferred.**
No dividends paid.
- 3. NanoVibronix Inc series A-2 preferred.**
No dividends paid.
- 4. NanoVibronix Inc series A-1 preferred.**
No dividends paid.
- 5. NanoVibronix Inc series C preferred.**
No dividends paid.
- 6. NanoVibronix Inc series D preferred.**
No dividends paid.

Annual Dividends:

- 1. NanoVibronix Inc common.**
No dividends paid.
- 2. NanoVibronix Inc series E preferred.**

- 3. NanoVibronix Inc series A-2 preferred.**
No dividends paid.
- 4. NanoVibronix Inc series A-1 preferred.**
No dividends paid.
- 5. NanoVibronix Inc series C preferred.**
No dividends paid.
- 6. NanoVibronix Inc series D preferred.**
No dividends paid.

NAUSICUS ROBOTICS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | [Ⓔ] 2021 |
|---|--------------|-------------------------|-------------------------|
| Cost of revenue (exclusive of items shown separately below) | 11,928,931 | ... | ... |
| Loss on contract | 2,542,913 | ... | ... |
| Service revenue | ... | 11,210,559 | ... |
| Service - related party revenue | 500 | 224,400 | ... |
| Service | 6,605,852 | ... | ... |
| Total revenue | 6,606,352 | 11,434,959 | ... |
| Cost of revenue | ... | 11,863,862 | ... |
| Depreciation | 729,412 | 516,949 | ... |
| General & administrative expenses | 18,271,832 | 15,056,565 | ... |
| Operating & formation costs | ... | ... | 1,201,383 |
| Franchise tax expense | ... | ... | 97,200 |
| Research & development | 1,399,560 | 2,376,912 | ... |
| Total costs & expenses | 61,704,075 | 29,814,288 | ... |
| Operating income (loss) | (55,097,723) | (18,379,329) | (1,298,583) |
| Other income, net | ... | 293,862 | ... |
| Transaction costs allocated to warrant liabilities | ... | ... | 155,037 |
| Net gain on investments held in Trust Account | (453,162) | ... | 5,428 |
| Change in fair value of warrant liabilities | 14,902,427 | (6,461,087) | 1,077,750 |
| Interest expense, net | ... | 3,714,017 | ... |
| Change in fair value of over-allotment option liability | ... | ... | 225,000 |
| Accretion of debt discount | (8,776,277) | ... | ... |
| Foreign currency transaction loss (gain) | (44,020) | ... | ... |
| Loss on exchange of warrants | (590,266) | ... | ... |
| Amortization of legal fees | (627,580) | ... | ... |
| Net Income before Tax | (50,686,601) | ... | ... |
| Total other income (expense), net | 4,411,122 | (9,881,242) | ... |
| Net income (loss) | (50,686,601) | (28,260,571) | (595,442) |
| Less: deemed dividend for earnout shares | ... | 4,957,366 | ... |
| Net income (loss) attributable to common stockholders | (50,686,601) | (33,217,937) | ... |
| Weighted average shares outstanding - basic | 40,943,444 | 18,982,139 | 11,781,678 |
| Weighted average shares outstanding - diluted | 40,943,444 | 18,982,139 | 11,781,678 |
| Year end shares outstanding | 50,035,824 | [Ⓔ] 47,250,771 | [Ⓔ] 21,562,500 |
| Net earnings (loss) | ... | ... | ... |

| | | | | |
|---|------------|-----------------|----------|----------|
| per share - basic | ... | \$(1.24) | \$(1.75) | \$(0.05) |
| Net earnings (loss) per share - diluted | ... | \$(1.24) | \$(1.75) | \$(0.05) |
| Full-Time Employees (Period End) | 72 | ... | ... | ... |
| Total number of employees | 72 | 93 | 4 | ... |
| Number of common stockholders | 37 | [Ⓔ] 38 | 10 | ... |
| Impairment of property and equipment | 25,354,791 | ... | ... | ... |
| Loss on lease termination | 1,476,636 | ... | ... | ... |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... | ... |
| Applicable to Common - Total | \$(1.24) | ... | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... | ... |
| Applicable to Common - Total | \$(1.24) | ... | ... | ... |

[Ⓔ] 2021 and prior periods for CleanTech Acquisition Corp., prior to reverse recapitalization with Nauticus Robotics Holdings, Inc.; [Ⓕ] Shares increased due to cancellation and exchange of convertible note, conversion of preferred share, reverse recapitalization, issuance of earnout shares and common stock for PIPE Investment; [Ⓖ] Shares increased due to the effect of common stock subject to redemption; [Ⓗ] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 753,398 | 17,787,159 |
| Restricted certificate of deposit | 201,822 | 250,375 |
| Short-term investments | ... | 4,959,263 |
| Accounts receivable, gross | 212,428 | 1,632,397 |
| Less: allowances for doubtful accounts | ... | 9,963 |
| Accounts receivable, net | 212,428 | 1,622,434 |
| Raw material & supplies | 898,335 | 1,499,030 |
| Work in progress | 1,300,462 | 5,167,882 |
| Inventories | 2,198,797 | 6,666,912 |
| Contract assets | ... | 573,895 |
| Prepaid insurance | ... | 2,392,978 |
| Prepaid material purchases | 1,889,218 | 2,454,298 |
| Other prepayments | ... | 199,323 |
| Other current assets | ... | 56,410 |
| Other current assets | 1,025,214 | 2,710,031 |
| Assets held for sale | 2,940,254 | ... |
| Other | 330,214 | ... |
| Term Loans Receivables | 695,000 | ... |
| Total current assets | 9,221,131 | 36,963,047 |
| Leasehold improvements | 796,136 | 789,839 |
| Property & equipment | 8,610,765 | 2,206,004 |
| Technology hardware equipment | 5,906,859 | 1,200,504 |
| Technology hardware equipment | 1,907,770 | ... |
| Less: accumulated depreciation | 2,035,034 | 2,003,341 |
| Construction in progress | 9,329,114 | 12,974,361 |
| Property & equipment, net | 15,904,845 | 15,167,367 |
| Operating lease right-of-use asset | 834,972 | 317,208 |
| Other assets | 187,527 | 155,490 |
| Total assets | 26,148,475 | 52,603,112 |
| Accounts payable | 7,035,450 | 324,484 |
| Accrued compensation | 618,630 | 1,501,736 |
| Accrued professional fees | ... | 794,021 |
| Accrued insurance | ... | 590,936 |
| Other accrued expenses | ... | 256,284 |
| Accrued liabilities | 7,339,099 | 3,142,977 |
| Accrued expenses - related party | 6,720,469 | ... |
| Operating lease liabilities - current | 244,774 | 410,158 |
| Contract liability | 2,767,913 | ... |

| | | |
|--|---------------|--------------|
| Total current liabilities | 17,387,236 | 3,877,619 |
| Warrant liabilities | 18,376,180 | 32,688,342 |
| Operating lease liabilities - long-term | 574,260 | 87,214 |
| Convertible secured debentures | 36,530,320 | |
| Less: debt discount, net | 31,597,649 | (20,608,202) |
| Notes payable - long-term, net of discount | 15,922,118 | |
| Total liabilities | 67,935,325 | 52,575,293 |
| Common stock | 5,004 | 4,725 |
| Additional paid in capital | 76,999,849 | 68,128,196 |
| Accumulated deficit | (118,791,703) | |
| Retained earnings (accumulated deficit) | (68,105,102) | |
| Total stockholders' equity (deficit) | (41,786,850) | 27,819 |
| Total Equity | (41,786,850) | |

Recent Dividends:**1. Nauticus Robotics Inc common.**

No dividends paid.

Annual Dividends:**1. Nauticus Robotics Inc common.**

No dividends paid.

NETCAPITAL INC**Earnings, 9 mos. to Jan 31(Consol. - \$):**

| | 2024 | 2023 |
|-----------------------------|--------------------|------------------|
| Total revenues | 4,604,260 | 5,379,960 |
| Cost & expenses | 6,506,217 | 4,467,548 |
| Operating income | (1,901,957) | 912,412 |
| Other income (expense), net | (2,781,128) | 2,013,684 |
| Invest. income | (406,060) | |
| Net before taxes | (4,718,869) | 2,443,114 |
| Income taxes | (2,339,288) | 499,000 |
| Net income | (2,379,581) | 1,944,114 |
| Balance for common | 1,944,114 | |
| Earnings common share | | |
| Primary | \$(0.25) | \$0.46 |
| Fully Diluted | \$(0.25) | \$0.46 |
| Common Shares: | | |
| Full Diluted | 9,457,740 | 4,208,466 |
| Year-end | 17,231,132 | 6,071,777 |

NEUROBO PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 (revised) |
|---|-----------------|-----------------|-----------------|
| Research & development expenses | 9,158 | 2,778 | 6,546 |
| Acquired in-process research & development | | 8,210 | |
| General & administrative expenses | 6,728 | 8,640 | 8,752 |
| Total operating expenses | 15,886 | 19,628 | 15,298 |
| Income (loss) from operations | (15,886) | (19,628) | (15,298) |
| Interest income | 461 | | 14 |
| Financing expense | | 2,191 | |
| Change in fair value of warrant liability | 2,955 | 7,935 | |
| Other expense | | 83 | |
| Total other income | | 5,661 | 14 |
| Income (loss) before income taxes | | (14,559) | (14,954) |
| Income (loss) before income taxes - foreign | | 592 | (330) |
| Income (loss) before income taxes | (12,470) | (13,967) | (15,284) |
| Net income (loss) | (12,470) | (13,967) | (15,284) |
| Weighted average shares outstanding | | | |

| | | | |
|--|----------|-----------|------------|
| - basic | 5,071 | 322 | 96 |
| Weighted average shares outstanding | | | |
| - diluted | 5,071 | 322 | 96 |
| Year end shares outstanding | 4,906 | 3,180 | 111 |
| Net income (loss) per share - basic | \$(2.46) | \$(43.44) | \$(158.48) |
| Net income (loss) per share - diluted | \$(2.46) | \$(43.44) | \$(158.48) |
| Number of full time employees | | 4 | 8 |
| Number of part time employees | | 2 | 3 |
| Total number of employees | | 6 | |
| Number of common stockholders | 52 | 73 | 69 |
| United States | (3,424) | | |
| Foreign | 176 | | |
| Total deferred income tax (benefit) provision | (3,248) | | |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(2.46) | | |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(2.46) | | |
| Income Taxes - Other - Deferred/Current | 3,424 | | |
| Income Taxes - Other - Deferred/Current | (176) | | |

Reclassified to conform with 2022 presentation; Adjusted for 1- for -8 stock split, December 21, 2023; Adjusted for 1- for-30 stock split, September 14, 2022; Shares increased due to the issuance of shares in connection with public offering and from exercise of warrants, and conversion of series A and B preferred shares to common shares; Shares increased due to the effect of issuance of common stock and warrants in connection with equity financing; As is; As of March 24, 2023; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|--------|--------|
| Cash | 22,435 | 33,364 |
| Prepaid and other current assets | 77 | |
| Prepaid expenses | | 168 |
| Total current assets | 22,512 | 33,532 |
| Right-of-use assets & other assets | 21 | |
| Office equipment | | 30 |
| Total property & equipment | 80 | 30 |
| Less: accumulated depreciation | 34 | 28 |
| Property & equipment, net | 46 | 2 |
| Right-of-use asset | 202 | |
| Total assets | 22,781 | 33,534 |
| Accounts payable | 821 | 708 |
| Other research & development expenses | 166 | |
| External research & development expenses | 3,822 | 109 |
| Payroll related | 118 | 100 |
| Professional services | 308 | 23 |
| Other accrued expenses | | 48 |
| Accrued liabilities | 4,414 | 280 |
| Warrant liabilities | 658 | 10,796 |
| Lease liability, short-term | 67 | |
| Total current liabilities | 5,960 | 11,784 |
| Lease & other long-term | | |

| | | |
|---|-----------|----------|
| liabilities | 136 | |
| Total liabilities | 6,096 | 11,784 |
| Common stock | 5 | 25 |
| Additional paid-in capital | 124,945 | 117,520 |
| Retained earnings (accumulated deficit) | (108,265) | (95,795) |
| Total stockholders' equity (deficit) | 16,685 | 21,750 |
| Total Equity | 16,685 | |

Recent Dividends:**1. NeuroBo Pharmaceuticals Inc common.**

No dividends paid.

Annual Dividends:**1. NeuroBo Pharmaceuticals Inc common.**

No dividends paid.

NEVADA CANYON GOLD CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|------------------|
| Exploration expenses | 72,523 | 20,758 | 15,482 |
| General & administrative expenses | 463,872 | 164,927 | 60,582 |
| Professional fees | 126,277 | 99,249 | 40,220 |
| Director compensation | | 988,471 | |
| Transfer agent & filing fees | 16,747 | 14,521 | 10,849 |
| Director and officer compensation | 1,571,805 | | |
| Consulting fees | 424,201 | | |
| Total operating expenses | 2,675,425 | 1,287,926 | 127,133 |
| Accrued interest | | 10,812 | 4,936 |
| Accretion expense | | 719,462 | 94,404 |
| Fair value gain (loss) on equity investments | (100,700) | 241,513 | (474,287) |
| Foreign exchange gain (loss) | 7 | (978) | 7,119 |
| Interest income | 121,168 | 10,080 | 755 |
| Realized gain on equity investments | | 211,530 | 315 |
| Net income (loss) before income taxes | (2,654,950) | | |
| Net income (loss) | (2,654,950) | (1,556,055) | (692,571) |
| Weighted average shares outstanding | | | |
| - basic | 12,589,698 | 3,034,022 | 4,466,682 |
| Weighted average shares outstanding - diluted | 12,589,698 | 3,034,022 | 4,466,682 |
| Year end shares outstanding | 25,240,051 | 11,077,394 | 8,685,093 |
| Net income (loss) per common share - basic | \$(0.21) | \$(0.51) | \$(0.16) |
| Net income (loss) per common share - diluted | \$(0.21) | \$(0.51) | \$(0.16) |
| Total number of employees | | 1 | 1 |
| Number of common stockholders | 1,417 | 49 | 28 |
| Total other income (expense) | 20,475 | | |

Shares increased due to the effect of shares issued on conversion of convertible notes; Shares increased due to the effect of issuance of common stock

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------|------------|-----------|
| Cash | | 1,007,018 |
| Prepaid expenses | 541,034 | 4,829 |
| Cash and cash equivalents | 9,744,392 | |
| Total current assets | 10,285,426 | 1,011,847 |
| Equity investment | | 156,805 |

| | | |
|---|-------------|-------------|
| Mineral property interests | 780,395 | 720,395 |
| Investment in equity security | 56,105 | ... |
| Total assets | 11,121,926 | 1,889,047 |
| Trade payables | ... | 802,648 |
| Accrued liabilities | ... | 41,800 |
| Accounts payable & accrued liabilities | 846,307 | 844,448 |
| Related party advances | ... | 477,031 |
| Related party payable | 460,000 | ... |
| Notes & advances payable | ... | 515 |
| Total current liabilities | ... | 1,321,994 |
| Total liabilities | 1,306,307 | 1,321,994 |
| Common stock | 2,523 | 1,107 |
| Additional paid in capital | 14,957,547 | 3,073,447 |
| Retained earnings (accumulated deficit) | (5,162,451) | (2,507,501) |
| Obligation to issue shares | 18,000 | ... |
| Total stockholders' equity (deficit) | 9,815,619 | 567,053 |
| Total Equity | 9,815,619 | ... |

Recent Dividends:

1. Nevada Canyon Gold Corp common.

No dividends paid.

Annual Dividends:

1. Nevada Canyon Gold Corp common.

No dividends paid.

NEWHYDROGEN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------------|---------------------|-------------------|
| General & administrative expenses | 2,972,266 | 10,988,885 | 51,229,031 |
| Research & development | 202,878 | 1,095,483 | 1,221,134 |
| Depreciation & amortization | 4,106 | 4,214 | 4,365 |
| Depreciation and amortization | 1,084 | ... | ... |
| Amortization of Brands, Patents, Trademarks, Marketing & Artistic Intangibles | 3,022 | ... | ... |
| Total operating expenses | 3,179,250 | 12,088,582 | 52,454,530 |
| Income (loss) from operations before other income (expenses) | (3,179,250) | (12,088,582) | (52,454,530) |
| Interest income | 1,718 | 3,054 | 3,632 |
| Gain on settlement of debt & derivatives | ... | ... | 93,180,986 |
| Gain (loss) on change in derivative liability | ... | ... | (29,966,084) |
| Interest expense | ... | ... | 574,524 |
| Total other income (expenses) | 1,718 | 3,054 | 62,644,010 |
| Income (loss) before provision for taxes | (3,177,532) | ... | ... |
| Net income (loss) | (3,177,532) | (12,085,528) | 10,189,480 |
| Income (loss) to common shareholders | ... | (12,085,528) | 10,189,480 |
| Weighted average shares outstanding - basic | 705,030,048 | 705,126,846 | 651,573,767 |
| Weighted average shares outstanding - diluted | 705,030,048 | 705,126,846 | 1,117,523,767 |
| Year end shares outstanding | 704,599,512 | 705,126,846 | 715,496,051 |
| Net income (loss) | | | |

| | | | |
|---------------------------------------|--------|----------|--------|
| per share - basic | \$0.00 | \$(0.02) | \$0.02 |
| Net income (loss) per share - diluted | \$0.00 | \$(0.02) | \$0.00 |
| Number of full time employees | ... | 21 | 22 |
| Number of common stockholders | 87 | 90 | 90 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash | 3,678,441 | 4,834,697 |
| Prepaid expenses | 10,311 | 10,540 |
| Total current assets | 3,688,752 | 4,845,237 |
| Machinery & equipment | 37,225 | 37,225 |
| Less: accumulated depreciation | 35,642 | 34,558 |
| Net property & equipment | 1,583 | 2,667 |
| Patents, gross | ... | 45,336 |
| Less: accumulated amortization | ... | 21,157 |
| Patents | 21,157 | 24,179 |
| Deposit | 770 | 770 |
| Total assets | 3,712,262 | 4,872,853 |
| Accounts payable and other payable | 9,810 | ... |
| Accounts payable | ... | 49 |
| Total current liabilities | 9,810 | 49 |
| Series C convertible preferred stock | ... | 3,485,313 |
| Common stock | 70,460 | 70,513 |
| Additional paid in capital | 176,279,264 | 174,272,031 |
| Retained earnings (accumulated deficit) | (176,132,585) | (172,955,053) |
| Preferred Stock - Redeemable - Convertible | 3,485,313 | ... |
| Total shareholders' equity (deficit) | 3,702,452 | 1,387,491 |
| Total Equity | 3,702,452 | ... |

Recent Dividends:

1. NewHydrogen Inc series C convertible preferred.

No dividends paid.

2. NewHydrogen Inc common.

No dividends paid.

Annual Dividends:

1. NewHydrogen Inc series C convertible preferred.

No dividends paid.

2. NewHydrogen Inc common.

No dividends paid.

NEWTEKONE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------|------------|------------|
| Investment income from non-affiliate investments - interest income - PPP loans | ... | ... | 49,989,000 |
| Investment income from non-affiliate investments - interest income - SBA loans | 84,001,000 | 35,696,000 | 25,951,000 |
| Total interest income | 94,373,000 | ... | ... |
| Investment income from non-affiliate investments - servicing income | 18,289,000 | 13,698,000 | 11,307,000 |
| Investment income from non-affiliate investments - other income | ... | 8,600,000 | 5,696,000 |
| Investment income from non-control | | | |

| | | | |
|--|-------------|------------|-------------|
| investments - interest income | ... | ... | 428,000 |
| Investment income from non-control investments - dividend income | ... | 83,000 | 95,000 |
| Total investment income from non-control investments | ... | 83,000 | 523,000 |
| Investment income from controlled investments - interest income | ... | 2,921,000 | 2,598,000 |
| Investment income from controlled investments - dividend income | ... | 24,574,000 | 9,801,000 |
| Investment income from controlled investments - other income | ... | 672,000 | 2,629,000 |
| Total investment income | ... | 86,244,000 | 108,494,000 |
| Loan servicing asset revaluation | (3,549,000) | ... | ... |
| Dividend income | 1,757,000 | ... | ... |
| Net gains on sales of loans | 50,734,000 | ... | ... |
| Other noninterest income | 23,762,000 | ... | ... |
| Other interest earning assets | 8,854,000 | ... | ... |
| Debt securities available-for-sale | 1,518,000 | ... | ... |
| Total noninterest income | 176,772,000 | ... | ... |
| Deposits | 15,849,000 | ... | ... |
| Notes and securitizations | 40,217,000 | ... | ... |
| Bank and FHLB borrowings | 11,673,000 | ... | ... |
| Total interest expense | 67,739,000 | ... | ... |
| Electronic payment processing costs | 18,327,000 | ... | ... |
| Salaries & benefits expense | 65,708,000 | 20,186,000 | 17,866,000 |
| Interest expenses - notes payable - securitization trusts | ... | 10,641,000 | 5,520,000 |
| Interest expenses - bank notes payable | ... | 3,998,000 | 1,536,000 |
| Interest expenses - notes due 2023 | ... | ... | 549,000 |
| Interest expenses - notes due 2024 | ... | 2,424,000 | 4,714,000 |
| Interest expenses - 6.85% notes due 2025 | ... | 379,000 | 1,134,000 |
| Interest expenses - 5.00% notes due 2025 | ... | 1,294,000 | ... |
| Interest expenses - notes due 2026 | ... | 7,042,000 | 6,675,000 |
| Interest expenses - notes payable - related parties | ... | 547,000 | 387,000 |
| Interest expenses | ... | 26,325,000 | 20,515,000 |
| Depreciation & amortization expense | 2,884,000 | 239,000 | 304,000 |
| Professional fees | 13,077,000 | 7,134,000 | 5,610,000 |
| Origination & loan processing | 9,433,000 | 11,606,000 | 10,234,000 |
| Origination & loan processing - related party | ... | 19,140,000 | 19,272,000 |
| Loss (gain) on extinguishment of debt | 271,000 | 417,000 | 1,552,000 |
| Other general & administrative | | | |

| | | | | | | | | | | |
|--|----------|----------|----------|--|----------|----------|--|-------------|-------------|-------------|
| expenses | 4,096 | 3,604 | 2,578 | Leasehold improvements | 419 | 228 | Total operating | | | |
| Income (loss) from operations | (3,477) | (3,348) | (2,570) | Construction in progress | 387 | 55 | expenses | 1,976,601 | 1,673,284 | 1,766,956 |
| Change in fair value of warrant liability & warrant modification expense | 96 | 76 | 8 | Property & equipment, gross | 2,225 | 1,315 | Income (loss) from operations | (1,976,601) | (1,673,284) | (1,766,956) |
| Forgiveness of debt | ... | ... | 275 | Less: accumulated depreciation & amortization | 726 | 594 | Interest expense | 87,682 | 70,515 | 33,369 |
| Debt financing costs | ... | ... | 68 | Property & equipment, net | 1,499 | 721 | Gain on settlement of debt | ... | ... | 15,955 |
| Unrealized gain on investments in marketable securities | 191 | 9 | ... | Operating lease - right of use asset | 1,855 | 1,737 | Other income | (296,948) | ... | ... |
| Gain (loss) on debt extinguishment | ... | (150) | (25) | Other assets | 95 | 63 | Net other income (expense) | (384,630) | (70,515) | (17,414) |
| Interest expense | 15 | 1,336 | 1,930 | Total assets | 9,955 | 10,357 | Income (loss) before income taxes | ... | (1,743,799) | (1,784,370) |
| Other income | 19 | 3 | ... | Accounts payable | 1,233 | 265 | - Unites States | ... | (1,743,799) | (1,784,370) |
| Other income /expense | (2) | ... | ... | Accrued salaries, benefits & incentive compensation | 61 | 56 | Income (loss) before provision for income taxes | (2,361,231) | (1,743,799) | (1,784,370) |
| Total other income (expense) | 289 | (1,398) | (1,740) | Franchise tax accrual | ... | 52 | Net income (loss) | (2,361,231) | (1,743,799) | (1,784,370) |
| Income attributable to non-controlling interest in joint venture | 31 | ... | ... | Other accrued expenses & other current liabilities | ... | 22 | Weighted average shares outstanding - basic | 28,466,560 | 27,802,153 | 21,529,360 |
| Net Income After Extraordinary Items applicable to Common | (3,157) | ... | ... | Accrued expenses & other current liabilities | 398 | 130 | Weighted average shares outstanding - diluted | 28,466,560 | 27,802,153 | 21,529,360 |
| Net income (loss) | (3,188) | (4,746) | (4,310) | Deferred revenue | 20 | ... | Year end shares outstanding | 28,546,834 | 28,346,834 | 27,385,437 |
| Weighted average shares outstanding - basic | 5,672 | 5,575 | 2,980 | Convertible notes payable, net of deferred financing costs | 245 | ... | Net gain (loss) per share from continuing operations - basic | \$(0.08) | ... | ... |
| Weighted average shares outstanding - diluted | 5,672 | 5,575 | 2,980 | Current portion of note payable | 80 | ... | Net gain (loss) per share - basic | \$(0.08) | \$(0.06) | \$(0.08) |
| Year end shares outstanding | 5,742 | 5,578 | 5,572 | Notes payable, current portion | ... | 15 | Net gain (loss) per share from continuing operations - diluted | \$(0.08) | ... | ... |
| Net income (loss) per share - basic | \$(0.56) | \$(0.85) | \$(1.45) | Warrant liability | 146 | 242 | Net gain (loss) per share from continuing operations - diluted | \$(0.08) | \$(0.06) | \$(0.08) |
| Net income (loss) per share - diluted | \$(0.56) | \$(0.85) | \$(1.45) | Operating lease liability, current portion | 233 | 207 | Number of full time employees | 6 | 6 | 8 |
| Number of full time employees | 19 | 12 | 10 | Other | 92 | ... | Number of common stockholders | 47 | 31 | 7 |
| Number of common stockholders | ... | 1,109 | 1,176 | Contingent consideration liability | 439 | ... | Total number of employees | 6 | ... | ... |
| Income from cont operations before income tax | (3,188) | ... | ... | Total current liabilities | 2,549 | 859 | | | | |
| Total number of employees | 19 | ... | ... | Operating lease liability, net of current portion | 1,727 | 1,593 | | | | |
| | | | | Notes payable, net of current portion | 513 | 268 | | | | |
| | | | | Total liabilities | 4,789 | 2,720 | | | | |
| | | | | Common stock | 6 | 6 | | | | |
| | | | | Additional paid-in capital | 19,406 | 19,189 | | | | |
| | | | | Accumulated deficit | (14,715) | ... | | | | |
| | | | | Retained earnings (accumulated deficit) | ... | (11,558) | | | | |
| | | | | Total stockholders' equity | 4,697 | 7,637 | | | | |
| | | | | Non-controlling interest in joint venture | 469 | ... | | | | |
| | | | | Total stockholders equity | 5,166 | ... | | | | |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock, restricted stock vesting, exercised of stock options and derivative liability - COVA; As is; As of March 27, 2023; Approximately; As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | |
|---|-------|-------|
| | 2023 | 2022 |
| Cash and cash equivalents | 2,700 | ... |
| Cash | ... | 1,101 |
| Marketable securities | ... | 5,508 |
| Accounts receivable, gross | 644 | 231 |
| Less: allowance for doubtful accounts | 11 | 9 |
| Accounts receivable, net | 633 | 222 |
| Raw materials | 899 | 295 |
| Work-in-progress | 12 | 51 |
| Finished goods | 408 | 156 |
| Inventory | 1,319 | 502 |
| Prepaid expenses & other current assets | 400 | 172 |
| Total current assets | 5,052 | 7,505 |
| Goodwill | 1,128 | 311 |
| Intangibles, net | 326 | 20 |
| Machinery & equipment | 1,280 | 973 |
| Office furniture & equipment | 139 | 59 |

Recent Dividends:

1. NexGel Inc common.

No dividends paid.

Annual Dividends:

1. NexGel Inc common.

No dividends paid.

NEXT MEATS HOLDINGS INC

Earnings, 9 mos. to Jan 31(Consol. - \$):

| | | |
|-----------------------------|-------------|-------------|
| | 2024 | 2023 |
| Total revenues | 740,259 | 1,092,882 |
| Cost & expenses | 1,503,063 | 3,025,340 |
| Operating income | (781,897) | (1,962,973) |
| Other income (expense), net | (37,544) | 149,685 |
| Net before taxes | (825,689) | (1,818,674) |
| Net income | (825,689) | (1,818,674) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 502,562,280 | ... |
| Year-end | 437,592,510 | 502,562,280 |

NEXT-CHEMX CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--------------------------|-----------|-----------|-----------|
| | 2023 | 2022 | 2021 |
| General & administrative | 1,976,601 | 1,673,284 | 1,766,956 |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of common stock issued for purchase of intangible asset; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2022 |
| Cash | ... | 28,355 |
| Cash & cash equivalents | 2,458 | ... |
| Prepaid expense & other current assets | 72,925 | 22,169 |
| Financial Asset | 64,944 | ... |
| Total current assets | 140,327 | 50,524 |
| Property & equipment, net | 12,621 | 17,957 |
| Intangible asset, net | 3,150,114 | 3,150,114 |
| Total assets | 3,303,062 | 3,218,595 |
| Accounts payable & accrued liabilities | ... | 1,548,740 |
| Other payable | 2,443,207 | 11,980 |
| Note payable | 32,238 | 926,007 |
| Due to related party | 511,980 | ... |
| Loan payable | 945,000 | ... |
| Total current liabilities | 3,932,425 | 2,486,727 |
| Total liabilities | 3,932,425 | 2,486,727 |
| Common stock | 28,547 | 28,347 |
| Additional paid-in capital | 5,396,053 | 4,396,254 |
| Accumulated deficit | (6,053,963) | ... |
| Retained earnings (accumulated deficit) | ... | (3,692,732) |
| Total stockholders' equity (deficit) | (629,363) | 731,868 |
| Total stockholders' equity (deficit) | (629,363) | ... |

As reported by the Company

Recent Dividends:

1. Next-ChemX Corp common.

No dividends paid.

Annual Dividends:**1. Next-ChemX Corp common.**

No dividends paid.

NEXPLAT CORP**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

2023 2022 2021

(revised)

Total revenues 37,756,000

Revenue 32,389,000

Net sales 11,710,142 7,739,910

Net revenues -

services 5,367,000

Cost of sales 26,445,000 9,221,294 5,880,187

Cost of revenue 26,313,000

Cost of services 132,000

Gross profit 11,311,000 2,488,848 1,859,723

Selling, general &

administrative

expenses 9,910,000 5,083,724 5,128,360

Salaries, wages &

payroll taxes

expenses 6,643,000 2,564,655 1,838,531

Professional fees 1,981,000 1,552,193 1,198,063

Depreciation &

amortization

expenses 2,110,000 490,059 317,102

Impairment -

Goodwill 13,895,000

Total operating

expenses 34,539,000 9,690,631 8,482,056

Income (loss) from

operations (23,228,000) (7,201,783) (6,622,333)

Interest earned 620,000 20,814 6,876

Asset write-off 28,000

Interest expense 79,000 24,497 1,467,300

Foreign currency

exchange rate

variance 107,000 (128,648) (45,737)

Gain on debt

extinguishment 20,832

Miscellaneous

income (expense) 317,000

Total other income

(expense) 937,000 (132,331) (1,485,329)

Income (loss)

before provision

for (benefit from)

income taxes -

domestic (8,187,662)

Income (loss)

before provision

for (benefit from)

income taxes -

foreign 80,000

Income (loss)

before provision

for (benefit from)

income taxes (22,291,000) (7,334,114) (8,107,662)

Current foreign

provision for

(benefit from)

income taxes 39,000 87,000

Federal (11,000)

Total current

provision for

(benefit from)

income taxes 28,000 87,000

Provision for

income taxes 28,000 87,000

Loss before equity

in net loss of

affiliate (7,421,114) (8,107,662)

Gain on

remeasurement of

fair value of

equity interest in

affiliate prior to

acquisition 11,352,000

Equity in net loss

of affiliate (1,440,000) (1,739,475)

Net loss

attributable to

noncontrolling

interest 8,629,000

Net Income After

Extraordinary Items

applicable to

Common (3,778,000)

Net income (loss) (12,407,000) (9,160,589) (8,107,662)

Weighted average

shares outstanding

- basic 17,494,000 9,629,589 4,080,833

Weighted average

shares outstanding

- diluted 17,494,000 9,629,589 4,080,833

Year end shares

outstanding 18,724,596 14,402,025 7,053,146

Income (loss) per

share from

continuing

operations - basic (0.22)

Net income (loss)

per share - basic (0.22) (0.95) (1.98)

Income (loss) per

share from

continuing

operations -

diluted (0.22)

Net income (loss)

per share - diluted (0.22) (0.95) (1.98)

Number of full time

employees 142 18

Number of part time

employees 24 1

Total number of

employees 166

Number of common

stockholders 491 495 455

Reclassified to conform with 2022 presentation; Shares in-

creased due to the effect of issuance of common stock related to

January and December offering; and stock-based compensation in

connection with restricted stock awards; Approximately; As

of March 30, 2023; As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash 26,307,000 18,891,232

Accounts receivable,

gross 9,195,000 383,786

Less: allowance for

doubtful accounts 272,000 0

Accounts receivable, net 8,923,000 383,786

Finished goods 5,195,000 1,286,612

Inventories - Other (60,000)

Inventory 5,135,000 1,286,612

Unbilled revenue 189,000 141,702

Value added tax

receivable 432,769

Prepaid expenses 640,000

Prepaid expenses -

current portion 45,679

VAT receivable 342,000

Receivables - Other - Net 1,846,000

Notes Receivables - Net 256,000

Total current assets 43,638,000 21,181,780

Office furniture &

fixtures 128,252

Computer equipment 117,000 72,345

Rental equipment 60,000 37,531

Appliques 2,160,096 2,160,096

Website development 527,000 665,030

Office equipment 587,000

Vehicles 595,000

Furniture, fixtures &

equipment 184,000

Leasehold improvements 124,000 47,792

Property and equipment

gross Construction In

Progress 22,000

Building 2,116,000

Property & equipment,

gross 6,492,000 3,111,046

Less: accumulated

depreciation 2,503,000 1,865,244

Property & equipment,

net 3,989,000 1,245,802

Right of use assets, net 1,566,000 854,862

Intangible assets, net 14,423,000 50,001

Equity method investment 5,260,525

Prepaid expenses - long

term portion 61,000 49,078

Goodwill 731,000

Finance right-of-use

assets, net 22,000

Total assets 64,469,000 28,642,048

Accounts payable 12,142,000 1,194,067

Rental deposits 4,325

Customer deposits payable 76,000 86,462

Accrued wages & payroll

liabilities 200,000 23,040

Value added tax liability

& sales tax payable 5,685

U.K. income tax payable 23,771

Accrued legal fees 84,685

Pre-merger accrued other

liabilities 88,448

Accrued interest 571,000 356

Accrued other liabilities 187,000 7,256

Accounts payable &

accrued expenses 1,518,095

Contract liabilities 42,000 36,415

Note payable Coronavirus

loans- current portion 312,000 60,490

Due to related party 18,000 28,467

Operating lease

liabilities - current 532,000 208,660

Income taxes payable 139,000 94,244

Stock subscription

payable 13,176,000

Liabilities from

discontinued operations 112,397

Finance lease liabilities

current portion 18,000

Total current liabilities 14,237,000 2,058,768

Notes payable Coronavirus

- long term 1,211,000 156,266

Operating lease

liabilities - long term 929,000 649,895

Finance lease

liabilities, net of

current portion 5,000

Total liabilities 16,382,000 2,864,929

Common stock 2,000 1,440

Additional paid-in

capital 67,170,000 56,963,200

Retained earnings

(accumulated deficit) (31,146,804)

Retained earnings

(accumulated deficit)

since inception of

exploration stage (April

25, 2011) (34,925,000)

Accumulated other

comprehensive income

(loss) (63,000) (40,717)

Total stockholders'

equity (deficit) 32,184,000 25,777,119

Equity attributable to

noncontrolling interests 15,903,000

Total Equity 48,087,000

Recent Dividends:

1. NextPlat Corp series C convertible preferred.

No dividends paid.

2. NextPlat Corp series A preferred.

No dividends paid.

3. NextPlat Corp series L preferred.

No dividends paid.

4. NextPlat Corp series J preferred.

No dividends paid.

5. NextPlat Corp series E preferred.

No dividends paid.

6. NextPlat Corp series D preferred.

No dividends paid.

7. NextPlat Corp series B convertible preferred.

No dividends paid.

8. NextPlat Corp series A convertible preferred.

No dividends paid.

9. NextPlat Corp series H preferred.
No dividends paid.

10. NextPlat Corp common.
No dividends paid.

11. NextPlat Corp series C preferred.
No dividends paid.

12. NextPlat Corp series I preferred.
No dividends paid.

13. NextPlat Corp series F preferred.
No dividends paid.

14. NextPlat Corp series K preferred.
No dividends paid.

15. NextPlat Corp series G preferred.
No dividends paid.

16. NextPlat Corp series D convertible preferred.
No dividends paid.

17. NextPlat Corp series B preferred.
No dividends paid.

Annual Dividends:

1. NextPlat Corp series C convertible preferred.
No dividends paid.

2. NextPlat Corp series A preferred.
No dividends paid.

3. NextPlat Corp series L preferred.
No dividends paid.

4. NextPlat Corp series J preferred.
No dividends paid.

5. NextPlat Corp series E preferred.
No dividends paid.

6. NextPlat Corp series D preferred.
No dividends paid.

7. NextPlat Corp series B convertible preferred.
No dividends paid.

8. NextPlat Corp series A convertible preferred.
No dividends paid.

9. NextPlat Corp series H preferred.
No dividends paid.

10. NextPlat Corp common.
No dividends paid.

11. NextPlat Corp series C preferred.
No dividends paid.

12. NextPlat Corp series I preferred.
No dividends paid.

13. NextPlat Corp series F preferred.
No dividends paid.

14. NextPlat Corp series K preferred.
No dividends paid.

15. NextPlat Corp series G preferred.
No dividends paid.

16. NextPlat Corp series D convertible preferred.
No dividends paid.

17. NextPlat Corp series B preferred.
No dividends paid.

NIGHTFOOD HOLDINGS INC
Earnings, 6 mos. to Dec 31(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 9,071 | 93,339 |
| Cost & expenses | 608,931 | 1,329,485 |
| Operating income | (599,860) | (1,236,146) |
| Other income (expense), net | | 72,464 |
| Net before taxes | (1,924,496) | |
| Net income | (1,924,496) | (5,761,372) |
| Balance for common | (1,945,267) | (9,447,037) |
| Earnings common share | | |
| Primary | \$(0.01) | \$(0.10) |
| Fully Diluted | \$(0.01) | \$(0.10) |
| Common Shares: | | |
| Full Diluted | 125,973,113 | 95,075,293 |
| Year-end | 127,221,301 | 99,812,854 |

NOCOPI TECHNOLOGIES INC MD
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-----------|-----------|-----------|
| | | (revised) | (revised) |
| Licenses, royalties & fees | 563,200 | 3,613,000 | 809,900 |
| Product & other sales | 1,520,700 | 1,014,200 | 1,142,000 |
| Total revenues | 2,083,900 | 4,627,200 | 1,951,900 |
| Cost of revenues - licenses, royalties & fees | ... | 174,200 | 168,000 |

| | | | | |
|---|--------------------|------------------|---------------|--|
| Cost of revenues - product & other sales | ... | 553,500 | 570,100 | |
| Product and other sales | 767,900 | ... | ... | |
| Licenses, royalties and fees | 214,100 | ... | ... | |
| Total cost of revenues | ... | 727,700 | 738,100 | |
| Gross profit (loss) | 1,101,900 | 3,899,500 | 1,213,800 | |
| Research & development | 163,400 | 140,400 | 181,500 | |
| Sales & marketing | 270,800 | 494,500 | 287,700 | |
| General & administrative | 2,538,300 | 1,219,200 | 719,400 | |
| Total operating expenses | 2,972,500 | 1,854,100 | 1,188,600 | |
| Net income (loss) from operations | (1,870,600) | 2,045,400 | 25,200 | |
| Interest income | 326,900 | 64,200 | 20,700 | |
| Interest expense & bank charges | 14,900 | 2,000 | 2,200 | |
| Total other income (expenses) | 312,000 | 62,200 | 18,500 | |
| Net income (loss) before income taxes | (1,558,600) | 2,107,600 | 43,700 | |
| Current federal income taxes | (166,700) | 167,800 | ... | |
| Current state income taxes | (16,000) | 126,700 | (5,700) | |
| Deferred income taxes | (389,000) | ... | ... | |
| Net Income After Taxes | (1,435,900) | ... | ... | |
| Change in valuation allowance | 449,000 | ... | ... | |
| Income taxes | (122,700) | 294,500 | (5,700) | |
| Net income (loss) | (1,435,900) | 1,813,100 | 49,400 | |
| Weighted average common shares outstanding - basic | 9,667,845 | 7,584,511 | 6,743,615 | |
| Weighted average common shares outstanding - diluted | 9,667,845 | 7,584,511 | 6,743,615 | |
| Year end common shares outstanding | 10,501,178 | ... | 6,751,178 | |
| Income (loss) per common share from continuing operations - basic | \$(0.15) | ... | ... | |
| Net income (loss) per common share - basic | \$(0.15) | \$0.24 | 0.01 | |
| Net income (loss) per common share - diluted | \$(0.15) | \$0.24 | 0.01 | |
| Number of full time employees | 7 | 8 | 5 | |
| Number of part time employees | ... | ... | 1 | |
| Total number of employees | 7 | ... | ... | |
| Total number of common stockholders | ... | ... | 520 | |
| Diluted EPS | ... | ... | ... | |
| Excluding ExtraOrd Items | \$(0.15) | ... | ... | |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-10 stock split, September 2, 2022; □ Approximately; □ As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| | | (revised) |
| Cash | ... | 5,337,800 |
| Cash & cash equivalents | 2,269,200 | ... |
| Accounts receivables, gross | 1,132,700 | 1,115,500 |
| Less: allowance for doubtful accounts | 12,000 | 12,000 |
| Accounts receivable less allowance for doubtful | ... | ... |

| | | |
|---|-------------|-------------|
| accounts | 1,120,700 | ... |
| Accounts receivable | ... | 1,103,500 |
| Inventory | 448,000 | 486,400 |
| Prepaid & other current assets | ... | 103,300 |
| Prepaid and other | 121,800 | ... |
| Interest Receivable | 160,000 | ... |
| Short-term investments | 7,985,600 | ... |
| Total current assets | 12,105,300 | 7,031,000 |
| Leasehold improvements | 81,500 | 58,400 |
| Furniture, fixtures & equipment | 169,800 | 164,400 |
| Fixed assets, gross | 251,300 | 222,800 |
| Less: accumulated depreciation & amortization | 214,800 | 167,800 |
| Fixed assets, net | 36,500 | 55,000 |
| Long-term receivables | 1,838,500 | 2,463,100 |
| Operating lease right of use - building | 17,600 | 68,300 |
| Total assets | 13,997,900 | 9,617,400 |
| Accounts payable | 27,500 | 97,700 |
| Accrued expenses | 94,600 | 173,700 |
| Income taxes | ... | 287,100 |
| Operating lease liability - current | 17,600 | 50,700 |
| Accrued severance | 1,347,100 | ... |
| Total current liabilities | 1,486,800 | 609,200 |
| Accrued expenses, non-current | 128,600 | 172,200 |
| Operating lease liability - non-current | ... | 17,600 |
| Total other liabilities | 128,600 | 189,800 |
| Common stock | 105,000 | 92,500 |
| Paid-in capital | 21,647,100 | 16,659,600 |
| Retained earnings (accumulated deficit) | (9,369,600) | (7,933,700) |
| Total stockholders' equity (deficiency) | 12,382,500 | 8,818,400 |
| Total Equity | 12,382,500 | ... |

Recent Dividends:

1. Nocopi Technologies Inc MD common.

No dividends paid.

Annual Dividends:

1. Nocopi Technologies Inc MD common.

No dividends paid.

NON-INVASIVE MONITORING SYSTEMS INC.

Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------|------------------|------------------|
| Cost & expenses | 115,000 | 105,000 |
| Operating income | (115,000) | (105,000) |
| Interest expense | 27,000 | 14,000 |
| Net before taxes | (142,000) | ... |
| Net income | (142,000) | (119,000) |
| Earnings common share | | |
| Primary | \$(0.00) | \$... |
| Fully Diluted | \$(0.00) | \$... |
| Common Shares: | | |
| Full Diluted | 154,811,000 | 154,811,000 |
| Year-end | 154,810,655 | 154,810,655 |

NORTHERN MINERALS & EXPLORATION LTD.

Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|-----------------|-----------------|
| Cost & expenses | 85,736 | 77,403 |
| Operating income | (85,736) | (77,403) |
| Interest expense | 5,730 | 3,170 |
| Other income (expense), net | ... | 1,946 |
| Net before taxes | (91,466) | (78,627) |
| Net income | (91,466) | (78,627) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 90,195,743 | 82,509,357 |
| Year-end | 93,301,023 | 82,509,357 |

NOVA LIFESTYLE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [□] 2021 (revised) | operations - diluted | | | (accumulated deficit) | |
|--|--------------------|------------------------|--------------------------------|-------------------------|-----|-----------|--------------------------------------|-------------------|
| Total revenues | 11,087,459 | ... | ... | \$0.00 | ... | \$(12.90) | ... | (36,706,553) |
| Net sales | 11,087,459 | 12,744,871 | 12,556,219 | | | | Total stockholders' equity (deficit) | 496,354 6,611,830 |
| Cost of sales | 6,913,902 | 20,526,484 | 7,034,482 | | | | Total Equity | 496,354 ... |
| Gross profit (loss) | 4,173,557 | (7,781,613) | 5,521,737 | | | | | |
| Selling expenses | 2,417,479 | 2,885,249 | 3,728,810 | | | | | |
| General & administrative expenses | 5,056,500 | 5,555,489 | 5,653,475 | | | | | |
| Research & Development Expense | 3,118,126 | ... | ... | | | | | |
| Total operating expenses | 10,592,105 | 8,440,738 | 9,382,285 | | | | | |
| Income (loss) from operations | (6,418,548) | (16,222,351) | (3,860,548) | | | | | |
| Non-operating income (expense) | 19,979 | 550 | 31,668 | | | | | |
| Foreign exchange transaction income (loss) | (417,690) | (639,432) | 98,075 | | | | | |
| Interest income (expense), net | (9,495) | (25,216) | (123,144) | | | | | |
| Financial expense | 166,411 | 187,068 | 207,274 | | | | | |
| Total other income (expenses), net | (573,617) | (851,166) | (200,675) | | | | | |
| Income (loss) before income taxes & discontinued operations | (6,992,165) | (17,073,517) | (4,061,223) | | | | | |
| Current income tax expense (benefit) - federal | ... | ... | 161,493 | | | | | |
| Current income tax expense (benefit) - state | 2,400 | 2,400 | 2,400 | | | | | |
| Current income tax expense (benefit) - Hong Kong | 728,692 | ... | ... | | | | | |
| Total current income tax expense (benefit) | 731,092 | ... | ... | | | | | |
| Income tax expense (benefit) | 731,092 | 2,400 | 163,893 | | | | | |
| Income (loss) from continuing operations | (7,723,257) | (17,075,917) | (4,225,116) | | | | | |
| Income (loss) from discontinued operations | ... | (25,754) | (15,737,377) | | | | | |
| Net income (loss) | (7,723,257) | (17,101,671) | (19,962,493) | | | | | |
| Weighted average shares outstanding - basic | 1,556,555 | [□] 1,385,913 | 1,219,326 | | | | | |
| Weighted average shares outstanding - diluted | 1,556,555 | [□] 1,385,913 | 1,219,326 | | | | | |
| Year end shares outstanding | 1,917,706 | [□] 1,423,836 | 1,367,348 | | | | | |
| Net income (loss) per share from continuing operations - basic | \$(4.96) | [□] \$(12.30) | \$(3.45) | | | | | |
| Earnings per share-inc from discontinued oper | \$0.00 | ... | ... | | | | | |
| Net income (loss) per share from discontinued operations - basic | \$0.00 | [□] \$0.00 | \$(12.90) | | | | | |
| Net income (loss) per share - basic | \$(4.96) | [□] \$(12.35) | \$(16.35) | | | | | |
| Net income (loss) per share from continuing operations - diluted | \$(4.96) | [□] \$(12.30) | \$(3.45) | | | | | |
| Earn per share-inc from discount oper | \$0.00 | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | ... | | | | | |
| Accumulated other comprehensive income | 521,425 | 77,242 | ... | | | | | |
| Accumulated deficits | (44,429,810) | ... | ... | | | | | |
| Retained earnings | ... | ... | ... | | | | | |
| Net income (loss) per share from discontinued | ... | ... | ... | | | | | |
| operations - | | | | | | | | |
| diluted | | | | | | | | |
| Additional paid-in capital | 44,402,821 | 43,233,942 | | | | | | |

| | | |
|--|---------------|---------------|
| Cash | 53,063 | 6,346 |
| Accounts receivable, administrative fees | ... | 12,000 |
| Prepaid expenses | 33,540 | 40,561 |
| Total current assets | 86,603 | 58,907 |
| Investment in Netco | | |
| Partners | 133,709 | 137,011 |
| Investment in NewStem Ltd. | 1,784,234 | 2,090,286 |
| Note receivable, NewStem | 250,000 | ... |
| Total assets | 2,254,546 | 2,286,204 |
| Accounts payable | 54,257 | 21,203 |
| Notes payable | 250,000 | ... |
| Accrued expenses | 42,223 | 43,673 |
| Total current liabilities | 346,480 | 64,876 |
| Derivative liabilities | 535,000 | ... |
| Total long-term liabilities | 3,859,599 | ... |
| Long-term note payable, including accrued interest | 3,324,599 | 288,450 |
| Total liabilities | 4,206,079 | 353,326 |
| Class C common | 468,815 | ... |
| Common stock | ... | 468,815 |
| Additional paid-in capital | 290,907,217 | 290,604,327 |
| Accumulated deficit | (293,127,811) | ... |
| Retained earnings (accumulated deficit) | ... | (288,940,510) |
| Treasury stock | 199,754 | 199,754 |
| Total Novelstem International Corporation shareholders' equity | (1,951,533) | 1,932,878 |
| Total shareholders' equity | (1,951,533) | ... |

Recent Dividends:

1. NovelStem International Corp common.
No dividends paid.

Annual Dividends:

1. NovelStem International Corp common.
No dividends paid.

NOVO INTEGRATED SCIENCES INC

Earnings, 6 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 7,061,810 | 5,975,789 |
| Cost & expenses | 11,919,215 | 10,004,559 |
| Operating income | (4,857,405) | (4,028,770) |
| Interest income | 4,696 | 4,524 |
| Other income (expense), net | (2,069) | ... |
| Net before taxes | (7,406,283) | (8,581,898) |
| Net income | (7,406,283) | (8,581,898) |
| Earnings common share | | |
| Primary | \$(0.43) | \$(1.50) |
| Fully Diluted | \$(0.43) | \$(1.50) |
| Common Shares: | | |
| Full Diluted | 17,184,569 | 5,646,937 |
| Year-end | 17,748,320 | 13,962,658 |

NOWTRANSIT INC Annual Report

Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 08/31/22 | 08/31/21 (revised) |
|---|------------------|-----------------|--------------------|
| General & administrative expenses | 706,257 | 91,921 | 25,610 |
| Consulting fees | 29,650 | ... | ... |
| Total operating expenses | 735,907 | 91,921 | 25,610 |
| Net income (loss) from operations | (251,500) | (91,921) | (25,610) |
| Gain (loss) on forgiveness of debt | ... | 8,713 | ... |
| Total other income | ... | 8,713 | ... |
| Net income (loss) before income taxes | (251,500) | (83,208) | (25,610) |
| Net income (loss) | (251,500) | (83,208) | (25,610) |
| Weighted average shares outstanding - basic | 33,764,675 | 5,461,500 | 5,461,500 |
| Weighted average shares outstanding - diluted | 33,764,675 | 5,461,500 | 5,461,500 |

| | | | |
|--|------------|-----------|-----------|
| Year end shares outstanding | 40,896,221 | 5,461,500 | 5,461,500 |
| Net earning (loss) per share - basic | \$(0.01) | \$(0.02) | \$0.00 |
| Net earning (loss) per share - diluted | \$(0.01) | \$(0.02) | \$0.00 |
| Common Shareholders - Number | 38 | ... | ... |
| Number of stockholders | ... | 13 | 18 |
| Revenues | 597,595 | ... | ... |
| Total Revenue | 597,595 | ... | ... |
| Cost of goods sold | 113,188 | ... | ... |
| Gross profit | 484,407 | ... | ... |
| Cost of Revenues - Total | 113,188 | ... | ... |

Reclassified to conform with 2022 presentation; As of October 26, 2022; As of November 24, 2021

Consolidated Balance Sheet, Years Ended (\$):

| | 12/31/23 | 08/31/22 |
|---|-----------|-----------|
| Cash | ... | 16,253 |
| Cash and cash equivalents | 19,238 | ... |
| Accounts receivable, net | 36,448 | ... |
| Inventories - Finished Goods | 37,702 | ... |
| Inventory | 37,702 | ... |
| Total current assets | 93,388 | 16,253 |
| Total assets | 93,388 | 16,253 |
| Accounts payable | 7,675 | 1,860 |
| Accrued interest - related party | 1,450 | ... |
| Due to related parties | 87,074 | ... |
| Deferred revenue | 3,949 | ... |
| Total current liabilities | 100,148 | ... |
| Total liabilities | ... | 1,860 |
| Series A convertible preferred stock | 14 | 10 |
| Common stock | 4,089 | 546 |
| Additional paid-in capital | 417,220 | 131,237 |
| Accumulated deficit | (428,083) | ... |
| Retained earnings (accumulated deficit) | ... | (117,400) |
| Total stockholders' equity | (6,760) | 14,393 |
| Total Equity | (6,760) | ... |

Recent Dividends:

1. Nowtransit Inc series A convertible preferred.

No dividends paid.

2. Nowtransit Inc common.

No dividends paid.

Annual Dividends:

1. Nowtransit Inc series A convertible preferred.

No dividends paid.

2. Nowtransit Inc common.

No dividends paid.

NSTS BANCORP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-----------|-----------|----------------|
| Service charges on deposits | 270,000 | ... | ... |
| Equipment and occupancy | 739,000 | ... | ... |
| Interest income on loans, including fees | 4,360,000 | 3,618,000 | 3,569,000 |
| Interest income on securities - taxable | 2,506,000 | 2,013,000 | 1,107,000 |
| Interest income on securities - tax-exempt | 396,000 | 402,000 | 248,000 |
| Interest income on federal funds sold & other | 348,000 | 259,000 | 35,000 |
| Interest income on time deposits with | ... | ... | ... |

| | | | |
|--|--------------------|---------------|-----------------|
| other financial institutions | ... | 41,000 | 66,000 |
| Interest income on Federal Home Loan Bank stock | ... | 15,000 | 13,000 |
| FHLB Stock | 94,000 | ... | ... |
| FHLB Stock | 24,000 | ... | ... |
| Total interest income | 7,728,000 | 6,348,000 | 5,038,000 |
| Interest on deposits | 1,336,000 | 764,000 | 940,000 |
| Net interest income | ... | 5,584,000 | 4,098,000 |
| Provision for (reversal of) loan losses | 176,000 | (230,000) | (23,000) |
| Net interest income after reversal of provision for loan losses | ... | 5,814,000 | 4,121,000 |
| Gain on sale of mortgage loans | 32,000 | 106,000 | 410,000 |
| Gain (loss) on sale of securities | (1,794,000) | ... | 131,000 |
| Rental income on office building | ... | 53,000 | 42,000 |
| Service charges on deposits | ... | 291,000 | 289,000 |
| Increase in cash surrender value of bank owned life insurance (BOLI) | 192,000 | 178,000 | 181,000 |
| Other noninterest income | 86,000 | 608,000 | 156,000 |
| Rental income on office building | 64,000 | ... | ... |
| Total noninterest income | (1,150,000) | 1,236,000 | 1,209,000 |
| Salaries & employee benefits | 4,554,000 | 3,846,000 | 3,141,000 |
| Equipment & occupancy | ... | 658,000 | 665,000 |
| Data processing | 684,000 | 632,000 | 613,000 |
| Professional services | 140,000 | 500,000 | 139,000 |
| Advertising | 104,000 | 90,000 | 71,000 |
| Supervisory fees & assessments | ... | 142,000 | 126,000 |
| Loan expenses | 601,000 | 86,000 | 129,000 |
| Deposit expenses | 217,000 | 203,000 | 183,000 |
| Director fees | 216,000 | 223,000 | 225,000 |
| Other noninterest expense | 480,000 | 497,000 | 307,000 |
| Loan expenses | (117,000) | ... | ... |
| Total noninterest expense | 7,852,000 | 6,877,000 | 5,599,000 |
| Income (losses) before income taxes | (2,958,000) | 173,000 | (269,000) |
| Current federal income tax expense (benefit) | 9,000 | (133,000) | 62,000 |
| Current income tax expense (benefit) | 9,000 | (133,000) | 62,000 |
| Deferred tax expense (benefit) | ... | 64,000 | (379,000) |
| Change in valuation allowance | ... | 215,000 | 103,000 |
| Deferred income tax expense (benefit) | 990,000 | 279,000 | (276,000) |
| Income tax expense (benefit) | 999,000 | 146,000 | (214,000) |
| Net income (losses) | (3,957,000) | 27,000 | (55,000) |
| Weighted average shares outstanding - basic | 5,004,498 | 4,729,236 | ... |
| Weighted average shares outstanding - diluted | 5,004,498 | 4,729,236 | ... |
| Year end shares outstanding | 5,315,261 | 5,397,959 | ... |
| Earnings (loss) per share - basic | \$(0.79) | \$0.01 | ... |
| Earnings (loss) per share - diluted | \$(0.79) | \$0.01 | ... |
| Number of full time | ... | ... | ... |

| | | | |
|--|-----------|------------------|------------------|
| employees..... | 46 | ² 35 | ² 35 |
| Number of common stockholders..... | 229 | ² 280 | ² 280 |
| Net interest income after provision for (reversal of) credit losses..... | 6,044,000 | ... | ... |
| Net interest income .. | 6,220,000 | ... | ... |
| Other Borrowings..... | 172,000 | ... | ... |
| Total interest expense..... | 1,508,000 | ... | ... |
| Total number of employees..... | 46 | ... | ... |

¹ Reclassified to conform with 2022 presentation; ² Full-time equivalent employees; ³ As of March 27, 2023; ⁴ Approximately; ⁵ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash & due from banks..... | 1,000,000 | 1,583,000 |
| Interest-bearing bank deposits..... | 30,388,000 | 11,564,000 |
| Time deposits with other financial institutions..... | 1,991,000 | ... |
| Cash & cash equivalents..... | 31,388,000 | 13,147,000 |
| Time deposits with other financial institutions..... | ... | 4,477,000 |
| Securities available for sale..... | ... | 121,205,000 |
| Federal Home Loan Bank stock..... | 550,000 | 550,000 |
| Loans held for sale..... | 380,000 | ... |
| First mortgage loans - 1-to-4 family residential..... | ... | 95,584,000 |
| First mortgage loans - multi-family..... | ... | 3,237,000 |
| First mortgage loans - commercial..... | ... | 3,921,000 |
| Total first mortgage loans..... | ... | 102,742,000 |
| Consumer loans..... | ... | 249,000 |
| Total loans..... | ... | 102,991,000 |
| Net deferred loan costs..... | ... | 992,000 |
| Loans, net of unearned income..... | 121,799,000 | 103,983,000 |
| Allowance for loan losses..... | 1,176,000 | 624,000 |
| Loans, net..... | 120,623,000 | 103,359,000 |
| Land & improvements..... | 2,940,000 | 2,703,000 |
| Building & improvements..... | 7,012,000 | 6,768,000 |
| Furniture & equipment..... | 1,424,000 | 1,390,000 |
| Total gross equipment..... | 11,376,000 | 10,861,000 |
| Less: accumulated depreciation..... | 6,091,000 | 5,826,000 |
| Premises & equipment, net..... | 5,285,000 | 5,035,000 |
| Accrued interest receivable..... | 758,000 | 852,000 |
| Bank-owned life insurance (BOLI)..... | 9,441,000 | 9,249,000 |
| Other assets..... | 4,225,000 | 6,332,000 |
| Securities available for sale..... | 82,135,000 | ... |
| Total assets..... | 256,776,000 | 264,206,000 |
| Noninterest bearing..... | 12,424,000 | 12,977,000 |
| Demand & NOW checking..... | ... | 18,659,000 |
| Money market accounts..... | ... | 42,624,000 |
| Savings accounts..... | 15,346,000 | 49,068,000 |
| Time deposits over \$250,000..... | ... | 8,801,000 |
| Other time deposits..... | 1,382,000 | 46,585,000 |
| Savings..... | 41,774,000 | ... |
| Time deposits over \$250,000..... | 9,975,000 | ... |
| Other time deposits..... | 57,280,000 | ... |
| Money market..... | 32,027,000 | ... |
| Total deposits..... | ... | 178,714,000 |
| Escrow deposits..... | 168,826,000 | 1,253,000 |
| Other borrowings..... | 5,000,000 | ... |
| Accrued expenses & other liabilities..... | 4,023,000 | 3,697,000 |
| Total liabilities..... | 179,231,000 | 183,664,000 |
| Common stock..... | 56,000 | 54,000 |

| | | |
|---|-------------|--------------|
| Additional paid-in capital..... | 50,920,000 | ... |
| Additional paid-in capital..... | ... | 50,420,000 |
| Retained earnings (accumulated deficit)..... | 41,055,000 | 45,291,000 |
| Unallocated common shares held by employee stock ownership plan ("ESOP")..... | ... | (4,098,000) |
| Accumulated other comprehensive income (loss), net..... | (8,223,000) | (11,125,000) |
| Unallocated common shares held by ESOP..... | (3,882,000) | ... |
| Treasury Stock, at cost (269,898 shares at 31, 2023)..... | 2,381,000 | ... |
| Total stockholders' equity..... | 77,545,000 | 80,542,000 |
| Total Equity..... | 77,545,000 | ... |

Recent Dividends:

1. NSTS Bancorp Inc common.

No dividends paid.

Annual Dividends:

1. NSTS Bancorp Inc common.

No dividends paid.

NU-MED PLUS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------------|------------------|-------------------------|
| General & administrative expense..... | 27,557 | 26,569 | 32,283 |
| Payroll expense..... | 41,800 | 24,095 | 267,458 |
| Rent expense..... | 12,900 | 12,971 | 23,040 |
| Professional & consulting fees..... | 38,269 | 116,265 | 507,299 |
| Depreciation expense..... | ... | 2,267 | 9,365 |
| Total operating expenses..... | 120,526 | 182,167 | 839,445 |
| Operating income (loss)..... | (120,526) | (182,167) | (839,445) |
| Gain on forgiveness of debt..... | ... | 50,000 | 9,384 |
| Gain on forgiveness of debt..... | ... | 3,000 | ... |
| Interest expense..... | 5,000 | 1,000 | ... |
| Total other income (expense)..... | (5,000) | 52,000 | 9,384 |
| Income (loss) before income taxes..... | (125,526) | (130,167) | (830,061) |
| Net income (loss)..... | (125,526) | (130,167) | (830,061) |
| Weighted average shares outstanding - basic..... | 81,673,948 | 79,951,209 | 73,374,113 |
| Weighted average shares outstanding - diluted..... | 81,673,948 | 79,951,209 | 73,374,113 |
| Year end shares outstanding..... | 83,548,469 | 81,348,469 | ¹ 79,348,469 |
| Net earnings (loss) per share - basic..... | \$0.00 | \$0.00 | \$(0.01) |
| Net earnings (loss) per share - diluted..... | \$0.00 | \$0.00 | \$(0.01) |
| Full-Time Employees (Period End)..... | 2 | ... | ... |
| Total number of employees..... | 2 | 2 | 2 |
| Number of common stockholders..... | 179 | ² 159 | ² 163 |

¹ Shares increased due to the effect of issuance of common stock for subscription agreements and cash stock based compensation; ² Approximately; ³ As of March 27, 2023; ⁴ As of March 26, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-----------|-------|--------|
| Cash..... | 6,806 | 73,195 |

| | | |
|--|-------------|-------------|
| Prepaid expense..... | 6,650 | 6,350 |
| Total current assets..... | 13,456 | 79,545 |
| Computer & office equipment..... | ... | 90,368 |
| Less: accumulated depreciation..... | ... | 90,368 |
| Total assets..... | 13,456 | 79,545 |
| Accounts payable..... | 8,089 | 7,192 |
| Accounts payable - related party..... | 46,118 | 34,378 |
| Notes payable..... | ... | 100,000 |
| Accrued expense..... | 6,000 | 1,000 |
| Loan payable, due on demand..... | 100,000 | ... |
| Total current liabilities..... | 160,207 | 142,570 |
| Total liabilities..... | 160,207 | 142,570 |
| Common stock..... | 83,549 | 81,349 |
| Additional paid-in capital..... | 9,594,687 | 9,555,087 |
| Retained earnings (accumulated deficit)..... | (9,824,987) | (9,699,461) |
| Total stockholders' equity (deficit)..... | (146,751) | (63,025) |
| Total Equity..... | (146,751) | ... |

Recent Dividends:

1. Nu-Med Plus Inc common.

No dividends paid.

Annual Dividends:

1. Nu-Med Plus Inc common.

No dividends paid.

NUTEX HEALTH INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 |
|--|-------------|-------------|-------------------|
| Stock-based compensation..... | 2,835,971 | ... | ... |
| Total sales..... | ... | ... | 18,793,783 |
| Capitation revenue, net..... | ... | ... | 16,620,488 |
| SaaS revenue..... | ... | ... | 1,653,806 |
| Management service revenue, net..... | ... | ... | 519,489 |
| Revenue - hospital division..... | 218,070,397 | 198,508,245 | ... |
| Revenue - population health management division..... | 29,575,919 | 20,786,061 | ... |
| Total revenue..... | 247,646,316 | 219,294,306 | ... |
| Cost of sales..... | ... | ... | 14,647,045 |
| Payroll expense..... | 108,377,938 | 102,892,734 | ... |
| Contract services..... | 42,349,982 | 37,567,131 | ... |
| Medical supplies..... | 14,151,140 | 12,118,893 | ... |
| Insurance expense..... | ... | 9,718,723 | ... |
| Depreciation & amortization expense..... | 17,591,572 | 13,131,374 | ... |
| Other expense..... | 30,401,513 | 30,413,069 | ... |
| Total operating costs & expenses..... | 212,872,145 | 205,841,924 | ... |
| Gross profit (loss)..... | 34,774,171 | 13,452,382 | 4,146,738 |
| Research & development expenses..... | ... | ... | 285,880 |
| Sales & marketing expenses..... | ... | ... | 24,449 |
| General & administrative expenses..... | 33,229,718 | 18,030,832 | 12,177,316 |
| Acquisition costs..... | 43,464 | 3,885,666 | ... |
| Impairment of goodwill..... | 1,139,297 | 398,135,038 | ... |
| Amortization..... | ... | ... | 677,168 |
| Facilities closing costs..... | 217,266 | ... | ... |
| Impairment of assets..... | 29,082,203 | ... | ... |
| Total operating expenses..... | ... | ... | 13,164,813 |
| Total corporate & other costs..... | 66,547,919 | 420,051,536 | ... |
| Operating income..... | ... | ... | ... |

| | | | |
|--|--------------|---------------|--------------|
| (loss) | (31,773,748) | (406,599,154) | (9,018,075) |
| Interest expense, net | 16,317,869 | 12,490,260 | ... |
| Other income (expense) | (399,182) | (559,299) | ... |
| Settlement payment from Accountable Care Medical Group of Florida, Inc. | ... | ... | 522,000 |
| Income from forgiveness of debt | ... | ... | 636,807 |
| Interest income | ... | ... | 917 |
| Interest expense - debt obligation | ... | ... | 784,012 |
| Interest expense - accretion of debt discount | ... | ... | 6,011,071 |
| Total other income (expenses) | ... | ... | (5,635,359) |
| Income (loss) before taxes | (48,490,799) | (419,648,713) | ... |
| Current income tax provision (benefit) - federal | (187,842) | 6,396,753 | ... |
| Current income tax provision (benefit) - state | 828,067 | 1,682,682 | ... |
| Deferred income tax provision (benefit) - federal | (4,156,778) | 4,292,445 | (984,810) |
| Deferred income tax provision (benefit) - state | (1,550,531) | 719,025 | ... |
| Income tax expense (benefit) - deferred | ... | ... | (984,810) |
| Income tax provision (benefit) | (5,067,084) | 13,090,905 | ... |
| Income (loss) from continuing operations | ... | ... | (14,653,434) |
| Net income (loss) | (43,423,715) | (432,739,618) | (13,668,624) |
| Net income attributable to noncontrolling interest | (2,362,899) | 7,959,172 | (891) |
| Net income (loss) attributable to Clinigence Holdings, Inc. | ... | ... | (13,669,515) |
| Net income (loss) attributable to Nutex Health Inc. | (45,786,614) | (424,780,446) | ... |
| Weighted average shares outstanding - basic | 44,083,197 | 42,325,175 | 2,488,337 |
| Weighted average shares outstanding - diluted | 44,083,197 | 42,325,175 | 2,488,337 |
| Year end shares outstanding | 45,111,994 | 43,348,256 | 3,215,472 |
| Earnings (loss) per share from continuing operations - basic | \$(1.05) | ... | \$(5.55) |
| Net earnings (loss) per common share - basic | \$(1.05) | \$(10.05) | \$(5.55) |
| Earnings (loss) per share from continuing operations - diluted | \$(1.05) | ... | \$(5.55) |
| Net earnings (loss) per common share - diluted | \$(1.05) | \$(10.05) | \$(5.55) |
| Number of full time employees | 800 | ... | 24 |
| Total number of employees | 800 | 1,150 | ... |
| Number of common stockholders | 870 | 953 | 942 |

2021 and prior periods financial for Clinigence Holdings, Inc. prior to reverse merger with Nutex Health Holdco LLC; Adjusted for 1-for-15 stock split, April 10, 2024; Shares increased due to the effect of issuance of common stock for cash, related party note payable, business acquisitions, and conversion of notes payable, warrants and options; Approximately; As of March 31, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash & cash equivalents | 22,002,056 | 34,255,264 |
| Accounts receivable | 58,624,301 | 57,777,386 |
| Accounts receivable - related parties | 4,152,068 | 538,183 |
| Inventories | 3,390,584 | 3,533,285 |
| Prepaid expenses & other current assets | 2,679,394 | 1,869,806 |
| Total current assets | 90,848,403 | 97,973,924 |
| Buildings & improvements | 9,878,325 | 8,521,996 |
| Land | 4,401,888 | 3,721,576 |
| Leasehold improvements | 27,606,383 | 28,855,239 |
| Construction in progress | 12,845,631 | 19,389,329 |
| Medical equipment | 33,519,026 | 28,744,664 |
| Office furniture & equipment | ... | 2,860,680 |
| Computer hardware & software | 3,698,874 | 1,713,434 |
| Vehicles | 135,590 | 135,590 |
| Signage | 1,576,475 | 1,163,722 |
| Computer software | 6,066,520 | ... |
| Property & equipment, gross | 99,728,712 | 95,106,230 |
| Less: accumulated depreciation | 18,341,063 | 13,011,878 |
| Property & equipment, net | 81,387,649 | 82,094,352 |
| Operating right-of-use assets | 11,853,082 | 20,466,632 |
| Financing right-of-use assets | 176,146,329 | 192,591,624 |
| Intangible assets, net | 20,512,636 | 21,191,390 |
| Goodwill, net | 17,066,263 | 17,010,637 |
| Other assets | 431,135 | 423,426 |
| Total assets | 398,245,497 | 431,751,985 |
| Accounts payable | 18,899,196 | 23,614,387 |
| Accounts payable - related parties | 6,382,197 | 3,915,661 |
| Lines of credit | ... | 2,623,479 |
| Current portion of long-term debt | 10,808,721 | 12,546,097 |
| Operating lease liabilities, current portion | 1,579,987 | 1,703,014 |
| Financing lease liabilities, current portion | 4,315,979 | 4,219,518 |
| Accrued wages & benefits | 6,590,710 | 4,235,167 |
| Accrued taxes | ... | 1,029,790 |
| Accrued other | 6,364,586 | 975,856 |
| Accrued expenses & other current liabilities | 12,955,296 | 6,240,813 |
| Loans payable - stockholders | 3,371,676 | ... |
| Total current liabilities | 58,313,052 | 54,862,969 |
| Term loans | ... | 35,710,051 |
| Line of credit | ... | 2,623,479 |
| Total debt | ... | 38,333,530 |
| Less: unamortized debt issuance costs | ... | (112,802) |
| Less: short-term lines of credit | ... | (2,623,479) |
| Less: current portion of long-term debt | ... | 12,546,097 |
| Long-term debt, net | 26,314,733 | 23,051,152 |
| Operating lease liabilities, net | 15,479,639 | 19,438,497 |
| Financing lease liabilities, net | 213,886,213 | 203,619,756 |
| Deferred tax liabilities | 5,145,754 | 10,452,211 |
| Total liabilities | 319,139,391 | 311,424,585 |
| Common stock | 676,680 | 650,224 |
| Additional paid-in capital | 469,849,049 | 458,498,402 |
| Retained earnings | ... | ... |

| | | |
|--|---------------|---------------|
| (accumulated deficit) | (409,072,539) | (363,285,925) |
| Nutex Health Inc. equity (deficit) | 61,453,190 | 95,862,701 |
| Noncontrolling interests | 17,652,916 | 24,464,699 |
| Total equity (deficit) | 79,106,106 | 120,327,400 |

Recent Dividends:
1. Nutex Health Inc common.
 No dividends paid.

Annual Dividends:
1. Nutex Health Inc common.
 No dividends paid.

NUVEEN CORE PLUS IMPACT FUND
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|---------------|-------------|
| Dividend income | 1,628,517 | 2,328,908 | 882,707 |
| Interest income | 28,093,315 | 29,405,221 | 13,858,493 |
| Tax withheld | ... | ... | (33,255) |
| Foreign tax withheld on dividend income | (12,099) | (4,705) | ... |
| Foreign tax withheld from interest income | ... | 270 | ... |
| Total investment income | 29,709,733 | 31,729,154 | 14,707,945 |
| Management fees | ... | 6,433,668 | 4,501,506 |
| Interest expense | ... | ... | 732,193 |
| Interest expense & amortization of offering costs | 12,766,241 | 5,600,982 | ... |
| Custodian fees | ... | 32,006 | 168,106 |
| Trustees fees | 30,324 | 14,309 | 19,590 |
| Professional fees | 66,978 | 166,741 | 199,948 |
| Shareholder reporting expenses | 63,016 | 26,638 | 104,764 |
| Shareholder servicing agent fees | 30,799 | 12,835 | 8,034 |
| Stock exchange listing fees | 8,672 | 18,338 | ... |
| Investor relations expenses | 97,835 | 45,783 | 35,660 |
| Other expenses | 5,289,100 | 12,629 | 2,368 |
| Professional fees | 221,549 | ... | ... |
| Other | 65,055 | ... | ... |
| Total expenses | 18,639,569 | 12,363,929 | 5,772,169 |
| Net investment income (loss) | 11,070,164 | 19,365,225 | 8,935,776 |
| Realized gain (loss) from investments | (36,132,614) | ... | ... |
| Net realized gain (loss) from investments & foreign currency | ... | (21,474,209) | 848,644 |
| Net realized gain forward foreign currency exchange contracts | 82,081 | 700,236 | 283,146 |
| Net realized gain (loss) from swaps | 824,930 | 373,177 | 156,234 |
| Change in unrealized appreciation (depreciation) of investments & foreign currency | ... | (178,993,983) | (1,252,416) |
| Change in unrealized appreciation of swaps | ... | 3,406,635 | 1,765,747 |
| Foreign currency translation | ... | ... | ... |
| Net realized gain (loss) | (35,369,541) | ... | ... |
| Change in unrealized appreciation (depreciation) on investments | 46,780,664 | ... | ... |
| Change in | ... | ... | ... |

| | | |
|--|---------------|---------------|
| Security deposit, long-term | 27,690 | 8,682 |
| Total assets | 20,950,506 | 41,199,590 |
| Accounts payables | 1,694,325 | 2,390,422 |
| Accrued expenses | 4,632,101 | 3,347,399 |
| Deferred revenue | 1,030,056 | 1,221,497 |
| Operating lease liabilities - current | 856,250 | 824,326 |
| Other liabilities | 105,141 | 113,844 |
| Total current liabilities | 8,317,873 | 7,897,488 |
| Operating lease liabilities - noncurrent | 4,646,383 | 5,090,170 |
| Warrants liability | ... | 220,884 |
| Derivative liability - non-controlling redeemable preferred shares | 309,728 | 359,225 |
| Other long-term liabilities | 681,438 | 393,179 |
| Total liabilities | 13,960,043 | 13,960,946 |
| Redeemable non-controlling interests, preferred shares | 4,193,629 | 3,547,765 |
| Class D incentive units | 216,229 | 445,479 |
| Deferred underwriting compensation | 4,621 | ... |
| Common stock | 5,927 | 2,427 |
| Additional paid-in capital | 155,615,962 | 144,073,505 |
| Accumulated other comprehensive income (loss) | 93,676 | 76,182 |
| Retained earnings (accumulated deficit) | (148,240,859) | (116,956,528) |
| Nuvve holding corp. stockholders' equity (deficit) | 7,474,706 | 27,195,586 |
| Non-controlling interests | (4,894,101) | (3,950,186) |
| Total stockholders' equity (deficit) | 2,580,605 | 23,245,400 |

Recent Dividends:
1. Nuvve Holding Corp common.
 No dividends paid.
2. Nuvve Holding Corp series A convertible preferred.
 No dividends paid.
3. Nuvve Holding Corp ordinary shares subject to possible redemption.
 No dividends paid.
4. Nuvve Holding Corp Levo series B redeemable preferred.
 No dividends paid.
5. Nuvve Holding Corp class D incentive unit.
 No dividends paid.
6. Nuvve Holding Corp ordinary share.
 No dividends paid.

Annual Dividends:
1. Nuvve Holding Corp common.
 No dividends paid.
2. Nuvve Holding Corp series A convertible preferred.
 No dividends paid.
3. Nuvve Holding Corp ordinary shares subject to possible redemption.
 No dividends paid.
4. Nuvve Holding Corp Levo series B redeemable preferred.
 No dividends paid.
5. Nuvve Holding Corp class D incentive unit.
 No dividends paid.
6. Nuvve Holding Corp ordinary share.
 No dividends paid.

OCEAN THERMAL ENERGY CORP (NEW)
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-----------------------------------|---------|---------|---------|
| Salaries & wages expenses | ... | ... | 830,655 |
| Professional fees | 451,717 | ... | 958,101 |
| General & administrative expenses | 138,048 | 170,160 | 193,125 |
| Warrant expense | ... | 557,055 | ... |
| Salaries and | | | |

| | | | |
|---|--------------------|--------------------|--------------------|
| compensation | 888,790 | 791,392 | ... |
| Total operating expenses | 1,478,555 | 1,518,607 | 1,981,881 |
| Net income (loss) from operations | (1,478,555) | (1,518,607) | (1,981,881) |
| Other income (expense) | 12,000 | ... | ... |
| Interest expense, net & loan default penalty | 2,186,557 | 1,815,800 | 1,745,194 |
| Amortization of debt discount | ... | ... | 362,259 |
| Change in fair value of derivative liability | (5,409,047) | (3,428,245) | 1,305,482 |
| Gain on conversion of debt | (88,540) | (210,351) | 113,215 |
| Gain on forgiveness of debt | 22 | 60,901 | ... |
| Total other income (expense) | (7,672,122) | (5,393,495) | (688,756) |
| Income (loss) before income taxes | (9,150,677) | (6,912,102) | (2,670,637) |
| Net profit (loss) | (9,150,677) | (6,912,102) | (2,670,637) |
| Weighted average shares outstanding - basic | 184,370,469 | 178,959,510 | 158,566,304 |
| Weighted average shares outstanding - diluted | 184,370,469 | 178,959,510 | 158,566,304 |
| Year end common shares outstanding | 184,370,469 | 184,370,469 | 174,370,469 |
| Income (loss) per share - continuing operations - basic | \$(0.05) | \$(0.04) | ... |
| Net income (loss) per common share - basic | \$(0.05) | \$(0.04) | \$(0.02) |
| Income (loss) per share - continuing operations - basic - diluted | \$(0.05) | \$(0.04) | \$(0.02) |
| Number of full time employees | 2 | 2 | ... |
| Total number of employees | 2 | 2 | 3 |
| Number of common stockholders | 1,470 | 1,474 | 1,478 |

□ Shares increased due to the effect of common stock issued for conversion pf notes payable and second commitment fee; □ Approximately; □ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 115,149 | 1,404 |
| Prepaid expenses | 5,000 | 5,000 |
| Total current assets | 120,149 | 6,404 |
| Total assets | 120,149 | 6,404 |
| Accounts payable & accrued expense | 22,524,164 | 20,517,881 |
| Convertible notes payable - related party | 117,500 | 114,721 |
| Notes payable | 3,649,431 | 3,655,932 |
| Convertible note payable, net | 2,570,412 | 2,531,401 |
| Derivative liability | 12,404,707 | 6,998,262 |
| Loans from shareholder | 2,294,170 | 2,329,473 |
| Advances payable - related party, net | 61,468 | 57,760 |
| Total current liabilities | 43,621,852 | 36,205,430 |
| Total liabilities | 43,621,852 | 36,205,430 |
| Preferred stock, series B | 519 | 519 |
| Preferred stock, series C | 2,300 | 2,300 |
| Preferred Stock, Series D, \$0001 par value; 1,400 shares authorized, 984 and 278 shares issued and outstanding, respectively | 1 | ... |
| Common stock | 184,371 | 184,371 |

| | | |
|---|---------------|--------------|
| Additional paid-in capital | 61,958,401 | 60,110,402 |
| Retained earnings (accumulated deficit) | (105,647,295) | (96,496,618) |
| Total stockholders' equity (deficiency) | (43,501,703) | (36,199,026) |
| Rep Total Equity & Minority Interest | (43,501,703) | (36,199,026) |

Recent Dividends:
1. Ocean Thermal Energy Corp (New) series C preferred.
 No dividends paid.
2. Ocean Thermal Energy Corp (New) common.
 No dividends paid.
3. Ocean Thermal Energy Corp (New) series D preferred.
 No dividends paid.
4. Ocean Thermal Energy Corp (New) series B preferred.
 No dividends paid.
5. Ocean Thermal Energy Corp (New) series A preferred.
 No dividends paid.
Annual Dividends:
1. Ocean Thermal Energy Corp (New) series C preferred.
 No dividends paid.
2. Ocean Thermal Energy Corp (New) common.
 No dividends paid.
3. Ocean Thermal Energy Corp (New) series D preferred.
 No dividends paid.
4. Ocean Thermal Energy Corp (New) series B preferred.
 No dividends paid.
5. Ocean Thermal Energy Corp (New) series A preferred.
 No dividends paid.

OCUGEN INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|---------------------|---------------------|
| Collaborative arrangement revenue | 6,036,000 | 2,488,000 | ... |
| Total revenues | 6,036,000 | 2,488,000 | ... |
| Research & development expenses | 39,573,000 | 56,159,000 | 35,108,000 |
| General & administrative expenses | 31,994,000 | 35,400,000 | 22,920,000 |
| Total operating expenses | 71,567,000 | 91,559,000 | 58,028,000 |
| Income (loss) from operations | (65,531,000) | (89,071,000) | (58,028,000) |
| Other income (expense), net | 2,453,000 | 2,267,000 | (389,000) |
| Income (loss) before income taxes | (63,078,000) | (86,804,000) | (58,417,000) |
| Income tax expense (benefit) | ... | ... | (52,000) |
| Net income (loss) | (63,078,000) | (86,804,000) | (58,365,000) |
| Weighted average shares outstanding - basic | 244,327,057 | 214,600,051 | 195,013,043 |
| Weighted average shares outstanding - diluted | 244,327,057 | 214,600,051 | 195,013,043 |
| Year end shares outstanding | 256,566,804 | 221,599,682 | 199,380,683 |
| Net earnings (loss) per common share - basic | \$(0.26) | \$(0.40) | \$(0.30) |
| Net earnings (loss) per common share - diluted | \$(0.26) | \$(0.40) | \$(0.30) |
| Number of full time employees | ... | ... | 56 |
| Number of common stockholders | 23 | ... | 17 |

□ Restated to reflect correction of errors; □ Reclassified to conform with 2022 presentation; □ As of February 15, 2022; □ Approximately; □ As of February 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------|------------|------------|
| Cash & cash equivalents | 39,462,000 | 77,563,000 |

| | | | | | | | | |
|---|---------------|---------------------------------------|---|---------------|----------------------------------|--|--------------|-------------|
| Marketable securities | 13,371,000 | Research & development expenses | 5,602,000 | 4,197,000 | 2,002,000 | Computers & computer software | 237,000 | 182,000 |
| Total current assets | 42,971,000 | 98,492,000 | Selling & marketing expenses .. | 699,000 | 908,000 | Leasehold improvements, office furniture and equipment- Gross | 171,000 | ... |
| Furniture & fixtures | 337,000 | Machinery & equipment | 1,557,000 | 1,685,000 | Salaries & related expense | 1,027,000 | 1,144,000 | |
| Leasehold improvements | 2,086,000 | 1,603,000 | Construction in progress | 14,540,000 | 3,049,000 | Stock-based compensation | 903,000 | 1,483,000 |
| Financing lease right-of-use asset | 337,000 | ... | Professional services | 859,000 | 1,193,000 | Patents | 292,000 | 798,000 |
| Total property & equipment, gross | 18,520,000 | 6,674,000 | Depreciation | 34,000 | 29,000 | Insurance | 337,000 | 386,000 |
| Less: accumulated depreciation - property & equipment | 1,230,000 | 621,000 | Vehicle expenses | 73,000 | 99,000 | Rent & maintenance & other expenses | 181,000 | 120,000 |
| Property & equipment, net | 17,290,000 | 6,053,000 | Other current liabilities | 13,343,000 | 9,900,000 | VAT provision | (129,000) | 229,000 |
| Other assets | 4,286,000 | 4,087,000 | Accrued other | 151,000 | ... | General & administrative expenses | 4,431,000 | 3,577,000 |
| Total assets | 64,547,000 | 108,632,000 | Clinical | 84,000 | ... | Operating income (loss) | (10,633,000) | (9,439,000) |
| Accounts payable | 3,172,000 | 8,062,000 | Research and development | 212,000 | ... | Financing income (expenses), net | (988,000) | 59,000 |
| Accrued research & development expenses | 1,894,000 | 1,894,000 | Operating lease obligations | 574,000 | 498,000 | Other income | 200,000 | 30,000 |
| Accrued clinical expenses | 3,310,000 | 3,310,000 | Deferred revenue relating to collaborative arrangements | 10,525,000 | ... | Income (loss) before taxes on income | (9,445,000) | (9,468,000) |
| Accrued professional fees | 580,000 | 437,000 | Total current liabilities | 17,089,000 | 18,460,000 | Net income (loss) | (9,445,000) | (9,468,000) |
| Accrued employee-related expenses | 1,791,000 | 2,752,000 | Operating lease obligations, less current portion | 3,567,000 | 3,587,000 | Weighted average shares outstanding - basic | 9,668,000 | 7,122,000 |
| Accrued other expenses | 1,507,000 | 1,507,000 | EB-5 loan agreement | 2,800,000 | 2,289,000 | Weighted average shares outstanding - diluted | 9,668,000 | 7,122,000 |
| Accrued expenses & other current liabilities | 13,343,000 | 9,900,000 | Other non-current liabilities | 527,000 | 244,000 | Year end shares outstanding | 10,443,768 | 7,121,737 |
| Accrued other | 151,000 | ... | Total non-current liabilities | 6,894,000 | 6,120,000 | Net income (loss) per share - basic | \$(0.98) | \$(1.33) |
| Clinical | 84,000 | ... | Total liabilities | 23,983,000 | 24,580,000 | Net income (loss) per share - diluted | \$(0.98) | \$(1.33) |
| Research and development | 212,000 | ... | Common stock | 2,567,000 | 2,217,000 | Number of full time employees | 49 | 45 |
| Operating lease obligations | 574,000 | 498,000 | Series B convertible preferred stock | 1,000 | 1,000 | Number of common stockholders | 41 | 35 |
| Deferred revenue relating to collaborative arrangements | 10,525,000 | ... | Treasury stock | 48,000 | 48,000 | EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.98) | ... |
| Total current liabilities | 17,089,000 | 18,460,000 | Accumulated other comprehensive income | 20,000 | 26,000 | EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(0.98) | ... |
| Operating lease obligations, less current portion | 3,567,000 | 3,587,000 | Additional paid-in capital | 324,191,000 | 294,874,000 | Total number of employees | 49 | ... |
| EB-5 loan agreement | 2,800,000 | 2,289,000 | Accumulated deficit | (286,167,000) | ... | | | |
| Other non-current liabilities | 527,000 | 244,000 | Retained earnings (accumulated deficit) | ... | (213,018,000) | | | |
| Total non-current liabilities | 6,894,000 | 6,120,000 | Total stockholders' equity (deficit) | 40,564,000 | 84,052,000 | | | |
| Total liabilities | 23,983,000 | 24,580,000 | Total Equity | 40,564,000 | ... | | | |
| Common stock | 2,567,000 | 2,217,000 | | | | | | |
| Series B convertible preferred stock | 1,000 | 1,000 | | | | | | |
| Treasury stock | 48,000 | 48,000 | | | | | | |
| Accumulated other comprehensive income | 20,000 | 26,000 | | | | | | |
| Additional paid-in capital | 324,191,000 | 294,874,000 | | | | | | |
| Accumulated deficit | (286,167,000) | ... | | | | | | |
| Retained earnings (accumulated deficit) | ... | (213,018,000) | | | | | | |
| Total stockholders' equity (deficit) | 40,564,000 | 84,052,000 | | | | | | |
| Total Equity | 40,564,000 | ... | | | | | | |

Recent Dividends:**1. Ocugen Inc convertible preferred.**

No dividends paid.

2. Ocugen Inc series B convertible preferred.

No dividends paid.

3. Ocugen Inc common.

No dividends paid.

Annual Dividends:**1. Ocugen Inc convertible preferred.**

No dividends paid.

2. Ocugen Inc series B convertible preferred.

No dividends paid.

3. Ocugen Inc common.

No dividends paid.

ODYSIGHT AI INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---------------------------|-----------|-----------|-----------|
| Revenue | 3,033,000 | 665,000 | 387,000 |
| Cost of revenues | 2,524,000 | 1,631,000 | 1,108,000 |
| Gross profit (loss) | 509,000 | (966,000) | (721,000) |

¹ Reclassified to conform with 2022 presentation; ² Shares increased due to the effect of issuance of shares and warrants, exercise of warrants and share-based compensation; ³ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 8,945,000 | 10,099,000 |
| Short terms deposits | 8,096,000 | 3,047,000 |
| Account receivable | 1,372,000 | 60,000 |
| Raw materials & supplies | 445,000 | 438,000 |
| Work in process | 34,000 | 148,000 |
| Finished goods | 25,000 | 44,000 |
| Inventory | 504,000 | ... |
| Inventory | ... | 630,000 |
| Other current assets | 432,000 | 281,000 |
| Total current assets | 19,349,000 | 14,117,000 |
| Contract fulfillment assets | 1,256,000 | 1,495,000 |
| Machinery & laboratory equipment | 626,000 | 619,000 |
| Leasehold improvements, office furniture & equipment | 1,034,000 | 351,000 |

Recent Dividends:**1. Odysight AI Inc common.**

No dividends paid.

Annual Dividends:**1. Odysight AI Inc common.**

No dividends paid.

OLB GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Processing and servicing costs | 21,181,499 | ... | ... |
| Transaction & processing fees | ... | 28,950,785 | 15,810,626 |
| Merchant equipment rental & sales | 89,532 | 64,900 | 131,802 |
| Revenue, net - cryptocurrency mining | 538,718 | 726,179 | 304,004 |
| Other revenue from monthly recurring subscriptions | 312,565 | 627,115 | 464,327 |
| Merchant equipment sales & other | 27,096,245 | ... | ... |
| Digital product revenue | 2,534,577 | ... | ... |
| Total revenue | 30,571,637 | 30,368,979 | 16,710,759 |
| Processing & servicing costs, excluding merchant portfolio amortization | ... | 23,152,397 | 13,480,212 |

| | | | |
|---|---------------------|--------------------|--------------------|
| Amortization expense | 4,172,117 | ... | ... |
| Amortization & depreciation expense | 3,664,488 | 1,703,401 | |
| Depreciation expense - cryptocurrency mining | 2,560,015 | 3,193,683 | 187,498 |
| Salaries & wages expenses | 3,817,508 | 3,073,598 | 2,126,451 |
| Professional fees | 2,336,785 | 964,541 | 1,590,520 |
| General & administrative expenses | 7,078,947 | 4,490,731 | 2,387,416 |
| Impairment - Fixed Assets | 12,902,788 | ... | ... |
| Total operating expenses | 38,539,438 | 21,475,498 | |
| Total operating expenses | 54,049,659 | ... | ... |
| Income (loss) from operations | (23,478,022) | (8,170,459) | (4,764,739) |
| Interest expense | 148,483 | ... | 116,737 |
| Gain on forgiveness of debt | ... | ... | 236,231 |
| Litigation expense | ... | ... | 333,158 |
| Other income | 40,320 | 383,190 | 45 |
| Realized gain (loss) on sale of cryptocurrency | 288,584 | ... | ... |
| Unrealized loss on investment | 23,662 | ... | ... |
| Total other income (expense) | 204,083 | 383,190 | (213,619) |
| Income (loss) before income taxes | (23,273,939) | ... | ... |
| Net loss attributed to noncontrolling interest | 93,276 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (23,180,663) | ... | ... |
| Net income (loss) | (23,273,939) | (7,787,269) | (4,978,358) |
| Less: preferred dividends (related parties) | 124,222 | 401,903 | 555,960 |
| Net income (loss) to common shareholders | (23,304,885) | (8,189,172) | (5,534,318) |
| Weighted average shares outstanding - basic | 15,203,708 | 14,678,990 | 7,918,263 |
| Weighted average shares outstanding - diluted | 15,203,708 | 14,678,990 | 7,918,263 |
| Year end shares outstanding | 15,217,905 | 15,207,714 | 11,984,396 |
| Net earnings (loss) per share - basic | \$(1.53) | \$(0.56) | \$(0.70) |
| Net earnings (loss) per share - diluted | \$(1.53) | \$(0.56) | \$(0.70) |
| Number of full time employees | 26 | 26 | 30 |
| Total number of employees | 26 | ... | ... |
| Number of common stockholders | 365 | 367 | 368 |
| Earnings per share from continuing operations | \$(1.53) | ... | ... |
| Earnings per share from continuing operations | \$(1.53) | ... | ... |

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|--------------|--------------|
| | 2023 | 2022 |
| Cash | 179,006 | 434,026 |
| Provision | 207,850 | ... |
| Accounts receivable, net | 674,740 | ... |
| - Balancing | 466,890 | 1,083,169 |
| Accounts receivable, net | 403,999 | ... |
| Notes receivable | 184,913 | 582,125 |
| Prepaid expenses | 312,103 | 1,288,951 |
| Other current assets | 273,662 | ... |
| Investment in equity securities | 1,820,573 | 3,388,271 |
| Total current assets | ... | 36,471 |
| Furniture & fixtures | 141,337 | 1,537,321 |
| Office equipment | ... | 182,345 |
| Computer software | ... | 113,676 |
| Leasehold improvements | 8,425,000 | 9,410,000 |
| Bitcoin mining equipment | ... | 409,296 |
| Plant & machinery | 186,600 | ... |
| Office Equipment | 409,296 | ... |
| Building | 2,383,396 | ... |
| Construction in Process | 11,545,629 | 11,689,109 |
| Property & equipment, gross | 5,673,878 | 4,363,897 |
| Less: accumulated depreciation | 5,871,751 | 7,325,212 |
| Property & equipment, net | 3,500,246 | 20,310,255 |
| Intangible assets, net | 8,139,889 | 6,858,216 |
| Goodwill | ... | 268,948 |
| Operating lease right-of-use assets | 395,952 | 502,917 |
| Other long-term assets | 17,907,838 | 35,265,548 |
| Total other assets | 19,728,411 | 38,653,819 |
| Total assets | ... | 513,266 |
| Accounts payable | 3,526,689 | ... |
| Accounts payable & accrued expenses | 1,017,708 | 378,206 |
| Accrued expenses | 418,606 | 294,384 |
| Preferred dividend payable (related parties) | 2,000,000 | 2,000,000 |
| Merchant portfolio purchase installment obligation | ... | 134,318 |
| Operating lease liability - current portion | 258,819 | 298,053 |
| Note payable - current portion | 12,678 | ... |
| Related party payable | 7,234,500 | 3,618,227 |
| Total current liabilities | 149,039 | 259,376 |
| Notes payable, net of current portion | ... | 138,439 |
| Operating lease liability - net of current portion | 7,383,539 | 4,016,042 |
| Total liabilities | ... | 10 |
| Series A preferred stock | 1,521 | 1,508 |
| Common stock | 109,988 | ... |
| Common Stock - Treasury/Repurchased | ... | 109,987 |
| Treasury stock, at cost | 68,909,001 | 68,140,480 |
| Additional paid-in capital | (56,574,896) | ... |
| Accumulated Deficit | ... | (33,394,233) |
| Retained earnings (accumulated deficit) | 10 | ... |
| Preferred Stock - Redeemable - Convertible | 12,225,648 | 34,637,777 |
| Total stockholders' equity (deficit) | 119,224 | ... |
| Noncontrolling interest | 12,344,872 | ... |
| Total Equity | ... | ... |

As reported by the Company

Recent Dividends:

- 1. OLB Group Inc common.**
No dividends paid.
- 2. OLB Group Inc series A preferred.**
No dividends paid.

Annual Dividends:

- 1. OLB Group Inc common.**
No dividends paid.
- 2. OLB Group Inc series A preferred.**

No dividends paid.

**OMNIQ CORP
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):
2023 2022 2021 (revised)

| | | | |
|---|---------------------|---------------------|---------------------|
| Oil revenues | 81,193,000 | ... | ... |
| Total revenues | 81,193,000 | 102,545,000 | 78,251,000 |
| Cost of goods sold | 65,485,000 | 80,441,000 | 61,582,000 |
| Gross profit | 15,708,000 | 22,104,000 | 16,669,000 |
| Research & development expenses | 2,154,000 | 1,826,000 | 1,873,000 |
| Selling, general & administrative expenses | 22,960,000 | 27,707,000 | 21,865,000 |
| Depreciation | 464,000 | 324,000 | 251,000 |
| Amortization | ... | 1,799,000 | 3,160,000 |
| Intangible amortization | 1,640,000 | ... | ... |
| Goodwill impairment expense | 14,686,000 | ... | ... |
| Total operating expenses | 41,904,000 | 31,656,000 | 27,149,000 |
| Income (loss) from operations | (26,196,000) | (9,552,000) | (10,480,000) |
| Interest expense | 3,303,000 | 3,496,000 | 2,515,000 |
| Other income (expenses) | (575,000) | (601,000) | 7,000 |
| Total other income (expenses) | (3,878,000) | (4,097,000) | (2,508,000) |
| Net income (loss) before income taxes | (30,074,000) | (13,649,000) | (12,988,000) |
| Provision (benefit) for income taxes - current | (643,000) | (35,000) | 156,000 |
| Total provision for income taxes | (643,000) | (35,000) | 156,000 |
| Net income (loss) | (29,431,000) | (13,614,000) | (13,144,000) |
| Net income attributable to non-controlling interest | ... | (67,000) | (218,000) |
| Net income (loss) attributable to OmniQ Corp | (29,431,000) | (13,681,000) | (13,362,000) |
| Less: dividends attributable to non-common stockholders' of OmniQ Corp | 32,000 | 206,000 | 77,000 |
| Net income (loss) attributable to common stockholders' of OmniQ Corp | ... | (13,820,000) | (13,439,000) |
| Non-common stockholder dividends attributable to non-controlling interest | ... | ... | 218,000 |
| Net income (loss) less non-common stockholder dividends | ... | (13,820,000) | (13,221,000) |
| Weighted average shares outstanding - basic | 8,412,494 | 7,576,434 | 6,082,763 |
| Weighted average shares outstanding - diluted | 8,412,494 | ... | ... |
| Year end shares outstanding | 10,675,802 | 7,714,780 | 7,459,534 |
| Earnings (loss) per share from continuing operations - basic | \$(3.50) | ... | ... |
| Net income (loss) per share - basic | \$(3.50) | \$(1.82) | \$(2.20) |
| Earnings (loss) per share from continuing operations - | ... | ... | ... |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock for common control acquisitions, exercise of warrants and conversion of preferred shares - related party; Shares increased due to the effect of exercise of warrants, issued for cash, director services and exercise of warrants due to related party; Approximately; As of March 28, 2023; As of March 18, 2022

| | | | | | | | | | | |
|---------------------|----------|-----|-----|---------------------------|---------------|--------------|---------------------|------------|------------|------------|
| diluted | \$(3.50) | ... | ... | Short term note payable | 240,000 | ... | Interest expense | 23,343 | 21,489 | 24,720 |
| Net income (loss) | | | | Total current liabilities | 72,705,000 | 73,541,000 | Impairment of | | | |
| per share - diluted | \$(3.50) | ... | ... | Notes payable | ... | 293,000 | investments | (88,945) | ... | ... |
| Number of full time | | | | Less current portion | ... | (293,000) | Reversal of | | | |
| employees | 160 | ... | 193 | Notes payable, related | | | allowance for | | | |
| Number of part time | | | | party, less current | | | obsolete inventory | 84,068 | ... | ... |
| employees | 22 | ... | ... | portion | 265,000 | ... | Total other income | | | |
| Total number of | | | | Accrued interest & | | | (expense) | (18,466) | (21,489) | 207,701 |
| employees | 182 | 216 | ... | accrued liabilities, | | | Income (loss) | | | |
| Foreign currency | | | | related party | ... | 72,000 | before income taxes | (214,606) | (195,909) | 18,209 |
| translation | | | | Total notes payable | ... | 11,627,000 | Current state | | | |
| adjustments | 365,000 | ... | ... | Less: current portion - | | | income taxes | | | |
| | | | | notes payable | ... | (11,572,000) | expense (benefit) | 800 | 800 | 800 |
| | | | | Notes payable, less | | | Current Tax - Total | 800 | ... | ... |
| | | | | current portion | ... | 55,000 | Income tax expense | | | |
| | | | | Lease liability | 1,011,000 | 1,404,000 | (benefit) | 800 | 800 | 800 |
| | | | | Accrued interest - | | | Net income (loss) | (215,406) | (196,709) | 17,409 |
| | | | | related parties | 73,000 | ... | Weighted average | | | |
| | | | | Other long term | | | shares outstanding | | | |
| | | | | liabilities | 452,000 | 265,000 | - basic | 21,948,091 | 21,948,091 | 21,600,189 |
| | | | | Total liabilities | 74,506,000 | 75,337,000 | Weighted average | | | |
| | | | | Series C preferred stock | 1,000 | 1,000 | shares outstanding | | | |
| | | | | Common stock | 11,000 | 8,000 | - diluted | 21,948,091 | 21,948,091 | 23,708,115 |
| | | | | Additional paid-in | | | Year end shares | | | |
| | | | | capital | 78,340,000 | 73,714,000 | outstanding | 21,948,091 | 21,948,091 | 21,948,091 |
| | | | | Accumulated (deficit) | (113,923,000) | ... | Net income (loss) | | | |
| | | | | Retained earnings | | | per share - basic | \$(0.01) | \$(0.01) | \$0.00 |
| | | | | (accumulated deficit) | ... | (84,460,000) | Net income (loss) | | | |
| | | | | Cumulative translation | | | per share - diluted | \$(0.01) | \$(0.01) | \$0.00 |
| | | | | adjustment | ... | (211,000) | Number of full time | | | |
| | | | | Accumulated other | | | employees | 6 | 6 | 6 |
| | | | | comprehensive income | | | Total number of | | | |
| | | | | (loss) | 551,000 | ... | employees | 6 | ... | ... |
| | | | | Total OmniQ Corp. | | | Number of common | | | |
| | | | | stockholders' equity | | | stockholders | 46 | 46 | 46 |
| | | | | (deficit) | (35,020,000) | (10,526,000) | Basic EPS Excluding | | | |
| | | | | Total equity (deficit) | (35,020,000) | (10,526,000) | ExtraOrdinary Items | \$(0.01) | ... | ... |
| | | | | | | | Diluted EPS | | | |
| | | | | | | | Excluding ExtraOrd | | | |
| | | | | | | | Items | \$(0.01) | ... | ... |

Reclassified to conform with 2022 presentation; Shares increased due to the effect of ESPP stock issuance, stock-based compensation, exercise and issuance of stock and warrant for services and acquisition, and conversion of equity and debt; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 1,678,000 | 1,311,000 |
| Accounts receivable | 18,654,000 | ... |
| Trade accounts receivable | 19,155,000 | 24,348,000 |
| Less allowance for doubtful accounts | 501,000 | 455,000 |
| Accounts receivable, net | ... | 23,893,000 |
| Raw materials | 457,000 | 649,000 |
| Inventory in transit | ... | 2,004,000 |
| Finished goods (less allowance) | 5,072,000 | 6,073,000 |
| Work in process | 737,000 | ... |
| Inventory | 6,028,000 | 8,726,000 |
| Prepaid expenses | 969,000 | 1,268,000 |
| allowance for obsolescence | (238,000) | ... |
| Other current assets | 25,000 | 473,000 |
| Total current assets | 27,354,000 | 35,671,000 |
| Office equipment, net of depreciation | 429,000 | ... |
| Manufacturing & lab equipment | 673,000 | 98,000 |
| Leasehold improvements | 647,000 | 521,000 |
| Software & computer equipment | ... | 987,000 |
| Furniture & equipment | 232,000 | 236,000 |
| Vehicle | 251,000 | 274,000 |
| Less: accumulated depreciation | 1,166,000 | 1,030,000 |
| Property & equipment, net | 1,066,000 | 1,086,000 |
| Goodwill | 1,788,000 | 16,542,000 |
| Trade name, gross | ... | 6,284,000 |
| Less: accumulated amortization - trade name | ... | 4,458,000 |
| Trade name, net | 1,377,000 | 1,826,000 |
| Customer relationships, gross | ... | 15,729,000 |
| Less: accumulated amortization - customer relationships | ... | 10,762,000 |
| Customer relationships, net | 3,777,000 | 4,967,000 |
| Other intangibles, gross | ... | 2,216,000 |
| Less: accumulated amortization - other intangibles | ... | 1,541,000 |
| Other intangibles, net | 504,000 | 675,000 |
| Right of use lease asset | 1,862,000 | 2,300,000 |
| Other assets | 1,758,000 | 1,744,000 |
| Total assets | 39,486,000 | 64,811,000 |
| Accounts payable & accrued liabilities | 56,741,000 | 54,736,000 |
| Line of credit | ... | 1,971,000 |
| Accrued payroll & sales tax | 1,537,000 | 2,633,000 |
| Notes payable - current portion | 10,196,000 | 11,572,000 |
| Lease liability - current portion | 885,000 | 942,000 |
| Notes payable, related parties - current portion | ... | 293,000 |
| Other current liabilities | 3,106,000 | 1,394,000 |

| | | |
|---|---------------|--------------|
| Notes payable, related party, less current portion | 265,000 | ... |
| Accrued interest & accrued liabilities, related party | ... | 72,000 |
| Total notes payable | ... | 11,627,000 |
| Less: current portion - notes payable | ... | (11,572,000) |
| Notes payable, less current portion | ... | 55,000 |
| Lease liability | 1,011,000 | 1,404,000 |
| Accrued interest - related parties | 73,000 | ... |
| Other long term liabilities | 452,000 | 265,000 |
| Total liabilities | 74,506,000 | 75,337,000 |
| Series C preferred stock | 1,000 | 1,000 |
| Common stock | 11,000 | 8,000 |
| Additional paid-in capital | 78,340,000 | 73,714,000 |
| Accumulated (deficit) | (113,923,000) | ... |
| Retained earnings (accumulated deficit) | ... | (84,460,000) |
| Cumulative translation adjustment | ... | (211,000) |
| Accumulated other comprehensive income (loss) | 551,000 | ... |
| Total OmniQ Corp. stockholders' equity (deficit) | (35,020,000) | (10,526,000) |
| Total equity (deficit) | (35,020,000) | (10,526,000) |

Recent Dividends:

1. OMNIQ Corp series B preferred.

No dividends paid.

2. OMNIQ Corp common.

No dividends paid.

3. OMNIQ Corp series A preferred.

No dividends paid.

4. OMNIQ Corp series C preferred.

No dividends paid.

Annual Dividends:

1. OMNIQ Corp series B preferred.

No dividends paid.

2. OMNIQ Corp common.

No dividends paid.

3. OMNIQ Corp series A preferred.

No dividends paid.

4. OMNIQ Corp series C preferred.

No dividends paid.

OMNITEK ENGINEERING CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--------------------------------------|-----------|-----------|----------------|
| Revenues | 1,055,314 | 1,070,787 | 1,097,467 |
| Total revenues | 1,055,314 | ... | ... |
| Cost of goods sold | 644,660 | 649,427 | 621,659 |
| Total cost of goods sold | ... | 649,427 | 621,659 |
| Gross margin | 410,654 | 421,360 | 475,808 |
| General & administrative expenses | 537,473 | 526,836 | 600,169 |
| Research & development expenses | 67,576 | 66,444 | 63,829 |
| Depreciation & amortization expenses | 1,745 | 2,500 | 1,302 |
| Total operating expenses | 606,794 | 595,780 | 665,300 |
| Income (loss) from operations | (196,140) | (174,420) | (189,492) |
| Other income (expense) | ... | ... | 32,100 |
| Forgiveness of debt | ... | ... | 200,321 |

| | | | |
|--|------------|------------|------------|
| Interest expense | 23,343 | 21,489 | 24,720 |
| Impairment of investments | (88,945) | ... | ... |
| Reversal of allowance for obsolete inventory | 84,068 | ... | ... |
| Total other income (expense) | (18,466) | (21,489) | 207,701 |
| Income (loss) before income taxes | (214,606) | (195,909) | 18,209 |
| Current state income taxes expense (benefit) | 800 | 800 | 800 |
| Current Tax - Total | 800 | ... | ... |
| Income tax expense (benefit) | 800 | 800 | 800 |
| Net income (loss) | (215,406) | (196,709) | 17,409 |
| Weighted average shares outstanding | | | |
| - basic | 21,948,091 | 21,948,091 | 21,600,189 |
| Weighted average shares outstanding | | | |
| - diluted | 21,948,091 | 21,948,091 | 23,708,115 |
| Year end shares outstanding | 21,948,091 | 21,948,091 | 21,948,091 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$0.00 |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$0.00 |
| Number of full time employees | 6 | 6 | 6 |
| Total number of employees | 6 | ... | ... |
| Number of common stockholders | 46 | 46 | 46 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

Reclassified to conform with 2022 presentation; Approximately; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash | 73,703 | 56,379 |
| Accounts receivable, net | 12,233 | 10,180 |
| Accounts receivable - related parties | 1,304 | 2,252 |
| Raw materials | 799,642 | 836,833 |
| Finished goods | 494,074 | 634,275 |
| Allowance for obsolete inventory | ... | 927,755 |
| Inventory Net - Balancing value | (922,878) | ... |
| Inventories, net | 370,838 | 543,353 |
| Deposits | 24,443 | 7,657 |
| Total current assets | 482,521 | 619,821 |
| Production equipment | 68,456 | 68,456 |
| Leasehold improvements | 4,689 | 4,689 |
| Less: accumulated depreciation | 67,478 | 65,733 |
| Property & equipment, net | 5,667 | 7,412 |
| Operating lease - right-of-use asset | 345,459 | 472,342 |
| Long-term deposit | 13,514 | 13,514 |
| Total assets | 847,161 | 1,113,089 |
| Accounts payable & accrued expenses | 323,236 | 353,591 |
| Accrued management compensation | 635,158 | 635,158 |
| Accounts payable - related parties | 131,285 | 127,192 |
| Notes payable - related parties, current portion | 37,940 | 15,000 |
| Convertible notes payable - related party | 10,000 | 32,827 |
| Customer deposits | 310,025 | 231,418 |
| Operating lease liabilities - current | 131,868 | 118,756 |
| Total current liabilities | 1,579,512 | 1,513,942 |
| Loans payable - small | ... | ... |

| | | |
|---|--------------|--------------|
| business administration ("SBA"), net of current portion | 199,000 | 199,000 |
| Operating lease liabilities - long-term | 254,339 | 386,207 |
| Total long-term liabilities | 453,339 | 585,207 |
| Total liabilities | 2,032,851 | 2,099,149 |
| Share capital | 8,607,086 | ... |
| Common stock | ... | 8,607,086 |
| Additional paid-in capital | 12,067,571 | 12,051,795 |
| Accumulated deficit | (21,860,347) | ... |
| Retained earnings (accumulated deficit) | ... | (21,644,941) |
| Total stockholders' equity (deficit) | (1,185,690) | (986,060) |
| Total Equity | (1,185,690) | ... |

Recent Dividends:

1. OmniTek Engineering Corp common.

No dividends paid.

Annual Dividends:

1. OmniTek Engineering Corp common.

No dividends paid.

ONCOLOGY INSTITUTE INC (THE)

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|---------------|--------------|----------------|
| Patient services revenue | 213,504,000 | 166,785,000 | 124,074,000 |
| Dispensary revenue | 79,343,000 | 72,550,000 | ... |
| Clinical trials & other revenue | 6,355,000 | 6,379,000 | ... |
| Dispensary | 103,835,000 | ... | ... |
| Clinical trials & other | 6,900,000 | ... | ... |
| Total operating revenue | 324,239,000 | 252,483,000 | 203,003,000 |
| Direct costs - patient services | 181,017,000 | 134,761,000 | 99,401,000 |
| Direct costs - dispensary | 83,071,000 | 65,111,000 | 62,102,000 |
| Direct costs - clinical trials & other | 578,000 | 518,000 | 652,000 |
| Goodwill impairment charges | 16,867,000 | 9,944,000 | ... |
| Selling, general & administrative expense | 113,851,000 | 119,689,000 | 83,365,000 |
| Depreciation & amortization | 5,873,000 | 4,411,000 | 3,341,000 |
| Total operating expenses | (401,257,000) | 334,434,000 | 248,861,000 |
| Income (loss) from operations | (77,018,000) | (81,951,000) | (45,858,000) |
| Interest expense, net | 6,777,000 | 4,082,000 | 320,000 |
| Change in fair value of derivative warrant liabilities | (286,000) | 1,843,000 | 3,686,000 |
| Change in fair value of earnout liabilities | 803,000 | 59,215,000 | 24,891,000 |
| Change in fair value of conversion option derivative liabilities | 878,000 | 24,200,000 | ... |
| Gain (loss) on loan forgiveness | ... | 183,000 | 4,957,000 |
| Other income (expense), net | ... | 501,000 | 1,046,000 |
| Other, net | (704,000) | ... | ... |
| Total other non-operating income (expense) | (6,086,000) | 81,860,000 | 34,260,000 |
| Income (loss) before income tax expense | (83,104,000) | (91,000) | (11,598,000) |
| Current U.S. federal income | ... | ... | ... |

| | | | |
|--|---------------------|----------------|---------------------|
| taxes | 83,000 | ... | (180,000) |
| Current state & local income taxes | (43,000) | 20,000 | 751,000 |
| Total current income taxes | 40,000 | 20,000 | 571,000 |
| Deferred U.S. federal income taxes | 2,000 | (135,000) | (904,000) |
| Deferred state & local income taxes | (78,000) | (128,000) | (338,000) |
| Total deferred income taxes | (76,000) | (263,000) | (1,242,000) |
| Income taxes (benefit) | (36,000) | (243,000) | (671,000) |
| Income (loss) attributable to participating securities | (15,191,000) | ... | ... |
| Net income (loss) | (83,068,000) | 152,000 | (10,927,000) |
| Weighted average shares outstanding - basic | 73,748,660 | 72,793,497 | 66,230,606 |
| Weighted average shares outstanding - diluted | 73,748,660 | 80,605,600 | 66,230,606 |
| Year end shares outstanding | 74,145,251 | 73,265,621 | 73,249,042 |
| Net income (loss) per share - basic | \$(0.92) | ... | \$(0.16) |
| Net income (loss) per share - diluted | \$(0.92) | \$(0.21) | \$(0.16) |
| Full-Time Employees (Period End) | 800 | ... | ... |
| Total number of employees | 800 | 750 | 658 |
| Number of common stockholders | 72 | 89 | 109 |
| Income tax benefit (expense) | (36,000) | ... | ... |

Reclassified to conform with 2022 presentation; Approximately, As of March 8, 2023; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash | 33,488,000 | ... |
| Cash & cash equivalents | ... | 14,010,000 |
| Marketable securities | 49,367,000 | 59,796,000 |
| Oral drug accounts receivable | ... | 4,165,000 |
| Capitated accounts receivable | ... | 1,623,000 |
| FFS accounts receivable | ... | 26,313,000 |
| Clinical trials accounts receivable | ... | 2,443,000 |
| Other trade receivables | 42,360,000 | 5,272,000 |
| Accounts receivable | ... | 39,816,000 |
| Other receivables | 551,000 | 617,000 |
| Oral drug inventory | ... | 2,130,000 |
| IV drug inventory | ... | 7,131,000 |
| Inventories, net | 13,678,000 | 9,261,000 |
| Prepaid expenses and other current assets | 4,049,000 | ... |
| Prepaid expenses | ... | 6,918,000 |
| Total current assets | 143,493,000 | 130,418,000 |
| Non-current investments | ... | 58,354,000 |
| Computers & software | 3,035,000 | 2,139,000 |
| Office furniture | 724,000 | 606,000 |
| Leasehold improvements | 9,214,000 | 6,655,000 |
| Medical equipment | 2,082,000 | 1,138,000 |
| Construction in progress | 1,801,000 | 1,144,000 |
| Finance lease right-of-use assets | 207,000 | 371,000 |
| Less: accumulated depreciation | 6,180,000 | 3,506,000 |
| Property, Plant & Equipment - Gross - Total | 17,063,000 | ... |
| Property & equipment, net | 10,883,000 | 8,547,000 |
| Operating lease right-of-use assets | 29,169,000 | 24,494,000 |
| Intangible assets, net | 17,904,000 | 17,957,000 |
| Goodwill | 7,230,000 | 21,418,000 |

| | | |
|---|---------------|--------------|
| Other assets | 561,000 | 477,000 |
| Total assets | 209,240,000 | 261,665,000 |
| Accounts payable | 14,429,000 | 9,372,000 |
| Current portion of operating lease liabilities | 6,363,000 | 5,498,000 |
| Income taxes payable | ... | 255,000 |
| Compensation, including bonuses, fringe benefits, & payroll taxes | 5,518,000 | 5,310,000 |
| Contract liabilities | ... | 1,139,000 |
| Directors & officers insurance premiums | ... | 3,010,000 |
| Deferred acquisition & contingent consideration | ... | 802,000 |
| Accrued interest | ... | 1,100,000 |
| Other liabilities | 3,601,000 | 3,234,000 |
| Accrued expenses & other current liabilities | 4,877,000 | 14,595,000 |
| Accrued expenses and other current liabilities - Balancing value | 13,996,000 | ... |
| Total current liabilities | 34,788,000 | 29,720,000 |
| Operating lease liabilities | 26,486,000 | 22,060,000 |
| Derivative warrant liabilities | 636,000 | 350,000 |
| Derivative earnout liabilities | ... | 803,000 |
| Conversion option derivative liabilities | 3,082,000 | 3,960,000 |
| Senior secured convertible note | ... | 110,000,000 |
| Less: unamortized debt issuance costs | ... | (3,454,000) |
| Less: unamortized debt discount | ... | (25,925,000) |
| Long term debt, net of unamortized debt discount & issuance costs | 86,826,000 | 80,621,000 |
| Other non-current liabilities | 365,000 | 868,000 |
| Deferred income taxes liability | 32,000 | 108,000 |
| Total liabilities | 152,215,000 | 138,490,000 |
| Common stock | 8,000 | 7,000 |
| Additional paid-in capital | 204,186,000 | 186,250,000 |
| Retained earnings (accumulated deficit) | (146,150,000) | (63,082,000) |
| Treasury Stock, 1,593,128 and 0 shares at 30, 2023 and 31, 2022 | 1,019,000 | ... |
| Total stockholders' equity (deficit) | 57,025,000 | 123,175,000 |
| Total Equity | 57,025,000 | ... |

Recent Dividends:

1. Oncology Institute Inc (The) common.

No dividends paid.

2. Oncology Institute Inc (The) class A common.

No dividends paid.

3. Oncology Institute Inc (The) class B common.

No dividends paid.

4. Oncology Institute Inc (The) Series A convertible preferred.

No dividends paid.

Annual Dividends:

1. Oncology Institute Inc (The) common.

No dividends paid.

2. Oncology Institute Inc (The) class A common.

No dividends paid.

3. Oncology Institute Inc (The) class B common.

No dividends paid.

4. Oncology Institute Inc (The) Series A convertible preferred.

No dividends paid.

ONCOTELIC THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|-----------------|--------|------|----------------|
| Service revenue | 70,000 | ... | ... |

due to initial public offering of class A common stock; [Ⓔ] As of April 1, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|--------------|-----------------------------|
| | 2023 | [Ⓔ] 2022 (revised) |
| Cash and cash equivalents | 47,008 | 301,730 |
| Prepaid expense | 165,538 | 100,945 |
| Accounts receivable, net of allowance | 151,640 | 18,975 |
| Receivable from SPAC IPO | | |
| Costs | | 900,152 |
| Investments held in Trust | | |
| Account | | 29,029,415 |
| Total current assets | 364,186 | 30,351,217 |
| accumulated depreciation | 183,415 | 179,895 |
| Computers - Gross | 246,578 | 259,207 |
| Furniture and equipment - Gross | 35,708 | 3,785 |
| Property, Plant & Equipment Net | 98,871 | 83,097 |
| Total assets | 463,057 | 30,434,314 |
| Excise tax | 113,353 | 69,966 |
| Amount due to related parties | 11,200 | 11,500 |
| Income tax payable | 120,017 | 214,850 |
| Accounts payable & accrued expenses | 4,184,398 | 2,814,570 |
| Deferred revenues | 253,997 | 183,683 |
| Canada Emergency Business Loan Act | 44,673 | |
| Loan Payable | 38,921 | |
| Pipe Notes, net of discount including interest | 1,549,820 | |
| Deferred underwriter fee payable | 3,525,000 | |
| loan extension | 2,991,679 | |
| Convertible promissory notes | | 8,490,000 |
| Total current liabilities | 12,833,058 | 11,784,569 |
| Warrant liabilities | 24,582 | 362,558 |
| Deferred underwriter fee payable | | 4,025,000 |
| Working capital loan | | 207,081 |
| Extension loans | | 2,545,839 |
| Loan, related party | 465,023 | 44,144 |
| Accrued interest | | 690,772 |
| Convertible promissory notes | | 1,500,000 |
| Total liabilities | 13,322,663 | 21,159,963 |
| Class A common stock | 2,357 | 425 |
| Class B common stock | | 59 |
| Additional paid-in capital | 42,220,714 | 24,032,561 |
| Accumulated deficit | (55,082,677) | (43,509,964) |
| Class A common stock subject to possible redemption; 10,597,751 shares at redemption value | | 28,750,110 |
| Preferred Shares A-1, par value \$00001, 4,400,000 shares authorized and, 3,204,000 shares issued and outstanding as of 30, 2023, and 31, 2022 | | 320 |
| Preferred Series A-2, par value \$00001, 4,200,000 shares authorized, and 3,861,197 shares issued and outstanding as of 30, 202 | | 385 |
| Common Stock - Issued & Paid | | 455 |
| Total stockholders' equity (deficit) | (12,859,606) | 9,274,351 |
| Total Equity | (12,859,606) | 9,274,351 |

[Ⓔ] Restated to reflect business combination

Recent Dividends:

1. OneMedNet Corp class A common stock subject to possible redemption.
No dividends paid.

2. OneMedNet Corp class B common.
No dividends paid.
3. OneMedNet Corp class A common.
No dividends paid.
Annual Dividends:
1. OneMedNet Corp class A common stock subject to possible redemption.
No dividends paid.
2. OneMedNet Corp class B common.
No dividends paid.
3. OneMedNet Corp class A common.
No dividends paid.

ONFOLIO HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|------------------------|------------------------|
| Revenue, services | 1,496,038 | 544,822 | 507,532 |
| Revenue, product sales | 3,743,948 | 1,674,993 | 1,301,011 |
| Total revenue | 5,239,986 | 2,219,815 | 1,808,543 |
| Cost of revenue, services | 1,159,267 | 356,957 | 447,325 |
| Total cost of revenue | 837,888 | | |
| Cost of revenue, product sales | | 664,405 | 626,185 |
| Total cost of revenue | 1,997,155 | 1,021,362 | 1,073,510 |
| Gross profit | 3,242,831 | 1,198,453 | 735,033 |
| Selling, general & administrative | 6,040,688 | 4,271,865 | 2,479,152 |
| Professional fees | 1,160,410 | 509,941 | 208,193 |
| Acquisition costs | 326,899 | 527,792 | |
| Impairment of goodwill and intangible assets | 3,952,433 | | |
| Total operating expenses | 11,480,430 | 5,309,598 | 2,687,345 |
| Income (loss) from operations | (8,237,599) | (4,111,145) | (1,952,312) |
| Equity method income | 13,190 | 34,432 | 50,684 |
| Dividend income | 1,610 | 3,193 | 9,970 |
| Interest expense | 75,041 | | |
| Interest income (expense), net | | (2,152) | (9,805) |
| Other income | 2,937 | 13,223 | |
| Impairment of investments | | 137,602 | |
| Gain (loss) on sale of asset | | (34,306) | |
| Total other income (expense) | 92,778 | (123,212) | 50,849 |
| Income (loss) before income taxes | (8,144,821) | (4,234,357) | (1,901,463) |
| Deferred tax expense (benefit) | | | (1,314) |
| Income tax provision (benefit) | | | (1,314) |
| Net income (loss) | (8,144,821) | (4,234,357) | (1,900,149) |
| Preferred dividends | 227,298 | 195,145 | 106,825 |
| Net income (loss) to common shareholders | (8,372,119) | (4,429,502) | (2,006,974) |
| Weighted average shares outstanding - basic | 5,107,395 | 3,285,934 | [Ⓔ] 2,080,733 |
| Weighted average shares outstanding - diluted | 5,107,395 | 3,285,934 | [Ⓔ] 2,080,733 |
| Year end shares outstanding | 5,107,395 | [Ⓔ] 5,110,195 | [Ⓔ] 2,353,645 |
| Net income (loss) per common share - basic | \$(1.64) | \$(1.35) | [Ⓔ] \$(0.96) |
| Net income (loss) per common share - diluted | \$(1.64) | \$(1.35) | [Ⓔ] \$(0.96) |
| Number of full time employees | 10 | 7 | 6 |
| Number of part time employees | 2 | 1 | 14 |

Number of common stockholders 67 [Ⓔ]78 [Ⓔ]113
Number of preferred stockholders ... [Ⓔ]68
Total number of employees 12 ...
[Ⓔ] Adjusted for 1-for-4.7619 reverse stock split, August 11, 2022;
[Ⓔ] Shares increased due to the effect of common stock sold for cash and stock based compensation; [Ⓔ] Approximately; [Ⓔ] As of April 11, 2023; [Ⓔ] As of August 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|-------------|
| Cash and cash equivalents | 982,261 | |
| Cash | | 6,701,122 |
| Accounts receivable, net | 90,070 | 137,598 |
| Inventory | 92,637 | 105,129 |
| Prepays & other current assets | 111,097 | 212,180 |
| Total current assets | 1,276,065 | 7,156,029 |
| Intangible assets | 3,110,204 | 3,864,618 |
| Goodwill | 1,167,194 | 4,209,126 |
| Due from related party | 150,974 | 111,720 |
| Investment in unconsolidated joint ventures, cost method | 273,042 | 154,007 |
| Investment in unconsolidated joint ventures, equity method | | 280,326 |
| Investments in Associates, Joint Ventures and Unconsolidated Subsidiaries | 154,007 | |
| Total assets | 6,131,483 | 15,775,826 |
| Accounts payable & other current liabilities | 493,816 | 550,454 |
| Dividends payable | 68,011 | 54,404 |
| Acquisition notes payable | 17,323 | 2,456,323 |
| Notes payable | | 68,959 |
| Contingent consideration | 60,000 | 60,000 |
| Deferred revenue | 149,965 | 113,251 |
| Total current liabilities | 789,115 | 3,303,391 |
| Total liabilities | 789,115 | 3,303,391 |
| Series A preferred stock | | 70 |
| Common stock | 5,108 | 5,110 |
| Additional paid-in capital | 21,107,311 | 19,950,774 |
| Accumulated other comprehensive income | 182,465 | 96,971 |
| Accumulated deficit | (15,952,609) | |
| Retained earnings (accumulated deficit) | | (7,580,490) |
| Series A Preferred stock, \$0001 par value, 1,000,000 shares authorized, 56,800 and 0 issued and outstanding at 31, 2021 and 2020, respectively | 93 | |
| Total stockholders' equity (deficit) | 5,342,368 | 12,472,435 |
| Total Equity | 5,342,368 | |

Recent Dividends:

1. Onfolio Holdings Inc series A preferred.

No dividends paid.

2. Onfolio Holdings Inc common.

No dividends paid.

Annual Dividends:

1. Onfolio Holdings Inc series A preferred.

No dividends paid.

2. Onfolio Holdings Inc common.

No dividends paid.

OPAL FUELS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓔ] 2021 |
|------------|------------|------|-------------------|
| RNG fuel | 66,292,000 | | |
| Revenues - | | | |

| | | | | | | | | | |
|--|-------------|--------------|--|-------------|-------------|------------|---|-------------|-------------|
| renewable natural gas ("RNG") Fuel | 126,830,000 | | diluted | 27,494,016 | 26,062,398 | 25,360,688 | ("CNG") or renewable natural gas ("RNG") | | |
| Revenues - fuel station services | 135,012,000 | 69,240,000 | Weighted average shares outstanding of class B ordinary shares - diluted | | | 7,611,848 | fueling stations | 51,749,000 | 34,567,000 |
| Revenues - renewable power | 54,804,000 | 39,461,000 | Year end shares outstanding | 172,464,400 | 173,876,803 | 38,895,381 | Construction in progress | 175,060,000 | 152,105,000 |
| Total revenues | 256,108,000 | 235,531,000 | Net income (loss) per class A common share - basic | \$0.70 | \$0.13 | \$(0.49) | Buildings | 2,585,000 | 2,585,000 |
| Cost of sales - RNG fuel | 32,028,000 | 78,953,000 | Net earnings (loss) per class B ordinary shares - basic | | | \$(0.49) | Land | 1,303,000 | 1,303,000 |
| Cost of sales - fuel station services | 115,322,000 | 61,514,000 | Net income (loss) per class A common share - diluted | \$0.69 | \$0.12 | \$(0.49) | Service equipment | 2,481,000 | 1,888,000 |
| Cost of sales - renewable power | 36,550,000 | 31,580,000 | Net earnings (loss) per class B ordinary shares - diluted | | | \$(0.49) | Leasehold improvements | 815,000 | 815,000 |
| Selling, general, & administrative | 51,262,000 | 48,569,000 | Number of full time employees | 326 | 298 | | Vehicles | 489,000 | 313,000 |
| Depreciation, amortization, & accretion | 14,565,000 | 13,136,000 | Total number of employees | 326 | | | Office furniture & equipment | 307,000 | 307,000 |
| General & administrative expenses | | 4,944,523 | Number of class A common stockholders | | 18 | 1 | Computer software | 277,000 | 277,000 |
| Total expenses | 233,752,000 | | Number of class B ordinary stockholders | | | 5 | Land Lease - finance lease | 6,469,000 | |
| Operating income (loss) | 1,779,000 | (4,944,523) | Depreciation of Financial Lease | 667,000 | | | Vehicles - finance leases | 2,580,000 | 1,236,000 |
| Interest & financing expense, net | 9,306,000 | 6,640,000 | Right-of-Use Assets | 12,814,000 | | | Other property, plant & equipment | 591,000 | 487,000 |
| Change in fair value of derivative instruments, net | 7,346,000 | 33,081,000 | Depreciation of Intangibles excluding Goodwill | 563,000 | | | Property, plant & equipment, gross | 449,894,000 | 397,538,000 |
| Other income | 124,472,000 | 1,943,000 | Amortization of Intangibles | | | | Less: accumulated depreciation | 110,401,000 | 100,215,000 |
| Loss on warrant exchange | (338,000) | (3,368,000) | Accretion - Site Closure & Reclamation Expenses | 521,000 | | | Property, plant & equipment, net | 339,493,000 | 297,323,000 |
| Income from equity method investments | 5,784,000 | | | | | | Operating right-of use assets | 12,301,000 | 11,744,000 |
| Change in fair value of derivative warrant liabilities | | (10,799,940) | | | | | Investment in other entities | 207,099,000 | 51,765,000 |
| Financing costs - warrant liabilities | | 462,620 | | | | | Note receivable - variable fee component | 2,302,000 | 1,942,000 |
| Net gain on investments held in trust account | | 12,421 | | | | | Derivative financial assets, non-current portion | | 954,000 |
| Income from equity method investments | 5,525,000 | | | | | | Deferred financing costs | | 3,013,000 |
| Loss on debt extinguishment | (2,190,000) | | | | | | Other long-term assets | 1,162,000 | 1,489,000 |
| Total other income (expense) | | (11,250,139) | | | | | Intangible assets, net | 1,604,000 | 2,167,000 |
| Income before provision for income taxes | 127,024,000 | 32,579,000 | | | | | Restricted cash - non-current | 4,499,000 | 4,425,000 |
| Net income (loss) | 127,024,000 | (16,194,662) | | | | | Goodwill | 54,608,000 | 54,608,000 |
| | | | | | | | Total assets | 754,609,000 | 644,856,000 |
| | | | | | | | Accounts payable | 13,901,000 | 22,679,000 |
| | | | | | | | Accounts payable, related party | 7,024,000 | 1,346,000 |
| | | | | | | | Fuel tax credits payable | 4,558,000 | 3,320,000 |
| | | | | | | | Accrued payroll | 9,023,000 | 8,979,000 |
| | | | | | | | Accrued capital expenses | 15,128,000 | 11,922,000 |
| | | | | | | | Accrued expenses & other | | |
| | | | | | | | current liabilities | 14,245,000 | 9,573,000 |
| | | | | | | | Contract liabilities | 6,314,000 | 8,013,000 |
| | | | | | | | Senior secured credit facility - term loan, current portion, net of debt issuance costs | | 15,250,000 |
| | | | | | | | Senior secured credit facility - working capital facility, current portion | | 7,500,000 |
| | | | | | | | OPAL term loan, current portion | | 27,732,000 |
| | | | | | | | Sunoma loan, current portion | 1,608,000 | 380,000 |
| | | | | | | | Convertible note payable | | 28,528,000 |
| | | | | | | | Municipality loan | | 76,000 |
| | | | | | | | Derivative financial liability, current portion | | 4,596,000 |
| | | | | | | | Operating lease liabilities - current portion | 638,000 | 630,000 |
| | | | | | | | Other current liabilities | 92,000 | 1,085,000 |
| | | | | | | | Asset retirement obligation, current portion | 3,860,000 | 1,296,000 |
| | | | | | | | Accrued Expenses - Balancing value | 13,418,000 | |
| | | | | | | | Vehicle leases | 827,000 | |
| | | | | | | | Total current liabilities | 76,391,000 | 152,905,000 |
| | | | | | | | Asset retirement obligation, non-current portion | 2,868,000 | 4,960,000 |
| | | | | | | | OPAL term loan | 176,532,000 | 66,600,000 |
| | | | | | | | Sunoma loan, net of debt issuance costs | 20,010,000 | 21,712,000 |
| | | | | | | | Operating lease | | |

| | | |
|--|---------------|---------------|
| liabilities - non-current portion | 11,824,000 | 11,245,000 |
| Earn out liabilities | 1,900,000 | 8,790,000 |
| Other long-term liabilities | 7,599,000 | 825,000 |
| Total liabilities | ... | 267,037,000 |
| Redeemable preferred non-controlling interests | 132,617,000 | 138,142,000 |
| Redeemable non-controlling interests | 802,720,000 | 1,013,833,000 |
| Class A common stock | 3,000 | 3,000 |
| Class D common stock | 14,000 | 14,000 |
| Retained earnings (accumulated deficit) | (467,195,000) | (800,813,000) |
| Accumulated other comprehensive income | (15,000) | 195,000 |
| Class A common stock in treasury, at cost; 1,635,783 and 0 shares at 31, 2023 and 31, 2022, respectively | 11,614,000 | ... |
| Total stockholders' (deficit) equity attributable to the company | (478,807,000) | (800,601,000) |
| Non-redeemable non-controlling interests | 955,000 | 26,445,000 |
| Total stockholders' (deficit) equity | (477,852,000) | (774,156,000) |

¹ Includes related to consolidated VIEs - cash and cash equivalents: \$12,506,000; ² Includes related to consolidated VIEs - accounts receivable, net: \$966,000; ³ Includes related to consolidated VIEs - restricted cash - current: \$6,971,000; ⁴ Includes related to consolidated VIEs - prepaid expense and other current assets: \$415,000; ⁵ Includes related to consolidated VIEs - property, plant, and equipment, net: \$73,140,000; ⁶ Includes related to consolidated VIEs - restricted cash - non-current: \$2,923,000; ⁷ Includes related to consolidated VIEs - accounts payable: \$4,896,000; ⁸ Includes related to consolidated VIEs - accrued capital expenses: \$7,821,000; ⁹ Includes related to consolidated VIEs - accrued expenses and other current liabilities: \$646,000; ¹⁰ Includes related to consolidated VIEs - Sunoma loan, current portion: \$380,000; ¹¹ Includes related to consolidated VIEs - Sunoma loan, net of debt issuance costs: \$21,712,000

Recent Dividends:

- 1. OPAL Fuels Inc class D common.**
No dividends paid.
 - 2. OPAL Fuels Inc class B ordinary.**
No dividends paid.
 - 3. OPAL Fuels Inc series A-I redeemable preferred.**
No dividends paid.
 - 4. OPAL Fuels Inc class A common.**
No dividends paid.
 - 5. OPAL Fuels Inc class A ordinary.**
No dividends paid.
 - 6. OPAL Fuels Inc series A redeemable preferred.**
No dividends paid.
- Annual Dividends:**
- 1. OPAL Fuels Inc class D common.**
No dividends paid.
 - 2. OPAL Fuels Inc class B ordinary.**
No dividends paid.
 - 3. OPAL Fuels Inc series A-I redeemable preferred.**
No dividends paid.
 - 4. OPAL Fuels Inc class A common.**
No dividends paid.
 - 5. OPAL Fuels Inc class A ordinary.**
No dividends paid.
 - 6. OPAL Fuels Inc series A redeemable preferred.**
No dividends paid.

OPTIMIZERX CORP

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|------------|------------|------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Net Revenue | 71,521,506 | ... | ... |
| Revenue | ... | 62,450,156 | 61,292,598 |
| Net revenue | 71,521,506 | ... | ... |
| Cost of revenues | 28,621,589 | 23,483,336 | 25,654,384 |
| Gross margin | 42,899,917 | 38,966,820 | 35,638,214 |
| Stock-based | | | |

| | | | |
|---|---------------------|---------------------|------------------|
| compensation | 13,717,333 | 15,745,822 | 5,491,957 |
| Depreciation, amortization, & noncash lease expense | 2,401,628 | 2,022,029 | 2,086,454 |
| Other general & administrative expenses | 44,302,771 | 33,489,707 | 27,698,703 |
| Loss on disposal of a business | (2,142,319) | ... | ... |
| Impairment charges | 6,737,580 | ... | ... |
| Total operating expenses | 69,301,631 | 51,257,558 | 35,277,114 |
| Income (loss) from operations | (26,401,714) | (12,290,738) | 361,100 |
| Interest income | 2,191,689 | 852,298 | 16,979 |
| Interest expense | 1,453,764 | ... | ... |
| Amortization of debt issuance costs (in Dollars) | 500,001 | ... | ... |
| Total other income (expense) | 1,237,926 | ... | ... |
| Income (loss) before provision for income taxes | (25,163,788) | (11,438,440) | 378,079 |
| Deferred tax benefit (expense) - Federal | (6,488,661) | ... | ... |
| Deferred tax benefit (expense) | (1,206,713) | ... | ... |
| Deferred tax benefit (expense) | (7,695,374) | ... | ... |
| Current tax benefit (expense) - State | 97,452 | ... | ... |
| Income Taxes - Total - Current | 97,452 | ... | ... |
| Income tax expense (benefit) | (7,597,922) | ... | ... |
| Net income (loss) | (17,565,866) | (11,438,440) | 378,079 |
| Weighted average shares outstanding - basic | 17,124,801 | 17,783,992 | 17,228,019 |
| Weighted average shares outstanding - diluted | 17,124,801 | 17,783,992 | 17,690,489 |
| Year end shares outstanding | 18,158,282 | 17,074,173 | 17,860,975 |
| Income (loss) per share - basic | \$(1.03) | \$(0.64) | \$0.02 |
| Income (loss) per share - diluted | \$(1.03) | \$(0.64) | \$0.02 |
| Number of full time employees | 116 | 109 | 97 |
| Number of part time employees | 1 | 1 | ... |
| Number of common stockholders | 8,453 | ¹ 350 | ² 400 |
| Earnings per share from continuing operations | \$(1.03) | ... | ... |
| Earnings per share from continuing operations | \$(1.03) | ... | ... |
| Total number of employees | 117 | ... | ... |

¹ Approximately; ² As of February 28, 2023; ³ As of February 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 13,852,456 | 18,208,685 |
| Short-term investments | ... | 55,931,821 |
| Accounts receivable, gross | ... | 22,507,344 |
| Less: allowance for doubtful accounts | ... | 352,043 |
| Accounts receivable, net | 36,253,214 | 22,155,301 |
| Prepaid revenue share & exclusivity payments | ... | 1,025,000 |
| Prepaid software | ... | 408,063 |
| Prepaid insurance | ... | 221,580 |
| Prepaid data | ... | 152,533 |
| Prepaid electronic health | ... | ... |

| | | |
|---|--------------|--------------|
| records (EHR) access fees | 3,189,468 | ... |
| Other prepaid expenses | ... | 473,652 |
| Prepaid expenses & other current assets | ... | 2,280,828 |
| Taxes receivable | 1,035,754 | ... |
| Total current assets | 54,330,892 | 98,576,635 |
| Computer equipment, cost | 266,370 | 230,467 |
| Furniture & fixtures, cost | 33,899 | 38,500 |
| Property & equipment, gross | 300,269 | 268,967 |
| Less: accumulated depreciation - property & equipment | 150,862 | 131,519 |
| Property & equipment, net | 149,407 | 137,448 |
| Goodwill | 78,357,074 | 22,673,820 |
| Technology assets, net | 9,012,756 | 7,702,895 |
| Patent rights, net | 6,184,742 | 1,940,178 |
| Right of use assets, net | 572,895 | 235,320 |
| Other intangible assets, net | 34,198,084 | 3,379,838 |
| Security deposits & other assets | 568,048 | 5,051 |
| Total assets | 183,373,898 | 134,651,185 |
| Accounts payable - trade | 2,227,177 | 1,549,979 |
| Accrued expenses | 7,754,781 | ... |
| Accrued expenses | ... | 2,601,246 |
| Revenue share payable | 5,505,701 | 3,990,440 |
| Current portion of lease liabilities | 221,625 | 89,902 |
| Deferred revenue | 171,841 | 164,309 |
| Current portion of long-term debt | 2,000,000 | ... |
| Total current liabilities | 17,881,125 | 8,395,876 |
| Lease liabilities, net of current portion | 371,438 | 144,532 |
| Long-term debt, net | 34,230,737 | ... |
| Deferred tax liabilities, net | 4,337,424 | ... |
| Total liabilities | ... | 8,540,408 |
| Common stock | 19,899 | 18,289 |
| Treasury stock | 1,741 | 1,214 |
| Additional paid-in-capital | 190,792,980 | 172,785,800 |
| Retained earnings (accumulated deficit) | (64,257,964) | (46,692,098) |
| Total stockholders' equity (deficit) | 126,553,174 | 126,110,777 |
| Total Equity | 126,553,174 | ... |

Recent Dividends:

- 1. OptimizeRx Corp series A preferred.**
No dividends paid.
 - 2. OptimizeRx Corp common.**
No dividends paid.
 - 3. OptimizeRx Corp series B preferred.**
No dividends paid.
- Annual Dividends:**
- 1. OptimizeRx Corp series A preferred.**
No dividends paid.
 - 2. OptimizeRx Corp common.**
No dividends paid.
 - 3. OptimizeRx Corp series B preferred.**
No dividends paid.

ORCHESTRA BIOMED HOLDINGS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 |
|--|--------------|-------------|-------------------|
| General & administrative expenses | 20,258,000 | 2,960,264 | 274,756 |
| Administrative fee - related party | ... | 120,000 | 120,000 |
| Total operating expenses | ... | ... | 394,756 |
| Total expenses | 54,266,000 | ... | ... |
| Income (loss) from operations | (51,506,000) | (3,080,264) | ... |
| Interest income from investments held in trust | ... | ... | ... |

| | | | |
|--|-------------|----------|----------|
| Net income (loss) per share - diluted | \$(1.91) | \$(0.59) | \$(0.74) |
| Number of full time employees | 146 | ... | ... |
| Total number of employees | 146 | 167 | 151 |
| Number of common stockholders | 346 | 305 | 185 |
| Loss from deconsolidation of Octomera | (5,343,000) | ... | ... |
| Credit loss on convertible loan receivable | (2,688,000) | ... | ... |

Reclassified to conform with 2022 presentation; As of March 22, 2023; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 837,000 | 5,311,000 |
| Restricted cash | 642,000 | 1,058,000 |
| Accounts receivable, net - Balancing value | 88,000 | ... |
| Accounts receivable, net | 88,000 | 36,183,000 |
| Prepaid expenses & other receivables | 2,017,000 | 958,000 |
| Convertible loan to related parties | ... | 2,688,000 |
| Grants receivable | 458,000 | ... |
| Inventory | 34,000 | 120,000 |
| Total current assets | 4,076,000 | 46,318,000 |
| Deposits | 38,000 | 331,000 |
| Investments & loans to associates | ... | 135,000 |
| Production facility | 55,000 | 3,944,000 |
| Office furniture & computers | 242,000 | 589,000 |
| Lab equipment | 1,061,000 | 4,811,000 |
| Advance payment | 692,000 | 17,442,000 |
| Subtotal property, plants and equipment | 2,050,000 | 26,786,000 |
| Less - accumulated depreciation - property, plants & equipment | 575,000 | 3,952,000 |
| Property, plants & equipment, net | 1,475,000 | 22,834,000 |
| Intangible assets, net | 7,375,000 | 9,694,000 |
| Operating lease right-of-use assets | 351,000 | 2,304,000 |
| Goodwill | 1,211,000 | 8,187,000 |
| Deferred tax | ... | 103,000 |
| Other assets | 18,000 | 1,022,000 |
| Equity investees | 8,000 | ... |
| Total non-current assets | 10,476,000 | 44,610,000 |
| Total assets | 14,552,000 | 90,928,000 |
| Accounts payable | 6,451,000 | 4,429,000 |
| Accrued expenses & other payables | 2,218,000 | 2,578,000 |
| Income tax payable | 740,000 | 289,000 |
| Employees & related payables | 1,079,000 | 1,860,000 |
| Related parties | 52,000 | ... |
| Advance payments on account of grant | 2,180,000 | 1,578,000 |
| Contract liabilities | ... | 70,000 |
| Current maturities of finance leases | 18,000 | 60,000 |
| Current maturities of operating leases | 216,000 | 542,000 |
| Current maturities of convertible loans | 2,670,000 | 4,504,000 |
| Convertible bonds | 650,000 | ... |
| Accounts payable related parties | 133,000 | ... |
| Total current liabilities | 16,407,000 | 15,910,000 |
| Non-current operating leases | 96,000 | 1,728,000 |
| Convertible loans | 18,967,000 | 13,343,000 |
| Retirement benefits obligation | ... | 163,000 |
| Long-term debt & finance leases | ... | 95,000 |
| Advance payments on | ... | ... |

| | | |
|--|---------------|---------------|
| account of grant | ... | 144,000 |
| Other long-term liabilities | 61,000 | 271,000 |
| Finance leases | 4,000 | ... |
| Total long-term liabilities | ... | 15,744,000 |
| Total liabilities | ... | 31,654,000 |
| Redeemable non-controlling interest | ... | 30,203,000 |
| Common stock | 3,000 | 3,000 |
| Additional paid-in capital | 156,837,000 | 150,355,000 |
| Accumulated other comprehensive income (loss) | 65,000 | (270,000) |
| Treasury stock at 31, 2020 55,309 shares | 1,266,000 | ... |
| Treasury stock | ... | 1,266,000 |
| Accumulated deficit | (176,622,000) | ... |
| Retained earnings (accumulated deficit) | ... | (121,261,000) |
| Equity (deficiency) attributable to Orgenesis Inc. | (20,983,000) | 27,561,000 |
| Non-controlling interests | ... | 1,510,000 |
| Total equity (deficiency) | (20,983,000) | 29,071,000 |

Recent Dividends:

1. Orgenesis Inc common. No dividends paid.

Annual Dividends:

1. Orgenesis Inc common. No dividends paid.

P3 HEALTH PARTNERS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------|-----------------|--------------|
| Capitated revenue | 1,252,309,000 | 1,034,800,000 | 57,224,000 |
| Other patientn service revenue | 14,066,000 | 14,671,000 | 1,538,000 |
| Total operating revenue | 1,266,375,000 | 1,049,471,000 | 58,762,000 |
| Medical expenses | 1,234,740,000 | 1,057,224,000 | 66,877,000 |
| Premium deficiency reserve | (12,705,000) | (11,461,000) | 26,277,000 |
| Corporate, general & administrative expenses | 122,362,000 | 157,284,000 | 16,983,000 |
| Sales & marketing expenses | 3,233,000 | 5,096,000 | 364,000 |
| Depreciation & amortization | 86,675,000 | 87,289,000 | 7,149,000 |
| Goodwill impairment | ... | 1,314,952,000 | ... |
| Total operating expenses | ... | 2,610,384,000 | 117,650,000 |
| Operating income (loss) | (167,930,000) | (1,560,913,000) | (58,888,000) |
| Interest expense, net | 15,985,000 | 11,404,000 | 851,000 |
| Mark-to-market of stock warrants | 433,000 | 9,865,000 | 2,272,000 |
| Other income (expense), net | (249,000) | 2,757,000 | (471,000) |
| Total other income (expense) | (15,801,000) | 1,218,000 | 950,000 |
| Income (loss) before income taxes - domestic | ... | (1,559,695,000) | (57,938,000) |
| Income (loss) before income taxes | (183,731,000) | (1,559,695,000) | (57,938,000) |
| Current federal income tax expense | 170,000 | 111,000 | ... |
| Current state income tax expense | 2,525,000 | 1,751,000 | ... |
| Total current income tax expense | ... | 1,862,000 | ... |
| Provision for income taxes | 2,695,000 | 1,862,000 | ... |
| Net income (loss) | (186,426,000) | (1,561,557,000) | (57,938,000) |
| Less: net income (loss) attributable to redeemable | ... | ... | ... |

| | | | |
|---|--------------|---------------|--------------|
| non-controlling interests | 128,653,000 | 1,291,430,000 | 47,857,000 |
| Net income (loss) attributable to controlling interests | (57,773,000) | (270,127,000) | (10,081,000) |
| Weighted average shares outstanding - basic | 94,889,000 | 41,579,000 | 41,579,000 |
| Weighted average shares outstanding - diluted | 94,889,000 | 41,579,000 | 41,579,000 |
| Year end shares outstanding | 313,157,000 | 243,170,902 | 238,132,413 |
| Net earnings (loss) per share - basic | \$(0.61) | \$(6.50) | \$(0.24) |
| Net earnings (loss) per share - diluted | \$(0.61) | \$(6.50) | \$(0.24) |
| Full-Time Employees (Period End) | 400 | ... | ... |
| Total number of employees | 400 | 600 | 500 |
| Number of unit holders | 67 | ... | ... |
| Number of class A common stockholders | ... | 14 | 36 |
| Number of class V common stockholders | ... | 56 | 55 |

Successor; From December 3, 2021; Reclassified to conform with 2022 presentation; Approximately; As of March 15, 2023; As of October 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash | 36,320,000 | 17,537,000 |
| Restricted cash | 4,614,000 | 920,000 |
| Health plan receivables | 118,497,000 | 72,092,000 |
| Clinic fees & insurance receivables, net | ... | 822,000 |
| Other receivables | 2,973,000 | 6,678,000 |
| Prepaid expenses & other current assets | 3,613,000 | 2,643,000 |
| Provision - Accounts & Notes Receivable - Trade | 150,000 | ... |
| Health plan receivable - Balancing value | 118,647,000 | ... |
| Total current assets | 166,017,000 | 100,692,000 |
| Leasehold improvements | 2,933,000 | 1,810,000 |
| Furniture & fixtures | ... | 1,262,000 |
| Computer equipment & software | 3,699,000 | 3,206,000 |
| Medical equipment | 1,106,000 | 1,067,000 |
| Software (development in process) | 3,877,000 | 3,460,000 |
| Vehicles | 654,000 | 618,000 |
| Other property & equipment | ... | 37,000 |
| Furniture & fixtures - Gross | 1,165,000 | ... |
| Other | 33,000 | ... |
| Property & equipment, gross | 13,467,000 | ... |
| Less: accumulated depreciation | 4,781,000 | 2,621,000 |
| Property & equipment, net | 8,686,000 | 8,839,000 |
| Intangible assets, net | 666,733,000 | 751,050,000 |
| Other long-term assets | 19,531,000 | 15,990,000 |
| Total long-term assets | ... | 775,879,000 |
| Total assets | 860,967,000 | 876,571,000 |
| Accounts payable | 34,992,000 | 11,542,000 |
| Accrued expenses & other current liabilities | 36,884,000 | 16,647,000 |
| Accounts payable & accrued expenses | 178,009,000 | ... |
| Accrued payroll | 3,506,000 | 8,224,000 |
| Health plans settlements payable | ... | 13,608,000 |
| Claims payable | ... | 151,207,000 |
| Premium deficiency reserve | 13,670,000 | 26,375,000 |
| Accrued interest | 23,648,000 | 14,061,000 |

| | | | | | | | | | |
|---|---------------|---------------|--|-----------|-----------|-----------|---|--------------|--------------|
| Accounts payable | 8,663,000 | ... | before income tax provision (benefit) | 261,435 | 195,655 | (490,503) | Deferred revenues | ... | 13,020 |
| Operating Lease Liabilities - Current | | | Current state | | | | Operating lease obligations - current | | |
| Portion/Short-Term | 2,700,000 | ... | provision (benefit) for income taxes | 856 | 1,356 | 456 | portion | 14,162 | 22,199 |
| Accounts Payable and Accrued Expenses - Balancing value | 5,963,000 | ... | Current foreign provision (benefit) for income taxes | 13,536 | (364,879) | 336,568 | Total current liabilities | 1,932,653 | 2,076,493 |
| Total current liabilities | 299,372,000 | 241,664,000 | Total current provision (benefit) for income taxes | ... | (363,523) | 337,024 | Deferred tax liability, net | 622,568 | 707,952 |
| Operating lease liability | 13,622,000 | 11,516,000 | Deferred foreign provision (benefit) form income taxes | (106,173) | (92,968) | (130,767) | Uncertain tax position liability | 278,704 | 265,167 |
| Warrant liabilities | 1,085,000 | 1,517,000 | Total deferred provision (benefit) for income taxes | ... | (92,968) | (130,767) | Total liabilities | 2,833,925 | 3,049,612 |
| Contingent consideration | 4,907,000 | 4,794,000 | Income tax provision (benefit) | (91,779) | (456,491) | 206,257 | Common stock | 8,154 | 7,840 |
| Repurchase promissory note | ... | 15,000,000 | Net income (loss) | 353,214 | 652,146 | (696,760) | Accrued common stock bonus | 84,576 | 82,180 |
| Term loan facility | 108,319,000 | 65,000,000 | Weighted average shares outstanding - basic | 7,939,210 | 7,770,298 | 7,444,732 | Additional paid-in capital | 73,505,439 | 72,800,976 |
| Unsecured promissory note | ... | 15,000,000 | Weighted average shares outstanding - diluted | 7,945,300 | 7,781,689 | 7,444,732 | Accumulated other comprehensive income (loss) | 342,968 | 316,360 |
| Long-term debt, gross | ... | 95,000,000 | Year end shares outstanding | 8,010,837 | 7,696,487 | 7,773,263 | Accumulated Deficit | (69,317,190) | ... |
| Less: unamortized debt issuance costs & original issue discount | ... | (579,000) | Net income (loss) per share - basic | \$0.04 | \$0.08 | \$(0.09) | Retained earnings (accumulated deficit) | ... | (69,670,404) |
| Total long-term debt | ... | 94,421,000 | Net income (loss) per share - diluted | \$0.04 | \$0.08 | \$(0.09) | Common stock in treasury, at cost | 164,840 | 164,840 |
| Long-term debt | ... | 94,421,000 | Number of full time employees | ... | 22 | 23 | Total shareholders' equity (deficit) | 4,459,107 | 3,372,112 |
| Total long-term liabilities | 427,305,000 | 353,912,000 | Number of part time employees | ... | 1 | 1 | Total Equity | 4,459,107 | ... |
| Redeemable non-controlling interest | ... | 516,805,000 | Number of common stockholders | 867 | 867 | 867 | | | |
| Class A common stock | 20,000 | 4,000 | Foreign currency translation adjustments | ... | (273,707) | ... | | | |
| Class V common stock | 12,000 | 20,000 | Basic EPS Excluding ExtraOrdinary Items | \$0.04 | ... | ... | | | |
| Additional paid-in capital | 509,442,000 | 315,375,000 | Diluted EPS Excluding ExtraOrd Items | \$0.04 | ... | ... | | | |
| Retained earnings (accumulated deficit) | (367,344,000) | (309,545,000) | | | | | | | |
| Total stockholders' equity (deficit) | 142,130,000 | 5,854,000 | | | | | | | |
| Redeemable Non-Controlling Interest | 291,532,000 | ... | | | | | | | |
| Total Equity | 433,662,000 | ... | | | | | | | |

Recent Dividends:
1. P3 Health Partners Inc class A common.
No dividends paid.
2. P3 Health Partners Inc class V common.
No dividends paid.
3. P3 Health Partners Inc class B common.
No dividends paid.

Annual Dividends:
1. P3 Health Partners Inc class A common.
No dividends paid.
2. P3 Health Partners Inc class V common.
No dividends paid.
3. P3 Health Partners Inc class B common.
No dividends paid.

PAID INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|-------------|
| Net revenues | 16,564,829 | ... | ... |
| Revenues, net | 16,564,829 | 16,585,929 | 14,889,716 |
| Cost of revenues | 12,779,181 | 12,896,948 | 11,436,235 |
| Gross profit | 3,785,648 | 3,688,981 | 3,453,481 |
| Salaries & related | 1,984,504 | 1,912,142 | 1,803,173 |
| General & administrative | 1,388,350 | 1,233,549 | 1,046,711 |
| Amortization of intangible assets | 296,856 | 311,809 | 490,567 |
| Share-based compensation | 703,761 | 172,488 | 603,533 |
| Total operating expenses | 4,373,471 | 3,629,988 | 3,943,984 |
| Income (loss) from operations | (587,823) | 58,993 | (490,503) |
| Other income | 645,833 | 136,662 | ... |
| Interest income | 203,425 | ... | ... |
| Income (loss) before income tax provision (benefit) | ... | (77,704) | (1,143,578) |
| - U.S. | ... | (77,704) | (1,143,578) |
| Income (loss) before income tax provision (benefit) - foreign | ... | 273,359 | 653,075 |
| Income (loss) | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 2,052,421 | 1,787,248 |
| Accounts receivable, net | 205,647 | 169,074 |
| Note receivable, net of discount | 2,453,425 | 1,604,167 |
| Prepaid expenses & other current assets | ... | 151,374 |
| Advanced royalties, net | 134,110 | ... |
| Total current assets | 4,845,603 | 3,711,863 |
| Computer equipment & software | ... | 139,769 |
| Office furniture & equipment | ... | 66,644 |
| Website development costs | ... | 396,997 |
| Property & equipment, gross | ... | 603,410 |
| Accumulated depreciation | ... | 579,923 |
| Property & equipment, net | 10,678 | 23,487 |
| Intangible assets, net | 2,422,590 | 2,663,311 |
| Operating lease right-of-use assets | 14,161 | 23,063 |
| Total assets | 7,293,032 | 6,421,724 |
| Accounts payable | 1,482,498 | 1,610,416 |
| Payroll & related costs | 238,161 | 195,803 |
| Professional & consulting fees | 40,075 | 3,685 |
| Royalties | ... | 40,075 |
| Accrued cost of revenues | 119,737 | 168,657 |
| Sales tax | 22,228 | 22,228 |
| Other accrued expenses | 410 | 410 |
| Accrued expenses | 420,611 | 430,858 |

Recent Dividends:
1. Paid Inc series A preferred.
No dividends paid.
2. Paid Inc common.
No dividends paid.
Annual Dividends:
1. Paid Inc series A preferred.
No dividends paid.
2. Paid Inc common.
No dividends paid.

PALISADE BIO INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|--------------|
| License revenue | 250,000 | ... | ... |
| Revenues | 250,000 | ... | ... |
| Research & development costs | 6,893,000 | 6,547,000 | 2,430,000 |
| In-process research & development | ... | ... | 30,117,000 |
| General & administrative expenses | 6,202,000 | 8,764,000 | 9,307,000 |
| Total operating expenses | 13,320,000 | 15,721,000 | 41,854,000 |
| Restructuring costs | 225,000 | 410,000 | ... |
| Operating income (loss) | (13,070,000) | (15,721,000) | (41,854,000) |
| Gain on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... | 279,000 |
| Loss on issuance of secured debt | ... | ... | 686,000 |
| Gain (loss) on change in fair value of warrant liability | ... | 2,426,000 | 23,033,000 |
| Gain (loss) on change in fair value of share liability | ... | ... | 91,000 |
| Interest expense | 15,000 | 13,000 | 2,398,000 |
| Other income | 785,000 | 158,000 | 47,000 |
| Loss on issuance of Leading Biosciences, Inc. ("LBS") series 1 preferred stock | ... | ... | 1,881,000 |
| Loss on issuance of warrants | ... | 1,110,000 | 3,247,000 |
| Total other income (expense), net | 770,000 | 1,461,000 | 15,238,000 |
| Net income (loss) | (12,300,000) | (14,260,000) | (26,616,000) |

| | | | | | | | | | |
|---|------------------------|----------------------|---------------------------|---|---------------|---------------|--|---------|---------|
| Weighted average shares outstanding | | | | Additional paid-in capital | 132,724,000 | 121,637,000 | | 2023 | 2022 |
| - basic | [Ⓐ] 456,014 | 58,687 | [Ⓐ] 12,413 | Retained earnings (accumulated deficit) | (121,506,000) | (109,190,000) | | 100,922 | 6,951 |
| Weighted average shares outstanding | | | | Total stockholders' equity (deficit) | 11,313,000 | 12,479,000 | | 263,970 | 206,127 |
| - diluted | [Ⓐ] 456,014 | 58,687 | [Ⓐ] 12,464 | Total Equity | 11,313,000 | ... | | | |
| Year end shares outstanding | [Ⓐ] 618,060 | [Ⓐ] 196,287 | [Ⓐ] 18,986 | | | | | | |
| Net earnings (loss) per share - basic | [Ⓐ] \$(27.00) | \$(247.95) | [Ⓐ] \$(2,144.25) | | | | | | |
| Net earnings (loss) per share - diluted | [Ⓐ] \$(27.00) | \$(247.95) | [Ⓐ] \$(2,546.10) | | | | | | |
| Number of full time employees | 9 | 12 | 13 | | | | | | |
| Total number of employees | 9 | ... | ... | | | | | | |
| Number of common stockholders | 158 | [Ⓐ] 180 | [Ⓐ] 193 | | | | | | |
| Income from cont operations before income tax | (12,300,000) | ... | ... | | | | | | |
| Earnings per share from continuing operations | \$(27.00) | ... | ... | | | | | | |
| Earnings per share from continuing operations | \$(27.00) | ... | ... | | | | | | |

[Ⓐ] Adjusted for 1-for-15 stock split, April 8, 2024; [Ⓑ] Adjusted for 1-for-50 stock split, November 16, 2022; [Ⓒ] Shares increased due to the effect of issuance of common stock upon warrant exercises, public offering of class A & class B units, and conversion of Series B convertible preferred stock; [Ⓓ] Approximately; [Ⓔ] As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 12,432,000 | 12,383,000 |
| Prepaid expenses | 428,000 | ... |
| Prepaid insurance | ... | 581,000 |
| Other receivables | 148,000 | 1,438,000 |
| Prepaid subscriptions & fees | 138,000 | 157,000 |
| Prepaid software licenses | 64,000 | 54,000 |
| Deferred equity issuance costs | 112,000 | 114,000 |
| Prepaid other | 6,000 | 6,000 |
| Prepaid expenses & other current assets | 896,000 | 2,350,000 |
| Total current assets | 13,328,000 | 14,733,000 |
| Restricted cash | 26,000 | 26,000 |
| Right-of-use asset | ... | 300,000 |
| Property & equipment, net | 10,000 | 10,000 |
| Prepaid insurance, less current portion | ... | 682,000 |
| Other noncurrent assets | 490,000 | 12,000 |
| Other noncurrent assets | ... | 694,000 |
| Operating lease right-of-use asset | 198,000 | ... |
| Total assets | 14,052,000 | 15,763,000 |
| Accounts payable | ... | 1,759,000 |
| Accrued accounts payable | 698,000 | 69,000 |
| Accrued clinical trial costs | ... | 184,000 |
| Accrued director stipends | ... | 141,000 |
| Accrued severance & benefits | ... | 180,000 |
| Accrued liabilities | 831,000 | 574,000 |
| Accrued compensation & benefits | 778,000 | 486,000 |
| Current portion of lease liability | 121,000 | 105,000 |
| Debt | 158,000 | 88,000 |
| Total current liabilities | 2,586,000 | 3,012,000 |
| Warrant liability | 61,000 | 61,000 |
| Lease liability, net of current portion | 90,000 | 211,000 |
| Warrant liability | 2,000 | ... |
| Total liabilities | 2,739,000 | 3,284,000 |
| Series A convertible preferred stock | 2,000 | 2,000 |
| Common stock | 93,000 | 30,000 |

Recent Dividends:
1. Palisade Bio Inc common.
 No dividends paid.
2. Palisade Bio Inc series A 4.5% convertible preferred.
 No dividends paid.
Annual Dividends:
1. Palisade Bio Inc common.
 No dividends paid.
2. Palisade Bio Inc series A 4.5% convertible preferred.
 No dividends paid.

PANACEA LIFE SCIENCES HOLDINGS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
|--|-------------|------------------|-----------------------------|
| REVENUE | 2,384,956 | ... | ... |
| Revenue | 2,384,956 | 1,626,978 | 2,059,627 |
| Cost of sales | 1,262,979 | 1,230,508 | 1,519,049 |
| Gross profit | 1,121,977 | 396,470 | 540,578 |
| Production related operating expenses | 5,211,719 | 4,955,348 | 4,959,059 |
| General & administrative expenses | 1,456,412 | 1,093,364 | 1,518,687 |
| Total operating expenses | 6,668,131 | 6,048,712 | 6,477,746 |
| Income (loss) from operations | (5,546,154) | (5,652,242) | (5,937,168) |
| Interest expense | 1,555,877 | 2,048,171 | 1,105,243 |
| Unrealized gain (loss) on marketable securities, net | ... | (2,660,105) | 1,008,046 |
| Realized gain on sale of securities | (1,092,429) | 22,816 | 160,296 |
| Other income (loss) | ... | 27,598 | ... |
| Employer retention credit | 178,411 | 253,791 | 396,679 |
| Rental income | ... | 232,183 | 236,560 |
| Gain (loss) on sale of assets | ... | ... | (297,351) |
| Gain on extinguishment of debt | 748 | 681,546 | 755,782 |
| Total other income (expense) | (2,469,147) | (3,490,342) | 1,154,769 |
| Income (loss) before income taxes | (8,015,301) | (9,142,584) | (4,782,399) |
| Net income (loss) | (8,015,301) | (9,142,584) | (4,782,399) |
| Weighted average shares outstanding - basic | 16,627,458 | 14,862,077 | 16,915,706 |
| Weighted average shares outstanding - diluted | 16,627,458 | 14,862,077 | 16,915,706 |
| Year end shares outstanding | 17,645,352 | 14,965,317 | 14,073,708 |
| Net income (loss) per share - basic | \$(0.48) | \$(0.62) | \$(0.28) |
| Net income (loss) per share - diluted | \$(0.48) | \$(0.62) | \$(0.28) |
| Number of full time employees | 40 | 19 | 29 |
| Number of part time employees | ... | ... | 6 |
| Total number of employees | 40 | ... | 35 |
| Number of common stockholders | 190 | [Ⓐ] 186 | [Ⓐ] 186 |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Approximately; [Ⓒ] As of March 28, 2023; [Ⓓ] As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|--------------|--------------|
| Cash & cash equivalents | 100,922 | 6,951 |
| Accounts receivable, net | 263,970 | 206,127 |
| Other receivables, related party | ... | 500,000 |
| Raw materials | 850,362 | 870,530 |
| Semi-finished | 1,870,978 | 1,863,501 |
| Finished goods | 1,262,674 | 1,694,574 |
| Packaging | 29,511 | 20,120 |
| Inventory | 4,013,525 | 4,448,725 |
| Marketable securities related party | 14,933 | 1,107,362 |
| Prepaid services | 263,003 | ... |
| Prepaid expenses & other current assets | ... | 113,098 |
| Total current assets | 4,656,353 | 6,382,263 |
| Operating lease right-of-use asset, net, related party | 3,864,591 | 3,242,381 |
| Computers & technological assets | 3,776,320 | 3,776,320 |
| Furniture & fixtures | 161,830 | 55,950 |
| Machinery & equipment | 7,846,788 | 7,765,466 |
| Land | 92,222 | 92,222 |
| Leasehold improvements | 1,806,755 | 1,508,915 |
| Property & equipment, gross | 13,683,915 | ... |
| Less: accumulated depreciation | 7,235,847 | 5,522,878 |
| Property & equipment, net | 6,448,068 | 7,675,995 |
| Goodwill | 3,014,450 | 2,188,810 |
| Total assets | 17,983,462 | 19,489,449 |
| Accounts payable & accrued expenses | 4,629,591 | 2,666,076 |
| Operating lease liability, current portion, related party | 2,913,781 | 2,090,271 |
| Notes payable | 99,100 | ... |
| Note payable-current, related party | 11,397,617 | 9,871,803 |
| Convertible note payable, net | 115,000 | 346,671 |
| Paycheck protection loan, small business administration loan | ... | 99,100 |
| First Bank note payable | 292,942 | ... |
| Total current liabilities | 19,448,031 | 15,073,921 |
| Operating lease liability, long-term portion, related party | 3,254,021 | 2,987,208 |
| Other long-term liabilities, related party | 3,572,864 | 3,572,864 |
| Total liabilities | 26,274,916 | 21,633,993 |
| Preferred stock series B-1 | ... | 150 |
| Preferred stock series B-2 | ... | 600 |
| Preferred stock series C | ... | 100 |
| Preferred stock series C-1 | ... | 1 |
| Preferred stock series D | ... | 1 |
| Common stock | 1,765 | 1,497 |
| Additional paid-in capital | 25,628,442 | 23,760,704 |
| Accumulated deficit | (33,922,898) | ... |
| Retained earnings (accumulated deficit) | ... | (25,907,597) |
| Series B-2 Preferred: \$ 0.0001 Par Value, 6,000,000 shares designated; 6,000,000 and 0 shares issued and outstanding on 31, 2021 and 31, 2020 respectively | 600 | ... |
| Series C Preferred: \$ 0.0001 Par Value, 1,000,000 shares designated; 1,000,000 and 1,000,000 shares issued and outstanding on 31, | | |

| | | | |
|---|-------------|-------------|--|
| 2021 and 31, 2020 respectively | 100 | ... | |
| Series B-1 Preferred: \$ 0.0001 Par Value, 32,000,000 shares designated; 1,500,000 and 0 shares issued and outstanding on 31, 2021 and 31, 2020 respectively | 150 | ... | |
| Series C-1 Preferred: \$ 0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on 31, 2023 and 31, 2022 respectively | 1 | ... | |
| Series D Preferred: \$ 0.0001 Par Value, 10,000 shares designated and 10,000 and 10,000 shares issued and outstanding on 31, 2023 and 31, 2022 respectively | 1 | ... | |
| Series E Preferred: \$ 0.000 Par Value, .85,000 shares designated and issued on , 202 | 385 | ... | |
| Total stockholders' equity (deficit) | (8,291,454) | (2,144,544) | |
| Total stockholders' equity (deficit) | (8,291,454) | | |

Recent Dividends:

- 1. Panacea Life Sciences Holdings Inc series E convertible preferred (new).**
No dividends paid.
- 2. Panacea Life Sciences Holdings Inc series D preferred.**
No dividends paid.
- 3. Panacea Life Sciences Holdings Inc series B-1 preferred.**
No dividends paid.
- 4. Panacea Life Sciences Holdings Inc series B-2 preferred.**
No dividends paid.
- 5. Panacea Life Sciences Holdings Inc series E 0% convertible preferred.**
No dividends paid.
- 6. Panacea Life Sciences Holdings Inc common.**
No dividends paid.
- 7. Panacea Life Sciences Holdings Inc series C preferred.**
No dividends paid.
- 8. Panacea Life Sciences Holdings Inc series C convertible preferred (new).**
No dividends paid.
- 9. Panacea Life Sciences Holdings Inc series D preferred (new).**
No dividends paid.
- 10. Panacea Life Sciences Holdings Inc series C-2 preferred.**
No dividends paid.
- 11. Panacea Life Sciences Holdings Inc series A preferred.**
No dividends paid.
- 12. Panacea Life Sciences Holdings Inc series C-1 preferred.**
No dividends paid.

Annual Dividends:

- 1. Panacea Life Sciences Holdings Inc series E convertible preferred (new).**
No dividends paid.
- 2. Panacea Life Sciences Holdings Inc series D preferred.**
No dividends paid.
- 3. Panacea Life Sciences Holdings Inc series B-1 preferred.**
No dividends paid.
- 4. Panacea Life Sciences Holdings Inc series B-2 preferred.**
No dividends paid.
- 5. Panacea Life Sciences Holdings Inc series E 0% convertible preferred.**
No dividends paid.
- 6. Panacea Life Sciences Holdings Inc common.**
No dividends paid.
- 7. Panacea Life Sciences Holdings Inc series C preferred.**
No dividends paid.
- 8. Panacea Life Sciences Holdings Inc series C convertible preferred (new).**
No dividends paid.
- 9. Panacea Life Sciences Holdings Inc series D preferred (new).**

- No dividends paid.
10. Panacea Life Sciences Holdings Inc series C-2 preferred.
No dividends paid.
11. Panacea Life Sciences Holdings Inc series A preferred.
No dividends paid.
12. Panacea Life Sciences Holdings Inc series C-1 preferred.
No dividends paid.

**PANBELA THERAPEUTICS INC (NEW)
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| General & administrative | 5,033,000 | 6,044,000 | 4,587,000 |
| Research & development | 20,614,000 | 28,049,000 | 5,423,000 |
| Operating income (loss) | (25,647,000) | (34,093,000) | (10,010,000) |
| Interest income | 123,000 | 14,000 | 1,000 |
| Interest expense | 317,000 | 288,000 | 12,000 |
| Other expenses | 8,000 | 682,000 | 602,000 |
| Gain on sale of intellectual property | 400,000 | | |
| Total other income (expense) | 198,000 | (956,000) | (613,000) |
| Income (loss) before income tax expense (benefit) | (25,449,000) | (35,049,000) | (10,623,000) |
| Current income tax expense (benefit) | (186,000) | (116,000) | |
| Income tax expense (benefit) | (186,000) | (116,000) | (488,000) |
| Net income (loss) | (25,263,000) | (34,933,000) | (10,135,000) |
| Weighted average shares outstanding | | | |
| - basic | 108,691 | 857 | 488 |
| Weighted average shares outstanding - diluted | 108,691 | 857 | 488 |
| Year end shares outstanding | 480,025 | 1,749 | 560 |
| Net income (loss) per share - basic | \$(316.52) | \$(40,746.00) | \$(20,784.00) |
| Net income (loss) per share - diluted | \$(316.52) | \$(40,746.00) | \$(20,784.00) |
| Number of full time employees | | 6 | 4 |
| Number of part time employees | | 1 | 2 |
| Total number of employees | | 7 | 6 |
| Number of common stockholders | 55 | 277 | 216 |
| Foreign currency translation adjustments | | 626,000 | 517,000 |

[¶] Reclassified to conform with 2022 presentation; [§] Adjusted for 1-for-30 stock split, June 1, 2023; [¶] Adjusted for 1-for-20 stock split, January 18, 2024; [§] Adjusted for 1-for-40 stock split, January 13, 2023; [¶] Shares increased due to the issuance of common share, options and warrants due to CPP acquisition, public offering, vesting of restricted share, exercise of options and warrants; [§] Shares increased due to the effect of issuance of shares for public offering, exercised warrants, options and vesting of restricted stock; [¶] As of March 13, 2023; [§] As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-----------|
| Cash & cash equivalents | 2,578,000 | 1,285,000 |
| Prepaid expenses & other current assets | 299,000 | 443,000 |
| Income tax receivable | 183,000 | 49,000 |
| Total current assets | 3,060,000 | 1,777,000 |
| Other noncurrent assets | 8,742,000 | 3,201,000 |
| Total assets | 11,802,000 | 4,978,000 |
| Accounts payable | 9,939,000 | 2,865,000 |
| Accrued deferred payroll & related expenses | 420,000 | |
| Accrued clinical trial & related expenses | 290,000 | 1,760,000 |

| | | |
|---|---------------|--------------|
| Accrued incentive compensation | | 550,000 |
| Severance pay & related payroll taxes | | 448,000 |
| Accrued professional services | 166,000 | 147,000 |
| Other accrued expenses | | 88,000 |
| Accrued expenses | 1,141,000 | 2,993,000 |
| Accrued interest | 238,000 | 325,000 |
| Note payable | | 650,000 |
| Debt, current portion | 1,000,000 | 1,000,000 |
| Other | 169,000 | |
| Accrued expenses - Balancing value | | 96,000 |
| Total current liabilities | 12,318,000 | 7,833,000 |
| Debt, net of current portion | 4,194,000 | 5,194,000 |
| Total non current liabilities | 4,194,000 | 5,194,000 |
| Total liabilities | 16,512,000 | 13,027,000 |
| Common stock | 480 | 1,000 |
| Additional paid-in capital | 120,043,000 | 82,285,000 |
| Retained earnings (accumulated deficit) | (125,497,000) | (91,094,000) |
| Accumulated comprehensive income (loss) | 745,000 | 759,000 |
| Common Stock - Treasury/Repurchased | 1,000 | |
| Total stockholders' equity (deficit) | (4,710,000) | (8,049,000) |
| Total Equity | (4,710,000) | |

Recent Dividends:

- 1. Panbela Therapeutics Inc (New) series A preferred.**
No dividends paid.
- 2. Panbela Therapeutics Inc (New) common.**
No dividends paid.

Annual Dividends:

- 1. Panbela Therapeutics Inc (New) series A preferred.**
No dividends paid.
- 2. Panbela Therapeutics Inc (New) common.**
No dividends paid.

**PANBELA THERAPEUTICS INC (NEW)
Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Cherry Bekaert LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Panbela Therapeutics, Inc. and Subsidiaries (the "Company") as of December 31, 2023 and 2022, and the related consolidated statements of operations and comprehensive loss, stockholders' deficit, and cash flows for each of the years then ended, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America. Substantial Doubt about the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company has recurring losses and negative cash flows from operations that raise substantial doubt about its ability to continue as a going concern. Management's evaluations of the events and conditions and management's plans regarding those matters are described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

**PARAGON TECHNOLOGIES INC
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 |
|-----------------------------|---------|-----------|---------|
| | | (revised) | |
| Total revenues | 125,274 | 134,244 | |
| of Sales | 113,244 | | |
| Net sales | 125,274 | 134,244 | 141,553 |
| Cost of sales | | 120,267 | 129,193 |
| Gross profit on sales | 12,030 | 13,977 | 12,360 |
| and Administrative Expenses | 8,198 | | |

| | | | | | | | | | | | | |
|---|---------|-------|-------|---|--------|--------|-----------------|--|--------------|--------------|-------------|--|
| Selling, general & administrative expenses | ... | ... | 5,841 | Technologies, Inc. & subsidiaries | 1,141 | 4,733 | 3,351 | Total liabilities | 41,667 | 32,173 | | |
| Asset purchase agreement expenses | 6,388 | ... | ... | Weighted average shares outstanding - basic | 1,717 | 1,714 | 1,705 | Common stock | 1,727 | 1,717 | | |
| Product development costs | 12 | 13 | ... | Weighted average shares outstanding - diluted | 1,717 | 1,714 | 1,705 | Additional paid-in capital | 3,640 | 3,560 | | |
| Total operating expenses | 8,198 | 6,400 | 5,854 | Year end shares outstanding | 1,727 | 1,717 | 1,705 | Retained earnings (accumulated deficit) | 14,957 | 13,816 | | |
| Operating income (loss) | 3,832 | 7,577 | 6,506 | Income (loss) per share from continuing operations - basic | \$0.66 | \$2.76 | ... | Accumulated other comprehensive income (loss) | (917) | (3,869) | | |
| Interest income | 187 | 74 | 16 | Net income (loss) per share - basic | \$0.66 | \$2.76 | \$1.97 | Total Paragon Technologies, Inc. & subsidiaries stockholders' equity (deficit) | 19,407 | 15,224 | | |
| Interest expense | 1,021 | 1,008 | 310 | Income (loss) per share from continuing operations - diluted | \$0.66 | \$2.76 | ... | Noncontrolling interest in subsidiary | 3,196 | 2,791 | | |
| Employee retention credit | ... | ... | 138 | Net income (loss) per share - diluted | \$0.66 | \$2.76 | ... | Total stockholders' equity | 22,603 | 18,015 | | |
| Realized gain (loss) on investment, marketable securities | (77) | 935 | (325) | Number of common stockholders | 154 | 169 | 174 | □ Reclassified to conform 2023 presentation | | | | |
| Unrealized gain (loss) on investment, equity securities | ... | ... | (110) | Foreign currency translation adjustments | ... | ... | (1,166) | Recent Dividends: | | | | |
| Gain (loss) on sale of fixed assets | 1 | ... | 1 | □ As is; □ As of March 24, 2021 | ... | ... | ... | 1. Paragon Technologies Inc common. | | | | |
| Grant income equity securities | 13 | 18 | 54 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | | | | | | |
| Total other income (expense), net | (1,112) | (192) | (536) | 2023 | | | □2022 (revised) | | | 2021 | | |
| Income (loss) before income taxes & noncontrolling interest | 2,720 | 7,385 | 5,970 | Cash & cash equivalents | 7,499 | 5,299 | ... | Revenues | ... | ... | 15,062 | |
| Current income tax expense (benefit) - federal | ... | ... | 291 | Short-term investments | 1,601 | 1,343 | ... | Cost of services | ... | ... | 17,275 | |
| Deferred income tax expense (benefit) - federal | ... | ... | 10 | Contract assets | 146 | 83 | ... | Gross margin | ... | ... | (2,213) | |
| Total federal income tax expense (benefit) | ... | ... | 301 | Prepaid expenses & other current assets | 6,142 | 4,266 | ... | Selling, general & administrative | 7,878,596 | 9,923,544 | 4,505,200 | |
| Current income tax expense (benefit) - state | ... | ... | 48 | Receivables, net | 22,574 | 14,752 | ... | Research & development | 8,100,765 | 2,665,427 | ... | |
| Deferred income tax expense (benefit) - state | ... | ... | 2 | Raw materials | 298 | 280 | ... | Income (loss) from operations | (15,979,361) | (12,588,971) | (4,507,413) | |
| Total state income tax expense (benefit) | ... | ... | 50 | Finished goods | 20,322 | 18,889 | ... | Change in fair value of warrant liabilities | 56,245 | 1,852,189 | 2,334,400 | |
| Current income tax expense (benefit) - foreign | ... | ... | 1,997 | Total current assets | 58,582 | 44,912 | ... | Interest expense | ... | ... | 508 | |
| Deferred income tax expense (benefit) - foreign | ... | ... | (449) | Real estate | 3,294 | 3,294 | ... | Gain on forgiveness of accounts payable | ... | 10,633 | ... | |
| Total foreign income tax expense (benefit) | ... | ... | 1,548 | Machinery & equipment | 712 | 572 | ... | Litigation settlements | ... | 1,001,736 | ... | |
| Net income before noncontrolling interest | 1,546 | 5,300 | 4,071 | Software | 732 | 541 | ... | Interest and dividends, net | 415,368 | ... | ... | |
| Foreign Tax | 1,989 | 1,638 | ... | Land | 15 | 12 | ... | Other income (expense), net | 471,613 | 861,086 | 2,333,892 | |
| State Tax | (10) | 92 | ... | Leasehold improvements | 303 | 230 | ... | Income (loss) before income taxes | (15,507,748) | (11,727,885) | (2,173,521) | |
| Current | (50) | 355 | ... | Capital additions in process | ... | 25 | ... | Net income (loss) | (15,961,658) | (13,936,452) | (2,173,521) | |
| Current | 16 | ... | ... | Property & equipment, at cost | 5,056 | 4,674 | ... | Weighted average common shares outstanding - basic | 1,226,600 | 1,262,339 | 520,233 | |
| State Tax | 2 | ... | ... | Less: accumulated depreciation | 2,203 | 1,529 | ... | Weighted average common shares outstanding - diluted | 1,226,600 | 1,262,339 | 520,233 | |
| Income Taxes - Foreign - Deferred | (773) | ... | ... | Total property & equipment, net | 2,853 | 3,145 | ... | Year end shares outstanding | 1,041,582 | 1,302,170 | 1,150,419 | |
| Income tax expense (benefit) | 1,174 | 2,085 | 1,899 | Operating lease right-of-use assets, net | 992 | 976 | ... | Net earnings (loss) per common share - basic | \$(12.64) | \$(9.29) | \$(4.20) | |
| Net income (loss) before noncontrolling interest | 1,546 | 5,300 | 4,071 | Intangible Assets - excluding Goodwill - Net | 213 | 280 | ... | Net earnings (loss) per common share - diluted | \$(12.64) | \$(9.29) | \$(4.20) | |
| Net income attributable to noncontrolling interest | (405) | (567) | (720) | - Total | 1,630 | 875 | ... | Number of part time employees | ... | ... | 3 | |
| Net income (loss) attributable to Paragon | ... | ... | ... | Deferred tax asset | 1,630 | 875 | ... | Number of full time employees | 8 | ... | 9 | |
| | | | | Total assets | 64,270 | 50,188 | ... | Number of common stockholders | 40 | ... | 46 | |
| | | | | Current installments of long-term debt | 375 | 750 | ... | Foreign currency translation adjustments | ... | ... | (10,561) | |
| | | | | Income taxes payable | 1,926 | 1,769 | ... | Income from continuing operations | (15,507,748) | (11,727,885) | ... | |
| | | | | Accounts payable | 18,326 | 13,936 | ... | Discontinued | ... | ... | ... | |
| | | | | Contract liabilities | 1,406 | 2,353 | ... | | | | | |
| | | | | Accrued salaries, wages & commissions | 432 | 408 | ... | | | | | |
| | | | | Accrued product warranties | 33 | 46 | ... | | | | | |
| | | | | Accrued other liabilities | 7,706 | 3,221 | ... | | | | | |
| | | | | Operating lease liabilities | 408 | 599 | ... | | | | | |
| | | | | Bank loan, line of credit, net | 10,467 | 8,334 | ... | | | | | |
| | | | | Total current liabilities | 41,079 | 31,416 | ... | | | | | |
| | | | | Operating lease liabilities, net of current | 588 | 382 | ... | | | | | |
| | | | | Promissory note, net of current | ... | 375 | ... | | | | | |
| | | | | Total long-term liabilities | 588 | 757 | ... | | | | | |

| | | | |
|--|-----------|-------------|-----|
| Operations before Tax - | | | |
| Income/Expense | (453,910) | (2,208,567) | ... |
| Discontinued Operations - Net - | | | |
| Income/Expense | (453,910) | (2,208,567) | ... |
| Earnings per share from continuing operations | \$(12.64) | \$(9.29) | ... |
| Earnings per share-inc from discontinued oper | \$(0.37) | \$(1.75) | ... |
| Earnings per share-total discontinued opers | \$(0.37) | \$(1.75) | ... |
| Earnings per share from continuing operations | \$(12.64) | \$(9.29) | ... |
| Earn per share-inc from discount opers - diluted | \$(0.37) | \$(1.75) | ... |
| Earning per share-total discount opers - diluted | \$(0.37) | \$(1.75) | ... |
| Total number of employees | 8 | ... | ... |

[□] Restated to reflect discontinued operations; [□] Shares increased due to the issuance of shares for cash and services, share adjustment, sale of units, common share and warrants and exercise of warrants for cash; [□] As of March 23, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | |
|---|--------------|--------------|--|
| | | (revised) | |
| Cash & cash equivalents | 16,331,052 | ... | |
| Cash | ... | 33,146,895 | |
| Prepaid expenses | 215,895 | 627,666 | |
| Other receivables | ... | 302,132 | |
| Amount due from sale of assets | 40,500 | ... | |
| Other current assets | 104,707 | ... | |
| Total current assets | 16,692,154 | 34,076,693 | |
| Leasehold improvements | 3,193 | 3,193 | |
| Medical equipment | 155,363 | 99,220 | |
| Office equipment | 6,140 | 307,388 | |
| Property & equipment, gross | 164,696 | 409,801 | |
| Less: accumulated depreciation | 23,488 | 31,018 | |
| Property & equipment, net | 141,208 | 378,783 | |
| Right of use asset-operating lease | 79,271 | 874,463 | |
| Intangibles, net | 7,941,314 | 8,587,239 | |
| Goodwill | 1,262,911 | 1,262,911 | |
| Total assets | 26,116,858 | 45,180,089 | |
| Accounts payable & accrued liabilities | 2,552,360 | 1,614,343 | |
| Lease liability - short term position | 81,680 | 263,291 | |
| Total current liabilities | 2,634,040 | 1,877,634 | |
| Lease liability | ... | 663,596 | |
| Warrant liabilities | 84,366 | 140,611 | |
| Total non-current liabilities | 84,366 | 804,207 | |
| Total liabilities | 2,718,406 | 2,681,841 | |
| Common stock, par value \$0001, 495,000,000 shares authorized; 13,208,371 and 7,469,125 shares issued and outstanding as of 30, 2021 and 31, 2020, respectively | 104 | ... | |
| Common stock | ... | 17,987 | |
| Additional paid-in capital | 58,721,538 | 61,837,802 | |
| Accumulated other comprehensive income (loss) | (4,652) | (661) | |
| Accumulated deficit | (35,318,538) | ... | |
| Retained earnings (accumulated deficit) | ... | (19,356,880) | |
| Total stockholders' equity | 23,398,452 | 42,498,248 | |

equity 23,398,452 42,498,248

Total Equity 23,398,452

Recent Dividends:

1. Pasithea Therapeutics Corp common.

No dividends paid.

Annual Dividends:

1. Pasithea Therapeutics Corp common.

No dividends paid.

PATRIOT GOLD CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Revenues | 1,930,348 | ... | ... |
| Revenues | 1,930,348 | 1,786,040 | 1,737,707 |
| Mineral costs | 426,265 | 101,366 | 505,788 |
| Consulting expense | 688,859 | 441,616 | 484,272 |
| Directors fees | 210,000 | 210,000 | 210,000 |
| General & administrative | 546,183 | 270,969 | 220,939 |
| Total operating expense | 1,871,307 | 1,023,951 | 1,420,999 |
| Net income (loss) from operations | 59,041 | 762,089 | 316,708 |
| Unrealized holding gain (loss) on marketable securities | ... | (79,426) | (106,851) |
| Currency exchange | (4,223) | ... | ... |
| Currency exchange gain (loss) | ... | 3,797 | (426) |
| Realized gain (loss) on sale of marketable securities | (4,080) | ... | ... |
| Other miscellaneous income | 16,241 | 51 | ... |
| Total other income (expense) | 7,938 | (75,578) | (107,277) |
| Net income before taxes | 66,979 | 686,511 | 209,431 |
| Income tax expense (benefit) | (16,000) | 65,000 | 57,000 |
| Net income (loss) | 82,979 | 621,511 | 152,431 |
| Weighted average shares outstanding - basic | 73,417,127 | 75,570,871 | 74,380,354 |
| Weighted average shares outstanding - diluted | 73,417,127 | 75,570,871 | 76,091,431 |
| Year end shares outstanding | 69,354,539 | 77,841,893 | 74,380,354 |
| Net earnings (loss) per share - basic | \$0.00 | \$0.10 | \$0.00 |
| Net earnings (loss) per share - diluted | \$0.00 | \$0.10 | \$0.00 |
| Number of Common Shareholders | 77 | ... | ... |
| Number of stockholders | ... | 78 | 78 |

[□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | |
|--|-----------|-----------|--|
| Cash and cash equivalents | 1,701,720 | ... | |
| Cash | ... | 2,157,336 | |
| Marketable securities | 32,237 | 36,104 | |
| Prepaid director fees | 161,439 | ... | |
| Royalty receivables | 358,645 | 803,883 | |
| Prepaid expenses | ... | 172,302 | |
| Total current assets | 2,254,041 | 3,169,625 | |
| Deferred tax asset, net of valuation allowance | 1,059,000 | 1,043,000 | |
| Total long-term assets | 1,059,000 | 1,043,000 | |
| Total assets | 3,313,041 | 4,212,625 | |
| Accounts payable & accrued liabilities | 39,229 | 29,253 | |
| Accounts payable & accrued liabilities - related parties | 238,836 | 193,175 | |
| Total current liabilities | 278,065 | 222,428 | |

| | | |
|---|--------------|--------------|
| Preferred Shareholders Equity - Total | 290 | ... |
| Series A preferred stock | ... | 290 |
| Common stock | 69,355 | 77,842 |
| Treasury stock | 9,093 | 9,093 |
| Additional paid-in capital | 28,200,259 | 29,230,625 |
| Common shares to be issued | 22,400 | 22,400 |
| Accumulated other comprehensive income (loss) | (15,414) | (16,067) |
| Accumulated deficit | (25,232,821) | ... |
| Retained earnings (accumulated deficit) | ... | (25,315,800) |
| Total stockholders' equity (deficit) | 3,034,976 | 3,990,197 |
| Total Equity | 3,034,976 | ... |

Recent Dividends:

1. Patriot Gold Corp common.

No dividends paid.

2. Patriot Gold Corp series A preferred.

No dividends paid.

Annual Dividends:

1. Patriot Gold Corp common.

No dividends paid.

2. Patriot Gold Corp series A preferred.

No dividends paid.

PAYSIGN INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|------------|-------------|
| | | (revised) | (revised) |
| Other | 1,271,466 | ... | ... |
| Total revenues | 47,274,162 | 38,033,667 | 29,464,849 |
| Plasma industry | 41,951,659 | 34,737,640 | 25,918,150 |
| Pharma industry | 4,051,037 | 3,007,140 | 3,361,869 |
| Other revenue | ... | 288,887 | 184,830 |
| Cost of revenues | 23,137,997 | 17,079,069 | 14,753,042 |
| Gross profit | 24,136,165 | 20,954,598 | 14,711,807 |
| Depreciation & amortization | 4,026,578 | 2,909,612 | 2,497,918 |
| Selling, general & administrative | 20,276,842 | 17,700,651 | 14,953,322 |
| Total operating expenses | 24,303,420 | 20,610,263 | 17,451,240 |
| Income (loss) from operations | (167,255) | 344,335 | (2,739,433) |
| Interest income, net | 2,531,071 | 790,917 | 28,297 |
| Income (loss) before income tax provision (benefit) & noncontrolling interest | 2,363,816 | 1,135,252 | (2,711,136) |
| Current federal income tax provision (benefit) | 60,864 | 30,200 | ... |
| Current state income tax provision (benefit) | 143,955 | 77,277 | 10,198 |
| Current income taxes (benefit) | 204,819 | 107,477 | 10,198 |
| Deferred federal income tax provision (benefit) | (4,002,660) | ... | ... |
| STATE - Local - Deferred | (297,070) | ... | ... |
| Deferred income tax provision (benefit) | (4,299,730) | ... | ... |
| Income tax provision (benefit) | (4,094,911) | 107,477 | 10,198 |
| Net income (loss) | 6,458,727 | 1,027,775 | (2,721,334) |
| Weighted average shares outstanding - basic | 52,487,840 | 52,048,127 | 50,975,794 |
| Weighted average shares outstanding - diluted | 54,162,485 | 52,933,255 | 50,975,794 |
| Year end shares outstanding | 52,754,374 | 52,346,932 | 51,791,932 |
| Net income (loss) | ... | ... | ... |

| | | | |
|--|--------|--------|----------|
| per share - basic | \$0.12 | \$0.02 | \$(0.05) |
| Net income (loss) per share - diluted | \$0.12 | \$0.02 | \$(0.05) |
| Full-Time Employees (Period End) | 123 | ... | ... |
| Total number of employees | 123 | 110 | 80 |
| Number of common stockholders | 9,380 | 10,907 | 11,145 |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$0.12 | ... | ... |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$0.12 | ... | ... |

Approximately

| | 2023 | 2022 |
|--|-------------|-------------|
| Cash | 16,994,705 | 9,708,238 |
| Restricted cash | 92,356,308 | 80,189,113 |
| Accounts receivable, net | 16,222,341 | 4,680,991 |
| Other receivables | 1,585,983 | 1,439,251 |
| Prepaid expenses & other current assets | 2,020,781 | 1,699,808 |
| Total current assets | 129,180,118 | 97,717,401 |
| Equipment | 2,399,243 | 2,161,424 |
| Software | 345,057 | 327,452 |
| Furniture & fixtures | ... | 757,661 |
| Website costs | 69,881 | 69,881 |
| Leasehold improvements | 236,904 | 229,772 |
| Leasehold equipment | 757,662 | ... |
| Total fixed assets | 3,808,747 | 3,546,190 |
| Less: accumulated depreciation | 2,719,098 | 2,290,898 |
| Fixed assets, net | 1,089,649 | 1,255,292 |
| Intangible assets, net | 8,814,327 | 5,656,722 |
| Operating lease right-of-use asset | 3,215,025 | 3,614,838 |
| Deferred tax asset | 4,299,730 | ... |
| Total assets | 146,598,849 | 108,244,253 |
| Accounts payable & accrued liabilities | 26,517,567 | 8,088,660 |
| Operating lease liability, current portion | 383,699 | 361,408 |
| Customer card funding | 92,282,124 | 80,189,113 |
| Total current liabilities | 119,183,390 | 88,639,181 |
| Operating lease liability, long term portion | 2,928,078 | 3,311,777 |
| Total liabilities | 122,111,468 | 91,950,958 |
| Common stock | 53,452 | 52,650 |
| Additional paid-in capital | 21,999,722 | 19,137,281 |
| Treasury stock at cost | 1,277,884 | 150,000 |
| Retained earnings (accumulated deficit) | 3,712,091 | (2,746,636) |
| Total Paysign, Inc. stockholders' equity (deficit) | 24,487,381 | 16,293,295 |
| Total stockholders' equity (deficit) | 24,487,381 | 16,293,295 |

Recent Dividends:

1. Paysign Inc common.

No dividends paid.

Annual Dividends:

1. Paysign Inc common.

No dividends paid.

PDS BIOTECHNOLOGY CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|------------------------|------|------|------|
| Research & development | | | |

| | | | |
|---|---------------------|---------------------|---------------------|
| expenses | 27,762,784 | 29,431,027 | 11,254,538 |
| General & administrative expenses | 15,282,450 | 12,241,394 | 10,184,773 |
| Total operating expenses | 43,045,234 | 41,672,421 | 21,439,311 |
| Income (loss) from operations | (43,045,234) | (41,672,421) | (21,439,311) |
| Interest income | 2,902,939 | 935,180 | 4,346 |
| Interest expense | 4,205,922 | 1,316,519 | ... |
| Interest income (expense), net | ... | (381,339) | 4,346 |
| Income (loss) before income taxes | (44,348,217) | (42,053,760) | (21,434,965) |
| Provision (benefit) from income taxes | (1,406,019) | (1,198,905) | (4,516,488) |
| Net income (loss) | (42,942,198) | (40,854,855) | (16,918,477) |
| Weighted average shares outstanding - basic | 30,952,060 | 28,599,221 | 25,597,125 |
| Weighted average shares outstanding - diluted | 30,952,060 | 28,599,221 | 25,597,125 |
| Year end shares outstanding | 33,094,521 | 30,170,317 | 28,448,612 |
| Net income (loss) per share - basic | \$(1.39) | \$(1.43) | \$(0.66) |
| Net income (loss) per share - diluted | \$(1.39) | \$(1.43) | \$(0.66) |
| Number of full time employees | 25 | 26 | ... |
| Total number of employees | 25 | 26 | 22 |
| Number of common stockholders | 41 | 44 | 44 |
| Non-operating Income/(Expense), Net | (1,302,983) | ... | ... |

Shares increased due to the issuance of common shares from exercise of share options and 401K match; As of March 16, 2023; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 56,560,517 | 73,820,160 |
| Prepaid expenses & other current assets | ... | 2,660,230 |
| Prepaid expenses and other | 2,494,558 | ... |
| Total current assets | 59,055,075 | 76,480,390 |
| Furniture & equipment | 14,964 | 14,964 |
| Computer & telephone equipment | 266,911 | 13,545 |
| Lab equipment | 238,402 | 86,911 |
| Computer and Telephone equipment | 13,545 | ... |
| Total furniture & equipment | ... | 115,420 |
| Less accumulated depreciation - property & equipment | 132,779 | 115,420 |
| Property & equipment, net | 134,132 | ... |
| Financing lease right-to-use assets | 200,873 | 374,888 |
| Operating lease right-to-use asset | ... | 152,645 |
| Total assets | 59,390,080 | 77,007,923 |
| Accounts payable | 6,982,824 | 1,219,287 |
| Accrued research & development costs | ... | 5,645,737 |
| Accrued professional fees | ... | 550,259 |
| Accrued compensation | 1,289,690 | 1,837,330 |
| Accrued interest on debt | 306,771 | 280,382 |
| Accrued Expenses - Balancing value | 828,231 | ... |
| Accrued expenses | 2,424,692 | 8,313,708 |
| Financing lease obligation - short term | 55,794 | 56,612 |
| Operating lease obligation - short term | ... | 231,429 |
| Notes payable - short | ... | ... |

| | | |
|---|---------------|---------------|
| term | 4,166,667 | ... |
| Total current liabilities | 13,629,977 | 9,821,036 |
| Note payable, net of debt discount | 19,506,183 | 23,020,844 |
| Financing lease obligation-long term | 122,973 | 164,013 |
| Total liabilities | 33,259,133 | 33,005,893 |
| Common stock | 10,921 | 9,956 |
| Additional paid-in capital | 170,620,641 | 145,550,491 |
| Retained earnings (accumulated deficit) | (144,500,615) | (101,558,417) |
| Total stockholders' equity (deficit) | 26,130,947 | 44,002,030 |
| Total Equity | 26,130,947 | ... |

Recent Dividends:

1. PDS Biotechnology Corp series C-1 convertible preferred.

No dividends paid.

2. PDS Biotechnology Corp common.

No dividends paid.

3. PDS Biotechnology Corp series B convertible preferred.

No dividends paid.

4. PDS Biotechnology Corp series B-1 convertible preferred.

No dividends paid.

5. PDS Biotechnology Corp series C convertible preferred.

No dividends paid.

6. PDS Biotechnology Corp series A convertible preferred.

No dividends paid.

Annual Dividends:

1. PDS Biotechnology Corp series C-1 convertible preferred.

No dividends paid.

2. PDS Biotechnology Corp common.

No dividends paid.

3. PDS Biotechnology Corp series B convertible preferred.

No dividends paid.

4. PDS Biotechnology Corp series B-1 convertible preferred.

No dividends paid.

5. PDS Biotechnology Corp series C convertible preferred.

No dividends paid.

6. PDS Biotechnology Corp series A convertible preferred.

No dividends paid.

PEREGRINE INDUSTRIES, INC.

Earnings, 6 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|------------------|------------------|
| Total revenues | 9,313 | 10,477 |
| Cost & expenses | 112,689 | 118,387 |
| Operating income | (103,376) | (159,828) |
| Other income (expense), net | ... | (3,725) |
| Net before taxes | (103,376) | (163,553) |
| Net income | (103,376) | (163,553) |
| Earnings common share | ... | ... |
| Common Shares: | ... | ... |
| Full Diluted | 252,124,200 | 251,252,461 |
| Year-end | 252,124,221 | 252,024,200 |

PETROS PHARMACEUTICALS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|------------|------------|----------------|
| Total revenues | 5,822,388 | ... | ... |
| Net sales | 5,822,388 | 5,992,054 | 7,811,264 |
| Cost of goods sold | 1,631,220 | 2,289,418 | 1,599,566 |
| Gross profit | 4,191,168 | 3,702,636 | 6,211,698 |
| General & administrative expenses | 9,261,471 | 12,209,162 | 15,593,233 |
| Research & development | 2,409,094 | 1,740,280 | 1,788,491 |
| Depreciation & amortization expense | 3,282,967 | 5,598,884 | 6,877,990 |
| Intangible asset impairment | ... | 7,460,000 | ... |
| Gain on settlement with Vivus, Inc. ("Vivus") | ... | 3,389,941 | ... |
| Warrant issuance costs | 2,855,000 | ... | ... |
| Total operating expenses | 17,808,532 | 23,618,385 | 24,259,714 |
| Income (loss) from | ... | ... | ... |

| | | | |
|---|--------------------|---------------------|--------------------|
| operations | (13,617,364) | (19,915,749) | (18,048,016) |
| Change in fair value of derivative liability | (11,088,997) | 460,000 | 9,430,000 |
| Interest income | 515,311 | 14,194 | ... |
| Interest expense, senior debt | ... | ... | 368,660 |
| Interest expense, promissory note | 536,138 | 596,018 | ... |
| Income (loss) before income taxes | (8,163,188) | (20,037,573) | ... |
| Income tax expense (benefit) | ... | 0 | ... |
| Distribution for Preferred Shares | 5,651,211 | ... | ... |
| Net income (loss) | (8,163,188) | (20,037,573) | (8,986,676) |
| Weighted average shares outstanding | | | |
| - basic | 2,176,017 | 2,070,210 | 1,088,977 |
| Weighted average shares outstanding - diluted | 2,176,017 | 2,070,210 | 1,088,977 |
| Year end shares outstanding | 2,991,377 | 2,079,387 | 2,068,472 |
| Net income (loss) per share - basic | \$(6.35) | \$(9.68) | \$(8.25) |
| Net income (loss) per share - diluted | \$(6.35) | \$(9.68) | \$(8.25) |
| Number of full time employees | 21 | 24 | 24 |
| Total number of employees | 21 | ... | ... |
| Number of common stockholders | 297 | 185 | 181 |
| Change in fair value of derivative liability | 2,590,000 | ... | ... |
| Change in fair value of warrant liability | 13,974,000 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (13,814,399) | ... | ... |

[□] Reclassified to conform with 2022 presentation; [▣] Adjusted for 1-for-10 stock split, December 1, 2022; [▢] Shares increased due to the effect of conversion of preferred stock to common stock, issuance of common stock, proceeds from exercise of warrants, non-employee stock-based compensation; [▤] Approximately; [▥] As of March 31, 2023; [▦] As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 13,336,975 | 9,426,264 |
| Gross accounts receivables | 2,461,248 | 2,757,839 |
| Distribution service fees | ... | (339,094) |
| Chargebacks accruals | ... | (1,960) |
| Cash discount allowances | ... | 99,671 |
| Allowance for doubtful accounts | 235,097 | 206,868 |
| Accounts receivable, net | 2,226,151 | 2,110,246 |
| Raw materials | 1,430,139 | 1,574,683 |
| Finished goods | 180,252 | 240,430 |
| Inventories | 1,610,391 | 1,815,113 |
| Prepaid insurance | 45,664 | 109,414 |
| Prepaid FDA fees | 937,652 | ... |
| Prepaid coupon fees | 2,033,980 | 71,500 |
| API purchase commitment asset | 704,729 | 663,984 |
| Other prepaid expenses | 234,459 | 333,158 |
| Other current assets | 111,476 | 138,226 |
| Prepaid samples | 1,182,899 | ... |
| Prepaid expenses & other current assets | ... | 1,316,282 |
| Total current assets | 20,390,396 | 14,667,905 |
| Fixed assets, net | 28,957 | 39,177 |
| Intangible assets, net | 8,971,737 | 12,244,484 |
| API purchase commitment asset | 4,178,446 | 5,111,176 |
| Operating lease | ... | ... |

| | | |
|---|--------------|--------------|
| right-of-use asset | 226,259 | ... |
| Other assets | 226,259 | 358,472 |
| Total assets | 33,795,795 | 32,421,214 |
| Current portion of promissory note | 1,156,550 | 1,089,683 |
| Accounts payable | 1,713,253 | 1,806,399 |
| Accrued product returns | 4,178,176 | 2,311,647 |
| Accrued contract rebates | 128,562 | 279,018 |
| Due to 3PL or wholesalers | 2,047,583 | 155,081 |
| Accrued bonuses | 665,184 | 427,500 |
| Accrued professional fees | 15,000 | 51,620 |
| Other accrued expenses | 297,428 | 409,796 |
| Due to third-party logistic provider | 75,727 | ... |
| Accrued expenses | 5,360,077 | 3,634,662 |
| Other current liabilities | 493,288 | 537,232 |
| Total current liabilities | 10,770,751 | 7,067,976 |
| Long-term portion of senior debt | 6,857,364 | ... |
| Promissory note, net of current portion | ... | 8,388,093 |
| Derivative liabilities | 3,550,000 | ... |
| Other long-term liabilities | 137,657 | 262,678 |
| Total liabilities | 21,315,772 | 15,718,747 |
| Common stock, net | 298 | 208 |
| Additional paid-in capital | 110,960,324 | 107,428,652 |
| Accumulated deficit | (98,889,581) | ... |
| Retained earnings (accumulated deficit) | ... | (90,726,393) |
| Preferred Stock - Redeemable | 408,982 | ... |
| Total stockholders' equity | 12,480,023 | 16,702,467 |
| Total Equity | 12,480,023 | ... |

Recent Dividends:

- Petros Pharmaceuticals Inc preferred.**
No dividends paid.
- Petros Pharmaceuticals Inc common.**
No dividends paid.
- Petros Pharmaceuticals Inc series A convertible redeemable preferred.**
No dividends paid.

Annual Dividends:

- Petros Pharmaceuticals Inc preferred.**
No dividends paid.
- Petros Pharmaceuticals Inc common.**
No dividends paid.
- Petros Pharmaceuticals Inc series A convertible redeemable preferred.**
No dividends paid.

PHARMACYTE BIOTECH INC

Earnings, 9 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|--------------|-------------|
| Cost & expenses | 5,353,792 | 5,552,211 |
| Operating income | (5,353,792) | (5,552,211) |
| Interest income | 2,651,721 | 1,214,562 |
| Other income (expense), net | 1,967,133 | 147,994 |
| Gains or losses | (278,000) | ... |
| Net before taxes | (1,012,938) | ... |
| Net income | (1,012,938) | (4,189,655) |
| Balance for common | (14,696,861) | ... |
| Earnings common share | | |
| Primary | \$(1.47) | \$(0.21) |
| Fully Diluted | \$(1.47) | \$(0.21) |
| Common Shares: | | |
| Full Diluted | 9,991,326 | 20,051,617 |
| Year-end | 8,521,159 | 18,209,018 |

PHI GROUP INC.

Annual Report

Consolidated Income Statement, Years Ended Jun. 30 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|---------|---------|----------------|
| Consulting, advisory & management services | ... | 30,000 | 61,000 |
| Sales | 25,000 | ... | ... |
| Total revenues | 25,000 | 30,000 | 61,000 |
| Salaries & wages | 360,000 | 360,000 | 247,500 |
| Professional | ... | ... | ... |

| | | | |
|---|----------------|----------------|----------------|
| services, including non-cash compensation | 95,242 | 15,347,903 | 508,280 |
| Asia diamond exchange development costs | 464,848 | 1,018,651 | ... |
| General & administrative | 105,533 | 203,374 | 157,836 |
| Total operating expenses | 1,025,623 | 16,929,928 | 913,616 |
| Income (loss) from operations | (1,000,623) | (16,899,928) | (852,616) |
| Other income | 488 | 1,118,195 | 406,776 |
| Interest expense | ... | 1,592,557 | 369,280 |
| Other expenses | ... | 3,780,153 | 5,738,058 |
| Other income (expense) | (3,674,139) | ... | ... |
| Debit interest expense | 934,872 | ... | ... |
| Net other income (expenses) | (4,608,523) | (4,254,515) | (5,700,562) |
| Income (loss) before minority interest | (5,609,146) | ... | ... |
| Net income (loss) | (5,609,146) | (21,154,443) | (6,553,178) |
| Weighted average shares outstanding | | | |
| - basic | 34,455,935,655 | 28,448,615,941 | 17,386,377,288 |
| Weighted average shares outstanding - diluted | 34,455,935,655 | 28,448,615,941 | 17,386,377,288 |
| Year end shares outstanding | 39,414,493,275 | 31,429,380,453 | 26,081,268,895 |
| Net income (loss) per share - basic | ... | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | ... | \$0.00 | \$0.00 |
| Number of common stockholders | 1,605 | 1,592 | 1,586 |

[□] Reclassified to conform with 2022 presentation; [▢] Shares increased due to the effect of common shares issued for conversion of note; [▣] Shares increased due to the effect of common shares issued for conversion of notes, for cash, for conversion of preferred stock, for investment and for note agreement; [▤] Approximately; [▥] As of January 12, 2023; [▦] As of October 10, 2021

Consolidated Balance Sheet, Years Ended Jun. 30 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 19,765 | 67,896 |
| Marketable securities | 420 | 546 |
| Other current assets | 241,426 | 365,360 |
| Total current assets | 261,611 | 433,802 |
| Investments | 32,604 | 36,161 |
| Total assets | 294,215 | 469,963 |
| Accounts payable | 616,245 | 615,805 |
| Sub-fund obligations | 1,624,775 | 1,574,775 |
| Accrued salaries | ... | 673,842 |
| Accrued payroll taxes | ... | 257,575 |
| Accrued expenses | 1,485,310 | 931,417 |
| Short-term loans & notes payable | 1,164,685 | 676,888 |
| Convertible promissory notes (net) | 297,805 | 756,250 |
| Due to officers | ... | 1,077,218 |
| Payable to related party | 1,027,782 | ... |
| Advances from customers | 1,079,038 | 665,434 |
| Derivative liabilities | 1,220,576 | ... |
| Derivative liabilities & note discount | ... | 715,677 |
| Total current liabilities | 8,516,217 | ... |
| Total liabilities | 8,516,217 | 7,013,465 |
| Preferred stock - class B series I | 600 | 600 |
| APIC - class B series I preferred stock | ... | 1,840 |
| Total preferred stock | ... | 2,440 |
| Common stock | 39,414,493 | 31,429,381 |
| APIC - common stock | 32,773,102 | 34,394,912 |
| Common stock to be cancelled | 22,500 | (35,500) |
| Additional paid-in-capital | 1,840 | ... |

| | | |
|---|--------------------------|--------------|
| Treasury stock | 44,170 | 44,170 |
| Accumulated deficit | (77,319,372) | ... |
| Retained earnings (accumulated deficit) | ... | (71,717,973) |
| Accumulated other comprehensive income (loss) | (3,035,495) | (572,591) |
| Common stock to be cancelled | (35,500) | ... |
| Total stockholders' equity (deficit) | (8,222,002) [□] | (6,543,502) |
| Total stockholders' equity (deficit) | (8,222,002) | ... |

[□] As reported by the Company

Recent Dividends:

1. PHI Group Inc. class B series I preferred.

No dividends paid.

2. PHI Group Inc. common.

No dividends paid.

3. PHI Group Inc. class A series II preferred.

No dividends paid.

Annual Dividends:

1. PHI Group Inc. class B series I preferred.

No dividends paid.

2. PHI Group Inc. common.

No dividends paid.

3. PHI Group Inc. class A series II preferred.

No dividends paid.

PHI GROUP INC.

Earnings, 6 mos. to Dec 31 (Consol. - \$):

| | 2023 | 2022 |
|-----------------------------------|----------------------------|--------------------|
| Total revenues | 5,000 | 25,000 |
| Cost & expenses | 432,423 | 501,980 |
| Operating income | (427,423) | (476,980) |
| Interest expense | 280,300 | 445,896 |
| Other income (expense), net | (3,994,117) | (1,515,080) |
| Net before taxes | (4,701,841) | ... |
| Net income | (4,701,841) | (2,437,956) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 42,675,273,083,009,795,067 | ... |
| Year-end | 43,292,138,033,645,885,430 | ... |

PHIO PHARMACEUTICALS CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [□] 2021 (revised) |
|---|---------------------|---------------------|-----------------------------|
| Research & development | 6,332,000 | 7,012,000 | 8,886,000 |
| General & administrative | 4,366,000 | 4,450,000 | 4,625,000 |
| Loss on impairment of property and equipment | 126,000 | ... | ... |
| Total operating expenses | 10,824,000 | 11,462,000 | 13,511,000 |
| Operating income (loss) | (10,824,000) | (11,462,000) | (13,511,000) |
| Other income (expense), net | (2,000) | ... | ... |
| Total other income (expense), net | (2,000) | (18,000) | 224,000 |
| Income (loss) before income taxes .. | (10,826,000) | (11,480,000) | (13,287,000) |
| Deferred income tax expense (benefit) - federal | (1,831,000) | (1,733,000) | (3,016,000) |
| Deferred income tax expense (benefit) - state | (718,000) | (553,000) | (1,329,000) |
| Total deferred income tax expense (benefit) | (2,549,000) | (2,286,000) | (4,345,000) |
| Valuation allowance | 2,549,000 | 2,286,000 | 4,345,000 |
| Net income (loss) | (10,826,000) | (11,480,000) | (13,287,000) |
| Weighted average shares outstanding - basic | 2,083,569 | 1,136,566 | [□] 1,069,234 |
| Weighted average shares outstanding - diluted | 2,083,569 | 1,136,566 | [□] 1,069,234 |

| | | | |
|---|-----------|-------------------------|------------------------|
| Year end shares outstanding | 3,747,329 | 1,139,024 ^{□□} | 1,127,916 |
| Net income (loss) per share - basic | \$(5.20) | \$(10.10) | [□] \$(12.43) |
| Net income (loss) per share - diluted | \$(5.20) | \$(10.10) | [□] \$(12.43) |
| Number of full time employees | 8 | 9 | 12 |
| Number of part time employees | 1 | 1 | ... |
| Number of common stockholders | 19 | ^{□□} 19 | ^{□□} 17 |
| Earnings per share from continuing operations | \$(5.20) | ... | ... |
| Earnings per share from continuing operations | \$(5.20) | ... | ... |
| Total number of employees | 9 | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-12 stock split, January 26, 2023; [□] Shares increased due to the effect of common stock issued for private placement, for registered direct offering and for exercise of warrants; [□] Approximately; [□] As of March 9, 2023; [□] As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash | ... | 11,781,000 |
| Cash & cash equivalents | 8,490,000 | ... |
| Restricted cash | ... | 50,000 |
| Prepaid expenses & other current assets | 832,000 | 615,000 |
| Total current assets | 9,322,000 | 12,446,000 |
| Right of use assets, net | 33,000 | 161,000 |
| Computer equipment | 62,000 | 116,000 |
| Machinery & equipment | 964,000 | 1,077,000 |
| Furniture & fixtures | 70,000 | 119,000 |
| Leasehold improvements | 46,000 | 46,000 |
| Total gross fixed assets | 1,142,000 | 1,358,000 |
| Less: accumulated depreciation | 1,136,000 | ... |
| Less: accumulated depreciation & amortization | ... | 1,175,000 |
| Property & equipment, net | 6,000 | 183,000 |
| Other assets | 3,000 | 24,000 |
| Total assets | 9,364,000 | 12,814,000 |
| Accounts payable | 657,000 | 779,000 |
| Accrued compensation & benefits | 222,000 | 408,000 |
| Accrued professional fees | 126,000 | 97,000 |
| Accrued research & development costs | 517,000 | 501,000 |
| Other accrued expenses | 942,000 | 19,000 |
| Other | 77,000 | ... |
| Accrued expenses | ... | 1,025,000 |
| Lease liability, current | 35,000 | 135,000 |
| Total current liabilities | 1,634,000 | 1,939,000 |
| Lease liability, net of current portion | ... | 35,000 |
| Total liabilities | 1,634,000 | 1,974,000 |
| Series D preferred stock | ... | 2,000 |
| Additional paid-in capital | 146,936,000 | 139,218,000 |
| Accumulated deficit | (139,206,000) | ... |
| Retained earnings (accumulated deficit) | ... | (128,380,000) |
| Total stockholders' equity (deficit) | 7,730,000 | 10,838,000 |
| Total Equity | 7,730,000 | ... |

Recent Dividends:

1. Phio Pharmaceuticals Corp series A-1 convertible preferred.

No dividends paid.

2. Phio Pharmaceuticals Corp series D preferred.

No dividends paid.

3. Phio Pharmaceuticals Corp common.

No dividends paid.

4. Phio Pharmaceuticals Corp series B convertible preferred.

No dividends paid.

5. Phio Pharmaceuticals Corp series A convertible preferred.

No dividends paid.

Annual Dividends:

1. Phio Pharmaceuticals Corp series A-1 convertible preferred.

No dividends paid.

2. Phio Pharmaceuticals Corp series D preferred.

No dividends paid.

3. Phio Pharmaceuticals Corp common.

No dividends paid.

4. Phio Pharmaceuticals Corp series B convertible preferred.

No dividends paid.

5. Phio Pharmaceuticals Corp series A convertible preferred.

No dividends paid.

PHOENIX MOTOR INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | [□] 2021 (revised) |
|--|-----------------|--------------------|-----------------------------|
| Total revenues | 3,122 | ... | ... |
| Revenues | 3,122 | ... | ... |
| Net revenues | ... | [□] 4,330 | 2,977 |
| Cost of revenues | 3,398 | 3,510 | 3,540 |
| Gross profit (loss) | (276) | 820 | (563) |
| Selling, general & administrative | 14,902 | 13,970 | 13,750 |
| Operating income (loss) | (20,506) | (13,150) | (14,313) |
| Interest income (expenses), net | (606) | (7) | (3) |
| Other income (expenses), net | 209 | 461 | (287) |
| Change in fair value of derivative liability | (319) | ... | ... |
| Loss on sales-type leases | (98) | ... | ... |
| Employee retention credit | (697) | ... | ... |
| Total other income (expenses), net | (117) | 454 | (290) |
| Income (loss) before income taxes .. | (20,623) | (12,696) | (14,603) |
| Current state income tax expenses .. | ... | 9 | 11 |
| Total current income tax expenses .. | ... | 9 | 11 |
| Income tax expenses .. | 22 | 9 | 11 |
| Net income (loss) | (20,645) | (12,705) | (14,614) |
| Weighted average shares outstanding - basic | 21,199 | 19,664 | 17,500 |
| Weighted average shares outstanding - diluted | 21,199 | 19,664 | 17,500 |
| Year end shares outstanding | 21,901 | 20,277 | 17,500 |
| Net earnings (loss) per common stock - basic | \$(0.97) | \$(0.65) | \$(0.84) |
| Net earnings (loss) per common stock - diluted | \$(0.97) | \$(0.65) | \$(0.84) |
| Number of full time employees | 30 | [□] 60 | [□] 55 |
| Number of common stockholders | 14 | ^{□□} 3 | ... |
| Impairment of long-lived assets | 4,968 | ... | ... |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.97) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |

| | | | | | | | | | |
|---|---------------|---------------|--|-------------|--------------|-------------|--|--------------|--------------|
| Accumulated other comprehensive income (loss) | 28,000 | (254,000) | Operating income (loss) from continuing operations before income taxes | (6,820,716) | (3,265,819) | (8,153,859) | Cash & cash equivalents | 3,575,283 | 2,187,540 |
| Retained earnings (accumulated deficit) | (314,964,000) | (290,421,000) | Current federal income taxes (benefit) | 17,622 | ... | 6,000 | Restricted cash & cash equivalents | 1,821,060 | 3,068,938 |
| Total stockholders' equity (deficit) | 26,758,000 | 27,929,000 | Current state income taxes (benefit) | 59,975 | 12,237 | 19,000 | Investments | ... | 2,666,766 |
| Total Equity | 26,758,000 | ... | Total current income taxes (benefit) | 77,597 | ... | 25,000 | Trade accounts receivable, gross | 5,104,903 | 5,673,168 |
| | | | Deferred federal income taxes (benefit) | 41,579 | ... | ... | Allowance for doubtful accounts | 94,085 | 108,636 |
| | | | Total deferred income taxes (benefit) | 41,579 | ... | ... | Trade accounts receivable | 5,010,818 | 5,564,532 |
| | | | Income tax expense (benefit) | 119,176 | 12,237 | 24,575 | Receivable from sale of discontinued operations | 46,448 | ... |
| | | | Net income (loss) from continuing operations | (6,939,892) | (3,278,056) | (8,178,434) | Inventories, net | 3,578,668 | 6,054,493 |
| | | | Net income (loss) from discontinued operations, net of tax | ... | (7,074,184) | 11,152,081 | Employee retention credit | 57,241 | 1,584,541 |
| | | | Net income (loss) from discontinued operations | (1,192,275) | ... | ... | Related party receivables | ... | 116,710 |
| | | | Net income (loss) | (8,132,167) | (10,352,240) | 2,973,647 | Prepaid expenses | 1,313,082 | 2,152,058 |
| | | | Weighted average shares outstanding - basic | 10,035,970 | 6,741,446 | 2,384,464 | Costs & estimated earnings in excess of billings | ... | 777,485 |
| | | | Weighted average shares outstanding - diluted | 10,035,970 | 6,741,446 | 2,418,880 | Other current assets | 376,048 | 634,362 |
| | | | Year end shares outstanding | 10,246,605 | 9,915,586 | 2,430,157 | Current assets held for sale | ... | 1,154,099 |
| | | | Income (loss) per share from continuing operations - basic | \$(0.69) | \$(2.99) | \$(3.44) | Total current assets | 15,778,648 | 25,961,524 |
| | | | Income (loss) per share from discontinued operations - basic | \$(0.12) | \$(1.05) | \$(4.68) | Leasehold improvements | 751,025 | 686,840 |
| | | | Net income (loss) per share - basic | \$(0.81) | \$(4.04) | \$(1.24) | Machinery & equipment | 1,182,664 | 544,479 |
| | | | Income (loss) per share from continuing operations - diluted | \$(0.69) | \$(2.99) | \$(3.40) | Furniture & fixtures | 93,013 | 57,753 |
| | | | Net income (loss) per share - diluted | \$(0.81) | \$(4.04) | \$(1.24) | Gross property, plant & equipment | 2,026,702 | 1,289,072 |
| | | | Dividends per common share | ... | ... | 14.00 | Less: accumulated depreciation | 514,824 | 98,140 |
| | | | Full-Time Employees (Period End) | 201 | ... | ... | Property, plant & equipment, net | 1,511,878 | 1,190,932 |
| | | | Total number of employees | 201 | 255 | 39 | Goodwill | 20,545,850 | 20,545,850 |
| | | | Number of common stockholders | 272 | 272 | 465 | Right of use asset | 4,516,102 | 4,166,838 |
| | | | Foreign currency translation adjustments | ... | ... | 699,576 | Intangible assets, net | 15,808,333 | 20,546,810 |
| | | | | | | | Other assets | 12,000 | 12,000 |
| | | | | | | | Noncurrent assets held for sale | ... | 2,271,533 |
| | | | | | | | Total assets | 58,172,811 | 74,695,487 |
| | | | | | | | Accounts payable | 7,677,261 | 7,594,181 |
| | | | | | | | Accrued compensation & benefits | 1,360,148 | 859,774 |
| | | | | | | | Operating lease liability | 394,042 | 220,763 |
| | | | | | | | Other current liabilities | 867,727 | 1,238,777 |
| | | | | | | | Other accrued liabilities | 268,004 | ... |
| | | | | | | | Related party payables | ... | 2,181,761 |
| | | | | | | | Income taxes payable | 5,373 | 1,650 |
| | | | | | | | Refundable customer deposits | 2,112,363 | 4,285,129 |
| | | | | | | | Billings in excess of costs & estimated earnings | 440,089 | 2,705,409 |
| | | | | | | | Current portion of loans payable | 1,654,881 | 346,290 |
| | | | | | | | Current portion of loans payable - related party | 3,402,522 | 5,339,265 |
| | | | | | | | Current liabilities held for sale | 2,500,000 | 1,161,159 |
| | | | | | | | Contingent value rights | 1,691,072 | ... |
| | | | | | | | Total current liabilities | 22,373,482 | 25,934,158 |
| | | | | | | | Loans payable & related interest | 8,030,562 | 3,138,194 |
| | | | | | | | Loans payable & related interest - related party | 2,097,194 | 4,635,914 |
| | | | | | | | Deferred income taxes | 41,579 | ... |
| | | | | | | | Operating lease liability | 4,193,205 | 3,961,340 |
| | | | | | | | Earnout consideration | 1,000,000 | 2,150,000 |
| | | | | | | | Contingent value rights | ... | 7,402,714 |
| | | | | | | | Long term liabilities held for sale | ... | 250,875 |
| | | | | | | | Total long-term liabilities | 15,362,540 | 21,539,037 |
| | | | | | | | Convertible preferred stock | 28,000 | 28,000 |
| | | | | | | | Common stock | 512,330 | 495,779 |
| | | | | | | | Additional paid-in capital | 46,977,870 | 45,798,069 |
| | | | | | | | Accumulated deficit | (27,081,411) | ... |
| | | | | | | | Retained earnings (accumulated deficit) | ... | (19,089,134) |
| | | | | | | | Unrealized gain (loss) on securities | ... | (10,422) |
| | | | | | | | Accumulated other comprehensive income | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):
 2023 2022

□ 2021 and prior periods for Company prior to reverse recapitalization with Communications Systems, Inc.; □ Rounding difference, breakdown taken from the notes; □ Adjusted for 1-for-4 stock split, March 21, 2022; □ As of March 1, 2022; □ Approximately

| | | |
|----------------------------------|------------|------------|
| (loss) | ... | (10,422) |
| Total stockholders' equity | 20,436,789 | 27,222,292 |
| Total Equity | 20,436,789 | ... |

Recent Dividends:**1. Pineapple Energy Inc common.**

No dividends paid.

Annual Dividends:**1. Pineapple Energy Inc common.**

No dividends paid.

POLAR POWER INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|--------------------|--------------------|
| Total revenues | 15,293,000 | ... | ... |
| Net sales | 15,293,000 | 16,056,000 | 16,896,000 |
| Depreciation in Cost of Revenues | 374,000 | ... | ... |
| Cost of sales - Balancing value | 13,246,000 | ... | ... |
| Cost of sales | 14,598,000 | 13,931,000 | 13,451,000 |
| Gross profit (loss) | 695,000 | 2,125,000 | 3,445,000 |
| Research & development expenses | 1,222,000 | 1,460,000 | 1,986,000 |
| Sales & marketing expenses | 1,172,000 | 1,471,000 | 1,488,000 |
| General & administrative expenses | 4,291,000 | 4,727,000 | 3,069,000 |
| Total operating expenses | 6,685,000 | 7,658,000 | 6,543,000 |
| Income (loss) from operations | (5,990,000) | (5,533,000) | (3,098,000) |
| Interest expense & finance costs | 559,000 | 58,000 | 60,000 |
| Gain from forgiveness of Paycheck Protection Program ("PPP") loan payable | ... | ... | 1,715,000 |
| Other income (expenses), net | 1,000 | 7,000 | 29,000 |
| Total other income (expenses), net | (558,000) | (51,000) | 1,684,000 |
| Income (loss) before income taxes | (6,548,000) | ... | ... |
| Net income (loss) | (6,548,000) | (5,584,000) | (1,414,000) |
| Weighted average shares outstanding - basic | 13,291,575 | 12,878,350 | 12,720,499 |
| Weighted average shares outstanding - diluted | 13,291,575 | 12,878,350 | 12,720,499 |
| Year end shares outstanding | 17,561,612 | 12,949,550 | 12,788,203 |
| Net income (loss) per share - basic | \$(0.49) | \$(0.43) | \$(0.11) |
| Net income (loss) per share - diluted | \$(0.49) | \$(0.43) | \$(0.11) |
| Number of full time employees | ... | 113 | 104 |
| Number of common stockholders | 21 | 21 | 10 |
| Earnings per share from continuing operations | \$(0.49) | ... | ... |
| Earnings per share from continuing operations | \$(0.49) | ... | ... |
| Rental Expenses in Cost of Revenues | 978,000 | ... | ... |

□ As of March 31, 2023; □ As of March 31, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-------------------------------|-----------|-----------|
| Cash & cash equivalents | 549,000 | 211,000 |
| Accounts receivable | 1,676,000 | 2,230,000 |

| | | |
|---|--------------|--------------|
| Employee retention credit receivable | 2,000,000 | 2,000,000 |
| Raw materials | 14,313,000 | 12,277,000 |
| Finished goods | 2,209,000 | 3,183,000 |
| Inventories, net | 16,522,000 | 15,460,000 |
| Prepaid expenses | 455,000 | 2,629,000 |
| Income taxes receivable | 787,000 | 787,000 |
| Total current assets | 21,989,000 | 23,317,000 |
| Operating lease right-of-use assets, net | 2,818,000 | 240,000 |
| Shop equipment & machinery | 3,565,000 | 3,371,000 |
| Production tooling, jigs, fixtures | 71,000 | 71,000 |
| Vehicles | 177,000 | 177,000 |
| Leasehold improvements | 390,000 | 390,000 |
| Office equipment | 106,000 | 185,000 |
| Software | ... | 106,000 |
| Office equipment | 185,000 | ... |
| Total property & equipment, cost | 4,494,000 | 4,300,000 |
| Less: accumulated depreciation & amortization | 4,150,000 | 3,762,000 |
| Property & equipment, net | 344,000 | 538,000 |
| Deposits | 108,000 | 93,000 |
| Total assets | 25,259,000 | 24,188,000 |
| Accounts payable | 1,762,000 | 230,000 |
| Customer deposits | 1,618,000 | 2,126,000 |
| Accrued liabilities & other current liabilities | 1,151,000 | 1,231,000 |
| Current portion of operating lease liabilities | 1,124,000 | 268,000 |
| Current portion of notes payable | 64,000 | 211,000 |
| Current portion of Paycheck Protection Program ("PPP") loan payable | 257,000 | ... |
| Line of credit | 4,238,000 | 1,884,000 |
| Total current liabilities | 10,214,000 | 5,950,000 |
| Notes payable, net of current portion | ... | 57,000 |
| Operating lease liabilities, net of current portion | 1,856,000 | ... |
| Total liabilities | 12,070,000 | 6,007,000 |
| Common stock | 2,000 | 1,000 |
| Additional paid-in capital | 38,886,000 | 37,331,000 |
| Accumulated deficit | (25,659,000) | ... |
| Retained earnings (accumulated deficit) | ... | (19,111,000) |
| Treasury Stock, at cost (17,477 shares) | 40,000 | ... |
| Treasury stock | ... | 40,000 |
| Total stockholders' equity | 13,189,000 | 18,181,000 |
| Total Equity | 13,189,000 | ... |

Recent Dividends:**1. Polar Power Inc common.**

No dividends paid.

Annual Dividends:**1. Polar Power Inc common.**

No dividends paid.

PONY GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|-----------------------|---------|---------|-------------------|
| Revenue | 177,570 | 114,288 | ... |
| Revenue | 177,570 | 114,288 | 157,627 |
| Cost of revenue | 96,107 | 77,043 | 102,314 |
| Gross profit | 81,463 | 37,245 | 55,313 |

| | | | |
|---|---------|---------|---------|
| General & administrative expenses | 229,301 | 322,787 | 160,812 |
| Research & development expense | ... | ... | 10,464 |
| Total operating | ... | ... | ... |

| | | | |
|---|------------------|------------------|-----------------|
| expenses | 229,301 | 322,787 | 171,276 |
| Income (loss) from operation | (147,838) | (285,542) | (115,963) |
| Other income (expense) | (683) | 1,514 | 17,957 |
| Total other income (expense) | (683) | 1,514 | 17,957 |
| Income (loss) before income taxes .. | (148,521) | (284,028) | (98,006) |
| Net income (loss) | (148,521) | (284,028) | (98,006) |
| Weighted average shares outstanding - basic | 11,500,000 | 11,500,000 | 11,500,000 |
| Weighted average shares outstanding - diluted | 11,500,000 | 11,500,000 | 11,500,000 |
| Year end shares outstanding | 11,500,000 | 11,500,000 | 11,500,000 |
| Earnings (loss) per common share - basic | \$(0.01) | \$(0.03) | \$(0.01) |
| Earnings (loss) per common share - diluted | \$(0.01) | \$(0.03) | \$(0.01) |
| Number of full time employees | 3 | ... | 3 |
| Number of part time employees | 1 | ... | 1 |
| Total number of employees | 4 | ... | 4 |
| Number of common stockholders | 22 | ... | 62 |

□ Restated to reflect correction of errors

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-----------|-----------|-------------------|
| Cash & cash equivalents | 16,578 | 33,996 | ... |
| Accounts receivables | 20,224 | 25,633 | ... |
| Other receivables | 260 | 43,344 | ... |
| Operating lease right-of-use assets | ... | 4,316 | ... |
| Total current assets | 37,062 | 107,289 | ... |
| Total assets | 37,062 | 107,289 | ... |
| Accounts payable | ... | 31,343 | ... |
| Other payable - related parties | 503,543 | 373,867 | ... |
| Other current liability | 51,649 | 58,317 | ... |
| Deferred revenue | ... | 14,910 | ... |
| Operating lease liabilities | ... | 4,316 | ... |
| Total current liabilities | 555,192 | 482,753 | ... |
| Total liabilities | 555,192 | 482,753 | ... |
| Ordinary shares | 11,500 | 11,500 | ... |
| Additional paid-in capital | 176,000 | 176,000 | ... |
| Accumulated foreign currency exchange income (loss) | (18,790) | (12,935) | ... |
| Retained earnings (accumulated deficit) | (724,420) | (575,899) | ... |
| Total Pony Group Inc stockholders' equity (deficit) | (518,130) | (375,464) | ... |
| Total equity (deficit) | (518,130) | (375,464) | ... |

□ Restated to reflect correction of errors

Recent Dividends:**1. Pony Group Inc common.**

No dividends paid.

Annual Dividends:**1. Pony Group Inc common.**

No dividends paid.

| | 2023 | 2022 | 2021 (revised) |
|----------------------------|------------|-----------|-------------------|
| Total revenues | 15,197,000 | ... | ... |
| Service revenue, net | 12,396,000 | 8,418,000 | 7,783,000 |
| Other revenue | 3,019,000 | 1,402,000 | 914,000 |

| | | | |
|---|-------------|--------------|-------------|
| Revenue, net of contractual allowances & adjustments | 9,820,000 | 8,697,000 | |
| Adjustment for allowance for doubtful accounts | 218,000 | 408,000 | (152,000) |
| Net sales | 15,197,000 | 9,412,000 | 8,849,000 |
| Cost of service revenue | 8,099,000 | 5,917,000 | 5,496,000 |
| Cost of sales - clinical research grants | 9,179,000 | | |
| Cost of other revenue | 1,080,000 | 985,000 | 961,000 |
| Total cost of sales | 6,902,000 | 6,457,000 | |
| Gross profit (loss) | 6,018,000 | 2,510,000 | 2,392,000 |
| Operating expenses | 13,638,000 | 15,307,000 | 12,005,000 |
| Total operating expenses | 13,638,000 | | |
| Operating income (loss) | (7,620,000) | (12,797,000) | (9,613,000) |
| Interest expense, net | 18,000 | 12,000 | 20,000 |
| Warrant revaluation | | 606,000 | 269,000 |
| Gain on settlement of liability | | 25,000 | 53,000 |
| Gain on forgiveness of paycheck protection program loan | | | 794,000 |
| Other income (expense), net | 65,000 | | |
| Gain on write-off of liability | (1,720,000) | | |
| Total other income (expense) | 1,767,000 | 619,000 | 1,096,000 |
| Income (loss) before income taxes | (5,853,000) | (12,178,000) | (8,517,000) |
| Net Income After Extraordinary Items applicable to Common | (5,853,000) | | |
| Net income (loss) | (5,853,000) | (12,178,000) | (8,517,000) |
| Less: net income attributable to noncontrolling interest in joint venture | | (25,000) | (13,000) |
| Net income (loss) attributable to Precipio, Inc. common stockholders | | (12,203,000) | (8,530,000) |
| Weighted average shares outstanding - basic | 1,297,851 | 1,137,573 | 1,054,910 |
| Weighted average shares outstanding - diluted | 1,297,851 | 1,137,573 | 1,054,910 |
| Year end shares outstanding | 1,420,125 | 1,141,013 | 1,135,422 |
| Income (loss) per share from continuing operations - basic | \$(4.51) | | |
| Net income (loss) per share - basic | \$(4.51) | \$(10.80) | \$(8.00) |
| Income (loss) per share from continuing operations - diluted | \$(4.51) | | |
| Net income (loss) per share - diluted | \$(4.51) | \$(10.80) | \$(8.00) |
| Number of full time employees | | 53 | 55 |
| Number of part time employees | | 3 | 1 |
| Number of common stockholders | 34 | 38 | 53 |

Adjusted for 1-for-20 stock split, September 22, 2023; Shares increased due to the effect of issuance of common stock

in connection with at the market offering, net of issuance costs; As of March 15, 2023; As of March 25, 2022; Approximately; As of March 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 1,502,000 | |
| Cash | | 3,445,000 |
| Accounts receivable, gross | 3,873,000 | 3,390,000 |
| Less: allowances for doubtful accounts | 2,572,000 | 2,354,000 |
| Accounts receivable, net | 1,301,000 | 1,036,000 |
| Gross inventories | 384,000 | |
| Inventories | | 708,000 |
| Other current assets | 495,000 | 521,000 |
| Total current assets | 3,682,000 | 5,710,000 |
| Furniture & fixtures | | 24,000 |
| Laboratory equipment | 965,000 | 931,000 |
| Computer equipment & software | 24,000 | 990,000 |
| Construction in process | 30,000 | 34,000 |
| Computer equipment and laboratory software | 1,097,000 | |
| Property & equipment, gross | 2,116,000 | 1,979,000 |
| Less: accumulated depreciation - property & equipment | 1,377,000 | |
| Less: accumulated depreciation & amortization - property & equipment | | 1,102,000 |
| Property & equipment, net | 739,000 | 877,000 |
| Finance lease right-of-use assets, net | 174,000 | 257,000 |
| Operating lease right-of-use assets | 612,000 | 763,000 |
| Intangibles, net | 12,818,000 | 13,768,000 |
| Other assets | 76,000 | 129,000 |
| Total assets | 18,101,000 | 21,504,000 |
| Current maturities of long-term debt, less debt issuance costs | 235,000 | 255,000 |
| Current maturities of finance lease liabilities | 132,000 | 162,000 |
| Current maturities of operating lease liabilities | 218,000 | 199,000 |
| Accounts payable | 622,000 | 2,042,000 |
| Accrued expenses | 764,000 | 983,000 |
| Accrued compensation | 754,000 | 491,000 |
| Accrued franchise, property & sales & use taxes | | 91,000 |
| Accrued interest | 19,000 | 19,000 |
| Accrued expenses | 1,824,000 | 1,584,000 |
| Deferred revenue | 110,000 | 119,000 |
| Accrued expenses - Balancing value | 287,000 | |
| Total current liabilities | 3,141,000 | 4,361,000 |
| Department of Economic & Community Development (DECD) | | 176,000 |
| DECD debt issuance costs | | (15,000) |
| Financed insurance loan | 106,000 | 228,000 |
| Current portion of long-term debt | | 255,000 |
| Finance lease liabilities, less current maturities | 18,000 | 68,000 |
| Operating lease liabilities, less current maturities | 407,000 | 574,000 |
| Total liabilities | 3,672,000 | 5,137,000 |
| Common stock | 14,000 | 228,000 |
| Additional paid-in capital | 112,565,000 | 108,371,000 |
| Retained earnings (accumulated deficit) | (98,150,000) | (92,297,000) |
| Total Precipio, Inc. stockholders' equity | 14,429,000 | 16,302,000 |
| Non-controlling interest | | |

| | |
|--------------------------------------|-----------------------|
| in joint venture | 65,000 |
| Total stockholders' equity (deficit) | 14,429,000 16,367,000 |

Recent Dividends:

- Precipio Inc series A-1 convertible preferred.**
No dividends paid.
 - Precipio Inc series C convertible preferred.**
No dividends paid.
 - Precipio Inc series B convertible preferred.**
No dividends paid.
 - Precipio Inc series B convertible preferred.**
No dividends paid.
 - Precipio Inc series A convertible preferred.**
No dividends paid.
 - Precipio Inc redeemable series A convertible preferred.**
No dividends paid.
 - Precipio Inc common.**
No dividends paid.
- Annual Dividends:**
- Precipio Inc series A-1 convertible preferred.**
No dividends paid.
 - Precipio Inc series C convertible preferred.**
No dividends paid.
 - Precipio Inc series B convertible preferred.**
No dividends paid.
 - Precipio Inc series B convertible preferred.**
No dividends paid.
 - Precipio Inc series A convertible preferred.**
No dividends paid.
 - Precipio Inc redeemable series A convertible preferred.**
No dividends paid.
 - Precipio Inc common.**
No dividends paid.

PREDICTIVE ONCOLOGY INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|----------------|
| Revenue | 1,780,093 | | |
| Revenue | 1,780,093 | 1,505,459 | 1,420,680 |
| Cost of sales | 634,796 | 505,107 | 487,024 |
| Gross profit (loss) | 1,145,297 | 1,000,352 | 933,656 |
| General & administrative expense | 9,428,496 | 11,110,735 | 10,932,125 |
| Operations expense | 4,127,268 | 3,798,425 | 2,698,565 |
| Sales & marketing expense | 1,510,861 | 1,358,907 | 774,530 |
| Loss on goodwill impairment | | 7,231,093 | 2,813,792 |
| Loss on impairment of intangibles | 162,905 | 3,349,375 | 2,893,548 |
| Loss on impairment of tangible fixed assets | | 185,469 | 1,249,727 |
| Total operating income (loss) | (14,084,233) | (26,033,652) | (20,428,631) |
| Other income | (64,967) | 185,646 | 184,528 |
| Other expense | | 5,275 | 239,631 |
| Gain on derivative instruments | 152,776 | 115,647 | 164,902 |
| Net income (loss) before income tax benefit | (13,983,967) | (25,737,634) | (20,318,832) |
| Income tax expense (benefit) | | | (661,658) |
| Total expense | 15,229,530 | | |
| Net income (loss) | (13,983,967) | (25,737,634) | (19,657,174) |
| Net income (loss) available to common shareholders | | (25,737,634) | (19,657,174) |
| Weighted average shares outstanding - basic | 4,014,848 | 3,649,899 | 2,743,802 |
| Weighted average shares outstanding - diluted | 4,014,848 | 3,649,899 | 2,743,802 |
| Year end shares outstanding | 4,062,853 | 3,938,135 | 3,280,730 |
| Net income (loss) per share - basic | \$(3.48) | \$(7.00) | \$(7.20) |
| Net income (loss) | | | |

| | | | |
|---|----------|-----------------------|------------------|
| per share - diluted | \$(3.48) | [Ⓐ] \$(7.00) | \$(7.20) |
| Number of full time employees | 34 | 31 | 30 |
| Number of part time employees | 1 | 3 | 2 |
| Total number of employees | 35 | ... | ... |
| Number of common stockholders | 155 | [Ⓐ] 154 | [Ⓐ] 157 |
| Earnings per share from continuing operations | \$(3.48) | ... | ... |
| Earnings per share from continuing operations | \$(3.48) | ... | ... |
| Gain on derivative instruments | 12,457 | ... | ... |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Adjusted for 1-for-20 stock split, April 24, 2023; [Ⓒ] Shares increased due to issuance of shares and warrants pursuant to private placement, equity line, consultant and other, and vesting expense and option repricing; [Ⓓ] Shares increased due to the effect of shares issued former CEO related to accrued interest, shelf offerings, February 2021 private placement, convertible debt, June 2021 direct placement, agreement with; [Ⓔ] Approximately; [Ⓕ] As of March 14, 2023; [Ⓖ] As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 8,728,660 | 22,071,523 |
| Accounts receivable | 333,697 | 331,196 |
| Finished goods | 254,376 | 290,616 |
| Raw materials | 239,998 | 133,183 |
| Work-in-process | ... | 6,694 |
| Inventories | 494,374 | 430,493 |
| Prepaid expense & other assets | 521,700 | 526,801 |
| Total current assets | 10,078,431 | 23,360,013 |
| Computers, software & office equipment | 480,882 | 463,292 |
| Laboratory equipment | 3,670,097 | 3,559,362 |
| Leasehold improvements | 506,162 | 535,527 |
| Manufacturing tooling | 4,821,980 | 121,120 |
| Demo equipment | 31,554 | 31,554 |
| Manufacturing tooling | 133,285 | ... |
| Fixed assets, gross | ... | 4,710,855 |
| Less: accumulated depreciation | 3,588,070 | 2,877,600 |
| Fixed assets, net | 1,233,910 | 1,833,255 |
| Intangibles, net | 252,457 | 253,865 |
| Operating lease right-of-use assets | 2,728,355 | 211,893 |
| Other long-term assets | 124,096 | 75,618 |
| Total assets | 14,417,249 | 25,734,644 |
| Accounts payable | 1,342,027 | 943,452 |
| Accrued expenses & other liabilities | 1,631,702 | 2,229,075 |
| Derivative liability | 1,376 | 13,833 |
| Contract liabilities | 308,091 | 602,073 |
| Operating lease liability - net of long-term portion | 517,427 | 94,237 |
| Convertible debenture | 150,408 | ... |
| Total current liabilities | 3,951,031 | 3,882,670 |
| Other long term liabilities | 5,459 | ... |
| Operating lease liability, long-term portion | 2,188,979 | 86,082 |
| Total liabilities | 6,145,469 | 3,968,752 |
| Series B convertible preferred stock | 792 | 792 |
| Common stock | 40,629 | 787,627 |
| Additional paid-in capital | 175,992,242 | 174,755,389 |
| Accumulated Deficit | (167,761,883) | ... |
| Retained earnings (accumulated deficit) | ... | (153,777,916) |
| Total stockholders' equity (deficit) | 8,271,780 | 21,765,892 |
| Total Equity | 8,271,780 | ... |

Recent Dividends:

- 1. Predictive Oncology Inc common.**
No dividends paid.
- 2. Predictive Oncology Inc series C convertible preferred.**
No dividends paid.
- 3. Predictive Oncology Inc series E convertible preferred.**
No dividends paid.
- 4. Predictive Oncology Inc series A convertible preferred.**
No dividends paid.
- 5. Predictive Oncology Inc series B convertible preferred.**
No dividends paid.
- 6. Predictive Oncology Inc series D convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Predictive Oncology Inc common.**
No dividends paid.
- 2. Predictive Oncology Inc series C convertible preferred.**
No dividends paid.
- 3. Predictive Oncology Inc series E convertible preferred.**
No dividends paid.
- 4. Predictive Oncology Inc series A convertible preferred.**
No dividends paid.
- 5. Predictive Oncology Inc series B convertible preferred.**
No dividends paid.
- 6. Predictive Oncology Inc series D convertible preferred.**
No dividends paid.

PRIMEENERGY RESOURCES CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | [Ⓐ] 2022 | [Ⓑ] 2021 |
|---|-------------|-------------------|-------------------|
| | | (revised) | (revised) |
| Field service | 11,744,000 | 11,094,000 | ... |
| Oil and gas production | 31,892,000 | 30,702,000 | ... |
| Production and advalorem taxes | 7,112,000 | 7,114,000 | ... |
| Oil sales | 87,906,000 | 90,803,000 | 50,474,000 |
| Natural gas sales | ... | ... | 11,432,000 |
| Natural gas liquids sales | 11,901,000 | 14,887,000 | 11,220,000 |
| Realized gain (loss) on derivative instruments, net | 414,000 | (12,039,000) | (5,045,000) |
| Field service income | 15,383,000 | 12,978,000 | 9,262,000 |
| Unrealized gain (loss) on derivative instruments | ... | ... | (4,914,000) |
| Interest & other income | 417,000 | 267,000 | ... |
| Other income | ... | ... | 29,000 |
| Gain on disposition of assets, net | 8,854,000 | 31,789,000 | ... |
| Total revenues | 132,810,000 | 157,113,000 | 72,458,000 |
| Lease operating expense | ... | ... | 24,419,000 |
| Field service expense | ... | ... | 9,152,000 |
| Depreciation, depletion, amortization & accretion on discounted liabilities | 30,976,000 | 27,401,000 | 26,325,000 |
| General & administrative expense | 15,645,000 | 20,233,000 | 9,084,000 |
| Gain (loss) on sale & exchange of assets | ... | ... | 1,478,000 |
| Income (loss) from operations | ... | ... | 4,956,000 |
| Write-down of investment | 684,000 | 667,000 | ... |
| Less: interest expense | ... | ... | 2,007,000 |
| Add: PPP loan forgiveness | ... | ... | 1,693,000 |
| Income (loss) before provision for (benefit from) income taxes | 34,222,000 | 58,993,000 | 4,642,000 |

| | | | |
|---|-------------------|-------------------|------------------|
| Current federal provision for (benefit from) income taxes | (891,000) | 8,330,000 | 81,000 |
| Current state provision for (benefit from) income taxes | (258,000) | 774,000 | 59,000 |
| Total current provision for (benefit from) income taxes | (1,149,000) | 9,104,000 | 140,000 |
| Deferred federal provision for (benefit from) income taxes | 724,000 | 339,000 | 574,000 |
| Total deferred provision for (benefit from) income taxes | 7,268,000 | 1,225,000 | 2,376,000 |
| Income tax expense (benefit) | 6,119,000 | 10,329,000 | 2,516,000 |
| Net income (loss) | 28,103,000 | 48,664,000 | 2,126,000 |
| Less: net (loss) income attributable to non-controlling interest | ... | ... | (28,000) |
| Net income (loss) attributable to PrimeEnergy Resources Corporation | ... | ... | 2,098,000 |
| Weighted average shares outstanding - basic | 1,849,780 | 1,953,916 | 1,992,077 |
| Weighted average shares outstanding - diluted | 2,608,786 | 2,711,170 | 2,744,162 |
| Year end shares outstanding | 1,820,100 | 1,901,000 | 1,992,077 |
| Net income (loss) per common share - basic | \$15.19 | \$24.91 | \$1.05 |
| Net income (loss) per common share - diluted | \$10.77 | \$17.95 | \$0.76 |
| Number of full time employees | 115 | ... | 113 |
| Total number of employees | 115 | ... | ... |
| Number of common stockholders | 200 | ... | [Ⓒ] 224 |
| Natural gas | 7,935,000 | 18,428,000 | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$15.19 | \$24.91 | ... |
| Diluted EPS Excluding ExtraOrd Items | \$10.77 | \$17.95 | ... |
| Interest | (535,000) | (909,000) | ... |

[Ⓐ] Reclassified to conform 2023 presentation; [Ⓑ] Reclassified to conform with 2022 presentation; [Ⓒ] As of April 20, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| | | (revised) |
| Cash & cash equivalents | 11,061,000 | 26,543,000 |
| Accounts receivable - joint interest billings | ... | 1,806,000 |
| Accounts receivable - trade receivables | ... | 1,762,000 |
| Accounts receivable - oil & gas sales | ... | 8,894,000 |
| Other accounts receivable | ... | 21,000 |
| Less: allowance for doubtful accounts | 674,000 | 336,000 |
| Joint interest billing | 2,560,000 | ... |
| Trade Receivables | 2,345,000 | ... |
| Oil and gas sales | 14,457,000 | ... |
| Due from related parties | ... | 388,000 |
| Prepaid obligations | 376,000 | 32,839,000 |

| | 2023 | 2022 | 2021 (revised) |
|---|---------------|-------------|-------------------|
| Class A common stock subject to possible redemption | 278,487,272 | | |
| Class B common stock | 4,000 | 690 | |
| Additional paid-in capital | 381,264,000 | 32,000 | |
| Accumulated deficit | (473,602,000) | | |
| Retained earnings (accumulated deficit) | (9,469,643) | | |
| Subscription receivables | (60,710,000) | | |
| Total stockholder's equity | (153,044,000) | (9,436,953) | |
| Total Equity | (153,044,000) | | |

Recent Dividends:**1. Priveterra Acquisition Corp class B common.**

No dividends paid.

2. Priveterra Acquisition Corp class A common.

No dividends paid.

Annual Dividends:**1. Priveterra Acquisition Corp class B common.**

No dividends paid.

2. Priveterra Acquisition Corp class A common.

No dividends paid.

PROCESSA PHARMACEUTICALS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Research & development expenses | 5,799,518 | 11,494,230 | 6,878,021 |
| Acquisition of in-process research & development | | | 566,583 |
| General & administrative expenses | 5,657,543 | 8,763,058 | 4,688,939 |
| Impairment of intangible asset | | 7,268,143 | |
| Operating income (loss) | (11,457,061) | (27,525,431) | (12,133,543) |
| Forgiveness of Payroll Protection Program loan & related accrued interest | | | 163,771 |
| Interest income | 335,541 | | |
| Interest income (expense), net | | 101,202 | 11,627 |
| Net operating income (loss) before income tax expense (benefit) | (11,121,520) | (27,424,229) | (11,958,145) |
| Deferred federal income tax expense (benefit) | | (5,887,151) | (2,853,937) |
| Deferred state income tax expense (benefit) | | (1,567,560) | (624,844) |
| Total deferred income tax expense (benefit) | | (7,454,711) | (3,478,781) |
| Valuation allowance | | 7,454,711 | 2,948,170 |
| Net deferred income tax expense (benefit) | | | (530,611) |
| Income tax expense (benefit) | | | (530,611) |
| Net income (loss) | (11,121,520) | (27,424,229) | (11,427,534) |
| Net income (loss) available to common stockholders | | (27,424,229) | (11,427,534) |
| Weighted average shares outstanding - basic | 1,311,572 | 805,465 | 765,973 |
| Weighted average shares outstanding - diluted | 1,311,572 | 805,465 | 765,973 |
| Year end shares outstanding | 1,286,000 | 801,770 | 785,512 |
| Net income (loss) per share - | | | |

| | | | |
|---|----------|-----------|-----------|
| continuing operations - basic | \$(8.48) | | |
| Net income (loss) per share - basic | \$(8.48) | \$(34.00) | \$(15.00) |
| Net income (loss) per share - continuing operations - diluted | \$(8.48) | | |
| Net income (loss) per share - diluted | \$(8.48) | \$(34.00) | \$(15.00) |
| Total number of employees | | 15 | 15 |
| Number of common stockholders | 187 | 199 | 215 |

¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-20 stock split, January 22, 2023; ³ As of March 27, 2023; ⁴ As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | |
|---|--------------|--------------|--|
| Cash & cash equivalents | 4,706,197 | 6,503,595 | |
| Prepaid expenses | 926,300 | | |
| Prepaid expenses & other current assets | | 1,883,134 | |
| Total current assets | 5,632,497 | 8,386,729 | |
| Property & equipment, net | 2,554 | | |
| Operating lease right-of-use assets, net | 146,057 | 227,587 | |
| Security deposit | 5,535 | | |
| Other assets | | 5,535 | |
| Total other assets | | 233,122 | |
| Total assets | 5,786,643 | 8,619,851 | |
| Current maturities of operating lease liability | 83,649 | 78,896 | |
| Accounts payable | 311,617 | 327,548 | |
| Due to licensor | 189,000 | 189,000 | |
| Due to related parties | 39 | 51 | |
| Accrued expenses | 146,274 | 403,061 | |
| Total current liabilities | 730,579 | 998,556 | |
| Non-current operating lease liability | 66,905 | 150,554 | |
| Total liabilities | 797,484 | 1,149,110 | |
| Common stock | 129 | 1,614 | |
| Additional paid-in capital | 80,658,111 | 72,016,688 | |
| Treasury stock | 300,000 | 300,000 | |
| Accumulated deficit | (75,369,081) | | |
| Retained earnings (accumulated deficit) | | (64,247,561) | |
| Total stockholders' equity | 4,989,159 | 7,470,741 | |
| Total Equity | 4,989,159 | | |

Recent Dividends:**1. Procepsa Pharmaceuticals Inc series B preferred.**

No dividends paid.

2. Procepsa Pharmaceuticals Inc series A preferred.

No dividends paid.

3. Procepsa Pharmaceuticals Inc series D preferred.

No dividends paid.

4. Procepsa Pharmaceuticals Inc common.

No dividends paid.

5. Procepsa Pharmaceuticals Inc series C preferred.

No dividends paid.

Annual Dividends:**1. Procepsa Pharmaceuticals Inc series B preferred.**

No dividends paid.

2. Procepsa Pharmaceuticals Inc series A preferred.

No dividends paid.

3. Procepsa Pharmaceuticals Inc series D preferred.

No dividends paid.

4. Procepsa Pharmaceuticals Inc common.

No dividends paid.

5. Procepsa Pharmaceuticals Inc series C preferred.

No dividends paid.

PROFESSIONAL DIVERSITY NETWORK INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | | | |
|--|---------|---------|---------|
| Net loss attributable to non-controlling interests | 103,366 | 554,672 | 192,755 |
| Net loss attributable to | | | |

| | | | |
|---|--------------------|--------------------|--------------------|
| Revenues - membership fees & related services | 530,745 | 639,271 | 985,446 |
| Revenues - lead generation revenue | 91,298 | | |
| Revenues - recruitment services | 4,639,642 | 4,861,761 | 4,646,786 |
| Revenues - contracted software development | 2,437,352 | 2,645,619 | 302,882 |
| Revenues - consumer advertising & marketing solutions | | 167,437 | 163,485 |
| Total revenues | 7,699,037 | 8,314,088 | 6,098,599 |
| Cost of revenues | 3,460,957 | 4,260,012 | 1,523,800 |
| Sales & marketing expenses | 3,700,997 | 2,805,542 | 2,457,019 |
| General & administrative expenses | 4,451,630 | 3,574,314 | 4,623,083 |
| Amortization of intangible assets | 59,507 | | |
| Depreciation and amortization - Balancing value | 12,723 | | |
| Amortization expenses | 551,774 | | |
| Depreciation & amortization expenses | 624,004 | 776,095 | 385,161 |
| Total costs & expenses | 12,237,588 | 11,415,963 | 8,989,063 |
| Income (loss) from continuing operations | (4,538,551) | (3,101,875) | (2,890,464) |
| Interest & other income (expense), net | | (3,652) | 7,999 |
| Interest and other income | 12,934 | | |
| Income (loss) before income tax expense (benefit) | (4,525,617) | (3,105,527) | (2,882,465) |
| Deferred provision (benefit) for federal income taxes | | (14,950) | (18,764) |
| Provision (benefit) for federal income taxes | | (14,950) | (18,764) |
| Deferred provision (benefit) for state income taxes | | 1,762 | (2,776) |
| Provision (benefit) for state income taxes | | 1,762 | (2,776) |
| Income Taxes - Local - Deferred | (110,961) | | |
| Income Taxes - Domestic - Deferred - Balancing value | (28,419) | | |
| Income tax expense (benefit) | (139,380) | (13,188) | (21,540) |
| Income (loss) from continuing operations, net of tax | | (3,092,339) | (2,860,925) |
| Discontinued Operations before Tax - Income/Expense | (28,428) | | |
| Income (loss) from discontinued operations | (28,428) | (65,055) | (88,813) |
| Net income (loss) | (4,414,665) | (3,157,394) | (2,949,738) |
| Net loss attributable to non-controlling interests | 103,366 | 554,672 | 192,755 |
| Net loss attributable to | | | |

| | | | |
|--|-------------------------|-------------------------|------------------------|
| Professional Diversity Network, Inc. | (4,311,299) | (2,602,722) | (2,756,983) |
| Weighted average shares outstanding | | | |
| - basic | 10,621,522 | [Ⓐ] 8,195,282 | 7,221,739 |
| Weighted average shares outstanding | | | |
| - diluted | 10,621,522 | [Ⓐ] 8,195,282 | 7,221,739 |
| Year end shares outstanding | 11,452,008 [Ⓐ] | 10,367,431 [Ⓐ] | 8,033,626 [Ⓐ] |
| Income (loss) per share from continuing operations - basic | \$(0.43) | [Ⓐ] \$(0.38) | \$(0.40) |
| Income (loss) per share from discontinued operations - basic | \$0.00 | [Ⓐ] \$(0.01) | \$(0.01) |
| Net income (loss) per share - basic | \$(0.43) | [Ⓐ] \$(0.39) | \$(0.41) |
| Income (loss) per share from continuing operations - diluted | \$(0.43) | [Ⓐ] \$(0.38) | \$(0.40) |
| Income (loss) per share from discontinued operations - diluted | \$0.00 | [Ⓐ] \$(0.01) | \$(0.01) |
| Net income (loss) per share - diluted | \$(0.43) | [Ⓐ] \$(0.39) | \$(0.41) |
| Number of full time employees | 45 | 37 | 32 |
| Number of part time employees | ... | 4 | 5 |
| Total number of employees | 45 | 41 | 37 |
| Number of common stockholders | 50 | [Ⓐ] 49 | [Ⓐ] 40 |
| Foreign currency translation adjustments | ... | (17,551) | ... |
| Income from continuing operations | (4,386,237) | ... | ... |

[Ⓐ] Reclassified to conform with the 2022 presentation; [Ⓑ] Adjusted for 1-for-2 stock split, January 5, 2023; [Ⓒ] Shares increased due to the effect of sale and issuance of common shares, and share-based compensation; [Ⓓ] Shares increased due to the effect of issuance of common shares and share-based compensation; [Ⓔ] As of March 31, 2023; [Ⓕ] As of March 28, 2022

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 627,641 | 1,236,771 |
| Customer receivables, gross | ... | 1,421,217 |
| Reserve for doubtful accounts | ... | 103,000 |
| Accounts receivable, net | 1,134,067 | 1,318,217 |
| Other receivables | 50,000 | 350,000 |
| Prepaid expense & other current assets | 556,698 | 347,807 |
| Current assets from discontinued operations | ... | 4,600 |
| Total current assets | 2,368,406 | 3,257,395 |
| Property & equipment, net | 42,043 | 35,341 |
| Capitalized technology, net | 186,103 | 64,499 |
| Goodwill | 1,417,753 | 1,274,785 |
| Intangible assets, net | ... | 225,221 |
| Right-of-use assets | 298,485 | 365,324 |
| Merchant reserve | 184,055 | ... |
| Security deposits | 66,340 | 66,340 |
| Long-term assets from discontinued operations | ... | 197,228 |
| Other assets | 1,537,499 | 1,350,000 |
| Total Intangibles | | |

| | | |
|---|--------------|--------------|
| excluding Goodwill, Net - Balancing value | 225,848 | ... |
| Total assets | 6,326,532 | 6,836,133 |
| Accounts payable | 524,854 | 338,600 |
| Litigation reserve | ... | 450,000 |
| Contractor expenses | ... | 247,909 |
| Accrued payroll liabilities | ... | 83,514 |
| Accrued legal fees | ... | 15,000 |
| Accrued board of director fees | ... | 50,112 |
| Accrued revenue sharing agreements | ... | 83,832 |
| Other accrued expenses | ... | 141,475 |
| Accrued expenses | 867,884 | 1,071,842 |
| Deferred revenue | 1,999,841 | 1,925,788 |
| Stock to be issued | 1,999,841 | ... |
| Lease liability, current portion | 82,652 | 103,555 |
| Current liabilities from discontinued operations | ... | 503,090 |
| Total current liabilities | 3,475,231 | 3,942,875 |
| Lease liability, non-current portion | 283,060 | 341,165 |
| Deferred tax liability | ... | 143,069 |
| Other long-term liabilities | ... | 100,000 |
| Total liabilities | 3,758,291 | 4,527,109 |
| Common stock | 114,520 | 103,675 |
| Additional paid-in capital | 102,873,474 | 101,728,600 |
| Accumulated other comprehensive income (loss) | ... | (10,986) |
| Retained earnings (accumulated deficit) | (99,902,718) | (98,382,540) |
| Treasury stock, at cost | 37,117 | 892,482 |
| Total Professional Diversity Network, Inc. stockholders' equity | 3,048,159 | 2,546,267 |
| Non-controlling interest | (479,918) | (237,243) |
| Total stockholders' equity | 2,568,241 | 2,309,024 |

Recent Dividends:
I. Professional Diversity Network Inc common.
 No dividends paid.
Annual Dividends:
I. Professional Diversity Network Inc common.
 No dividends paid.

PROGRESSIVE CARE INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
|---|------------|------------|-----------------------------|
| Sales of products, net | 40,605,000 | ... | ... |
| Revenues from services | 9,122,000 | ... | ... |
| Sales - net | 49,727,000 | ... | ... |
| Revenues, net | 49,727,000 | 40,601,859 | 38,852,580 |
| Costs of revenue | 34,565,000 | ... | ... |
| Costs of products | 34,323,000 | ... | ... |
| Costs of services | 242,000 | ... | ... |
| Cost of revenue | 34,565,000 | 30,898,783 | 28,678,742 |
| Gross profit (loss) | 15,162,000 | 9,703,076 | 10,173,838 |
| Salaries and wages | 7,273,000 | ... | ... |
| Selling, general & administrative expenses | ... | 12,285,174 | 11,209,715 |
| General & administrative expenses | 1,554,000 | ... | ... |
| Bad debt expense (recovery) | ... | (3,300) | 208,953 |
| Other selling, general & administrative expense | 4,859,000 | ... | ... |
| Depreciation and amortization | 1,600,000 | ... | ... |
| Goodwill impairment | 13,895,000 | ... | ... |
| Total operating | | | |

| | | | |
|--|---------------------|------------------------|------------------------|
| expenses | 29,181,000 | 12,281,874 | 11,418,668 |
| Income (loss) from operations | (14,019,000) | (2,578,798) | (1,244,830) |
| Change in fair value of derivative liability | ... | (3,322,500) | 1,821,100 |
| Gain on debt extinguishment | ... | 953,228 | 1,054,951 |
| Grant revenue | ... | 2,079,297 | ... |
| Other finance costs | ... | 147,622 | ... |
| Abandoned offering costs | ... | 635,545 | ... |
| Day one loss on issuance of units | ... | 1,026,155 | ... |
| Day one loss on debt modification | ... | 523,526 | ... |
| Gain (loss) on disposal of fixed assets | 3,000 | 11,562 | (17,621) |
| Interest income | 76,000 | 84,742 | 10 |
| Interest expense | 269,000 | 797,715 | 1,395,617 |
| Debt conversion expense | 5,206,000 | ... | ... |
| Total other income (loss) | (5,396,000) | (3,324,234) | 1,462,823 |
| Income (loss) before income taxes | (19,415,000) | (5,903,032) | 217,993 |
| Income taxes | ... | 866 | ... |
| Net income (loss) | (19,415,000) | (5,903,898) | 217,993 |
| Series A preferred stock dividend associated with induced conversion | ... | 541,278 | ... |
| Net income (loss) attributable to common shareholders | (19,415,000) | (6,445,176) | 217,993 |
| Weighted average shares outstanding | | | |
| - basic | 6,196,000 | 2,911,684 | [Ⓐ] 2,603,203 |
| Weighted average shares outstanding | | | |
| - diluted | 6,196,000 | 2,911,684 | [Ⓐ] 3,090,451 |
| Year end shares outstanding | 6,222,781 | [Ⓐ] 3,347,440 | [Ⓐ] 2,724,422 |
| Earnings (loss) per share from continuing operations-basic | \$(2.36) | ... | ... |
| Net income (loss) per common share - basic | \$(2.36) | \$(2.21) | \$0.08 |
| Earnings (loss) per share from continuing operations-diluted | \$(2.36) | ... | ... |
| Net income (loss) per common share - diluted | \$(2.36) | \$(2.21) | \$0.07 |
| Number of full time employees | 143 | [Ⓐ] 98 | ... |
| Number of part time employees | ... | [Ⓐ] 7 | ... |
| Total number of employees | 143 | 105 | 118 |
| Number of common stockholders | 222 | [Ⓐ] 219 | 211 |
| Number of common beneficiary stockholders | ... | ... | 5,938 |
| Number of preferred stockholders | ... | ... | 1 |
| Number of preferred beneficiary stockholders | ... | ... | 1 |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Adjusted for 1-for-200 stock split, December 29, 2022; [Ⓒ] Shares increased due to the effect of common stock issuance for services, debt modification agreement, in exchange for redemption, cancellation of series A preferred stock and stock-based compensation; [Ⓓ] Approximately; [Ⓔ] As of March 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | | | | | | |
|---------------------------|------------|-------------|---------------------------|--------------|--------------|--------------------------|--------------|-------------------------------------|
| Cash | ... | 6,742,876 | notes payable | ... | 226,931 | for income taxes | (7,074,000) | (138,000) (2,286,000) |
| Cash & cash equivalents | 7,895,000 | ... | Notes payable, net of | | | Income tax expense | | |
| Gross accounts receivable | ... | ... | current portion | 1,110,000 | 2,248,626 | (benefit) | (6,018,000) | 4,445,000 (968,000) |
| - trade | 8,611,000 | 3,875,686 | Operating lease | | | Income (loss) from | | |
| Less: allowance for | | | liabilities - net of | | | operations after | | |
| doubtful accounts | 272,000 | 203,900 | current portion | 214,000 | 278,602 | income taxes | ... | 18,463,000 6,273,000 |
| Accounts receivable - | | | Finance lease liabilities | | | Net income (loss) | (16,782,000) | 18,463,000 6,273,000 |
| trade, net | 8,339,000 | 3,671,786 | - net of current portion | 5,000 | 24,198 | Weighted average | | |
| Receivables - other | 1,846,000 | 2,004,805 | Total liabilities | 13,820,000 | 10,396,623 | shares outstanding | | |
| Inventory, net | 3,069,000 | 713,284 | Series B preferred stock | ... | 3 | - basic | 17,207,000 | 15,845,000 15,172,000 |
| Prepaid expenses | 334,000 | 245,983 | Common stock | 67,000 | 66,947 | Weighted average | | |
| Total current assets | 21,483,000 | 13,378,734 | Additional paid-in | | | shares outstanding | | |
| Building | 2,116,000 | 1,651,069 | capital | 60,886,000 | 22,525,214 | - diluted | 17,207,000 | 18,651,000 18,393,000 |
| Building improvements | ... | 513,075 | Accumulated deficit | (34,389,000) | ... | Year end shares | | |
| Furniture & equipment | 388,000 | 423,829 | Retained earnings | | | outstanding | 18,045,029 | 16,210,776 [□] 15,485,900 |
| Leasehold improvements & | | | (accumulated deficit) | ... | (14,974,113) | Income (loss) per | | |
| fixtures | 76,000 | 276,614 | Total stockholders' | | | share from | | |
| Vehicles | 595,000 | 251,715 | equity (deficit) | 26,564,000 | 7,618,051 | continuing | | |
| Land | 184,000 | 184,000 | Total Equity | 26,564,000 | ... | operations - basic | \$(0.98) | ... |
| Computer equipment & | | | | | | Net income (loss) | | |
| software | ... | 101,230 | | | | per share - basic | \$(0.98) | \$1.17 \$0.41 |
| Computer equipment | 39,000 | ... | | | | Income (loss) per | | |
| Property & equipment, | | | | | | share from | | |
| gross | 3,420,000 | 3,401,532 | | | | continuing | | |
| Less: accumulated | | | | | | operations - | | |
| depreciation | 136,000 | 818,779 | | | | diluted | \$(0.98) | ... |
| Construction in progress | 22,000 | ... | | | | Net income (loss) | | |
| Property & equipment, | | | | | | per share - diluted | \$(0.98) | \$1.02 \$0.40 |
| net | 3,284,000 | 2,582,753 | | | | Dividends per share | ... | \$0.60 |
| Goodwill | 731,000 | 1,387,860 | | | | Number of full time | | |
| Intangible assets, net | 14,398,000 | 126,696 | | | | employees | 113 | 129 129 |
| Operating lease | | | | | | Total number of | | |
| right-of-use assets, net | 427,000 | 446,180 | | | | employees | 113 | ... |
| Finance lease | | | | | | Number of common | | |
| right-of-use assets, net | ... | 53,814 | | | | stockholders | 162 | ^{□□} 172 ^{□□} 200 |
| Deposits | 39,000 | 38,637 | | | | | | |
| Right of Use Tangible | | | | | | | | |
| Assets - Capital/Finance | | | | | | | | |
| Lease - Net | 22,000 | ... | | | | | | |
| Total assets | 40,384,000 | 18,014,674 | | | | | | |
| Accounts payable - trade | ... | 6,517,496 | | | | | | |
| Accrued payroll & | | | | | | | | |
| payroll taxes | 167,000 | 228,957 | | | | | | |
| Accrued direct & | | | | | | | | |
| indirect remuneration | | | | | | | | |
| (DIR) fees | ... | 500,589 | | | | | | |
| Other accrued liabilities | 164,000 | 137,294 | | | | | | |
| Accounts payable & | | | | | | | | |
| accrued liabilities | 11,256,000 | 7,384,336 | | | | | | |
| Notes payable & accrued | | | | | | | | |
| interest, net of | | | | | | | | |
| unamortized debt discount | ... | 226,931 | | | | | | |
| & debt issuance costs | ... | ... | | | | | | |
| Operating lease | | | | | | | | |
| liabilities - current | | | | | | | | |
| portion | 170,000 | 200,314 | | | | | | |
| Finance lease liabilities | | | | | | | | |
| - current portion | 18,000 | 33,616 | | | | | | |
| Notes payable | 145,000 | ... | | | | | | |
| Accounts payable and | | | | | | | | |
| accrued liabilities | 12,158,000 | ... | | | | | | |
| Accrued PBM fees | 571,000 | ... | | | | | | |
| Total current liabilities | 12,491,000 | 7,845,197 | | | | | | |
| Convertible notes payable | | | | | | | | |
| & accrued interest - | | | | | | | | |
| collateralized | ... | 2,837,910 | | | | | | |
| Mortgage note payable - | | | | | | | | |
| commercial bank - | | | | | | | | |
| collateralized | ... | 1,225,913 | | | | | | |
| Note payable - | | | | | | | | |
| uncollateralized | ... | 25,000 | | | | | | |
| Note payable - | | | | | | | | |
| collateralized | ... | 137,017 | | | | | | |
| Insurance premium | | | | | | | | |
| financing | ... | 70,302 | | | | | | |
| Notes payable - subtotal | ... | 4,296,142 | | | | | | |
| Less: unamortized debt | | | | | | | | |
| discount | ... | (1,820,585) | | | | | | |
| Total notes payable | | | | | | | | |
| before current portion of | | | | | | | | |
| notes payable | ... | 2,475,557 | | | | | | |
| Less: current portion of | | | | | | | | |

Recent Dividends:

1. Progressive Care Inc common.

No dividends paid.

2. Progressive Care Inc series B.

No dividends paid.

3. Progressive Care Inc series A super-voting preferred.

No dividends paid.

Annual Dividends:

1. Progressive Care Inc common.

No dividends paid.

2. Progressive Care Inc series B.

No dividends paid.

3. Progressive Care Inc series A super-voting preferred.

No dividends paid.

PROPHASE LABS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---------------------|--------------|-------------|-------------|
| | | | (revised) |
| Net sales | 44,384,000 | ... | ... |
| Revenues, net | 44,384,000 | 122,647,000 | 79,042,000 |
| Cost of revenues | 28,145,000 | 51,993,000 | 37,054,000 |
| Gross profit | 16,239,000 | 70,654,000 | 41,988,000 |
| Diagnostic expenses | 1,932,000 | 12,022,000 | 9,174,000 |
| General & | | | |
| administration | 34,502,000 | 34,385,000 | 22,493,000 |
| Research & | | | |
| development | 1,418,000 | 652,000 | 520,000 |
| Total operating | | | |
| expense | 37,852,000 | 47,059,000 | 32,187,000 |
| Income (loss) from | | | |
| operations | (21,613,000) | 23,595,000 | 9,801,000 |
| Interest income, | | | |
| net | 78,000 | 153,000 | 642,000 |
| Interest expense | 1,275,000 | 764,000 | 1,148,000 |
| Change in fair | | | |
| value of investment | | | |
| securities | ... | (76,000) | (240,000) |
| Impairment of | | | |
| secured promissory | | | |
| note receivable | (10,000) | ... | 3,750,000 |
| Income (loss) from | | | |
| operations before | | | |
| income taxes | (22,800,000) | 22,908,000 | 5,305,000 |
| Current provision | | | |
| (benefit) for | | | |
| federal income | 772,000 | 1,040,000 | ... |
| taxes | | | |
| Current provision | | | |
| (benefit) for state | | | |
| income taxes | 284,000 | 3,543,000 | 1,318,000 |
| Total current | | | |
| provision (benefit) | | | |
| for income taxes | 1,056,000 | 4,583,000 | 1,318,000 |
| Deferred provision | | | |
| (benefit) for | | | |
| federal income | | | |
| taxes | (5,459,000) | 72,000 | (1,511,000) |
| Deferred provision | | | |
| (benefit) for state | | | |
| income taxes | (1,615,000) | (210,000) | (775,000) |
| Total deferred | | | |
| provision (benefit) | | | |

[□] Shares increased due to the effect of issuance of common stock and warrants for cash from public and private offering, issuance of common shares related to business acquisition, repurchase of common sh; [□] Approximately; [□] As of March 24, 2023; [□] As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------|------------|------------|
| Cash & cash equivalents | 1,609,000 | 9,109,000 |
| Restricted cash | 540,000 | ... |
| Marketable debt | | |
| securities, available for | | |
| sale | 3,127,000 | 8,328,000 |
| Trade accounts receivable | ... | 37,568,000 |
| Unbilled accounts | | |
| receivable | ... | 2,626,000 |
| Accounts receivable, | | |
| gross | 40,177,000 | 40,194,000 |
| Less: allowance for | | |
| doubtful accounts | 3,864,000 | 3,140,000 |
| Accounts receivable, net | 36,313,000 | 37,054,000 |
| Diagnostic services | | |
| testing material | 623,000 | 1,739,000 |
| Raw materials | 1,619,000 | 1,639,000 |
| Work in process | 306,000 | 754,000 |
| Finished goods | 1,551,000 | 356,000 |
| Inventory, gross | (258,000) | 4,488,000 |
| Inventory valuation | | |
| reserve | ... | 512,000 |
| Inventory | 3,841,000 | ... |
| Inventory, net | ... | 3,976,000 |
| Prepaid expenses & other | | |
| current assets | 2,155,000 | 2,366,000 |
| Total current assets | 47,585,000 | 60,833,000 |
| Land | 352,000 | 352,000 |
| Building improvements | 1,746,000 | 1,729,000 |
| Leasehold improvements | 374,000 | ... |
| Machinery | 6,103,000 | 5,048,000 |
| Computer software | 2,744,000 | ... |
| Lab equipment | 12,667,000 | 5,788,000 |
| Computer equipment | ... | 2,350,000 |
| Furniture & fixtures | 446,000 | 461,000 |
| Property, plant & | | |
| equipment, gross | 24,432,000 | 15,728,000 |
| Less: accumulated | | |
| depreciation | 11,534,000 | 8,440,000 |
| Property, plant & | | |

| | | |
|--|-------------|-------------|
| equipment, net | 12,898,000 | 7,288,000 |
| Prepaid expenses, net of current portion | 832,000 | 121,000 |
| Right-of-use asset, net | 4,572,000 | 4,059,000 |
| Intangible asset, net | 12,333,000 | 8,475,000 |
| Goodwill | 5,231,000 | 5,709,000 |
| Other assets | 1,163,000 | 1,163,000 |
| Deferred taxes | 7,313,000 | ... |
| Total assets | 91,927,000 | 87,648,000 |
| Accounts payable | 9,383,000 | 5,905,000 |
| Accrued diagnostic services | 314,000 | 1,009,000 |
| Accrued advertising & other allowances | 24,000 | 99,000 |
| Lease liabilities | 953,000 | 301,000 |
| Deferred revenue | 2,382,000 | 2,499,000 |
| Income tax payable | 3,278,000 | 4,190,000 |
| Accrued diagnostic services commissions | ... | 1,093,000 |
| Accrued payroll | 181,000 | 202,000 |
| Accrued expenses | 1,445,000 | 714,000 |
| Accrued returns | 3,000 | 13,000 |
| Accrued benefits & vacation | 54,000 | 50,000 |
| Other current liabilities | 2,683,000 | 2,072,000 |
| Finance lease liabilities | 1,840,000 | ... |
| Accrued bonus | 1,000,000 | ... |
| Total current liabilities | 20,857,000 | 16,075,000 |
| Deferred revenue, net of current portion | 1,100,000 | 1,059,000 |
| Deferred tax liability, net | ... | 224,000 |
| Unsecured convertible promissory notes, net | 2,924,000 | 2,400,000 |
| Lease liabilities, net of current portion | 4,237,000 | 4,259,000 |
| Total non-current liabilities | 21,687,000 | 7,942,000 |
| Total liabilities | 42,544,000 | 24,017,000 |
| Due to sellers | 2,000,000 | ... |
| Finance lease liabilities, net of current portion | 4,092,000 | ... |
| Unsecured promissory notes, net of discount of \$376 and \$0 | 7,334,000 | ... |
| Common stock | 18,000 | 16,000 |
| Additional paid-in capital | 118,694,000 | 109,138,000 |
| Retained earnings (accumulated deficit) | (5,029,000) | 11,753,000 |
| Treasury stock, at cost | 64,000,000 | 58,033,000 |
| Accumulated comprehensive income (loss) | (300,000) | 757,000 |
| Total stockholders' equity (deficit) | 49,383,000 | 63,631,000 |
| Rep Total Equity & Minority Interest | 49,383,000 | ... |

| | | | |
|---|-------------|-------------|-------------|
| expenses | 4,526,974 | 3,557,788 | 4,140,413 |
| Income (loss) from operations | (4,526,974) | (3,557,788) | (4,140,413) |
| Interest income | 264,476 | 185,790 | 33,207 |
| Interest expense | 107,682 | 137,456 | 496,912 |
| Realize gain (loss) on foreign exchange transactions | (630,317) | ... | ... |
| Realized gain (loss) on marketable securities | ... | (46,051) | (2,486) |
| Change in fair value of derivative liability | ... | ... | 83,670 |
| Total other income (expenses) | (473,523) | 2,283 | (382,521) |
| Income (loss) before income taxes - domestic | ... | (3,522,834) | (4,522,862) |
| Income (loss) before income taxes - foreign | ... | (32,671) | (72) |
| Income (loss) before tax | (5,000,497) | (3,555,505) | (4,522,934) |
| Net income (loss) | (5,000,497) | (3,555,505) | (4,522,934) |
| Weighted average shares outstanding - basic | 4,344,580 | 4,317,875 | 3,685,206 |
| Weighted average shares outstanding - diluted | 4,344,580 | 4,317,875 | 3,685,206 |
| Year end shares outstanding | 4,435,132 | 4,321,315 | 4,302,403 |
| Income (loss) per share - continuing operations - basic | \$(1.15) | ... | ... |
| Income (loss) per share - continuing operations - diluted | \$(1.15) | ... | ... |
| Net income (loss) per common share - diluted | \$(1.15) | \$(0.82) | \$(1.24) |
| Number of part time employees | 2 | 2 | 2 |
| Total number of employees | 2 | ... | ... |
| Number of common stockholders | 3,000 | 3,000 | 3,000 |
| Number of series B preferred stockholders | ... | 0 | 0 |

| | | |
|--|--------------|--------------|
| accrued expenses - related party | ... | 105,928 |
| Payment-in-kind ("PIK") convertible notes payable, net of debt discount | ... | 150,591 |
| Payment-in-kind ("PIK") convertible notes payable, net of debt discount - related parties | ... | 193,639 |
| Accrued expenses | 113,802 | ... |
| Total current liabilities | 655,252 | 1,119,862 |
| Total liabilities | 655,252 | 1,119,862 |
| Common stock, \$0.001 par value, 100,000,000 shares authorized, 8,307,915 shares issued and outstanding at September 30, 2016, 7,612,838 shares issued and 6,612,838 shares outstanding at December 31, 2015 | 444 | ... |
| Common stock | ... | 434 |
| Additional paid-in-capital | 34,559,091 | 33,371,406 |
| Accumulated deficit | (30,777,872) | ... |
| Retained earnings (accumulated deficit) | ... | (25,777,375) |
| Accumulated other comprehensive income (loss) | (113,546) | (676,907) |
| Total stockholders' equity (deficit) | 3,668,117 | 6,917,558 |
| Total shareholders' equity (deficit) | 3,668,117 | ... |

Recent Dividends:

- Protagenic Therapeutics Inc series B convertible preferred.**
No dividends paid.
- Protagenic Therapeutics Inc common.**
No dividends paid.
- Protagenic Therapeutics Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- Protagenic Therapeutics Inc series B convertible preferred.**
No dividends paid.
- Protagenic Therapeutics Inc common.**
No dividends paid.
- Protagenic Therapeutics Inc series A convertible preferred.**
No dividends paid.

Recent Dividends:

- ProPhase Labs Inc common.**

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 05/24/2021 | 0.30 | 05/13/2021 | 05/25/2021 | 06/03/2021 |
| 02/28/2022 | 0.30 | 02/16/2022 | 03/01/2022 | 03/10/2022 |
| 05/24/2022 | 0.30 | 05/13/2022 | 05/25/2022 | 06/03/2022 |

Annual Dividends:

- ProPhase Labs Inc common.**

| | | | |
|------|------|------|------|
| 2021 | 0.30 | 2022 | 0.60 |
|------|------|------|------|

PROTAGENIC THERAPEUTICS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|----------------------------------|-----------|-----------|----------------|
| Research & development expense | 3,319,867 | 1,589,239 | 1,136,790 |
| General & administrative expense | 1,207,107 | 1,968,549 | 3,003,623 |

Adjusted for 1-for-4 stock split, March 23, 2023; Shares increased due to exercise of options and warrants, issuance of shares and warrants from offering, conversion of preferred stock, notes and interest and issuance of stock for underwriter; As approximately; As of March 31, 2023; As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash in Hand & with Banks | 1,287,893 | ... |
| Cash | ... | 215,189 |
| Marketable securities, current | 2,768,119 | 7,763,517 |
| Prepaid expenses | 144,025 | 56,939 |
| Total current assets | 4,200,037 | 8,035,645 |
| Equipment - net | 123,332 | 1,775 |
| Total assets | 4,323,369 | 8,037,420 |
| Research & development | 498,366 | ... |
| Legal | 6,334 | ... |
| Accounts payable & accrued expenses | 655,252 | 669,704 |
| Accounts payable & accrued expenses - related party | 36,750 | ... |
| Accounts payable & | ... | ... |

PROVCTUS BIOPHARMACEUTICALS INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---------------------------------------|-----------|-----------|----------------|
| OTC product revenue | 557,710 | ... | ... |
| Grant revenue | ... | 989,042 | ... |
| Total revenues | 557,710 | ... | ... |
| Research & development | 1,749,240 | 2,389,360 | 2,608,357 |
| General & administrative | 1,709,720 | 2,027,628 | 2,063,897 |
| Payroll and taxes | 284,616 | ... | ... |
| Rent and utilities | 34,262 | ... | ... |
| Directors fees | 385,000 | ... | ... |
| Legal and litigation | 387,189 | ... | ... |
| Insurance | 179,846 | ... | ... |
| Other general and administrative cost | 40,793 | ... | ... |
| Payroll and taxes | 250,685 | ... | ... |
| Professional fees | 469,438 | ... | ... |
| Rent and utilities | 19,134 | ... | ... |
| Foreign currency translation | 24,227 | ... | ... |
| Depreciation in Selling, General & | ... | ... | ... |

| | | | | | | | | | | |
|---|--------------------|--------------------|--------------------|---|---------------|---------------|--|---|--------------------|------------------|
| Administrative Expenses | 1,862 | ... | ... | Other accrued expenses | 3,240,436 | 2,404,012 | development | 1,144,000 | 1,326,000 | 1,130,000 |
| Depreciation in Research & Development Expenses | 7,059 | ... | ... | Accrued interest | 22,600 | 30,844 | Total operating expenses | 11,334,000 | 10,374,000 | 10,055,000 |
| Total operating expenses | 3,458,960 | 4,416,988 | 4,672,254 | Accrued interest - related parties | 123,828 | 40,992 | Operating income (loss) | (2,921,000) | (1,083,000) | 209,000 |
| Total operating income (loss) | (2,901,250) | (3,427,946) | (4,672,254) | Notes payable | 277,815 | 239,394 | Gain on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... | 2,181,000 |
| Research & development tax credit | (15,696) | (36,954) | (31,315) | Convertible notes payable | 800,000 | 625,000 | Settlements | 507,000 | ... | 3,150,000 |
| Gain on forgiveness of PPP loan & interest | ... | ... | 63,094 | Convertible notes payable - related parties | 1,875,000 | 1,202,500 | Other income (expense) | (10,000) | 43,000 | (61,000) |
| Interest expense, net | 216,214 | 163,691 | 961,698 | Operating lease liability | 48,077 | 44,422 | Total other income (expenses) | ... | 43,000 | (1,030,000) |
| Net Pre-Tax Loss | (3,101,768) | ... | ... | Accrued Payroll and taxes | 719,460 | ... | Net income (loss) before provision for (benefit from) income taxes | (3,438,000) | (1,040,000) | (821,000) |
| Total other income (expense), net | (200,518) | (126,737) | (867,289) | Total current liabilities | 9,016,895 | 8,192,380 | Current federal income taxes | 99,000 | 552,000 | 131,000 |
| Net income (loss) | (3,101,768) | (3,554,683) | (5,539,543) | Operating lease liability, non-current portion | 25,299 | 73,376 | Current state income taxes | (75,000) | 23,000 | 84,000 |
| Weighted average shares outstanding - basic | 419,508,146 | 419,470,338 | 408,223,004 | Total liabilities | 9,042,194 | 8,265,756 | Total current income taxes | 24,000 | 575,000 | 215,000 |
| Weighted average shares outstanding - diluted | 419,508,146 | 419,470,338 | 408,223,004 | Series D convertible preferred stock | ... | 12,373 | Deferred federal income taxes | 146,000 | (959,000) | (704,000) |
| Year end shares outstanding | 419,522,119 | 419,497,119 | 419,447,119 | Series D-1 convertible preferred stock | 10,361 | 9,747 | Deferred state income taxes | 546,000 | 428,000 | 333,000 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.01) | Preferred Stock - Redeemable - Convertible | 12,373 | ... | Total deferred income taxes | 692,000 | (531,000) | (371,000) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.01) | Common stock | 419,522 | 419,497 | Provision for (benefit from) income taxes | 716,000 | 44,000 | (156,000) |
| Number of full time employees | 4 | 4 | 4 | Additional paid-in capital | 244,714,967 | 242,954,193 | Net income (loss) | (4,154,000) | (1,084,000) | (665,000) |
| Total number of employees | 4 | ... | ... | Accumulated other comprehensive income (loss) | (60,165) | (35,679) | Weighted average shares outstanding - basic | 5,740,000 | 5,626,000 | 5,549,000 |
| Number of common stockholders | 820 | 821 | 821 | Retained earnings (accumulated deficit) | (252,690,409) | (249,588,641) | Weighted average shares outstanding - diluted | 5,740,000 | 5,626,000 | 5,549,000 |
| Foreign currency translation adjustments | ... | (1,212) | ... | Total stockholders' equity (deficiency) | (7,593,351) | (6,228,510) | Year end shares outstanding | 5,806,000 | 5,681,000 | 5,589,000 |
| Income Taxes - Domestic - Deferred | (566,183) | ... | ... | Total Equity | (7,593,351) | ... | Net income (loss) per share - basic | \$(0.72) | \$(0.19) | \$(0.12) |
| Income Taxes - Local - Deferred | (138,445) | ... | ... | Recent Dividends: | | | Net income (loss) per share - diluted | \$(0.72) | \$(0.19) | \$(0.12) |
| Current income tax expense (benefit) | 704,628 | ... | ... | 1. Provectus Biopharmaceuticals Inc common. | | | Dividends declared per share | ... | \$0.21 | \$0.05 |
| Basic and Diluted Loss Per Common Share | \$(0.01) | ... | ... | No dividends paid. | | | Number of full time employees | 116 | ... | ... |
| Insurance | 229,774 | ... | ... | 2. Provectus Biopharmaceuticals Inc series A 8% convertible preferred stock. | | | Total number of employees | 116 | 133 | 139 |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... | No dividends paid. | | | Number of common stockholders | 146 | 157 | 157 |
| Clinical trial and research expenses | 1,193,529 | ... | ... | 3. Provectus Biopharmaceuticals Inc series D convertible preferred. | | | Number of beneficiary stockholders | ... | 3,100 | 3,100 |
| | | | | No dividends paid. | | | Earnings per share from continuing operations | \$(0.72) | ... | ... |
| | | | | 4. Provectus Biopharmaceuticals Inc series D-1 convertible preferred. | | | Earnings per share from continuing operations | \$(0.72) | ... | ... |
| | | | | No dividends paid. | | | | | | |
| | | | | 5. Provectus Biopharmaceuticals Inc 8% convertible redeemable preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 6. Provectus Biopharmaceuticals Inc series B convertible preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | Annual Dividends: | | | | | | |
| | | | | 1. Provectus Biopharmaceuticals Inc common. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 2. Provectus Biopharmaceuticals Inc series A 8% convertible preferred stock. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 3. Provectus Biopharmaceuticals Inc series D convertible preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 4. Provectus Biopharmaceuticals Inc series D-1 convertible preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 5. Provectus Biopharmaceuticals Inc 8% convertible redeemable preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | 6. Provectus Biopharmaceuticals Inc series B convertible preferred. | | | | | | |
| | | | | No dividends paid. | | | | | | |
| | | | | PSYCHEMEDICS CORP. | | | | | | |
| | | | | Annual Report | | | | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | |
| | | | | | 2023 | 2022 | 2021 (revised) | | | |
| | | | | Revenues | 22,098,000 | ... | ... | Cash & cash equivalents | 1,964,000 | ... |
| | | | | Revenues | 22,098,000 | 25,240,000 | 24,909,000 | Cash | ... | 4,750,000 |
| | | | | Cost of revenues | 13,685,000 | 15,949,000 | 14,645,000 | Accounts receivable, gross | 3,751,000 | 3,826,000 |
| | | | | Gross profit (loss) | 8,413,000 | 9,291,000 | 10,264,000 | Less: allowance for doubtful accounts | 64,000 | 87,000 |
| | | | | General & administrative | 7,192,000 | 5,857,000 | 6,126,000 | Accounts receivable, net of allowance for doubtful accounts | 3,687,000 | ... |
| | | | | Marketing & selling | 2,998,000 | 3,191,000 | 2,799,000 | Accounts receivable, net | ... | 3,739,000 |
| | | | | Research & | ... | ... | ... | Prepaid expenses & other current assets | 1,136,000 | 1,136,000 |
| | | | | | ... | ... | ... | Income tax receivable | 18,000 | 339,000 |
| | | | | | ... | ... | ... | Total current assets | 6,805,000 | 9,964,000 |
| | | | | | ... | ... | ... | Computer software | 4,774,000 | 4,648,000 |

□ Reclassified to conform with 2022 presentation; □ As of March 28, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

| | | |
|---|-----------|-----------|
| Cash & cash equivalents | 76,576 | 21,605 |
| Restricted cash | 950,223 | 1,410,102 |
| Prepaid expenses & other current assets | 337,522 | ... |
| Short-term receivables | 476 | 394 |
| Prepaid expenses & other current assets | ... | 467,081 |
| Total current assets | 1,364,797 | 1,899,182 |
| Equipment & furnishings, gross | 123,014 | 123,014 |
| Depreciation | 110,994 | ... |
| Less: accumulated depreciation | ... | 102,073 |
| Equipment & furnishings | 12,020 | 20,941 |
| Operating lease right-of-use asset | 72,026 | 117,123 |
| Total assets | 1,448,843 | 2,037,246 |
| Accounts payable | 1,675,891 | 2,094,258 |
| Unearned grant revenue | 953,248 | 1,510,958 |
| Accrued expenses | 2,520,976 | ... |

□ As of March 15, 2023; □ As of March 24, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

| | | |
|---|-----------|-----------|
| Cash & cash equivalents | 1,964,000 | ... |
| Cash | ... | 4,750,000 |
| Accounts receivable, gross | 3,751,000 | 3,826,000 |
| Less: allowance for doubtful accounts | 64,000 | 87,000 |
| Accounts receivable, net of allowance for doubtful accounts | 3,687,000 | ... |
| Accounts receivable, net | ... | 3,739,000 |
| Prepaid expenses & other current assets | 1,136,000 | 1,136,000 |
| Income tax receivable | 18,000 | 339,000 |
| Total current assets | 6,805,000 | 9,964,000 |
| Computer software | 4,774,000 | 4,648,000 |

| | | |
|--|--------------|--------------|
| Office furniture & equipment | 2,253,000 | 2,247,000 |
| Laboratory equipment | 16,038,000 | 16,013,000 |
| Leasehold improvements | 3,629,000 | 3,629,000 |
| Property & equipment, gross | 26,694,000 | 26,537,000 |
| Accumulated depreciation & amortization | 23,633,000 | 21,964,000 |
| Property & equipment, net | 3,061,000 | 4,573,000 |
| Other assets | 632,000 | 823,000 |
| Deferred tax assets | ... | 691,000 |
| Operating lease right-of-use assets | 1,828,000 | 2,681,000 |
| Total assets | 12,326,000 | 18,732,000 |
| Accounts payable | 752,000 | 448,000 |
| Accrued compensation & employee benefits | 640,000 | 442,000 |
| Accrued vacation expense | ... | 409,000 |
| Accrued taxes | ... | 771,000 |
| Accrued shipping expense | ... | 338,000 |
| Accrued legal settlement | ... | 1,150,000 |
| Other accrued expenses | 1,964,000 | 829,000 |
| Current portion of long-term debt | 305,000 | 294,000 |
| Current portion of operating lease liabilities | 1,048,000 | 1,037,000 |
| Total current liabilities | 4,709,000 | 5,718,000 |
| Long-term debt | ... | 305,000 |
| Long-term portion of operating lease liabilities | 945,000 | 1,938,000 |
| Total liabilities | 5,654,000 | 7,961,000 |
| Common stock | 32,000 | 32,000 |
| Additional paid-in capital | 35,129,000 | 34,275,000 |
| Treasury stock | 10,082,000 | ... |
| Less - treasury stock, at cost | ... | 10,082,000 |
| Accumulated deficit | (16,773,000) | ... |
| Retained earnings (accumulated deficit) | ... | (11,820,000) |
| Accumulated other comprehensive income (loss) | (1,634,000) | (1,634,000) |
| Total shareholders' equity | 6,672,000 | 10,771,000 |
| Total Equity | 6,672,000 | ... |

Recent Dividends:
1. Psychemedics Corp. common.
 No dividends paid.
Annual Dividends:
1. Psychemedics Corp. common.
 No dividends paid.

PULMATRIX INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|-----------------------------------|---------------------|---------------------|---------------------|
| Revenues | 7,298,000 | ... | ... |
| Research & development | 15,518,000 | 18,240,000 | 15,382,000 |
| General & administrative | 6,520,000 | 6,778,000 | 6,377,000 |
| Impairment of goodwill | ... | ... | 3,577,000 |
| Total operating expenses | 22,038,000 | 25,018,000 | 25,336,000 |
| Income (loss) from operations | (14,740,000) | (18,947,000) | (20,167,000) |
| Interest income | 867,000 | 309,000 | 7,000 |
| Other income (expense), net | (248,000) | (198,000) | (11,000) |
| Total other income (expense), net | 619,000 | 111,000 | (4,000) |
| Income (loss) before income tax | (14,121,000) | ... | ... |
| Net income (loss) | (14,121,000) | (18,836,000) | (20,171,000) |
| Less: deemed dividend - | ... | ... | ... |

| | | | |
|---|-----------|--------------|--------------|
| beneficial conversion feature of preferred stock | ... | ... | 3,197,000 |
| Net income (loss) attributable to common stockholders | ... | (18,836,000) | (23,368,000) |
| Weighted average shares outstanding - basic | 3,651,911 | 3,447,701 | 2,708,558 |
| Weighted average shares outstanding - diluted | 3,651,911 | 3,447,701 | 2,708,558 |
| Year end shares outstanding | 3,652,285 | 3,639,185 | 3,222,037 |
| Net income (loss) per share - basic | \$(3.87) | \$(5.46) | \$(8.63) |
| Net income (loss) per share - diluted | \$(3.87) | \$(5.46) | \$(8.63) |
| Number of full time employees | 22 | 28 | 24 |
| Number of part time employees | ... | 1 | 1 |
| Total number of employees | 22 | ... | ... |
| Number of common stockholders | 43 | 43 | 43 |
| Earnings per share from continuing operations | \$(3.87) | ... | ... |
| Earnings per share from continuing operations | \$(3.87) | ... | ... |

□ Shares increased due to the effect of issuance of common stock, exercise of warrants and stock options; □ Approximately; □ As of March 27, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 19,173,000 | 35,628,000 |
| Restricted cash | ... | 153,000 |
| Accounts receivable | 928,000 | 1,298,000 |
| Prepaid insurance | ... | 286,000 |
| Software & hosting costs | ... | 99,000 |
| Clinical & consulting | ... | 517,000 |
| Other prepaid expenses & current assets | ... | 166,000 |
| Total current assets | 20,843,000 | 38,147,000 |
| Laboratory equipment | ... | 1,827,000 |
| Computer equipment | 237,000 | 275,000 |
| Office furniture & equipment | 401,000 | 217,000 |
| Leasehold improvements | ... | 664,000 |
| Capital in progress | 600,000 | ... |
| Medical equipment | 1,656,000 | ... |
| Total property & equipment | 2,894,000 | 2,983,000 |
| Less accumulated depreciation & amortization - property & equipment | 1,736,000 | 2,748,000 |
| Property & equipment, net | 1,158,000 | 235,000 |
| Operating lease right-of-use asset | 10,309,000 | 710,000 |
| Long-term restricted cash | 1,472,000 | 1,472,000 |
| Other long-term assets | 176,000 | 389,000 |
| Total assets | 33,958,000 | 40,953,000 |
| Accounts payable | 1,915,000 | 1,188,000 |
| Accrued wages & incentives | 70,000 | 1,130,000 |
| Accrued clinical & consulting | ... | 475,000 |
| Accrued legal & patents | 42,000 | ... |
| Accrued other expenses | ... | 33,000 |
| Accrued expenses & other current liabilities | 99,000 | 1,638,000 |
| Accrued expenses and other current liabilities | 947,000 | ... |
| Accrued expenses and other current liabilities - Balancing value | 389,000 | ... |
| Wages and incentives | 347,000 | ... |

| | | |
|---|---------------|---------------|
| Operating lease liability | 429,000 | 857,000 |
| Deferred revenue | 618,000 | 1,339,000 |
| Total current liabilities | 3,909,000 | 5,022,000 |
| Deferred revenue, net of current portion | 3,727,000 | 4,822,000 |
| Operating lease liability, net of current portion | 8,327,000 | ... |
| Total liabilities | 15,963,000 | 9,844,000 |
| Common stock | 365 | ... |
| Additional paid in capital | 305,592,000 | 304,585,000 |
| Retained earnings (accumulated deficit) | (287,597,000) | (273,476,000) |
| Total stockholders' equity (deficit) | 17,995,000 | 31,109,000 |
| Total Equity | 17,995,000 | ... |

Recent Dividends:
1. Pulmatrix Inc common.
 No dividends paid.
2. Pulmatrix Inc series A convertible preferred.
 No dividends paid.
Annual Dividends:
1. Pulmatrix Inc common.
 No dividends paid.
2. Pulmatrix Inc series A convertible preferred.
 No dividends paid.

PULSE BIOSCIENCES INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|---------------------|
| Product revenues | ... | 700,000 | 1,418,000 |
| Total revenues | ... | 700,000 | 1,418,000 |
| Cost of revenues | ... | 11,944,000 | 1,968,000 |
| General & administrative expenses | 15,777,000 | 13,955,000 | 19,073,000 |
| Research & development expenses | 27,797,000 | 20,839,000 | 28,640,000 |
| Sales & marketing | ... | 12,019,000 | 14,751,000 |
| Total cost & expenses | 43,574,000 | 58,757,000 | 64,432,000 |
| Income (loss) from operations | (43,574,000) | (58,057,000) | (63,014,000) |
| Interest income (expense), net | 1,364,000 | (448,000) | (646,000) |
| Total other income (expense) | 1,364,000 | (448,000) | (646,000) |
| Income (loss) from operations, before income taxes - domestic | ... | (58,505,000) | (63,660,000) |
| Income (loss) from operations, before income taxes | (42,210,000) | (58,505,000) | (63,660,000) |
| Net income (loss) | (42,210,000) | (58,505,000) | (63,660,000) |
| Weighted average shares outstanding - basic | 48,038,000 | 33,935,000 | 27,964,000 |
| Weighted average shares outstanding - diluted | 48,038,000 | 33,935,000 | 27,964,000 |
| Year end shares outstanding | 55,144,000 | 37,235,000 | 29,716,000 |
| Net earnings (loss) per share - basic | \$(0.88) | \$(1.72) | \$(2.28) |
| Net earnings (loss) per share - diluted | \$(0.88) | \$(1.72) | \$(2.28) |
| Number of full time employees | 56 | ... | 142 |
| Total number of employees | 56 | 61 | ... |
| Number of common stockholders | 11 | 11 | 12 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.88) | ... | ... |
| EPS - Diluted - | ... | ... | ... |

excluding
Extraordinary Items
Applicable to
Common - Total \$(0.88)

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of shares in Rights Offering, employee stock purchase plan, and exercise of warrants; □ As proximately; □ As of March 27, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash & cash equivalents | 44,365,000 | 61,139,000 |
| Prepaid expenses & other | | |
| current assets | 963,000 | 1,008,000 |
| Total current assets | 45,328,000 | 62,147,000 |
| Leasehold improvements | 2,519,000 | 2,519,000 |
| Laboratory equipment | 1,247,000 | 1,118,000 |
| Furniture, fixtures & equipment | 966,000 | 966,000 |
| Software | 272,000 | 289,000 |
| Construction in progress | ... | 22,000 |
| Property & equipment, gross | 5,004,000 | 4,914,000 |
| Less: accumulated depreciation | 3,476,000 | ... |
| Less: accumulated depreciation & amortization | ... | 2,953,000 |
| Property & equipment, net | 1,528,000 | 1,961,000 |
| Intangible assets, net | 1,886,000 | 2,551,000 |
| Goodwill | 2,791,000 | 2,791,000 |
| Right-of-use assets | 7,256,000 | 8,062,000 |
| Other asset | 365,000 | 365,000 |
| Total assets | 59,154,000 | 77,877,000 |
| Accounts payable | 1,836,000 | 1,573,000 |
| Compensation expense | 3,199,000 | 1,377,000 |
| Director & officer liability insurance | ... | 571,000 |
| Clinical trial fees & costs | 84,000 | 64,000 |
| Professional fees | ... | 318,000 |
| Warranty | 3,814,000 | 50,000 |
| Other accrued expenses | ... | 215,000 |
| Warranty Other | 343,000 | ... |
| Warranty Other | 188,000 | ... |
| Accrued expenses | ... | 2,595,000 |
| Lease liability, current | 1,058,000 | 896,000 |
| Related party note payable, current | ... | 917,000 |
| Total current liabilities | 6,708,000 | 5,981,000 |
| Lease liability, less current portion | 8,086,000 | 9,144,000 |
| Related party note payable, less current | ... | 65,000,000 |
| Total liabilities | 14,794,000 | 80,125,000 |
| Common stock | 55,000 | 37,000 |
| Additional paid-in capital | 381,220,000 | 292,420,000 |
| Retained earnings (accumulated deficit) | (336,915,000) | (294,705,000) |
| Total stockholders' equity (deficit) | 44,360,000 | (2,248,000) |
| Total Equity | 44,360,000 | ... |

Recent Dividends:

1. Pulse Biosciences Inc common.
No dividends paid.

Annual Dividends:

1. Pulse Biosciences Inc common.
No dividends paid.

PURE CYCLE CORP.

Earnings, 6 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------------|-----------|-------------|
| Total revenues | 8,583,000 | 4,330,000 |
| Cost & expenses | 6,899,000 | 5,822,000 |
| Operating income | 1,388,000 | (1,729,000) |
| Interest expense | ... | 97,000 |
| Other income (expense), net | 259,000 | 1,438,000 |
| Net before taxes | 2,961,000 | 568,000 |
| Income taxes | 778,000 | 220,000 |

| | | |
|-------------------------|------------|------------|
| Net income | 2,183,000 | 348,000 |
| Earnings common share | | |
| Primary | \$0.09 | \$0.01 |
| Fully Diluted | \$0.09 | \$0.01 |
| Common Shares: | | |
| Full Diluted | 24,149,524 | 24,114,089 |
| Year-end | 24,088,734 | 24,054,843 |

**QS ENERGY INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------------|
| Operating expenses .. | 688,000 | 765,000 | (revised) 837,000 |
| Research & development expenses | 203,000 | 486,000 | 350,000 |
| Income (loss) from operations | (891,000) | (1,251,000) | (1,187,000) |
| Paycheck Protection Program loan debt forgiveness | ... | 63,000 | ... |
| Interest & financing expense | 333,000 | 360,000 | 233,000 |
| Income (loss) before provision for income taxes | (1,224,000) | ... | ... |
| Net income (loss) | (1,224,000) | (1,548,000) | (1,420,000) |
| Weighted average shares outstanding - basic | 385,561,786 | 361,790,243 | 336,041,213 |
| Weighted average shares outstanding - diluted | 385,561,786 | 361,790,243 | 336,041,213 |
| Year end shares outstanding | 392,586,471 | 376,074,096 | 355,300,222 |
| Net income (loss) per common share - basic | ... | \$0.00 | \$0.00 |
| Net income (loss) per common share - diluted | ... | \$0.00 | \$0.00 |
| Number of full time employees | 1 | 2 | 2 |
| Number of common stockholders | 1,000 | □□1,000 | □□1,000 |
| Total number of employees | 1 | ... | ... |

□ Approximately; □ As of March 24, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash | 70,000 | 133,000 |
| Prepaid expenses & other | | |
| current assets | 12,000 | 19,000 |
| Total current assets | 82,000 | 152,000 |
| Office equipment | ... | 35,000 |
| Furniture & fixtures | 5,000 | 5,000 |
| Dies & molds | 35,000 | ... |
| Testing equipment | 37,000 | 37,000 |
| Leasehold improvements | 25,000 | 25,000 |
| Subtotal property & equipment | 102,000 | 102,000 |
| Less accumulated depreciation | 100,000 | 96,000 |
| Property & equipment, net | 2,000 | 6,000 |
| Total assets | 84,000 | 158,000 |
| Accounts payable - license agreements - past due | ... | 1,962,000 |
| Accounts payable & accrued expenses | 972,000 | 946,000 |
| Convertible notes payable, net | 2,101,000 | □1,865,000 |
| Accrued expenses & accounts payable - related parties | 2,198,000 | ... |
| Paycheck Protection Program loan payable | ... | 75,000 |
| PPP Loan payable | 57,000 | ... |
| Total current liabilities | 5,328,000 | 4,848,000 |

| | | |
|---|---------------|---------------|
| Total liabilities | 5,328,000 | 4,848,000 |
| Common stock | 392,587 | 376,075 |
| Additional paid-in capital | 119,729,413 | 119,075,925 |
| Accumulated deficit | (125,366,000) | ... |
| Retained earnings (accumulated deficit) | ... | (124,142,000) |
| Total stockholders' equity (deficit) | (5,244,000) | (4,690,000) |
| Stockholders equity (deficiency) | (5,244,000) | ... |

□ Includes in default - convertible debentures: \$1,730,000

Recent Dividends:

1. QS Energy Inc common.

No dividends paid.

Annual Dividends:

1. QS Energy Inc common.

No dividends paid.

QSAM BIOSCIENCES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 |
|--|-------------|-------------|--------------|
| Compensation & related expenses | 1,001,704 | 2,899,987 | 8,290,699 |
| Professional fees | ... | 1,262,860 | 1,985,780 |
| Sales expenses | 1,533,507 | ... | ... |
| General & administrative expenses | 247,306 | 275,923 | 117,483 |
| Research & development expenses | 1,159,993 | 1,022,412 | 647,302 |
| Total operating expenses | 3,942,510 | 5,461,182 | 11,041,264 |
| Income (loss) from operations | (3,942,510) | (5,461,182) | (11,041,264) |
| Financing costs including interest | ... | 74,390 | 44,171 |
| Loss (gain) on equity method investment | ... | ... | 100,000 |
| Interest expense | 52,688 | ... | ... |
| Loss (gain) on conversion of bridge notes & accrued interest | ... | ... | 744,505 |
| Gain loss on convertible debt | (397,928) | 54,281 | ... |
| Loss (gain) on debentures & accrued expenses converted to common stock | ... | ... | 390,067 |
| Gain (loss) on forgiveness of debt from Paycheck Protection Program ... | ... | ... | 142,942 |
| Total other income (expenses), net | (450,616) | (20,109) | (935,801) |
| Income (loss) from operations before income taxes | (4,393,126) | (5,481,291) | (11,977,065) |
| Net income (loss) | (4,393,126) | (5,481,291) | (11,977,065) |
| Series A convertible contractual dividends | 27,998 | 27,620 | 29,538 |
| Series B convertible contractual dividends | 150,895 | 151,310 | 153,343 |
| Deemed dividend series B warrant modification | 283,685 | 41,225 | 850,214 |
| Deemed dividends on series A conversion to common stock | ... | ... | 542,500 |
| Deemed dividends from series A & B conversion price reduction | 305,541 | 373,435 | ... |

| | | | |
|--|-------------|-------------|--------------|
| Net income (loss) attributable to common stockholders | (5,161,245) | (6,074,881) | (13,552,660) |
| Weighted average shares outstanding | | | |
| - basic | 3,046,052 | 1,762,160 | 791,599 |
| Weighted average shares outstanding | | | |
| - diluted | 3,046,052 | 1,762,160 | 791,599 |
| Year end shares outstanding | 3,609,382 | 2,279,019 | 1,652,102 |
| Net income (loss) per share from continuing operations - basic | \$(1.69) | ... | ... |
| Net income (loss) per share - basic | \$(1.69) | \$(3.45) | \$(17.20) |
| Net income (loss) per share from continuing operations - diluted | \$(1.69) | ... | ... |
| Net income (loss) per share - diluted | \$(1.69) | \$(3.45) | \$(17.20) |
| Number of full time employees | 4 | 4 | 4 |
| Number of part time employees | ... | 1 | 1 |
| Total number of employees | 4 | 5 | 5 |
| Number of common stockholders | 342 | 309 | 315 |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-40 stock split, March 10, 2022; Shares increased due to the effects of shares issued for services and cash, reverse split fractional shares adjustment, and conversion of debentures, accrued expenses, deferred employee compensation; Shares increased due to the effect of conversion of preferred stock to common stock; As of March 27, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 1,386,387 | 225,276 |
| Prepaid expenses & other assets | 250,000 | 139,345 |
| Prepaid expenses and other assets | 68,860 | ... |
| Total current assets | 1,705,247 | 364,621 |
| Total assets | 1,705,247 | 364,621 |
| Accounts payable & accrued expenses | 569,851 | 745,011 |
| Accrued payroll & related expenses | ... | 79,166 |
| Accrued series B preferred stock dividends | 455,548 | 304,653 |
| Notes payable, net of discount | ... | 443,700 |
| Notes payable - related parties | ... | 7,500 |
| Loans payable | 7,500 | ... |
| Total current liabilities | ... | 1,580,030 |
| Total Liabilities | ... | 1,580,030 |
| Redeemable convertible preferred stock - series A | 509,198 | 721,200 |
| Preferred stock | 2 | ... |
| Preferred stock, series B | ... | 2 |
| Common stock | 361 | 228 |
| Unearned deferred compensation | (1,345,509) | (187,329) |
| Additional paid-in capital | 41,666,897 | 33,428,115 |
| Retained earnings (accumulated deficit) | (40,158,601) | (35,177,625) |
| Total stockholders' equity (deficit) | 163,150 | (1,936,609) |
| Total Equity | 163,150 | ... |

Recent Dividends:

1. QSAM Biosciences Inc series A redeemable convertible preferred.

No dividends paid.
2. QSAM Biosciences Inc common.
 No dividends paid.
3. QSAM Biosciences Inc series E-1 preferred.
 No dividends paid.
4. QSAM Biosciences Inc series B preferred.
 No dividends paid.
Annual Dividends:
1. QSAM Biosciences Inc series A redeemable convertible preferred.
 No dividends paid.
2. QSAM Biosciences Inc common.
 No dividends paid.
3. QSAM Biosciences Inc series E-1 preferred.
 No dividends paid.
4. QSAM Biosciences Inc series B preferred.
 No dividends paid.

QUALIGEN THERAPEUTICS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|---------------------|---------------------|---------------------|
| Net product sales | ... | ... | 5,021,721 |
| License revenue | ... | ... | 632,004 |
| Total revenues | ... | ... | 5,653,725 |
| Cost of product sales | ... | ... | 4,332,485 |
| General & administrative | 6,095,607 | 10,274,600 | 11,724,964 |
| Research & development | 5,209,250 | 4,486,120 | 11,716,718 |
| Sales & marketing | ... | ... | 542,594 |
| Total expenses | 11,304,857 | 14,760,720 | ... |
| Total expenses | ... | ... | 28,316,761 |
| Income (loss) from operations | (11,304,857) | (14,760,720) | (22,663,036) |
| Interest income | (1,524,722) | (34,397) | ... |
| Change in fair value of warrant liabilities | 2,035,469 | 907,203 | 4,723,187 |
| Interest income (expense), net | ... | ... | 42,693 |
| Gain on loan extinguishment | (625,653) | ... | ... |
| Other income, net | 38,994 | ... | 5,446 |
| Loss on fixed asset disposal | (21,747) | ... | ... |
| Loss on voluntary conversion of convertible debt | (1,077,287) | ... | ... |
| Total other expense (income) | (1,174,946) | 872,806 | 4,771,326 |
| Income (loss) before provision for income taxes | (12,479,803) | (13,887,914) | (17,891,710) |
| Provision for income taxes | (4,793) | 6,548 | 5,427 |
| Net income (loss) | (13,760,250) | (21,034,643) | (17,897,137) |
| Net income (loss) attributable to noncontrolling interest | 343,038 | 2,394,100 | ... |
| Net income (loss) attributable to Qualigen Therapeutics, Inc. | (13,417,212) | (18,640,543) | (17,897,137) |
| Weighted average shares outstanding | | | |
| - basic | 5,072,709 | 3,840,340 | 2,933,487 |
| Weighted average shares outstanding | | | |
| - diluted | 5,072,709 | 3,840,340 | 2,933,487 |
| Year end shares outstanding | 5,362,128 | 4,210,737 | 3,529,018 |
| Net earnings (loss) per share - basic | \$(2.64) | \$(4.85) | \$(6.10) |
| Net earnings (loss) per share - diluted | \$(2.64) | \$(4.85) | \$(6.10) |
| Number of full time employees | ... | ... | 39 |
| Number of part time employees | ... | ... | 7 |
| Total number of employees | ... | ... | 46 |

| | | | |
|---|--------------|--------------|-----|
| employees | ... | ... | 46 |
| Number of common stockholders | 287 | ... | 692 |
| Income from continuing operations | (12,475,010) | (13,894,462) | ... |
| Loss from discontinued operations, net of tax | (683,008) | (7,140,181) | ... |
| Sale of Discontinued Operations - Net - Gain/Loss | (602,232) | ... | ... |
| Earnings per share from continuing operations | \$(2.46) | \$(3.62) | ... |
| Earnings per share-disp of discontinued ops | \$(0.12) | \$0.00 | ... |
| Earnings per share-inc from discontinued oper | \$(0.13) | \$(1.86) | ... |
| Earnings per share-total discontinued ops | \$(0.25) | \$(1.86) | ... |
| Earnings per share from continuing operations | \$(2.46) | \$(3.62) | ... |
| Earns per share-disp of discont ops - diluted | \$(0.12) | \$0.00 | ... |
| Earn per share-inc from discont ops - diluted | \$(0.13) | \$(1.86) | ... |
| Earning per share-total discont ops - diluted | \$(0.25) | \$(1.86) | ... |

Restated to reflect discontinued operations; Reclassified to conform with 2022 presentation; Adjusted for 1-for-10 stock split, November 23, 2022; Shares increased due to the effect of issuance of stock for exercise of warrants, conversion of preferred stock, issuance pursuant to securities purchase agreements, and for professional services; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash | 401,803 | 7,034,434 |
| Accounts receivable, gross | ... | 726,449 |
| Less: allowance | ... | 187,862 |
| Accounts receivable, net | ... | 538,587 |
| Raw materials | ... | 949,796 |
| Work in process | ... | 200,318 |
| Finished goods | ... | 436,183 |
| Inventoy, net | ... | 1,586,297 |
| Prepaid insurance | ... | 1,377,323 |
| Prepaid manufacturing expenses | ... | 43,820 |
| Prepaid investor relations expenses | 764,964 | ... |
| Other prepaid expenses | ... | 227,451 |
| Other current assets | ... | 12,626 |
| Prepaid expenses & other current assets | ... | 1,661,220 |
| Total current assets | 1,166,767 | 10,820,538 |
| Restricted cash | ... | 5,690 |
| Right-of-use assets | ... | 1,422,538 |
| Machinery & equipment | ... | 2,510,148 |
| Computer equipment | ... | 395,836 |
| Leasehold improvements | ... | 333,271 |
| Molds & tooling | ... | 260,002 |
| Furniture & fixtures | ... | 144,832 |
| Equipment held for lease | ... | 1,399,444 |
| Property & equipment, gross | ... | 5,043,533 |
| Less: accumulated depreciation | ... | 4,623,446 |
| Fixed asset impairment | ... | 75,000 |
| Property & equipment, net | ... | 345,087 |

| | | |
|---|---------------|---------------|
| Intangible assets, net | 5,845,702 | |
| Goodwill | 625,602 | |
| Other assets | 866,481 | 18,334 |
| Total assets | 2,033,248 | 19,083,491 |
| Accounts payable | 2,222,983 | 857,311 |
| Accrued vacation | | 467,948 |
| Accrued board compensation | 129,499 | 70,000 |
| Equipment held for lease | | 154,433 |
| Accrued franchise, sales & use taxes | | 27,531 |
| Accrued income taxes | | 4,663 |
| Accrued interest | | 2,829 |
| Accrued payroll | 151,286 | 209,303 |
| Accrued professional fees | 121,775 | 238,211 |
| Accrued research & development | 104,402 | 322,987 |
| Accrued royalties | | 13,158 |
| Accrued warranty liability | | 137,568 |
| Accrued license fees | 8,850 | 150,130 |
| Other accrued expenses & current liabilities | 560,006 | 181,043 |
| Accrued expenses & other current liabilities | | 1,511,856 |
| Research & development grant liability | | 780,682 |
| Notes payable, current portion | 1,299,216 | |
| Deferred revenue, current portion | | 116,161 |
| Payroll | 1,215 | |
| Operating lease liability, current portion | | 240,645 |
| Short term debt - related party | | 950,722 |
| Warrants liabilities | 54,600 | 788,100 |
| Warrant liabilities - related party | | 2,834,547 |
| Convertible debt - related party | | 60,197 |
| Other liabilities | 32,975 | |
| Interest (Convertible debt) | 10,004 | |
| Total current liabilities | 4,136,805 | 8,608,169 |
| Operating lease liability, net of current portion | | 1,301,919 |
| Deferred revenue, net of current portion | | 49,056 |
| Deferred tax liability | | 357,757 |
| Total liabilities | 4,136,805 | 10,316,901 |
| Common stock | 43,262 | 42,110 |
| Additional paid-in capital | 114,655,565 | 110,528,050 |
| Accumulated other comprehensive income (loss) | | 50,721 |
| Accumulated deficit | (116,802,384) | |
| Retained earnings (accumulated deficit) | | (103,385,172) |
| Total stockholders' equity (deficit) | (2,103,557) | 7,235,709 |
| Noncontrolling interest | | 1,530,881 |
| Total stockholders' equity | (2,103,557) | 8,766,590 |

Recent Dividends:

- 1. Qualigen Therapeutics Inc common.**
No dividends paid.
 - 2. Qualigen Therapeutics Inc series Alpha convertible preferred.**
No dividends paid.
 - 3. Qualigen Therapeutics Inc series B convertible preferred.**
No dividends paid.
 - 4. Qualigen Therapeutics Inc series C convertible preferred.**
No dividends paid.
 - 5. Qualigen Therapeutics Inc series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Qualigen Therapeutics Inc common.**
No dividends paid.

- 2. Qualigen Therapeutics Inc series Alpha convertible preferred.**
No dividends paid.
- 3. Qualigen Therapeutics Inc series B convertible preferred.**
No dividends paid.
- 4. Qualigen Therapeutics Inc series C convertible preferred.**
No dividends paid.
- 5. Qualigen Therapeutics Inc series A convertible preferred.**
No dividends paid.

**QUALIS INNOVATIONS INC
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2021 | 2020 |
|---|------------------|--------------------|---------|
| Research & development | 1,500 | 480,067 | |
| Stock based compensation - related party | 30,348 | 165,378 | |
| General & administrative | 152,630 | 922,945 | |
| Stock based compensation - related party | 45,763 | | |
| Income (loss) from operation | (230,241) | (1,568,390) | |
| Settlement of dispute | (500,000) | | |
| Impairment of assets | 23,403 | | |
| Impairment of inventory | 76,008 | | |
| adjustment | 40,175 | | |
| Gain on cancellation of shares for services | (18,000) | | |
| Total other income | (574,780) | | |
| Income (loss) before income tax expense | (805,021) | (1,568,390) | |
| Net income (loss) | (805,021) | (1,568,390) | |
| Weighted average shares outstanding - basic | 8,475,950 | 6,936,196 | 396,650 |
| Weighted average shares outstanding - diluted | 8,475,950 | 6,936,196 | 396,650 |
| Year end shares outstanding | 8,439,950 | 8,239,950 | 396,650 |
| Net income (loss) per share - basic | \$(0.09) | \$(0.23) | |
| Net income (loss) per share - diluted | \$(0.09) | \$(0.23) | |
| Number of full time employees | 0 | 1 | |
| Total number of employees | 0 | | |
| Number of common stockholders | 150 | | |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.09) | | |

December 31, 2020 and prior period for Qualis Innovations, Inc. prior to reverse merger with mPathix Health, Inc.

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|--------------------------------|--------|---------|
| Cash and Bank Accounts | 2,431 | |
| Cash | | 528,284 |
| Inventory | | 80,775 |
| Deposit | | 54,000 |
| Other current assets | | 101,144 |
| Total current assets | 2,431 | 764,203 |
| Machinery & equipment | 82,530 | |
| Tooling | | 84,317 |
| Computer Equipment | 1,787 | |
| Less: Accumulated depreciation | 84,317 | 27,957 |
| Property & equipment, net | | 56,360 |
| Intangible assets, net | | 143,226 |
| Total assets | 2,431 | 963,789 |

| | | |
|---|-------------|-------------|
| Accrued expenses & other payables | 16,285 | |
| Other current liabilities | | 11,400 |
| Short-term note payable | 9,102 | |
| Short-term share settlement | 500,000 | |
| Total current liabilities | 525,387 | 29,648 |
| Common stock | 8,440 | |
| Total liabilities | 525,387 | |
| Common stock - Additional paid-in (distribution of) capital | 3,898,912 | 3,466,947 |
| Accumulated deficit | (4,430,308) | |
| Retained earnings (accumulated deficit) | | (2,541,046) |
| Total stockholders equity (deficit) | (522,956) | 934,141 |
| Total Equity | (522,956) | |

Recent Dividends:

- 1. Qualis Innovations Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. Qualis Innovations Inc common.**
No dividends paid.

**QUALSTAR CORP
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 |
|--|------------|-----------|------------|
| Net revenues | 10,616 | 9,845 | 9,164 |
| Cost of goods sold | 7,336 | 6,850 | 5,997 |
| Gross profit (loss) | 3,280 | 2,995 | 3,167 |
| Engineering expenses | | 336 | 451 |
| Sales & marketing expenses | | | 1,476 |
| General & administrative expenses | 1,353 | 1,215 | 809 |
| Research & development expenses | 393 | | |
| General & administrative expenses | 1,394 | 1,352 | |
| Total operating expenses | 3,140 | 2,903 | 2,736 |
| Income (loss) from operations | 140 | 92 | 431 |
| Other income (expenses) | 54 | (32) | 2 |
| Interest income | 46 | | |
| Income (loss) before income taxes | 194 | 60 | 433 |
| Current state provision (benefit) for income taxes | 3 | 5 | 3 |
| Current provision (benefit) for income taxes | 3 | 5 | 3 |
| Net income (loss) | 191 | 55 | 430 |
| Weighted average shares outstanding - basic | 1,570 | 1,829 | 1,934 |
| Weighted average shares outstanding - diluted | 1,570 | 1,829 | 1,934 |
| Year end shares outstanding | 1,447 | 1,627 | 1,884 |
| Net income (loss) per share - basic | \$0.12 | \$0.03 | \$0.22 |
| Net income (loss) per share - diluted | \$0.12 | \$0.03 | \$0.22 |
| Number of common stockholders | | | 23 |
| Revenues | 10,616 | | |
| Net sales | | 9,845 | |
| Basic EPS Excluding ExtraOrdinary Items | \$0.12 | | |

| | | | |
|---------------------|--------|-----|-----|
| Diluted EPS | | | |
| Excluding ExtraOrd | | | |
| Items | \$0.12 | ... | ... |
| Gains on foreign | | | |
| currency exchange | 3 | ... | ... |
| Realized and | | | |
| unrealized gains on | | | |
| marketable | | | |
| securities | 5 | ... | ... |

| | | | |
|--------------------------|---------------------|---------------------|---------------------|
| Cost of revenue | 195,640 | 60,934 | ... |
| Gross profit | 162,407 | 74,714 | ... |
| Salaries & | | | |
| benefits | 4,047,910 | 4,326,733 | 2,488,877 |
| Consulting | ... | 1,278,170 | 1,076,901 |
| Research & | | | |
| development | | | |
| expenses | 6,447,703 | 4,561,794 | 2,585,796 |
| Stock based | | | |
| compensation | 8,722,766 | 17,761,467 | 9,401,345 |
| Selling, general & | | | |
| administrative | 7,326,713 | 8,725,892 | 1,577,174 |
| Operating expenses | ... | 36,654,056 | 17,130,093 |
| Income (loss) from | | | |
| operations | (27,221,277) | (36,579,342) | (17,130,093) |
| Interest income - | | | |
| money market | 295,478 | ... | 7,378 |
| Interest income | ... | 46,891 | ... |
| Misc. income - | | | |
| government grants | (861,071) | ... | 218,371 |
| Interest expense - | | | |
| promissory notes | ... | 225,282 | ... |
| Interest expense - | | | |
| warrants | ... | ... | 10,715,799 |
| Interest expense - | | | |
| financing expenses | 1,341,743 | 946,748 | 161,250 |
| Interest expense - | | | |
| preferred dividends | 602,059 | 889,219 | 117,454 |
| Net other income | | | |
| (expense) | (2,509,395) | (2,014,358) | (10,768,754) |
| Income (loss) | | | |
| before federal | | | |
| income taxes | (29,730,672) | ... | ... |
| Net income (loss) | (29,730,672) | (38,593,700) | (27,898,847) |
| Weighted average | | | |
| shares outstanding | | | |
| - basic | 77,451,356 | 55,963,334 | 29,156,815 |
| Weighted average | | | |
| shares outstanding | | | |
| - diluted | 77,451,356 | 55,963,334 | 29,156,815 |
| Year end shares | | | |
| outstanding | 77,451,356 | 55,963,334 | 29,156,815 |
| Net earnings (loss) | | | |
| per share - basic | \$(0.38) | \$(0.69) | \$(0.96) |
| Net earnings (loss) | | | |
| per share - diluted | \$(0.38) | \$(0.69) | \$(0.96) |
| Number of full time | | | |
| employees | 39 | 38 | 25 |
| Number of part time | | | |
| employees | ... | 6 | 7 |
| Number of common | | | |
| stockholders | 263 | 239 | 260 |
| Total number of | | | |
| employees | 39 | ... | ... |

| | | |
|---------------------------|---------------|---------------|
| Accrued expense | 195,923 | ... |
| Accrued expenses | ... | 3,559,981 |
| Lease liability | ... | 1,357,924 |
| Dividends payable - | | |
| preferred | 215,119 | 219,844 |
| Notes payable - other | 2,496,480 | ... |
| Loans payable - short | | |
| term | ... | 535,684 |
| Other current liabilities | 250,116 | ... |
| Deferred revenue | 458 | ... |
| Total current liabilities | 4,619,637 | 6,545,320 |
| Loans payable - long term | ... | 7,632,998 |
| Accrued interest - long | | |
| term | ... | 225,282 |
| Operating lease | | |
| liabilities | 840,085 | ... |
| Long term liabilities - | | |
| subtotal | ... | 7,858,280 |
| Total liabilities | 5,459,722 | 14,403,600 |
| Series A convertible | | |
| preferred | 149 | 150 |
| Common stock | 7,745 | 5,596 |
| Additional paid-in | | |
| capital | 167,944,651 | 151,163,909 |
| APIC - beneficial | | |
| conversion feature in | | |
| equity | 4,898,835 | 4,898,835 |
| APIC - stock based | | |
| compensation | 50,135,626 | 38,816,022 |
| Accumulated deficit | (149,718,453) | ... |
| Retained earnings | | |
| (accumulated deficit) | ... | (119,987,781) |
| Total stockholders' | | |
| equity (deficit) | 73,268,553 | 74,896,731 |
| Total Equity | 73,268,553 | ... |

□ As is; □ Approximately; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---------------------------|----------|----------|
| Cash & cash equivalents | 2,275 | 2,767 |
| Marketable securities | 140 | ... |
| Marketable securities, | | |
| short-term | ... | 33 |
| Accounts receivable, net | 2,174 | 1,643 |
| Raw materials | 161 | 145 |
| Finished goods | 2,709 | 2,891 |
| Inventories, net | 2,870 | 3,036 |
| Prepaid expenses & other | | |
| current assets | 343 | 138 |
| Total current assets | 7,802 | 7,617 |
| Machinery & equipment | 389 | 382 |
| Furniture & fixtures & | | |
| computer equipment | 258 | 258 |
| Leasehold improvements | 119 | 119 |
| Property & equipment, | | |
| gross | 766 | 759 |
| Less: accumulated | | |
| depreciation & | | |
| amortization | 714 | 677 |
| Property & equipment, | | |
| net | 52 | 82 |
| Right-of-use asset | 88 | 243 |
| Deferred tax assets | 30 | 30 |
| Other assets | 59 | 71 |
| Total assets | 8,031 | 8,043 |
| Accounts payable | 1,482 | 946 |
| Accrued salaries, wages | | |
| & payroll taxes | 26 | 32 |
| Accrued bonuses | 113 | 108 |
| Accrued other payroll & | | |
| related liabilities | 139 | 140 |
| Deferred service revenue | 577 | 687 |
| Lease liabilities, short | | |
| term | 95 | 165 |
| Total current liabilities | 2,423 | 2,071 |
| Lease liabilities, long | | |
| term | ... | 95 |
| Deferred service revenue, | | |
| long-term | 567 | 510 |
| Other long-term | | |
| liabilities | 27 | 27 |
| Total long-term | | |
| liabilities | 594 | 632 |
| Total liabilities | 3,017 | 2,703 |
| Common stock | 17,701 | 18,218 |
| Accumulated deficit | (12,687) | ... |
| Retained earnings | | |
| (accumulated deficit) | ... | (12,878) |
| Total shareholders' | | |
| equity (deficit) | 5,014 | 5,340 |
| Total Equity | 5,014 | 5,340 |

Recent Dividends:

1. Qualstar Corp common.

No dividends paid.

Annual Dividends:

1. Qualstar Corp common.

No dividends paid.

QUANTUM COMPUTING INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-----------------|---------|---------|------|
| Professional | | | |
| Services | 838,592 | ... | ... |
| Revenue | 358,047 | ... | ... |
| Total revenue | 358,047 | 135,648 | ... |
| Cost of revenue | 195,640 | ... | ... |

□ Non-consolidated; □ Approximately; □ As of March 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | (revised) |
|--------------------------|------------|------------|-----------|
| Cash & cash equivalents | 2,059,285 | 5,308,466 | ... |
| Accounts receivable | 557,236 | 12,774 | ... |
| Loans receivable | 65,000 | ... | ... |
| Inventory | 72,650 | ... | ... |
| Prepaid expenses | 138,460 | 224,302 | ... |
| Other current assets | 289,117 | 42,105 | ... |
| Subtotal current assets | 3,181,748 | 5,587,647 | ... |
| Computers & office | | | |
| equipment | 3,092,664 | ... | ... |
| Hardware & equipment | 3,141,939 | 1,026,829 | ... |
| Software | 49,275 | 18,889 | ... |
| Total cost of property & | | | |
| equipment | ... | 1,045,718 | ... |
| Less: accumulated | | | |
| depreciation | 272,281 | 70,549 | ... |
| Fixed assets (net of | | | |
| depreciation) | 2,869,658 | 975,169 | ... |
| Lease right of use | 799,942 | 1,327,746 | ... |
| Security deposits | 129,045 | 60,271 | ... |
| Intangible assets-net of | | | |
| amortization | 11,388,015 | 22,223,725 | ... |
| Goodwill | 60,359,867 | 59,125,773 | ... |
| Subtotal other assets | ... | 82,737,515 | ... |
| Total assets | 78,728,275 | 89,300,331 | ... |
| Accounts payable | 1,461,541 | 871,887 | ... |

Recent Dividends:

1. Quantum Computing Inc common.

No dividends paid.

2. Quantum Computing Inc series A convertible preferred.

No dividends paid.

Annual Dividends:

1. Quantum Computing Inc common.

No dividends paid.

2. Quantum Computing Inc series A convertible preferred.

No dividends paid.

QUARTA-RAD INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---------------------|----------|-----------|-----------|
| Sales - Quarta Rad, | | | |
| Inc., net | ... | 127,000 | 993,481 |
| Sales - Sellavir, | | | |
| Inc., net - related | | | |
| party | ... | 973,431 | 252,500 |
| Sales, net, related | | | |
| party | 187,000 | ... | ... |
| Sales, net | 321,316 | ... | ... |
| Total sales, net | ... | ... | 1,245,981 |
| Total sales, net | 508,316 | 1,100,431 | ... |
| Cost of goods sold | | | |
| - Sellavir, Inc. | 91,009 | 81,658 | 11,123 |
| Cost of goods sold | | | |
| - Quarta Rad, Inc. | 233,944 | 622,123 | 751,775 |
| Gross profit (loss) | 183,363 | 396,650 | 483,083 |
| General & | | | |
| administrative | | | |
| expenses | 31,518 | 47,705 | 38,531 |
| Advertising | | | |
| expenses | 49,940 | 43,735 | 78,328 |
| Professional & | | | |
| consulting fees | 114,671 | 167,766 | 245,410 |
| Operating expenses | 196,129 | 259,206 | 362,269 |
| Net income (loss) | | | |
| from operations | (12,766) | 137,444 | 120,814 |
| Other income - | | | |
| interest & | | | |
| dividends | 303 | 285 | 10 |
| Other income - | | | |
| unrealized loss on | | | |
| investments | 25,769 | (78,158) | (68,433) |
| Other income - | | | |

| | 2023 | 2022 | 2021 (revised) | | | |
|---|------------|------------|-------------------|---|-------------|-------------|
| realized loss on investments | (3,529) | (41,118) | (39,636) | | | 5,453,204 |
| Other expense - interest | ... | ... | 75 | Sales | 13,152,500 | ... |
| Net income (loss) before provision (benefit) for income taxes | 56,319 | 18,453 | 12,680 | Patent licensing fees | ... | 451,194 |
| Deferred federal income tax expense (benefit) | 11,827 | 3,875 | 2,663 | Total revenues | 13,152,500 | ... |
| Adjustment for prior periods | ... | ... | 2,674 | Litigation & licensing expenses | 5,534,596 | 303,671 |
| Total deferred income taxes | 11,827 | 3,875 | 5,337 | Gross margin | 7,617,904 | 147,523 |
| Income tax expense (benefit) | 11,827 | 3,875 | 5,337 | Selling, general & administrative expenses | 2,740,554 | 1,979,718 |
| Net income (loss) | 44,492 | 14,578 | 7,343 | Total operating expenses | 2,740,554 | 1,979,718 |
| Weighted average shares outstanding - basic | 15,674,483 | 15,674,483 | 15,661,956 | Income (loss) from operations | 4,877,350 | (1,832,195) |
| Weighted average shares outstanding - diluted | 15,674,483 | 15,674,483 | 15,661,956 | Gain on forgiveness of debt | ... | ... |
| Year end shares outstanding | 15,674,483 | 15,674,483 | 15,674,483 | Gain on settlement of accounts payable & accrued expenses | ... | 1,725,965 |
| Number of common stockholders | 39 | 39 | 39 | Warrant expense | ... | 1,154,905 |
| Other income - interest - related party | 46,578 | ... | ... | Change in fair market value of warrant liability | (136,381) | 1,490,759 |
| Other expense - foreign currency translation loss | (36) | ... | ... | Loss on conversion of debt | ... | ... |
| | | | | Loss on debt extinguishment | ... | (730,378) |
| | | | | Loss on impairment of assets | ... | 1,651,614 |
| | | | | Interest expense | 1,061,387 | 413,333 |
| | | | | Total other income (expense), net | (1,197,768) | 1,077,426 |
| | | | | Net income (loss) before income tax | 3,679,582 | (754,769) |
| | | | | State income taxes | ... | (1,253) |
| | | | | Foreign | 30,000 | ... |
| | | | | Income tax | 30,000 | (1,253) |
| | | | | Net income (loss) | 3,649,582 | (753,516) |
| | | | | Weighted average shares outstanding - basic | 5,331,973 | 5,332,660 |
| | | | | Weighted average shares outstanding - diluted | 5,331,973 | 5,332,660 |
| | | | | Year end shares outstanding | 5,331,973 | 5,331,973 |
| | | | | Net earnings (loss) per share - basic | \$0.68 | \$(0.14) |
| | | | | Net earnings (loss) per share - diluted | \$0.68 | \$(0.14) |
| | | | | Total number of employees | ... | 1 |
| | | | | Number of common stockholders | 422 | 417 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------|---------|
| Cash | 72,625 | 293,878 |
| Accounts receivable | 7,289 | 61,658 |
| Marketable securities, trading | 52,148 | 173,882 |
| Inventory | 30,398 | 186,068 |
| Notes receivable - related party - current portion | 80,813 | ... |
| Total current assets | 243,273 | 715,486 |
| Computer equipment, gross | 4,005 | 2,370 |
| Accumulated depreciation | 2,435 | 1,635 |
| Computer Equipment | 1,570 | 4,005 |
| Fixed assets, net | 1,570 | 2,370 |
| Other assets - deferred tax asset | 24,069 | 35,896 |
| Trade receivable | 28,673 | ... |
| Note receivable - related party | 341,557 | ... |
| Interest receivable - related party | 44,172 | ... |
| Total assets | 683,314 | 753,752 |
| Accounts payable & accrued expenses | 105,244 | 83,299 |
| Payable - related parties | 184,477 | 134,352 |
| Deferred revenue - related party | ... | 187,000 |
| Total current liabilities | 289,721 | 404,651 |
| Common stock | 1,568 | 1,568 |
| Additional paid-in capital | 346,726 | 346,726 |
| Retained earnings (accumulated deficit) | 45,299 | 807 |
| Total stockholders' equity (deficit) | 393,593 | 349,101 |
| Total Equity | 393,593 | 349,101 |

Recent Dividends:

1. Quarta-Rad Inc common.
No dividends paid.

Annual Dividends:

1. Quarta-Rad Inc common.
No dividends paid.

QUEST PATENT RESEARCH CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 563,484 | 90,601 |
| Accounts receivables, gross | 3,008,250 | ... |
| Allowance for doubtful accounts | 0 | ... |
| Accounts receivable, net | 3,008,250 | ... |
| Other current assets | 28,121 | 5,321 |
| Total current assets | 3,599,855 | 95,922 |
| Patents, gross | 6,087,000 | 2,757,000 |
| Less: accumulated amortization | 2,412,397 | 1,625,846 |
| Patents, net | 3,674,603 | 1,131,154 |
| Total assets | 7,274,458 | 1,227,076 |
| Accounts payable & accrued liabilities | 296,536 | 148,533 |
| Loans payable | 138,000 | 138,000 |
| Loans payable - third party | 2,796,500 | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------|---------|
| Revenue | 21,198 | 16,180 |
| Cost of revenue | 6,711 | 7,378 |
| Gross profit (loss) | 14,487 | 8,802 |
| Research & development | 6,448 | 5,001 |
| Selling, general & administrative | 7,969 | 7,601 |
| Income (loss) from operations | 70 | (3,800) |
| Interest expense | 215 | 148 |
| Gain on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... |
| Interest income & other income (expense), net | (116) | (221) |
| Income (loss) before income taxes - United States | (225) | (4,116) |
| Income (loss) before income taxes - Foreign | (36) | (53) |
| Income (loss) before income taxes | (261) | (4,169) |
| Current provision for (benefit from) income taxes - state | 9 | 3 |
| Current provision for (benefit from) income taxes - foreign | (6) | 36 |
| Total current provision for (benefit from) income taxes | 3 | 39 |
| Deferred provision for (benefit from) income taxes - foreign | (1) | 59 |
| Total provision for (benefit from) income taxes - deferred | (1) | 59 |
| Provision for | ... | ... |

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|--------------|-------------------|
| Funding liability | ... | ... | ... |
| Loan payable - related party | 7,325,502 | 2,796,500 | ... |
| Warrant liability | 281,809 | 145,428 | ... |
| Accrued interest | 1,096,985 | 904,573 | ... |
| Total current liabilities | 11,935,332 | 9,586,238 | ... |
| Loan payable - small business association (SBA) | ... | 150,000 | ... |
| Purchase price of patents | 53,665 | 53,665 | ... |
| Loan payable - SBA | 150,000 | ... | ... |
| Total liabilities | 12,138,997 | 9,789,903 | ... |
| Common stock | 160 | 160 | ... |
| Additional paid-in capital | 17,674,985 | 17,626,279 | ... |
| Retained earnings (accumulated deficit) | (22,539,912) | (26,189,494) | ... |
| Total Quest Patent Research Corporation shareholders' equity (deficit) | (4,864,767) | (8,563,055) | ... |
| Non-controlling interest in subsidiary | 228 | 228 | ... |
| Total stockholders' equity (deficit) | (4,864,539) | (8,562,827) | ... |

Recent Dividends:

1. Quest Patent Research Corp common.
No dividends paid.

Annual Dividends:

1. Quest Patent Research Corp common.
No dividends paid.

QUICKLOGIC CORP

Annual Report

Consolidated Income Statement, Years Ended (\$000):

| | 12/31/23 | 01/01/23 | 01/02/22 (revised) |
|---|----------|----------|-----------------------|
| Revenue | 21,198 | 16,180 | 12,685 |
| Cost of revenue | 6,711 | 7,378 | 5,266 |
| Gross profit (loss) | 14,487 | 8,802 | 7,419 |
| Research & development | 6,448 | 5,001 | 6,927 |
| Selling, general & administrative | 7,969 | 7,601 | 8,008 |
| Income (loss) from operations | 70 | (3,800) | (7,516) |
| Interest expense | 215 | 148 | 130 |
| Gain on forgiveness of Paycheck Protection Program ("PPP") loan | ... | ... | 1,192 |
| Interest income & other income (expense), net | (116) | (221) | (43) |
| Income (loss) before income taxes - United States | (225) | (4,116) | (6,461) |
| Income (loss) before income taxes - Foreign | (36) | (53) | (36) |
| Income (loss) before income taxes | (261) | (4,169) | (6,497) |
| Current provision for (benefit from) income taxes - state | 9 | 3 | 3 |
| Current provision for (benefit from) income taxes - foreign | (6) | 36 | 22 |
| Total current provision for (benefit from) income taxes | 3 | 39 | 25 |
| Deferred provision for (benefit from) income taxes - foreign | (1) | 59 | 94 |
| Total provision for (benefit from) income taxes - deferred | (1) | 59 | 94 |
| Provision for | ... | ... | ... |

¹ Reclassified to conform with the 2022 presentation; ² Adjusted for 1-for-100 stock split, August 18, 2022; ³ Shares increased due to the effect of restricted shares issued for services and conversion of debt; ⁴ As of March 31, 2023; ⁵ As of March 22, 2022

| | | | | | | | | | |
|--|----------|----------|----------|--------------------------------|--------|--------|---------------------------------------|-----------|------------|
| (benefit from) income taxes | 2 | 98 | 119 | Accrued compensation | 1,910 | 865 | | 2023 | 2022 |
| Net income (loss) | (263) | (4,267) | (6,616) | Accrued employee benefits | 57 | 40 | | | |
| Weighted average common shares outstanding - basic | 13,453 | 12,588 | 11,535 | Accrued payroll tax | 197 | 57 | Cash & cash equivalents | 342,014 | 477,987 |
| Weighted average common shares outstanding - diluted | 13,453 | 12,588 | 11,535 | Other accrued liabilities | ... | 547 | Accounts receivable, gross | 1,379,787 | 1,110,277 |
| Year end common shares outstanding | 14,118 | 13,202 | 11,863 | Accrued Expenses | 509 | ... | Less: allowance for doubtful accounts | 225,000 | 200,000 |
| Net income (loss) per common share - basic | \$(0.02) | \$(0.34) | \$(0.57) | Accrued liabilities | 2,673 | 1,509 | Accounts receivable, net | 1,154,787 | 910,277 |
| Net income (loss) per common share - diluted | \$(0.02) | \$(0.34) | \$(0.57) | Deferred revenue | 1,052 | 272 | Prepaid expenses | 133,478 | 231,694 |
| Full-Time Employees (Period End) | 49 | ... | ... | Lease liabilities, current | 302 | 850 | Other current assets | 104,931 | 29,092 |
| Total number of employees | 49 | □45 | □48 | Note payable, current | 946 | ... | Total current assets | 1,735,210 | 1,649,050 |
| Number of common stockholders | 93 | □□115 | □□117 | Total current liabilities | 29,630 | 20,022 | Deposits | 16,850 | 15,002 |
| Net sales | 21,198 | ... | ... | Lease liabilities, non-current | 681 | 544 | Computer equipment | 1,575,514 | 1,493,705 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.02) | ... | ... | Other long-term liabilities | 125 | 125 | Office furniture & equipment | 1,616,870 | 27,783 |
| Diluted EPS Excluding ExtraOrd Items | \$(0.02) | ... | ... | Note payable, non-current | 461 | ... | Leasehold improvements | 13,573 | 13,573 |
| | | | | Total liabilities | 30,897 | 20,691 | Capitalized application software | 4,552,910 | 16,214,697 |

Recent Dividends:

1. QuickLogic Corp common.

No dividends paid.

Annual Dividends:

1. QuickLogic Corp common.

No dividends paid.

QUOTEMEDIA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

□ As is; □ As of March 20, 2023; □ As of March 14, 2022

Consolidated Balance Sheet, Years Ended (\$000):

| | 12/31/23 | 01/01/23 |
|--|----------|----------|
| Cash & cash equivalents & restricted cash | 24,606 | 19,201 |
| Accounts receivable, gross | 1,659 | 2,707 |
| Allowances for doubtful accounts | 34 | 18 |
| Accounts receivable, net | 1,625 | 2,689 |
| Contract assets | 3,609 | 1,987 |
| Work-in-process | 1,602 | 1,826 |
| Finished goods | 427 | 667 |
| Inventories | 2,029 | 2,493 |
| Prepaid taxes | 498 | ... |
| Other | 144 | ... |
| Prepaid expenses | ... | 1,305 |
| Other current assets | ... | 265 |
| Prepaid expenses & other current assets | 1,561 | 1,570 |
| Note receivable | 1,200 | ... |
| Other prepaid taxes, royalties, and other prepaid expenses | 629 | ... |
| Total current assets | 34,630 | 27,940 |
| Equipment | 10,503 | 10,133 |
| Software | 1,803 | 1,803 |
| Furniture & fixtures | 65 | 65 |
| Leasehold improvements | 580 | 466 |
| Tooling | 9,248 | ... |
| Property & equipment, gross | 22,199 | 12,467 |
| Less: accumulated depreciation & amortization | 13,251 | 12,002 |
| Property & equipment, net | 8,948 | 465 |
| Capitalized internal-use software, net | ... | 1,514 |
| Right of use assets, net | 981 | 1,397 |
| Intangible assets, net | 537 | 645 |
| Non-marketable equity investment | 300 | 300 |
| Goodwill | 185 | 185 |
| Other assets | 142 | 140 |
| Capitalized internal-use software | 2,069 | ... |
| Right of use assets - Balancing value | 981 | ... |
| Total assets | 47,792 | 32,586 |
| Revolving line of credit | 20,000 | 15,000 |
| Trade payables | 4,657 | 2,391 |

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|-------------|----------------|
| REVENUE | 18,907,725 | ... | ... |
| Revenue | 18,907,725 | 17,527,605 | 15,174,372 |
| Cost of revenue | 9,263,073 | 8,972,129 | 8,438,658 |
| Gross profit | 9,644,652 | 8,555,476 | 6,735,714 |
| Sales & marketing | 3,130,051 | 2,952,968 | 2,507,169 |
| General & administrative | 3,346,157 | 3,015,453 | 2,538,429 |
| Software development | 2,757,031 | 2,096,404 | 1,712,558 |
| Total operating expenses | 9,233,239 | 8,064,825 | 6,758,156 |
| Operating income (loss) | 411,413 | 490,651 | (22,442) |
| Foreign exchange gain (loss) | (45,017) | (40,307) | 107,382 |
| Interest expense | 1,846 | 2,818 | 2,641 |
| Other income | ... | ... | 133,257 |
| Total other income (expenses), net | (46,863) | (43,125) | 237,998 |
| Income (loss) before income taxes | 364,550 | 447,526 | 215,556 |
| Income tax expense (benefit) | 2,966 | 3,056 | 3,184 |
| Net income (loss) | 361,584 | 444,470 | 212,372 |
| Weighted average shares outstanding - basic | 90,477,798 | 90,477,798 | 90,477,798 |
| Weighted average shares outstanding - diluted | 121,030,357 | 119,545,723 | 119,313,662 |
| Year end shares outstanding | 90,477,798 | 90,477,798 | 90,477,798 |
| Net income (loss) per share - basic | ... | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | ... | \$0.00 | \$0.00 |
| Number of full time employees | 131 | 121 | 94 |
| Total number of employees | 131 | ... | ... |
| Number of common stockholders | 145 | 150 | □□155 |

□ Approximately; □ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|--------------|--------------|
| Cash & cash equivalents | 342,014 | 477,987 |
| Accounts receivable, gross | 1,379,787 | 1,110,277 |
| Less: allowance for doubtful accounts | 225,000 | 200,000 |
| Accounts receivable, net | 1,154,787 | 910,277 |
| Prepaid expenses | 133,478 | 231,694 |
| Other current assets | 104,931 | 29,092 |
| Total current assets | 1,735,210 | 1,649,050 |
| Deposits | 16,850 | 15,002 |
| Computer equipment | 1,575,514 | 1,493,705 |
| Office furniture & equipment | 1,616,870 | 27,783 |
| Leasehold improvements | 13,573 | 13,573 |
| Capitalized application software | 4,552,910 | 16,214,697 |
| Office furniture and equipment | 27,783 | ... |
| Total property & equipment | ... | 17,749,758 |
| Less: accumulated depreciation | 1,314,646 | 13,541,508 |
| Property & equipment, net | 302,224 | 4,208,250 |
| Goodwill | 110,000 | 110,000 |
| Intangible assets | 65,636 | 73,572 |
| Operating lease right-of-use assets | 393,472 | 506,219 |
| Total assets | 7,176,302 | 6,562,093 |
| Accounts payable & accrued liabilities | 2,210,933 | 2,512,837 |
| Deferred revenue | 1,456,381 | 1,166,848 |
| Current portion of operating lease liabilities | 206,146 | 174,166 |
| Total current liabilities | 3,873,460 | 3,853,851 |
| Long-term portion of operating lease liabilities | 191,735 | 323,685 |
| Preferred stock warrant liability | 611,563 | 629,375 |
| Series A redeemable convertible preferred stock | 2,983,857 | 2,983,857 |
| Common stock | 90,479 | 90,479 |
| Additional paid-in capital | 18,910,482 | 18,903,272 |
| Accumulated Deficit | (19,860,842) | ... |
| Retained earnings (accumulated deficit) | ... | (20,222,426) |
| Total stockholders' equity (deficit) | (859,881) | (1,228,675) |
| Long-term portion of deferred revenue | 375,568 | ... |

Recent Dividends:

1. QuoteMedia Inc common.

No dividends paid.

2. QuoteMedia Inc series A redeemable convertible preferred.

No dividends paid.

Annual Dividends:

1. QuoteMedia Inc common.

No dividends paid.

2. QuoteMedia Inc series A redeemable convertible preferred.

No dividends paid.

RAPHAEL PHARMACEUTICAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 (revised) |
|---------------------------------|---------|-----------|-----------------|
| Research & development expenses | 569,000 | 1,178,000 | 776,000 |
| Professional services | ... | 289,000 | 697,000 |
| Share based compensation | ... | 1,690,000 | ... |
| Consulting services | ... | 113,000 | 120,000 |
| Rent & office | ... | ... | ... |

| | | |
|---|--------------------|--------------------|
| maintenance | 9,000 | 31,000 |
| Others general & administrative expenses | 703,000 | 38,000 |
| General & administrative expenses | 2,139,000 | 853,000 |
| Operating income (loss) | (3,317,000) | (1,629,000) |
| Total expenses | 1,272,000 | ... |
| Bank fees | 3,000 | 2,000 |
| Exchange rate differences | (38,000) | 7,000 |
| Total financial expense | (12,000) | ... |
| Total financial income (expense), net | (41,000) | 5,000 |
| Net income (loss) before income taxes .. | (1,284,000) | ... |
| Net income (loss) | (1,284,000) | (1,624,000) |
| Weighted average shares outstanding - basic | 16,716,905 | 14,341,518 |
| Weighted average shares outstanding - diluted | 16,716,905 | 14,341,518 |
| Year end shares outstanding | 18,502,918 | 15,624,040 |
| Net income (loss) per share - basic | \$(0.07) | \$(0.23) |
| Net income (loss) per share - diluted | \$(0.07) | \$(0.23) |
| Full-Time Employees (Period End) | 0 | ... |
| Total number of employees | 0 | ... |
| Number of common stockholders | 192 | 187 |
| Basic EPS Excluding ExtraOrdinary Items .. | \$(0.07) | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.07) | ... |

[□] Reclassified to conform with 2022 presentation; [■] Shares increased due to the effect of issuance of common stock and warrants and issuance of common stock in exchange for services; [▣] Shares increased due to the effect of issuance of common stock & warrants; [▤] As of March 23, 2023; [▥] As of March 30, 2022

| | | |
|--|-------------|-------------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
| | 2023 | 2022 |
| Cash & cash equivalents | 230,000 | 288,000 |
| Receivables from governmental authorities | ... | 38,000 |
| Prepaid expenses | ... | 5,000 |
| Other current assets | 107,000 | 43,000 |
| Total current assets | 337,000 | 331,000 |
| Fixed asset, net | 2,000 | 2,000 |
| Total assets | 339,000 | 333,000 |
| Account payables | ... | 72,000 |
| Accrued expenses | 25,000 | 152,000 |
| Other accounts payable & accrued expenses | 34,000 | 224,000 |
| Accounts payable | 9,000 | ... |
| Loans payable - related party | 38,000 | ... |
| Payable to related party | ... | 3,000 |
| Total current liabilities | 72,000 | 227,000 |
| Common stock | 185,000 | 157,000 |
| Additional paid in capital | 7,392,000 | 5,974,000 |
| Retained earnings (accumulated deficit) | (7,310,000) | (6,025,000) |
| Total stockholders' equity (deficit) | 267,000 | 106,000 |
| Total Equity | 267,000 | ... |

Recent Dividends:
1. Raphael Pharmaceutical Inc common.
 No dividends paid.
Annual Dividends:

| | | | |
|---|--------------------|------------------|--------------------|
| 1. Raphael Pharmaceutical Inc common. | | | |
| No dividends paid. | | | |
| REAL BRANDS INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| Revenues | 60,453 | ... | 5,546 |
| Net sales revenue | ... | 11,133 | ... |
| Total revenues | 60,453 | 11,133 | 5,546 |
| Cost of goods sold | 85,610 | 7,507 | 262,620 |
| Gross profit (loss) | (25,157) | 3,626 | (257,074) |
| General & administrative expense | 895,436 | 252,305 | 471,494 |
| Professional fees | ... | ... | 194,556 |
| Payroll & related expenses | 212,311 | ... | 326,424 |
| Stock option expense | ... | 122,570 | 1,065,390 |
| Sales expense | ... | 420,112 | ... |
| Sales & marketing expenses | 58,250 | ... | ... |
| Total operating expenses | ... | 794,987 | 2,057,864 |
| Operating income (loss) | (1,191,154) | (791,361) | (2,314,938) |
| Forgiveness of PPP debt | (3,549) | ... | 143,485 |
| Depreciation expense | 82,472 | 82,076 | 167,536 |
| Impairment of assets | ... | ... | 385,989 |
| Warrant expense | ... | ... | 37,753 |
| Interest expense | 55,176 | 32,507 | 33,040 |
| Total other income (expense) | (141,197) | (114,583) | (480,833) |
| Income (loss) from operations | (1,332,351) | (905,944) | (2,795,771) |
| Net income (loss) | (1,332,351) | (905,944) | (2,795,771) |
| Weighted average shares outstanding - basic | 2,690,640,226 | 2,680,730,333 | 2,624,071,816 |
| Weighted average shares outstanding - diluted | 2,690,640,226 | 2,680,730,333 | 2,624,071,816 |
| Year end shares outstanding | 2,690,640,226 | 2,690,640,226 | 2,677,529,115 |
| Number of full time employees | 1 | 3 | 4 |
| Total number of employees | 1 | 3 | ... |
| Number of common stockholders | 553 | 555 | 561 |

| | | | |
|--|-----------|-----------|-----------|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 79,345 | 2,845 | 2,845 |
| Accounts receivable | ... | 750 | 750 |
| Total current assets | 79,345 | 3,595 | 3,595 |
| Deposits | 530 | 530 | 530 |
| Buildings | ... | 475,000 | 475,000 |
| Building improvements | 785,823 | 785,823 | 785,823 |
| Furniture & equipment | 475,000 | ... | 475,000 |
| Gross fixed assets | 1,260,823 | 1,260,823 | 1,260,823 |
| Less: accumulated depreciation | 185,560 | 103,089 | 103,089 |
| Property & equipment, net | 1,075,262 | 1,157,733 | 1,157,733 |
| Investment Bh Bah ic | 125,000 | ... | 125,000 |
| Total assets | 1,280,137 | 1,161,859 | 1,161,859 |
| Accounts payable | 140,769 | 98,720 | 98,720 |
| Accrued expenses | 392,278 | 371,935 | 371,935 |
| Accrued interest | 17,332 | 3,621 | 3,621 |
| Credit cards payable | 550,851 | 476,543 | 476,543 |
| Accrued expenses related party | 930,930 | 675,349 | 675,349 |
| Loan payable related party | ... | 273,605 | 273,605 |
| Convertible note payable related party | 300,000 | 200,000 | 200,000 |
| Notes payable | 43,003 | 43,003 | 43,003 |
| Contingent liabilities | 45,625 | 45,625 | 45,625 |

| | | |
|---|--------------|--------------|
| Short-term notes payable, including related parties | 394,105 | ... |
| Loan payable | 215,672 | 75,000 |
| Credit cards payable | 472 | ... |
| Mortgage payable short term | 25,040 | ... |
| Total current liabilities | 2,505,226 | 1,789,125 |
| Non-interest bearing advances from an officer | ... | 2,267 |
| PPP loan | 78,718 | 125,629 |
| Common stock | 2,690,640 | 2,690,640 |
| Common stock subscribed | 96,403 | 96,403 |
| Additional paid-in capital | 9,816,056 | 9,034,617 |
| Accumulated Deficit | (13,906,906) | ... |
| Retained earnings (accumulated deficit) | ... | (12,574,555) |
| Total stockholders' equity (deficit) | (1,303,807) | (752,895) |
| Total Equity | (1,303,807) | (752,895) |

Recent Dividends:
1. Real Brands Inc common.
 No dividends paid.
2. Real Brands Inc series A preferred.
 No dividends paid.
Annual Dividends:
1. Real Brands Inc common.
 No dividends paid.
2. Real Brands Inc series A preferred.
 No dividends paid.

| | | | |
|---|--------------------|--------------------|--------------------|
| REBORN COFFEE INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Net revenues - stores | ... | 3,184,491 | 2,204,201 |
| Net revenues - wholesale & online | ... | 56,032 | 75,871 |
| Stores | 5,712,630 | ... | ... |
| Wholesale and online | 241,356 | ... | ... |
| Total net revenues | 5,953,986 | 3,240,523 | 2,280,072 |
| Product, food & drink costs - stores | 1,758,494 | 1,092,573 | 821,713 |
| Cost of sales - wholesale & online | 105,714 | 24,542 | 33,231 |
| General & administrative expenses | 7,967,856 | 5,663,950 | 3,988,805 |
| Total operating costs & expenses | 9,832,064 | 6,781,065 | 4,843,749 |
| Income (loss) from operations | (3,878,078) | (3,540,542) | (2,563,677) |
| Other income | (6,283) | 16,440 | 7,631 |
| Paycheck protection program (PPP) loan forgiven income | ... | ... | 115,000 |
| Interest expense | 129,480 | 29,195 | 16,172 |
| Gain (loss) on extinguishment of debt | ... | ... | (982,383) |
| Gain on the sale of building | 16,955 | ... | ... |
| Total other income (expense), net | (118,808) | (12,755) | (875,924) |
| Income (loss) before income taxes .. | (3,996,886) | (3,553,297) | (3,439,601) |
| Current state provision (benefit) for income taxes | ... | 1,600 | 800 |
| Current provision (benefit) - State | 800 | ... | ... |
| Total current provision (benefit) for income taxes | 800 | 1,600 | 800 |
| Provision for income taxes | 800 | 1,600 | 800 |
| Net income (loss) | (3,997,686) | (3,554,897) | (3,440,401) |
| Weighted average | | | |

| | | | |
|-------------------------------------|------------|------------|-----------|
| shares outstanding | | | |
| - basic | 13,230,613 | □1,521,629 | 1,340,618 |
| Weighted average shares outstanding | | | |
| - diluted | 13,230,613 | □1,521,629 | 1,340,618 |
| Year end shares outstanding | 14,929,390 | □1,645,391 | 1,454,315 |
| Net income (loss) | | | |
| per share - basic | \$(0.30) | □\$(2.32) | \$(2.56) |
| Net income (loss) | | | |
| per share - diluted | \$(0.30) | □\$(2.32) | \$(2.56) |
| Number of full time employees | ... | ... | 24 |
| Number of part time employees | ... | ... | 51 |
| Number of common stockholders | ... | □□412 | ... |

| | | | |
|---|--------------|--------------|--|
| Operating lease liabilities, less current portion | 3,556,999 | 2,529,985 | |
| Total liabilities | 7,426,576 | 4,171,012 | |
| Common Stock, \$00001 par value, 40,000,000 shares authorized; 11,634,523 and 10,443,721 shares issued and outstanding at 31, 2021 and 2020, respectively | 1,493 | ... | |
| Common stock | ... | 1,316 | |
| Additional paid-in capital | 17,601,837 | 16,317,014 | |
| Accumulated deficit | (16,029,487) | ... | |
| Retained earnings (accumulated deficit) | ... | (12,031,801) | |
| Total stockholders' equity (deficit) | 1,573,843 | 4,286,529 | |
| Total Equity | 1,573,843 | ... | |

| | | | |
|---|-----------|------------|------------|
| outstanding | 4,187,291 | □2,519,485 | □1,874,680 |
| Net earnings (loss) | | | |
| per share - basic | \$(4.39) | \$(9.07) | □\$(9.00) |
| Net earnings (loss) | | | |
| per share - diluted | \$(4.39) | \$(9.07) | □\$(9.00) |
| Number of full time employees | 21 | □22 | 31 |
| Total number of employees | 21 | ... | ... |
| Number of common stockholders | 165 | □□165 | □170 |
| Basic EPS Excluding ExtraOrdinary Items | \$(4.39) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(4.39) | ... | ... |

□ Adjusted for 1-for-8 stock split, January 22, 2024; □ Approximately; □ As of April 7, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 676,448 | 3,019,035 |
| Accounts receivable, gross | 47,361 | 780 |
| Less: allowance for doubtful accounts | ... | 0 |
| Accounts receivable, net of allowance for doubtful accounts of \$0 and \$0, respectively | 47,361 | ... |
| Accounts receivable, net | ... | 780 |
| Inventories, net | 166,281 | 132,343 |
| Prepaid expense & other current assets | 773,949 | 477,850 |
| Total current assets | 1,664,039 | 3,630,008 |
| Furniture & equipment | 1,459,400 | 1,203,737 |
| Leasehold improvement | 645,032 | 639,602 |
| Store construction | 361,575 | 251,745 |
| Store | ... | 300,000 |
| Vehicle | 103,645 | 57,859 |
| Store- Gross | 663,651 | ... |
| Total property & equipment | 3,233,303 | 2,452,943 |
| Less: accumulated depreciation | 1,133,157 | 871,138 |
| Property & equipment, net | 2,100,146 | 1,581,805 |
| Operating lease right-of-use asset | 4,227,815 | 3,010,564 |
| Other assets | 1,008,419 | 235,164 |
| Total assets | 9,000,419 | 8,457,541 |
| Accounts payable | 399,346 | 87,809 |
| Accrued expenses & current liabilities | 598,468 | 233,053 |
| Loans payable to financial institutions | ... | 44,664 |
| Current portion of loan payable, emergency injury disaster loan (EIDL) | 30,060 | 30,060 |
| Current portion of loan payable, payroll protection program (PPP) | 45,678 | 45,678 |
| Current portion of equipment loan payable | 791,353 | ... |
| Current portion of operating lease liabilities | 847,990 | 624,892 |
| Loan payable to other | 300,000 | ... |
| Total current liabilities | 3,012,895 | 1,066,156 |
| Loans payable to financial institutions, less current portion | 335,147 | 6,234 |
| Loan payable, emergency injury disaster loan (EIDL), less current portion | ... | 469,940 |
| Loan payable, payroll protection program (PPP), less current portion | 51,595 | 98,697 |
| Equipment loan payable, less current portion | 469,940 | ... |

Recent Dividends:
1. Reborn Coffee Inc common.
 No dividends paid.

Annual Dividends:
1. Reborn Coffee Inc common.
 No dividends paid.

REEDS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|--------------|
| | | | (revised) |
| Total revenues | 44,711,000 | ... | ... |
| Net Sales | 44,711,000 | ... | ... |
| Sales, net | ... | 53,041,000 | 49,599,000 |
| Inventory write-offs associated with exited categories and major packaging and formula changes | 1,848,000 | ... | ... |
| Product quality hold write-down | 1,267,000 | ... | ... |
| Cost of goods sold | 31,884,000 | 40,929,000 | 36,001,000 |
| Gross profit | 9,712,000 | 12,112,000 | 13,598,000 |
| Delivery & handling expenses | 4,865,000 | 11,603,000 | 11,939,000 |
| Selling & marketing expense | ... | 7,316,000 | 9,665,000 |
| General & administrative expenses | 6,118,000 | 7,489,000 | 7,965,000 |
| Provision for disputed receivable with former related party | 585,000 | 538,000 | ... |
| Delivery and handling expense | 7,561,000 | ... | ... |
| Total operating expenses | 19,129,000 | 26,946,000 | 29,569,000 |
| Income (loss) from operations | (9,417,000) | (14,834,000) | (15,971,000) |
| Interest expense | 6,106,000 | 5,223,000 | 1,201,000 |
| Gain on extinguishment of PPP note payable | ... | ... | 770,000 |
| Income (loss) before provision for income taxes | (15,523,000) | ... | ... |
| Net income (loss) | (15,523,000) | (20,057,000) | (16,402,000) |
| Dividends on series A convertible preferred stock | 5,000 | 5,000 | 5,000 |
| Net income (loss) attributable to common stockholders | (15,528,000) | (20,062,000) | (16,407,000) |
| Weighted average shares outstanding | | | |
| - basic | 3,537,882 | 2,211,319 | □1,824,688 |
| Weighted average shares outstanding | | | |
| - diluted | 3,537,882 | 2,211,319 | □1,824,688 |
| Year end shares | | | |

□ Adjusted for 1-for-50 stock split, January 27, 2023; □ Shares increased due to the effect of fair value of vested restricted shares granted to officers, common shares issued for financing costs, interest payment and rights offering; □ Full time equivalent employees; □ Approximately; □ As of March 31, 2023; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|-------------|
| Cash | 603,000 | 533,000 |
| Trade accounts receivable, gross | 5,648,000 | 5,923,000 |
| Less: allowance | 860,000 | 252,000 |
| Accounts receivable, net | 4,788,000 | 5,671,000 |
| Receivable from former related party | 259,000 | 777,000 |
| Raw materials & packaging | 6,445,000 | 8,526,000 |
| Finished products | 4,855,000 | 7,649,000 |
| Inventory | 11,300,000 | ... |
| Inventory, net | ... | 16,175,000 |
| Prepaid & other current assets | 811,000 | 939,000 |
| Total current assets | 17,761,000 | 24,095,000 |
| Right-of-use assets under operating leases | ... | 724,000 |
| Computer hardware & software | 400,000 | 400,000 |
| Machinery & equipment | 352,000 | 429,000 |
| Right-of-use assets under operating leases | 724,000 | ... |
| Construction in progress | 85,000 | ... |
| Total property & equipment, gross | 1,561,000 | 1,553,000 |
| Less: accumulated depreciation & amortization | ... | 787,000 |
| Less: accumulated depreciation | 1,068,000 | ... |
| Property & equipment, net | 493,000 | 766,000 |
| Intangible assets | 629,000 | 626,000 |
| Total assets | 18,883,000 | 25,487,000 |
| Accounts payable | 9,133,000 | 9,805,000 |
| Payable to former related party | 259,000 | 2,025,000 |
| Current portion of convertible notes payable, net | ... | □2,434,000 |
| Accrued expenses | 1,096,000 | 233,000 |
| Revolving line of credit | 9,758,000 | ... |
| Revolving line of credit, net | ... | □10,974,000 |
| Current portion of lease liabilities | 207,000 | 187,000 |
| Current portion of convertible notes payable, net of debt discount of \$ 414 and \$0, respectively | 7,325,000 | ... |
| Total current liabilities | 27,778,000 | 25,658,000 |
| Convertible note payable, net | ... | □8,092,000 |
| Lease liabilities, less current portion | ... | 207,000 |

| | | |
|--|---------------|---------------|
| Convertible note payable, net of debt discount of \$ 769 and \$0, respectively, less current portion | 10,286,000 | ... |
| Total liabilities | 38,064,000 | 33,957,000 |
| Series A convertible preferred stock | 94,000 | 94,000 |
| Common stock | 419 | ... |
| Additional paid-in capital | 119,452,000 | 114,635,000 |
| Accumulated Deficit | (138,727,000) | ... |
| Retained earnings (accumulated deficit) | ... | (123,199,000) |
| Total stockholders' equity (deficit) | (19,181,000) | (8,470,000) |
| Total Equity | (19,181,000) | ... |

¹ Net of debt discount - current portion of convertible notes payable: \$414,000; ² Capitalized financing costs - revolving line of credit, net: \$363,000; ³ Net of debt discount - convertible notes payable: \$562,000

Recent Dividends:

1. Reeds Inc series A convertible preferred.

No dividends paid.

2. Reeds Inc series B convertible preferred.

No dividends paid.

3. Reeds Inc common.

No dividends paid.

Annual Dividends:

1. Reeds Inc series A convertible preferred.

No dividends paid.

2. Reeds Inc series B convertible preferred.

No dividends paid.

3. Reeds Inc common.

No dividends paid.

REFLECT SCIENTIFIC INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|--|------------|------------|--------------------------------|
| Revenues | 1,080,154 | ... | ... |
| Cost of goods sold | 483,733 | 822,147 | 884,066 |
| Gross profit | 596,421 | 1,219,150 | 1,930,604 |
| Salaries & wages | 645,517 | 636,038 | 608,065 |
| Research & development | 29,542 | 73,425 | 58,340 |
| General & administrative | 388,640 | 419,589 | 436,399 |
| Total operating expenses | 1,063,699 | 1,129,052 | 1,102,804 |
| Income from operations | (467,278) | 90,098 | 827,800 |
| Gain on forgiveness of debt - Paycheck Protection Program loan | ... | ... | 111,265 |
| Other income | 8,562 | ... | ... |
| Total other income (expenses) | ... | ... | 111,265 |
| Net income before income taxes | (458,716) | 90,098 | 939,065 |
| Current federal & state income taxes | ... | 702 | ... |
| Current Tax - Total | 312 | ... | ... |
| Income tax expense (benefit) | 312 | 702 | ... |
| Net income (loss) | (459,028) | 89,396 | 939,065 |
| Weighted average shares outstanding - basic | 85,217,785 | 84,990,935 | 84,739,770 |
| Weighted average shares outstanding - diluted | 85,217,785 | 85,440,935 | 85,489,770 |
| Year end shares outstanding | 85,664,086 | 85,214,086 | 84,989,086 |
| Income (loss) per share from continuing operations - basic | \$(0.01) | ... | ... |
| Net income (loss) per share - basic | \$(0.01) | \$0.00 | \$0.01 |

| | | | |
|--|----------|----------------|------------------|
| Income (loss) per share from continuing operations - diluted | \$(0.01) | ... | ... |
| Net income (loss) per share - diluted | \$(0.01) | \$0.00 | \$0.01 |
| Number of full time employees | ... | ² 7 | ³ 7 |
| Number of part time employees | ... | ² 2 | ³ 2 |
| Number of common stockholders | 107 | ... | ³ 107 |

¹ Reclassified to conform with 2022 presentation; ² As of March 24, 2023; ³ As of March 23, 2022; ⁴ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash and cash equivalents | 1,277,951 | ... |
| Cash | ... | 1,381,927 |
| Accounts receivable, gross | 112,191 | ... |
| Allowance for doubtful accounts | 4,000 | ... |
| Accounts receivable, net | 108,191 | 129,329 |
| Finished goods, net | 493,565 | 376,334 |
| Raw materials | 584,772 | 527,062 |
| Total inventories | 972,293 | 903,396 |
| Less reserve for obsolescence | 106,044 | 106,044 |
| Inventories, net | ... | 797,352 |
| Prepaid expenses & other current assets | 11,715 | 20,221 |
| Total current assets | 2,370,150 | 2,328,829 |
| Operating lease right-of-use assets | 235,653 | 54,265 |
| Goodwill | 60,000 | 60,000 |
| Other long-term assets | 3,100 | 3,100 |
| Total assets | 2,668,903 | 2,446,194 |
| Trade accounts payable | 56,931 | 55,011 |
| Credit cards payable | 86,241 | 23,958 |
| Accounts payable & accrued expenses | ... | 78,969 |
| Royalty payable | 29,310 | ... |
| Customer deposits | ... | 13,230 |
| Contract liabilities | 447,444 | ... |
| Current portion of operating lease liabilities | 62,681 | 57,393 |
| Total current liabilities | 596,366 | 149,592 |
| Operating lease liabilities, net of current portion | 179,963 | ... |
| Total liabilities | 776,329 | 149,592 |
| Common stock | 856,640 | 852,140 |
| Additional paid in capital | 20,302,681 | 20,252,181 |
| Retained earnings (accumulated deficit) | (19,266,747) | (18,807,719) |
| Total stockholders' equity | 1,892,574 | 2,296,602 |
| Total stockholders equity (deficit) | 1,892,574 | ... |

Recent Dividends:

1. Reflect Scientific Inc common.

No dividends paid.

Annual Dividends:

1. Reflect Scientific Inc common.

No dividends paid.

REGENCY AFFILIATES INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-------------------------------------|-----------|-----------|-----------|
| Rental | 4,815,937 | 4,880,502 | 4,324,733 |
| Insurance, late fees & other income | 418,844 | 375,329 | 363,446 |
| Total revenues | 5,234,781 | 5,255,831 | 4,688,179 |
| Self-storage costs | ... | ... | ... |

| | | | |
|---|-------------|-------------|---------------------|
| of operations | 1,363,250 | 1,452,251 | 1,578,190 |
| Self-storage depreciation expense | 795,818 | 791,637 | 786,037 |
| General & administrative expenses | 1,227,260 | 1,419,628 | 1,506,249 |
| Total operating expenses | 3,386,328 | 3,663,516 | 3,870,476 |
| Income (loss) from operations | 1,848,453 | 1,592,315 | 817,703 |
| Management agreement income | 137,344 | 160,699 | 156,528 |
| Income from equity investment in partnerships/LLC | (3,780,131) | (1,854,545) | 1,984,692 |
| Other income (expenses) | (50,824) | ... | ... |
| Interest income | 221,956 | 70,332 | 38,841 |
| Other expenses | ... | 62,583 | 63,807 |
| Interest expense | 1,231,643 | 1,217,219 | 1,240,175 |
| Amortization of debt discount | 12,624 | 12,625 | 12,625 |
| Realized loss on sale of short-term investments | (28,100) | (36,581) | ... |
| Total other income | (4,744,022) | (2,952,522) | 863,454 |
| Net income (loss) before income taxes | (2,895,569) | (1,360,207) | 1,681,157 |
| Current income tax expense (benefit) - federal | (549,392) | 588,468 | 250,219 |
| Current income tax expense (benefit) - state | (303,935) | 259,631 | 18,023 |
| Total current income tax expense (benefit) | (853,327) | 848,099 | 268,242 |
| Deferred income tax expense (benefit) - federal | ... | ... | 151,683 |
| Deferred income tax expense (benefit) - state | ... | ... | 76,850 |
| Total deferred income tax expense | (2,042,242) | (2,208,306) | ... |
| Net income (loss) before income tax expense | (853,327) | 848,099 | ¹ 39,709 |
| Net income (loss) attributable to noncontrolling interest | (385,501) | (356,420) | (214,230) |
| Net income (loss) allocated to shareholders | (2,427,743) | (2,564,726) | 1,427,218 |
| Weighted average shares outstanding - basic | 4,815,058 | ... | ... |
| Weighted average shares outstanding - diluted | 4,815,058 | ... | ... |
| Year end shares outstanding | 4,815,058 | 4,815,058 | 4,815,058 |
| Income (loss) per share - continuing operations - basic | \$(0.50) | ... | ... |
| Net income (loss) per share - basic | \$(0.50) | ... | ... |
| Income (loss) per share - continuing operations - diluted | \$(0.50) | ... | ... |
| Net income (loss) per share - diluted | \$(0.50) | ... | ... |
| Dividends per common share | \$0.29 | \$0.28 | \$0.28 |
| Number of common stockholders | 93 | 93 | 93 |

¹ As reported by the Company

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------|------|
|--|------|------|

| | | |
|---|------------|------------|
| Cash & cash equivalents | 459,979 | 2,730,853 |
| Restricted cash | 563,567 | 419,442 |
| Short-term investments | 5,069,553 | 3,994,423 |
| Prepaid expenses | 1,185,341 | 387,319 |
| Prepaid insurance | ... | 71,225 |
| Rent receivable | 53,615 | 56,623 |
| Management fee receivable | 13,734 | 13,734 |
| Total current assets | 7,345,789 | 7,673,619 |
| Land | ... | 4,870,000 |
| Less accumulated depreciation | 6,038,680 | 5,242,862 |
| Land | 4,760,502 | ... |
| Buildings | 30,494,117 | 30,435,838 |
| Furniture & equipment | 119,108 | 107,902 |
| Machinery & equipment | 79,614 | 50,462 |
| Property and Equipment | 30,643 | 6,618 |
| Property, plant & equipment, gross | 35,373,727 | 35,413,740 |
| Machinery and equipment - Accumulated Depreciation & Impairment | 48,971 | 43,844 |
| Property, plant & equipment, net | 29,335,047 | 30,170,878 |
| Investments in partnerships or LLC | 50,479,487 | 54,259,618 |
| Other assets | 10,638 | 150,997 |
| Operating lease right-of-use asset | 253,058 | 176,812 |
| Total assets | 87,454,662 | 92,438,542 |
| Accounts payable & accrued expenses | 146,934 | 254,033 |
| Mortgage note payable, net | 435,858 | 416,452 |
| Deferred revenue | 241,484 | 263,811 |
| Income tax payable | ... | 694,021 |
| Dividends payable | 213,106 | 551,303 |
| Tenant security deposits | 3,653 | 4,540 |
| Operating lease liability | 50,709 | 193,699 |
| Total current liabilities | 1,091,744 | 2,377,859 |
| Mortgage note payable, net | 23,417,748 | 23,830,699 |
| Operating Lease Liabilities - Long-Term | 204,122 | ... |
| Total liabilities | 24,713,614 | 26,208,558 |
| respectively | 48,151 | ... |
| Common stock | ... | 48,151 |
| Additional paid-in capital | 14,014,556 | 14,014,556 |
| Retained earnings | 47,627,276 | 51,475,461 |
| Total shareholders' equity | 61,689,983 | 65,538,168 |
| Non-controlling interest | 1,051,065 | 691,816 |
| Total equity | 62,741,048 | 66,229,984 |

Recent Dividends:

- 1. Regency Affiliates Inc. common.**
No dividends paid.
- 2. Regency Affiliates Inc. series B 6% cumulative preferred (stated value: \$10).**

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 12/30/2020 | 0.07 | 12/08/2020 | 12/31/2020 | 01/07/2021 |
| 03/30/2021 | 0.07 | 03/08/2021 | 03/31/2021 | 04/07/2021 |
| 06/29/2021 | 0.07 | 06/10/2021 | 06/30/2021 | 07/07/2021 |
| 09/29/2021 | 0.07 | 09/10/2021 | 09/30/2021 | 10/07/2021 |
| 12/30/2021 | 0.07 | 12/06/2021 | 12/31/2021 | 01/07/2022 |
| 03/30/2022 | 0.07 | 03/15/2022 | 03/31/2022 | 04/07/2022 |
| 06/29/2022 | 0.07 | 06/07/2022 | 06/30/2022 | 07/05/2022 |
| 09/29/2022 | 0.07 | 09/13/2022 | 09/30/2022 | 10/06/2022 |
| 12/29/2022 | 0.07 | 12/13/2022 | 12/30/2022 | 01/05/2023 |
| 03/30/2023 | 0.07 | 03/08/2023 | 03/31/2023 | 04/06/2023 |
| 06/29/2023 | 0.07 | 06/07/2023 | 06/30/2023 | 07/06/2023 |
| 09/28/2023 | 0.07 | 09/12/2023 | 09/29/2023 | 10/05/2023 |
| 12/28/2023 | 0.07 | 12/12/2023 | 12/29/2023 | 01/05/2024 |
| 03/27/2024 | 0.07 | 03/12/2024 | 03/29/2024 | 04/05/2024 |

- 3. Regency Affiliates Inc. series C cumulative preferred (stated value: \$100).**
No dividends paid.

- 4. Regency Affiliates Inc. junior series D 7% cumulative preferred (stated value: \$10).**
No dividends paid.

Annual Dividends:

- 1. Regency Affiliates Inc. common.**
No dividends paid.
- 2. Regency Affiliates Inc. series B 6% cumulative preferred (stated value: \$10).**

| | | | | | |
|------|------|------|------|------|------|
| 2021 | 0.27 | 2022 | 0.28 | 2023 | 0.29 |
| 2024 | 0.15 | | | | |

- 3. Regency Affiliates Inc. series C cumulative preferred (stated value: \$100).**
No dividends paid.

- 4. Regency Affiliates Inc. junior series D 7% cumulative preferred (stated value: \$10).**
No dividends paid.

REGO PAYMENT ARCHITECTURES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|---------------------|---------------------|---------------------|
| Net revenue | ... | 2,073 | 2,628 |
| Transaction expense | 229,672 | 258,746 | 165,018 |
| Sales & marketing expenses | 1,822,444 | 1,681,040 | 1,454,325 |
| Product development expenses | 2,923,937 | 2,059,890 | 2,837,012 |
| General & administrative expenses | 10,815,593 | 11,425,026 | 5,612,413 |
| Total operating expenses | 15,791,646 | 15,424,702 | 10,068,768 |
| Net operating income (loss) | (15,791,646) | (15,422,629) | (10,066,140) |
| Interest income | ... | 1,043 | 333 |
| Interest expense | 1,016,548 | 1,015,228 | 1,080,391 |
| Forgiveness of debt | 88,617 | 92,660 | 95,425 |
| Total other income (expense) | (927,931) | (921,525) | (984,633) |
| Net income (loss) | (16,719,577) | (16,344,154) | (11,050,773) |
| Less: accrued preferred dividends | 2,136,273 | 1,286,651 | 732,955 |
| Net income (loss) attributable to noncontrolling interests | ... | 101 | 101 |
| Net income (loss) attributable to common stockholders | (18,855,850) | (17,630,704) | (11,783,627) |
| Weighted average shares outstanding - basic | 131,577,880 | 123,634,367 | 122,775,473 |
| Weighted average shares outstanding - diluted | 131,577,880 | 123,634,367 | 122,775,473 |
| Year end shares outstanding | 135,848,105 | 124,160,885 | 123,441,102 |
| Net earnings (loss) per common share - basic | \$(0.14) | \$(0.14) | \$(0.10) |
| Net earnings (loss) per common share - diluted | \$(0.14) | \$(0.14) | \$(0.10) |
| Number of employees | 4 | ... | ... |
| Total number of employees | 4 | 4 | 3 |
| Number of common stockholders | 141 | 141 | 150 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.14) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.14) | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 6,256,634 | 6,005,667 |
| Prepaid expenses | 18,322 | 17,758 |
| Deposits | 341 | 341 |
| Total current assets | 6,275,297 | 6,023,766 |
| Patents & trademarks, gross | ... | 644,114 |
| Less: accumulated amortization - patents & | | |

| | | |
|--|---------------------|---------------|
| trademarks | ... | 291,255 |
| Patents & trademarks, net | 325,150 | 352,859 |
| Total assets | 6,600,447 | 6,376,625 |
| Accounts payable & accrued expenses | 7,785,443 | 6,861,314 |
| Accounts payable & accrued expenses - related parties | 2,059 | 2,610 |
| Loans payable | ... | 42,600 |
| 10% secured convertible notes payable - stockholders | 42,600 | 3,316,357 |
| Convertible notes payable - stockholders | 3,316,357 | ... |
| Notes payable - stockholders | 595,000 | 595,000 |
| 4% secured convertible notes payable - stockholders | 14,981,250 | 14,981,250 |
| Preferred stock dividend liability | ... | 9,214,850 |
| Common stock to be issued | 11,267,790 | 5,350,000 |
| Total current liabilities | 37,990,499 | 40,363,981 |
| Preferred stock series A | 10 | 10 |
| Preferred stock series B | 24 | 17 |
| Common stock | 13,585 | 12,416 |
| Additional paid in capital | 104,707,296 | 83,255,319 |
| Retained earnings (deficit) accumulated during the development stage | (136,110,967) | ... |
| Retained earnings (accumulated deficit) | ... | (117,157,414) |
| Noncontrolling interests | ... | (97,704) |
| Stockholders' equity (deficit) | (31,390,052) | (33,987,356) |
| STOCKHOLDERS DEFICIT | (31,390,052) | ... |

Recent Dividends:

- 1. Rego Payment Architectures Inc series B cumulative convertible preferred.**
No dividends paid.
 - 2. Rego Payment Architectures Inc series A cumulative convertible preferred.**
No dividends paid.
 - 3. Rego Payment Architectures Inc common.**
No dividends paid.
- Annual Dividends:**
- 1. Rego Payment Architectures Inc series B cumulative convertible preferred.**
No dividends paid.
 - 2. Rego Payment Architectures Inc series A cumulative convertible preferred.**
No dividends paid.
 - 3. Rego Payment Architectures Inc common.**
No dividends paid.

REKOR SYSTEMS INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|------------|------------|----------------|
| Cost of revenue | 16,499,000 | ... | ... |
| Professional services | 34,933,000 | ... | ... |
| Revenue | 34,933,000 | 19,920,000 | 11,575,000 |
| Cost of revenue, excluding depreciation & amortization | ... | 10,890,000 | 4,549,000 |
| General & administrative expenses | 27,038,000 | 26,612,000 | 23,006,000 |
| Selling & marketing expenses | 7,347,000 | 8,329,000 | 4,474,000 |
| Research & development expenses | 18,271,000 | 18,616,000 | 8,292,000 |
| Goodwill impairment | ... | 34,835,000 | ... |
| Depreciation & amortization expenses | 7,894,000 | 6,422,000 | 3,088,000 |

| | | | |
|---|------------------|------------------|------------------|
| (expense) | (179,000) | 223,000 | 9,631,000 |
| Income (loss) before income tax expense (benefit) | (726,000) | (569,000) | 8,877,000 |
| Current federal income tax expense (benefit) | ... | 113,000 | 743,000 |
| Current state income tax expense (benefit) | 14,000 | 57,000 | 241,000 |
| Consolidated net income (loss) | (740,000) | ... | ... |
| Income tax expense (benefit) | 14,000 | 170,000 | 984,000 |
| Consolidated net income (loss) | (740,000) | (739,000) | 7,893,000 |
| Weighted average shares outstanding - basic | 300,000,000 | 300,000,000 | 300,000,000 |
| Weighted average shares outstanding - diluted | 300,000,000 | 300,000,000 | 300,000,000 |
| Year end shares outstanding | 300,000,000 | 300,000,000 | 300,000,000 |
| Net income (loss) per share - basic | \$0.00 | \$0.00 | \$0.03 |
| Net income (loss) per share - diluted | \$0.00 | \$0.00 | \$0.03 |
| Number of full time employees | 172 | ... | ... |
| Total number of employees | 172 | [□] 22 | [□] 20 |
| Number of common stockholders | 525 | [□] 523 | [□] 527 |
| Income Taxes - Total | 14,000 | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] As of March 26, 2023; [□] As of March 30, 2022; [□] As of March 22, 2023; [□] As of March 29, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|---|-----------|------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents | 822,000 | 227,000 | |
| Accounts receivable, unfactored | 2,819,000 | ... | |
| Accounts receivable, factored | 174,000 | ... | |
| Trade receivables, net of allowance for doubtful accounts | 2,993,000 | 6,337,000 | |
| Retention credit receivable | 10,000 | 1,219,000 | |
| Notes receivable from related parties | 5,501,000 | 5,251,000 | |
| Inventory advance payment | 442,000 | ... | |
| Prepaid expenses & other current assets | ... | 430,000 | |
| Total current assets | 9,768,000 | 13,464,000 | |
| Office equipment | 60,000 | 54,000 | |
| Computer software | 108,000 | 110,000 | |
| Property, plant & equipment, cost | 168,000 | 164,000 | |
| Accumulated depreciation | 153,000 | 138,000 | |
| Property, plant & equipment, net | 15,000 | 26,000 | |
| Other intangible assets, net | 3,000 | ... | |
| Total assets | 9,786,000 | 13,490,000 | |
| Factoring liability | 174,000 | 2,619,000 | |
| Accounts payable | 548,000 | 698,000 | |
| Accrued vendor costs | ... | 199,000 | |
| Financed insurance payable | ... | 124,000 | |
| Other accrued expenses | ... | 16,000 | |
| Accrued expenses | 290,000 | 339,000 | |
| Accrued payroll | 637,000 | 981,000 | |
| Deferred revenue | 206,000 | 176,000 | |
| Income taxes payable | ... | 6,000 | |
| Total current liabilities | 1,855,000 | 4,819,000 | |
| Total liabilities | 1,855,000 | ... | |
| Additional paid-in capital | 750,000 | 750,000 | |

| | | | |
|---|-----------|-----------|--|
| Retained earnings | 7,181,000 | ... | |
| Retained earnings (accumulated deficit) | ... | 7,921,000 | |
| Total stockholders' equity | 7,931,000 | 8,671,000 | |
| Total equity | 7,931,000 | ... | |

Recent Dividends:**1. Reliability Inc common.**

No dividends paid.

Annual Dividends:**1. Reliability Inc common.**

No dividends paid.

RELIANCE GLOBAL GROUP INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | [□] 2022 | 2021 |
|---|---------------------|-------------------|------------------------|
| | | (revised) | (revised) |
| Marketing and advertising | 364,974 | 170,311 | ... |
| Commission income | 13,731,826 | 11,761,882 | 9,710,334 |
| Total revenue | 13,731,826 | 11,761,882 | 9,710,334 |
| Commission expense | 3,732,939 | 3,140,725 | 2,427,294 |
| Salaries & wages | 7,503,052 | 7,508,312 | 4,672,988 |
| General & administrative expenses | ... | ... | 3,589,221 |
| Marketing & advertising | 4,089,989 | 4,959,151 | 325,838 |
| Contractor costs | 1,716,873 | 524 | ... |
| Depreciation & amortization | 2,609,191 | 2,563,518 | 1,607,313 |
| Goodwill impairment | 7,594,000 | ... | ... |
| Depreciation | 45,632 | 37,638 | ... |
| Amortization of Intangibles excluding Goodwill | 2,563,559 | 2,525,880 | ... |
| Total operating expenses | 27,611,018 | 18,342,541 | 12,622,654 |
| Income (loss) from operations | (13,879,192) | (6,580,659) | (2,912,320) |
| Gain on settlement of payables | 6,530 | (4,341) | ... |
| Gain on disposition | 5,503,647 | 29,064,958 | ... |
| Interest expense | 1,506,186 | 911,106 | ... |
| Other expense, net | ... | ... | 533,337 |
| Recognition & change in fair value of warrant liabilities | ... | ... | (17,652,808) |
| (Loss) income from continuing operations before tax | (10,025,268) | 21,561,932 | ... |
| Interest expense, related parties | (150,067) | (6,920) | ... |
| Total other income (expense) | 3,853,924 | 28,142,591 | (18,186,145) |
| Income from continuing operations | (10,025,268) | 21,561,932 | ... |
| Loss from discontinued operations before tax | (1,984,714) | (15,095,770) | ... |
| Net income (loss) | (12,009,982) | 6,466,162 | (21,098,465) |
| Adjustments to Net Income - Other | 2,539,757 | 6,930,335 | ... |
| Net income to common | (12,565,025) | 14,631,597 | ... |
| Weighted average shares outstanding - basic | 2,820,275 | 1,094,781 | [□] 673,137 |
| Weighted average shares outstanding - diluted | 2,820,275 | 1,094,781 | [□] 673,137 |
| Year end shares outstanding | 4,761,974 | 1,219,573 | [□] 730,407 |
| Net earnings (loss) per share - basic | \$(5.16) | \$(0.42) | [□] \$(31.34) |
| Net earnings (loss) per share - diluted | \$(5.16) | \$(0.42) | [□] \$(31.34) |

| | | | |
|---|----------|-----------|------------------|
| Number of full time employees | 67 | ... | ... |
| Total number of employees | 67 | ... | ... |
| Number of common stockholders | 522 | ... | [□] 521 |
| Earnings per share from continuing operations | \$(5.16) | \$13.36 | ... |
| Earnings per share-inc from discontinued oper | \$(0.70) | \$(13.79) | ... |
| Earnings per share-total discontinued opers | \$(0.70) | \$(13.79) | ... |
| Earnings per share from continuing operations | \$(5.16) | \$13.36 | ... |
| Earn per share-inc from discont opers - diluted | \$(0.70) | \$(13.79) | ... |
| Earning per share-total discont opers - diluted | \$(0.70) | \$(13.79) | ... |

[□] Restated to reflect correction of errors; [□] Adjusted for 1-for-15 stock split, February 23, 2023; [□] Shares increased due to the effect of shares issued for services, over-allotment shares from offering, conversion of preferred stock debt, and rounding shares related to initial public offering; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| | | (revised) |
| Cash | 1,329,016 | 505,410 |
| Restricted cash | 1,409,895 | 1,404,359 |
| Accounts receivable, Accounts receivable, related party | 1,298,863 | 994,321 |
| Other receivables | 6,603 | 18,292 |
| Prepaid expense & other current assets | 899 | 11,464 |
| Current assets - discontinued operations | 333,756 | 245,535 |
| Total current assets | 4,379,032 | 3,265,379 |
| Office equipment & furniture | 47,652 | 40,693 |
| Leasehold improvements | 120,378 | 122,830 |
| Computer equipment | 110,350 | 92,278 |
| Property & equipment, gross | 278,380 | 255,801 |
| Less: accumulated depreciation | 138,381 | 93,034 |
| Property & equipment, net | 139,999 | 162,767 |
| Right-of-use assets | 739,830 | 1,018,952 |
| Intangibles, net | 11,042,757 | 13,439,369 |
| Goodwill | 6,693,099 | 14,287,099 |
| Other non-current assets | 20,292 | 23,284 |
| Investment in NSURE, Inc. | ... | 900,000 |
| Other Assets - Discontinued Operations | ... | 5,330,879 |
| Total assets | 23,015,009 | 38,427,729 |
| Accounts payable | 635,339 | 747,469 |
| Accrued expenses | 40,540 | 109,502 |
| Accrued credit card payables | 54,416 | 58,120 |
| Other accrued liabilities | 105,188 | 36,291 |
| Accounts payable & other accrued liabilities | 835,483 | 951,382 |
| Short term financing agreements | 56,197 | 154,017 |
| Current portion of loans payable, related parties | 454,953 | 1,422,249 |
| Other payables | 7,414 | 101,113 |
| Current portion of long-term debt | 1,390,766 | 1,118,721 |
| Current portion of leases payable | 285,171 | 339,937 |
| Warrant commitment | 159,867 | 2,153,478 |
| Current liabilities - discontinued operations | ... | 1,600,636 |
| Total current liabilities | 3,189,851 | 7,841,533 |
| Loans payable, related | | |

| | | | |
|---|----------|----------|----------|
| outstanding | 10,694 | 9,098 | 8,934 |
| Net earnings (loss) per share - basic | \$(0.99) | \$(1.09) | \$(1.21) |
| Net earnings (loss) per share - diluted | \$(0.99) | \$(1.09) | \$(1.21) |
| Number of full time employees | 8 | ... | 6 |
| Total number of employees | 8 | 9 | ... |
| Number of common stockholders | 120 | 120 | 120 |
| Income from cont operations before income tax | (10,232) | ... | ... |

| | | | |
|--|-------------|-------------|-----------|
| Depreciation, depletion, amortization & valuation provisions | 5,895,470 | 2,802,006 | 2,726,938 |
| Gain on disposition of oil & gas properties | 19,491 | 198,443 | 16,313 |
| General, administrative & other expenses | 2,606,906 | 2,082,525 | 1,963,585 |
| Total operating costs & expenses | 14,647,568 | 9,741,059 | 8,459,229 |
| Income (loss) from operations | (1,271,466) | 6,429,825 | 657,197 |
| Equity income (loss) in investees | 107,865 | (164,497) | (154,041) |
| Net realized & unrealized gain (loss) on equity securities | ... | (1,635,240) | 573,631 |
| Gain (loss) on other asset sales | 115,603 | 49,823 | (201,119) |
| Interest income | 440,244 | 98,231 | 23,999 |
| Dividend income | 58,193 | 264,035 | 364,469 |
| Income from other investments | 363,738 | 108,034 | 3,255 |
| Miscellaneous income & expenses | (7,192) | (70,044) | (70,985) |
| Interest & other expenses | 67,919 | ... | ... |
| Other income (loss), net | 970,586 | (1,185,161) | 693,250 |
| Interest expense | ... | 34,523 | ... |
| Income (loss) before income taxes & non-controlling interest | (260,934) | 5,045,644 | 1,196,406 |
| Current income tax provision (benefit) - federal | 224,976 | 3,812 | (38,552) |
| Current income tax provision (benefit) - state | 3,707 | 437 | 970 |
| Total current income tax provision (benefit) | 228,683 | 4,249 | (37,582) |
| Deferred income tax provision (benefit) | (400,084) | 1,068,275 | (17,307) |
| Income tax provision (benefit) | (171,401) | 1,072,524 | (54,889) |
| Net Income After Extraordinary Items applicable to Common | (55,648) | ... | ... |
| Net income (loss) | (89,533) | 3,973,120 | 1,251,295 |
| Less: net income (loss) attributable to non-controlling interest | 33,885 | 27,631 | ... |
| Net income (loss) attributable to common stockholders | ... | 4,000,751 | 1,251,295 |
| Weighted average shares outstanding - basic | 155,915 | 156,163 | 156,483 |
| Weighted average shares outstanding - diluted | 155,915 | 156,163 | 156,483 |
| Year end shares outstanding | 155,696 | ... | 156,173 |
| Income per share - continuing operations - basic | \$(0.36) | ... | ... |
| Net income (loss) per share - basic | \$(0.36) | \$25.62 | \$8.00 |
| Net income (loss) per share - diluted | \$(0.36) | \$25.62 | \$8.00 |
| Cash dividends per share | \$10.00 | \$10.00 | \$5.00 |
| Full-Time Employees (Period End) | 7 | ... | ... |
| Total number of employees | 7 | 6 | 6 |

| | | | |
|--------------------------------------|-----------|-------|-------|
| Number of common stockholders | 1,521 | 1,588 | 1,616 |
| Production | 4,383,384 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.36) | ... | ... |

Reclassified to conform with 2022 presentation; As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 5,218,474 | 7,299,224 |
| Available-for-sale debt securities | 2,220,901 | 4,208,648 |
| Equity securities | 2,664,066 | 2,302,959 |
| Refundable income taxes | 317,755 | 120,230 |
| Accounts receivable | 2,366,663 | 2,318,183 |
| Total current assets | 12,787,859 | 16,249,244 |
| Equity method investments | 2,818,790 | 2,469,644 |
| Other investments | 5,332,553 | 5,085,806 |
| Total investments | 8,151,343 | 7,555,450 |
| Oil & gas properties, at cost - unproved | 3,403,051 | 1,846,543 |
| Oil & gas properties, at cost - proved | 69,152,923 | 65,328,501 |
| Oil & gas properties, gross | 72,555,974 | 67,175,044 |
| Less - accumulated depreciation, depletion, amortization & valuation allowance | 57,622,564 | 52,773,978 |
| Other property & equipment, at cost | 820,965 | 758,256 |
| Less - accumulated depreciation | 306,587 | 236,883 |
| Property, plant & equipment, net | 15,447,788 | 14,922,439 |
| Total assets | 36,386,990 | 38,727,133 |
| Accounts payable | 537,796 | 399,735 |
| Other current liabilities | 12,839 | 75,675 |
| Note payable, current portion | 142,136 | 136,637 |
| Total current liabilities | 692,771 | 612,047 |
| Asset retirement obligation | 2,566,368 | 2,809,257 |
| Deferred tax liability, net | 1,219,511 | 1,619,595 |
| Note payable, less current portion | 1,158,736 | 1,300,872 |
| Total long-term liabilities | 4,944,615 | 5,729,724 |
| Total liabilities | 5,637,386 | 6,341,771 |
| Common stock | 92,368 | 92,368 |
| Additional paid-in capital | 65,000 | 65,000 |
| Retained earnings (accumulated deficit) | 32,212,066 | 33,828,418 |
| Less - treasury stock, at cost | 1,820,527 | 1,749,858 |
| Total equity applicable to the Reserve Petroleum Company | 30,548,907 | 32,235,928 |
| Non-controlling interests | 200,697 | 149,434 |
| Total equity | 30,749,604 | 32,385,362 |

Recent Dividends:
1. Reserve Petroleum Co. common.

| | | | | |
|------------|-------|------------|------------|------------|
| ExDate | Amt | Declared | Record | Payable |
| 06/08/2021 | 5.00 | 05/25/2021 | 06/09/2021 | 06/22/2021 |
| 06/07/2022 | 10.00 | 05/24/2022 | 06/08/2022 | 06/21/2022 |
| 06/06/2023 | 10.00 | 05/23/2023 | 06/07/2023 | 06/20/2023 |

Annual Dividends:
1. Reserve Petroleum Co. common.

| | | | | | |
|------|------|------|-------|------|-------|
| 2021 | 5.00 | 2022 | 10.00 | 2023 | 10.00 |
|------|------|------|-------|------|-------|

RESHAPE LIFESCIENCES INC (NEW)
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

Stocks increased due to the effect of preferred stock conversion upon initial public offering, issuance upon initial public offering and stock options exercised; As is; Approximately; As of March 24, 2023; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|----------|----------|
| Cash & cash equivalents | 1,173 | 4,391 |
| Short-term marketable securities | ... | 2,049 |
| Prepaid expenses & other current assets | 101 | 825 |
| Prepaid expenses and other current assets | 192 | ... |
| Total current assets | 1,466 | 7,265 |
| Total assets | 1,466 | 7,265 |
| Common stock warrant liability | 561 | ... |
| Accounts payable | ... | 534 |
| Accrued clinical trials | 470 | 88 |
| Employee benefits | 75 | 475 |
| Accrued personnel | 69 | ... |
| Other accrued expenses | 614 | 5 |
| Accrued expenses | ... | 568 |
| Total current liabilities | 1,175 | ... |
| Common warrant liability | 3,291 | ... |
| Total liabilities | 4,466 | 1,102 |
| Additional paid-in capital | 38,404 | 37,318 |
| Common stock | 1 | 1 |
| Accumulated other comprehensive income | ... | 17 |
| Accumulated deficit | (41,405) | ... |
| Retained earnings (accumulated deficit) | ... | (31,173) |
| Total stockholders' equity (deficit) | (3,000) | 6,163 |
| Total Equity | (3,000) | ... |

Recent Dividends:
1. RenovoRx Inc common.
 No dividends paid.

Annual Dividends:
1. RenovoRx Inc common.
 No dividends paid.

RESERVE PETROLEUM CO.
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---------------------------------------|------------|------------|-----------|
| Oil & gas sales | 12,490,047 | 14,869,219 | 9,034,540 |
| Lease bonuses & other revenues | 190,588 | 295,544 | 9,804 |
| Water well drilling services | 695,467 | 1,006,121 | 72,082 |
| Total operating revenues | 13,376,102 | 16,170,884 | 9,116,426 |
| Production costs & expenses | ... | 3,639,924 | 2,721,827 |
| Exploration | 708,823 | ... | ... |
| Exploration costs & expenses | ... | 474,773 | 687,648 |
| Water well drilling services | 1,072,476 | 907,447 | 375,544 |
| Grand Woods Development, LLC expenses | ... | 32,827 | ... |

| | | |
|---|---------------|---------------|
| Operating lease liabilities, current portion | 391,000 | |
| Due under bank line of credit | 1,832,000 | |
| Due under factoring agreement | 1,866,000 | 3,150,000 |
| Due under insurance premium finance agreements | 75,000 | 185,000 |
| Finance lease liabilities, current portion | 132,000 | 125,000 |
| Long term debt, current portion | | 996,000 |
| Due to related parties | 2,466,000 | |
| Current maturities of long-term debt | 137,000 | |
| Accrued legal | 1,985,000 | |
| Total current liabilities | 8,960,000 | 11,364,000 |
| Operating lease liabilities, less current portion | | 1,557,000 |
| Finance lease liabilities, less current portion | 402,000 | 325,000 |
| Mortgage promissory note | | 2,211,000 |
| Progress payment agreement | 2,960,000 | 39,000 |
| Equipment notes | | 42,000 |
| Less: current portion | | 996,000 |
| Derivative warrant liability | | 69,000 |
| Total liabilities | 12,322,000 | 14,524,000 |
| Preferred stock, series G, convertible | | 75,000 |
| Common stock | 330,202,000 | 328,551,000 |
| Retained earnings (accumulated deficit) | | (315,717,000) |
| Accumulated deficit attributable to noncontrolling interest in Nutra SA | (333,277,000) | |
| Preferred Stock | 75,000 | |
| Total shareholders' equity (deficit) | (3,000,000) | 12,909,000 |
| Total equity | (3,000,000) | |

□ As reported by the Company

Recent Dividends:

1. **RiceBran Technologies seventh series of preferred, series G, convertible (stated value: \$225).**
No dividends paid.
2. **RiceBran Technologies common.**
No dividends paid.
3. **RiceBran Technologies series F convertible preferred.**
No dividends paid.
4. **RiceBran Technologies convertible series C preferred stock (\$1,000 stated value).**
No dividends paid.
5. **RiceBran Technologies series D preferred.**
No dividends paid.
6. **RiceBran Technologies convertible series B preferred stock (\$1,000 stated value).**
No dividends paid.
7. **RiceBran Technologies mandatorily redeemable common.**
No dividends paid.

Annual Dividends:

1. **RiceBran Technologies seventh series of preferred, series G, convertible (stated value: \$225).**
No dividends paid.
2. **RiceBran Technologies common.**
No dividends paid.
3. **RiceBran Technologies series F convertible preferred.**
No dividends paid.
4. **RiceBran Technologies convertible series C preferred stock (\$1,000 stated value).**
No dividends paid.
5. **RiceBran Technologies series D preferred.**
No dividends paid.
6. **RiceBran Technologies convertible series B preferred stock (\$1,000 stated value).**
No dividends paid.

7. RiceBran Technologies mandatorily redeemable common.

No dividends paid.

RICHARDSON ELECTRONICS LTD

Earnings, 9 mos. to (Consol. - \$000):

| | | |
|-----------------------------|----------|----------|
| | 03/02/24 | 02/25/23 |
| Total revenues | 149,086 | 149,086 |
| Net Sales | 149,086 | 203,826 |
| Cost & expenses | 148,624 | 180,235 |
| Operating income | 296 | 23,591 |
| Other income (expense), net | (43) | 29 |
| Foreign currency | | (305) |
| Net before taxes | 296 | 23,494 |
| Income taxes | 116 | 5,281 |
| Net income | 180 | 18,213 |
| Earnings common share | | |
| Primary | \$0.01 | \$1.33 |
| Fully Diluted | \$0.01 | \$1.27 |
| Common Shares: | | |
| Full Diluted | 14,532 | 12,524 |
| Year-end | 14,279 | 14,137 |

RIDGEFIELD ACQUISITION CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|-----------|------------------|------------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| General & administrative expenses | 60,082 | 58,923 | 50,148 |
| Total operating expenses | 60,082 | 58,923 | 50,148 |
| Operating income (loss) | (60,082) | (58,923) | (50,148) |
| Other income (expense) | (2,400) | (2,565) | (2,704) |
| Interest expense | 10,500 | 2,411 | 5,681 |
| Total other income (expense) | (12,900) | (4,976) | (8,385) |
| Net income (loss) | (72,982) | (63,899) | (58,533) |
| Weighted average shares outstanding | | | |
| - basic | 2,860,773 | 2,860,773 | 2,505,217 |
| Weighted average shares outstanding - diluted | 2,860,773 | 2,860,773 | 2,505,217 |
| Year end shares outstanding | 2,860,773 | 2,860,773 | 2,860,773 |
| Income (loss) per share from continuing operations - basic | \$ (0.03) | ... | ... |
| Net income (loss) per share - basic | \$ (0.03) | \$ (0.02) | \$ (0.02) |
| Income (loss) per share from continuing operations - diluted | \$ (0.03) | ... | ... |
| Net income (loss) per share - diluted | \$ (0.03) | \$ (0.02) | \$ (0.02) |
| Total number of employees | ... | □ ₁ | □ ₁ |
| Number of common stockholders | 643 | □ ₆₄₃ | □ ₆₄₃ |

□ Shares increased due to the effect of issuance of common stock; □ As of February 28, 2023; □ As of March 11, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---------------------------------------|-----------|-----------|
| | 2023 | 2022 |
| Cash & cash equivalents | 24,415 | 21,200 |
| Total current assets | 24,415 | ... |
| Total assets | 24,415 | 21,200 |
| Accounts payable & accrued expenses | ... | 810 |
| Related party note & interest payable | 142,911 | 82,411 |
| Commission payable | 16,507 | ... |
| Total current liabilities | 159,418 | 83,221 |
| Common stock | 2,861 | 2,861 |
| Additional paid in capital | 1,914,819 | 1,914,819 |

| | | |
|---|-------------|-------------|
| Retained earnings (accumulated deficit) | ... | (1,979,701) |
| Accumulated deficit | (2,052,683) | ... |
| Total stockholders' equity (deficit) | (135,003) | (62,021) |
| Total Liabilities | 159,418 | ... |
| Total Equity | (135,003) | ... |

Recent Dividends:

1. **Ridgefield Acquisition Corp common.**

No dividends paid.

Annual Dividends:

1. **Ridgefield Acquisition Corp common.**

No dividends paid.

RISE GOLD CORP

Earnings, 6 mos. to Jan 31 (Consol. - \$):

| | | |
|-----------------------------|-------------|-------------|
| | 2024 | 2023 |
| Cost & expenses | 2,057,244 | 1,418,524 |
| Operating income | (1,985,950) | (1,418,524) |
| Other income (expense), net | 89,232 | (727,492) |
| Foreign currency | (7,899) | ... |
| Net before taxes | (1,975,911) | ... |
| Net income | (1,975,911) | (2,146,016) |
| Earnings common share | | |
| Primary | \$(0.05) | \$(0.04) |
| Fully Diluted | \$(0.05) | \$(0.04) |
| Common Shares: | | |
| Full Diluted | 42,499,527 | 32,837,257 |
| Year-end | 45,740,341 | 37,236,864 |

RUBICON TECHNOLOGY INC

Earnings, 9 mos. to Sep 30 (Consol. - \$000):

| | | |
|-----------------------------|--------|-------|
| | 2023 | 2022 |
| Total revenues | 1,573 | 2,468 |
| Cost & expenses | 975 | 2,103 |
| Operating income | 598 | 365 |
| Interest income | 28 | 97 |
| Interest expense | 91 | 13 |
| Other income (expense), net | 250 | 18 |
| Invest. income | 18 | ... |
| Net before taxes | 535 | 717 |
| Income contin. oper. | 535 | 717 |
| Net income | 536 | 734 |
| Earnings common share | | |
| Primary | \$0.23 | ... |
| Fully Diluted | \$0.23 | ... |
| Common Shares: | | |
| Full Diluted | 2,406 | 2,459 |
| Year-end | 2,378 | 2,463 |

RUMBLEON INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|---------------|-------------------|-------------------|
| | 2023 | □ ₂₀₂₂ | □ ₂₀₂₁ |
| | | (revised) | (revised) |
| Transportation | 42,500,000 | 42,200,000 | ... |
| Parts, service and accessories | 131,500,000 | 135,300,000 | ... |
| Revenue: vehicle sales - powersports | ... | ... | 323,303,000 |
| Revenue: vehicle sales - automotive | ... | ... | 460,888,000 |
| Parts, service & accessories | 241,800,000 | 247,600,000 | 66,969,000 |
| Vehicle logistics | 951,400,000 | 1,033,900,000 | 43,878,000 |
| Finance & insurance, net | 117,000,000 | 123,400,000 | 29,133,000 |
| Transportation and Vehicle Logistics | 56,200,000 | 54,000,000 | ... |
| Total revenue | 1,366,400,000 | 1,458,900,000 | 924,171,000 |
| Cost of revenue - powersports | ... | ... | 264,872,000 |
| Cost of revenue - automotive | ... | ... | 430,142,000 |
| Cost of revenue - parts, service & accessories | ... | ... | 36,702,000 |
| Cost of revenue - vehicle logistics | ... | ... | 34,278,000 |
| Cost of revenue - finance & insurance | 832,500,000 | 839,700,000 | ... |
| Total cost of | | | |

| | | | | | | | | | | | |
|---|---------------|---------------|--------------|---|-------------|---------------|-----|---|---------------|---------------|--|
| revenue | 1,006,500,000 | 1,017,200,000 | 765,994,000 | Discontinued operations | (1,100,000) | (28,000,000) | ... | Vehicle floor plan note payable | 291,300,000 | 220,100,000 | |
| Gross profit (loss) | 359,900,000 | 441,700,000 | 158,177,000 | Income tax provision (benefit) | 59,300,000 | (72,000,000) | ... | Current portion lease liabilities | 23,900,000 | 24,100,000 | |
| Advertising, marketing & selling | ... | ... | 14,425,000 | Earnings (loss) per share - basic from continuing operations | \$(12.08) | \$(14.71) | ... | Current portion of senior secured debt, convertible debt & notes payable | 35,600,000 | 3,700,000 | |
| Compensation & related costs | ... | ... | 63,473,000 | Earnings (loss) per share - diluted from continuing operations | \$(12.08) | \$(14.71) | ... | Current liabilities of discontinued operations | 300,000 | 8,400,000 | |
| Facilities | ... | ... | 9,568,000 | Earn per share-inc from discount opers - diluted | \$(0.06) | \$(1.76) | ... | Accounts payable and other current liabilities | - | - | |
| General & administrative | ... | ... | 45,400,000 | Earning per share-total discount opers - diluted | \$(0.06) | \$(1.76) | ... | - Balancing value | 67,800,000 | 79,500,000 | |
| Stock based compensation | ... | ... | 29,219,000 | Earnings per share-inc from discontinued oper | \$(0.06) | \$(1.76) | ... | Total current liabilities | 395,000,000 | 311,700,000 | |
| Technology development & software | ... | ... | 1,992,000 | Earnings per share-total discontinued opers | \$(0.06) | \$(1.76) | ... | Line of credit & notes payable | 236,900,000 | 374,400,000 | |
| Selling, general & administrative | 347,300,000 | 354,500,000 | 164,077,000 | Total number of employees | 2,409 | ... | ... | Operating lease liabilities | 134,100,000 | 126,700,000 | |
| Impairment of goodwill & franchise rights | 60,100,000 | 324,300,000 | ... | ☐ Restated to reflect discontinued operations; ☑ Reclassified to conform with 2022 presentation; ☑ Shares increased due to the effect of issuance of common stock, restricted stock units and acquisition; ☑ Approximately; ☑ As of April 5, 2022 | | | | Financing lease liabilities | 49,800,000 | ... | |
| Insurance recovery proceeds | ... | ... | 3,135,000 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Deferred tax liabilities | 400,000 | ... | |
| Depreciation & amortization expenses | 22,000,000 | 23,000,000 | 6,103,000 | 2023 (revised) | | | | Other long-term liabilities | 4,500,000 | 8,400,000 | |
| Operating income (loss) | (69,500,000) | (260,100,000) | (8,868,000) | Cash | 58,900,000 | 46,800,000 | ... | Long-term debt, net of current maturities | 286,700,000 | ... | |
| Interest expense | 77,200,000 | 52,100,000 | 16,405,000 | Restricted cash | 18,100,000 | 10,000,000 | ... | Total long-term liabilities | 425,700,000 | 509,500,000 | |
| Other income | (8,400,000) | 4,200,000 | ... | Contracts in transit | 16,000,000 | 13,100,000 | ... | Total liabilities | 820,700,000 | 821,200,000 | |
| Change in derivative liability | ... | ... | (8,799,000) | Trade receivables | 9,800,000 | 9,700,000 | ... | Common stock | 50 | 50 | |
| Forgiveness of Paycheck Protection Program loan | ... | 2,500,000 | 2,682,000 | Factory receivables | 9,600,000 | 6,200,000 | ... | Class B common stock | 35,072 | 16,184 | |
| Income (loss) before income taxes | (155,100,000) | (305,500,000) | (31,390,000) | Accounts receivable - other | 50,300,000 | 28,000,000 | ... | Additional paid in capital | 701,000,000 | 585,900,000 | |
| Current federal income tax expense | 400,000 | 4,100,000 | ... | Accounts receivable - gross | 50,800,000 | 29,000,000 | ... | Retained earnings (accumulated deficit) | (591,100,000) | (375,600,000) | |
| Current state income tax expense (benefit) | 400,000 | 300,000 | 880,000 | Less: allowance for doubtful accounts | 500,000 | 1,000,000 | ... | Class B stock in treasury, at cost | 4,300,000 | 4,300,000 | |
| Total current income tax expense | 800,000 | 4,400,000 | 880,000 | Inventory | 347,500,000 | 323,500,000 | ... | Total stockholders' equity (deficit) | 105,600,000 | 206,000,000 | |
| Deferred federal income tax expenses (benefit) | 49,500,000 | (62,500,000) | (21,028,000) | Prepaid expense & other current assets | 6,000,000 | 7,400,000 | ... | Total Equity | 105,600,000 | 206,000,000 | |
| Deferred state income tax expenses (benefit) | 9,000,000 | (13,900,000) | (1,517,000) | Receivable from the sale of the ROF loan portfolio | 15,400,000 | ... | ... | ☐ Restated to reflect discontinued operations | | | |
| Total deferred income tax expense (benefit) | 58,500,000 | (76,400,000) | (22,545,000) | Current assets of discontinued operations | ... | 11,400,000 | ... | Recent Dividends: | | | |
| Income tax expense (benefit) | 59,300,000 | (72,000,000) | (21,665,000) | Loans receivable held for sale | ... | 33,700,000 | ... | 1. RumbleON Inc class A common. No dividends paid. 2. RumbleON Inc class B common. No dividends paid. 3. RumbleON Inc class B preferred. No dividends paid. | | | |
| Net income (loss) | (215,500,000) | (261,500,000) | (9,725,000) | Total current assets | 480,800,000 | 460,800,000 | ... | Annual Dividends: | | | |
| Weighted average shares outstanding - basic | 17,740,525 | 15,871,005 | 6,920,318 | Land | 11,900,000 | 11,500,000 | ... | 1. RumbleON Inc class A common. No dividends paid. 2. RumbleON Inc class B common. No dividends paid. 3. RumbleON Inc class B preferred. No dividends paid. | | | |
| Weighted average shares outstanding - diluted | 17,740,525 | 15,871,005 | 6,920,318 | Buildings & improvements | 43,600,000 | 38,900,000 | ... | RYVYL INC Annual Report | | | |
| Year end shares outstanding | 35,121,955 | 16,234,264 | ☑14,932,022 | Leasehold improvements | 19,000,000 | 14,200,000 | ... | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| Net income (loss) per share - basic | \$(12.15) | \$(16.48) | \$(1.41) | Equipment | 7,200,000 | 5,400,000 | ... | 2023 | 2022 | ☑2021 | |
| Net income (loss) per share - diluted | \$(12.15) | \$(16.48) | \$(1.41) | Technology development | 2,900,000 | 2,600,000 | ... | 2023 | (revised) | (revised) | |
| Number of full time employees | 2,357 | ... | ☑1,949 | Vehicles | 12,900,000 | 7,700,000 | ... | Cost of goods sold | 40,157,000 | ... | |
| Number of part time employees | 52 | ... | ☑70 | Technology development | 18,100,000 | 15,800,000 | ... | Payroll and payroll taxes | 12,017,000 | ... | |
| Number of common stockholders | 50 | ... | ☑52 | Total property & equipment | 115,600,000 | 96,100,000 | ... | Transaction apparel sales | 65,869,000 | ... | |
| Number of class A common stockholders | ... | ... | ☑52 | Less: accumulated depreciation & amortization | 38,800,000 | 20,000,000 | ... | Net revenue | 65,869,000 | 32,909,112 | |
| Number of class B common stockholders | ... | ... | ☑320 | Property & equipment, net | 76,800,000 | 76,100,000 | ... | Cost of revenue | ... | 16,786,593 | |
| Income from continuing operations | (214,400,000) | (233,500,000) | ... | Right-of-use assets | 163,900,000 | 161,800,000 | ... | Gross profit | 25,712,000 | 16,122,519 | |
| Loss from discontinued operations | (1,100,000) | ... | ... | Goodwill | 800,000 | 21,100,000 | ... | Advertising & marketing | 80,000 | 1,337,019 | |
| | | | | Intangible assets, net | 202,500,000 | 247,400,000 | ... | Research & development | 5,757,000 | 6,275,883 | |
| | | | | Deferred tax assets | ... | 58,100,000 | ... | Payroll & payroll taxes | 1,853,000 | 10,547,381 | |
| | | | | Other assets | 1,500,000 | 1,900,000 | ... | Professional fees | 7,076,000 | 5,311,678 | |
| | | | | Total assets | 926,300,000 | 1,027,200,000 | ... | Stock compensation for employees | ... | 166,800 | |
| | | | | Accounts payable | 7,100,000 | 13,700,000 | ... | Stock grant expense | ... | 2,305,650 | |
| | | | | Accrued interest | 2,700,000 | 1,700,000 | ... | Stock compensation for services | ... | 496,497 | |
| | | | | Accrued payroll | 11,600,000 | 13,900,000 | ... | General & administrative | 8,678,000 | 6,602,967 | |
| | | | | Customer deposits | 3,500,000 | 5,400,000 | ... | Depreciation & amortization | 2,553,000 | 20,916,868 | |
| | | | | State & local taxes | 10,400,000 | 10,000,000 | ... | | | 912,677 | |
| | | | | Professional fees | 900,000 | 1,900,000 | ... | | | | |
| | | | | Other accrued expenses | 7,700,000 | 8,800,000 | ... | | | | |
| | | | | Current portion of long term debt - related party | 35,600,000 | ... | ... | | | | |

| | | | |
|--|-----------|----------|-----|
| Income (loss) from discontinued operations | (261,528) | 344,172 | ... |
| Earnings per share from continuing operations | \$(0.48) | \$(0.70) | ... |
| Earnings per share-inc from discontinued oper | \$(0.01) | \$0.02 | ... |
| Earnings per share-total discontinued opers | \$(0.01) | \$0.02 | ... |
| Earnings per share from continuing operations | \$(0.48) | \$(0.70) | ... |
| Earn per share-inc from discount opers - diluted | \$(0.01) | \$0.02 | ... |
| Earning per share-total discount opers - diluted | \$(0.01) | \$0.02 | ... |
| Total number of employees | 8 | ... | ... |

Restated to reflect discontinued operations; Shares increased due to issuance of common stock in public offering, for intellectual property and services, upon conversion of notes and exercise of cashless options; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|---|--------------|----------------|
| Cash | 3,833,349 | 1,931,068 |
| Inventory | 795,824 | 441,404 |
| Accounts receivable, gross | ... | 647,530 |
| Less: allowance | ... | 0 |
| Accounts receivable | 5,585 | 647,530 |
| Prepaid expenses and deposits | 1,469,733 | ... |
| Prepaid expenses & deposits | 86,174 | 814,114 |
| Investment in affiliates | 842,976 | 2,917,373 |
| Investment in SRM Entertainment Inc | 657,183 | ... |
| Total current assets | 7,690,824 | 6,751,489 |
| Right of use assets | 479,027 | 643,977 |
| Intangible assets, net | ... | 291,533 |
| Goodwill | ... | 941,937 |
| Fixed assets, net | 28,272 | 61,827 |
| Intellectual property | 4,511,057 | ... |
| Total assets | 12,709,180 | 8,690,763 |
| Accounts payable | 1,493,809 | 1,927,188 |
| Convertible notes, net of discounts | ... | 2,000,000 |
| Current portion of lease liability | 214,752 | 164,170 |
| Accrued liabilities | 60,450 | 366,619 |
| Covid - 19 Small Business Administration ("SBA") loan | ... | 47,533 |
| Convertible notes | 1,500,000 | ... |
| Covid 19 SBA Loan | 48,974 | ... |
| Accrued interest | 269,152 | ... |
| Total current liabilities | 3,587,137 | 4,505,510 |
| Long-term portion lease liability | 304,907 | 519,659 |
| Total liabilities | ... | 5,025,169 |
| Common stock | 45,634 | 22,339 |
| Additional paid-in capital | 73,726,987 | 53,763,929 |
| Common stock payable | 725,230 | 477,000 |
| Accumulated deficits | (65,680,715) | ... |
| Retained earnings (accumulated deficits) | ... | (50,597,674) |
| Total shareholders' equity (deficit) | 8,817,136 | 3,665,594 |
| Total Equity | 8,817,136 | ... |

Recent Dividends:
1. Safety Shot Inc common.
 No dividends paid.
Annual Dividends:
1. Safety Shot Inc common.

No dividends paid.

SAKER AVIATION SERVICES, INC.
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-----------|-----------|----------------|
| REVENUE | 8,837,614 | ... | ... |
| Revenue | 8,837,614 | 7,598,597 | 2,400,316 |
| Cost of revenue | 2,556,394 | 2,985,281 | 575,362 |
| Gross profit (loss) | 6,281,220 | 4,613,316 | 1,824,954 |
| Selling, general & administrative expenses | 2,768,310 | 3,880,902 | 1,384,408 |
| Operating income (loss) | 3,512,910 | 732,414 | 440,546 |
| Bad debt recovery | (212,000) | (125,000) | ... |
| Life insurance proceeds, former president | ... | 500,000 | ... |
| Gain on extinguishment of debt - PPP loan | ... | ... | 304,833 |
| Interest income | 220,098 | 3,302 | 3,780 |
| REALIZED GAIN ON INVESTMENTS | 8,479 | ... | ... |
| Total other income (expense) | 440,577 | 628,302 | 308,613 |
| Income tax expense (benefit) | 1,507,043 | 300,000 | 150,000 |
| Income (loss) from discontinued operations | ... | (65,413) | 179,125 |
| Gain on sale of assets from discontinued operations | ... | 431,318 | ... |
| Income tax expense | ... | (180,000) | (52,100) |
| Income from discontinued operations, net of income taxes | ... | 185,905 | 127,025 |
| Net income (loss) | 2,446,444 | 1,246,621 | 726,184 |
| Weighted average shares outstanding - basic | 976,782 | 976,048 | 1,023,709 |
| Weighted average shares outstanding - diluted | 989,686 | 987,149 | 1,026,729 |
| Year end shares outstanding | 985,888 | 976,330 | 975,074 |
| Income (loss) per share from continuing operations - basic | \$2.50 | ... | ... |
| Income (loss) per share from total discontinued operations - basic | \$0.00 | ... | ... |
| Net income (loss) per share - basic | \$2.50 | \$1.28 | \$0.71 |
| Income (loss) per share from continuing operations - diluted | \$2.47 | ... | ... |
| Income (loss) per share from total discontinued operations - diluted | \$0.00 | ... | ... |
| Net income (loss) per share - diluted | \$2.47 | \$1.26 | \$0.71 |
| Number of full time employees | 11 | 12 | ... |
| Number of part time employees | ... | 1 | ... |
| Total number of employees | 11 | 13 | ... |
| Number of common stockholders | 475 | 156 | ... |

Restated to reflect the discontinued operation of FBO Air-Garden City, Inc.; Approximately; As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & restricted cash | 6,931,709 | 5,977,157 |
| Accounts receivable | 294,521 | 244,543 |
| Non-compete receivable | ... | 160,000 |
| Other inventory | 1,142 | ... |
| Inventories | ... | 13,551 |
| Income tax receivable | 44,899 | 119,899 |
| Prepaid expenses | 745,606 | 354,913 |
| Investments | 2,543,321 | ... |
| Total current assets | 10,561,198 | 6,870,063 |
| Office furniture & equipment | 424,242 | 413,574 |
| Leasehold improvements | 2,753,074 | 2,740,750 |
| Property & equipment, gross | 3,177,316 | 3,154,324 |
| Less: accumulated depreciation & amortization | 3,127,876 | 3,111,462 |
| Property & equipment, net | 49,440 | 42,862 |
| Total assets | 10,610,638 | 6,912,925 |
| Accounts payable | ... | 328,505 |
| Customer deposits | 253,446 | 204,633 |
| Accrued expenses | 1,333,092 | 597,262 |
| Accounts payable & accrued expenses | 705,133 | ... |
| Total current liabilities | 2,291,671 | 1,130,400 |
| Total liabilities | 2,291,671 | 1,130,400 |
| Common stock | 29,577 | 29,290 |
| Additional paid-in capital | 19,902,505 | 19,812,794 |
| Accumulated deficit | (11,613,115) | ... |
| Retained earnings (accumulated deficit) | ... | (14,059,559) |
| Total stockholders' equity (deficit) | 8,318,967 | 5,782,525 |
| Total equity | 8,318,967 | ... |

Recent Dividends:
1. Saker Aviation Services, Inc. common.
 No dividends paid.
Annual Dividends:
1. Saker Aviation Services, Inc. common.
 No dividends paid.

SALARIUS PHARMACEUTICALS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|----------------|
| Grant revenue | ... | ... | 1,840,216 |
| General & administrative expenses | 5,721,197 | 7,138,403 | 6,104,627 |
| Research & development expenses | 7,173,747 | 15,836,828 | 8,548,520 |
| Loss on impairment of goodwill | ... | 8,865,909 | ... |
| Total operating expenses | 12,894,944 | 31,841,140 | 14,653,147 |
| Income (loss) before other income (expense) | (12,894,944) | (31,841,140) | (12,812,931) |
| Change in fair value of warrant liability | ... | 14,454 | 44,693 |
| Interest income, net | 352,251 | 218,730 | ... |
| Net income (loss) | (12,542,693) | (31,607,956) | (12,768,238) |
| Income (loss) attributable to common stockholders | ... | (31,607,956) | (12,768,238) |
| Weighted average shares outstanding - basic | 3,264,620 | 2,124,511 | 1,654,638 |
| Weighted average shares outstanding - diluted | 3,264,620 | 2,124,511 | 1,654,638 |
| Year end shares outstanding | 3,938,433 | 2,255,899 | 1,809,672 |
| Net earnings (loss) | ... | ... | ... |

| | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|--------------|--------------|-------------|------|------|
| per common share - basic | \$(3.84) | \$(14.88) | Ⓜ\$(7.75) | | |
| Earnings (loss) per share - continuing operations - diluted | \$(3.84) | ... | ... | | |
| Net earnings (loss) per common share - diluted | \$(3.84) | \$(14.88) | Ⓜ\$(7.75) | | |
| Number of full time employees | ... | Ⓜ12 | Ⓜ16 | | |
| Number of common stockholders | 149 | Ⓜ151 | Ⓜ143 | | |
| Income from cont operations before income tax | (12,542,693) | ... | ... | | |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(3.84) | ... | ... | | |
| <p>Ⓜ Adjusted for 1-for-25 stock split, October 17, 2022; Ⓜ Stocks increased due to the effect issuance of stocks and issuance for in-process research and development technology; Ⓜ Shares increased due to the effect issuance of equity securities, warrants exercised, equity-based compensation and issuance of equity securities for services; Ⓜ As of March 8, 2023; Ⓜ As of March 12, 2022; Ⓜ Approximately; Ⓜ As of March 20, 2023</p> | | | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | |
| | 2023 | 2022 | | | |
| Cash & cash equivalents | 5,899,910 | 12,106,435 | | | |
| Grants receivable from Cancer Prevention & Research Institution of Texas ("CPRIT") | ... | 1,610,490 | | | |
| Prepaid clinical trial expenses | ... | 11,185 | | | |
| Prepaid insurance | 468,495 | 624,612 | | | |
| Other prepaid & current assets | 151,268 | 167,576 | | | |
| Prepaid expenses & other current assets | 619,763 | 803,373 | | | |
| Total current assets | 6,519,673 | 14,520,298 | | | |
| Other assets | 66,850 | 130,501 | | | |
| Total assets | 6,586,523 | 14,650,799 | | | |
| Accounts payable | 602,853 | 2,858,330 | | | |
| Note payable | 289,643 | ... | | | |
| Total liabilities | 1,299,241 | 4,266,191 | | | |
| Common stock | 393 | 225 | | | |
| Additional paid-in capital | 81,634,730 | 74,189,531 | | | |
| Retained earnings (accumulated deficit) | (76,347,841) | (63,805,148) | | | |
| Total stockholders' equity (deficit) | 5,287,282 | 10,384,608 | | | |
| Total Equity | 5,287,282 | ... | | | |
| Recent Dividends: | | | | | |
| 1. Saliarius Pharmaceuticals Inc series A convertible preferred. | | | | | |
| No dividends paid. | | | | | |
| 2. Saliarius Pharmaceuticals Inc series B convertible preferred. | | | | | |
| No dividends paid. | | | | | |
| 3. Saliarius Pharmaceuticals Inc common. | | | | | |
| No dividends paid. | | | | | |
| Annual Dividends: | | | | | |
| 1. Saliarius Pharmaceuticals Inc series A convertible preferred. | | | | | |
| No dividends paid. | | | | | |
| 2. Saliarius Pharmaceuticals Inc series B convertible preferred. | | | | | |
| No dividends paid. | | | | | |
| 3. Saliarius Pharmaceuticals Inc common. | | | | | |
| No dividends paid. | | | | | |
| SAMSARA LUGGAGE INC | | | | | |
| Annual Report | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | |
| | 2023 | 2022 | 2021 | 2020 | 2019 |
| Revenues from sales | 361,000 | ... | ... | | |
| Revenues from sales | 361,000 | 1,171,000 | 345,000 | | |
| Cost of sales | 208,000 | 822,000 | 293,000 | | |
| Gross profit | 153,000 | 349,000 | 52,000 | | |
| Research & development expenses | ... | 178,000 | 332,000 | | |
| Selling & marketing expenses | ... | 651,000 | 377,000 | | |
| Professional fees | ... | 172,000 | 297,000 | | |
| Share based compensation | ... | 508,000 | 881,000 | | |
| Management fees | ... | 100,000 | 100,000 | | |
| Other expenses | ... | 113,000 | 26,000 | | |
| General & administrative | 439,000 | 893,000 | 1,304,000 | | |
| Project development & general & administrative expenses | 213,000 | ... | ... | | |
| Total operating expenses | 652,000 | 1,722,000 | 2,013,000 | | |
| Operating income (loss) | (499,000) | (1,373,000) | (1,961,000) | | |
| Interest on convertible loan & convertible note | 227,000 | 1,243,000 | 109,000 | | |
| Income (expenses) in respect of warrants issued & convertible component in convertible loan, net interest expenses | ... | 210,000 | (1,747,000) | | |
| Total financing income (expense) | (79,000) | (1,033,000) | (1,856,000) | | |
| Reversal of derivative liability | 661,000 | ... | ... | | |
| Income (loss) before income tax | (144,000) | ... | ... | | |
| Net income (loss) | (144,000) | (2,406,000) | (3,817,000) | | |
| Weighted average shares outstanding - basic | 9,043,866 | 2,858,961 | 1,284,300 | | |
| Weighted average shares outstanding - diluted | 9,043,866 | 2,858,961 | 1,284,300 | | |
| Year end shares outstanding | 13,922,414 | Ⓜ4,406,312 | 2,055,487 | | |
| Net earnings (loss) per share - basic | \$0.00 | \$(0.84) | \$(2.97) | | |
| Net earnings (loss) per share - diluted | \$0.00 | \$(0.84) | \$(2.97) | | |
| Full-Time Employees (Period End) | 2 | ... | ... | | |
| Total number of employees | 2 | 7 | 7 | | |
| Number of common stockholders | 169 | Ⓜ166 | Ⓜ166 | | |
| <p>Ⓜ Shares increased due to the effect of shares issued due to conversion of convertible note; Ⓜ As of April 3, 2023; Ⓜ As of March 24, 2022</p> | | | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | |
| | 2023 | 2022 | | | |
| Cash & cash equivalents | 12,000 | 168,000 | | | |
| Accounts receivables | ... | 1,000 | | | |
| Inventory | ... | 155,000 | | | |
| Other current assets | ... | 21,000 | | | |
| Total current assets | 12,000 | 345,000 | | | |
| Total assets | 12,000 | 345,000 | | | |
| Accounts payable | 327,000 | ... | | | |
| Accounts payable | ... | 47,000 | | | |
| Other current liabilities | 146,000 | 285,000 | | | |
| Related party payables | 193,000 | 121,000 | | | |
| Deferred revenue | ... | 6,000 | | | |
| Convertible notes & short-term loans | 1,398,000 | 1,167,000 | | | |
| Fair value of convertible | ... | ... | | | |
| component in convertible loan, net of discounts & debt issue costs | ... | 632,000 | | | |
| Note payable, net | ... | 61,000 | | | |
| Fair value of warrants issued in convertible loan | ... | 1,000 | | | |
| Total current liabilities | 2,064,000 | 2,320,000 | | | |
| Total liabilities | 2,064,000 | 2,320,000 | | | |
| Convertible & redeemable preferred shares | 66,000 | 161,000 | | | |
| Common stock | 1,000 | ... | | | |
| Additional paid-in capital | 10,625,000 | 10,464,000 | | | |
| Accumulated Deficit | (12,744,000) | ... | | | |
| Retained earnings (accumulated deficit) | ... | (12,600,000) | | | |
| Total stockholders' equity (deficit) | (2,118,000) | (2,136,000) | | | |
| Recent Dividends: | | | | | |
| 1. Samsara Luggage Inc common. | | | | | |
| No dividends paid. | | | | | |
| Annual Dividends: | | | | | |
| 1. Samsara Luggage Inc common. | | | | | |
| No dividends paid. | | | | | |
| SANARA MEDTECH INC | | | | | |
| Annual Report | | | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | |
| | 2023 | Ⓜ2022 | 2021 | 2020 | 2019 |
| Consulting fee income | 64,989,842 | 45,842,845 | ... | | |
| Net revenue | ... | ... | 24,143,919 | | |
| Cost of goods sold | 7,852,686 | 6,360,851 | 2,311,221 | | |
| Gross profit (loss) | 57,137,156 | 39,481,994 | 21,832,698 | | |
| Selling, general & administrative expenses | ... | ... | 28,053,176 | | |
| Research & development | 4,132,425 | 3,367,032 | 558,704 | | |
| General & administrative expenses | 56,994,753 | 45,976,328 | ... | | |
| Depreciation | 456,138 | 407,769 | ... | | |
| Amortization of Intangibles excluding Goodwill | 3,218,888 | 1,963,299 | ... | | |
| Depreciation & amortization | 3,675,026 | 2,371,068 | 596,975 | | |
| Loss on disposition of assets held for sale | 3,449,895 | (284,746) | ... | | |
| Total operating expenses | 61,352,309 | 51,999,174 | 29,208,855 | | |
| Operating income (loss) | (4,215,153) | (12,517,180) | (7,376,157) | | |
| Interest & accretion expense | 475,783 | ... | 711 | | |
| Share of earnings (losses) from equity method investment | ... | (379,633) | (616,927) | | |
| Gain (loss) on disposal of investment | 251,034 | (1,040,311) | ... | | |
| Total other income (expense) | ... | ... | (617,638) | | |
| Income (loss) before income taxes | (4,439,902) | (13,937,124) | (7,993,795) | | |
| Income tax expense (benefit) | ... | (5,844,796) | ... | | |
| Net Income After Extraordinary Items applicable to Common | (4,303,197) | (7,937,497) | ... | | |
| Net income (loss) | (4,439,902) | (8,092,328) | (7,993,795) | | |
| Less: net income (loss) attributable to noncontrolling interest | 136,705 | 154,831 | 71,881 | | |
| Net income (loss) attributable to | ... | ... | ... | | |

| | | | |
|---|-----------|-----------|-------------|
| Sanara MedTech Inc. common shareholders | ... | ... | (7,921,914) |
| Weighted average shares outstanding - basic | 8,278,949 | 7,906,794 | 7,341,580 |
| Weighted average shares outstanding - diluted | 8,278,949 | 7,906,794 | 7,341,580 |
| Year end shares outstanding | 8,535,239 | 8,299,957 | 7,676,662 |
| Income (loss) per share - continuing operations - basic | \$(0.52) | \$(1.00) | ... |
| Net income (loss) per common share - basic | \$(0.52) | \$(1.00) | \$(1.08) |
| Income (loss) per share - continuing operations - diluted | \$(0.52) | \$(1.00) | ... |
| Net income (loss) per common share - diluted | \$(0.52) | \$(1.00) | \$(1.08) |
| Number of full time employees | 107 | ... | 63 |
| Number of part time employees | 1 | ... | 5 |
| Total number of employees | 108 | ... | 68 |
| Number of common stockholders | 283 | ... | 238 |

Reclassified to conform 2023 presentation; Shares increased due to the effect of issuance of common stock for asset acquisitions and equity offering; and share-based compensation; As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| | | (revised) |
| Cash | 5,147,216 | 8,958,995 |
| Accounts receivable, gross | 9,002,995 | 7,075,611 |
| Less: allowance for bad debt | 528,030 | 269,850 |
| Accounts receivable, net | ... | 6,805,761 |
| Accounts receivable - related party | 8,400 | 98,548 |
| Royalty receivable | 49,344 | 99,594 |
| Inventory, gross | 4,717,533 | 4,072,832 |
| Less: allowance for obsolescence | ... | 523,832 |
| Inventory, net | ... | 3,549,000 |
| Receivables, net | 8,474,965 | ... |
| Prepaid & other assets | 608,411 | 1,104,611 |
| Total current assets | 19,005,869 | 20,616,509 |
| Computers | ... | 172,154 |
| Office equipment | 201,785 | 87,225 |
| Furniture & fixtures | 304,338 | 258,414 |
| Leasehold improvements | 134,170 | 19,631 |
| Internal use software | 1,618,999 | 1,618,998 |
| Capitalized software development costs | 194,788 | ... |
| Property & equipment, gross | 2,454,080 | 2,156,422 |
| Less: accumulated depreciation | 1,196,124 | 739,986 |
| Property & equipment, net | 1,257,956 | 1,416,436 |
| Right of use assets - operating lease | 1,995,204 | 806,402 |
| Intangible assets, net | 44,926,061 | 31,509,980 |
| Investment in equity securities | 3,084,278 | 3,084,278 |
| Goodwill | 3,601,781 | 3,601,781 |
| Total assets | 73,871,149 | 61,035,386 |
| Accounts payable | 1,924,082 | 1,392,701 |
| Accounts payable - related parties | 77,805 | 34,036 |
| Accrued royalties & payables | 2,047,678 | 2,144,475 |
| Accrued bonuses & commissions | 7,676,770 | 7,758,284 |
| Earnout liabilities - | ... | ... |

| | | |
|--|--------------|--------------|
| current | 1,100,000 | 1,162,880 |
| Operating lease liabilities - current | 361,185 | 313,933 |
| Current portion of debt | 580,357 | ... |
| Total current liabilities | 13,767,877 | 12,806,309 |
| Earnout liabilities - long-term | 2,723,001 | 6,003,811 |
| Operating lease liabilities - long-term | 1,737,445 | 505,291 |
| Notes payable | 9,113,123 | ... |
| Other long-term liabilities | 1,941,686 | ... |
| Total long-term liabilities | 15,515,255 | 6,509,102 |
| Total liabilities | 29,283,132 | 19,315,411 |
| Common stock | 8,535 | 8,300 |
| Additional paid-in capital | 72,860,556 | 65,213,987 |
| Retained earnings (accumulated deficit) | (28,036,814) | (23,394,757) |
| Total Sanara MedTech Inc. shareholders' equity (deficit) | 44,832,277 | 41,827,530 |
| Equity (deficit) attributable to noncontrolling interest | (244,260) | (107,555) |
| Total shareholders' equity (deficit) | 44,588,017 | 41,719,975 |

Recent Dividends:

- Sanara MedTech Inc series D convertible preferred. No dividends paid.
- Sanara MedTech Inc common. No dividends paid.
- Sanara MedTech Inc series F convertible preferred. No dividends paid.
- Sanara MedTech Inc series C convertible preferred. No dividends paid.

Annual Dividends:

- Sanara MedTech Inc series D convertible preferred. No dividends paid.
- Sanara MedTech Inc common. No dividends paid.
- Sanara MedTech Inc series F convertible preferred. No dividends paid.
- Sanara MedTech Inc series C convertible preferred. No dividends paid.

SATIVUS TECH CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-------------|-------------|
| | | | (revised) |
| Research & development | 253,000 | 673,000 | 911,000 |
| General & administrative | 562,000 | 660,000 | 1,639,000 |
| Operating income (loss) | (815,000) | (1,333,000) | (2,550,000) |
| Bank interest & commissions | 7,000 | 13,000 | 2,000 |
| Financial income (expenses) related to revaluation of convertible component in convertible loans | ... | (420,000) | 890,000 |
| Commissions on loans | ... | ... | 98,000 |
| Financial income (expenses) related to interest & revaluation of warrants | ... | 11,000 | (2,232,000) |
| Foreign currency transactions & other | (45,000) | (58,000) | 51,000 |
| Financial expenses, net | (228,000) | 480,000 | 1,391,000 |
| Net income (loss) | (587,000) | (1,813,000) | (3,941,000) |
| Non-controlling interests | 263,000 | 286,000 | 322,000 |
| Net income (loss) attributable to | ... | ... | ... |

| | | | |
|--|-----------|-------------|-------------|
| equity holders of the Company | (324,000) | (1,527,000) | (3,619,000) |
| Weighted average number of ordinary shares - basic | 4,215,571 | 4,194,443 | 3,607,476 |
| Weighted average number of ordinary shares - diluted | 4,215,571 | 4,194,443 | 3,607,476 |
| Year end shares outstanding | 4,215,571 | 4,215,571 | 4,204,385 |
| Net income (loss) per share - basic | \$(0.08) | \$(0.36) | \$(1.00) |
| Net income (loss) per share - diluted | \$(0.08) | \$(0.36) | \$(1.00) |
| Total number of employees | ... | ... | 3 |
| Number of common stockholders | 87 | 86 | 87 |
| Net Income before Tax | (587,000) | ... | ... |
| Financial expenses related to warrants | (175,000) | ... | ... |
| Financial expenses related to warrants | 441,000 | ... | ... |
| Interest income on deposits | 14,000 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 176,000 | 810,000 |
| Restricted cash | 11,000 | 6,000 |
| Advances to suppliers | 313,000 | ... |
| Prepaid expenses & other receivables | ... | 85,000 |
| Short-Term deposits | 637,000 | ... |
| Total current assets | 1,137,000 | 901,000 |
| Right-of-use asset | 15,000 | 30,000 |
| Property & equipment, net | 256,000 | 219,000 |
| Total non-current assets | 271,000 | 249,000 |
| Total assets | 1,408,000 | 1,150,000 |
| Accounts payables | ... | 55,000 |
| Convertible loans | ... | 2,031,000 |
| Loans | ... | 114,000 |
| Convertible loans | 2,074,000 | ... |
| Other accounts payable | 46,000 | ... |
| Fair value of convertible component in convertible loans | 885,000 | 1,327,000 |
| Other accounts liabilities | 112,000 | 160,000 |
| Short term lease liability | 13,000 | 32,000 |
| Total current liabilities | ... | 3,719,000 |
| Ordinary shares | 4,000 | 4,000 |
| Additional paid in capital | 20,640,000 | 19,756,000 |
| Accumulated deficit | (22,928,000) | ... |
| Retained earnings (accumulated deficit) | ... | (22,604,000) |
| Total shareholders' equity (deficit) before non-controlling interests | (2,284,000) | (2,844,000) |
| Non-controlling interests | 562,000 | 275,000 |
| Total shareholders' equity (deficit) | (1,722,000) | (2,569,000) |
| Total current liabilities | 3,130,000 | ... |

Recent Dividends:

- Sativus Tech Corp ordinary. No dividends paid.

Annual Dividends:

- Sativus Tech Corp ordinary. No dividends paid.

SCIENTIFIC INDUSTRIES INC

Annual Report

Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 12/31/22 | 06/30/22 |
|------------------|------------|-----------|------------|
| | | | (revised) |
| Revenues | 11,111,500 | ... | ... |
| Revenues | 11,111,500 | 5,237,800 | 11,400,500 |
| Cost of revenues | 6,009,500 | 2,919,700 | 5,663,800 |

| | | | | | | | | | | | |
|--|-------------|-------------|--------------|--|----------|----------|----------|---|-------------|--------------|--------------|
| Gross profit (loss) | 5,102,000 | 2,318,100 | 5,736,700 | from discount operations - diluted | \$0.00 | ... | ... | Total stockholders' equity (deficit) | 13,885,400 | 14,792,600 | |
| General & administrative expenses | 5,417,900 | 2,658,800 | 5,816,600 | Income (loss) per share from discontinued operations - diluted | \$0.00 | \$0.00 | \$0.00 | Total Equity | 13,885,400 | ... | |
| Selling expenses | ... | 2,349,000 | 4,310,800 | Net income (loss) per share - diluted | \$(1.27) | \$(0.58) | \$(2.06) | | | | |
| Research & development expenses | 3,566,200 | 1,395,800 | 2,873,300 | Total number of employees | ... | 84 | ... | Recent Dividends: | | | |
| Impairment of goodwill & intangible asset | ... | 51,500 | 4,280,100 | Number of common stockholders | 288 | 256 | ... | 1. Scientific Industries Inc common. | | | |
| Selling | 5,377,800 | ... | ... | Foreign currency translation adjustments | ... | 88,600 | ... | No dividends paid. | | | |
| Total operating expenses | 14,361,900 | 6,455,100 | 17,280,800 | | | | | Annual Dividends: | | | |
| Income (loss) from operations | (9,259,900) | (4,137,000) | (11,544,100) | | | | | 1. Scientific Industries Inc common. | | | |
| Other income (expense), net | 62,900 | 63,900 | 185,100 | | | | | No dividends paid. | | | |
| Interest income | 107,200 | ... | 77,300 | | | | | SCOTT'S LIQUID GOLD, INC. | | | |
| Total other income (expense), net | 170,100 | 63,900 | 262,400 | | | | | Annual Report | | | |
| Income (loss) before income taxes - United States | ... | (3,285,900) | (8,985,600) | | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| Income (loss) before income taxes - Foreign | ... | (787,200) | (2,296,100) | | | | | 2023 | 2022 | 2021 | |
| Income (loss) from continuing operations before income tax expense (benefit) | (9,089,800) | (4,073,100) | (11,281,700) | | | | | (revised) | (revised) | (revised) | |
| Current federal income taxes | ... | ... | (99,200) | | | | | Net sales | 3,403,000 | 2,980,000 | 29,742,000 |
| Income tax expense (benefit), current | ... | ... | (99,200) | | | | | Cost of sales | 1,956,000 | 1,607,000 | 16,805,000 |
| Deferred federal income taxes | ... | ... | 1,693,700 | | | | | Impairment of inventories | ... | ... | 404,000 |
| Deferred foreign income taxes | ... | ... | 800,300 | | | | | Total revenues | 3,403,000 | 2,980,000 | ... |
| Income tax expense (benefit), deferred | 0 | ... | 2,490,000 | | | | | Total cost of sales | ... | ... | 17,209,000 |
| Loss from continuing operations before income tax expense (benefit) | (9,089,800) | ... | ... | | | | | Gross profit | 1,447,000 | 1,373,000 | 12,533,000 |
| Total income tax expense (benefit) | ... | ... | 2,390,800 | | | | | Advertising expenses | 330,000 | 641,000 | 639,000 |
| Income (loss) from continuing operations | (9,089,800) | (4,073,100) | (13,672,500) | | | | | Selling expenses | 1,528,000 | 2,928,000 | 8,956,000 |
| Gain (loss) from discontinued operations, net of tax | 3,300 | (6,300) | 4,400 | | | | | General & administrative expenses | 3,053,000 | 3,059,000 | 4,611,000 |
| Net income (loss) | (9,086,500) | (4,079,400) | (13,668,100) | | | | | Intangible asset amortization | 180,000 | 232,000 | 802,000 |
| Weighted average shares outstanding - basic | 10,145,211 | 7,003,599 | 6,637,471 | | | | | Impairment of goodwill & intangible assets | ... | ... | 4,050,000 |
| Weighted average shares outstanding - diluted | 10,145,211 | 7,003,599 | 6,637,471 | | | | | Impairment of property & equipment | 1,471,000 | 4,427,000 | ... |
| Year end shares outstanding | 10,145,211 | 7,003,599 | 7,003,599 | | | | | Total operating expenses | 6,562,000 | 11,287,000 | 19,058,000 |
| Income (loss) per share from continuing operations - basic | \$(1.27) | \$(0.58) | \$(2.06) | | | | | Income (loss) from operations | (5,115,000) | (9,914,000) | (6,525,000) |
| Earnings per share-inc from discontinued oper | \$0.00 | ... | ... | | | | | Interest income | 68,000 | ... | ... |
| Income (loss) per share from discontinued operations - basic | \$0.00 | \$0.00 | \$0.00 | | | | | Interest expense | 145,000 | 141,000 | 341,000 |
| Net income (loss) per share - basic | \$(1.27) | \$(0.58) | \$(2.06) | | | | | Income (loss) before income taxes & discontinued operations | (5,192,000) | (10,055,000) | (6,866,000) |
| Income (loss) per share from continuing operations - diluted | \$(1.27) | \$(0.58) | \$(2.06) | | | | | Current provision (benefit) for income taxes - federal | ... | ... | 39,000 |
| Earn per share-inc | | | | | | | | Total current provision (benefit) for income taxes | ... | ... | 39,000 |
| | | | | | | | | Deferred provision (benefit) for income taxes - federal | ... | ... | 1,040,000 |
| | | | | | | | | Total deferred provision (benefit) for income taxes | ... | ... | 1,040,000 |
| | | | | | | | | Income tax expense (benefit) | 9,000 | 63,000 | 1,079,000 |
| | | | | | | | | Income (loss) from continuing operations | ... | ... | (7,945,000) |
| | | | | | | | | Discontinued Operations before Tax - | | | |
| | | | | | | | | Income/Expense | 1,016,000 | 1,422,000 | ... |
| | | | | | | | | Income (loss) from discontinued operations, net of taxes | ... | ... | (3,146,000) |
| | | | | | | | | Gain on disposal, net | 4,565,000 | (155,000) | ... |
| | | | | | | | | Net income (loss) | 380,000 | (8,851,000) | (11,091,000) |
| | | | | | | | | Weighted average shares outstanding - basic | 12,927,000 | 12,758,000 | 12,678,000 |
| | | | | | | | | Weighted average shares outstanding - diluted | 12,927,000 | 12,758,000 | 12,678,000 |
| | | | | | | | | Year end shares | | | |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 796,100 | 1,927,100 |
| Investment securities | 4,928,700 | 4,272,100 |
| Trade accounts receivable, gross | 1,172,700 | 1,346,500 |
| Less allowance for doubtful accounts | 15,600 | 33,600 |
| Trade accounts receivable | 1,157,100 | 1,312,900 |
| Raw materials | ... | 3,703,900 |
| Work-in-process | ... | 66,700 |
| Finished goods | ... | 1,695,000 |
| Less: non-current portion | 4,883,900 | (606,000) |
| Inventories | ... | 4,859,600 |
| Income tax receivable | 161,400 | 161,400 |
| Prepaid expenses & other current assets | 413,500 | 456,800 |
| Total current assets | 12,340,700 | 12,989,900 |
| Automobiles | 22,000 | 22,000 |
| Computer equipment | 497,300 | 432,700 |
| Machinery & equipment | 1,624,300 | 1,533,000 |
| Furniture & fixtures | 108,500 | 105,200 |
| Leasehold improvements | 279,600 | 272,400 |
| Property & equipment, gross | 2,531,700 | 2,365,300 |
| Less accumulated depreciation | 1,449,400 | 1,202,100 |
| Property & equipment, net | 1,082,300 | 1,163,200 |
| Goodwill | 115,300 | 115,300 |
| Other intangible assets, net | 1,249,900 | 1,763,000 |
| Inventories | ... | 606,000 |
| Operating lease right-of-use assets | 1,273,900 | 1,373,600 |
| Other assets | 59,400 | 58,200 |
| Inventories - Long-Term | 609,000 | ... |
| Total assets | 16,730,500 | 18,069,200 |
| Accounts payable | 711,700 | 887,300 |
| Accrued expenses | 777,900 | 821,800 |
| Contract liabilities | ... | 134,400 |
| Lease liabilities, current portion | 324,100 | 276,900 |
| Billings in excess of costs & estimated earnings | 23,600 | ... |
| Total current liabilities | 1,837,300 | 2,120,400 |
| Lease liabilities, less current portion | 1,007,800 | 1,156,200 |
| Total liabilities | 2,845,100 | 3,276,600 |
| Common stock | 507,300 | 351,200 |
| Additional paid-in capital | 40,844,600 | 32,900,800 |
| Accumulated other comprehensive income (loss) | 18,600 | (8,400) |
| Accumulated deficit | (27,485,100) | ... |
| Retained earnings (accumulated deficit) | ... | (18,398,600) |
| Less common stock held in treasury at cost | ... | 52,400 |

□ For 6 months due to fiscal year end change; □ Restated to reflect change in it's deferred tax asset valuation or the Company's impairment of goodwill and intangible assets; □ As reported by the Company; □ As of April 12, 2023

| | | | |
|---|-------------|--------------|------------|
| outstanding | 13,006,000 | 12,797,000 | 12,727,000 |
| Income (loss) per share-continuing operations - basic | \$(0.40) | \$(0.79) | \$(0.63) |
| Income (loss) per share-discontinued operations - basic | \$0.43 | \$0.10 | \$(0.25) |
| Net income (loss) per share - basic | \$0.03 | \$(0.70) | \$(0.88) |
| Income (loss) per share-continuing operations - diluted | \$(0.40) | \$(0.79) | \$(0.63) |
| Income (loss) per share-discontinued operations - diluted | \$0.43 | \$0.10 | \$(0.25) |
| Net income (loss) per share - diluted | \$0.03 | \$(0.70) | \$(0.88) |
| Full-Time Employees (Period End) | 8 | ... | ... |
| Total number of employees | 8 | ... | 27 |
| Number of common stockholders | 612 | ... | 638 |
| Discontinued Operations - Net of Taxes | 5,581,000 | 1,267,000 | ... |
| Net Income Before Extraordinary and Preferred Dividends | (5,201,000) | (10,118,000) | ... |

□ Restated to reflect discontinued operations; □ Restated to reflect the sale of the Prell® product line as discontinued operations; □ Approximately; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-----------|
| | | (revised) | (revised) |
| Cash & cash equivalents | 3,677,000 | ... | ... |
| Cash | ... | 49,000 | ... |
| Restricted cash | 250,000 | ... | ... |
| Trade receivables, gross | 316,000 | ... | ... |
| Allowance for doubtful accounts | 9,000 | ... | ... |
| Accounts receivable, net | 307,000 | 1,833,000 | ... |
| Finished goods | 365,000 | 4,568,000 | ... |
| Raw materials | ... | 124,000 | ... |
| Inventories | 365,000 | 4,692,000 | ... |
| Income taxes receivable | ... | 239,000 | ... |
| Prepaid expenses | 207,000 | 243,000 | ... |
| Due from buyers | 145,000 | ... | ... |
| Total current assets | 4,951,000 | 7,056,000 | ... |
| Office furniture & equipment | ... | 151,000 | ... |
| Less accumulated depreciation | ... | 150,000 | ... |
| Property & equipment, net | ... | 1,000 | ... |
| Intangible assets, net | ... | 1,137,000 | ... |
| Operating lease right-of-use assets | 1,376,000 | 2,491,000 | ... |
| Other assets | 40,000 | 46,000 | ... |
| Total assets | 6,367,000 | 10,731,000 | ... |
| Accounts payable | 544,000 | 1,407,000 | ... |
| Accrued expenses | 19,000 | 311,000 | ... |
| Current portion of long-term debt, net of debt issuance costs | ... | 3,384,000 | ... |
| Operating lease liabilities, current portion | 291,000 | 270,000 | ... |
| Total current liabilities | 854,000 | 5,372,000 | ... |
| Operating lease liabilities, net of current | 2,221,000 | 2,512,000 | ... |
| Other liabilities | 27,000 | 27,000 | ... |
| Total liabilities | 3,102,000 | 7,911,000 | ... |
| Common stock | 1,301,000 | 1,280,000 | ... |
| Capital in excess of par | 7,956,000 | 7,912,000 | ... |
| Retained earnings (accumulated deficit) | (5,992,000) | (6,372,000) | ... |
| Total shareholders' equity (deficit) | 3,265,000 | 2,820,000 | ... |
| Total Equity | 3,265,000 | ... | ... |

Recent Dividends:

1. Scott's Liquid Gold, Inc. common.

No dividends paid.

Annual Dividends:

1. Scott's Liquid Gold, Inc. common.

No dividends paid.

SEAFARER EXPLORATION CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|---------------|---------------|---------------|
| | | | (revised) |
| Service income | 19,235 | 12,972 | 23,761 |
| Consulting & contractor expenses | 1,750,806 | 1,487,446 | 1,234,353 |
| Vessel maintenance & dockage | 330,070 | 158,496 | 109,182 |
| Research & development | 325,156 | 172,877 | 439,816 |
| Professional fees | 125,480 | 70,271 | 83,196 |
| General & administrative expense | 359,044 | 406,560 | 376,696 |
| Depreciation expense | 48,775 | 21,860 | 21,860 |
| Rent expense | 38,328 | 46,077 | 41,182 |
| Travel & entertainment expense | 93,067 | 74,768 | 63,096 |
| Total operating expenses | 3,070,726 | 2,438,355 | 2,369,381 |
| Income (loss) from operations | (3,051,491) | (2,425,383) | (2,345,620) |
| Interest expense | 104,801 | 62,268 | 177,499 |
| Gain (loss) on extinguishment of debt | (24,354) | (43,950) | (121,847) |
| Net gain (loss) on settlement of accounts payable | ... | ... | (448) |
| Proceeds from sale of asset | ... | ... | 20,000 |
| Loss on disposal of asset | ... | (85,000) | ... |
| Total other income (expenses) | ... | (191,218) | (279,794) |
| Net income (loss) before income taxes | (3,180,646) | (2,616,601) | (2,625,414) |
| Net income (loss) | (3,180,646) | (2,616,601) | (2,625,414) |
| Weighted average shares outstanding - basic | 7,741,579,477 | 6,686,861,948 | 5,645,802,431 |
| Weighted average shares outstanding - diluted | 7,741,579,477 | 6,686,861,948 | 5,645,802,431 |
| Year end shares outstanding | 8,314,141,446 | 7,172,668,896 | 6,176,318,579 |
| Net earnings per share - basic | ... | \$0.00 | \$0.00 |
| Net earnings per share - diluted | ... | \$0.00 | \$0.00 |
| Number of common stockholders | 2,187 | 2,101 | 2,054 |
| Service income | 19,235 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------|---------|------|
| Cash | 606,267 | 177,409 | ... |
| Deposits | 15,791 | 750 | ... |
| Total current assets | 622,058 | 178,159 | ... |
| Property, plant & equipment, net | 248,922 | 154,761 | ... |
| Right of Use Tangible Assets - Operating Lease | ... | ... | ... |
| - Gross | 37,502 | ... | ... |
| accumulated amortization | 7,212 | ... | ... |
| Right of use assets | 30,290 | 10,464 | ... |
| Total assets | 901,270 | 343,384 | ... |
| Accounts payable & | ... | ... | ... |

| | | | |
|--|--------------|--------------|-----|
| accrued expenses | 565,009 | 624,574 | ... |
| Deferred revenue | 140,000 | 140,000 | ... |
| Convertible notes payable - related parties, net | ... | 40,000 | ... |
| Convertible notes payable, in default | 355,300 | 235,300 | ... |
| Convertible notes payable, in default - related parties | 789,500 | 644,500 | ... |
| Notes payable, in default | 112,000 | 118,000 | ... |
| Notes payable, in default - related parties | ... | 18,500 | ... |
| Notes payable - related parties | 18,500 | ... | ... |
| Shareholder loan | 5,000 | 7,400 | ... |
| Lease liability, current | 18,483 | 10,807 | ... |
| Finance lease liability, current | 22,263 | ... | ... |
| Notes payable, net of discount of \$95,214 and \$0, respectively | 404,786 | ... | ... |
| Total current liabilities | 2,430,841 | 1,839,081 | ... |
| Lease liability, long-term | 11,974 | ... | ... |
| Finance lease liability, long-term | 99,917 | ... | ... |
| Total liabilities | 2,542,732 | 1,839,081 | ... |
| Common stock | 831,415 | 717,268 | ... |
| Common stock to be issued | 3,104 | 7,197 | ... |
| Unearned compensation | 18,935 | 488 | ... |
| Additional paid-in capital | 25,890,412 | 22,947,138 | ... |
| Retained earnings (accumulated deficit) | (28,347,458) | (25,166,812) | ... |
| Total stockholders' equity (deficit) | (1,641,462) | (1,495,697) | ... |
| Total Equity | (1,641,462) | ... | ... |

Recent Dividends:

1. Seafarer Exploration Corp series A preferred.

No dividends paid.

2. Seafarer Exploration Corp common.

No dividends paid.

3. Seafarer Exploration Corp mezzanine common.

No dividends paid.

4. Seafarer Exploration Corp series B preferred.

No dividends paid.

Annual Dividends:

1. Seafarer Exploration Corp series A preferred.

No dividends paid.

2. Seafarer Exploration Corp common.

No dividends paid.

3. Seafarer Exploration Corp mezzanine common.

No dividends paid.

4. Seafarer Exploration Corp series B preferred.

No dividends paid.

SELLAS LIFE SCIENCES GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Licensing revenue | ... | 1,000,000 | 7,600,000 |
| Cost of revenue | ... | 100,000 | 200,000 |
| Research & development | 24,007,000 | 20,268,000 | 15,674,000 |
| General & administrative | 13,862,000 | 12,582,000 | 11,320,000 |
| Acquired in-process research & development | ... | 10,000,000 | ... |
| In-process research & development impairment charge | ... | ... | 5,700,000 |
| Total operating expenses | 37,869,000 | 42,950,000 | 32,894,000 |
| Income (loss) from operations | (37,869,000) | (41,950,000) | (25,294,000) |
| Gain (loss) on warrant derivative liability | 4,000 | ... | ... |
| Change in fair value of warrant liability | ... | 36,000 | 15,000 |

| | | | | | | | | | | |
|---|--------------|--------------|--------------|---|---------------|---------------|---|--------------|--------------|------------|
| Change in fair value of contingent consideration | ... | (296,000) | (4,337,000) | Accrued compensation & related benefits | 1,493,000 | 1,439,000 | class B shares outstanding - diluted | ... | ... | 5,418,853 |
| Interest income | 525,000 | 317,000 | 6,000 | Clinical trial costs | 42,000 | 4,509,000 | General and administrative | 37,176,000 | 38,225,000 | ... |
| Total non-operating income (expense), net | 529,000 | 649,000 | 4,358,000 | Operating lease liabilities | 446,000 | 372,000 | Weighted average shares outstanding - diluted | 44,372,223 | 44,062,534 | ... |
| Income before income taxes - United States | ... | (17,825,000) | (6,956,000) | Acquired in-process research & development payable | ... | 5,500,000 | Year end shares outstanding | 45,700,161 | 44,062,534 | 29,465,500 |
| Income before income taxes - non - U.S. | ... | (23,476,000) | (13,980,000) | Clinical trial costs | 5,672,000 | ... | Net income (loss) per class A share - basic | ... | ... | \$(0.17) |
| Income (loss) before income taxes | (37,340,000) | (41,301,000) | (20,936,000) | Total current liabilities | 13,735,000 | 15,515,000 | Net income (loss) per class B share - basic | ... | ... | \$(0.17) |
| Current state income tax expense | ... | ... | 2,000 | Operating lease liabilities, non-current | 460,000 | 573,000 | Net income (loss) per share - basic | \$(1.60) | \$(1.32) | ... |
| Total current income tax expense | ... | ... | 2,000 | Warrant liability | ... | 4,000 | Net income (loss) per class A share - diluted | ... | ... | \$(0.17) |
| Deferred federal income tax expense (benefit) | ... | ... | (239,000) | Total liabilities | 14,195,000 | 16,092,000 | Net income (loss) per class B share - diluted | ... | ... | \$(0.17) |
| Total deferred income tax expense (benefit) | ... | ... | (239,000) | Common stock | 3,000 | 2,000 | Net income (loss) per share - diluted | \$(1.60) | \$(1.32) | ... |
| Income tax expense (benefit) | ... | ... | (237,000) | Additional paid-in capital | 209,265,000 | 184,753,000 | Total number of employees | ... | ... | 4 |
| Net income (loss) | (37,340,000) | (41,301,000) | (20,699,000) | Retained earnings (accumulated deficit) | ... | (179,904,000) | Income from cont operations before income tax | (83,406,000) | (49,665,000) | ... |
| Net income (loss) attributable to common stockholders | ... | (41,301,000) | (20,699,000) | Accumulated deficit | (217,244,000) | ... | Income from continuing operations | (83,406,000) | (49,665,000) | ... |
| Weighted average shares outstanding - basic | 27,777,111 | 19,395,709 | 15,481,113 | Total stockholders' equity | (7,976,000) | 4,851,000 | Change in fair value of contingent earnout liability | 207,000 | 9,461,000 | ... |
| Weighted average shares outstanding - diluted | 27,777,111 | 19,395,709 | 15,481,113 | Total Equity | (7,976,000) | ... | Other income (expense) | (33,000) | (32,000) | ... |
| Year end shares outstanding | 32,132,890 | 21,005,405 | 15,895,637 | Recent Dividends: | | | GeneFab sublease income - related party | 2,323,000 | ... | ... |
| Earnings per share from continuing operations - basic | \$(1.34) | ... | ... | 1. SELLAS Life Sciences Group Inc common. No dividends paid. | | | Change in fair value of GeneFab Note Receivable - related party | 626,000 | ... | ... |
| Net income (loss) per common share - basic | \$(1.34) | \$(2.13) | \$(1.34) | Annual Dividends: | | | Change in fair value of GeneFab Economic Share - related party | 16,000 | ... | ... |
| Earnings per share from continuing operations - diluted | \$(1.34) | ... | ... | 1. SELLAS Life Sciences Group Inc common. No dividends paid. | | | Change in fair value of GeneFab Option - related party | 3,318,000 | ... | ... |
| Net income (loss) per common share - diluted | \$(1.34) | \$(2.13) | \$(1.34) | SEMILEDS CORP | | | Gain on extinguishment of convertible notes | ... | 1,289,000 | ... |
| Number of full time employees | ... | 17 | 11 | Earnings, 6 mos. to (Consol. - \$000): | | | Non-Operating Income/Expense - Total | 9,321,000 | 12,419,000 | ... |
| Number of common stockholders | 35 | 27 | 30 | Total revenues | 2,536 | 2,847 | Total operating expenses | 95,288,000 | 66,370,000 | ... |
| | | | | Cost & expenses | 4,187 | 4,203 | Impairment of property and equipment | 25,962,000 | ... | ... |
| | | | | Operating income | (1,651) | (1,356) | Discontinued Operations - Net - Income/Expense | 12,348,000 | (8,545,000) | ... |
| | | | | Interest expense | ... | 152 | EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| | | | | Other income (expense), net | 636 | 471 | Applicable to Common - Total | \$(1.88) | \$(1.13) | ... |
| | | | | Gains or losses | 3 | ... | EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| | | | | Foreign currency | 12 | (17) | Common Shareholders - Number | 63 | ... | ... |
| | | | | Net before taxes | (1,153) | (1,054) | Earning per share-total discounters - diluted | \$0.28 | \$(0.19) | ... |
| | | | | Net income | (1,153) | (1,054) | Earnings per | ... | ... | ... |
| | | | | Earnings common share | ... | ... | | | | |
| | | | | Primary | \$(0.24) | \$(0.22) | | | | |
| | | | | Fully Diluted | \$(0.24) | \$(0.22) | | | | |
| | | | | Common Shares: | ... | ... | | | | |
| | | | | Full Diluted | 4,907 | 4,841 | | | | |
| | | | | Year-end | 7,175 | 4,892 | | | | |
| | | | | SENTI BIOSCIENCES INC | | | | | | |
| | | | | Annual Report | | | | | | |
| | | | | Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | | | |
| | | | | 2023 | 2022 | 2021 | | | | |
| | | | | | (revised) | | | | | |
| | | | | Professional fees & other expenses | 32,150,000 | 28,145,000 | 3,702,033 | | | |
| | | | | Franchise tax expense | ... | ... | 163,839 | | | |
| | | | | Income (loss) from operations | (92,727,000) | (62,084,000) | (3,865,872) | | | |
| | | | | Interest & dividend income on investments held in trust account | 2,864,000 | 1,701,000 | 8,784 | | | |
| | | | | Grant income | 583,000 | 1,000,000 | ... | | | |
| | | | | Contract revenue | 1,978,000 | 3,286,000 | ... | | | |
| | | | | Net income (loss) | (71,058,000) | (58,210,000) | (3,857,088) | | | |
| | | | | Total revenues | 2,561,000 | 4,286,000 | ... | | | |
| | | | | Weighted average class A shares outstanding - basic | ... | ... | 16,872,995 | | | |
| | | | | Weighted average class B shares outstanding - basic | ... | ... | 5,418,853 | | | |
| | | | | Weighted average shares outstanding - basic | 44,372,223 | 44,062,534 | ... | | | |
| | | | | Weighted average class A shares outstanding - diluted | ... | ... | 16,872,995 | | | |
| | | | | Weighted average | ... | ... | ... | | | |
| | | | | Cash & cash equivalents | 2,530,000 | 17,125,000 | ... | | | |
| | | | | Restricted cash & cash equivalents | ... | 100,000 | ... | | | |
| | | | | Restricted cash | 100,000 | ... | ... | | | |
| | | | | Clinical development | 399,000 | ... | ... | | | |
| | | | | Insurance | ... | 219,000 | ... | | | |
| | | | | Clinical trial costs | 87,000 | 184,000 | ... | | | |
| | | | | Professional fees | 56,000 | 82,000 | ... | | | |
| | | | | Other prepaid expenses & current assets | ... | 46,000 | ... | | | |
| | | | | Prepaid expenses & other current assets | 542,000 | 531,000 | ... | | | |
| | | | | Total current assets | 3,172,000 | 17,756,000 | ... | | | |
| | | | | Operating lease right-of-use assets | 858,000 | 874,000 | ... | | | |
| | | | | Goodwill | 1,914,000 | 1,914,000 | ... | | | |
| | | | | Deposits & other assets | 275,000 | 399,000 | ... | | | |
| | | | | Total assets | 6,219,000 | 20,943,000 | ... | | | |
| | | | | Accounts payable | 5,639,000 | 3,357,000 | ... | | | |

□ Shares increased due to the effect of issuance of common stock, warrants under employee stock purchase plan and vesting of restricted stock units; □ As of March 1, 2023; □ Approximately; □ As of March 15, 2023; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash & cash equivalents | 2,530,000 | 17,125,000 |
| Restricted cash & cash equivalents | ... | 100,000 |
| Restricted cash | 100,000 | ... |
| Clinical development | 399,000 | ... |
| Insurance | ... | 219,000 |
| Clinical trial costs | 87,000 | 184,000 |
| Professional fees | 56,000 | 82,000 |
| Other prepaid expenses & current assets | ... | 46,000 |
| Prepaid expenses & other current assets | 542,000 | 531,000 |
| Total current assets | 3,172,000 | 17,756,000 |
| Operating lease right-of-use assets | 858,000 | 874,000 |
| Goodwill | 1,914,000 | 1,914,000 |
| Deposits & other assets | 275,000 | 399,000 |
| Total assets | 6,219,000 | 20,943,000 |
| Accounts payable | 5,639,000 | 3,357,000 |

| | | | | | | |
|--------------------------|--------|----------|----------------------------|------------|-------------|--|
| share-total | | | Total stockholders' | | | |
| discontinued opers . . . | \$0.28 | \$(0.19) | equity (deficit) | 66,913,000 | 127,263,000 | |
| | | | Total Equity | 66,913,000 | 127,263,000 | |

Net loss (5,627,591)

[Ⓐ] Restated to reflect discontinued operations; [Ⓑ] From March 1, 2021 (date of inception)

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|--|---------------|-------------------|
| Prepaid expenses (including prepaid rent) | 2,546,000 | 1,871,000 |
| GeneFab prepaid expenses related party | 14,787,000 | ... |
| Cash and cash equivalents | 35,926,000 | 57,621,000 |
| Deposits | 42,000 | 1,418,000 |
| Other | 195,000 | 101,000 |
| Accounts receivable | 112,000 | 626,000 |
| Prepaid expenses and other current assets | 2,783,000 | 3,390,000 |
| GeneFab receivable related party | 17,592,000 | ... |
| Short-term investments | ... | 40,942,000 |
| Total current assets | 71,200,000 | 102,579,000 |
| Restricted cash | 3,522,000 | 3,366,000 |
| accumulated depreciation | 6,182,000 | 2,986,000 |
| Property and equipment at cost | 31,520,000 | 59,122,000 |
| Leasehold improvements | 22,648,000 | 1,869,000 |
| Furniture and fixtures | 326,000 | 326,000 |
| Computer equipment and software | 360,000 | 389,000 |
| Lab equipment | 8,186,000 | 8,265,000 |
| Construction in progress | ... | 48,273,000 |
| Property and equipment, net | 25,338,000 | 56,136,000 |
| Operating lease right-of-use assets | 16,274,000 | 18,418,000 |
| Other long-term assets | 215,000 | 293,000 |
| GeneFab receivable - related party, net of current portion | 1,119,000 | ... |
| GeneFab Economic Share - related party | 1,816,000 | ... |
| Total Non-Current Assets | ... | 78,213,000 |
| Total assets | 119,484,000 | 180,792,000 |
| Accounts payable & other current liabilities | 1,250,000 | 2,267,000 |
| Early exercise liability, current portion | 135,000 | 135,000 |
| Accrued expenses and other current liabilities | 5,927,000 | 12,864,000 |
| Operating lease liabilities | 4,031,000 | 1,988,000 |
| Accrued employee-related expenses | 2,363,000 | 3,743,000 |
| Accrued expenses and other current liabilities - Balancing value | 3,564,000 | 9,121,000 |
| Finance lease liabilities - related party, current portion | 97,000 | ... |
| GeneFab sublease deferred income - related party | 989,000 | 799,000 |
| Current liabilities of discontinued operations | 243,000 | ... |
| Total current liabilities | 12,672,000 | 18,053,000 |
| Operating lease liabilities, net of current portion | 33,538,000 | 35,103,000 |
| Contingent earnout liability | 20,000 | 227,000 |
| Early exercise liability, net of current portion | 10,000 | 146,000 |
| GeneFab Option - related party | 6,331,000 | ... |
| Total Non-Current Liabilities | ... | 35,476,000 |
| Total liabilities | 52,571,000 | 53,529,000 |
| Class A common stock | 5,000 | 4,000 |
| Additional paid-in capital | 311,252,000 | 300,544,000 |
| Retained earnings (accumulated deficit) | (244,344,000) | (173,286,000) |
| Accumulated other comprehensive income | ... | 1,000 |

Recent Dividends:

1. Senti Biosciences Inc class B common.

No dividends paid.

2. Senti Biosciences Inc common.

No dividends paid.

3. Senti Biosciences Inc class A common.

No dividends paid.

Annual Dividends:

1. Senti Biosciences Inc class B common.

No dividends paid.

2. Senti Biosciences Inc common.

No dividends paid.

3. Senti Biosciences Inc class A common.

No dividends paid.

SEQLL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
|--|--------------------|------------------------|--------------------------------|
| Sales | ... | 1,177 | 48,021 |
| Grant revenue | ... | 77,482 | 161,974 |
| Total revenue | ... | 78,659 | 209,995 |
| Cost of sales | ... | 690 | 57,690 |
| Gross profit | ... | 77,969 | 152,305 |
| Research & development expense | 2,253,354 | 1,568,266 | 530,076 |
| General & administrative expense | 3,479,155 | 2,506,851 | 2,170,857 |
| Total operating expenses | 5,732,509 | 4,075,117 | 2,700,933 |
| Operating income (loss) | (5,732,509) | (3,997,148) | (2,548,628) |
| Investment income | 82,665 | ... | ... |
| Interest & dividend income | ... | 44,879 | 36,463 |
| Other income | ... | ... | 190,193 |
| Unrealized gain (loss) on marketable equity securities | ... | 54,508 | (43,078) |
| Realized gain (loss) on marketable equity securities | 106,051 | (106,324) | ... |
| Change in fair value of convertible notes | ... | ... | (195,962) |
| Gain (loss) on extinguishment of convertible notes | ... | ... | (934,257) |
| Interest Expense on Financial Lease Liabilities | 15,428 | ... | ... |
| Interest expense - Balancing value | 68,370 | ... | ... |
| Interest expense | 83,798 | 90,748 | 208,289 |
| Net income (loss) | (5,627,591) | (4,094,833) | (3,703,558) |
| Weighted average shares outstanding - basic | 374,484 | [Ⓐ] 297,159 | 180,400 |
| Weighted average shares outstanding - diluted | 374,484 | [Ⓐ] 297,159 | 180,400 |
| Year end shares outstanding | 380,648 | [Ⓐ] 297,159 | [Ⓐ] 297,159 |
| Net earnings (loss) per share - basic | \$(15.03) | [Ⓐ] \$(13.60) | \$(20.40) |
| Net earnings (loss) per share - diluted | \$(15.03) | [Ⓐ] \$(13.60) | \$(20.40) |
| Full-Time Employees (Period End) | 7 | ... | ... |
| Total number of employees | 7 | 7 | 7 |
| Common Shareholders - Number | 17 | ... | ... |
| Number of stockholders | ... | [Ⓐ] 17 | [Ⓐ] 22 |

[Ⓐ] Reclassified to conform with 2022 presentation; [Ⓑ] Adjusted for 1-for-40 stock split, August 31, 2023; [Ⓒ] Shares increased due to the effect of conversion of preferred stock and convertible notes into common stock, and issuance of common stock to underwriters, units and warrants in initial public offering; [Ⓓ] As of March 1, 2023; [Ⓔ] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 2,693,991 | 2,180,525 |
| Marketable securities | ... | 4,036,014 |
| Accounts receivable, gross | 27,230 | 27,230 |
| Allowance for doubtful accounts | 24,507 | 6,016 |
| Accounts receivable, net | 2,723 | 21,214 |
| Other receivables | ... | 60,000 |
| Raw materials | ... | 114,175 |
| Work in process | ... | 51,677 |
| Inventory | ... | 165,852 |
| Prepaid expenses | 32,933 | 171,859 |
| Total current assets | 2,729,647 | 6,635,464 |
| Lab equipment | 739,557 | 767,010 |
| Leasehold improvements | 357,006 | 312,758 |
| Office equipment | ... | 23,193 |
| Other property & equipment | 23,193 | ... |
| Property & equipment, gross | 1,119,756 | 1,102,961 |
| Less: accumulated depreciation | 494,396 | 572,853 |
| Property & equipment, net | 625,360 | 530,108 |
| Operating lease right-of-use asset | 998,346 | 1,129,715 |
| Other assets | 83,008 | 118,954 |
| Total assets | 4,436,361 | 8,414,241 |
| Accounts payable | 522,940 | 622,436 |
| Accrued interest | 375,191 | 306,821 |
| Accrued bonuses | ... | 135,000 |
| Other accrued expenses | 375,191 | 53,641 |
| Accrued expenses | ... | 495,462 |
| Non-convertible promissory notes - current portion | 1,375,000 | ... |
| Operating lease liabilities | 198,314 | 110,114 |
| Current portion of finance lease liability | 59,659 | ... |
| Total current liabilities | 2,531,104 | 1,228,012 |
| Operating lease liability, less current portion | 1,246,033 | 1,444,343 |
| Non-convertible promissory notes - long-term | ... | 1,375,000 |
| Finance lease liability, less current portion | 51,481 | ... |
| Total non-current liabilities | 1,297,514 | 2,819,343 |
| Total liabilities | 3,828,618 | 4,047,355 |
| Common stock | 4 | 119 |
| Additional paid-in capital | 24,744,014 | 22,853,000 |
| Accumulated deficit | (24,136,275) | ... |
| Retained earnings (accumulated deficit) | ... | (18,508,684) |
| Accumulated other comprehensive income (loss) | ... | 22,451 |
| Total stockholders' equity (deficit) | 607,743 | 4,366,886 |
| Total Equity | 607,743 | ... |

Recent Dividends:

1. SeqLL Inc common.

No dividends paid.

Annual Dividends:

1. SeqLL Inc common.

No dividends paid.

SHARPS TECHNOLOGY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|--------------------|--------------------|--------------------|
| Research & development | 1,605,547 | 2,280,933 | 1,690,865 |
| General & administrative | 8,521,103 | 6,457,860 | 2,806,801 |
| Total operating expenses | 10,126,650 | 8,738,793 | 4,497,666 |
| Income (loss) from operations | (10,126,650) | (8,738,793) | (4,497,666) |
| Interest income (expense) | 138,118 | (1,320,416) | (166,746) |
| Fair market value adjustment on contingent stock & warrants | 169,583 | 5,392,911 | ... |
| Foreign currency & other income (expense) | ... | 26,636 | ... |
| Net income (loss) | (9,841,638) | (4,639,662) | (4,664,412) |
| Weighted average shares outstanding - basic | 13,032,717 | 8,100,410 | 4,876,899 |
| Weighted average shares outstanding - diluted | 13,032,717 | 8,100,410 | 4,876,899 |
| Year end shares outstanding | 15,274,457 | 9,407,415 | 5,187,062 |
| Net income (loss) per share - basic | \$(0.76) | \$(0.57) | \$(0.96) |
| Net income (loss) per share - diluted | \$(0.76) | \$(0.57) | \$(0.96) |
| Number of full time employees | ... | 58 | 3 |
| Number of common stockholders | ... | 117 | 113 |
| Foreign currency translation adjustments | ... | 214,253 | ... |
| Foreign currency and other | (52,689) | ... | ... |
| Income from cont operations before income tax | (9,871,638) | ... | ... |
| Deferred tax benefit | (30,000) | ... | ... |
| Income Taxes - Total | (30,000) | ... | ... |

¹ Non-consolidated; ² Adjusted for 1-for-3.5 reverse stock split, March 22, 2022; ³ Shares increased due to the effect of issuance of shares for contingent share liability and services, issuance of shares in Initial Public Offering and fractional share adjustment; ⁴ Approximately; ⁵ As of March 27, 2023; ⁶ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash | 3,012,908 | 4,170,897 |
| Prepaid expenses | 116,508 | ... |
| Prepaid expenses & other current assets | ... | 66,749 |
| Raw materials | 254,461 | 106,088 |
| Work in process | 170,464 | 49,144 |
| Finished goods | 1,284,210 | 30,572 |
| Inventories | 1,709,135 | 185,804 |
| Current assets | 4,838,551 | 4,423,450 |
| Land | 260,460 | 242,240 |
| Building | 3,022,490 | 2,824,481 |
| Machinery & equipment | 4,464,317 | 4,601,293 |
| Website | 290,661 | 16,600 |
| Fixed assets, at cost | 8,037,928 | 7,684,614 |
| Less: accumulated depreciation | 1,215,786 | 679,724 |
| Fixed assets, net of accumulated depreciation | 6,822,142 | 7,004,890 |
| Intangibles, net | ... | 62,480 |
| Deposits or advance payments on machinery, molds & components | ... | 336,466 |

| | | |
|---|--------------|--------------|
| Other assets | ... | 12,370 |
| Other assets | 128,575 | 411,316 |
| Total assets | 11,789,268 | 11,839,656 |
| Accounts payable & accrued liabilities | 794,107 | 854,684 |
| Warrant liability | 2,422,785 | 1,151,838 |
| Accrued and other current liabilities | 476,090 | ... |
| Total current liabilities | 3,692,982 | 2,006,522 |
| Deferred tax liability | 162,000 | 192,000 |
| Total liabilities | 3,854,982 | 2,198,522 |
| Common stock | 1,528 | 941 |
| Additional paid-in capital | 32,489,950 | 24,733,306 |
| Accumulated other comprehensive income (loss) | 591,812 | 214,253 |
| Retained earnings (accumulated deficit) | (25,149,004) | (15,307,366) |
| Total stockholders' equity | 7,934,286 | 9,641,134 |
| Total Equity | 7,934,286 | ... |

Recent Dividends:**1. Sharps Technology Inc preferred.**

No dividends paid.

2. Sharps Technology Inc common.

No dividends paid.

Annual Dividends:**1. Sharps Technology Inc preferred.**

No dividends paid.

2. Sharps Technology Inc common.

No dividends paid.

SHIMMICK CORP**Annual Report****Consolidated Income Statement, Years Ended (\$000):**

| | 12/29/23 | 12/30/22 | 12/31/21 |
|--|----------------|--------------|---------------|
| Revenue | 632,806 | ... | ... |
| Revenue | 632,806 | 664,158 | 572,666 |
| Cost of revenue | 610,434 | 640,643 | 705,470 |
| Gross margin | 22,372 | 23,515 | (132,804) |
| Selling, general and administrative expenses | 61,507 | 60,442 | 77,519 |
| Amortization of intangible | 2,618 | 2,632 | 2,632 |
| Total operating expenses | 64,125 | 63,074 | 80,151 |
| Equity in earnings of unconsolidated joint ventures | ... | 52,471 | 1,067 |
| Income (loss) from operations | ... | 12,912 | (211,888) |
| Bargain purchase gain | ... | ... | 233,147 |
| Other (expense) income | (2,721) | (8,731) | 453 |
| Net income before income taxes | (2,286) | 4,181 | 21,712 |
| Current federal income taxes | ... | 1,030 | ... |
| Current state income taxes | ... | 244 | ... |
| Total current taxes | ... | 1,274 | ... |
| Deferred federal income taxes | ... | ... | (19,262) |
| Deferred state income taxes | ... | ... | (4,860) |
| Deferred income taxes | ... | ... | (24,122) |
| Income tax (expense) benefit | ... | 1,274 | (24,122) |
| Net income (loss) | (2,286) | 2,907 | 45,834 |
| Net (loss) income attributable to non-controlling interests | (260) | 853 | (431) |
| Net income attributable to SCCI National Holdings, Inc. and Subsidiaries | (2,546) | 3,760 | 45,403 |

| | | | |
|---|----------|--------|--------|
| Weighted average shares outstanding - basic | 25,494 | 21,909 | 21,909 |
| Weighted average shares outstanding - diluted | 25,494 | 21,909 | 21,909 |
| Year end shares outstanding | 25,494 | 21,909 | 21,909 |
| Net income (loss) per share - basic | \$(0.10) | \$0.17 | \$2.07 |
| Net income (loss) per share - diluted | \$(0.10) | \$0.17 | \$2.07 |
| Full-Time Employees (Period End) | 1,300 | ... | ... |
| Total number of employees | 1,300 | 1,500 | ... |
| Number of common stockholders | 5 | 4 | ... |
| Equity in earnings of unconsolidated joint ventures | 10,354 | ... | ... |
| Gain on sale of assets | 31,834 | ... | ... |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.10) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.10) | ... | ... |

Consolidated Balance Sheet, Years Ended (\$000):

| | 12/29/23 | 12/30/22 |
|--|----------|----------|
| Cash and cash equivalents | 62,939 | 77,762 |
| Restricted cash | 971 | 4,323 |
| Accounts receivable, gross | 55,202 | 57,395 |
| Allowance for doubtful accounts | 1,024 | 965 |
| Accounts receivable, net | 54,178 | 56,430 |
| Costs and estimated earnings in excess of billings on uncompleted contracts | 125,943 | 80,901 |
| Due from unconsolidated joint ventures | ... | 313 |
| Prepays and other current assets | 13,427 | 13,747 |
| Total current assets | 257,458 | 233,476 |
| Building and land | 4,002 | 3,887 |
| Machinery, equipment, and vehicles | 70,250 | 67,698 |
| Office furniture and equipment | 9,324 | 7,891 |
| Property, plant and equipment, gross | 83,576 | 79,476 |
| Accumulated depreciation | 37,203 | 24,268 |
| Property, plant and equipment, net | 46,373 | 55,208 |
| Intangible assets, net | 9,244 | 12,044 |
| Costs and estimated earnings in excess of billings on uncompleted contracts, non-current | 48,316 | 35,219 |
| Retainage receivable | ... | 48,805 |
| Lease right-of-use assets | 23,855 | 22,690 |
| Investment in unconsolidated joint ventures | 21,283 | 17,363 |
| Deferred tax assets | 17,252 | 18,851 |
| Other assets | 2,871 | 3,143 |
| Operating Lease right of use asset | 23,568 | ... |
| Finance lease right of use asset | 287 | ... |
| Total assets | 426,652 | 446,799 |
| Accounts payable | 81,589 | 67,541 |
| Billings on uncompleted contracts in excess of costs and estimated | ... | ... |

| | | | | | | | | | |
|--|---------|---------|---|--------------|--------------|-------------|---|--------------|--------------|
| earnings | 115,785 | 55,117 | A preferred Stock | 202,599 | ... | ... | Accounts payable & accrued interest - related party | 4,716,964 | 566,636 |
| Forward loss reserve | ... | 108,608 | Net income (loss) | (14,328,348) | (12,839,968) | (3,746,138) | Contract liability | 77,124 | 60,932 |
| Accrued salaries, wages and benefits | 26,911 | 36,248 | Weighted average shares outstanding - basic | 619,986 | 171,658 | 111,612 | Contract liability - related party | ... | 14,982 |
| Construction accruals | ... | 60,758 | Weighted average shares outstanding - diluted | 619,986 | 171,658 | 111,612 | Factoring liability | ... | 502,349 |
| Other current liabilities | 13,071 | 12,672 | Year end shares outstanding | 1,083,173 | 180,227 | 165,740 | Deferred revenue - related party | 43,173 | ... |
| Accrued Expenses | 33,897 | ... | Net income (loss) per share - basic | \$(23.11) | \$(75.00) | \$(34.00) | Note payable | 2,587,900 | 1,599,150 |
| Total current liabilities | 271,253 | 340,944 | Net income (loss) per share - diluted | \$(23.11) | \$(75.00) | \$(34.00) | Operating lease liability | 119,272 | 199,158 |
| Lease liabilities, bon-current | 15,045 | 14,442 | Number of full time employees | 72 | 64 | 37 | Accounts payable and accrued interest - related party | 677,039 | ... |
| Billings on uncompleted contracts in excess of costs and estimated earnings, non-current | 3,215 | 1,846 | Number of part time employees | 10 | 7 | ... | Notes payable | 2,017,286 | ... |
| Contingent consideration | 15,488 | 15,662 | Number of class A common stockholders | 9,327 | 6,873 | 29 | Credit card liability | 93,826 | ... |
| Deferred tax liabilities | 17,252 | 18,851 | Net Income After Extraordinary Items applicable to Common | (14,530,947) | ... | ... | Dividends/Distributions Payable | 16,566 | ... |
| Other liabilities | 4,282 | 3,459 | Total number of employees | 82 | ... | ... | Total current liabilities | 12,219,356 | 6,359,052 |
| Long-Term Debt | 29,627 | ... | Adjusted for 1-for-100 stock split, December 20, 2023; As of March 15, 2023; As of March 31, 2022 | ... | ... | ... | Operating lease liability - non-current | ... | 63,310 |
| Operating Lease Liabilities - Long-Term | 15,017 | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | 2023 | 2022 | ... | Total liabilities | 12,219,356 | 6,422,362 |
| Capitalized Lease Obligations - Long-Term | 28 | ... | | | | | Class A common stock | 98 | 802 |
| Total liabilities | 356,162 | 395,204 | | | | | Class B common stock | 10 | 1,000 |
| Common Stock - Issued & Paid | 255 | ... | | | | | Additional paid-in capital | 49,918,441 | 32,129,257 |
| Common stock | ... | 219 | | | | | Accumulated deficit | (42,786,793) | ... |
| Additional paid-in-capital | 24,445 | 3,341 | | | | | Retained earnings (accumulated deficit) | ... | (28,255,846) |
| Retained earnings | 46,537 | 49,083 | | | | | Total stockholders' equity (deficit) | 7,131,756 | 3,875,213 |
| Non-controlling interests | (747) | (1,048) | | | | | Total Equity | 7,131,756 | ... |
| Total stockholders' equity (deficit) | 70,490 | 51,595 | | | | | | | |
| Total Equity | 70,490 | ... | | | | | | | |

Recent Dividends:

1. Shimmick Corp common. No dividends paid.

Annual Dividends:

1. Shimmick Corp common. No dividends paid.

SIDUS SPACE INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------|--------------|----------------|
| Revenue | 5,010,565 | 6,250,780 | 789,400 |
| Revenue - related parties | 952,220 | 1,042,628 | 619,324 |
| Total - revenue | 5,962,785 | 7,293,408 | 1,408,724 |
| Cost of revenue | 4,321,482 | 5,855,275 | 1,775,299 |
| Gross profit (loss) | 1,641,303 | 1,438,133 | (366,575) |
| Payroll expenses | 5,553,025 | 1,503,236 | ... |
| Sales & marketing expenses | 559,096 | 71,111 | ... |
| Lease expense | 338,389 | 253,311 | ... |
| Depreciation expense | 138,930 | 34,767 | ... |
| Professional fees | 2,461,077 | 335,604 | ... |
| General & administrative expense | 14,166,617 | 4,431,915 | 948,928 |
| Total operating expenses | 14,166,617 | 13,482,432 | 3,146,957 |
| Net income (loss) from operations | (12,525,314) | (12,044,299) | (3,513,532) |
| Other income | 17,950 | ... | ... |
| Other expense | ... | ... | 504 |
| Interest expense | 747,420 | 781,376 | 42,882 |
| Interest expense - related party | 917,848 | ... | 54,145 |
| Factoring expense | ... | 14,293 | ... |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 633,830 |
| Finance expense | ... | ... | 768,905 |
| Asset-based loan expense | 155,716 | ... | ... |
| Total other income (expense) | (1,803,034) | (795,669) | (232,606) |
| Income (loss) before income taxes | (14,328,348) | (12,839,968) | (3,746,138) |
| Dividend on Series | ... | ... | ... |

| | | | |
|--|------------|------------|-----|
| Cash | 1,216,107 | 2,295,259 | ... |
| Accounts receivable, gross | ... | 872,840 | ... |
| Less: allowance for doubtful accounts | ... | 22,500 | ... |
| Accounts receivable, net | 1,175,077 | 850,340 | ... |
| Accounts receivable - related parties | 67,447 | 168,170 | ... |
| Work in process | ... | 583,437 | ... |
| Inventory | 1,217,929 | 583,437 | ... |
| Contract asset | 77,124 | 60,932 | ... |
| Contract asset - related party | 43,173 | 14,982 | ... |
| Prepaid insurance | ... | 994,450 | ... |
| Prepaid components & licenses | ... | 950,679 | ... |
| Prepaid satellite service | ... | 1,367,125 | ... |
| Other prepaid expense | ... | 110,984 | ... |
| VAT receivable | ... | 7,204 | ... |
| Other current assets | ... | 46,306 | ... |
| Prepaid & other current assets | 5,405,453 | 3,476,748 | ... |
| Total current assets | 9,202,310 | 7,449,868 | ... |
| Office equipment | 482,127 | 17,061 | ... |
| Computer equipment | 41,233 | 37,296 | ... |
| Vehicle | 35,424 | 28,143 | ... |
| Software | ... | 158,212 | ... |
| Machinery | 3,209,719 | 3,386,111 | ... |
| Research & development software | ... | 386,182 | ... |
| Leasehold improvements | 397,536 | 372,867 | ... |
| Construction in progress | 8,609,902 | 1,497,276 | ... |
| Office equipment | 17,061 | ... | ... |
| Capitalized R&D cost | 9,655 | ... | ... |
| Property & equipment, gross | 12,802,657 | 5,883,148 | ... |
| Accumulated depreciation | 3,232,443 | 3,328,156 | ... |
| Property & equipment, net | 9,570,214 | 2,554,992 | ... |
| Operating lease right-of-use assets | 115,573 | 249,937 | ... |
| Other assets | 64,880 | 42,778 | ... |
| Intangible asset | 398,135 | ... | ... |
| Total assets | 19,351,112 | 10,297,575 | ... |
| Accounts payable | ... | 1,483,467 | ... |
| Payroll liabilities | 1,250,330 | 820,451 | ... |
| Credit cards | ... | 44,650 | ... |
| Other payable | 156,885 | 239,110 | ... |
| Insurance payable | 462,991 | 828,167 | ... |
| Accounts payable & other current liabilities | 6,697,562 | 3,415,845 | ... |

Recent Dividends:

1. Sidus Space Inc class B common.

No dividends paid.

2. Sidus Space Inc Series A convertible preferred.

No dividends paid.

3. Sidus Space Inc class A common.

No dividends paid.

Annual Dividends:

1. Sidus Space Inc class B common.

No dividends paid.

2. Sidus Space Inc Series A convertible preferred.

No dividends paid.

3. Sidus Space Inc class A common.

No dividends paid.

SILO PHARMA INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-------------|-------------|----------------|
| License fee revenues | ... | 72,102 | 71,264 |
| Revenues | 72,102 | ... | ... |
| Sales | 72,102 | ... | ... |
| Cost of revenues | 5,838 | 5,838 | 5,004 |
| Gross profit | 66,264 | 66,264 | 66,260 |
| Compensation expense | 871,625 | 577,651 | 395,123 |
| Professional fees | ... | 1,496,687 | 1,598,367 |
| Research & development | 845,092 | 1,286,434 | 693,910 |
| Insurance expense | 89,007 | 125,889 | 108,750 |
| Bad debt expense (recovery) | ... | (20,000) | (148,500) |
| General & administrative expenses | 1,726,061 | ... | ... |
| Selling, general & administrative expenses | 390,071 | 227,259 | 162,953 |
| Total operating expenses | 3,921,856 | 3,693,920 | 2,810,603 |
| Income (loss) from continuing operations | (3,855,592) | (3,627,656) | (2,744,343) |
| Interest & dividend income (expense), net | 398,530 | 72,637 | 1,210 |
| Other income from equity shares earned for lock up | ... | ... | ... |

| | | | | | | | | | | | |
|--|--------------------|--------------------|------------------------|---|---------------|------------------|------------------|--|--------------------|----------------------|------------------------|
| agreement | (166,034) | 85,733 | ... | employees | 3 | ... | ² | Full Diluted | 101,212 | 100,802 | |
| Gain on forgiveness of Paycheck Protection Program note payable | ... | ... | 19,082 | Number of common stockholders | 97 | ⁵ 104 | ⁴ 148 | Year-end | 99,989 | 100,054 | |
| Interest expense | 4,869 | 2,199 | 3,036 | ¹ Reclassified to conform with 2022 presentation; ² Adjusted for 1-for-50 stock split, September 15, 2022; ³ As of March 23, 2023; ⁴ As of March 10, 2022; ⁵ As of March 8, 2023 | | | | | | | |
| Net realized gain (loss) on equity investments | ... | (104,700) | 6,660,483 | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | | | | |
| Net unrealized gain (loss) on equity investments | ... | (331,203) | 248,588 | 2023 2022 | | | | | | | |
| Unrealized loss on short-term investments | (3,118) | ... | ... | Cash & cash equivalents | 3,524,308 | 11,367,034 | ... | Product revenue | 1,226,000 | 601,000 | 606,000 |
| Total other income (expense) | 224,509 | (279,732) | 6,926,327 | Equity investments | ... | 3,118 | ... | Total revenue | 2,627,000 | 1,561,000 | 606,000 |
| Income (loss) from continuing operations before provision for income taxes | (3,631,083) | (3,907,388) | 4,181,984 | Note receivable | ... | 66,010 | ... | Grant & contract revenue | 1,401,000 | 960,000 | ... |
| Provision for income taxes | ... | ... | 24,876 | Prepaid expenses & other current assets | 15,970 | 135,894 | ... | Costs of revenue | 784,000 | 265,000 | 449,000 |
| Income (loss) from continuing operations | (3,631,083) | (3,907,388) | 4,157,108 | Short-term investments | 4,140,880 | ... | ... | Gross profit | 1,843,000 | 1,296,000 | 157,000 |
| Gain from sale of assets of discontinued operations, net of tax | ... | ... | 1,553 | Total current assets | 7,681,158 | 11,572,056 | ... | Research & development | 8,713,000 | 6,450,000 | 5,886,000 |
| Gain (loss) from discontinued operations, net of tax | (69,600) | (1,163) | (254,920) | Prepaid expenses & other assets - non-current | ... | 70,821 | ... | General & administrative expenses | 4,222,000 | 3,990,000 | 3,603,000 |
| Net income (loss) | (3,700,683) | (3,908,551) | 3,903,741 | Prepaid expenses - non-current | 64,983 | ... | ... | Sales & marketing expenses | 1,137,000 | 1,336,000 | 1,288,000 |
| Gain (loss) from discontinued operations | (69,600) | (1,163) | (253,367) | Total assets | 7,746,141 | 11,642,877 | ... | Grant & contract expenses | 1,129,000 | 855,000 | ... |
| Deemed dividend | ... | ... | 1,403,997 | Accounts payable & accrued expenses | 703,488 | 364,216 | ... | Total operating expenses | 15,201,000 | 12,631,000 | 10,777,000 |
| Net income (loss) available to common stockholders | (3,700,683) | (3,908,551) | 2,499,744 | Deferred revenue - current portion | 72,102 | 72,102 | ... | Income (loss) from operations | (13,358,000) | (11,335,000) | (10,620,000) |
| Weighted average shares outstanding - basic | 3,079,874 | 2,284,240 | ² 1,897,315 | Total current liabilities | 775,590 | 436,318 | ... | Interest income | 135,000 | 23,000 | 101,000 |
| Weighted average shares outstanding - diluted | 3,079,874 | 2,284,240 | ² 1,918,444 | Deferred revenue - long-term portion | 793,680 | 865,782 | ... | Interest expense | 2,000 | 17,000 | 25,000 |
| Year end shares outstanding | 2,906,241 | 3,158,797 | ² 1,972,739 | Total long term liabilities | 793,680 | 865,782 | ... | Change in fair value of derivative liabilities | 5,718,000 | (1,091,000) | 696,000 |
| Net earnings (loss) per share from continuing operations - basic | \$(1.18) | \$(1.71) | ² \$1.45 | Total liabilities | 1,569,270 | 1,302,100 | ... | Forgiveness of Paycheck Protection Program loan | ... | ... | 391,000 |
| Earnings per share-inc from discontinued oper | \$(0.02) | ... | ... | Common stock | 316 | 316 | ... | Gain (loss) on the disposal of assets | 17,000 | (1,000) | 144,000 |
| Net earnings (loss) per share from discontinued operations - basic | \$(0.02) | \$0.00 | ² \$(0.13) | Additional paid-in capital | 17,525,714 | 17,511,589 | ... | Other income (expense) | 17,000 | 382,000 | 4,000 |
| Net earnings (loss) per share - basic | \$(1.20) | \$(1.71) | \$1.32 | Retained earnings (accumulated deficit) | (10,871,811) | (7,171,128) | ... | Offering costs of derivative liabilities | (786,000) | ... | ... |
| Net earnings (loss) per share from continuing operations - diluted | \$(0.02) | \$0.00 | ² \$(0.13) | Accumulated other comprehensive loss | (6,227) | ... | ... | Total other income (expense), net | 5,099,000 | (704,000) | 1,311,000 |
| Earn per share-inc from discount opers - diluted | \$(0.02) | ... | ... | Treasury stock | 471,121 | ... | ... | Net income (loss) before income taxes | (8,259,000) | (12,039,000) | (9,309,000) |
| Net earnings (loss) per share from discontinued operations - diluted | \$(0.02) | \$0.00 | ² \$(0.13) | Total stockholders' equity (deficit) | 6,176,871 | 10,340,777 | ... | Net income (loss) | (8,259,000) | (12,039,000) | (9,309,000) |
| Net earnings (loss) per share - diluted | \$(1.20) | \$(1.71) | \$1.32 | Total Equity | 6,176,871 | ... | ... | Deemed dividend related to beneficial conversion feature on convertible preferred stock | 26,000 | 4,450,000 | ... |
| Number of full time employees | 3 | ³ | ² | Recent Dividends: | | | | Net income (loss) attributable to common stockholders | (8,285,000) | (16,489,000) | (9,309,000) |
| Total number of | ... | ... | ... | 1. Silo Pharma Inc series C convertible preferred. | | | | Weighted average shares outstanding - basic | 3,736,412 | 301,610 | ² 246,919 |
| | | | | No dividends paid. | | | | Weighted average shares outstanding - diluted | 3,736,412 | 317,323 | ² 250,701 |
| | | | | 2. Silo Pharma Inc series B convertible preferred. | | | | Year end shares outstanding | 5,320,671 | ² 542,145 | ² 247,106 |
| | | | | No dividends paid. | | | | Earnings (loss) per share - continuing operations - basic | \$(2.22) | ... | ... |
| | | | | 3. Silo Pharma Inc common. | | | | Earnings (loss) per share - basic | ... | \$(39.92) | ² \$(37.70) |
| | | | | No dividends paid. | | | | Earnings (loss) per share - deemed dividend & accretion of a discount on conversion of preferred stock - basic | ... | \$(14.75) | ... |
| | | | | 4. Silo Pharma Inc series A redeemable convertible preferred. | | | | Net earnings (loss) per share - basic | \$(2.22) | \$(54.67) | ² \$(37.70) |
| | | | | No dividends paid. | | | | Earnings (loss) per share - continuing operations - diluted | \$(2.22) | ... | ... |
| | | | | Annual Dividends: | | | | Earnings (loss) per | ... | ... | ... |
| | | | | 1. Silo Pharma Inc series C convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 2. Silo Pharma Inc series B convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 3. Silo Pharma Inc common. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | 4. Silo Pharma Inc series A redeemable convertible preferred. | | | | | | | |
| | | | | No dividends paid. | | | | | | | |
| | | | | SIMPLY GOOD FOODS COMPANY (THE) | | | | | | | |
| | | | | Earnings, 6 mos. to (Consol. - \$000): | | | | | | | |
| | | | | | 02/24/24 | 02/25/23 | | | | | |
| | | | | Total revenues | 620,877 | ... | ... | | | | |
| | | | | Net Sales | 620,877 | 597,462 | ... | | | | |
| | | | | Cost & expenses | 512,405 | 493,795 | ... | | | | |
| | | | | Operating income | 99,903 | 94,995 | ... | | | | |
| | | | | Interest income | 2,014 | 253 | ... | | | | |
| | | | | Interest expense | ... | 15,552 | ... | | | | |
| | | | | Other income (expense), net | 6 | 6 | ... | | | | |
| | | | | Foreign currency | 203 | (106) | ... | | | | |
| | | | | Net before taxes | 90,496 | 79,596 | ... | | | | |
| | | | | Income taxes | 21,812 | 18,094 | ... | | | | |
| | | | | Net income | 68,684 | 61,502 | ... | | | | |
| | | | | Earnings common share | | | ... | | | | |
| | | | | Primary | \$0.69 | \$0.62 | ... | | | | |
| | | | | Fully Diluted | \$0.68 | \$0.61 | ... | | | | |
| | | | | Common Shares: | | | ... | | | | |

SINTX TECHNOLOGIES INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | ¹ 2021 (revised) |
|--|--------------------|----------------------|-----------------------------|
| Product revenue | 1,226,000 | 601,000 | 606,000 |
| Total revenue | 2,627,000 | 1,561,000 | 606,000 |
| Grant & contract revenue | 1,401,000 | 960,000 | ... |
| Costs of revenue | 784,000 | 265,000 | 449,000 |
| Gross profit | 1,843,000 | 1,296,000 | 157,000 |
| Research & development | 8,713,000 | 6,450,000 | 5,886,000 |
| General & administrative expenses | 4,222,000 | 3,990,000 | 3,603,000 |
| Sales & marketing expenses | 1,137,000 | 1,336,000 | 1,288,000 |
| Grant & contract expenses | 1,129,000 | 855,000 | ... |
| Total operating expenses | 15,201,000 | 12,631,000 | 10,777,000 |
| Income (loss) from operations | (13,358,000) | (11,335,000) | (10,620,000) |
| Interest income | 135,000 | 23,000 | 101,000 |
| Interest expense | 2,000 | 17,000 | 25,000 |
| Change in fair value of derivative liabilities | 5,718,000 | (1,091,000) | 696,000 |
| Forgiveness of Paycheck Protection Program loan | ... | ... | 391,000 |
| Gain (loss) on the disposal of assets | 17,000 | (1,000) | 144,000 |
| Other income (expense) | 17,000 | 382,000 | 4,000 |
| Offering costs of derivative liabilities | (786,000) | ... | ... |
| Total other income (expense), net | 5,099,000 | (704,000) | 1,311,000 |
| Net income (loss) before income taxes | (8,259,000) | (12,039,000) | (9,309,000) |
| Net income (loss) | (8,259,000) | (12,039,000) | (9,309,000) |
| Deemed dividend related to beneficial conversion feature on convertible preferred stock | 26,000 | 4,450,000 | ... |
| Net income (loss) attributable to common stockholders | (8,285,000) | (16,489,000) | (9,309,000) |
| Weighted average shares outstanding - basic | 3,736,412 | 301,610 | ² 246,919 |
| Weighted average shares outstanding - diluted | 3,736,412 | 317,323 | ² 250,701 |
| Year end shares outstanding | 5,320,671 | ² 542,145 | ² 247,106 |
| Earnings (loss) per share - continuing operations - basic | \$(2.22) | ... | ... |
| Earnings (loss) per share - basic | ... | \$(39.92) | ² \$(37.70) |
| Earnings (loss) per share - deemed dividend & accretion of a discount on conversion of preferred stock - basic | ... | \$(14.75) | ... |
| Net earnings (loss) per share - basic | \$(2.22) | \$(54.67) | ² \$(37.70) |
| Earnings (loss) per share - continuing operations - diluted | \$(2.22) | ... | ... |
| Earnings (loss) per | ... | ... | ... |

| | | | |
|--|----------|-----------|------------|
| share - diluted | ... | \$(46.79) | Ⓐ\$(39.91) |
| Earnings (loss) per share - deemed dividend & accretion of a discount on conversion of preferred stock - diluted | ... | \$(14.02) | ... |
| Net earnings (loss) per share - diluted | \$(2.22) | \$(60.81) | Ⓐ\$(39.91) |
| Total number of employees | ... | Ⓐ41 | Ⓐ36 |
| Number of common stockholders | 159 | Ⓐ158 | Ⓐ155 |

Ⓐ Reclassified to conform with 2022 presentation; Ⓐ Adjusted for 1-for-100 stock split, December 20, 2022; Ⓐ Shares increased due to the effect of stock based compensation, conversion of preferred stock and round up shares issued in reverse split; Ⓐ As of March 1, 2023; Ⓐ As of March 1, 2022; Ⓐ Approximately; Ⓐ As of January 23, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 3,340,000 | 6,245,000 |
| Account & other receivables, net of allowance | ... | 328,000 |
| Account and other receivables | 685,000 | ... |
| Prepaid expenses & other current assets | 539,000 | 344,000 |
| Raw materials | 691,000 | ... |
| Work in process | 426,000 | ... |
| Finished goods | 104,000 | ... |
| Inventory | 333,000 | ... |
| Inventories | 888,000 | 284,000 |
| Other current assets | 80,000 | 8,000 |
| Total current assets | 5,532,000 | 7,209,000 |
| Inventories, net | 333,000 | 453,000 |
| Manufacturing & lab equipment | 5,597,000 | 6,192,000 |
| Leasehold improvements | 2,034,000 | 951,000 |
| Software & computer equipment | 136,000 | 741,000 |
| Furniture & equipment | ... | 119,000 |
| Software and computer equipment | 751,000 | ... |
| Property & equipment, gross | 8,518,000 | 8,003,000 |
| Less: accumulated depreciation | 3,692,000 | 2,312,000 |
| Property & equipment, net | 4,826,000 | 5,691,000 |
| Intangible assets, net | 21,000 | 26,000 |
| Operating lease right of use asset | 4,094,000 | 2,309,000 |
| Other long-term assets | 559,000 | 85,000 |
| Total assets | 15,365,000 | 15,773,000 |
| Accounts payable | 636,000 | 434,000 |
| Payroll & related expenses | 610,000 | 524,000 |
| Accrued payables | 163,000 | 464,000 |
| Other accrued liabilities | ... | 630,000 |
| Other | 631,000 | ... |
| Accrued liabilities - Balancing value | 1,404,000 | ... |
| Accrued liabilities | ... | 1,618,000 |
| Current portion of long term debt | 46,000 | 160,000 |
| Derivative liabilities | 304,000 | 5,126,000 |
| Current portion of operating lease liability | 512,000 | 738,000 |
| Other current liabilities | 4,000 | 2,000 |
| Total current liabilities | 2,906,000 | 8,078,000 |
| Operating lease liability, net of current portion | 3,687,000 | 1,621,000 |
| Other long-term liabilities | ... | 2,000 |
| Long term debt, net of current portion | ... | 368,000 |

| | | |
|---|---------------|---------------|
| Total liabilities | 6,593,000 | 10,069,000 |
| Common stock | 53,000 | 5,000 |
| Additional paid-in capital | 279,433,000 | 268,154,000 |
| Retained earnings (accumulated deficit) | (270,714,000) | (262,455,000) |
| Total stockholders' equity (deficit) | 8,772,000 | 5,704,000 |
| Total stockholders equity | 8,772,000 | ... |

Recent Dividends:

- SiNtx Technologies Inc series D convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc series E convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc common.**
No dividends paid.
- SiNtx Technologies Inc series C convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc series B convertible preferred.**
No dividends paid.

Annual Dividends:

- SiNtx Technologies Inc series D convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc series E convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc common.**
No dividends paid.
- SiNtx Technologies Inc series C convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc convertible preferred.**
No dividends paid.
- SiNtx Technologies Inc series B convertible preferred.**
No dividends paid.

SKINVISIBLE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|-------------|-------------|-------------|
| Revenues | 20,000 | 279,296 | 663,426 |
| Cost of revenues | ... | 4,808 | 3,300 |
| Gross profit (loss) | 20,000 | 274,488 | 660,126 |
| Depreciation & amortization | 18,771 | 18,738 | 17,939 |
| Selling general & administrative | 491,604 | 494,182 | 454,107 |
| Total operating expenses | 510,375 | 512,920 | 472,046 |
| Income (loss) form operations | (490,375) | (238,432) | 188,080 |
| Interest expense | 1,887,150 | 1,162,869 | 1,213,043 |
| Gain (loss) on change in derivative liability | (4,915) | 32,035 | (157,478) |
| Gain (loss) on settlement of debt | ... | 144,379 | 109,688 |
| Total other income (expense) | (1,892,065) | (986,455) | (1,260,833) |
| Net income (loss) before tax provision | (2,382,440) | ... | ... |
| Net income (loss) | (2,382,440) | (1,224,887) | (1,072,753) |
| Weighted average shares outstanding - basic | 4,539,843 | 4,539,843 | 4,539,843 |
| Weighted average shares outstanding - diluted | 4,539,843 | 4,539,843 | 4,539,843 |
| Year end shares outstanding | 4,539,843 | 4,539,843 | 4,539,843 |
| Net income (loss) per common share - basic | \$(0.52) | \$(0.27) | \$(0.24) |
| Net income (loss) per common share - diluted | \$(0.52) | \$(0.27) | \$(0.24) |
| Number of full time employees | 2 | ... | ... |
| Total number of employees | 2 | 2 | 2 |

| | | |
|---|----------|------|
| Number of common stockholders | ... | Ⓐ252 |
| Total Revenue | 20,000 | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.52) | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.52) | ... |

Ⓐ As of March 22, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash | 888 | 81,378 |
| Accounts receivable | 5,000 | 19,073 |
| Accounts receivable - Related party | 21,592 | ... |
| Prepaid expense & other current assets | 7,980 | 9,495 |
| Total current assets | 35,460 | 109,946 |
| Patents & trademarks, net | 127,409 | 136,847 |
| Total assets | 162,869 | 246,793 |
| Accounts payable & accrued liabilities | 438,668 | 1,201,937 |
| Accrued interest payable | 2,575,595 | 1,955,820 |
| Loans payable | 433,600 | 433,600 |
| Convertible notes payable | 6,000 | 40,000 |
| Derivative liability | 18,544 | 13,629 |
| Convertible notes payable | 40,000 | ... |
| Total current liabilities | 3,512,407 | 3,644,986 |
| Convertible notes payable related party, net | ... | Ⓐ2,992,143 |
| Convertible notes payable | 301,102 | Ⓐ250,267 |
| Convertible Debt - Long-Term | 5,372,403 | ... |
| Total liabilities | 9,185,912 | 6,887,396 |
| Common stock | 4,540 | 4,540 |
| Additional paid-in capital | 30,352,905 | 30,352,905 |
| Accumulated deficit | (39,380,488) | ... |
| Retained earnings (accumulated deficit) | ... | (36,998,048) |
| Total stockholders' equity (deficit) | (9,023,043) | (6,640,603) |
| Total Equity | (9,023,043) | ... |

Ⓐ Net of unamortized debt discount - convertible notes payable related party: \$1,228,066,000; Ⓐ Net of unamortized debt discount - convertible notes payable: \$101,808,000

Recent Dividends:

- Skinvisible Inc common.**
No dividends paid.

Annual Dividends:

- Skinvisible Inc common.**
No dividends paid.

SKKYNET CLOUD SYSTEMS INC

Earnings, 3 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------------|------------|------------|
| Total revenues | 630,536 | 492,119 |
| Cost & expenses | 591,569 | 625,351 |
| Operating income | 38,356 | (133,845) |
| Other income (expense), net | 2,987 | 10 |
| Foreign currency | (19,959) | (13,371) |
| Net before taxes | 21,384 | (147,206) |
| Net income | 21,384 | (147,206) |
| Balance for common | 18,479 | (150,111) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 61,217,272 | 53,143,822 |
| Year-end | 53,143,822 | 53,143,822 |

Consolidated Balance Sheet Items, as of (\$):

| | 2024 |
|----------------------------|-----------|
| Assets: | |
| Cash & equivalents | 922,098 |
| Current assets | 1,309,512 |
| Net property & equip. | 4,085 |
| Total assets | 1,313,597 |
| Liabilities: | |
| Current liabilities | 554,119 |
| Stockholders' equity | 759,480 |
| Net current assets | 755,393 |

SKYE BIOSCIENCE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|---|---------------------|---------------------|--------------------|
| Research & development expenses | 5,819,461 | 6,011,805 | 2,931,437 |
| General & administrative expenses | 7,852,340 | 6,094,617 | 4,916,277 |
| Estimated legal contingency | 21,215,214 | 6,205,310 | ... |
| Estimated legal contingency | (151,842) | ... | ... |
| Total operating expenses | 34,735,173 | 18,311,732 | 7,847,714 |
| Operating income (loss) | (34,735,173) | (18,311,732) | (7,847,714) |
| Change in fair value of derivative liability | (1,383,285) | 59,729 | (21,165) |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 117,953 |
| Related party interest expense - stated rate | 202,254 | 169,640 | 174,911 |
| Interest Expense - insurance premium loan payable | 6,485 | 5,896 | ... |
| Legal judgment interest expense | 234,750 | ... | ... |
| Bond premium | 59,929 | ... | ... |
| Premium on irrevocable letter of credit | 69,861 | ... | ... |
| Paycheck Protection Program ("PPP") loan interest expense - stated rate | ... | ... | 446 |
| Non-cash interest expense - amortization of debt discount | 320,828 | 488,238 | 592,154 |
| Non-cash interest expense - amortization of transaction costs | 9,063 | 1,359 | 1,648 |
| Other interest expense | 3,100 | ... | ... |
| Interest expense | 906,270 | 665,133 | 769,159 |
| Interest income | 99,974 | 19,011 | 3 |
| Finance charge | ... | 120,228 | ... |
| Wind-down costs | 409,347 | 456,508 | ... |
| Gain (loss) on disposal of equipment | (307,086) | ... | ... |
| Change in fair value of warrant liability | 3 | ... | ... |
| Total other income (expense), net | (2,906,011) | (1,163,129) | (672,368) |
| Income (loss) before the income tax provision - United States | ... | (18,801,570) | (8,446,034) |
| Income (loss) before the income tax provision - foreign | ... | (673,291) | (74,048) |
| Income (loss) before income taxes | (37,641,184) | (19,474,861) | (8,520,082) |
| Current income tax expense: state | ... | 6,741 | 2,100 |
| Provision for income taxes | 3,600 | 6,741 | 2,100 |
| Net income (loss) | (37,644,784) | (19,481,602) | (8,522,182) |
| Net income (loss) available to common shareholders | ... | (19,481,602) | (8,522,182) |
| Weighted average | | | |

| | 2023 | 2022 | 2021 (revised) |
|--|------------|-----------|-------------------|
| shares outstanding - basic | 7,006,038 | 2,221,080 | 1,626,398 |
| Weighted average shares outstanding - diluted | 7,006,038 | 2,221,080 | 1,626,398 |
| Year end shares outstanding | 12,349,243 | 3,654,116 | 1,904,434 |
| Earnings (loss) per share - basic | \$(5.37) | \$(10.00) | \$(5.00) |
| Earnings (loss) per share - diluted | \$(5.37) | \$(10.00) | \$(5.00) |
| Number of full time employees | 11 | 11 | 9 |
| Number of common stockholders | 109 | 82 | 61 |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(5.37) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(5.37) | ... | ... |
| Total number of employees | 11 | ... | ... |

Reclassified to conform with 2022 presentation; Adjusted for 1-for-250 stock split, September 8, 2023; Shares increased due to the effect of common stock, options and warrants issued for asset acquisition, exercise of pre-funded warrants & stock-based compensation expense; Shares increased due to the effect of stock-based compensation, issuance of common stock & warrants, exercise of pre-funded warrants, exercise of common stock warrants & stock options; As of March 29, 2023; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|-----------|
| Cash & cash equivalents | 1,256,453 | 1,244,527 |
| Restricted cash | 9,080,202 | 4,580 |
| Prepaid expenses | 425,259 | 850,377 |
| Assets held for sale | ... | 6,432,216 |
| Other current assets | 888,929 | 412,018 |
| Total current assets | 11,650,843 | 8,943,718 |
| Property, plant & equipment, net | 43,276 | 87,854 |
| Operating lease right-of-use asset, net | 237,983 | 71,191 |
| Total assets | 11,940,411 | 9,111,072 |
| Accounts payable | 1,155,785 | 1,669,997 |
| Accounts payable - related parties | ... | 124,901 |
| Accrued interest - related party | 126,027 | 15,814 |
| Accrued payroll liabilities | 888,381 | 657,734 |
| Accrued research & development costs | 467,784 | 40,597 |
| Accrued legal expense | ... | 227,350 |
| Accrued insurance loan payable | ... | 55,451 |
| Accrued deposit - Verdelite SPA | ... | 553,800 |
| Acquisition related contingent liability | ... | 134,896 |
| Total other accrued liabilities | 22,190 | 410,348 |
| Other current liabilities - related parties | 998,552 | 1,422,442 |
| Other current liabilities | 47,400 | 95,850 |
| Derivative liability | ... | 3 |
| Estimate for legal contingency | 6,053,468 | 6,205,310 |
| Secured convertible promissory note - related party, net of discount | 4,371,998 | ... |
| Convertible multi-draw credit agreement - related party, net | ... | 1,848,375 |
| Operating lease | ... | ... |

| | 2023 | 2022 |
|---|---------------|--------------|
| liability, current portion | 72,038 | 78,700 |
| Legal fees | 258,213 | ... |
| Accrued interest legal contingency | 234,750 | ... |
| EHT Acquisition related liabilities | 180,897 | ... |
| professional fee | 22,068 | ... |
| Total current liabilities | 13,900,999 | 12,119,126 |
| Operating lease liability, net of current portion | 171,230 | ... |
| Total liabilities | 14,072,229 | 12,119,126 |
| Common stock | 12,349 | 913,528 |
| Additional paid-in-capital | 102,238,382 | 62,816,183 |
| Retained earnings (accumulated deficit) | (104,382,549) | (66,737,765) |
| Total stockholders' equity (deficit) | (2,131,818) | (3,008,054) |
| Total Equity | (2,131,818) | ... |

Recent Dividends:

- Skye Bioscience Inc redeemable convertible series B preferred.**
No dividends paid.
- Skye Bioscience Inc convertible series D preferred.**
No dividends paid.
- Skye Bioscience Inc redeemable convertible series F preferred.**
No dividends paid.
- Skye Bioscience Inc convertible series C preferred.**
No dividends paid.
- Skye Bioscience Inc common.**
No dividends paid.

Annual Dividends:

- Skye Bioscience Inc redeemable convertible series B preferred.**
No dividends paid.
- Skye Bioscience Inc convertible series D preferred.**
No dividends paid.
- Skye Bioscience Inc redeemable convertible series F preferred.**
No dividends paid.
- Skye Bioscience Inc convertible series C preferred.**
No dividends paid.
- Skye Bioscience Inc common.**
No dividends paid.

SKYLINE BANKSHARES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$'000):**

| | 2023 | 2022 | 2021 (revised) |
|---|--------|--------|-------------------|
| Interest income on loans & fees on loans | 39,877 | 32,687 | 33,089 |
| Interest income on interest-bearing deposits with banks | 279 | 788 | 88 |
| Interest income on federal funds sold | 29 | 29 | 44 |
| Interest on taxable securities | 2,829 | 2,716 | 1,372 |
| Interest on nontaxable securities | 195 | 242 | 53 |
| Interest income on dividends | 156 | 105 | 110 |
| Total interest income | 43,365 | 36,567 | 34,756 |
| Interest expense on demand deposits | ... | 365 | 298 |
| Interest expense on savings deposits | ... | 196 | 198 |
| Interest expense on time deposits | ... | 1,181 | 1,847 |
| Interest expense on deposits | 6,617 | 1,742 | 2,343 |
| Interest on borrowings | 1,150 | 188 | 86 |
| Total interest expense | 7,767 | 1,930 | 2,429 |

| | | | |
|--|--------------|---------------|--------------|
| Net interest income . . . | 35,598 | 34,637 | 32,327 |
| Provision for loan losses | (50) | 606 | 723 |
| Net interest income after provision for loan losses | 35,648 | 34,031 | 31,604 |
| Service charges on deposit amounts | 2,186 | 1,906 | 1,541 |
| Other service charges & fees | ... | 3,171 | 2,606 |
| Net realized gains (losses) on securities | (16) | (10) | 265 |
| Mortgage loan origination fees | ... | 399 | 1,061 |
| Increase in cash value of life insurance | 576 | 513 | 446 |
| Other income | 427 | 61 | 649 |
| Life insurance income | 69 | 217 | ... |
| Total noninterest income | 6,970 | 6,257 | 6,568 |
| Salaries & employee benefits expenses | 16,704 | 14,823 | 14,680 |
| Occupancy & equipment expenses | 376 | 4,410 | 3,618 |
| Data processing expense | 2,231 | 1,971 | 2,026 |
| FDIC assessments | 588 | 430 | 430 |
| Advertising | 768 | 657 | 702 |
| Bank franchise tax | ... | 506 | 499 |
| Director fees | 349 | 354 | 368 |
| Professional fees | 722 | 684 | 639 |
| Telephone expense | 556 | 482 | 390 |
| Core deposit intangible amortization | 369 | 478 | 595 |
| Other expense | 2,847 | 2,693 | 2,320 |
| Occupancy and Equipment | 5,032 | ... | ... |
| Total noninterest expenses | 30,542 | 27,488 | 26,267 |
| Income before income taxes | 12,076 | 12,800 | 11,905 |
| Current income taxes (benefit) | 2,431 | 1,620 | 2,096 |
| Deferred income taxes | (55) | 899 | 327 |
| Income tax expense | 2,376 | 2,519 | 2,423 |
| Net income | 9,700 | 10,281 | 9,482 |
| Weighted average shares outstanding - basic | 5,580 | 5,588 | 5,968 |
| Year end shares outstanding | 5,584 | 5,617 | 5,606 |
| Net earnings (loss) per share - basic | \$1.74 | \$1.84 | \$1.59 |
| Dividends per common share | \$0.42 | \$0.32 | \$0.27 |
| Number of full time employees | 230 | 223 | 219 |
| Number of part time employees | ... | 4 | 5 |
| Total number of employees | 230 | 227 | ... |
| Number of common stockholders | 1,301 | 1,334 | 1,372 |
| Financial Service Other | 3,473 | ... | ... |
| Mortgage Banking | 255 | ... | ... |
| EPS - Diluted - including Extraordinary Items Applicable to Common - Total | \$1.74 | ... | ... |
| Diluted (in shares) | 5,580 | ... | ... |

| | | | |
|---|-----------|----------|-----|
| Cash & due from banks | 16,811 | 19,299 | ... |
| Interest-bearing deposits with banks | 4,808 | 10,802 | ... |
| Federal funds sold | 474 | 960 | ... |
| Investment securities available for sale | ... | 135,151 | ... |
| Restricted equity securities | 3,338 | 1,950 | ... |
| Construction & development | 53,473 | 49,728 | ... |
| Farmland | 25,598 | 23,688 | ... |
| Residential | 400,947 | 358,526 | ... |
| Commercial mortgage | 269,666 | 263,664 | ... |
| Commercial & agricultural | 47,681 | 39,434 | ... |
| Small business administration - paycheck protection program ("SBA-PPP") loans | ... | 71 | ... |
| Consumer & other loans | ... | 19,761 | ... |
| Consumer & Other, Gross | 20,339 | ... | ... |
| Total loans | 817,704 | 754,872 | ... |
| Allowance for loan losses | 6,739 | 6,248 | ... |
| Loans, net | 810,965 | 748,624 | ... |
| Cash value of life insurance | 22,909 | 22,484 | ... |
| Other real estate owned | ... | 235 | ... |
| Land | 8,478 | 8,429 | ... |
| Buildings & improvements | 48,435 | 25,835 | ... |
| Furniture & equipment | 14,126 | 13,221 | ... |
| Buildings and improvements | 25,831 | ... | ... |
| Property & equipment, gross | ... | 47,485 | ... |
| Less: accumulated depreciation | 17,252 | 15,732 | ... |
| Properties & equipment, net | 31,183 | 31,753 | ... |
| Accrued interest receivable | 3,463 | 2,979 | ... |
| Core Deposit - Gross | 1,286 | ... | ... |
| Amortization expense | 369 | ... | ... |
| Core deposit intangible | 917 | 1,286 | ... |
| Goodwill | 3,257 | 3,257 | ... |
| Deferred tax assets, net | 5,046 | 5,744 | ... |
| Other assets | 15,283 | 13,210 | ... |
| Investment securities available for sale | 127,389 | ... | ... |
| U.S. Govt Agency Securities ? AFS | 21,438 | ... | ... |
| Mortgage Backed Securities - AFS | 61,697 | ... | ... |
| Corporate Securities - AFS | 1,442 | ... | ... |
| State & Municipal Securities - AFS | 40,366 | ... | ... |
| U.S. Treasury Securities ? AFS | 2,446 | ... | ... |
| Total assets | 1,045,843 | 997,734 | ... |
| Non-interest bearing deposits | 305,115 | 310,510 | ... |
| Interest bearing deposits | 623,627 | 609,817 | ... |
| Total deposits | 928,742 | 920,327 | ... |
| Accrued interest payable | 531 | 95 | ... |
| Other liabilities | 6,188 | 4,376 | ... |
| FHLB advances | 27,500 | ... | ... |
| Total liabilities | 962,961 | 924,798 | ... |
| Surplus | 33,356 | 33,613 | ... |
| Retained earnings (accumulated deficit) | 68,866 | 62,229 | ... |
| Unrealized gains & losses on available for sale securities | (17,964) | (20,942) | ... |
| Minimum pension liability | (1,376) | (1,964) | ... |
| Accumulated other comprehensive income (loss) | (19,340) | (22,906) | ... |
| Stockholders' equity | 82,882 | 72,936 | ... |
| Total Equity | 82,882 | ... | ... |

No dividends paid.
Annual Dividends:
1. Skyline Bankshares Inc common.
 No dividends paid.
SKYWARD SPECIALTY INSURANCE GROUP INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|---------------|---------------|----------------|
| Net earned premiums | 829,143 | 615,994 | 499,823 |
| Commission & fee income | 6,064 | 5,199 | 3,973 |
| Net investment income | 40,322 | 36,931 | 24,646 |
| Net investment gains (losses) | 11,072 | (15,705) | 17,107 |
| Net realized gain on sale of business | ... | ... | 5,077 |
| Other income (loss) | (632) | 1 | (445) |
| Total revenues | 885,969 | 642,420 | 550,181 |
| Losses & loss adjustment expenses | 515,237 | 402,512 | 354,411 |
| Underwriting, acquisition & insurance expenses | 243,444 | 182,171 | 138,498 |
| Impairment charges | ... | ... | 2,821 |
| Interest expense | 10,024 | 6,407 | 4,622 |
| Amortization expense | 1,798 | 1,547 | 1,520 |
| Other expenses | 5,364 | ... | ... |
| Total expenses | 775,867 | 592,637 | 501,872 |
| Income (loss) before income taxes | 110,102 | 49,783 | 48,309 |
| Current income tax expense (expense) | 14,736 | 120 | ... |
| Deferred tax expense (benefit) related to temporary differences | 9,382 | 10,267 | 9,992 |
| Income tax expense (benefit) | 24,118 | 10,387 | 9,992 |
| Net income (loss) | 85,984 | 39,396 | 38,317 |
| Net income attributable to participating securities | 1,677 | 18,879 | 18,507 |
| Net income (loss) attributable to common shareholders | 84,307 | 20,517 | 19,810 |
| Weighted average shares outstanding - basic | 36,032 | 16,568 | 16,309 |
| Weighted average shares outstanding - diluted | 38,318 | 32,653 | 32,468 |
| Year end shares outstanding | 39,864 | 16,600 | 16,534 |
| Net income (loss) per share - basic | \$2.34 | \$1.24 | \$1.21 |
| Net income (loss) per share - diluted | \$2.24 | \$1.21 | \$1.18 |
| Full-Time Employees (Period End) | 515 | ... | ... |
| Total number of employees | 515 | 448 | 441 |
| Number of common stockholders | 15 | 171 | ... |

Reclassified to conform with 2022 presentation; As is; Approximately; As of September 30, 2022; As of March 22, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|------|--------|
| Fixed maturity securities, available for sale - U.S. government securities | ... | 48,541 |
| Fixed maturity securities, available for sale - corporate | ... | ... |

Full time equivalent employees; As is; As of March 27, 2023; As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):
 2023 2022

Recent Dividends:
1. Skyline Bankshares Inc common.

| | | |
|--|---------------|---------------|
| Operating lease liabilities, current | 1,898,428 | 1,130,624 |
| Royalty obligations, current | 800,000 | 2,638,000 |
| Convertible notes, current related parties | ... | 950,000 |
| Convertible notes, current | 1,175,000 | 350,000 |
| Notes payable, current | ... | 405,931 |
| Notes payable, accrued expenses | 5,724,129 | ... |
| Accounts payable and accrued expenses | 12,388,475 | ... |
| Deferred revenues | 1,475,519 | ... |
| Total current liabilities | 24,192,550 | 7,424,378 |
| Notes payable | 1,016,924 | 4,867,004 |
| Operating lease liabilities | 22,267,558 | 22,758,496 |
| Convertible notes | 5,758,778 | ... |
| Royalty obligations | 3,100,000 | ... |
| Long term accrued expenses | 744,953 | ... |
| Consideration payable | 3,038,430 | ... |
| Total long-term liabilities | 35,926,643 | 27,625,500 |
| Total liabilities | 60,119,193 | 35,049,878 |
| Redeemable preferred stock - subject to redemption | ... | 220,099 |
| Common stock | 162,025,024 | ... |
| Common stock & additional paid-in capital | ... | 114,039,638 |
| Accumulated deficit | (145,803,014) | ... |
| Retained earnings (accumulated deficit) | ... | (106,070,358) |
| Accumulated other comprehensive income (loss) | ... | (62,147) |
| Total stockholders' equity (deficit) | 16,222,010 | 7,907,133 |
| Total equity (deficit) | 16,222,010 | 7,907,133 |

Recent Dividends:
1. SKYX Platforms Corp common.
 No dividends paid.
2. SKYX Platforms Corp redeemable preferred - subject to redemption.
 No dividends paid.
Annual Dividends:
1. SKYX Platforms Corp common.
 No dividends paid.
2. SKYX Platforms Corp redeemable preferred - subject to redemption.
 No dividends paid.

SMART POWER CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-----------|-------------|----------------|
| Bad debts expense (reversal) | ... | ... | (34,688) |
| Litigation expense | ... | 2,281,277 | ... |
| General & administrative | 798,473 | 1,599,156 | 842,842 |
| Income (loss) from operations | (798,473) | (3,880,433) | (808,154) |
| Loss on note conversion | 7,291 | 135,103 | 151,275 |
| Interest income | 251,668 | 431,489 | 414,468 |
| Interest expense | 435,241 | 686,581 | 3,106,965 |
| Gain on termination of buy-back agreement of Chengli project | ... | ... | 3,165,887 |
| Impairment loss on long-term equity investment | ... | ... | 11,625,195 |
| Other income (expenses), net | 339,251 | (117,047) | (172,096) |
| Total non-operating income (expenses), net | 148,387 | (507,242) | (11,475,176) |
| Income (loss) | | | |

| | | | |
|---|------------------|--------------------|---------------------|
| before income tax | (650,086) | (4,387,675) | (12,283,330) |
| Current income tax expense (benefit) | 96,700 | 69,652 | (53,140) |
| Income tax expense (benefit) | 96,700 | 69,652 | (53,140) |
| Net income (loss) | (746,786) | (4,457,327) | (12,230,190) |
| Weighted average shares outstanding - basic | 7,784,868 | 7,334,971 | 5,608,631 |
| Weighted average shares outstanding - diluted | 7,784,868 | 7,334,971 | 5,608,631 |
| Year end shares outstanding | 7,963,444 | 7,391,996 | 7,044,408 |
| Net earnings (loss) per share - basic | \$(0.10) | \$(0.61) | \$(2.18) |
| Net earnings (loss) per share - diluted | \$(0.10) | \$(0.61) | \$(2.18) |
| Number of full time employee | 14 | 14 | 14 |
| Total number of employees | 14 | ... | ... |
| Number of common stockholders | 2,726 | 2,726 | 2,726 |
| Foreign currency translation adjustments | ... | (11,639,753) | ... |
| Earnings per share from continuing operations | \$(0.10) | ... | ... |
| Earnings per share from continuing operations | \$(0.10) | ... | ... |

☐ Shares increased due to the effect of conversion of long-term notes into common shares, equity financing and stock compensation expense; ☒ Approximately; ☓ As of May 5, 2023; ☔ As of September 12, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash & cash equivalents | 32,370 | ... |
| Cash | ... | 138,813,673 |
| VAT receivable | 170,694 | 173,589 |
| Short term loan receivables | 68,773,208 | ... |
| Prepaid expenses | 67,440,761 | 31,923 |
| Operating lease right-of-use assets, net | ... | 62,177 |
| Other receivables | 48,519 | 49,690 |
| Total current assets | 136,465,552 | 139,131,052 |
| Fixed assets, net | 3,994 | 4,653 |
| Total non-current assets | 3,994 | 4,653 |
| Total assets | 136,469,546 | 139,135,705 |
| Accounts payable | 70,083 | 71,271 |
| Taxes payable | 4,277,091 | 3,681,352 |
| Accrued interest on notes | 2,664,461 | 261,035 |
| Education & union fund & social insurance payable | 181,394 | 270,116 |
| Consulting & legal expenses | 95,508 | ... |
| Accrued payroll & welfare | 263,472 | 251,021 |
| Accrued litigation | 2,124,087 | 2,203,149 |
| Other accrued liabilities & other payables | ... | 52,128 |
| Operating lease liability | ... | 62,178 |
| Payable for purchase 10% equity interest of Zhonghong | 423,567 | 430,750 |
| Interest payable on entrusted loans | 341,459 | 347,249 |
| Entrusted loan payable | ... | 11,055,911 |
| Accrued interest on Cinda note | 2,290 | ... |
| Notes payable, net | 10,871,560 | 5,697,727 |
| Notes payable, net of unamortized OID | 5,222,743 | ... |
| Total current liabilities | 23,873,254 | 24,383,887 |
| Income tax payable | 3,350,625 | 3,958,625 |
| Total noncurrent liabilities | 3,350,625 | 3,958,625 |

| | | |
|---|--------------|--------------|
| Total liabilities | 27,223,879 | 28,342,512 |
| Common stock | 7,963 | 7,392 |
| Additional paid in capital | 164,870,025 | 163,663,305 |
| Statutory reserve | 15,191,645 | 15,168,003 |
| Accumulated other comprehensive income | (10,326,595) | (8,318,564) |
| Accumulated deficit | (60,497,371) | ... |
| Retained earnings (accumulated deficit) | ... | (59,726,943) |
| Total Company stockholders' equity | 109,245,667 | 110,793,193 |
| Total equity | 109,245,667 | ... |

☐ Net of unamortized original issue discount (OID) - notes payable: \$31,250

Recent Dividends:
1. Smart Power Corp common.
 No dividends paid.
Annual Dividends:
1. Smart Power Corp common.
 No dividends paid.

SMARTKEM INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|-------------|--------------|----------------|
| Revenue | 27,000 | ... | ... |
| Revenue | 27,000 | 40,000 | 18,000 |
| Cost of revenue | 23,000 | ... | ... |
| Cost of revenue | 23,000 | 33,000 | 8,000 |
| Gross profit | 4,000 | 7,000 | 10,000 |
| Other operating income | 836,000 | 1,172,000 | 1,285,000 |
| Research & development | 5,556,000 | 5,802,000 | 8,199,000 |
| Salaries & benefits | ... | ... | 5,366,000 |
| Rent & property tax expense | ... | ... | 24,000 |
| Insurance expense | ... | ... | 486,000 |
| Utilities | ... | ... | 4,000 |
| Sales & marketing | ... | ... | 749,000 |
| Legal & professional fees | ... | ... | 1,132,000 |
| Other selling, general, & administrative expenses | 5,188,000 | ... | 308,000 |
| Selling, general & administrative expense | ... | 5,071,000 | 8,069,000 |
| Transaction expenses | ... | ... | 1,329,000 |
| Loss on foreign currency transactions | (87,000) | ... | ... |
| Total operating expenses | ... | 10,873,000 | 17,597,000 |
| Income (loss) from operations | (9,991,000) | (9,694,000) | (16,302,000) |
| (Loss) on foreign currency transactions | 1,213,000 | (1,782,000) | (808,000) |
| Other income | (198,000) | ... | ... |
| Interest expense | ... | ... | 19,000 |
| Interest income | 12,000 | 5,000 | 3,000 |
| Change in fair value of the warrant liability | 465,000 | ... | ... |
| Total non-operating income (expense) | 1,492,000 | (1,777,000) | (824,000) |
| Income (loss) before income taxes - United States | ... | 584,000 | (5,039,000) |
| Income (loss) before income taxes - Foreign | ... | (12,055,000) | (12,087,000) |
| Income (loss) before income taxes | (8,499,000) | (11,471,000) | (17,126,000) |
| Current state income tax expense | ... | 2,000 | ... |
| Current foreign | ... | ... | ... |

| | | | | | | | | |
|--|-------------|--------------|---|-----------|---|-------------|-------------|-------------|
| income tax expense | 22,000 | ... | Accounts payable & accrued expenses | 931,000 | (loss) | 70,624,936 | 65,868,858 | 16,507,750 |
| Total current income tax expense | 24,000 | ... | Income taxes payable | 22,000 | Interest expense | 61,804,621 | 41,511,911 | 33,383,604 |
| Income tax expense | 24,000 | ... | Lease liabilities, current | 230,000 | Net gain (loss) on extinguishment of debt | ... | (2,393,475) | (2,444,788) |
| Net income (loss) | (8,499,000) | (11,495,000) | (17,126,000) | 360,000 | Other income (expense) | 3,128,867 | (848,805) | (2,055,351) |
| Weighted average shares outstanding - basic | 1,344,892 | □824,623 | 720,954 | 448,000 | Current federal income taxes | 191,115 | 170,874 | 182,034 |
| Weighted average shares outstanding - dilutive | 1,344,892 | □824,623 | 720,954 | 1,768,000 | Current state income taxes | 33,326 | 27,020 | 32,559 |
| Year end shares outstanding | 889,668 | □771,000 | □730,123 | 19,000 | Current income taxes - Canadian | 480,391 | 320,639 | ... |
| Net income (loss) per common share - basic | \$(6.32) | □\$(14.00) | \$(23.80) | 1,372,000 | Current income taxes | 704,832 | 518,533 | 214,593 |
| Net income (loss) per common share - dilutive | \$(6.32) | □\$(14.00) | \$(23.80) | 3,159,000 | Deferred federal income taxes | (10,477) | (499,077) | (1,750,248) |
| Number of full time employees | 29 | 50 | 41 | ... | Deferred state income taxes | (1,596) | (76,050) | (266,704) |
| Number of part time employees | 2 | 5 | 3 | 1,372,000 | Deferred income taxes - Canadian | (3,288,615) | (498,191) | (8,916) |
| Total number of employees | 31 | 55 | 44 | 8,113,000 | Deferred income taxes | (3,300,688) | (1,073,318) | (2,025,868) |
| Number of common stockholders | ... | □102 | □139 | 8,113,000 | Income tax expense (benefit) | (2,595,856) | (554,785) | (1,811,275) |

□ Adjusted for 1-for-35 stock split, September 21, 2023; □ Shares increased due to the effect of exercise of stock-option, repurchase of common stock, reverse capitalization, common shares to vendor and warrant in private placement; □ As of March 24, 2023; □ As of March 14, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|-----------|
| Cash & cash equivalents | 8,836,000 | 4,235,000 |
| Accounts receivable, net | 268,000 | 30,000 |
| Research & development tax credit receivable | 610,000 | 1,121,000 |
| Prepaid service charges & property taxes | ... | 55,000 |
| Prepaid utilities | ... | 51,000 |
| Prepaid insurance | ... | 358,000 |
| Prepaid administrative expenses | ... | 35,000 |
| Prepaid technical fees | ... | 22,000 |
| Prepaid consulting fees | ... | 304,000 |
| Value added tax receivable | ... | 195,000 |
| Other receivable & other prepaid expenses | ... | 36,000 |
| Prepaid expenses & other current assets | 811,000 | 1,056,000 |
| Total current assets | 10,525,000 | 6,442,000 |
| Plant & equipment | 1,584,000 | 1,478,000 |
| Furniture & fixtures | ... | 218,000 |
| Computer hardware & software | 108,000 | 24,000 |
| Computer hardware and software | 24,000 | ... |
| Property, plant & equipment, gross | 1,716,000 | 1,720,000 |
| Accumulated depreciation | 1,261,000 | 1,118,000 |
| Property, plant & equipment, net | 455,000 | 602,000 |
| Right-of-use assets, net | 285,000 | 475,000 |
| Other assets, non-current | 7,000 | 6,000 |
| Total assets | 11,272,000 | 7,525,000 |
| Accounts payable | 355,000 | 230,000 |
| Accrued expenses - lab refurbishments | ... | 117,000 |
| Accrued expenses - technical fees | ... | 130,000 |
| Accrued expenses - variable rent & utilities | ... | 15,000 |
| Accrued expenses - audit & accounting fees | ... | 128,000 |
| Other accrued expenses | 1,178,000 | 80,000 |
| Credit card liabilities | ... | 20,000 |
| Payroll & social security liabilities | 375,000 | 211,000 |

Recent Dividends:

1. SmartKem Inc common.

No dividends paid.

2. SmartKem Inc preferred.

No dividends paid.

Annual Dividends:

1. SmartKem Inc common.

No dividends paid.

2. SmartKem Inc preferred.

No dividends paid.

SMARTSTOP SELF STORAGE REIT INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | □2021 (revised) |
|--|-------------|-------------|-----------------|
| Self storage rental revenue | 206,494,202 | 191,749,578 | 150,610,337 |
| Ancillary operating revenue | 8,826,868 | 8,445,803 | 7,552,597 |
| Managed REIT platform revenue | 11,906,311 | 7,819,216 | 6,322,970 |
| Reimbursable costs from managed REITs | 5,764,363 | 4,628,497 | 4,278,667 |
| Total revenues | 232,991,744 | 212,643,094 | 168,764,571 |
| Property operating expenses | 65,362,857 | 58,437,110 | 48,127,657 |
| Managed REIT platform expenses | 3,365,491 | 2,485,290 | 1,451,166 |
| Reimbursable costs from managed REITs | 5,764,363 | 4,628,497 | 4,278,667 |
| General & administrative expenses | 27,451,533 | 28,253,905 | 23,265,196 |
| Depreciation expenses | ... | 49,417,679 | 40,946,406 |
| Intangible amortization expense | 6,593,853 | 15,200,854 | 12,422,205 |
| Acquisition expenses | 192,358 | 888,009 | 934,838 |
| Contingent earnout adjustment | ... | 1,514,447 | 12,619,744 |
| Write-off of equity interest & preexisting relationships in SST IV upon acquisition of control | ... | 2,049,682 | 8,389,573 |
| Depreciation | 53,636,353 | ... | ... |
| Total operating expenses | 162,366,808 | 162,875,473 | 152,435,452 |
| Gain on equity interests upon acquisition | ... | 16,101,237 | ... |
| Gain on sale of real estate | ... | ... | 178,631 |
| Operating income | | | |

| | | | |
|---|-------------|-------------|--------------|
| Net income (loss) attributable to the noncontrolling interests | (1,892,458) | (2,847,572) | 2,663,123 |
| Less: distributions to preferred stockholders | 12,500,000 | 12,500,000 | 12,500,000 |
| Net income (loss) attributable to SmartStop Self Storage REIT, Inc. common stockholders | (3,114,552) | 6,321,880 | (29,401,595) |
| Weighted average class A shares outstanding - basic | ... | 83,857,222 | 71,454,798 |
| Weighted average class T shares outstanding - basic | ... | 8,081,950 | 7,983,576 |
| Weighted average class A shares outstanding - diluted | 96,807,939 | 83,974,488 | 71,454,798 |
| Weighted average class T shares outstanding - diluted | ... | 8,081,950 | 7,983,576 |
| Year end shares outstanding | 96,874,962 | 96,939,004 | □85,113,941 |
| Net income (loss) per Class A & Class T share - basic | \$(0.03) | \$0.07 | \$(0.37) |
| Net income (loss) per Class A & Class T share - diluted | \$(0.03) | \$0.07 | \$(0.37) |
| Full-Time Employees (Period End) | 500 | ... | ... |
| Number of employees | 500 | □450 | □420 |
| Number of common stockholders | 19,000 | □□19,500 | □□18,100 |
| Comprehensive Income - Attributable to Owners of Parent Company - Total | 6,946,803 | ... | ... |
| Net Income before Tax | 9,050,904 | ... | ... |
| Shares used to calculate Basic EPS - Total | 96,807,939 | ... | ... |
| Equity in earnings (losses) from investments in JV Properties | (1,625,135) | ... | ... |

Equity in earnings (losses) from investments in Managed REITs (1,273,143) ...

Reclassified to conform with 2022 presentation; Shares increased due to the effect of issuance of common stock in connection with SST IV merger; Approximately; As of March 1, 2023; As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Land | 420,522,591 | ... |
| Buildings | 1,401,981,394 | 1,377,311,421 |
| Site improvements | 91,896,415 | 89,371,633 |
| Real estate facilities, gross | ... | 1,887,205,645 |
| Less: accumulated depreciation | 255,844,284 | 202,682,688 |
| Real estate facilities before construction in progress | ... | 1,684,522,957 |
| Construction in process | 5,976,946 | 4,490,926 |
| Land - Gross | 430,868,563 | ... |
| Investment Property - Net | 1,674,879,034 | ... |
| Real estate facilities, net | ... | 1,689,013,883 |
| Cash & cash equivalents | 45,079,371 | 39,486,588 |
| Restricted cash | 8,347,805 | 6,551,803 |
| Investments in unconsolidated real estate ventures | 35,831,600 | 28,522,082 |
| Investments in & advances to Managed REITs | 34,390,866 | 62,371,167 |
| Other assets, net | 21,701,107 | 34,131,543 |
| Intangible assets, net of accumulated amortization | 1,170,100 | 15,553,303 |
| Trademarks, net of accumulated amortization | ... | 15,911,765 |
| Goodwill | 53,643,331 | 53,643,331 |
| Debt issuance costs, net of accumulated amortization | 377,258 | 2,031,922 |
| Trademarks | 15,770,588 | ... |
| Deferred tax assets | 4,449,665 | ... |
| Total assets | 1,895,640,725 | 1,947,217,387 |
| Loan | ... | 1,072,958,927 |
| Premium on secured debt, net | ... | (93,147) |
| Debt issuance costs, net | ... | (4,493,824) |
| Secured debt | 1,087,401,334 | ... |
| Debt, net | ... | 1,068,371,956 |
| Accounts payable & accrued liabilities | 28,977,714 | 28,151,741 |
| Due to affiliates | 415,980 | 409,730 |
| Distributions payable | 9,155,808 | 9,324,453 |
| Deferred tax liabilities | 6,193,675 | 6,205,620 |
| Total liabilities | 1,132,144,511 | 1,112,463,500 |
| Redeemable common stock | 71,277,195 | 76,578,073 |
| Series A convertible preferred stock | 196,356,107 | 196,356,107 |
| Class A common stock | 88,762 | 88,853 |
| Class T common stock | 8,114 | 8,085 |
| Additional paid-in capital | 894,856,554 | 894,283,954 |
| Distributions | (324,190,556) | (266,151,517) |
| Retained earnings (accumulated deficit) | (167,270,293) | (164,524,595) |
| Accumulated other comprehensive income (loss) | 847,183 | 3,654,682 |
| Total SmartStop Self Storage REIT, Inc. equity | 404,339,764 | 467,359,462 |
| Noncontrolling interests in our Operating Partnership | 91,488,207 | 94,405,766 |
| Other noncontrolling interests | 34,941 | 54,479 |
| Total noncontrolling interests | ... | 94,460,245 |
| Total equity (deficit) | 495,862,912 | 561,819,707 |

Recent Dividends:

1. SmartStop Self Storage REIT Inc class A common.
No dividends paid.
2. SmartStop Self Storage REIT Inc series A convertible preferred.
No dividends paid.
3. SmartStop Self Storage REIT Inc class T common.
No dividends paid.
Annual Dividends:
1. SmartStop Self Storage REIT Inc class A common.
No dividends paid.
2. SmartStop Self Storage REIT Inc series A convertible preferred.
No dividends paid.
3. SmartStop Self Storage REIT Inc class T common.
No dividends paid.

SNAIL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|-------------|-------------|
| Revenues, net | 60,902,098 | 74,444,141 | ... |
| Revenues, net | 60,902,098 | 74,444,141 | 106,734,149 |
| Cost of revenues | 48,306,403 | 53,121,676 | 63,686,242 |
| Gross profit | 12,595,695 | 21,322,465 | 43,047,907 |
| General & administrative expenses | 15,816,088 | 18,713,958 | 16,396,958 |
| Research & development expenses | 5,057,421 | 2,955,592 | 834,818 |
| Advertising & marketing expenses | 1,582,464 | 714,492 | 275,370 |
| Depreciation & amortization | 432,306 | 565,906 | 798,813 |
| Loss on disposal of fixed assets | (427) | 17,067 | (117,316) |
| Impairment of intangible assets | ... | ... | 16,325,000 |
| Total operating expenses | 22,888,706 | 22,932,881 | 34,748,275 |
| Income (loss) from operations | (10,293,011) | (1,610,416) | 8,299,632 |
| Interest income | 129,854 | 200,913 | 85,276 |
| Interest income - related parties | 2,000 | 582,632 | 1,595,372 |
| Interest expense | 1,531,719 | 922,293 | 415,793 |
| Interest expense - related parties | ... | 3,222 | 8,000 |
| Other income | 265,980 | 302,086 | 493,687 |
| Foreign currency transaction gain (loss) | (68,180) | (1,945) | (41,579) |
| Equity in earnings (loss) of unconsolidated entity | ... | ... | (314,515) |
| Total other income (loss), net | (1,202,065) | 158,171 | 1,394,448 |
| Income (loss) before provision for (benefit from) income taxes - United States | ... | ... | 9,476,520 |
| Income (loss) before provision for (benefit from) income taxes - Foreign | ... | ... | 217,560 |
| Income (loss) before provision for (benefit from) income taxes | (11,495,076) | (1,452,245) | 9,694,080 |
| Current income tax provision (benefit from) - U.S. federal | 112,344 | (499,784) | 4,975,632 |
| Current income tax provision (benefit from) - U.S. State | 82,595 | (2,535,117) | (61,333) |
| Current income tax provision (benefit from) - foreign | 49,373 | ... | 30,041 |

| | | | |
|---|-------------|-------------|-------------|
| from) | 244,312 | (3,034,901) | 4,944,340 |
| Deferred income tax provision (benefit from) - U.S. federal | (2,577,737) | 602,102 | (2,988,575) |
| Deferred income tax provision (benefit from) - U.S. State | (67,227) | (11,686) | (174,984) |
| Deferred income tax provision (benefit from) - foreign | ... | (1,938) | 3,768 |
| Deferred income tax provision (benefit from) | (2,644,964) | 588,478 | (3,159,791) |
| Income tax provision (benefit from) | (2,400,652) | (2,446,423) | 1,784,549 |
| Net income (loss) | (9,094,424) | 994,178 | 7,909,531 |
| Net loss attributable to non-controlling interests | 8,349 | (46,371) | 558,865 |
| Net income (loss) attributable to Snail Games USA, Inc. | (9,086,075) | 947,807 | 8,468,396 |
| Weighted average class A common stockholders outstanding - basic | ... | ... | 35,000,000 |
| Weighted average class A common stockholders outstanding - diluted | ... | ... | 35,000,000 |
| Net income (loss) per share attributable to class A & B common stockholders - basic | \$(0.25) | \$0.02 | \$0.24 |
| Net income (loss) per share attributable to class A & B common stockholders - diluted | \$(0.25) | \$0.02 | \$0.24 |
| Year end shares outstanding | 36,673,725 | 36,802,351 | 500,000 |
| Number of full time employees | 97 | ... | 63 |
| Shares used to calculate Basic EPS - Total | 36,659,949 | 38,000,000 | ... |
| Shares used to calculate Diluted EPS - Total | 36,659,949 | 38,000,000 | ... |
| Common Shareholders - Number | 5 | ... | ... |
| Total number of employees | 97 | ... | ... |

Reclassified to conform 2023 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 15,198,123 | 12,863,817 |
| Restricted escrow deposit | ... | 1,003,804 |
| Accounts receivable, gross | 25,658,308 | 6,777,953 |
| Less: allowance | 523,500 | 19,929 |
| Accounts receivable, net | 25,134,808 | 6,758,024 |
| Accounts receivable - related party | ... | 11,344,184 |
| Loan & interest receivable - related party | 103,753 | 101,753 |
| Prepaid expenses - related party | 6,044,404 | ... |
| Prepaid income taxes | 9,529,755 | 9,822,603 |
| Other prepaids | 70,967 | 80,271 |
| Other current assets | 463,315 | 662,267 |
| Prepaid expenses & other current assets | 10,169,448 | 10,565,141 |

| | | |
|---|--------------|--------------|
| Deferred offering costs | 105,411 | ... |
| Total current assets | 56,650,536 | 42,636,723 |
| Restricted cash & cash equivalents | 1,116,196 | 6,374,368 |
| Prepaid expenses - related party | 7,784,062 | 5,582,500 |
| Building | 1,874,049 | 1,874,049 |
| Land | 2,700,000 | 2,700,000 |
| Building improvements | 1,010,218 | 1,010,218 |
| Leasehold improvements | 1,537,775 | 1,537,775 |
| Autos & trucks | 178,695 | 178,695 |
| Computer equipment & software | 411,801 | 1,821,819 |
| Furniture & fixtures | ... | 411,801 |
| Computer and equipment | 1,809,214 | ... |
| Property, plant & equipment, gross | 9,521,752 | 9,534,357 |
| Less: accumulated depreciation & amortization | 4,839,686 | 4,419,558 |
| Property, plant & equipment, net | 4,682,066 | 5,114,799 |
| Intangible assets, net - license - related parties | ... | 1,384,058 |
| Intangible assets, net - other | 271,717 | 272,521 |
| Deferred income taxes | 10,247,500 | 7,602,536 |
| Other noncurrent assets | 164,170 | 198,668 |
| Operating lease right-of-use assets, net | 2,440,690 | 3,606,398 |
| Accounts & Notes Receivable - Trade - Net - Long-Term | 7,500,592 | ... |
| Total assets | 90,857,529 | 72,772,571 |
| Accounts payable | 12,102,929 | 9,452,391 |
| Accounts payable - related party | 23,094,436 | 19,918,259 |
| Accrued expenses & other liabilities | 2,887,193 | 1,474,088 |
| Interest payable - related parties | 527,770 | 527,770 |
| Revolving loan | ... | 9,000,000 |
| Short term note | 6,000,000 | 5,416,666 |
| Current portion of long-term debt | 2,811,923 | 86,524 |
| Current portion of deferred revenue | 19,252,628 | 4,335,404 |
| Current portion of operating lease liabilities | 1,505,034 | 1,371,227 |
| Notes payable | 2,333,333 | ... |
| Convertible notes, net of discount | 797,361 | ... |
| Total current liabilities | 71,312,607 | 51,582,329 |
| Accrued expenses | 254,731 | 457,024 |
| 2021 revolving loan | ... | 9,000,000 |
| 2021 promissory note | ... | 2,891,820 |
| 2022 short-term note | ... | 5,833,333 |
| Total long-term debt including current portion | ... | 17,725,153 |
| Less: current portion | ... | (14,503,190) |
| Long-term debt, net of current portion | ... | 3,221,963 |
| Deferred revenue, net of current portion | 15,064,078 | 5,216,042 |
| Operating lease liabilities, net of current portion | 1,425,494 | 2,930,529 |
| Total liabilities | 88,056,910 | 63,407,887 |
| Class A common stock | 927 | 925 |
| Class B common stock | 2,875 | 2,875 |
| Additional paid-in capital | 26,171,575 | 23,436,942 |
| Accumulated other comprehensive income (loss) | (254,383) | (307,200) |
| Accumulated deficit | (13,949,325) | ... |
| Retained earnings (accumulated deficit) | ... | (4,863,250) |
| Total equity (deficit) before treasury stock | ... | 18,270,292 |
| Common Stock - Treasury/Repurchased | 3,671,806 | ... |
| Treasury stock | ... | 3,414,713 |

| | | |
|---|-------------|-------------|
| Total Snail, Inc. & Snail Games USA Inc. equity (deficit) | 8,299,863 | 14,855,579 |
| Noncontrolling interests | (5,499,244) | (5,490,895) |
| Total equity (deficit) | 2,800,619 | 9,364,684 |

Recent Dividends:**1. Snail Inc class A common.**

No dividends paid.

2. Snail Inc class B common.

No dividends paid.

Annual Dividends:**1. Snail Inc class A common.**

No dividends paid.

2. Snail Inc class B common.

No dividends paid.

SOBR SAFE INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | [□] 2021 (revised) |
|--|--------------|--------------|-----------------------------|
| Cost of goods sold | 94,942 | ... | ... |
| Revenues | 157,292 | ... | ... |
| Revenues | 157,292 | 35,322 | ... |
| Cost of goods sold | ... | 19,315 | ... |
| Gross profit | 62,350 | 16,007 | ... |
| General & administrative | 6,400,723 | 7,606,218 | 3,882,706 |
| Stock-based compensation expense | 2,245,871 | 1,426,178 | 473,748 |
| Research & development | ... | 1,397,053 | 1,198,780 |
| Total operating expenses | 9,662,896 | 10,429,449 | 5,555,234 |
| Income (loss) from operations | (9,600,546) | (10,413,442) | (5,555,234) |
| Other income | 216,211 | 230,414 | ... |
| Research & development costs | 1,016,302 | ... | ... |
| Gain (loss) on debt extinguishment, net | (26,125) | 245,105 | ... |
| Gain (loss) on fair value adjustment - derivatives | ... | 1,040,000 | (60,000) |
| Interest expense | 804,261 | 2,535,519 | 1,420,063 |
| Amortization of interest - debt discount | ... | 921,488 | 835,081 |
| Total other income (expense), net | (614,175) | (1,941,488) | (2,315,144) |
| Income (loss) before provision for income taxes | (10,214,721) | (12,354,930) | (7,870,378) |
| Net income (loss) | (10,214,721) | (12,354,930) | (7,870,378) |
| Less: net income (loss) attributable to noncontrolling interest | 17 | 17 | 106 |
| Net income (loss) attributable to SOBR Safe, Inc. | (10,214,704) | (12,354,913) | (7,870,272) |
| Deemed dividends related to underwritten public offering warrants down round provision | ... | 5,005,857 | ... |
| Deemed dividend related to original warrants & new warrant down round provision | ... | 3,495,583 | ... |
| Net income (loss) attributable to common stockholders | ... | (20,856,353) | (7,870,272) |
| Weighted average shares outstanding | ... | ... | ... |
| - basic | 18,147,830 | 11,003,049 | [□] 8,658,616 |
| Weighted average shares outstanding - diluted | 18,147,830 | 11,003,049 | [□] 8,658,616 |
| Year end shares | ... | ... | ... |

| | | | |
|---|------------|-------------------------|------------------------|
| outstanding | 18,569,912 | [□] 16,984,570 | [□] 8,778,555 |
| Net income (loss) per share - basic | \$(0.56) | \$(1.90) | [□] \$(0.91) |
| Net income (loss) per share - diluted | \$(0.56) | \$(1.90) | [□] \$(0.91) |
| Number of full time employees | ... | [□] 15 | [□] 9 |
| Number of common stockholders | 3,550 | [□] 4,200 | [□] 175 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.56) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.56) | ... | ... |

[□] Reclassified to conform with 2022 presentation; [□] Adjusted for 1-for-3 stock split, April 28, 2022; [□] Shares increased due to shares issued for restricted stock units vested, convertible debt, reverse stock split, public and private equity offering, warrants and options exercised, and for services; [□] As of March 14, 2023; [□] As of March 11, 2022; [□] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|----------------------|
| Cash | 2,790,147 | 8,578,997 |
| Raw materials | 59,157 | 68,643 |
| Finished goods | 283,625 | 146,850 |
| Deposits | 15,736 | ... |
| Inventory | 342,782 | 215,493 |
| Prepaid insurance | ... | 150,344 |
| Prepaid deposits | 156,724 | 15,736 |
| Other prepaid expenses | 213,261 | 34,825 |
| Other | 24,087 | ... |
| Rent | 16,714 | ... |
| Prepaid expenses | ... | 200,905 |
| Accounts receivable | 25,280 | 30,322 |
| Total current assets | 3,371,470 | 9,025,717 |
| SOBR safe intellectual technology, gross | ... | 3,854,675 |
| Less: accumulated amortization - SOBR safe intellectual technology | ... | 995,782 |
| SOBR safe intellectual technology, net | 2,473,429 | 2,858,893 |
| Other assets | 27,427 | 27,427 |
| Operating lease right-of-use assets | 274,713 | ... |
| Total assets | 6,147,039 | 11,912,037 |
| Accounts payable | 525,665 | 142,965 |
| Registration rights & default damages & penalties | 220,000 | ... |
| Consulting services | 328,196 | 197,897 |
| Taxes & other | 178,744 | 194,385 |
| Accrued expenses | ... | 392,282 |
| Accrued interest payable | 726,940 | 469,691 |
| Related party payables | ... | 1,887 |
| Current portion notes payable - related parties | 11,810 | [□] 866,262 |
| Current portion notes payable - non-related parties | 64,331 | [□] 948,597 |
| Accrued interest payable | 96,988 | ... |
| Operating lease liabilities, current portion | 97,108 | ... |
| Total current liabilities | ... | 2,821,684 |
| Notes payable - non-related parties - less current portion | 2,305,898 | ... |
| Operating lease liabilities - less current portion | 203,295 | ... |
| Accrued interest payable | 132,467 | ... |
| Total liabilities | ... | 2,821,684 |
| Series B convertible preferred stock | ... | 30 |
| Common stock | 186 | 170 |
| Common Stock - Treasury/Repurchased | 38,015 | ... |
| Treasury stock, at cost | ... | 38,015 |
| Additional paid in | ... | ... |

| | | |
|--|--------------|--------------|
| capital | 89,840,017 | 87,509,666 |
| Accumulated deficit | (87,765,981) | ... |
| Retained earnings (accumulated deficit) | ... | (78,327,845) |
| Total SOBR Safe, Inc. stockholders' equity (deficit) | 2,036,207 | 9,144,006 |
| Noncontrolling interest | (53,670) | (53,653) |
| Total stockholders' equity (deficit) | 1,982,537 | 9,090,353 |

□ Includes unamortized debt discount related to warrants and beneficial conversion features - Current portion notes payable - related parties: \$145,548; □ Includes unamortized debt discount related to warrants and beneficial conversion features - Current portion notes payable - non-related parties: \$144,878

Recent Dividends:

1. **Sobr Safe Inc common.**
No dividends paid.
2. **Sobr Safe Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

1. **Sobr Safe Inc common.**
No dividends paid.
2. **Sobr Safe Inc series A convertible preferred.**
No dividends paid.

SOCKET MOBILE INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|---------------|------------------|
| Product revenue | 17,033,593 | ... | ... |
| Revenues | 17,033,593 | 21,237,768 | 23,199,061 |
| Cost of revenues | 8,570,739 | 10,871,312 | 10,762,617 |
| Gross profit | 8,462,854 | 10,366,456 | 12,436,444 |
| Research & development | 4,831,905 | 4,362,119 | 3,964,599 |
| Sales & marketing | 4,016,373 | 3,638,113 | 3,002,573 |
| General & administrative | 2,735,569 | 2,812,243 | 2,771,891 |
| Total operating expenses | 11,583,847 | 10,812,475 | 9,739,063 |
| Operating income (loss) | (3,120,993) | (446,019) | 2,697,381 |
| Interest income & other income (expense) | (242,161) | ... | ... |
| Interest expense, net | ... | 175,050 | 198,935 |
| Other income | ... | ... | 65,082 |
| Net income (loss) before income taxes | (3,363,154) | (621,069) | 2,563,528 |
| Deferred federal income taxes expense (benefit) | (967,300) | (313,000) | (1,354,991) |
| Deferred state income taxes expense (benefit) | (476,700) | (395,000) | (547,738) |
| Income tax expense (benefit) | (1,444,000) | (708,000) | (1,902,729) |
| Net income (loss) | (1,919,154) | 86,931 | 4,466,257 |
| Weighted average shares outstanding - basic | 7,230,074 | 7,184,847 | 6,991,194 |
| Weighted average shares outstanding - diluted | 7,230,074 | 7,532,924 | 8,923,487 |
| Year end shares outstanding | 7,336,121 | 7,089,676 | 7,183,874 |
| Net income (loss) per share - basic | \$(0.27) | \$0.01 | \$0.58 |
| Net income (loss) per share - diluted | \$(0.27) | \$0.01 | \$0.48 |
| Number of full time employees | 61 | ... | ... |
| Total number of employees | 61 | 56 | 53 |
| Number of beneficiary stockholders | ... | ... | □10,000 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.27) | ... | ... |
| Diluted EPS | ... | ... | ... |

| | | | |
|---|--------------|--------------|-----|
| Excluding ExtraOrd Items | \$(0.27) | ... | ... |
| □ As of March 25, 2022 | | | |
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 2,826,630 | 3,623,469 | |
| Accounts receivable, gross | ... | 2,700,512 | |
| Less: allowance for doubtful accounts | ... | 40,651 | |
| Accounts receivable, net | 1,699,696 | 2,659,861 | |
| Raw materials & sub-assemblies | 5,839,176 | 6,193,453 | |
| Finished goods | 500,814 | 289,181 | |
| Inventory reserves | 930,943 | 880,943 | |
| Inventories, net | 5,409,047 | 5,601,691 | |
| Prepaid insurance | 75,626 | 92,644 | |
| Product certification costs | 75,604 | 87,293 | |
| Prepaid inventory purchases | 123,736 | 196,512 | |
| Prepaid maintenance contracts & other prepaid expenses | 165,764 | 240,739 | |
| Prepaid expenses & other current assets | 440,730 | 617,188 | |
| Deferred cost on shipments to distributors | 322,580 | 266,327 | |
| Total current assets | 10,698,683 | 12,768,536 | |
| Machinery & office equipment | 2,700,759 | 1,533,087 | |
| Computer equipment | 3,631,945 | 2,715,121 | |
| Property & equipment, gross | 6,332,704 | 4,248,208 | |
| Accumulated depreciation | 3,299,503 | 2,590,999 | |
| Property & equipment, net | 3,033,201 | 1,657,209 | |
| Intangible assets, net | 1,559,369 | 1,693,927 | |
| Other long-term assets | 249,715 | 250,239 | |
| Deferred tax assets | 10,112,419 | 8,668,419 | |
| Operating lease right-of-use asset | 3,088,087 | 3,559,658 | |
| Total assets | 28,741,474 | 28,597,988 | |
| Accounts payable & accrued expenses | 1,605,231 | 1,665,028 | |
| Accrued payroll & related expenses | 579,974 | 742,541 | |
| Deferred revenue on shipments to distributors | 825,670 | 594,793 | |
| Short term portion of deferred service revenue | 19,885 | 22,599 | |
| Notes payable - current portion | ... | 125,000 | |
| Subordinated convertible notes payable, net of discount | 150,000 | 147,409 | |
| Subordinated convertible notes payable, net of discount-related party | 2,835,864 | 1,230,530 | |
| Operating lease - current portion | 483,161 | 444,529 | |
| Total current liabilities | 6,499,785 | 4,972,429 | |
| Long term portion of deferred service revenue | 12,813 | 11,767 | |
| Long-term portion of operating lease | 2,808,872 | 3,292,035 | |
| Total liabilities | 9,321,470 | 8,276,231 | |
| Common stock | 7,336 | 7,090 | |
| Additional paid-in capital | 68,383,230 | 67,157,650 | |
| Treasury stock | 1,037,988 | 829,563 | |
| Retained earnings (accumulated deficit) | (47,932,574) | (46,013,420) | |
| Total stockholders' equity (deficit) | 19,420,004 | 20,321,757 | |
| Total Equity | 19,420,004 | ... | |

Recent Dividends:

1. **Socket Mobile Inc common.**
No dividends paid.

2. Socket Mobile Inc series F redeemable convertible preferred.

No dividends paid.

Annual Dividends:

1. **Socket Mobile Inc common.**
No dividends paid.
2. **Socket Mobile Inc series F redeemable convertible preferred.**
No dividends paid.

No dividends paid.

SONIM TECHNOLOGIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | □2021 (revised) |
|--|-------------|-----------------|-----------------|
| Total Net Revenues | 93,632 | ... | ... |
| Net revenues | ... | 69,828 | 54,570 |
| Cost of revenues | 74,308 | 58,205 | 48,156 |
| Gross profit | 19,324 | 11,623 | 6,414 |
| Research & development expenses | 1,772 | 7,973 | 17,696 |
| Sales & marketing expenses | 8,768 | 7,274 | 9,566 |
| General & administrative expenses | 8,271 | 9,612 | 10,284 |
| Legal expenses | ... | 1,054 | 6,869 |
| Total operating expenses | 18,811 | 25,913 | 44,415 |
| Income (loss) from operations | 513 | (14,290) | (38,001) |
| Interest expense | 15 | 97 | ... |
| Other income (expense), net | (214) | 484 | (459) |
| Income (loss) before income taxes - domestic income (loss) | (425) | 13,885 | 39,065 |
| Income (loss) before income taxes - foreign subsidiaries income (loss) | 709 | (18) | 605 |
| Income (loss) before income taxes | 284 | (13,903) | (38,460) |
| Current federal income tax expense (benefit) | 2 | ... | ... |
| Current state income tax expense (benefit) | 56 | 21 | 17 |
| Current foreign income tax expense (benefit) | 250 | 306 | 169 |
| Total current income tax expense (benefit) | 308 | 327 | 186 |
| Deferred foreign income tax expense (benefit) | 66 | (143) | (19) |
| Total deferred income tax expense (benefit) | 66 | (143) | (19) |
| Income tax expense (benefit) | 374 | 184 | 167 |
| Net income (loss) | (90) | (14,087) | (38,627) |
| Weighted average shares outstanding - basic | 41,689 | 28,889 | 9,465 |
| Weighted average shares outstanding - diluted | 41,689 | 28,889 | 9,465 |
| Year end shares outstanding | 43,081 | □40,775 | □18,809 |
| Net earnings (loss) per share - basic | \$(0.00) | \$(0.49) | \$(4.08) |
| Net earnings (loss) per share - diluted | \$(0.00) | \$(0.49) | \$(4.08) |
| Number of full time employees | 67 | □54 | □477 |
| Other number of employees | ... | □23 | □425 |
| Total number of | ... | ... | ... |

| | | | | | | | | | | |
|--|---------|----------|----------|--|-------|--------|--------|---|---------|---------|
| Cost of revenues | 202,070 | 201,452 | 200,796 | employees | 541 | 25,000 | 25,000 | Long-term debt | 310 | 1,376 |
| Gross profit (loss) | 55,480 | 51,012 | 47,522 | Number of | | | | Total liabilities | 50,035 | 56,537 |
| Selling, general & administrative expense | 43,673 | 41,135 | 36,778 | stockholders | | 169 | 166 | Series B convertible preferred stock | 7 | 9 |
| Majority stockholders change of control agreement | ... | ... | 4,478 | Number of common stockholders | 2,360 | ... | ... | Common stock | 232 | 229 |
| Depreciation & amortization | 2,001 | 2,033 | 2,083 | Foreign currency translation adjustments | ... | (391) | ... | Treasury Stock | 285 | ... |
| Impairment of goodwill | ... | 2,458 | ... | Loss on sale of business | (408) | ... | ... | Treasury stock, at cost | ... | 285 |
| Operating income (loss) | 9,398 | 5,386 | 4,183 | | | | | Additional paid-in capital | 21,004 | 20,708 |
| Interest expense, net | 1,919 | 965 | 585 | | | | | Accumulated other comprehensive income (loss) | (3,341) | (4,941) |
| Other income (expense), net | (346) | 482 | 510 | | | | | Retained earnings | 10,609 | ... |
| Income (loss) before income tax expense - domestic | ... | (4,079) | (5,672) | | | | | Retained earnings (accumulated deficit) | ... | 6,707 |
| Income (loss) before income tax expense - foreign | ... | 8,982 | 9,780 | | | | | Total stockholders' equity (deficit) attributable to SPAR Group, Inc. | 28,226 | 22,427 |
| Income (loss) before income tax expense | 7,133 | 4,903 | 4,108 | | | | | Non-controlling interest | 12,020 | 15,634 |
| Current federal income tax expense (benefit) | (54) | 24 | ... | | | | | Total stockholders' equity (deficit) | 40,246 | 38,061 |
| Current foreign income tax expense (benefit) | 2,311 | 2,705 | 2,438 | | | | | | | |
| Current state income tax expense (benefit) | 150 | 66 | 117 | | | | | | | |
| Deferred federal income tax expense (benefit) | (145) | (128) | (654) | | | | | | | |
| Deferred foreign income tax expense (benefit) | 91 | 317 | 219 | | | | | | | |
| Deferred state income tax expense (benefit) | 4 | (207) | (12) | | | | | | | |
| Income tax expense (benefit) | 2,357 | 2,777 | 2,108 | | | | | | | |
| Net income (loss) | 4,776 | 2,126 | 2,000 | | | | | | | |
| Less: net income (loss) attributable to non-controlling interest | (874) | (2,858) | (3,779) | | | | | | | |
| Net income (loss) attributable to SPAR Group, Inc. | 3,902 | (732) | (1,779) | | | | | | | |
| Weighted average shares outstanding - basic | 23,333 | 22,110 | 21,266 | | | | | | | |
| Weighted average shares outstanding - diluted | 24,455 | 22,110 | 21,266 | | | | | | | |
| Year end shares outstanding | 23,241 | 22,854 | 21,320 | | | | | | | |
| Income (loss) per share from continuing operations - basic | \$0.17 | ... | ... | | | | | | | |
| Net income (loss) per common share - basic | \$0.17 | \$(0.03) | \$(0.08) | | | | | | | |
| Income (loss) per share from continuing operations - diluted | \$0.16 | ... | ... | | | | | | | |
| Net income (loss) per common share - diluted | \$0.16 | \$(0.03) | \$(0.08) | | | | | | | |
| Number of full time employees | 462 | ... | ... | | | | | | | |
| Number of part time employees | 79 | ... | ... | | | | | | | |
| Total number of | | | | | | | | | | |

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$000): | | | |
|--|--------|--------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents | 10,719 | 9,345 | |
| Accounts receivable - trade | 61,237 | 53,658 | |
| Accounts receivable - unbilled | ... | 10,436 | |
| Accounts receivable - non-trade | ... | 1,274 | |
| Less: allowance for doubtful accounts | 1,461 | 1,654 | |
| Accounts receivable, net | 59,776 | 63,714 | |
| Prepaid expenses & other current assets | ... | 7,861 | |
| Prepaid program costs | 5,614 | ... | |
| Total current assets | 76,109 | 80,920 | |
| Equipment | 5,062 | 5,109 | |
| Furniture & fixtures | ... | 2,319 | |
| Leasehold improvements | 366 | 352 | |
| Capitalized software development costs | 18,336 | 17,298 | |
| Property and equipment - Balancing value | 2,330 | ... | |
| Property & equipment, gross | 26,094 | 25,078 | |
| Less: accumulated depreciation & amortization - property & equipment | 23,223 | 21,817 | |
| Property & equipment, net | 2,871 | 3,261 | |
| Operating lease right-of-use assets | 2,323 | 969 | |
| Goodwill | 1,382 | 1,708 | |
| Intangible assets, net | 1,180 | 2,040 | |
| Deferred tax assets, net | 4,687 | 3,766 | |
| Other assets | 1,729 | 1,934 | |
| Total assets | 90,281 | 94,598 | |
| Line of credit & notes payable | 16,410 | ... | |
| Accounts payable | 9,488 | 10,588 | |
| Taxes payable | 1,598 | 2,660 | |
| Accrued salaries & wages | 9,206 | 9,327 | |
| Accrued accounting & legal expenses | ... | 2,186 | |
| Loans from domestic & international local investors | 3,205 | ... | |
| Accrued third party labor | ... | 2,411 | |
| Majority stockholders change of control agreement | 1,975 | ... | |
| Other accrued expense & current liabilities | ... | 3,677 | |
| Accrued expenses due to affiliates | 15,274 | ... | |
| Due to affiliates | ... | 2,964 | |
| Customer incentives & deposits | 1,905 | 2,399 | |
| Lines of credit & short-term loans | 17,530 | 17,980 | |
| Current portion of operating lease liabilities | 1,163 | 363 | |
| USA - Resource Plus Seller Notes | 1,120 | ... | |
| Total current liabilities | 48,565 | 54,555 | |
| Operating lease liabilities, net of current portion | 1,160 | 606 | |

| Recent Dividends: | | | |
|--|--|--|--|
| 1. SPAR Group, Inc. series B convertible preferred. | | | |
| No dividends paid. | | | |
| 2. SPAR Group, Inc. common. | | | |
| No dividends paid. | | | |
| 3. SPAR Group, Inc. preferred. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. SPAR Group, Inc. series B convertible preferred. | | | |
| No dividends paid. | | | |
| 2. SPAR Group, Inc. common. | | | |
| No dividends paid. | | | |
| 3. SPAR Group, Inc. preferred. | | | |
| No dividends paid. | | | |

| SPARTA COMMERCIAL SERVICES INC | | | |
|--|------------|-------------|--|
| Earnings, 9 mos. to Jan 31(Consol. - \$): | | | |
| | 2024 | 2023 | |
| Total revenues | 151,433 | 189,042 | |
| Cost & expenses | 924,455 | 1,313,410 | |
| Operating income | (773,023) | (1,124,368) | |
| Other income (expense), net | 492,090 | 5,045,352 | |
| Gains or losses | ... | (625,064) | |
| Net before taxes | (721,240) | ... | |
| Net income | (721,240) | 3,115,706 | |
| Balance for common | ... | 3,105,912 | |
| Earnings common share | | | |
| Primary | \$(0.04) | \$0.17 | |
| Fully Diluted | \$(0.04) | \$0.17 | |
| Common Shares: | | | |
| Full Diluted | 18,074,511 | 18,074,511 | |
| Year-end | 26,141,106 | 21,581,449 | |

| SPECTRAL AI INC | | | |
|---|--------------|-------------|-------------|
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| General & administrative expenses | 20,864,000 | 1,251,036 | 3,420,593 |
| Income (loss) from operations | (12,984,000) | (1,251,036) | (3,420,593) |
| Change in fair value of warrants | 335,000 | 9,748,442 | 1,683,358 |
| Transaction costs allocated to warrant liabilities | ... | ... | 438,283 |
| Interest earned on investment held in trust account | ... | 3,155,965 | 27,240 |
| Foreign exchange transaction loss | (24,000) | ... | ... |
| Net interest income | 172,000 | ... | ... |
| Transaction costs | (8,342,000) | ... | ... |
| Total other income (expense), net | ... | 12,904,407 | 1,272,315 |
| Income (loss) before provision for income taxes | (20,843,000) | 11,653,371 | (2,148,278) |
| Current provision | ... | ... | ... |

| | | | |
|---|---------------------|-------------------|--------------------|
| for federal income taxes | (5,000) | 614,297 | ... |
| Deferred provision for federal income taxes | ... | (214,262) | ... |
| Change in valuation allowance | ... | 214,262 | ... |
| US State | 16,000 | ... | ... |
| Provision for income taxes (expense) | 11,000 | 614,297 | ... |
| Net income (loss) | (20,854,000) | 11,039,074 | (2,148,278) |
| Weighted average class A shares outstanding - basic | ... | 25,095,264 | 21,972,877 |
| Weighted average class B shares outstanding - basic | ... | 6,325,000 | 6,216,507 |
| Weighted average shares outstanding - basic | 14,087,586 | ... | ... |
| Weighted average class A shares outstanding - diluted | ... | 25,095,264 | 21,972,877 |
| Weighted average class B shares outstanding - diluted | ... | 6,325,000 | 6,216,507 |
| Weighted average shares outstanding - diluted | 14,087,586 | ... | ... |
| Year end shares outstanding | 16,294,935 | 6,783,716 | 31,625,000 |
| Net earnings (loss) per class A share - basic | ... | \$0.35 | \$(0.08) |
| Net earnings (loss) per class B share - basic | ... | \$0.35 | \$(0.08) |
| Net earnings (loss) per share - basic | \$(1.48) | ... | ... |
| Net earnings (loss) per class B share - diluted | ... | \$0.35 | \$(0.08) |
| Net earnings (loss) per class B share - diluted | ... | \$0.35 | \$(0.08) |
| Net earnings (loss) per share - diluted | \$(1.48) | ... | ... |
| Full-Time Employees (Period End) | 78 | ... | ... |
| Total number of employees | 78 | 3 | 3 |
| Number of class A ordinary stockholders | ... | □□1 | □1 |
| Research and development revenue | 18,056,000 | ... | ... |
| Cost of revenue | 10,176,000 | ... | ... |
| Total Revenue | 18,056,000 | ... | ... |
| Gross profit | 7,880,000 | ... | ... |
| Total operating costs and expenses | 20,864,000 | ... | ... |

□ As of March 30, 2023; □ Approximately; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|-----------|
| Cash | ... | 785,038 |
| Prepaid expenses | 1,452,000 | 153,575 |
| Cash and cash equivalents | 4,790,000 | ... |
| Accounts receivable, net | 2,346,000 | ... |
| Inventory | 230,000 | ... |
| Other Current Assets | 801,000 | ... |
| Deferred Offering Costs | 283,000 | ... |
| Total current assets | 9,902,000 | 938,613 |
| Investments & cash held in trust account | ... | 4,626,107 |
| Property and equipment, net | 12,000 | ... |
| Right-of-use assets | 778,000 | ... |
| Total assets | 10,692,000 | 5,564,720 |

| | | | |
|---|--------------|--------------|-----|
| Accrued expenses | 4,300,000 | 3,352,296 | ... |
| Accrued offering costs | 720,000 | ... | ... |
| Income taxes payable | ... | 255,297 | ... |
| Due to sponsor | ... | 16,152 | ... |
| Accounts payable | 2,683,000 | ... | ... |
| Lease liabilities, short-term | 853,000 | ... | ... |
| Notes payable | 436,000 | ... | ... |
| Warrant liabilities | 1,818,000 | ... | ... |
| Deferred revenue | 2,311,000 | ... | ... |
| Salary and wages | 1,910,000 | ... | ... |
| Taxes | 107,000 | ... | ... |
| Operating expenses | 1,563,000 | ... | ... |
| Total current liabilities | 12,401,000 | 3,623,745 | ... |
| Warrant liabilities | ... | 394,200 | ... |
| Deferred underwriting fee payable | ... | 8,855,000 | ... |
| Total liabilities | 12,401,000 | 12,872,945 | ... |
| Class A common stock subject to possible redemption | ... | 4,787,977 | ... |
| Class B common stock | 2,000 | 633 | ... |
| Additional paid in capital | 31,065,000 | ... | ... |
| Accumulated deficit | (32,788,000) | ... | ... |
| Retained earnings (accumulated deficit) | ... | (12,096,835) | ... |
| Accumulated other comprehensive income | 12,000 | ... | ... |
| Total stockholders' equity (deficit) | (1,709,000) | (12,096,202) | ... |
| Total Equity | (1,709,000) | ... | ... |

Recent Dividends:
1. Spectral Ai Inc common.
 No dividends paid.
2. Spectral Ai Inc class B common.
 No dividends paid.
3. Spectral Ai Inc class A common.
 No dividends paid.
Annual Dividends:
1. Spectral Ai Inc common.
 No dividends paid.
2. Spectral Ai Inc class B common.
 No dividends paid.
3. Spectral Ai Inc class A common.
 No dividends paid.

SPECTRAL CAPITAL CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------------|------------------|------------------|
| Revenues | ... | 98,323 | ... |
| Gross income | ... | 98,323 | ... |
| Selling, general & administrative expenses | 71,477 | 195,383 | 28,230 |
| Wages & benefits expenses | 144,000 | 144,000 | 144,000 |
| Total operating expenses | 215,477 | 339,383 | 172,230 |
| Net income (loss) before non-controlling interest | (215,477) | (241,060) | (172,230) |
| Income (loss) attributable to non-controlling interest | 90 | 72 | 61 |
| Net income (loss) attributable to Spectral Capital Corporation | (215,387) | (240,988) | (172,169) |
| Weighted average shares outstanding - basic | 42,017,948 | 34,644,111 | □11,785,762 |
| Weighted average shares outstanding - diluted | 42,017,948 | 34,644,111 | □11,785,762 |
| Year end shares outstanding | 42,017,948 | □42,017,948 | □11,785,762 |
| Net income (loss) per common share - | ... | ... | ... |

| | | | |
|--|-----------|----------|---------|
| basic | \$(0.01) | \$(0.01) | □\$0.00 |
| Net income (loss) per common share - diluted | \$(0.01) | \$(0.01) | □\$0.00 |
| Number of full time employees | 1 | 1 | 1 |
| Total number of employees | 1 | ... | ... |
| Number of common stockholders | 97 | □97 | □90 |
| Total operating expenses | (215,477) | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

□ Adjusted for 1-for-10 stock split, December 2, 2022; □ Shares increased due to the effect of proceeds from sale of common stock and conversion of convertible note; □ Approximately; □ As of March 24, 2023; □ As of January 31, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|--------------|
| Cash & cash equivalents | 240 | 10,672 |
| Accounts receivable | ... | 25,000 |
| Total current assets | 240 | 35,672 |
| Total assets | 240 | 35,672 |
| Accounts payable & accrued liabilities | 6,150 | 222,174 |
| Related party advances & accruals | 36,450 | 5,500 |
| Accounts payable and accrued liabilities | 290,119 | ... |
| Total current liabilities | 332,719 | 227,674 |
| Total liabilities | ... | 227,674 |
| Common stock | 4,202 | 4,202 |
| Additional paid-in capital | 29,181,804 | 29,106,804 |
| Retained earnings (accumulated deficit) | (29,296,599) | (29,081,212) |
| Total stockholders' equity (deficit) | (110,593) | 29,794 |
| Non-controlling interest | (221,886) | (221,796) |
| Total stockholders' equity (deficit) | (332,479) | (192,002) |

Recent Dividends:
1. Spectral Capital Corp common.
 No dividends paid.
Annual Dividends:
1. Spectral Capital Corp common.
 No dividends paid.

SPIRITS TIME INTERNATIONAL INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------------|------------------|------------------|
| Professional fees | 63,136 | 78,337 | 50,410 |
| Selling, general & administrative | 11,994 | 10,077 | 10,586 |
| Total operating expenses | 75,130 | 88,414 | 60,996 |
| Income (loss) from operations | (75,130) | (88,414) | (60,996) |
| Impairment loss on inventory | 275,000 | 80,404 | ... |
| Interest expense | 122,388 | 117,810 | 120,072 |
| Total other income (expenses) | (397,388) | (198,214) | (120,072) |
| Income (loss) before income taxes | (472,518) | (286,628) | (181,068) |
| Current federal income taxes | ... | 62,000 | 35,000 |
| Stock compensation | ... | (4,000) | ... |
| Change in valuation allowance | ... | (58,000) | (35,000) |
| Net income (loss) | (472,518) | (286,628) | (181,068) |
| Weighted average shares outstanding - basic | 7,394,107 | 7,361,005 | 7,361,005 |

| | | | |
|---|-----------|-----------|-----------|
| Weighted average shares outstanding - diluted | 7,394,107 | 7,361,005 | 7,361,005 |
| Year end shares outstanding | 7,498,305 | 7,361,005 | 7,361,005 |
| Net income (loss) per share - basic | \$(0.06) | \$(0.04) | \$(0.02) |
| Net income (loss) per share - diluted | \$(0.06) | \$(0.04) | \$(0.02) |
| Number of common stockholders | 40 | 40 | 40 |
| LOSS BEFORE INCOME TAXES | (472,518) | | |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.06) | | |
| Diluted EPS Excluding ExtraOrd Items | \$(0.06) | | |

□ Approximately

| | | | |
|--|-------------|-------------|--|
| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | |
| Cash & cash equivalents | 493 | 707 | |
| Total current assets | 493 | 707 | |
| Intangible assets | | 275,000 | |
| Total assets | 493 | 275,707 | |
| Accounts payable | 207,775 | 178,409 | |
| Accounts payable - related party | 9,500 | 10,500 | |
| Accrued interest | 351,285 | 290,153 | |
| Accrued interest - related parties | 164,819 | 127,684 | |
| Loans payable - related parties | | 235,375 | |
| Notes payable - related parties | 271,675 | | |
| Convertible notes payable - related parties | 55,000 | 55,000 | |
| Convertible note payable | 290,000 | 290,000 | |
| Notes payable | 85,000 | 75,000 | |
| Total current liabilities | 1,435,054 | 1,262,121 | |
| Total liabilities | 1,435,054 | 1,262,121 | |
| Preferred stock designated, series A | 5 | 450 | |
| Preferred stock designated, series D | 450 | 5 | |
| Common stock | 7,498 | 7,361 | |
| Additional paid-in capital | 986,354 | 962,120 | |
| Accumulated deficit | (2,428,868) | | |
| Retained earnings (accumulated deficit) | | (1,956,350) | |
| Total stockholders' equity (deficit) | (1,434,561) | (986,414) | |
| Total Equity | (1,434,561) | | |

Recent Dividends:

- Spirits Time International Inc common.**
No dividends paid.
 - Spirits Time International Inc series A convertible preferred.**
No dividends paid.
 - Spirits Time International Inc series D preferred.**
No dividends paid.
- Annual Dividends:**
- Spirits Time International Inc common.**
No dividends paid.
 - Spirits Time International Inc series A convertible preferred.**
No dividends paid.
 - Spirits Time International Inc series D preferred.**
No dividends paid.

SPIRITS TIME INTERNATIONAL INC

Auditor's Report Auditor's Report

The following is an excerpt from the Report of the Independent Auditors, Pinnacle Accountancy Group of Utah, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying balance sheet of Spirits Time International, Inc. (the Company) as of December 31, 2022, and the related statements of operations, stockholders' equity (deficit), and cash flows for the year then ended, and the related notes (collectively referred to as the financial statements). In our opinion, the

financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022, and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Consideration of the Company's Ability to Continue as a Going Concern The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The Company has suffered recurring losses since inception, has a working capital deficit, and has not achieved profitable operations, which raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are described in Note 4. The financial statements do not include any adjustments that might result from the outcome of this uncertainty."

SPRINGBIG HOLDINGS, INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|---------------------|------------------|----------------|
| | 2023 | 2021 | 2020 (revised) |
| Operating & formation costs | | 2,035,074 | 5,064 |
| Income (loss) from operations | (8,340,000) | (2,035,074) | |
| Change in fair value of warrant liabilities | 334,000 | 12,960,000 | |
| Transaction costs allocated to warrant liabilities | | 853,386 | |
| Compensation expense | | 2,400,000 | |
| Interest earned on investments held in trust account | 24,000 | 35,810 | |
| Interest Expense | 2,247,000 | | |
| Total other income (expense), net | | 9,742,424 | |
| Net income (loss) | (10,233,000) | 7,707,350 | (5,064) |
| Weighted average class A ordinary shares outstanding - basic | | 17,369,863 | |
| Revenues | 28,050,000 | | |
| Weighted average class B ordinary shares outstanding - basic | | 4,917,808 | 4,375,000 |
| Total revenues | 28,050,000 | | |
| Weighted average shares outstanding - basic | 36,147,187 | | |
| Weighted average shares outstanding - diluted | 36,147,187 | 5,000,000 | 4,375,000 |
| Year end shares outstanding | 45,339,762 | 25,000,000 | 5,031,250 |
| Net earnings (loss) per class A ordinary share - basic | | \$0.35 | |
| Net earnings (loss) per class B ordinary share - basic | | \$0.35 | \$0.00 |
| Selling, servicing and marketing | 8,278,000 | | |
| General and administrative | 13,615,000 | | |
| Net earnings (loss) per share - basic | \$(0.28) | | |
| Net earnings (loss) per class B ordinary share - diluted | \$(0.28) | \$0.34 | \$0.00 |
| Full-Time Employees (Period End) | 83 | | |
| Total number of employees | 83 | 3 | 3 |
| Number of unit stockholders | | 1 | |
| Number of class A ordinary stockholders | | 1 | |

| | | | |
|---|--------------|---|--|
| Number of class B ordinary stockholders | | 4 | |
| Income from cont operations before income tax | (10,229,000) | | |
| Total operating expenses | 29,904,000 | | |
| Technology and software development | 8,011,000 | | |
| Gross Profit | 21,564,000 | | |
| Income Taxes - State - Current | 4,000 | | |
| Net loss | 4,000 | | |
| Cost of Revenues - Total | 6,486,000 | | |
| Common Shareholders - Number | 42 | | |

□ From January 24, 2020 (inception); □ Reclassified to conform with 2021 presentation; □ Shares increased due to the effect of issuance of class A common stock sold in initial public offering; □ As of March 9, 2021

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|--|------------|-------------|
| | 2023 | 2021 |
| Cash and cash equivalents | 331,000 | |
| Cash | | 621,472 |
| Prepaid expenses | 425,000 | 259,939 |
| Prepaid insurance | 379,000 | |
| Accounts receivable, net | 2,948,000 | |
| Contract assets | 273,000 | |
| Prepaid expenses and other current assets | 893,000 | |
| Unbilled receivables | 4,543,000 | |
| allowance for credit losses | 1,595,000 | |
| Deposits | 89,000 | |
| Total current assets | 4,445,000 | 881,411 |
| Investments held in Trust | | 200,035,810 |
| Account | | |
| Computer Equipment - Gross | 416,000 | |
| accumulated depreciation and amortization | 728,000 | |
| Software - Gross | 197,000 | |
| Furniture | 149,000 | |
| Data Warehouse - Gross | 286,000 | |
| Property, Plant & Equipment - Gross - Total | 1,048,000 | |
| Property and equipment, net | 320,000 | |
| Operating lease assets | 340,000 | |
| Total assets | 5,105,000 | 200,917,221 |
| Accounts payable & accrued expenses | 2,925,000 | 1,555,405 |
| Accrued offering costs | 176,000 | 108,000 |
| Promissory note - related party | 1,000,000 | |
| Other liabilities | 382,000 | |
| Accrued expense and other current liabilities | 1,951,000 | |
| Accrued Wages, Commission and Bonus | 393,000 | |
| Current maturities of long-term debt | 4,360,000 | |
| Operating lease liabilities - current | 99,000 | |
| Deferred payroll tax credits | 1,751,000 | |
| Related party payable | 540,000 | |
| Short-term cash advance | 1,925,000 | |
| Total current liabilities | 13,551,000 | 1,663,405 |
| Warrant liabilities | 3,000 | 9,440,000 |
| Deferred underwriting fee payable | | 7,000,000 |
| Operating lease liabilities - non-current | 225,000 | |
| Total liabilities | 13,779,000 | 18,103,405 |
| Class A ordinary shares subject to possible redemption | | 200,000,000 |

| | | |
|---|--------------|--------------|
| Class B ordinary shares | 4,000 | 500 |
| Additional paid in capital | 27,887,000 | ... |
| Accumulated deficit | (36,565,000) | ... |
| Retained earnings (accumulated deficit) | ... | (17,186,684) |
| Total shareholder's equity | (8,674,000) | (17,186,184) |
| Total Equity | (8,674,000) | ... |

Recent Dividends:

1. SpringBig Holdings, Inc class A common.

No dividends paid.

2. SpringBig Holdings, Inc common.

No dividends paid.

3. SpringBig Holdings, Inc class B common.

No dividends paid.

Annual Dividends:

1. SpringBig Holdings, Inc class A common.

No dividends paid.

2. SpringBig Holdings, Inc common.

No dividends paid.

3. SpringBig Holdings, Inc class B common.

No dividends paid.

SS INNOVATIONS INTERNATIONAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------|-------------|-------------------|
| Research & development expense | 576,168 | 72,959 | 1,000 |
| Stock-Based Compensation in Selling, General & Administrative Expenses | 13,425,319 | ... | ... |
| Compensation expense | 2,215,620 | 1,135,468 | 947,237 |
| General & administrative expenses | 5,164,713 | 1,239,179 | 458,801 |
| Loss from operations | (20,668,373) | ... | ... |
| Total operating expenses | 21,381,820 | 2,447,606 | 1,407,038 |
| Investment gain (loss) | ... | ... | (77,392) |
| Interest earned | ... | 148 | 118 |
| Interest expenses | 523,356 | 45,529 | ... |
| Origination fees | 120,000 | 279,975 | ... |
| Interest and other income, net | 129,758 | ... | ... |
| Total other income & (expenses), net | (273,599) | 234,594 | (77,274) |
| Income (loss) before income tax | ... | ... | ... |
| taxes | (20,941,972) | (2,213,012) | (1,484,313) |
| Net income (loss) | (20,941,972) | (2,213,012) | (1,484,313) |
| Weighted average shares outstanding | ... | ... | ... |
| - basic | 128,445,575 | 4,087,882 | 2,848,097 |
| Weighted average shares outstanding | ... | ... | ... |
| - diluted | 128,445,575 | 4,087,882 | 2,848,097 |
| Year end shares outstanding | 170,711,881 | 5,388,774 | 3,784,891 |
| Net earnings (loss) per common share - basic | \$(0.16) | \$(0.50) | \$(0.50) |
| Net earnings (loss) per common share - diluted | \$(0.16) | \$(0.50) | \$(0.50) |
| Number of full time employees | 239 | 2 | 4 |
| Number of part time employees | ... | 3 | 6 |
| Total number of employees | 239 | ... | ... |
| Number of common stockholders | 341 | 191 | 181 |
| System Sales | 5,692,721 | ... | ... |
| Warranty Sales | 186,989 | ... | ... |

| | | | |
|---------------------|-----------|-----|-----|
| Cost of revenue | 5,166,263 | ... | ... |
| GROSS (LOSS) PROFIT | 713,447 | ... | ... |

As reported by the Company; Adjusted for 1-for-10 stock split, April 17, 2023; Shares increased due to the effect of issuance of common stock and stock issued for services; Shares increased due to the effect of stock based compensation expense, conversion of debt to equity, security offerings, stock issued for services, private placement, common stock issued; As of March 30, 2023; As of November 1, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 2,022,276 | 1,351,364 |
| Other prepaid expenses & deposit | ... | 8,678 |
| Notes receivables - acquisition | ... | 3,000,000 |
| Prepays and other current assets | 3,375,168 | ... |
| Accounts receivable, net of allowances | 1,647,274 | ... |
| Inventory | 6,327,256 | ... |
| Restricted cash | 5,010,725 | ... |
| Total current assets | 18,382,700 | 4,360,042 |
| SubTotal | 311,703 | ... |
| Property and equipment at cost Furniture And Fixtures | 177,417 | ... |
| Property and equipment at cost Vehicles | 184,694 | ... |
| Property and equipment at cost Leasehold Improvements | 154,194 | ... |
| Computer and office equipment | 287,518 | ... |
| R & D Equipments | 39,950 | ... |
| Server & Networking | 21,999 | ... |
| Equipment | 1,213,596 | 98,592 |
| Accumulated depreciation | 423,432 | 87,193 |
| Total equipment, net | 790,164 | 11,399 |
| Website | 36,122 | ... |
| Long Term Receivable | 2,640,341 | ... |
| Right of use asset | 2,199,418 | ... |
| Loans & Advances (Related Party) | 1,466,462 | ... |
| Total other assets, net | 7,096,386 | ... |
| Total assets | 25,479,086 | 4,371,441 |
| Accounts payable | 900,903 | ... |
| Accrued expenses | ... | 5,700 |
| Accrued interest | ... | 45,529 |
| Notes payable - related party | ... | 4,000,000 |
| Other accrued liabilities | 2,041,372 | ... |
| Deferred tax liability | 20,482 | ... |
| Bank Overdraft Facility | 6,018,926 | ... |
| Right of use liability, current portion | 288,988 | ... |
| Total current liabilities | 9,270,670 | 4,051,229 |
| Common stock | 17,071 | 5,389 |
| Additional paid in capital | 49,039,341 | 11,005,895 |
| Retained earnings (accumulated deficit) | (35,329,246) | (10,691,071) |
| Preferred Stock | 1 | ... |
| Translation adjustment | (329,100) | ... |
| Accumulated other comprehensive income (loss) | 899,917 | ... |
| Total stockholders' equity (deficit) | 14,297,984 | 320,213 |
| Right of use liability, non current portion | 1,910,432 | ... |
| Total Liabilities | 11,181,102 | ... |
| Total Equity | 14,297,984 | ... |

Recent Dividends:

1. SS Innovations International Inc common.

No dividends paid.

2. SS Innovations International Inc series A non-convertible preferred.

No dividends paid.

Annual Dividends:

1. SS Innovations International Inc common.

No dividends paid.

2. SS Innovations International Inc series A non-convertible preferred.

No dividends paid.

STAR GOLD CORP

Earnings, 9 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------|------------|------------|
| Cost & expenses | 167,071 | 237,776 |
| Operating income | (167,071) | (237,776) |
| Net before taxes | (198,580) | (254,831) |
| Net income | (198,580) | (254,831) |
| Earnings common share | ... | ... |
| Common Shares: | ... | ... |
| Full Diluted | 97,290,810 | 97,290,810 |
| Year-end | 97,290,810 | 97,290,810 |

STARCO BRANDS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

2023 2022 2021 (revised)

| | | | |
|--|--------------|-------------|-------------|
| Revenues, net related party | 65,211,238 | ... | ... |
| Revenue, net | 65,211,238 | 7,812,728 | 673,329 |
| Cost of goods sold | 37,431,277 | 776,127 | ... |
| Gross profit | 27,779,961 | 7,036,601 | 673,329 |
| Compensation expense | 15,899,492 | 1,175,267 | 285,837 |
| Professional fees | 5,861,649 | 1,822,927 | 460,363 |
| General & administrative expenses | 21,643,733 | ... | ... |
| Marketing, general & administrative | ... | 2,756,808 | 1,159,520 |
| Marketing, related party | ... | 131,614 | 1,058,210 |
| Fair value share adjustment loss (gain) | (215,531) | ... | ... |
| Goodwill impairment | 29,612,700 | ... | ... |
| Total operating expenses | 73,233,105 | 5,886,616 | 2,963,930 |
| Income (loss) from operations | (45,453,144) | 1,149,985 | (2,290,601) |
| Interest expense | 850,105 | 68,721 | 30,973 |
| Other income (expense) | (98,872) | (103,406) | (3,500) |
| Total other income (expense) | (948,977) | (172,127) | (34,473) |
| Income (loss) before provision for income taxes | (46,402,121) | 977,858 | (2,325,074) |
| Net income (loss) | (46,402,121) | 977,858 | (2,325,074) |
| Net income (loss) attributable to non-controlling interest | 210,871 | (167,891) | 73,909 |
| Net income (loss) attributable to starco Brands | (46,191,250) | 809,967 | (2,251,165) |
| Weighted average shares outstanding | ... | ... | ... |
| - basic | 447,083,254 | 178,679,069 | 159,140,665 |
| Weighted average shares outstanding | ... | ... | ... |
| - diluted | 447,083,254 | 192,927,018 | 159,140,665 |
| Year end shares outstanding | 488,926,717 | 291,433,430 | 159,140,665 |
| Net income (loss) per share - basic | \$(0.10) | \$0.00 | \$(0.01) |
| Net income (loss) per share - diluted | \$(0.10) | \$0.00 | \$(0.01) |
| Number of full time employees | 36 | ... | ... |
| Number of common stockholders | 306 | 309 | 188 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.10) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.10) | ... | ... |
| Total number of | ... | ... | ... |

employees..... 36
[¶] Reclassified to conform with the 2022 presentation; [¶] From related parties - revenue: \$6,786,051; [¶] From related parties - revenue: \$673,329; [¶] Shares increased due to the effect of shares issued for cash and stock payable, AOS acquisition, Skylar acquisition, and fair value of contributed services; [¶] As of April 17, 2023; [¶] As of May 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|------------------------|
| Cash & cash equivalents | 1,761,225 | 1,480,371 |
| Reserve for doubtful accounts | 2,625,713 | ... |
| Accounts receivable - Balancing value | 12,286,376 | ... |
| Accounts receivable, net | 9,660,663 | [¶] 2,555,525 |
| Raw materials | 1,283,991 | 1,294,865 |
| Finished goods | 9,391,548 | 1,738,789 |
| Inventory | 10,675,540 | [¶] 3,033,653 |
| Prepaid consulting | 3,138,162 | ... |
| Prepaid expenses & other assets | ... | 902,090 |
| Total current assets | 25,235,590 | 7,971,639 |
| Operating lease right-of-use assets | ... | 61,353 |
| Equipment | 147,903 | ... |
| Computer equipment | 127,497 | 25,913 |
| Tools & equipment | ... | 16,434 |
| Furniture & fixtures | ... | 217 |
| Furniture | 39,202 | ... |
| Property, plant & equipment, gross | 314,602 | 42,564 |
| Less: accumulated depreciation | 256,443 | 16,691 |
| Property & equipment, net | 58,159 | 25,873 |
| Intangible, net | 31,362,388 | 198,403 |
| Goodwill | 26,689,391 | 32,836,563 |
| Notes receivable | ... | [¶] 95,640 |
| Total assets | 83,345,528 | 41,189,471 |
| Accounts payable | 9,799,040 | 3,245,573 |
| Other payables & accruals | ... | 1,135,803 |
| Accrued interest | ... | [¶] 6,960 |
| Accrued interest, related party | 34,041 | ... |
| Lease liability | ... | 61,605 |
| Loans payable - related party | 65,700 | ... |
| Treasury stock payable, current | 36,931,330 | 131,400 |
| Loans & advances payable, related party | 2,447,826 | ... |
| Notes payable | 4,559,219 | [¶] 3,109,535 |
| Line of Credit | 3,835,247 | ... |
| Total current liabilities | 57,672,403 | 7,690,876 |
| Treasury stock payable, net of current portion | ... | 65,700 |
| Loans payable, net of current portion | ... | [¶] 572,500 |
| Total liabilities | 57,672,403 | 8,329,076 |
| Common stock | 488,926 | 291,433 |
| Additional paid in capital | 75,130,223 | 43,332,886 |
| Treasury stock at cost | 394,200 | 394,200 |
| Equity consideration payable | 5,707,261 | 7,114,513 |
| Accumulated deficit | (63,769,469) | ... |
| Retained earnings (accumulated deficit) | ... | (17,578,219) |
| Total Starco Brands Inc. stockholders' equity (deficit) | 17,162,741 | 32,766,413 |
| Non-controlling interest | 8,510,384 | 93,982 |
| Total stockholders' equity (deficit) | 25,673,125 | 32,860,395 |

[¶] From related parties - account receivable, net: \$2,107,015; [¶] As reported by the Company; [¶] From related parties - accrued interest: \$95,640; [¶] From related parties - accrued interest: \$6,960;

[¶] From related parties - notes payable: \$3,047,533; [¶] From related parties - loans payable, net of current portion \$572,500

Recent Dividends:

1. Starco Brands Inc common.

No dividends paid.

2. Starco Brands Inc class A common.

No dividends paid.

Annual Dividends:

1. Starco Brands Inc common.

No dividends paid.

2. Starco Brands Inc class A common.

No dividends paid.

STARTECH LABS INC

Earnings, 9 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-------------------|-----------------|-----------------|
| Cost & expenses | 31,521 | 26,172 |
| Operating income | (31,521) | (26,172) |
| Interest expense | 22,183 | 22,102 |
| Net before taxes | (53,704) | (48,274) |
| Net income | (53,704) | (48,274) |

Earnings common share

Common Shares:

| | 2023 | 2022 |
|--------------|------------|------------|
| Full Diluted | 60,647,380 | 60,648,433 |
| Year-end | 60,647,380 | 60,648,433 |

STRAN & COMPANY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [¶] 2021 |
|--|---------------|------------------|-------------------|
| | | (revised) | (revised) |
| Total revenues | 75,893,871 | ... | ... |
| Purchases | 45,399,202 | ... | ... |
| Freight | 5,613,169 | ... | ... |
| Sales | 75,893,871 | 58,953,467 | 39,702,714 |
| Cost of sales - purchases | ... | 37,391,939 | 23,972,797 |
| Cost of sales - freight | ... | 4,991,854 | 3,893,847 |
| Total cost of sales | 51,012,371 | 42,383,793 | 27,866,644 |
| Gross profit | 24,881,500 | 16,569,674 | 11,836,070 |
| General & administrative expenses | 26,030,030 | 18,075,369 | 12,273,949 |
| Total operating expenses | 26,030,030 | 18,075,369 | 12,273,949 |
| Earnings (loss) from operations | (1,148,530) | (1,505,695) | (437,879) |
| Other income (expense) | 375,063 | 112,507 | 702,280 |
| Interest income (expense) | 570,387 | 94,680 | (136,661) |
| Unrealized gain (loss) on short-term investments | 269,587 | (179,120) | ... |
| Total other income & (expense) | 1,215,037 | 28,067 | 565,619 |
| Earnings (loss) before income taxes | 66,507 | (1,477,628) | 127,740 |
| Current federal income taxes | ... | 48,282 | ... |
| Deferred federal income taxes | ... | (532,700) | (76,300) |
| Total federal income taxes | ... | (484,418) | (76,300) |
| Current state income taxes | ... | (19,469) | 5,500 |
| Deferred state income taxes | ... | (195,300) | (36,700) |
| Total state income taxes | ... | (214,769) | (31,200) |
| State | 13,409 | ... | ... |
| Current | 18,040 | ... | ... |
| Income Taxes - Total - Current | 31,449 | ... | ... |
| Provision for income taxes | 31,449 | (699,187) | (107,500) |
| Net earnings (loss) | 35,058 | (778,441) | 235,240 |
| Weighted average shares outstanding - basic | 18,519,615 | 19,202,619 | 10,928,043 |

Weighted average shares outstanding

[¶] Reclassified to conform with 2022 presentation; [¶] Shares increased due to the effect of issuance of IPO shares, exercise of warrants, issuance of PIPE shares and share based compensation; [¶] As of March 24, 2022; [¶] Approximately

| | | | |
|---|------------|------------|-------------------------|
| Year end shares | 29,453,206 | 19,202,619 | 21,023,688 |
| outstanding | 18,534,073 | 18,475,521 | [¶] 19,753,852 |
| Net earnings per common share - basic | \$0.00 | \$(0.04) | \$0.02 |
| Net earnings per common share - diluted | \$0.00 | \$(0.04) | \$0.01 |
| Number of full time employees | ... | 98 | 66 |
| Number of part time employees | ... | 10 | ... |
| Number of common stockholders | 66 | 18,316,253 | [¶] 6 |

[¶] Reclassified to conform with 2022 presentation; [¶] Shares increased due to the effect of issuance of IPO shares, exercise of warrants, issuance of PIPE shares and share based compensation; [¶] As of March 24, 2022; [¶] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| | | (revised) |
| Cash | 7,988,803 | 15,253,756 |
| Short-term investments | 10,463,799 | 9,779,355 |
| Accounts Receivable - Balancing value | 20,782,967 | ... |
| Accounts receivable, net | 20,465,564 | 14,442,626 |
| Deferred income taxes | 841,000 | 841,000 |
| Finished goods (branded products) | 6,041,816 | 6,557,040 |
| Goods in process (un-branded products) | 597,542 | 310,524 |
| Inventory | 6,639,358 | 6,867,564 |
| Prepaid corporate taxes | 16,800 | 87,459 |
| Prepaid expenses | 952,691 | 386,884 |
| Deposits | 1,717,444 | 910,486 |
| Provision - Accounts & Notes Receivable - Trade | 317,403 | ... |
| Total current assets | 49,085,459 | 48,569,130 |
| Leasehold improvements | 5,664 | 5,664 |
| Office furniture & equipment | 558,329 | 501,395 |
| Software | 2,467,804 | 1,525,376 |
| Transportation equipment | 62,424 | 62,424 |
| Property & equipment, gross | ... | 2,094,859 |
| Less: accumulated depreciation | 1,573,288 | 1,094,769 |
| Property & equipment, net | 1,520,933 | 1,000,090 |
| Intangible assets - customer lists, net | 9,659,481 | 6,272,205 |
| Right of use asset - office leases | 1,335,653 | 784,683 |
| Total other assets | ... | 7,056,888 |
| Total assets | 61,601,526 | 56,626,108 |
| Current portion of long term debt | 2,870,274 | ... |
| Current portion of contingent earn-out liabilities | ... | 1,809,874 |
| Current portion of lease liability | 527,548 | 324,594 |
| Accounts payable & accrued expenses | 4,316,198 | 4,051,657 |
| Accrued payroll & related | 2,563,238 | 608,589 |
| Unearned revenue | 5,171,479 | 633,148 |
| Rewards program liability | 875,000 | 6,000,000 |
| Sales tax payable | 343,944 | 365,303 |
| Note payable - Wildman Business Group, LLC | ... | 162,358 |
| Total current liabilities | 16,667,681 | 13,955,523 |
| Long-term debt, net of current portion | 4,586,765 | ... |
| Long-term contingent earn-out liabilities | ... | 2,845,944 |
| Long-term lease liability | 797,558 | 460,089 |
| Total long-term liabilities | 5,384,323 | 3,306,033 |
| Common stock | 1,854 | 1,848 |
| Additional paid-in | ... | ... |

| | | |
|---|------------|------------|
| capital | 38,429,057 | 38,279,151 |
| Retained earnings (accumulated deficit) | 1,118,611 | 1,083,553 |
| Total stockholders' equity | 39,549,522 | 39,364,552 |
| Total Equity | 39,549,522 | ... |

Recent Dividends:

1. Stran & Company Inc common.
No dividends paid.

Annual Dividends:

1. Stran & Company Inc common.
No dividends paid.

STRATA SKIN SCIENCES INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) | 2021 (revised) |
|--|---------------------|--------------------|--------------------|
| Impairment of intangible assets | 2,284,000 | ... | ... |
| Revenues, net | 33,358,000 | ... | ... |
| Revenues, net | 33,358,000 | 36,161,000 | 29,977,000 |
| Cost of revenues | 14,897,000 | 14,393,000 | 10,127,000 |
| Gross profit (loss) | 18,461,000 | 21,768,000 | 19,850,000 |
| Engineering & product development | 1,317,000 | 1,029,000 | 1,434,000 |
| Selling & marketing | ... | 15,301,000 | 13,106,000 |
| General & administrative | 10,508,000 | 10,087,000 | 9,712,000 |
| Selling, general & administrative expense | 12,956,000 | ... | ... |
| Total operating expenses | 27,065,000 | 26,417,000 | 24,252,000 |
| Income (loss) from operations | (8,604,000) | (4,649,000) | (4,402,000) |
| Interest expense | 1,640,000 | 926,000 | 314,000 |
| Interest income | 231,000 | 89,000 | 15,000 |
| Gain on forgiveness of debt | ... | ... | (2,029,000) |
| Loss on debt extinguishment | (909,000) | ... | ... |
| Total other income (expense) | (2,318,000) | (837,000) | 1,730,000 |
| Income (loss) before income taxes | (10,922,000) | (5,486,000) | (2,672,000) |
| Current state income taxes | ... | 23,000 | 22,000 |
| Current income tax provision (benefit) | 28,000 | 23,000 | 22,000 |
| Deferred federal income tax (benefit) | (68,000) | 23,000 | 23,000 |
| Deferred state income tax provision (benefit) | (52,000) | 17,000 | (11,000) |
| Deferred income tax provision (benefit) | (120,000) | 40,000 | 12,000 |
| Income tax expense (benefit) | (92,000) | 63,000 | 34,000 |
| Net income (loss) | (10,830,000) | (5,549,000) | (2,706,000) |
| Weighted average shares outstanding - basic | 34,920,291 | 34,712,246 | 34,050,274 |
| Weighted average shares outstanding - diluted | 34,920,291 | 34,712,246 | 34,050,274 |
| Year end shares outstanding | 35,060,920 | 34,723,046 | 34,364,679 |
| Income (loss) per share from continuing operations - basic | \$(0.31) | ... | ... |
| Net income (loss) per share - basic | \$(0.31) | \$(0.16) | \$(0.08) |
| Income (loss) per share from continuing operations - diluted | \$(0.31) | ... | ... |
| Net income (loss) per share - diluted | \$(0.31) | \$(0.16) | \$(0.08) |

| | | | |
|-------------------------------|----|-----|-----|
| Number of full time employees | 99 | 114 | 115 |
| Total number of employees | 99 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 (revised) |
|---|---------------|-------------------|
| Cash & cash equivalents | 6,784,000 | 5,434,000 |
| Restricted cash | 1,334,000 | 1,361,000 |
| Accounts receivable, gross | 4,662,000 | 4,853,000 |
| Less: allowance for doubtful accounts | 222,000 | 382,000 |
| Accounts receivable, net | 4,440,000 | 4,471,000 |
| Raw materials & work-in-process | 2,192,000 | 2,966,000 |
| Finished goods | 481,000 | 129,000 |
| Inventories | 2,673,000 | 3,095,000 |
| Prepaid expenses & other current assets | 312,000 | 691,000 |
| Total current assets | 15,543,000 | 15,052,000 |
| Laboratory & research equipment | 293,000 | 293,000 |
| Lasers placed-in-service | 32,095,000 | 28,790,000 |
| Furniture & fixtures | 240,000 | 235,000 |
| Leasehold improvements | 203,000 | 136,000 |
| Lasers-in-process | 3,231,000 | 2,452,000 |
| Property & equipment, gross | 36,062,000 | 31,906,000 |
| Less: accumulated depreciation & amortization | 24,284,000 | 21,956,000 |
| Property & equipment, net | 11,778,000 | 9,950,000 |
| Operating lease right-of-use assets | 626,000 | 975,000 |
| Intangible assets, net | 7,319,000 | 17,394,000 |
| Goodwill | 6,519,000 | 8,803,000 |
| Other assets | 231,000 | 98,000 |
| Total assets | 42,016,000 | 52,272,000 |
| Accounts payable | 3,343,000 | 3,425,000 |
| Warranty obligations | 180,000 | 136,000 |
| Compensation & related benefits | 1,679,000 | 1,997,000 |
| Accrued sales & other taxes | 4,316,000 | 3,986,000 |
| Accrued expenses & other current liabilities | 6,306,000 | 6,555,000 |
| Professional fees and other | 131,000 | 436,000 |
| Deferred placement revenue | 1,820,000 | 2,378,000 |
| Deferred revenues | 2,120,000 | 2,778,000 |
| Current portion of operating lease liabilities | 352,000 | 355,000 |
| Current portion of contingent consideration | 53,000 | 313,000 |
| short-term contract liabilities | 300,000 | 400,000 |
| Total current liabilities | 12,174,000 | 13,426,000 |
| Long-term debt, net | 15,044,000 | 7,476,000 |
| Deferred revenues & other liabilities | 400,000 | 200,000 |
| Deferred tax liability | 186,000 | 306,000 |
| Operating lease liability, net of current portion | 237,000 | 610,000 |
| Contingent consideration, net of current portion | 1,135,000 | 8,309,000 |
| Deferred revenues and other liabilities | 552,000 | 314,000 |
| Deferred revenues and other liabilities - Balancing value | 152,000 | 114,000 |
| Total liabilities | 29,328,000 | 30,441,000 |
| Common stock | 35,000 | 35,000 |
| Additional paid-in capital | 250,711,000 | 249,024,000 |
| Retained earnings (accumulated deficit) | (238,058,000) | (227,228,000) |
| Total stockholders' equity (deficit) | 12,688,000 | 21,831,000 |

| | | |
|--------------|------------|------------|
| Total Equity | 12,688,000 | 21,831,000 |
|--------------|------------|------------|

□ Reclassified to conform 2023 presentation

Recent Dividends:

1. Strata Skin Sciences Inc common.

No dividends paid.

2. Strata Skin Sciences Inc series C convertible preferred.

No dividends paid.

3. Strata Skin Sciences Inc series B convertible preferred.

No dividends paid.

Annual Dividends:

1. Strata Skin Sciences Inc common.

No dividends paid.

2. Strata Skin Sciences Inc series C convertible preferred.

No dividends paid.

3. Strata Skin Sciences Inc series B convertible preferred.

No dividends paid.

STRATEGIC REALTY TRUST INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|------------|---------------------|---------------------|
| Rental & reimbursements revenue | ... | 2,787,000 | 2,431,000 |
| Operating & maintenance expense | ... | 1,689,000 | 2,082,000 |
| General & administrative expense | ... | 1,509,000 | 1,335,000 |
| Depreciation & amortization expense | ... | 1,098,000 | 1,373,000 |
| Interest expense | ... | 2,418,000 | 1,265,000 |
| Loss on early lease termination | ... | 190,000 | 648,000 |
| Loss on impairment of real estate | ... | 6,035,000 | 6,897,000 |
| Total expense | ... | 12,939,000 | 13,600,000 |
| Operating income (loss) | ... | (10,152,000) | (11,169,000) |
| Net gain (loss) on disposal of real estate | ... | (1,610,000) | 422,000 |
| Net income (loss) | ... | (11,762,000) | (10,747,000) |
| Net loss (income) attributable to non-controlling interests | ... | 217,000 | 211,000 |
| Net loss attributable to common stockholders | ... | (11,545,000) | (10,536,000) |
| Weighted average shares outstanding - basic | ... | 10,752,966 | 10,740,882 |
| Weighted average shares outstanding - diluted | ... | 10,752,966 | 10,740,882 |
| Year end shares outstanding | 10,752,966 | 10,752,966 | 10,752,966 |
| Net earnings (loss) per share - basic | ... | \$(1.07) | \$(0.98) |
| Net earnings (loss) per share - diluted | ... | \$(1.07) | \$(0.98) |
| Number of common stockholders | ... | □2,832 | □□2,826 |

□ Reclassified to conform with 2022 presentation; □ As of March 13, 2023; □ Approximately; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------|------------|
| Investments in real estate - land | ... | 12,374,000 |
| Investments in real estate - building & improvements | ... | 22,140,000 |
| Investments in real estate - tenant improvements | ... | 947,000 |
| Investments in real estate, gross | ... | 35,461,000 |

| | | |
|---|--------------|------------|
| Accumulated depreciation - investments in real estate | 4,838,000 | |
| Real estate | 26,260,000 | |
| Investments in real estate, net | 30,623,000 | |
| Cash, cash equivalents & restricted cash | 1,569,000 | 3,471,000 |
| Tenant receivables, net | 446,000 | 841,000 |
| Deferred leasing costs, net | 353,000 | |
| Lease intangibles, net | 308,000 | |
| Total assets | 28,304,000 | 35,748,000 |
| Unsecured loans | 18,000,000 | |
| Notes payable, net | 18,000,000 | |
| Accounts payable & accrued expenses | 272,000 | 285,000 |
| Amounts due to affiliates | 34,000 | 37,000 |
| Other liabilities | 118,000 | 172,000 |
| Below-market lease liabilities, net | 4,718,000 | 108,000 |
| Total liabilities | 23,142,000 | 18,602,000 |
| Common stock | | 110,000 |
| Additional paid-in capital | 94,644,000 | |
| Retained earnings (accumulated deficit) | (77,852,000) | |
| Total stockholders' equity | 5,162,000 | 16,902,000 |
| Non-controlling interests | | 244,000 |
| Total equity | 5,162,000 | 17,146,000 |

[¶] Net of bad debt reserve - Tenant receivables: \$19,000

Recent Dividends:

1. Strategic Realty Trust Inc common.

No dividends paid.

Annual Dividends:

1. Strategic Realty Trust Inc common.

No dividends paid.

SUIC WORLDWIDE HOLDINGS LTD

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|-------------|-------------------------|-----------------------------|
| | 2023 | 2022 | [¶] 2021 (revised) |
| Revenue | 150,000 | | |
| Revenue | 150,000 | 221,000 | 379,000 |
| Cost of revenues | 40,000 | 82,143 | 96,000 |
| Gross profit (loss) | 110,000 | 138,857 | 283,000 |
| General & administrative | 80,920 | 64,364 | 266,416 |
| Total operating expenses | | 64,364 | 266,416 |
| Income (loss) from operations | | 74,493 | 16,584 |
| Other income | (9,000) | 19,091 | 13,887 |
| Other income from cancellation of liability | 3,000 | 30,000 | |
| Other income-interest and miscellaneous | 4,836 | | |
| Interest expense - related party | 19,948 | | |
| Interest expense - other | 143 | 21,002 | 18,447 |
| Bad debts expense | | 105,000 | |
| Total other income (expense) | | (126,002) | (18,447) |
| Income (loss) from continuing operations before income tax provision | 7,825 | (2,419) | 12,024 |
| Income (loss) from continuing operations | | (2,419) | 12,024 |
| Net income (loss) | 7,825 | (2,419) | 12,024 |
| Weighted average shares outstanding - basic | 4,125,300 | [¶] 3,350,360 | 3,350,360 |
| Weighted average shares outstanding - diluted | 283,125,300 | [¶] 32,050,360 | 3,350,360 |

| | | | |
|--|------------|------------------------|------------------|
| Year end shares outstanding | 11,356,638 | [¶] 3,350,360 | 3,350,360 |
| Earnings (loss) per share from continuing operations - basic | \$0.00 | [¶] \$0.00 | \$0.00 |
| Earnings (loss) per share from discontinued operations - basic | | [¶] \$0.00 | \$0.00 |
| Net earnings (loss) per share - basic | \$0.00 | [¶] \$0.00 | \$0.00 |
| Earnings (loss) per share from continuing operations - diluted | \$0.00 | [¶] \$0.00 | \$0.00 |
| Earnings (loss) per share from discontinued operations - diluted | | [¶] \$0.00 | \$0.00 |
| Net earnings (loss) per share - diluted | \$0.00 | [¶] \$0.00 | \$0.00 |
| Number of full time employees | 9 | | |
| Total number of employees | 9 | 9 | 14 |
| Number of common stockholders | 108 | [¶] 81 | [¶] 118 |

[¶] Reclassified to conform with 2022 presentation; [¶] As reported by the Company; [¶] Adjusted for 1-for-10 stock split, July 25, 2023; [¶] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|----------------------|
| Cash | 7,600 | 16,072 |
| Accounts receivable, gross | 186,799 | 362,525 |
| Accounts receivable, net | 186,799 | 362,525 |
| Short-term investment - held-for-trading | 30,000 | 30,000 |
| Total current assets | 224,399 | 408,597 |
| Office equipment | 100 | |
| Fixed assets | | 150 |
| Other receivables - income from held-for-trading | 11,702 | 9,000 |
| Other interest receivables - Sinoway International | | 7,202 |
| Other receivables - SUIC Beneway USA Inc. | 2,000 | 2,000 |
| Other receivables | 146,078 | 146,078 |
| Total assets | 384,279 | [¶] 573,028 |
| Accounts payable | 30,000 | |
| Accounts payable - related parties | 5,474 | |
| Credit card payable | | 1,764 |
| Convertible promissory note - other | | 287,000 |
| Short term debts | 107,734 | 172,734 |
| Accrued expenses & other liabilities | | 170,115 |
| Accrued expenses | 4,832 | |
| Total current liabilities | 148,040 | 631,613 |
| Long-term debt | 279,000 | |
| Total Non-current Liabilities | 279,000 | |
| Total liabilities | | 631,613 |
| Common stock | 41,504 | 33,504 |
| Additional paid-in capital | 1,647,731 | 1,647,731 |
| Accumulated deficit | (1,731,996) | |
| Retained earnings (accumulated deficit) | | (1,739,820) |
| Total stockholders' equity (deficiency) | (42,761) | (58,585) |
| Total Equity | (42,761) | |

[¶] As reported by the Company

Recent Dividends:

1. Suic Worldwide Holdings Ltd common.

No dividends paid.

Annual Dividends:

1. Suic Worldwide Holdings Ltd common.

No dividends paid.

SUNSHINE BIOPHARMA INC.

Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|------------------------|----------------------|-----------------------------|
| | 2023 | 2022 | [¶] 2021 (revised) |
| Cost of sales | 15,753,616 | | |
| Office | 2,142,355 | | |
| Director fees | 400,000 | | |
| Legal | 512,199 | | |
| Consulting | 850,173 | | |
| Revenue | 24,092,787 | | |
| Revenue | 24,092,787 | 4,345,603 | 228,426 |
| Cost of sales | 15,753,616 | 2,649,028 | 117,830 |
| Gross profit | 8,339,171 | 1,696,575 | 110,596 |
| Accounting expenses | | 341,139 | 118,423 |
| Legal expenses | | 565,265 | 232,616 |
| Marketing expenses | 734,248 | 578,085 | |
| Consulting expenses | | 842,894 | 50,873 |
| Office expenses | 463,705 | 796,007 | 248,561 |
| Depreciation | 149,147 | | |
| Research & development expenses | 1,855,830 | 811,858 | 672,209 |
| Salaries expenses | | 6,054,962 | 1,215,307 |
| Taxes | 289,737 | | |
| Taxes expenses | | 55,233 | |
| Amortization & depreciation expenses | | 25,163 | 12,741 |
| Goodwill impairment expenses | | 18,326,719 | |
| Director fees | 5,712,968 | 300,000 | |
| Public relations expenses | 14,108 | | |
| Total general & administrative expenses | 13,124,470 | 28,697,325 | 2,550,730 |
| Income (loss) from operations | (4,785,299) | (27,000,750) | (2,440,134) |
| Interest expense | 137,308 | 39,412 | 328,818 |
| Loss on debt conversions | | | 9,726,485 |
| Foreign exchange | (245) | (476) | 50 |
| Interest income | 811,974 | 518,650 | |
| Interest forgiveness | | | 7,909 |
| Debt forgiveness | | 10,852 | 51,031 |
| Total other income (expenses) | | 489,614 | (9,996,313) |
| Net income (loss) before income taxes | (4,110,878) | (26,511,136) | (12,436,447) |
| State | 50 | | |
| Foreign | 379,246 | | |
| Foreign | 15,870 | | |
| Income Taxes - Total - Current | 379,296 | | |
| Income Taxes - Total - Deferred | 15,870 | | |
| Provision for income taxes | 395,166 | 233,304 | |
| Net income (loss) | (4,506,044) | (26,744,440) | (12,436,447) |
| Weighted average shares outstanding - basic | [¶] 243,319 | 151,809 | 26,121 |
| Weighted average shares outstanding - diluted | [¶] 243,319 | 151,809 | 26,121 |
| Year end shares outstanding | [¶] 280,243 | [¶] 225,856 | [¶] 25,912 |
| Income (loss) per share - continuing operations - basic | [¶] \$(19.00) | | |
| Net income (loss) per share - basic | [¶] \$(19.00) | \$(176.00) | \$(476.00) |
| Income (loss) per share - continuing operations - | | | |

| | | | |
|---------------------------------------|------------|------------|------------|
| diluted..... | Ⓔ\$(19.00) | ... | ... |
| Net income (loss) | | | |
| per share - diluted.... | Ⓔ\$(19.00) | \$(176.00) | \$(476.00) |
| Full-Time Employees (Period End)..... | 44 | ... | ... |
| Total number of employees..... | 44 | 46 | 3 |
| Number of common stockholders..... | 149 | Ⓔ149 | Ⓔ147 |

Ⓔ Reclassified to conform with 2022 presentation; Ⓔ Adjusted for 1-for-100 stock split, April 17, 2024; Ⓔ Shares increased due to the effect of shares issued for reverse stock split, common stock and warrants issued in offerings, warrants exercised, and stock issued as part of Nora Pharma Inc. acquisition; Ⓔ Shares increased due to the effect of common stock issued or reduction of debt and interest and services; Ⓔ Approximately; Ⓔ As of March 31, 2023; Ⓔ As of January 31, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|--|--------------|--------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents..... | 16,292,347 | 21,826,437 | |
| Accounts receivable..... | 2,552,362 | 1,912,153 | |
| Inventory..... | 5,734,755 | 3,289,945 | |
| Prepaid expenses..... | 310,591 | 283,799 | |
| Total current assets..... | 24,890,055 | 27,312,334 | |
| Right-of-use-asset..... | 646,779 | 760,409 | |
| Total Equipment..... | 171,859 | ... | |
| Total Computer Equipment..... | 7,368 | ... | |
| Total Furniture And Fixtures..... | 34,132 | ... | |
| Total Leasehold Improvements..... | 17,664 | ... | |
| Total Vehicles..... | 324,841 | ... | |
| Equipment, gross..... | 555,864 | ... | |
| Less: accumulated depreciation..... | 189,996 | ... | |
| Property & equipment..... | 365,868 | 394,249 | |
| Intangible assets..... | 1,444,259 | 776,856 | |
| Total assets..... | 27,346,961 | 29,243,848 | |
| Accounts payable & accrued expenses..... | ... | 2,802,796 | |
| Earn-out payable..... | 2,585,466 | 3,632,000 | |
| Income tax payable..... | 299,869 | 373,191 | |
| Current portion - right-of-use-liability..... | 118,670 | 123,026 | |
| Right-of-use-liability..... | 539,035 | 642,232 | |
| Deferred tax liability..... | 48,729 | 43,032 | |
| Total long-term liabilities..... | 587,764 | 685,264 | |
| Earnout payable..... | 2,547,831 | ... | |
| Total current liabilities..... | 5,551,836 | Ⓔ6,931,014 | |
| Total liabilities..... | 6,139,600 | 7,616,278 | |
| Preferred stock, series B..... | 1,000 | 1,000 | |
| Common stock..... | 28,024 | 22,585 | |
| Capital paid in excess of par value..... | 84,387,890 | 80,841,752 | |
| Accumulated other comprehensive income (loss)..... | 696,105 | 161,847 | |
| Accumulated (deficit)..... | (63,905,658) | ... | |
| Retained earnings (accumulated deficit)..... | ... | (59,399,614) | |
| Total shareholders' equity (deficit)..... | 21,207,361 | 21,627,570 | |
| Total Equity..... | 21,207,361 | ... | |

Ⓔ As reported by the Company

Recent Dividends:

- 1. Sunshine Biopharma Inc. preferred.**
No dividends paid.
 - 2. Sunshine Biopharma Inc. series B preferred.**
No dividends paid.
 - 3. Sunshine Biopharma Inc. common.**
No dividends paid.
- Annual Dividends:**
- 1. Sunshine Biopharma Inc. preferred.**
No dividends paid.
 - 2. Sunshine Biopharma Inc. series B preferred.**
No dividends paid.
 - 3. Sunshine Biopharma Inc. common.**
No dividends paid.

**SUNSTOCK INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|------------|-------------|-------------|
| Revenues..... | 12,397,189 | ... | ... |
| Revenues..... | 12,397,189 | 13,013,682 | 14,016,479 |
| Cost of revenue..... | 12,041,893 | 12,735,272 | 13,731,669 |
| Gross profit (loss)..... | 355,296 | 278,410 | 284,810 |
| Professional fees..... | 119,992 | 113,328 | 250,846 |
| Compensation..... | ... | 820 | 31,960 |
| Lawsuit judgment..... | 77,863 | ... | 260,308 |
| Other operating expenses..... | 31,266 | 35,895 | 50,770 |
| Operating expenses..... | 229,121 | 150,043 | 593,884 |
| Operating profit (loss)..... | 126,175 | 128,367 | (309,074) |
| Gain (loss) on sale of precious metals..... | 13,553 | 56,709 | 83,714 |
| Unrealized gain (loss) in precious metals..... | ... | 21,445 | (43,359) |
| Interest expense..... | 5,772 | 5,772 | 5,778 |
| Interest expense - related party..... | 2,070 | 14,105 | 4,089 |
| Gain (loss) from settlement of debt with related party..... | (123,600) | (3,867,927) | (1,775,668) |
| Gain on extinguishment of debt..... | ... | 30,250 | ... |
| Other income (expense)..... | (117,889) | (3,779,400) | (1,745,180) |
| Income (loss) before income tax..... | 8,286 | (3,651,033) | (2,054,254) |
| Current income taxes - state..... | 2,400 | 800 | 2,400 |
| Total current income taxes..... | 2,400 | 800 | 2,400 |
| Net income (loss)..... | 5,886 | (3,651,833) | (2,056,654) |
| Weighted average shares outstanding - basic..... | 4,924,783 | 4,209,501 | 3,892,416 |
| Weighted average shares outstanding - diluted..... | 4,924,783 | 4,209,501 | 3,892,416 |
| Year end shares outstanding..... | 5,021,857 | 4,815,857 | 4,126,387 |
| Net income (loss) per share - basic..... | \$0.00 | \$(0.87) | \$(0.53) |
| Net income (loss) per share - diluted..... | \$0.00 | \$(0.87) | \$(0.53) |
| Number of full time employees..... | 3 | 3 | 3 |
| Number of part time employees..... | ... | 2 | 2 |
| Number of common stockholders..... | 78 | Ⓔ77 | Ⓔ81 |
| Total number of employees..... | 3 | ... | ... |

Ⓔ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash..... | 13,790 | 16,691 |
| Inventory - coins..... | ... | 950,637 |
| Inventory - precious metals..... | 814,574 | 801,022 |
| Prepaid expenses..... | 9,327 | 5,155 |
| Inventory..... | 1,272,999 | ... |
| Total current assets..... | 2,110,690 | 1,773,505 |
| Furniture & equipment..... | 58,460 | 58,460 |
| Less - accumulated depreciation..... | 58,257 | 58,036 |
| Property & equipment - net..... | 203 | 424 |
| Right of use lease asset..... | 37,120 | 11,114 |
| Total assets..... | 2,148,013 | 1,785,043 |
| Lawsuit judgement..... | ... | 260,308 |
| Accrued consultant fees..... | 133,649 | 131,500 |
| Accrued interest payable related party..... | 12,726 | 16,176 |

| | | |
|---|--------------|--------------|
| Accrued interest payable..... | 20,208 | 14,436 |
| Accrued audit fees..... | 14,934 | 8,089 |
| Accrued dividends - preferred stock..... | 338,171 | 36,326 |
| Expenses owed related party..... | ... | 4,631 |
| Other accrued expenses..... | 8,919 | 8,671 |
| Accounts payable & accrued expenses..... | ... | 480,137 |
| Operating lease liability - current..... | 16,233 | 11,114 |
| Small Business Administration loan - current..... | 8,368 | 5,047 |
| Stock payable..... | 564,933 | ... |
| Loan payable - related parties..... | ... | 6,000 |
| Loan from shareholder..... | 25,681 | ... |
| Accrued dividends - preferred stock..... | 36,326 | ... |
| Total current liabilities..... | 615,215 | 502,298 |
| Small Business Administration loan..... | 141,632 | 144,953 |
| Operating lease liability - non-current..... | 20,887 | ... |
| Total liabilities..... | 777,734 | 647,251 |
| Common stock..... | 502 | 481 |
| Additional paid-in capital..... | 67,279,869 | 67,053,289 |
| Accumulated deficit..... | (65,910,092) | ... |
| Retained earnings (accumulated deficit)..... | ... | (65,915,978) |
| Total stockholders' equity (deficit)..... | 1,370,279 | 1,137,792 |
| Total Equity..... | 1,370,279 | ... |

Recent Dividends:

- 1. Sunstock Inc series A convertible preferred.**
No dividends paid.
- 2. Sunstock Inc common.**
No dividends paid.

Annual Dividends:

- 1. Sunstock Inc series A convertible preferred.**
No dividends paid.
- 2. Sunstock Inc common.**
No dividends paid.

**SURGE COMPONENTS INC
Annual Report**

| Consolidated Income Statement, Years Ended Nov. 30 (\$): | | | |
|---|------------|------------|------------|
| | 2023 | 2022 | 2021 |
| Net sales..... | 36,276,542 | 51,910,790 | 39,828,257 |
| Cost of goods sold..... | 26,347,854 | 37,593,369 | 28,942,477 |
| Gross profit..... | 9,928,688 | 14,317,421 | 10,885,780 |
| Selling & shipping expenses..... | 3,010,509 | 3,305,714 | 2,586,607 |
| General & administrative expenses..... | 5,337,395 | 6,210,892 | 5,075,806 |
| Depreciation expense..... | 70,247 | ... | ... |
| Depreciation & amortization..... | ... | 78,398 | 70,098 |
| Total operating expenses..... | 8,418,151 | 9,595,004 | 7,732,511 |
| Income (loss) before other income (expense) & income taxes..... | 1,510,537 | 4,722,417 | 3,153,269 |
| Other income PPP..... | ... | ... | 449,700 |
| Interest expense..... | ... | 405 | 1,166 |
| Other income..... | 114,970 | 185,696 | 1,245 |
| Other income (expense)..... | 114,970 | 185,291 | 449,779 |
| Income (loss) before income taxes..... | 1,625,507 | 4,907,708 | 3,603,048 |
| Current income taxes - federal..... | 444,557 | 723,992 | ... |
| Current income taxes - states..... | 221,070 | 269,418 | 191,979 |
| Total current income taxes..... | 665,627 | 993,410 | 191,979 |
| Deferred income | | | |

| | | | |
|--|------------|-----------|-----------|
| taxes (benefit) - federal | (9,662) | 138,959 | 711,244 |
| Deferred income taxes (benefit) - state | (2,568) | 39,193 | 189,064 |
| Total deferred income taxes (benefit) | (12,230) | 178,152 | 900,308 |
| Income taxes (benefit) | 653,397 | 1,171,562 | 1,092,287 |
| Net income (loss) | 972,110 | 3,736,146 | 2,510,761 |
| Dividends on preferred stock | 5,000 | 5,000 | 5,000 |
| Net income (loss) available to common shareholders | 967,110 | 3,731,146 | 2,505,761 |
| Weighted average shares outstanding - basic | 5,559,609 | 5,534,361 | 5,490,515 |
| Weighted average shares outstanding - diluted | 5,745,058 | 5,734,852 | 5,675,282 |
| Year end shares outstanding | 5,577,698 | 5,541,342 | 5,515,342 |
| Net earnings (loss) per share - basic | \$0.17 | \$0.67 | \$0.46 |
| Net earnings (loss) per share - diluted | \$0.17 | \$0.65 | \$0.44 |
| Number of full time employees | 44 | ... | ... |
| Total number of employees | 44 | 46 | 43 |
| Number of common stockholders | 176 | ... | ... |
| Total number of stockholders | ... | 176 | 176 |
| Total Revenue | 36,276,542 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$0.17 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.17 | ... | ... |

□ Approximately

Consolidated Balance Sheet, Years Ended Nov. 30 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 7,634,799 | 8,690,040 |
| Marketable securities - available for sale | 3,204,772 | ... |
| Accounts receivable, gross | 6,176,752 | 7,404,200 |
| Allowance for doubtful accounts | 79,341 | 173,565 |
| Accounts receivable - net | 6,097,411 | 7,230,635 |
| Inventory, gross | 5,422,824 | ... |
| Inventory, net | ... | 6,408,551 |
| Prepaid expenses & income taxes | 520,104 | 470,847 |
| Total current assets | 22,879,910 | 22,800,073 |
| Furniture & fixtures | 329,186 | 327,971 |
| Leasehold improvements | 1,070,044 | 1,062,449 |
| Computer equipment | 528,662 | 494,104 |
| Less: accumulated depreciation | 1,757,772 | 1,687,525 |
| Fixed assets, net | 170,120 | 196,999 |
| Operating lease right of use asset | 1,350,998 | 1,362,305 |
| Deferred income taxes | 241,328 | 229,098 |
| Other assets | 34,299 | 34,299 |
| Total assets | 24,676,655 | 24,622,774 |
| Accounts payable | 3,216,590 | 4,147,595 |
| Operating lease liabilities, current maturities | 351,957 | 309,216 |
| Accrued commissions | ... | 366,766 |
| Accrued preferred stock dividends | 166,569 | 161,569 |
| Other accrued expenses | 338,932 | 370,924 |
| Accrued salaries | 667,058 | 598,519 |
| Commissions | 229,882 | ... |
| Total current liabilities | 4,970,988 | 5,954,589 |
| Operating lease liabilities net of | | |

| | | |
|---|------------|------------|
| current maturities | 1,136,766 | 1,164,722 |
| Total liabilities | 6,107,754 | 7,119,311 |
| Series C preferred stock | 10 | 10 |
| Common stock | 5,576 | 5,541 |
| Additional paid-in capital | 17,710,525 | 17,613,060 |
| Accumulated other comprehensive income (loss) | 828 | ... |
| Retained earnings (accumulated deficit) | 851,962 | (115,148) |
| Total shareholders' equity | 18,568,901 | 17,503,463 |
| Rep Total Equity & Minority Interest | 18,568,901 | ... |

Recent Dividends:

1. Surge Components Inc series C non-voting redeemable convertible preferred.

No dividends paid.

2. Surge Components Inc common.

No dividends paid.

Annual Dividends:

1. Surge Components Inc series C non-voting redeemable convertible preferred.

No dividends paid.

2. Surge Components Inc common.

No dividends paid.

SURGEPAYS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|-------------|-------------|----------------|
| Revenues | 137,141,832 | ... | ... |
| Revenues | 137,141,832 | 121,544,190 | 51,060,589 |
| Cost of revenue | ... | 108,074,782 | 44,890,610 |
| Oil & natural gas production expenses | 101,499,341 | ... | ... |
| Amortization expense | 653,507 | ... | ... |
| Depreciation | 281,532 | ... | ... |
| Amortization of Computer Software | 129,060 | ... | ... |
| Depreciation & amortization expenses | 1,064,099 | 931,593 | 759,383 |
| Selling, general & administration expenses | 15,713,008 | 11,904,030 | 11,403,164 |
| General & administrative expenses | 16,777,107 | 12,835,623 | 12,162,547 |
| Total cost & expenses | 118,276,448 | 120,910,405 | 57,053,157 |
| Income (loss) from operations | 18,865,384 | 633,785 | (5,992,568) |
| Interest expense | 595,975 | 1,843,396 | 3,840,616 |
| Derivative expense | ... | ... | 1,775,057 |
| Change in fair value of derivative liabilities | ... | ... | 1,806,763 |
| Gain (loss) on investment in Centercom | 110,203 | (89,082) | 28,676 |
| Gain (loss) on settlement of liabilities | ... | ... | 1,469,641 |
| Amortization of debt discount | ... | 115,404 | 3,677,121 |
| Gain on deconsolidation of True Wireless | ... | ... | 1,895,871 |
| Settlement expense | ... | ... | 3,750,000 |
| Warrant modification expense | ... | ... | 74,476 |
| Gain on forgiveness of PPP loan - government | ... | 524,143 | ... |
| Other income | ... | 336,726 | 377,743 |
| Total other income (expense) - net | ... | (1,187,013) | (7,538,576) |
| Net income (loss) | ... | ... | ... |

| | | | |
|---|-------------|------------|--------------|
| before provision for income taxes | 18,379,612 | ... | ... |
| Current | 570,000 | ... | ... |
| Deferred | (2,835,000) | ... | ... |
| Provision for income taxes | (2,265,000) | ... | ... |
| Net income (loss) including non-controlling interest | 20,644,612 | (553,228) | (13,531,144) |
| Net Income After ExtraOrdinary Items applicable to Common | 20,617,903 | ... | ... |
| Non-controlling interest | (26,709) | (127,535) | ... |
| Net loss available to common stockholders | ... | (680,763) | (13,531,144) |
| Weighted average shares outstanding - basic | 14,258,172 | 12,395,364 | 4,381,709 |
| Weighted average shares outstanding - diluted | 14,922,881 | 12,395,364 | 4,381,709 |
| Year end shares outstanding | 14,403,261 | 14,116,832 | 12,063,834 |
| Net income (loss) per common share - basic | \$1.45 | \$(0.05) | \$(3.09) |
| Net income (loss) per common share - diluted | \$1.38 | \$(0.05) | \$(3.09) |
| Total number of employees | ... | 20 | 32 |
| Number of common stockholders | 7,277 | 3,657 | 430 |
| Basic EPS Excluding ExtraOrdinary Items | \$1.45 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$1.38 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Approximately; □ As of March 22, 2022; □ As of March 30, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash | ... | 7,035,654 |
| Cash & cash equivalents | 14,622,060 | ... |
| Accounts receivable, gross | 9,553,599 | 9,247,890 |
| Allowance for doubtful accounts | 17,525 | 17,525 |
| Accounts receivable - net | 9,536,074 | 9,230,365 |
| Inventory | 9,046,594 | 11,186,242 |
| Prepays | ... | 111,524 |
| Prepaid Expenses & Other | 161,933 | ... |
| Total current assets | 33,366,661 | 27,563,785 |
| Computer equipment & software | 1,089,038 | 1,006,286 |
| Furniture & fixtures | 82,752 | 82,752 |
| Computer Equipment and Software | 1,006,286 | ... |
| Property & equipment, gross | ... | 1,089,038 |
| Less: accumulated depreciation | 727,197 | ... |
| Less: accumulated depreciation or amortization | ... | 445,665 |
| Property & equipment - net | 361,841 | 643,373 |
| Note receivable | 176,851 | 176,851 |
| Intangibles - net | 2,126,470 | 2,779,977 |
| Internal use software development costs - net | 539,424 | 387,180 |
| Goodwill | 1,666,782 | 1,666,782 |
| Investment in Centercom | 464,409 | 354,206 |
| Operating lease right of use asset - net | 387,869 | 431,352 |
| Total other assets | ... | 5,796,348 |
| Deferred Tax - Asset - | ... | ... |

| | | | |
|---|--------------|--------------|--|
| Net | 2,835,000 | ... | |
| Total assets | 41,925,307 | 34,003,506 | |
| Accrued income taxes payable | 570,000 | ... | |
| Accounts payable & accrued expenses | 6,439,120 | 5,784,374 | |
| Accounts payable & accrued expenses - related party | 1,048,224 | 1,728,721 | |
| Installment sale liability | ... | 13,018,184 | |
| Deferred revenue | 20,000 | 243,110 | |
| Operating lease liability | 43,137 | 39,490 | |
| Loans payable - related parties | 4,584,563 | ... | |
| Notes payable - related parties | ... | 1,108,150 | |
| Notes payable - net | ... | 1,542,033 | |
| Total current liabilities | 12,705,044 | 23,464,062 | |
| Loans payable - related parties | ... | 4,493,798 | |
| Note payable | ... | 53,134 | |
| Notes payable - SBA government | 460,523 | 474,846 | |
| Operating lease liability | 356,276 | 399,413 | |
| Total long term liabilities | 816,799 | 5,421,191 | |
| Total liabilities | 13,521,843 | 28,885,253 | |
| Common stock | 14,404 | 14,117 | |
| Additional paid in capital | 43,421,019 | 40,780,707 | |
| Retained earnings (accumulated deficit) | (15,186,203) | (35,804,106) | |
| Total stockholders' equity (deficit) | 28,249,220 | 4,990,718 | |
| Non-controlling interest | 154,244 | 127,535 | |
| Total stockholders' equity | 28,403,464 | 5,118,253 | |

Recent Dividends:

- 1. SurgePays Inc series C convertible preferred.**
No dividends paid.
 - 2. SurgePays Inc common.**
No dividends paid.
 - 3. SurgePays Inc series A preferred.**
No dividends paid.
- Annual Dividends:**
- 1. SurgePays Inc series C convertible preferred.**
No dividends paid.
 - 2. SurgePays Inc common.**
No dividends paid.
 - 3. SurgePays Inc series A preferred.**
No dividends paid.

SURROZEN INC

Annual Report

| | | | |
|---|---------------------|---------------------|---------------------|
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Collaboration & license revenue | ... | 12,500,000 | ... |
| Research & development expenses | 27,230,000 | 37,013,000 | 40,177,000 |
| General & administrative expenses | 15,798,000 | 19,826,000 | 14,214,000 |
| Restructuring | 2,752,000 | ... | ... |
| Total operating expenses | 45,780,000 | 56,839,000 | 54,391,000 |
| Income (loss) from operations | (45,780,000) | (44,339,000) | (54,391,000) |
| Interest income | 2,340,000 | 781,000 | 72,000 |
| Other income (expense), net | 398,000 | 7,554,000 | (329,000) |
| Net income (loss) | (43,042,000) | (36,004,000) | (54,648,000) |
| Weighted average shares outstanding - basic | 2,018,000 | 2,314,800 | 1,645,933 |
| Weighted average shares outstanding - diluted | 2,018,000 | 2,314,800 | 1,645,933 |
| Year end shares outstanding | 2,063,000 | 2,005,867 | 2,335,629 |

| | | | |
|---|--------------|------------|------------|
| Net earnings (loss) per share - basic | \$(21.33) | Ⓐ\$(15.60) | Ⓒ\$(33.15) |
| Net earnings (loss) per share - diluted | \$(21.33) | Ⓐ\$(15.60) | Ⓒ\$(33.15) |
| Number of full time employees | ... | Ⓐ74 | 83 |
| Number of common stockholders | 56 | Ⓐ73 | Ⓐ123 |
| Net Income before Tax | (43,042,000) | ... | ... |

Ⓐ Reclassified to conform with 2022 presentation; Ⓒ Adjusted for 1- for -15 stock split, December 14, 2023; Ⓐ As of March 01, 2023; Ⓐ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|---------------|---------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 36,043,000 | 24,690,000 |
| Accounts receivable | 2,152,000 | 1,978,000 |
| Short-term marketable securities | ... | 51,148,000 |
| Prepaid expenses & other current assets | 2,937,000 | 3,489,000 |
| Total current assets | 41,132,000 | 81,305,000 |
| Leasehold improvements | 1,116,000 | 7,052,000 |
| Lab equipment | 7,703,000 | 7,515,000 |
| Furniture & office equipment | 316,000 | 299,000 |
| Computer equipment | 202,000 | 119,000 |
| Property & equipment, gross | 9,337,000 | 14,985,000 |
| Less: accumulated depreciation & amortization | 7,368,000 | 11,355,000 |
| Property & equipment, net | 1,969,000 | 3,630,000 |
| Operating lease right-of-use assets | 1,889,000 | 3,268,000 |
| Restricted cash | 688,000 | 405,000 |
| Other assets | 402,000 | 827,000 |
| Total assets | 46,080,000 | 89,435,000 |
| Accounts payable | 525,000 | 658,000 |
| Accrued payroll & related expenses | 2,508,000 | 3,964,000 |
| Accrued research & development expenses | 1,261,000 | 1,665,000 |
| Accrued professional service fees | 4,126,000 | 638,000 |
| Liability for early exercised stock options | 3,000 | 89,000 |
| Other accrued & liabilities | 289,000 | 492,000 |
| Accrued & other liabilities | ... | 6,848,000 |
| Lease liabilities, current portion | 2,497,000 | 2,226,000 |
| Accrued liabilities - Balancing value | 65,000 | ... |
| Total current liabilities | 7,148,000 | 9,732,000 |
| Lease liabilities, noncurrent portion | 882,000 | 3,376,000 |
| Warrant liabilities | 115,000 | 326,000 |
| Total liabilities | 8,145,000 | 13,434,000 |
| Common stock | ... | 3,000 |
| Additional paid-in-capital | 259,630,000 | 254,892,000 |
| Accumulated other comprehensive income (loss) | ... | (241,000) |
| Accumulated deficit | (221,695,000) | ... |
| Retained earnings (accumulated deficit) | ... | (178,653,000) |
| Total stockholders' equity | 37,935,000 | 76,001,000 |
| Total Equity | 37,935,000 | ... |

Recent Dividends:

- 1. Surrozen Inc ordinary class A.**
No dividends paid.
- 2. Surrozen Inc ordinary class B.**
No dividends paid.
- 3. Surrozen Inc common.**

No dividends paid.
Annual Dividends:
1. Surrozen Inc ordinary class A.
 No dividends paid.
2. Surrozen Inc ordinary class B.
 No dividends paid.
3. Surrozen Inc common.
 No dividends paid.

SUSTAINABLE PROJECTS GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|--------------------|------------------|------------------|
| | 2023 | 2022 | 2021 |
| | | (revised) | |
| Gross revenues | ... | ... | 5,353 |
| Cost of goods sold | ... | ... | 6,673 |
| Gross margin | ... | ... | (1,320) |
| Administrative & other operating expenses | 108,087 | 9,785 | 24,520 |
| Advertising & promotion expenses | 329,116 | 102,777 | 1,156 |
| Depreciation | 33,659 | ... | ... |
| Depreciation expense | ... | ... | 29,582 |
| Management fees | 775,165 | 108,190 | 36,000 |
| Professional fees | ... | ... | 51,568 |
| Wages and salaries | 516,926 | ... | ... |
| Stock based compensation | 492,708 | ... | ... |
| Amortized right of use assets | 178,022 | ... | ... |
| General & administrative expenses | 104,988 | ... | ... |
| Advertising and Promotion | 33,391 | ... | ... |
| General and administrative expenses | 57,393 | 2,192 | ... |
| Interest on lease | 134,324 | ... | ... |
| Vehicle expense | 46,500 | ... | ... |
| Office maintenance and utilities | 128,651 | ... | ... |
| Rent | 58,823 | ... | ... |
| Total operating expenses | 2,997,753 | 222,944 | 142,826 |
| Operating income (loss) before other items | (2,997,753) | (222,944) | (144,146) |
| Interest expense | 1,288 | ... | 6,265 |
| Income (loss) from continuing operations | ... | ... | (150,411) |
| Net income (loss) before gain on deconsolidation | 251,089 | ... | (150,411) |
| Operating income (loss) before income taxes including non-controlling interests | (2,747,952) | (222,944) | ... |
| Net income (loss) | (2,747,952) | (222,944) | (150,411) |
| Net income (loss) attributed to non-controlling interest - continuing operations | ... | ... | 7,313 |
| Net income (loss) attributed to non-controlling interest | ... | ... | 7,313 |
| Net income (loss) attributable to shareholders | ... | ... | (143,098) |
| Weighted average shares outstanding - basic | 254,941,752 | 50,000 | 7,833,548 |
| Weighted average shares outstanding - diluted | 254,941,752 | 50,000 | 7,833,548 |
| Year end shares outstanding | 296,037,813 | 50,000 | 8,085,877 |

| | | | | | | | | | |
|--|----------|----------|----------|---|-------------|--------------|---|------------|------------|
| Net income (loss) per share from continuing operations - basic | \$(0.01) | \$(4.55) | \$(0.02) | capital | 3,438,273 | 17,007,531 | security | 1,438,500 | ... |
| Net income (loss) per share - basic | \$(0.01) | \$(4.55) | \$(0.02) | Accumulated Deficit | (3,359,757) | ... | Total current assets | 30,532,760 | 38,585,661 |
| Net income (loss) per share from continuing operations - diluted | \$(0.01) | \$(4.55) | \$(0.02) | Retained earnings (accumulated deficit) | ... | (17,375,748) | Equity method investment | 562,402 | ... |
| Net income (loss) per share - diluted | \$(0.01) | \$(4.55) | \$(0.02) | Other accumulated comprehensive income (loss) | (49,228) | (2,983) | Total assets | 31,113,667 | 38,607,806 |
| Number of full time employees | ... | ... | 2 | Total stockholders' equity (deficit) | 58,892 | (342,481) | Accounts payable | 444,633 | 660,206 |
| Number of common stockholders | 118 | ... | 93 | TOTAL STOCKHOLDERS DEFICIT | 58,892 | ... | Accrued Series B Convertible Preferred payments payable | 3,395,945 | ... |

□ Restated to reflect correction of errors; □ 2021 and prior period financials for the Company prior to share reorganization with Lithium Harvest ApS

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| | | (revised) | (revised) |
| Cash & cash equivalents | 847,724 | 9,363 | ... |
| Other receivables | ... | 32,180 | ... |
| YER brands (materials) | ... | 3,939 | ... |
| Inventory | ... | 3,939 | ... |
| Prepaid expenses | 398,067 | ... | ... |
| Prepaid expenses & deposits | ... | 4,403 | ... |
| Total current assets | 1,245,791 | 49,885 | ... |
| Right of use (ROU) asset - lease | 1,688,003 | ... | ... |
| Office furniture & equipment, cost | 21,088 | 9,789 | ... |
| Less: accumulated depreciation - office furniture & equipment | ... | 9,164 | ... |
| Office equipment | 69,060 | 625 | ... |
| Intangible assets | 32,903 | 74,778 | ... |
| Goodwill | ... | 156,752 | ... |
| Computer - Accumulated Depreciation & Impairment | 8,461 | ... | ... |
| Equipment - Accumulated Depreciation & Impairment | 5,000 | ... | ... |
| Office Furniture & Equipment - Accumulated Depreciation & Impairment | 26,260 | ... | ... |
| Computer - Net | 12,627 | ... | ... |
| Equipment - Gross | 5,000 | ... | ... |
| Office Furniture & Equipment - Gross | 95,320 | ... | ... |
| Machinery under construction - Gross | 21,220 | ... | ... |
| Machinery under construction - Net | 21,220 | ... | ... |
| Office equipment and furniture | 102,907 | ... | ... |
| Total assets | 3,069,604 | 282,040 | ... |
| Accounts payable | ... | 164,906 | ... |
| Accrued liabilities | 67,250 | 114,982 | ... |
| Payroll liabilities | 149,148 | ... | ... |
| Accounts payable & accrued liabilities | 382,702 | 279,888 | ... |
| Amount due to related parties | 502,397 | 287,911 | ... |
| Lease liability | 183,913 | ... | ... |
| Deferred revenue | 76,545 | ... | ... |
| Notes payable | 69,605 | ... | ... |
| Other payables ? Note 4 | 19,334 | ... | ... |
| Accounts payable and accrued liabilities | 449,952 | ... | ... |
| Total current liabilities | 1,450,894 | 567,799 | ... |
| Note payable | ... | 56,722 | ... |
| Obligations under operating lease | 1,559,818 | ... | ... |
| Total non-current liabilities | 1,559,818 | 56,722 | ... |
| Total liabilities | 3,010,712 | 624,521 | ... |
| Common stock | 29,604 | 28,719 | ... |
| Additional paid in | ... | ... | ... |

Recent Dividends:

1. Sustainable Projects Group Inc common.

No dividends paid.

Annual Dividends:

1. Sustainable Projects Group Inc common.

No dividends paid.

SYNAPTOGENIX INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|-------------|--------------|
| | | (revised) | (revised) |
| Research & development | 1,974,924 | 6,324,928 | 4,336,414 |
| General & administrative | 6,338,930 | 9,810,068 | 8,281,893 |
| Total operating expenses | 8,313,854 | 16,134,996 | 12,618,307 |
| Interest income | 1,648,950 | 335,039 | 7,110 |
| Change in fair value of warrant liability | 1,370,000 | 8,405,000 | ... |
| Change in fair value of derivative liability | (743,600) | 1,821,000 | ... |
| Total other income (expense) | ... | 10,561,039 | 7,110 |
| Net income (loss) before income taxes | (6,038,504) | (5,573,957) | (12,611,197) |
| Deemed dividend-preferred stock extinguishment | 5,693,000 | ... | ... |
| Net income (loss) | (6,038,504) | (5,573,957) | (12,611,197) |
| Preferred stock dividends | 2,047,774 | 115,890 | ... |
| Net income (loss) attributable to common shareholders | (13,779,278) | (5,689,847) | (12,611,197) |
| Weighted average shares outstanding - basic | □466,076 | 279,568 | 200,604 |
| Weighted average shares outstanding - diluted | □466,076 | 279,568 | 200,604 |
| Year end shares outstanding | □963,586 | 290,681 | 269,207 |
| Net earnings (loss) per share - basic | □\$(29.50) | \$(20.25) | \$(62.75) |
| Net earnings (loss) per share - diluted | □\$(29.50) | \$(20.25) | \$(62.75) |
| Number of full time employees | 5 | 5 | 5 |
| Number of part time employees | ... | ... | 2 |
| Total number of employees | 5 | ... | ... |
| Number of common stockholders | 195 | □197 | □200 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 28,661,498 | 37,478,480 |
| Prepaid clinical trial expenses | 375,085 | 367,714 |
| Prepaid expenses & other current assets | 57,677 | 739,467 |
| Available for sale debt | ... | ... |

| | | |
|---|--------------|--------------|
| security | 1,438,500 | ... |
| Total current assets | 30,532,760 | 38,585,661 |
| Fixed assets, net of accumulated depreciation | 18,505 | 22,145 |
| Equity method investment | 562,402 | ... |
| Total assets | 31,113,667 | 38,607,806 |
| Accounts payable | 444,633 | 660,206 |
| Accrued Series B Convertible Preferred payments payable | 3,395,945 | ... |
| Accrued expenses | 435,891 | 536,714 |
| Dividends payable | ... | 115,890 |
| Total current liabilities | 4,276,469 | 1,312,810 |
| Warrant liability | 140,000 | 1,510,000 |
| Derivative liability | 1,113,000 | 370,300 |
| Total liabilities | 5,529,469 | 3,193,110 |
| Series B convertible redeemable preferred stock | ... | 2,721,723 |
| Common Stock - Issued & Paid | 2,411 | ... |
| Common stock | ... | 728 |
| Additional paid-in capital | 57,954,693 | 52,523,762 |
| Accumulated deficit | (33,610,748) | ... |
| Retained earnings (accumulated deficit) | ... | (19,831,517) |
| Preferred Stock - Redeemable | 1,236,940 | ... |
| Comprehensive Income - Accumulated | 902 | ... |
| Total shareholders' equity | 25,584,198 | 32,692,973 |
| Total Equity | 25,584,198 | ... |

Recent Dividends:

1. Synaptogenix Inc series B convertible redeemable preferred.

No dividends paid.

2. Synaptogenix Inc common.

No dividends paid.

Annual Dividends:

1. Synaptogenix Inc series B convertible redeemable preferred.

No dividends paid.

2. Synaptogenix Inc common.

No dividends paid.

T STAMP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-------------|--------------|-------------|
| | | (revised) | (revised) |
| Net revenue | 4,560,275 | ... | ... |
| Net revenue | 4,560,275 | 5,385,077 | 3,677,896 |
| Cost of services provided (exclusive of depreciation & amortization) | 914,176 | 1,785,167 | 1,151,057 |
| Research & development | 2,350,677 | 2,474,327 | 2,529,501 |
| Selling, general & administrative | 8,395,638 | 12,444,009 | 8,314,575 |
| Depreciation & amortization | 789,586 | 760,497 | 573,755 |
| Total operating expenses | 12,450,077 | 17,464,000 | 12,568,888 |
| Operating income (loss) | (7,889,802) | (12,078,923) | (8,890,992) |
| Interest expense | ... | 8,890 | 39,970 |
| Change in fair value of warrant liability | 5,033 | 113,125 | (86,944) |
| Impairment of digital assets | ... | 27,934 | ... |
| Grant income | (2,981) | ... | 61,601 |
| Other income | 309,896 | 50,354 | 56,932 |
| Other expense | ... | 118,196 | 159,533 |
| Interest income (expense) | (73,273) | ... | ... |
| Total other income (expense), net | 238,675 | 8,459 | (167,914) |
| Income (loss) before income taxes | ... | ... | ... |

| | | | | | | | | |
|---------------------------|-------------|--------------|----------------------------|---------------------------|---------------------------|-----------|-------------|-----------|
| - U.S. | (7,911,970) | (4,808,983) | Phone equipment | 297,150 | provision (benefit) ... | 62,000 | 96,000 | 70,000 |
| Income (loss) | | | Property & equipment, | | Total current | | | |
| before income taxes | | | gross | 180,066 | income tax | | | |
| - non U.S. | (4,158,494) | (4,249,923) | Less: accumulated | | provision (benefit) ... | 401,000 | 659,000 | 388,000 |
| Net income (loss) | | | depreciation | 123,630 | Deferred federal | | | |
| before taxes | (7,651,127) | (12,070,464) | (9,058,906) | Property & equipment, | income tax | | | |
| US State- Current | 2,425 | ... | net | 56,436 | provision (benefit) ... | 12,000 | (89,000) | 124,000 |
| Non US- Current | (15,910) | ... | Operating lease right of | | Deferred state | | | |
| Income tax benefit | | | use assets | 164,740 | income tax | | | |
| (expense) | (13,485) | ... | Digital assets | ... | provision (benefit) ... | (1,000) | (37,000) | 88,000 |
| Income tax expense .. | (13,485) | 21,076 | Other assets | 29,468 | Increase | | | |
| Net income (loss) | | | Total assets | 7,893,314 | (decreased) in | | | |
| including | | | Accounts payable | 1,232,118 | valuation allowance .. | ... | (1,915,000) | (212,000) |
| noncontrolling | | | Related party payables .. | 82,101 | Total deferred | | | |
| interest | (7,637,642) | (12,091,540) | (9,058,906) | Compensation payable .. | income tax | | | |
| Net income (loss) | | | Commission liability | 377,403 | provision (benefit) ... | 11,000 | ... | ... |
| attributable to | | | Accrued employee taxes .. | 115,099 | Income tax | | | |
| non-controlling | | | Accrued mobile expenses .. | 624,525 | provision (benefit) ... | 412,000 | (1,382,000) | 388,000 |
| interest | ... | ... | 1,743 | Other accrued expenses .. | 1,845,000 | 3,208,000 | 2,010,000 | |
| Net income (loss) | | | Commission liability | 26,863 | Net income (loss) | | | |
| attributable to T | | | Accrued expenses | ... | attributable to | | | |
| Stamp Inc. | (7,637,642) | (12,091,540) | (9,057,163) | Deferred revenue | Taitron Components | | | |
| Weighted average | | | Income tax payable | 10,800 | Inc. | ... | 3,208,000 | 2,010,000 |
| shares outstanding | | | Short-term operating | 1,975 | Weighted average | | | |
| - basic | 7,127,560 | 4,732,774 | lease liabilities | 81,236 | class A shares | | | |
| Weighted average | | | Short-term financial | | outstanding - basic ... | ... | 5,233,568 | 5,076,087 |
| shares outstanding | | | liabilities | 162,130 | Weighted average | | | |
| - diluted | 7,127,560 | 4,732,774 | (2,714,250) | 4,447,573 | shares outstanding | | | |
| Year end shares | | | Warrant liabilities | 256,536 | - basic | 6,005,277 | 5,996,180 | 5,838,699 |
| outstanding | 9,143,355 | 4,854,302 | (2,409,529) | 953,877 | Weighted average | | | |
| Net income (loss) | | | Long-term financial | | class A shares | | | |
| per share - basic | \$(1.07) | \$(2.55) | liabilities | ... | outstanding - | | | |
| Net income (loss) | | | Long-term operating lease | | diluted | ... | 5,272,568 | 5,157,087 |
| per share - diluted | \$(1.07) | \$(2.55) | (2,409,529) | 53,771 | Weighted average | | | |
| Number of full time | | | liabilities | 3,978,434 | shares outstanding | | | |
| employees | 80 | 78 | 89 | 5,786,774 | - diluted | ... | 6,035,180 | 5,919,699 |
| Number of part time | | | 10 | 91,434 | Year end shares | | | |
| employees | 8 | 5 | 10 | 54,375,622 | outstanding | 6,021,180 | 5,996,180 | 5,876,180 |
| Number of class A | | | Stockholders' notes | | Net earnings (loss) | | | |
| common stockholders | 2,758 | 2,834 | 3,009 | ... | per class A share - | | | |
| Foreign currency | | | receivable | ... | basic | ... | \$0.54 | \$0.34 |
| translation | | | Accumulated other | 139,670 | Net earnings (loss) | | | |
| adjustments | ... | 53,352 | comprehensive income .. | 237,252 | per class B share - | | | |
| EPS - Basic - | | | Accumulated deficit | (50,853,285) | basic | ... | \$0.54 | \$0.34 |
| excluding | | | Retained earnings | | Net earnings (loss) | | | |
| Extraordinary Items | | | (accumulated deficit) .. | ... | per share - basic | \$0.31 | ... | ... |
| Applicable to | | | Total stockholders' | 3,753,441 | Net earnings (loss) | | | |
| Common - Total | \$(1.07) | ... | equity | 463,705 | per class A share - | | | |
| EPS - Diluted - | | | Noncontrolling interest .. | 161,439 | diluted | ... | \$0.53 | \$0.34 |
| excluding | | | Total stockholders' | 3,914,880 | Net earnings (loss) | | | |
| Extraordinary Items | | | equity | 625,144 | per class B share - | | | |
| Applicable to | | | | | diluted | ... | \$0.54 | \$0.34 |
| Common - Total | \$(1.07) | ... | | | Net earnings (loss) | | | |
| Total number of | | | | | per share - diluted | \$0.31 | ... | ... |
| employees | 88 | ... | | | Cash dividends | | | |

⊠ Reclassified to conform with 2022 presentation; ⊡ Adjusted for 1-for-5 stock split, March 23, 2023; ⊢ Approximately; ⊣ As of March 29, 2023; ⊤ As of April 6, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash & cash equivalents | 3,140,747 | 1,254,494 |
| Accounts receivable | 686,327 | 1,008,375 |
| Related party receivables | ... | 31,446 |
| Prepaid operating expenses | 826,781 | 225,756 |
| Rent deposit | ... | 55,981 |
| VAT receivable associated with Sunflower Artificial Intelligence Technologies (SAIT) | ... | 71,742 |
| Tax credit receivable | ... | 218,239 |
| Miscellaneous receivable | 44,087 | 8,368 |
| Prepaid expenses & other current assets | ... | 580,086 |
| Total current assets | 4,697,942 | 2,874,401 |
| Capitalized internal-use software, net | 1,472,374 | 1,418,672 |
| Goodwill | 1,248,664 | 1,248,664 |
| Intangible assets, net | 223,690 | 251,686 |
| Computer equipment | 152,014 | 148,832 |
| Furniture & fixtures | 28,052 | 27,220 |

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| Total revenues | 6,108,000 | ... | ... |
| Net product revenue .. | 6,108,000 | 8,423,000 | 8,643,000 |
| Cost of products sold | 2,660,000 | 4,030,000 | 4,522,000 |
| Gross profit (loss) | 3,448,000 | 4,393,000 | 4,121,000 |
| Selling, general & administrative expenses | 2,248,000 | 2,158,000 | 2,029,000 |
| Operating income (loss) | 1,200,000 | 2,235,000 | 2,092,000 |
| Interest income, net | 221,000 | 40,000 | 19,000 |
| Other income (loss), net | 836,000 | (449,000) | 287,000 |
| Income (loss) before income taxes .. | 2,257,000 | 1,826,000 | 2,398,000 |
| Current federal income tax provision (benefit) ... | 339,000 | 563,000 | 318,000 |
| Current state income tax | | | |

TAITRON COMPONENTS INC. Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| Total revenues | 6,108,000 | ... | ... |
| Net product revenue .. | 6,108,000 | 8,423,000 | 8,643,000 |
| Cost of products sold | 2,660,000 | 4,030,000 | 4,522,000 |
| Gross profit (loss) | 3,448,000 | 4,393,000 | 4,121,000 |
| Selling, general & administrative expenses | 2,248,000 | 2,158,000 | 2,029,000 |
| Operating income (loss) | 1,200,000 | 2,235,000 | 2,092,000 |
| Interest income, net | 221,000 | 40,000 | 19,000 |
| Other income (loss), net | 836,000 | (449,000) | 287,000 |
| Income (loss) before income taxes .. | 2,257,000 | 1,826,000 | 2,398,000 |
| Current federal income tax provision (benefit) ... | 339,000 | 563,000 | 318,000 |
| Current state income tax | | | |

⊠ As of March 15, 2023; ⊡ As of March 15, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|----------------------------------|-----------|-----------|
| Cash & cash equivalents | 6,205,000 | 5,217,000 |
| Accounts receivable, gross | 99,000 | 690,000 |

| | | |
|---|------------|------------|
| Less: allowances | 7,000 | 7,000 |
| Accounts receivable | 92,000 | 683,000 |
| Short-term investments | 3,630,000 | 2,034,000 |
| Inventories, gross | 7,738,000 | 8,969,000 |
| Less: reserves for | | |
| obsolescence | 5,141,000 | 5,069,000 |
| Inventories | 2,597,000 | 3,900,000 |
| Prepaid expenses & other | | |
| current assets | 283,000 | 148,000 |
| Total current assets | 12,807,000 | 11,982,000 |
| Land | 1,284,000 | 1,284,000 |
| Buildings & improvements | 5,075,000 | 4,867,000 |
| Furniture & equipment | 801,000 | 797,000 |
| Computer software & hardware | 7,760,000 | 597,000 |
| Computer software and hardware | 600,000 | ... |
| Total property & equipment | ... | 7,545,000 |
| Less: accumulated depreciation & amortization | 4,790,000 | 4,623,000 |
| Property & equipment, net | 2,970,000 | 2,922,000 |
| Deferred taxes | 2,043,000 | 2,047,000 |
| Investment in securities | | |
| - Zowie technology | ... | 186,000 |
| Other assets | 186,000 | ... |
| Total assets | 18,006,000 | 17,137,000 |
| Accounts payable | 194,000 | 211,000 |
| Accrued liabilities | 969,000 | 790,000 |
| Total current liabilities | 1,163,000 | 1,001,000 |
| Total liabilities | ... | 1,001,000 |
| Class A common stock | 5,000 | 5,000 |
| Class B common stock | 1,000 | 1,000 |
| Additional paid-in capital | 11,474,000 | 11,407,000 |
| Accumulated other comprehensive income (loss) | (61,000) | (58,000) |
| Retained earnings | 5,424,000 | ... |
| Retained earnings (accumulated deficit) | ... | 4,781,000 |
| Total shareholders' equity - Taitron | | |
| Components Inc. | 16,843,000 | 16,136,000 |
| Total equity | 16,843,000 | 16,136,000 |

Recent Dividends:**1. Taitron Components Inc. class B common.**

No dividends paid.

2. Taitron Components Inc. class A common.

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 02/11/2021 | 0.04 | 01/29/2021 | 02/12/2021 | 02/26/2021 |
| 05/13/2021 | 0.04 | 04/30/2021 | 05/14/2021 | 05/28/2021 |
| 08/12/2021 | 0.04 | 07/30/2021 | 08/13/2021 | 08/31/2021 |
| 11/10/2021 | 0.04 | 10/29/2021 | 11/12/2021 | 11/30/2021 |
| 02/10/2022 | 0.04 | 01/29/2022 | 02/11/2022 | 02/28/2022 |
| 05/12/2022 | 0.04 | 04/29/2022 | 05/13/2022 | 05/31/2022 |
| 05/12/2022 | 0.10 | 04/29/2022 | 05/13/2022 | 05/31/2022 |
| 08/11/2022 | 0.04 | 07/29/2022 | 08/12/2022 | 08/31/2022 |
| 11/09/2022 | 0.05 | 10/28/2022 | 11/11/2022 | 11/30/2022 |
| 02/09/2023 | 0.05 | 01/27/2023 | 02/10/2023 | 02/28/2023 |
| 05/11/2023 | 0.05 | 04/28/2023 | 05/12/2023 | 05/31/2023 |
| 08/10/2023 | 0.05 | 07/28/2023 | 08/11/2023 | 08/31/2023 |
| 11/09/2023 | 0.05 | 10/27/2023 | 11/10/2023 | 11/30/2023 |
| 02/15/2024 | 0.05 | 02/02/2024 | 02/16/2024 | 02/29/2024 |

Annual Dividends:**1. Taitron Components Inc. class B common.**

No dividends paid.

2. Taitron Components Inc. class A common.

| | | | | | |
|------|------|------|------|------|------|
| 2021 | 0.17 | 2022 | 0.29 | 2023 | 0.20 |
| 2024 | 0.05 | | | | |

TANCHENG GROUP CO LTD**Annual Report****Consolidated Income Statement, Years Ended (\$):**

12/31/23 07/31/22 07/31/21

General & administrative

| | | | |
|---|------------------|-----------------|-----------------|
| costs | 623,879 | 45,670 | 22,934 |
| Amortization expense | ... | 900 | ... |
| Professional fees | ... | 16,820 | 22,764 |
| Rent expense | ... | 313 | 355 |
| Selling and marketing expenses | 27,714 | ... | ... |
| Total expenses | ... | 63,703 | 46,053 |
| Income (loss) from operations | (290,746) | (63,703) | (46,053) |
| Net income (loss) after tax | (289,666) | (63,703) | (46,053) |
| Weighted average shares outstanding | | | |
| - basic | 4,381,550 | 4,381,550 | 4,381,550 |
| Weighted average shares outstanding - diluted | 4,381,550 | 4,381,550 | 4,381,550 |
| Year end shares outstanding | 4,381,550 | 4,381,550 | 4,381,550 |
| Net income (loss) per common share - basic | \$(0.07) | \$(0.01) | \$(0.01) |
| Net income (loss) per common share - diluted | \$(0.07) | \$(0.01) | \$(0.01) |
| Full-Time Employees (Period End) | 17 | ... | ... |
| Total number of employees | 17 | 1 | 1 |
| Number of common stockholders | 13 | 30 | 26 |
| REVENUES | 1,969,094 | ... | ... |
| Total Revenue | 1,969,094 | ... | ... |
| LOSS BEFORE INCOME TAXES | (289,666) | ... | ... |
| OTHER INCOME | 1,080 | ... | ... |
| GROSS PROFIT | 360,847 | ... | ... |
| Cost of Revenues | 1,608,247 | ... | ... |

As of October 8, 2021

Consolidated Balance Sheet, Years Ended (\$):

12/31/23 07/31/22

| | | | |
|---|-------------|-----------|--------|
| Cash | ... | 1,889 | ... |
| Prepaid rent | ... | 72 | ... |
| Prepaid expenses | ... | 621 | ... |
| Cash and cash equivalents | 412,154 | ... | ... |
| Other receivables | 731 | ... | ... |
| Inventories | 1,252,150 | ... | ... |
| Advance to suppliers | 16,200 | ... | ... |
| Amounts due from related parties | 1,695,750 | ... | ... |
| Total current assets | 3,376,985 | 2,582 | 21,084 |
| Intangible assets, net | ... | ... | ... |
| Motor vehicle | 124,568 | ... | ... |
| Total Non-Current Assets | 124,568 | ... | ... |
| Total assets | 3,501,553 | 23,666 | ... |
| Accounts payable | 153,572 | 5,990 | ... |
| Payroll liabilities | ... | 68,400 | ... |
| Related party payable | ... | 71,724 | ... |
| Other payables and accruals | 12,553 | ... | ... |
| Amounts due to related parties | 4,387,838 | ... | ... |
| Advance from customers | 142,889 | ... | ... |
| Total current liabilities | 4,696,852 | 146,114 | ... |
| Total liabilities | 4,696,852 | 146,114 | ... |
| Common stock | 4,382 | 4,381 | ... |
| Additional paid in capital | 162,864 | 16,750 | ... |
| Retained earnings (accumulated deficit) | (1,413,226) | (143,579) | ... |
| Foreign currency translation reserves | 50,681 | ... | ... |
| Total stockholders' equity (deficit) | (1,195,299) | (122,448) | ... |
| Total Equity | (1,195,299) | ... | ... |

Recent Dividends:**1. Tancheng Group Co Ltd common.**

No dividends paid.

Annual Dividends:**1. Tancheng Group Co Ltd common.**

No dividends paid.

TANDY LEATHER FACTORY INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

2023 2022 2021

(revised)

| | | | |
|---|------------------|------------------|------------------|
| Net sales | 76,229,000 | 80,335,000 | 82,661,000 |
| Cost of sales | 31,066,000 | 33,838,000 | 35,662,000 |
| Gross profit | 45,163,000 | 46,497,000 | 46,999,000 |
| Operating expenses | 40,753,000 | 45,109,000 | 44,699,000 |
| Income (loss) from operations | 4,410,000 | 1,388,000 | 2,300,000 |
| Interest expense | ... | (9,000) | 16,000 |
| Interest income (expense) | 93,000 | ... | ... |
| Other income (expense), net | 42,000 | 11,000 | (91,000) |
| Total other income (expense) | 135,000 | 20,000 | (107,000) |
| Income (loss) from continuing operations before income taxes - United States | ... | 733,000 | 2,552,000 |
| Income (loss) from continuing operations before income taxes - Spain | ... | (83,000) | (135,000) |
| Income (loss) from continuing operations before income taxes - Canada | ... | 758,000 | (229,000) |
| Income (loss) from continuing operations before income taxes - Australia | ... | ... | (1,000) |
| Income (loss) from continuing operations before income taxes - United Kingdom | ... | ... | 6,000 |
| Income (loss) before income taxes | 4,545,000 | 1,408,000 | 2,193,000 |
| Current provision (benefit) for federal income taxes | 892,000 | 16,000 | 640,000 |
| Current provision (benefit) for state income taxes | 181,000 | 41,000 | 98,000 |
| Current provision (benefit) for foreign income taxes | 102,000 | 96,000 | ... |
| Current provision (benefit) for related to UTP | (34,000) | 28,000 | 19,000 |
| Total current provision (benefit) for income taxes | 1,141,000 | 181,000 | 757,000 |
| Deferred provision (benefit) for federal income taxes | (266,000) | ... | ... |
| Deferred provision (benefit) for state income taxes | (103,000) | ... | ... |
| Deferred provision (benefit) for foreign income taxes | 5,000 | ... | 82,000 |
| Total deferred provision (benefit) for income taxes | ... | ... | 82,000 |
| Income tax provision (benefit) | 777,000 | 181,000 | 839,000 |
| Net income (loss) | 3,768,000 | 1,227,000 | 1,354,000 |
| Weighted average shares outstanding | | | |
| - basic | 8,339,658 | 8,363,390 | 8,709,866 |

| | | | |
|--|-----------|-----------|-----------|
| Weighted average shares outstanding - diluted | 8,369,976 | 8,394,567 | 8,720,469 |
| Year end shares outstanding | 8,399,245 | 8,293,149 | 8,547,335 |
| Income (loss) per share from continuing operations - basic | \$0.45 | ... | ... |
| Net income (loss) per share - basic | \$0.45 | \$0.15 | \$0.16 |
| Income (loss) per share from continuing operations - diluted | \$0.45 | ... | ... |
| Net income (loss) per share - diluted | \$0.45 | \$0.15 | \$0.16 |
| Number of full time employees | 389 | 494 | 492 |
| Number of part time employees | ... | 111 | 101 |
| Total number of employees | 389 | 605 | 593 |
| Number of common stockholders | 278 | 283 | 286 |
| Foreign currency translation adjustments | ... | (527,000) | (81,000) |

□ Approximately; □ As of February 28, 2023; □ As of February 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------------|------------|------------|
| Cash & cash equivalents | 12,159,000 | 7,975,000 |
| Accounts receivable - trade, gross | 295,000 | 426,000 |
| Allowance for doubtful accounts | 31,000 | 56,000 |
| Accounts receivable-trade, net | 264,000 | ... |
| Finished goods held for sale | 33,350,000 | 35,234,000 |
| Raw materials & work in process | 1,774,000 | 925,000 |
| Inventory in transit | 2,869,000 | 2,068,000 |
| Inventory | 37,993,000 | 38,227,000 |
| Income tax receivable | 248,000 | 302,000 |
| Prepaid expenses | 475,000 | 272,000 |
| Other current assets | 113,000 | 106,000 |
| Total current assets | 51,252,000 | 47,252,000 |
| Building | 9,277,000 | 9,266,000 |
| Land | 1,451,000 | 1,451,000 |
| Leasehold improvements | 1,875,000 | 1,870,000 |
| Equipment & machinery | 8,469,000 | 7,931,000 |
| Furniture & fixtures | 7,452,000 | 7,471,000 |
| Vehicles | 154,000 | 135,000 |
| Property & equipment, at cost | 28,678,000 | 28,124,000 |
| Less accumulated depreciation | 18,131,000 | 16,962,000 |
| Property & equipment, net | 10,547,000 | 11,162,000 |
| Operating lease assets | 8,995,000 | 9,742,000 |
| Financing lease assets | 23,000 | 31,000 |
| Deferred income taxes | 880,000 | ... |
| Other intangibles, gross | ... | 554,000 |
| Less: accumulated amortization | ... | 549,000 |
| Other intangibles, net | ... | 5,000 |
| Other assets | 438,000 | 387,000 |
| Total assets | 72,135,000 | 68,579,000 |
| Accounts payable-trade | 2,333,000 | 3,082,000 |
| Accrued employee related costs | 992,000 | 1,432,000 |
| Unearned gift card revenue | 223,000 | 256,000 |
| Estimated returns | 523,000 | 72,000 |
| Sales & payroll taxes payable | 288,000 | 693,000 |
| Accrued vendor payables | ... | 228,000 |
| Accrued expenses & other liabilities | 3,140,000 | ... |

| | | |
|---|-------------|-------------|
| Income taxes payable | ... | 211,000 |
| Current portion of operating lease liabilities | 3,172,000 | 2,881,000 |
| Current portion of finance lease liabilities | ... | 15,000 |
| sales and payroll taxes payable | 1,141,000 | ... |
| Total current liabilities | 8,933,000 | 8,870,000 |
| Uncertain tax positions | 388,000 | 450,000 |
| Other non-current liabilities | 205,000 | 326,000 |
| Operating lease liabilities, non-current | 6,253,000 | 7,469,000 |
| Finance lease liabilities, non-current | 1,000 | 1,000 |
| Deferred income taxes | 9,000 | ... |
| Common stock | 23,000 | 23,000 |
| Paid-in capital | 3,981,000 | 3,222,000 |
| Retained earnings | 63,659,000 | 59,891,000 |
| Treasury stock at cost | 9,773,000 | 9,773,000 |
| Accumulated other comprehensive income (loss), net of tax | (1,544,000) | (1,900,000) |
| Total stockholders' equity | 56,346,000 | 51,463,000 |
| Total Equity | 56,346,000 | ... |

Recent Dividends:

1. Tandy Leather Factory Inc common.

No dividends paid.

Annual Dividends:

1. Tandy Leather Factory Inc common.

No dividends paid.

TARGET GROUP INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|-----------|-----------|-----------|
| Revenue | 3,720,169 | ... | ... |
| Revenue | 3,720,169 | ... | ... |
| Cost of good sold | 2,065,149 | ... | ... |
| Gross profit | 1,655,020 | ... | ... |
| Advisory & consultancy fee | ... | 18,926 | 21,702 |
| Management services fee | 312,969 | 143,677 | 149,819 |
| Salaries & wages | ... | ... | (9,271) |
| Legal & professional fees | ... | 243,670 | 232,151 |
| Marketing expenses | 212,427 | ... | ... |
| Donation | 147,787 | ... | ... |
| Rent | 241,110 | ... | ... |
| Depreciation expense | 811,649 | 885,229 | 971,524 |
| Operating lease expense | 233,859 | (74,059) | 1,761 |
| Office & general | 410,576 | 22,071 | (17,991) |
| Travel & Entertainment | 706 | ... | ... |
| Operating lease expense | 190,185 | ... | ... |
| Recoverable expenses from JVCo related to rent and utilities | (284,784) | ... | ... |
| Total operating expenses | 2,086,299 | 1,239,514 | 1,349,695 |
| Change in fair value of derivative & warrant liability | ... | 14,383 | 2,930,894 |
| Gain (loss) on settlement | 7,238 | ... | 26,049 |
| Interest & bank charges | 1,410,974 | 1,121,595 | 985,634 |
| Exchange income (loss) | (51,811) | 126,314 | (73,163) |
| Day one interest expense | 49,520 | ... | ... |
| Other income | 16,782 | 811,464 | 30,769 |
| Recovery of sales tax recoverable | ... | 496 | 19,453 |

| | | | |
|---|-----------|-------------|-----------|
| Impairment of inventory | ... | 99,000 | ... |
| Impairment of goodwill | ... | 3,315,749 | ... |
| Share of income (loss) from joint venture | 24,152 | 354,736 | (272,995) |
| Debt issuance cost | ... | 51,599 | 52,797 |
| Gain on settlement | 1,571,742 | ... | ... |
| Total other income (expenses) | ... | (3,280,550) | 1,622,576 |
| Net income (loss) before income taxes | (323,670) | (4,520,064) | 272,881 |
| Net income (loss) | (323,670) | (4,520,064) | 272,881 |

| | | | |
|---|-------------|-------------|-------------|
| Weighted average shares outstanding - basic | 617,025,999 | 617,025,999 | 595,347,680 |
| Weighted average shares outstanding - diluted | 617,025,999 | 617,025,999 | 595,347,680 |
| Year end shares outstanding | 617,025,999 | 617,025,999 | 617,025,999 |
| Net income (loss) per share - basic | \$(0.00) | \$(0.01) | \$0.00 |
| Net income (loss) per share - diluted | \$(0.00) | \$(0.01) | \$0.00 |

| | | | |
|---|----------|-----|-----|
| Full-Time Employees (Period End) | 49 | ... | ... |
| Total number of employees | 49 | 56 | 45 |
| Number of common stockholders | 430 | 430 | 432 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.00) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.00) | ... | ... |

□ Reclassified to conform with 2022 presentation

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|-----------|
| Cash | 736,323 | 223,843 |
| Restricted cash | 8,696 | 8,490 |
| Accounts receivable | 1,031,530 | ... |
| Accounts & Notes Receivable - Trade | ... | ... |
| Gross Accounts receivable, no allowance | 1,086,439 | ... |
| Inventories - Finished Goods | 784,354 | ... |
| Inventories - Work in Progress | 431,574 | ... |
| Inventory | 1,215,928 | ... |
| Prepaid asset | 42,720 | 41,714 |
| Receivable from joint venture | ... | 630,180 |
| Other receivable | 3,781 | 3,692 |
| Other assets | 55,268 | ... |
| Provision - Accounts & Notes Receivable - Trade | 54,909 | ... |
| Total current assets | 3,094,246 | 909,987 |
| Furniture & fixtures, at cost | 1,453,783 | 712,768 |
| Less: accumulated depreciation - furniture & fixtures | ... | 233,219 |
| Machinery & equipment, at cost | 770,218 | 769,251 |
| Less: accumulated depreciation - machinery & equipment | 753,151 | 741,764 |
| Software, at cost | 43,555 | 43,502 |
| Less: accumulated depreciation - software | 581,301 | 43,067 |
| Leasehold improvements, at cost | 6,886,818 | 6,702,383 |
| Less: accumulated | ... | ... |

| | | |
|---|--------------|--------------|
| depreciation - leasehold improvements | 2,346,107 | 1,655,629 |
| Leasehold Improvements | | |
| Net | 4,540,711 | ... |
| Machinery And Equipment | | |
| Net | 17,067 | ... |
| Fixed assets, gross | 8,227,904 | ... |
| Less: accumulated depreciation | 2,673,679 | ... |
| Accumulated depreciation of Software And Software Development Costs | 43,555 | ... |
| Fixed assets | 5,430,260 | 5,554,225 |
| Fixed assets | 872,482 | ... |
| Investment in joint venture | 775,577 | ... |
| Goodwill | 269,460 | 263,117 |
| Operating lease right-of-use assets | 46,936 | 62,728 |
| Total long term assets | 5,746,656 | 6,655,647 |
| Total assets | 8,840,902 | 7,565,634 |
| Bank overdraft | 506 | 506 |
| Accounts payable & accrued liabilities | 245,851 | 2,296,935 |
| Deferred revenue | 43,098 | ... |
| Settlement payable | 11,415,557 | ... |
| Sales tax payable | 48,581 | 35,254 |
| Payable to related parties, net | 4,468,535 | ... |
| Operating lease liability - current portion | 127,478 | 110,586 |
| Convertible promissory notes, net | 480 | 480 |
| Derivative liability | 8,021 | 15,125 |
| Accounts Payable | 126,095 | ... |
| Interest on promissory notes and loans | 1,628,007 | ... |
| Accrued professional fees | 945,615 | ... |
| Accounts payable and accrued liabilities - Balancing value | 2,945,568 | ... |
| Total current liabilities | 14,589,289 | 6,927,421 |
| Payable to related parties, net - non-current portion | 5,877,930 | ... |
| Operating lease liability - non-current portion | 1,223,955 | 1,319,619 |
| Warrant liability | 355 | ... |
| Warranty liability | 489 | ... |
| Total long term liabilities | 1,224,310 | 7,198,038 |
| Total liabilities | 15,813,599 | 14,125,459 |
| Preferred stock | 100 | 100 |
| Common stock | 61,703 | 61,703 |
| Shares to be issued | 175,439 | 175,182 |
| Additional paid-in capital | 24,985,697 | 24,985,697 |
| Retained earnings (accumulated deficit) | (31,107,348) | (30,783,678) |
| Accumulated comprehensive income (loss) | (1,088,288) | (998,829) |
| Total stockholders' equity (deficiency) | (6,972,697) | (6,559,825) |
| Total Equity | (6,972,697) | ... |

Recent Dividends:**1. Target Group Inc series A preferred.**

No dividends paid.

2. Target Group Inc common.

No dividends paid.

Annual Dividends:**1. Target Group Inc series A preferred.**

No dividends paid.

2. Target Group Inc common.

No dividends paid.

TAYLOR DEVICES INC**Earnings, 9 mos. to (Consol. - \$):**

| | | |
|-----------------------------|------------|------------|
| | 02/29/24 | 02/28/23 |
| Total revenues | 32,517,596 | ... |
| Net Sales | 32,517,596 | 29,479,337 |
| Cost & expenses | 25,551,177 | 24,739,555 |
| Operating income | 6,966,419 | 4,739,782 |
| Other income (expense), net | 1,122,713 | 432,984 |

| | | |
|-----------------------|------------------|------------------|
| Net before taxes | 8,089,132 | 5,172,766 |
| Income taxes | 1,563,000 | 952,000 |
| Net income | 6,526,132 | 4,220,766 |
| Earnings common share | | |
| Primary | \$1.91 | \$1.20 |
| Fully Diluted | \$1.91 | \$1.20 |
| Common Shares: | | |
| Full Diluted | 3,416,823 | 3,502,982 |
| Year-end | 3,093,964 | 3,509,152 |

TECOGEN INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

2023 2022 2021

(revised)

Revenues - products .. 8,859,946 11,156,099 10,133,329

Revenues - services .. 14,523,054 12,060,661 12,525,594

Revenues - energy production .. 1,756,419 1,785,854 1,739,150

Total revenues .. 25,139,419 25,002,614 24,398,073

Service .. 7,909,202

Product .. 5,923,096

Energy Service .. 1,105,503

Cost of sales - products .. 7,413,320 5,601,046

Cost of sales - services .. 5,525,493 6,134,953

Cost of sales - energy production .. 996,990 1,074,421

Total cost of sales .. 14,937,801 13,935,803 12,810,420

Gross profit (loss) .. 10,201,618 11,066,811 11,587,653

General & administrative expenses .. 11,880,389 10,909,251 9,795,823

Selling expenses .. 1,931,037 1,811,085 2,471,929

Research & development expenses .. 840,011 732,873 542,079

Gain (loss) on sale of assets .. 36,207 41,931 10,486

Long-lived asset impairment .. 4,674 7,400

Total operating expenses .. 14,615,230 13,415,952 12,806,745

Income (loss) from operations .. (4,413,612) (2,349,141) (1,219,092)

Interest & other income .. (61,003) (34,713) (23,746)

Interest expense .. 16,050 16,255 14,238

Gain on extinguishment of debt .. 3,773,014

Employee retention credit .. (1,276,021)

Gain on the sale of investments .. 6,046

Unrealized gain (loss) on investment securities .. 18,749 (37,497)

Total other income (expense), net .. (77,053) (32,219) 4,979,600

Income (loss) before income taxes .. (4,490,665) (2,381,360) 3,760,508

State income tax provision (benefit) .. 32,491 16,352 19,491

Consolidated net income (loss) .. (4,523,156) (2,397,712) 3,741,017

Loss (income) attributable to the noncontrolling interest .. (74,952) (50,215) (45,017)

Net income (loss) attributable to Tecogen Inc. .. (4,598,108) (2,447,927) 3,696,000

Weighted average shares outstanding - basic .. 24,850,261 24,850,261 24,850,261

Weighted average shares outstanding - diluted .. 24,850,261 24,850,261 25,115,518

Year end shares outstanding .. 24,850,261 24,850,261 24,850,261

Net income (loss) per share - basic .. \$(0.19) \$(0.10) \$0.15

| | | | |
|---------------------------------------|----------|----------|--------|
| Net income (loss) per share - diluted | \$(0.19) | \$(0.10) | \$0.15 |
| Number of full time employees | 92 | 85 | 77 |
| Number of part time employees | 1 | 1 | 2 |
| Number of common stockholders | 57 | 57 | 57 |
| Net income (loss) per share diluted | \$(0.19) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.19) | ... | ... |
| Total number of employees | 93 | ... | ... |

As of March 23, 2023; As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

2023 2022

Cash & cash equivalents .. 1,351,270 1,913,969

Account receivable, gross .. 7,075,319

Less: allowance for doubtful accounts .. 361,197

Accounts receivable, net .. 6,735,336 6,714,122

Employee retention credit .. 46,148 713,269

Unbilled revenue .. 1,258,532 1,805,330

Work-in-process .. 798,522 498,139

Finished goods .. 951,843 983,099

Net raw materials .. 8,803,054

Inventory, net .. 10,553,419 10,482,729

Prepaid & other current assets .. 360,639 401,189

Total current assets .. 20,305,344 22,030,608

Energy systems .. 2,810,232 2,810,232

Machinery & equipment .. 1,744,596 1,624,885

Furniture & fixtures .. 212,963 196,007

Computer software .. 192,865 192,865

Leasehold improvements .. 466,789 466,789

Property, plant & equipment, gross .. 5,427,445 5,290,778

Less - accumulated depreciation & amortization .. 4,264,868 3,883,058

Property, plant & equipment, net .. 1,162,577 1,407,720

Right of use assets .. 743,096 1,245,549

Intangible assets, net .. 2,436,230 997,594

Goodwill .. 2,743,424 2,406,156

Other assets .. 201,771 165,230

Right of Use Tangible Assets -

Total/Unspecified - Net .. 943,283

Right of Use Tangible Assets - Capital/Finance

Lease - Net .. 200,187

Total assets .. 27,792,629 28,252,857

Accounts payable .. 4,514,415 3,261,952

Accrued expenses .. 2,504,629 2,384,447

Deferred revenue .. 1,647,206 1,115,627

Lease obligations .. 248,933 687,589

Unfavorable contract liabilities, current .. 176,207 236,705

Acquisition liabilities, current .. 845,363

Related party notes .. 505,505

Capitalized Leases - Current Portion .. 40,540

Lease Liabilities - Unspecified - Current Portion/Short-Term .. 289,473

Total current liabilities .. 10,482,798 7,686,320

Deferred revenue, net current portion .. 369,611 371,823

Lease obligations, long-term .. 523,660 623,452

Unfavorable contract liability, long-term .. 422,839 583,512

Acquisition liabilities, net of current portion .. 1,181,779

Capitalized Lease Obligations - Long-Term .. 159,647

Lease Liabilities - Unspecified - Long -Term .. 683,307

| | | |
|---|--------------|--------------|
| Total liabilities | 13,140,334 | 9,265,107 |
| Common stock | 24,850 | 24,850 |
| Additional paid-in capital | 57,601,402 | 57,351,008 |
| Retained earnings (accumulated deficit) | (42,879,656) | (38,281,548) |
| Total Tenogen Inc. stockholders' equity (deficit) | 14,746,596 | 19,094,310 |
| Noncontrolling interest | (94,301) | (106,560) |
| Total stockholders' equity (deficit) | 14,652,295 | 18,987,750 |

Recent Dividends:

1. Tecogen Inc common.

No dividends paid.

Annual Dividends:

1. Tecogen Inc common.

No dividends paid.

TECTONIC FINANCIAL INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Interest income - loan, including fees | 41,612,000 | 30,885,000 | 28,379,000 |
| Interest income - securities | 2,091,000 | 1,887,000 | 955,000 |
| Interest income - federal funds sold | 45,000 | 12,000 | 1,000 |
| Interest income - interest-bearing deposits | 2,719,000 | 601,000 | 49,000 |
| Total interest income | 46,467,000 | 33,385,000 | 29,384,000 |
| Savings & interest-bearing demand | 17,749,000 | 49,000 | 35,000 |
| Money market deposit accounts | ... | 1,639,000 | 432,000 |
| Time deposits | ... | 3,252,000 | 2,015,000 |
| Interest expense - deposits | ... | 4,940,000 | 2,482,000 |
| FHLB & other borrowings | ... | 53,000 | 270,000 |
| Subordinated notes | ... | 911,000 | 875,000 |
| Interest expense - borrowed funds | 1,357,000 | 964,000 | 1,145,000 |
| Total interest expense | 19,106,000 | 5,904,000 | 3,627,000 |
| Net interest income | 27,361,000 | 27,481,000 | 25,757,000 |
| Provision for loan losses | 1,288,000 | 1,264,000 | 2,214,000 |
| Net interest income after provision for loan losses | 26,073,000 | 26,217,000 | 23,543,000 |
| Trust income | 6,442,000 | 6,098,000 | 6,252,000 |
| Gain on sale of loans | 581,000 | ... | 101,000 |
| Advisory income | 14,910,000 | 13,549,000 | 13,472,000 |
| Brokerage income | 7,527,000 | 11,754,000 | 9,644,000 |
| Service fees & other income | 10,037,000 | 8,293,000 | 6,790,000 |
| Rental income | ... | 346,000 | 365,000 |
| Rental income | 307,000 | ... | ... |
| Total non-interest income | 39,804,000 | 40,040,000 | 36,624,000 |
| Salaries & employee benefits | 31,288,000 | 31,093,000 | 24,947,000 |
| Occupancy & equipment | 1,984,000 | 1,707,000 | 1,837,000 |
| Trust expenses | 2,265,000 | 2,243,000 | 2,416,000 |
| Brokerage & advisory direct costs | 1,936,000 | 2,015,000 | 2,051,000 |
| Professional fees | 1,813,000 | 1,480,000 | 1,539,000 |
| Data processing | 941,000 | 794,000 | 964,000 |
| Other non-interest expense | 6,594,000 | 5,473,000 | 4,576,000 |
| Total non-interest expense | 46,821,000 | 44,805,000 | 38,330,000 |
| Income (loss) | | | |

| | | | |
|---|-------------------|-------------------|-------------------|
| before income taxes | 19,056,000 | 21,452,000 | 21,837,000 |
| Current federal income taxes | ... | 3,986,000 | 4,860,000 |
| Current state income taxes | ... | 125,000 | 159,000 |
| Total current income taxes | ... | 4,111,000 | 5,019,000 |
| Deferred federal income taxes | ... | 311,000 | (216,000) |
| Income tax expense | 3,836,000 | 4,422,000 | 4,803,000 |
| Net income (loss) | 15,220,000 | 17,030,000 | 17,034,000 |
| Preferred stock dividends | 1,553,000 | 1,552,000 | 1,552,000 |
| Net income available to common stockholders | 13,667,000 | 15,478,000 | 15,482,000 |
| Weighted average common shares outstanding | 7,057,430 | 7,061,519 | 6,804,228 |
| Weighted average diluted shares outstanding | 7,292,668 | 7,336,195 | 7,021,766 |
| Year end shares outstanding | 7,102,680 | 7,068,884 | 7,061,953 |
| Net earnings (loss) per share - basic | \$1.94 | \$2.19 | \$2.28 |
| Net earnings (loss) per share - diluted | \$1.87 | \$2.11 | \$2.21 |
| Full-Time Employees (Period End) | 199 | ... | ... |
| Total number of employees | 199 | 182 | 168 |
| Number of stockholders | ... | 98 | 98 |
| Dividends Per Share - Common - Gross - by Period End Date | \$0.90 | ... | ... |

□ Approximately; □ As of March 29, 2023; □ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-------------|-------------|
| Cash & due from banks | 5,016,000 | 8,549,000 |
| Interest-bearing deposits | 52,481,000 | 32,562,000 |
| Federal funds sold | 1,270,000 | 1,044,000 |
| Total cash & cash equivalents | 58,767,000 | 42,155,000 |
| Securities available for sale | 22,977,000 | 20,633,000 |
| Securities held to maturity | ... | 25,262,000 |
| Securities, restricted at cost | ... | 3,496,000 |
| Securities, not readily marketable | 4,176,000 | 100,000 |
| Loans held for sale | 26,573,000 | 33,902,000 |
| Commercial & industrial | ... | 92,946,000 |
| Consumer installment | ... | 1,058,000 |
| Real estate - residential | ... | 5,566,000 |
| Real estate - commercial | ... | 63,924,000 |
| Real estate - construction & land | ... | 3,873,000 |
| Small business associations (SBA) - guaranteed | ... | 149,374,000 |
| Small business associations (SBA) - unguaranteed | ... | 56,268,000 |
| Small business associations (SBA) - U.S. Department of Agriculture (USDA) | ... | 2,235,000 |
| Factored receivables | ... | 22,420,000 |
| Gross loans | 501,095,000 | 450,332,000 |
| Less: allowance for loan losses | 6,308,000 | 4,513,000 |
| Loans, net | 494,787,000 | 445,819,000 |
| Land | ... | 698,000 |
| Leasehold improvements | ... | 223,000 |
| Building | ... | 4,455,000 |
| Furniture & equipment | ... | 474,000 |
| Bank premises & equipment, gross | ... | 5,850,000 |

| | | |
|--------------------------------------|-------------|-------------|
| Less: accumulated depreciation | ... | 1,221,000 |
| Bank premises & equipment, net | 4,758,000 | 4,629,000 |
| Core deposit intangible, net | 359,000 | 569,000 |
| Goodwill | 21,440,000 | 21,440,000 |
| Deferred tax assets | 889,000 | 636,000 |
| Other assets | 18,426,000 | 13,895,000 |
| Securities held to maturity | 24,194,000 | ... |
| Total assets | 677,346,000 | 612,536,000 |
| Non-interest-bearing demand deposits | 68,433,000 | 94,187,000 |
| Interest-bearing demand (NOW) | ... | 6,216,000 |
| Money market accounts | ... | 122,880,000 |
| Savings accounts | 308,435,000 | 8,052,000 |
| Interest-bearing demand deposits | ... | 137,148,000 |
| Time deposits | ... | 261,690,000 |
| Interest-bearing | 150,023,000 | ... |
| Total deposits | 526,891,000 | 493,025,000 |
| Borrowed funds | 21,000,000 | ... |
| Subordinated notes | 12,000,000 | 12,000,000 |
| Other liabilities | 10,598,000 | 11,013,000 |
| Total liabilities | 570,489,000 | 516,038,000 |

| | | |
|--|-------------|-------------|
| Series B non-cumulative preferred stock | ... | 17,000 |
| Common stock | 72,000 | 71,000 |
| Additional paid-in capital | 51,246,000 | 50,695,000 |
| Treasury stock | 1,575,000 | ... |
| Treasury stock, at cost | ... | 481,000 |
| Retained earnings | 58,917,000 | 48,564,000 |
| Accumulated other comprehensive income (loss) | (1,820,000) | (2,368,000) |
| Preferred stock, 900% fixed to floating rate Series B non-cumulative, perpetual (\$001 par value; 1,725,000 shares authorized, 1,725,000 shares issued and outstanding at 31, 2020 and 2019) | 17,000 | ... |
| Total shareholders' equity | 106,857,000 | 96,498,000 |
| Total Equity | 106,857,000 | ... |

Recent Dividends:

1. Tectonic Financial Inc 9.00% fixed to floating rate series B non-cumulative perpetual preferred.

No dividends paid.

2. Tectonic Financial Inc 10.0% series A non-cumulative perpetual preferred.

No dividends paid.

3. Tectonic Financial Inc common.

No dividends paid.

Annual Dividends:

1. Tectonic Financial Inc 9.00% fixed to floating rate series B non-cumulative perpetual preferred.

No dividends paid.

2. Tectonic Financial Inc 10.0% series A non-cumulative perpetual preferred.

No dividends paid.

3. Tectonic Financial Inc common.

No dividends paid.

TEGO CYBER INC

Earnings, 6 mos. to Dec 31(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 10,731 | ... |
| Cost & expenses | 1,951,519 | 2,108,927 |
| Operating income | (1,940,788) | (2,108,927) |
| Other income (expense), net | (8,306) | (536,351) |
| Net before taxes | (6,327,151) | ... |
| Net income | (6,327,151) | (2,645,278) |
| Earnings common share | | |
| Primary | \$(0.12) | \$(0.10) |
| Fully Diluted | \$(0.12) | \$(0.10) |
| Common Shares: | | |
| Full Diluted | 53,750,203 | 26,821,676 |
| Year-end | 61,446,616 | 27,816,377 |

TELESIS BIO INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31
(\$000):

| | 2023 | 2022 | 2021 (revised) |
|--|-----------------|-----------------|-------------------|
| Product revenue | ... | 10,913 | 6,818 |
| Service revenue | 6,291 | 7,121 | 1,644 |
| Royalties | 2,837 | ... | ... |
| Collaboration revenue | 8,690 | 6,650 | 160 |
| Royalties & other revenue | ... | 2,751 | 2,421 |
| Product sales | 9,691 | ... | ... |
| Total revenue | 27,509 | 27,435 | 11,043 |
| Cost of revenue | 10,559 | 11,840 | 6,744 |
| Gross profit | 16,950 | 15,595 | 4,299 |
| Research & development | 17,496 | 23,460 | 14,466 |
| Sales & marketing | 13,514 | 16,489 | 10,958 |
| General & administrative | 21,090 | 22,131 | 14,249 |
| Goodwill impairment | 11,389 | ... | ... |
| Total operating expenses | 63,489 | 62,080 | 39,673 |
| Income (loss) from operations | (46,539) | (46,485) | (35,374) |
| Interest expense, net | 3,105 | 1,217 | 1,369 |
| Change in fair value of derivative liabilities | 331 | 8 | (1,521) |
| Loss on extinguishment of debt | ... | (727) | (618) |
| Other income (expense), net | (130) | (26) | (62) |
| Interest income | 1,743 | ... | ... |
| Total other income (expense), net | ... | (1,962) | (3,570) |
| Income (loss) before provision for income taxes - domestic | ... | (48,556) | (39,026) |
| Income (loss) before provision for income taxes - foreign | ... | 109 | 81 |
| Income (loss) before provision for income taxes | (47,700) | (48,447) | (38,944) |
| Provision for income taxes | 24 | 24 | 14 |
| Redeemable convertible preferred stock dividends | 1,300 | ... | ... |
| Net income (loss) | (47,724) | (48,471) | (38,958) |
| Net income (loss) attributable to common stockholders | ... | (48,471) | (38,958) |
| Weighted average shares outstanding - basic | 29,850 | 29,463 | 18,222 |
| Weighted average shares outstanding - diluted | 29,850 | 29,463 | 18,222 |
| Year end shares outstanding | 30,063 | 29,647 | 29,319 |
| Net earnings (loss) per share - basic | \$(1.64) | \$(1.65) | \$(2.14) |
| Net earnings (loss) per share - diluted | \$(1.64) | \$(1.65) | \$(2.14) |
| Number of full time employees | 137 | 223 | 81 |
| Number of part time employees | 10 | 20 | ... |
| Number of common stockholders | 37 | 212 | 52 |
| Net Income After Extraordinary Items applicable to Common | (49,024) | ... | ... |
| Total number of | | | |

employees

147

...

...

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of shares of common stock, conversion of convertible preferred stock into common stock, issuance of warrant and conversion into common stock; □ As is; □ Approximately; □ As of January 6, 2023; □ As of January 6, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 1,570 | 30,419 |
| Restricted cash | 175 | 175 |
| Short-term investments | 17,588 | 13,159 |
| Accounts receivable, gross | 6,929 | 6,194 |
| Allowance for bad debts | 944 | 343 |
| Accounts receivable, net | 5,985 | 5,851 |
| Raw materials | 2,026 | 1,044 |
| Work in process & sub-assemblies | 1,031 | 647 |
| Finished goods | 968 | 509 |
| Inventory | 4,025 | 2,200 |
| Prepaid expenses & other current assets | 1,008 | 3,288 |
| Total current assets | 30,351 | 55,092 |
| Machinery & equipment | 6,527 | 5,647 |
| Furniture & fixtures | 908 | 64 |
| Computer hardware & software | 10,773 | 1,531 |
| Leasehold improvements | 332 | 58 |
| Construction in progress | 586 | 1,501 |
| Computer hardware and software | 2,420 | ... |
| Property & equipment, gross | ... | 8,801 |
| Less: accumulated depreciation & amortization | 3,473 | 1,940 |
| Property & equipment, net | 7,300 | 6,861 |
| Right-of-use assets | 27,220 | 1,660 |
| Other long-term assets | 676 | 981 |
| Goodwill | 3,497 | 14,886 |
| Other intangible assets, net | 1,367 | 1,882 |
| Total assets | 70,411 | 81,362 |
| Accounts payable | 3,284 | 1,295 |
| Accrued employee expenses | 2,142 | 5,858 |
| Finance lease liability, current portion | 112 | 59 |
| Operating lease liability, current portion | 1,710 | 578 |
| Deferred revenue, current portion | 338 | 3,958 |
| Other accrued liabilities | 506 | 1,377 |
| Other current liabilities | 92 | 373 |
| Total current liabilities | 8,184 | 13,498 |
| Finance lease liability, net of current portion | 147 | 30 |
| Operating lease liability, net of current portion | 27,142 | 1,111 |
| Notes payable, net of discount & current portion | 5,269 | 19,649 |
| Derivative liabilities | 36 | 367 |
| Deferred revenue, net of current portion | 95 | 142 |
| Total liabilities | 40,873 | 34,797 |
| Common stock | 5 | 5 |
| Additional paid-in capital | 161,698 | 160,304 |
| Accumulated other comprehensive loss | ... | (3) |
| Accumulated deficit | (161,465) | ... |
| Retained earnings (accumulated deficit) | ... | (113,741) |
| Redeemable convertible preferred stock | 29,300 | ... |
| Total stockholders' equity (deficit) | 29,538 | 46,565 |
| Total Equity | 29,538 | ... |

Recent Dividends:

1. Telesis Bio Inc common.
No dividends paid.

2. Telesis Bio Inc redeemable convertible preferred.
No dividends paid.

Annual Dividends:

1. Telesis Bio Inc common.
No dividends paid.

2. Telesis Bio Inc redeemable convertible preferred.
No dividends paid.

TENAX THERAPEUTICS INC
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):
(\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|--------------------|---------------------|---------------------|
| Other costs | 831,908 | ... | ... |
| Research salaries expense | 2,176,682 | ... | ... |
| General & administrative expenses | 1,967,276 | 5,675,231 | 7,580,847 |
| Research & development expenses | 3,228,806 | 5,377,412 | 25,147,394 |
| General & administrative expense | 5,005,135 | ... | ... |
| Office & printing expense | 29,269 | ... | ... |
| Total operating expenses | 8,233,941 | 11,052,643 | 32,728,241 |
| Net operating income (loss) | (8,233,941) | (11,052,643) | (32,728,241) |
| Interest expense | ... | 4,443 | 949 |
| Interest on debt instrument | 23,967 | ... | ... |
| Other income (expense), net | 547,235 | 9,191 | 254,832 |
| Net income (loss) | (7,710,673) | (11,047,895) | (32,474,358) |
| Weighted average shares outstanding - basic | 248,447 | 18,391 | 12,861 |
| Weighted average shares outstanding - diluted | 248,447 | 18,391 | 12,861 |
| Year end shares outstanding | 298,281 | 28,648 | 15,754 |
| Net income (loss) per share - basic | \$(31.04) | \$(600.80) | \$(2,524.80) |
| Net income (loss) per share - diluted | \$(31.04) | \$(600.80) | \$(2,524.80) |
| Number of full time employees | 5 | 7 | 8 |
| Number of part time employees | 1 | 1 | 1 |
| Total number of employees | 6 | ... | ... |
| Number of common stockholders | 1,337 | 1,339 | 1,338 |
| Net loss | (7,710,673) | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(31.04) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(31.04) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-80 stock split, January 3, 2024; □ Adjusted for 1-for-20 stock split, January 5, 2023; □ Shares increased due to the effect of exercise of pre-funded warrants; □ Shares increased due to the effect of common stock issued for asset acquisition, common stock issued for convertible preferred stock, warrants and stock options exercised; □ Approximately; □ As of March 28, 2023; □ As of March 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------------|------------|-----------|
| Cash & cash equivalents | 9,792,130 | 2,123,682 |
| Prepaid expenses | ... | 738,927 |
| Prepaid expenses - other | 1,639,797 | ... |
| Other current assets | 251,583 | 345,856 |
| Total current assets | 11,683,510 | 3,208,465 |

| | | |
|---|---------------|---------------|
| Right of use asset | 179,503 | |
| Property & equipment, net | 7,189 | |
| Other assets | 1,117 | 9,552 |
| Total assets | 11,684,627 | 3,404,709 |
| Accounts payable | 2,073,149 | 448,425 |
| Accrued operating costs | | 245,391 |
| Accrued lease liability | | 119,393 |
| Accrued employee related | 775,590 | 410,261 |
| Note payable | | 624,302 |
| Notes payable to shareholders | 500,903 | |
| Accrued interest convertible debentures | 236,878 | |
| Total current liabilities | 3,586,520 | 1,847,772 |
| Lease liability - Total long term liabilities | | 64,196 |
| Total liabilities | 3,586,520 | 1,911,968 |
| Common stock | 30 | 4,584 |
| Additional paid-in capital | 305,350,830 | 291,030,237 |
| Accumulated deficit | (297,252,753) | |
| Retained earnings (accumulated deficit) | | (289,542,080) |
| Total stockholders' equity (deficit) | 8,098,107 | 1,492,741 |
| Total Equity | 8,098,107 | |

Recent Dividends:

- Tenax Therapeutics Inc preferred.**
No dividends paid.
 - Tenax Therapeutics Inc common.**
No dividends paid.
 - Tenax Therapeutics Inc series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- Tenax Therapeutics Inc preferred.**
No dividends paid.
 - Tenax Therapeutics Inc common.**
No dividends paid.
 - Tenax Therapeutics Inc series A convertible preferred.**
No dividends paid.

**TENON MEDICAL INC
Annual Report**

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|---------------------|--------------------|
| Revenue | 2,928,000 | | |
| Revenue | 2,928,000 | 691,000 | 160,000 |
| Cost of sales | 1,687,000 | 1,332,000 | 55,000 |
| Gross profit | 1,241,000 | (641,000) | 105,000 |
| Research & development expenses | 3,163,000 | 2,828,000 | 1,718,000 |
| Sales & marketing expenses | 6,778,000 | 7,833,000 | 2,141,000 |
| General & administrative expenses | 7,027,000 | 7,423,000 | 2,707,000 |
| Total operating expenses | 16,968,000 | 18,084,000 | 6,566,000 |
| Income (loss) from operations | (15,727,000) | (18,725,000) | (6,461,000) |
| Gain (loss) on investments | 167,000 | 180,000 | 2,000 |
| Interest expense | 21,000 | 354,000 | 621,000 |
| Other expense, net | | 18,000 | 1,000 |
| Total other income (expense) | 146,000 | (192,000) | (620,000) |
| Net income (loss) | (15,581,000) | (18,917,000) | (7,081,000) |
| Loss (income) attributable to non-controlling interest | | | 33,000 |
| Net income (loss) attributable to Tenon Medical, Inc. | (18,917,000) | (7,048,000) | |
| Weighted average shares outstanding - basic | 1,814,000 | 800,800 | 90,268 |
| Weighted average shares outstanding | | | |

| | | | |
|---|--------------|-----------|-----------|
| - diluted | 1,814,000 | 800,800 | 90,268 |
| Year end shares outstanding | 2,600,311 | 1,123,680 | 98,995 |
| Net income (loss) per share - basic | \$(8.59) | \$(23.60) | \$(78.10) |
| Net income (loss) per share - diluted | \$(8.59) | \$(23.60) | \$(78.10) |
| Number of full time employees | | 22 | 10 |
| Number of part time employees | | 5 | 5 |
| Number of common stockholders | | 159 | |
| Foreign currency translation adjustments | | 7,000 | |
| Income from cont operations before income tax | (15,581,000) | | |

Adjusted for 1- for -10 stock split, November 2, 2023; Shares increase due to the effect of issuance of common stock & warrant, Common stock issued upon conversion of Series A & B preferred stock & series B & debt & common stock issued for services; As of March 10, 2023; As of April 26, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|------------|
| Cash & cash equivalents | 2,428,000 | 2,129,000 |
| Short term investments | | 6,441,000 |
| Accounts receivables, gross | | 228,000 |
| Less: allowance for doubtful accounts | | 0 |
| Accounts receivable | 518,000 | 228,000 |
| Raw materials | 22,000 | 9,000 |
| Finished goods | 532,000 | 406,000 |
| Inventory, net | 554,000 | |
| Inventory | | 415,000 |
| Prepaid expenses | 389,000 | 134,000 |
| Total current assets | 3,889,000 | 9,347,000 |
| Construction in progress | 602,000 | 601,000 |
| Catamaran tray sets | 538,000 | 193,000 |
| IT equipment | 1,234,000 | 56,000 |
| Lab equipment | 14,000 | 14,000 |
| IT equipment, net | 56,000 | |
| Office furniture | | 9,000 |
| Fixed assets, gross | | |
| Leasehold Improvements | 15,000 | |
| Fixed assets, gross | | |
| Office Equipment | 9,000 | |
| Less: accumulated depreciation | 273,000 | 80,000 |
| Fixed assets - net | 961,000 | 793,000 |
| Deposits | 51,000 | 51,000 |
| Operating lease right-of-use asset | 646,000 | 873,000 |
| Deferred offering costs | 798,000 | 25,000 |
| Total assets | 6,345,000 | 11,089,000 |
| Accounts payable | 433,000 | 550,000 |
| Accrued compensation | 334,000 | 452,000 |
| Other accrued expenses | 474,000 | 265,000 |
| Accrued expenses | 808,000 | 717,000 |
| Current portion of accrued commissions | 470,000 | 1,035,000 |
| Current portion of operating lease liability | 256,000 | 228,000 |
| Convertible notes payable and accrued interest, net of debt discount of \$77 and \$0 at 31, 2023 and 2022, respectively | 1,173,000 | |
| Total current liabilities | 3,140,000 | 2,530,000 |
| Accrued commissions, net of current portion | | 1,624,000 |
| Operating lease liability, net of current portion | 428,000 | 683,000 |
| Accrued Expenses - Long-Term | 1,999,000 | |
| Total liabilities | 5,567,000 | 4,837,000 |
| Common stock | 3,000 | 11,000 |
| Additional paid-in | | |

| | | |
|--|--------------|--------------|
| capital | 55,894,000 | 45,833,000 |
| Accumulated deficit | (55,073,000) | |
| Retained earnings (accumulated deficit) | | (39,492,000) |
| Accumulated other comprehensive income (loss) | (46,000) | (100,000) |
| Total Tenon Medical, Inc. stockholders' equity deficit | 778,000 | 6,252,000 |
| Total stockholders' equity (deficit) | 778,000 | 6,252,000 |

Recent Dividends:

- Tenon Medical Inc common.**
No dividends paid.
- Annual Dividends:**
- Tenon Medical Inc common.**
No dividends paid.

TETON ADVISORS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2021 | 2020 |
|--|------------|------------|-------------|
| Investment advisory fees | | 16,404,470 | 13,704,762 |
| Distribution fees | 18,598 | 30,105 | 51,929 |
| Other income (expense), net | | 3,442 | 50,422 |
| Investment advisory fees - mutual funds | 10,923,634 | | |
| Other income | 1,102,504 | | |
| Total revenues | 12,044,736 | 16,438,017 | 13,807,113 |
| Compensation | 5,102,161 | 5,501,495 | 4,575,357 |
| Marketing & administrative fees | 179,543 | 1,436,309 | 1,324,788 |
| Distribution expenses | 1,505,402 | 1,704,012 | 1,718,386 |
| Advanced commissions | 18,379 | 18,296 | 47,398 |
| Sub-advisory fees | | 2,780,853 | 2,555,063 |
| Other operating expenses | 2,020,302 | 1,567,796 | 1,652,141 |
| Distribution expenses | 1,369,024 | | |
| Depreciation and amortization expense | 336,727 | | |
| Impairment of intangible assets | 59,000 | | |
| Total operating expenses | | 13,008,761 | 11,873,133 |
| Income before interest, taxes, depreciation, amortization & impairment | | 3,429,256 | 1,933,980 |
| Depreciation & amortization expense | | 358,077 | 792,350 |
| Impairment of intangible assets | | | 5,550,000 |
| Income (loss) before income tax | 1,454,198 | 3,071,179 | (4,408,370) |
| Current provision for federal income taxes | | 465,828 | 172,389 |
| Deferred provision (benefit) for federal income taxes | | 154,202 | (1,134,997) |
| Current provision for state income taxes | | 142,112 | 48,417 |
| Deferred provision (benefit) for state income taxes | | (32,962) | 59,634 |
| Current Tax - Domestic | 217,352 | | |
| Current Tax - State & Local | 1,731 | | |
| Deferred Tax - Domestic | 145,887 | | |

| | | | |
|---|------------------|------------------|--------------------|
| Deferred Tax - State & Local | (115,890) | ... | ... |
| Income tax provision (benefit) | 249,080 | 729,180 | (854,557) |
| Net income | 1,205,118 | 2,341,999 | (3,553,813) |
| Income attributable to Teton shareholders | ... | 2,341,999 | (3,553,813) |
| Weighted average shares outstanding - basic | 1,599,440 | 1,260,988 | 1,261,293 |
| Weighted average shares outstanding - diluted | 1,612,300 | 1,268,828 | 1,261,293 |
| Year end shares outstanding | 1,642,140 | 1,320,487 | 1,302,988 |
| Net income per share - basic | \$0.75 | \$1.86 | \$(2.82) |
| Net income per share - diluted | \$0.75 | \$1.85 | \$(2.82) |
| Dividends declared - per share | ... | ... | \$0.05 |
| Number of full time employees | 22 | 22 | 20 |
| Number of class A common stockholders | ... | 19 | 20 |
| Number of class B common stockholders | ... | 104 | 117 |
| Number of Common Shareholders | 114 | ... | ... |
| Total number of employees | 22 | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|---|------------|------------|
| Cash & cash equivalents | 20,781,885 | 21,506,861 |
| Investment advisory fees receivable | 846,781 | 1,374,135 |
| Investment in securities | 2,706,683 | ... |
| Deferred tax asset | 3,002,595 | 3,452,913 |
| Distribution & shareholder service expense reimbursement receivable | 42,404 | 53,086 |
| Receivable from affiliates | 1,110 | 2,800 |
| Intangible Assets - excluding Goodwill - Net - Total | 2,589,113 | ... |
| Intangible assets, net | ... | 3,699,909 |
| Contingent deferred sales commission | 6,651 | 17,827 |
| Right-of-use assets | 140,525 | 385,352 |
| Other assets | 351,092 | 276,039 |
| Acc Depr/Imp of Property/Plant/Equipment | 28,289 | ... |
| Total Property/Plant/Equipment, Net - Balancing value | 379,381 | ... |
| Total assets | 30,468,839 | 30,768,922 |
| Due to broker | 191,801 | 7,999,316 |
| Compensation payable | 746,277 | 707,926 |
| Payable to affiliates | 216,340 | 395,745 |
| Distribution costs payable | ... | 233,409 |
| Income tax payable | 81,040 | 23,225 |
| Lease liabilities | 140,525 | 447,469 |
| Accrued expenses & other liabilities | 1,012,587 | 1,205,724 |
| Total liabilities | 2,388,570 | 11,012,814 |
| Class A common stock | 1,310 | 974 |
| Class B common stock | 339 | 339 |
| Additional paid-in capital | 10,884,291 | 5,297,930 |
| Treasury stock | 1,254,002 | 1,185,409 |
| Retained earnings | 18,448,331 | 15,642,274 |
| Total stockholders' equity | 28,080,269 | 19,756,108 |
| Total Equity | 28,080,269 | ... |

[□] Accumulated depreciation - Other assets, net: \$46,326

Recent Dividends:**1. Teton Advisors Inc class A common.**

No dividends paid.

2. Teton Advisors Inc class B common.

No dividends paid.

Annual Dividends:**1. Teton Advisors Inc class A common.**

No dividends paid.

2. Teton Advisors Inc class B common.

No dividends paid.

TEXAS MINERAL RESOURCES CORP**Earnings, 6 mos. to (Consol. - \$):**

| | 02/29/24 | 02/28/23 |
|-----------------------------|------------------|--------------------|
| Cost & expenses | 469,044 | 1,255,937 |
| Operating income | (469,044) | (1,255,937) |
| Other income (expense), net | 106,391 | 14,925 |
| Net before taxes | (362,653) | ... |
| Net income | (362,653) | (1,241,012) |
| Earnings common share | | |
| Primary | \$ | \$(0.02) |
| Fully Diluted | \$ | \$(0.02) |
| Common Shares: | | |
| Full Diluted | 73,791,720 | 72,896,768 |
| Year-end | 73,932,575 | 72,918,912 |

THEGLOBE.COM INC.**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | [□] 2021 |
|---|------------------|------------------|-------------------|
| General & administrative expenses | 116,708 | 120,348 | 141,873 |
| Total operating expenses | 116,708 | 120,348 | 141,873 |
| Operating income (loss) | (116,708) | (120,348) | (141,873) |
| Related party interest expense | 75,032 | 64,296 | 52,974 |
| Income (loss) from operations before income taxes | (191,740) | (184,644) | (194,847) |
| Loss from Operations Before Income Tax | (191,740) | ... | ... |
| Income (loss) from operations | ... | (184,644) | (194,847) |
| Net income (loss) | (191,740) | (184,644) | (194,847) |
| Weighted average shares outstanding - basic | 441,480,473 | 441,480,473 | 441,480,473 |
| Weighted average shares outstanding - diluted | 441,480,473 | 441,480,473 | 441,480,473 |
| Year end shares outstanding | 441,480,473 | 441,480,473 | 441,480,473 |
| Number of common stockholders | 420 | [□] 445 | [□] 466 |

[□] Reclassified to conform with 2022 presentation; [□] Approximately; [□] As of March 20, 2023; [□] As of March 6, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|---------------|---------------|
| Cash | 9,105 | 6,771 |
| Total current assets | 9,105 | 6,771 |
| Total assets | 9,105 | 6,771 |
| Accounts payable | 3,661 | 2,000 |
| Interest payable | 281,204 | ... |
| Accrued interest due to related party | ... | 206,172 |
| Notes payable due to related party | 977,000 | 861,000 |
| Total current liabilities | 1,287,613 | 1,093,539 |
| Common stock | 441,480 | 441,480 |
| Additional paid in capital | 296,594,042 | 296,594,042 |
| Retained earnings (accumulated deficit) | (298,314,030) | (298,122,290) |
| Total stockholders' equity (deficit) | (1,278,508) | (1,086,768) |
| Total Equity | (1,278,508) | ... |

Recent Dividends:**1. theglobe.com inc. common.**

No dividends paid.

Annual Dividends:**1. theglobe.com inc. common.**

No dividends paid.

THERMOGENESIS HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|---------------------|------------------------|------------------------|
| Net revenues | 9,445,000 | 10,483,000 | 9,294,000 |
| Total net revenues | 9,445,000 | ... | ... |
| Cost of revenues | 7,514,000 | 7,773,000 | 5,801,000 |
| Gross profit (loss) | 1,931,000 | 2,710,000 | 3,493,000 |
| Selling, general & administrative expense | 7,221,000 | 7,244,000 | 8,515,000 |
| Research & development expense | 1,284,000 | 1,659,000 | 2,209,000 |
| Impairment charges | 2,036,000 | ... | ... |
| Total operating expenses | 10,541,000 | 8,903,000 | 10,724,000 |
| Income (loss) from operations | (8,610,000) | (6,193,000) | (7,231,000) |
| Interest expense | 10,032,000 | 5,616,000 | 6,103,000 |
| Gain (loss) on extinguishment of debt | (326,000) | ... | 652,000 |
| Employee retention tax credit & other income (expense) | 49,000 | (3,000) | 802,000 |
| Total other income (expense) | (10,309,000) | (5,619,000) | (4,649,000) |
| Income (loss) before income taxes | (18,919,000) | ... | ... |
| Net income (loss) | (18,919,000) | (11,812,000) | (11,880,000) |
| Income (loss) attributable to non-controlling interests | 944,000 | 542,000 | 501,000 |
| Net income (loss) attributable to company | (17,975,000) | ... | ... |
| Net income (loss) attributable to common stockholders | ... | (11,270,000) | (11,379,000) |
| Weighted average shares outstanding - basic | 2,368,112 | 550,993 | [□] 262,135 |
| Weighted average shares outstanding - diluted | 2,368,112 | 550,993 | [□] 262,135 |
| Year end shares outstanding | 3,617,886 | [□] 1,037,138 | [□] 264,706 |
| Income (loss) per share before accounting change - basic | \$(7.59) | ... | ... |
| Net income (loss) per share - basic | \$(7.59) | \$(20.45) | [□] \$(43.41) |
| Income (loss) per share before accounting change - diluted | \$(7.59) | ... | ... |
| Net income (loss) per share - diluted | \$(7.59) | \$(20.45) | [□] \$(43.41) |
| Number of full time employees | 25 | 40 | 39 |
| Number of part time employees | ... | 1 | 1 |
| Total number of employees | 25 | 41 | 40 |
| Number of common stockholders | 141 | [□] 140 | [□] 154 |
| Foreign currency translation adjustments | ... | 80,000 | ... |

[□] Adjusted for 1-for-45 stock split, December 22, 2022; [□] Shares increased due to the effect of issuance of common stock, sale of common stock and warrants, exercised pre-funded warrants and conversion of related party note payable to common

stock; [Ⓐ] Shares increased due to issuance of shares via at-the market offering; [Ⓑ] Approximately; [Ⓒ] As of March 1, 2023; [Ⓓ] As of March 1, 2022

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 (revised) |
|--|--------------------|-------------------------|--------------------------------|
| Stock based compensation | ... | 1,411,000 | ... |
| Advertising & marketing | ... | 43,957 | ... |
| General & administrative | 5,696,477 | 931,346 | 128,900 |
| Advertising expenses | 841,922 | ... | ... |
| Total operating expenses | 6,538,399 | 2,386,303 | 128,900 |
| Profit (loss) from operations | (6,538,399) | (2,386,303) | (128,900) |
| Accretion of debt discount | ... | 241,876 | 509,950 |
| Interest expense | 2,556,418 | 3,737,108 | 1,279,622 |
| Gain on extinguishment of debt | ... | 901,000 | 621,798 |
| Interest expense related to derivative liability | 142,225 | ... | ... |
| Other expense | 27,835 | ... | ... |
| Total other income (expense) | ... | (3,080,170) | (1,126,998) |
| Change in derivative liability | (6,028) | 2,186 | (40,776) |
| Income (loss) before income taxes & discontinued operations | (9,258,849) | (5,466,473) | (1,255,898) |
| Income (loss) from continuing operations | ... | (5,466,473) | (1,255,898) |
| Discontinued operations | ... | ... | (116,652) |
| Net income (loss) | (9,258,849) | (5,466,473) | (1,372,550) |
| Net loss attributable to the common stockholders | ... | (5,466,473) | (1,372,550) |
| Weighted average shares outstanding - basic | 73,269,271 | 71,354,434 | 76,735,271 |
| Weighted average shares outstanding - diluted | 73,269,271 | 71,354,434 | 76,735,271 |
| Year end shares outstanding | 111,665,039 | [Ⓓ] 25,140,735 | 80,140,735 |
| Net income (loss) per share from continuing operations - basic | \$(0.13) | \$(0.08) | \$(0.02) |
| Net income (loss) per share from discontinued operations - basic | ... | ... | \$0.00 |
| Net income (loss) per share - basic | \$(0.13) | \$(0.08) | \$(0.02) |
| Net income (loss) per share from continuing operations - diluted | \$(0.13) | \$(0.08) | \$(0.02) |
| Net income (loss) per share from discontinued operations - diluted | ... | ... | \$0.00 |
| Net income (loss) per share - diluted | \$(0.13) | \$(0.08) | \$(0.02) |
| Number of full time employees | ... | 1 | [Ⓓ] 1 |
| Number of common stockholders | 226 | 74 | 76 |

[Ⓐ] Restated to reflect the discontinued operations of the Nature Consulting LLC ; [Ⓑ] Shares increased due to the effect of common shares returned to treasury for cancellation; [Ⓒ] As of October 18,

2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|-------------|
| Cash | 596 | 48,881 |
| Notes receivable - related party | 7,403 | 26,200 |
| Deferred offering costs | ... | 9,000 |
| Prepaid expenses | 146,520 | 61,811 |
| Total current assets | 154,519 | 145,892 |
| Total assets | 154,519 | 145,892 |
| Accounts payable | 1,180,382 | 82,819 |
| Accrued expenses | 58,300 | 283,745 |
| Accrued interest | 7,311,752 | 4,756,266 |
| Derivative liability | 79,562 | 85,590 |
| Short-term convertible notes payable, net | 750,766 | 1,568,366 |
| Total current liabilities | 9,380,762 | 6,776,786 |
| Convertible notes payable, net | ... | 8,000 |
| Total non-current liabilities | ... | 8,000 |
| Total liabilities | 9,380,762 | 6,784,786 |
| Preferred stock - series A | 50,000 | 50,000 |
| Preferred stock - series B | 48 | 5 |
| Preferred stock - series C | 10 | 10 |
| Common stock | 111,665 | 25,140 |
| Additional paid-in-capital | 7,270,820 | 720,888 |
| Accumulated deficit | (16,745,786) | ... |
| Retained earnings (accumulated deficit) | ... | (7,486,937) |
| Total stockholders' equity (deficit) | (9,226,243) | (6,638,894) |
| Common stock to be issued | 87,000 | 52,000 |
| Total Equity | (9,226,243) | ... |

Recent Dividends:

- 1. Thunder Energies Corp common.**
No dividends paid.
- 2. Thunder Energies Corp series A convertible preferred.**
No dividends paid.
- 3. Thunder Energies Corp series C preferred.**
No dividends paid.
- 4. Thunder Energies Corp series B convertible preferred.**
No dividends paid.

Annual Dividends:

- 1. Thunder Energies Corp common.**
No dividends paid.
- 2. Thunder Energies Corp series A convertible preferred.**
No dividends paid.
- 3. Thunder Energies Corp series C preferred.**
No dividends paid.
- 4. Thunder Energies Corp series B convertible preferred.**
No dividends paid.

TIGO ENERGY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓐ] 2021 |
|---|-------------|-------------|-------------------|
| Formation & operating costs | 9,496,000 | 1,429,105 | 415,858 |
| Income (loss) from operations | (8,275,000) | (1,429,105) | (415,858) |
| Interest earned on marketable securities held in trust account | 2,322,000 | 1,645,906 | 13,316 |
| Change in fair value of preferred stock warrant and contingent shares liability | 1,109,000 | ... | ... |
| Change in fair value of derivative liability | 12,247,000 | ... | ... |
| Loss on debt extinguishment | (171,000) | ... | ... |
| Interest expense | (8,115,000) | ... | ... |
| Other (income) | ... | ... | ... |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 2,000,000 | 4,177,000 |
| Accounts receivable, gross | 953,000 | 2,014,000 |
| Less: allowance for doubtful accounts | 4,000 | 149,000 |
| Accounts receivable, net | 949,000 | 1,865,000 |
| Inventory, gross | 1,406,000 | ... |
| Inventories | ... | 3,334,000 |
| Prepaid expenses & other current assets | 825,000 | 1,508,000 |
| Total current assets | 5,180,000 | 10,884,000 |
| Inventories, non-current | ... | 1,003,000 |
| Machinery & equipment | 7,705,000 | 6,610,000 |
| Computer & software | 268,000 | 631,000 |
| Office equipment | 631,000 | 256,000 |
| Leasehold improvements | 1,555,000 | 932,000 |
| Total equipment | 10,159,000 | 8,429,000 |
| Less accumulated depreciation | 7,573,000 | 7,175,000 |
| Equipment & leasehold improvements, net | 2,586,000 | 1,254,000 |
| Right-of-use operating lease assets, net | 122,000 | 372,000 |
| Right-of-use operating lease assets - related party, net | 3,088,000 | 3,550,000 |
| Goodwill | ... | 781,000 |
| Intangible assets, net | ... | 1,286,000 |
| Other assets | 256,000 | 256,000 |
| Total assets | 11,232,000 | 19,386,000 |
| Accounts payable | 948,000 | 820,000 |
| Accrued payroll & related expenses | 376,000 | 399,000 |
| Deferred revenue - short term | 670,000 | 782,000 |
| Convertible promissory note - related party | ... | 5,777,000 |
| Interest payable - related party | 634,000 | 1,492,000 |
| Convertible promissory note, net | 378,000 | 962,000 |
| Other current liabilities | 1,478,000 | 1,277,000 |
| Current portion of note payable to related party | 7,278,000 | ... |
| Total current liabilities | 11,762,000 | 11,509,000 |
| Operating lease obligations - long term | ... | 131,000 |
| Operating lease obligations - related party - long-term | 2,900,000 | 3,495,000 |
| Deferred revenue - long term | 127,000 | 911,000 |
| Other noncurrent liabilities | 27,000 | 17,000 |
| Total liabilities | 14,816,000 | 16,063,000 |
| Common stock | 4,000 | 1,000 |
| Additional paid in capital | 282,383,000 | 270,377,000 |
| Accumulated deficit | (284,168,000) | ... |
| Retained earnings (accumulated deficit) | ... | (266,193,000) |
| Accumulated other comprehensive income (loss) | 114,000 | 111,000 |
| Total ThermoGenesis Holdings, Inc. stockholders' equity | (1,667,000) | 4,296,000 |
| Noncontrolling interests | (1,917,000) | (973,000) |
| Total equity | (3,584,000) | 3,323,000 |

Recent Dividends:

- 1. ThermoGenesis Holdings Inc common.**
No dividends paid.

Annual Dividends:

- 1. ThermoGenesis Holdings Inc common.**
No dividends paid.

THUNDER ENERGIES CORP

| | | | |
|---|-------------|------------|-----------|
| from continuing operations - diluted | \$(7.41) | ... | ... |
| Net income (loss) per common share - diluted | \$(7.41) | Ⓔ\$(15.20) | \$(18.00) |
| Number of full time employees | ... | Ⓔ4 | Ⓔ11 |
| Number of common stockholders | 98 | Ⓔ94 | Ⓔ94 |
| Income from cont operations before income tax | (5,569,000) | ... | ... |

| | | |
|--------------------------------------|-----------|-----------|
| equity | 6,642,000 | 1,363,000 |
| Total stockholders' equity (deficit) | 6,642,000 | ... |

| | | | |
|---|----------|----------|--------|
| outstanding | 5,154 | 5,154 | 5,154 |
| Income (loss) per share - continuing operations - basic | \$(0.07) | ... | ... |
| Net income (loss) per share - basic | \$(0.07) | \$(0.10) | \$0.03 |
| Net income (loss) per share - diluted | \$(0.07) | \$(0.10) | \$0.03 |
| Number of full time employees | 5 | ... | Ⓔ5 |
| Total number of employees | 5 | Ⓔ5 | ... |
| Number of common stockholders | 277 | Ⓔ290 | Ⓔ306 |
| Diluted EPS Excluding ExtraOrd Items | \$(0.07) | ... | ... |

Recent Dividends:
1. Titan Pharmaceuticals Inc (DE) series C convertible preferred.
 No dividends paid.
2. Titan Pharmaceuticals Inc (DE) common.
 No dividends paid.
3. Titan Pharmaceuticals Inc (DE) series AA convertible preferred.
 No dividends paid.

Annual Dividends:
1. Titan Pharmaceuticals Inc (DE) series C convertible preferred.
 No dividends paid.
2. Titan Pharmaceuticals Inc (DE) common.
 No dividends paid.
3. Titan Pharmaceuticals Inc (DE) series AA convertible preferred.
 No dividends paid.

Ⓔ Reclassified to conform with the 2022 presentation; Ⓔ Adjusted for 1- for -20 stock split, January 9, 2024; Ⓔ Shares increased due to the effect of issuance of common stock, warrants exercised and amortization of restricted stock; Ⓔ Shares increased due to the effect of issuance of common stock; Ⓔ As of March 24, 2023; Ⓔ As of March 23, 2022

Ⓔ Reclassified to conform with 2022 presentation; Ⓔ As is; Ⓔ Approximately; Ⓔ As of March 27, 2023; Ⓔ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents | 6,760,000 | 2,937,000 |
| Restricted cash | 13,000 | 196,000 |
| Receivables | 46,000 | 36,000 |
| Raw materials & supplies | ... | 60,000 |
| Finished goods | ... | 46,000 |
| Inventory | ... | 106,000 |
| Prepaid sponsored research | 199,000 | ... |
| Prepaid expenses & other current assets | ... | 314,000 |
| Discontinued operations - current assets | ... | 14,000 |
| Notes receivable | 1,000,000 | ... |
| Total current assets | 8,018,000 | 3,603,000 |
| Furniture & office equipment | 132,000 | 132,000 |
| Laboratory equipment | ... | 1,108,000 |
| Computer equipment | 579,000 | 577,000 |
| Property & equipment, gross | 711,000 | 1,817,000 |
| Less accumulated depreciation & amortization | 706,000 | 1,593,000 |
| Property & equipment, net | 5,000 | 224,000 |
| Other assets | ... | 48,000 |
| Operating lease right-of-use asset | 63,000 | 183,000 |
| Total assets | 8,086,000 | 4,058,000 |
| Accounts payable | 348,000 | 695,000 |
| Accrued clinical trials expenses | ... | 5,000 |
| Other accrued liabilities | 519,000 | 1,483,000 |
| Operating lease liability, current | 65,000 | 122,000 |
| Deferred grant revenue | 12,000 | 196,000 |
| Discontinued operations - current liabilities | ... | 129,000 |
| Note payable to related party | 500,000 | ... |
| Total current liabilities | 1,444,000 | 2,630,000 |
| Operating lease liability, non-current | ... | 65,000 |
| Total liabilities | 1,444,000 | 2,695,000 |
| Common stock | 1,000 | 15,000 |
| Additional paid-in capital | 398,470,000 | 387,609,000 |
| Accumulated Deficit | (391,830,000) | ... |
| Retained earnings (accumulated deficit) | ... | (386,261,000) |
| Preferred stock, at amounts paid-in, \$ 000 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at 0, 202 and no shares issued and outstanding at , 2022 | 1,000 | ... |
| Total stockholders' | ... | ... |

TOFUTTI BRANDS INC Annual Report

Consolidated Income Statement, Years Ended (\$000):

| | 12/30/23 | 12/31/22 | Ⓔ01/01/22 (revised) |
|--|--------------|--------------|---------------------|
| Total revenues | 10,068 | ... | ... |
| Net sales | 10,068 | 12,827 | 12,590 |
| Cost of sales | 7,271 | 10,485 | 9,248 |
| Gross profit | 2,797 | 2,342 | 3,342 |
| Store operations | 1,391 | ... | ... |
| Selling & warehousing | 1,054 | 1,147 | 1,206 |
| Marketing | ... | 564 | 281 |
| Product development costs | 166 | 143 | 124 |
| General & administrative | 424 | 1,404 | 1,489 |
| Total operating expenses | 3,035 | 3,258 | 3,100 |
| Income (loss) from operations | (238) | (916) | 242 |
| Small business administration (SBA) loan forgiveness | ... | 165 | ... |
| Income before interest expense & income taxes | ... | (751) | 242 |
| Interest expense | 2 | 2 | 25 |
| Income (loss) before provision for income taxes | (240) | (753) | 217 |
| Current income taxes expense (benefit) - federal | ... | ... | 64 |
| Current income taxes expense - state | 5 | 26 | 39 |
| Total current income taxes expense | 5 | 26 | 103 |
| Deferred income tax expense (benefit) - federal | 91 | (190) | (22) |
| Deferred income tax expense (benefit) - state | 30 | (64) | (7) |
| Total deferred income tax expense (benefit) | 121 | (254) | (29) |
| Provision (benefit) for income taxes | 126 | (228) | 74 |
| Net income (loss) | (366) | (525) | 143 |
| Weighted average common shares outstanding - basic | 5,154 | 5,154 | 5,154 |
| Weighted average common shares outstanding - diluted | 5,154 | 5,154 | 5,154 |
| Year end shares | ... | ... | ... |

Consolidated Balance Sheet, Years Ended (\$000):

| | 12/30/23 | 12/31/22 |
|--|----------|----------|
| Cash & cash equivalents | 837 | ... |
| Cash | ... | 1,072 |
| Accounts receivable, gross | 1,353 | 1,800 |
| Allowance for doubtful accounts & sales promotions | 525 | 495 |
| Accounts receivable, net of allowance for doubtful accounts and sales promotions | 828 | ... |
| Accounts receivable, net | ... | 1,305 |
| Finished products | 1,366 | 1,387 |
| Raw materials & packaging | 2,475 | 1,076 |
| Raw Materials and packaging | 1,109 | ... |
| Inventories, net | ... | 2,463 |
| Prepaid expenses & other current assets | ... | 80 |
| Prepaid expenses | 93 | ... |
| Total current assets | 4,233 | 4,920 |
| Deferred tax assets | 246 | 367 |
| Operating lease right-of-use assets | 81 | 158 |
| Finance lease right-of-use asset | 36 | 53 |
| Other assets | 19 | 19 |
| Total assets | 4,615 | 5,517 |
| Accounts payable | 237 | 684 |
| Accrued expenses | 541 | 555 |
| Financing lease liability, current portion | 15 | 15 |
| Income taxes payable | ... | 41 |
| Total current liabilities | 793 | 1,295 |
| Operating lease liabilities, net of current portion | 7 | 85 |
| Finance lease liability, net of current portion | 23 | 39 |
| Total liabilities | 823 | 1,419 |
| Common stock | 52 | 52 |
| Additional paid-in capital | 323 | 263 |
| Retained earnings | 3,417 | ... |
| Retained earnings (accumulated deficit) | ... | 3,783 |
| Total stockholders' equity | 3,792 | 4,098 |
| Total Equity | 3,792 | ... |

Recent Dividends:
1. Tofutti Brands Inc common.
 No dividends paid.
Annual Dividends:
1. Tofutti Brands Inc common.
 No dividends paid.

TOKEN COMMUNITIES LTD

| | | | |
|---|----------|--------|----------|
| share-continuing operations - basic | \$(0.30) | ... | ... |
| Net earnings (loss) per share - basic | \$(0.30) | \$0.02 | \$(0.37) |
| Earnings (loss) per share-continuing operations - diluted | \$(0.30) | ... | ... |
| Net earnings (loss) per share - diluted | \$(0.30) | \$0.02 | \$(0.37) |
| Total number of employees | ... | 53 | 57 |
| Number of common stockholders | ... | 86 | 86 |
| Foreign currency translation adjustments | ... | (165) | ... |

□ As is; □ Approximately; □ As of March 1, 2023; □ As of April 1, 2022; □ As of March 30, 2023; □ As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|--|----------|----------|
| Cash & cash equivalents | 185 | 48 |
| Receivables, gross | 1,685 | 3,123 |
| Allowance for uncollectible accounts | 154 | 291 |
| Receivable | 1,531 | 2,832 |
| Receivables, net | ... | 2,535 |
| Raw materials | 2,102 | 18 |
| Work-in-progress | 18 | 252 |
| Finished goods | 252 | 2,372 |
| Inventories | 2,372 | 148 |
| Prepays & other assets | 148 | 4,236 |
| Total current assets | 4,236 | 2,077 |
| Rental equipment | 1,049 | 938 |
| Depreciation Rental equipment | 938 | 1,852 |
| Rental equipment, net | 111 | 225 |
| Machinery, fixture & equipment | 3,200 | 2,856 |
| Leaseholds & improvements | 23 | 23 |
| Machinery, fixtures and equipment | 3,177 | ... |
| Property, plant & equipment, gross | ... | 2,879 |
| Less accumulated depreciation | 1,422 | 1,164 |
| Property, plant & equipment, net | 1,778 | 1,715 |
| Right of use assets | 1,971 | 765 |
| Restricted cash | 200 | ... |
| Prepays | ... | 34 |
| Total long-term assets | 4,094 | 2,739 |
| Total assets | 8,330 | 9,412 |
| Accounts payable | 8,420 | 6,339 |
| Taxes payable | ... | 1,179 |
| Interest payable | ... | 1,513 |
| Warranty reserve | ... | 562 |
| Deferred revenues | ... | 140 |
| Compensation & employee benefits | ... | 311 |
| Audit fees | ... | 134 |
| Other accrued liabilities | 5,352 | 440 |
| Current portion of long-term debt | 3,776 | 3,768 |
| Current lease liabilities | 352 | 393 |
| Customer deposits | 213 | 1,183 |
| Total current liabilities | 18,113 | 15,962 |
| 8 1/4% limited convertible senior subordinated notes | ... | 302 |
| 9 1/2% subordinated debentures | ... | 220 |
| Revolving credit line - related party | ... | 2,246 |
| Term loans - related party | ... | 1,000 |
| Term loans | ... | 500 |
| Total debt | ... | 4,268 |
| Net debt | ... | 4,268 |
| Less: portion due within one year | ... | ... |
| Long-term debt, less current portion | 535 | 500 |
| Long-term lease liabilities | 1,644 | 412 |
| Deferred pension liability & other liabilities | ... | 2,862 |
| Deferred pension liability and other | 2,248 | ... |
| Total long-term liabilities | 4,427 | 3,774 |
| Total liabilities | 22,540 | 19,736 |
| Common stock | 13 | 13 |
| Additional paid-in-capital | 41,508 | 41,444 |
| Accumulated deficit | (46,719) | ... |
| Retained earnings (accumulated deficit) | ... | (42,652) |
| Pension plan actuarial gain (loss) | ... | (6,164) |
| Foreign currency translation gain (loss) | ... | 98 |
| Accumulated other comprehensive income (loss) | (5,949) | (6,066) |
| Treasury Stock | 3,063 | ... |
| Treasury stock - at cost | ... | 3,063 |
| Total stockholders' equity (deficit) | (14,210) | (10,324) |
| Rep Total Equity & Minority Interest | (14,210) | ... |

| | | |
|--|----------|----------|
| one year | ... | (3,768) |
| Long-term debt, less current portion | 535 | 500 |
| Long-term lease liabilities | 1,644 | 412 |
| Deferred pension liability & other liabilities | ... | 2,862 |
| Deferred pension liability and other | 2,248 | ... |
| Total long-term liabilities | 4,427 | 3,774 |
| Total liabilities | 22,540 | 19,736 |
| Common stock | 13 | 13 |
| Additional paid-in-capital | 41,508 | 41,444 |
| Accumulated deficit | (46,719) | ... |
| Retained earnings (accumulated deficit) | ... | (42,652) |
| Pension plan actuarial gain (loss) | ... | (6,164) |
| Foreign currency translation gain (loss) | ... | 98 |
| Accumulated other comprehensive income (loss) | (5,949) | (6,066) |
| Treasury Stock | 3,063 | ... |
| Treasury stock - at cost | ... | 3,063 |
| Total stockholders' equity (deficit) | (14,210) | (10,324) |
| Rep Total Equity & Minority Interest | (14,210) | ... |

Recent Dividends:

- 1. Trans-Lux Corp. series A redeemable convertible preferred.**
No dividends paid.
 - 2. Trans-Lux Corp. common.**
No dividends paid.
 - 3. Trans-Lux Corp. class B common.**
No dividends paid.
 - 4. Trans-Lux Corp. series B convertible preferred (stated value: \$200).**
No dividends paid.
- Annual Dividends:**
- 1. Trans-Lux Corp. series A redeemable convertible preferred.**
No dividends paid.
 - 2. Trans-Lux Corp. common.**
No dividends paid.
 - 3. Trans-Lux Corp. class B common.**
No dividends paid.
 - 4. Trans-Lux Corp. series B convertible preferred (stated value: \$200).**
No dividends paid.

TRANSCODE THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | □2022 | 2021 |
|--|--------------|--------------|-------------|
| | | (revised) | (revised) |
| Research & development | 12,263,530 | 10,232,366 | 2,753,966 |
| General & administrative | 7,154,986 | 8,401,462 | 3,397,169 |
| Total operating expenses | 19,418,516 | 18,633,828 | 6,151,135 |
| Operating income (loss) | (19,418,516) | (18,633,828) | (6,151,135) |
| Change in fair value of derivative liabilities | ... | ... | (867,000) |
| Change in fair value of warrant liability | ... | ... | (6,109) |
| Grant income | 923,035 | 1,080,436 | 278,333 |
| Gain (loss) on sale of equipment | ... | ... | (3,082) |
| Interest expense | 55,899 | 31,986 | 95,070 |
| Interest income | 5,285 | 20,410 | 664 |
| Total other income (expense) | 872,421 | 1,068,860 | (692,264) |
| Income (loss) before income taxes | (18,546,095) | (17,564,968) | ... |

| | | | |
|---|--------------|---------------|-------------|
| Net income (loss) | (18,546,095) | (17,564,968) | (6,843,399) |
| Weighted average shares outstanding - basic | □179,006 | □16,222 | 10,532 |
| Weighted average shares outstanding - diluted | □179,006 | □16,222 | 10,532 |
| Year end shares outstanding | □627,448 | □16,222 | □16,131 |
| Net income (loss) per share - basic | □\$(103.61) | □\$(1,082.79) | \$(648.00) |
| Net income (loss) per share - diluted | □\$(103.61) | □\$(1,082.79) | \$(648.00) |
| Number of full time employees | 10 | ... | ... |
| Number of part time employees | ... | ... | 9 |
| Total number of employees | 10 | ... | ... |
| Number of common stockholders | 20 | ... | □722 |

□ Reclassified to conform 2023 presentation; □ Adjusted for 1-for-40 stock split, January 16, 2024; □ Adjusted for 1-for-20 stock split, May 23, 2023; □ Shares increased due to the effect of issuance of common stock in IPO, conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of IPO; □ Reclassified to conform 2023 presentation; □ Approximately; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|--------------|------------|
| | | (revised) |
| Cash & cash equivalents | 2,767,598 | ... |
| Cash | ... | 4,968,418 |
| Grant receivable | ... | 360,229 |
| Prepaid operating expenses | 116,607 | 122,428 |
| Contract manufacturers & research organizations | 717,686 | 241,111 |
| Insurance premiums | 431,061 | 1,255,317 |
| Prepaid FICA | 422,492 | 422,492 |
| Deposits | ... | 9,410 |
| Prepaid expenses & other current assets | 1,687,846 | 2,050,758 |
| Total current assets | 4,455,444 | 7,379,405 |
| Laboratory equipment | ... | 348,441 |
| Less: accumulated depreciation | 263,343 | 139,860 |
| Laboratory and computer equipment | 384,050 | ... |
| Property & equipment, net of depreciation | 120,707 | 208,581 |
| Right-of-use asset | 481,694 | ... |
| Security deposit | 111,856 | ... |
| Total assets | 5,169,701 | 7,587,986 |
| Professional fees | 375,550 | ... |
| Professional & general consulting fees | ... | 758,816 |
| Research & development billings - CMOs, CROs, supplies, equipment & consulting | ... | 2,397,038 |
| General expenses | ... | 124,676 |
| Insurance premiums | ... | 844,283 |
| Payroll & benefits | 589,404 | 164,657 |
| Accrued license payments | 129,983 | 57,820 |
| Accounts payable & accrued expenses | 1,956,322 | 4,347,290 |
| Deferred grant income | 27,057 | ... |
| Accounts payable and accrued expenses - Balancing value | 3,051,259 | ... |
| Short-term lease liability | 412,280 | ... |
| Total current liabilities | 3,490,596 | 4,347,290 |
| Long-term lease liability | 38,291 | ... |
| Total liabilities | 3,528,887 | 4,347,290 |
| Common stock | 63 | 1,298 |
| Additional paid-in capital | 48,057,095 | 31,109,647 |
| Accumulated deficit | (46,416,344) | ... |
| Retained earnings | ... | ... |

| | | | |
|--|-----------|-----------|--------------|
| (accumulated deficit) | | | (27,870,249) |
| Total stockholders' equity (deficit) | 1,640,814 | 3,240,696 | |
| Total Equity | 1,640,814 | | |

Recent Dividends:**1. TransCode Therapeutics Inc common.**

No dividends paid.

Annual Dividends:**1. TransCode Therapeutics Inc common.**

No dividends paid.

TRAWS PHARMA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 | 2021 |
|--|----------|----------|----------|
| Revenue | 226 | ... | ... |
| Revenue | 226 | 226 | 226 |
| General & administrative expenses | 9,094 | 8,447 | 9,425 |
| Research & development expenses | 11,430 | 11,406 | 7,297 |
| Total operating expenses | 20,524 | 19,853 | 16,722 |
| Income (loss) from operations | (20,298) | (19,627) | (16,496) |
| Change in fair value of warrant liability | ... | ... | 321 |
| Other income (loss), net | 1,350 | 663 | 12 |
| Net income (loss) before income taxes .. | (18,948) | ... | ... |
| Net income (loss) attributable to Onconova Therapeutics, Inc. | (18,948) | (18,964) | (16,163) |
| Weighted average shares outstanding - basic | 20,989 | 20,908 | 16,832 |
| Weighted average shares outstanding - diluted | 20,989 | 20,908 | 16,832 |
| Year end shares outstanding | 21,003 | 20,926 | 20,896 |
| Net income (loss) per share - basic | \$(0.90) | \$(0.91) | \$(0.96) |
| Net income (loss) per share - diluted | \$(0.90) | \$(0.91) | \$(0.96) |
| Number of full time employees | 16 | 16 | 14 |
| Number of part time employees | ... | 1 | 1 |
| Total number of employees | 16 | 17 | 15 |
| Number of common stockholders | 97 | 97 | 98 |
| Foreign currency translation adjustments | ... | (19) | (28) |

□ As is; □ Approximately; □ As of February 28, 2023; □ As of February 28, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|--------|--------|
| Cash & cash equivalents | 20,821 | 38,757 |
| Receivables | 18 | 29 |
| Prepaid research & development | 1,060 | 233 |
| Prepaid manufacturing | 1,821 | 97 |
| Prepaid insurance | ... | 191 |
| Other prepaid expenses & other current assets | ... | 40 |
| Prepaid expenses & other current assets | ... | 561 |
| Insurance | 174 | ... |
| Other | 401 | ... |

| | | |
|--|-----------|-----------|
| Manufacturing | 186 | ... |
| Total current assets | 22,660 | 39,347 |
| Computer & office equipment | 84 | 70 |
| Property and equipment, gross Furniture And Fixtures | 84 | ... |
| Less accumulated depreciation - property & equipment | ... | 46 |
| accumulated depreciation | 62 | ... |
| Property & equipment, net | 22 | 24 |
| Other non-current assets | 1 | 1 |
| Total assets | 22,683 | 39,372 |
| Accounts payable | 5,619 | 3,860 |
| Accrued research & development | 2,196 | 2,593 |
| Accrued employee compensation | 1,002 | 1,187 |
| Accrued professional fees | 3,375 | 180 |
| Deferred revenue | 226 | 226 |
| Total current liabilities | 9,220 | 8,046 |
| Deferred revenue, non-current | 2,791 | 3,017 |
| Total liabilities | 12,011 | 11,063 |
| Common stock | 210 | 209 |
| Additional paid in capital | 493,116 | 491,816 |
| Accumulated deficit | (482,631) | ... |
| Retained earnings (accumulated deficit) | ... | (463,683) |
| Accumulated other comprehensive income (loss) | (23) | (33) |
| Total Onconova Therapeutics, Inc. stockholders' equity (deficit) | 10,672 | 28,309 |
| Total stockholders' equity (deficit) | 10,672 | 28,309 |

Recent Dividends:**1. Traws Pharma Inc common.**

No dividends paid.

Annual Dividends:**1. Traws Pharma Inc common.**

No dividends paid.

TRENDMAKER INC LTD**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|------------|------------|------------|
| General & administrative | 38,287 | 39,990 | 23,051 |
| Income (loss) before income tax | (38,287) | (39,990) | (23,051) |
| Net income (loss) | (38,287) | (39,990) | (23,051) |
| Weighted average shares outstanding - basic | 13,537,000 | 13,537,000 | 13,537,000 |
| Weighted average shares outstanding - diluted | 13,537,000 | 13,537,000 | 13,537,000 |
| Year end shares outstanding | 13,537,000 | 13,537,000 | 13,537,000 |
| Net income (loss) per share - basic | \$(0.00) | \$(0.00) | \$(0.00) |
| Net income (loss) per share - diluted | \$(0.00) | \$(0.00) | \$(0.00) |
| Full-Time Employees (Period End) | 0 | ... | ... |
| Total number of employees | 0 | 0 | 0 |
| Number of common stockholders | 31 | 31 | 55 |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.00) | ... | ... |
| EPS - Diluted - excluding | ... | ... | ... |

| | | | |
|--|----------|-----|-----|
| Extraordinary Items Applicable to Common - Total | \$(0.00) | ... | ... |
|--|----------|-----|-----|

□ For 5 months due to fiscal year end change

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Due from related party | 147,322 | 185,013 |
| Total current asset | 147,322 | 185,013 |
| Total assets | 147,322 | 185,013 |
| Accrued liabilities | 10,894 | ... |
| Accrued expenses | ... | 10,298 |
| Due to related party | 214,842 | 214,842 |
| Total current liabilities | 225,736 | 225,140 |
| Total liabilities | 225,736 | 225,140 |
| Common stock | 1,354 | 1,354 |
| Additional paid in capital | 825,166 | 825,166 |
| Retained earnings (accumulated deficit) | (904,934) | (866,647) |
| Total stockholders' equity (deficit) | (78,414) | (40,127) |
| Total Equity | (78,414) | ... |

Recent Dividends:**1. Trendmaker Inc Ltd common.**

No dividends paid.

Annual Dividends:**1. Trendmaker Inc Ltd common.**

No dividends paid.

TREVENA INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|--------------|
| License revenue | 3,179,000 | 20,000 | 69,000 |
| Product revenue | (54,000) | (438,000) | 498,000 |
| Total revenue | 3,125,000 | (418,000) | 567,000 |
| Cost of goods sold | 1,670,000 | 3,018,000 | 954,000 |
| Selling, general & administrative | 20,410,000 | 34,728,000 | 38,112,000 |
| Research & development expenses | 16,333,000 | 18,211,000 | 13,426,000 |
| Total operating expenses | 38,413,000 | 55,957,000 | 52,492,000 |
| Income (loss) from operations | (35,288,000) | (56,375,000) | (51,925,000) |
| Change in fair value of warrant liability | 2,126,000 | 11,180,000 | 6,000 |
| Other income (expense), net | ... | (7,681,000) | 172,000 |
| Interest income | 1,398,000 | 451,000 | 162,000 |
| Interest expense | 3,644,000 | 1,256,000 | 1,000 |
| Gain (loss) on foreign currency exchange | (41,000) | 11,000 | (2,000) |
| Other income, net | (4,522,000) | ... | ... |
| Total other income (expense), net | ... | 2,705,000 | 337,000 |
| Income (loss) before foreign income tax expense .. | (39,971,000) | ... | (51,588,000) |
| Foreign income tax expense | 318,000 | ... | ... |
| Net income (loss) | (40,289,000) | (53,670,000) | (51,588,000) |
| Weighted average shares outstanding-basic | 12,735,010 | 7,072,362 | 6,531,732 |
| Weighted average shares outstanding-diluted | 12,735,010 | 7,072,362 | 6,531,732 |
| Year end shares outstanding | 17,289,104 | 7,744,692 | 6,620,800 |
| Net earnings (loss) per share - basic | \$(3.16) | \$(7.59) | \$(8.00) |
| Net earnings (loss) per share - diluted | \$(3.16) | \$(7.59) | \$(8.00) |
| Full-Time Employees (Period End) | 23 | ... | ... |

| | | | |
|--------------------------------------|---------|-----|-----|
| Total number of employees..... | 23 | 35 | 43 |
| Number of common stockholders..... | 5 | 5 | 5 |
| Income Taxes - Foreign - Current.... | 318,000 | ... | ... |
| Income Taxes - Total - Current..... | 318,000 | ... | ... |

□ Non-consolidated; □ Adjusted for 1-for-25 stock split, November 9, 2022; □ As of March 29, 2023; □ As of March 29, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|---------------|---------------|
| Cash & cash equivalents..... | 32,975,000 | 38,320,000 |
| Inventories..... | ... | 906,000 |
| Prepaid expenses & other current assets..... | 2,230,000 | 1,782,000 |
| Total current assets..... | 35,205,000 | 41,008,000 |
| Restricted cash..... | 540,000 | 1,960,000 |
| Computers & software..... | ... | 408,000 |
| Office equipment & furniture..... | 224,000 | 721,000 |
| Manufacturing equipment..... | 10,000 | 10,000 |
| Leasehold improvements..... | 3,082,000 | 3,082,000 |
| Leased assets..... | 29,000 | 29,000 |
| Laboratory equipment..... | 449,000 | ... |
| Total property & equipment, gross..... | 3,794,000 | 4,250,000 |
| Less accumulated depreciation & amortization..... | 2,599,000 | 2,762,000 |
| Property & equipment, net..... | 1,195,000 | 1,488,000 |
| Right-of-use lease asset..... | 3,665,000 | 4,224,000 |
| Total assets..... | 40,605,000 | 48,680,000 |
| Accounts payable..... | 2,303,000 | 2,372,000 |
| Compensation & benefits..... | 2,093,000 | 1,965,000 |
| Commercial expenses..... | 43,000 | 93,000 |
| Legal expenses..... | 423,000 | 381,000 |
| Clinical trial expenses..... | 38,000 | 1,421,000 |
| Pharmaceutical development expenses..... | 398,000 | 201,000 |
| Credit balances due to customers..... | ... | 67,000 |
| Accrued purchases..... | 1,244,000 | ... |
| Accrued interest..... | 4,239,000 | 522,000 |
| Other accrued expenses & other current liabilities..... | ... | 811,000 |
| Lease liability..... | 1,002,000 | 899,000 |
| Current portion of lease liabilities..... | 10,000 | ... |
| Current portion of lease liabilities..... | 1,012,000 | ... |
| Total current liabilities..... | 7,554,000 | 8,732,000 |
| Leases, net of current portion..... | 4,424,000 | 5,436,000 |
| Loans payable, net..... | 30,809,000 | 13,430,000 |
| Capital leases, net of current portion..... | 7,000 | ... |
| Warrant liability..... | 5,475,000 | 5,483,000 |
| Operating lease liabilities, net of current portion - Balancing value..... | 4,417,000 | ... |
| Total liabilities..... | 48,262,000 | 33,081,000 |
| Common stock..... | 17,000 | 8,000 |
| Additional paid-in capital..... | 580,387,000 | 563,362,000 |
| Accumulated deficit..... | (588,061,000) | ... |
| Retained earnings (accumulated deficit)..... | ... | (547,772,000) |
| Accumulated other comprehensive income (loss)..... | ... | 1,000 |
| Total stockholders' equity (deficit)..... | (7,657,000) | 15,599,000 |
| Total Equity..... | (7,657,000) | ... |

Recent Dividends:

1. Trevena Inc series C redeemable convertible preferred. No dividends paid.
2. Trevena Inc series B redeemable convertible preferred.

- No dividends paid.
3. Trevena Inc series B-1 redeemable convertible preferred. No dividends paid.
 4. Trevena Inc series A redeemable convertible preferred. No dividends paid.
 5. Trevena Inc common. No dividends paid.
- Annual Dividends:**
1. Trevena Inc series C redeemable convertible preferred. No dividends paid.
 2. Trevena Inc series B redeemable convertible preferred. No dividends paid.
 3. Trevena Inc series B-1 redeemable convertible preferred. No dividends paid.
 4. Trevena Inc series A redeemable convertible preferred. No dividends paid.
 5. Trevena Inc common. No dividends paid.

TREVENA INC Auditor's Report Auditor's Report

The following is an excerpt from the Independent Auditors, Ernst & Young LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of Trevena, Inc. (the Company) as of December 31, 2023 and 2022, the related consolidated statements of operations and comprehensive loss, stockholders' (deficit) equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2023 and 2022, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2023, in conformity with U.S. generally accepted accounting principles. The Company's Ability to Continue as a Going Concern The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company's ability to continue as a going concern. Management's evaluation of the events and conditions and management's plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

TREX ACQUISITION CORP

Earnings, 6 mos. to Dec 31(Consol. - \$):

| | 2023 | 2022 |
|-----------------------|------------|-------------|
| Total revenues..... | 15,824 | 37,787 |
| Cost & expenses..... | 583,882 | 1,044,548 |
| Operating income..... | (568,058) | (1,006,762) |
| Net before taxes..... | (568,058) | (1,006,762) |
| Net income..... | (568,058) | (1,006,762) |
| Earnings common share | | |
| Primary..... | \$(0.02) | \$(0.05) |
| Fully Diluted..... | \$(0.02) | \$(0.05) |
| Common Shares: | | |
| Full Diluted..... | 18,223,953 | 19,666,705 |
| Year-end..... | 18,223,953 | 19,840,618 |

TRILINC GLOBAL IMPACT FUND, LLC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2021 | 2020 |
|--|------------|------------|------------|
| Interest income..... | 15,847,343 | 36,414,948 | 42,240,413 |
| Interest from cash.... | 2,371 | 41,937 | 96,445 |
| Total investment income..... | 15,849,714 | 36,456,885 | 42,336,858 |
| Asset management fees..... | 5,539,005 | 7,065,751 | 7,334,178 |
| Incentive fees..... | ... | 3,320,467 | 5,320,776 |
| Professional fees..... | ... | 3,237,170 | 3,842,481 |
| Interest expense..... | 2,097,564 | 195,056 | 254,682 |
| General & administrative expenses..... | 1,252,473 | 1,314,923 | 1,414,586 |
| Board of managers fees..... | ... | 257,500 | 257,500 |
| Total expenses..... | 5,794,194 | 15,390,867 | 18,424,203 |
| Expense support payment to Sponsor .. | 257,500 | ... | ... |
| NET INVESTMENT | | | |

| | | | |
|--|--------------|--------------|--------------|
| INCOME..... | 908,978 | ... | ... |
| Net expenses..... | 14,940,736 | ... | ... |
| Net investment income..... | 414,599 | 21,066,018 | 23,912,655 |
| Net change in unrealized depreciation on investments..... | ... | (13,643,894) | (15,037,022) |
| Realized gain (loss) on investments..... | ... | (4,008,719) | ... |
| Foreign exchange gain (loss)..... | ... | (11,554) | 17,207 |
| Net increase in net assets resulting from operations..... | ... | 3,401,851 | 8,892,840 |
| Weighted average units outstanding - basic..... | 47,759,797 | 47,102,346 | 46,529,861 |
| Weighted average units outstanding - diluted..... | 47,759,797 | 47,102,346 | 46,529,861 |
| Year end units outstanding..... | 47,777,985 | 47,619,327 | 46,807,115 |
| Net investment income per unit - basic..... | \$0.01 | \$0.45 | \$0.51 |
| Net investment income per unit - diluted..... | \$0.01 | \$0.45 | \$0.51 |
| Earnings per unit - basic..... | ... | \$0.07 | \$0.19 |
| Earnings per unit - diluted..... | ... | \$0.07 | \$0.19 |
| Distributions per unit..... | ... | \$0.55 | \$0.62 |
| Number of class A unitholders..... | ... | 3,752 | ... |
| Number of class C unitholders..... | ... | 1,917 | ... |
| Number of class I unitholders..... | ... | 1,913 | ... |
| Number of class W unitholders..... | ... | 4 | ... |
| Number of class Y unitholders..... | ... | 224 | ... |
| Number of class Z unitholders..... | ... | 2 | ... |
| Net realized losses on investments..... | (15,238,313) | ... | ... |
| Net change in unrealized appreciation (depreciation) on investments..... | 14,738,290 | ... | ... |
| Net Income before Tax..... | 414,599 | ... | ... |
| Foreign exchange gain..... | 5,644 | ... | ... |
| Common Shareholders - Number..... | 7,789 | ... | ... |

□ Reclassified to conform with 2021 presentation; □ As of March 30, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|--|-------------|-------------|
| Investments owned, at fair value..... | 261,680,707 | 301,603,725 |
| Cash..... | 980,741 | 16,795,342 |
| Interest receivable..... | 15,894,031 | 26,523,185 |
| Due from affiliates..... | ... | 4,240,231 |
| Other assets..... | 201,860 | 1,048,606 |
| Total assets..... | 278,757,339 | 350,211,089 |
| Due to unitholders..... | ... | 1,399,510 |
| Management fee payable..... | 1,206,930 | 1,727,974 |
| Incentive fee payable..... | ... | 141,685 |
| Notes payable..... | ... | 5,000,000 |
| Unit repurchases payable..... | ... | 1,712,444 |
| Accrued distribution & other fees..... | 350,000 | 446,000 |
| Accrued expenses..... | 3,650,966 | 1,058,419 |
| Other payables..... | 694,571 | ... |

| | | | | | | | | | |
|------------------------|--------------|-------------|---------------------|--------------|--------------|-------------|---------------------------|-------------|-------------|
| Total liabilities | 5,902,467 | 11,486,032 | Franchise tax | | | | Income taxes payable | 1,790,081 | 979,475 |
| Offering costs | (17,355,402) | ... | expense | 282,500 | 200,000 | 200,000 | Franchise tax payable | 458,226 | 400,000 |
| Net capital paid in on | | | Income (loss) from | | | | Working capital loans | ... | 625,700 |
| Class A units | 112,737,934 | ... | operation costs | ... | (18,499,257) | (1,391,593) | Advances - related party | ... | 425,835 |
| Net capital paid in on | | | Interest earned on | | | | Promissory note - related | | ... |
| Class C units | 47,502,038 | ... | cash held in trust | | | | party | 41,000 | ... |
| Net capital paid in on | | | account | 13,852,774 | 4,257,469 | 7,098 | Convertible note payable | | ... |
| Class I units | 65,125,371 | ... | Loss before income | | | | Sponsor | 3,883,945 | ... |
| Net capital paid in on | | | taxes | (18,342,039) | (14,241,788) | (1,384,495) | Notes Payable | 500,000 | ... |
| Class Y units | 16,525,284 | ... | Current | (3,742,611) | ... | ... | Total current liabilities | 56,176,695 | 22,472,852 |
| Net capital paid in on | | | State and local | | | | Deferred underwriter fee | | ... |
| Class W units | 150,239 | ... | Current | (796,963) | ... | ... | payable | 10,062,500 | 10,062,500 |
| Net capital paid in on | | | Change in valuation | | | | Total liabilities | 66,239,195 | 32,535,352 |
| Class Z units | 48,169,408 | ... | allowance | 8,088,176 | ... | ... | Class A common stock | | ... |
| Total net assets | 272,854,872 | 338,725,057 | Income tax expense | 3,548,602 | 979,475 | ... | subject to possible | | ... |
| Net assets per share | ... | \$7.12 | Net income (loss) | (21,890,641) | (15,221,263) | (1,384,495) | redemption | ... | 298,951,176 |
| NET ASSETS | 272,854,872 | ... | Weighted average | | | | Class A common stock | 308,645,005 | 127 |

Amortized cost - investments owned, at fair value: \$343,249,977

Recent Dividends:

1. TriLine Global Impact Fund, LLC class W unit.

No dividends paid.

2. TriLine Global Impact Fund, LLC class Y unit.

No dividends paid.

3. TriLine Global Impact Fund, LLC class A unit.

No dividends paid.

4. TriLine Global Impact Fund, LLC class C unit.

No dividends paid.

5. TriLine Global Impact Fund, LLC class I unit.

No dividends paid.

6. TriLine Global Impact Fund, LLC class Z unit.

No dividends paid.

Annual Dividends:

1. TriLine Global Impact Fund, LLC class W unit.

No dividends paid.

2. TriLine Global Impact Fund, LLC class Y unit.

No dividends paid.

3. TriLine Global Impact Fund, LLC class A unit.

No dividends paid.

4. TriLine Global Impact Fund, LLC class C unit.

No dividends paid.

5. TriLine Global Impact Fund, LLC class I unit.

No dividends paid.

6. TriLine Global Impact Fund, LLC class Z unit.

No dividends paid.

TRIUMPH FINANCIAL INC

Earnings, 3 mos. to Mar 31(Consol. - \$000):

| | | |
|-----------------------|---------|--------|
| | 2024 | 2023 |
| Cost & expenses | 108,281 | 96,336 |
| Operating income | 4,767 | 12,510 |
| Net before taxes | 4,767 | 12,510 |
| Income taxes | 609 | 1,500 |
| Net income | 4,158 | 11,010 |
| Balance for common | 3,357 | 10,209 |
| Earnings common share | | |
| Primary | \$0.14 | \$0.44 |
| Fully Diluted | \$0.14 | \$0.43 |
| Common Shares: | | |
| Full Diluted | 23,650 | 23,816 |
| Year-end | 23,335 | 23,371 |

Consolidated Balance Sheet Items, as of (\$000):

| | | |
|-----------------------|-------------|--|
| Assets: | 2024 | |
| Cash & equivalents | 417,033 | |
| Current assets | 421,797 | |
| Net property & equip. | 162,544 | |
| Total assets | 5,575,493 | |
| Liabilities: | | |
| Current liabilities | 4,450,963 | |
| Long-term debt | 180,696 | |
| Stockholders' equity | 872,339 | |
| Net current assets | (4,029,166) | |

TRUMP MEDIA & TECHNOLOGY GROUP CORP

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|-----------------------------------|------------|------------|-----------|
| | 2023 | 2022 | 2021 |
| | | (revised) | (revised) |
| General & administrative expenses | 20,752,819 | ... | ... |
| Formation & operating costs | 12,240,732 | 18,299,257 | 1,191,593 |

| | | | |
|---|--------------|--------------|-------------|
| Franchise tax | 282,500 | 200,000 | 200,000 |
| Income (loss) from operation costs | ... | (18,499,257) | (1,391,593) |
| Interest earned on cash held in trust account | 13,852,774 | 4,257,469 | 7,098 |
| Loss before income taxes | (18,342,039) | (14,241,788) | (1,384,495) |
| Current | (3,742,611) | ... | ... |
| State and local | | | |
| Current | (796,963) | ... | ... |
| Change in valuation allowance | 8,088,176 | ... | ... |
| Income tax expense | 3,548,602 | 979,475 | ... |
| Net income (loss) | (21,890,641) | (15,221,263) | (1,384,495) |
| Weighted average class A common stock outstanding - basic | ... | 30,026,769 | 9,404,134 |
| Weighted average class B common stock outstanding - basic | ... | 7,187,500 | 7,187,500 |
| Weighted average shares outstanding - basic | 37,205,357 | ... | ... |
| Weighted average class A common stock outstanding - diluted | ... | 30,026,769 | 9,404,134 |
| Weighted average class B common stock outstanding - diluted | ... | 7,187,500 | 7,187,500 |
| Weighted average shares outstanding - diluted | 37,205,357 | ... | ... |
| Year end shares outstanding | 37,150,856 | 37,209,076 | 37,214,734 |
| Net income (loss) per class A common stock - basic | ... | \$(0.41) | \$(0.08) |
| Net income (loss) per class B common stock - basic | ... | \$(0.41) | \$(0.08) |
| Net income (loss) per share - basic | \$(0.59) | ... | ... |
| Net income (loss) per class A common stock - diluted | ... | \$(0.41) | \$(0.08) |
| Net income (loss) per class B common stock - diluted | ... | \$(0.41) | \$(0.08) |
| Net income (loss) per share - diluted | \$(0.59) | ... | ... |
| Full-Time Employees (Period End) | 36 | ... | ... |
| Total number of employees | 36 | ... | 2 |
| Number of class A common stockholders | ... | ... | 38 |
| Number of class B common stockholders | ... | ... | 23 |
| Insurance recoveries | 1,081,238 | ... | ... |
| Total other income | 14,934,012 | ... | ... |
| Common Shareholders - Number | 289 | ... | ... |

As of April 11, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|----------------------------|-------------|-------------|
| | 2023 | 2022 |
| | | (revised) |
| Cash | ... | 989 |
| Prepaid assets | ... | 168,350 |
| Current asset - cash | 395,011 | ... |
| Total current assets | 395,011 | 169,339 |
| Cash held in trust account | 310,623,083 | 300,330,651 |
| Total assets | 311,018,094 | 300,499,990 |
| Convertible note payable | 47,104,743 | ... |
| Accrued expenses | ... | 17,166,842 |
| Note payable - sponsor | 2,398,700 | 2,875,000 |

| | | |
|---|--------------|--------------|
| Income taxes payable | 1,790,081 | 979,475 |
| Franchise tax payable | 458,226 | 400,000 |
| Working capital loans | ... | 625,700 |
| Advances - related party | ... | 425,835 |
| Promissory note - related party | 41,000 | ... |
| Convertible note payable | | ... |
| Sponsor | 3,883,945 | ... |
| Notes Payable | 500,000 | ... |
| Total current liabilities | 56,176,695 | 22,472,852 |
| Deferred underwriter fee payable | 10,062,500 | 10,062,500 |
| Total liabilities | 66,239,195 | 32,535,352 |
| Class A common stock subject to possible redemption | ... | 298,951,176 |
| Class A common stock | 308,645,005 | 127 |
| Class B common stock | 716 | 719 |
| Accumulated deficit | (63,866,949) | ... |
| Retained earnings (accumulated deficit) | ... | (30,987,384) |
| Common Stock - Issued & Paid | 127 | ... |
| Total stockholders' equity (deficit) | 244,778,899 | (30,986,538) |
| Total Equity | 244,778,899 | ... |

Recent Dividends:

1. Trump Media & Technology Group Corp class B common.

No dividends paid.

2. Trump Media & Technology Group Corp class A common.

No dividends paid.

3. Trump Media & Technology Group Corp class A common subject to possible redemption.

No dividends paid.

Annual Dividends:

1. Trump Media & Technology Group Corp class B common.

No dividends paid.

2. Trump Media & Technology Group Corp class A common.

No dividends paid.

3. Trump Media & Technology Group Corp class A common subject to possible redemption.

No dividends paid.

TSS INC DE

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|------------|------------|-------------|
| | 2023 | 2022 | 2021 |
| | | | (revised) |
| Revenue | 54,399,000 | ... | ... |
| Revenue | 54,399,000 | 30,637,000 | 27,410,000 |
| Cost of revenue | 43,398,000 | 21,657,000 | 21,049,000 |
| Gross profit | 11,001,000 | 8,980,000 | 6,361,000 |
| Selling, general & administrative expenses | 8,931,000 | 7,683,000 | 6,656,000 |
| Depreciation & amortization expenses | 320,000 | 383,000 | 536,000 |
| Amortization of Intangibles excluding Goodwill | 35,000 | ... | ... |
| Depreciation | 285,000 | ... | ... |
| Income (loss) from operations | 1,750,000 | 914,000 | (831,000) |
| Interest expense | 1,616,000 | ... | ... |
| Interest income (expense), net | ... | (964,000) | (430,000) |
| Other income | ... | 33,000 | 29,000 |
| Income (loss) before income tax provision | 134,000 | (17,000) | (1,232,000) |
| Current income tax expense (benefit) - state | 60,000 | 56,000 | 65,000 |
| Income tax provision (benefit) | 60,000 | 56,000 | 65,000 |
| Net income (loss) | 74,000 | (73,000) | (1,297,000) |
| Weighted average shares outstanding | | | |

| | | | |
|---------------------------------------|------------|------------|------------|
| - basic | 21,602,000 | 20,061,000 | 18,363,000 |
| Weighted average shares outstanding | | | |
| - diluted | 21,602,000 | 20,061,000 | 18,363,000 |
| Year end shares outstanding | 21,771,000 | 21,540,000 | 18,862,000 |
| Net income (loss) per share - basic | \$0.00 | \$0.00 | \$(0.07) |
| Net income (loss) per share - diluted | \$0.00 | \$0.00 | \$(0.07) |
| Number of full time employees | 81 | 70 | ... |
| Number of part time employees | ... | ... | 67 |
| Total number of employees | 81 | ... | ... |
| Number of common stockholders | 84 | 86 | 74 |

As of March 31, 2023; As of March 30, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|---|--------------|--------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents | 11,831,000 | 20,397,000 | |
| Contract & other receivables | 3,534,000 | 2,752,000 | |
| Allowance for doubtful accounts | 7,000 | 7,000 | |
| Costs & estimated earnings in excess of billings on uncompleted contracts | ... | 231,000 | |
| Materials & component parts | 258,000 | 406,000 | |
| Reseller inventories | 2,106,000 | 460,000 | |
| Reserve | 21,000 | 4,000 | |
| Inventories, net - Balancing value | 2,343,000 | ... | |
| Inventories, net | ... | 862,000 | |
| Prepaid expenses & other current assets | 1,310,000 | 175,000 | |
| Prepaid expenses and other current assets | 302,000 | ... | |
| Total current assets | 19,313,000 | 24,410,000 | |
| Trade equipment | 398,000 | 322,000 | |
| Leasehold improvements | 1,050,000 | 964,000 | |
| Furniture & fixtures | ... | 36,000 | |
| Computer equipment & software | 28,000 | 2,233,000 | |
| Computer equipment and software | 2,335,000 | ... | |
| Property & equipment, gross | 3,811,000 | 3,555,000 | |
| Less accumulated depreciation | 3,183,000 | 2,968,000 | |
| Property & equipment, net | 628,000 | 587,000 | |
| Lease right-of-use asset | 4,062,000 | 4,717,000 | |
| Goodwill | 780,000 | 780,000 | |
| Other intangible assets, net | ... | 35,000 | |
| Other assets | 817,000 | 877,000 | |
| Total assets | 25,600,000 | 31,406,000 | |
| Accounts payable | 12,414,000 | 19,959,000 | |
| Legal settlement | 14,362,000 | ... | |
| Accrued expenses | 746,000 | 494,000 | |
| Compensation, benefits & related taxes | 1,087,000 | 1,102,000 | |
| Other accrued expenses | 115,000 | 61,000 | |
| Deferred revenues | 3,370,000 | 2,080,000 | |
| Current portion of lease liabilities | 688,000 | 467,000 | |
| Total current liabilities | 18,420,000 | 24,163,000 | |
| Non-current portion of lease liabilities | 3,631,000 | 4,309,000 | |
| Total liabilities | 22,051,000 | 28,472,000 | |
| Common stock | 2,000 | 2,000 | |
| Additional paid-in capital | 72,103,000 | 71,522,000 | |
| Treasury stock, at cost | 2,245,000 | 2,205,000 | |
| Retained earnings (accumulated deficit) | (66,311,000) | (66,385,000) | |
| Total stockholders' equity (deficiency) | 3,549,000 | 2,934,000 | |

| | | | |
|---|---------------|---------------|----------------|
| Total Equity | 3,549,000 | ... | |
| Recent Dividends: | | | |
| 1. TSS Inc DE common. | | | |
| No dividends paid. | | | |
| Annual Dividends: | | | |
| 1. TSS Inc DE common. | | | |
| No dividends paid. | | | |
| TUCOWS INC | | | |
| Annual Report | | | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
| | 2023 | 2022 | 2021 (revised) |
| Net revenues | 339,337,000 | ... | ... |
| Net revenues | 339,337,000 | 321,142,000 | 304,337,000 |
| Cost of revenues - cost of revenues | ... | 196,268,000 | 193,039,000 |
| Cost of revenues - network expenses | ... | 17,433,000 | 14,769,000 |
| Cost of revenues - depreciation of property & equipment | ... | 27,589,000 | 17,452,000 |
| Cost of revenues - amortization of intangible assets | 1,506,000 | 1,512,000 | 583,000 |
| Impairment of property & equipment | 4,822,000 | 92,000 | 201,000 |
| Direct cost of revenues | 202,256,000 | ... | ... |
| Network, other costs | 28,222,000 | ... | ... |
| Network, depreciation of property and equipment | 35,864,000 | ... | ... |
| Total cost of revenues | 272,670,000 | 242,894,000 | 226,044,000 |
| Gross profit | 66,667,000 | 78,248,000 | 78,293,000 |
| Customer support expenses | 67,806,000 | ... | ... |
| Development expenses | 19,217,000 | ... | ... |
| Sales & marketing expenses | ... | 53,937,000 | 39,471,000 |
| Technical operations & development expenses | ... | 14,187,000 | 14,310,000 |
| General & administrative expenses | 33,406,000 | 30,845,000 | 22,370,000 |
| Depreciation of property & equipment | 567,000 | 598,000 | 534,000 |
| Gain (loss) on disposition of property & equipment | ... | (461,000) | (234,000) |
| Amortization of intangible assets | 9,323,000 | 9,882,000 | 9,424,000 |
| Gain (loss) on currency forward contracts | ... | ... | 277,000 |
| Total expenses | (130,319,000) | (109,910,000) | (86,066,000) |
| Income (loss) from operations | (63,652,000) | (31,662,000) | (7,773,000) |
| Interest income (expense), net | (41,771,000) | (14,456,000) | (4,617,000) |
| Income earned on sale of transferred assets, net | ... | 18,507,000 | 20,030,000 |
| Gain on sale of Ting customer assets, net | 17,033,000 | ... | ... |
| Other income (expense), net | ... | (177,000) | (370,000) |
| Loss on debt extinguishment | (14,680,000) | ... | ... |
| Total other income (expense) | (39,418,000) | 3,874,000 | 15,043,000 |
| Income (loss) | ... | ... | ... |

| | | | |
|---|---------------------|---------------------|------------------|
| before provision for income taxes | (103,070,000) | (27,788,000) | 7,270,000 |
| Provision for (recovery of) income taxes | (6,873,000) | (217,000) | 3,906,000 |
| Net income (loss) for the period | (96,197,000) | (27,571,000) | 3,364,000 |
| Weighted average shares outstanding - basic | 10,864,086 | 10,769,280 | 10,662,337 |
| Weighted average shares outstanding - diluted | 10,864,086 | 10,769,280 | 10,817,468 |
| Year end shares outstanding | 10,903,405 | 10,817,110 | 10,747,417 |
| Net income (loss) per common share - basic | \$(8.85) | \$(2.56) | \$0.32 |
| Net income (loss) per common share - diluted | \$(8.85) | \$(2.56) | \$0.31 |
| Number of full time employees | 1,045 | 1,020 | 1,000 |
| Number of part time employees | ... | 80 | ... |
| Number of employees | 1,045 | ... | ... |
| Number of common stockholders | 74 | 74 | 76 |
| Basic EPS Excluding ExtraOrdinary Items | \$(8.85) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(8.85) | ... | ... |

Reclassified to conform with 2022 presentation; Approximately; As of March 13, 2023; As of March 1, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | |
|---|-------------|-------------|--|
| | 2023 | 2022 | |
| Cash & cash equivalents | 92,687,000 | 23,496,000 | |
| Restricted cash | 3,639,000 | ... | |
| Accounts receivable, gross | 22,717,000 | 19,097,000 | |
| Allowance for doubtful accounts | 511,000 | 693,000 | |
| Accounts receivable, net | 22,206,000 | 18,404,000 | |
| Contract asset, current portion | 1,417,000 | 5,159,000 | |
| Inventory | 6,786,000 | 7,284,000 | |
| Prepaid royalties | 17,387,000 | ... | |
| Prepaid expenses & deposits | ... | 17,005,000 | |
| Derivative instrument asset, current portion | 2,277,000 | 1,903,000 | |
| Deferred costs of fulfillment, current portion | 95,649,000 | 94,198,000 | |
| Income taxes recoverable | 709,000 | 2,471,000 | |
| Total current assets | 242,757,000 | 169,920,000 | |
| Contract asset, long-term portion | 8,652,000 | 2,328,000 | |
| Deferred costs of fulfillment, long-term portion | ... | 16,476,000 | |
| Prepaid domain name registry fees, net | 15,419,000 | ... | |
| Computer equipment | 53,818,000 | 43,440,000 | |
| Computer software | 1,926,000 | 1,935,000 | |
| Capitalized internal use software | ... | 25,172,000 | |
| Furniture & equipment | 1,880,000 | 1,708,000 | |
| Vehicles & tools | 10,594,000 | 9,144,000 | |
| Fiber network | 215,205,000 | 168,587,000 | |
| Customer equipment & installations | 48,041,000 | 36,382,000 | |
| Land | 1,109,000 | 1,109,000 | |
| Building | 9,118,000 | 8,864,000 | |
| Asset under construction | 75,519,000 | 62,588,000 | |
| Leasehold improvements | 727,000 | 624,000 | |
| Office equipment | 38,379,000 | ... | |
| Property & equipment, gross | 456,316,000 | 359,553,000 | |
| Less accumulated | ... | ... | |

| | | | | | | | | | |
|--|--------------|-------------|---|-------------|-------------|-------------|--|------------|------------|
| depreciation | 116,672,000 | 78,058,000 | Other income | 9,898 | 155,137 | 538 | software | 159,342 | 123,088 |
| Property & equipment | 339,644,000 | 281,495,000 | Gain from insurance recovery | 103,941 | ... | 434,724 | Boat molds | 5,871,373 | 3,007,903 |
| Right of use operating lease asset | 27,467,000 | 20,489,000 | Net change in fair value of marketable securities | ... | (133,988) | (32,465) | Vehicles | 143,360 | 95,534 |
| Contract costs | 2,581,000 | 1,827,000 | Government grant income | 1,267,055 | 355,987 | 608,224 | Electric prototypes & tooling | ... | 142,526 |
| Investments | 2,012,000 | 2,012,000 | Gain (loss) on disposal of assets | 87,781 | (60,088) | (254,600) | New model development | 40,299 | ... |
| Intangible assets | 29,484,000 | 39,790,000 | Interest expense | 221,157 | 164,155 | 136,709 | Assets under construction | 142,526 | ... |
| Goodwill | 130,410,000 | 130,410,000 | Interest income | 48,370 | 75,401 | ... | Land | 1,119,758 | ... |
| Total assets | 798,426,000 | 664,747,000 | Dividend income | 909,215 | ... | ... | Assets under construction | 2,977,894 | ... |
| Accounts payable | 12,676,000 | 17,171,000 | Total other income (expense) | ... | 228,294 | 619,712 | Total property & equipment, gross | 14,676,820 | 6,594,293 |
| Accrued liabilities | 35,356,000 | 22,653,000 | Income (loss) before income tax | (9,782,196) | (5,793,414) | (1,011,009) | Less accumulated depreciation & amortization | 2,382,832 | 1,058,391 |
| Customer deposits | 19,335,000 | 15,783,000 | Net income (loss) | (9,782,196) | (5,793,414) | (1,011,009) | Property & equipment, net | 12,293,988 | 5,535,902 |
| Derivative instrument liability, current portion | ... | 389,000 | Less: net income (loss) attributable to noncontrolling interests | 2,590,020 | 656,162 | ... | Operating right of use asset | 854,990 | 1,329,620 |
| Operating lease liability, current portion | 5,397,000 | 4,642,000 | Net income (loss) attributed to stockholders of Twin Vee PowerCats Co, Inc. | (7,192,176) | (5,137,252) | (1,011,009) | Security deposit | 51,417 | 32,517 |
| Deferred revenue, current portion | 126,733,000 | 122,894,000 | Weighted average shares outstanding - basic | 9,520,000 | 7,624,938 | 5,331,400 | Total assets | 39,846,713 | 38,231,480 |
| Accreditation fees payable, current portion | 609,000 | 809,000 | Weighted average shares outstanding - diluted | 9,520,000 | 7,624,938 | 5,331,400 | Accounts payable | 2,399,026 | 2,065,680 |
| Income taxes payable | 1,235,000 | 2,248,000 | Year end shares outstanding | 9,520,000 | 9,520,000 | 7,000,000 | Contract liabilities | 44,195 | 5,300 |
| Other current liabilities | ... | 1,600,000 | Net earnings (loss) per share - basic | \$(0.76) | \$(0.76) | \$(0.19) | Warranty reserve | 192,894 | ... |
| Total current liabilities | 201,341,000 | 188,189,000 | Net earnings (loss) per share - diluted | \$(0.76) | \$(0.76) | \$(0.19) | Capital leases | 214,715 | ... |
| Deferred revenue, long-term portion | 21,350,000 | 22,237,000 | Number of full time employees | 99 | 170 | 120 | Operating lease right of use liability | 482,897 | 479,314 |
| Accreditation fees payable, long-term portion | ... | 142,000 | Number of common stockholders | 278 | 297 | 2 | Accrued wages & benefits | 343,511 | 333,976 |
| Operating lease liability, long-term portion | 18,255,000 | 12,438,000 | Earnings per share from continuing operations | \$(0.76) | ... | ... | Accrued interest | 33,245 | 47,607 |
| Loan payable, long-term portion | 210,354,000 | 238,930,000 | Earnings per share from continuing operations | \$(0.76) | ... | ... | Accrued bonus | ... | 20,000 |
| Redeemable preferred shares | 111,390,000 | 90,434,000 | Total number of employees | 99 | ... | ... | Accrued warranty | 1,075,512 | ... |
| Deferred tax liability | 2,966,000 | 15,720,000 | | | | | Accrued rebates | ... | 15,000 |
| Notes payable | 222,895,000 | ... | | | | | Accrued professional fees | ... | 89,500 |
| Class A common | 34,373,000 | ... | | | | | Other accrued operating expense | 115,037 | 64,601 |
| Common stock | ... | 31,868,000 | | | | | Accrued inventory | ... | 577,712 |
| Additional paid-in capital | 14,072,000 | 8,106,000 | | | | | Warranty reserve | ... | 92,373 |
| Retained earnings (accumulated deficit) | (40,298,000) | 55,899,000 | | | | | Accrued assets under construction | 390,825 | ... |
| Gains and losses on cash flow hedges | 2,275,000 | ... | | | | | Accrued liabilities | ... | 1,240,769 |
| Tax impact | (547,000) | ... | | | | | Total current liabilities | 4,216,345 | 3,791,063 |
| Accumulated other comprehensive income (loss) | 1,728,000 | 784,000 | | | | | Economic injury disaster loan | 499,900 | 499,900 |
| Total stockholders' equity (deficiency) | 9,875,000 | 96,657,000 | | | | | Operating lease liability - noncurrent | 436,730 | 919,628 |
| Total Equity | 9,875,000 | ... | | | | | Finance lease liability - noncurrent | 2,644,123 | ... |

Recent Dividends:**1. Tucows Inc common.**

No dividends paid.

Annual Dividends:**1. Tucows Inc common.**

No dividends paid.

TWIN VEE POWERCATS CO**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 (revised) |
|-----------------------------------|--------------|-------------|----------------|
| Net sales | 33,425,912 | 31,987,724 | 15,774,170 |
| Revenue | 33,425,912 | ... | ... |
| Cost of goods sold | 23,702,885 | 21,330,918 | 9,498,384 |
| Gross profit | 9,723,027 | 10,656,806 | 6,275,786 |
| Salaries & wages | 13,929,580 | 11,457,569 | 5,389,599 |
| Selling, general & administrative | 3,734,406 | 2,759,625 | 1,726,345 |
| Research & development costs | 1,443,569 | 941,533 | 211,111 |
| Professional fees | 1,249,388 | 966,037 | 380,929 |
| Depreciation | 1,353,383 | ... | ... |
| Depreciation & amortization | ... | 553,750 | 198,523 |
| Total operating expenses | 21,710,326 | 16,678,514 | 7,906,507 |
| Income (loss) from operations | (11,987,299) | (6,021,708) | (1,630,721) |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 16,497,703 | 23,501,007 |
| Accounts receivable | 80,160 | 14,167 |
| Marketable securities | 4,462,942 | 1,481,606 |
| Raw materials | 5,001,512 | 3,406,371 |
| Inventory in transit | ... | 222,607 |
| Work in process | 96,721 | 246,734 |
| Finished product | 206,144 | 132,620 |
| Inventory - Balancing value | 4,884,761 | ... |
| Inventories - Other | (419,616) | ... |
| Inventories | ... | 4,008,332 |
| Prepaid expenses & other current assets | 463,222 | 882,417 |
| Restricted cash | 257,530 | ... |
| Total current assets | 26,646,318 | 29,887,529 |
| Marketable securities - non current | ... | 1,445,912 |
| Machinery & equipment | 2,692,473 | 2,018,203 |
| Furniture & fixtures | ... | 23,211 |
| Leasehold improvements | 1,228,860 | 979,549 |
| Software & website development | 300,935 | 204,279 |
| Computer hardware & | ... | ... |

Recent Dividends:**1. Twin Vee PowerCats Co common.**

No dividends paid.

Annual Dividends:**1. Twin Vee PowerCats Co common.**

No dividends paid.

TWINLAB CONSOLIDATED HOLDINGS INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$000):**

| | 2023 | 2022 (revised) | 2021 |
|--|---------|----------------|---------|
| Net sales | 13,617 | 17,208 | 72,089 |
| Cost of sales | 8,605 | 9,024 | 55,511 |
| Gross profit | 5,012 | 8,184 | 16,578 |
| Selling expenses | 1,161 | 2,656 | 3,416 |
| General & administrative expenses | 5,240 | 6,970 | 9,736 |
| Impairment of goodwill & intangible assets | ... | 340 | 11,118 |
| Income (loss) from operations | (1,389) | (1,782) | (7,692) |

| | | | |
|--|-----------------|----------------|-----------------|
| Interest expense, net..... | 8,271 | 7,902 | 8,611 |
| Other income (expense), net..... | 41 | 1,676 | 1,376 |
| Total other income (expense)..... | (8,230) | (6,226) | (7,235) |
| Income (loss) before income taxes .. | (9,619) | (8,008) | (14,927) |
| Current state income tax provision (benefit) ... | 43 | 25 | 13 |
| Total current income tax expense .. | ... | ... | 13 |
| Deferred federal income tax provision (benefit) ... | 1,177 | (900) | 2,841 |
| Deferred state income tax provision (benefit) ... | 1,036 | 416 | 957 |
| Change in valuation allowance | ... | ... | (3,798) |
| Income Taxes - Total - Current | 43 | 25 | ... |
| Change in valuation allowance-other | ... | ... | ... |
| Deferred | (2,213) | 484 | ... |
| Provision (benefit) for income taxes | 43 | 25 | 13 |
| Total net income (loss) | (13,714) | (8,222) | (14,940) |
| Weighted average shares outstanding - basic | 259,093 | 259,093 | 258,838 |
| Weighted average shares outstanding - diluted | 259,093 | 259,093 | 258,838 |
| Year end shares outstanding | 259,093 | 259,093 | 259,093 |
| Net income (loss) per common share - basic | \$(0.05) | \$(0.03) | \$(0.06) |
| Net income (loss) per common share - diluted | \$(0.05) | \$(0.03) | \$(0.06) |
| Number of full time employees | ... | ... | 66 |
| Number of common stockholders | 375 | ... | 375 |
| Total Revenue | 13,617 | 17,208 | ... |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.04) | \$(0.03) | ... |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(0.04) | \$(0.03) | ... |
| Discontinued Operations - Net - Income/Expense | (4,052) | (189) | ... |
| Net Income Before Extraordinary and Preferred Dividends .. | (9,662) | (8,033) | ... |
| Earn per share-inc from discount opers - diluted | \$(0.02) | \$(0.00) | ... |
| Earning per share-total discount opers - diluted | \$(0.02) | \$(0.00) | ... |
| Earnings per share-inc from discontinued oper | \$(0.02) | \$(0.00) | ... |
| Earnings per share-total discontinued opers ... | \$(0.02) | \$(0.00) | ... |

| | | |
|--|-----------|-----------|
| Cash | 19 | 868 |
| Accounts receivable, gross | 4,108 | 5,651 |
| Less: allowances | 2,036 | 1,546 |
| Accounts receivable, net | 2,072 | 4,105 |
| Raw materials | 119 | 906 |
| Finished goods | 3,362 | 8,724 |
| Reserve for obsolete inventory | 79 | 223 |
| Inventories, net | ... | 9,407 |
| Prepaid expenses & other current assets | 194 | 758 |
| Total current assets | 5,687 | 15,138 |
| Machinery & equipment | ... | 124 |
| Leasehold improvements | ... | 118 |
| Computers & other property & equipment | 54 | 68 |
| Computers and other | 54 | ... |
| Property & equipment, gross | ... | 310 |
| Accumulated depreciation & amortization | 45 | 122 |
| Property & equipment, net | 9 | 188 |
| Right-of-use assets | 1,889 | 4,165 |
| Intangible assets, net | 120 | 120 |
| Other assets | 1,290 | 1,301 |
| Total assets | 8,995 | 20,912 |
| Accounts payable | 6,803 | 6,621 |
| Lease liabilities | 1,426 | 1,159 |
| Accrued expenses & other current liabilities | 2,022 | 3,708 |
| Accrued interest | 39,851 | 33,316 |
| Current portion of long-term debt | 93,637 | ... |
| Notes payable & current portion of long-term debt, net | ... | 97,381 |
| Accrued expenses and other current liabilities | 4,106 | ... |
| Contract Liabilities - Guaranteed Returns | 127 | ... |
| Accrued expenses and other current liabilities - Balancing value | 1,957 | ... |
| Total current liabilities | 145,823 | 142,185 |
| Lease liabilities | 2,197 | 4,038 |
| Related party debt | ... | 91,073 |
| Senior credit facility | ... | 6,308 |
| Less current portion | ... | 97,381 |
| Total long-term liabilities | 2,197 | 4,038 |
| Total liabilities | 148,020 | 146,223 |
| Common stock | 394 | 394 |
| Additional paid-in capital | 231,249 | 231,249 |
| Stock subscriptions receivable | (30) | (30) |
| Treasury stock | 500 | 500 |
| Retained earnings (accumulated deficit) | (370,138) | (356,424) |
| Total stockholders' equity (deficit) | (139,025) | (125,311) |
| Total Equity | (139,025) | ... |

Recent Dividends:
1. Twinlab Consolidated Holdings Inc common.
 No dividends paid.

Annual Dividends:
1. Twinlab Consolidated Holdings Inc common.
 No dividends paid.

TWINLAB CONSOLIDATED HOLDINGS INC

Earnings, 9 mos. to Sep 30(Consol. - \$):

| | 2023 | 2022 |
|-----------------------------------|-------------|-------------|
| Total revenues | 10,473,000 | 14,271,000 |
| Net Sales | 10,473,000 | 14,271,000 |
| Cost & expenses | 11,177,000 | 15,019,000 |
| Operating income | (704,000) | (748,000) |
| Other income (expense), net | 14,000 | 1,676,000 |
| Net before taxes | (7,119,000) | (4,948,000) |
| Income taxes | 32,000 | ... |
| Income contin. oper. | (7,151,000) | (4,948,000) |
| Income discont. oper. | (5,015,000) | 79,000 |

| | | |
|-------------------------|---------------------|--------------------|
| Net income | (12,166,000) | (4,869,000) |
| Earnings common share | | |
| Primary | \$(0.05) | \$(0.02) |
| Fully Diluted | \$(0.05) | \$(0.02) |
| Common Shares: | | |
| Full Diluted | 259,092,833 | 259,092,833 |
| Year-end | 259,092,833 | 259,092,833 |

TWO HANDS CORP
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|---------------------|---------------------|
| Sales | 783,489 | 731,302 | 930,096 |
| Cost of goods sold | 721,377 | 682,109 | 832,816 |
| Gross profit | 62,112 | 49,193 | 97,280 |
| General & administrative expenses | 1,341,299 | 17,845,327 | 3,267,279 |
| Total expenses | 1,341,299 | 17,845,327 | 3,267,279 |
| Income (loss) from operations | (1,279,187) | (17,796,134) | (3,169,999) |
| Amortization of debt discount & interest expense | 159,335 | 131,828 | 357,213 |
| Gain (loss) on settlement of debt | (6,775,835) | (3,668,750) | (12,890,764) |
| Initial derivative expense | ... | 36,521 | 126,322 |
| Change in fair value of derivative liabilities | ... | 59,878 | (208,261) |
| Gain on disposition .. | 50,695 | ... | ... |
| Net Income before Tax | (8,163,662) | ... | ... |
| Total other income (expense) | (6,884,475) | (3,896,977) | (13,166,038) |
| Net income (loss) | (8,163,662) | (21,693,111) | (16,336,037) |
| Net income (loss) attributable to Two Hands Corporation ... | ... | (21,693,111) | (16,336,037) |
| Less: deemed dividend - Series A Stock modification ... | ... | 1,396,721 | ... |
| Add: deemed contribution - Series B Stock modification | ... | (1,354,515) | ... |
| Add: deemed contribution - Series C Stock modification | (2,211,884) | (834,001) | ... |
| Add: deemed contribution - Series D Stock modification | (190,040) | (749,085) | ... |
| Less: deemed contribution - Series E Stock | ... | (57,218) | ... |
| Net income (loss) attributable to Two Hands Corporation common shareholders | (5,761,738) | (20,095,013) | (16,336,037) |
| Weighted average shares outstanding - basic | 10,352,044 | 87,625 | 2,820 |
| Weighted average shares outstanding - diluted | 10,352,044 | 87,625 | 2,820 |
| Year end shares outstanding | 42,090,329 | 137,403 | 6,000 |
| Net income (loss) per share - basic | \$(0.56) | \$(230.00) | \$(5,790.00) |
| Net income (loss) per share - diluted | \$(0.56) | \$(230.00) | \$(5,790.00) |
| Number of common stockholders | 23 | 51 | 51 |
| Total Revenue | 783,489 | ... | ... |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.56) | ... | ... |
| EPS - Diluted - | ... | ... | ... |

Restated to reflect correction of errors; As is; Approximately; As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):
 2023 2022 (revised)

excluding
Extraordinary Items
Applicable to
Common - Total \$(0.56)

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-1,000 stock split, September 29, 2023; □ Adjusted for 1-for-1,000 stock split, April 27, 2022; □ Shares increased due to the effect of stock issued for conversion of non-redeemable convertible notes and series C stock, consulting and for officer and director compensation; □ Approximately; □ As of March 23, 2023; □ As of March 30, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|--|--------------|--------------|
| | 2023 | 2022 |
| Cash | 24,351 | 17,137 |
| Taxes receivable | 3,080 | ... |
| VAT taxes receivable | ... | 8,157 |
| Inventory | 39,489 | 73,621 |
| Prepaid expense | 10,000 | ... |
| Accounts receivable | 197,633 | ... |
| Allowance for doubtful accounts | 105,072 | ... |
| Accounts receivable, net | 92,561 | 94,182 |
| Total current assets | 169,481 | 193,097 |
| Property & equipment, net | 9,513 | 13,667 |
| Operating lease right-of-use asset | 15,559 | 23,438 |
| Total assets | 194,553 | 230,202 |
| Accounts payable & accrued liabilities | 523,486 | 555,220 |
| Due to related party | 883,534 | 185,473 |
| Notes payable | 113,333 | 13,443 |
| Deferred revenue | ... | 22,107 |
| Current portion of operating lease right-of-use liability | 8,759 | 8,230 |
| Line of credit | 629,507 | ... |
| Total current liabilities | 2,158,619 | 784,473 |
| Line of credit | ... | 293,298 |
| Promissory notes | 247,862 | 229,194 |
| Promissory notes - related party | ... | 84,377 |
| Non-redeemable convertible notes, net | 502,500 | 517,621 |
| Operating lease right-of-use liability, net of current portion | 6,800 | 15,208 |
| Total long-term liabilities | 757,162 | 1,139,698 |
| Total liabilities | 2,915,781 | 1,924,171 |
| Series A convertible preferred stock | ... | 249,505 |
| Series B convertible preferred stock | ... | 109,783 |
| Series C convertible preferred stock | 76,116 | 2,584,951 |
| Total temporary equity | ... | 2,944,239 |
| Common stock; \$0.0001 par value; 12,000,000,000 shares authorized, 42,090,329 and 137,403 shares issued and outstanding, respectively | 4,210 | ... |
| Common stock | ... | 13,742 |
| Common stock to be issued | ... | 336,000 |
| Accumulated other comprehensive income | 6,270 | 39,141 |
| Additional paid-in capital | 89,278,354 | 78,895,425 |
| Accumulated deficit | (92,086,178) | ... |
| Retained earnings (accumulated deficit) | ... | (83,922,516) |
| Total stockholders' equity (deficit) | (2,797,344) | (4,638,208) |
| Total Equity | (2,797,344) | ... |

Recent Dividends:

- 1. Two Hands Corp series C convertible preferred.**
No dividends paid.
- 2. Two Hands Corp series B convertible preferred.**
No dividends paid.

3. Two Hands Corp common.

No dividends paid.

4. Two Hands Corp series A convertible preferred.

No dividends paid.

Annual Dividends:**1. Two Hands Corp series C convertible preferred.**

No dividends paid.

2. Two Hands Corp series B convertible preferred.

No dividends paid.

3. Two Hands Corp common.

No dividends paid.

4. Two Hands Corp series A convertible preferred.

No dividends paid.

**UAS DRONE CORP
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | □2021 (revised) |
|--|------------------|--------------------|--------------------|
| Revenues | 300,000 | ... | ... |
| Revenues | 300,000 | ... | 500,000 |
| Cost of revenues | 273,000 | ... | ... |
| Gross profit (loss) | 27,000 | ... | ... |
| General & administrative expenses | 826,000 | 1,104,000 | 1,026,000 |
| Other income | ... | ... | 98,000 |
| Research & development expenses | 3,000 | 20,000 | 14,000 |
| Operating income (loss) | (802,000) | (1,124,000) | (442,000) |
| Financing expense | ... | 19,000 | 448,000 |
| Financing income | ... | 42,000 | 2,000 |
| Financing expense (income), net | 76,000 | ... | ... |
| Total other income (expense) | 76,000 | ... | ... |
| Income (loss) before income taxes | (726,000) | ... | ... |
| Net income (loss) | (726,000) | (1,101,000) | (888,000) |
| Weighted average shares outstanding - basic | 54,530,423 | 54,318,060 | 49,212,028 |
| Weighted average shares outstanding - diluted | 54,530,423 | 54,318,060 | 49,212,028 |
| Year end shares outstanding | 54,218,813 | 54,218,813 | □54,018,813 |
| Net income (loss) per common share - basic | \$(0.02) | \$(0.06) | \$(0.02) |
| Net income (loss) per common share - diluted | \$(0.02) | \$(0.06) | \$(0.02) |
| Number of full time employees | 1 | 1 | 1 |
| Total number of employees | 1 | ... | ... |
| Number of common stockholders | ... | □154 | □151 |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.02) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(0.02) | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of issuance of shares in exchange for convertible loans and cash; □ As of March 23, 2023; □ As of March 7, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-----------------------------------|-----------|-----------|
| Cash & cash equivalents | 2,281,000 | 2,849,000 |
| Prepaid & deferred expenses | 24,000 | 78,000 |
| Government institutions | 17,000 | 8,000 |
| Other current assets | 41,000 | 86,000 |

| | | |
|--|-------------|-------------|
| Total current assets | 2,322,000 | 2,935,000 |
| Lease deposit | 117,000 | 15,000 |
| Computers | 10,000 | 10,000 |
| Furniture & office equipment | 14,000 | 12,000 |
| Leasehold improvements | 66,000 | 50,000 |
| Property & equipment, gross | ... | 72,000 |
| Less - accumulated depreciation | 50,000 | 30,000 |
| Property & equipment, net | 40,000 | 42,000 |
| Total assets | 2,479,000 | 2,992,000 |
| Accounts payable | 98,000 | 85,000 |
| Accrued expenses | ... | 160,000 |
| Other accounts liabilities | 161,000 | 16,000 |
| Other liabilities | ... | 176,000 |
| Operating Lease Liabilities - Current Portion/Short-Term | 52,000 | ... |
| Total current liabilities | 311,000 | 261,000 |
| Loans | 314,000 | 305,000 |
| Operating lease liability | 46,000 | ... |
| Total liabilities | 671,000 | 566,000 |
| Common stock | 5,000 | 5,000 |
| Additional paid-in capital | 11,750,000 | 11,437,000 |
| Retained earnings (accumulated deficit) | (9,947,000) | (9,016,000) |
| Total shareholders' equity (deficit) | 1,808,000 | 2,426,000 |
| Total Equity | 1,808,000 | ... |

Recent Dividends:**1. UAS Drone Corp common.**

No dividends paid.

Annual Dividends:**1. UAS Drone Corp common.**

No dividends paid.

**UN MONDE INTERNATIONAL LTD
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2021 | □2020 |
|---|-----------------|-----------------|----------------|
| Professional fees | 35,543 | 28,139 | ... |
| Other general & administrative expense | 33,444 | 30,267 | 5,629 |
| Total operating expenses | 68,987 | 58,406 | 5,629 |
| Income (loss) from operations | (68,987) | (58,406) | (5,629) |
| Net income (loss) before income taxes | (68,987) | (58,406) | (5,629) |
| Net income (loss) | (68,987) | (58,406) | (5,629) |
| Net loss attributable to common stockholders | ... | (58,406) | (5,629) |
| Weighted average shares outstanding - basic | 6,493,346 | 7,769,833 | 7,727,103 |
| Weighted average shares outstanding - diluted | 6,493,346 | 7,769,833 | 7,727,103 |
| Year end shares outstanding | 6,493,346 | 6,493,346 | 7,769,833 |
| Net earnings (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.00) |
| Net earnings (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.00) |
| Number of part time employees | ... | 2 | ... |
| Number of common stockholders | 87 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

□ As reported from the December 31, 2021 10K

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|-------------|-------------|
| | 2023 | 2021 |
| Security deposit | 9,107 | ... |
| Other current receivables and prepayments | 1,486 | ... |
| Total current assets | 10,593 | ... |
| Total assets | 10,593 | ... |
| Accounts payable & accrued expenses | 179,860 | 3,764 |
| Due to related party | ... | 62,308 |
| Accounts Payable and Accrued Expenses | 2,441 | ... |
| Total current liabilities | 182,301 | 66,072 |
| Total liabilities | 182,301 | 66,072 |
| Common stock | 6,493 | 6,493 |
| Additional paid up capital | 2,317,217 | 2,317,217 |
| Retained earnings (accumulated deficits) | ... | (2,389,782) |
| Accumulated loss | (2,495,418) | ... |
| Total stockholders' equity (deficit) | (171,708) | (66,072) |
| Rep Total Equity & Minority Interest | (171,708) | ... |

Recent Dividends:

1. Un Monde International Ltd common.

No dividends paid.

Annual Dividends:

1. Un Monde International Ltd common.

No dividends paid.

UNICYCIVE THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | | | |
|--|-----------------|-----------------|-----------------|
| | 2023 | 2022 | 2021 |
| Licensing revenues | 675 | 951 | ... |
| Total revenues | 675 | ... | ... |
| Research & development | 12,902 | 12,436 | 6,080 |
| General & administrative | 8,547 | 6,567 | 2,897 |
| Total operating expenses | 21,449 | 19,003 | 8,977 |
| Income (loss) from operations | (20,774) | (18,052) | (8,977) |
| Interest expense | 82 | 6 | 628 |
| Loss on debt conversion | ... | ... | 431 |
| Gain on extinguishment of debt | ... | ... | 19 |
| Interest income | 615 | ... | ... |
| Change in fair value of warrants | (10,303) | ... | ... |
| Total other income (expenses) | (9,770) | (6) | (1,040) |
| Deemed dividend to Series A-1 preferred stockholders | 867 | ... | ... |
| Net income (loss) | (30,544) | (18,058) | (10,017) |
| Weighted average shares outstanding - basic | 24,539 | 15,057 | 11,676 |
| Weighted average shares outstanding - diluted | 24,539 | 15,057 | 11,676 |
| Year end shares outstanding | 34,756 | 15,232 | 14,997 |
| Net earnings (loss) per share - basic | \$(1.28) | \$(1.20) | \$(0.86) |
| Net earnings (loss) per share - diluted | \$(1.28) | \$(1.20) | \$(0.86) |
| Number of full time employees | 14 | 12 | 9 |
| Total number of employees | 14 | ... | ... |
| Number of common stockholders | 109 | 73 | 977 |
| Net Income After Extraordinary Items | ... | ... | ... |

| | | | |
|---|----------|-----|-----|
| applicable to Common | (31,411) | ... | ... |
| Income from cont operations before income tax | (30,544) | ... | ... |

□ Shares increased due to the effect of initial public offering, conversion of convertible notes into common stock and issuance of common stock for exercise of options and anti-dilution clause; □ As is; □ As of March 30, 2023; □ As of March 31, 2022; □ As of March 28, 2023; □ As of March 4, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | | |
|---|----------|----------|
| | 2023 | 2022 |
| Cash and cash equivalents | 9,701 | ... |
| Cash | ... | 455 |
| Prepaid directors & officers liability | ... | ... |
| insurance premiums | 270 | 476 |
| Prepaid preclinical services | 3,103 | 1,554 |
| Other prepaid expenses & other current assets | ... | 159 |
| Prepaid expenses & other current assets | 3,698 | 2,189 |
| other | 325 | ... |
| Total current assets | 13,399 | 2,644 |
| Right of use asset, net | 766 | 152 |
| Leasehold improvements | 21 | 15 |
| Furniture & fixtures | 21 | 14 |
| Property, plant & equipment, subtotal | 42 | 29 |
| Less: accumulated depreciation | 16 | 7 |
| Property, plant & equipment, net | 26 | 22 |
| Total assets | 14,191 | 2,818 |
| Trade accounts payable | 839 | 846 |
| Credit card liability | 13,134 | 46 |
| Accounts payable | ... | 892 |
| Accrued labor costs | 1,917 | ... |
| Other | 283 | ... |
| Accrued liabilities - Balancing value | 3,234 | ... |
| Accrued drug development costs | 1,034 | ... |
| Accrued liabilities | ... | 2,237 |
| Operating lease liability - current | 327 | 155 |
| Total current liabilities | 17,534 | 3,284 |
| Operating lease liability - long term | 466 | ... |
| Total liabilities | ... | 3,284 |
| Common stock | 35 | 15 |
| Additional paid-in capital | 60,697 | 33,516 |
| Retained earnings (accumulated deficit) | (64,541) | (33,997) |
| Total stockholders' equity (deficit) | (3,809) | (466) |
| Total Equity | (3,809) | ... |

Recent Dividends:

1. Unicycive Therapeutics Inc Series A-2 preferred.

No dividends paid.

2. Unicycive Therapeutics Inc common.

No dividends paid.

Annual Dividends:

1. Unicycive Therapeutics Inc Series A-2 preferred.

No dividends paid.

2. Unicycive Therapeutics Inc common.

No dividends paid.

UNITED HEALTH PRODUCTS INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|--|-----------|-----------|----------------|
| | 2023 | 2022 | 2021 (revised) |
| Revenues | ... | 37,500 | 59 |
| Cost of sales | ... | 18,644 | 25 |
| Gross profit (loss) | ... | 18,856 | 34 |
| Selling, general & administrative expenses | 1,827,729 | 2,196,331 | 29,563,211 |

| | | | |
|---|--------------------|--------------------|---------------------|
| Research & development expenses | 598,810 | 624,564 | 237,458 |
| Total operating expenses | 2,426,539 | 2,820,895 | 29,800,669 |
| Income (loss) from operations | (2,426,539) | (2,802,039) | (29,800,635) |
| Interest expense | 40,512 | 17,022 | 226,139 |
| Interest expense - related party | 75,684 | 61,823 | 392,112 |
| Other income | ... | 1,402,981 | 304,273 |
| Gain (loss) on settlement of debt | (80,532) | (209,598) | (434,570) |
| Net Income before Tax | (2,623,267) | ... | ... |
| Total other income (expense) | (196,728) | 1,114,538 | (748,548) |
| Net income (loss) | (2,623,267) | (1,687,501) | (30,549,183) |
| Weighted average shares outstanding - basic | 239,080,282 | 229,718,142 | 225,741,684 |
| Weighted average shares outstanding - diluted | 239,080,282 | 229,718,142 | 225,741,684 |
| Year end shares outstanding | 244,783,222 | 230,871,034 | 228,667,229 |
| Net income (loss) per common share - basic | \$(0.01) | \$(0.01) | \$(0.14) |
| Net income (loss) per common share - diluted | \$(0.01) | \$(0.01) | \$(0.14) |
| Number of full time employees | ... | 7 | 7 |
| Number of common stockholders | 401 | 404 | 413 |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.01) | ... | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.01) | ... | ... |

□ Shares increased due to the effect of stock issued for litigation settlement, settle accrued liabilities and related party advances, services, compensation and conversion of notes payable and interest; □ As of March 27, 2023; □ As of March 31, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|---------|-----------|
| | 2023 | 2022 |
| Cash & cash equivalents | 95,420 | 13,377 |
| Finished goods | 33,598 | 34,730 |
| Inventory | 33,598 | 34,730 |
| Prepaid & other current assets | 22,804 | 22,932 |
| Total current assets | 151,822 | 71,039 |
| Deferred offering costs | 21,051 | 243,039 |
| Patents, net | 32,400 | 36,450 |
| Operating lease right-of-use asset | 76,520 | ... |
| Security deposit | 2,850 | ... |
| Total assets | 284,643 | 350,528 |
| Accounts payable & accrued expenses | 987,567 | 1,255,232 |
| Accrued liabilities - related parties | 226,475 | 172,579 |
| Accrued litigation settlement | ... | 300,000 |
| Promissory note payable | ... | 9,136 |
| Loans payable - related parties | ... | 4,000 |
| Convertible notes payable, net of debt discount | 207,500 | 196,177 |
| Convertible loans payable - related parties, net of debt discount | ... | 478,331 |
| Short term loans | 500,000 | ... |

No dividends paid.

7. Vaccinex Inc common.
No dividends paid.

VANECK ETF TRUST - ETHEREUM STRATEGY ETF Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 |
|--|---------|
| Interest income | 87,254 |
| Total income | 87,254 |
| Management fees | 18,152 |
| Futures commission merchant fees | 3,844 |
| Reimbursement by the Adviser | 3,844 |
| Net expenses | 18,152 |
| Net investment income, before income taxes | 69,102 |
| Net current and deferred tax benefit/(expense) | 15,443 |
| Net investment income (loss) | 53,659 |
| Year end shares outstanding | 700,000 |
| Net investment income (loss) per share | \$0.12 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 |
|---|------------|
| Investments, at value unaffiliated issuers | 8,447,654 |
| Cash | 1,617,126 |
| Cash on deposit with broker for futures contracts | 5,600,949 |
| Total assets | 15,665,729 |
| Due to adviser | 5,467 |
| Federal and State income taxes | 695,937 |
| Net variation margin on futures contracts | 56,850 |
| Net deferred tax | 379 |
| Total liabilities | 758,633 |
| Net assets | 14,907,096 |
| Aggregate paid-in capital | 12,284,657 |
| Total distributable earnings (loss) | 2,622,439 |
| Net assets | 14,907,096 |
| Net assets value per share | \$21.30 |

Recent Dividends:
1. VanEck ETF Trust - Ethereum Strategy ETF fund.
No dividends paid.

Annual Dividends:
1. VanEck ETF Trust - Ethereum Strategy ETF fund.
No dividends paid.

VANJIA CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Revenue | 82,720 | ... | ... |
| Revenue | 82,720 | ... | 34,160 |
| General & administrative expenses | 9,301 | 11,412 | 32,373 |
| Profit (loss) from operations | 73,419 | (11,412) | 1,787 |
| Income (loss) before income taxes | 73,419 | ... | ... |
| Net income (loss) | 73,419 | (11,412) | 1,787 |
| Weighted average shares outstanding - basic | 30,000,000 | 30,000,000 | 30,000,000 |
| Weighted average shares outstanding - diluted | 30,000,000 | 30,000,000 | 30,000,000 |
| Year end shares outstanding | 30,000,000 | 30,000,000 | 30,000,000 |
| Net earnings (loss) per share - basic | \$0.00 | \$0.00 | \$0.00 |
| Net earnings (loss) per share - diluted | \$0.00 | \$0.00 | \$0.00 |

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--------------------------|---------|---------|
| Cash & cash equivalents | 22,568 | 18,134 |
| Account Receivables | 68,985 | ... |
| Total current assets | 91,553 | ... |
| Land held for investment | 742,000 | 742,000 |
| Total assets | 833,553 | 760,134 |

| | | | | | | |
|---|-----------|-----------|---|-------------|-------------|-------------|
| Common stock | 3,000 | 3,000 | (benefit) | 11,000 | (1,064,000) | 11,000 |
| Additional paid-in capital | 936,400 | 936,400 | Total deferred income tax expense (benefit) | 51,000 | (4,788,000) | 52,000 |
| Retained earnings (accumulated deficit) | (105,847) | (179,266) | Income tax expense (benefit) | 100,000 | (4,743,000) | 151,000 |
| Total stockholders' equity | 833,553 | 760,134 | Net income (loss) | 4,805,000 | 11,294,000 | 6,100,000 |
| Total Equity | 833,553 | ... | Weighted average shares outstanding - basic | 174,441,000 | 173,065,000 | 171,688,000 |

Recent Dividends:
1. Vanjia Corp common.
No dividends paid.

Annual Dividends:
1. Vanjia Corp common.
No dividends paid.

VASO CORP Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|------------|-------------|------------|
| Revenues - managed IT systems & services | ... | ... | 42,916,000 |
| Revenues - professional sales services | ... | ... | 29,441,000 |
| Revenues - equipment sales & services | ... | ... | 3,222,000 |
| Total revenues | 81,024,000 | 79,294,000 | 75,579,000 |
| Cost of managed IT systems & services | ... | ... | 26,242,000 |
| Cost of professional sales services | ... | ... | 5,535,000 |
| Cost of equipment sales & services | ... | ... | 669,000 |
| Total cost of revenues | 30,431,000 | 31,392,000 | 32,446,000 |
| Gross profit | 50,593,000 | 47,902,000 | 43,133,000 |
| Selling, general & administrative | 45,643,000 | 40,843,000 | 38,593,000 |
| Research & development | 755,000 | 605,000 | 1,721,000 |
| Total operating expenses | 46,398,000 | 41,448,000 | 40,314,000 |
| Operating income (loss) | 4,195,000 | 6,454,000 | 2,819,000 |
| Interest & financing costs | 50,000 | 44,000 | 312,000 |
| Interest & other income, net | 764,000 | 143,000 | 98,000 |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 3,646,000 |
| Gain (loss) on disposal of fixed assets | (4,000) | (2,000) | ... |
| Total other income (expense), net | 710,000 | 97,000 | 3,432,000 |
| Income before provision for income taxes - domestic | ... | ... | 5,720,000 |
| Income (loss) before provision for income taxes - foreign | ... | ... | 531,000 |
| Income (loss) before income taxes | 4,905,000 | 6,551,000 | 6,251,000 |
| Current state income tax expense | 50,000 | 36,000 | 47,000 |
| Current foreign income tax expense (benefit) | (1,000) | 9,000 | 52,000 |
| Total current income tax expense | 49,000 | 45,000 | 99,000 |
| Deferred federal income tax expense (benefit) | 40,000 | (3,724,000) | 41,000 |
| Deferred state income tax expense | ... | ... | ... |

| | | | |
|---|------------|-------------|------------|
| Revenues - managed IT systems & services | ... | ... | 42,916,000 |
| Revenues - professional sales services | ... | ... | 29,441,000 |
| Revenues - equipment sales & services | ... | ... | 3,222,000 |
| Total revenues | 81,024,000 | 79,294,000 | 75,579,000 |
| Cost of managed IT systems & services | ... | ... | 26,242,000 |
| Cost of professional sales services | ... | ... | 5,535,000 |
| Cost of equipment sales & services | ... | ... | 669,000 |
| Total cost of revenues | 30,431,000 | 31,392,000 | 32,446,000 |
| Gross profit | 50,593,000 | 47,902,000 | 43,133,000 |
| Selling, general & administrative | 45,643,000 | 40,843,000 | 38,593,000 |
| Research & development | 755,000 | 605,000 | 1,721,000 |
| Total operating expenses | 46,398,000 | 41,448,000 | 40,314,000 |
| Operating income (loss) | 4,195,000 | 6,454,000 | 2,819,000 |
| Interest & financing costs | 50,000 | 44,000 | 312,000 |
| Interest & other income, net | 764,000 | 143,000 | 98,000 |
| Gain on forgiveness of Paycheck Protection Program loan | ... | ... | 3,646,000 |
| Gain (loss) on disposal of fixed assets | (4,000) | (2,000) | ... |
| Total other income (expense), net | 710,000 | 97,000 | 3,432,000 |
| Income before provision for income taxes - domestic | ... | ... | 5,720,000 |
| Income (loss) before provision for income taxes - foreign | ... | ... | 531,000 |
| Income (loss) before income taxes | 4,905,000 | 6,551,000 | 6,251,000 |
| Current state income tax expense | 50,000 | 36,000 | 47,000 |
| Current foreign income tax expense (benefit) | (1,000) | 9,000 | 52,000 |
| Total current income tax expense | 49,000 | 45,000 | 99,000 |
| Deferred federal income tax expense (benefit) | 40,000 | (3,724,000) | 41,000 |
| Deferred state income tax expense | ... | ... | ... |

□ Restated to reflect correction of errors; □ Approximately; □ As of March 25, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 11,342,000 | 11,821,000 |
| Short-term investments | 13,979,000 | 8,504,000 |
| Trade receivables | 22,085,000 | 22,471,000 |
| Allowance for doubtful accounts & commission adjustments | 9,708,000 | 6,947,000 |
| Receivables due from related parties | 929,000 | 421,000 |
| Raw materials | 832,000 | 751,000 |
| Work in process | 11,000 | 6,000 |
| Finished goods | 627,000 | 716,000 |
| Inventories | 1,470,000 | 1,473,000 |
| Deferred commission expense | 3,285,000 | 3,249,000 |
| Prepaid expenses & other current assets | 1,717,000 | 1,008,000 |
| Total current assets | 45,099,000 | 42,000,000 |
| Patents | 1,894,000 | ... |
| Office, laboratory & other equipment | 2,084,000 | 1,928,000 |
| Equipment furnished for customer or clinical uses | 8,233,000 | 7,981,000 |
| Right of use assets - finance leases | 1,116,000 | 1,119,000 |
| Furniture & fixtures | 99,000 | 99,000 |
| Property & equipment, gross | 11,532,000 | 11,127,000 |
| Less: accumulated depreciation | 10,358,000 | 9,787,000 |
| Property & equipment, net | 1,174,000 | 1,340,000 |
| Operating lease right of use assets | 1,949,000 | 1,568,000 |
| Goodwill | 15,588,000 | 15,614,000 |
| Intangibles, net | 1,406,000 | 1,511,000 |
| Deferred tax assets, net | 4,956,000 | 5,007,000 |
| Deferred commission expense - noncurrent | ... | 3,864,000 |
| Trade receivables - noncurrent | ... | 792,000 |
| Other assets, net | ... | 70,000 |
| Other assets, net | 4,902,000 | 4,726,000 |
| Investment in EECPC Global Corporation | 683,000 | 889,000 |
| Accumulated Amortization | 1,894,000 | ... |
| Total assets | 75,757,000 | 72,655,000 |
| Accrued expenses | 2,142,000 | ... |
| Accounts payable | 2,670,000 | 2,270,000 |
| Accrued commissions | 2,482,000 | 3,720,000 |

No dividends paid.
4. Verb Technology Co Inc series A convertible preferred.
 No dividends paid.
5. Verb Technology Co Inc class A unit.
 No dividends paid.
Annual Dividends:
1. Verb Technology Co Inc class B unit.
 No dividends paid.
2. Verb Technology Co Inc series C preferred.
 No dividends paid.
3. Verb Technology Co Inc common.
 No dividends paid.
4. Verb Technology Co Inc series A convertible preferred.
 No dividends paid.
5. Verb Technology Co Inc class A unit.
 No dividends paid.

VERDE BIO HOLDINGS INC

Earnings, 9 mos. to Jan 31(Consol. - \$):

| | 2024 | 2023 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 211,181 | ... |
| Cost & expenses | 1,063,218 | 1,590,476 |
| Operating income | (1,040,771) | (1,237,913) |
| Interest expense | 11,562 | 39,762 |
| Other income (expense), net | (18,625) | (56,160) |
| Gains or losses | (1,070,842) | ... |
| Net before taxes | (2,141,800) | ... |
| Net income | (2,141,800) | (1,333,835) |
| Balance for common | (2,199,184) | (1,402,624) |
| Earnings common share | ... | ... |
| Common Shares: | ... | ... |
| Full Diluted | 1,731,165,090 | 300,490,001 |
| Year-end | 1,931,932,723 | 423,521,611 |

VERDE CLEAN FUELS

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|---------------------|--------------------|------------------|
| Formation & operating costs | ... | 5,715,022 | 456,765 |
| Income (loss) from operations | (10,545,386) | (5,715,022) | (456,765) |
| Interest earned on marketable securities held in trust account | ... | 2,455,873 | 4,680 |
| Interest expense on promissory note - related party | ... | 7,363 | ... |
| Unrealized loss on fair value changes of over-allotment option liability | ... | ... | 22,500 |
| Interest Expense | 236,699 | ... | ... |
| Other (income) | 447,074 | ... | ... |
| Total other income (expense), net | ... | 2,448,510 | (17,820) |
| Income from cont operations before income tax | (10,335,011) | (3,266,512) | ... |
| Current federal income taxes | ... | 312,446 | ... |
| Deferred federal income taxes | ... | 19,422 | ... |
| Change in valuation allowance | ... | 99,764 | ... |
| Provision for income taxes | 166,265 | 431,632 | ... |
| Noncontrolling interest | 7,757,688 | ... | ... |
| Net Income After Extraordinary Items applicable to Common | (2,743,588) | ... | ... |
| Net income (loss) | (10,501,276) | (3,698,144) | (474,585) |
| Selling, general & administrative expense | 11,515,192 | ... | ... |
| Weighted average shares outstanding, common stock subject to redemption - basic | ... | 17,250,000 | 6,462,329 |
| Weighted average | ... | ... | ... |

shares outstanding, non-redeemable common stock - basic 4,502,250 4,029,134
 Weighted average shares outstanding, common stock subject to redemption - diluted 17,250,000 6,462,329
 Weighted average shares outstanding, non-redeemable common stock - diluted 4,502,250 4,029,134
 Weighted average class B shares outstanding - diluted 6,140,529 ...
 Year end shares outstanding 9,387,836 21,752,250 ²¹21,752,250
 Net earnings (loss) per share, common stock subject to redemption - basic ... \$(0.17) \$(0.05)
 Net earnings (loss) per share, non-redeemable common stock - basic \$(0.17) \$(0.05)
 Earnings (loss) per share - basic \$(0.45) ...
 Net earnings (loss) per share, common stock subject to redemption - diluted \$(0.17) \$(0.05)
 Net earnings (loss) per share, non-redeemable common stock - diluted \$(0.17) \$(0.05)
 Full-Time Employees (Period End) 6 ...
 Total number of employees 6 5 2
 Number of common unitholders 33 ...
 Number of class A common stockholders ²⁸28 ³3
 Number of class B common stockholders ¹1 ¹⁹19
 Contingent consideration (1,299,000) ...
 Research and development expenses 329,194 ...
 Shares used to calculate Basic EPS - Total 6,140,529 ...
 EPS - Diluted - including Extraordinary Items Applicable to Common - Total \$(0.45) ...

¹ Non-consolidated; ² Shares increased due to the effect of issuance of class B common stock to initial stockholders and issuance of representative shares to underwriters; ³ As of March 31, 2023; ⁴ As of March 18, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-------------|
| Cash | ... | 127,965 |
| Prepaid expenses | 373,324 | 6,667 |
| Cash and cash equivalents | 28,779,177 | ... |
| Restricted cash | 100,000 | ... |
| Total current assets | 29,252,501 | 134,632 |
| Deferred offering costs | ... | 511,760 |
| Marketable securities held in trust account | ... | 177,790,585 |
| Security deposits | 160,669 | ... |
| Computers, office | ... | ... |

equipment and hardware 16,956 ...
 Furniture and fixtures 47,256 ...
 Machinery and equipment 43,799 ...
 Property, Plant & Equipment - Gross - Total 108,011 ...
 Property, Plant & Equipment - Accumulated Depreciation & Impairment 45,506 ...
 Property, equipment and improvements, net 62,505 ...
 Operating lease right-of-use assets, net 524,813 ...
 Intellectual patented technology 1,925,151 ...
 Total Non-Current Assets 2,673,138 ...
 Total assets 31,925,639 178,436,977
 Accrued liabilities 1,976,812 ...
 Accrued liabilities - Balancing value 1,976,812 ...
 Accounts payable 184,343 ...
 Accounts payable & accrued expenses 5,029,363 ...
 Promissory note - related party 1,950,000 ...
 Interest payable 7,363 ...
 Income taxes payable 312,446 ...
 Deferred tax liability 119,186 ...
 Operating lease liabilities - current portion 297,380 ...
 Total current liabilities 2,458,535 7,418,358
 Deferred underwriters' discount 4,312,500 ...
 Operating lease liabilities 232,162 ...
 Promissory note related party 409,612 ...
 Total Non-Current Liabilities 641,774 ...
 Total liabilities 3,100,309 11,730,858
 Class A common stock subject to possible redemption 177,578,871 ...
 Class A common stock 939 368
 Class B common stock 2,250 82
 Additional paid-in capital 35,014,836 ...
 Accumulated deficit (23,922,730) ...
 Retained earnings (accumulated deficit) (10,873,202) ...
 Total stockholder's equity 11,095,295 (10,872,752)
 Noncontrolling interest 17,730,035 ...
 Total Equity 28,825,330 ...

Recent Dividends:
1. Verde Clean Fuels class C common.
 No dividends paid.
2. Verde Clean Fuels class A common stock subject to possible redemption.
 No dividends paid.
3. Verde Clean Fuels class A common.
 No dividends paid.
4. Verde Clean Fuels class B common.
 No dividends paid.
Annual Dividends:
1. Verde Clean Fuels class C common.
 No dividends paid.
2. Verde Clean Fuels class A common stock subject to possible redemption.
 No dividends paid.
3. Verde Clean Fuels class A common.
 No dividends paid.
4. Verde Clean Fuels class B common.
 No dividends paid.

VERICITY INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 |
|---------------|------|------|------|
| Net insurance | ... | ... | ... |

[Ⓛ] Non-consolidated; [Ⓜ] Includes share-based compensation - general and administrative expenses: \$1,468,000; [Ⓝ] Includes share-based compensation - general and administrative expenses: \$1,716,000; [Ⓞ] Includes share-based compensation - corporate payroll expenses: \$1,716,000; [Ⓟ] Includes share-based compensation - sales and marketing: \$1,468,000; [Ⓠ] Includes share-based compensation - sales and marketing: \$1,716,000; [Ⓡ] Shares increased due to the effect of common stock issued for services, relation to public offering of securities, and restricted stock awards; [Ⓢ] As of March 7, 2022; [Ⓣ] Approximately; [Ⓤ] As of March 16, 2023

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|--------------|--------------|
| | 2023 | 2022 |
| Cash and cash equivalents including restricted cash | 3,095,000 | ... |
| Cash and cash equivalents including restricted cash - Balancing value | 3,032,000 | ... |
| Cash & cash equivalents | ... | 3,411,000 |
| Provision - Accounts & Notes Receivable - Trade | 165,000 | ... |
| Accounts receivable - Balancing value | 3,182,000 | ... |
| Accounts receivable | 3,017,000 | 4,448,000 |
| Unbilled revenue | 1,282,000 | 1,185,000 |
| Prepaid expenses & other current assets | ... | 333,000 |
| Prepaid expenses | 254,000 | ... |
| Inventory | 38,000 | 81,000 |
| Restricted Accounts - Short-Term | 63,000 | ... |
| Total current assets | 7,686,000 | 9,458,000 |
| Property & equipment, net | 240,000 | 292,000 |
| Right of use asset | 468,000 | 469,000 |
| Intangible assets, net | 6,927,000 | 6,412,000 |
| Goodwill | 5,384,000 | 3,988,000 |
| Deferred implementation costs | ... | 133,000 |
| Total assets | 20,705,000 | 20,752,000 |
| Current portion of debt | 500,000 | 500,000 |
| Accounts payable | ... | 3,912,000 |
| Other accrued expense | 988,000 | 902,000 |
| Lease liability - current | 170,000 | 115,000 |
| Accounts payable & other accrued expenses | 3,310,000 | ... |
| Contingent liability-current | 173,000 | ... |
| Total current liabilities | 5,141,000 | 5,429,000 |
| Long-term lease liability | 307,000 | 359,000 |
| Term note | 875,000 | 1,375,000 |
| Long-term derivative liability | ... | 3,000 |
| Accrued interest - related parties | 751,000 | ... |
| Convertible note related party | 475,000 | ... |
| Convertible Note | 625,000 | ... |
| Total liabilities | 8,174,000 | 7,166,000 |
| Common stock | 10,000 | 10,000 |
| Additional paid in capital | 95,031,000 | 92,987,000 |
| Treasury stock as cost | 659,000 | 949,000 |
| Accumulated deficit | (81,849,000) | ... |
| Retained earnings (accumulated deficit) | ... | (78,459,000) |
| Accumulated other comprehensive income (loss) | (2,000) | (3,000) |
| Total stockholders' equity (deficit) | 12,531,000 | 13,586,000 |
| Total Equity | 12,531,000 | ... |

Recent Dividends:

- 1. VerifyMe Inc series A convertible preferred.**
No dividends paid.
- 2. VerifyMe Inc series B convertible preferred.**
No dividends paid.
- 3. VerifyMe Inc common.**
No dividends paid.
- 4. VerifyMe Inc series D convertible preferred.**
No dividends paid.

- 5. VerifyMe Inc series C convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. VerifyMe Inc series A convertible preferred.**
No dividends paid.
 - 2. VerifyMe Inc series B convertible preferred.**
No dividends paid.
 - 3. VerifyMe Inc common.**
No dividends paid.
 - 4. VerifyMe Inc series D convertible preferred.**
No dividends paid.
 - 5. VerifyMe Inc series C convertible preferred.**
No dividends paid.

VERU INC

| Earnings, 3 mos. to Dec 31(Consol. - \$): | | |
|---|--------------------|---------------------|
| | 2023 | 2022 |
| Total revenues | 2,140,726 | 2,507,794 |
| Net Sales | 2,140,726 | 2,507,794 |
| Cost & expenses | 10,023,383 | 39,962,731 |
| Operating income | (7,882,657) | (37,454,937) |
| Other income (expense), net | 79,092 | 220,932 |
| Gains or losses | (379,898) | (670,000) |
| Net before taxes | (8,348,420) | (38,777,235) |
| Income taxes | (72,439) | (68,278) |
| Net income | (8,275,981) | (38,708,957) |
| Earnings common share | | |
| Primary | \$(0.08) | \$(0.48) |
| Fully Diluted | \$(0.08) | \$(0.48) |
| Common Shares: | | |
| Full Diluted | 100,601,946 | 80,558,670 |
| Year-end | 146,381,186 | 80,623,128 |

Consolidated Balance Sheet Items, as of (\$):

| | 2023 | 2022 |
|-----------------------|------------|------|
| Assets: | | |
| Cash & equivalents | 40,579,059 | ... |
| Inventories | 6,912,203 | ... |
| Current assets | 53,344,667 | ... |
| Net property & equip. | 1,560,325 | ... |
| Total assets | 80,566,885 | ... |
| Liabilities: | | |
| Current liabilities | 16,624,753 | ... |
| Long-term debt | 8,883,432 | ... |
| Stockholders' equity | 51,602,272 | ... |
| Net current assets | 36,719,914 | ... |

VIEWBIX INC

Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | [Ⓤ] 2021 |
|---|------------|------------|-------------------|
| Revenues | 79,613,000 | ... | ... |
| Revenues | 79,613,000 | 96,603,000 | 41,000 |
| Gross profit | ... | ... | 41,000 |
| Traffic-acquisition & related costs | 2,893,000 | 83,011,000 | ... |
| Research & development | ... | 3,255,000 | 64,000 |
| Selling & marketing | ... | 2,479,000 | 2,000 |
| Wages, salaries & related expenses | ... | ... | 140,000 |
| Salaries & related expenses | ... | 1,099,000 | ... |
| Professional fees | ... | ... | 150,000 |
| Professional services | ... | 904,000 | ... |
| Share-based compensation | ... | (2,000) | ... |
| Other general & administrative expenses | 2,805,000 | 156,000 | 14,000 |
| General & administrative | 2,877,000 | 2,157,000 | 304,000 |
| Other expenses (income) | ... | ... | 25,000 |
| Depreciation & amortization expenses | 2,952,000 | 2,809,000 | ... |
| Business acquisition & related costs | 70,451,000 | 166,000 | ... |
| Goodwill impairment | 5,107,000 | ... | ... |
| Total operating expenses | ... | ... | 395,000 |
| Income (loss) from | | | |

| | | | |
|---|--------------------|--------------------|------------------------|
| operations | (7,472,000) | 2,726,000 | (354,000) |
| Exchange rate differences | (347,000) | 187,000 | ... |
| Interest income on loan to Parent company | 87,000 | 143,000 | ... |
| Finance income | ... | ... | 1,000 |
| Bank interest & fees | 73,000 | 133,000 | ... |
| Interest expense on bank loans | 916,000 | 565,000 | ... |
| Interest expense on loans from parent company | ... | 52,000 | ... |
| Exchange rate differences | ... | (858,000) | ... |
| Other finance expense | ... | (178,000) | ... |
| Finance expense | (16,000) | ... | 31,000 |
| Financial income (expenses), net | (1,281,000) | (1,456,000) | ... |
| Income (loss) before taxes on income - United States of America | ... | (595,000) | 164,000 |
| Income (loss) before taxes on income - Israel | ... | 1,865,000 | 220,000 |
| Income (loss) before taxes on income | (8,753,000) | 1,270,000 | (384,000) |
| Current tax expenses | ... | 782,000 | ... |
| Tax benefit in respect of prior years | ... | (84,000) | ... |
| Deferred tax income | ... | (545,000) | ... |
| Taxes on income | (66,000) | 153,000 | 2,000 |
| Net income (loss) | (8,687,000) | 1,117,000 | (386,000) |
| Less: net income (loss) attributable to non-controlling interests | 1,364,000 | (1,089,000) | ... |
| Net income (loss) attributable to shareholders of Viewbix Inc. | (7,323,000) | 28,000 | ... |
| Net income (loss) attributable to ordinary stockholders | ... | ... | (386,000) |
| Weighted average shares outstanding - basic | 14,866,230 | 14,783,964 | [Ⓜ] 1,241,202 |
| Weighted average shares outstanding - diluted | 14,866,230 | 15,044,630 | [Ⓜ] 1,241,202 |
| Year end shares outstanding | 14,920,585 | 14,783,964 | [Ⓜ] 1,241,202 |
| Income (loss) per share - continuing operations - basic | \$(0.49) | ... | ... |
| Net income (loss) per share - basic | \$(0.49) | \$0.00 | [Ⓜ] \$(0.31) |
| Income (loss) per share - continuing operations - diluted | \$(0.49) | ... | ... |
| Net income (loss) per share - diluted | \$(0.49) | \$0.00 | [Ⓜ] \$(0.31) |
| Number of full time employees | ... | [Ⓝ] 51 | ... |
| Total number of employees | ... | ... | 2 |
| Number of common stockholders | 2,690 | [Ⓞ] 2,689 | [Ⓟ] 2,692 |

[Ⓠ] 2021 and prior periods for Viewbix Inc prior to reverse acquisition with Gix Media Ltd; [Ⓡ] Adjusted for 1-for-28 stock split, September 6, 2022; [Ⓢ] As of March 9, 2023; [Ⓣ] Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------|------|
|--|------|------|

| | | | |
|---|---------------------|------------------------|------------------------|
| Income (loss) from operations | (15,689,789) | (21,845,133) | (12,025,500) |
| Interest expense | ... | ... | 92,822 |
| Other income | 500,281 | 194,413 | 62,259 |
| Total other income (expense) | 500,281 | 194,413 | (30,563) |
| Income (loss) before tax provision | (15,189,508) | (21,650,720) | (12,056,063) |
| Net income (loss) | (15,189,508) | (21,650,720) | (12,056,063) |
| Weighted average shares outstanding - basic | 1,171,233 | [□] 1,171,219 | 667,727 |
| Weighted average shares outstanding - diluted | 1,171,233 | [□] 1,171,219 | 667,727 |
| Year end shares outstanding | 1,171,233 | [□] 1,171,428 | [□] 1,171,489 |
| Net earnings (loss) per share - basic | \$(12.97) | [□] \$(18.50) | \$(18.10) |
| Net earnings (loss) per share - diluted | \$(12.97) | [□] \$(18.50) | \$(18.10) |
| Number of full time employees | ... | [□] 7 | [□] 7 |
| Common Shareholders - Number | 38 | ... | ... |
| Number of stockholders | ... | [□] 39 | [□] 40 |

[□] Adjusted for 1-for-10 stock split, March 1, 2024; [□] Stocks increased due to the effect of issuance in pursuant to underwritten public offering, for to initial public offering and cashless stock options and warrants exercised; [□] As of March 21, 2023; [□] As of March 31, 2022; [□] Approximately; [□] As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash | 9,141,512 | 18,995,284 |
| Prepaid insurance | 136,241 | 156,754 |
| Research & development | 283,370 | 496,270 |
| Other prepaid expenses & current assets | 67,222 | 25,341 |
| Prepaid expenses & other current assets | 486,833 | 678,365 |
| Total current assets | 9,628,345 | 19,673,649 |
| Total assets | 9,628,345 | 19,673,649 |
| Accrued payroll | 493,780 | 654,765 |
| Deferred CEO compensation | 1,694,024 | ... |
| Research & development expenses | ... | 254,904 |
| Legal expenses | 97,089 | 147,277 |
| Professional fees | 230,627 | ... |
| Other accounts payable & accrued expenses | ... | 37,644 |
| Accounts payable & accrued expenses | 711,000 | 1,094,590 |
| Estimated litigation liability | 6,000,000 | 2,000,000 |
| Other | 143,071 | ... |
| Other | 18,457 | ... |
| Total current liabilities | 7,694,024 | 3,094,590 |
| Total liabilities | 7,694,024 | 3,094,590 |
| Common stock | 12 | 117 |
| Additional paid-in capital | 61,478,444 | 60,933,569 |
| Retained earnings (accumulated deficit) | (59,544,135) | (44,354,627) |
| Total stockholders' equity (deficit) | 1,934,321 | 16,579,059 |
| Total Equity | 1,934,321 | ... |

Recent Dividends:
1. Virpax Pharmaceuticals Inc common.
 No dividends paid.
Annual Dividends:
1. Virpax Pharmaceuticals Inc common.
 No dividends paid.

VIRTRA INC Annual Report Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|------------------|------------------|-------------------------|
| Net sales | 38,043,360 | 28,302,244 | 24,434,056 |
| Total revenues | 38,043,360 | 28,302,244 | 24,434,056 |
| Cost of sales | 11,378,264 | 12,047,366 | 13,028,844 |
| Gross profit | 26,665,096 | 16,254,878 | 11,405,212 |
| General & administrative expenses | 14,235,194 | 11,054,333 | 8,085,295 |
| Research & development expense | 2,794,314 | 2,606,840 | 1,865,880 |
| Net operating expense | 17,029,508 | 13,661,173 | 9,951,175 |
| Income (loss) from operations | 9,635,588 | 2,593,705 | 1,454,037 |
| Other income | 888,464 | 194,523 | 97,100 |
| Gain on forgiveness of note payable | ... | ... | 1,320,714 |
| Other income (expense) | ... | 260,688 | 85,712 |
| Other income (expenses) | (302,382) | ... | ... |
| Net other income (expense) | 586,082 | (66,165) | 1,332,102 |
| Income (loss) before provision for income taxes | 10,221,670 | 2,527,540 | 2,786,139 |
| Current income tax expense | 4,924,686 | 1,136,170 | 28,283 |
| Deferred income tax expense | (3,105,874) | (564,528) | 217,767 |
| Income tax expense/(benefit) | 1,818,812 | 571,642 | 246,050 |
| Net income (loss) | 8,402,858 | 1,955,898 | 2,540,089 |
| Weighted average shares outstanding - basic | 10,958,448 | 10,863,680 | 10,007,386 |
| Weighted average shares outstanding - diluted | 10,963,477 | 10,873,606 | 10,060,748 |
| Year end shares outstanding | 11,107,230 | 10,924,724 | [□] 10,807,130 |
| Net earnings (loss) per share before accounting change-basic | \$0.77 | ... | ... |
| Net income (loss) per share - basic | \$0.77 | \$0.18 | \$0.25 |
| Net earnings (loss) per share before accounting change-diluted | \$0.77 | ... | ... |
| Net income (loss) per share - diluted | \$0.77 | \$0.18 | \$0.25 |
| Total number of employees | 112 | ... | ... |
| Number of full time employees | 112 | [□] 121 | [□] 121 |
| Number of Common Shareholders | 39 | ... | ... |
| Number of stockholders | ... | [□] 36 | [□] 38 |

[□] Shares increased due to the effect of stock options exercised, stock issued for cash in offering, net, stock issued for services; [□] As of March 10, 2023; [□] As of July 25, 2022; [□] Approximately; [□] As of March 30, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---------------------------------|------------|------------|
| Cash & cash equivalents | 18,849,842 | 13,483,597 |
| Accounts receivable, gross | ... | 3,037,926 |
| Reserve for doubtful accounts | ... | 35,039 |
| Accounts receivable, net | 15,724,147 | 3,002,887 |
| Raw materials | 12,834,368 | ... |
| Raw materials & work in process | ... | 9,894,759 |
| Less: reserves | ... | 302,431 |
| Inventory | 12,404,880 | ... |
| Reserve | (429,488) | ... |
| Inventory, net | ... | 9,592,328 |
| Unbilled revenue | 1,109,616 | 7,485,990 |

| | (revised) | | |
|---|------------|------------|--|
| Prepaid expenses & other current assets | 906,803 | 531,051 | |
| Total current assets | 48,995,288 | 34,095,853 | |
| Land | 1,778,987 | 1,778,987 | |
| Building & building improvements | 9,146,556 | 9,129,364 | |
| Computer equipment | 1,236,989 | 1,210,021 | |
| Furniture & office equipment | 295,208 | 289,379 | |
| Machinery & equipment | 2,865,014 | 2,788,803 | |
| Subscription Training Equipment Partnership | ... | ... | |
| equipment | 2,241,291 | 1,954,430 | |
| Leasehold improvements | 358,584 | 347,384 | |
| Construction in progress | 2,456,259 | 1,749,332 | |
| Less: accumulated depreciation & amortization | 4,888,876 | 3,980,567 | |
| Property & equipment, net | 15,487,012 | 15,267,133 | |
| Operating lease right of use asset | 716,687 | 1,212,814 | |
| Intangible assets, net | 567,540 | 587,777 | |
| Security deposits, long-term | 35,691 | 35,691 | |
| Other assets, long-term | 201,670 | 376,461 | |
| Deferred tax asset, net | 3,630,154 | 2,238,762 | |
| Total assets | 69,634,042 | 53,814,491 | |
| Accounts payable | 2,282,427 | 1,251,240 | |
| Accrued salaries & wages payable | 457,565 | 502,940 | |
| Employee benefits payable | 54,811 | 31,618 | |
| Accrued paid time off | 361,418 | 590,491 | |
| Accrued property tax | 354,000 | ... | |
| Accrued profit sharing payable | 3,970,559 | 369,841 | |
| Accrued compensation & related costs | 2,221,416 | 1,494,890 | |
| Manufacturer's warranties | ... | 358,000 | |
| Taxes payable | 3,411,669 | 1,294,110 | |
| Miscellaneous payable | 204,890 | 265,812 | |
| Note payable, current | 226,355 | 232,537 | |
| Operating lease liability, short-term | 317,840 | 557,683 | |
| Deferred revenue, short-term | 6,736,175 | 4,302,492 | |
| Profit sharing payable | 1,347,622 | ... | |
| Total current liabilities | 15,754,772 | 9,756,764 | |
| Deferred revenue, long-term | 3,012,206 | 1,605,969 | |
| Note payable, long-term | 7,813,021 | 8,050,116 | |
| Operating lease liability, long-term | 432,176 | 720,023 | |
| Total non-current liabilities | 11,257,403 | 10,376,108 | |
| Total liabilities | 27,012,175 | 20,132,872 | |
| Common stock | 1,109 | 1,089 | |
| Additional paid-in capital | 31,957,765 | 31,420,395 | |
| Retained earnings | 10,662,993 | ... | |
| Retained earnings (accumulated deficit) | ... | 2,260,135 | |
| Total stockholders' equity (deficit) | 42,621,867 | 33,681,619 | |
| Total Equity | 42,621,867 | ... | |

Recent Dividends:
1. VirTra Inc common.
 No dividends paid.
Annual Dividends:
1. VirTra Inc common.
 No dividends paid.

VISIONEERING TECHNOLOGIES INC Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2021 | [□] 2020 |
|-------------------|-----------|-----------|-------------------|
| Net sales | 8,670,000 | ... | ... |
| Net revenue | 8,670,000 | 7,154,000 | 5,105,000 |
| Cost of sales | 3,910,000 | 4,187,000 | 2,881,000 |
| Gross profit | 4,760,000 | 2,967,000 | 2,224,000 |
| Sales & marketing | 3,592,000 | 4,897,000 | 5,179,000 |
| Clinical & | ... | ... | ... |

| | | | | | | | | | | |
|---|-------------|-------------|-------------|---|--------------|--------------|--|---------|----------|---------|
| manufacturing | 2,184,000 | 2,144,000 | 1,438,000 | equipment, gross | ... | 229,000 | before income taxes | 16,970 | 1,171 | 10,781 |
| General & administrative expenses | 2,974,000 | 3,194,000 | 3,319,000 | Less: accumulated depreciation | ... | 220,000 | Current federal income tax provision (benefit) | 1,213 | ... | ... |
| Total operating expenses | 8,750,000 | 10,235,000 | 9,936,000 | Property, plant & equipment, net | ... | 9,000 | Current domestic income tax provision (benefit) | ... | 1,097 | 87 |
| Operating income (loss) | (3,990,000) | (7,268,000) | (7,712,000) | Right to use assets, net | 182,000 | 98,000 | Current foreign income tax provision (benefit) | (920) | 4,233 | 3,968 |
| Interest income & other, net | 471,000 | ... | 9,000 | Patents -Net | 289,000 | ... | Total current income tax provision (benefit) | 293 | 5,330 | 4,055 |
| Interest expense | 83,000 | 322,000 | 334,000 | Intangible assets, net | ... | 162,000 | Deferred domestic income tax provision (benefit) | ... | 1,379 | 2,458 |
| Gain (loss) on extinguishment of paycheck protection program note payable | ... | 921,000 | ... | Other non-current assets | 8,000 | 197,000 | Deferred federal income tax provision (benefit) | 2,170 | ... | ... |
| Gain (loss) on fair value of derivative liability | 99,000 | 128,000 | (130,000) | Total assets | 7,646,000 | 14,914,000 | Deferred foreign income tax provision (benefit) | 1,071 | (2,182) | (295) |
| Gain (loss) on fair value of freestanding options | 56,000 | 4,212,000 | (1,069,000) | Account payable | 493,000 | 543,000 | Total deferred income tax provision (benefit) | 3,241 | (803) | 2,163 |
| Income (loss) before income taxes | (3,447,000) | (2,329,000) | (9,236,000) | Accrued payroll | 610,000 | 583,000 | Income tax provision (benefit) | 3,534 | 4,527 | 6,218 |
| Current state income tax expense | 4,000 | 5,000 | 3,000 | Derivative liability | ... | 325,000 | Net income (loss) | 13,436 | (3,356) | 4,563 |
| Total current income tax expense | 4,000 | 5,000 | 3,000 | Other accrued liabilities | 653,000 | 668,000 | Less: net income (loss) attributable to noncontrolling interests | 70 | 137 | 179 |
| Deferred federal income tax expense (benefit) | (899,000) | (1,551,000) | (1,660,000) | Operating Lease Liabilities - Current Portion/Short-Term | 81,000 | ... | Net income (loss) attributable to Viskase Companies, Inc | 13,506 | (3,219) | 4,742 |
| Deferred state income tax expense (benefit) | (223,000) | (393,000) | (467,000) | Other accrued liabilities - Balancing value | 572,000 | ... | Weighted average shares outstanding - basic | 103,191 | 103,191 | 64,698 |
| Total deferred income tax expense (benefit) | ... | (1,944,000) | (2,127,000) | Total current liabilities | 1,756,000 | 2,119,000 | Weighted average shares outstanding - diluted | 103,191 | 103,191 | 64,698 |
| Valuation allowance | 1,122,000 | 1,944,000 | 2,127,000 | Convertible notes payable | ... | 2,741,000 | Year end shares outstanding | 103,191 | 103,191 | 103,191 |
| Income tax expense | 4,000 | 5,000 | 3,000 | Other non-current liabilities | 132,000 | 9,000 | Income (loss) per share from continuing operations - basic | \$0.13 | ... | ... |
| Net income (loss) | (3,451,000) | (2,334,000) | (9,239,000) | Total liabilities | 1,888,000 | 4,869,000 | Net income (loss) per share - basic | \$0.13 | \$(0.03) | \$0.07 |
| Weighted average shares outstanding - basic | 34,851,715 | 20,588,557 | 7,455,107 | Common stock | 52,000 | 24,000 | Income (loss) per share from continued operations - diluted | \$0.13 | \$(0.03) | \$0.07 |
| Weighted average shares outstanding - diluted | 34,851,715 | 20,588,557 | 7,455,107 | Additional paid-in capital | 98,168,000 | 93,178,000 | | | | |
| Year end shares outstanding | 52,378,773 | 23,635,500 | 9,932,776 | Retained earnings (accumulated deficit) | (92,462,000) | (83,157,000) | | | | |
| Net earnings (loss) per share - basic | \$(0.10) | \$(0.11) | \$(1.24) | Total Stockholders' equity | 5,758,000 | 10,045,000 | | | | |
| Net earnings (loss) per share - diluted | \$(0.10) | \$(0.11) | \$(1.24) | Total Equity | 5,758,000 | ... | | | | |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.10) | ... | ... | | | | | | | |
| EPS - Diluted - excluding Extraordinary Items Applicable to Common - Total | \$(0.10) | ... | ... | | | | | | | |
| <p>As reported from the December 31, 2021 Annual Report; Shares increased due to the effect of issuance of stock through March 2021 placement & SPP, rounding adjustments for reverse stock split</p> | | | | <p>Recent Dividends:</p> <p>1. Visioneering Technologies Inc preferred. No dividends paid.</p> <p>2. Visioneering Technologies Inc class A common. No dividends paid.</p> <p>3. Visioneering Technologies Inc common. No dividends paid.</p> <p>Annual Dividends:</p> <p>1. Visioneering Technologies Inc preferred. No dividends paid.</p> <p>2. Visioneering Technologies Inc class A common. No dividends paid.</p> <p>3. Visioneering Technologies Inc common. No dividends paid.</p> | | | | | | |
| <p>Consolidated Balance Sheet, Years Ended Dec. 31 (\$):</p> | | | | <p>VISKASE COS, INC.</p> <p>Annual Report</p> <p>Consolidated Income Statement, Years Ended Dec. 31 (\$000):</p> | | | | | | |
| | 2023 | 2021 | | | 2023 | 2021 | 2020 | | | |
| Cash & cash equivalents | 2,999,000 | 10,985,000 | | Net sales | 445,984 | 415,672 | 408,887 | | | |
| Accounts receivable | 966,000 | 909,000 | | Total revenues | 445,984 | ... | ... | | | |
| Inventory | 2,161,000 | ... | | Cost of sales | 352,221 | 343,636 | 327,850 | | | |
| Inventory, net | ... | 1,408,000 | | Gross margin | 93,763 | 72,036 | 81,037 | | | |
| Prepaid expenses & other current assets | 1,041,000 | 1,146,000 | | Selling, general & administrative expenses | 52,436 | 48,169 | 49,812 | | | |
| Total current assets | 7,167,000 | 14,448,000 | | Amortization of intangibles | 1,606 | 1,755 | 1,657 | | | |
| Computer equipment & software | ... | 116,000 | | Asset impairment charge | 338 | 498 | 372 | | | |
| Office equipment | ... | 49,000 | | Restructuring expense (income) | ... | 507 | 398 | | | |
| Furniture & fixtures | ... | 52,000 | | Operating income (loss) | 39,383 | 21,107 | 28,798 | | | |
| Leasehold improvements | ... | 12,000 | | Interest income | ... | ... | 19 | | | |
| Property, plant & equipment, gross | ... | ... | | Interest expense, net | 12,018 | 6,157 | 11,396 | | | |
| Less: accumulated depreciation | ... | ... | | Loss on early extinguishment of debt | ... | ... | (280) | | | |
| Acc Depr. Land and improvements | ... | ... | | Other income (expense), net | (10,395) | (13,779) | (6,360) | | | |
| Acc Depr. Buildings and | ... | ... | | Income (loss) before income taxes - domestic | (2,995) | (4,680) | 6,922 | | | |
| | | | | Income (loss) before income taxes - foreign | 19,965 | 5,851 | 3,860 | | | |
| | | | | Income (loss) | ... | ... | ... | | | |

| | | | | | | | | | | |
|---|--------------|--------------|-------------|--|--------------|--------------|-------------|---|--------------|------------|
| | | | | Deferred state income taxes | 59,440 | (3,082,578) | (332,139) | manufacturing equipment | 507,620 | 524,025 |
| Recent Dividends: | | | | Deferred income taxes | 88,323 | ... | (1,051,007) | Finance lease right-of-use assets - | | |
| 1. Vislink Technologies Inc series A convertible preferred. | | | | Consolidated net loss | (10,835,275) | ... | ... | Gross | 3,579,544 | 3,579,544 |
| No dividends paid. | | | | Income Taxes - Total - Current | 4,380 | ... | ... | Equipment- Gross | 942,880 | 801,313 |
| 2. Vislink Technologies Inc common. | | | | Provision for (benefit from) income taxes | 92,703 | (4,436,691) | (1,050,207) | Equipment - Accumulated Depreciation & Impairment | 435,260 | 277,288 |
| No dividends paid. | | | | Net income (loss) | (10,835,275) | (20,247,621) | (7,654,660) | Office furniture and equipment | 7,175 | 9,086 |
| 3. Vislink Technologies Inc series A preferred. | | | | Net income (loss) attributable to Vivakor, Inc. | (10,738,625) | (19,438,422) | (5,484,171) | Construction in Progress | 21,669,266 | 18,665,152 |
| No dividends paid. | | | | Dividend on preferred stock | ... | ... | 42,196 | - Net | 21,669,266 | 18,665,152 |
| Annual Dividends: | | | | Net income (loss) attributable to Vivakor, Inc. | (10,738,625) | (19,438,422) | (5,484,171) | Finance lease right-of-use assets - Accumulated Depreciation | 1,484,324 | 349,253 |
| 1. Vislink Technologies Inc series A convertible preferred. | | | | Weighted average shares outstanding - basic | 19,261,143 | 15,985,103 | 11,976,116 | Property Net | 17,000 | 140,000 |
| No dividends paid. | | | | Weighted average shares outstanding - diluted | 19,261,143 | 15,985,103 | 11,976,116 | Property & equipment, net | 24,299,317 | 22,578,876 |
| 2. Vislink Technologies Inc common. | | | | Year end shares outstanding | 26,220,508 | 18,064,838 | 12,330,859 | Royalty participation rights, net | ... | 1,772,153 |
| No dividends paid. | | | | Net earnings (loss) per share - basic | \$(0.56) | \$(1.22) | \$(0.46) | Right-of-use assets - operating leases | 1,534,870 | 1,880,056 |
| 3. Vislink Technologies Inc series A preferred. | | | | Net earnings (loss) per share - diluted | \$(0.56) | \$(1.22) | \$(0.46) | Licenses agreements, net | 1,651,324 | ... |
| No dividends paid. | | | | Number of full time employees | ... | ... | 25 | Intellectual property, net | 23,437,654 | 28,251,053 |
| VIVAKOR INC | | | | Full-Time Employees (Period End) | 5 | 10 | ... | Finance lease right-of-use assets, net | 2,095,220 | 3,230,291 |
| Annual Report | | | | Total number of employees | 5 | 10 | ... | Goodwill | 14,984,768 | 12,678,108 |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | | Number of common stockholders | 534 | 559 | 570 | Total assets | 71,235,743 | 76,342,500 |
| | 2023 | 2022 | 2021 | Basic EPS Excluding ExtraOrdinary Items | \$(0.56) | \$(1.22) | ... | Accounts payable | 5,226,071 | 5,022,302 |
| Impairment of tangible assets | ... | 11,138,830 | ... | As of April 5, 2022 | | | | Office access deposits | 669,747 | 235 |
| Product sales revenues | ... | 28,107,223 | ... | Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | | | Accrued compensation | 1,968,063 | 1,302,890 |
| Research services revenues | ... | 21,458,150 | ... | | 2023 | 2022 | | Accrued tax penalties & interest | 9,107,297 | 524,286 |
| Product revenue - related party | 46,252,141 | 6,649,073 | ... | Cash & cash equivalents | 744,307 | 3,101,186 | | Operating leases liabilities, current | 435,906 | 471,991 |
| Product revenue - related party | 13,069,611 | ... | ... | Cash & cash equivalents attributed to variable interest entity | ... | 81,607 | | Loans & notes payable, current | ... | 885,204 |
| Revenues | 59,321,752 | 28,107,223 | 1,088,428 | Accounts receivable, gross | ... | 3,563,706 | | Loans & notes payable, current attributed to variable interest entity | ... | 1,924,500 |
| Cost of revenues | 54,300,788 | 25,239,962 | 1,050,676 | Accounts receivable-related party | 174,083 | ... | | Long-term debt, current | 2,477,970 | 9,363 |
| Gross profit (loss) | 5,020,964 | 2,867,261 | 37,752 | Accounts receivable | 2,458,730 | ... | | Loans & advances from related parties | 1,933,817 | ... |
| Cost of revenues | ... | 392,914 | ... | Accounts receivable | ... | 3,563,706 | | Grant payable | 16,578,642 | 8,688,535 |
| Sales & marketing expenses | 3,070 | ... | 849,107 | Marketable securities | 495,826 | 1,652,754 | | Working interest payable | 1,396,528 | 380,175 |
| General & administrative expenses | 7,416,810 | 9,963,836 | 4,652,069 | Inventories | 44,632 | 47,180 | | Finance lease liabilities, current | 963,900 | 963,900 |
| Bad debt expense | ... | 1,162,007 | ... | Prepaid expenses & other assets | 1,118,188 | 700,298 | | Accrued interest | 178,999 | 1,437,711 |
| Amortization & depreciation expenses | 3,932,744 | 2,953,629 | 1,462,492 | Prepaid expenses & deposits | 74,876 | 31,523 | | Unearned Revenue | ... | 20,936 |
| Depreciation | 148,603 | 638,073 | ... | Total current assets | 5,110,642 | 9,178,254 | | Loans and notes payable, current- related parties | 15,626,168 | ... |
| Amortization of Intangibles excluding Goodwill | 3,784,141 | 2,315,556 | ... | Other investments | 4,000 | 4,000 | | Accounts payable and accrued expenses- related parties | 1,933,817 | ... |
| Total operating expenses | 11,352,624 | 25,611,216 | 6,963,668 | Notes receivable | 213,168 | ... | | Total current liabilities | 39,984,466 | 12,943,493 |
| Income (loss) from operations | (6,331,660) | (22,743,955) | (6,925,916) | Office furniture & equipment, gross | 14,998 | 14,998 | | Long-term notes payable | 856,034 | 28,683,950 |
| Gain (loss) on disposition of asset | ... | (578,464) | 87,044 | Less: accumulated depreciation - office furniture & equipment | 7,823 | 5,912 | | Operating leases liabilities, long term | 1,193,915 | 1,457,483 |
| Unrealized gain (loss) on marketable securities | (1,156,928) | ... | (1,094,054) | Office furniture & equipment, net | 17,000 | 140,000 | | Loans & notes payable, long term | 5,590,008 | ... |
| Gain (loss) on disposition of assets | ... | 2,456 | ... | Vehicles, gross | 36,432 | 36,432 | | Long-term debt | 4,433,630 | 3,897,553 |
| Interest income | 14,953 | 23,725 | 3,312 | Less: accumulated depreciation - vehicles | 33,396 | 26,110 | | Deferred income tax liabilities | 88,323 | ... |
| Interest expense-related parties | 3,058,940 | ... | ... | Vehicles, net | 3,036 | 10,322 | | Finance lease liabilities - Long-Term | 1,852,178 | 2,298,960 |
| Interest expense | 966,137 | ... | ... | Construction in progress - bioreactors & Laboratory & | 21,669,266 | 18,665,152 | | Total liabilities | 53,998,554 | 49,281,439 |
| Interest expense | ... | 1,519,281 | 900,552 | | | | | Common stock | 26,221 | 18,065 |
| Other income | 318,041 | 131,207 | 125,299 | | | | | Additional paid-in capital, common stock | 83,097,553 | 74,026,163 |
| Gain on deconsolidation of variable interest entity | 438,099 | ... | ... | | | | | Treasury stock, at cost | 20,000 | ... |
| Total other income (loss) | ... | ... | (1,778,951) | | | | | Treasury stock | ... | 20,000 |
| Earnings (loss) before provision for income taxes | (10,742,572) | (24,684,312) | (8,704,867) | | | | | Accumulated deficit | (65,908,406) | ... |
| Current state income taxes | 4,380 | ... | 800 | | | | | Recent Dividends: | | |
| Current-State | ... | 800 | ... | | | | | 1. Vivakor Inc series B-I preferred. | | |
| Total current income taxes | ... | ... | 800 | | | | | No dividends paid. | | |
| Deferred federal income taxes | 28,883 | (1,354,913) | (718,868) | | | | | | | |

2. Vivakor Inc series B preferred.
No dividends paid.

3. Vivakor Inc series A preferred.
No dividends paid.

4. Vivakor Inc series C-1 preferred.
No dividends paid.

5. Vivakor Inc common.
No dividends paid.

Annual Dividends:

1. Vivakor Inc series B-1 preferred.
No dividends paid.

2. Vivakor Inc series B preferred.
No dividends paid.

3. Vivakor Inc series A preferred.
No dividends paid.

4. Vivakor Inc series C-1 preferred.
No dividends paid.

5. Vivakor Inc common.
No dividends paid.

VIVANI MEDICAL, INC.
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|---------------------|---------------------|--------------------|
| Cost of sales | ... | ... | (130,000) |
| Gross profit (loss) | ... | ... | 130,000 |
| Research & development expenses, net of grants | 16,968,000 | 14,169,000 | 2,370,000 |
| Clinical & regulatory expenses, net of grants | ... | ... | 378,000 |
| General & administrative expenses | 9,997,000 | 7,072,000 | 6,315,000 |
| Total operating expenses | 26,965,000 | 21,241,000 | 9,063,000 |
| Income (loss) from operations | (26,965,000) | (21,241,000) | (8,933,000) |
| Interest income | ... | ... | 12,000 |
| Other income | 1,313,000 | 475,000 | ... |
| Gain on bargain purchase | ... | 6,877,000 | ... |
| Net income (loss) | (25,652,000) | (13,889,000) | (8,921,000) |
| Weighted average shares outstanding - basic | 50,853,000 | 38,241,000 | 10,939,000 |
| Weighted average shares outstanding - diluted | 50,853,000 | 38,241,000 | 10,939,000 |
| Year end shares outstanding | 51,031,000 | 50,735,770 | 13,136,333 |
| Net income (loss) per share - basic | \$(0.50) | \$(0.36) | \$(0.81) |
| Net income (loss) per share - diluted | \$(0.50) | \$(0.36) | \$(0.81) |
| Full-Time Employees (Period End) | 44 | ... | ... |
| Total number of employees | 44 | 50 | 15 |
| Number of common stockholders | 110 | 123 | 77 |
| Foreign currency translation adjustments | ... | 35,000 | 69,000 |
| Net Income Before Tax | (25,652,000) | ... | ... |
| Non-operating Income/(Expense), Net | 1,313,000 | ... | ... |
| Diluted EPS - Net Income excl Extra Items applicable to Common - (Company Level) | \$(0.50) | ... | ... |
| EPS - Basic - excluding Extraordinary Items Applicable to Common - Total | \$(0.50) | ... | ... |

2021 and prior periods for Second Sight Medical Products, Inc prior to reverse merger with Nano Precision Medical, Inc; Adjusted for 1-for-3 stock split, August 19, 2022; Shares increased due to issuance of common stock and exercise of underwriter's warrants; Approximately; As of March 24, 2023; As of March 17, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|--------------|--------------|
| Cash & cash equivalents | 20,654,000 | 45,076,000 |
| Prepaid expenses & other current assets | 2,408,000 | 2,452,000 |
| Total current assets | 23,062,000 | 47,528,000 |
| Equipment | 3,511,000 | 3,520,000 |
| Furniture | ... | 10,000 |
| Leasehold improvements | ... | 12,000 |
| Computer software costs | 7,000 | 51,000 |
| Computer hardware & software | 354,000 | ... |
| Property and equipment, gross | 4,171,000 | 3,593,000 |
| Construction In Progress | 299,000 | ... |
| Property & equipment, net | 1,729,000 | 1,182,000 |
| Right-of-use asset | 19,616,000 | 779,000 |
| Restricted cash | 1,338,000 | 1,366,000 |
| Deposits & other assets | 52,000 | 275,000 |
| Total assets | 45,797,000 | 51,130,000 |
| Accounts payable | 542,000 | 1,177,000 |
| Accrued expenses | 1,727,000 | 2,358,000 |
| Litigation accrual | 1,675,000 | 1,675,000 |
| Accrued compensation expense | 396,000 | 657,000 |
| Current operating lease liabilities | 1,383,000 | 955,000 |
| Total current liabilities | 5,723,000 | 6,822,000 |
| Long term operating lease liabilities | 19,313,000 | ... |
| Common stock | 5,000 | 109,050,000 |
| Additional paid-in capital | 119,054,000 | 8,009,000 |
| Accumulated other comprehensive income (loss) | 140,000 | 35,000 |
| Accumulated deficit | (98,438,000) | ... |
| Retained earnings (accumulated deficit) | ... | (72,786,000) |
| Total liabilities | 25,036,000 | 6,822,000 |
| Total stockholders' equity (deficit) | 20,761,000 | 44,308,000 |
| Total Equity | 20,761,000 | ... |

2021 and prior periods for Second Sight Medical Products, Inc prior to reverse merger with Nano Precision Medical, Inc

Recent Dividends:

1. Vivani Medical, Inc. common.
No dividends paid.

Annual Dividends:

1. Vivani Medical, Inc. common.
No dividends paid.

VIVOS THERAPEUTICS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|---------------------|---------------------|---------------------|
| Cost of sales (exclusive of depreciation and amortization shown separately below) | 5,530,000 | ... | ... |
| Product revenue | 6,270,000 | 8,381,000 | 6,520,000 |
| Service revenue | 7,531,000 | 7,643,000 | 10,365,000 |
| Total revenue | 13,801,000 | 16,024,000 | 16,885,000 |
| Cost of sales | ... | 6,005,000 | 4,281,000 |
| Gross profit | 8,271,000 | 10,019,000 | 12,604,000 |
| General & administrative expenses | ... | ... | ... |
| Sales & marketing expenses | 2,467,000 | 5,340,000 | 5,551,000 |
| Impairment loss | ... | ... | 911,000 |
| Depreciation & amortization expenses | 621,000 | 669,000 | 733,000 |
| Total operating expenses | 25,567,000 | 35,050,000 | 32,986,000 |
| Operating income (loss) | (17,296,000) | (25,031,000) | (20,382,000) |
| Interest expense | ... | ... | 14,000 |
| Other expense | 212,000 | 190,000 | 9,000 |
| Payroll Protection Program loan forgiveness | ... | 1,287,000 | ... |
| Other income | 147,000 | 89,000 | 117,000 |
| Income (loss) before income taxes - domestic | ... | (23,945,000) | (20,307,000) |
| Income (loss) before income taxes - foreign | ... | 100,000 | 19,000 |
| Income (loss) before income taxes | (13,583,000) | (23,845,000) | (20,288,000) |
| Net income (loss) | (13,583,000) | (23,845,000) | (20,288,000) |
| Net income (loss) attributable to common stockholders | ... | (23,845,000) | (20,288,000) |
| Weighted average shares outstanding - basic | 1,219,381 | 920,485 | 849,339 |
| Weighted average shares outstanding - diluted | 1,219,381 | 920,485 | 849,339 |
| Year end shares outstanding | 1,833,877 | 920,485 | 920,485 |
| Net earnings (loss) per share - basic | \$(11.14) | \$(26.00) | \$(24.00) |
| Net earnings (loss) per share - diluted | \$(11.14) | \$(26.00) | \$(24.00) |
| Number of full time employees | 114 | 154 | 158 |
| Number of part time employees | ... | 9 | 9 |
| Total number of employees | 114 | 163 | 167 |
| Number of common stockholders | 7,309 | 560 | 5,400 |
| Change in fair value of warrant liability | 10,231,000 | ... | ... |
| Excess warrant fair value | (6,453,000) | ... | ... |

expenses

Sales & marketing expenses

Impairment loss

Depreciation & amortization expenses

Total operating expenses

Operating income (loss)

Interest expense

Other expense

Payroll Protection Program loan forgiveness

Other income

Income (loss) before income taxes - domestic

Income (loss) before income taxes - foreign

Income (loss) before income taxes

Net income (loss)

Net income (loss) attributable to common stockholders

Weighted average shares outstanding - basic

Weighted average shares outstanding - diluted

Year end shares outstanding

Net earnings (loss) per share - basic

Net earnings (loss) per share - diluted

Number of full time employees

Number of part time employees

Total number of employees

Number of common stockholders

Change in fair value of warrant liability

Excess warrant fair value

Reclassified to conform with 2022 presentation; Adjusted for 1-for-25 stock split, October 27, 2023; Shares increased due to issuance of shares in follow-on public offering, to consultants for services and upon exercise of stock options; Approximately; As of March 28, 2023; As of March 23, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|-----------|-----------|
| Cash & cash equivalents | 1,643,000 | 3,519,000 |
| Accounts receivable, gross | 452,000 | 1,169,000 |
| Less: allowance | 250,000 | 712,000 |
| Accounts receivable, net | 202,000 | 457,000 |
| Prepaid expenses & other current assets | 616,000 | 1,448,000 |
| Total current assets | 2,461,000 | 5,424,000 |
| Goodwill | 2,843,000 | 2,843,000 |
| Furniture & equipment | 1,321,000 | 1,265,000 |
| Leasehold improvements | 2,479,000 | 2,479,000 |
| Construction in progress | 1,435,000 | 948,000 |
| Molds | 405,000 | 143,000 |
| Less accumulated depreciation | 2,326,000 | 1,753,000 |
| Gross property & equipment | 5,640,000 | 4,835,000 |
| Property & equipment, net | 3,314,000 | 3,082,000 |

| | | |
|---|--------------|--------------|
| Operating lease right of use asset | 1,385,000 | 1,695,000 |
| Intangible assets, net | 420,000 | 302,000 |
| Deposits & other long-term assets | 307,000 | 374,000 |
| Total assets | 10,730,000 | 13,720,000 |
| Accounts payable | 2,145,000 | 1,411,000 |
| Accrued payroll | 1,498,000 | 1,358,000 |
| Accrued legal & other accrued expenses | ... | 473,000 |
| Accrued lab rebate liabilities | ... | 81,000 |
| Accrued expenses - Balancing value | 836,000 | ... |
| Accrued expenses | 2,334,000 | 1,912,000 |
| Current portion of contract liabilities | 2,138,000 | 2,926,000 |
| Current portion of operating lease liability | 474,000 | 419,000 |
| Other current liabilities | 198,000 | 145,000 |
| Total current liabilities | 7,289,000 | 6,813,000 |
| Contract liabilities, net of current portion | 289,000 | 112,000 |
| Operating lease liability, net of current portion | 1,521,000 | 1,994,000 |
| Employee retention credit liability | 1,220,000 | ... |
| Total liabilities | 10,319,000 | 8,919,000 |
| Common stock | 183 | 2,000 |
| Additional paid-in capital | 93,462,000 | 84,267,000 |
| Retained earnings (accumulated deficit) | (93,051,000) | (79,468,000) |
| Total stockholders' equity (deficit) | 411,000 | 4,801,000 |
| Total Equity | 411,000 | ... |

Recent Dividends:**1. Vivos Therapeutics Inc class A voting common.**

No dividends paid.

Annual Dividends:**1. Vivos Therapeutics Inc class A voting common.**

No dividends paid.

VIVOS THERAPEUTICS INC**Auditor's Report Auditor's Report**

The following is an excerpt from the Report of the Independent Auditors, Moss Adams, LLP, as it appeared in Co.'s 2023 10-K: "Opinion on the Consolidated Financial Statements We have audited the accompanying consolidated balance sheet of Vivos Therapeutics, Inc. and subsidiaries (the "Company") as of December 31, 2023, the related consolidated statements of operations, stockholders' equity and cash flows for the year then ended, and the related notes (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Company as of December 31, 2023, and the consolidated results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America. Going Concern Uncertainty The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty."

VOLCON INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|-----------------------------|-------------|-------------|--------------|
| | | | (revised) |
| Revenue | 3,260,988 | ... | ... |
| Revenues | 3,260,988 | 4,546,686 | 448,819 |
| Cost of goods sold | 11,391,040 | 13,412,820 | 10,507,454 |
| Gross margin | (8,130,052) | (8,866,134) | (10,058,635) |
| Sales & marketing expense | 7,405,705 | 5,694,556 | 2,872,620 |
| Product development expense | 7,868,985 | 8,456,157 | 10,465,186 |
| General & | | | |

| | | | |
|--|---------------------|---------------------|---------------------|
| administrative expenses | 6,388,007 | 9,046,778 | 15,783,409 |
| Total operating expenses | 21,662,697 | 23,197,491 | 29,121,214 |
| Income (loss) from operations | (29,792,749) | (32,063,625) | (39,179,850) |
| Other income (expense) | (40,555) | 87,765 | (854,022) |
| Interest expense | 4,969,590 | 2,259,545 | 91,238 |
| Loss from extinguishment | (22,296,988) | ... | ... |
| Issuance costs | (1,444,547) | ... | ... |
| Gain on derivative liabilities and warrant liabilities | (13,473,218) | ... | ... |
| Total other income (expense) | (15,278,462) | (2,171,780) | (945,260) |
| Income (loss) before provision for income taxes | (45,071,211) | (34,235,405) | (40,125,109) |
| Net income (loss) | (45,071,211) | (34,235,405) | (40,125,109) |
| Weighted average common shares outstanding - basic | 192,312 | 105,274 | 20,298 |
| Weighted average common shares outstanding - diluted | 192,312 | 105,274 | 20,298 |
| Year end shares outstanding | 1,030,070 | 108,561 | 76,930 |
| Net income (loss) per common share - basic | \$(234.37) | \$(326.25) | \$(1,977.75) |
| Net income (loss) per common share - diluted | \$(234.37) | \$(326.25) | \$(1,977.75) |
| Number of part time employees | 1 | 53 | ... |
| Number of full time employees | 35 | 1 | ... |
| Total number of employees | 36 | 54 | 75 |
| Number of common stockholders | 1,159 | 1,210 | 1,381 |

□ As reported by the Company; □ Adjusted for 1-for-5 stock split, October 16, 2023; □ Adjusted for 1-for-45 stock split, February 5, 2024; □ Shares increase due to the effect of issuance of common stock for public offering, cashless exercise of warrants, exercise of stock options & restricted shares & stock based compensation; □ Shares increased due to issuance of series A & B preferred stock, issuance of common stock, conversion of preferred stock, exercise of warrants and stock based compensation; □ As of March 15, 2022; □ As of March 3, 2023; □ As of March 21, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash | 7,983,346 | 10,986,592 |
| Restricted cash | 210,000 | 551,250 |
| Accounts receivables, gross | ... | 927,408 |
| Less: allowance for doubtful accounts | ... | 62,451 |
| Accounts receivable, net | 203,303 | 864,957 |
| Raw materials | 6,770,892 | 3,060,160 |
| Work in process | ... | 439,839 |
| Finished goods | 2,202,242 | 2,145,884 |
| Inventory | 8,973,134 | 5,645,883 |
| Inventory deposits | 258,316 | 427,662 |
| Prepaid expenses & other current assets | 1,904,197 | 1,850,666 |
| Total current assets | 19,532,296 | 20,327,010 |
| Machinery, tooling & equipment | 1,015,568 | 352,137 |
| Vehicles | 213,528 | 156,648 |
| Internal use manufactured vehicles | 22,906 | 274,385 |
| Fixtures & furnitures | ... | 50,768 |
| Leasehold improvements | 44,663 | 44,663 |
| Computers | 90,768 | 228,671 |
| Computers | 221,571 | ... |

| | | |
|---|---------------|--------------|
| Property & equipment, gross | 1,609,004 | 1,107,272 |
| Less accumulated depreciation | 350,397 | 505,506 |
| Property & equipment, net | 1,258,607 | 601,766 |
| Intangibles assets, net | ... | 5,813 |
| Other long-term assets | 199,281 | 285,037 |
| Right of use asset - operating lease | 1,136,213 | 1,505,987 |
| Total assets | 22,126,397 | 22,725,613 |
| Accounts payable | 831,184 | 1,036,628 |
| Accrued liabilities | 3,128,906 | 2,045,239 |
| Accrued purchase commitments | ... | 28,600 |
| Current portion of notes payable | 15,278 | 18,670 |
| Convertible notes, net of issuance costs | 30,149,579 | 17,353,748 |
| Right of use operating lease liability, short term | 399,611 | 391,117 |
| Customer deposits | 417,485 | 23,471 |
| Simple Agreement for Future Equity (SAFE) liability | 5,971,067 | ... |
| Total current liabilities | 40,913,110 | 20,897,472 |
| Notes payable, net of discount & current portion | 69,138 | 50,116 |
| Right of use operating lease liability, long term | 775,170 | 1,143,011 |
| Total liabilities | 41,757,418 | 22,090,599 |
| Common stock | 10 | 198 |
| Additional paid-in capital | 101,175,107 | 76,369,742 |
| Retained earnings (accumulated deficit) | (120,806,138) | (75,734,927) |
| Total stockholders' equity (deficit) | (19,631,021) | 635,013 |
| Total Equity | (19,631,021) | ... |

□ As reported by the Company

Recent Dividends:**1. Volcon Inc common.**

No dividends paid.

Annual Dividends:**1. Volcon Inc common.**

No dividends paid.

**WAG! GROUP CO
Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|-----------|
| | | (revised) | (revised) |
| Revenues | 83,916,000 | 54,865,000 | ... |
| Cost of revenues | 5,477,000 | 4,024,000 | ... |
| Platform operations & support | 1,791,000 | 13,825,000 | ... |
| Sales & marketing | 50,523,000 | 35,156,000 | ... |
| General & administrative | 19,223,000 | 32,415,000 | 832,564 |
| Depreciation & amortization | 1,673,000 | 571,000 | ... |
| Platform operations and support | 12,475,000 | ... | ... |
| Total expenses | ... | ... | 832,564 |
| Total costs & expenses | 91,162,000 | 85,991,000 | ... |
| Income on investments held in trust account & other interest | ... | ... | 3,001 |
| Change in fair value of derivative liability | 21,000 | 4,958,000 | ... |
| Interest expense, net | 7,417,000 | 2,886,000 | ... |
| Interest income | 907,000 | 416,000 | ... |
| Total other income | ... | ... | 3,001 |
| Income (loss) before income taxes | (13,777,000) | (38,554,000) | ... |
| Current Tax - State | 93,000 | 34,000 | ... |

| | | | |
|---|---------------------|---------------------|------------------|
| Total Current Tax Expense | 93,000 | 34,000 | ... |
| Deferred Tax - Federal | ... | (20,000) | ... |
| Deferred Tax - State | ... | (1,000) | ... |
| Total Deferred Tax Expense | ... | (21,000) | ... |
| Income tax benefit (expense) | 93,000 | 13,000 | ... |
| Net income (loss) | (13,317,000) | (38,567,000) | (829,563) |
| Weighted average shares outstanding of redeemable ordinary shares - basic | ... | ... | 4,284,703 |
| Weighted average shares outstanding of non-redeemable ordinary shares - basic | ... | ... | 3,171,069 |
| Weighted average shares outstanding - basic | 38,402,000 | 18,641,000 | ... |
| Weighted average shares outstanding of redeemable ordinary shares - diluted | ... | ... | 4,284,703 |
| Weighted average shares outstanding of non-redeemable ordinary shares - diluted | ... | ... | 3,171,069 |
| Weighted average shares outstanding - diluted | 38,402,000 | 18,641,000 | ... |
| Year end shares outstanding | 39,597,000 | 36,849,076 | 15,687,500 |
| Net earnings (loss) per redeemable share - basic | ... | ... | \$(0.11) |
| Net earnings (loss) per non-redeemable share - basic | ... | ... | \$(0.11) |
| Net earnings (loss) per share - basic | \$(0.35) | \$(2.07) | ... |
| Net earnings (loss) per redeemable share - diluted | ... | ... | \$(0.11) |
| Net earnings (loss) per non-redeemable share - diluted | ... | ... | \$(0.11) |
| Net earnings (loss) per share - diluted | \$(0.35) | \$(2.07) | ... |
| Full-Time Employees (Period End) | 84 | ... | ... |
| Total number of employees | 84 | ... | 4 |
| Number of common stockholders | 126 | ... | 24 |
| Revenues | 83,916,000 | 54,865,000 | ... |
| Equity in net earnings of equity method investment | 553,000 | ... | ... |
| EPS - Basic - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.35) | \$(2.07) | ... |
| EPS - Diluted - excluding Extraordinary Items | ... | ... | ... |
| Applicable to Common - Total | \$(0.35) | \$(2.07) | ... |

⊠ Reclassified to conform 2023 presentation; ⊡ Non-consolidated; ⊢ December 31, 2021 and prior periods for CHW Acquisition Corporation prior to reverse merger with Wag Labs, Inc.; ⊣ Shares increased due to the effect of issuance of representative shares and issuance of ordinary shares to sponsor; ⊤ As of March 9, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---|---------------|----------------|
| | 2023 | 2022 (revised) |
| Cash & cash equivalents | 18,323,000 | 38,966,000 |
| Accounts receivable, net | 10,023,000 | 5,872,000 |
| Prepaid expenses & other assets | 3,428,000 | 2,585,000 |
| Total current assets | 31,774,000 | 47,423,000 |
| Equipment | 240,000 | 200,000 |
| Capitalized software | 762,000 | 460,000 |
| Property, plant & equipment, gross | 1,002,000 | 660,000 |
| Less: accumulated depreciation & amortization | 655,000 | 572,000 |
| Property, plant & equipment, net | 347,000 | 88,000 |
| Operating lease, right of use assets, net | 1,045,000 | 695,000 |
| Intangible assets, net | 8,828,000 | 2,590,000 |
| Goodwill | 4,646,000 | 1,451,000 |
| Other assets | 57,000 | 64,000 |
| Total assets | 46,697,000 | 52,311,000 |
| Accounts payable | 9,919,000 | 7,174,000 |
| Accrued expenses & other current liabilities | 547,000 | 4,765,000 |
| Deferred revenue | 1,781,000 | 2,232,000 |
| Deferred purchase consideration - current portion | ... | 750,000 |
| Operating lease liabilities | 386,000 | 306,000 |
| Notes payable - current portion | 1,751,000 | 1,264,000 |
| Accrued expenses and other current liabilities | 4,015,000 | ... |
| Total current liabilities | 18,399,000 | 16,491,000 |
| Operating lease liabilities - non-current portion | 816,000 | 435,000 |
| Notes payable - non-current portion | ... | 24,970,000 |
| Deferred purchase consideration - non-current portion | ... | 493,000 |
| Other non-current liabilities | 172,000 | ... |
| Notes payable - non-current portion, net of debt discount and warrant allocation of \$ 6.4 million and \$ 7.0 million as of 31,2023 and 31,2022, respectively | 25,664,000 | ... |
| Total liabilities | 45,051,000 | 42,389,000 |
| Common stock | 4,000 | 4,000 |
| Additional paid-in capital | 163,376,000 | 158,335,000 |
| Accumulated deficit | (161,734,000) | ... |
| Retained earnings (accumulated deficit) | ... | (148,417,000) |
| Total stockholders' equity (deficit) | 1,646,000 | 9,922,000 |
| Total Equity | 1,646,000 | ... |

Recent Dividends:

1. Wag! Group Co ordinary.
No dividends paid.

Annual Dividends:

1. Wag! Group Co ordinary.
No dividends paid.

WARPSPEED TAXI INC

Earnings, 6 mos. to Jan 31 (Consol. - \$):

| | | |
|-----------------------|-----------------|-----------------|
| | 2024 | 2023 |
| Cost & expenses | 10,156 | 18,317 |
| Operating income | (10,156) | ... |
| Net before taxes | (10,156) | ... |
| Net income | (10,156) | (18,317) |
| Earnings common share | ... | ... |
| Common Shares: | ... | ... |
| Full Diluted | 239,370,000 | 239,370,000 |
| Year-end | 239,590,000 | 239,370,000 |

WB BURGERS ASIA INC

Earnings, 6 mos. to Jan 31 (Consol. - \$):

| | | |
|-----------------------------|------------------|--------------------|
| | 2024 | 2023 |
| Total revenues | 289,841 | 267,223 |
| Cost & expenses | 800,712 | 2,004,429 |
| Operating income | (510,871) | (1,737,206) |
| Other income (expense), net | 27,608 | 151,502 |
| Foreign currency | 7,450 | 2,546 |
| Net before taxes | (475,760) | (1,583,158) |
| Income taxes | ... | 60 |
| Net income | (475,760) | (1,583,218) |
| Earnings common share | ... | ... |
| Primary | \$(0.02) | ... |
| Fully Diluted | \$(0.02) | ... |
| Common Shares: | ... | ... |
| Full Diluted | 19,744,471 | 10,533,394 |
| Year-end | 20,726,424 | 10,573,408 |

WEED INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | | | |
|---|-----------------|--------------------|--------------------|
| | 2023 | 2022 | 2021 (revised) |
| General & administrative expenses | 394,617 | 567,159 | 797,683 |
| Professional fees | 323,559 | 826,689 | 1,873,904 |
| Depreciation | 49,791 | ... | ... |
| Amortization of Trademark | 2,600 | ... | ... |
| Depreciation & amortization | 52,392 | 111,426 | 129,789 |
| Total operating expenses | 770,568 | 1,505,274 | 2,801,376 |
| Net operating income (loss) | (770,568) | (1,505,274) | (2,801,376) |
| Loss (gain) on disposal of equipment | 988,375 | ... | ... |
| Interest expense | 45,374 | 117,124 | 39,244 |
| Other income | (203,010) | ... | ... |
| Gain (loss) on sale of fixed asset | ... | 639,773 | ... |
| Other expense | ... | 719 | 1,230 |
| Impairment of goodwill & inventory | ... | 544,761 | ... |
| Total other income (expense) | 739,991 | (22,831) | (40,474) |
| Net income (loss) before income tax | (30,577) | (1,528,105) | (2,841,850) |
| Net income (loss) | (31,557) | (1,528,105) | (2,841,850) |
| Weighted average shares outstanding | ... | ... | ... |
| - basic | 123,709,123 | 122,076,877 | 116,733,164 |
| Weighted average shares outstanding - diluted | 123,709,123 | 122,076,877 | 116,733,164 |
| Year end shares outstanding | 123,482,685 | 123,482,685 | 119,222,685 |
| Net income (loss) per share - basic | \$(0.00) | \$(0.01) | \$(0.02) |
| Net income (loss) per share - diluted | \$(0.00) | \$(0.01) | \$(0.02) |
| Number of full time employees | 2 | 2 | 2 |
| Number of common stockholders | 281 | 280 | 275 |
| INCOME TAX EXPENSE | 980 | ... | ... |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.00) | ... | ... |
| Diluted EPS | ... | ... | ... |
| Excluding ExtraOrd Items | \$(0.00) | ... | ... |
| Total number of employees | 2 | ... | ... |

⊠ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | | |
|---------------------|---------|---------|
| | 2023 | 2022 |
| Cash | 290,409 | 315,826 |
| Prepaid expenses | 24,622 | 24,626 |
| Other current asset | 4,855 | 1,623 |

| | | | | | | | |
|---|--------------|--------------|---------------------|--------------|---------------------------|---------------|--------------|
| Total current assets | 319,886 | 342,075 | charges | 46,500,000 | Accounts receivable | 74,012,000 | 66,653,000 |
| Land | 258,319 | 372,069 | Restructuring & | | Raw materials & supplies | 125,421,000 | 129,131,000 |
| Building | 218,681 | 1,109,931 | other expenses | 4,503,000 | Work in process | 1,505,000 | 1,835,000 |
| Computers & equipment | 147,771 | 137,772 | Goodwill impairment | | Finished goods | 82,345,000 | 88,009,000 |
| Property & equipment, | | | charges | 7,230,000 | Inventories | 209,271,000 | 218,975,000 |
| gross | 624,771 | 1,619,772 | Operating income | | Prepaid expenses & other | | |
| Less: accumulated | | | (loss) | 15,395,000 | current assets | 6,429,000 | 10,530,000 |
| depreciation | 108,431 | 410,942 | Change in fair | (24,646,000) | Total current assets | 320,225,000 | 324,834,000 |
| Property & equipment, | | | value of warrant | | Machinery, equipment & | | |
| net | 516,340 | 1,208,830 | liabilities | 1,232,000 | other | 42,276,000 | 39,695,000 |
| License | 667 | 667 | Interest (expense) | 29,000 | Buildings & improvements | 22,431,000 | 21,565,000 |
| Intangible assets, gross | 50,667 | 50,667 | income, net | (30,600,000) | Land - Net | 5,930,000 | |
| Trademark | 50,000 | 50,000 | Gain (loss) on | (24,589,000) | Property, plant & | | |
| Less: accumulated | | | extinguishment & | | equipment, gross | 64,707,000 | 61,260,000 |
| amortization | 14,484 | 11,884 | debt transaction | | Less: accumulated | | |
| Intangible assets, net | 36,183 | 38,783 | costs | (5,513,000) | depreciation | 16,169,000 | 11,410,000 |
| Right-of-use | 31,653 | 44,130 | Other income | | Property, plant & | | |
| Total assets | 904,062 | 1,633,818 | (expense), net | (3,188,000) | equipment after | | |
| Accounts payable | 183,565 | 189,779 | Income (loss) | 1,051,000 | accumulated depreciation | | 49,850,000 |
| Accrued expense | 64,778 | 42,206 | before income taxes | 196,000 | Land | | 5,951,000 |
| Accrued officer | | | - domestic | (86,952,000) | Construction in progress | 469,000 | 2,291,000 |
| compensation | 182,500 | 434,750 | Income (loss) | (36,205) | Property, plant & | | |
| Accrued interest | 13,000 | 42,266 | before income taxes | | equipment, net | 48,538,000 | |
| Convertible notes payable | 133,073 | | - foreign | 33,989,000 | Property, plant & | | |
| Notes payable, related | | | Income (loss) | 29,144 | equipment, net | 54,937,000 | 58,092,000 |
| parties | 723 | 706,507 | before income taxes | (31,767,000) | Operating lease | | |
| Notes payable | 3,661 | 3,661 | Current federal | (52,963,000) | right-of-use assets | 19,223,000 | 18,238,000 |
| Lease liability | 31,653 | 44,130 | income taxes | (7,061,000) | Goodwill | 193,610,000 | 193,139,000 |
| Due to officer | | 723 | Current state & | 916,000 | Other intangible assets, | | |
| Asset retirement | | | local income taxes | 283,000 | net | 229,936,000 | 245,376,000 |
| obligation | 35,800 | | Current foreign | 283,000 | Deferred tax assets, net | 500,000 | 539,000 |
| Total current liabilities | 648,753 | 1,464,022 | income taxes | 4,746,000 | Other assets | 7,266,000 | 8,785,000 |
| Total liabilities | 648,753 | 1,464,022 | Current income | 3,957,000 | Total assets | 825,697,000 | 849,003,000 |
| Common stock | 123,483 | 123,483 | taxes | 6,245,000 | Accounts payable | 55,662,000 | 47,002,000 |
| Additional paid-in | | | Deferred federal | 5,156,000 | Accrued expenses and | | |
| capital | 83,818,351 | 83,796,857 | income taxes | (6,498,000) | other current liabilities | 32,173,000 | 27,488,000 |
| Subscription payable | 701,250 | 611,250 | Deferred state & | (2,944,000) | Current portion of | | |
| Accumulated Deficit | (84,392,563) | | local income taxes | (2,801,000) | operating lease | | |
| Retained earnings | | | Deferred foreign | (8,804,000) | liabilities | 7,370,000 | 8,804,000 |
| (accumulated deficit) | | (84,361,006) | income taxes | 3,069,000 | Current portion of | | |
| Foreign currency | | | Deferred income | (3,001,000) | long-term debt | 3,750,000 | 3,750,000 |
| translation | (4,788) | 788 | taxes | (12,300,000) | Total current liabilities | 98,955,000 | 87,044,000 |
| Total stockholders' | | | Provision (benefit) | (456,000) | Term loan | | 368,438,000 |
| equity (deficit) | 255,309 | 169,796 | for income taxes | 6,329,000 | Revolving credit facility | | 76,000,000 |
| Total Equity | 255,309 | | Net income (loss) | (58,752,000) | Less: current portion | | 3,750,000 |
| | | | Net income (loss) | 83,000 | Less: unamortized debt | | |
| Recent Dividends: | | | attributable to | | issuance costs | 417,929,000 | (8,516,000) |
| 1. Weed Inc common. | | | common shareholders | (58,752,000) | Long-term debt | | 432,172,000 |
| No dividends paid. | | | Weighted average | 83,000 | Warrant liabilities | | 216,000 |
| Annual Dividends: | | | shares outstanding | | Deferred tax liabilities, | | |
| 1. Weed Inc common. | | | - basic | 42,483,083 | net | 31,579,000 | 32,585,000 |
| No dividends paid. | | | Weighted average | 41,481,079 | Operating lease | | |
| WEWARDS INC | | | shares outstanding | 39,876,387 | liabilities, less current | | |
| Earnings, 9 mos. to (Consol. - \$): | | | - diluted | 42,483,083 | portion | 14,336,000 | 12,664,000 |
| | 02/29/24 | 02/28/23 | Year end shares | 41,994,355 | Other liabilities | 11,208,000 | 9,771,000 |
| Cost & expenses | 132,616 | 188,218 | outstanding | 38,871,646 | Total liabilities | 574,007,000 | 574,452,000 |
| Operating income | (132,616) | (188,218) | Net earnings (loss) | | Common stock | 4,000 | 4,000 |
| Interest income | 15,649 | 4,504 | per share - basic | \$(0.90) | Additional paid-in | | |
| Net before taxes | (511,077) | | Net earnings (loss) | \$(1.42) | capital | 365,721,000 | 360,777,000 |
| Net income | (511,077) | (576,386) | per share - diluted | \$(0.90) | Accumulated deficit | (123,284,000) | |
| Earnings common share | | | Full-Time Employees | | Retained earnings | | |
| Primary | \$ | \$(0.01) | (Period End) | 590 | (accumulated deficit) | | (85,188,000) |
| Fully Diluted | \$ | \$(0.01) | Total number of | | Net currency translation | | |
| Common Shares: | | | employees | 590 | gains | (748,000) | (4,711,000) |
| Full Diluted | 107,483,450 | 107,483,450 | Number of common | 760 | Funded states of benefit | | |
| Year-end | 107,483,450 | 107,483,450 | stockholders | 745 | plans | 9,249,000 | 3,669,000 |
| | | | Foreign currency | 15 | Funded status of benefit | | |
| WHOLE EARTH BRANDS INC | | | translation | 18 | plans | 2,921,000 | |
| Annual Report | | | adjustments | | Cash Flow Hedges | 7,076,000 | |
| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | Interest Expense - | | Accumulated other | | |
| | 2023 | 2022 | Net of Capitalized | | comprehensive income | | (1,042,000) |
| | | | Interest | 43,974,000 | Total stockholder's | | |
| | | | | | equity (deficit) | 251,690,000 | 274,551,000 |
| Total revenues | 550,913,000 | | | | Total Equity | 251,690,000 | |
| Product revenues, | | | | | | | |
| net | 550,913,000 | 538,272,000 | | | | | |
| Cost of goods sold | 407,236,000 | 398,060,000 | | | | | |
| Gross profit | 143,677,000 | 140,212,000 | | | | | |
| Selling, general & | | | | | | | |
| administrative | | | | | | | |
| expenses | 102,354,000 | 99,735,000 | | | | | |
| Amortization of | | | | | | | |
| intangible assets | 18,698,000 | 18,623,000 | | | | | |
| Asset impairment | | | | | | | |

¹ Reclassified to conform with 2022 presentation; ² Approximately; ³ As of March 10, 2023; ⁴ As of March 10, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|-----------------------------------|------------|------------|
| Cash & cash equivalents | 30,513,000 | 28,676,000 |
| Accounts receivable, gross | 75,472,000 | 68,267,000 |
| Allowance for accounts receivable | 1,460,000 | 1,614,000 |

Recent Dividends:

- 1. Whole Earth Brands Inc class B common.**
No dividends paid.
- 2. Whole Earth Brands Inc ordinary shares subject to possible redemption.**
No dividends paid.
- 3. Whole Earth Brands Inc class A common.**
No dividends paid.
- 4. Whole Earth Brands Inc common.**

No dividends paid.
Annual Dividends:
1. Whole Earth Brands Inc class B common.
 No dividends paid.
2. Whole Earth Brands Inc ordinary shares subject to possible redemption.
 No dividends paid.
3. Whole Earth Brands Inc class A common.
 No dividends paid.
4. Whole Earth Brands Inc common.
 No dividends paid.

WILHELMINA INTERNATIONAL, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|------------|--------------|-------------------|
| Service revenues | 17,182 | 17,750 | 16,069 |
| License fees | 30 | 30 | 33 |
| Total revenues | 17,212 | 17,780 | 16,102 |
| Salaries & service costs | 11,481 | 10,907 | 8,644 |
| Office & general expenses | 3,830 | 3,168 | 2,973 |
| Amortization & depreciation expenses | 208 | 193 | 855 |
| Cybersecurity incident expenses | ... | ... | 575 |
| Corporate overhead | 965 | 1,093 | 897 |
| Total operating expenses | 16,484 | 15,361 | 13,944 |
| Operating income (loss) | 728 | 2,419 | 2,158 |
| Foreign exchange gain (loss) | (106) | 164 | (80) |
| Gain on forgiveness of loan | ... | ... | 1,994 |
| Employee retention payroll tax credit | ... | ... | (1,320) |
| Interest expense | 7 | 8 | 51 |
| Interest income | 76 | ... | ... |
| Interest expense | 7 | ... | ... |
| Total other income (expense), net | (37) | 156 | 3,183 |
| Income (loss) before provision for income taxes | 691 | 2,575 | 5,341 |
| Current federal income tax expense (benefit) | (40) | 62 | ... |
| Current state income tax expense (benefit) | 61 | 47 | 34 |
| Current foreign income tax expense (benefit) | 7 | ... | 190 |
| Current provision for income taxes | 28 | 109 | 224 |
| Deferred federal income tax expense (benefit) | 258 | (1,057) | 552 |
| Deferred state income tax expense (benefit) | 20 | (6) | 47 |
| Deferred foreign income tax provision (benefit) | (48) | ... | ... |
| Deferred provision for income taxes | 230 | (1,063) | 599 |
| Income tax expense (benefit) | 258 | (954) | 823 |
| Net income (loss) | 433 | 3,529 | 4,518 |
| Weighted average shares outstanding - basic | 5,157 | 5,157 | 5,157 |
| Weighted average shares outstanding - diluted | 5,157 | 5,157 | 5,157 |
| Year end shares outstanding | 5,157 | 5,157 | 5,157 |
| Income (loss) per common share - continuing | | | |

| | | | |
|--|--------|--------|--------|
| operations - basic | \$0.08 | ... | ... |
| Net income (loss) per share - basic | \$0.08 | \$0.68 | \$0.88 |
| Income (loss) per common share - continuing operations - diluted | \$0.08 | ... | ... |
| Net income (loss) per share - diluted | \$0.08 | \$0.68 | \$0.88 |
| Number of full time employees | 87 | ... | ... |
| Total number of employees | 87 | 85 | 80 |
| Number of common stockholders | 437 | 435 | 437 |
| Foreign currency translation adjustments | ... | (521) | (104) |

As is, As of March 22, 2023; As of March 16, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 |
|---|----------|----------|
| Cash & cash equivalents | 6,117 | 11,998 |
| Short-term investments | 6,596 | ... |
| Accounts receivable, gross | 10,406 | 11,131 |
| Less: allowance for doubtful accounts | 1,901 | 1,664 |
| Accounts receivable, net of allowance for doubtful accounts | 8,505 | 9,467 |
| Accounts receivable, net | ... | 9,467 |
| Prepaid expenses & other current assets | 203 | 181 |
| Total current assets | 21,421 | 21,646 |
| Furniture & fixtures | 325 | 422 |
| Software & software development costs | 433 | ... |
| Computer & equipment | ... | 1,033 |
| Leasehold improvements | 96 | 68 |
| Total property & equipment, at cost | 854 | 1,523 |
| Less: accumulated depreciation - property & equipment | 534 | 1,216 |
| Property & equipment, net | 320 | 307 |
| Right of use assets-operating | 3,457 | 3,565 |
| Right of use assets-finance | 152 | 138 |
| Trademarks & trade names with indefinite lives | 8,467 | 8,467 |
| Goodwill | 7,547 | 7,547 |
| Other assets | 301 | 322 |
| Total assets | 41,665 | 41,992 |
| Accounts payable & accrued liabilities | ... | 4,306 |
| Due to models | 3,941 | 8,378 |
| Contract liabilities | ... | 270 |
| Lease liabilities - operating, current | 712 | 385 |
| Lease liabilities - finance, current | 32 | 62 |
| Due to models | 7,645 | ... |
| Total current liabilities | 12,330 | 13,401 |
| Deferred income tax, net | 1,215 | 985 |
| Lease liabilities - operating, non-current | 3,102 | 3,310 |
| Lease liabilities - finance, non-current | 122 | 85 |
| Total long-term liabilities | 4,439 | 4,380 |
| Total liabilities | 16,769 | 17,781 |
| Common stock | 65 | 65 |
| Treasury stock, at cost | 6,371 | 6,371 |
| Additional paid-in capital | 88,854 | 88,770 |
| Retained earnings (accumulated deficit) | (57,276) | (57,709) |
| Accumulated other comprehensive income | | |

| | | |
|--------------------------------------|--------|--------|
| (loss) | (376) | (544) |
| Total shareholders' equity | 24,896 | 24,211 |
| Rep Total Equity & Minority Interest | 24,896 | ... |

Recent Dividends:

1. Wilhelmina International, Inc. series A convertible preferred.
 No dividends paid.
2. Wilhelmina International, Inc. common.
 No dividends paid.

Annual Dividends:

1. Wilhelmina International, Inc. series A convertible preferred.
 No dividends paid.
2. Wilhelmina International, Inc. common.
 No dividends paid.

WILLAMETTE VALLEY VINEYARD INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|--|--------------------|------------------|-------------------|
| Sales, net | 39,136,114 | 33,934,081 | 31,786,864 |
| Net revenues | 39,136,114 | ... | ... |
| Cost of sales | 16,578,986 | ... | ... |
| Cost of sales | ... | 15,119,985 | 13,121,191 |
| Gross profit | 22,557,128 | 18,814,096 | 18,665,673 |
| Sales & marketing | 17,564,103 | 13,640,290 | 9,603,723 |
| General & administrative | 6,200,227 | 5,720,224 | 5,371,931 |
| Total operating expenses | 23,764,330 | 19,360,514 | 14,975,654 |
| Income (loss) from operations | (1,207,202) | (546,418) | 3,690,019 |
| Interest income | 27 | 5,496 | 12,412 |
| Interest expense | 594,106 | 367,745 | 391,272 |
| Other income (expense), net | 114,827 | 142,529 | 155,183 |
| Income (loss) before income taxes | (1,686,454) | (766,138) | 3,466,342 |
| Current income tax expense (benefit) - federal | 4,296 | 34,120 | 459,640 |
| Current income tax expense (benefit) - state | 36,702 | 2,263 | 215,831 |
| Total current income tax expense (benefit) | 40,998 | 36,383 | 675,471 |
| Deferred income tax expense (benefit) - federal | (425,065) | (121,662) | 263,911 |
| Deferred income tax expense (benefit) - state | (103,794) | (34,367) | 81,497 |
| Total deferred income tax expense (benefit) | (528,859) | (156,029) | 345,408 |
| Income tax expense (benefit) | (487,861) | (119,646) | 1,020,879 |
| Income from continuing operations | (1,198,593) | ... | ... |
| Net income (loss) | (1,198,593) | (646,492) | 2,445,463 |
| Preferred stock dividends | 2,047,097 | 1,866,451 | 1,444,283 |
| Income (loss) applicable to common shareholders | (3,245,690) | (2,512,943) | 1,001,180 |
| Weighted average shares outstanding - basic | 4,964,529 | 4,964,529 | 4,964,529 |
| Weighted average shares outstanding - diluted | 4,964,529 | 4,964,529 | 4,964,529 |
| Year end shares outstanding | 4,964,529 | 4,964,529 | 4,964,529 |
| Income (loss) per share from continuing operations - basic | \$(0.65) | ... | ... |
| Net income (loss) | | | |

| | | | | | | | | | |
|--|----------|----------|--------|---|------------|---|--------------|---------------|---------------|
| per share - basic | \$(0.65) | \$(0.51) | \$0.20 | issuance costs | 6,446,447 | preferred stock | | | |
| Income (loss) per share from continuing operations - diluted | \$(0.65) | ... | ... | Lease liabilities, net of current portion | 11,402,714 | dividend | 6,360,000 | ... | 34,000 |
| Net income (loss) per share - diluted | \$(0.65) | \$(0.51) | \$0.20 | Deferred income taxes | 2,911,618 | Deemed dividend on exchange of convertible preferred stock for common stock | ... | ... | 1,192,000 |
| Number of full time employees | 223 | 169 | 177 | Total liabilities | 35,072,944 | Net income (loss) attributable to common stockholders | (25,081,000) | (16,151,000) | (13,046,000) |
| Number of part time employees | 123 | 193 | 89 | Redeemable preferred stock | 42,388,036 | Weighted average shares outstanding - basic | 52,656 | 1,299 | 827 |
| Total number of employees | 346 | ... | ... | Common stock | 8,512,489 | - diluted | 52,656 | 1,299 | 827 |
| Number of common stockholders | 3,177 | 2,115 | 2,146 | Retained earnings (accumulated deficit) | 19,734,680 | Year end shares outstanding | 222,379 | 4,750 | 1,055 |
| Dividends per common share | \$0.22 | ... | ... | Total shareholders' equity (deficit) | 70,635,205 | Net income (loss) per share - basic | \$(477.00) | \$(12,433.50) | \$(15,780.00) |
| | | | | Total Equity | 70,635,205 | Net income (loss) per share - diluted | \$(477.00) | \$(12,433.50) | \$(15,780.00) |

□ Approximately; □ As of March 28, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-------------|------------|
| Cash & cash equivalents | 238,482 | 338,676 |
| Accounts receivables, gross | 3,004,829 | 4,236,948 |
| Allowance for doubtful accounts | 10,000 | 10,000 |
| Accounts receivables, net | 2,994,829 | 4,226,948 |
| Winemaking & packaging materials | 1,113,170 | 1,162,850 |
| Work-in-process (costs relating to unprocessed & or unbottled wine products) | 15,952,118 | 12,047,579 |
| Finished goods (bottled wine & related products) | 11,249,491 | 8,991,070 |
| Inventories, gross | 28,314,779 | ... |
| Inventories, net | 22,201,499 | ... |
| Prepaid expenses & other current assets | 522,854 | 454,085 |
| Income tax receivable | 121,959 | 557,224 |
| Total current assets | 32,192,903 | 27,778,432 |
| Other assets | 13,824 | 13,824 |
| Vineyard development costs, net | 8,704,352 | 8,448,925 |
| Construction in progress | 639,840 | 2,037,128 |
| Land & improvements | 14,491,827 | ... |
| Land, improvements & other buildings | 79,226,788 | 14,491,827 |
| Winery buildings & tasting rooms | 43,991,586 | 40,806,365 |
| Equipment | 20,103,535 | 18,805,695 |
| Property & equipment, gross | ... | 76,141,015 |
| Accumulated depreciation | 25,857,151 | 22,593,770 |
| Property & equipment, net | 53,369,637 | 53,547,245 |
| Operating lease right of use assets | 11,427,433 | 8,895,556 |
| Total assets | 105,708,149 | 98,683,982 |
| Bank overdraft | 393,416 | ... |
| Accounts payable | 2,026,352 | 3,067,886 |
| Accrued expenses | 1,482,254 | 1,428,380 |
| Investor deposits for preferred stock | 718,857 | 147,511 |
| Line of credit | 2,684,982 | 166,617 |
| Current portion of note payable | ... | 1,201,038 |
| Current portion of long-term debt | 522,798 | 496,970 |
| Current portion of lease liabilities | 450,452 | 768,818 |
| Unearned revenue | 1,970,661 | 1,442,401 |
| Grapes payable | 2,446,233 | 1,208,673 |
| Note payable | 1,100,735 | ... |
| Total current liabilities | 13,796,740 | 9,928,294 |
| Northwest Farm Credit Services Loan | ... | 7,062,654 |
| Debt issuance costs | ... | (119,237) |
| Less: current portion | ... | 496,970 |
| Long-term debt, net of current portion & debt | ... | ... |

Recent Dividends:

1. Willamette Valley Vineyard Inc. common. No dividends paid.
2. Willamette Valley Vineyard Inc. redeemable series A preferred.

| ExDate | Amt | Declared | Record | Payable |
|------------|------|------------|------------|------------|
| 12/06/2021 | 0.22 | 11/05/2021 | 12/07/2021 | 12/31/2021 |
| 12/06/2022 | 0.22 | 11/03/2022 | 12/07/2022 | 12/30/2022 |
| 12/06/2023 | 0.22 | 11/09/2023 | 12/07/2023 | 12/29/2023 |

Annual Dividends:

1. Willamette Valley Vineyard Inc. common. No dividends paid.
2. Willamette Valley Vineyard Inc. redeemable series A preferred.

| 2021 | 2022 | 2023 |
|------|------|------|
| 0.22 | 0.22 | 0.22 |

WISA TECHNOLOGIES INC

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|---|--------------|--------------|--------------|
| Revenue, Net | 2,083,000 | ... | ... |
| Revenue, net | 2,083,000 | 3,365,000 | 6,541,000 |
| Cost of revenue | 5,540,000 | 2,970,000 | 4,677,000 |
| Gross profit (loss) | (3,457,000) | 395,000 | 1,864,000 |
| Research & development expenses | 7,456,000 | 7,144,000 | 5,236,000 |
| Sales & marketing expenses | 5,177,000 | 6,140,000 | 4,123,000 |
| General & administrative expenses | 5,367,000 | 5,155,000 | 4,016,000 |
| Total operating expenses | 18,000,000 | 18,439,000 | 13,375,000 |
| Income (loss) from operations | (21,457,000) | (18,044,000) | (11,511,000) |
| Interest expense, net | 932,000 | 898,000 | 9,000 |
| Change in fair value of warrant liability | 4,510,000 | 2,852,000 | ... |
| Change in fair value of derivative liability | ... | (47,000) | ... |
| Gain on forgiveness of Paycheck Protection Program loan | (837,000) | ... | 859,000 |
| Other income (expense), net | (1,000) | (12,000) | (11,000) |
| Warrant inducement expense | ... | ... | 1,146,000 |
| Income before income taxes - domestic | ... | (16,149,000) | (11,818,000) |
| Income (loss) before provision for income taxes | (18,717,000) | (16,149,000) | (11,818,000) |
| Current provision for income taxes - state | ... | 2,000 | 2,000 |
| Provision for income taxes | 4,000 | 2,000 | 2,000 |
| Net income (loss) | (18,721,000) | (16,151,000) | (11,820,000) |
| Convertible | | | |

| | 2023 | 2022 | 2021 |
|---|------------|---------------|---------------|
| Weighted average shares outstanding - basic | 52,656 | 1,299 | 827 |
| Weighted average shares outstanding - diluted | 52,656 | 1,299 | 827 |
| Year end shares outstanding | 222,379 | 4,750 | 1,055 |
| Net income (loss) per share - basic | \$(477.00) | \$(12,433.50) | \$(15,780.00) |
| Net income (loss) per share - diluted | \$(477.00) | \$(12,433.50) | \$(15,780.00) |
| Full-Time Employees (Period End) | 46 | ... | ... |
| Total number of employees | 46 | 49 | 46 |
| Number of common stockholders | 125 | 123 | 118 |

□ Reclassified to conform with 2022 presentation; □ Adjusted for 1-for-150 stock split, April 15, 2024; □ Adjusted for 1-for-100 stock split, January 27, 2023; □ Shares increased due to stock-based compensation, release of vested restricted common stock and issuance of common stock and warrants; □ Shares increased due to common stock issued upon warrant exercise, exchange of convertible preferred stock for common stock, stock-based compensation, and registered direct offering; □ As of March 14, 2023; □ As of March 9, 2022; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|-----------|------------|
| Cash & cash equivalents | 411,000 | 2,897,000 |
| Accounts receivable | 294,000 | 273,000 |
| Raw materials | 621,000 | 3,043,000 |
| Work in progress | ... | 13,000 |
| Finished goods | 2,116,000 | 4,014,000 |
| Inventories | 2,737,000 | 7,070,000 |
| Prepaid expenses & other current assets | 641,000 | 890,000 |
| Total current assets | 4,083,000 | 11,130,000 |
| Machinery & equipment | 741,000 | 691,000 |
| Tooling | 11,000 | 127,000 |
| Computer software | ... | 11,000 |
| Total property & equipment, gross | 752,000 | 829,000 |
| Less: accumulated depreciation & amortization - property & equipment | ... | 655,000 |
| Accumulated depreciation and amortization | 659,000 | ... |
| Property & equipment, net | 93,000 | 174,000 |
| Other assets | 647,000 | 148,000 |
| Total assets | 4,823,000 | 11,452,000 |
| Accounts payable | 2,320,000 | 2,042,000 |
| Accrued vacation | ... | 422,000 |
| Accrued rebate | 215,000 | 215,000 |
| Accrued compensation | 127,000 | 136,000 |
| Accrued bonus | 418,000 | ... |
| Accrued audit fees | 211,000 | 179,000 |
| Accrued lease liability, current portion | ... | 169,000 |
| Customer advances | 19,000 | 44,000 |
| Accrued legal fees | ... | 43,000 |
| Accrued other | 327,000 | 424,000 |
| Accrued liabilities - Balancing value | 1,317,000 | ... |
| Accrued liabilities | ... | 1,632,000 |
| Total current liabilities | 3,637,000 | 3,674,000 |
| Convertible note payable | ... | 457,000 |
| Other liabilities | 636,000 | 39,000 |

| | | |
|--|---------------|---------------|
| Derivative liability | 5,460,000 | 333,000 |
| Warrant liabilities | ... | 8,945,000 |
| Total liabilities | 9,733,000 | 13,448,000 |
| Common stock | 7,000 | 7,000 |
| Additional paid-in capital | 241,878,000 | 226,318,000 |
| Accumulated deficit | (247,042,000) | ... |
| Retained earnings (accumulated deficit) | ... | (228,321,000) |
| Series B Convertible Redeemable Preferred Stock, par value \$0.0001; 375,000 shares authorized as of 31, 2023; 38,335 shares issued and outstanding as of 31, 2023 (none as of 31, 2022); mandatorily redeemable on 15, 2025 f | 247,000 | ... |
| Total stockholders' equity (deficit) | (4,910,000) | (1,996,000) |
| Total Equity | (4,910,000) | ... |

Recent Dividends:

- 1. WISA Technologies Inc common.**
No dividends paid.
 - 2. WISA Technologies Inc series B convertible redeemable preferred.**
No dividends paid.
 - 3. WISA Technologies Inc series A 8% senior convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. WISA Technologies Inc common.**
No dividends paid.
 - 2. WISA Technologies Inc series B convertible redeemable preferred.**
No dividends paid.
 - 3. WISA Technologies Inc series A 8% senior convertible preferred.**
No dividends paid.

WOLVERINE RESOURCES CORP

Earnings, 9 mos. to (Consol. - \$):

| | 02/29/24 | 02/28/23 |
|-----------------------------|------------------|------------------|
| Cost & expenses | 285,119 | 273,985 |
| Operating income | (285,119) | (273,985) |
| Other income (expense), net | (1,704) | (78,538) |
| Foreign currency | 1,908 | 4,550 |
| Net before taxes | (284,915) | ... |
| Net income | (284,915) | (347,973) |
| Earnings common share | | |
| Common Shares: | | |
| Full Diluted | 102,750,061 | 78,649,062 |
| Year-end | 100,974,373 | 91,024,373 |

WORKSPORT LTD

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|-----------------------------------|---------------------|---------------------|--------------------|
| Total revenues | 1,529,632 | ... | ... |
| Net sales | 1,529,632 | 116,502 | 303,750 |
| Cost of goods sold | 1,289,118 | 56,967 | 350,702 |
| Gross profit (loss) | 240,514 | 59,535 | (46,952) |
| General & administrative | 9,643,680 | 4,978,582 | 1,855,238 |
| Sales & marketing | 1,483,054 | 2,446,266 | 1,386,692 |
| Professional fees | 3,853,134 | 5,418,863 | 4,268,684 |
| Gain (loss) on foreign exchange | 2,693 | 10,461 | (4,165) |
| Income (loss) from operations | (14,736,661) | (12,773,715) | (7,561,731) |
| Interest expense | 616,214 | 488,704 | 294,923 |
| Interest income | 239,353 | 212,290 | 3,694 |
| Bad debt expense | ... | ... | 62,329 |
| Rental income | 184,564 | 213,383 | ... |
| Gain (loss) on settlement of debt | ... | 302,332 | 18,204 |
| Total other income (expense) | (192,297) | 239,301 | (335,354) |
| Income (loss) before income tax | (14,928,958) | ... | ... |
| Net income (loss) | (14,928,958) | (12,534,414) | (7,897,085) |

| | | | |
|---|------------|------------|------------|
| Weighted average shares outstanding - basic | 17,689,911 | 17,078,480 | 11,504,147 |
| Weighted average shares outstanding - diluted | 17,689,911 | 17,078,480 | 11,504,147 |
| Year end shares outstanding | 20,320,503 | 17,159,376 | 16,951,034 |
| Net income (loss) per share - basic | \$(0.84) | \$(0.73) | \$(0.69) |
| Net income (loss) per share - diluted | \$(0.84) | \$(0.73) | \$(0.69) |
| Number of full time employees | 70 | 21 | 11 |
| Number of part time employees | 2 | 4 | ... |
| Number of common stockholders | 170 | 25 | 189 |
| Earnings per share from continuing operations | \$(0.84) | ... | ... |
| Cost of Revenues/COGS | 1,289,118 | ... | ... |
| Total number of employees | 72 | ... | ... |

□ Including non-cash expense: \$884,446; □ Including non-cash expense: \$3,035,596; □ Shares increased due to the effect of conversion of preferred stock and promissory note, issuance for services, public offering, private placement, warrants exercised and loan repayment; □ As of March 31, 2023

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|--|------------|------------|
| Cash & cash equivalents | 3,365,778 | 14,620,757 |
| Accounts receivable net | 463,122 | 62,601 |
| Other receivable | 165,865 | 268,032 |
| Promotional items | 101,660 | 50,790 |
| Finished goods | 1,717,669 | 1,200,759 |
| Raw materials | 1,812,163 | 94,823 |
| Inventory | 3,631,492 | 1,346,372 |
| Consulting, services & advertising | 1,497,249 | 1,313,799 |
| Prepaid insurance | ... | 20,781 |
| Deposits | ... | 699,765 |
| Prepaid expenses & deposits | ... | 2,034,345 |
| Total current assets | 9,123,506 | 18,332,107 |
| Investment | 90,731 | 24,423 |
| Equipment, gross | ... | 2,344,946 |
| Furniture, gross | ... | 143,449 |
| Product molds, gross | ... | 122,675 |
| Product molds, net | 524,476 | ... |
| Computers, gross | 84,070 | 78,885 |
| Leasehold improvements | 861,332 | 675,751 |
| Building | 6,079,410 | 6,079,410 |
| Land | 2,239,405 | 2,239,405 |
| Automobile, gross | ... | 168,497 |
| Deposits | ... | 605,000 |
| Less accumulated depreciation | 1,664,580 | 557,346 |
| Equipment | 2,784,098 | ... |
| Furniture | 146,049 | ... |
| Automobile | 168,497 | ... |
| Property and Equipment, gross | 3,260,679 | ... |
| Property & equipment, net | 14,483,436 | 11,900,672 |
| Right-of-use assets | 917,354 | 1,238,055 |
| Intangible Assets - Balancing value | 1,338,889 | ... |
| Intangible assets, net | ... | 1,268,873 |
| Total assets | 25,953,916 | 32,764,130 |
| Accounts payable & accrued liabilities | 1,451,181 | 2,028,305 |
| Payroll taxes payable | 85,010 | ... |
| Related party loan | 2,192 | 46,096 |
| Promissory notes payable | 5,300,000 | ... |
| Current lease liability | 328,229 | 387,329 |

| | | |
|---|--------------|--------------|
| Total current liabilities | ... | 2,461,730 |
| Long term - lease liability | 608,761 | 884,146 |
| Loan payable | ... | 5,300,000 |
| Total liabilities | 7,775,373 | 8,645,876 |
| Share Capital | 2,032 | ... |
| Common stock | ... | 1,716 |
| Additional paid-in capital | 64,685,693 | 56,919,625 |
| Share subscriptions receivable | (1,577) | (1,577) |
| Share subscriptions payable | 1,814,152 | 591,289 |
| Retained earnings (accumulated deficit) | ... | (33,384,219) |
| Cumulative translation adjustment | (8,580) | (8,580) |
| Equity accumulated during development stage | (48,313,177) | ... |
| Total shareholders' equity (deficit) | 18,178,543 | 24,118,254 |
| Total Equity | 18,178,543 | ... |

Recent Dividends:

- 1. WorkSport Ltd series A preferred.**
No dividends paid.
 - 2. WorkSport Ltd series A preferred.**
No dividends paid.
 - 3. WorkSport Ltd common.**
No dividends paid.
- Annual Dividends:**
- 1. WorkSport Ltd series A preferred.**
No dividends paid.
 - 2. WorkSport Ltd series A preferred.**
No dividends paid.
 - 3. WorkSport Ltd common.**
No dividends paid.

WRIGHT INVESTORS' SERVICE HOLDINGS, INC.

Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$000):

| | 2023 | 2022 | 2021 (revised) |
|---|----------------|----------------|----------------|
| Compensation & benefits | 458 | 460 | 450 |
| Other operating expenses | 714 | 768 | 719 |
| Total operating expenses | 1,172 | 1,228 | 1,169 |
| Income (loss) from operations | (1,172) | (1,228) | (1,169) |
| Interest & other income, net | 166 | 21 | 53 |
| Income (loss) from operations before income taxes | (1,006) | (1,207) | (1,116) |
| Current state & local income tax expense (benefit) | ... | ... | 2 |
| Total current income tax expense (benefit) | ... | ... | 2 |
| Income tax expense (benefit) | ... | ... | 2 |
| Net income (loss) | (1,006) | (1,207) | (1,118) |
| Weighted average shares outstanding - basic | 20,621 | 20,504 | 20,287 |
| Weighted average shares outstanding - diluted | 20,621 | 20,504 | 20,287 |
| Year end shares outstanding | 20,621 | 20,336 | 20,211 |
| Income (loss) per share - continuing operations - basic | \$(0.05) | ... | ... |
| Net income (loss) per share - basic | \$(0.05) | \$(0.06) | \$(0.06) |
| Income (loss) per share - continuing operations - diluted | \$(0.05) | ... | ... |
| Net income (loss) | ... | ... | ... |

| | | | |
|---|--------|----------|----------|
| per share - diluted | \$0.01 | \$(0.09) | \$(0.06) |
| Number of full time employees | 207 | 134 | 116 |
| Number of part time employees | 8 | 1 | 2 |
| Total number of employees | 215 | 135 | 118 |
| Number of common stockholders | 166 | 170 | 173 |
| Basic EPS Excluding ExtraOrdinary Items | \$0.01 | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$0.01 | ... | ... |

□ Reclassified to conform with 2022 presentation; □ Shares increased due to the effect of private placement and issuance of common stock on vesting of restricted stock units; □ As of March 3, 2023; □ As of March 8, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|-------------|
| Cash & cash equivalents | 5,715,000 | 20,298,000 |
| Restricted cash | 208,000 | 209,000 |
| Trade accounts receivable, gross | 21,651,000 | 11,368,000 |
| Allowance for doubtful accounts - trade accounts receivable | 920,000 | 515,000 |
| Trade accounts receivable, net | 20,731,000 | 10,853,000 |
| Raw materials | 7,269,000 | 5,628,000 |
| Work in process | 1,562,000 | 798,000 |
| Finished goods | 28,054,000 | 10,859,000 |
| Inventories | 36,885,000 | 17,285,000 |
| Prepaid & other current assets | 1,330,000 | 673,000 |
| Total current assets | 64,869,000 | 49,318,000 |
| Equipment | 6,858,000 | 5,598,000 |
| Computer equipment | 1,330,000 | 1,043,000 |
| Computer software | 230,000 | 230,000 |
| Leasehold improvements | 4,347,000 | 4,105,000 |
| Surgical instruments | 28,372,000 | 11,266,000 |
| Assets not yet in service | 959,000 | 1,507,000 |
| Surgical instruments | 14,648,000 | ... |
| Property & equipment, total cost | ... | 23,749,000 |
| Less: accumulated depreciation | 19,680,000 | 17,964,000 |
| Property & equipment, net | 8,692,000 | 5,785,000 |
| Right of use asset, net | 1,523,000 | 1,380,000 |
| Goodwill | 7,302,000 | 3,205,000 |
| Intangible assets, net | 10,085,000 | 344,000 |
| Other assets | 141,000 | 197,000 |
| Total assets | 92,612,000 | 60,229,000 |
| Accounts payable | 7,054,000 | 3,490,000 |
| Accrued interest payable | 1,529,000 | ... |
| Wages or commissions payable | 8,890,000 | 4,464,000 |
| Other accrued liabilities | 10,419,000 | 1,032,000 |
| Current portion of lease liability | 830,000 | 458,000 |
| Current portion of finance lease obligations | 65,000 | 62,000 |
| Line of credit | 4,622,000 | 3,379,000 |
| Current portion of long-term debt | ... | 2,333,000 |
| Total current liabilities | 22,990,000 | 15,218,000 |
| Financing lease obligations, net | 116,000 | 181,000 |
| Lease liability, net | 759,000 | 972,000 |
| Amounts due under term facility | ... | 12,000,000 |
| Accrued end-of-term payments | ... | 216,000 |
| Less: unamortized debt issuance costs | ... | (196,000) |
| Less: current maturities | ... | (2,333,000) |
| Long-term debt, plus premium & less issuance costs | 17,167,000 | 9,687,000 |
| Deferred tax liability | 21,000 | ... |

Recent Dividends:
1. Xtant Medical Holdings Inc common.
 No dividends paid.

Annual Dividends:
1. Xtant Medical Holdings Inc common.
 No dividends paid.

YALE TRANSACTION FINDERS INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2021 | 2020 |
|---|-----------|-----------|-----------|
| General & administrative expenses | 35,275 | 24,125 | 27,235 |
| Management fees - related party | ... | 20,000 | 40,000 |
| Total operating expenses | ... | 44,125 | 67,235 |
| Interest expense - related party | 3,035 | 45,896 | 42,885 |
| Income (loss) from operations | (35,275) | (90,021) | (110,120) |
| Net income (loss) before income taxes | (38,310) | (90,021) | (110,120) |
| Net income (loss) | (38,310) | (90,021) | (110,120) |
| Weighted average shares outstanding - basic | 5,199,000 | 5,199,000 | 5,199,000 |
| Weighted average shares outstanding - diluted | 5,199,000 | 5,199,000 | 5,199,000 |
| Year end shares outstanding | 5,199,000 | 5,199,000 | 5,199,000 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.02) | \$(0.02) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.02) | \$(0.02) |
| Number of common stockholders | 68 | 50 | 50 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

□ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|---|-------------|-------------|
| Cash | 2,601 | ... |
| Total current assets | 2,601 | ... |
| Total assets | 2,601 | ... |
| Accrued liabilities | 9,650 | 37,092 |
| Accrued interest-related party | 4,556 | 338,502 |
| Note payable - related party | 73,000 | 783,122 |
| Total current liabilities | 87,206 | 1,158,716 |
| Total liabilities | ... | 1,158,716 |
| Common stock | 520 | 520 |
| Additional paid-in capital | 1,229,743 | 49,280 |
| Retained earnings (accumulated deficit) | (1,314,868) | (1,208,516) |
| Total stockholders' equity | (84,605) | (1,158,716) |
| Total Equity | (84,605) | ... |

Recent Dividends:
1. Yale Transaction Finders Inc common.
 No dividends paid.

Annual Dividends:
1. Yale Transaction Finders Inc common.
 No dividends paid.

YIELD10 BIOSCIENCE INC
Annual Report

Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|--|--------------|--------------|--------------|
| Grant revenue | 60,000 | 450,000 | 614,000 |
| Total revenue | 60,000 | 450,000 | 614,000 |
| Research & development expenses | 8,323,000 | 7,750,000 | 6,201,000 |
| General & administrative expenses | 6,154,000 | 6,151,000 | 6,105,000 |
| Total expenses | 14,477,000 | 13,901,000 | 12,306,000 |
| Income (loss) from operations | (14,417,000) | (13,451,000) | (11,692,000) |
| Gain (loss) on investment in related party | ... | ... | 700,000 |
| Other income (expense), net | (38,000) | 41,000 | (3,000) |
| Total other income (expense), net | (38,000) | 41,000 | 697,000 |
| Net income (loss) from operations before income taxes expense (benefit) - domestic | (3,817,000) | (13,504,000) | (11,062,000) |
| Net income (loss) from operations before income taxes expense (benefit) - foreign | (10,638,000) | 94,000 | 67,000 |
| Income (loss) from operations before income taxes expense (benefit) - foreign | (14,455,000) | (13,410,000) | (10,995,000) |
| Deferred foreign income tax expense (benefit) | ... | 156,000 | 36,000 |
| Total deferred income tax expense (benefit) | ... | 156,000 | 36,000 |
| Income tax provision | ... | 156,000 | 36,000 |
| Net income (loss) | (14,455,000) | (13,566,000) | (11,031,000) |
| Weighted average shares outstanding - basic | 7,946,281 | 4,914,565 | 4,731,833 |
| Weighted average shares outstanding - diluted | 7,946,281 | 4,914,565 | 4,731,833 |
| Year end shares outstanding | 12,032,425 | 4,944,202 | 4,881,851 |
| Net income (loss) per share - continuing operations - basic | \$(1.82) | ... | ... |
| Net income (loss) per share - basic | \$(1.82) | \$(2.76) | \$(2.33) |
| Net income (loss) per share - continuing operations - diluted | \$(1.82) | ... | ... |
| Net income (loss) per share - diluted | \$(1.82) | \$(2.76) | \$(2.33) |
| Number of full time employees | 29 | 30 | 29 |
| Number of common stockholders | 28 | 27 | 38 |
| Foreign currency translation adjustments | ... | (61,000) | ... |
| Total number of employees | 29 | ... | ... |

□ Shares increased due to the effect of issuance of common shares for 401(k) match, warrant exercises, offerings, upon vest-

ing of restricted share units and conversion of preferred shares;[□]
As of March 8, 2023;[□] As of March 23, 2022

| Consolidated Balance Sheet, Years Ended Dec. 31 (\$): | | |
|---|---------------|---------------|
| | 2023 | 2022 |
| Cash & cash equivalents | 1,068,000 | 2,356,000 |
| Short-term investments | ... | 1,991,000 |
| Unbilled receivables | ... | 30,000 |
| Prepaid expenses & other | ... | ... |
| current assets | 332,000 | 641,000 |
| Total current assets | 1,400,000 | 5,018,000 |
| Restricted cash | 264,000 | 264,000 |
| Equipment | 59,000 | 533,000 |
| Furniture & fixtures | ... | 59,000 |
| Leasehold improvements | 1,437,000 | 1,425,000 |
| Equipment | 554,000 | ... |
| Total property & equipment, at cost | 2,050,000 | 2,017,000 |
| Less: accumulated depreciation & amortization | 1,502,000 | 1,242,000 |
| Property & equipment, net | 548,000 | 775,000 |
| Right-of-use assets | 1,653,000 | 1,961,000 |
| Other assets | 42,000 | 67,000 |
| Total assets | 3,907,000 | 8,085,000 |
| Accounts payable | 1,202,000 | 109,000 |
| Accrued employee compensation & benefits | 103,000 | 39,000 |
| Accrued leased facilities | 27,000 | 81,000 |
| Accrued professional services | 452,000 | 264,000 |
| Accrued field trials & related expenses | 1,032,000 | 273,000 |
| Other accrued expenses | 2,010,000 | 269,000 |
| Other | 396,000 | ... |
| Accrued expenses | ... | 926,000 |
| Lease liabilities | 669,000 | 575,000 |
| Convertible Note Payable, Net of Issuance Cost | 984,000 | ... |
| Total current liabilities | 4,865,000 | 1,610,000 |
| Lease liabilities, net of current portion | 1,525,000 | 2,075,000 |
| Total liabilities | 6,390,000 | 3,685,000 |
| Common stock | 120,000 | 49,000 |
| Additional paid-in capital | 411,814,000 | 404,277,000 |
| Accumulated other comprehensive income (loss) | (265,000) | (229,000) |
| Accumulated Deficit | (414,152,000) | ... |
| Retained earnings (accumulated deficit) | ... | (399,697,000) |
| Total stockholders' equity (deficit) | (2,483,000) | 4,400,000 |
| Total Equity | (2,483,000) | ... |

Recent Dividends:

- 1. Yield10 Bioscience Inc common.**
No dividends paid.
 - 2. Yield10 Bioscience Inc series A convertible preferred.**
No dividends paid.
 - 3. Yield10 Bioscience Inc series B convertible preferred.**
No dividends paid.
 - 4. Yield10 Bioscience Inc series A convertible preferred.**
No dividends paid.
- Annual Dividends:**
- 1. Yield10 Bioscience Inc common.**
No dividends paid.
 - 2. Yield10 Bioscience Inc series A convertible preferred.**
No dividends paid.
 - 3. Yield10 Bioscience Inc series B convertible preferred.**
No dividends paid.
 - 4. Yield10 Bioscience Inc series A convertible preferred.**
No dividends paid.

YUBO INTERNATIONAL BIOTECH LTD Annual Report

| Consolidated Income Statement, Years Ended Dec. 31 (\$): | | | |
|--|---------|---------|-----------|
| | 2023 | 2022 | 2021 |
| Sales of products and services | 604,676 | ... | ... |
| Sales | ... | 104,283 | 1,244,373 |

| | | | |
|---|-------------|-------------|-------------|
| Cost of goods and services sold | 185,491 | ... | ... |
| Cost of goods sold | ... | 51,631 | 423,726 |
| Total revenues | 604,676 | ... | ... |
| Gross profit | 419,185 | 52,652 | 820,647 |
| Sales commissions | ... | 9,582 | 182,369 |
| Employee compensation | 617,887 | 674,720 | 681,918 |
| Occupancy | 489,591 | 362,346 | 628,656 |
| Selling, general & administrative expenses | 489,591 | ... | ... |
| Provision for doubtful accounts | ... | (45,130) | 46,854 |
| Depreciation & amortization of property & equipment | 178,312 | 18,098 | 13,222 |
| Amortization of intangible assets | 11,700 | 9,439 | 8,180 |
| Other operating expenses | 316,401 | 228,820 | 802,313 |
| Total operating expenses | 1,613,891 | 1,257,875 | □2,373,512 |
| Income (loss) from operations | (1,194,706) | (1,205,223) | (1,542,865) |
| Interest income (expense) | (377) | 229 | 427 |
| Total other income (expenses) | (377) | 229 | 427 |
| Income (loss) before provision for income tax | (1,195,083) | (1,204,994) | (1,542,438) |
| Net income (loss) | (1,195,083) | (1,204,994) | (1,542,438) |
| Weighted average shares outstanding - basic | 119,820,790 | 118,721,045 | 118,130,820 |
| Weighted average shares outstanding - diluted | 119,820,790 | 118,721,045 | 118,130,820 |
| Year end shares outstanding | 119,820,790 | ... | 118,182,332 |
| Net income (loss) per share - basic | \$(0.01) | \$(0.01) | \$(0.01) |
| Net income (loss) per share - diluted | \$(0.01) | \$(0.01) | \$(0.01) |
| Number of full time employees | 18 | ... | ... |
| Total number of employees | 18 | 20 | 20 |
| Number of class A common stockholders | ... | 448 | □449 |
| Number of class B common stockholders | ... | 37 | □37 |
| Number of beneficiary stockholders | 485 | ... | ... |
| Foreign currency translation adjustments | ... | (48,410) | 116,457 |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.01) | ... | ... |
| Diluted EPS Excluding ExtraOrd Items | \$(0.01) | ... | ... |

□ As reported by the Company; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 |
|-----------------------------|---------|---------|------|
| Cash | 6,359 | 18,220 | ... |
| Receivables | 79,654 | 51,932 | ... |
| Nebulizers & components | 47,718 | 50,894 | ... |
| Oral liquid health products | 67,242 | 76,239 | ... |
| Other product inventory | ... | 2,815 | ... |
| Beauty care products | 97,988 | 104,500 | ... |
| Soft drinks | ... | 87,725 | ... |
| Other | ... | 1,627 | ... |
| Inventory | 214,575 | 322,173 | ... |
| Due from related parties | 285,974 | 293,434 | ... |
| Prepaid expenses | 138,673 | 64,253 | ... |
| Total current assets | 725,235 | 750,012 | ... |

| | | | |
|---|-------------|-------------|---------|
| Leasehold improvements | 514,288 | 282,681 | ... |
| Construction in progress | ... | ... | 323,832 |
| Air conditioning equipment | 27,512 | 20,343 | ... |
| Office equipment | ... | ... | 28,230 |
| Machinery & equipment | 19,826 | ... | ... |
| Property & equipment, gross | 561,626 | 655,086 | ... |
| Less accumulated depreciation & amortization | 186,417 | 38,434 | ... |
| Property & equipment, net | 375,209 | 616,652 | ... |
| Intangible assets, net | 54,408 | 67,679 | ... |
| Operating lease right of use assets | 391,913 | 790,499 | ... |
| Lease security deposits | 120,502 | 123,709 | ... |
| Total assets | 1,667,269 | 2,348,551 | ... |
| Notes payable & accrued interest payable to related parties | 1,859,276 | ... | ... |
| Accounts payable & accrued expense | 825,632 | 549,838 | ... |
| Advances from prospective customers or distributors | 434,151 | 459,970 | ... |
| Due to related parties | ... | 1,113,617 | ... |
| Operating lease liabilities - current | 276,386 | 400,054 | ... |
| Total current liabilities | 3,395,445 | 2,523,479 | ... |
| Operating lease liabilities - non-current | 115,527 | 390,445 | ... |
| Total liabilities | 3,510,972 | 2,913,924 | ... |
| Common stock, class A | 119,816 | 119,816 | ... |
| Common stock, class B | 4 | 4 | ... |
| Additional paid in capital | 2,935,190 | 2,935,190 | ... |
| Accumulated deficit | (4,885,509) | ... | ... |
| Retained earnings (accumulated deficit) | ... | (3,690,426) | ... |
| Accumulated other comprehensive income (loss) | (13,204) | 70,043 | ... |
| Total shareholders' equity (deficit) | (1,843,703) | (565,373) | ... |
| Total Equity | (1,843,703) | ... | ... |

Recent Dividends:

- 1. Yubo International Biotech Ltd class A common.**
No dividends paid.
 - 2. Yubo International Biotech Ltd class B common.**
No dividends paid.
- Annual Dividends:**
- 1. Yubo International Biotech Ltd class A common.**
No dividends paid.
 - 2. Yubo International Biotech Ltd class B common.**
No dividends paid.

YUENGLINGS ICE CREAM CORP Annual Report

| Consolidated Income Statement, Years Ended Oct. 31 (\$): | | | |
|--|-----------|-----------|-----------------|
| | 2023 | 2021 | □2020 (revised) |
| Revenue | 20 | 3,450 | 57,460 |
| Cost of goods sold | 56,211 | 148,014 | 45,168 |
| Gross margin | (56,191) | (144,564) | 12,292 |
| General & administrative expenses | 23,200 | 90,223 | 147,448 |
| Consulting - related party | ... | 85,000 | ... |
| Professional fees | 79,522 | 171,692 | 84,940 |
| Officer compensation | 7,000 | ... | ... |
| Total operating expenses | 109,722 | 346,915 | 232,388 |
| Income (loss) from operations | (165,913) | (491,479) | (220,096) |
| Interest expense | 336,465 | 176,157 | 127,934 |
| Interest income | ... | 738 | 2,072 |
| Change in fair value of derivative | 60,833 | 14,875 | 154,620 |
| Loss on issuance of convertible notes | 38,477 | 59,028 | ... |
| Gain on sale of | ... | ... | ... |

| | | | |
|---|-------------|-------------|-------------|
| asset | 1,000 | 416 | |
| Early payment penalty | 17,819 | | |
| Gain (loss) on extinguishment of debt | 78,683 | 151,418 | |
| Loss on extinguishment of debt | 7,608 | (26,000) | (1,966) |
| Gain on debt conversion | 30,300 | | |
| Total other income (expense) | (258,118) | (110,973) | 27,208 |
| Income (loss) before provision for income tax | (424,031) | (602,452) | (192,888) |
| Net income (loss) | (424,031) | (602,452) | (192,888) |
| Weighted average shares outstanding - basic | 161,178,454 | 161,178,454 | 161,178,454 |
| Weighted average shares outstanding - diluted | 161,178,454 | 161,178,454 | 161,178,454 |
| Year end shares outstanding | 332,488,710 | 332,488,710 | 332,488,710 |
| Net income (loss) per share - basic | \$0.00 | \$0.00 | \$0.00 |
| Net income (loss) per share - diluted | \$0.00 | \$0.00 | \$0.00 |
| Number of full time employees | 60 | 3 | |
| Number of common stockholders | 1,386 | 12 | 13 |
| Total Revenue | 20 | | |
| Total number of employees | 60 | | |

Reclassified to conform with 2021 presentation; Adjusted for 1-for-150 stock split, August 8, 2022; Shares increased due to the effect of issuance of shares for conversion of debt, services and cash; Approximately; As of January 17, 2022

| Consolidated Balance Sheet, Years Ended Oct. 31 (\$): | | | |
|---|-------------|-------------|--|
| | 2023 | 2021 | |
| Cash | 350,905 | 56,212 | |
| Inventory | 20 | 20 | |
| Account receivable | 20 | 407,117 | |
| Total current assets | 30,300 | 30,300 | |
| Automobile | 30,300 | 20 | |
| Plant & equipment, net | 20 | 437,417 | |
| Total assets | 217,192 | 195,822 | |
| Accounts payable | 15,000 | 144,759 | |
| Accrued Compensation | 144,759 | 38,166 | |
| Accrued interest | 184,296 | 132,121 | |
| Notes payable | 589,092 | 659,002 | |
| Loans payable | 489,439 | 800,000 | |
| Line of credit | 17,410 | | |
| Notes payable, related parties | 1,657,188 | 1,825,111 | |
| Total current liabilities | 1,657,188 | 1,981,611 | |
| Loan payable, net of current portion | 156,500 | | |
| Total liabilities | 1,657,188 | 1,981,611 | |
| Preferred stock to be issued | 437,850 | | |
| Total mezzanine equity | 437,850 | | |
| Preferred stock | 48 | 5,000 | |
| Common stock | 332,489 | 1,535,181 | |
| Preferred stock to be issued | 357,022 | | |
| Discount to common stock | (701,917) | | |
| Common stock to be issued | 165,000 | | |
| Additional paid in capital | 2,109,429 | 565,465 | |
| Retained earnings (accumulated deficit) | (4,456,156) | (3,550,773) | |
| Total stockholders' equity (deficit) | (1,657,168) | (1,982,044) | |
| Total Equity | (1,657,168) | | |

Recent Dividends:
1. Yuenglings Ice Cream Corp common.

No dividends paid.
2. Yuenglings Ice Cream Corp preferred.
No dividends paid.
Annual Dividends:
1. Yuenglings Ice Cream Corp common.
No dividends paid.
2. Yuenglings Ice Cream Corp preferred.
No dividends paid.

YUNHONG GREEN CTI LTD
Annual Report
Consolidated Income Statement, Years Ended Dec. 31 (\$):

| | 2023 | 2022 | 2021 (revised) |
|---|------------|-------------|----------------|
| Total revenues | 17,804,000 | 18,048,000 | 24,086,000 |
| Net sales | 17,804,000 | 18,048,000 | 24,086,000 |
| Cost of sales | 14,546,000 | 14,910,000 | 20,322,000 |
| Gross profit | 3,258,000 | 3,138,000 | 3,764,000 |
| General & administrative | 2,995,000 | 3,720,000 | 3,815,000 |
| Administration expenses | 131,000 | | |
| Selling expense | | 136,000 | 132,000 |
| Advertising & marketing | | 402,000 | 323,000 |
| Advertising | 531,000 | | |
| Total operating expenses | 3,657,000 | 4,258,000 | 4,270,000 |
| Income (loss) from operations | (399,000) | (1,120,000) | (506,000) |
| Interest expense | 628,000 | 450,000 | 564,000 |
| Gain on sale & leaseback transaction | | | 3,357,000 |
| Reclassification of cumulative foreign currency gain (loss) | | | (5,885,000) |
| Gain (loss) on sale of subsidiary | | | (4,325,000) |
| Other income (expense) | 792,000 | 103,000 | 195,000 |
| Total other income (expense), net | 164,000 | (347,000) | (7,222,000) |
| Income (loss) from continuing operations before taxes | (235,000) | (1,467,000) | (7,728,000) |
| Income (loss) from continuing operations | (235,000) | (1,467,000) | (7,728,000) |
| Income (loss) from discontinued operations, net of tax | | | 174,000 |
| Net income (loss) | (235,000) | (1,467,000) | (7,554,000) |
| Less: net income (loss) attributable to noncontrolling interest | | | (718,000) |
| Net income (loss) attributable to CTI Industries Corporation | (235,000) | (1,467,000) | (8,272,000) |
| Deemed dividends on preferred stock & amortization of beneficial conversion feature | 11,000 | 584,000 | 3,573,000 |
| Income (loss) attributable to Yuhong CTI Ltd common shareholders | (246,000) | (2,051,000) | (11,845,000) |
| Weighted average shares outstanding - basic | 19,526,633 | 9,301,888 | 5,878,887 |
| Weighted average shares outstanding - diluted | 19,526,633 | 9,301,888 | 5,878,887 |
| Year end shares outstanding | 20,771,937 | 16,059,991 | 5,886,750 |
| Income (loss) from continuing operations per common share - | | | |

| | | | |
|---|----------|----------|----------|
| basic | \$(0.01) | \$(0.22) | \$(2.04) |
| Income (loss) from discontinued operations per common share - basic | \$0.00 | | \$0.03 |
| Net income (loss) per common share - basic | \$(0.01) | \$(0.22) | \$(2.01) |
| Income (loss) from continuing operations per common share - diluted | \$(0.01) | \$(0.22) | \$(2.04) |
| Income (loss) from discontinued operations per common share - diluted | \$0.00 | | \$0.03 |
| Net income (loss) per common share - diluted | \$(0.01) | \$(0.22) | \$(2.01) |
| Number of full time employees | 57 | 58 | 66 |
| Number of common stockholders | 30 | 400 | 400 |
| Number of beneficial stockholders | | 30 | 30 |
| Total number of employees | 57 | | |

Reclassified to conform with 2022 presentation; Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 921,000 | 146,000 |
| Accounts receivable, net | 3,975,000 | 1,618,000 |
| Raw materials | 1,156,000 | 1,457,000 |
| Work in process | 2,511,000 | 2,513,000 |
| Finished goods | 4,124,000 | 4,355,000 |
| In transit | 7,791,000 | |
| Inventories | | 8,325,000 |
| Prepaid expenses | 332,000 | 389,000 |
| Total current assets | 13,019,000 | 10,478,000 |
| Machinery & equipment | 17,940,000 | 17,723,000 |
| Office furniture & equipment | 2,084,000 | 2,084,000 |
| Intellectual property | 783,000 | 783,000 |
| Leasehold improvements | 39,000 | 39,000 |
| Fixtures & equipment at customer locations | 519,000 | 519,000 |
| Projects under construction | 112,000 | 108,000 |
| Property, plant & equipment, gross | 21,477,000 | 21,256,000 |
| Less: accumulated depreciation & amortization | 20,613,000 | 20,334,000 |
| Total property, plant & equipment, net | 864,000 | 922,000 |
| Operating lease right-of-use | 3,364,000 | 3,882,000 |
| Total assets | 17,247,000 | 15,282,000 |
| Trade payables | 917,000 | 1,313,000 |
| Line of credit | 4,991,000 | 2,878,000 |
| Notes payable - current portion | 140,000 | 289,000 |
| Notes payable - officers, subordinated | 1,344,000 | |
| Operating lease liabilities | 522,000 | 518,000 |
| Accrued liabilities | 2,226,000 | 2,480,000 |
| Total current liabilities | 10,140,000 | 7,478,000 |
| Notes payable, net of current portion | 533,000 | 427,000 |
| Operating lease liabilities | 2,842,000 | 3,364,000 |
| Notes payable - officers, subordinated | | 1,267,000 |
| Total long-term liabilities | 3,375,000 | 5,058,000 |
| Total liabilities | 13,515,000 | 12,536,000 |

| | | |
|---|--------------|--------------|
| Series B preferred stock | 1,851,000 | |
| Common stock | 21,283,000 | 21,283,000 |
| Paid-in-capital | 6,967,000 | 3,895,000 |
| Accumulated deficit | (24,357,000) | ... |
| Retained earnings (accumulated deficit) | ... | (24,122,000) |
| Less: treasury stock | 161,000 | 161,000 |
| Total CTI Industries Corporation stockholders' equity (deficit) | 3,732,000 | 2,746,000 |
| Total equity | 3,732,000 | 2,746,000 |

Recent Dividends:

- Yunhong Green CTI Ltd series D preferred.**
No dividends paid.
- Yunhong Green CTI Ltd series B preferred.**
No dividends paid.
- Yunhong Green CTI Ltd common.**
No dividends paid.
- Yunhong Green CTI Ltd series A preferred.**
No dividends paid.
- Yunhong Green CTI Ltd series C preferred.**
No dividends paid.

Annual Dividends:

- Yunhong Green CTI Ltd series D preferred.**
No dividends paid.
- Yunhong Green CTI Ltd series B preferred.**
No dividends paid.
- Yunhong Green CTI Ltd common.**
No dividends paid.
- Yunhong Green CTI Ltd series A preferred.**
No dividends paid.
- Yunhong Green CTI Ltd series C preferred.**
No dividends paid.

ZEO SCIENTIFIX INC**Earnings, 3 mos. to Jan 31(Consol. - \$):**

| | 2024 | 2023 |
|-----------------------------|--------------------|--------------------|
| Total revenues | 1,154,000 | 1,070,000 |
| Cost & expenses | 2,316,000 | 3,246,000 |
| Operating income | (1,162,000) | (2,176,000) |
| Interest expense | 27,000 | 61,000 |
| Other income (expense), net | 149,000 | (50,000) |
| Net before taxes | (1,040,000) | (2,287,000) |
| Net income | (1,040,000) | (2,287,000) |

Earnings common share

| | | |
|---------------|----------|----------|
| Primary | \$(0.17) | \$(0.33) |
| Fully Diluted | \$(0.17) | \$(0.33) |

Common Shares:

| | | |
|--------------|-----------|-----------|
| Full Diluted | 6,190,794 | 7,009,549 |
| Year-end | 6,125,482 | 7,443,789 |

Consolidated Balance Sheet Items, as of (\$):

| | 2024 | 2023 |
|-----------------------|-------------|-------------|
| Assets: | | |
| Cash & equivalents | 1,172,000 | 316,000 |
| Inventories | 1,892,000 | 533,000 |
| Current assets | 1,892,000 | 533,000 |
| Net property & equip. | 2,432,000 | ... |
| Total assets | 2,432,000 | ... |
| Liabilities: | | |
| Current liabilities | 3,923,000 | 17,000 |
| Long-term debt | 17,000 | ... |
| Stockholders' equity | (1,508,000) | (2,031,000) |
| Net current assets | (2,031,000) | ... |

ZEVRA THERAPEUTICS, INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|---|------------|------------|------------|
| Acquired in-process research & development | 17,663,000 | ... | ... |
| Revenue | 27,461,000 | 10,161,000 | ... |
| Revenue, net | ... | ... | 28,650,000 |
| Cost of revenue | 2,945,000 | 222,000 | ... |
| Research & development | 39,806,000 | 19,803,000 | 10,161,000 |
| Royalty & direct contract acquisition costs | ... | ... | 2,059,000 |
| General & administrative | 34,314,000 | 15,038,000 | 8,701,000 |
| Total operating expenses | ... | ... | 20,921,000 |

| | | | |
|--|---------------------|---------------------|--------------------|
| Income (loss) from operations | (49,604,000) | (42,565,000) | 7,729,000 |
| Gain (loss) on extinguishment of debt | ... | ... | (16,096,000) |
| Interest expense related to amortization of debt issuance costs & discount | ... | ... | 150,000 |
| Interest expense | 1,501,000 | 335,000 | 226,000 |
| Fair value adjustment related to derivative & warrant liability | (98,000) | 15,159,000 | (26,000) |
| Fair value adjustment related to investments | 613,000 | (577,000) | ... |
| Interest & other income, net | 4,541,000 | 1,513,000 | 248,000 |
| Total other income (expense) | 3,555,000 | 15,760,000 | (16,250,000) |
| Income (loss) before income taxes | (46,049,000) | (26,805,000) | (8,521,000) |
| Income tax expense (benefit) | ... | (33,000) | 34,000 |
| Net income (loss) | (46,049,000) | (26,772,000) | (8,555,000) |
| Deemed dividend | ... | ... | 54,342,000 |
| Net income (loss) attributable to common stockholders | ... | ... | (62,897,000) |
| Weighted average shares outstanding - basic | 35,452,460 | 34,488,800 | 29,766,347 |
| Weighted average shares outstanding - diluted | 35,452,460 | 34,488,800 | 29,766,347 |
| Year end shares outstanding | 41,534,668 | 34,540,304 | 35,005,640 |
| Net earnings (loss) per share - basic | \$(1.30) | \$(0.78) | \$(2.11) |
| Net earnings (loss) per share - diluted | \$(1.30) | \$(0.78) | \$(2.11) |
| Number of full time employees | 65 | ... | 24 |
| Total number of employees | 65 | ... | ... |
| Number of common stockholders | 96 | ... | 104 |
| Earnings per share from continuing operations | \$(1.30) | \$(0.78) | ... |
| Earnings per share from continuing operations | \$(1.30) | \$(0.78) | ... |

□ Restated to reflect correction of errors; □ Non-consolidated; □ Shares increased due to the effect of common stock issued as a result of warrant exercises, common stock issued as a result of the public offering & series B-2 preferred stock conversions; □ Approximately

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|---|------------|------------|
| Cash & cash equivalents | 43,049,000 | 65,466,000 |
| Securities at fair value | ... | 16,900,000 |
| Short-term investments - other | 24,688,000 | 481,000 |
| Other receivables | 16,119,000 | 7,185,000 |
| Accounts & other receivables | 17,377,000 | 8,299,000 |
| Prepaid insurance | 1,172,000 | 577,000 |
| Prepaid offering costs | 1,824,000 | 1,688,000 |
| Other receivables | 1,258,000 | 1,114,000 |
| Other prepaid expenses & current assets | 652,000 | 1,111,000 |
| Total current assets | 86,938,000 | 92,834,000 |
| Inventories | 9,841,000 | 671,000 |
| Laboratory equipment | 643,000 | 462,000 |
| Furniture & office equipment | 157,000 | 104,000 |
| Computers & hardware | 2,370,000 | 2,237,000 |
| Leasehold improvements | 710,000 | 710,000 |
| Finance lease | ... | ... |

| | | |
|---|---------------|---------------|
| right-of-use assets | 149,000 | 251,000 |
| Laboratory equipment | 711,000 | 710,000 |
| Less: accumulated depreciation & amortization | 1,634,000 | 1,443,000 |
| Property & equipment, net | 736,000 | 794,000 |
| Operating lease right-of-use assets | 790,000 | 988,000 |
| Long-term investments - other | ... | 20,000,000 |
| Other long-term assets | 94,000 | 53,000 |
| Intangible assets, net | 69,227,000 | ... |
| Goodwill | 4,701,000 | ... |
| Total assets | 172,327,000 | 115,340,000 |
| Accrued payroll | 10,671,000 | 1,673,000 |
| Accrued professional fees | 675,000 | 256,000 |
| Accounts payable | 13,987,000 | 3,611,000 |
| Other accrued expenses | 3,070,000 | 629,000 |
| Current portion of operating lease liabilities | 543,000 | 480,000 |
| Current portion of discount & rebate liabilities | 4,550,000 | 4,655,000 |
| Other current liabilities | 2,524,000 | 719,000 |
| Line of credit payable | 37,700,000 | ... |
| Total current liabilities | 73,720,000 | 12,023,000 |
| Derivative & warrant liability | 5,066,000 | ... |
| Operating lease liabilities, less current portion | 456,000 | 843,000 |
| Loans payable, less current portion | ... | 12,800,000 |
| Discount & rebate liabilities, less current portion | 7,663,000 | 4,327,000 |
| Other long-term liabilities | 7,458,000 | 25,000 |
| Derivative and warrant liability | 16,100,000 | 10,202,000 |
| Total liabilities | 110,463,000 | 40,220,000 |
| Common stock | 4,000 | 3,000 |
| Additional paid-in capital | 472,664,000 | 436,269,000 |
| Treasury stock, at cost | 10,983,000 | 7,536,000 |
| Accumulated deficit | (399,778,000) | (353,729,000) |
| Accumulated other comprehensive income | (43,000) | 113,000 |
| Total stockholders' equity (deficit) | 61,864,000 | 75,120,000 |
| Total Equity | 61,864,000 | 75,120,000 |

□ Restated to reflect correction of errors

Recent Dividends:

- Zevra Therapeutics, Inc common.**
No dividends paid.
- Zevra Therapeutics, Inc series A convertible preferred.**
No dividends paid.

Annual Dividends:

- Zevra Therapeutics, Inc common.**
No dividends paid.
- Zevra Therapeutics, Inc series A convertible preferred.**
No dividends paid.

ZONED PROPERTIES INC**Annual Report****Consolidated Income Statement, Years Ended Dec. 31 (\$):**

| | 2023 | 2022 | 2021 |
|-------------------------------------|-----------|-----------|-----------|
| Rental revenues | 2,481,892 | 1,795,719 | 1,261,059 |
| Advisory revenues | ... | 244,750 | 146,031 |
| Brokerage revenues | ... | 619,621 | 413,395 |
| Total real estate services revenues | 405,099 | 864,371 | 559,426 |
| Total revenues | 2,886,991 | 2,660,090 | 1,820,485 |
| Compensation & benefits | 1,326,485 | 1,232,414 | 488,607 |
| Professional fees | 388,807 | 352,643 | 397,877 |
| Brokerage fees | 64,680 | 431,029 | 265,208 |
| General & administrative expenses | 367,175 | 275,862 | 201,625 |

| | | | | | | | | | |
|---|------------|------------|------------|--|--------------|--------------|---|---------------|---------|
| Real estate taxes | 163,896 | 116,912 | 87,769 | Right of use asset, net | 32,213 | 65,381 | - diluted | 6,183 | |
| Depreciation & amortization | 380,761 | 360,493 | 386,643 | Investment in unconsolidated joint ventures | 4,923 | 58,293 | Weighted average class B common shares outstanding | | |
| Gain on sale of property & equipment | | 312 | 51,944 | Investment in equity securities | 50,000 | 50,000 | - diluted | 53,571 | |
| Total operating expenses, net | 2,717,804 | 2,769,041 | 1,775,785 | Security deposits | 2,272 | 2,272 | General and administrative | 11,213,201 | |
| Income (loss) from operations | 169,187 | (108,951) | 44,700 | Deferred rent | 371,472 | | Year end shares outstanding | 4,052,057 | 284,967 |
| Interest expenses | 624,693 | 160,550 | 120,000 | Capitalized permit costs | 38,016 | | Net income (loss) per share - basic | \$(108.97) | \$0.00 |
| Interest expenses - related party | | 600 | 1,200 | Total assets | 14,437,551 | 14,380,847 | Net income (loss) per class A common share - basic | \$(4.20) | |
| Interest income | | 13,000 | 12,127 | Convertible note payable | 2,000,000 | 2,000,000 | Net income (loss) per class B common share - basic | \$(4.20) | |
| Change in fair value of interest rate swap | (32,642) | (90,237) | | Notes payable, net | 6,111,702 | 5,727,750 | Net income (loss) per class A common share - diluted | \$(108.97) | \$0.00 |
| Loss on note receivable investment | | (210,756) | | Accounts payable | 116,947 | 107,371 | Net income (loss) per class B common share - diluted | \$(4.20) | \$0.00 |
| Impairment loss from unconsolidated joint ventures | (7,110) | | (73,970) | Accrued expenses | 176,837 | 188,535 | Net income (loss) per class A common share - diluted | \$(4.20) | |
| Loss from unconsolidated joint ventures | | (16,261) | (27,476) | Lease liability | 32,867 | 65,941 | Net income (loss) per class B common share - diluted | \$(4.20) | |
| Impairment of investment in unconsolidated joint ventures | 45,000 | | | Contract liabilities | 346,176 | 303,315 | Net income (loss) per class A common share - diluted | \$(4.20) | |
| Total other income (expenses), net | | (465,404) | (210,519) | Derivative liability - interest rate swap, at fair value | 122,879 | 90,237 | Net income (loss) per share - diluted | \$(108.97) | \$0.00 |
| Income (loss) before income taxes | (540,258) | (574,355) | (165,819) | Security deposits payable | 290,460 | 219,400 | Net income (loss) per class A common share - diluted | \$(4.20) | |
| Net income (loss) | (540,258) | (574,355) | (165,819) | Total liabilities | 9,197,868 | 8,702,549 | Net income (loss) per class B common share - diluted | \$(4.20) | |
| Weighted average shares outstanding - basic | 12,179,356 | 12,201,548 | 12,175,623 | Preferred stock | 2,000 | 2,000 | Net income (loss) per class A common share - diluted | \$(4.20) | |
| Weighted average shares outstanding - diluted | 12,179,356 | 12,201,548 | 12,175,623 | Common stock | 12,202 | 12,202 | Net income (loss) per class B common share - diluted | \$(4.20) | |
| Year end shares outstanding | 12,101,548 | 12,201,548 | 12,201,548 | Additional paid-in capital | 21,453,961 | 21,337,318 | Net income (loss) per class A common share - diluted | \$(4.20) | |
| Net income (loss) per share - basic | \$(0.04) | \$(0.05) | \$(0.01) | Retained earnings (accumulated deficit) | (16,213,480) | (15,673,222) | Full-Time Employees (Period End) | 7 | |
| Net income (loss) per share - diluted | \$(0.04) | \$(0.05) | \$(0.01) | Treasury stock, at cost (100,000 and no shares on 31, 2023 and 2022, respectively) | 15,000 | | Total number of employees | 7 | 2 |
| Number of full time employees | 9 | 9 | 4 | Total stockholders' equity (deficit) | 5,239,683 | 5,678,298 | Number of class B common stockholders | 95 | 12 |
| Total number of employees | 9 | | | Total Equity | 5,239,683 | | Income from cont operations before income tax | (107,753,776) | |
| Number of common stockholders | 101 | 103 | 103 | | | | Total Operating Expenses | 107,754,233 | |
| Property portfolio business development costs | 26,000 | | | | | | Federal | (19,104,800) | |
| Basic EPS Excluding ExtraOrdinary Items | \$(0.04) | | | | | | Deferred tax benefit: State | (4,468,170) | |
| Diluted EPS Excluding ExtraOrd Items | \$(0.04) | | | | | | Change in valuation allowance | 14,093,900 | |
| | | | | | | | Deferred tax benefit | (23,572,970) | |
| | | | | | | | Income Taxes - Local - Current | 23,240 | |
| | | | | | | | Income Taxes - Total - Current | 23,240 | |
| | | | | | | | Income tax benefit | (9,455,830) | |
| | | | | | | | Impairment of in-process research and development | 81,438,426 | |
| | | | | | | | Impairment of goodwill | 11,895,033 | |
| | | | | | | | Net Income After Extraordinary Items applicable to Common | (106,246,155) | |

Recent Dividends:

1. Zoned Properties Inc common.

No dividends paid.

2. Zoned Properties Inc preferred.

No dividends paid.

Annual Dividends:

1. Zoned Properties Inc common.

No dividends paid.

2. Zoned Properties Inc preferred.

No dividends paid.

ZYVERSA THERAPEUTICS INC

Annual Report

Consolidated Income Statement, Years Ended (\$):

| | 12/31/23 | 12/31/21 | 05/07/21 |
|--|---------------|-----------|----------|
| Formation costs | | | 1,106 |
| Formation & operating costs | 3,207,573 | 235,267 | |
| Operating income (loss) | (107,754,233) | (235,267) | |
| Change in fair value of derivative liability | | (5,433) | |
| Interest (income) expense | 457 | | |
| Total other income (expense) | | (5,433) | |
| Deemed dividend to preferred stockholders | 7,948,209 | | |
| Net income (loss) | (98,297,946) | (240,700) | (1,106) |
| Weighted average shares outstanding - basic | 975,035 | | 53,571 |
| Weighted average class A common shares outstanding - basic | | 6,183 | |
| Weighted average class B common shares outstanding - basic | | 53,571 | |
| Weighted average shares outstanding - diluted | 975,035 | | 53,571 |
| Weighted average class A common shares outstanding | | | |

From March 17, 2021 (date of inception); Adjusted for 1-for-35 stock split, December 5, 2023; Shares increased due to private placement class A shares, conversion of note payable to class A common and issuance of class A stock subject to possible redemption; As of April 13, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2021 |
|---|-----------|------------|
| Cash | 3,137,674 | 928,389 |
| Prepaid expenses | | 251,800 |
| Prepaid expenses and other current assets | 215,459 | |
| Total current assets | 3,353,133 | 1,180,189 |
| Prepaid expenses | | 213,168 |
| Investments held in trust account | | 75,750,000 |
| Medical equipment - Gross | 52,000 | |
| Medical equipment - Net | 6,933 | |
| Medical equipment - Accumulated Depreciation & Impairment | 45,067 | |
| Property, Plant & Equipment - Net - Total | 6,933 | |
| In-process research and | | |

Reclassified to conform with 2022 presentation; Approximately; As of March 28, 2023; As of March 24, 2022

Consolidated Balance Sheet, Years Ended Dec. 31 (\$):

| | 2023 | 2022 |
|----------------------------------|------------|-----------|
| Cash | 3,099,795 | 4,335,840 |
| Accounts receivable | 136,572 | 138,825 |
| Deferred rent receivable | | 204,079 |
| Lease incentive receivable | 449,541 | 477,064 |
| Building & building improvements | 9,258,431 | 8,087,997 |
| Land | 3,353,378 | 2,514,848 |
| Construction in progress | 18,976 | |
| Less: accumulated depreciation | 2,590,261 | 2,214,709 |
| Rental properties, net | 10,040,524 | 8,388,136 |
| Prepaid expenses & other assets | 27,476 | 59,129 |
| Escrow deposits | 177,048 | 590,000 |
| Property & equipment, net | 7,699 | 11,828 |

| | | |
|---------------------------------|---------------|-------------|
| development | 18,647,903 | ... |
| Operating lease | | |
| right-of-use asset | 7,839 | ... |
| Security deposit | 98,476 | ... |
| Total assets | 22,114,284 | 77,143,357 |
| Accrued expenses | 41,969 | 200,247 |
| Derivative liability | ... | 76,588 |
| Accounts Payable | 8,431,583 | ... |
| Accrued expenses and | | |
| other current liabilities | 1,754,533 | ... |
| Operating lease liability | 8,656 | ... |
| Payroll accrual | 668,803 | ... |
| Accrued Expenses - | | |
| Balancing value | 1,043,761 | ... |
| Total current liabilities | 10,194,772 | 276,835 |
| Business combination fee | | |
| payable | ... | 3,375,000 |
| Deferred tax liability | 844,914 | ... |
| Total liabilities | 11,039,686 | 3,651,835 |
| Class A common stock | | |
| subject to possible | | |
| redemption | ... | 75,750,000 |
| Class A common stock | 405 | 32 |
| Class B common stock | ... | 216 |
| Additional paid-in | | |
| capital | 114,300,484 | ... |
| Retained earnings | | |
| (accumulated deficit) | (103,219,124) | (2,258,726) |
| Treasury stock, at cost, | | |
| 2,159 and 0 shares at | | |
| 30, 2023 and 31, 2022, | | |
| respectively | 7,168 | ... |
| Successor Series B | | |
| preferred stock | 1 | ... |
| Total stockholders' | | |
| equity (deficit) | 11,074,598 | (2,258,478) |
| Total Equity | 11,074,598 | ... |

Recent Dividends:

- ZyVersa Therapeutics Inc series B preferred.**
No dividends paid.
- ZyVersa Therapeutics Inc common.**
No dividends paid.
- ZyVersa Therapeutics Inc class A common.**
No dividends paid.
- ZyVersa Therapeutics Inc series A preferred.**
No dividends paid.
- ZyVersa Therapeutics Inc class B common.**
No dividends paid.
- ZyVersa Therapeutics Inc class A common subject to possible redemption.**
No dividends paid.

Annual Dividends:

- ZyVersa Therapeutics Inc series B preferred.**
No dividends paid.
- ZyVersa Therapeutics Inc common.**
No dividends paid.
- ZyVersa Therapeutics Inc class A common.**
No dividends paid.
- ZyVersa Therapeutics Inc series A preferred.**
No dividends paid.
- ZyVersa Therapeutics Inc class B common.**
No dividends paid.
- ZyVersa Therapeutics Inc class A common subject to possible redemption.**
No dividends paid.

*

MERGENT OTC UNLISTED News Reports 0895-3252 is published weekly online on Tuesdays and printed the last Friday of the month by Mergent, Inc., 444 Madison Ave., New York, NY 10022. The News Reports are part of the OTC UNLISTED Manual and provide periodic updates. Send address changes to MERGENT OTC UNLISTED, 580 Kingsley Park Drive, Fort Mill, SC 29715.

Copyright©2024 by Mergent. All information contained herein is copyrighted in the name of Mergent, Inc., and none of such information may be copied or otherwise reproduced, repackaged, further transmitted, transferred, disseminated, redistributed or resold, or stored for subsequent use for any such purpose, in whole or in part, in any form or matter or by any means whatsoever, by any person without Mergent's prior written consent.

All information contained is obtained by Mergent, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical error, as well as other factors, however, such information is provided "as is", without warranty of any kind. NO WARRANTY, EXPRESS OR IMPLIED, AS TO THE ACCURACY, TIMELINESS, COMPLETENESS, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE OF ANY INFORMATION IS GIVEN OR MADE BY MERGENT IN ANY FORM OR MANNER WHATSOEVER. Under no circumstances shall Mergent have any liability to any person or entity for (a) any loss or damage in whole or in part caused by, resulting from, or relating to, any error (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analyzing, editing, transcribing, transmitting, communicating or delivering any such information, or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if Mergent is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, any such information.